{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Importing the dataset."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                   unique_hash  \\\n",
      "1387  7a8715045689fb77862e6425eed0f55ee079ae1c   \n",
      "4501  8d529f21081d99b0617c9d75f6b075ee2009d645   \n",
      "3529  7e4d46b93bb99228dbef2eeaa7575885baebbf75   \n",
      "38    5eca9f0458bac17bf89188de1b9a61fcea05e7ce   \n",
      "3831  fb209c6d722149601c7501da59f8a79bb8ece92e   \n",
      "3950  1d959e48be7bf21f90946815832cab56338e3dd5   \n",
      "655   ad9fa9f8a10dfa7fb4418332e69a0abd209cab7d   \n",
      "561   e317399c733ab82402cfcf29ae38d19f0ce2879f   \n",
      "3635  7c5d8a7d5406e4b07cdeaaadc882b0ccfa834f94   \n",
      "646   5227f82ddc10bb18c80bd80094ad86b74e67fc24   \n",
      "\n",
      "                                                   text           drug  \\\n",
      "1387  hello smurf i remember you being on here. ther...        gilenya   \n",
      "4501  I have been living with Crohn’s disease for ov...         humira   \n",
      "3529  Hi Janet, I’m sorry to hear of your brother’s ...        tarceva   \n",
      "38    In May of 2017, I started on the targeted trea...       mekinist   \n",
      "3831  Cladribine Tablets were expected to be one of ...     cladribine   \n",
      "3950  Dr. McKay, Medical Oncologist, Assistant Profe...  pembrolizumab   \n",
      "655   Glad to hear Contentprof! I've been well mysel...        entyvio   \n",
      "561   hateuc..you may be right, but I am really not ...         humira   \n",
      "3635  Our son wants to pursue overseas job opprtunti...       remicade   \n",
      "646   Hi Jeannie, Most often, patients begin at the ...        tarceva   \n",
      "\n",
      "      sentiment  \n",
      "1387          2  \n",
      "4501          2  \n",
      "3529          2  \n",
      "38            1  \n",
      "3831          2  \n",
      "3950          2  \n",
      "655           2  \n",
      "561           2  \n",
      "3635          2  \n",
      "646           2  \n"
     ]
    }
   ],
   "source": [
    "pharmacy_med_reviews_trainset = pd.read_csv(\"C:/Users/kvknb/OneDrive/Desktop/PharmacyMedReviews/train.csv\")\n",
    "print(pharmacy_med_reviews_trainset.sample(10))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                   unique_hash  \\\n",
      "2812  6feb110fd96646c56796196a7abeca19df7e7db9   \n",
      "836   054188eeda69933eb8d472a8584332a426545fc5   \n",
      "54    6cff04f207455085cdce32ed6adbd3c95616bb04   \n",
      "999   c989b0961ead21ae9799177390b351c43a402c03   \n",
      "1049  e214ddca2f46039c7e97c72fe9989c15cd3cf0d3   \n",
      "2338  6baa30287277c911ab9efb4c5dfed0a0c9df26ca   \n",
      "1164  ccca6a06b48de7c5fb7370da2d3e9e3922fe3187   \n",
      "749   77c300671056a5ec94725aa189f10012fc7594c0   \n",
      "360   328c5712c7120d4fb64516f99c3cd87743004c6a   \n",
      "593   3b5ddd14aeb7464252f53d270d89484f92fc9a08   \n",
      "\n",
      "                                                   text          drug  \n",
      "2812  After failing Remicade, Humira, Cimzia, and En...       stelara  \n",
      "836   By Pete Farley ‘Unprecedented’ Effects in Rela...       ocrevus  \n",
      "54    I usually would have a mild flare once a year....        humira  \n",
      "999   Thanks for the replies. I am male, Notsosickly...  upadacitinib  \n",
      "1049  Yes, he had a relapse on fingolimod. He had be...    fingolimod  \n",
      "2338  MaybeG will do it, the headline results of a n...     siponimod  \n",
      "1164  My Neuro is recommending Ocrevus in addition t...       ocrevus  \n",
      "749   No it doesn't help at all. Prednisone feels li...       entyvio  \n",
      "360   Sorry MOA = mechanism of action Yes any hospit...   ocrelizumab  \n",
      "593   Age Related Macular Degeneration (AMD) is dama...      lucentis  \n"
     ]
    }
   ],
   "source": [
    "pharmacy_med_reviews_testset = pd.read_csv(\"C:/Users/kvknb/OneDrive/Desktop/PharmacyMedReviews/test.csv\")\n",
    "print(pharmacy_med_reviews_testset.sample(10))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Finding the number of drugs."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 2160x1440 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Countplot to see the frequency of the drugs in the traning set.\n",
    "plt.figure(figsize=(30,20))\n",
    "sns.countplot(pharmacy_med_reviews_trainset['drug'])\n",
    "plt.xticks(rotation=90)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Observations:\n",
    "##### From the graphs we can see that the drugs about which most of the reviews were given are \"Ocrevus\" followed by \"Gilenya\" and \"Ocrelizumab\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABsMAAAT2CAYAAAB3Mt3kAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADl0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uIDIuMi4zLCBodHRwOi8vbWF0cGxvdGxpYi5vcmcvIxREBQAAIABJREFUeJzs3W/or3ddx/HXW49pYeVqJ/9sgyO2wHWjGScZeU+DSrAZJKwbJjLYGCscSFDeSSGhqBwmMVqsmCKYpKCGd8xW4A1nZ7am8xCuv64tPZE6IxK2Pt041/DgDvN09rvOb3udxwN+/K7v5/p8vrzvP7m+16y1AgAAAAAAAI2eddgDAAAAAAAAwF7EMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1jhz2AE/FpZdeuo4dO3bYYwAAAAAAAHCB3XPPPf+x1jr6nfY9o2PYsWPHcuLEicMeAwAAAAAAgAtsZv7lXPb5mUQAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqHTnsAXj6+/fb3nFe5150028c8CQAAAAAAAD/P54MAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGodOewB2M+Xb/ud8z77wpt+9QAnAQAAAAAAOByeDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBau8WwmXnezHxmZv5uZu6fmXds6y+dmbtn5osz86cz813b+nO3zw9s94/tNRsAAAAAAAAXhz2fDPtmklevtX4sydVJfmZmrkny20luXWtdmeSrSa7f9l+f5KtrrR9Ocuu2DwAAAAAAAM7bbjFsnfZf28fnbH8ryauT/Nm2fmeS12/X126fs91/zczMXvMBAAAAAADQb9d3hs3Ms2fm3iRfSfKJJP+Q5GtrrUe3LQ8muWy7vizJl5Jku//1JD94lu+8YWZOzMyJU6dO7Tk+AAAAAAAAz3C7xrC11mNrrauTXJ7klUlefrZt2/+zPQW2nrCw1u1rreNrreNHjx49uGEBAAAAAACos2sMe9xa62tJ/irJNUleMDNHtluXJ3lou34wyRVJst3//iT/eSHmAwAAAAAAoNNuMWxmjs7MC7br707yU0lOJrkryS9s296U5CPb9Ue3z9nu/+Va6wlPhgEAAAAAAMC5OvKdt5y3Fye5c2aendPR7YNrrT+fmS8k+cDM/GaSv01yx7b/jiTvm5kHcvqJsOt2nA0AAAAAAICLwG4xbK11X5JXnGX9H3P6/WHfvv4/Sd6w1zwAAAAAAABcfC7IO8MAAAAAAADgMIhhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAECt3WLYzFwxM3fNzMmZuX9m3rKtv31m/m1m7t3+XnvGmV+fmQdm5u9n5qf3mg0AAAAAAICLw5Edv/vRJG9da312Zr43yT0z84nt3q1rrd89c/PMXJXkuiQ/muQlSf5iZn5krfXYjjMCAAAAAABQbLcnw9ZaD6+1PrtdfyPJySSXPcmRa5N8YK31zbXWPyV5IMkr95oPAAAAAACAfhfknWEzcyzJK5LcvS398szcNzN/PDOXbGuXJfnSGccezFni2czcMDMnZubEqVOndpwaAAAAAACAZ7rdY9jMPD/Jh5LcstZ6JMltSV6W5OokDyf5vce3nuX4esLCWrevtY6vtY4fPXp0p6kBAAAAAABosGsMm5nn5HQIe/9a68NJstb68lrrsbXW/yb5o3zrpxAfTHLFGccvT/LQnvMBAAAAAADQbbcYNjOT5I4kJ9da7zpj/cVnbPv5JJ/frj+a5LqZee7MvDTJlUk+s9d8AAAAAAAA9Duy43e/Kskbk3xuZu7d1t6W5Bdn5uqc/gnEf05yY5Kste6fmQ8m+UKSR5PcvNZ6bMf5AAAAAAAAKLdbDFtrfSpnfw/Yx5/kzDuTvHOvmQAAAAAAALi47PrOMAAAAAAAADhMYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqLVbDJuZK2bmrpk5OTP3z8xbtvUfmJlPzMwXt/+XbOszM78/Mw/MzH0z8+N7zQYAAAAAAMDFYc8nwx5N8ta11suTXJPk5pm5KsmvJfnkWuvKJJ/cPifJzya5cvu7IcltO84GAAAAAADARWC3GLbWenit9dnt+htJTia5LMm1Se7ctt2Z5PXb9bVJ3rtO+3SSF8zMi/eaDwAAAAAAgH4X5J1hM3MsySuS3J3khWuth5PTwSzJD23bLkvypTOOPbitfft33TAzJ2bmxKlTp/YcGwAAAAAAgGe43WPYzDw/yYeS3LLWeuTJtp5lbT1hYa3b11rH11rHjx49elBjAgAAAAAAUGjXGDYzz8npEPb+tdaHt+UvP/7zh9v/r2zrDya54ozjlyd5aM/5AAAAAAAA6LZbDJuZSXJHkpNrrXedceujSd60Xb8pyUfOWP+lOe2aJF9//OcUAQAAAAAA4Hwc2fG7X5XkjUk+NzP3bmtvS/JbST44M9cn+dckb9jufTzJa5M8kOS/k7x5x9kAAAAAAAC4COwWw9Zan8rZ3wOWJK85y/6V5Oa95gEAAAAAAODis+s7wwAAAAAAAOAwiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1Dpy2AM8nZy67U/O69zRm958wJMAAAAAAABwEDwZBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACg1pHDHgB4+vibP3zdeZ/9iRs/doCTAAAAAADAwfBkGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBaYhgAAAAAAAC1xDAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFDryGEPAByMe2973Xmdu/qmjx3wJAAAAAAA8PThyTAAAAAAAABqiWEAAAAAAADUEsMAAAAAAACoJYYBAAAAAABQSwwDAAAAAACglhgGAAAAAABALTEMAAAAAACAWmIYAAAAAAAAtcQwAAAAAAAAaolhAAAAAAAA1BLDAAAAAAAAqCWGAQAAAAAAUEsMAwAAAAAAoJYYBgAAAAAAQC0xDAAAAAAAgFpiGAAAAAAAALXEMAAAAAAAAGqJYQAAAAAAANQSwwAAAAAAAKglhgEAAAAAAFBLDAMAAAAAAKCWGAYAAAAAAEAtMQwAAAAAAIBa5xTDZuaT57IGAAAAAAAATydHnuzmzDwvyfckuXRmLkky263vS/KSnWcDAAAAAACAp+RJY1iSG5PcktPh6558K4Y9kuQPdpwLAAAAAAAAnrInjWFrrXcneffM/Mpa6z0XaCYAAAAAAAA4EN/pybAkyVrrPTPzk0mOnXlmrfXeneYCAAAAAACAp+ycYtjMvC/Jy5Lcm+SxbXklEcMAAAAAAAB42jqnGJbkeJKr1lprz2EAAAAAAADgID3rHPd9PsmL9hwEAAAAAAAADtq5Phl2aZIvzMxnknzz8cW11s/tMhUAAAAAAAAcgHONYW/fcwgAAAAAAADYwznFsLXWX+89CAAAAAAA/8fe3cbqfdd1HP/+4KgPDEbI2m2soGj2ADE6TV2ImDjA0K4d9HZj4FwpN2UCE4gEMFExIgmQEW6GYxTYnRN207uVtVvBRSRKCMyEkIEaFphQ1rUdEEM0MQF/Ptg1OZCCZ//+r3Od8zmvV3Jyruvf63vONzkP+uCd3/8PwNgWFMNaa9+tqj55+9NV9VNV9Z+995+b1mIAAAAAAABwuhZ6MuwJ89+31jZX1flT2QgAAAAAAABG8rghQ733A1X1nJF3AQAAAAAAgFEt9DaJW+e9fVxVra0f3DYRAAAAAAAAlqQFxbCqev6819+rqgeqatPo2wAAAAAAAMCIFvrMsJ3TXgQAAAAAAADGtqBnhrXW1rTW9rfWTrTWjrfW9rbW1kx7OQAAAAAAADgdC4phVXV9VR2sqidX1TlV9fHJNQAAAAAAAFiyFvrMsFW99/nx64bW2uumsRDAUnTkIxsGza172eGRNwEAAAAA4LFY6Mmwh1trl7XWHj/5uqyqvjXNxQAAAAAAAOB0LTSGvbSqLqmqh6rqWFVtr6qd01oKAAAAAAAAxrDQ2yS+tap29N6/U1XVWntSVV1Vj0QyAAAAAAAAWJIWejLs1x4NYVVVvfdvV9VvTGclAAAAAAAAGMdCY9jjWmtPfPTN5GTYQk+VAQAAAAAAwEwsNGi9q6o+01rbU1W9Hnl+2NumthUAAAAAAACMYEExrPd+U2vt3qp6TlW1qtrae//yVDcDAAAAAACA07TgWx1O4pcABgAAAAAAwLKx0GeGAQAAAAAAwLIjhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMSaWgxrrV3XWjvRWrtv3rW/aK19s7X2hcnXhnn/9iettftba//WWls3rb0AAAAAAABYOaZ5MuyGqlp/iuvv7r2fN/k6XFXVWvuVqrq0qp4xmbmmtfb4Ke4GAAAAAADACjC1GNZ7/3RVfXuBH99UVbf03v+79/61qrq/qs6f1m4AAAAAAACsDLN4ZthrWmtfnNxG8YmTa+dU1Tfmfebo5BoAAAAAAAAMttgx7ANV9ctVdV5VHauqd02ut1N8tp/qB7TWdrXW7m2t3Xvy5MnpbAkAAAAAAECERY1hvffjvffv997/p6o+VD+4FeLRqnrKvI+uqaoHf8zP2N17X9t7X7tq1arpLgwAAAAAAMCytqgxrLV29ry3W6rqvsnrg1V1aWvtZ1prT6uqc6vqc4u5GwAAAAAAAHnmpvWDW2sfq6oLquqM1trRqnpLVV3QWjuvHrkF4gNV9cqqqt77l1prt1XVl6vqe1X16t7796e1GwAAAAAAACvD1GJY7/1Fp7j8kZ/w+bdV1dumtQ8AAAAAAAArz6LeJhEAAAAAAAAWkxgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAADjUkV3AAAgAElEQVQAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGLNzXoBgGm658MbB8099+WHRt4EAAAAAIBZcDIMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMSam/UCMAv//r4tg+Z+4Y/2j7wJAAAAAAAwTU6GAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCzPDBvZyWt3D5pbdcWukTcBAAAAAADAyTAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAseZmvQArx4PXvHHQ3JNf9c6RNwEAAAAAAFYKJ8MAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWHOzXoBTO3Ht1YPmVl9x5cibAAAAAAAALF9OhgEAAAAAABBLDAMAAAAAACBWxG0ST37g5kFzq/7wspE3AQAAAAAAYClxMgwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiDW1GNZau661dqK1dt+8a09qrX2ytfaVyfcnTq631tr7Wmv3t9a+2Fr7zWntBQAAAAAAwMoxzZNhN1TV+h+59uaquqf3fm5V3TN5X1V1YVWdO/naVVUfmOJeAAAAAAAArBBTi2G9909X1bd/5PKmqrpx8vrGqto87/pN/RGfraqfb62dPa3dAAAAAAAAWBnmFvn3ndl7P1ZV1Xs/1lpbPbl+TlV9Y97njk6uHfvRH9Ba21WPnB6rpz71qdPdFhjkM7svGjT327vuHHkTAAAAAABWumneJvGxaKe41k/1wd777t772t772lWrVk15LQAAAAAAAJazxY5hxx+9/eHk+4nJ9aNV9ZR5n1tTVQ8u8m4AAAAAAACEWewYdrCqdkxe76iqO+Zdv7w94plV9R+P3k4RAAAAAAAAhpraM8Naax+rqguq6ozW2tGqektVvb2qbmutvayqvl5VF08+friqNlTV/VX1X1W1c1p7AQAAAAAAsHJMLYb13l/0Y/7puaf4bK+qV09rFwAAAAAAAFamxb5NIgAAAAAAACwaMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACx5ma9ACxnX3n/pkFz577mjpE3AQAAAAAATsXJMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABizc3il7bWHqiq71bV96vqe733ta21J1XVrVX1i1X1QFVd0nv/ziz2AwAAAAAAIMMsT4Y9u/d+Xu997eT9m6vqnt77uVV1z+Q9AAAAAAAADLaUbpO4qapunLy+sao2z3AXAAAAAAAAAswqhvWq+kRr7Z9ba7sm187svR+rqpp8X32qwdbartbava21e0+ePLlI6wIAAAAAALAczeSZYVX1rN77g6211VX1ydbavy50sPe+u6p2V1WtXbu2T2tBAAAAAAAAlr+ZnAzrvT84+X6iqvZX1flVdby1dnZV1eT7iVnsBgAAAAAAQI5Fj2GttZ9trT3h0ddV9byquq+qDlbVjsnHdlTVHYu9GwAAAAAAAFlmcZvEM6tqf2vt0d//0d773a21z1fVba21l1XV16vq4hnsBgAAAAAAQJBFj2G9969W1a+f4vq3quq5i70PAAAAAAAAuWbyzDAAAAAAAABYDGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxJqb9QIAzMae69cPmtu+8+6RNwEAAAAAmB4nwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYc7NeAAAApm3D/j8fNHd4y1+OvAkAAACw2JwMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQa27WC8BK96VrXjBo7hmvOjjyJgAAAAAAkMfJMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAECsuVkvAAAwK2/Ys37Q3FXb7x55EwAAAACmxckwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMQSwwAAAAAAAIglhgEAAAAAABBrbtYLAMBYbrjxeYPmXrLjEyNvAjB9G/e9a9Dcoa1/PPImAAAAsLQ5GQYAAAAAAEAsMQwAAAAAAIBYbpMIAFNw7d+sGzR3xR8cGXkTAAAAAFjZnAwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAscQwAAAAAAAAYolhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEEsMAwAAAAAAINbcrBcAWEkOXXfhoLmNL71r5E0AYDwb9/31oLlDW1898iYsFxfdvmfQ3J0Xbx95EwAAYCVwMgwAAAAAAIBYYhgAAAAAAACxxDAAAAAAAABiiWEAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWHOzXgAAgEwXHrhy0Nxdm68eeRMAAABgJXMyDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGJ5ZhgALFFX/+26wbNX/v6RETdhMVx2YP2guZs33/1/ry88+PzBv/+uF3x88CyPzYb97xg0d3jLm0beBAAAAFYGJ8MAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABALDEMAAAAAACAWHOzXgCA5euW69cNmrt055GRNwEAAGCxHL714UFzG154xsibAMDCOBkGAAAAAABALDEMAAAAAACAWGIYAAAAAAAAsTwzDACAH3LhHTsHzd216fqRNwEAAAA4fU6GAQAAAAAAEEsMAwAAAAAAIJbbJLKsHH3/KwfNrXnNB0feBAAAAAAAWA6cDAMAAAAAACCWGAYAAAAAAEAst0kEAIAVauO+9w6ePbT1tSNuwmK4aM9HB83duf3FI28CAACwuJwMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhiGAAAAAAAALHEMAAAAAAAAGKJYQAAAAAAAMSam/UCALCUfPimdYPmXn75kZE3AQAAAADG4GQYAAAAAAAAscQwAAAAAAAAYrlNIgAAwJRctPfGQXN3btsx8iYAAAArl5NhAAAAAAAAxBLDAAAAAAAAiCWGAQAAAAAAEMszwwAAgCVh495rB80d2nbFyJsAALAUHb3qoUFza95w1sibAMuNk2EAAAAAAADEEsMAAAAAAACIJYYBAAAAAAAQSwwDAAAAAAAglhgGAAAAAABArLlZLwDw4/zDhzYOmvvdVxwaeRNY3t790XWD5l7/4iMjb5LpVfvWD5q7ZuvdI2+SacOBNw6aO7z5nSNvAgD8f968/5uD5t6+5ZyRNwEA+GFOhgEAAAAAABBLDAMAAAAAACCWGAYAAAAAAEAszwwDAAAAVoRte+8dNLd329qRNwFSfe76E4Pmzt+5euRNAJjPyTAAAAAAAABiiWEAAAAAAADEcptEAGbu5hvWDZq77CVHRt6En+Qdtwz7O73pUn8nYPm5aO91g+bu3PbSkTdhJdm0Z/j/mXdsH/b/NFRVXbH/G4Pmrt3ylJE3Gc979j80aO51W84aeZOl5cDtDw+e3XzxGSNuAgCLy8kwAAAAAAAAYolhAAAAAAAAxHKbRAAAABbkoj23Dpq7c/sLR94EYPm4ad/JQXOXb1018iYAsHI5GQYAAAAAAEAsMQwAAAAAAIBYYhgAAAAAAACxPDMMAFg0f3XrukFzf/rCIyNvAkCC5+/ZP2ju49u3jLzJ0rJ5z98Nmjuw/fdG3oSf5JK9/zJo7rZtTx95E4Dp+9p7Hxo097TXnjXyJvDYnbj67wfNrb7y2SNvwulwMgwAAAAAAIBYYhgAAAAAAACx3CYRAAAATtML9hwaNHdw+8aRNxnPlr2fGjS3f9sF837GPw78Gb8zaA5gqH+66eSguWddvmrkTZi2Y+88Omju7DeuGXmTTMff8/lBc2e+7rdG3gR+mJNhAAAAAAAAxBLDAAAAAAAAiOU2iQDAsvNnt68fNPfWi+8eeRNgqdm490OD5g5te8XImwBj2rr3s4Pm9m175sibsNLs3ndi0NyuratH3qTqtr0PD5q7ZNsZI2+ytHzq5mG3N7zgsvzbG973weOD5n71lWeOvEmmh6766qC5s97wSyNvMp7j7/7CoLkzX3/eyJvA+JwMAwAAAAAAIJYYBgAAAAAAQCwxDAAAAAAAgFhL7plhrbX1VfXeqnp8VX249/72Ga8EsKQcuO7CQXP/y965x+s2Vu3/e21ybjsr3pyTQ1JEJUoqHREKCUk5vCl00uGlSL0VpZKKhJ1QTqUQcj4lYWM7e0l5O0uvopBD1++PcU9rrmc/a615z3kve7V/8/p8ns+z5rPWPdZ45rwP4x73GNfY6t3nFtakR48ePf7/w5vO+GyrdudsfUBhTXr8/4TNTz+xVbuz37ZTYU3mTmx5+pmt2p35ti0La9Lj3wXb/uCmVu1Oe+s6hTWB7X/Yrl4NwCnbTM2aNf99xh9atdt/62ULa9Lj6cAF329X72uzHebuel83HNOuVt26u5WvVXfnN9rVHQNY/X197bEm+ONhd7Zq9+wPrz4i48u3tJPxobVbtXs68KfDf96q3bP23XC0nK9d0U7OPq9o1W483HfEBa3aLbP3ZiMyvt7ev7fM+0d8ivd946x2Mt63xajr+75xRks5W4/I+Oap7WTstV3W30+pzDBJ8wDfAN4IrAXsIGmtOatVjx49evTo0aNHjx49evTo0aNHjx49evTo0aNHj39XTKnDMOAlwN2277H9GHAy8JY5rFOPHj169OjRo0ePHj169OjRo0ePHj169OjRo0ePf1PI9pzW4SlIehvwBtu7peudgZfafn/tb/YA9kiXqwMT5ZEuBdxfQL0ScnpdJlfOVNKllJxel8mVM5V0KSWn12Vy5UwlXUrJ6XWZXDlTSZdScnpdJldOr8vkyplKupSS0+syuXKmki6l5PS6TK6cqaRLKTm9LpMrp9dlcuVMJV1Kyel1mVw5U0mXUnJ6XSZXzlTSpZScfzddVrQ9MX+u7SnzArYl6oRV1zsDR3SUeV0h3TrL6XXpv1Ovy9SSM5V0mRu/01TSpf9OvS79d5o7v9NU0mVu/E5TSZf+O/W69N9p7vxOU0mX/jv1uvTfaWrp0n+nXpf+O82d32kq6dJ/p/+/dLE95WgSfwssX7t+DvD7OaRLjx49evTo0aNHjx49evTo0aNHjx49evTo0aNHj39zTLXDsGuB1SStLGk+4O3AmXNYpx49evTo0aNHjx49evTo0aNHjx49evTo0aNHjx7/pph3TitQh+0nJL0f+CkwD3Cc7Vs7ij26u2bF5PS6TK6cqaRLKTm9LpMrZyrpUkpOr8vkyplKupSS0+syuXKmki6l5PS6TK6cXpfJlTOVdCklp9dlcuVMJV1Kyel1mVw5U0mXUnJ6XSZXTq/L5MqZSrqUktPrMrlyppIupeT0ukyunKmkSyk5c6MuKPEu9ujRo0ePHj169OjRo0ePHj169OjRo0ePHj169Ogx12Gq0ST26NGjR48ePXr06NGjR48ePXr06NGjR48ePXr06FEM/WFYjx49evTo0aNHjx49evTo0aNHjx49evTo0aNHj7kW/WFYjx49evTo0aNHjx49evTo0aNHC0jaqMlnPXr06NGjR48ePeYs+pphPXr06NGjR48ePXr06NEjG5J+ABwHnGv7X3Nanx495gQkXW97vYk+69FjMiDp5cBKwLzVZ7a/O8cU6tGjR48ePaYw5p34T/49IGmJ8X5v+/9ayFwAeA/wfGCBmqx3Z8h4FrBBurzG9n1zQo8kZ1vgPNsPSToAWA/4rO3rc3XqMTtKPacka3FgtQE5l7eQsyKwmu0LJS0IzGv7oUwZLwRekS6vsD2rhR7PA44EnmV7bUnrAFva/myGjH1tHz7RZw3kLAocxMh3ugw42PbfMuWsB2wMGPhZm3EkaXPgnBLOI0lrA2sxus9kbYJKzBFpHOzFyL25EjjS9qOZuhQbT0ne9Gie1/9LQdKSRL/biJH7crDtv2TK6Xx/03jcD1iR0ZvmV+foUpP3bOAlSZ9rbf+xhYzW40nSCbZ3bjMfDJG1NLA7szsU2szj21B7TrbPyGhbzKYpNSZLoeN92cn2iZI+NOz3tr+cqUuRtbYU2o4lSa+2fXG6t7PB9g8byil9f4vMe0lW5zlc0pbAK9PlZbbPaiGjdf8dIms+YI0k607bj7WQ0fk7JTldvteRwK7A1ySdBnzH9h1t9Ei6dF5TSqDg/qvzulJyLJVAIVuk2L5U0puZ/TkdnCmj1fOWtCHwcmDpgblzOjBPjg5J3mttXzjw2S62j8+UU3L+7bTnkbQKcDiwIfAv4OfAB23fkylnIeDDwAq2d5e0GrC67bNz5CRZneby5OP5HLCc7TdKWgvY0PaxmXJKjKUTgFWBG4En08cGcveBnffaY9khFTLskSnRfyVNA26yvXbu/y2tS0mUGpNJVhG7qKsvQ9L7gZNsP9Dm/w/Iam2HSFrD9h3pWc+GJs9c0kdtHyrpiKTDoIx9muqT5JV83p1stMK+ohJy1geWB54A7mpqv0o6iyHPpoLtLXP0GJDdes9T0NdZYm3aBjgEWAZQetn29Ba6FPMLVpibaBJnAtel9z8D/wPclX6e2VLmCcCzgdcTneg5QOMOKWk74BpgW2A74BeS3vZ061HDJ9OGY+Mk63hiA5sFSUtL+pKkcyRdXL2eTjmSvprez5J05uArU4/VJJ0u6TZJ91Sv3O9DoeckaTfgcuCnwKfT+0Et5OwOnA58K330HOBHmTL2BU4iJrBlgBMl7Z2rC/Bt4BPA4wC2bwLeniljlyGfvauFLscBDxJjcrv084wcAZI+RYyfJYGlgBlpI5+LtwN3STpU0pot2lf6HAgckV6bAocCbRbgEnPEd4mF6gjg68CaxNjIRanxtL6km4GbgFskzZL04oZth84vbeYZ4GTgPuCtwNuItemUTBlQ5v6eBlwPHEAcilWvbKT56hpgG+J7XS0p11HYdTy9WHHw/25Ji0taov7K0QX4MbAocCHwk9orC5K+CfwncDNwC7CnpG9kiChp03TqMyXHQYH7snB6f+YYrxxdSq21L5N0raS/S3pM0pOSHmwhp8tY2iS9bzHktXmGGsXub0Lnea/LHD4g5/PAvsBt6bVP+ixHRtf+W5f1ZuCXwNeIcXm3pDdmyuj8nZKcTt/L9oW2dyQOM34NXCDpKkm7SnpGpi6d15Qkp4RtX2r/VWJdKWJDFNzzlLBFSu1LjwK2B/YmHC3bEsE+uWj7vOcDFiEOOuvz5YPEs8rFpyQdKWlhSc9KDrctWsgp1WdK7Hm+B5xK3N/lCDv0+7m6EPu1fxIOXYDfAo0DKysUmsu/Q9gNy6Xr/wE+kKsLZcbS+sBGtveyvXd6ZTnLE0rstd8DHAvsmF7HADuRb49Mif6bAlZnSVoh93+X1qUmp4TdWWRMlrKLCvkyng1cK+lUSW+QpFw9ki5d7ZAqKOKwIa8vNZRxe3qv9oKDr1yUet4lbLRSvqKu+9tNJF0HfIHwD+4JHCvpUknLNxDxJYY/4+qVjUJ7ns6+zoQSz+lQIgFiUdvTbT8z9yAsoZQ9Phq256oXcBTwptr1G4HDWsq6Ib3flN/WAtUAACAASURBVN6fAVyc0X4WsEztemlg1tOtxxA5nwfeUf8sU875hKFzO+GAOQ445OmUA7w4vW8y7JWpx5XAa4hJZ0XCGfbpOficbiZOvG9M12sAp7SQcyOxQbuhLjtTxk3AwrXrhavvlynn2sH+Vn2/Bm13AM4CHgDOrL0uAS5sc1+afDaBjNuBBWrXCwK35+qS2k4nFt+riSidPYBntugz06r5BXgWcFYLXTrPEcPmuDk8790EvKJ2vXHTPlybUw4nNmCVc/l7wOcy9Zg55LPrWnyfzvd3mC5tX8CdwJK16yWJDIccGZ3GE7BPkvFP4B7gV7XXPZm6ZM0F48i5FYKKOl1PA25tIaezTdO1zxQeB6Xuy/JDPnt2poxSa+11wHOBG4gsgF2B/24hp/NYKvFK3+GDhWR1nve6zOFD5Ewb+J5Zckr139T2DuC5tetVgTue7u9U6nul/rpvGg9nEocTRwCXZsopMg4oYNtTzg7pvK6UGEul7kuSU8IWKbUvvWngfRHg/BZyuu77V+z6nJMcAR8hAmDuAnaYw32m854H+MWQz65uoct1g/0kt9+lNiXmvNZ72wE5JcbSacCybfpJaj/WXvtSMvfawNl1XYBlgR+20Gkq9d+LCcfrRfX7Myd0qe4DHe3OgmOylF1fypchwmF+MnA3kb25aqaMTnYIsG16XyVX/3FkTifTPzRJz7vEvr+Ur6jr/vYGYOn088rAGennzci0IQif69rp9YwOz6nznocCvs5Sz4nIfm11LwafVXV/0nsre3zwNdfQJNawge3/rC5snyvpMy1lPZ7e/6pI2/0jQXHRFNM8mhbxL7TLxuuqR4XfSfoW8FrgEEnzt9RnSdvHKtLmLwMuk3TZ0ynH9kxJ8wC7296pxf+uY0HbF0mS7XuBgyRdARyYKafUc3rU9qOSkDS/I8169RZy/mn7sSooRtK8jJPKOwbECN0C6ec2UTb3S1q1+v+KDMk/NGx7VfrbpRgdZfEQsWDk4hFJG9u+MumyEfBIpoxfE07UKk14fiLCOxu2H1TU21iQiCjcGthP0tdsH9FQzCO2/yXpCUVa9X3AKi3UKTFH3CDpZbavBpD0UuBnLXQpNZ4esn1FdWH7SkmNIknSvISkz9h+Ze1XZ0nKpVK7RNLbiagsiGiq7IwjytzfsyTtBZxBHCAB7eiEiajc+v18CPhNpoxf02E82f4aQc91pO33Zv7vQZwt6U22z+ko505gBeDedL087earEjZNpz5TeByUui/3SDodeI/th9Nn5xCZKU1Raq3F9t2S5rH9JBHpe1ULMZ3HUpqz38rsdGyN6cJsP6mg3vtKzv8eAyXmvdZz+BAsBlTz3KIt2pfqvwD32b67dn0PsXbnout3go7fS9IPicPkE4AtbFf23Skp6jYHJdYUKGPbl7JDSqwrpWyIUnueErZIqX1pZTs8LGk5Yr+9cgs5XZ/3/JKOZvb5N5eCenHgpYQd9BxgxfS8cvdwpfrMr2lpo2kkO/8SSR8nHNQmDsvb6PKYgva/2k+uSs2OzUCJufwfCiq/SpeXAVk0VAklxtJSwG2SrmG0Xd80s6bkXnul2hoA8CfgeZkyYAr03xo+3eL/TpYuQHu7cxLGZCm7qIgvw7Yl/ZGYv58g5tPTJV1g+6MNxXS1Qz5BHFCfTt6+ZDYoKPxmENnGkvRX4N22G2WHTcLzLmGjlfIVdZUzj+0/p5//l5RRbvsCJRayJpD0KiLj89eEn3R5BbVxG9r9EnueEr5OKPOcrpN0CsFOVl+bGtHl1lDKHh+FufEw7H5FuvGJxEDfiTCK2+BoRT2JA4gIkEWAT2a0P0/STxlJQd2ecNY83XpU2A54A/Al23+VtCztqLGqzvgHBc3L7wlj/WmVkxw2S0uazy3qLNTwqIIP+i4F1/DvCErAXJR6Tr+VtBgxaVwg6QHi3uTiMkn/BSwoaTOC8zW3lsQMgt6z4n7eiqA+yMX7gKOBNST9jsjYaHSImTbr9wIbajRH8Z22n2ihy3uB4xV8uhBRcLs0aagR3uZ/ArdKuiBdb0ZE22ZB0hbAu4mI8BOAl9i+T8GJfzsRVd0E16U+820idf7vRAp7LlrPEYqUbhORGu+U9L/pekWCvikXw8bTp5o21ghP9zXJ2fJ9Roy/SzN1WVrSKk682pJWJjJ9m+jxUPq/ImgTqvTyeYjn1MgBVfj+Vv29/mxNxqZDI3UxfkfMET9OMt5Cw75XajxJmm77QWB/DaFFzDzk2xf4L0n/JNaoLG5rjfCHLwrcnhwTJhxbbQ5IWts0kzAmu4yD0vflFuAK4ApJ29n+JfmBGqXW2ocVtZ9ulHQo4VBaeII2T6HEWKrhx4QzbibtHIQVrpL0dSIT8B/Vh25Y22LIvHdi+tU0Gs57hedwiOyTGyRdkvR6JeGwmBAl+69G6qncKukcwtFngtrt2hxZdPhOSZdS3+vrtofSnNtev6EuJccBlLHtS9n11bryGPAYGetKKRuihk73pfC6Umpfelaay79IUECbsIdz0fV5n0Zkcx/D6EDCXFwNfMH2ceng5xDCAfXyJo1LzL9JTgkbbWZNFwgmjAoGcoN7DgTOI5yNJxH1pN7VtHFhW+RDRD9ZVdLPCHuoMS1m4bF0UObfj0K115b0WkYOJZ5HBDncnCnu0pr/y0RJgEuaNi64byq2Z6+CwtqitP+AbnZnkTE5CXZ9Z1+GpH2IPe79xDy8n+3HqzUPGPcwrKAd8pdkl62sIXTyGYfUEMxZe1UHJApa4RnAOg3bl3reJfb9Rea8gnPndZKOJTI+30LaWyQ/XE69z8OA19m+M7V/HjH/NaY3LLznGebrfFeGLiXXpunAw8Drap8ZyD0Mq+yzT9LCLzgWlB9kNLWRHGEHMlJM+nKC/iEr4j1Nmm+zfeqEfzy+nKqgpIDLnV+ctYgeSdZQrmPb/5spZ3PCCbU84ayfTtzj3NohneWkyWI9YlDUHTaNi7xL2oA4eFiMWBCmA1+sTsEz5Kxs+1cTfZYpcxPCyDgv98Av9Z33EJOPCF7zY3IjCzVS6LXqwzfktB+QtTCRMdmm9tN7iLF9cdJlE6IY5HGZcuZJB6nTITKzMtqOe2jm/OLW3yWeyWyRI5JeY/uiHHmp3UrAdEddtqZtpqcMtaH1lZrMn4qaTWMibbSeNiQjdCw4J1JX0huIw9yqrsZKwJ62f9pewzxMwfs77mbU9oRRlKXGk6SzbW8u6VeMNviTGLfJkmyFNGePidwNdRebpnSfGWMc7GH7/AZtS9+X622vp4h2+zbwMeK+tIrA7LjWrkhEPs8HfDDJ+eZA1s947TuPpZqsW1ygyPsY82fWvDlJOnTSJTnbNyDmiF+4YdHvkv1X0ozxRTUrBi1JRADZE7T4TklGke+lMkW2i42DJG/Qtl8UODTHtp8Mu35Oo+t9KbGulLA5a7KmAS+zfVW6np+gIcstFN95vy1ppu3seoZD5KwwuDeX9MqWUeZd9Ci65ykFRTbWy4g572rb92e0LW2LzAusnnS50/bjEzSpty1toz2LWAsArvFodqKmMmYCryCyaa4m6PgedtSEzJGzTZIDLfxfJVCy/yqy/o4gaubMRzjK/5ERKFfaf9DJ7iyB0mNpQPZKZPoyUruDgWOHjR1Ja9q+fUiz+t8UsUPSQeV6xEHubkPk5NiMP7O90USfTTYK7fuLzHkF5TwD2B1YiyhvdFzyES5IlDpqKucm2+tM9NkEMiZjz5Pt60ztppTPaTIx1x2GVUgP/1+2/95BxuUeTQmU235hgobnSQX1zurAuTmGUgk9anKqU14RKdorE4bb8zPlLJF7uDhZGGtiznQerdvlgKcm5/pBR1zbjVGK+ljN9gxJSwOLPJ2b75Ib1SSvM3WTpDuBl9v+S7peErjKdhatVYpuOI+IeL8493BwMpDmq/p9aXR/Ja3hoPYa6gB28yj+4ocJkpYh5plKSO6h+75E5NNDhLN7PeDjTRzvk4HUh9dIl3fYbpR1UfAZlXQePYOIGqrWlUuBb+WuTVMJyTG8fG4/q7Uv8pymEkrP40lmq3FQGpJusL1u+nlZYj5f3/ZCDdqWXt92Bn7kWpCHpM1tn50jpwQUFF1H2M6N5J40KCL5VmP0evC0OXXnxrFdoZTzvYAepxJrdZWBsgOwuO1t55xWI0gHHYu0cAgUsevT+rQjsLLtzygKsy9re8Jo6qnWf0vMn6VtTkk/t71hTpsx5HTd9x9EUHt1oqCu9ZdVbB+sCGZ9dpP+MkTWHJ1/B3RZm3A61nX5bsO24wa6zKl5XNLLmX1v2/Q7lbTrtyMyIy8lxtMriKyY05vKSHKqQKO9CUrVQ+v21tOBqTbnJZ2uIzLcTgPWB95J+Gn+aw7oMg9wvLuXCek0Jkuh9NiW9EJGDmKvsD2rrW5dIWlpj9Dw5bat7svOwEKMzhR6wPb+LWTO0eddas6bjP1tF0g6jng2VRbrjsC8tnd9OvWo6fMksR58ovJzDrNnx2lfcm16DhFIsBEjwXL72v5tUxlJzmLEvLsSo9fbfXLkzCZ3CviBi0LSC4DvAtXDux/YxfYtLWR9kuDXHKSJaTpQS0XXdNJjHLnrEdkNe074x6Pb3QXcSDiqz809TNBIqvhQtOnUkp4ZTfMPP9NJ/LKEgXOy7Vsz268BPB84lNH0HtMJQzT3sPFAwtBa3fbzFPz3p7lhBEjt0HMomkQpDNmoPvUr2m1Uz2OEuukp6hDbh43ZaHYZFwFvdIraV0TdnGP7tZm6LAhsQRi16xGFfk924tVtKGM1gp5o0KDIvS97EJG5jzBynxvfX0nftr37GNEk9tMYxV/TaUsiXXw5wimwIlEcOHcczLL9QkmvJ2g2PwnMaLqQD8h6MzFG688q5yB2IYKqY8V0v1cjxueEzm5JR9veo+szKuk8knQMkfpeRSLuDDxpe7botXFkfNX2BzRCkzEKzqCAKDieWjuGCz6nK21vrBGal6d+leQ0iiKtyVuaoPUY7L8T6jMJDsfOh6jqGF1bk7OsazUpFNHZL2/i5Bvjvjz13uK+/JXgid/BKeo0c9NRcizdRhRV/xXhjK2+U+PoxCRnSSIjsZ7pc7BTMEqGnN0IirjnEHbjy4Cf565NXebwEmO79LhOMhcgsvcHv1ejzLAk4xvAd2zn0isOyuka9T7L9gsn+mwCGcXGQZL3PeA/CZtzJhE5/2XbX2zQtrRdfyTwL+DVttdMBxTn295ggqbF1qaavPWB/QnbrO5QaDRHlF5XSkDSp4kaNT/M3ZMOyOm67x8WtNhmTWndXwbkdJp/JZ1qe7ux9pU560ra276KsPPOAd4IXGm7Ea1grf8vQOyRZxF9bx0iI3bjprokeZ1tEUknEDT3NzKyt3VTP0Zhu34WsJlTNliyHS/MmYNTuxuILN+vEDVZb5V0s+0XNGhbZJ2chDmv8x5D0nW211ct20PSVbYbUZeW1CXJ+SlRn7N1mZCuY7Imp6v9UGxsK2gS92CEgm1r4Gg3rMFeyg4pIWeM/l8TkT0OSj3vOb4vLSjnDbbPSz8vCnyZyK69Bfig7T81lDM/4at6ikmLyNRsHDAqaSfbJ2qEjnIUnMd6dhMR+L8usL3t/1NGUEPhtekC4HuMHBTuBOxoe7OmMpKcq4jzlJsJ+6hSplOG+txYM+xbwIdsXwKgKGh3NA15tgdQbUjfV/vMNK+rItsPK+jdjnCKrpkDegyF7esVdBm5eB5R7PjdwBGKonjfsf0/DdtXxbQ3IibkU9L1tsSGtTEUEQ4nkA4/Jd0PvNMZB1q2N1XUotqO4COdDpxi+7MNRawObE5QjmxR+/whIvU2F1sTk9f1Sb/fKw77mmLz9F71l3qUwsNNBNjePL23KUA9DM+x/YaOMoZyFFeLRtNFwvYjRI2OU9MG83DgMvK4gWcQjsKvAJsCuzJ6oWiK/YDnO4Piow7bu6f3Tdu0H4Ski2y/ZqLPJsBniA33hbbXlbQpESWerU56fxNxCDZLUvY9lnQUEVG1KcEf/jby64/MIOamKvL4t8Th+YSHYbb3SO+dnlHhMbnBwAb54rSRzkE1r3ypgD6lxtPVkjZo4xiunhNx4D6K2is5rZvK2Ti958zZ4+EkYo3cnHDs7gI0ijKchHn8SOIQ9Zvpeuf0WeNDVODrDImubaHL/0l6BwMRYsQGZFxMwn35FXGocbqkg2yfRl7/LTmW3lhABkSB7cuJjG4I++EUwvbLwb7ExvLqZGutQWYh+q5zeIk5eBLGNcRzvwN4PXAwcY/HpfAZgk2BPSXdSzjvWx1+0n1cliiyXXIcAKzliGzdkXD8fIxYxyc8DKO8Xf9SR7bFDQC2H1AEdE2IUjZEDScRtucoh0JTlJw/Jb3H9rG163mAA5xJiUkEKy0MPCHpUdofUnfabxdcU1r3lwF0nX/3Te+bj/tXzfA24IXADbZ3VVD6HdO0cdX/JZ1M0DPfnK7XBj7SQp8Stsj6xDzT6gC2sC0yzaNpEf9C1IjLxQeIupNnpIOwVWhY76vUOjkJc16JPUan2rCFdYEIwPqZoh5VqzIhdByTNXQaS4XH9m7E/PmPJOMQ4Oc0r8Feyg7pLKdg/69Q6nnP8X1pwbnzc8ShEUQg9x8Im28b4kxhq4b6/JM4SMsZf4Oo5pMS+4wnbH9UkTF8haR3Mk6ixCAKr01L267Tw39H0gdayFnA9tCDwi6YGw/DFq4OwgBsX6qgK8xGgQ4gSRsSG9z3pM+y73kp43rgpHkakRWTnbqbjL4LiILzmxK0KHslZ+rHbf98gvbHJ33eBWzqFFWeHB65FGhHM/vh57fJPPx01Fj4WorC+ChRkK/RYZjtHwM/lrThRN+9IR6zbUlVWmtW/3XicZW0kUdnk31cUeA3JyPmx4RT7Me2Gx2kjYGrJL3A3aibfpleFX6c3rMXDQXP9faE4/Ba4iA0BwvavkiS0v0+SNIV5Bcy/yUNDyiHQcHJPiZsNypOmZz9CwFLpQPCyjCfTmR45eBx23+RNE3SNNuXJGM0FzMlnQ+sDHwiHQhnO26IbJF1UjTfpyUdRn7RzlVtby9pB4gD1ZYHc63pVAbk/AezR3Xn0N48KWlV279M8lYhs9i77ZnpvTUnfA2lxlMJx/BVxNo40WcTIjn2nsXo55RL47ik7WMl7Zvu9WWSsu95gT4DZQ5RsX23Uu1GYEaK9srFjxnJNm5F1ajINj7M9jm1z46uHYw2hR3BRZsA308HAY2DK0qOJdv3qgxFzBK260W1Pyup0aZwAI/aflQSkuZ3UB9lURtTZg4fa738G3CzM2qrFBrXAM+1va2kt9g+XpHJlFuHstThZ9dx+VJGimwDrADcrpRR0mQOLrymADxDkc26FfB1249XdnUDXUrb9Y+nflPZ9UvTwp4pZEP82Zk1nsfRp+u68hpJbyX2yEsBxxHBaVkoeEi9pjsEw6S/L0FDVaS/0HH+dcq+dpn6II/Y/pekJxRBp/fRLqh3jfpe0vYtkl7URqECtsgtwLMJB2onFBhL5ymyhb6frrcnggCyUNmZtet7gMaMPQpK2ptcoHZpkldiziuxx9iZsOveT9ToWp6RYKGnWxeA36fXNNo7z0uNyVJ2fYmxLUbvZ58k47CxlB1SySGYcUbZly1s4E7sCDWUet5TaV9aTA5BtV/1t69ogjp/AzoMy57+G5EA8lk3YNWw/a30nhsMNFSlJOtUSbcS68IKrQR1v7/3S9qJkbVpByJYIxcnSNqdCERvTUM9iLnxMOweBc1BPRUvq9aSpFfbvngsR3NTBzMdomuG6FTCuK4vlk8APwF+0EKXJYn7ujNRvHNv4EzgRURUSNPDu+WSTlUnXoR8x3vnw09JaxJG47YErebJwIcz9QD4o6QvM7vRlkXtQmQsfQtYLA36dxMHfLlYWNLGTvR/yaDMPRj+MnFvviDpGiIS5OzBzWIDbAy8S5Fu24q6qVocJC3sFPHTBkmHG4nssP1ayno0Gfx3SXo/kbW2TAs5nyAOCn/B6Im96cajilhehjgAvjhdb0pQmDWdq/Yk5qvlCOdyZTg+CHyjoYwKf5W0CJFVcJKk+4j5JhfvIeaUexwZtksSEXS5eCS9P6ygHP0LzeeoCo8p6DUrx8SqZDrgNQadCkHrmyPnEGJM3jYgJ8cw2Q+4RNI9xLNekXb3FkkbAQcxYii1oZorNZ5aO4YV2cH/ASwoaV1GHwhPWIdqiLy9ic3tnxhxYpmg/chBRUH4h7QZ+j1BeZSjS4k+AwUOUSkXXVsi23hl4GOKbMJq87F+CzmVw/B+Ba3rIUC2I6jEWFLUWtydkbn/xHTA1zQqtsIlkt5OrJMQEaU/yZQB8FsFz/uPiACqB4g+nIMSczjEmrIhI3b4qwjKjedJOtj2CWM1rFBwXMPI2P5rsvH/SNiPOfis7Z0HdDyBsM9z0HVcdh2LT6HQmgIR1ftrgnLpckVB8EY1wyR91PahwDuUgmDqyLDRKnyNqCO1jKT/JsbTATkCStkQwIEKquSLGG13Zh0wl1hXbL9D0vZEltrDBNVsbkZhpU+J2lidgmE0Bg0V+c+oc39JKDH/VoEEhxB2mWiXeXdd0uXbxD7j7+SzNEAcsh9DBOKa8EfkZtRCGVtkKeC2tD+uj6VcStcSY2m/dLC8EfF8jrZ9RoYORejhkrN9lqQVWgaJ1HUqNed13mPUDoQfITO7vbQu6aB8Edv7TfjH46PUmCxl15cY2zMIFqGq728FHDvO3w9FQTvkCkmftH1qkvthwhZdK0OXEgw3UO55T5l9aQE5yyiSRQRMT4fU1fyXk1l7bvr/30vXb08y/wZ8h9EMA+NCEfyyO7P7kxtTqFNjbElnEBvTMMttQJcSz+ndRPboV1LbqxjJws/BYwSzw/6MrFGdmfLmxpphixOLVJ2z8yDbD2TI+LTtAyXNGPJrZ3bGSmar4s2pbSmO13Vtt6FpHJTzP8Rh4wwPFL+T9DHbjbJAJO1KLDSVY2IT4lk15v5Mi931jD78XN924wEv6WritPo029mbhJqcWcSCO8hl2iZaYjPgdUQf/qntC1rIeDERZblo+uivwLvdovBsMrxeTUzOb8jcAJGcELMhJ9pQkWV5LDGOVlBEv+9pe69MXaa3GYcDMjYgDLTFCFrARYFDnSiCMuRcQ2yUO/HfSjob2L2K4pS0LPAN2+Nmjg2Rs3cLp+mgjIWBiqZmR+LenNQkKmaIrM7RPorgiCOA1xAHewaOsf3JDBmbEY6ItYjs1Y2Ad9m+NEPG7XSgU6nJuRNYxxk81GPImZ+gghJwR1t5ku4goiQH6wE2ft4Fx9MJwxzDg5+N0XYX4F3EYci1jByGPUTQAOc6Cu8mqDraRD/V5WwOXEFEoR5BHM592hmR/QX7zGuIjeaoQ9R6QEoDGSsS0YjPIPrNogSv+t2ZuhxN0E+3zjaWdD3wEsLxuDxhP1zizLqEkl4BXJUiYqvPXlyLDG0qp8RYugnY0CMUMQsTNWKa1gOqan2IcGZU69I04O+5a/+A7E2I532eM+pclJjDk5yzgN2cagAoKGIqms/L3SCSvdS4TrJ2IwLS1iHG1SLAp2wflSFjVG26ZKvdbLuxoyW1KzUul2H0YUS2M7TEOBhH9ry2JwzOkbSF7bM0RmRwro2WZK5B9GEBFznVF8xoX8qGOBFYA7iV2oFu7t62xLqiqJ9zPGEDr0k4XD7kTCYKda+NVQXDnAi8g9HBMEfZXqOhnJsZoaF6YZpjjrHd2BFWk9WpvwyR12r+TW3vJuoTddKhJm8lYLrtm1q0XYDRtUsvB47MDdIsMeelezobcvf9pWy0LqhslhLfSdLFBD3nNYym8Ms9JCw157XeY6hAHfZSugzIyS1hMJG8lWg/JkvZD6XG9nrU/MBtfJ+l7JDkjzma8Is8i3j2H7b99wwZN3mEHWEdRcDxD22/LkeXAZkr0f55T6V9aSc5ycdexzdt/znZBIfafmdDOT/zaDaupz5Tw5qLtXZXEfd3sO81TmBR1Lr/MLCCM2vdD8iZ42tTTZdfEvuvVqVlxpQ7tx2GTSWoQ/HmATlFjGsFBeCyRPbWyc6oqzUgp35q3glpsnlpuvyFg64wp3398BNi4fx0zuFnkrMgMWHcmdNuQMYvbL904r98eqFIhZbtv7VsvyAR0bA9ER15tu29m/5vR82GJYb93hmprYrsqbcBZzoVgJR0SxMHVvrbjzrq9n1tDF1yI307Qy2K744hZ9R9UAeaCpWj8ps+ICMrjVljRKPkbqYGZM5PcA5njwVFZtrLCOP66tzFWNJpwD7VgWVbSDoX2DbHkK61LZX1XJc5Zea9Eo5hSW/NMTjHkXMJUcy8TVZkUXTpM0NkFTlELaDHbcBzicz/VtnGqhUTVtA2fxhY3HZuhOPDJLrd2kHLqL7YUE7nsZTsxQ0q50FyLlybsxErjWSnLc/o9SA7KCfJ6jKHj9qQShIxP6ythoWlp8q4lvQJ4L+ABRmhWhYROXm07U88zfpsSdRbWI5wiq1I0AM9v4WsImuKIktyBhHQcAxRi/fjtnPp2DtjDBv4ISea+IYyStkQWY6ZceR0XleSw/H9ti9M4/FDRNBeVr+p5j3CNntROkj6tO3tG7YfKxjmQeD4praRpGtsv0TSTCKK/yHglqbfZ6y9UoVcOzrJ7Dz/DnP0tYGkdZh9f5Ftd04lJJ9MVX/9GmdQ7tZkdLHrr7S9sUYCWZ76FfnZe0VQ8JCwyJzXBRojmLeCy1CIZkNBF70a4dOrHzjmBu7NVWNS0uHAKbbb0DTW5RTb20p6H8EE9C9aZD9XuiiC97ch2BFusZ1db3mqPO9S+9KS+9uOeswi6t39Il2/BPh28ts32l/UZN3oEbrGtvqcQpw9vDPtcRYkAoSy5HZcmyq/6xEMzzbO8rsq6iO+3d3K9syGuY4mUdL6xAZxJUYP9GwKE0Uq6TuHyGr68LoUb66jCMero3jus4n6SEcnWafYt/bD7gAAIABJREFUblQbq4bVJH2E2e9Lowi8CpKqyI/q4Op5kp7nvMyPRQefhyLq5toMPbYgClzOB6ys4Cc+uIXT/fAUYXA+o+kSGm06NDoiu4hBqxrHsFKJI2dwDKfJ9KVEcclvAJfazuGt/x5RYHMmI9+tQnZqq+3faHSpphyKriqiMStafxjSPLM/s2ct5c4zl0jaAziLbvy3l2qEK95EenY2JasKUFJI2pOoS/cIYfhV/Tl3ztqKiGLpGjU0D/BmavOVJJxRZFgjRd5/UsmUdKDzeJ2L0KkQjs8bFfWOcqk1NyGoNIcFUpgWdXiIPvzF1DZ73oPu46nuGJb0ICPzzGNERF4OnpPWxocIKon1aOdAvYcYlz9h9H1p1O/GMh5rcnKMyC59pq7TPMDrGRlLr2kxljYnomEHqUdy17cStZKeysCx/Z3kUH1fCzl3EnbdpWmuuIrRa11TdB5LjKaIEfAWWlDEwFNO1E60Y5I+QziZ72E0rWBje7HEHJ5whSKL+rR0/VaCPm9hInO+CTqN6zq67DFsfx74vKTPlzj4KjAuP0MEi1xoe11FPeHZ6AUbosQ4gDhUOVxBXbo0QQU8g4zaxAVtveuJA4kHiHu7GEExdB+R1d/ELi1lQ1wtaS3bt2W2G0SJdeUlTkwNtg0clhweuehaG+t44Hh1D4bpSkNV3yutwOj+8r+QRw9bYv5NuC7tB39ES2pNSccRWbCjMhJpaHdKOtX2dhojUyd3TJawRSRtR1r7U/sjJO1n+/QcXegwlmxvnN6L1M1TGXq4N9n+2IDcQ8ivB1iKhrL1PF76sKvgmrIEcShSH8tZ+7iuY7Imp4hdr8he+Tyzl4XJ6XvXAwdIeh5BNXuK7ety9EgoYodIuoCgjVybyFw+TtLltj+SIebstK58kfh+JgJ8slDwea9MlMhZifZlYYrsS7vKUdR4vj356xcEPk7s+28DPufmgXe7Ec92kXT9ELBb2l98vqGMCmdLepNr9axboEite7rd38rv2mb8DcOTSZdLWugyJua6zDBFOt9+zE47lr2YKdIUrx4iqxE9hqJg3YuIA4Gv275M0iyPLkDfRM43CUff24nI5b8DN9puVeMlyXwB8FFge9vzZbadRTiRBtM3cymBzqpdLkDQFc3MOVRT0BxtYft36fqVBD1cTjrqTMKYuNQjUeI3tTCsP0/Uafglo6lHcjcdRaAxOIZtvydDxusJ50ZuXZjikHQ6UcPs64TTZR+CEvPtc0CXIvOMon7ZIHI3HZWsbYBXpMvLncEVX5PRmZJC0l0ETVenNGaVixo6h6AnGHxWjQ+yFFm+ixE830sSDrXLcoxZlYuU7EzbJGll27+a6LOGsoYdumbNewXHU2fHcLVGp7nvfcAnCUrg3CyfocWwm/a7sZ5zTU7O8y5C9VVoLN1NRDbe3GaeUcFs4ySvRNT89bbXSxv5Uwh64ne36DOdx1KSU1HEAFzhdhQxnWjHanLuBF7gTFquARmd+12SI+IArKqpciXwg5x+2HVcD8jqtMdIMrYGLq427Mlh8irbP8rUpeu4vM72+ml/sK4jgO8a2y9pIavUOKgohQ4n7PszlB+hW2ptOoqoH/3TdP06os7aqcDhbhCBXtCGuJ0IemqdVZvklLBFSlH5nEEcdn6A2M89ADzD9psy5XyOoEb6a7penKC0yq7XpW40VEcRLBjnpOs3Aq+1nVXPusT8m+R0Lhsh6TZn0rcOtF/W9h9UgHY/yes05yUZs4hM4fvS9dLEnjnXz1NiLLWmCR9oU4KuebbM+JZ+lZI0lJ3mcZWpm1fUT9kVXcdkTU7nsZTkXEnUZP0KEbS5K+GrHmp3TSBrCcLeezuxvmRlURW0Q7aq22OS5gU+YfszOXJq7buwI5R63p3LwhTcl3aSk3z1L7T9hIJ+/2HgdIKi+IXOLzeyKNFnmwbYDZPxEEFT/0+iPlubQI2riO/ws7Q/XRX4fq5NXmht2tb2aRN91lIXuwV71aCEuepF1NIqJev6ju33IQpjngNP1de4oqPMlQjuzjZt1ySifW4lonPeCyzTQs7MSXp2yxMDNadNlQX2bOBNhNNm+UwZv0jvN9Q+u6mF/ncA8xW4D18iDiS6yrlp4H0R4PxMGdcBexHUUV312YY4zDoM2KpF+6WAk4jC9fcR3P5LZrQ/CzhzrFemLsXmman0IiLml+0o4zxgoQK6/AC4G/gWUdPna8DXWsjJHstjyNkeuJ+Izt1oTj+rjt9ltrVtsub1hvqUXLe3THPol4DN2/YX4HBg6/TzDaX0+3d+lRhLRMbqtA7tz07vvyKi3X9Ve92TKetg4DdEVPcl6XVxC53qtsPChIP7iTn4nNYjDrL2BtZrKeNmIkjpxnS9BhFhmyvnB7SwM0v3u6n4GjYPt5Bx45DPsuerAuPywmRjHkFkqB9O1NGbk/e3ygK7iwgMe2buOldqbQKuG+uzYc9wku/LisNec+gZnUIEZt6Srhfsej+IDPgtabEfGzZ2mozTNOeO+Wqhx2z9dFgfaiCn8/xb8FkfS4G9bU3edCI7ZglgiRbtO815ScbNA9fTBj97Gu/v9QPX8wK3tZDziw46vDfZDv8Abqq9fkXUjp5Tfa/zPE7sR9ecCrokOc8DLqrNnesAB2TKKDImS4ylJGdmer+59lkrvykRYH8YEaB+Vsn+9HS/iKy7eWvX04kgzVw5pZ536zliQM6CRPDLnLy3t9d+HpxDG9siRD24Y4Fz0/VawHvm4Pd6HeHr/zPhO/01sOkc0mWYzyl7/wPs2+Sz3NdcR5MIHCjpGGKBaJXKX8MJknYHzqYFhZntyoFb4V4FdUgjpOjeMX/nfMqQGcQmdTPbv89sW8dZkvYi0o+7ULsN4rdEGnFj2L5W0j7EhvdR4rv9OfP/3iLpHcA8KSpxH6AN1/AsInskmy98AHcA307RIzOIA8I29b4eSe8PS1qOSKfPotggImp2Ba6VdF3S53ynGagpUnbjc4n+B/Cfkjaz3ZiSypFptGPO/x3Al9L7NsTh6YnpegdikchBkXlG0jMYXSz2UuBbzqgjkeS8jHBCrUnQfc4D/MP51GMlKCk+AVylqPHWJY25OqjsinMlvc4d6oSkeWFfwrGwJrBzijCfkLdYhfj8VYAiRlFH4/nAohpdN2w6NUqKhvrsZPtESR8a9nvn0YaVGk+fJzZAJ6WP9pW0kfOyxWZKOp+YKz8h6ZnUIt8a6PBV2x9QZD4Pe0659C4XEBmS9Uj1k22/vkHborRCFBhLhOPzHEmX0Y5m7gvpfU1nFtUegu0JKolOUfOuZZrY/gewnaQVmrYvOZYkfQrYlpirBMyQdJrz6bA70Y7V8HngBkm30H5NKdHvOq2Tpcd1Qqc9RsK0IZ+12dt1HZdvIWzODxJ22qLEYXNjFF5TIDK5X0Qckj+sqPuZy6hRak/5f5I+BpycrrcHHlBQgI67vhS0IaY7KAkfytR9UE7JdaUTlY+GZwjfnN4XAXL3pfOk+e6fSf6CwPwN2h02zu9MPi3h/ZIOIPYpBnYi9nC56DT/qmzNj+OBn0v6I90yEutU7JVOJp+KveucB3CeRijqIcZ1Y2qrQnb9IE04MFI/sqkuNXShh/secC7R7z5e+/yhnHWt1JxXQ4l5/E+2b5/4z54WXSCoWPcjAkaxfZOCxSTH1isyJikzlgAeVdQ8v0vS+4mEgmVyBCjoOLchDsFOAT7jjCydUnZI4T48L0F/vivhvzoivXJR6nl3KgsDoI4lagraIbdI2tX2DGCWpPVtX6eg2czxxX2H8JHun67/h+h/c4Sm3vb5Cuazqtb9vs5gbCq0Nr2RSFT5D0n185DpQJu6y7sQgXZ1vGvIZ1mYGw/DdiUiWJ9BBz7UhMcIftb9yTC4JppIieyYJihqXNt+WTLsGztpxsAu6X2/AX2yDNEB43oasWmd1bDtoENiIeBvwLGKWhI5jom9iWf8T8KQ+yl5xkSFZwF3SLqWDtzWto8BjkmOp12BmyT9jCjEeEmGqM4cw7bvBvaX9Emi9tdxwL8UvMOHZxi3mwBrV4doko5nZMPaCKnNvgNO4cPckKbDKX1b0mdsv7L2q7MkZdVBodw8c2SS8c10vXP6bLdMOV8nDi5PIwqAv5M4fMzFQS3aDOJbRF2qUenzubB9fDVf2b6zgz5XA2ckA7tVujmRVThY5P1a4mBpXLgcn/++6X3zDjJWT+0XY3TdsIeA3TNlLZzeh32vrMNyyo2nNwMvcqprmOaMG4gD2qbo6kA9Ib1/ady/ao6l6xs52w9Iaro5LNFn6igxlv6boHpegNgE5eJw4MVEwEoWDeEQ3EKBABZJCxD95vmMPlRuSiFVciztQNDUPZp0+wKx/ufaNL9N9sOPgAskPQC0CaI6nqAW6rIelOh30G2dLD2uoeUeYwDXSfoyUdPVhD3bpi5q63GZDnR+bPu1xDPOormpoeQ4qNqsRcx/Byf5WUEflFub3kHQP/2IEYrOdxAHstuN17CgDVGqhm/JdeWxZOdVe4NVqe2fGmDYd6nQ5oDkROAiBS2giTl8wv5su3Gga0PsQPSXM5Iel9OuBl/X+bdkzY/jiD1Op70B8BHg+TmOvTHQ1RbB9n6KwLKNiT54tPMo6juPJReuH0nUCYdYI5/6NzTwOTkCd/8G7JDWhWcRvsZFJC1i+3+bKFBwzqtQYh7vXDevoC4QDCzXDMQO5DqYS43JzmMp4QOEP28fIhtqU0Z8jhMi7c//TrdSDUXskJJ92PYnFDWbfkFQAL8y+edyUep5vyDJeTW0rkV5EBG8eimA7RsVtciaopQdshtxuHcAwf7zc0m/IVhDcnxxS9k+NQUn4KBdbFViRmPQ1JNXa/ki268h1bof+KwJStzf3xO2w5aM3pc8RATONUIKlnoHcWhaD5J/Ju2ChEbDcyh9b7JeFExPJ6IKlmrRbs/0fuCw1xy8N1sQhd5/la5fRCY9XGF9dqm9diSDeow4XBnzNYe+TzFdiA3yWwijaybwMcIhf3JLefMDi7Zsuw7B33wnken4UoLjPyd9+IfUaFgIWpZcSsxh9CVt6IBuB1apXa9MLU26oYwi8wwwq8lnDeRUdDs31T5rRVGUns1r088LAc/MbF+EGqnUfEVQqa1DcDi31WX6kM9Wy5RxQpPPGsg5pMlnE8jYsMQzSrJmm7dz5vL096XG003U6HII+pw2lLeLE0b6K6tXCxlF0vnT/L9C7XpFMukFSvSZ1KbEWMqmehpofzURfXcfNfpUWtCoEs6e3xEBMK0oc5Oc04iN+y8Je+Z8IlgkV06JsXQusFjtejEStWSHe74J7WnHLuvyv0v1u3rf67JOlhrXqV2rPcaAjIWJbMnr0utzwMJt700HPc6kpY05RFbncZDaHEkcEt6erhcHrs2UMUcoz8bQpYgNUVCfErbIZsxO5fOqOXyf30Aceh8GvD6z7QJEsNQPiezcDxD1XXJkzAN8sdB36Tz/JjnbNvlsAhnZFMRjyClFxd5pzksyFgbmST+vntbJZ7SQU8pG62y7FnpG7yccy7cSjvebaWeLl9o3dZ7HCbtz8HXcnNAlyTmXqP14fbp+G4miLUNGqTFZYiwVmfcoRPlfyg4ppMsr01j6BBHUch6wXAs5pZ5357IwlCtRU2rufCbwQiLY8lkt2l9K1JSvxuPL2q6/dKCpT+2WIJJLFmeESnglMn2dpV5t1sSB9isCryIOBDepvdajRh/a9jU3ZoZdLWkt27cVkHUrUUgvC7a/lSJiHrT9la5KKAoMf4hwiO2hlgWGGX4Kv9Kc0Cfdn81s75T7/2Eky6cE1IGGajJ0SlG+WxDZNZ+zfU361SGKwqtN5byP4Oj+q+1/SlpI0l62vzlh4xEZM4G/Emm+H3eiDiHStTdq0L7K4FsUuF1Bv2fiQC2XinKapMVtP5BkL0G77NYPApdKuiddrwTskSmj1DzzpKRVbf8SQNIq1AoWZ+BhSfMBN0o6FPgDI9FNjaGgbNqDWDhXBf4DOIoowtkUl0jagzi87UKjehDdooYq3EVwqrtF2wpPpOzIUUXek+ymGJVFpqBBfXELXTYjDsfreOOQz8bDDWl+GJXJ4oxi6DUcwewZOsM+Gw+lxlNFCXQJEaX7SvKywopEZCXsQpl0/v2BKxP9CMR3yp2vSvQZKDOWLlQ3yrvNgdcSz6NNBkwdJbKWAJ5re1tJb3FktFYZ5rkoMZb+Cdya7BoTz/7KiqLCDWmtUobGb9OaL2KdXIjIZsrBTAV96Zm0pFOhTL+DMutkqXENLfcYdThoOT+eou7/3kFU13H5KHBz6nf/qOmXS48MZcYBwEsdhcNvSLo8kJ5/DoqsTWlNmq3/2s5ZV4rYEMl2v9H2PyTtRNzXr7ph1kYNndcV2xdIup72VD7j9onMeabC7UTNxwvTvumZtptSS36XiHquKKx2ILJKt236z20/KamNbTgMJeZfCDtqsNj9sM/Gwx1pbRzcG+RmxJSiYu8650Fk7L0i+Q0uJAIStief0r/zWOpqu07EauQ8yrsPEH6hrlH7pfZNnedx27kUu5OmS8L7CBrMNST9jqjLlutTKzUmO4+lat6TpI623tWSNrB9bQcZUM4OKYEvEX7K2wBSNurFxCFJDko97xJlYUqVqOk0d0paLPlJH6IhO9kY+BCxzq6qYPNamjigboMuNPV7EvPvcgQrSIUHieCwLKhMGZaVkh2yFqN9To0y923fC9wLbJjxPxtjbjwM2xjYRdKv6MaHCuGUvjFtYrIMrjSpb0lk1HTFDMLp8/J0/VvCAM09DHvC9t/UnI590vRJ92dpSfO5Rb0Ozc7B+9SvyKfPWcrtaagmg9v6FsKQXcmRAr8C8Ox0KPaSDDm7235q4kvfa3dGKPmaYFvb99Q/kLSy7V/Z3masRjWUpBQ6jNgAnU7c5+2I1Pws2D4vLbyVEXFH7ZCvKUrNM/sRh0f3JBkr0pxaq46dCarR9xOHfcsDb20h531EH/sFgO27csZCwjvSe/0QwuTT1Qybr9oYyH8gDj/PpT2XeTXnVQtx4zlPs/P5V18oi89f0nuBvYBVJN1U+9UzgZ81lZNwAhHZ9XqCPmpHRuhwmuqzIbEGLD2weZ5OGEs5KDKebH9f0qXABknGx2z/MVOXfVP7q21vqqiz9ummjUun86f5aj1GnIUfbOosrPWZVQv0GSgzlt4HfFTSP2lBeZe++8mSbrfdZeMCcL+jtmtXVLzyf5W0NvBH4vCoEQqPpTPSq8Klme0r/ABYX9JziWCYM4mI1Ddlyqnqqb2s9pnJO1wu0e+gwzpZelwntN5j1PR6OUF/vQiwgqQXEuwUe2Xq0mlcElQsP5nwr8ZB4XEA8Lgi8M5J/tLkH3qXsvU+Uvt5AaLfNaK0GmJDQLeaQEcCL0x95aPE+D6BiLRtok9nW2TIIdYf0vsKklbIOKwpWk5A3QPCVrf9wtr1JZLarFM3pHnmNEYfLuc6LTvNvypb82NBYgy9bkCX3O9UhIqd7nMeRLbyw5LeAxzhqK92Q+PGZe36TrYr49PD5eI3BF1iK0zCnNd6HlfZunmddBn4v/cAr5W0MDAt48C+jlJjssRYgqC1/7GkLvPepkRd+l8nGVn3dxLskBLY0PZTgdK2f6iRAMkclHreJcrCdCpRU3DuvD/5Db4P/MAZ9eXqsH29pE2IQGkBd9rOqTlWR2uaetuHE7SPe9tuU1duECXKsMwg2PG+QozPXRlObT0Uk+BnH4W58TDsDQVl/Si92uIqSV8nCujVJ/XciKxOBYZrKHUKX0qfXwM/SwZ//f5M6OBwOR5piBpYK1RRkZJWZA7xAidsQBj4ryYc1Q8RjqkNHHzcTTGtHmGTnAK5UbGnM3sUzOk0jMxywQw+29+VdB1xXwRs0yaySlHfZS/CIDVwhaSjnGqsNESpeeZKokBmtXje0VLOUily4lHS5kdRnDSXU/qfth+rhrMiCi/rAMp2m+ytYSg1X/0qveajPZd56znP5fj8ixSmTiiRyTIf4YCdl9Gb5wfJj4bqNJ6GONZ+m96Xk7Rc5prbJSILoo/+AViK0Y66hwgaxzaYH/g/4l6vpaiL2aTOYck+AwXGUsF18kFFFvVK1GzZzM1Yqaj5oxWR4QckWYsAn8xoX2ws2W5br2kQ/3Jw3m9NZI0ckePkq+lTopZOiTkc2/cqMoNWIjb/d2YEY03GuO66x4DYXL6e6HfYniXpleM3mR1dx6XL1PgsuaZAUKeeASwj6b+TjAMyZRSx9WwPZrH+rKkzq6ANUeEJ25b0FoLO9VhJu2S0L7GuFDnEKjS/1NE1IOwGSS+zfTWApJfSLvBkCeKQvX4fsp2WBe5PkZofSZdSmTVP2B6rJntjFLJFlJznOxJ1QyHPt1bSRutku9r+VvrxiMH/rXxWjnuIAJaf0CKAxfbnJR0CHON2jBWD6DKPV36GEnXzoNCaoqhH9EXgEzU/z/W2G2culRqTBe36EvPeGzvqUNoOaQ2lbE1g3zFcDlkBYQXn4APbNpR0gu2diYD9/YkDsTYoNXfeDnyVyOI+VNKVxMHYj20/0lRIId8iALa3Tj8elILlFiW+axM9qkSF39V+rsvOPfjE9t2S5kkHsjMk5friFrR9UfJJ30t8ryto2I8mwc8+CnPNYZik6bYfJAy0IijgVKgypw6uiyWfbqlrgeEKnU7hJ0Gf36fXNEYWnFap0WmzUk+9zKH76ERDpaDrGxMtDNoS1C4Qz/dUSUcR9/U/CZ7hCZEiyp4PLDowmU4nowB5qdN8SdMILuG1GTFM26IzjQkt++kQ/DwZrk850xSUMblp+N+WtIvtm5OMtxMb1bMy5VwmqYrG24xY2LNkSHrnsM9tfzdTlyLzle2cyMix0HnOcxTA3ZKYXwAudR7VrW3/WkFvOAqSlsicZzplsiRlLiP6y3eScdMFXcdTyejw1hFZUD6dPzkEtico1eqFiic8DHNkVj4EvKDAMyoylsZy1Dc83KvjR0RGw1m0jw7vnLWU1qYHHfS9l5OfAVt0LEnanKhftiJh47eNnHs8Hf7vQtA2QxR8z9XnU8M+t33wsM/H+NsScziS3kxkefySuC8rS9rT9oSbzPq4TgFTqzlo1BYkom2z9x6lDi5t/2bAUZJNtdx1XKbgmy8RjqSVJb0IODjncHpwHEh6Znzcjv7R9kkKqu/XEM97K9uNMqBrdn2RPeXAPmEaEVD27Ewx10hatAqKS+vUq2znHqg+pMi82Al4ZQqUazy20///G2E71/dfiyjoOpvsv450FJtfxQPsE22gcuUEugaEvRR4p6TqHqxAUMTfTEZ2QimnZdf515F9PUvS99w+yr3SZQbDM2tyDzuKULEXskX2JVgwzrB9q4Lq/pKM9iXt+k62aw1nSXpj8qkhaU0iK2DtDBn/m15dAqf+pcheLYEue4ztCRaQxRxZF3NSlzpuJdaS8yVtn/pKVmB6qTFZ0K4/xvao4AE1KMkx8D/vlbQxYaPNUGSEL5LRvuTetitKZmsWe97uFuj+4mRDv1vSdxnos03nvLodkuaJV6RfXUEEjzbF48lOODvZ81sQmVDfkPRT2+8Yv/lTKOFbBEYdGD51ryWdQLBbTIQtxvldmyzAEvTyj6a98l2S3k/U6s5hYCvtZx8t350p+KcGJJ1te3NF2rEZPbjshryUAzIrWaPQRlYXSHod4RReiyjMvhGwq+3GBlfa7HzB9n4F9NmMiK6s6/Mu25dmytnW9mkTfTaBjC0JR+hyBHftikSBwOeP23CkvQh+7UcYoaH6ufM464f2OUacUFn9RcGD/nKi0Pd6aSE/3/a6EzQdlDON4I6tHAHnE4bGhI4SRcToVkQ0YJ0S6CGinlqbDJ1OkHQSEQGVW9dgUM4sj6YxGfrZBDJuZuQZLwCsTESZN+13zyboV04kqJeqvjMdOMp2Fg902oCdTkQnbkykMW/uvEzCqs+8h0ihF3EAdYwzFgoFlUSFBYj+d73tpzWiqqZP51odJeY8RQbKS4gi8RCG0nVuGOldco1T1Bb4AbAOkb6+CPAp20dlyPiq7Q9opC7gKOQ4QbuOp8mCgvJgUeA8Z9L5qgzPNoo6kes4n8q1LqPT3Fn4WdcP1xcgxsTMnPGY5PzC9ktz2kwWJF1uOzsbZ4iczvVLJd0NbEMUaW9t4Etaiwig+bmDfnRlYHvbX8iU8+Ha5QJEzbfbczbfJebwJOcOYl28O12vCvwkZ71VjUbN9qrJ6X6U7Zy6mpWsznsMBW30lwkqk5cRGdTr2357pi6dxmU6dHo1EeSxbvrsZtsvyNEjtVubcCJUG+D7gV1s35Ihox5AlY0h62z1nNra9XV5TxCZjgfbvjJDxo22XzTw2Q0t9gbPJuzOa21foaBif5UzA5bSAeiXabH/UspgUGYmwzjyTiEyl95pe+3k1Pr54P1qIOdQok7yO4mArL2A2xwR7E3arzje75s6Vws6qTvPv0nOakQEfquaH0lGnZJ2AWBr4PfOpJlLY2kQbcZkEVukCybDd5XkdrFd30zQp76ZYC35LrCj7Rtb6LGwo65lK0j6BvAdd6z/1GWPIek2ItvoTOBVtHTel9BlQE41h25HZFi8E/h2znxacEyWsutnWw9y1whJBxJ0bqvbfp6k5YDTbDc6VCu535lqKPi86wHu8xHBNI32t5L2Ad5LBA7+jo5zXpK3ByOHPFsDR7shReBYNpSkRYkAqkZBayV8i7V2o/p88uHfbHutDBlVJlcnJJvmT8Rz/iCxrnyz2kc1lLEBkYG3GBGsuShwqFMGfYP2Rf3ss8mfWw7DJgOSlqxdLkCc7i5he2ik1ZD2w9L4/0YsEFlGRdKlOqy5Ouewpibj4lJGXiF9Six6s4gN+IW215W0KbCD7ZzMrpm2ixQrTqfXqzF6s5AVQSFpRyISaT3geBK1S84hYSlI2tD2zzvK6OSUqMm5mKCQvIbRtJpZhomk7xAevCCSAAAgAElEQVTOqzqNyS7Or7FRl7keUadjz4Z/vwvwLsJgq1MvPAgc7xZpzJKeR0QE/oZYwBund9dkLExQbTyZrucB5rf9cK6smsxFgRNaPKfOjuHUrj62n6rVYfujDdtXB+YP02HOU3Bav8j2v9L1PMANblfPco5D0ottz0yb7tmQO+8NyM4dT6+2fbGGUAIkXRqPJ0mHA6e444G/gtJ1Np7tpk61mpxziXHQKjsiyeg0d07ys16eMIp3yGz3DmKtPZ9MikOVLRSPpE8SATWDlNi5TpLZNmW5zu50cPSaap5pC0WG2Tld5QyROz9wZuYBX6c5vCZn1KFlmtsvc8ZBpqQbSTRqBQ59Ou0xkoylgMOB18JTQU/72m5bx6ySmzUulQ6n6/1V0k1t1jcFBcv+TgF/kl4FfM72y8dtOLucUgFUne36Ehh2P9v2vdR2OqMpZnPnq9b7r2TfzQu8iIjkHoUW9uJ1ttcf6H/ZjiiVCQhbnKhHWL+3WdS7pZyWQ+Rmz7+p3ZWM1PzYglTzw3YXuqxpRN952g6fxkMbW0QRrPpRgkmlPj80DSLY2PaVkhZwCzqtJKN41LykrYjv9UyiJMFdme03JDL3F7HdupZlOohanSirkV3/aRy5jfcYpZ33XXQZaFef655PULutYHuxDroUGZMt7IeqTtcHiDmmwnRg65x5PNlo6xJBuNm2yGTud3Kh0XUah+nSdT0o9by3Al5i+78y2hxp+71d/m+ScxNRU+0f6XphIhCm6fP+iO0vFdDjO3T0LapWK5HwOY2qMe8Mmux0gHQ6MMPtSspcZPs1kg6x/bHc9pOFybDH5yaaxHEPUHIN0dRmcDP51WQQNt2orp9eVcTEm4FricKOp9k+tImQqkNSK05d+ywHnQryDrnHrQoeq2xB3sdt/0XSNEnTbF+ioJXKwdWSNnD3yKPdCMqE5wA3Eo7zq2heeBnoRu2S9DjV9nYaiT4alJ9jRN6toM1bidEbu8ZRhQ6qg1mq1WVriSJUSYymMTEpmlWZNCZ1OApnbpDx98cDx0t6q+0f5P6/CkOe8RJEBsovFHWFcr/LRYRTrXK8L0g417KcUAN4mFi4crGUa4VMHXShObUbqnata3Wk9pb0I8eB+U8mbDA+FmMkfX/RNgIUNXwudguqpLGc/xVyDgFq9/U64JGBQ775m8oZQ3bWeAI2IQqqb0EtWqj2nnO4fD1wgOJw+QziYKxVrQB359mGGD83SrqI0Yc+OZugTnNn9awnaRP4W/Lodyq8gKCMeDWj6SObbOrGox5pEyFWrYd1qiOTT5nYqX5pwkeBc9Icl12ro4a3E0WYf0BsphrbIBNgITLvS9c5vHZIfqukc4BTifu6LWGT56BzXc0KBfYYEA7pHdv8/wmQOy5L1fgEWNg15gvblyYHRy6WJZ556wCqUna9ggbtJI8O7tnB9jczxFynqJP4DaLP7c3oOk5NddmToO9/hJG+22a+6rL/ejMR8HcC49McN0UR+v5kx3w7vbIh6TNEoNsvGX1vs5yNg/sCSd8HLmyj0wCy59+ETjU/xsBqBI1kFiQ9gziceIpyHPiWO9I40s4WOYkIgtmcyKTeBfhzRvvDCcrUq8inx68wk9mj5is0HtcKVo/6WjadqP21d9pP5ticX6VALUu6138aipw9hu2vAV8r5bzvokuFdIjxlL3poOjcmGD06YJWY3IIcsdSyTpdj6V9e7UWZNkO6SBsHqKm1U6Z/7s0tiGYwRYHHpgE+UWet+0fSfr4xH85qs17AdStzA3EvFfPgHqS4XPhWHrMdhAmaRnb92Xq0Zki2WXrw65D7OOOSfPFcURA+YMN2y+bDoS3lHQyzJYR2yTwdGh2ZU1GbtBTEXt8EHPNYRhla4YAsx3+TCMOtnJ4W5cE1nOK6Fak7p5OGHAzgXEPwxTF+BYClkobpzqV2nIZelToWpiy1D0uVpCXqHmzCFGr4yRJ95F/oLYpsKeke+kWebQvEX1/te1NFXW3Wjkhbd8B3NGmbdIDwjjvih8TUZsX0qIORQ2dnRK2L9PoWh0LEQc/uXgDYVhU/MKXE7QojTFwqDCN2MTkbIAqvDgdbNcdJB+23bTIe4lnXMcCrmWg2P57us+NMbD4TSNoVdpkNZZwDA9GTbat1VHiwPzzREDCJcQc80qi1kAuDrR9RnVh+69pbWlSN2Qyio92PkDtOp48Ep18C7NTW/1N0ovcMBu7dlC9BJGBckjqh7kHuiV4tiGcCWdO+FfjoNTcqeDuP4jZ61HlUCXVHS7TiMyAWbm6EJHyqziTAgjAI4XiVyGyaOrzbxvH7JoeiOpO9lsuOtUvTfhvYiwuQMtaHQC2d1JkjuxAHOSaoFT9vu3GdZQGAjbmAZZmdB3dJjK6zuF1Dv0/EYfnEHPM4jm6UKCuZoUCewyAqxQRoKcAP6gHkGTq0nVc1mt8fp/IqPlMG12AexTZliek650IWsFclAigKmXX7277G9VFCu7ZHcg5DNsb+CTxrCHW2aa2Yh0fAZ7vFoweA2i9/0rz9tWSXm67je08iIOImsjLKzICNyKylxphSGDZKGTsB7cDVm2zLk2AtgdHw+bfNuOyU82PpMtg7eg/Am0izo8kaLmqsbNz+my3TH1K2CJL2j5W0r4eqTWUEzT0uIIS8zkakgXS5ADK9soZ/288DAZ9ZR+01+ECtSzdsf5ThRJ79lLO+0K6/EvSYdRqEycndy7VbZEx2XUsuWydrlMlfQtYLK2x7yYzuMH2k5KWljTfJMzlOXiQOOw/k/BVdkLB511nYals1yz/jMagWSaybHMwgwgAr/wiWxFZqU31GMysFVGfdV0i2KxpZu0bmv7PBvivdI83Ju7rFU0CnutI+7RvA99OgQjfB76ioFb/jCemOfwU8HHi4GkwmLKpz79zxt0AivnZ65hrDsNsd54khuAwRgb3E0Sadk4hvBWI1MYKjwMr2n5EUpOItT2JlOHlCKOkinJ/iKgPkAV3LMhb6h57pCDv/xH1GrrQ8OxDRM5/kKiXtChDKDcmQKnIo0dtPyoJSfPbvkPS6oVkN4btP6T3e2F2KpRMLOQy6bGdJyvVanUAqxI1t44iPyJgK2LT9ENiTJ1A8Gw34hdOqDusniAyhtpkeL3RtbTy5CB5Ew0dHLVn/CXgOLdIhR7APyStV0V8KOipcukW64vfE8C9tn/bQpcSjmEYHTVZ1ep4T6aMzgfmjro7lxILuYCP2f5jph4QhucgGo1v26WyK+vofIBKufH0YsIoP5O4x62ysROeC6xBZMW2GVc7E8/q/cT6tDxxuJYF28crIt5XsH1nCz1Kzp3HEt9lJu2DI+oOlyeIw5WfjfXH42AWkWmZG71XxzqePfs0q/5OwrCo7uxIb9vnpQOSio71gy0c1kvYfl1mm7H0eVCRGbYgYYtuDewn6WsZ62U9YOMJ4E+2cwOWOs3hXW3fAXw8/e+bCRv9HOCYlrLqB6/VHmO7HAG2V5P0EiICdH8FrdTJtk/M1KXTuHRQKe+fXl3xbsJmrAL1LifjYKOmU4lM1lJ2/TRJsl1Fq/8/9s473JKqzN7vasFBMgg66pAVEJGgZDFgRlFU0gAqEhQwAD8UHUxERVDQAZWkIiAowUGRISM5JwkijILOoKMCDgIShMb1++Pb1afuued2166qvufc2/U+D09zzr21e/cJu/b+wlrPITNZ7ZAB+jdJC7uBbC7RtVRb+rrE5sBTjD1/ZSW6gSUkfYnx6hO5nVQXKhQ1irVzz8y1cyvy97qDuJPm96U2E0dtrL8Q6/+CxJn7ICIQtkPOALbbKsZa12Nl036ukOzMpY29SNGN9keF19b/EsHDqmxGFJO9kYbJJ03QeWX7iirXu+SN03TPCdwvaSPAqShsDyLQnYVK/k9E0Ht+wmu7kv9TicZnjBaD922ddy5UyKn+R3FfyaXF72Rb+/qlJX2DXsEdkFWMAFGQczGRSFqF8MO+qMZcfkeoEJzN2CLuXJWFJhxDFHmsyNjXuIgH56ostPV+lwvMir3r5pljHEzcr8fILOdOxPYRKbayMfG67Gj71owhHgL6E7AvIVRiKr/GLSRxy3yLiEH8MD3eTdJbbH9sNteMIe0x30nsnZcnzhunEI0A5wIrz+5622cCZ6bCtG+m31+AjKRnS3vwMnMlzj7tPMPUYvt8quzdgrGbdNuutNlPH6D3Et01EIvH2cQH8jhXlDaR9EXgGykw8QUiwHKQ8zXIT2RAFbQrSt6pRV+WNN4PiKqW2jI8ku4kkhmHEQGbQwnz8A1ne+HgsZpW+5xFLDp7ERvbh4H5bb8jdy5toAmkUJxXxX8wcI3tc+fCFLNQS14daqgvnK55LfG6PFt67lU1vpO3Ewe7v6fHzwNucr6R7i7EZ28+etX7j+SMkcZZF/gRcaCD6OjbxuNlqmY3xhcIw+P7S899xPZxNeazFL3gxrU1AsOtoAlM0atsftSyhK+k7xGdjGWppCVsfyhjjFbM2dNYVwOf6EugfrPOGtwUSRcAW7jXjb0w0Y39XsKrc47mswqZp/cRAcPTgLOc0W2hlnW20wH8a8Bzba8gaS3gQOdJfbW1dl5ve/2ca+YW6fCzBpHsLMsB5rwutxESow+nx0sSHlKVXhdJ/0wcmn4AbMfY7v1jbK9adS5pPBFB5RVtHyhpWeCfbd+QMcZXCBnVC3P+7gHjvJu4p6xE7LFOtP1ASnT/yvbANbF0fes+Jk1pc90bRdL98ghge9tZnZ+SPgD8xKWuP0mb2T6n4vUrEx1Hy9MgqZHGarS/knSV7Y0HJBSKIpY5mryXxmplXy/pq8Rrc0ya027A/bY/mTHGRkTitakPz9qkamrqS++2QlqDj6GvwCJnz5nGGWcdMOi52Vx/i+1XSTrZ9gdy/u6+cdYhzvx3UvO+1CaSvgsc5VJnvKT9be8/hLlcQsQczi09d5wzPL7TNbcQPqr3pscrAmc6w2+8LRTemlcSxU5HEff+A2xndfNLWtNRKNxkLuUO5QWIPd/NuWtwS3vOVrws1dD/qU3Ugkd9y/N5jFCbmEkUJdS5v7XynWwLSfcA+xDFRrMK5XMSDSlu9a9EMuN7wAV1koUpETsOz52i0jnNpS1/rbbW4GXKMZ703D87o8BXPZ/P24C1Hd2ON9her+L1rZwxJH2KWKf2sX1Heu63bq/jNhtJvwRWLz63iq7sO3Jig5LuAy4Fvus+D3RFQWOl/Z6imHYPxkoTXptzX1GoVww6e2Ulc+dWnH06JsO+Q1SOFBUuHwCetZ3VPp/GOp8IOt7C2E16ZRmdtDF+DXGTuso1vEeKG7+iVfzLRDLts7lBKTU0Z5d0gO39SgGFMb4sNQOphQzPjmmsLBmelMg4lOgIWITIeh/qjG6zFPQ5nL5qn9yERN+YryeqJM/3kFqsJf2aSPrUTiCkzdaCRIfjM2RutgYEI8aQuWkbY9Cu8Oq4JXdTrJANWddJ1kqR9L4xJzAs6QkiCLu17T+n527JPYxJ+jQhF1p8p3YizK1zOljK461CfJe2Ba4mOt4unf1V48aYn6imEnC3MwsJFFI5DwEfK/7umq9N48BwGude4Ku2jyk9d47tyhKTgwIkVYMmClnEiXCNg+pChFRS+ZB5sFNyt+IYrZmzq50E6jpER0GTakAk/QpYs1hzFWbxv7D98qr3Okm7EQUaK1LyPnPF6lpFZ8buRICvnCApxslNft5MbPouq5vIanHt/AohtfQfjA30VdEOn0iGqpYssVowt5b0QUKq9Mw0t62BL9k+ebYX9q7fgfCHWYe4HxTv9aNE8ii3QOhoIgDwxvSZXQK40HZlP4lSgOTv1Lhnl8Y5DfhW+XOvlOCV9Cbbl8zh+uLwM9DHJOcQ1MYanq5pvO6l4OdBjJcKzXp901iLAx9kfAIpZz6LEv+OfyUSl2cBp9dIJvyVqO7d1qkwLee+3VZSI43Vyv6qbZrs61MwY1d6XsAXAt9xKeFXYYzrCf+Us0v3gjttZ/kcKeTKr2J8wPHECS8ae32xry/OgLN+RH4w9maHH2st1LMTuBR4A4wpSDjP9ssrjnMn8FVCGmif/p9XXctTEOtYxr+2WRXSLQYtf0/sx4+wfVJ6rs5+fJD3xyNEt8Kx7pMJnmCM+4D7iWKNAxrM5U3Emek+4v1ejugGyD3rtLaWN0VRTHA08ELbq0taA3i37YMbjLkMcJjtrG6LNvacbVEEx9VLVmcVr07wuZ2F8xJ8jYL3pXHaLBxZkpBQLRdy5+yB2/pOtvJdUipkyblmgnEEvJWIh6xD+MR+1ymBnjnWQjnn61Gmxff7GeLctJPtJ+uMI+liQqnpEGApIv66ru1KFgt9Z4xB+5CcM8a/AF8nXpv9gNtyrm8bSf9BKIMU6k/LAV/JWcvTGDu5ZgNMaZw76EkTrqUkTWh7m4wxnl96uADRib+k7Rx/5P4xW4uzTxuZxBJttc8D/IvtRhqgtm9SmOktAKCSB04GxWHpnUS18U8l7V9jOjMkLeGxVdCVPwNu0ZelNGZTGZ5niM6n5xGv8W+dL7t4EC206pbJPfjMJdqQQlmMSEisUEpIvKjqxU4t2ZIOJGQ+TiY+N9uT741xudrx6mikL5y4hzg4XyZpZ0fVRWXDzgLbhym6w4rExkG2L8gdB0DREr1q+u8hQkZsb0m72v7XimN8sO+ptRXGyTk65H8g2uXPkHSm7a9S47Uh/AD+QRzKDiTkYX9M3JRzeAbYRNL6RBX100Q3Rw5jEuPpta4UwHHoGs8gEtN1ZCP6x3uckOpqMkZr5uy2b0ybo9oJVKKIYVw1YA1OJXxIyt3YP0wH6KpSh88CP6evCorqnpht6GyXmWn7EY31XsitYmpr7SwKcNbpm0uVf1Or/oZt3GNtnyTpJmL+At7nDKlZh4TlyUQC4ZSm8wHWTwGfW9P4Dyskhirj9mRQXubxCeBNCXnX2SbC0jzarKpsYw1va937BtE5eofduJrwXOA6mq17txF+kQfavrbBXArpyTMVnSNnkHffnmn76AZ/f5lW9ldt02TNSeeSo9N/TebQ2IeHeK/2nvOvTTiHNr1Hfybpo0QSt1xgUbVztC07gd2Ic8nijJWAIo1XtbDhIdvjvJ9qsALwGYVXbdGJsM7sLpiAB4gk4Slp/dyTet+l+wi/sUK2aRvCf3FlwpekSjfdX4lk8JEpSfH+GvPA9iWSXsbYPWcV64l+Gq/lCg+rDzM+sZFbHHw8sQc+Nl1/u6RTCSmxuvweyEqUJxrvOdVQiahEU/+nNj1rBnkkZqtOER7axxBdvrW92BWKMHsy9qxyDXny5618J2lvX7SfoqnhEsbeD7IKy2xb0p+IuNNMwhv2TEkX2f50lTEkbUjEhhYGandijxhtvd93Eh2xV0naOiUZc+8rmxPx21oyy8UZI8VXascp01i/B7ZSdMVeRBTYZKNQC1mPWC9vdD0rDIDnA79KhUsQca9rFZKdVZP4K7gdG4DG0oQe3xH8DUlXEfGSWrQZZ5+OybBnJa3kse3zdW8210h6pVPbZC4a33G0LHA3+frCf0ibgTcDhyqq3Qf5xsyJw4kv0xnp8VaE2XourfiypEVnJ3oyPOu5JMNDSA7MiRsJSYp1icXjWElb2t4y49/zjO2/SJohaYbtSxVSWVOdfYnPcBMplG/RTkLibR7byXh0mldOB1QrXh1uri+chvE5ipb+0xTSdXU3gL8iDh8XS1pQ0iKu2BlZoDDSfTcRxP+ye91Th6Y5VqX8vi5AbJpuIdOU1/b/pKqNo9N687yc6xONA8OJJ2xvo+jCu1LS1lR8ryTtCxRJhEfpbfaeBirLPjoqCL9Gyey4Lunw/WniPlKuBsyuKixRy5y9xCrAamk+dRKoDzpTVmYQtg+SdC697/Zu7nVjV5IlJuQAahu0ugWd7T7ulLQd8JwUANqDOPDm0NbaWds31C3pqatFCbQ0r7uo5wlXXP8PhSRxG8mwZ1KivZDGWJqKSRJJq6ZDysDKTFeXmNudSJaumAo1ChYhuo2zSXvhWdLlrii9V6L2Gj4H6qx79wN3tpAIg/BbrJ2USKyYAj+LqJmXlG3fku7bP0yB8zlKLaonVdM0qdE/l7b2VyNBWrsPoXefBLJlYlrx4QEulfQRoiCi1nuVAlC3O7MrbQCF71S5GyvHp+PfgX/XYDuByslh21cRgb2bbOcWx5W5WdIhxPk4q3u6j7aClrL9KPAuRRHt5UTQMZe1bZc9qX4m6Qrbr1N0w1Wdy0zgo5I+RHQnLlFjLhBxiOWJONaaNfac0M5a/lMiKHwxDRIbhD/3DX0JqCxvN0lH0VsnZwBrEcUSubSx52zFj9X211IBVy3/pzYDpsRr2e9Rv3CNcdoqHNmTBmeVRFvfybb2RTsSBb3z09v75hQjIGkP4r7yEHHO2cf2M+me9Wvi/FyFbwBvI9ZybN+mCXz5phBtvd+2/W1Fs8nPJH2GjD1aOuf81Pabife5Ulf6BLQVp8T2zxQdayvlXpuS018k4nACjpJ0oO3v5Y5FgyRRiUYNMCV+r1Cx+AlwkaSH6SkBVaLvXDqDyCG0WVTViOmYDNuH2OiPaZ/PGUA9OZ/5gB3TWH+nF2ypKufTVsfR1sDbga/Z/qukFzFAxmFOOKqgf0N8CP9BJAHqVJI+H3iVe74s+xHtsq8jKvOqJji2Ar7uvupj209Iqlo9tHMp2PknYHOF90EObVX7jBrHEotyk6rjthISz0ranpBTM/E9yDo4pKDjiYTPgYF76m680sE093BaRmmcXyv8LU4g/GvyBolKt48ASxI335cQFWM5lV0Qm/PNbc/q9lBPUqWyhIPtT/TNbzEiUZ3DTWmsp4j182NU7KLqo3ZguI/ivTpMIf9xAfF6zxHbhwCHSDrE9r41/u4yjc2OE6cQXlabEdXMOwAP5gyg8TJHdc3Zi/X/DUSQ71yie+Qq8hKorVQDpmtuppkReVsGrX8i7il1O8wKPkFISP6d6Hy7gMxqYUdXwvHkVdSOI60H+9FLbFxOdKRU9ieUtAFR6PJy4LlEwP3xqkksJwkVt9ud0JSLFLrzpzHWaDs3EXAkkUx4gaQvEZJon6947d7EvaQs411eZ6p+7k4FziMC9+UO1MfqJDYU0prr0ksW7inpNZnrae01vG8u5QSqic6GqoGRgk8D50q6nLFrVR1T9ZPTHuAc6ieQXqHoTlySUAd6ENjB9p2Zc/lj+rsfkvQ2Qn68SqLjZsYqRdRKavTRyv5qxDiBWDu/DmxCnEtzK6l3I3x4XkJ0fVwIVDZUL7Fd+rP8Hcx6r9J+/DbVUzspj9NWB+mWjqrwjYG3EOvg0fS6mavO57sp4bg8Yzt9qu5nioD/BuVhyb/vl4OWO1A/aDmryMj2/opO6DoJ+KXL77Wi+n6p9LOqEkWzZG5tfz/FWrI/v2m9W4nYVxXnSJNZtEc7a/mCbsEbFnhI0kr0zjtbktbkDMo2HDMJy4k6BSyD9pwHZY7RViAW2xcpimfnK8bK3Yu0VIywSdpLzwre9xUMVaWtwpE2ziqtfCdpb1+0ppvLcS5FqDyMKcBL96wshQq304k9SrT1fhd7tKsVsrWnEUnMSth+VtITkhbLOT9OQFtxyoJXA+tJerHzvJf3IYpG/gKzpAGvIXzrsmgpiX840RAxxgagxlzem/53f4Xtx2LA+TXmUjCTkGTfOncuc4tp5xkGoOicqt0+r9DmnJD+BXY247SiL9wWkvYEdiEqLETIwx3vanKE5XEa+7KUxlqOkOO5WNLzgPmc2RXTFEVXzT5Etrqo9lnT9s6TOY+2kXSNK2rvzmaM64GNiHbfV6WExIU573EaZ3niEP8aYlG+GtjL9u8yxngncSMv2rFXIFrWz8uZy9yiTlBAYQ68HnC9G2izqyUd6AHjzk9U/1byXWiTlDzdhqjwPZEUGHbIN+WM866+JOFyRLCwcjt+qijbjmg7P0ihxf8iZ/iXqee/9yw1zY7TODfbfrVKJtKSLrc90ENpbpM202sCt9peU9ILCS+Ufqmh2Y3xA2Ij/UtK1YCu4UPZFLVk0KoWdLbTOGs7v3O1f4y29Px/TMhjlD1Z17T9vowxbiL8jc4gCnM+CLzU9udy5jJKKLTr+3FmoKUYa1V6vkKXOPk3ZVy/NaGhXu6QOMj5nQmtkIJFa6UgUlEReqszPOLaWMNL1/Z7bNgV/QDT9RcCf2O8J1C2qXoqFPkS0QUyK0mX87mRdA3wOff8Od9AdIc32vvlImkB9/kGDXquwfiNki7DpnTfnrW/k3Sl7ddWvP45wB62vz5XJ5qBpJ8T97gbGFsEkOPDsyCRnFnW9kdS0HoVZ3aPqueHeQgh1XVq7nk0jTMw0eIafqpNUHQbXwcUn49rgI8PY0+U5vMOxp+/PgpcBnzY9jdmc+2i6X40sIChRmLjV8BqbhjAamMtl3QwcI1L3m4157IioTaxEbHn/C2wfdV4U5uo5+G7PL0EljPv2Y38WEvj7Ep0ezxJvEfZfkBpnKvoFSO8i1SM4J79x+yuLbrlVwJ+U/rRIsDVtrO6NtvaL7ZxVklJ7UGTyY1ltLIvknQ8USRfW62hLVIS4QhC4WMDokNyHVe0nRgl5sIa/CLbfyw9ng/YKHMvfTrxul7E2P1D1r22aZyyHJdXFKd9jEhUvxX4me2vVBznEmDTUmz8ucC5ju63LNSwaLQ0zmr0bAAuGYXv1Sgy7TrDJPUHZVaS9AixOX6gyhgtbj5GreNoZ2ADJyNIhRTgtVSTIyzThi/LoK6Yf6FeV0xT2qr2GTUaS6HQrFJ9FinptXnudX0cTrxXvwFQVNH9J1HFPilI+rSjOn0iT4DcA/PfbT9dVB6lDUWdA14rkioaazY8g6iiO73itafb3lq9ztox5Byk0u+fougCKALD78kJDCvJhhEys/1JwVyZrnIb/kHEpv9b5LXhN/LfK1HcQ/6YEsT/S6ydlRnwekCYof+3o2110oEAACAASURBVBo5hydTocdMSYsSksC5SYA2qgFbwe1UQUF7HWZHKLrBzwB+ZLuqJFGZtvT8V7K9RenxASmhn4Xt30h6ju1ngRNSQH/K4obdDX0H1Afo+bLUqYL+vO3T1bBDomUWB4p/Q2WJrpbXcDTYYyO3W3NJ22/N/bsnYG8iEfxQgzEWKhJhALYvS3vxSkj6hu29+u79s8hIbFxDJF7n9Nzs5lLsr8pyX2UmNSHRMk+loppfS/o44a36gqoXOyqpNyeCuY1oKwFFviTXIE4guguL5O3viXtd7lzashNYhxqJFknvt/0DSQO7rpzfIbEA0U1bdMd/nwxpY7UvJ3xu+pysSq/QuEh0T5gIS5xKKBn0d5FCve7RO4F/Jr9zqp/aa7nGqit8VtLfib15rdeXKE4+F7iU+Nw+Drw5JdEr7bEmOHs9QnSMHezxvi0TcQrwKeJ1rqUq44Z+rCU+Bbyi4T0S4HkOrzmlGN/+kq4kEmRzotVu+ab7xdI4bZxV/pPe53gBIsl9N/lec23tizYGdkgJwzqKXG0yqBN7qvqFtbIGF/c5YFuN7ZgrqJwMIz57/5nx+xPRNE45f+n/PwK8xfaDCmuL64DZJsNK9/w/ANen2LiJmGflguk+vsn4otGX5Q7ihjYAbTHBvugRoPL9bW4y7ZJhRMJnQ3qanW8gPswrK7Q7cyW/mtCWvnBbiLEtvs9CtkxHW74sENn39QjZu0ISpfLhsCnlah+15I0xYrQhhdIoIVEgaQHiu9nvc5RT5fhAkQhL3EcEDieT4t/eRIatzOWSCk+qtxCfx5/N4ZpBtKUDXTYbnkkkR35f8do9059ZMgT9tBgY/iRhbH34gJ/lyta00Ybflq71wQq5uk8ShQyLEveYHL5NBClvJ77XryTuV8+XtJvzpAFuUuhJH098L/5G/gbwOkmrjVrVkptJFTTW2U5z2ERhyrs1cFxKOJ5mO0cqsS09/yclbezwV0HSa4iK3RyeSN+dX0g6jAhoVQ7ejyKKDtrdKfliAcfarlr81H9ALd6nQsY0J1hY7PHeCRxj+6cKr5hhcQhwawrWiHiNqkoktrmGQzseGxdLemvmGjkRvyTOCE24T9EBWJxt3k90FVSluO5rs/2tCUhr00uIPcza9D7Di5JvQl7sr26a7W9NTfYiXo89iIKaTYgARw5XS/om4+VYc7s+W0lA2b5c0Qle7GFuqFp0WmIlhx/gtmnMJzVBlG0OtGInQP1ES3EPa0u+d2di39lfvDpRId4Y3JKcsKQ32v75gELjFRU+XXOUsra9WfqzLUnMpYC7JN3A2ELPyh2JidpredPXdQDrMNaLfXvyvdjPI+7/p6bHRQfLo0Qytapaw4MudWI3YEmim+EESUtLWsF2zr0JohOx6T0SGhQjOGTcHqGezcksZvNdKv6ebFn40rW1zir9RYip6GjXGkO1tS96e8Pr2+Rwohu3kPpcIj03lO7cJrS4Brd2n7N9YjoLrgqzrE+qSu6Wx2kap5yR3tsZRCztwTTu45KqFAcXr8W96b+Cnw743cpMs6LR4v5W3FfeSf79ba4x7WQSU3XjLrb/nB6/kKiK3QW4ws3NfnPmMk6mTCVpq8kmZWZ3IDLoEJVI3/ds5A3m8nyut72+evIW8wG3TNbrkwLKS9BStU/HxEg6g6g22o5IBGwP/Mr2nrO9kDHdnm8hZL5OJ26cWxE3z0/OlUlPAmlzvjPRji1Cm/07NapSd7V9bOnxq4GPZSYbW0HSCsAfi6pRhfzpC11REjNVhE0YGHYN6bGmqAW50OJ+oJJ0j6TbbK9Z8fpDbX9G0lbOlIocMNaPCOm0X6bHqxGBo4MIT7O1ao67PLCo7azOWoXszUpEEHfY1YCtI+n1pKrNOpv90jivJLT5t7FdORkraV3ivW2k5y9pLaJ7ejHiPfo/Qq6u8vutkLj7MyH98P/SWN/uK3SYUij87uZnrHzks7Z3qTFWv4xfVqBD0jlEoOfNhPb9k0SQutI6MzdIgel1ic/M9bb/NKR53Gh7XUU34/q2/y7pFznrXeoIWIj4HjXpBChkjl5BdAOUv5eVO6DSIf4AQoJaRGXu/rb/WmM+2YEJhZ/Rh4iD7o307tuPAifmBvgUcoBfsV0nkTGyqCc9thy9SuSse1xKKPdj21lJYfUk/GvtRUrjbA18lUj+i5D028f2mRljXEMEsa5O+6OVCK+jYdkJXAqsRRT0NEm0NJ3HHcC6pX30AsT+s1IHvSaQwyqoesaVdIDt/SSdMHiYOZ8xNFiJoDxIVjI37acGjZOVEGhjLZd0ie03zem5CuNcAGzhnhf7woTE4HuJ6vnVKoxxte3XDHpOGfL7Cg+gbWng4avwEl6H6DhdWdKLgTP651dhnLWJ5P311LxHpnHWJYotFif2wosCX7V9Xc44TWjjuzQZDIpdVrimzX3RxoR9ygnprL1wjSRqYzRAZnfQc1MJSe8l7DQeSY8XB95g+yeZ44wrTM5Ndiukd49lyNYnkn5HSYKVkHv8U1qDr6obD2k4pyuIM9x3CP/xPwIfGuY5rglt3N/mJtOxM2z5IhGWeABY2fb/SZoUiUKNaMeR7SMkXUavo2tHN/QiacjlGt8Vc/YcrmmNtqp9RhW1J4XSBi+1vZWkzVM1SGHKW4VyNdufgeIg9CD1up9qowmkhApyDswp6HOiQ2/8+CbzKifC0uObyahe0ngplVk/In9Dewa9imOISsUzqNgB5VLl0qDAcFUmqr4r/T05Qbo25EKfSe95YZC9NHkSJO+Q9Hmiq6JRMgxY1SW5Pdt3Kbyp7lPFouzZBTgkvSozwDFK1YCtkxukKSPp5YR33pbAX4AfER0zOXyJ6NhbgEhC1cIhZ7CmojsN24/WGOZVhI76o7QjszUKrNt3SPm5wis2Cw2W8SuCxVVpq0OiFSSdTXT3nu3U5ZBxbZtrOLTQrel2OwJ+kv5rwkrAMkRV63zEZ+WNQFYhgQZ4sqYim9kGJmyfCJwoaQvbP64x//7xnk3FPNONU4jv4RhPlUx2tn1f+QmF11AuT6cipWIvshKlQHMGnyPWvgfSOEsDFxNBjjmi2GwcQ0h7LSPpFCKp+6Eac2mL/Yf4d5c5gZBcKhevfjfj+kFyWAWVu41T8H4GcJ7tSpLpAxjU2VueS1Yyt8l+qm+c2mt5Sk4uBCyVChLKHbEvrjHkskC5+OAZYDlHp2TV7+bCkta3fX2a43r01Ihy5M93JIoi5qfk4UtPsrMK7wXWBm4BsP2/kuq83scSSk9N1k2AmSkQ+zfi3zfpuOdPtpvtMe/pnJLXcwuNlS+bQezPH8wdp619UTmJSqyB8wM/IO4Lk80MSUu41xm2JFM/br6f7eKeQjoj7Ef+PvRnkjYtzoDpnHoGefKaRzBk6xMA28tP8KN/EOtYJdL+59OMV8DKVbCAKKh8DvBxomh0GWCL2V4x2rRxf5trTPUv9SCuTJWxRbBwC+AKhYZ+dqVkTVrVF26TFKAcipH6AM4gKvDuINqyzyUy4B3t0JYWfxsUiei/SlqdeJ+Xr3Kh7aFsXCeglpTQIFLQZ2lJz61SgT03aTnAN1/53+PwRMsOwLcQGJ6dJEjWwc7tyIU2TaidDzwELCTpUcYGOXITlvdIOppIrEAkW/5L4bNRtWikCHAsQBxebktzWoOo4tw4Yz7Tq0W9XU4gkglvtZ0ts5hoRc9f0vMJj4WNAStMyQ90dS8KgHcD30iVbz8CLnC+T92o8ayklWzfC7MC1M/O4ZpBNJbxs/0EpbXNYXLd1FulCYcT68tXFLJWpwHnuOc3MztaW8OhPT/AFPzs797L8Uoorjlxzr81Rxr7uyQaebK2kQgrcWtKop7BWDnA2jJSI8CDtpsW+53JeA+2M4gO0Eq0nICa4bGyiH8hw6fLtiXtSSgjbEDsH/Z0c3+g2rSVaGlK0+JVtydJiMMT9uNU9A8ecP0mbc0FxhXvPZcImD9edQ+s5EU5UUFXxUKuXQnp0xczNqbyKCGJnksbXuy7AN9LVfdKc9kljXFIxlza8PB9On2/i4R7XSnsmbYH+vBl0ob3blv8RyoMngkUUsP/ScY63iLls//MNI/se7mk1w16vsa+qK0kahscDlwj6UxivdmaKCycygy6P9fJBXyZSIi9k0hcnkSeTQ6MhvUJMGtftB4h+W2iSO6GzI7EU4jzzWaE39wO1EgsAzh8DSGUPaZD0Wgb97e5xnSUSRSRACskQ64Cfuzp9g+dBki6hWj7vD093hbYy/Ywjd6nDWpJCqWluexCbLDWIIK7CwNftH1MhWtna6ruTLmEtkiVtcvavqfBGMcSwY2zGRv0yTXbHhkkXQQcVQR+FKbvezhfNuQOeoHhtYrAsO1tWp90tfksQVTnzNo4ZnY/kf4NRULtkhoJNST91Pbmudf1jfE8ohO3CLRcRfiIPQUsmCooq471I+BLtu9Ij1cHPmX7QxljFMbfZRPne2y/ouoYHRMj6SuENEYjPf/03b6CqNSEOPy8wfabM8eZH9iUSJJsDFzkGpKCo4JCVugE4jAHUeixo+1BsmazG6exjN+oouiKfSPhAfb2zOT9yDBBkca1OdWfkk63vXVp3RuD86TzrnLyB2qCpCtsv670WMDl5ecmC424jFQd1EB6LO0bXgEcxtguz0UJWcKs+2Qq7CknoK6rk4CS9FViT1/4um4D3G77MxljfIuQ678x9+9vk+J7pPEqCbXlvkYFSe+m5GfpGuogCl/CJxnvV1e5wFfNvTUnGvc9wHq2P1vx94+3/WG1IDsq6RO2j6r6+3MY69WU9uTuebHnjrMYEd+rVQAu6Xjg627g4SvpU0TByFuIRNxOwKm5r1UqHPxvwmumvG5mF5ar5727DbF25nrvtoKkDxOeOVsQZ8qziTNTGz6kuXMZJ7s/6LkK45Q95hYgEgs353bFSLrB9nrq2QosROyvhmUvsxqxby3O7EMP3DdB0veIxpBvEfe5TwBL5JzXS2O9h+iEWgR4n+1fV7xupKxPJL2ViH/8mpCYh9jfvxT4aNXvpaSbbb9aJTskSZfbHijrO4exBp0NHiH8dA/OLEAdCRRS4bNyM3Xvb3ODaZcM65g6pOrpMwkfqdcSZtKbOWnZdjRDI6bFXxdJ77L9M4U3xThaqq7OnhPRJfZc2ysovHQOdKavgKI9vR/bPrCNeQ6D9Dk7haiYFHA/8EFnegK1FRhOB8P96B3ALyfeq8rrjKSDiMrpe+ltULIOzW2isab11zsZvg5pLuPek6YB/FSxu6vtOkbO0wqFvO0hwGqM7USpLI+llvT8i81+33M32V4nZ5x03fyEnN+OwGttL507xqigkEz6JL2u1YuIYFKV7qfyOGcRr8dexAH8YWB+2+9ocbqTTkq+v4sIQr2K6Az7RMb1jdfwtmijSEPSi2z/UeGfN45SVWiVsRr5u4xaYCLN6USiQ+iv6fESwOFTPBn2A0J67JeUpMeq/JtSQdF7iK7acnfZY0SXQ5axepsJKEnl4tMrXJJgqnj9XcDKRMD7cXr3pinpF5r2Zl8GXmx70xRM3dB2jsRhm/P5CrFenZKe2ha4yfa+meMUXr5jyNyHtOatOWDs62xv0HScGn/vQoSM1SjYEaDo1OiX6co6T6oFD19JhxKSqWU/7DfnJMrTOIM6M5zzuRswZi3v3TaR9DFi/7s8cdbJWsNbnMc4f7BBz9UYdxngMNtZNiRtJVE7BpPWqy8QflQCLiSSK5UkzAcUpb+RKAL8HVQrTp+g2Klg0oue0nq3qft87SWtQEj6v7ziONfZ3kDhj3Uk0V12pu2VaszpMEJd5NT01L8S79cjwMa2Z6eaMbJIegFj703/M8TpzGLaJcPSwe5Q4AXEB2fKV3VNZyStTGjV3k9Ijz055ClNC1JV7weAnYkg6oUkKRTbl03iPGYrb+Ap2gGVKmvfSFRZFl13t+ccFtI1rVRljSJKUh22H6t5fSuBYUk/JiSkygfwNW3P1o+mb4x7gFd6yHKWaS5bEYnYy6C2aX3jBEtprB8SQawfEJvk9xOGx428GNs4kE0HFFKE+wFfJxIKOxLfq0GJ9Lk9l68RlWmFXNKWwCty5iLp7cTGfhPiM3wacKGnsFSipNMJSaJywHEJ21s1GPP1JBm/UVh36iLpNGB9QpbtdOKemSXn18Ya3hZtFWm0OJ/aSZZ0fSuBiRTcO6UvgbWt7W9Xub5vrOloXH+HG0qPSdrQ9rUtzGVkElBtJIRHCUnnEV3Cn7O9pqT5gFubvvcN5nM7sFax5io6dG+tcVYpqwkYuBI4JufMrgHKJIOeqzBOed2fQch0v972hjWuH0fVQoI01mmEHcEHba+eXqdrh3E/kHQMsCCxt/oOsT+7wfbOmeO0UaQxKMmSfUZuCw323v2xx8q8zu05lOMhRYzmDuBWmNx4iKRNgXcQnXKnlX60KLCaGxZNpxjU7XXWPUlvoZREtX1Rk7l0tMdERekFHkJxelMk/Rp4ef8ZVGHvcZftl1YcZzPivrgMcBTxXTrANeSxJV1t+zWDnmtjLznZKLrTDyeK5B8gPMTu9oio/0xHz7DDgHe5hvxUx+Sg8e2fSxJGgddLypKI6RiMPTJa/IXW8yAj50qZeEX7/YS/68xurJaYafuR2O81Yl96/oaze25KUa5OLF6j3OpEt+TvAqxku2w8ekAKZOZwJ7A4Q9Kz7uPzNDCtT5xAL8GyCSnBUnM+OxLSN3umx1cAR+cMoJZMnKcpz7N9iSSlYMT+kq4k3r/Zona8McrsCuwNnEx8XmYAj6f3r2rR0Q7E4XtX95mIT2FW6QvoXSrptiYDekS8a1rgBGA723U81AraWMPb4veSFieKuC6S9DBRAVoZjZdim/Uj8ov3Gvm7uD1P1g/bnuWVY/thhRxUdjKM6Wlcf52k1dxMZuk3kj5LdBOU5ZpzK6k3bTCHVj+/UzXpNRuWsn26pH0BbM+U1GTta4PFgUJWbrGaY5xIFHwcmR5vm57bOmOMtrw1y1XxM4muhBzp8Da9KFeyvY3C5gHbT6qFg2FNNrK9Rko6HSDpcDJ9NaHZd1LS7kTSdMWUiC1YBLi6xnhbEQVBj0n6PHE2OMgZ/nmJE4gEWBPv3ab0e1+dNcHzk8H/EoVt7yaSuQWPEZ2OWfR1DM0A1iJ8pLNJya8uATYXSLGUQR2+lVRu2kx2KRQ1dmZ8J+tkKwB8D7hRYflwf3puGaJos3JHt3vdwI8QcZUmLCxpfdvXA0haj7CXgbjnTTUOImLRF9teW9ImxB5iJJjqh4tB/LlLhI08mw17AvMI1wEr2v7PYU3A9gEwsexNxWG+Npem14Q7JW0HPCd12ewBVJY5KFVlvUTSkaUfLcrUvNHNYqLqxCZjNgwMPylpY9tXpfm9hvA+yOEQ4FZJdzJWimoYidhGpvWJ2gmWfhxScF9P/9WlFRPnacpTkmYAv1aY2P+B6Hyvwt7ARxi81prouKyM7UaH9lSVvrTtnzQZZwS5VdIGtq8DkLQ+NQI/0wlJb7T9c+JesHl/fDCn+p521vBWaKNIo+n3qI9GSRa158k6I91PnMZ9DlBXgmo6GtdvDOygkP2qJT0G/JSoPL6YekkEoHkCquXP73TjcUnPJ32XJG1ABMeGRbF3vZT4zL2OKLjLpY2Cj33SdfeluSxHyKBl0TSB32IBAMDTqRuseL9XonRGmGSKe+ITkl5MnA1WmOQ5nAqcR3zu/q30/GOu4fMFfMH2GZI2Bt5GxAOOIbrNK+MhSGgOmMMB5ceSFnJFebq5MJfbgNskneqGnn2Jsv/PTMKSo/IeuOUCoY6J+VTp/xcgfOuyY05pD74/sYbPR+99ylGXORm4m/heH0h4UE96/N72IZJ+SiSGNyT+Lb8Hts/ZVytkFT/B+GKlOnGiXYDvKRSWIJLUuyhkLg+pMd6wecb2XyTNkDTD9qUKKd2RYDomw25Kbes/oYZ+fsfcZxpWAo4qmwC7Shq6FAqwhktmvqlquKrkzRdtv0nSoc7UG5+LfAL4HLHGnErooecY8bZalTVitFKd2CK7AScpfGcg5BZn2+o/gBMJ+d076ElRDYvzFJrUZdP6czPHaJJgGYPakVy8ywPkQpniHZItsReRUNiDqK7ahPDXnCO2P5L+bFSl1laHme1nJT0haTFPL2/Q9YEPSir0z5cFflV0wc+j3e6vB35Orwq/CHSI/Or73YET0xouosvhQ+1Mszppzbzd9upQv0hD0qK2H00dT+PIDBo2TbIUwYemZtYXAKenYhgT9906ndzYPknSTfSM69/XsKNqFHh7C2MsOEJ74I7B7E34uq0k6WpgaaIgbNJJHUpXERXZ6xLfpc/Y/lON4RoXfKQCrJcBq6S53J3THT5Rwr40ftXEfTFeG16U+xHr3DKSTiHZEeTMo0XOSV3LXwVuIV6r4ydzAum1e4T2qv6LpP87gaNt/1TS/rmDqAXPu7aQtCHRcbIwsKykNQmlhI9O9lyAtyk8sfuTGrnJp8Vt/3v5CUl79j83EV2BxeRg++a+p66WVGcf+10iVnUz9QtzXmp7K0mb2z5RUhFLm3TS/vKutCd3oUqQyU+I1+VnNIwTOfxcX1mcecrxU3o2BVOJv6bE3pXAKZIeYIQK/6ejZ9gg/XsPoe2yo2OoaIS0+FMF4Rv6ZG8udwV5H4W/we5ENdh29Mm5VQ3EtkWqeP6K7X1aGGv+lqqyRgZJ19teX9J1wPuI6sQ7bb9sCHOZAWzpkK1ZFMD2ozXGudz261ufYA1SNc31RBBUhCzhBjlBMknrEkHQxYkEy2KE2fF1NebT2NNKc8nEeTogaR0i8b4cYT4P+WbmjaRmJB3nMIe/tPT0rM2jK0pspLFOJ4JzFxFFGsUYWYGsUWKie23BvFwApJBC2YKx1ZJ2pmxuGqv2Gt4WKeC5rxsYP0s6x/ZmpQBdeU+TVV07Kvu8dK/dFXgTzDJm/46byWN2lJB0MHCN7dzil45JROETViR87hnmHl/SzbZf3eD6wtZgfuLf9D/p8XJEEdPqGWPdC3zV9jGl586xXUktRi371aglL8rUCVjYEVznybcjGIekfwIWmOpFR5LOIYr13gy8muh+u8H5PnPPLz1cANgKWNL2F9uaa8ZcricS5Ge75zl+Z853qcW5/IY4p99RdHXXHGfQGW5K+3xOR/oKsGYQ36kjba+SOc71trO6MweMcYPt9SRdQUir/on4bk9qglrSsoTF0hvpdXEvRhTz/Zvt31Ucp/FrUhrrhcCXgRfb3lTSasCGtivLNo4SqaPtKeIeuT3x+p5i+y9DnVhi2iXDOjo6Rg9JHySkOcbI3tg+ucK1WxK6whszvnrZOYHYtpD08yZ/r6TTbW+t8f55AFPaN0/SFwjz0DcB3yJVJw7j0JHmc4Xt1835N2c7xhFE1f3ZjO04ntREbJpLa8bUkhYhvkN/azCfm22/WiVTV0lX2n5thWvnqonzdEDSPYS80JiuxJxgd/H5UEjNHEJIzXw2d+MuaWsiqfZo+p4XSbXK34OJAlq5gayOqYGk84G/EpXqRWLErmAWr7FeguOoMkbbSPo50WVxA2OTucOQzG0NSSsTEjrLM1biZdL3Vx2DUUhJLQg8DTxDJyE1kkjaiPHfo5OGNJdvAd9PleZ1rm+t0EPS3YSP0BNEJ8zTOQFzSSfb/kBOx8kcxvuF7bXm9FyFcdZg/Ps96WoYkuYnCkeL885lwLFTueBS0oJEl/EzxFnyZmAR2xe2MPZVtjduOk6Nv7coGJ312Zd0W26Cr6W5XAq8yXatThaFV952RHzmytKPFgGetf3m5rPsaIu+AqyZwG+JbtirMsf5CvAcQuGhVkxE0i6EHcIrge8TnZJfsH1szlyaIula4BvAmUXxVip63wrYyxUlVhXWKS8jCsEaxYkknUf4HH7O9pqpwObWKg0Eo0pK8K2bHt7gsXYfQ2XayCSqPd37jo6OlnED2RvbZwJnpuDrN4GVicquYWbyb5V0NiHjVg6IVT0A7Zn+PIEIqt0/m9+dUtg+KP3vj1NV37CrEy+S9Cki2VJ+r3KkqIrDenlTlO251AS1aEwt6ZXAScCS6fFDwA6276wxtSaSi9NZLrQtHrR9dsMxWpGaAT6fuiw3Bt5CePscTYZ/Q5f0muf4F9t1JeIK6ZxViENU8T14F9EROwwWZqzvrQgJ3VpIeh8RSDJwpYfnp3cG0X3/HTJkb6ZzYc8IshhRVbuC7QNTRfOLhjynjhKSTgZWAn5BKflP7LeGQSO5/JY7TJ+wvY2kTwNXpuKanHPcq1NybidJJzFeJSTXk6qxF6Wk7wFrAL+kV6yUKwPcFkcTHXzfTo8/kJ7bZQhzaYtdCF+5HxPv93GE9GNWMkxjJb5nAOsw1qt4Mrk/Jcwt6bmEBPqkeyUlPg2cq5DKKwfwqxYaXQP8EViKsd7EjwG3D7yiY2jYbstDsDjzrVMengoxkb4it8K/8Vvpz4WaTy2bpWyXi3FJSbEfKSREq/JKYs19I2PvBXXiREuls/a+aT4zJU1ZlYV0r/8qUaAh4ChJ+6T47tCZNp1hkv5i+/mS9iI8YcbQBWA6OqY2kj5MbBr/hThobgBcO6TOsFbkWCXtR3TF/B/wI6Iy5c8tTHFoKCQxTwNOs33vCMzntwOe9mS34jdFoR29BC0YU0u6hqg4ujQ9fgPwZdsb1ZhXY8lFTUO50LaQ9CbCf+ESavqgtig1c6vttSUdQsiqnJorhaIR8m7omPtIOg44yvYdDca4ENjC9mPp8SLAGQ2SbLVpuTP328BLGev/eK/tjzWfafZcasmpSXqR7T9O1EHScjB9nkbS0USQ5Y22Xy5pCeBC2+vO4dKOSULSr4iu9pEIrozS97KvE6ZQjljSdqXiKUl7EJ1PKxL7mdrysmm8NYkk5Rg/YduVg/iS7rK9Ws7fO7cY1F00rI6jtkiFfxvafjw9Xog492fdb1MHVPGdnAn8O7XyUAAAIABJREFUDvia7f9qcbpV57IU8O/EfryQFN6jRjK3jblcCPyN8coTB0z2XDrmHqnoakIms5M1xb1ggiI325OavJf0IyIGdyK9wvRlCG/5pWxvXXGcu4E1bD/dwpwuI+TlL7L9KkkbAId6ROw6cklxwbcU3WCSlgYuHpV703RKht0FbEp8qcaZxQ/jJtPR0dEeqfJ4XUKTfS1JqwIH2N5myFNrTJLZ2Ia4+f1+KksLpMP3Num/fxCJsdPdwGNl2Gj66Te3fmhW+Pm4CFhnXvsyIsm3GtH1CXQJEgBJPwBWpa/yOCfx3pbUTBtJNY2Qd0PH3CftzV9KyLH8nczOhDTG3YSXy9/T438CbrO96lyY8kRzmNWZC5SLPBYBrrb9/hpj/hJYvQicpw7bO2y/ooUp585lf+AB4CzGJt1zCy0WZaxcWHf2aokiETsK8lodg5F0BhHY/uOw5wI9acE5PTdJc3mX7Z+VHi8LfMiZ/pGSjra9ewvzKToUFk5//o3wjLnZ9i8qjvFd4PCqSidzE0m3AFsVRYiSViQKLKes925x7rf9VHq8AHCjK8qFld5jMdaf0zA0qeXX2L56Ts9N0lxusr3OnH9zwuuvsr2xQsK3HFDuJHxHiAkKuAuyC7nTmO8EXsHYM3vltXxUitxSd+bOwObAS4jP7u+JfMJ3i3NHhXFOAz7hFuT/UifrUcTr+0tgaWDLnEKNUUIlG430eAZxhhsJ2cdpI5NItIKfTxxUy75CxQ1wng+qdXRMcZ6y/ZQkJP2T7bslZZl+toWkE4E9bf81PV6COBBlbygSDxDmoX+husTcSJIqTg8DDktJji8QMlLPGcZ80uHpo5SkqIBjisNVRb5P0m9Oj/+LSPJNyWQYcJ9CdrTw7Hs/EazORtI6xGuzSHr8CLCT7Ztne+FYTgD2A75OFLPsSJ8EzjzMmi1sGFuRmiG6WN9OVNT+VdKLCD+zyni8Ye43JF0FdMmw6cmmLYxxMnCDpLOINfy9TL7s2KnAebTQmVviHmBZoOjSWIbhSQsVXn7l73Pls5OkXYEDiQR5ERTrzl7t8ozCy6JIni5NqZq/YyRYCrhL0g2MTSoPy1NwTGJd4T2S3QHaEudIej+wYiloen7ViyUtavtR4HOSluz/eY11eJ3039nEvmg74EZgN0ln2D6swhgnAtdK+hM1iz1aZB/gUkn3pXksR0+GbKpyAnB9uvcDvIe8c1e/1PJPiddmmFLLRxF+u3N6bjK4WNJbcwvjCpw812wPS3KyowK2W10HJB1D+JduQkhrb0lYfuSwLOF/WvA04b04qaROrqPTf014IXC3pBtpfu+/iyhMe4KQHP0JEXeaqpwv6QLGqmCcN8T5jGHadIYVtFUx1NHRMVqkzfCOwF6EBu/DwPy23zGEuYyTBsuVC0vX7E7cFJYGziSkBYdeYdgUScsTgfNtCN+E02wfPrtr5uJcTic2Ez9IT20LLGF7q4wxbrS9bl9FdrbR9qiQkrcHEAlCiEPhAbbHSQxXGOt24GO2r0yPNwa+ndn5cbPtV5erhyRdafu1ufOZbkg6Hvh6k3WhLamZNtBg74bdu+6GjtmRPjfFenCF7VuHOZ82UPh0rEsviLAucC1xAB5mAD0bSb8m1piHhj2X6Yqk7Yk91auIIPyWhI/jGUOdWMcsJA2UMbJ9+STPY1/gs8DzSOsJkQR4GjjO9r6TOZ80p0Yyn5LOsb2ZelLLTWUSLyA6E/6WHi9MnMPeS3SHzVH+UNJvgL0ZLzM3FHnY1DW9CvHa3F21q2GUSff+jYl/U617/yh0oUjaENiIiGF8vfSjRYH3DmMPnDq6FiLWhaep2dGVZNx+WXp9FwZeYfv6lqfc0QCF3cJ+wOvSU5cDBzrT111JGrz058LAf9h+a8YYnyPiROUit9NsH5Izl7mBBsihV7imtXt/ils9CpySnsqOW40a6vkjF+v4WXO4ZNKYTp1hAHSJsI6O6Ynt96b/3V+h/70YGVWFLTND0hJF8iBVKdZZT5cD9qoqyTEVkHQ9YeJ8BiHZcd+Qp7RK3yHjUoV+cQ6PJ3m3oiJ7A0JOZUqSPrd7tDTcY0UiLI19VTpg5fBUapv/taSPE1J8U7pDskU2BnZIAaC6lcciktIFzzK8zrvDGe/dMGU3+B2TxoLAo7ZPkLS0pBVs1+pmHSFGqhtS0uqMl6qt2oF3L72ge8dcwPYpkm4G3kSs3++x/ashT6ujhO3LFbLaRYLnhjZkk2rM4xDgEEmHEYmaFW0fkKQJ/3my55NY30nmM83x4SRRVYmUCBPwercju97fmfAMsJztJyVVTSL9j+2z5/xrcx9JHwNOKaS0JC0haWfb3x7y1Bph+xbglobDjEIXynMJSc756HWsQQS9t5zkuQCtdnQdzdjOticGPNcxfL4H3EkkoQA+QHRfztZTbABPpj+fkPRiQtVohZwBbH9J0nn0itx2HKEit+zzccsFL23ErUYGSSsA5zp500l6nqTlbf9uuDMLpl0yrKOjY/oz2VWWAzickMYoKnK3Ar6UO4jtf5vzb005drB997AnUeJWSRvYvg5A0vpArjb73oSUyoqSribpN7c7zclD0kVEorIs8/kj22+rMdwNko4l2t9NVK5fVnQApYPsnNiLCHbvARxESC/sMNsr5h3aqFxtKjXTGPW8G85hvHfDZsCkezd0TA0UhtvrEBXvJxDFFj8AXjPMeTVlBPYxs0iv8RuIZNi5hLzlVVSXo9wXuCYVw5QlYtoquugA0t5qlPZXHSUkbQ18FbiMuMcdJWkf22cOaUqLAhsQahoHECoJP6aXrJtMGst82nbax7Qh9XgqcJ2kn6bH7wJ+mDrnq3bi3y3pVOBnjF33/qOF+eXyYdvfKs3hYUkfBqZ0MqwlBkktnziZE0j3+8slfb/oHExFgAsn+c9JJyWXtwdWsH2QpGWAF9nOlbyTS1Jjtv+RJFk7RouVbG9RenyApDrF2OdIWpy4191CfKe+kztIS4nuRihsV/qLH/6zxjhl37znEueUx3O7LBNtxK1GiTOIrtiCZ9Nzw9iHjKNbqDo6OjoysX1SksdYhzjM7Wj72iFPa1R4WGEq/WLbm0pajZBPmuzg+x3ExmR+4IOSikrSZal+0C2YbvrNSxWJMJh1aK7biVVIRRZdDoVP50bpzzdOdKF6Ru4b2b6RMDCf6h4HrdKG3I7tIyRdRk+iYBgVeKPo3dAxNXgvsDbp0Gz7f5PM0ZREo2k6vyWwJnCr7R1Td0tOcONY4Of0yYV1dMxjfA5Yt+gGSwmfiwn5vWGwXpNurJY5kthHv0DSl4g15ws1xrlO0rppz1ibFPw/l96+aDfbhef89hWHeR6RBCvLgxkYRjJshqRZSYmUeBzWez1SjFgXyiGSdiMCwjcDi0k6wvZXhzCXb5OkS4lCxL8B3yI/SH2fpD3o+S59FBi2KkzHeJ6UtLHtqwAkvYZel1dlbB+U/vfHks4BFsiVWhwhrgVeVYpHYPvzuYP0d1lKeg+wXs05rc/4uNWvirhWpjLMKDCfw5sNCJ+2Ie5DxtElwzo6OjoykbQnsAtx4BFwrKTjbR813JmNBN8nqvc/lx7/F3Aak9yJQnSbtMVJhJTFl9PjbYlKw6kq7/YPScsWUjOSlmNsUDaHy/oeG8A9g/TZ8er0d+8k6ST6pAmcb4jeMQHDrsCzfQDM8m54VclbYH+iQqyjYyKeTh0BRZBvoWFPqAkeTdP5p1I190xJiwIPADkePDNt7z3nX+vomNbM6JNF/AvhjTksGndjtUWLMp+bALtJ+h3wOPWko4s53UwkJGphe5SKty4ATpd0DPF+78bwrARGjmHvgUusZvtRhQfkucBniM/gMJJhjaRLS+xGJLs/T3z2LgE+0t40O1piN+AkhXcYwMPUUGGRtBVwfjrH7UMkkw4aIZnDHJ4raQdgI4Wv1Rjqdvna/omkuupPk+ZlOEk8KOndhaSwpM2BkfEX7pJhHR0dHfnsDGxg+3EASYcS1SVdMiy6jk5XGHhje6akZ+d0UduUO2qSDOAyjL3n5XTcTCv9ZiJReZWkQqbrddQ/uPyt9P8LEEnIqgGOY4jD+oqMDUgU3WVZhugdU4JR8G7omFqcnqRYF0+yTzsBxw95TtOGJJV0e5K9OZ5Yi/8G5EglXSrpI4yXC+sKGjrmJc6XdAEhGw0hG33uEOczqBsru+q9DUqV93cPeC6HTdudWX0kLUCcB1/BWK/FnYYwnc8AuwK7E3voC6khXdYx15lf0vyEXPk3bT8Tt+Ch0EqyPBUA/GvLc+tokSTJuYrtNVPBEw3kOb9g+wxJGwNvA75GnOfXb2e2k8puRCfw4owtoi7iEJWSYX2JtBmEclStIuM2FGFGjN2AUyQVMr73E351I0GXDOvo6OjIR4TEQcGz1DDcnKY8Lun59DbXGwBDa5+XdBDwIeBeehuT2cr3DWBa6TfbPj95em2Qnvp/tmtV6dg+vPxY0tcIf7Uq1x4JHCnpaGIj/br0oytsT+VkY8fEDN27oWPK8Q/gSqI7d2Xgi7YvGu6Upg+p626tJJ17jKTzgUVt354xzHbpz33LQ9MVNHTMQ9jeJwXFCum942yfNYfL5uZ82urGaoNXlB8kT6Fs7y/b/52CsC+zfUIK4C/c0hxzOZlI7r0NOJAIqg7l9U2dvd8lvB4N3GN70gsRO+bIMcBvgduBK5I6xrDOyK0kyyWtTEgkvtD26pLWAN5t++BWZ9tRm7Q+fBw4vQWPumJdeSdwtO2fJpWPKUeSjLxK0l2ErOzGxPp5JT3Zzyq8q/T/M4HfAZu3NM0pje17gQ0kLUz4Cz427DmVUcnvsKOjo6OjApL2JlrLi0Pue4Dv2/7G8GY1GqQky1HEwfeXwNLAlpmBtTbncw/wyrJecY0xfkV4HY3RbyaCtFNRvxlJ76aXfLrM9jktjbsEcIPtl2Vc0y87+h6gkx2dpqQ1ovBuuGKKSmt0TBKS9gO2Bv4P+BFwpu0/D3dW04tUsfn9pj48HR3zMknC9Snbz0pahdg3nmf7mSFPbWgklYjPEv5aT5R+9AyRLNx34IUTj7cfUXW/iu2VJb0YOMP2a9qac8ZcbrW9tqTbba+ROn4usJ1TbNfWXN5AFBb9jthHLwPsYLvzZB0h0ue3wEQXyXNs1/HPa2M+q9JLll9SJ1meVEb2AY61vXZ67k7bq7c62Y5GSPoC4RF2GiExC+R38CefsD8AbyYKGp4kzv1rzvbCEUbSGURS+pT01LbA4ra3rnj9Mrbv73vun23/qd2ZTj2SLOd+9GJOlwMHjorPXJcM6+jo6KhBCugW1Z9dQDeRZEM+TlRKPkaSj7T91JDm82Ng9z4fh9wxlpvdz6daS7ukrxAGyeVN3025QYk01h30Ou6eQyQ/D7T9zYwxbgc2LMmOLgRcOxWTjB0dHXOHVG28DbAF8Hvbbx7ylKYNqSp2ZUI+uJYPj6TVgdUYKxd2UstT7egYWVIX1muBJYDrgJuAJ2xvP9SJjQCSDgEOI9aZYo1wbrJG0i+AtYFbSoH324exX5R0g+31JF0BfBT4ExEUnvSO2PTZ2872PenxysAPbWd333XMPSR9svRwlrT8ZEprSlpydj+vkRy50fa6RXI4PfcL22s1mWdHu0j6LQOk+3LXK0kLEr5Wd9j+taQXEUXHF7Yz08lH0m39ybxBz83m+meAM4GdbD+ZnrvF9qvan+3UIsXh7qSnAvMBYE3b4zzahkEnk9jR0dFRgxEy4x01TiLkrL6cHm9LSIlsNaT5HELIHN7JWC+Td1cdYKoluyrwDmAt2/8AkHQicCtjJa6qUtbYngn82fbMzDE62dGOjo458QARbPwL8IIhz2W60ciHJ1W7v4FIhp2bxruK2A90dMwryPYTknYmisAOk9QVygX3AVcA/wL8gpDpvpY8yXKAp5O0ayHFvlCrs8zjuKSG8HlCHnxh4ItDmsv8RSIMwPZ/pU61jhGiibR8i9xMJEWKc1aRIKnr1/yQpJWKcSRtCfyxhXl2tMtqRNK+LAV4TNWLJS2aJBYXAC5Lzy1JxFZuanuyk0xTO4w7idfzKklbJ2nALo4RrGR7i9LjA1JRy0jQJcM6Ojo6Otpklb5KmkslDdP/6UTgUOAOahgDT2MWJ2THABarO0hLicITgOuTjxSETOJ3Wxi3o6NjiiNpd6IjbGmi8vLDtu8a7qymFy2s41sCawK32t5R0guB7zSfWUfHlEKSNiS8o3ZOz3WxlmAPQpHgOtubJHm2A2qMc7qkY4HFJX0Y2Ak4vsV5VsZ2scZdwfD9EW9KnmEnp8fbE0mPjtFmQSb5s2N7heL/UzLjZZQ6umvwMeA4YFVJfyA80eb5btgR5ESiWPnI9Hjb9FwlKUDgVEnvAh6iJ8daMNU9YtcHPihpjB1GoX5TofPYtr+d4l0/k/QZBnThzaM8KWnj5M+GpNcQ0pojQbdB6+jo6Ohok6bVNW3zkO0j5/xr8xRFt9ylxGb2dYSnw1CwfYSky+jJju7YyY52dHQklgP2sj0ylYQd43gyGbTPlLQo0cU3lQMjHR112JPosD/L9i8lrQhcOuQ5jQpP2X5KEpL+yfbdyVctl6Io4lHCk+2LhHfNpCPpZODjhfdJklT/nu03DWE6uxNJiT1I8v3At4Ywj47ZMJG0/JDmsguxZpW7Na8hPMRy+ANR1HgpsCTx3dyBIf27OiakUbGy7c1glgTmdJP/e3vD6wVg+2pJbyJ82VZtPKvpwW7ASck7DOBhYn0YCTrPsI6Ojo6OxpQ2+PMTB9T/SY+XA+4alpGupCOIFv6zGSuTOE9LXCaN73WJDdz1nclrR0dHR0cdJH2bKKj4V+CTwN+AX9jecagT6+joGAlS5/+OwF6ENOLDhLTfOzLHGefDMkTPsF2B/wfsDbwE2Af4pO2fDWEue9r+9zk91zFc+jyo60rLtzWXO+h1a65VdGva3iZznPOBvxLWEbMk7/slITuGi6TvA8f0FSvvYPujmeN8EzjR9o3tz3JqIulFtv9YejwfsFGuJ+Z0RNIKtn+bCuWw/Wjx3LDnBl0yrKOjo6OjBfo2+OMYlu9W6n7qx7ZzfQqmDZIu6a9cHfRcR0dHR0dHDpKWBxa1ffuQp9LRMalIWhr4NPAKSrJj8/J+cxCSXk/Ic59v++mK1+xO+N2sCNxb+tEiwNW239/6RKvNa2OiI+YhYO1hFZZNkCS81fbaw5hPx+gj6Ubb6yb/nvVt/z11/ayVOc6dwyp47ZgzbRcrS7oLWBn4b+BxktfcMAoSho2k99v+gaS9B/3c9hGTPadRY4J70822Xz2sOZXpZBI7Ojo6OhozrGTXnLC9ybDnMCpIWoDQp18qmX4Xet+LAi8e2sQ6Ojo6OqY0kl5CBFfmS49f11XFdsxjnELII21GSAPtADw41BmNILYvr3HZqcB5hMz3v5Wef8z2/w2+ZO4i6QPAF4APAmsA50ra0fak+SRL2hbYDlhB0tmlHy0K/GWy5tExJfm9pMWBnwAXSXoY+N8a41wj6ZW272h3eh0tsVnL423a8nhTmYXSn4sMdRYjSOo0fQWwmKT3lX60KM08Clul6wzr6Ojo6Ji2SHoh8GXgxbY3lbQasKHt7w55apOOpD0JiZoXM/bA8yhwvO1vDmViHR0dHR1TFkmHAtsAd9GTSbLtdw9vVh0dk0tR7VyW7ZN0ue3XD3tuHe0j6SfAR2w/kB6vBxyX21nTcA7LASswIEkI3D4sCb6OqUWdbs3StXcBLwV+S9gRzLOdQh0dHYGkzYH3AO8mrEoKHgN+ZPuaoUysjy4Z1tHR0dExbZF0HmHs+znbayYd51ttv3LIUxsakj5h+6hhz6Ojo6OjY+oj6R5gDdt/n+Mvd3RMUyRdZ3sDSRcARxJFR2faXmnIU+uYJCQ9NzeZ0OLf/ULCAwrghiJJ19ExN5nIJmFUFWM6OtpC0pGz+7ntPSZrLqOKpA1tXzvseUxEJ5PY0dHR0TGdWcr26ZL2BbA9U9Kzc7pomnOspD2A16XHlwHH2n5meFPq6Ojo6Jii3Ef4UXTJsI55mYMlLQZ8EjiKkAP6f8OdUsfcQtLKwNHAC22vLmkNogr+4CHMZSvga8R+XsBRkvaxfeZkz6Vj3qJLenXMw9w87AlMAe6XdBbwGsKr7ipgT9u/H+60gq4zrKOjo6Nj2iLpMmAL4CLbr5K0AXDovCxbI+k7RODyxPTUB4Bnbe8yvFl1dHR0dExFJP0YWBO4hFJCrKuK7ejomK5IuhzYhygmWzs9d6ft1Ycwl9uAt5QkG5cGLra95mTPpaOjo2NeRNIihETo34Y9l1FB0kWE5+fJ6an3A9vbfsvwZtWj6wzr6Ojo6JjO7E1oFa8o6WpgaWDL4U5p6Kzbd0D+eTpId3R0dHR05HI2Yz0BOjrmOVIC4sPA8pRiLLZ3GtacOuYqC9q+QVL5uWF5dM3ok0X8CzBjSHPp6OjomGeQtDqR7FkyHupB4IO2fzncmY0EL7B9Qunx9yXtNbTZ9NElwzo6Ojo6pjN3AWcBTxCmnT8B/muoMxo+z0payfa9AJJWBOZ16ciOjo6Ojnr8BTjX9j+GPZGOjiHyU+BK4GK6PdW8wEOSViKkn5C0JfDHIc3l/ORV98P0eBvg3CHNpaOjo2Ne4jhgb9uXAkh6A3A8sNEwJzUiPCjp/fTuTdsSZ4aRoJNJ7Ojo6OiYtkg6HXgUOCU9tS2whO2thjer4SLpTcAJhM+LgOWAHYtNXEdHR0dHR1Uk/QDYEPgxcILtXw15Sh0dk46kX9hea9jz6JgcUiHZcUTA82Hgt4T801A8lCRtQfiyCLjC9lnDmEdHR0fHvISk2/olaQc9Ny8iaVngm8QZwcA1hGfYSHgNdsmwjo6Ojo5pS7dBGYykfwJWIQ7Nd9v++xwu6ejo6OjoGIikRYlikx2JA+8JwA9tPzbUiXV0TBKSDgausd115ExjJO3d99TzCEnCxwFsHzHpk+ro6OjoGAqSzgJuYawv1jq23zO8WXVUoZNJ7Ojo6OiYztwq/f/27j/asrqs4/j7M2OIzgyCohnqQJhOIg6CGj8Gw1/4W0kBy4VgalmxDNOyrDSRtFJTl0KKIihgGqCoSKkYa3QEBJIZfumotUTAikUi4gAJAk9/7H3hMtwZZsbu+Z5z9vu11l3n7u++d+bzx8w6Z+9nf58ne1XV+QBJ9gTObZxpHDyBu+Za7JaEqjqpbSRJ0iSqqp8k+TTdjeE/Al4EvCHJ+6vq6LbppPmTZB1dATjAXyS5BfhZf1xVtU3LfPp/t6R/XQY8ia49ZoBDgVUtAiV5MfAO4CF9Fv/tSdJovBJ4K3B6f7wK+O1macbIuM9SdWeYJGlqJVlLd8F6Vb+0FFgL3EF3obi8VbZWkpwMPBK4mLvmWlRVHdEulSRpEiV5Ad3NgEfSPRl7YlVdm+T+wNqq2rFpQEn6f5bkLODAmd2vSZYAp1XVsxtk+Q/gBbaolaTRSnJwVZ12b2tDlOQ8ulmqFzFrlmpVfbpZqFkshkmSplaSjd6EG5eexaPUFwh3KT8ASJJ+TklOAj5SVffYFZHk6VV1doNY0kglObuqnn5va5oOSb4N7DbTZrxvP35JVf1qgyznVtWKUf+9kjR0SVZX1R73tjZE4z5L1TaJkqSpNcRi1ya4HHgo8N+tg0iSJltVHbaRcxbCNNWSbA0sArZPsh1dizqAbYAdmgXTfDsZuLCfF1N0rWFPHGWAvj0iwDeSnAJ8FrhzBnBVnT7nL0qSfi5JngM8F3hYkvfPOrUNcFubVGPnzCTPHddZqu4MkyRpAJJ8nu6CfQnweOBC7n7R/MJG0SRJE2bWrKQ5Oa9GQ5DktXRz8nYA/mvWqZ8Ax1XVMU2Cad4l2QN4cn+4qqrWjPjv/+hGTte4zGWRpGmTZDe6+ylHAX8169Q6YGVVXd8k2BhYb5bqIuBWulmqMEbzLC2GSZI0AEn229j5qvrqqLJIkqZDkqOAa+h2SgQ4BFhSVe9sGkwaoSR/WFVHt84hSZLmX5KFwElVdUjrLNp8FsMkSRqYJA8Ffo3uqZ1/q6prGkeSJE2gJBdU1Z73tiZNsySLgNcBS6vq1UkeBSyrqjMbR9OUS7Iz8D5gL7rP9V8H/qiqrmgaTJKmXJIvAi+sqltbZxlHfTvffenem75WVZ9tHOlOC1oHkCRJo5Pkd+haJL4YOAg4P4mtVCRJW+L2JIckWZhkQZJDgNtbh5JG7AS6VkD79Mc/AN7WLo4G5BPAqcAv0bXrPA34p6aJJGkYrgTOTfLmJK+f+Wodahwk+QDw+8BldDPrfz/JP7RNdRd3hkmSNCBJvgPsU1XX9ccPAs6rqmVtk0mSJk2Sneh2Jazol86h25Xw/UaRpJFL8o2qemKSNVW1e792SVXt1jqbptsGdueeX1V7tcokSUOQ5C1zrVfVW0edZdwk+Sawa/VFpyQLgMuq6rFtk3Xu0zqAJEkaqR/QDXedsQ64ulEWSdIE64teB7TOITV2a5L70bUCIskjgVvaRtJArEzyRrrdYAX8JvDPSR4IUFU/ahlOkqbVTNEryaKquql1njHzHWAp3e45gEcAl7aLc3fuDJMkaUCSnAQ8Dvgc3UXzAXRtE78LUFXvaZdOkjRJkjwcOJpuZ1jR7Qx7bVX9oGkwaYSS7A+8CdgFOIvu/8NvV9VXWubS9EuysdlgVVU7jyyMJA1Ikr2B44HFVbU0yW7A71XV4Y2jNZfkq8CT6O4z0X//deBmgKp6YaNogMUwSZIGZUPb+We4rV+StKmSfJluZs3J/dLLgEOqav92qaTR69tO7wUEOL+qftg4kiRJmidJLqCbwX7GrBbJl1fVrm2TtZdkv42dr6qvjirLXCyGSZIkSZI2W5KLq+rx97YmTbsky4GdmDWKoqpObxZIkiTNm5mZjc4LnTzODJMkSZIkbYkfJnkZ8Mn++KXAdQ3zSCOX5ARgOfBN4I5fe9yhAAAOfElEQVR+uQCLYZIkTaerk+wDVJKtgCOAtY0zaRO4M0ySJEmStNmSLAWOAfamu/l/HnBEVV3VNJg0Qkm+VVW7tM4hSZJGI8n2wPuAZ9C1SD6Lbm6uD4WNOXeGSZI0EEkW0t2kfG/rLJKkqfCI9YdgJ1kBWAzTkHw9yS5V9a3WQTQMSfbY2PmqWj2qLJI0RP1s0ENa59Dmc2eYJEkDkuQrVfWU1jkkSZMvyeqq2uPe1qRpluTXgc8D1wC30D0hXlW1vGkwTa0kKzdyuqrqaSMLI0kDlOREup1gP+6PtwPeXVWvbJusnSSX0XWKuMcpxuhzkTvDJEkalnOTHAOcAtw0s+gTpJKkTZVkb2Af4MFJXj/r1DbAwjappGZOAA4FLuOumWHSvKmqp7bOIEkDt3ymEAZQVdcn2b1loDHw/NYBNoXFMEmShmWf/vWoWWsF+ASpJGlTbQUsprueXDJr/SfAQU0SSe1cVVVntA6hYUqyK7ALsPXMWlWd1C6RJA3CgiTbVdX1AEkeyMDrLFV1ZesMm8I2iZIkSZKkzZZkx6q6MskSuvYnN7bOJI1akg8A29K1SrxlZr2qTm8WSoOQ5C3AU+iKYf8CPAc4p6p8KEGS5lGSw4A/Bz5F93DxS4C3V9XJTYONgSR7AUcDj6F7gG4hcFNVbdM0WG/QFUtJkoYmyS8CfwPsUFXPSbILsHdVHd84miRp8ixJsgZ4IECSHwIvr6rL28aSRup+dEWwZ85aK8BimObbQcBuwJqqekX/Of8jjTNJ0tSrqpOSfIOuw06AF1fVtxrHGhfHAL8FnAY8ETgM+JWmiWaxGCZJ0rB8DPgo8Jf98Xfp5odZDJMkba4PA6+vqpUASZ7Sr+2zsV+SpklVvaJ1Bg3W/1bVHUluS7INcC2wc+tQkjQEffHLAtgcquo/kiysqtuBjyY5r3WmGRbDJEkalu2r6tQkfw5QVbclub11KEnSRFo0UwgDqKqvJFnUMpA0akm2Bl4FPJa7z216ZbNQGopvJNkWOA64CLgRuLBtJEnSwN2cZCvg4iTvBP4bGJvrgwWtA0iSpJG6KcmD6Nr3zPRzvqFtJEnShPpekjcn2an/ehNwRetQ0oidDDwUeBbwVeDhwLqmiTQIVXV4Vf24qo4F9qdrU+tORUlSS4fS1ZxeA9wEPAI4sGmiWVJVrTNIkqQRSbIH3TDTXYHLgQcDB1XVpU2DSZImTpLtgLcC+9LNS1gFHFlV1zcNJo1QkjVVtXuSS6tqeZJfAL5UVU9rnU3TL8nDgB2Z1fmpqla1SyRJ0viyTaIkSQNSVauT7Acso7tx+Z2q+lnjWJKkCdQXvY5onUNqbOZz1I+T7ApcA+zULo6GIsk7gN+km1kz0/a86B5MkCRp5JKsAI7kng9qjMVMS4thkiQNSJKDgS9W1Tf7dlZ7JHlbVa1unU2SNFmSPBr4E7ob/7Mvdt0RoyH5cL9L8k3AGcBi4K/aRtJA/AawrKpuaR1EkqTe8cDr6GZZjt18etskSpI0ILNa+OwL/C3w98BfVNWejaNJkiZMkkuAY1nvYreqLmoWSpIGIskXgIOr6sbWWSRJAkhywTjfX3JnmCRJwzJzs/J5wAer6nNJjmyYR5I0uW6rqg+2DiG1lORk4DVVdUN/vCNwQlU9vW0yDcDNwMVJzgbu3B1WVbavlSS1sjLJu4DTuft701h0I7IYJknSsPxnkg8BzwDekeS+wILGmSRJEyTJA/tvP5/kcOAz3P1i90dNgkltnANckOT1wMOANwB/3DaSBuKM/kuSpHExsyvsibPWChiLNuq2SZQkaUCS3B94NnBZVf17kl8CHldVZzWOJkmaEEmuoLuozRyna1wGZEuj0refXgn8ENi9qq5pHEmSJEnrsRgmSdIAJXkIsPXMcVVd1TCOJEnSREpyKPBm4C3AcuBZwCuq6pKmwTS1kpxaVS9Jchndgwl3U1XLG8SSJA1YkpdV1cf7nfL3UFXvGXWmudgmUZKkAUnyQuDdwA7AtcBS4NvAY1vmkiRNniRbA4cD+9LdkP0acGxV/bRpMGm0DgT2raprgU8m+QxwIvD4trE0xV7bvz6/aQpJku6yqH9dMse5sdmN5c4wSZIGJMkldL2a/7Wqdk/yVOClVfXqxtEkSRMmyanAOuDj/dJLge2q6uB2qaT2kmxVVbe2zqHpluQdVfVn97YmSdKoJFlRVefe21orC1oHkCRJI/WzqroOWJBkQVWtxCeXJUlbZllVvaqqVvZfrwYe3TqUNEpJHp3k7CSX98fLgT9tHEvDsP8ca88ZeQpJku5y9CauNWGbREmShuXHSRYDq4B/THItcFvjTJKkybQmyV5VdT5Akj2BsXjqUxqh44A3AB8CqKpLk3wCeFvTVJpaSf6ArkXtzkkunXVqCXBem1SSpCFLsjewD/Dg9eaGbQMsbJPqniyGSZI0LAcAPwVeBxwCPAA4qmkiSdKk2hM4LMlV/fFSYG2Sy4CqquXtokkjc/+qujDJ7DUfNNJ8+gTwBeBvgTfOWl9XVT9qE0mSNHBbAYvp6k2z54b9BDioSaI5ODNMkiRJkrTZkuy4sfNVdeWoskitJPkC8BrgtKraI8lBwKuqynZ1mndJ9gUeVVUfTbI9sKSqrmidS5I0TEl2rKorkyyqqpta51mfxTBJkgYgyTpgrjf90D29v82II0mSJE28JDsDH6ZrDXQ9cAXwsqr6fstcmn5J3gI8kW5+46OT7EBXlF3ROJokaaD6donHA4urammS3YDfq6rDG0cDLIZJkiRJkiT9XJIsAhZU1brWWTQMSS4GdgdWV9Xu/dqltqiVJLWS5AK6tohnzHpvuryqdm2brOPMMEmSJEmSpM2w3nD42esAVNV7RhpIQ3RrVVWSgjsLspIkNVVVV683S/X2VlnWZzFMkiRJkiRp88wMh18GPAk4oz9+AbCqSSINzalJPgRsm+R3gVcCxzXOJEkatquT7ANUkq2AI4C1jTPdyTaJkiRJkiRJWyDJWcCBM+0Rkyyhm9v07LbJNARJ9geeSTcH+EtV9eXGkSRJA5Zke+B9wDPo3pvOAl5bVdc1DdZzZ5gkSZIkSdKWWQrcOuv4VmCnNlE0FEkW0hW/ngFYAJMkNde/Nx1aVYe0zrIhFsMkSZIkSZK2zMnAhUk+AxTwIuDEtpE07arq9iQ3J3lAVd3QOo8kSf170wHAe1tn2RDbJEqSJEmSJG2hJHsAT+4PV1XVmpZ5NAxJTgX2otsZdtPMelUd0SyUJGnQkrwdeABwCnd/b1rdLNQsFsMkSZIkSZKkCZLk5XOtV5U7EyVJTSRZOcdyVdXTRh5mDhbDJEmSJEmSJEmSNLUWtA4gSZIkSZIkadMlWZHky0m+m+R7Sa5I8r3WuSRJAkhyZusM67tP6wCSJEmSJEmSNsvxwOuAi4DbG2eRJGl9D2sdYH0WwyRJkiRJkqTJckNVfaF1CEmSNmBN6wDrc2aYJEmSJEmSNEGS/B2wEDgduGVmvapWNwslSdIYsxgmSZIkSZIkTZAkK+dYrqp62sjDSJJEN88SOBLYka4rYejem3ZumWuGxTBJkiRJkiRJkiRtsSTfZo55llV1XbNQszgzTJIkSZIkSZowSZ4HPBbYematqo5ql0iSNHBjPc/SYpgkSZIkSZI0QZIcC9wfeCrwEeAg4MKmoSRJQ7cyybsY03mWtkmUJEmSJEmSJkiSS6tq+azXxcDpVfXM1tkkScM07vMs3RkmSZIkSZIkTZb/7V9vTrIDcB3wyw3zSJIGrqqe2jrDxlgMkyRJkiRJkibLmUm2Bd4FrAYKOK5tJEnS0I3zPEvbJEqSJEmSJEkTKsl9ga2r6obWWSRJw7WheZZV9aqmwXoWwyRJkiRJkqQJkmRr4HBgX7pdYecAH6yqnzYNJkkarHGfZ7mgdQBJkiRJkiRJm+UkujZURwPHAI8BTm6aSJI0dOvPs/wZYzTP0plhkiRJkiRJ0mRZVlW7zTpemeSSZmkkSRrzeZa2SZQkSZIkSZImSJKPAcdW1fn98Z7Ay6vq8KbBJEliPOdZWgyTJEmSJEmSJkiStcAy4Kp+aSmwFrgDqKpa3iqbJGmYxn2epcUwSZIkSZIkaYIk2XFj56vqylFlkSQJIMmpwDrg4/3SS4HtqurgdqnuYjFMkiRJkiRJkiRJWyzJJevNs5xzrZUFrQNIkiRJkiRJkiRpoq1JstfMQT/P8tyGee7GnWGSJEmSJEmSJEnaYuM+z9JimCRJkiRJkiRJkrbYuM+ztBgmSZIkSZIkSZKkqeXMMEmSJEmSJEmSJE0ti2GSJEmSJEmSJEmaWhbDJEmSJGmMJTkyyZ+0ziFJkiRJk8pimCRJkiRNmCT3aZ1BkiRJkiaFF1CSJEmSNGaS/CVwGHA18D/ARUm+ApwHrADOSPI44Myq+lT/OzdW1eIkC4BjgP2AK+gegjxh5uckSZIkaWgshkmSJEnSGEnyBOC3gN3prtlWAxf1p7etqv36n/vYBv6IFwM7AY8DHgKsBU6Yv8SSJEmSNN4shkmSJEnSeHky8JmquhkgyRmzzp2yCb+/L3BaVd0BXJNk5TxklCRJkqSJ4cwwSZIkSRo/tYH1m2Z9fxv9NV2SAFv165nHXJIkSZI0cSyGSZIkSdJ4WQW8KMn9kiwBXrCBn/s+8IT++wOAX+i/Pwc4MMmCJL8IPGUes0qSJEnS2LNNoiRJkiSNkapaneQU4GLgSuBrG/jR44DPJbkQOJu7do19Gng6cDnwXeAC4IZ5DS1JkiRJYyxVG+q+IUmSJEmaREkWV9WNSR4EXAisqKprWueSJEmSpBbcGSZJkiRJ0+fMJNvSzRH7awthkiRJkobMnWGSJEmSJEmSJEmaWgtaB5AkSZIkSZIkSZLmi8UwSZIkSZIkSZIkTS2LYZIkSZIkSZIkSZpaFsMkSZIkSZIkSZI0tSyGSZIkSZIkSZIkaWr9H1MAUeqSa2ILAAAAAElFTkSuQmCC\n",
      "text/plain": [
       "<Figure size 2160x1440 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Countplot to see the frequency of the drugs in the test set.\n",
    "plt.figure(figsize=(30,20))\n",
    "sns.countplot(pharmacy_med_reviews_testset['drug'])\n",
    "plt.xticks(rotation=90)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Observations:\n",
    "##### From the graphs we can see that the drugs about which most of the reviews were given are \"Gilenya\" followed by \"Ocrevus\" and \"Fingolimod\"\n",
    "##### We can clearly see that there was some changes in the amount of reviews given for certain drugs."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Countplot to see the frequency of the sentiments in the sentiment column in training set.\n",
    "sns.countplot(pharmacy_med_reviews_trainset['sentiment'])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "# WordCloud before preprocessing of the data for the training set.\n",
    "from wordcloud import WordCloud,ImageColorGenerator,STOPWORDS\n",
    "\n",
    "text_string = \" \".join(pharmacy_med_reviews_trainset['text'].str.lower())\n",
    "wordcloud = WordCloud(background_color='white').generate(text_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1440x1440 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Showing the wordcloud.\n",
    "plt.figure(figsize=(20,20))\n",
    "plt.clf()\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis('off')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 2160x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# WordCloud before preprocessing of the data for the testing set\n",
    "text_string = \" \".join(pharmacy_med_reviews_testset['text'].str.lower())\n",
    "wordcloud = WordCloud(background_color='white').generate(text_string)\n",
    "plt.figure(figsize=(30,30))\n",
    "plt.clf()\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis('off')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### -----------------------------------------------------------------------------------------------------------"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## NLP Pipeline:"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Preprocessing of the data using NeatText Package for both training and testing sets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Importing the necessary libraries.\n",
    "\n",
    "from neattext import TextCleaner"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>unique_hash</th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2e180be4c9214c1f5ab51fd8cc32bc80c9f612e0</td>\n",
       "      <td>Autoimmune diseases tend to come in clusters. ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>9eba8f80e7e20f3a2f48685530748fbfa95943e4</td>\n",
       "      <td>I can completely understand why you’d want to ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>fe809672251f6bd0d986e00380f48d047c7e7b76</td>\n",
       "      <td>Interesting that it only targets S1P-1/5 recep...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>bd22104dfa9ec80db4099523e03fae7a52735eb6</td>\n",
       "      <td>Very interesting, grand merci. Now I wonder wh...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>b227688381f9b25e5b65109dd00f7f895e838249</td>\n",
       "      <td>Hi everybody, My latest MRI results for Brain ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                unique_hash  \\\n",
       "0  2e180be4c9214c1f5ab51fd8cc32bc80c9f612e0   \n",
       "1  9eba8f80e7e20f3a2f48685530748fbfa95943e4   \n",
       "2  fe809672251f6bd0d986e00380f48d047c7e7b76   \n",
       "3  bd22104dfa9ec80db4099523e03fae7a52735eb6   \n",
       "4  b227688381f9b25e5b65109dd00f7f895e838249   \n",
       "\n",
       "                                                text        drug  sentiment  \n",
       "0  Autoimmune diseases tend to come in clusters. ...     gilenya          2  \n",
       "1  I can completely understand why you’d want to ...     gilenya          2  \n",
       "2  Interesting that it only targets S1P-1/5 recep...  fingolimod          2  \n",
       "3  Very interesting, grand merci. Now I wonder wh...     ocrevus          2  \n",
       "4  Hi everybody, My latest MRI results for Brain ...     gilenya          1  "
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Data frame for the training set.\n",
    "p_m_r_df = pd.DataFrame(pharmacy_med_reviews_trainset)\n",
    "p_m_r_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>unique_hash</th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9e9a8166b84114aca147bf409f6f956635034c08</td>\n",
       "      <td>256 (previously stable on natalizumab), with 5...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>e747e6822c867571afe7b907b51f0f2ca67b0e1a</td>\n",
       "      <td>On fingolimod and have been since December 201...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>50b6d851bcff4f35afe354937949e9948975adf7</td>\n",
       "      <td>Apparently it's shingles! :-/ I do have a few ...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7f82ec2176ae6ab0b5d20b5ffc767ac829f384ae</td>\n",
       "      <td>If the Docetaxel doing once a week x3 weeks th...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>8b37d169dee5bdae27060949242fb54feb6a7f7f</td>\n",
       "      <td>CC, Stelara worked in a matter of days for me....</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                unique_hash  \\\n",
       "0  9e9a8166b84114aca147bf409f6f956635034c08   \n",
       "1  e747e6822c867571afe7b907b51f0f2ca67b0e1a   \n",
       "2  50b6d851bcff4f35afe354937949e9948975adf7   \n",
       "3  7f82ec2176ae6ab0b5d20b5ffc767ac829f384ae   \n",
       "4  8b37d169dee5bdae27060949242fb54feb6a7f7f   \n",
       "\n",
       "                                                text        drug  \n",
       "0  256 (previously stable on natalizumab), with 5...  fingolimod  \n",
       "1  On fingolimod and have been since December 201...  fingolimod  \n",
       "2  Apparently it's shingles! :-/ I do have a few ...      humira  \n",
       "3  If the Docetaxel doing once a week x3 weeks th...    tagrisso  \n",
       "4  CC, Stelara worked in a matter of days for me....     stelara  "
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Data Frame for the testing set.\n",
    "p_m_r_df1 = pd.DataFrame(pharmacy_med_reviews_testset)\n",
    "p_m_r_df1.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame(p_m_r_df[['text','drug','sentiment']])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "df1 = pd.DataFrame(p_m_r_df1[['text','drug']])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "docx = TextCleaner()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Removing the numbers."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Removing the numbers from the text for training set.\n",
    "df['text'] = df.apply(lambda docx: TextCleaner(docx['text']).remove_numbers(),axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend to come in clusters. ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I can completely understand why you’d want to ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting that it only targets SP-/ receptor...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting, grand merci. Now I wonder wh...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody, My latest MRI results for Brain ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  Autoimmune diseases tend to come in clusters. ...     gilenya          2\n",
       "1  I can completely understand why you’d want to ...     gilenya          2\n",
       "2  Interesting that it only targets SP-/ receptor...  fingolimod          2\n",
       "3  Very interesting, grand merci. Now I wonder wh...     ocrevus          2\n",
       "4  Hi everybody, My latest MRI results for Brain ...     gilenya          1"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(previously stable on natalizumab), with % sw...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod and have been since December ; t...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently it's shingles! :-/ I do have a few ...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If the Docetaxel doing once a week x weeks the...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC, Stelara worked in a matter of days for me....</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0   (previously stable on natalizumab), with % sw...  fingolimod\n",
       "1  On fingolimod and have been since December ; t...  fingolimod\n",
       "2  Apparently it's shingles! :-/ I do have a few ...      humira\n",
       "3  If the Docetaxel doing once a week x weeks the...    tagrisso\n",
       "4  CC, Stelara worked in a matter of days for me....     stelara"
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the numbers from the text for training set.\n",
    "df1['text'] = df1.apply(lambda docx: TextCleaner(docx['text']).remove_numbers(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Removing the email_id's"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend come clusters As Gile...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I completely understand youd want try But resu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting targets SP receptors rather like F...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting grand merci Now I wonder lemt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody My latest MRI results Brain Cervi...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text\n",
       "0  Autoimmune diseases tend come clusters As Gile...\n",
       "1  I completely understand youd want try But resu...\n",
       "2  Interesting targets SP receptors rather like F...\n",
       "3  Very interesting grand merci Now I wonder lemt...\n",
       "4  Hi everybody My latest MRI results Brain Cervi..."
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the email address from the reviews of training set.\n",
    "df['text'] = df.apply(lambda docx: TextCleaner(docx['text']).remove_emails(),axis=1)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(previously stable on natalizumab), with % sw...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod and have been since December ; t...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently it's shingles! :-/ I do have a few ...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If the Docetaxel doing once a week x weeks the...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC, Stelara worked in a matter of days for me....</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0   (previously stable on natalizumab), with % sw...  fingolimod\n",
       "1  On fingolimod and have been since December ; t...  fingolimod\n",
       "2  Apparently it's shingles! :-/ I do have a few ...      humira\n",
       "3  If the Docetaxel doing once a week x weeks the...    tagrisso\n",
       "4  CC, Stelara worked in a matter of days for me....     stelara"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the email address from the reviews of the testing set.\n",
    "df1['text'] = df1.apply(lambda docx: TextCleaner(docx['text']).remove_emails(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Removing Phone Numbers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend to come in clusters. ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I can completely understand why you’d want to ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting that it only targets SP-/ receptor...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting, grand merci. Now I wonder wh...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody, My latest MRI results for Brain ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  Autoimmune diseases tend to come in clusters. ...     gilenya          2\n",
       "1  I can completely understand why you’d want to ...     gilenya          2\n",
       "2  Interesting that it only targets SP-/ receptor...  fingolimod          2\n",
       "3  Very interesting, grand merci. Now I wonder wh...     ocrevus          2\n",
       "4  Hi everybody, My latest MRI results for Brain ...     gilenya          1"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the phone numbers from the reviews of training set.\n",
    "df['text'] = df.apply(lambda docx: TextCleaner(docx['text']).remove_phone_numbers(),axis=1)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(previously stable on natalizumab), with % sw...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod and have been since December ; t...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently it's shingles! :-/ I do have a few ...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If the Docetaxel doing once a week x weeks the...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC, Stelara worked in a matter of days for me....</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0   (previously stable on natalizumab), with % sw...  fingolimod\n",
       "1  On fingolimod and have been since December ; t...  fingolimod\n",
       "2  Apparently it's shingles! :-/ I do have a few ...      humira\n",
       "3  If the Docetaxel doing once a week x weeks the...    tagrisso\n",
       "4  CC, Stelara worked in a matter of days for me....     stelara"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the phone numbers from the reviews of testing set.\n",
    "df1['text'] = df1.apply(lambda docx: TextCleaner(docx['text']).remove_phone_numbers(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Special Characters."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend to come in clusters A...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I can completely understand why youd want to t...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting that it only targets SP receptors ...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting grand merci Now I wonder wher...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody My latest MRI results for Brain a...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  Autoimmune diseases tend to come in clusters A...     gilenya          2\n",
       "1  I can completely understand why youd want to t...     gilenya          2\n",
       "2  Interesting that it only targets SP receptors ...  fingolimod          2\n",
       "3  Very interesting grand merci Now I wonder wher...     ocrevus          2\n",
       "4  Hi everybody My latest MRI results for Brain a...     gilenya          1"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the special charcaters from the reviews training set.\n",
    "df['text'] = df.apply(lambda docx: TextCleaner(docx['text']).remove_special_characters(),axis=1)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previously stable on natalizumab with  switch...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod and have been since December  th...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently its shingles  I do have a few red s...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If the Docetaxel doing once a week x weeks the...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC Stelara worked in a matter of days for me I...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0   previously stable on natalizumab with  switch...  fingolimod\n",
       "1  On fingolimod and have been since December  th...  fingolimod\n",
       "2  Apparently its shingles  I do have a few red s...      humira\n",
       "3  If the Docetaxel doing once a week x weeks the...    tagrisso\n",
       "4  CC Stelara worked in a matter of days for me I...     stelara"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the special charcaters from the reviews testing set.\n",
    "df1['text'] = df1.apply(lambda docx: TextCleaner(docx['text']).remove_special_characters(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Emojis Removal"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend to come in clusters A...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I can completely understand why youd want to t...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting that it only targets SP receptors ...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting grand merci Now I wonder wher...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody My latest MRI results for Brain a...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  Autoimmune diseases tend to come in clusters A...     gilenya          2\n",
       "1  I can completely understand why youd want to t...     gilenya          2\n",
       "2  Interesting that it only targets SP receptors ...  fingolimod          2\n",
       "3  Very interesting grand merci Now I wonder wher...     ocrevus          2\n",
       "4  Hi everybody My latest MRI results for Brain a...     gilenya          1"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the emojis from the reviews of training set.\n",
    "df['text'] = df.apply(lambda docx: TextCleaner(docx['text']).remove_emojis(),axis=1)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previously stable on natalizumab with  switch...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod and have been since December  th...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently its shingles  I do have a few red s...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If the Docetaxel doing once a week x weeks the...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC Stelara worked in a matter of days for me I...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0   previously stable on natalizumab with  switch...  fingolimod\n",
       "1  On fingolimod and have been since December  th...  fingolimod\n",
       "2  Apparently its shingles  I do have a few red s...      humira\n",
       "3  If the Docetaxel doing once a week x weeks the...    tagrisso\n",
       "4  CC Stelara worked in a matter of days for me I...     stelara"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the emojis from the reviews of testing set.\n",
    "df1['text'] = df1.apply(lambda docx: TextCleaner(docx['text']).remove_emojis(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Stopwords Removal"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Autoimmune diseases tend come clusters As Gile...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I completely understand youd want try But resu...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Interesting targets SP receptors rather like F...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Very interesting grand merci Now I wonder lemt...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Hi everybody My latest MRI results Brain Cervi...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  Autoimmune diseases tend come clusters As Gile...     gilenya          2\n",
       "1  I completely understand youd want try But resu...     gilenya          2\n",
       "2  Interesting targets SP receptors rather like F...  fingolimod          2\n",
       "3  Very interesting grand merci Now I wonder lemt...     ocrevus          2\n",
       "4  Hi everybody My latest MRI results Brain Cervi...     gilenya          1"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the stop words from the reviews of training set.\n",
    "df['text'] = df.apply(lambda x: TextCleaner(x['text']).remove_stopwords(),axis=1)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previously stable natalizumab switching fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>On fingolimod since December way I describe be...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Apparently shingles I red spots left breast ap...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If Docetaxel week x weeks week claim less hars...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CC Stelara worked matter days If GI willing ju...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0  previously stable natalizumab switching fingol...  fingolimod\n",
       "1  On fingolimod since December way I describe be...  fingolimod\n",
       "2  Apparently shingles I red spots left breast ap...      humira\n",
       "3  If Docetaxel week x weeks week claim less hars...    tagrisso\n",
       "4  CC Stelara worked matter days If GI willing ju...     stelara"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Removing the stop words from the reviews of testing set.\n",
    "df1['text'] = df1.apply(lambda x: TextCleaner(x['text']).remove_stopwords(),axis=1)\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Making everything to lower case."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>autoimmune diseases tend come clusters as gile...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>i completely understand youd want try but resu...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>interesting targets sp receptors rather like f...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>very interesting grand merci now i wonder lemt...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>hi everybody my latest mri results brain cervi...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  autoimmune diseases tend come clusters as gile...     gilenya          2\n",
       "1  i completely understand youd want try but resu...     gilenya          2\n",
       "2  interesting targets sp receptors rather like f...  fingolimod          2\n",
       "3  very interesting grand merci now i wonder lemt...     ocrevus          2\n",
       "4  hi everybody my latest mri results brain cervi...     gilenya          1"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Making all the text in the reviews of the training set to lower case.\n",
    "df['text'] = df['text'].apply(lambda x: \" \".join(x.lower() for x in x.split()))\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previously stable natalizumab switching fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>on fingolimod since december way i describe be...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>apparently shingles i red spots left breast ap...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>if docetaxel week x weeks week claim less hars...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>cc stelara worked matter days if gi willing ju...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0  previously stable natalizumab switching fingol...  fingolimod\n",
       "1  on fingolimod since december way i describe be...  fingolimod\n",
       "2  apparently shingles i red spots left breast ap...      humira\n",
       "3  if docetaxel week x weeks week claim less hars...    tagrisso\n",
       "4  cc stelara worked matter days if gi willing ju...     stelara"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Making all the text in the reviews of the testing set to lower case.\n",
    "df1['text'] = df1['text'].apply(lambda x: \" \".join(x.lower() for x in x.split()))\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Stemming using the NLTk package"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk.stem.snowball import SnowballStemmer\n",
    "stemmer = SnowballStemmer(\"english\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>autoimmun diseas tend come cluster as gilenya ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>i complet understand youd want tri but result ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>interest target sp receptor rather like fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>veri interest grand merci now i wonder lemtrad...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>hi everybodi my latest mri result brain cervic...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  autoimmun diseas tend come cluster as gilenya ...     gilenya          2\n",
       "1  i complet understand youd want tri but result ...     gilenya          2\n",
       "2  interest target sp receptor rather like fingol...  fingolimod          2\n",
       "3  veri interest grand merci now i wonder lemtrad...     ocrevus          2\n",
       "4  hi everybodi my latest mri result brain cervic...     gilenya          1"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Stemming for the reviews in the training set.\n",
    "df['text'] = df['text'].apply(lambda x: ' '.join([stemmer.stem(word) for word in x.split()]))\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previous stabl natalizumab switch fingolimod</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>on fingolimod sinc decemb way i describ better...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>appar shingl i red spot left breast appear day...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>if docetaxel week x week week claim less harsh...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>cc stelara work matter day if gi will jump hoo...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0       previous stabl natalizumab switch fingolimod  fingolimod\n",
       "1  on fingolimod sinc decemb way i describ better...  fingolimod\n",
       "2  appar shingl i red spot left breast appear day...      humira\n",
       "3  if docetaxel week x week week claim less harsh...    tagrisso\n",
       "4  cc stelara work matter day if gi will jump hoo...     stelara"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Stemming for the reviews in the testing set.\n",
    "df1['text'] = df1['text'].apply(lambda x: ' '.join([stemmer.stem(word) for word in x.split()]))\n",
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Parts of Speech Tagging"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package averaged_perceptron_tagger to\n",
      "[nltk_data]     C:\\Users\\kvknb\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package averaged_perceptron_tagger is already up-to-\n",
      "[nltk_data]       date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('averaged_perceptron_tagger')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Parts of speech tagging for the training set.\n",
    "parts_of_speech = nltk.pos_tag(df['text'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('autoimmun diseas tend come cluster as gilenya feel good dont think wont chang anyth wast time energi im take tysabri feel amaz symptom dodgi color vision ive sinc alway dont know i dont know last month year decad ive decid enjoy ride point worri',\n",
       "  'NN'),\n",
       " ('i complet understand youd want tri but result report lectur dont alway stand scrutini peerreview public there much still convinc i hope work i realli and your awar happi risk that great i think import present balanc way understand dont move straight first show promis anim studi use drug human there still lot anim data gather human data gather anyon tell safe effect i cant tell mani time anim studi dont follow human one major attrit point drug develop youv unpredict issu cladribinegilenya interact wasnt predict but peopl tri doctor see pattern work what go clemastinemetformin excit given youv said current condit person risk toler make sens tri it definit wouldnt everyon',\n",
       "  'NN'),\n",
       " ('interest target sp receptor rather like fingolimod hope soon see ae sae yes im sure mean exact quot nine patient report serious advers event mg mg mg mg serious advers event report patient new safeti signal occur compar bold studi if patient report sae state serious advers event report patient mayb i havent read right mayb there misprint im pleas someth develop spms encourag siponimod doesnt linger long bodi',\n",
       "  'JJ'),\n",
       " ('veri interest grand merci now i wonder lemtrada ocrevus sale would go prove anticd induct',\n",
       "  'NN'),\n",
       " ('hi everybodi my latest mri result brain cervic cord next neurologist appoint next coupl week therer new lesion braincord ive relaps i gilenya this good sign but one line cervic cord review concern it goe lesion c t show hypointens post gadolinium t imag this could repres artifact earli axon loss that bothersom read what kind symptom cc lesion i awar would result chang dmt thank',\n",
       "  'NN'),\n",
       " ('i cant give advic lemtrada i chose cladribin have thought drug the doctor bart keen give peopl spms you read httpmultiplesclerosisresearchblogspotcomsupposetherewastherapyforallhtml',\n",
       "  'JJ'),\n",
       " ('repli post jesszidek hi jess sorri read challeng health you mention lot post i want share info point first i know said scare humira humira biolog success reduc symptom induc maintain diseas remiss to reduc level fear help learn treatment option you learn treatment option to learn view understand ibd medic brochur httpwwwcrohnscolitisfoundationorgassetspdfsunderstandingibdmedsnovpdf if would like talk contact help center',\n",
       "  'NN'),\n",
       " ('well expect neurologist want start tysabri i kept say i wasnt happi kept say yes but i still not if lemtrada avail i think i would definit go thatbut like everi thing way behind took year longer australia get gilenya tysabri i take gilenya everi second daybut vital still lowwhit blood count last week on day i dont take i box birdsa normal i again i realli dont want tysabri and consid attend i voic concernsbut it seem even itif toler ok averag time stop though becom jvc posit two year',\n",
       "  'VBP'),\n",
       " ('whi think fingolimod miser failur progress ms trial human anim abort biogen if fact stimul neuron gene express axon growth regener want progress patient human trial fail',\n",
       "  'JJ'),\n",
       " ('thank muchim learn lot grace i mention husband cancer bone liver adren addit lung brain met i mention i truli appreci comment hospic start hospic week agomi insur allow palliat care along continu anticanc treatment i thought hospic endoflif care thus hesit truli bless theyv help equip medicin twice week visit give us bit measur husband they extrem help i meant askdo opdivo andor tagrisso penetr blood brain barrier ive heard yes my husband start opdivo treatment switch irinotecan chemo brain met after first chemo end hospit pneumonia thank gina',\n",
       "  'NN'),\n",
       " ('i vision one eye unrel eye inject howev problem began good eye get inject one eye alway horrifi experi mental it still scari till today dont get use i mani eye inject my first i year old year ago i develop eye infect one could pinpoint exact so one one everi antibiot inject eye period week total inject it big relief last antibiot avail job option left two year later i cataract surgeri within week i develop retin vein occlus also macular oedema came play well and began avasrin inject lucenti i would get frequent and year later becam month inject i stop count sometim inject becom pitch black the first time i terrifi but i told due eye pressur injur came back normal main thing i make sure may may happen procedur eye condit least i prepar it true australia neither lucenti eylea cover govern unless one macular degener even though condit also vision threaten eylea extend time period inject biggest mileston achiev date i grate all ophthalmologist gone beyond profess make inject process comfort possibl and research well done keep go the eye priceless',\n",
       "  'NN'),\n",
       " ('there signific bleed right eye need laser possibl surgeri longer term there thank less left treat inject assess click expand ah ok it mention macular oedema doesnt caus vitreous haemorrhag didnt mention prolif diabet retinopathi pdr caus vitreous haemorrhag i know mention laser differ type sometim macular oedema treat macular laser the type use pdr call prp panretin photocoagul appli peripheri retina there good inform inject macular oedema httpwwwdiabeticretinopathyorguklucentispatientsdrhtm good inform laser treatment',\n",
       "  'NN'),\n",
       " ('object to review evid support european union market author drug multipl sclerosi ms assess far postmarket research address inform gap time approv method through databas identifi drug approv european medicin agenc gather data pivot trial european public assess report correspond public we search medlin embas cochran librari trial registri postmarket random control trial test drug identifi form diseas result sinc approv interferon glatiram agenc examin drug treatment ms includ studi alemtuzumab daclizumab dimethyl fumar fampridin fingolimod peginterferona natalizumab teriflunomid we analyz pivot trial enrol almost particip eleven compar new drug placebo interferona annual relaps rate primari outcom twothird coprimari disabl progress studi alemtuzumab of postmarket trial report final result ongo termin complet result avail none direct compar approv drug thus leav respect therapeut valu unknown data prevent diseas progress scarc none diseasemodifi drug show effect disabl progress conclus the lack compar evid data clinic effect hamper assess therapeut valu place therapi drug approv ms',\n",
       "  'NN'),\n",
       " ('multipl sclerosi ms thought inflammatori process involv differ area central nervous system cns various point time what caus this diseas the caus multipl sclerosi known both environment genet factor thought predispos person develop diseas multipl sclerosi result destruct myelin surround nerv cns myelin fatti substanc insul nerv allow transmit inform brain if myelin damag transmit inform delay also may misinterpret brain the myelin destruct also known demyelin thought caus bodi immun cell enter cns the disrupt normal barrier entri cell term bloodbrain barrier lead local swell known edema also damag nerv cell bodi term neuron loss prolong term axon loss a plaqu area inflamm demyelin axon loss edema scar repres typic multipl sclerosi lesion area injuri what initi trigger immun system attack known microglia cell cns take fragment myelin present fragment immun cell in healthi individu present myelin fragment thought trigger immun cell attack cns in peopl multipl sclerosi present myelin fragment may trigger exagger respons immun cell lead format plaqu around blood vessel cns what are sign symptom share your stori perhap common symptom ms sensori disturb manifest tingl numb sensat throughout bodi visual disturb also among common symptom blur hazi vision color percept alter vision loss may occur develop optic neuriti inflamm optic nerv in typic case optic neuriti person multipl sclerosi experi ocular pain eye movement other common symptom includ loss balanc fine motor skill facial pain weak vertigo spin sensat limb weak paralysi impair control bladder bowel function fatigu depress memori loss individu advanc diseas lose abil walk may becom bedridden requir assist activ is there cure ms no current vaccin treatment cure multipl sclerosi what drug treat symptom share your stori sever medic avail decreas number attack period relaps multipl sclerosi delay progress physic disabl your doctor health care profession prescrib medic therapi treat general symptom associ diseas depress muscl spasm fatigu bladder problem tremor shaki poor coordin sexual dysfunct interferon glatiram acet capaxon interferon betaa avonex rebif interferon betab betaseron glatiram acet copaxon exampl immunemodifi drug use ms general medic tend decreas frequenc attack patient mildtomoder relaps remit ms rrms the rate new lesion appear magnet reson imag mri also reduc approxim onethird with interferon drug effect direct relat dose higher dose ifn toler general effect whether delay onset new attack drug ultim longterm impact disabl associ multipl sclerosi controversi howev clinic trial suggest patient receiv earli treatment benefici impact relaps disabl may match patient treatment delay research regard continu the abil respond longterm interferon betaa betab may limit patient develop persist high titer neutral antibodi patient treat glatiram also eventu develop antibodi antibodi seem limit glatiram activ multipl sclerosi slideshow make msfriend home take ms quiz corticosteroid methylprednisolon solumedrol corticosteroid frequent use intraven speed recoveri ms attack it help administ short within day onset attack how corticosteroid work corticosteroid affect immunolog action inflamm swell immun respons associ acut sudden attack multipl sclerosi corticosteroid use short period reduc durat sever symptom associ sudden attack who use medic individu allerg corticosteroid individu activ peptic ulcer diseas individu system fungal infect who use caution use medic peopl diabet seizur hypertens congest heart failur osteoporosi tuberculosi viral infect impair liver function peopl take medic these peopl consult doctor level medic may elev use along corticosteroid use solumedrol administ intraven iv day treat sudden multipl sclerosi attack steroid impact degre clinic recoveri rather shorten time recoveri drug food interact mani drug interact possibl contact doctor pharmacist take new prescript overthecount medic aspirin nonsteroid antiinflammatori drug ibuprofen advil naproxen alev medic associ stomach ulcer may increas risk develop stomach ulcer corticosteroid may decreas potassium level therefor caution must use take medic decreas potassium level diuret exampl furosemid lasix side effect ideal corticosteroid use short period order control sudden flare multipl sclerosi symptom shortterm use may caus fluid retent potassium loss stomach distress weight gain chang emot longterm use associ serious side effect osteoporosi calcium vitamin d supplement advis adren insuffici psychosi immunosuppress peptic ulcer hypertens insomnia menstrual irregular acn skin atrophi elev blood sugar abnorm appear face cushingoid face increas risk infect cataract induct problem blood sugar level worsen diabet control chang diet initi oral antidiabet medic insulin may requir for individu alreadi diabet dosag chang may need insulin antidiabet medic weight gain this common problem highdos corticosteroid due fluid retent endocrin alter salt restrict advis doctor approv potassium supplement may need a doctor may prescrib diuret water pill increas urin elimin excess fluid immunosuppress mitoxantron novantron food drug administr fda approv immunosuppress use treatment multipl sclerosi other immunosuppress cyclophosphamid cytoxan azathioprin imuran methotrex rheumatrex trexal prescrib primarili special center efficaci multipl sclerosi remain controversi fda approv use these drug substitut immunemodul drug firstlin agent newli diagnos relaps remit multipl sclerosi rrms some physician find role cytoxan imuran methotrex lastresort measur patient respond fda approv drug fulmin malign cours multipl sclerosi may life threaten how immunosuppress work this group includ wide varieti agent work mani differ way interfer immunesystem process caus inflamm who use medic individu allerg medic women pregnant breastfeed individu preexist bone marrow suppress individu diseas caus low blood count dose depend drug prescrib immunosuppress may administ oral intraven drug food interact the use immunosuppress increas risk infect increas toxic bone marrow blood cell may lead cancer mani drug interact possibl contact doctor pharmacist begin new prescript overthecount medic side effect immunosuppress safe pregnanc may caus bone marrow blood cell toxic may lead cancer patient impair kidney liver function may need lower dose close monitor methotrex may caus toxic liver lung fibrosi pneumon even damag nervous system leukoencephalopathi myelopathi mitoxantron may caus heart problem requir monitor echocardiogram ultrasonographi heart therapi cyclophosphamid may caus bleed within bladder even bladder cancer follow doctor recommend fluid intak take medic indic immunosuppress drug multipl sclerosi mitoxantron novantron indic reduc neurolog disabl andor frequenc clinic relaps patient secondari chronic progress progress relaps worsen relapsingremit multipl sclerosi ie patient whose neurolog status signific abnorm relaps novantron indic treatment patient primari progress multipl sclerosi bad bug their bite sex drive killer cancer tumor multipl sclerosi adult skin problem habit that wreck your teeth manag diabet minut erectil dysfunct type diabet warn sign health benefit sex scalp hair nail adhd symptom children other therapi avail ms symptom fingolimod gilenya fingolimod gilenya daili oral medic treat ms approv us fda septemb first oral medic treat ms although exact mechan action fingolimod unclear appear work reduc number lymphocyt type white blood cell import immun inflamm process blood fingolimod taken daili capsul form it cure ms shown decreas number ms flare slow develop physic disabl caus ms like mani inject therapi ms longterm safeti fingolimod unknown the common side effect fingolimod headach flu diarrhea back pain elev liver enzym blood cough other side effect also possibl includ eye problem take drug regular ophthalmolog evalu plasmapheresi plasma exchang this therapi sometim attempt treatment sever attack diseas respond corticosteroid this therapi expens fda approv multipl sclerosi efficaci controversi iv immun globulin ivig although fda approv multipl sclerosi studi suggest ivig reduc rate second attack ivig administ week follow first attack other research found benefit given patient condit least year yet other studi ivig given regular month schedul found small signific benefit improv clinic disabl fewer relaps new investig drug research addit treatment option continu advanc multipl approach investig base increas knowledg immun system abnorm cns lesion format multipl sclerosi these includ approach counteract reduc immun system activ blood brain barrier disrupt neuron loss myelin loss among investig effort',\n",
       "  'NN'),\n",
       " ('your mom diagnosi similar mine detect januari chest xray pneumonia discov well spot lung non operablestag i began treatment march radiat chemo i abl keep yoga class walk my side affect end treatment i sever radiat burn they pain it took week get fatigu recov burn i say i feel better januari last the pneumonia brutal i place drug tagrisso it prevent cancer spreadingi see oncologist today get result last scanstay activ help treatment prayer mom',\n",
       "  'NN'),\n",
       " ('humira adalimumab inject protein antibodi use treat rheumatoid arthriti juvenil idiopath arthriti psoriat arthriti ankylos spondyl plaqu psoriasi humira also use treat crohn diseas drug tri without success treatment symptom common side effect humira includ inject site reaction red itch pain bruis swell bleed headach suffi nose sinus pain stomach pain tell doctor serious side effect humira includ fastirregularpound heartbeat stomach pain blood stool mentalmood chang sever headach easi bruis bleed dark urin yellow eye skin leg pain swell numb tingl armshandslegsfeet unsteadi unexplain muscl weak difficulti speakingchewingswallowingfaci movement vision chang extrem fatigu joint pain butterflyshap rash nose cheek the recommend dose humira adult patient rheumatoid arthriti ra psoriat arthriti psa ankylos spondyl as mg administ everi week pediatr dosag determin child weight other drug may interact humira tell doctor prescript overthecount medic supplement use dure pregnanc humira use prescrib it unknown drug pass breast milk similar drug pass breast milk consult doctor breastfeed our humira adalimumab side effect drug center provid comprehens view avail drug inform potenti side effect take medic this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda rheumatoid arthriti slideshow take ra quiz jointfriend exercis slideshow humira consum inform get emerg medic help sign allerg reaction hive difficulti breath swell face lip tongu throat stop use adalimumab call doctor right away symptom lymphoma fever swollen gland night sweat general feel ill joint muscl pain skin rash easi bruis bleed pale skin feel lighthead short breath cold hand feet pain upper stomach may spread shoulder loss appetit feel full eat small amount weight loss also call doctor new worsen psoriasi rais silveri flake skin liver problem fever bodi ach tired stomach pain rightsid upper stomach pain vomit loss appetit dark urin claycolor stool jaundic yellow skin eye lupuslik syndrom joint pain swell chest pain short breath patchi skin color worsen sunlight nerv problem numb tingl dizzi vision problem weak arm leg sign tuberculosi fever ongo cough weight loss fat muscl older adult may like develop infect cancer use adalimumab common side effect may includ headach cold symptom stuffi nose sinus pain sneez sore throat rash red bruis itch swell inject given this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda read entir detail patient monograph humira adalimumab inject solut subcutan administr learn more rheumatoid arthriti slideshow take ra quiz jointfriend exercis slideshow humira profession inform side effect the serious advers reaction describ elsewher label includ follow serious infect see warn and precaut malign see warn and precaut clinic trial experi becaus clinic trial conduct wide vari condit advers reaction rate observ clinic trial drug cannot direct compar rate clinic trial anoth drug may reflect rate observ practic the common advers reaction humira inject site reaction in placebocontrol trial patient treat humira develop inject site reaction erythema andor itch hemorrhag pain swell compar patient receiv placebo most inject site reaction describ mild general necessit drug discontinu the proport patient discontinu treatment due advers reaction doubleblind placebocontrol portion studi patient ra ie studi rai raii raiii raiv patient take humira placebotr patient the common advers reaction lead discontinu humira ra studi clinic flare reaction rash pneumonia infect in control portion global humira clinic trial adult patient ra psa as cd uc ps hs uv rate serious infect per patientyear humiratr patient versus rate per patientyear controltr patient serious infect observ includ pneumonia septic arthriti prosthet postsurg infect erysipela cellul diverticul pyelonephr see warn and precaut tuberculosi and opportunist infect in global control uncontrol clinic trial ra psa as cd uc ps hs uv includ humiratr patient rate report activ tuberculosi per patientyear rate posit ppd convers per patientyear in subgroup us canadian humiratr patient rate report activ tb per patientyear rate posit ppd convers per patientyear these trial includ report miliari lymphat periton pulmonari tb most tb case occur within first eight month initi therapi may reflect recrudesc latent diseas in global clinic trial case serious opportunist infect report overal rate per patientyear some case serious opportunist infect tb fatal see warn and precaut autoantibodi in rheumatoid arthriti control trial patient treat humira placebotr patient negat baselin ana titer develop posit titer week two patient treat humira develop clinic sign suggest newonset lupuslik syndrom the patient improv follow discontinu therapi no patient develop lupus nephriti central nervous system symptom the impact longterm treatment humira develop autoimmun diseas unknown liver enzym elev there report sever hepat reaction includ acut liver failur patient receiv tnfblocker in control phase trial humira mg sc everi week patient ra psa as control period durat rang week alt elev x uln occur humiratr patient controltr patient sinc mani patient trial also take medic caus liver enzym elev eg nsaid mtx relationship humira liver enzym elev clear in control phase trial humira patient polyarticular jia year alt elev x uln occur humiratr patient controltr patient alt common ast liver enzym test elev frequent among treat combin humira mtx treat humira alon in general elev lead discontinu humira treatment no alt elev x uln occur openlabel studi humira patient polyarticular jia year in control phase trial humira initi dose mg mg mg mg day respect follow mg everi week adult patient cd control period durat rang week alt elev x uln occur humiratr patient controltr patient in phase trial humira pediatr patient crohn diseas evalu efficaci safeti two bodi weight base mainten dose regimen follow bodi weight base induct therapi week treatment alt elev x uln occur patient receiv concomit immunosuppress baselin none patient discontinu due abnorm alt test in control phase trial humira initi dose mg mg day respect follow mg everi week patient uc control period durat rang week alt elev x uln occur humiratr patient controltr patient in control phase trial humira initi dose mg mg everi week patient ps control period durat rang week alt elev x uln occur humiratr patient controltr patient in control trial humira initi dose mg week mg week follow mg everi week start week subject hs control period durat rang week alt elev x uln occur humiratr subject controltr subject in control trial humira initi dose mg week follow mg everi week start week adult patient uveiti exposur pys pys humiratr controltr patient respect alt elev x uln occur humiratr patient controltr patient immunogen patient studi rai raii raiii test multipl time point antibodi adalimumab month period approxim adult ra patient receiv humira develop lowtit antibodi adalimumab least treatment neutral vitro patient treat concomit methotrex mtx lower rate antibodi develop patient humira monotherapi versus no appar correl antibodi develop advers reaction observ with monotherapi patient receiv everi week dose may develop antibodi frequent receiv week dose in patient receiv recommend dosag mg everi week monotherapi acr respons lower among antibodyposit patient among antibodyneg patient the longterm immunogen humira unknown in patient polyarticular jia year age adalimumab antibodi identifi humiratr patient in patient receiv concomit mtx incid compar humira monotherapi in patient polyarticular jia year age year age older weigh kg adalimumab antibodi identifi humiratr patient one patient receiv concomit mtx in patient as rate develop antibodi adalimumab humiratr patient compar patient ra in patient psa rate antibodi develop patient receiv humira monotherapi compar patient ra howev patient receiv concomit mtx rate compar ra in adult patient cd rate antibodi develop in pediatr patient crohn diseas rate antibodi develop patient receiv humira howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcgml among patient whose serum adalimumab level mcgml approxim total patient studi immunogen rate in patient moder sever activ uc rate antibodi develop patient receiv humira howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcgml among patient whose serum adalimumab level mcgml approxim total patient studi immunogen rate in patient ps rate antibodi develop humira monotherapi howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcgml among patient whose serum adalimumab level mcgml approxim total patient studi immunogen rate in ps patient humira monotherapi subsequ withdrawn treatment rate antibodi adalimumab retreat similar rate observ prior withdraw antiadalimumab antibodi measur clinic trial subject moder sever hs two assay origin assay capabl detect antibodi serum adalimumab concentr declin mcgml new assay capabl detect antiadalimumab antibodi titer subject independ adalimumab concentr use origin assay rate antiadalimumab antibodi develop subject treat humira among subject stop humira treatment week adalimumab serum level subsequ declin mcgml approxim total subject studi immunogen rate use new titerbas assay antiadalimumab antibodi titer measur hs subject treat humira antibodi adalimumab associ reduc serum adalimumab concentr in general extent reduct serum adalimumab concentr greater increas titer antibodi adalimumab no appar associ antibodi develop safeti observ in adult patient noninfecti uveiti antiadalimumab antibodi identifi patient treat adalimumab howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcgml among patient whose serum adalimumab level mcgml approxim total patient studi immunogen rate use assay could measur antiadalimumab antibodi titer patient titer measur noninfecti uveiti adult patient treat adalimumab no correl antibodi develop safeti efficaci outcom observ the data reflect percentag patient whose test result consid posit antibodi adalimumab titer high depend assay the observ incid antibodi includ neutral antibodi posit assay high depend sever factor includ assay sensit specif assay methodolog sampl handl time sampl collect concomit medic under diseas for reason comparison incid antibodi adalimumab incid antibodi product may mislead other advers reaction rheumatoid arthriti clinic studi the data describ reflect exposur humira patient includ expos month expos greater one year adequ wellcontrol studi studi rai raii raiii raiv humira studi primarili placebo control trial longterm follow studi month durat the popul mean age year femal caucasian moder sever activ rheumatoid arthriti most patient receiv mg humira everi week tabl summar reaction report rate least patient treat humira mg everi week compar placebo incid higher placebo in studi raiii type frequenc advers reaction second year openlabel extens similar observ oneyear doubleblind portion tabl advers reaction report patient treat humira dure placebocontrol period pool ra studi studi rai raii raiii raiv humira mg subcutan everi other week n placebo n advers reaction prefer term respiratori upper respiratori infect sinus flu syndrom gastrointestin nausea abdomin pain laboratori test laboratori test abnorm hypercholesterolemia hyperlipidemia hematuria alkalin phosphatas increas other headach rash accident injuri inject site reaction back pain urinari tract infect hypertens laboratori test abnorm report advers reaction european trial doe includ inject site erythema itch hemorrhag pain swell less common advers reaction in rheumatoid arthriti clinic studi other infrequ serious advers reaction appear warn precaut advers reaction section occur incid less humiratr patient ra studi bodi as a whole pain extrem pelvic pain surgeri thorax pain cardiovascular system arrhythmia atrial fibril chest pain coronari arteri disord heart arrest hypertens encephalopathi myocardi infarct palpit pericardi effus pericard syncop tachycardia digest system cholecyst cholelithiasi esophag gastroenter gastrointestin hemorrhag hepat necrosi vomit endocrin system parathyroid disord hemic and lymphat system agranulocytosi polycythemia metabol and nutrit disord dehydr heal abnorm ketosi paraproteinemia peripher edema musculoskelet system arthriti bone disord bone fractur spontan bone necrosi joint disord muscl cramp myasthenia pyogen arthriti synov tendon disord neoplasia adenoma nervous system confus paresthesia subdur hematoma tremor respiratori system asthma bronchospasm dyspnea lung function decreas pleural effus special sens cataract thrombosi thrombosi leg urogenit system cystiti kidney calculus menstrual disord juvenil idiopath arthriti clinic studi in general advers reaction humiratr patient polyarticular juvenil idiopath arthriti jia trial studi jiai jiaii similar frequenc type seen adult patient see warn and precaut advers reaction import find differ adult discuss follow paragraph in studi jiai humira studi patient year age polyarticular jia sever advers reaction report studi includ neutropenia streptococc pharyng increas aminotransferas herp zoster myositi metrorrhagia append serious infect observ patient within approxim year initi treatment humira includ case herp simplex pneumonia urinari tract infect pharyng herp zoster in studi jiai patient experienc infect receiv humira without concomit mtx first week treatment the type infect report humiratr patient general similar common seen polyarticular jia patient treat tnf blocker upon initi treatment common advers reaction occur patient popul treat humira inject site pain inject site reaction respect a less common report advers event patient receiv humira granuloma annular lead discontinu humira treatment in first week treatment studi jiai nonseri hypersensit reaction seen approxim patient includ primarili local allerg hypersensit reaction allerg rash in studi jiai patient treat humira negat baselin antidsdna antibodi develop posit titer week treatment no patient develop clinic sign autoimmun clinic trial approxim patient treat humira develop mildtomoder elev creatin phosphokinas cpk studi jiai elev exceed time upper limit normal observ sever patient cpk level decreas return normal patient most patient abl continu humira without interrupt in studi jiaii humira studi patient year age year age older weigh kg polyarticular jia the safeti profil patient popul similar safeti profil seen patient year age polyarticular jia in studi jiaii patient experienc infect receiv humira these includ nasopharyng bronchiti upper respiratori tract infect otiti media most mild moder sever serious infect observ patient receiv humira studi includ dental cari rotavirus gastroenter varicella in studi jiaii nonseri allerg reaction observ patient includ intermitt urticaria rash mild sever psoriat arthriti and ankylos spondyl clinic studi humira studi patient psoriat arthriti psa two placebocontrol trial open label studi patient ankylos spondyl as two placebocontrol studi the safeti profil patient psa as treat humira mg everi week similar safeti profil seen patient ra humira studi rai iv adult crohn diseas clinic studi humira studi adult patient crohn diseas cd four placebocontrol two openlabel extens studi the safeti profil adult patient cd treat humira similar safeti profil seen patient ra pediatr crohn diseas clinic studi humira studi pediatr patient crohn diseas one doubleblind studi studi pcdi one openlabel extens studi the safeti profil pediatr patient crohn diseas treat humira similar safeti profil seen adult patient crohn diseas dure week open label induct phase studi pcdi common advers reaction occur pediatr popul treat humira inject site pain inject site reaction respect a total children experienc infect receiv humira studi pcdi these includ upper respiratori tract infect nasopharyng a total children experienc serious infect receiv humira studi pcdi these includ viral infect devic relat sepsi cathet gastroenter hn influenza dissemin histoplasmosi in studi pcdi allerg reaction observ children nonseri primarili local reaction ulcer coliti clinic studi humira studi patient ulcer coliti uc two placebocontrol studi one openlabel extens studi the safeti profil patient uc treat humira similar safeti profil seen patient ra plaqu psoriasi clinic studi humira studi subject plaqu psoriasi ps placebocontrol openlabel extens studi the safeti profil subject ps treat humira similar safeti profil seen subject ra follow except in placebocontrol portion clinic trial ps subject humiratr subject higher incid arthralgia compar control vs hidraden suppurativa clinic studi humira studi subject hidraden suppurativa hs three placebocontrol studi one openlabel extens studi the safeti profil subject hs treat humira week consist known safeti profil humira flare hs defin increas baselin abscess inflammatori nodul count minimum addit lesion document subject withdrawn humira treatment follow primari efficaci timepoint two studi uveiti clinic studi humira studi adult patient uveiti uv placebocontrol openlabel extens studi pediatr patient uveiti studi puvi the safeti profil patient uv treat humira similar safeti profil seen patient ra postmarket experi the follow advers reaction identifi postapprov use humira becaus reaction report voluntarili popul uncertain size alway possibl reliabl estim frequenc establish causal relationship humira exposur gastrointestin disord diverticul larg bowel perfor includ perfor associ diverticul appendic perfor associ append pancreat general disord administr site condit pyrexia hepatobiliari disord liver failur hepat immun system disord sarcoidosi neoplasm benign malign unspecifi includ cyst polyp merkel cell carcinoma neuroendocrin carcinoma skin nervous system disord demyelin disord eg optic neuriti guillainbarr syndrom cerebrovascular accid respiratori disord interstiti lung diseas includ pulmonari fibrosi pulmonari embol skin reaction steven johnson syndrom cutan vascul erythema multiform new worsen psoriasi subtyp includ pustular palmoplantar alopecia lichenoid skin reaction vascular disord system vascul deep vein thrombosi',\n",
       "  'NN'),\n",
       " ('well theori gi tell accur standard practic endoscop histolog remiss need done while scope suck day take better short long term health pancol uc sinc sept averag bmsday time respons remiss therapi salofalkasa enema oral g clinic trial drug fail therapi entyvio antimadcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       "  'NN'),\n",
       " ('my good minni i realli wish could use curs word forum describ fistula they deserv color languag uccrohn test posit map antibodi mycobacterium pg remiss chronic fistula fail setonsit pure tortur start stelara may mg imuran current day most normal stelara ivig occas',\n",
       "  'FW'),\n",
       " ('sebastian agre entir we know alemtuzumab due long term use oncolog plus brain atrophi data look good im yet see brain atrophi data ocrelizumab let alon posit data adam yes rituximab ocrelizamub target primarili bcell seem safe base trial result short term i suspect malign take time develop present at least alemtuzumab bodi opportun rebuild compet immun system without disrupt everi month',\n",
       "  'JJ'),\n",
       " ('good luck reg a day ago went listen top neuro speak new treatment progress ms local hospit ocrevus one i went quit curious came quit confus he recommend unfortun avail canada yet he said there way get one train administ it sound like best bet far im interest hear make hear observ might make afterward thank post',\n",
       "  'NN'),\n",
       " ('bmc ophthalmol jan intravitr dexamethason implant versus intravitr antivegf treatment treat patient retin vein occlus metaanalysi gao l et al background retin vein occlus rvo common retin venous disord caus vision loss no specif therapi develop controversi exist regard two treatment intravitr dexamethason implant antivascular endotheli growth factor vegf the goal studi compar effect safeti dexamethason implant antivegf treatment rvo method the pubm embas cochran librari databas search studi compar dexamethason implant antivegf patient rvo bestcorrect visual acuiti bcva central subfield thick cst intraocular pressur chang conjunctiv haemorrhag reduc va macular oedema extract final includ studi revman use conduct quantit analysi bias assess result four randomis control trial assess eye includ the antivegf treatment show better bcva improv mean differ md p cst decreas md p dexamethason implant howev dexamethason implant requir fewer inject as advers effect dexamethason implant show signific higher intraocular pressur iop cataract antivegf treatment no signific differ found conjunctiv haemorrhag reduc va macular oedema conclus antivegf treatment show better function anatom improv less risk iop elev cataract format compar dexamethason implant thus antivegf treatment first choic treat rvo patient pmid pmcid pmc doi',\n",
       "  'NN'),\n",
       " ('my father egfr exon insert mutat we found today pdl appar rare exon insert mean immunotherapi option the treatment plan right keytruda carboplatin pemetrex has anyon combin',\n",
       "  'NN'),\n",
       " ('repli post flower girl hi a year i got pregnant daughter i cimzia mg prednison throughout pregnanc well i nurs i healthi perfect year old i crohn i flare littl first trimest steroid ok take pregnant got control i found last week im pregnant this time littl differ im entyvio low dose azathiaprin im scare well medsmoreno azathiaprin gi doc rheumatologist told safe everyth i read say you mention drugwhat think sinc i found i havent taken my doc isnt gonna happi',\n",
       "  'NN'),\n",
       " ('hello snigdha my father diagnos lung cancer juli he took tarceva iressa tagrisso he took tagrisso last ten month unfortun pass away week ago hospit sinc decemb rd from end last year live well travel lot collater damag tagrisso realli good id like tell hospit admiss heart issu doctor say may caus tagrisso my father hasnt done heart exam start tagrisso i dont know exam could made live mayb would good talk cardiologist im send posit vibe i hope mom continu without pain i think mani year hapi father and lot time tell much love pleas contact whenev want best wish lms',\n",
       "  'NNS'),\n",
       " ('the first recommend stanford oncologist the last recommend regular kaiser oncologist kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'VBP'),\n",
       " ('you mention recent develop issu interest regard progress ms thus creat immpress massiv ongo activ around yet care examin reveal talk drug way enhanc drug trial design even inform quest umbrella drug trial tend support argument interpet trial basic research wherev hard evid present eager set asid circumstanti if took step back could see disproport drugorient road offer it destin fail long run rememb wornaway hype inf gilenya tysabri bg alemtuzumab you still talk newer drug stretch expect point break first t b memoryb t it fruit road research patient how mani drug market chang cours get back answer basic ms',\n",
       "  'RB'),\n",
       " ('of cours short i post everyth good updat i began develop gilenya cough it like deep bronchiti like cough im cough anyth i also realli short breath particular even toward end week i wonder increas i run around i discov gas tank much smaller use huge adjust i see neuro wednesday normal follow ill obvious discuss',\n",
       "  'JJ'),\n",
       " ('rituxan main ms drug rituxan not technic approv fda food drug administr multipl sclerosi sister ocrelizumab come ive explain comparison two post httpwwwmultipleexperiencesorgocrelizumabversusrituximabrituxan it basic thing frustrat fda wont recogn biotin vitamin mg per day this base clinic studi done i link studi month take biotin post you need specialti pharmaci get counter high dosag dont need prescript httpwwwmultipleexperiencesorghighdosebiotininmultiplesclerosismonth alpha lipoic acid vitamin mg also studi done regard multipl sclerosi i inform studi post httpwwwmultipleexperiencesorgalphalipoicacidandmultiplesclerosi gabapentin mg generic neurontin take time day i take twitch i get weird back like seizur i get baclofen mg take time day i take muscl relax anti spastic agent toviaz mg overact bladder godsend topiram mg migrain also godsend relpak mg migrain take need b vitamin mcg vitamin d mg fiber pill',\n",
       "  'NN'),\n",
       " ('last updat januari share comment tellafriend here editor healthday consid import develop neurolog decemb this roundup includ latest research news journal articl well fda approv regulatori chang like affect clinic practic no effect bup tap cathet chronic pain after breast recon friday dec healthday news for patient undergo autolog breast reconstruct incid chronic postsurg pain cpsp differ patient receiv transversus abdomini plane tap cathet deliv bupivacain salin bolus accord studi publish onlin dec pain practic full text subscript payment may requir iron defici anemia up risk hear loss us adult thursday dec healthday news among us adult hear loss associ iron defici anemia ida accord studi publish onlin dec jama otolaryngologyhead neck surgeri full text case report adopt tcell tx show promis glioblastoma thursday dec healthday news treatment autolog chimer antigen receptor carengin t cell target tumorassoci antigen interleukin receptor alpha ilr associ tumor regress recurr multifoc glioblastoma accord case report publish dec issu new england journal medicin full text subscript payment may requir selumetinib activ children with neurofibromatosi type thursday dec healthday news the oral select inhibitor mapk kinas selumetinib activ children neurofibromatosi type inoper plexiform neurofibroma accord studi publish dec issu new england journal medicin full text subscript payment may requir postlunch nap tie better cognit elder wednesday dec healthday news moder postlunch nap tie better cognit older adult accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir bell palsi tie quadrival meningococc vaccin wednesday dec healthday news bell palsi prespecifi advers event associ menacwycrm quadrival meningococc conjug vaccin accord studi publish onlin dec pediatr full text opicapon as levodopa adjunct cut motor fluctuat pd tuesday dec healthday news for patient parkinson diseas pd receiv levodopa therapi experienc endofdos motor fluctuat treatment mgday opicapon associ reduct mean daili offtim accord studi publish onlin dec jama neurolog full text subscript payment may requir editori subscript payment may requir person health care spend continu soar us tuesday dec healthday news from consider increas person health care spend unit state highest amount diabet ischem heart diseas low back neck pain accord studi publish dec issu journal american medic associ full text editori subscript payment may requir is dementia older women tie year rate weight loss tuesday dec healthday news for women surviv late life rate weight loss year associ develop mild cognit impair mci dementia accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir research postcraniotomi analgesia uneven qualiti friday dec healthday news studi report pharmacolog adjuv analges modal postcraniotomi pain control signific diverg research method accord review publish onlin dec pain practic full text subscript payment may requir induc hypothermia futil convuls status epilepticus friday dec healthday news for critic ill patient convuls status epilepticus hypothermia ad standard care associ signific improv good function outcom day accord studi publish dec issu new england journal medicin full text subscript payment may requir va echo program feasibl manag sleep disord thursday dec healthday news a us depart veteran affair extens communiti healthcar outcom vaecho program feasibl increas comfort manag common sleep complaint accord research publish onlin dec annal american thorac societi full text subscript payment may requir ocrelizumab target role b cell multipl sclerosi thursday dec healthday news ocrelizumab new fulli human monoclon anticd antibodi caus bcell deplet associ lower relaps rate lower rate progress among patient relaps primari progress multipl sclerosi respect accord research publish onlin dec new england journal medicin abstract hauser full text abstract montalban full text editori risk postconcuss symptom down with earli exercis tuesday dec healthday news particip physic activ within seven day injuri associ reduc rate persist postconcuss symptom ppcs accord studi publish dec issu journal american medic associ full text editori subscript payment may requir health care provid burnout negat affect qualiti safeti tuesday dec healthday news health care provid burnout negat associ qualiti safeti health care accord metaanalysi publish recent journal general intern medicin full text subscript payment may requir therapeut hypothermia benefit adult with tbi tuesday dec healthday news for adult children traumat brain injuri therapeut hypothermia benefici accord metaanalysi publish onlin dec critic care medicin full text subscript payment may requir dea announc critic chang registr renew process monday dec healthday news the drug enforc administr dea announc critic chang registr renew process accord report publish american academi famili physician more inform noncardiovascular caus death more common chd patient monday dec healthday news for patient coronari heart diseas chd mortal often due noncardiovascular caus accord studi publish jan issu the american journal cardiolog full text subscript payment may requir dysglycemia affect brain structur cognit senior monday dec healthday news in older adult dysglycemia associ brain structur cognit accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir ischem stroke risk up eight week after pci friday dec healthday news the risk ischem stroke highest first two day percutan coronari intervent pci decreas gradual stay elev eight week accord studi publish jan issu the american journal cardiolog full text subscript payment may requir integr neurolog medic home cut health care use friday dec healthday news a model neurologist integr coloc primari care leverag curbsid electron tradit consult reduc unnecessari health care use accord studi publish onlin dec journal evalu clinic practic full text subscript payment may requir mri up diagnost accuraci fetal brain abnorm friday dec healthday news followup magnet reson imag mri midpregn ultrasound could help improv diagnosi possibl fetal brain abnorm accord studi publish onlin dec the lancet full text subscript payment may requir editori subscript payment may requir zikarel birth defect more extens than thought thursday dec healthday news zika abil damag infant brain may even farreach insidi previous thought two new studi suggest full text editori abstract full text editori fda issu new safeti info use anesthesia thursday dec healthday news repeat lengthi use longer three hour general anesthet sedat drug may harm develop brain fetus children younger year old us food drug administr warn wednesday drug safeti communic more inform stroke afib recurr low one year after af ablat wednesday dec healthday news stroke atrial fibril af recurr low one year af ablat accord studi publish onlin dec journal cardiovascular electrophysiolog full text subscript payment may requir outcomesbas price suggest new cost drug wednesday dec healthday news outcomesbas price novel expens biopharmaceut support idea opinion piec publish onlin dec annal intern medicin full text subscript payment may requir cathet ablat afib link more stroke elder tuesday dec healthday news cathet ablat ca atrial fibril af associ stroke patient least year old associ complic accord studi publish onlin dec journal cardiovascular electrophysiolog full text subscript payment may requir blocker may not be appropri dementia patient tuesday dec healthday news blocker may medicin choic nurs home resid dementia accord studi publish onlin dec jama intern medicin full text subscript payment may requir editori subscript payment may requir risk ischem hemorrhag stroke up with type diabet tuesday dec healthday news the risk ischem hemorrhag stroke increas type diabet increment increas risk increas hemoglobin ac hbac accord studi publish novemb issu journal intern medicin full text effect statin alzheim may depend gender race monday dec healthday news effect statin use alzheim prevent may depend specif statin gender race ethnic patient accord studi publish onlin dec jama neurolog full text cdc colombia see increas zikarel microcephali monday dec healthday news colombia experienc sharp increas case infant microcephali accord research publish dec earlyreleas issu us center diseas control prevent morbid mortal week report full text prefront brain activ may predict risk fall elder thursday dec healthday news measur healthi older adult brain activ may help determin futur risk fall accord studi publish onlin dec neurolog abstract full text subscript payment may requir higher ntprobnp tie lower brain volum older adult thursday dec healthday news for older adult without dementia higher ntermin probtyp natriuret peptid ntprobnp associ lower total brain volum accord studi publish onlin dec radiolog abstract full text nusinersen show promis spinal muscular atrophi thursday dec healthday news an experiment drug infant spinal muscular atrophi type appear effect accord research publish onlin dec the lancet full text subscript payment may requir editori subscript payment may requir read taken clinic may underestim ambulatori bp wednesday dec healthday news ambulatori blood pressur may better indic health risk clinic blood pressur accord new report publish onlin dec circul full text subscript payment may requir editori subscript payment may requir preval disabl percent us medic school wednesday dec healthday news the preval disabl percent among medic student us allopath medic school accord research letter publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir learn intervent can improv med student wellb wednesday dec healthday news specif learn intervent may improv emot wellb among medic student accord review publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir editori subscript payment may requir patient mortal up with endofrot team transit tuesday dec healthday news hospit patient hand origin medic team new set caregiv may ultim face higher risk earli mortal accord research publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir full text subscript payment may requir editori subscript payment may requir depress suicid ideat preval medic student tuesday dec healthday news the preval depress depress symptom suicid ideat percent respect among medic student accord review publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir editori subscript payment may requir potenti unsaf med script up dual user with dementia tuesday dec healthday news for veteran dementia veteran affair vamedicar part d dualsystem user increas rate potenti unsaf medic pum prescrib accord studi publish onlin dec annal intern medicin full text subscript payment may requir editori subscript payment may requir colon diverticular diseas may increas dementia risk tuesday dec healthday news patient colon diverticular diseas may increas risk dementia accord studi publish nov journal gastroenterolog hepatolog full text subscript payment may requir mani with postconcuss syndrom dont recov monday dec healthday news a minor patient postconcuss syndrom pcs recov twothird recov within one year accord studi publish onlin nov journal neurotrauma full text augment realiti game may help reliev phantom limb pain friday dec healthday news ampute experi phantom limb pain may benefit play virtual realiti game simul movement miss limb accord studi publish onlin dec the lancet full text subscript payment may requir editori subscript payment may requir vitamin d pregnanc might help prevent ms offspr friday dec healthday news newborn low level vitamin d may higher odd develop multipl sclerosi ms later life accord studi publish onlin nov neurolog abstract full text subscript payment may requir editori subscript payment may requir csf rtquic has high diagnost specif sensit prion friday dec healthday news cerebrospin fluid csf realtim quakinginduc convers rtquic high diagnost specif sensit prion diseas accord studi publish onlin nov annal neurolog full text subscript payment may requir dabigatran may be better than warfarin after bleed episod friday dec healthday news dabigatran less like warfarin caus recurr bleed atrial fibril patient experienc major bleed event accord studi publish onlin dec stroke full text subscript payment may requir cdc fewer us famili struggl pay medic bill thursday dec healthday news the number peopl famili problem pay medic bill fell near million first six month accord report publish us center diseas control prevent nation center health statist nchs more inform',\n",
       "  'VB'),\n",
       " ('hi i rebif year rotat inject site rememb take pain relief afterward et flu symptom i use alo vera gel inject site i relaps rebif go fingolimod good luck',\n",
       "  'NN'),\n",
       " ('i tarceva month im copingjustwith rashexcept eye lid eye drive insan but refrain scratchingi use moisturis sorbelenerecommend oncolog nurs i find i use everi min skin dri fast bit depress honestperhap someth better sorbelen sharon',\n",
       "  'NN'),\n",
       " ('hi thank repli i offici offer anyth realli when look treatment would treat psoriasi well ms neuro mention rituximab would wait see dermatologist letter said i could move one fair easili want take advic first the dermatologist said retuximab wouldnt work i heard say i probabl give gilenya but im scare side effect eye im alreadi risk diabet so i dont know risk im will take the ms nurs sent info three treatment read support worri im lean toward tysabri i dont know i say i dont know i explain well enough i guess i wait see thank repli it appreci xx',\n",
       "  'NN'),\n",
       " ('anyon return previous chemo drug given period', 'IN'),\n",
       " ('sorri lab be forc doctorshop youv alreadi got doctor your perfect happi suck massiv ive was forc find new gp i move three year ago the current one good gp i still miss old one sometim plus lot lax prescrib stuff i know shouldnt reason want stay gp yeah as gi ive seven year look forward day leav if replac isnt good ill make decis whether switch hospit i hope find good gi quick dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('no problem i know hard lone journey im happi help so doctor feel tecentriq keep stabl if that great a random thought if insur isnt cover tecentriq could tri appeal drugmak they sometim provid medic free charg return monitor progress have consid gamma knife brain lesion werent surgic remov my mom doctor basic decid would approach get littl spot pop if tecentriq prove work youll probabl bridg journey nowaday mani advanc come mani cancer seem breakthrough everi year two new treatment sclc nonexist last year someth happen year ago seem like lot promis develop everi month so idea new treatment come work bridg get patient next point if bridg stop work usual point someth new provid next bridg that hope anyway realli best luck husband i feel',\n",
       "  'NN'),\n",
       " ('hahaha thank laugh f uc symptom start januari diagnosi juli colonoscopi balsalazid juli januari predison septnov decjan march present mgday one dose lialda march confirm i cannot toler mesalamin doctor want humira i worri side effect',\n",
       "  'NN'),\n",
       " ('hi rich told inject sever tablet form dmd tecfidera gilenya aubagio mayb cant think right could ask neuro carol x',\n",
       "  'NN'),\n",
       " ('publish onlin june j neurooncol doi margolin k ernstoff ms hamid o et al ipilimumab patient melanoma brain metastas openlabel phase trial lancet oncol goldberg sb getting sn mahajan a et al pembrolizumab patient melanoma nonsmallcel lung cancer untreat brain metastas earli analysi nonrandomis openlabel phase trial lancet oncol nation comprehens cancer network melanoma nccn guidelin version httpnccnorg updat februari access juli',\n",
       "  'NN'),\n",
       " ('in may i start target treatment medic taflinar mekinist fatigu worst side effect i exper read more',\n",
       "  'NN'),\n",
       " ('httpswwwmedicalnewstodaycomarticlesphp new multipl sclerosi culprit identifi it still unclear caus multipl sclerosi new research close faulti immun system mechan involv develop condit new research identifi anoth type immun cell may play role ms multipl sclerosi ms autoimmun diseas caus immun system mistaken attack myelin myelin substanc coat axon project allow neuron connect transmit inform this process known demyelin affect correct function central nervous system the condit character problem balanc coordin well eyesight name effect in unit state ms affect peopl research still dont know sure caus ms littl littl uncov mechan play reveal cellular culprit involv now neurologist roland martin immunologist mireia sospedra univers zurich univers hospit zurich switzerland colleagu shown type immun cell call b cell key autoimmun reaction character ms in studi whose result publish journal cell scientist explain b cell influenc activ anoth type immun cell t cell caus inflamm we abl show first time certain b cell cell immun system produc antibodi activ specif t cell caus inflamm brain nerv cell lesion roland martin b cell influenc t cell studi ms tend focus role play t cell develop condit sinc t cell task trigger appropri immun respons detect presenc pathogen when t cell malfunct mistak healthi cell bodi pathogen caus harm lesion inflamm associ autoimmun diseas ms martin colleagu howev found t cell may actual mistaken activ special immun cell b cell this becam appar research observ effect certain drug use treat ms martin say a class ms drug call rituximab ocrelizumab led us believ b cell also play import part pathogenesi diseas these drug author note halt brain inflamm remov b cell suggest immun cell ultim respons t cell activ a chain reaction in order better understand role play b cell inflamm research analyz blood sampl peopl ms experiment vitro method they notic b cell interact special t cell boost activ influenc divid thus feed attack cycl it becam clear b cell caus t cell activ elimin former latter stop prolifer this mean explain previous unclear mechan ms drug explain martin the investig also note activ t cell studi blood sampl includ popul t cell activ brain inflamm relat ms martin team suggest t cell abl read protein releas b cell recogn nerv cell brain the scientist say t cell first activ peripher blood migrat brain end attack myelin our find explain new ms drug take effect also pave way novel approach basic research therapi ms say martin',\n",
       "  'NN'),\n",
       " ('just saw peggi thank kc ruth suggest i worri i go rhumetologist suggest someth might interfer opdivo alway concern new med treatment and i look descript side effect opdivo take coleridg',\n",
       "  'NN'),\n",
       " ('hello everyon im new first post ive made i diagnos ms may year sever sudden serious attack januarymay my diagnosi delay i also grave diseas post thyroidectomi amongst myriad symptom biggest complaint intens chest pain the doctor focus chest pain basic ignor symptom month it almost relief receiv diagnosi i final refer physician examin proper order necessari mris i start transit om lifestyl best i could soon i diagnos i great medit i use music lot though ive make huge effort diet exercis ive period struggl diet havent fulli adher difficulti social situat famili friend im im realli enjoy way eat one thing i adher though flax oil i take fish oil vitamin e i simpli feel better im take fish oil i still use flax oil toast instead butter includ linse diet i also start take vitamin get serum level around least got nmoll nmoll winter but i mris thing start move quick dmd front base mris symptom neurologist want dmd asap ran option right examin take radiolog report she rule interferon bat discuss tecfidera aubagio gilenya tysabri lemtrada she told prefer would tysabri lemtrada two sound terrifi it pretti overwhelm i left clinic first appoint bare hold togeth cri walk home i couldnt consid lemtrada i multipl autoimmun diseas histori grave diseas i couldnt consid tecfidera time i couldnt handl prospect drug caus nausea like id hideous nausea month stage i end focus gilenya tysabri prescreen test i lean toward gilenya i knew jcv status it took month i result back knew i jcv negat enough time gather inform emot reconcil risk pml i chose start tysabri first line treatment ive treatment moment im realli glad i chose drug i toler well basic sideeffect about week first infus i anoth attack far milder id earlier year pain loss mobil patch numb leg torso didnt spread bit weak slight worsen balanc after second infus i felt like rubbish whole month extrem letharg listless i worst brainfog ive ever experienc it unpleas the third treatment turn point though i notic improv dure infus i could feel head clear i felt refresh full energi treatment i ran skip hospit day amaz i havent gotten quit kick last treatment ive still steadi improv i feel linger symptom the paresthesia feet final went away the symptom i current white flash peripher left eye occasion pain rib memento one spinal lesion i hope i continu drug without serious event i tend joke belittl risk pml one way i deal and om focus tri make decis go also huge help it make futur feel lot less bleak',\n",
       "  'NN'),\n",
       " ('conclus these reallif result suggest intravitr dexamethason implant effect safe eye dmeophthalmologica sourc ophthalmologica',\n",
       "  'NN'),\n",
       " ('adalimumab rch consum medicin inform what leaflet this leaflet answer common question humira it contain avail inform it take place talk doctor pharmacist all medicin risk benefit your doctor weigh risk use medicin benefit expect if concern use medicin ask doctor pharmacist read leaflet care use humira keep medicin you may need read what humira use humira use treatment rheumatoid arthriti humira use reduc sign symptom moder sever activ rheumatoid arthriti pain diseas joint well slow protect damag joint sign symptom rheumatoid arthriti includ joint pain tender swell stiff polyarticular juvenil idiopath arthriti humira use reduc sign symptom moder sever activ polyarticular juvenil idiopath arthriti inflammatori diseas involv multipl joint patient year age older enthesitisrel arthriti humira use treat enthesitisrel arthriti inflammatori diseas joint children psoriat arthriti humira use reduc sign symptom well inhibit progress joint damag moder sever activ psoriat arthriti diseas joint skin similar rheumatoid arthriti well psoriasi factor ankylos spondyl humira use reduc sign symptom patient activ ankylos spondyl inflammatori diseas spine sign symptom ankylos spondyl includ back pain morn stiff crohn diseas humira use treatment moder sever crohn diseas inflammatori diseas digest tract adult children age year reduc sign symptom diseas induc maintain period symptom longer present humira given patient respond well enough convent therapi lost respons intoler infliximab anoth medicin use treat crohn diseas ulcer coliti humira use treatment moder sever ulcer coliti inflammatori bowel diseas patient respond well enough convent therapi intoler medic contraind therapi patient show respons within week continu treatment psoriasi humira use treat chronic plaqu psoriasi inflammatori diseas skin plaqu psoriasi also affect nail caus crumbl thicken lift away nail bed pain humira use moder sever form diseas adult sever form children adolesc year age respond well enough topic therapi phototherapi cannot given treatment hidraden suppurativa humira use treatment adult adolesc year age activ moder sever hidraden suppurativa acn inversa chronic often pain inflammatori skin diseas symptom may includ tender nodul lump abscess boil may leak pus it common affect specif area skin breast armpit inner thigh groin buttock scar may also occur affect area your doctor schedul followup appoint check progress continu treatment uveiti humira use treat noninfecti intermedi posterior panuv inflammatori diseas uveal tract eye humira use adult respond well corticosteroid whose diseas flare taper corticosteroid sign symptom includ inflamm vision impair pain the activ ingredi medicin adalimumab fulli human monoclon antibodi monoclon antibodi protein made type blood cell fight foreign protein bodi adalimumab recognis bind specif protein tumour necrosi factor tnfalpha present increas level inflammatori diseas rheumatoid arthriti polyarticular juvenil idiopath arthriti enthesitisrel arthriti psoriat arthriti ankylos spondyl crohn diseas ulcer coliti hidraden suppurativa psoriasi uveiti ask doctor question medicin prescrib your doctor may prescrib anoth reason this medicin addict this medicin avail doctor prescript the long term effect humira growth develop children known befor use humira when must use do use humira you allergi medicin contain adalimumab ingredi list end leaflet symptom allerg reaction may includ chest tight short breath wheez difficulti breath swell face lip tongu part bodi hive itch skin rash you sever infect includ infect bloodstream activ tuberculosi infect occur bodi natur defenc lower you alreadi use anakinra kineret medicin rheumatoid arthriti you moder sever heart failur do use medicin expiri date print label blister carton packag torn show sign tamper return pharmacist dispos befor use tell doctor allergi medicin food preserv dye tell doctor follow medic condit infect includ longterm localis infect exampl leg ulcer histori recurr infect condit increas risk infect histori tuberculosi close contact someon tuberculosi if symptom tuberculosi persistentcough weight loss listless mild fever infect appear therapi tell doctor immedi as case tuberculosi report patient treat humira doctor check sign symptom tuberculosi start medicin this includ thorough medic histori chest xray tuberculin test hepat b virus hbv carrier activ hbv think might risk contract hbv humira caus reactiv hbv peopl carri virus in rare case especi take medicin suppress immun system reactiv hbv life threaten fungal infect live travel countri fungal infect common these infect may develop becom sever take humira if suffer uveiti doctor may check sign symptom neurolog diseas start medicin multipl sclerosi diseas nervous system demyelin diseas allerg reaction chest tight wheez dizzi swell rash blood disord low resist diseas heart condit includ congest heart failur heart attack worsen exist heart condit cancer autoimmun diseas lung diseas call chronic obstruct pulmonari diseas kidney liver problem tell doctor schedul vaccin tell doctor schedul vaccin it recommend children possibl brought date immunis agreement current immunis guidelin prior initi humira therapi patient receiv humira receiv live vaccin tell doctor psoriasi suffer undergon phototherapi tell doctor pregnant plan becom pregnant you consid use adequ contracept prevent pregnanc continu use least month last humira treatment humira use pregnanc clear need a pregnanc studi found higher risk birth defect mother use humira pregnanc compar mother diseas use humira if use humira pregnanc babi may higher risk get infect it import tell babi doctor healthcar profession humira use pregnanc babi receiv vaccin tell doctor breastfeed plan breastfe it known whether humira pass breast milk if breastfeed doctor may advis stop breastfeed use medicin if told doctor pharmacist tell start use humira take medicin tell doctor pharmacist take medicin includ get without prescript pharmaci supermarket naturopath health food shop some medicin humira may interfer your doctor pharmacist inform medicin care avoid use medicin tell doctor pharmacist take anakinra kineret abatacept orencia medicin use treat form arthriti take two medicin togeth may increas risk infect humira taken togeth medicin use treat arthriti methotrex steroid pain medic includ nonsteroid antiinflammatori drug nsaid ibuprofen tell doctor take medicin treat condit how use humira follow direct given doctor pharmacist care they may differ inform contain leaflet if understand instruct label leaflet ask doctor pharmacist help alway use humira exact doctor instruct check doctor pharmacist unsur how much use adult rheumatoid arthriti psoriat arthriti ankylos spondyl the usual dose adult rheumatoid arthriti psoriat arthriti ankylos spondyl one mg inject fortnight crohn diseas ulcer coliti the usual dose adult crohn diseas ulcer coliti initi dose mg given four inject one day two inject day two day follow mg two week later given one day mg start two week later continu everi two week psoriasi uveiti the usual dose adult psoriasi uveiti initi dose mg given inject follow mg given fortnight start one week initi dose for adult psoriasi depend respons doctor may increas dose frequenc mg everi week hidraden suppurativa the usual dose adult hidraden suppurativa initi dose mg given inject one day inject per day two consecut day follow mg dose inject day two week later after two week continu dose mg everi week your doctor may prescrib medicin condit arthriti take medicin children polyarticular juvenil idiopath arthriti the usual dose children polyarticular juvenil idiopath arthriti enthesitisrel arthriti depend bodi weight bodi weight kg usual dose mg given fortnight bodi weight kg less kg recommend dose mg fortnight bodi weight kg less kg usual dose mg fortnight crohn diseas the usual dose children crohn diseas depend bodi weight sever diseas bodi weight kg start dose mg given four inject one day two inject two day follow mg two week later given one day after two week continu mg mg everi two week depend sever diseas bodi weight less kg start dose mg given two inject one day follow mg two week later after two week continu mg mg everi two week depend sever diseas treatment crohn diseas children support good nutrit allow appropri growth psoriasi the usual dose children psoriasi depend bodi weight bodi weight kg usual dose mg given week first two week fortnight bodi weight less kg usual dose mg given week first two week fortnight hidraden suppurativa the usual dose adolesc year weigh least kg hidraden suppurativa initi dose mg two mg inject one day follow mg fortnight start one week later if inadequ respons doctor may increas dose mg everi week it recommend use antisept wash daili affect area if humira effect child condit week doctor may tell stop use humira how use humira inject skin the inject selfadminist given anoth person exampl famili member friend proper train inject techniqu doctor hisher assist instruct prepar give inject humira use humira prefil syring provid product inform inject instruct leaflet product read instruct care follow step step these instruct explain selfinject medicin do attempt selfinject sure understand prepar give inject your doctor hisher assist also show best selfinject do mix inject syring vial medicin set wash hand thorough set follow item clean surfac one prefil syring humira inject one alcohol pad look expiri date syring do use product month year shown check colour chang particl solut if cloudi discolour flake particl must use do use solut frozen choos inject site choos site thigh stomach except area around navel chang place inject time becom sore one area each new inject given least cm last inject site rotat thigh stomach prepar inject site do inject area skin tender redden bruis hard this may mean infect wipe inject site enclos alcohol pad use circular motion do touch area inject inject humira do shake syring the presenc one bubbl syring normal remov cap needl syring care touch needl let touch surfac with one hand gentl grasp clean area skin hold firm with hand hold syring degre angl skin groov side with one quick short motion push needl way skin releas skin first hand push plunger inject solut take second empti syring when syring empti remov needl skin care keep angl insert use thumb piec gauz appli pressur inject site second a littl bleed may occur do rub inject site use plaster want throw away suppli the humira syring never reus never recap needl after inject humira immedi throw away use syring special sharp contain instruct doctor nurs pharmacist keep contain reach sight children how long use keep use humira long doctor tell humira cure condit help control symptom ask doctor sure long take medicin if forget use if forget give inject inject next dose humira soon rememb then inject next dose would origin schedul day forgotten dose do tri make miss dose take one dose time if use much overdos if accident inject humira frequent told doctor immedi telephon doctor poison inform centr australia telephon go accid emerg nearest hospit do even sign discomfort poison you may need urgent medic attent alway take outer carton medicin while use humira thing must check doctor receiv vaccin it recommend children possibl brought date immunis agreement current immunis guidelin prior initi humira therapi some vaccin oral polio vaccin given receiv humira if becom pregnant use humira tell doctor immedi if start new medicin tell doctor use humira tell doctor dentist pharmacist treat use humira if go surgeri tell surgeon anaesthetist use humira your doctor may recommend temporari discontinu humira keep doctor appoint progress check thing must do give humira anyon els even condit do use humira treat complaint unless doctor tell do stop take humira without check doctor do take humira anakinra kineret togeth do take humira abatacept orencia togeth anakinra abatacept medicin use treat certain form arthriti thing care it import tell doctor get symptom fever wound feel tire dental problem you might get infect easili receiv humira treatment these infect may serious includ tuberculosi infect caus virus fungi bacteria opportunist infect sepsi may rare case lifethreaten your doctor may recommend temporari discontinu humira be care drive oper machineri know humira affect the effect abil drive use machin whilst take medicin known side effect tell doctor soon possibl problem use humira even think problem connect medicin list leaflet all medicin unwant side effect sometim serious time you may need medic attent get sideeffect do alarm list possibl side effect you may experi ask doctor pharmacist question may tell doctor immedi go accid emerg nearest hospit experi follow sign allerg reaction chest tight short breath wheez difficulti breath swell face lip tongu part bodi hive itch skin rash sign symptom suggest heart failur short breath exert upon lie swell feet sign symptom suggest blood disord persist fever bruis bleed pale the list includ serious side effect you may need urgent medic attent hospitalis these side effect uncommon tell doctor soon possibl notic follow sign tuberculosi persist cough weight loss listless fever sign infect fever malais wound dental problem burn urin you might get infect easili receiv humira treatment sign nervous system disord numb tingl throughout bodi arm leg weak doubl vision sign soft tissu infect bump open sore doesnt heal the list includ serious side effect you may need urgent medic attent serious side effect rare tell doctor notic follow worri inject site reaction includ pain swell red itch upper respiratori tract infect includ cold runni nose sinus infect sore throat lower respiratori tract infect bronchiti pneumonia ear infect eye inflamm inflamm eye lid chang vision headach dizzi vertigo sensat disord increas cough sore throat abdomin symptom nausea vomit abdomin pain rash itch fatigu mouth inflamm ulcer muscl bone pain elev lipid depress anxieti increas heart rate viral infect includ flu cold sore blister chicken pox shingl bacteri infect includ urinari tract infect fungal infect chang mood feel low anxious the list includ common side effect humira they usual mild shortliv laboratori result some side effect observ humira may symptom may discov blood test these includ increas lipid blood elev liver enzym increas uric acid blood tell doctor pharmacist notic anyth els make feel unwel other side effect list may occur peopl there case certain kind cancer patient take humira tnf blocker peopl serious rheumatoid arthriti diseas long time may higher chanc get kind cancer affect lymph system call lymphoma affect blood call leukaemia if take humira risk may increas on rare occas specif sever type lymphoma observ patient take humira some patient also treat azathioprin mercaptopurin in addit rare case skin cancer observ patient take humira if new skin lesion appear therapi exist lesion chang appear tell doctor there case cancer lymphoma patient specif type lung diseas call chronic obstruct pulmonari diseas copd treat anoth tnf blocker if copd heavi smoker discuss doctor whether treatment tnf blocker appropri after use humira storag keep prefil syring pack time use keep humira refriger c c do freez keep humira refriger way children cannot get keep medicin right temperatur travel this import travel car bus train plane form transport store prefil syring room temperatur c maximum period day protect light onc remov refriger store room temperatur syring must use within day discard even return refriger write date first remov syring refriger label check long dispos after inject humira immedi throw away use prefil syring special sharp contain instruct doctor nurs pharmacist if doctor tell stop use humira expiri date pass ask pharmacist medicin left product descript what look like humira mgml clear colourless steril solut mg adalimumab ml solut syring aust r mg adalimumab ml solut syring aust r mg adalimumab ml solut syring aust r the follow prefil syring pack avail prefil syring alcohol pad humira mg ml humira mgml prefil syring prefil syring alcohol pad humira mg ml prefil syring ingredi humira contain adalimumab activ ingredi for humira mgml mg ml mgml prefil syring also contain ingredi includ mannitol citric acid monohydr sodium citrat dihydr monobas sodium phosphat dihydr dibas sodium phosphat dihydr sodium chlorid polysorb water inject distributor humira distribut australia abbvi pti ltd abn oriordan street mascot nsw this leaflet prepar',\n",
       "  'VBZ'),\n",
       " ('it bit surpris im honest id background retinopathi pop the convers i optometrist still effect background retinopathi proxim macula concern becom maculopathi signific observ in nhs clinic trial eylea perform best three drug offer macula odoema the swell i describ first post',\n",
       "  'JJ'),\n",
       " ('del egfr lr egfr wt fig d order nice mirror trend experiment determin affin inhibitor to quantifi differenti bind tkis various mutant egfr calcul bind free energi use mmpbsa approach of cours afatinib coval bond egfr henc one cannot use classic method comput bind energet carri use quantum mechan method outsid scope current studi therefor calcul bind free energi erlotinib gefitinib wildtyp mutant lrdel egfr explor whether model construct accord experi it clear calcul mirror experiment trend bind affin experiment ic figur s the differ experiment affin wild type egfr first glanc much larger calcul one howev upon care examin experiment data avail literatur find spread valu wild type egfr quit larg shown error bar',\n",
       "  'NN'),\n",
       " ('epicaptur a urin dna methyl test earli detect aggress prostat cancer e oreilli et al jco precis oncolog januari use artifici intellig detect cervic cancer nih director blog januari cancer surgeri genom era winter d c et al the british journal surgeri ee commentari the role breast cancer surgeon person cancer care clinic util gene assay iglehart j dirk et al american journal surgeri jun costeffect genet test breast cancer riskrespons fols henri et al cancer prevent research philadelphia pa apr cypd genotyp use tamoxifen breast cancer berri donald et al journal nation cancer institut sep data mine digit health record resourceconstrain set reveal time immunophenotyp associ improv breast cancer outcom lpezpineda arturo et al bmc cancer sep experi attitud toward risk recurr test women breast cancer systemat review leggett laura e et al breast cancer research treatment apr genet cancer suscept test increas technolog increas complex yu peter paul et al journal clinic oncolog offici journal american societi clinic oncolog nov impact webbas case conferenc cancer genet train outcom communitybas clinician blazer kathleen r et al journal cancer educ offici journal american associ cancer educ jun inform various databas cdc inform nih resourc cdcauthor public state public health genom program tier tabl epidemiolog studi translationimplement studi evid synthesi guidelin reviewscommentari toolsmethod ethicalleg social issu amd week clip gwas catalog grant support public genet test gtr genet diseas omim pubm review pubm clinic queri pharmgkb from cdc inform databas this databas includ general cdc public health inform specif diseas health relat topic when avail databas display genom inform various cdc web page user also encourag conduct search cdc websit addit inform prevent cervic cancer st centuri cdc public health grand round januari famili histori cancer cdc divis cancer control prevent when should you be screen colorect cancer s bowen et al cdc blog post august skin cancer prevent progress report cdc use genet risk score cancer screen are we there yet robert m et al cdc blog post juli cancer men sun safe selfi near million peopl treat skin cancer year unit state skin cancer serious expens sometim even dead marleah stori for marleah breast cancer young age run famili prevent colorect cancer we can do it ca gelb cdc blog post mar thing you can do prevent cancer look gene your famili health cancer histori affect futur protect your daughter cervic cancer colorect cancer famili histori cdc youtub video breast cancer awar fast fact about breast cancer cme activityclin antholog educ medic provid about breast cancer young women what should i know about screen take action lower your breast ovarian cancer risk summer sun safeti protect yourself uv radiat should i get screen prostat cancer improv health qualiti life after cancer cancer precis medicin more popul scienc ahead mj khouri et al cdc blog post viral hepat liver cancer what are risk factor colorect cancer colorect cancer awar breast cancer cancer tobacco use tobacco use caus mani cancer cdc vital sign novemb lung cancer awar breast cancer young women the cancer moonshot hereditari cancer popul genet screen mj khouri et al cdc blog post octob breast ovarian cancer breast cancer awar prostat cancer awar have you famili member had colorect colon cancer what are risk factor skin cancer us healthcar facil capac meet colorect cancer screen goal news releas june cancer famili histori use genom prevent watch video cdc public health grandround april health dispar cancer liver cancer inform how much know colorect cancer take cdc quiz what are risk factor colorect cancer colorect cancer screen save live talk doctor get screen cdc blog post famili histori eileen cancer survivor stori i famili histori cervic uterin cancer i didnt get check i symptom recommend realiti what person stori hereditari cancer can tell us r green fisk cdc blog post cervic cancer awar protect your daughter cervic cancer my person prescript surviv cancer g hilliard cdc cancer blog post novemb bring your brave campaign doe breast ovarian cancer run your famili fast fact vagin vulvar cancer pdf kb fast fact ovarian cancer pdf kb fast fact uterin endometri cancer pdf kb gynecolog cancer awar what risk factor prostat cancer hereditari breast ovarian cancer public health implement toolkit cdc ovarian cancer inform colorect cancer awar genet test hereditari colorect cancer a famili health histori lung cancer risk factor lung cancer what lower lung cancer risk hpv cancer the futur epidemiolog age precis medicin cancer cardiovascular diseas beyond what i know screen cervic cancer prevent fact sheet cervic cancer pdf kb cancer survivorship can use genet stratif popul screen cancer human diseas bad luck act genet environment factor reduc cancer risk cancer prevent control cdc medscap expert commentari genet brca primari care katherin kolor medscap octob use genom precis prevent breast cancer muin j khourygenom health impact blog april most case melanoma deadliest kind skin cancer caus exposur ultraviolet uv light cdc inform cancer prevent start childhood cdc paper target cancer screen averagerisk individu p marcus et al am j prev medicin juli cdc paper meet healthi peopl object reduc cancer mortal h weir et al prevent chronic diseas juli cdc inform improv health qualiti life after cancer cancer men check gene report risk outcom brain cancer huge navig cdc inform cancer screen test cdc inform skin cancer awar check gene report relat risk male breast cancer huge navig cdc inform can men get breast cancer cdc inform cancer women prevent control skin cancer cdc public health grand round cdc inform health dispar cancer cdc inform new analysi breast cancer subtyp could lead better risk stratif annual report nation show mortal incid cancer continu declin cdc tier genom applic implement toolkit public health depart detail inform hereditari breast ovarian cancer hboc cdc inform doe breast ovarian cancer run your famili know brca chang my life by debbi wasserman schultz cdc blog post cdc knowbrca tool some women carri certain genet chang brca gene increas risk get breast ovarian kind cancer young age cdc inform what kidney cancer pdf kb cdc inform skin cancer prevent travel spring break dont forget pack protect sun go screen life nation colorect cancer action campaign cdc inform colorect cancer awar cdc inform world cancer day cdc join peopl organ govern agenc around world take proactiv approach fight cancer highlight solut within reach the fight cancer beyond us go cdc inform databas from cdcauthor genom public databas this databas contain cdcauthor public public health genom includ infecti diseas newborn screen reproduct health genet test cancer chronic diseas birth defect development disabl environment occup health well laboratori bioinformat statist method populationbas assess hpv genotypespecif cervic cancer surviv cdc cancer registri sentinel surveil system hallowel benjamin d et al jnci cancer spectrum communic about hereditari cancer social media a content analysi tweet about hereditari breast ovarian cancer lynch syndrom allen caitlin g et al journal cancer educ offici journal american associ cancer educ dec collabor method perform studi measur nicotin metabolit total nicotin equival human urin wang lanq et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog may timecours analysi micrornainduc mesenchymaltoepitheli transit underscor complex under molecular process lili loukia n et al cancer letter may mammographi use among women age year unit state qin jin et al breast cancer research treatment dec evalu modular decis support applic for colorect cancer screen militello laura g et al appli clinic informat feb precis medicin requir precis laboratori rajeevan mangalathu s et al the journal molecular diagnost jmd mar util genet test analysi genespecif bill medicar claim data lynch juli a et al genet medicin offici journal american colleg medic genet aug the gut microbiota convent serrat precursor colorect cancer peter brandilyn a et al microbiom dec emerg depart util californian sickl cell diseas paulukoni susan t et al pediatr blood cancer jun cdc grand round famili histori genom tool cancer prevent control rodriguez juan l et al mmwr morbid mortal week report nov comparison dna test strategi monitor human papillomavirus infect preval simul lin carol y et al bmc infecti diseas nov pattern trend agespecif blackwhit differ breast cancer incid mortal unit state richardson lisa c et al mmwr morbid mortal week report oct hepatocellular carcinoma risk alaska nativ children young adult hepat b virus retrospect cohort analysi gounder prabhu p et al the journal pediatr aug consensus report weinman intern confer mesothelioma carbon michel et al journal thorac oncolog offici public intern associ studi lung cancer aug the cancer epidemiolog descript cohort databas a tool support populationbas interdisciplinari research kennedi ami e et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog jul the activ impact state program address hereditari breast ovarian cancer triver katrina f et al healthcar basel switzerland valid standard extract method formalinfix paraffinembed tissu sampl lagheden camilla et al journal clinic virolog offici public pan american societi clinic virolog apr incid hepatocellular carcinoma accord hepat b virus genotyp alaska nativ peopl ching lanc k et al liver intern offici journal intern associ studi liver mar adher primari care physician evidencebas recommend reduc ovarian cancer mortal stewart sherri l et al journal women health mar implement gene recurr score test unit state lynch juli a et al genet medicin offici journal american colleg medic genet feb gene integr set profil analysi contextbas approach infer biolog endpoint kowalski jeann et al nucleic acid research jan what predict advancedstag diagnosi breast cancer sort out influenc method detect access care biolog factor lipscomb joseph et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog jan human papillomavirus genotyp oropharynx cancer surviv unit state america goodman marc t et al european journal cancer oxford england dec malign transform hymenolepi nana human host muehlenbach ati et al the new england journal medicin nov when genom test costeffect test lynch syndrom patient newlydiagnos colorect cancer their relat gross scott d et al healthcar basel switzerland contribut sickl cell diseas pediatr stroke burden among hospit discharg africanamericansunit state baker charlott et al pediatr blood cancer dec the costeffect routin test lynch syndrom newli diagnos patient colorect cancer unit state correct estim gross scott d et al genet med jun quantit analysi relat mutagen five chemic constitu tobacco smoke mous lymphoma assay guo xiaoq et al mutagenesi may reduc risk breast cancer associ recreat physic activ vari her status ma huiyan et al cancer med jul further confirm germlin glioma risk variant rs tp it implic tumor tissu via integr analysi tcga data wang zhaom et al hum mutat jul annual report nation status cancer featur incid breast cancer subtyp raceethn poverti state kohler betsi a et al j natl cancer inst jun djv evolut driver translat cancer epidemiolog analysi fund grant literatur lam tram kim et al am j epidemiol apr lam et al respond drive evolut lam tram kim et al american journal epidemiolog apr opportun translat epidemiolog import role observ studi advanc precis oncolog marron michael et al cancer epidemiol biomark prev mar character larg structur genet mosaic human autosom machiela mitchel j et al am j hum genet mar the author repli spitz margaret r et al american journal epidemiolog mar leverag biospecimen resourc discoveri valid marker earli cancer detect schulli sheri d et al journal nation cancer institut apr clinic util geneexpress profil women earli breast cancer overview systemat review marron michael et al genet med jul seer cancer registri biospecimen research yesterday tomorrow altekrus sean f et al cancer epidemiol biomark prev dec the cancer genom epidemiolog navig an nci onlin tool enhanc cancer epidemiolog research schulli sheri d et al cancer epidemiol biomark prev nov an overview recommend translat mileston genom test cancer chang christin q et al genet med jun endogen antibodi respons epiderm growth factor receptor associ immunoglobulin allotyp overal surviv patient glioblastoma pandey janardan p et al neurooncolog may an action plan translat cancer survivorship research care alfano catherin m et al j natl cancer inst nov the next generat largescal epidemiolog research implic train cancer epidemiologist spitz margaret r et al am j epidemiol nov thymidyl synthas genotypedirect chemotherapi patient gastric gastroesophag junction cancer goff laura w et al plos one e imput subsetbas associ analysi across differ cancer type identifi multipl independ risk loci tertclptml region chromosom p wang zhaom et al hum mol genet dec util busi teutsch steven m et al genet medicin offici journal american colleg medic genet dec outbreak pseudomona aeruginosa klebsiella pneumonia bloodstream infect outpati chemotherapi center dobb thoma e et al am j infect control jul characterist associ genet counsel referr brca test among women larg integr health system bellcross cecelia a et al genet med jan collabor biomedicin age big data case cancer shaikh abdul r et al j med internet res e cancer screen genet tale two paradigm hamilton jada g et al cancer epidemiol biomark prev jun the associ demograph behavior characterist sunburn among us adult nation health interview survey holman dawn m et al prev med jun qa muin khouri cancer epidemiolog khouri muin j et al cancer discov feb total bodi skin examin skin cancer screen among us adult lakhani nahe a et al prev med apr epigenet research cancer epidemiolog trend opportun challeng verma mukesh et al cancer epidemiol biomark prev feb potenti increas risk cancer common use medic umbrella review metaanalys ioannidi j p a et al ann oncol jan urinebas human papillomavirus dna test screen tool cervic cancer highrisk women mendez keimari et al int j gynaecol obstet feb person histori diabet genet suscept diabet risk brain glioma pool analysi observ studi kitahara cari m et al cancer epidemiol biomark prev jan genet test strategi newli diagnos endometri cancer patient aim reduc morbid mortal lynch syndrom index case her relat stewart alison et al plos curr a systemat review cancer gwas candid gene metaanalys reveal limit overlap similar effect size chang christin q et al eur j hum genet mar a cancer genet toolkit improv access genet servic document use famili histori primarycar clinician scheuner maren t et al genet med jan biolog network predict chemic hepatocarcinogen use gene express data treat mice relev across human rat speci thoma reuben et al plos one e hepatocellular carcinoma hepat b virus famili matter mcmahon brian j et al clin gastroenterol hepatol dec the microrna famili target multipl nonsmal cell lung cancer prognost marker h cell beasb cell pacurari maricica et al int j oncol aug compar effect research cancer genom precis medicin current landscap futur prospect simond naoko i et al j natl cancer inst jul mortal risk black women white women invas breast cancer hormon receptor her p status ma huiyan et al bmc cancer compar effect research cancer fund knowledg gap remain glasgow russel e et al j natl cancer inst jun opportun public health communic intervent futur research breast cancer younger women buchanan natasha et al j women health larchmt apr transform epidemiolog st centuri medicin public health khouri muin j et al cancer epidemiol biomark prev apr util epiderm growth factor receptor egfr test unit state case studi t translat research lynch juli a et al genet med aug use state cancer registri recruit young breast cancer survivor highrisk relat protocol random trial test efficaci target versus tailor intervent increas breast cancer screen katapodi maria c et al bmc cancer provoc question cancer epidemiolog time scientif innov budgetari constraint lam tram kim et al cancer epidemiol biomark prev apr how polygen inherit use popul screen common diseas khouri muin j et al genet medicin offici journal american colleg medic genet jun preval healthcar action women larg health system famili histori meet uspstf recommend brca genet counsel referr bellcross cecelia a et al cancer epidemiol biomark prev apr driver translat cancer epidemiolog st centuri need opportun lam tram kim et al cancer epidemiol biomark prev feb opportun challeng select emerg technolog cancer epidemiolog mitochondri epigenom metabolom telomeras profil verma mukesh et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog feb effect communic molecular genet test result primari care provid scheuner maren t et al genet med jun known glioma risk loci associ glioma famili histori brain tumour casecontrol gene associ studi melin beatric et al int j cancer may knowledg integr cancer current landscap futur prospect ioannidi john p a et al cancer epidemiol biomark prev jan human papillomavirus genotyp highgrad cervic lesion unit state hariri susan et al j infect dis dec health behavior cancer screen among californian famili histori cancer townsend juli s et al genet med mar associ adult height genet suscept risk glioma kitahara cari m et al int j epidemiol aug multiwal carbon nanotubeinduc gene signatur mous lung potenti predict valu human lung cancer risk prognosi guo nanci l et al j toxicol environ health part a genomewid associ studi glioma metaanalysi rajaraman preetha et al hum genet dec a smokingassoci gene signatur lung cancer diagnosi prognosi wan yingwooi et al int j oncol oct frontier cancer epidemiolog challeng research communiti epidemiolog genom research program nation cancer institut khouri muin j et al cancer epidemiol biomark prev jul multilevel research challeng implement genom medicin khouri muin j et al j natl cancer inst monograph may urinari naphthol metabolit chromosom aberr yearold children orjuela manuela a et al cancer epidemiol biomark prev jul genet variant igfi igfii igfbp adiponectin gene colon cancer risk african american white keku temitop o et al cancer caus control jul detect clonal mosaic relationship age cancer jacob kevin b et al nat genet jun chronic occup exposur arsenic induc carcinogen gene signal network neoplast transform human lung epitheli cell stueckl todd a et al toxicol appl pharmacol jun build evid base decis make cancer genom medicin use compar effect research goddard katrina a b et al genet medicin offici journal american colleg medic genet jul stakehold assess evid cancer genom test insight three case studi deverka patricia a et al genet medicin offici journal american colleg medic genet jul estrogenrel gene contribut racial differ breast cancer risk rede kerryn w et al cancer caus control may relev pathogenesi test algorithm mismatch repairdefect colorect carcinoma report associ molecular patholog funkhous william k et al j mol diagn cancer children nonchromosom birth defect fisher paul graham et al j pediatr jun how stimul translat research cancer genom beyond bench bedsid schulli sheri d et al genet med jan implement screen lynch syndrom among patient newli diagnos colorect cancer summari public healthclin collabor meet bellcross cecelia a et al genet medicin offici journal american colleg medic genet jan use famili histori clinic guidelin diabet colorect cancer peterson brent a et al am j prev med jan go cdcauthor genom public databas from state public health genom program databas this databas focus state nation activ integr genom public health program clinic practic get record from tier tabl databas cdc offic public health genom ophg conduct horizon scan systemat research method find follow novel technolog appear literatur identifi track progress genom test move research clinic public health practic as aid organ horizon scan result ophg rank genom test famili health histori applic level evid see detail get record from huge literatur finder databas this databas contain publish literatur genet associ human genom epidemiolog get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from from advanc molecular detect clip databas this databas includ publish scientif literatur popular press articl tool databas emerg role pathogen genom hostpathogen interact infecti diseas control prevent it includ inform method evolut pathogen detect diagnosi outbreak epidemiolog transmiss antimicrobi vaccin hostpathogen interact get record from nation institut health web site a surpris match cancer immunotherapi mismatch repair franci collin director blog june adren cancer from ncat genet rare diseas inform center adren medulla cancer from ncat genet rare diseas inform center after tcga build clinic genom resourc pi wang nci blog may anal cancer from ncat genet rare diseas inform center anaplast thyroid cancer from ncat genet rare diseas inform center anemia from nhlbi health topic site annual report nation overal cancer mortal continu declin prostat cancer mortal stabil nci press releas may approach blue ribbon panel recommend the case lynch syndrom approach identifi care individu inherit cancer syndrom u clinic trial requir nci moonshot fund announc august approach identifi care individu inherit cancer syndrom u nci fund announc septemb approv osimertinib necitumumab increas lung cancer treatment option are some tumor just born be bad nih director blog may asbestosrel lung diseas from nhlbi health topic site aspirin reduc cancer risk bile duct cancer from ncat genet rare diseas inform center biliari tract cancer from ncat genet rare diseas inform center biomark signatur prostat cancer nih research matter juli biomark test could reduc unnecessari biopsi detect prostat cancer nci june bladder cancer childhood from ncat genet rare diseas inform center brain stem cancer from ncat genet rare diseas inform center brca exchang aggreg data thousand brca variant inform understand cancer risk nci januari brca popul screen predict breast cancer g lippi et al ann tran med juli brca hereditari breast ovarian cancer syndrom from ncat genet rare diseas inform center brca hereditari breast ovarian cancer syndrom from ncat genet rare diseas inform center breast cancer prevent pdqpatient version breast cancer childhood from ncat genet rare diseas inform center breast cancer male from ncat genet rare diseas inform center bring precis screen cancer cancer control planet portal cancer control planet portal provid access data resourc help planner program staff research design implement evalu evidencebas cancer control program cancer dispar cancer genom transform studi diagnos treat cancer nhgri apr cancer moonshot blue ribbon panel report cancer moonshot cartilagin cancer from ncat genet rare diseas inform center cathet ablat from nhlbi health topic site ccg fund opportun biospecimen process storag cerebr ventricl cancer from ncat genet rare diseas inform center check genet condit test associ pancreat cancer nih genet test registri check in cancer checkpoint inhibitor childhood cancer genom pdq health profession version childhood ovarian cancer from ncat genet rare diseas inform center colorect cancer childhood from ncat genet rare diseas inform center coronari calcium scan from nhlbi health topic site crizotinib show promis childhood cancer cryoem imag captur key enzym tie cancer age nih director blog may decod telomer biolog cancer risk nih intramur research detect earli sign cancer blood nih research matter august dicerrel pleuropulmonari blastoma cancer predisposit syndrom from ncat genet rare diseas inform center diffus gastric cancer from ncat genet rare diseas inform center dissemin intravascular coagul from nhlbi health topic site divid conquer the molecular diagnosi cancer dna misfold reveal novel oncogen mechan dualbiomark blood test show promis pancreat cancer earli detect nci news august enhanc riskbas lung cancer screen may prevent more death current approach epigenet may hold key arsenic role cancer e hood the environment factor nieh januari esophag cancer from ncat genet rare diseas inform center esophag cancer childhood from ncat genet rare diseas inform center establish universallynch syndrom screen communiti fallopian tube cancer from ncat genet rare diseas inform center famili colorect cancer from ncat genet rare diseas inform center famili pancreat cancer from ncat genet rare diseas inform center famili prostat cancer from ncat genet rare diseas inform center famili stomach cancer from ncat genet rare diseas inform center fanconi anemia from nhlbi health topic site fda approv alectinib alkposit nonsmal cell lung cancer fda approv pembrolizumab tumor specif genet featur nci june fda grant orphan drug status selumetinib neurofibromatosi type nf treatment nci cancer research may fecal microbiota transplant help restor benefici bacteria cancer patient nih septemb find genet condit test associ thyroid cancer nih genet test registri find genet condit test associ kidney cancer nih genet test registri find pediatr cancer genom data pgdi nci septemb for some children cancer genom inform may help guid treatment decis gallbladd cancer from ncat genet rare diseas inform center gene fusion may drive rare childhood brain tumor genet disord test associ gastric cancer from nih genet test registri genet breast gynecolog cancer pdq nci octob genet colorect cancer pdq health profession version pdq cancer genet editori board nci februari genet prostat cancer pdq health profession version pdq cancer genet editori board nci may genet skin cancer pdqhealth profession version genom studi seek clue help explain breast cancer dispar nci june head neck cancer build evid base precis oncolog post februari dr franci collin heart transplant from nhlbi health topic site hemochromatosi from nhlbi health topic site hereditari breast ovarian cancer move toward more precis prevent nih director blog post april hereditari diffus gastric cancer from ncat genet rare diseas inform center hereditari leiomyomatosi renal cell cancer from ncat genet rare diseas inform center how genom is shape precis medicin oncolog httpswwwcancergovnewseventscancercurrentsbloggenomicprofilingtestscanc nci dec httpswwwcancergovnewseventscancercurrentsblogearlystagelungcancerbiomark nci januari hurthl cell thyroid cancer from ncat genet rare diseas inform center hypopharyng cancer from ncat genet rare diseas inform center idiopath pulmonari fibrosi from nhlbi health topic site inflammatori breast cancer from ncat genet rare diseas inform center insight precis public health summit kidney renal cell cancerpati version kidney cancer childhood from ncat genet rare diseas inform center larg studi verifi cancer risk women carri brca brca mutat nci juli laryng cancer from ncat genet rare diseas inform center laryng cancer childhood from ncat genet rare diseas inform center from grantom grantom search engin analysi tool grant inform associ publish literatur evidencebas translat genom discoveri improv health care diseas prevent human genom epidemiologyth literatur inform genom health impact scan databas huge literatur finder databaseth grant inform extract grant data pubm record nih report grant inform search diseasecondit environment risk factor gene studi free text simpl analysi perform get record from gwas catalog the catalog qualiti control manual curat literaturederiv collect publish genomewid associ studi get record from nih the genet test registri the genet test registri gtr provid central locat voluntari submiss genet test inform provid the scope includ test purpos methodolog valid evid test use laboratori contact credenti the overarch goal gtr advanc public health research genet basi health diseas search genet test registri cancer from nih omim omim comprehens authorit compendium human gene genet phenotyp freeli avail updat daili search omim cancer from pubm clinic queri pubm clinic queri util offer pubm search scientif literatur specif clinic research area search pubm clinic queri cancer from pharmgkb the pharmgkb pharmacogenom knowledg resourc encompass clinic inform includ dose guidelin drug label potenti clinic action genedrug associ genotypephenotyp relationship search pharmgkb cancer from pubm pubm compris million citat biomed literatur medlin life scienc journal onlin book citat may includ link fulltext content pubm central publish web site pubm link genet review articl cancer disclaim articl list public health knowledg base select cdc offic public health genom provid current awar literatur news inclus updat necessarili repres view center diseas control prevent impli endors articl method find cdc dhhs assum respons factual accuraci item present the select omiss content item impli endors posit taken cdc dhhs opinion find conclus express origin author item includ updat person quot therein strict way meant repres opinion view cdc dhhs refer public news sourc noncdc websit provid sole inform purpos impli endors cdc dhhs',\n",
       "  'NN'),\n",
       " ('i real eye open diet fecal fat test requir mg fat intak day i tend snack thing like pretzel rice cake recent ad fat dairi i normal feel like give grace thing week drive nut i alway petit i almost doubl chin stick leg arm have hard time love right yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat balsalazid hosp day start humira reaction entyvio mg pred still wait chang',\n",
       "  'NN'),\n",
       " ('hi nev you may abl get tysabri most class nd line drug this mean general need first line drug fail ie relaps whilst unabl take eg side effect you also get assum avail area ms activ ie youv relaps within year mri show new lesion it also depend drug therapi offer area tecfidera like avail everywher old inject drug betaferon avonex rebif copaxon although often slight differ form copaxon three time week drug avonex plegridi per week subcutan rather week intramuscular gilenya anoth nd line drug interest lemtrada often first drug peopl ms high activ it odd situat peopl told go away think drug want find option limit avail area plus neurologist prefer also sometim neurologist describ person ms high activ qualifi drug lesion brain alway manifest number relaps symptom so good know prefer possibl get dont becom firm attach choic your complet devast find cant there plenti issu relat dmds could offer your ms nurs abl tell drug avail area also drug neurologist like offer sue',\n",
       "  'NN'),\n",
       " ('the first quarter busi period medic oncolog group australia a new group traine commenc special train medic oncolog traine recent complet train award fellowship move ahead career plan moga membership continu grow current traine consult member dr zarni lwin deputi chair i progress new workforc studi complet pilot project late an extens onlin survey distribut moga member come month gather import new data workforc assist long term servic facil workforc plan oncolog drug treatment the oncolog drug group chair dr deme karikio continu make good progress advoc access oncolog drug record number notabl achiev late respons advic moga breast cancer expert pharmaceut benefit advisori committe pbac amend pharmaceut benefit schedul list medicin her posit metastat breast cancer recommend chang list lapatinib her posit metastat breast cancer the restrict trastuzumab emtansin amend allow patient access follow treatment lapatinib pbac also recommend restrict word nab paclitaxel updat consist restrict trastuzumab the group also made submiss prioriti approv number oncolog drug consid pbac march meet includ nivolumab nonsmal cell lung cancer bevacizumab cervic cancer lenvatinib thyroid cancer olaparib ovarian cancer tamoxifen breast cancer prevent at time group indic support submiss cetuximab metastat head neck cancer nintedanib nonsmal cell lung cancer vismodegib basal cell carcinoma these list address import area unmet need cancer patient increas risk cancer clinician the list support strong randomis clinic trial data keep intern clinic best practic a success submiss support chang list tamoxifen primari prevent breast cancer patient moder high risk result uniqu collabor in moga tabl posit paper prepar lead australian breast cancer specialist prof kellyann phillip the use tamoxifen prevent breast cancer implic recent research this paper present strong research data support approv list tamoxifen therapeut good administr pbac placement pharmaceut benefit scheme reduct risk invas breast cancer women moder high risk sinc prof phillip prof fran boyl chair moga breast cancer group anz breast cancer trial group work moga tga pbac depart health age astrazeneca enact chang educ profession educ plan well advanc australia asia pacif clinic oncolog research develop workshop acord septemb applic review particip offer place career enhanc program acordorgau communic skill earli career oncologist new program develop young oncologist group australia yoga held april this program includ seri workplac relat role play train actor relat plenari session burnout mind communic challeng could assist medic oncologist daytoday clinic practic dr georg auyeung yoga presid report good communic core profess medic oncologist this innov educ initi provid young oncologist challeng valuabl learn opportun help build profession communic skill the moga annual scientif meet implement innov immunotherapi held gold coast august immunotherapi becom increas import therapeut strategi cancer patient medic oncologist clinic trial demonstr signific clinic advantag array cancer stream convenor prof ken o byrn plan scientif program focus innov approach implement immunotherapi practic includ major immunooncolog forum conven prof grant macarthur dr alexand menzi prof justin steb imperi colleg london present keynot address meet share insight futur medic oncolog',\n",
       "  'NN'),\n",
       " ('on st juli scientif communiti mark birthday alfr gilman dr gilman receiv nobel prize physiolog medicin work gprotein these transmembran protein everi neurosci student know day import compon cellular signal they involv practic manner intercellular communic brain cell the best prionlik protein longterm memori mainten despit recent progress understand brain function still limit knowledg format storag longterm memori a semin paper publish month view serious breakthrough field research demonstr longterm memori maintain prionlik protein the protein call cpeb shown involv process like typic prion involv varieti neurodegen disord cpeb exist solubl aggreg form when learn someth new synapt connect made solubl form cpeb synaps get convert insolubl aggreg these aggreg turn synthesi protein need maintain memori new better compound depress antidepress prozac select serotonin reuptak inhibitor ssris work slowli produc appreci effect mani week month administr they also known associ number side effect as result mani medic profession voic concern increas use ssris howev new compound call gabanam work complet differ mechan may revolution treatment depress in anim experi shown treat depress less hour minim side effect this serious improv compar ssris hope high drug soon test human antimalari treat parkinson diseas drug repurpos becom increas common strategi come look new approach treat various condit the reason lie fact mani patholog process share common biochem mechan as result drug develop one condit may turn help treat someth els the resent rather remark exampl repurpos involv parkinson diseas it turn drug use prevent treatment malaria chloroquin amodiaquin reduc symptom improv behavior rat diseas there hope drug might quick develop treatment human fingolimod drug multipl sclerosi treatment huntington diseas anoth success drug repurpos stori came search treatment huntington diseas it turn month cours fingolimod drug multipl sclerosi improv memori restor synapt plastic hippocampus mice huntington diseas the drug good safeti profil research current plan studi human patient crosstalk immun system agerel cognit declin last year research stanford demonstr blood young rat revers cognit declin old anim continu studi subject scientist found opposit true blood older anim circul bodi young rat it turn blood older anim contain increas amount beta microglobulin bm bm compon immun system also particip shape communic brain cell in experi increas amount bm blood clear link worsen perform memori test interest effect bm revers cognit abil get restor bm level decreas the discoveri might pave way develop target drug prevent agerel cognit declin the worst human probabl good distinguish odor a paper smell percept publish scienc claim human distinguish least trillion odor but new paper publish week ago elif journal signific smaller impact factor cast serious doubt valid claim this new paper show number smell heavili depend number particip strict statist test use estim it also appear origin claim base unproven assumpt human smell percept rather poor understood present nonetheless trillion odor claim alreadi make way neurosci textbook a case bad scienc perhap vitamin b provid benefit older peopl moder defici the fact lack vitamin b lead serious problem nervous system well establish vitamin b supplement provid obvious improv patient sever defici these day vitamin b also routin prescrib older patient moder mild defici hope supplement help improv cognit motor function howev result new clinic trial show b supplement patient provid benefit whatsoev british research gave either b pill placebo group elder year old patient one year at end studi scientist compar patient perform batteri clinic test surpris singl differ pretrial result spot clear time rethink current strategi b supplement tini brain lesion serious risk stroke brain imag provid lot inform state health not inform howev taken account clinician mean signific certain chang brain simpli alway clear one tradit disregard thing small lesion alway view insignific normal even healthi peopl but new find publish month indic lesion associ increas risk stroke even death the risk much three time higher compar patient without lesion this clear someth take consider medic profession antidepress may affect cognit develop interf rem sleep the use antidepress grow fast recent year mani pediatrician even prescrib children various disord the latter might serious concern howev compound tend disturb socal rapid eye movement rem sleep rem sleep import convert daytim experi memori new find suggest rem sleep particular crucial period rapid brain remodel ie children adolesc lot higher cognit function skill get acquir develop antidepress serious disturb rem sleep thus potenti affect children abil learn adapt sleep depriv good night sleep might benefici traumat experi both convent wisdom medic advic say good night sleep help reduc effect traumat event intrus memori flashback this might wrong approach howev in recent experi research subject peopl watch emot disturb movi either interrupt sleep sleep laboratori allow sleep comfort home it turn peopl sleepdepriv group good rememb emot disturb detail movi sleep known consolid memori it appear sleep depriv might help prevent consolid traumat memori refer dangour a allen e clark r elbourn d fletcher a letley l richard m whyte k uauy r mill k effect vitamin b supplement neurolog cognit function older peopl random control trial american journal clinic nutrit doi ajcn dumoulin bridi m aton s seibt j renouard l coleman t frank m rapid eye movement sleep promot cortic plastic develop brain scienc advanc doi sciadv fioriti l myer c huang y li x stephan j trifilieff p colnaghi l kosmidi s drisaldi b pavlopoulo e kandel e the persist hippocampalbas memori requir protein synthesi mediat prionlik protein cpeb neuron doi jneuron fischel j van dyke a kvarta m legat t thompson s rapid antidepress action restor excitatori synapt strength after chronic stress negat modul alphacontain gabaa receptor neuropsychopharmacolog doi npp gerkin r castro j the number olfactori stimuli human discrimin still unknown elif doi elif kim c han b moon j kim d shin j rajan s nguyen q sohn m kim w han m jeong i kim k lee e tu y naffinolivo j park c ring d yoon h petsko g kim k nuclear receptor nurr agonist enhanc dual function improv behavior deficit anim model parkinson diseas proceed nation academi scienc doi pnas porcheret k holm e goodwin g foster r wulff k psycholog effect analogu traumat event reduc sleep depriv sleep doi sleep smith l he y park j bieri g snethlag c lin k gontier g wabl r plambeck k udeochu j wheatley e bouchard j eggel a narasimha r grant j luo j wysscoray t villeda s microglobulin system proag factor impair cognit function neurogenesi natur medicin doi nm windham b deer b griswold m wang w bezerra d shibata d butler k knopman d gottesman r heiss g mosley t small brain lesion incid stroke mortal annal intern medicin doi m wood h neurodegen diseas could fingolimod provid cognit benefit patient huntington diseas natur review neurolog doi nrneurol imag via fotohunt shutterstock',\n",
       "  'NN'),\n",
       " ('ipoop that reason point the way gi explain sinc i tri humira first potenti remicad still may produc signific result had i tri remicad first said would essenti reason tri humira there great chanc would work either she gave quick overview entyvio i never heard somewhat disappoint never even came possibl old gi i digress i great intrigu possibl like said focus specif gi tract oppos block wbc entir bodi i think im interest tri entyvio point doe work well imuran sinc today mark one month point first day actual mg u b i think your right give increas humira tri move im get test done friday check humira level bodi see i built antibodi it may show even worth up dosag may show stay system time i may tri benedryl ill give anyth shot buy even one night bliss sleep boy i miss day notsosickgirl is bentyl prescript ion drug otc i may give enema anoth shot i rememb i tri one i couldnt hold i evacu quick ive also tri proctofoam past saw real result either this third round pred i mg week i saw mild improv it mg thing dip i got im stay steadi i never got dose pred nocturn bms occur essenti sinc flare start last june some day i realli dont know i energi what keep go imagin good im go feel much energi ill i start get full night sleep ill abl accomplish anyth day final come after research night entyvio seem like better option that cours pend result upcom humira blood work mayb ill get lucki use iv yet mayb up humira help diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free most dairi free sinc jan flare sinc june signific inflamm doc word post edit ihatepoop pm gmt',\n",
       "  'NN'),\n",
       " ('combin clemastin fumar biotin ocrevus azt', 'NN'),\n",
       " ('i dont know anyth st mark sound place dont sound experienc uc surgeon someth odd first surgeri leav much colon also surgeri offer option like remicad biolog steroid may use want reduc inflamm quick i would go remicad get switch better hospit remicad work allow reduc steroid faster know within day respond remicad tell make sure st mark know dire circumst year old femal diagnos sever uc remicad mgkg imuran mg librax zofran need calcium vitamin slow fe',\n",
       "  'NN'),\n",
       " ('omnitrop somatropin form human growth hormon import growth bone muscl omnitrop use treat growth failur children adult lack natur growth hormon this includ peopl turner syndrom praderwilli syndrom short statur birth catchup growth caus omnitrop may also use purpos list medic guid import inform you use omnitrop cancer eye problem caus diabet treat praderwilli syndrom overweight sever breath problem you use omnitrop serious ill due lung failur complic recent surgeri injuri medic trauma befor receiv omnitrop tell doctor past present medic condit especi allergi trauma surgeri diabet cancer breath problem liver kidney diseas scoliosi high blood pressur pancrea disord underact thyroid brain tumor also tell doctor medic use especi steroid diabet medic your dosag medicin may need chang start use omnitrop do stop use steroid sudden chang medic dose without doctor advic call doctor sudden sever pain upper stomach nausea vomit fast heartbeat increas thirst urin weight loss vision chang sudden sever pain behind eye befor take medicin you use omnitrop allerg somatropin benzyl alcohol serious ill due lung failur complic recent surgeri injuri medic trauma cancer eye problem caus diabet diabet retinopathi treat praderwilli syndrom overweight sever breath problem includ sleep apnea to make sure omnitrop safe tell doctor diabet pituitari gland disord abnorm curvatur spine scoliosi underact thyroid histori head injuri brain tumor histori childhood brain cancer radiat treatment some brand somatropin expect harm unborn babi includ genotropin omnitrop saizen serostim it known whether certain brand somatropin harm unborn babi includ humatrop norditropin nutropin zomacton zorbtiv tell doctor pregnant plan becom pregnant treatment it may safe breastfe babi use medicin ask doctor risk how i use omnitrop use omnitrop exact prescrib doctor your dose depend treat follow direct prescript label do use medicin larger smaller amount longer recommend omnitrop inject muscl skin you may shown use inject home do selfinject medicin understand give inject proper dispos use needl syring your care provid show best place bodi inject omnitrop use differ place time give inject do inject omnitrop place two time row prepar inject readi give do shake medicin do use medicin chang color particl call pharmacist new medicin use dispos needl syring follow state local law throw away use needl syring use punctureproof sharp dispos contain ask pharmacist get one throw away keep contain reach children pet while use omnitrop may need frequent blood test your growth progress need test often your eye may also need check if praderwilli syndrom treatment program may also includ weight control follow doctor instruct close throw away omnitrop left expir date label pass see also dosag inform detail what happen i miss dose use miss dose soon rememb skip miss dose almost time next schedul dose do use extra medicin make miss dose call doctor miss dose row what happen i overdos seek emerg medic attent call poison help line overdos caus tremor shake cold sweat increas hunger headach drowsi weak dizzi fast heartbeat nausea longterm overdos may caus excess growth what i avoid use omnitrop get emerg medic help sign allerg reaction omnitrop hive difficult breath swell face lip tongu throat serious breath problem may occur patient praderwilli syndrom use omnitrop if praderwilli syndrom call doctor prompt develop sign lung breath problem short breath cough new increas snore also call doctor pain knee hip walk limp ear pain swell warmth drainag numb tingl wrist hand finger sever swell puffi hand feet pain swell joint pancreat sever pain upper stomach spread back nausea vomit high blood sugar increas thirst increas urin dri mouth fruiti breath odor increas pressur insid skull sever headach ring ear dizzi nausea vision problem pain behind eye sign adren gland problem extrem weak sever dizzi weight loss chang skin color feel weak tire common omnitrop side effect may includ swell rapid weight gain muscl joint pain headach pain itch skin chang medicin inject this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda what drug affect omnitrop tell doctor current medicin start stop use treatment omnitrop especi birth control pill hormon replac therapi insulin oral diabet medicin steroid medicin prednison dexamethason methylprednisolon other this list complet other drug may interact somatropin includ prescript overthecount medicin vitamin herbal product not possibl interact list medic guid see also drug interact detail further inform rememb keep medicin reach children never share medicin other use omnitrop indic prescrib',\n",
       "  'NN'),\n",
       " ('i recent join egfr resist group it i learn healthunlock today weeksi first episod may first side effect tagrisso it seem combin onset menopaus bit intens subsid soon i gobbl oz water bottl to honest i terrifi like littl kid first seem get use find better way manag great i scour site egfr site learn tip help remedi dri skin rash basha',\n",
       "  'NN'),\n",
       " ('sure thing there reason reinvent wheel disclaim ani inform find site consid medic advic all decis made consent doctor otherwis risk top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew thu nov pm everyon know i adament benefit lipitor ms sinc i start fingolimod trial dec th i stop mg lipitor ooooooohhhhhhh chang my foot drop bad i miss lipitor bad i restart wks ago now i cant get back i i mg od bare feel posit aspect i must admit spastic better i much better oct i stop i cant wait get new drug i wonder go lipitor i high hope i think i bad patient i take lipitor even i studi drug contraind new drug cant give lipitor past now i wonder i ever get effect top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust fri dec carolew wrote i must admit spastic better i much better oct i stop are say spastic reduc sinc stop lipitor sinc oct top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew sun dec the lipitor realli help spastic i back mg od i better i keep first dose fti thursday what i new drug doesnt lipitor top robbi famili elder post join thu jan pm locat northern ontario canada quot post robbi sun dec the lipitor realli help spastic how help carolew my leg lock right get hard rockveri pain u think might help top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust sun dec pm carolew wrote what i new drug doesnt lipitor look first prioriti take lipitor i hope go onto trial well i plan keep take lipitor stuff work i would expect even better the research told contraind understand work total differ biolog mechan by stop lipitor go downhil way tell doesnt work it may work well lipitor i think real test help take ie still exist regimin serious look health first prioriti top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew mon dec pm robbi it lock exact instead get like stiff stick lipitor spasm much less gradual lipitor i realiz easier get toilet bowl chair i sure work everyon magic thank cureorbust i agre i may stay sinc contraind fti lipitor affect liver so i would realli watch liver function test by way today i saw neurologist gave month suppli studi drug oh what a feel for first time accept studi wow final i could placebo i sure hope i feel like i lipitor fall back onto need i would prefer realli someth activ my first dose day drum roll take care i keep post carolew top pauldog newbi post join wed aug pm has anyon tri natur statin drug quot post pauldog wed aug pm a friend mine ms think never got sever form take statin drug cholesterol mani year but main question red rice yeast contain natur form activ substanc statin drug has anyon tri form result ani advic dosag etc top dim famili elder post join thu feb pm locat greec contact contact dim websit quot post dim mon jan pm policosanol there drug brand vanachol contain natur substanc high cholesterol daili dose contain policosanol mg omega gr phytosterol mg b mg b mg pholic acid mg interest ah top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust mon jan pm it propos specif lower cholesterol statin antiinflamatori properti assist ms top peekaboo famili elder post join sun feb pm locat arizona contact contact peekaboo icq quot post peekaboo fri apr niacin taken w statin combin reduc heart attack risk accord univers washington studi suggest dose mg taken prevent mag may pg take statin ms therapi benefit may ouy weigh risk top jimmyleg volunt moder post join sat mar pm been thank time quot post jimmyleg fri apr niacin establish altern statin take easi liver niacin flush fun your bit masochist take straight niacin dont flush that whole worm s',\n",
       "  'NN'),\n",
       " ('hello angc i offer copaxon tecfidera i rule tecfidera i stomach issu nurs said caus stomach issu first i rule copaxon first time round i left aubagio i realli confus mif moment drug thing gilenya effect tecfidera wasnt offer i never offer tysabri lemtrada i would rather hit aggress rather wait i bad turn round say sorri sp drug apolog rant dont fulli understand it budget postcod i suppos sam',\n",
       "  'NN'),\n",
       " ('as enamour might tecfidera habit tri monitor www news resourc ensur peopl sudden keel news regard tecfidera biogen pharmaceut make invari come financi page big citi fat cat eager check share price trend appar biogen share price taken knock late usual good sign thank due failur tragedi due competitor get close make anoth drug avail appar pipelin compani call celgen hot latest big hope suppos effect safer tecfidera gilenya the side effect thus far headach increas risk uti runni nose has anyon els heard ozanimod',\n",
       "  'NN'),\n",
       " ('ocrevus fulli licens lemtrada tysabri tecfidera the instant heart problem ocrevus put right back shit ill tri next list my order prefer futur need follow lemtrada cladrabin book inject type not mavenclad hsct done mexico food better moscow warmer russian dont like us much right risk septicaemia compar near uk nhs anyth come along interim ocrevus',\n",
       "  'NN'),\n",
       " ('at glanc cladribin look signific better anyth els', 'NNS'),\n",
       " ('not sure oz what ocrevus us im bit touch', 'JJ'),\n",
       " ('well know remicad work well id consid anoth similar biolog within class remicad cimzia humira tnfalphablock biolog develop antibodi one tnfalphablock doesnt mean develop antibodi cimziahumira molecular structur differ enough immun system must start groundup antibodi develop process you might never develop antibodi cimziahumira could increas odd stelara complet differ class biolog complet differ mechan action itd gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa there two certainti life pay tax prednison side effect',\n",
       "  'JJ'),\n",
       " ('hi janin thank respons due word limit i unabl make clear mum tragic pass away end februari whilst tagrissoazd month my question realli gain sort closur i notic anoth forum research respons rate tagrisso tm posit realli thought would work when i met oncologist pass away said mother might doesnt work cancer becom aggress erlotinib i wonder mani case patient tm posit tagrisso hasnt work i find posit find i wonder cancer allow progress got drug earlier would made differ perhap chemotherapi etc the link post seem tm negat advic appreci thank',\n",
       "  'NN'),\n",
       " ('when i last saw neurologist back april last year told saw sign ms shift secondari progress sinc i saw ive develop foot drop walk speed probabl halv distanc i walk plummet i dont know criteria spms rather rrms im hope i dont meet im happi take gilenya dmts spms interferon mitoxantron i cant take interferon caus depress i took year ago mitoxantron effect peopl relaps i dont like sound side effect way gilenya seem keep relaps bay apart one year ago i dont know bad i would suffer i taken yes rrms spms label howev gentl blunt theyr appli a label wont make differ feel daytoday where make differ avail treatment condit so im content say i rrms till neurologist say otherwis gentl i hope',\n",
       "  'NN'),\n",
       " ('my daughter test ros posit nsclc take crizotinib week recent scan ct bone show slight progress liver possibl new spot bone spine rib cancer lung node appear stabl even smaller her blood work show high ldh low albumin is reason believ crizotinib effect is possibl ros detect fals posit the test perform paraffin embed biopsi tissu fluoresc situ hybrid cell posit ros gene rearrang this topic modifi year month ago fano this topic modifi year month ago fano this topic modifi year month ago fano this topic modifi year month ago fano',\n",
       "  'NN'),\n",
       " ('okay anoth question remicad humira antitnf one would assum bodi produc antibodi toward one sinc famili drug knowledg',\n",
       "  'VBP'),\n",
       " ('thank info jerri took first treatment friday opdivo believ someth runnung low grade fever also lost appetit weak hope good sign',\n",
       "  'NN'),\n",
       " ('i remicad year month ago i start get sever joint pain swell wrist knee elbow etc the pain swell move around i call gi doctor get bloodwork check remicad antibodi he call prometheus test anyway call coupl week later said everyth look fine continu infus see rheumatologist check caus joint pain so i got referr cant get see rheumatologist month in meantim pcp bloodwork show posit ana possibl lupus he sent antidsdna test came back posit suggest lupus so i hope pain might caus remicad prometheus test antibodi negat so i realli confus if prometheus test show antibodi remicad mean i might full blown lupus drug induc lupus has anyon similar problem',\n",
       "  'NN'),\n",
       " ('as research learn mechan behind diseas target therapi patient egfrposit lung cancer becom wide use but given myriad way malign evolv treatment landscap constant shift accord edward garon at th annual winter lung cancer confer miami beach cure sister public oncliv sat garon director thorac oncolog david geffen school medicin ucla discuss find recent clinic studi impact futur use immunotherapi nonsmal cell lung cancer you spoke bring immunotherapi egfr mutat can start discuss optim regimen patient right garon i think point dont optim approach immunotherapi popul patient one thing i address talk dearth data regard popul patient the strongest data date i would argu impow studi three separ arm control arm regimen carboplatin paclitaxel avastin bevacizumab two studi arm one swap avastin tecentriq atezolizumab anoth quadruplet use drug carboplatin paclitaxel avastin tecentriq that studi patient complet therapi egfr inhibitor what shown group patient receiv quadruplet benefit respect progressionfre surviv and although hazard ratio cross one least numer suggest overal surviv advantag well group patient interest clear benefit least clear benefit tecentriq substitut avastin realli beg question whether someth particular four drug togeth that i think date compel data set it part approv quadruplet regimen someth often abl get patient base recommend nation comprehens cancer network what next step data i think data data it patient larg clinic trial i dont know whether effort replic larger number patient i know pd pdl inhibitor look studi design although general incorpor avastin one thing advantag impow studi compani own avastin tecentriq make easier run studi look quadruplet nonetheless biolog reason imagin inclus avastin import we know particular data japan certain progressionfre surviv addit avastin clear add egfr inhibitor tarceva erlotinib two studi assess we also await data studi tarceva without cyramza ramucirumab are concern toxic fourdrug regimen like there certain concern toxic if one look impow studi one might expect toxic littl bit wors quadruplet would triplet that way expect one issu asid toxic backbon regimen carboplatin paclitaxel avastin although reason approv regimen mani year lost favor among mani practition instead opt carboplatin pemetrex it littl hard find object data reason theyr compar respect efficaci outcom particular dispar but talk practition tell toler as part pointbreak studi toler assess one interest thing neuropathi one toxic clear differ two the frank big issu practic hair loss mani patient continu work dont want lose hair lose hair someth associ peopl mind sick dont like that anoth issu where see potenti role later line therapi earlier i think right thought would complet egfrtki the data support pd pdl inhibitor prior egfrtki quit scant that i would forese now one thing i would also argu im hope best get immunotherapi egfrmut nonsmal cell lung cancer i think toxic signific regimen efficaci although studi certain look better chemotherapi alon still hope better hope well see come year',\n",
       "  'IN'),\n",
       " ('yesterday i went see team qmc followup recent moar mother of all relaps thing certain chang realm diseas modifi therapi most notic seem failur toler attitud treatment which first relaps year first almost year sinc i start take tecfidera neurologist ms nurs keen discuss chang medic stepup first line treatment aggress effect second line option so back realm weigh drug like stick wet finger air see way wind blow key contend finngolimod aka gilenya one pill day promis reduct relaps rate mean there huge amount choos tecfidera still class first line like ive said various team would like see move someth bit effect tysabri aka natalizumab intraven infus everi four week the ms nurs describ act like velcro immun cell blood stream prevent pass blood vessel wall central nervous system nerv damag occur as say ms trust public diseas modifi drug link open pdf tysabri high effect categori dmd reduc number relaps two third sound great yeah but hang treatment tysabri may increas risk progress multifoc leukoencephalopathi pml uncommon brain infect lead sever disabl even death pml caus mutat jc virus common infect complet unrel ms so there and final alemtuzumab aka lemtrada aka campath taken two fiveday intraven infus month apart again high effect categori dmd reduc number relaps around becaus alemtuzumab suppress immun system peopl vulner infect there usual headach nausea but sure that right three serious side effect report clinic trial overact underact thyroid gland lead thyroid disord affect peopl idiopath thrombocytopen purpura itp serious disord prevent blood clot affect peopl kidney problem affect peopl these side effect potenti serious treatabl caught earli enough peopl take lemtrada inform earli sign symptom side effect when i talk ms nurs impli alemtuzumab risk associ certain ms trust public impli most intens effect wipe lymphocyt read done so next week im go back qmc blood test see i jc virus therefor less like develop pml on first glanc i lean toward tysabri im sure post stevedomino email this blogthi share twitter share facebook share pinterest label drug medic ms nurs relaps treatment comment swisslet said jesus what set choic i realli feel brother just tri rememb there probabl wrong choic or equal right choic sigh wed jul pm stevedomino said i know your say sound pretti crappi but least is choic talk kate love ms nurs peopl first diagnos day get put straight onto dmt often one time chang consider less toler ill see goe attitud thu jul swisslet said it kate taught inject fact fan she love maxin wrote letter take australia show doctor dive medic made differ decis i sent postcard great barrier reef shes never forgotten bless',\n",
       "  'JJ'),\n",
       " ('thank merri you world knowledg support i actual join chemo support group fb everyon share knowledg experi i get wig coupl week ago order coupl chemo cap look horribl guess i wear around hous i need poof have read better buzz head rather shave yes hard i one curl style hair everi day now i havent wash week i guess sinc i given mani option treatment almost seem futil i want die time soon i would talk wakeke i make decis was think mayb go scripp would difficult i hate far home will see say morn jump post saw dictir morn my neutrophol he us skip chemo week recheck blood work tuesday chemo next week day day granix inject go tri schedul get port put shudder pet scan i go ask thought i guess cant answer scan ask pain i get didnt know had pain cgest left arm pit morn hard believ done fir mani year answer tod i found coupl post peopl lcnelc also get keytruda opvido say immunotherapi wakele wari tri undiagnos sure i immun probkem go sinc cancer diagnosi guess wait see wish talkat',\n",
       "  'NN'),\n",
       " ('i sure evil doctor bed pharmaceut compani make sensat conspiraci theori headlin i think realiti that like lot bore base verif guidelin as i said biolog arent first line treatment i believ patient need diseas sever patient unrespons lesser treatment much stronger precursor prescrib biolog insur compani protocol procedur ensur medic tri first endoscop treatment use qualifi etc im sure there occasion bad egg outlier vast major doctor patient need heart sever nonrespons case warrant fast medic escal milder case nih uk differ nation run system give individu practic much overhead regul newer medic approv slowli uk usa take entyvio exampl same goe newer equip procedur id say usa quicker access new treatment idea process the disadvantag usa cost without thorough vet new methodolog may better wast the nih certain cautious both system pros con howev neither system full peopl littl regard patient outcom moder ulcer coliti john uc histolog remiss rx remicad mgskgwks word contain uc liter figur suck ouch deuc mucus fed lucif luck post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('hi everyon i wonder anyon experienc pretti bad pseudorelaps know i bad relaps space month second one happen week start gilenya i start regain mobil christma final felt like i recov i woke christma morn nasti cold everyon get it weaken amount i abl walk expect noth mad the thing sinc i cant shake ive full night sleep sinc rd decemb im sure insomnia caus cold increas dose baclofen i start middec either way result i complet lost use right leg yesterday aw nerv pain come exact last relaps sept i recov could pseudorelaps caus cold fact im sleep could anoth fullblown relaps',\n",
       "  'NNS'),\n",
       " ('gilenya make slight prone infect that winter flu inject recommend should must later year',\n",
       "  'VBP'),\n",
       " ('health canada approv mavenclad therapi reduc frequenc ms exacerb delay diseas progress the treatment general recommend patient fail respond adequ unabl toler one ms therapi high activ ms',\n",
       "  'JJ'),\n",
       " ('imuran metabol mp within bodi take mp save step cyclosporin like prednison temporari rescu medic remicadehumirasimponi tnfalpha blocker similar med prescrib base patientdoctor prefer xeljanz jakinhibitor complet differ entyvio madcamblock complet differ stelera target regulatori cytokin il il complet differ general want tri least differ class biolog differ mechan action consid surgeri so far youv tri one class as there point diminish return fail two class can third sometim work yes happen rescu third chanc success drop consider fail second moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc post edit ipoop pm gmt',\n",
       "  'NN'),\n",
       " ('i lag plus opdivo clinic trial i trial year i side effect all tumor continu shrink i fantast ct scan i pdl negat also me cea number went i stay trial year i know combin drug save life i stage iv lung cancer met liver pelvi subclavian the mutat i her p',\n",
       "  'NN'),\n",
       " ('patient untreat nonsmal cell lung cancer nsclc mutat epiderm growth factor receptor egfr central nervous system cns metastas baselin report better cns progressionfre surviv pfs compar firstgener egfr tyrosin kinas inhibitor tkis gefitinib erlotinib cns pfs reach certain subset patient administ osimertinib month standard egfrtki therapi p these result preplan exploratori analysi phase flaura studi registr studi got osimertinib approv use firstlin therapi patient egfr mutat advanc nsclc report journal clinic oncolog the flaura studi random doubleblind studi patient untreat egfr nsclc compar osimertinib standard egfrtki therapi gefitinib erlotinib subset analysi patient from flaura with cns metastas the subset patient flaura includ current analys document cns metastas baselin seen brain scan assess neurologist blind manner relat articl pdpdl inhibitor may increas risk hyperprogress diseas nsclc s plus carboplatin may be effect nsclc patient with interstiti lung diseas gefitinib continu therapi may be effect nsclc postprogress of patient includ studi data provid patient measur andor nonmeasur cns metastas avail baselin brain scan cns fullanalysi set cfas sixtyon patient treat osimertinib standard egfrtki end point assess includ cns pfs cns object respons rate orr cns durat respons dor cns diseas control rate dcr cns progress median followup cns pfs month patient osimertinib month patient standard egfrtki while patient characterist balanc baselin median sum baselin cns tumor lesion size larger patient standard egfrtki vs mm osimertinib arm for end point cns pfs differ arm consid nomin statist signific cns progress seen approxim twice mani patient standard egfrtki vs osimertinib result new cns lesion patient osimertinib patient standard egfrtki cnn orr patient osimertinib patient standard egfrtki odd ratio or p in patient least measur lesion baselin cns evalu respons set cefr osimertinib patient standard egfrtki patient cns orr patient osimertinib patient standard egfrtki or p in cns evaluableforrespons set cefr popul median time respons week group howev median cns dor longer patient receiv egfrtki compar osimertinib vs month respect also popul cns dcr similar across group osimertinib egfrtki p the studi author note taken togeth data report flaura data indic subgroup patient without known treat cns metastas baselin osimertinib provid protect effect develop brain metastas',\n",
       "  'NNS'),\n",
       " ('good thought thank california risk analysi continu the internet certain plenti say rituximabocrelizumab issu quit',\n",
       "  'NN'),\n",
       " ('hi marcel i write i jpouch psc i sever pancol respond medicin the surgeon describ colon look like bomb went insid i dont post much i live life am i i uc jpouch no i inconveni jpouch noth compar i went uc if dont psc i wouldnt spend time worri i diagnos jpouch surgeri who know whether i psc first uc doesnt matter doesnt chang diagnosi the initi diagnosi scare i babi yes jpouch surgeri i afraid i wouldnt watch grow now i know lot psc yes monitor yes i might someday need liver transplant good worri today the worst problem i today itch manag i agre ipoop good understand medic issu make crazi focus good control take care year old femal buckey state init misdiagnos crohn oct nd opinion cleveland clinic rediagnos sever pancolitisulc coliti jun recurr cdiff spring fecal transplant may psc diagnosi fail med asacol hd prednison humira flagyl vanco dificid step jpouch surgeri finish februari',\n",
       "  'VBP'),\n",
       " ('hi i felt fair tire first week gilenya didnt last hope itll cheer', 'NN'),\n",
       " ('hi guy im think come gilenya anyon come gilenya experi side effect', 'NN'),\n",
       " ('i i wet macular eye both inject lucenti one year eyelea the right eye six week left hold month inject i use give thought inject i hope eye hold util i finish book seventh year',\n",
       "  'JJ'),\n",
       " ('what site anyway imac end mean monoclon antibodi rituximab ocrevus end ocrevus rituxan areus non hodgkin lymphoma tooand myesthenia gravi sp linda be kind woman feet hit floor morn devil saysoh crap shes repli with quot the follow user say thank howi jeani z stillstannd sunshin suzeq',\n",
       "  'NN'),\n",
       " ('prolong corticosteroid therapi inflammatori bowel diseas ibd associ signific increas mortal risk compar antitumor necrosi factor therapi landmark studi spotlight edward v loftus jr md gastroenterolog updat ibd liver diseas meet this one sever key studi safeti issu involv ibd medic publish past year other highlight dr loftus copanelist william j sandborn md includ studi provid persuas evid tnf inhibitor modest increas lymphoma risk ibd patient degre similar thiopurin sever report address question whether preoper use vedolizumab patient undergo major abdomin oper ibd boost postop infect risk mortal impact prolong steroid vs antitnf therapi bruce jancinmdedg news dr edward v loftus jr left dr william j sandborn a retrospect cohort studi medicar medicaid patient ibd demonstr prolong corticosteroid therapi defin mg prednison equival month period signific higher mortal rate compar ibd patient antitnf agent that come unpleas surpris mani physician there widespread reluct turn continu chronic immunosuppress via antitnf therapi patient challeng ibd particular elder individu multipl comorbid condit mani physician heard read much biolog risk serious advers event opt instead multipl cours corticosteroid diseas control this serious mistak emphas dr loftus professor medicin director ibd interest group mayo clinic rochest minn when say oh ill give patient anoth prednison taper doesnt want start take tnf inhibitor your actual patient harm your actual affect patient life expect declar the messag yes steroid cheap steroid easi nobodi afraid steroid afraid steroid the crohn diseas patient enter cohort new user antitnf therapi subsequ mortal incid rate per personyear compar rate per personyear enter studi period prolong steroid user in multivari analysi account potenti confound factor translat high signific relat risk reduct mortal patient went antitnf therapi am j gastroenterol jan doi ajg a similar trend seen ulcer coliti cohort the ulcer coliti patient enter cohort new antitnf therapi user mortal incid rate per personyear compar rate receiv mg prednison next month this repres relat risk reduct although favor trend achiev statist signific perhap smaller size ulcer coliti cohort',\n",
       "  'NN'),\n",
       " ('hello i diagnos high activ rrms juli i relaps regular first year diagnosi i start tecfidera i take tecfidera sinc april seem okay part march year i relaps i scan follow relaps show lesion brain spine also activ coupl lesion i alreadi i told continu tecfidera moment told i need move onto differentstrong treatment tecfidera isnt work anymor the option suggest fingolimod lemtrada i wont go much i assum peopl know differ medic avail i chosen lemtrada success rate whilst fimgolimod success i know everyon experi complet differ i wonder anyon lemtrada treatment felt was rough were side effect would recommend treatment mani thank advanc',\n",
       "  'NN'),\n",
       " ('my year old husband diagnos ppms januari start ocrevus march novemb second infus weve notic thing may improv still cautious optimist realiz cure may take sever infus see slow progress',\n",
       "  'NN'),\n",
       " ('decemb immunotherapi tnbc the begin begin as immunotherapi emerg import approach treat rang cancer research increas interest tnbc potenti target agent tnbc immunogen cancer that mean tumor like generat immun respons cancer tumor immunogen usual have multipl mutat have cell call tumor infiltr lymphocyt tnbc meet criteria the first studi note possibl role immunotherapi tnbc keynot trial publish june that studi found singl agent pembrolizumab keytruda produc intrigu respons tnbc patient heavili treat chemotherapi while number small sever advanc patient respons continu month even year that studi open door mani trial look differ aspect immunotherapi tnbc in octob impass studi show signific respons combin immunotherapi agent chemotherapi first line therapi patient metastat nonsurg treatabl tnbc there studi look combin immunotherapi parp inhibitor chemotherapi studi investig patient like benefit cours treatment immunotherapi effect there also number new immunotherapi agent trial two studi highlight sabc the first scientif complex studi aim determin patient highest respons rate immunotherapi agent known atezolizumab agent impass studi that trial show patient marker call pdl benefit treatment atezolizumab this help research design futur trial person treatment tnbc patient the second studi phase i trial cart therapi patient specif target mutat includ tnbc patient cart technic complex form treatment cell remov patient genet reengin inject back patient goal stimul ongo immun respons tumor it use clinic trial patient rang leukemia lymphoma non small cell lung cancer tumor first trial includ tnbc patient this phase i studi small number patient earli result onli four tnbc patient includ data present sabc three respons treatment still far soon draw conclus futur cart therapi tnbc',\n",
       "  'NN'),\n",
       " ('wynterstorm may due rais liver enzym side effect gilenya have blood test yet sinc start medic if id arrang medic team ps im medic thought googl around',\n",
       "  'NN'),\n",
       " ('although interferon betaa ifna b ifnb fingolimod approv multipl sclerosi ms treatment yet includ nation list essenti medicin nlem formulari thailand this studi aim evalu costutil ms treatment compar best support care bsc base societ perspect thailand method a markov model cost health outcom lifetim horizon month cycl length conduct relapsingremit ms rrms patient cost outcom data obtain publish studi collect major ms clinic thailand discount rate percent appli the increment costeffect ratio icer calcul univari probabilist sensit analys perform result when compar bsc icer patient rrms age year receiv fingolimod ifnb ifna us dollar usd per qualityadjust lifeyear qali gain respect at thai societ willing pay wtp threshold usd per qali gain bsc highest probabl costeffect percent wherea ifnb fingolimod treatment show lower chanc costeffect percent percent respect conclus compar fingolimod interferon treatment bsc remain costeffect treatment rrms thailand base wtp threshold usd per qali gain the result support inclus fingolimod interferon nlem treatment rrms unless price decreas special schema arrang',\n",
       "  'VBD'),\n",
       " ('when bg approv ms tecifdera i heard present perform notic it might cannib natalizumab tysabri bg high effect agent low pml risk in last yrs seen bg tec moder effect treatment fingo gilenya crab drug i think daclizumab place what opinion mousedoctor profg',\n",
       "  'JJ'),\n",
       " ('claudepa great hear wife remiss congratul i wonder vaccin fo mention my mother ovarian cancer tri keytruda immunotherapi she two infus she monotherapi despit heard could work alon thank help',\n",
       "  'NN'),\n",
       " ('my dr put rituxan well ask ocrelizumab dr said almost medicin person would choos rituxan use longi hope best',\n",
       "  'JJS'),\n",
       " ('hi emmad cladribin eager await here inform respect neuro bart httpmultiplesclerosisresearchblogspotcomsupposetherewastherapyforallhtml',\n",
       "  'NN'),\n",
       " ('hi beachgirl welcom gilenya seem welltoler seem effect you read member firsthand account use forum search function magnifi glass top left search gilenya',\n",
       "  'NN'),\n",
       " ('my name charl i diagnos stage b nsclc brochoscopi wbiopsi confirm a pet scan also confirm tumor cm x cm right lung suspect partial lung collaps went radiat treatment chemo infus taxol carboplatin relat side effect treatment lung continu make excess mucous inflamm month day treatment stop initi ct scan treatment scan show tumor least smaller cm dont know exact much smaller lot seen scan suspect inflamm andor die tissueso shrinkag could except continu cough expel less less matter pinkish red mucus today cough continu improv slowli lung appear feel like heal i schedul start immunotherapi durvalumab tomorrow jan i anxious nervous the differ whirlwind cancer other immunotherapi blog main durvalumab blog seem i tri proactiv plan other seem i could wrong though i disqualifi first radiat doctor consult fit criteria treatment expect he seem complac nonchal case without even see scan seem want put radiat part treatment chemo research shown chemo radiat concurr kill tumor better consecut treatment type cancer boy im glad i research one part success far tumor shrinkag goe also sinc i part treatment anyth i help treatment i feel i like tri eat healthi food like fresh veget close raw i stand maintain bodili ph level due research belief help ph test strip chemo radiat continu keep ph immuno bless onc dr primari care provid radiat dr so far indic research gone well i havent read anywher x cm tumor shrunk much i believ contribut medic treatment work hand hand and one biggest factor god i pray god help presenc know time work direct caus miracl hand i consid decis help treatment part miracl i nervous await time initi pet scan treatment hope immuno goe well i know durvalumab given curat intent eye cannot hurt goal curat i comment long wind i hope i whirlwind subsid i hope correct place air comment i never comment way i tri monitor post immuno pet scan progress answer one repli thanxm charli',\n",
       "  'NN'),\n",
       " ('hi hardwal like i similar situat my partner diagnos year ago last year cognit abil decreas signific point convers last min ultim end loop repetit struggl word last month issu eye point longer read struggl make peopl face photograph like wife partner doesnt let bother within famili unithom accord neuro suffer dont actual realis problem she accept small problem memori god bless she find go quit hard shes afraid peopl find stupid heartbreak use fierc independ but muddl still tri fulfil life also children although oldest i wonder interest partner ever gilenya',\n",
       "  'NN'),\n",
       " ('likewis welcom back kind that troubl ms manag ignor start think mayb given then stick ugli littl head tell woohoo im still chanc youv symptom late got activ show mri the neurologist probabl wouldnt troubl mri result entir possibl new ms activ without actual relaps symptom so there valu worri person unless relaps symptom good news youv got appoint fair quick i guess ms nurs initi say theyv shift neuro appoint there lot dmds get werent avail if bit think research appoint least idea youd prefer get avail ie postcod lotteri allow tecfidera obvious easi one avail might abl get tysabri well given youv alreadi fail first line drug or cours there gilenya betainterferon although youv isr problem past may good option and there heavi duti drug lemtrada like may feel would activ relaps risk side effect i cant see reason wouldnt abl take dmd whilst shift work best luck appoint sue',\n",
       "  'NN'),\n",
       " ('this free educ event ocrevus treatment relaps multipl sclerosi venu offer wheelchair access a modest meal provid',\n",
       "  'JJ'),\n",
       " ('on apr am alana wrote hello everyon i nscl stage diagnos august treatment work they put tarceva mg take two year well minor rash mild diarrhea i bad cold cough cough lot blood present anyon experi cough blood i would appreci respons pleaselov prayer allmik i complet week radio therapi lung cancer i cough blood last week i put treatment sure i wait anoth week see doctor good luck',\n",
       "  'NN'),\n",
       " ('repli post hippopostr im sorri hear potenti diagnosi my son diagnos year old well he it distress overwhelm pleas stay focuslearn everyth diseas good communic healthcar team my son mp allopurinol mani year work dr stop combin she start anoth medic good liver she kept lialda hope go anoth flare he month ago he went back dr time dr said need start remicad we never allow biolog younger also refus he determin get better without biolog rememb specif carbohydr diet scd diet i cook make scd yougurt twice week bake almond bread i familiar diet found tri hard becuas love bad food candi pizza hamburg fri etch well diet i see improv bleed stop form stoolsi know bad chron flare hospit week year old pleas googl specif carbohydr diet cours alway follow drs direct special daughter strong symptom it hard strong posit heal possibl best luck pray quick recoveri daughter',\n",
       "  'NN'),\n",
       " ('live light my presenc light shine bright live other sarah young jesus call ok march mad sport fan care person march mad definit begun get march off ground the month kick march ct scan morn chemo afternoon in midst recov sunday march tim i flew denver tim confer swanapalooza want know i tag along day perfect opportun meet dr camidg more i season travel stupid carri heavi stuff plane across airport mad rush come home i learn someth experi sure on monday dr kim call us give us result ct scan his exact word stabl stabl stabl yay so mean i keep keep alimta chemo everi four week my next scan june after phone call i lunch one best friend grow trista i realiz spent much time talk catch almost hour i didnt even take pictur what heck it onceinyear moment i didnt captur photo i guess i excit see talk catch pictur didnt even cross mind veri odd jeeper on note friday i also forgot take chemo pictur first time i think i much go live part take document partwhich good thing but mayb i hire paparazzi follow around month captur month pictur when i got back hotel lunch i pretti much went bed didnt wake next morn i wipe chemo friday travel sunday long lunch time chang whatev but i feel much better tuesday on tuesday appoint dr ross camidg may rememb follow rosder one top ros expert world he work univers colorado anschutz cancer pavilion tim i talk phone twice big decis make want get opinion know us somewhat but i want actual facetofac meet least great opportun i realli didnt mani question didnt much sinc scan know im stabl chat littl bit i got question answer i head airport anoth full day travel this time tim stay confer second birthday celebr my second celebr first one punta cana past weekend relax casual time bluffton sc friend mitch jill move year ago sheryl greg join us hung togeth it realli nice stressfre saturday realli day girl went old town bluffton walk around brunch then took pontoon boat around lake neighborhood built around that fun we got back hous i took nice short twohour nap went dinner allinal awesom see mitch jill alway nice relax weekend midst crazi month lung forward updat as moment i peopl team donat person page bitlylungekk it may sound like much yet still two month team kk reach team member donat it begun thank everyon alreadi donat im excit year best year ever teamkk a help hint want donat person page and want team member donat link first then join team it much less confus way tshirt i will new tshirt year i may dedic next blog post inform probabl team updat i hate hijack blog i want sure info get whoever would want team tshirt i alreadi lot peopl ask anyway i meet vendor week i get back shirt color style price everyth asap get order time',\n",
       "  'NN'),\n",
       " ('dorothi my mom keytruda year she began carbo alimta keytruda session went keytruda weve learn quit bit along way as far thyroid need monitor regular mom tsh test everi week receiv infus her free t test everi month thyroid issu common side effect arent monitor alreadi my mom doc dont bring regular visit unless someth wrong need chang med so mayb doc test thyroid give info as far muscl pain mom doesnt uncommon ive heard sever enough caus someon limp i also havent heard tendon pain immunotherapi caus inflamm even joint could relat immunotherapi but i dont think explain red skin so i agre tom contact doc report symptom he may sort unrel infect need address asap as far continu walk that hard say dont exact know root problem hope help bit take care steff',\n",
       "  'NN'),\n",
       " ('emma dont think bristol trial use chemo although hsct seem chemo cure stem cell rebuild immun system think ocrelizumab avail soon approv u s at price cours john',\n",
       "  'JJ'),\n",
       " ('ive got agre ipoop longterm pred simpli isnt viabl option i didnt feel bad surgeri either i mg pred which i felt quit good wasnt actual thing heal colon the patholog report show i sever chronic acut inflamm throughout colon as test could get pred summer still okay i tend alway flare wors winter acut flareup year happen autumn winter dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('my friend recent diagnos nsclc stage it lung met brain c she start drug call tagrisso would benefit consult msk',\n",
       "  'NN'),\n",
       " ('februari there final progress hunt treatment difficult form multipl sclerosi form stubborn resist everi attempt find therapi the catch expert say peopl form diseas keep expect low even new drug that last stage develop doesnt appear big clinic impact the reason new drug generat much interest though first time therapi primari progress ms impact and first ms drug ever receiv breakthrough design food drug administr put experiment medicin fast track get review process quick possibl the agenc grant design earlier week read father daughter fight differ form ms primari progress ms relat rare form neurolog diseas person doesnt sever attack way peopl common relapsingremit kind instead suffer slow steadi physic deterior hope recoveri the fda approv drug treat relapsingremit ms none shown work peopl primari progress diseas the new breakthrough drug call ocrelizumab one six various stage develop recalcitr form one affect percent estim american live ms on friday compani behind ocrelizumab roch subsidiari genentech releas new phase trial data confer america committe treatment research multipl sclerosi held new orlean genentech alreadi publish first round result show impact wide rang measur peopl primari progress ms the new data includ detail ocrelizumab affect subgroup patient well new inform work peopl relapsingremit ms show whether also work common varieti diseas continu articl found ms view news help provid educ inform person affect ms keep current multipl sclerosi news inform optingin websit click thank',\n",
       "  'NN'),\n",
       " ('i silicon lubric bubbl eye randi after much research i think i learn issu appar various type syring avastin typic us anyway come steakon steakedon syring wherea eylea typic come luer lock syring the largest manufactur various type syring us use silicon lubric all the syring make chanc get silicon patient eye differ on luerlock syring lubric far less likelihood get onto needl steakon type i switch avastin eylea next inj i hope work wet macular degener and i hope inform syring correct date i cannot swear i expert',\n",
       "  'JJ'),\n",
       " ('j pain res dec abstract read full text paper hugo cl chen z chen y et al a multicent random control trial two group educ program fatigu multipl sclerosi short mediumterm benefit mult scler dec epub ahead print abstract ferraro d planton d morselli f et al systemat assess character chronic pain multipl sclerosi patient neurol sci dec epub ahead print abstract heesen c haas r melzig s et al percept valu bodili function multipl sclerosi acta neurol scand dec epub ahead print abstract vitamin d hongel k silva dg ritter s et al efficaci safeti outcom vitamin d supplement user fingolimod phase trial j neurol dec epub ahead print',\n",
       "  'NN'),\n",
       " ('hello my name patrick i yearold data scientist base dubai i ms i gay i diagnos ms i andi gilenya sinc diagnosi so far i found consider relief drug howev i come conserv irish famili my father alway hard grow i flamboy i normal child want appar freak i also never like use releas temper onto mother bigot mindset exert henc i alway made busi relationship go in first year univers main due incred shelter upbring still closet i bulli merciless housem it culmin near assault i subsequ take next year anxieti condit i thank occur reason i gain courag came gay i diagnos ms gp regular appoint notic one eye blink slower sent neurologist i diagnos i return univers got degre upon graduat i join consult firm i stay month even though i spent year america homophob environ even got slap colleagu outsid work event i never went hr fear i tell famili i work dubai lgbtinclus firm yes i understand ironi lgbt dubai howev i main work american now june hear i depend father send medic i say threw hous last christma eve one anger fit i never got proper apolog howev wors part came last june i leav ireland back dubai last visit home he corn hallway hous menac said lowbreath you lucki i longer control i would let g yes i word appear benign sentiment want control life scare i know hate fact i activ gay he want know everyth would spout emot psycholog rhetor i grew i put way eldest sister hi favorit took year tell first boyfriend cathol relat marriag just get optic conservat on arriv back dubai i subsequ appear experi frequent anxieti attack upon return dubai but wors first time sinc diagnosi ms i begun experienc serious ms symptom i doubt anxieti ms mutuallyexclus case when i email neurologist said normal ok last mri said i stabl but i told result i say i see neurologist everi month annual mrii up i alway thought i never receiv mri report post sent patient bad news yes i know i fool upon investig i discov father open medic post subsequ destroy notifi result to make matter wors day discoveri juli decid begin charg gilenya pos ask littl extra now i know one would pay back postag expens help parent but domin man violent temper duplicit stuff i nt think i thank got enough suppli friend ireland last month i enough next appoint what advic would give someon situat difficult overbear homophob parent vocal zero faith career homophobia etc caus much sorrow behaviour should i mention neurologist next appoint i never spoke medic profession one situat fear father manipul he appear saint public demon behind door he would threaten deni i told sibl i often hear mother tell other think listen mike father treat patrick bad gay yet would never tell someon power fear i would appreci advic may give i apologis i went rant i admir work websit great you make differ kind regard patrick',\n",
       "  'NN'),\n",
       " ('chipofbag opdivo keytruda equival they go target t cell would unnecessari the opdivoyervoy combo make lot sens opdivo most act t cell tumor wherea yervoy most act t cell circul cytotox tlymphocyteassoci protein ctla blockad impact human immun system expand pool circul t cell may mechanist relat induct autoimmun inflammatori toxic httpclincancerresaacrjournalsorgcontentful what say reason pd inhibitor well toler wherea ctla inhibitor sever side effect also blockad differ target t cell shut immun escap rout cancer usual use',\n",
       "  'NN'),\n",
       " ('keytruda creat autoimmun diseas lung pneumon i put hospit day pneumonia put oxi read more',\n",
       "  'VBD'),\n",
       " ('case studi increas use infliximab biosimilar could lower cost million annual san francisco ca prnewswir a new studi releas today pacif research institut found remov barrier hold back increas use biosimilar save could signific in case studi infliximab use treat rheumatoid arthriti crohn diseas ill reform could realiz annual save million million click download copi studi american save lot prescript drug cost increas use lowercost generic medic said dr wayn winegarden author new studi as next generat treatment develop govern market barrier must stand way use cheaper biosimilar biologicallycomplex treatment my studi found could save signific barrier lift biosimilar use often biosimilar medicin lowercost altern patient provid unlik generic medic chemic ident origin product size complex biolog molecul make imposs make ident biolog molecul winegarden note greater use biosimilar potenti reduc cost treatment way increas use generic medic reform enact feder law reduc excess regulatori burden generic drug manufactur extend term clarifi right patent holder generic save us health system trillion alon biolog medic arent common use signific potenti it estim global market grow billion billion one industri estim project increas biosimilar use cut price around percent in impedi stronger biosimilar market winegarden use case studi biosimilar infliximab common known remicad use fight rheumatoid arthriti crohn diseas ulcer coliti chronic sever plaqu psoriasi activ psoriat arthriti show increas use biosimilar benefit patient employ taxpay among find annual per patient save remicad biosimilar would rang if biosimilar grew becom onehalf infliximab market annual cost reduct employersponsor health plan would high percent million million less save taxpay lower medicar cost util biosimilar could high percent million save annual collect could save million million year increas use biosimilar one drug alon dr wayn winegarden senior fellow busi econom pacif research institut he also princip capitol econom advisor manag editor econostat the pacif research institut wwwpacificresearchorg champion freedom opportun person respons advanc freemarket polici idea follow pri facebook twitter linkedin',\n",
       "  'JJ'),\n",
       " ('home ms inform public ms research updat siponimod baf siponimod baf in updat main articl introduct fdaapprov medic experiment medic new direct ms research close note approv diseasemodifi therapi ms pdf refer experiment medic new sp receptor modul compani novarti oral medic studi sever dose be studi spms previous ublituximab next ozanimod siponimod drug mechan action similar gilenya like gilenya work sp receptor famili block movement lymph cell lymph node howev siponimod appear interact fewer receptor gilenya primari action sp sp receptor siponimod relat short halflif compar gilenya mean drug stay bodi long research hope small differ minim cardiac issu expand phase iii multin studi siponimod involv peopl secondaryprogress ms publish the lancet march the particip random ratio receiv siponimod placebo the trial schedul run three year prespecifi number confirm disabl progress event cdp occur the primari endpoint time threemonth cdp the studi found relat placebo siponimod reduc risk threemonth cdp percent cut risk sixmonth cdp percent slow rate brain volum loss percent reduc annual relaps rate percent no signific differ found siponimod placebo term two walk test studi trial eighteen percent patient siponimod group percent receiv placebo experienc serious advers event a decreas white blood cell heart rate rhythm abnorm well hypertens swell macula eye varicella zoster reactiv convuls occur often patient receiv siponimod placebo group the rate infect cancer death differ group adjust initi dose siponimod mitig cardiac effect seen earli treatment medic novarti develop siponimod announc file new drug applic nda fda seek approv use sp receptor modul spms in rrms meanwhil result phase ii dosefind studi siponimod first report the trial complex design primari goal determin appropri dose carri forward futur trial approxim peopl particip studi at six month proport relapsefre patient percent mg group percent mg group percent mg group compar percent placebo group after six month arr annual relaps rate lower individu take one three higher dose addit regard mri paramet mg dose reach statist signific versus placebo reduct activ lesion approxim percent previous ublituximab also known tg next ozanimod former rpc',\n",
       "  'JJ'),\n",
       " ('was present ectrim ocrevus relat death', 'NN'),\n",
       " ('dear member staff my sister age diagnos nsclc stage iv adenocarcinom egfr mutat exon lr year ago she tarceva littl less year follow chemotherapi carboplatin alimta when develop tmutat well tagrisso year howev summer general wellb declin xray show tumour progress a new biopsi main tumour reveal tumour transform squamous lung cancer accord mutat analysi tumour follow marker p ck posit pdlnegat her oncologist suggest second round chemotherapycarboplatin gemzar we would much appreci suggest regard treatment sister could pleas note live europesweden would good idea add cetuximab chemotherapi consid diagnos squamous lung cancer are awar clinic trial could suitabl case i saw articl ly phase trial uk your advic would high appreci thank attent best regard eva this topic modifi month week ago evani this topic modifi month week ago evani',\n",
       "  'NN'),\n",
       " ('im get initi infus stelara today how feel jf', 'NN'),\n",
       " ('hello my cancer mix origin egfr exon mutat still sensit tarceva tm tp rc notch ek fgfr ll will mutat sensit tagrisso apart tm mutat thank kempten',\n",
       "  'VBP'),\n",
       " ('melmel differ patient anoth i get relaps everi tear sever year even i treatment year but ms keep play around brain silent when i reber avonex i use get relaps everi month but differ person anoth group peopl havent got well gilenya but bad rebef',\n",
       "  'NN'),\n",
       " ('hi my question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl weekson face bodi stop take zykadia dermatologist gave medicin rash sudden swear headach and take dexa get normal ct scan report today say there mm hyperdens lesion area punctat calcif target like fashion within right parietaltempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema this caus effac ipsilater later ventricl subfalcin herniat along mid line shift no patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right parietaltempor lobe whole brain radiat suggest my question we scare radiat cyberknif option or gammaknif which option best he shouldnt stop take zykadia or need stop zykadia day till radiat stop zykadia jump nivolumab as zykadia result better except brain lesion if need carri zykadia avoid brain lesion zykadia doesnt cross brain barrier can get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       "  'NN'),\n",
       " ('the major random receiv drug therapi given relat mild ms medic includ copaxon beta interferon tecfidera gilenya minor receiv tysabri ive alway wonder new drug compar rebif avonex is anyon actual use anyway it make hard understand drug effect whi cant compar one drug i think i know answer anyway im accept new trial chicago they ad ivig part experiment portion everyon receiv chemo time i question i want ask brain fog get way ugh',\n",
       "  'IN'),\n",
       " ('even stick ostomi crohn point may need medic actual good amount crohn patient if go jpouch crohn diagnosi i wonder stat need medic futur surgeon mention patient without issu keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'JJ'),\n",
       " ('there mani imod trial moment as work sp worklik fingolimod we dont need give free advertis the surpris would didnt work as trial announc may report approv report it remain seen happen fingolimod patent extend the price plung make interest see imod top',\n",
       "  'JJ'),\n",
       " ('continu dr west also express doubt efficaci first second generat tkis tagrisso failur if action mutat shown primari option would like standard chemotherapi regimen egfr mutat posit patient tend respond well immunotherapi option respons rate group patient tend low good luck whichev treatment path chosen jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('i dont think anyon onlin address happen cancer center perhap ask direct serum test tm blood sampl definit possibl ive seen posit result tm lead tagrisso standard care time i wouldnt bank insur cover test blood there mani vendor test rang guardant health biocept foundat medicin other becaus real issu realli primarili whether tm mutat might make sens look lab hundr i think biocept individu test costeffect option instanc other rather long list test thousand dollar good luck dr west',\n",
       "  'JJS'),\n",
       " ('ive tagrisso sinc juli i great initi respons visibl cancer shrink point longer detect cancer journey in treatment cancer type lung cancer diseas learn pet scan kidney valu requir my husband follow valu kidney function creatinin normal rang urea normal rang would valu cancer journey in treatment cancer type lung cancer diseas learn mix result treatment has anyon mix result chemoimmunotherapi my uncl diagnos stage iv nsclc exon mutat it spread bone cancer journey in treatment cancer type lung cancer diseas learn video post onctalk local therapi metastat lung cancer who what whi when how on saturday novemb grace partner swedish cancer institut present live webcast discuss local therapi cancer journey in treatment cancer type lung cancer diseas learn lung cancer general lung cancer chemotherapi rd line beyond scan petct etc surgic immunotherapi radiat therapi non small cell lung cancer nonsmal cell lung cancer patient caregiv opportun particip studi rare patient voic hi all i approach whatnext group partner rare patient voic opportun particip studi specif non cancer journey survivorship cancer type lung cancer diseas learn lung cancer general lung cancer',\n",
       "  'NN'),\n",
       " ('so im tomorrow ocrevus infusioni toler well i think work here info possibl secondari posit effect ocrevus deplet tcell etc this seem excit news though small studi i hope data born overal for i hope mani other ocrevus work wonder i encourag peopl research mayb your think contact neuro andor nurs copay assist program happi new year way hope dawn well lot peopl',\n",
       "  'NN'),\n",
       " ('ocrevus first proven medic slow progress disabl even nice eventu agre there guarante us would get my current edss full time wheeli need crutch stand i guess mean ive miss boat i think ppms proven dmds whilst may need multipl med cope symptom dont need dmds ani drug unlik costeffect option nice sad ppms suffer sonia x',\n",
       "  'NN'),\n",
       " ('i see focus offlabel promot thread seem unusu vagu case where bodi progress was egfr exon detect genestrat dna detect whi cant get regular biopsi tagrisso holi water it side effect i would reluct use without solid justif our motto first harm i suggest send pleural fluid tumor tissu egfr it requir much tissu test as janin point sbxrt reason option singl site progress chemotherapi immunotherapi still proven option patient older age hope help',\n",
       "  'NN'),\n",
       " ('meet coverag registri data lemtrada more effect compet ms tx better fingolimod interferon compar natalizumab john gever manag editor medpag today london data larg multipl sclerosi patient registri suggest alemtuzumab lemtrada effect key efficaci measur two common drug ms similar efficaci third research said in analysi cover patient recent start alemtuzumab fingolimod gilenya interferonbetaa rebif avonex natalizumab tysabri alemtuzumab better fingolimod interferon least one follow outcom measur relaps risk disabl progress function improv less effect efficaci measur report toma kalincik md phd univers melbourn australia and alemtuzumab natalizumab virtual dead heat relaps prevent reduc disabl progress kalincik told attende oral latebreak session european committe treatment research multipl sclerosi annual meet there one outcom analyz entir studi alemtuzumab inferior anoth drug natalizumab like produc improv function abil first year treatment though subsequ year howev studi specif support one drugmak import limit address safeti efficaci outcom analyz includ effect mridetect brain lesion nevertheless robert fox md cleveland clinic involv analysi said data import inform clinician realworld experi agent this type analysi told medpag today allow us compar drug headtohead werent compar head head trial probabl wont no major surpris evid result fox said still data provid confid emerg pictur alemtuzumab gain approv less year ago he also point signific strength analysi use propens match make observ studi appl appl comparison put for studi kalincik colleagu drew msbase databas current includ ms patient countri treat cumul patientyear out research focus patient treat alemtuzumab receiv interferonbetaa treat fingolimod treat natalizumab to includ patient meet follow criteria definit ms standard diagnost criteria new treatment one four agent baselin score expand disabl status scale age ms durat year at least one relaps past year at least month data prior start drug least month postiniti followup minimum two postbaselin visit least month apart patient also select could match other differ treatment type accord clinic demograph data propens match highlight comparison cite kalincik alemtuzumab vs interferon superior mitig relaps activ patient high activ diseas disabl progress improv function abil alemtuzumab vs fingolimod superior prevent relaps otherwis compar alemtuzumab vs natalizumab compar relaps activ disabl progress natalizumab superior earli regress disabl kalincik said group also perform numer sensit analys various paramet definit prebaselin diseas activ specifi differ minimum followup interv alter there import chang overal result said kalincik disclos relev relationship roch genzym novarti merck kgaa biogen webmd global sanofigenzym teva biocsl coauthor disclos multipl relev relationship industri',\n",
       "  'NN'),\n",
       " ('i alimta year ago along i cisplatin one worst alimta i told doctor good chemo mainten chemo didnt caus symptom i think carbo like cisplatin caus problem dad describ his symptom might also cancer i also given iv fluid steroid everi day day chemo this thing kept throw sick i gain weight i didt care help dont let dad get sick hes lose weight like talk dad oncologist iv ifus fluid steroid that pick appetit also my heart goe',\n",
       "  'JJ'),\n",
       " ('janin thank much linksveri good articl video i know i refer back i dont think full genom test would make sens i progress time soon mayb ifwhen mutat discov test right i dont think i would uncov anyth worthwhil cathi dx stage iv adeno dec kras gd pdl tumor sampl st line carboplatinalimta alimta mainten work well nd line keytruda didnt work rd line imrt lung radiat gy current watch wait',\n",
       "  'NN'),\n",
       " ('thank much info i see neurologist morn hope posit news i also copaxon i first diagnos i last month i start serious side effect right inject how feel gilenya',\n",
       "  'NN'),\n",
       " ('i think efficaci wise rough ocrevus may better safeti profil depend use continu use ocrevus risk infect increas',\n",
       "  'NNS'),\n",
       " ('hi jimc thank quick respons my father oncologist suggest chemo unfortun couldnt toler firstlow dose infus chemo clear question he receiv radiat treatment bone pretti clear new bone met radiat treatment i also brought idea possibl combin two differ egfr tki oncologist respons wont outsid clinic trial seem think even probabl wont help much ad toxic patient bodi go back tarceva go help either im sure i agre i total understand combin might work i couldnt agre give someth especi someon life without even give tri i think oncologist act good faith doesnt want suffer side effect drug i think realli get second opinion thank much advic thought',\n",
       "  'VBD'),\n",
       " ('just quick updat mom onc appoint infus appoint the onc recommend mom stay alimta respond alimta well sinc diagnosi the onc feel keep ros mutat news back pocket futur mom stop respond alimta i kind agre onc whi fix someth aint broken mom th round alimta session back perki self ani reason i overlook consid crizotinib alimta i also read crizotinib tendenc prevent brain met mom met whatsov knock wood alimta that anoth reason i comfort onc recommend thank bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('sam i think ive seen paper even discuss i rememb unfortun way find discuss thread what i see pdl express almost ec normal e it littl bigger differ pdl but high ec posit pd express opdivo keytruda work especi type ii ec but also spliceosom mutat fine',\n",
       "  'NN'),\n",
       " ('hi everyon i hope your well ive cced letter st georg neurolog consult sent dr royal london hospit she ask consid treat cladribin mavenclad i wonder anyon treatment ive read it cours appear taken consecut day two month then nd cours month later can treatment taken home or hospit treatment im wonder hope royal london dr treat if give insight would great thank best wish jo',\n",
       "  'NN'),\n",
       " ('phx i get accept biotin trial test high dosag mg x daili mani doc recommend evid isnt supplement accord one studi could make ms wors well see goe month im slower still im terribl optimist my insur cover ocrevus i may switch tri differ drug altogeth dave bexfield activems',\n",
       "  'VBZ'),\n",
       " ('what therapeut lag fingolimod month tecfidera month apart b therapi', 'JJ'),\n",
       " ('hi emili it good hear husband respons wbr puls tarceva it hard know approach caus improv although scan period puls tarceva wbr might provid clue there good discuss radiat puls tarceva intrathec chemo herenon faculti member thread endors intrathec chemo lmc lung cancer doesnt tend work near well breast cancer lmc case it also note tend especi difficult toler dr west conclud remark i especi fear negat side effect wbrt im also wild optimist likelihood help i least feel less intens intrathec chemotherapi i might consid fair option patient isnt declin week week if appear thing worsen readili i believ id priorit comfort inclin minim intervent given possibl puls tarceva drive husband improv togeth general lack enthusiasm intrathec chemo seem continu puls tarceva may reason option my best husband jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('leogirl seem depend great risk pml case this risk greater tysabri henc frequent monitor howev would worth ask question next time see neuro',\n",
       "  'NN'),\n",
       " ('my mother diagnos stage b lung cancer januari she surgeri remov lower left lobe follow round cisplatin andetoposid after chemo complet follow ct scan the first scan clear month later next scan indic pleural effus nodul she pet scan thoracentsi confirm cancer returnedthank cancer still contain lung start hasnt spread elsewher now mainten chemo carboplatin taxol avastin after complet round drug receiv avastin longer work i would appreci inform drug type cancer',\n",
       "  'NN'),\n",
       " ('hi lefteyego sorri hear pain similar lucenti recent eyelea they use differ antisept i think chlorhexidin i havent ask other luckili lot rins seem trick i take painkil hour inj paracetamol i think site eye also make differ skill injector plus quick take long eye dri my clinic give sooth drop inj help i use lot prescrib drop hylotear dri eye pain underestim eye tear dri need lubric at end day weigh week pain worth week sight differ everyon depend see i guess wish well go forward hope thing get better x send hug x',\n",
       "  'NN'),\n",
       " ('i think find much possibl ms kind theyv decid various drug option open ocrevus one offer mayb youv diagnos progress side effect as well actual financi cost if option ocrevus pp still need understand drug potenti benefit risk start if benefit dont outweigh risk cost dont take if afford togeth health insur look benefit think worth but tri get inform sort head ie husband start sue',\n",
       "  'NN'),\n",
       " ('continu tradit provid time market feedback asco obr mdoutlook pleas share result mdoutlook th annual postasco survey field among global network cancer physician the first quickpol publish obr blog cover one hottest topic asco melanoma follow result analysi well publish tumor type list introduct quick poll methodolog respond geograph distribut american societi clinic oncolog asco annual meet held chicago il june melanoma quick poll launch email morn friday june th seri asco quick poll other quickpol includ nonsmal cell lung cancer nsclc gu prostat renal cancer gi cancer melanoma sent global distribut medic oncologist clinician clinic interest melanoma data taken june th complet respons respons usa respons receiv differ countri total no financi incent provid particip survey result melanoma treater plan treat major their ve braf melanoma patient vemurafenib conclus us melanoma treater slight higher anticip usag vemurafenib a major place stage iii stage iv melanoma patient vemurafenib exus melanoma treater like place stage iv melanoma patient vemurafenib stage iii unresect melanoma patient place stage iv melanoma patient oppos stage iii patient physician plan select usag ipilimumab their advanc metastat melanoma patient ipilimumab conclus largest proport us melanoma treater use ipilimumab unresect stage iii stage iv melanoma patient largest proport exus melanoma treater use ipilimumab unresect stage iii stage iv melanoma patient less exus melanoma treater use ipilimumab vs us melanoma treater melanoma treater rate clinic import clinic trial gsk mek inhibitor gsk braf high import conclus overal melanoma treater view clinic trial test gsk gsk combin high the major clinician rate clinic import high high less rate clinic import low major melanoma patient will be screen ve braf mutat next year conclus the major us exus melanoma patient screen ve braf mutat upcom year us patient exus patient less patient screen previous year increas us increas exus overal conclus melanoma treater plan use vemurafenib ve braf melanoma patient clinician plan use ipilimumab advanc metastat melanoma patient veri littl differ usag unresect stage iii stage iv melanoma patient respond view clinic trial test gsk gsk combin high clinic import melanoma treater doubl number patient screen ve braf mutat next year final thought quick poll fast way measur expect accept clinic data post major medic meet perhap use make assumpt adopt amongst provid in today inform hungri environ speed poll conduct analyz advantag market plan pressur test accept data amongst key stakehold submit stefan terwindt evp the arca group',\n",
       "  'NN'),\n",
       " ('clinic efficaci cladribin tablet patient relapsingremit multipl sclerosi rrms final result week phase iiib extens trial clariti studi abstract',\n",
       "  'NN'),\n",
       " ('the profg suggest alemtuzumab may treatment last resort show data suggest ocrelizumab induct therapi',\n",
       "  'IN'),\n",
       " ('golimumab detect circul fetus whose mother treat drug ulcer coliti accord case studi francereut health inform httpwwwmedscapecomviewarticlesrcrsshttpwwwmedscapecomviewar sourc medscap medic news headlin',\n",
       "  'NN'),\n",
       " ('after neuro told want either tecfidera gilenya lemtrada i given appoint ms nurs explain everyth detail is chanc could get appoint there risk drug brain diseas tecfidera pml skin cancer gilenya henc difficult decis have look ms trust websit i think detail drug rachel',\n",
       "  'NN'),\n",
       " ('we read interest find le berr et al report first case combin biolog agent tofacitinib manag inflammatori bowel diseas ibd the recent approv small molecul tofacitinib treatment ulcer coliti multipl small molecul therapeut pipelin make co mbinat increas attract approach tri close therapeut gap ibd furthermor lack immunogen offer advantag biolog agent potenti allow sequenti therapi sourc clinic gastroenterolog hepatolog',\n",
       "  'NN'),\n",
       " ('ive receiv sever ten inject eylea eye last year i also sever issu pain procedur my doctor decid tri procedur without use lid speculum this made differ world i get sore afterward howev mild comparison i experienc previous he still use iodin doubl tripl wash afterward',\n",
       "  'NN'),\n",
       " ('donna i appreci time taken tell experi disabl system i file paperwork letter came request hear unfortun nc attorney repres with hear system back log way attorney insur profit onli thing repres talk behalf i complet paperwork thank one thing regard husband i tysabri month infus last yrs one guy usual infus wheelchair yrs ago he start take cbd oil hemp daili within week could walk i ask md drug test read fals posit told purchas chronic pain current cut pain med night liver would great i know isnt relev l ask i seen chang drastic final i hope i didnt offend suggest i tri normal life sherri byrd',\n",
       "  'NN'),\n",
       " ('the team led dr murphi use genet engin mice human lung cancer cell cultur investig role altern erbb signal mutat kras driven adenocarcinoma found neratinib suppress tumor growth import enhanc activ mek inhibitor we show prophylact treatment multierbb inhibitor neratinib could complet prevent kras mutant cancer aris dr emilio casanova team vienna demonstr therapeut efficaci similar drug afatinib preexist lung tumor dr murphi said it import note studi demonstr requir simultan inhibit multipl egfrerbb receptor drug target singl member famili ineffect slow tumor growth a limit studi preclin design work need determin whether multierbb inhibit strategi would work patient accord dr murphi multierbb inhibitor alreadi approv use egfr mutant erbbamplifi cancer make path clinic trial kras mutant diseas much direct howev drug sever ontarget sideeffect skin gut epithelium toxic present limit relat articl biomarkerbas blood test may extend reach ct screen certain lung cancer role braf mutat nonsmal cell lung cancer still emerg evolv bevacizumab plus erlotinib may be new standard care nonsmal cell lung cancer determin way focus drug deliveri target organ would make drug use clinic set he ad clinic use singleag afatinib neratinib would like use combin trametinib anoth erkmek inhibitor we found multierbb inhibit ineffect establish diseas use singl agent effect combin second smallmolecul inhibitor small molecul screen could reveal excit new combin therapi extend benefit drug although addit research definit need result two studi offer hope patient advanc kras driven lung adenocarcinoma beyond develop therapi direct target mutant kras there present approv drug target mutant kras lung cancer inde kras mutat wide use exclud patient treatment firstgener egfrtarget therapeut dr murphi conclud these two paper demonstr secondgener egfr inhibitor also block signal erbb famili receptor show unexpect efficaci set need reevalu new clinic trial specif diseas cohort refer',\n",
       "  'NN'),\n",
       " ('pleas crowdacur cladribin get licens uk knock effect worldwid promot label indic global',\n",
       "  'JJ'),\n",
       " ('re will forc receiv rituximab offlabel i suspect alreadi tri get nhs england give us permiss use rituximab postnatalizumab patient jcvseroposit we wait hear back indic wont abl it also incorrect assum rituximab biosimilar ocrelizumab vice versa they differ product rituximab less humanis henc higher incid antidrug antibodi infus reaction the drug also slight differ effector mechan way work base differ unlik nhs england treat interchang drug',\n",
       "  'NN'),\n",
       " ('repli post bms i new site i want suggest possibl appli assist help pay medic mom take so mani drug expens insan for exampl i take remicad appli jansen care path program most compani seem offer someth similar they annoy paperwork follow phone call etc help pay worth i hope help small way best luck famili',\n",
       "  'NN'),\n",
       " ('said scope bad theyd talk go mgs mgs week humira switch entyvio ani discuss decis regard option moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa but dont look sick trust i look like i feel everyon would run scare within inch life',\n",
       "  'NN'),\n",
       " ('arsenic heck id drink point i shove nitroglycerin ass stop scream abscess hope work keep us updat femal canada ivig pentasa entyvio infusionsno respons discontinu uccrohn test posit map antibodi mycobacterium pg remiss flare almost yearsin bad way due abx treatment gone wrong sigh',\n",
       "  'JJ'),\n",
       " ('the biolog price competit innov act bpci act sign law march part afford care act the bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product a total evid approach taken fda evalu biosimilar approv the result clinic trial import data preclin work also consid onc biosimilar approv use fda approv addit indic condit base concept call extrapol data if data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct for instanc clinic trial biosimilar filgrastimsndz studi effect safeti clinic trial whose particip treat breast cancer when approv grant fda filgrastimsndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth bloodform cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac bloodform stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastimsndz current twelv biosimilar approv fda treatment specif condit in fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas these drug list order approv infliximabdyyb inflectra origin product infliximab remicad etanerceptszz erelzi origin product etanercept enbrel adalimumabatto amjevita origin product adalimumab humira infliximababda renflexi origin product infliximab remicad adalimumabadbm cyltezo origin product adalimumab humira infliximabqbtx ixifi origin product infliximab remicad in septemb fda approv bevacizumabawwb mvasi treatment five type cancer nonsquam nonsmal cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumabawwb approv indic origin drug bevacizumab avastin could reach us market soon patent bevacizumab expir in decemb fda approv trastuzumabdkst ogivri treatment peopl herposit breast cancer herposit gastric cancer her growthpromot protein found surfac cancer cell the origin drug trastuzumab herceptin patent expir',\n",
       "  'NN'),\n",
       " ('i get keytruda treatment month treatment everi week my lung cancer dr call today gave best news ever after pet scan yesterday mass lung shrink thank you jesus',\n",
       "  'NN'),\n",
       " ('to best knowledg tagrisso activ regular egfr mutat tm i understand tagrisso also activ her her less common discuss nonreceptor protein howev i havent heard tagrisso activ fgfr notch given tm presenc seem reason tri',\n",
       "  'JJ'),\n",
       " ('same thing first chemo carboplatin abrazan kill brain met doc said less happen although i keep take lamict scar weird visio stuff happen otherwis as chronic condit prognosi ive gotten pretti much vibe oncologist im opdivo tumor pretti much gone away hypermetabol medspeak goodgo year stage nsclc feel great good luck',\n",
       "  'NN'),\n",
       " ('shurel sound like ideal candid lemtrada fast act ms diagnos two year ago peopl spms well here quot paper subject lemtrada call campath quot patient spms campath show sustain accumul disabl due uncontrol progress mark unrel cerebr atrophi attribut ongo axon loss the rate cerebr atrophi greatest patient establish cerebr atrophi highest inflammatori lesion burden treatment in contrast patient rr diseas show impress reduct disabl month campathh mean edss point perhap owe suppress ongo inflamm patient unusu activ diseas this j neurol jan epub jul the window therapeut opportun multipl sclerosi evid monoclon antibodi therapi i know peopl get bore bang cladribin drum im go anyway here link blogspot post suggest cladribin work peopl spms well rrms im wait work second dose last week httpmultiplesclerosisresearchblogspotcomsupposetherewa',\n",
       "  'NN'),\n",
       " ('momofyroldboy i constant think son hope remicad bring need relief my son first remicad infus saw huge differ attain clinic remiss our doctor nd infus two week month later rd infus administ we tri week interv saw symptom reappear like mucus trace blood stool now week interv remicad he take methotrax remicad stop constant cold abl shake for last infus complaint tight chest within minut infus disappear afterward i dont know much diseas thought share first hand inform i hope thing improv son soon let us hope kind cure crohn avail soon i thank peopl updat post experi provid guidanc various situat this websit gotoplac anxieti strike often',\n",
       "  'JJ'),\n",
       " ('sandramacgowan patient advic leaflet accompani gilenya suggest overdosag may induc bradycardia slow heart rate the usual manag situat monitor heart rate ecg overnight whilst regular check blood pressur if happen day ago seem toler error get contact neuro team suggest',\n",
       "  'JJS'),\n",
       " ('barryb i also spms relaps neuro recent offer lemtrada i worri possibl side effect decid pursu cladribin support gp unfortun wait list see dr schmierer least month ms patient referr wait list becom longer cladribin consider my ms activ i keep told time brain i could access lemtrada fair soon difficult know especi i dont know whether i would accept cladribin',\n",
       "  'NN'),\n",
       " ('everywher littl growth brain met heart met met mandibula as littl growth fit asp progress better pseudoprogress if would aggress growth would fit better pseudoprogress in summer effus pericardium disappear i use opdivo radiat mayb i respons immunotherapi respons weak later subcutan lesion start shrink avastin ad treatment so tini hole theori i didnt respond immunotherapi but unfortun like explan still immunotherapi isnt work moth i buy time differnt tki obvious i havent yet accept unavoid death difficult avoid point',\n",
       "  'NN'),\n",
       " ('hello melissag condasmum besid ms i happen work compani sponsor mavenclad im uk product packag differ languag adveva name patient support program current held uk market i promot mavenclad way ive much train i think i contribut part knowledg product i go ocrevus im rrms ppms mavenclad opinion three main advantag medic it short cours oral treatment rrms tabletsyear two year sustain neda rate almost patient year no edss progress patient compar mab lemtrada ocrevus tysabri unlik tysabri natalizumab gilenya fingolimod mavenclad induc continu immunosuppress it deplet b cell slowli recov time this suppos prevent longterm damag immun system no case pml report year clinic trial led mavenclad approv ema the frequent advers event ae lymphopenia one would expect mechan action drug herp zoster infect one disadvantag i would point switch mavenclad therapi quit tricki youd wait time switch therapi i guess neurologist handl wise also sure check famili plan start advis procreat mavenclad specif period time cours medic doesnt matter your boy girl hope i help best luck',\n",
       "  'NN'),\n",
       " ('navig world multipl sclerosi ms daunt task time whether diagnos sever year newli diagnos everchang natur ms make live challeng from random relaps flare unpredict progress enough drive person mad fortun ms treatment make seem insurmount beast somewhat tameabl tradit multipl sclerosi treatment option mani multipl sclerosi treatment option exist ms there pill inject infus sever altern treatment avail find one give best result key when i diagnos neurologist initi tri tecfidera twice day pill help keep troublesom symptom ms bay unfortun i success treatment physician refer doctor special multipl sclerosi my ms physician put ocrevus infus i receiv everi six month while i new lesion infus therapi i relief symptom acquir new one there mani differ type multipl sclerosi relapsingremit rrms primari progress ppms secondari progress spms progress relaps prms sinc i diagnos rrms i focus treatment help form ms the follow tradit multipl sclerosi treatment option rrms oral therapi common choic comfort needl they requir regular dose schedul taken either twice daili these includ tecfidera dimethyl fumar aubagio teriflunomid gilenya fingolimod selfinject offer option choos you train health profession administ medic they includ betaseron interferon betab avonex interferon betaa copaxon glatiram acet zinbryta daclizumab plegridi pegyl interferon betaa rebif interferon betaa extavia interferon betab glatopa glatiram acet intraven infus inject direct vein requir often selfinject these includ ocrevus ocrelizumab lemtrada alemtuzumab tysabri natalizumab novantron mitoxantron all option medic come side effect may includ headach flulik symptom red pain andor swell inject site low white blood cell count nausea vomit diarrhea itch joint pain infect this complet list possibl side effect consult medic websit physician complet list mani medic also requir regular blood monitor natur therapi ms if want steer clear chemic treatment know also natur way help treat symptom ms they far less expens tradit treatment may effect though medicin properti mani fda approv yet research proven method manag ms symptom see also ms treatment medic sleep problem ms best ms treatment center relaps ms you might also like ms age ashwagandha indian herb also known queen ayurveda it shown help stress cancer neurolog diseas the leav plant help memori cognit function root help mobil movement issu ginkgo biloba shown help fatigu troublesom symptom ms take supplement daili dandelion root leaf antioxid antiinflammatori agent also help reliev fatigu common symptom ms ginger also strong antiinflammatori properti among mani thing help ms symptom turmer natur herb common use season it contain curcuminoid shown neuroprotect properti import neurolog diseas like ms chines hemp seed becom popular choic help manag ms symptom it calm effect central nervous system help spastic part cannabi famili contain fatti acid make great option natur treatment multipl sclerosi becaus vitamin d defici shown play major part develop ms take supplement help elimin least eas mani ms symptom dha docosahexaeno acid omega fatti acid found fish like salmon tuna mackerel it help inflamm neurolog function protect central nervous system magnesium found natur green leafi veget fish nut supplement pill form it excel sourc help myelin damag as alway check physician make chang multipl sclerosi treatment plan',\n",
       "  'JJ'),\n",
       " ('this medicin may caus harm unborn babi take pregnant do take pregnant may get pregnant use birth control prevent pregnanc a pregnanc test done show not pregnant start arava leflunomid use birth control trust prevent pregnanc take drug keep use birth control go process get rid extra leflunomid bodi you need blood test show bodi free leflunomid stop take birth control if get pregnant take arava leflunomid call doctor right away veri bad sometim dead liver problem happen arava leflunomid tell doctor liver diseas this medicin must use peopl certain liver problem have liver function check told doctor tell doctor take drug rais chanc liver problem there mani drug ask doctor pharmacist sure use arava see also orencia it use treat rheumatoid arthriti what i need tell doctor befor i take arava if allergi leflunomid part arava leflunomid if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if health problem bone marrow diseas low blood cell count if infect if weak immun system if take teriflunomid if breastfeed do breastfe take arava leflunomid this list drug health problem interact arava leflunomid tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take arava leflunomid drug health problem do start stop chang dose drug without check doctor what thing i need know i take arava tell health care provid take arava leflunomid this includ doctor nurs pharmacist dentist have blood work check told doctor talk doctor high blood pressur happen arava leflunomid have blood pressur check told doctor talk doctor get vaccin take arava leflunomid stop take vaccin use arava leflunomid may either rais chanc infect make vaccin work well talk doctor you may chanc get infect wash hand often stay away peopl infect cold flu you may bleed easili be care avoid injuri use soft toothbrush electr razor this medicin may lower abil bone marrow make blood cell bodi need this lead bad sometim dead bleed problem infect tell doctor right away sign infect like fever chill bad sore throat ear sinus pain cough sputum chang color sputum pain pass urin mouth sore wound heal bruis bleed feel tire weak you need tb tuberculosi test start arava leflunomid this medicin stay bodi time stop take sometim doctor may give drug get rid drug faster talk doctor this medicin may add chanc get type cancer talk doctor nerv problem happen arava leflunomid most time nerv problem went away arava leflunomid stop sometim peopl nerv problem go away even arava leflunomid stop talk doctor if take warfarin talk doctor you may need blood work check close take arava leflunomid if older use arava leflunomid care you could side effect if man sex femal could get pregnant wish father child talk doctor if woman miss period unprotect sex think birth control work call doctor right away how medicin arava best taken use arava leflunomid order doctor read inform given follow instruct close take without food to gain benefit miss dose keep take arava leflunomid told doctor health care provid even feel well what i i miss dose take miss dose soon think if close time next dose skip miss dose go back normal time do take dose time extra dose see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign liver problem like dark urin feel tire hungri upset stomach stomach pain lightcolor stool throw yellow skin eye sign high blood pressur like bad headach dizzi pass chang eyesight a burn numb tingl feel normal pale skin a bad skin reaction stevensjohnson syndrom toxic epiderm necrolysi may happen it caus bad health problem may go away sometim death get medic help right away sign like red swollen blister peel skin without fever red irrit eye sore mouth throat nose eye veri bad sometim dead lung problem happen arava leflunomid call doctor right away lung breath problem like troubl breath short breath cough new wors what side effect arava all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away upset stomach throw diarrhea hair loss feel tire weak belli pain back pain headach dizzi these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw arava store room temperatur protect light store dri place do store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin some drug may anoth patient inform leaflet check pharmacist if question arava leflunomid pleas talk doctor nurs pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'JJ'),\n",
       " ('consid cladribin httpmultiplesclerosisresearchblogspotcomsupposethereistherapyformsthatishtml i st dose last month easi toler probabl safer effect fingolimod it offlabel generic publish data show good efficaci send email dr k websit dose info',\n",
       "  'NN'),\n",
       " ('in us entyvio avail dosag form powder solut pharmacolog class monoclon antibodi use for vedolizumab vedolizumab inject use treat crohn diseas ulcer coliti patient help medicin vedolizumab monoclon antibodi work immun system vedolizumab given direct supervis doctor befor use vedolizumab in decid use medicin risk take medicin must weigh good this decis doctor make for vedolizumab follow consid allergi tell doctor ever unusu allerg reaction vedolizumab medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform relationship age effect vedolizumab inject pediatr popul safeti efficaci establish geriatr appropri studi perform date demonstr geriatricspecif problem would limit use vedolizumab inject elder pregnanc pregnanc categori explan all trimest b anim studi reveal evid harm fetus howev adequ studi pregnant women or anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetus breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when receiv vedolizumab especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use vedolizumab follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin infliximab tofacitinib interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use vedolizumab make sure tell doctor medic problem especi infectionmay decreas bodi abil fight infect proper use vedolizumab a doctor train health profession give vedolizumab it given needl place one vein vedolizumab come medic guid read follow instruct care ask doctor question precaut while use vedolizumab it import doctor check progress regular visit make sure vedolizumab work proper blood test may need check unwant effect vedolizumab may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow troubl breath swell face tongu throat vedolizumab may caus serious allerg reaction includ anaphylaxi anaphylaxi lifethreaten requir immedi medic attent call doctor right away rash itch troubl breath troubl swallow swell hand face mouth vedolizumab your bodi abil fight infect may reduc vedolizumab avoid near peopl sick wash hand often tell doctor ever infect would go away infect kept come back check doctor right away fever chill cough flulik symptom unusu tired weak vedolizumab may increas risk get rare brain infect call progress multifoc leukoencephalopathi pml call doctor right away back pain blur vision confus dizzi drowsi fever headach seizur unusu tired weak check doctor right away pain tender upper stomach pale stool dark urin loss appetit nausea vomit yellow eye skin these could symptom serious liver problem while treat vedolizumab immun vaccin without doctor approv your vaccin need current receiv vedolizumab do take medicin unless discuss doctor this includ prescript nonprescript overthecount otc medicin herbal vitamin supplement vedolizumab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur more common bodi ach pain chill difficulti breath ear congest fever headach loss voic nasal congest runni nose sneez sore throat unusu tired weak less common back pain chest tight flush nausea vomit weak rare cough difficulti swallow dizzi fast heartbeat hive itch skin rash puffi swell eyelid around eye face lip tongu tight chest incid known abdomin stomach pain blur vision claycolor stool confus convuls dark urin drowsi headach loss appetit lower back side pain pain difficult urin unpleas breath odor vomit blood yellow eye skin some side effect may occur usual need medic attent these side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question more common difficulti move muscl pain stiff pain joint other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'NN'),\n",
       " ('the angiogenesi foundat conven lead retina specialist patient caregiv vision advoc discuss need improv longterm outcom peopl live neovascular agerel macular degener amd the event cochair dr rishi p singh cleveland clinic diana savill chief innov offic angiogenesi foundat the particip gave recommend improv treatment pathway amd discuss solut better longterm patient outcom agerel macular degener lead caus blind peopl age there two form amd wet dri the progress amd vari ultim lead partial complet blind amd widespread impact mani million peopl us as world popul age amd even preval the number peopl amd worldwid project reach million the diseas great impact qualiti life make difficult imposs read drive watch televis recogn love one live independ up treatment avail peopl diagnos amd today wet amd high treatabl groundbreak medicin call antivegf therapi includ ranibizumab aflibercept these antivegf treatment work block molecul caus abnorm blood vessel growth eye drive progress wet amd antivegf treatment dramat chang wet amd patient outcom help prevent even revers vision loss case while antivegf therapi revolutionari treatment wet amd longterm studi data show dispar patient outcom long term without regular inject close monitor long term patient larg followup studi lose vision gain made clinic trial set our mission alway improv live peopl diseas impact angiogenesi said diana savill the neovascular wet form agerel macular degener perfect exampl huge differ made yet much work outcom signific better day medicin it get point patient doctor forget like day medicin it pretti aw said retina specialist dr carl baker we see patient general improv vision studi show time mani improv go away and there lot interest lot research figur dure summit doctor patient advoc engag substant frank discuss current amd treatment landscap area futur improv discuss topic includ differ shortterm longterm patient outcom caus differ outcom identifi barrier desir futur state recommend action im happi treatment i still vision i still thing i alway done the first coupl year get shot stress thing said particip dan berkeri live amd receiv antivegf treatment im hope shot continu job greatest hope research find cure realli aw lot peopl macular degener the full summit followup roundtabl discuss synthes white paper publish fall the foundat conven patientcent amd summit octob patient share perspect experi live agerel macular degener',\n",
       "  'NN'),\n",
       " ('ive follow post whole time i think trust next step given youv it terribl youv ongo ordeal long i commend make decis manag that unfold best there shift mindset point possibl put suffer behind you damag choos get rid jpouch i see you gave best shot time choos life point new chapter live forward mani opportun ahead much joy you shown tremend fortitud everi step way it forev make compassion other struggl hardship deepen gratitud life just opinion what ahead send optim much support well respect admir youv endur young age uc yrs for flare i use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mos due joint pain antitnf induc lupus neuropathi on entyvio sinc oct far ok',\n",
       "  'NN'),\n",
       " ('hello i oncolog nurs i saw post there studi use opdivo yervoy the studi checkmat studi trial well small cell carcinoma you might want ask doctor candid regimen im assum still etoposid carboplatin i knew patient use opdivo yervoy combin pretti well quit i hope help',\n",
       "  'NN'),\n",
       " ('so i bloat belli everi time i eat bad burn whole tract i look pregnant i rememb doc said i might sibo small intestin bacteria overgrowth took xifaxim bam hour like pressur releas stomach almost near flat entyvio worst make gut churn stelara best i guess i need use antibiot bit i keep post not much blood late still feel happi i tri probiot burn digest enzym luck i dont want mess help also still pred mg yo yo ing tri get uc sinc mayo clinic say chronscol dx chronic lyme no biolog work took rafaximin sibo work awesom take asacol hd',\n",
       "  'NN'),\n",
       " ('id say answer depend there guarante first lot inflamm within intestin there bodywid collater consequ thereof that aggress immun system may target thing beyond larg intestin extraintestinalmanifest uc caus arthriti eye inflamm sinus inflamm rash etc etc we wbcs immun system attack dog other circul whole bodi within blood often flare arthriti muscl pain worst talk doublewhammi often remiss muscl pain arthriti pain gone complet that suggest collater damag immun system quietquiesc state issu gone if that id say there good chanc surgeri would help reliev pain second there joint muscl pain unconnect state uc flareremiss cycl share mention pattern we realli bad pain uc remiss exampl if case surgeri may reliev pain it someth els go unrel uc activ bodi inflamm if want pursu uc medic youv tri tnfalphablock class uc biolog humira inflectraremicad there entyvio madcamblock there xeljanz jak inhibitor complet differ mechan action chanc help moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa how long minut depend side bathroom door',\n",
       "  'JJ'),\n",
       " ('thank carm pdl isnt relev opdivo i believ think may keytruda is as stat dianem i understand your say good advic cancer includ nsclc isnt sclc nsclc mani new advanc stat longer reflect someon diagnos today no luck sclcnoth new long time though potenti sign progress recent so i know stat reflect individu case reflect overal realiti type cancer hope someth id rather avoid given prognosi id rather focus concret decis step take each time someon write lot encourag thing typic turn thet basic talk involv nsclcsclc anoth ball wax unfortun so fatal danger get excit general progress cancer treatment doesnt appli case overal im tri thank day take balanc view toward futurebas educ make plan make much room either hope worri despair',\n",
       "  'NN'),\n",
       " ('from admit limit knowledg ie patient i would surpris use avastin lucenti eyelea produc benefit i encount use prior antivegf as first trial seri might work us appear need gravit mean eventu roll altern current test',\n",
       "  'JJS'),\n",
       " ('and clarifi i wasnt say tecentriq wouldnt work oncologist couldnt give data info i receiv i read mayb would help publish data individu did help their genet testingagesexstag etc at point i havent seen anyth doesnt mean isnt and i also impress sclc isnt test genet profilesmutationsmark at least current doctor initi doctor penn said didnt nsclc my apolog i wrong talk doctor due dilig research seem deck stack he male alreadi spread brain diagnosi so i dont feel posit mayb work peopl mayb even i dont want set horribl fall worst news famili could receiv i appreci everyon respons kind word',\n",
       "  'NN'),\n",
       " ('the main question i keep confus gi doctor explain antibodi remicad caus lupus like condit sent bloodwork prometheus test told fine stay remicad are ana antidsana test total differ test antibodi how remicad antibodi evid one test antibodi due remicad infus caus dile and isnt gi doctor pcp awar they told see rheumatologist find caus joint pain this make question possibl lupus isnt biolog i hope rheumatologist lot knowledg help get right treatment stop remicad hope see improv humira option i tri first fail i surgeri colostomi thank repli friend i appreci input',\n",
       "  'NN'),\n",
       " ('epiderm growth factor receptor egfr suppress matur specif tumoursuppressorlik mirna respons hypox stress phosphoryl argonaut ago tyr the associ egfr ago enhanc hypoxia lead elev ago y phosphoryl turn reduc bind dicer ago inhibit mirna process precursor mirna matur mirnasthes find suggest modul mirna biogenesi import stress respons tumour cell potenti clinic implic tag ago argonaut egfr epiderm growth factor receptor lung cancer microrna phosphoryl rc impact egfr inhibitor nonsmal cell lung cancer progressionfre overal surviv a metaanalysi lee ck brown c gralla rj hirsh v et al j natl cancer inst apr we examin impact epiderm growth factor receptortyrosin kinas inhibitor egfrtki progressionfre surviv pfs overal surviv os advanc nonsmal cell lung cancer nsclc patient without egfr mutat egfrtki therapi statist signific delay diseas progress egfr mutationposit egfrmut patient demonstr impact os egfr mutat predict biomark pfs benefit egfrtki treatment set these find support egfr mutat assess initi treatment egfrtki consid frontlin therapi egfrmut advanc nsclc patient tag egfr epiderm growth factor receptor lung cancer rc tyrosin kinas inhibitor preexist interstiti lung diseas invers correl tumor epiderm growth factor receptor mutat patient lung adenocarcinoma fujimoto d tomii k takahashi y imai y lung cancer feb interstiti lung diseas ild especi idiopath pulmonari fibrosi shown associ lung carcinogenesi howev associ epiderm growth factor receptor egfr mutat status preexist ild patient lung adenocarcinoma unknown this studi show patient pulmonari adenocarcinoma ild lower probabl carri tumor egfr mutat tag egfr epiderm growth factor receptor interstiti lung diseas lung cancer rc a random phase studi paclitaxel carboplatin without conatumumab firstlin treatment advanc nonsmallcel lung cancer pazar l blint b hsu cp ramlau r j thorac oncol jan this studi evalu efficaci safeti pharmacokinet conatumumab combin paclitaxelcarboplatin pc firstlin treatment advanc nonsmallcel lung cancer nsclc although well toler addit conatumumab pc improv outcom unselect patient previous untreat advanc nsclc tag remagdepreotid bcll betain bim blood test carboplatin cd cd chemotherapi chfr cholin conatumumab cox cyclooxygenas detect diet ecadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat her her hierarch model histon deacetylas immun system inflamm kras lung cancer matrix metalloproteinas metastasi model mutat neuregulin nonsmal cell lung cancer nrg nuclear medicin oncimmun paclitaxel paml patient phase trial phase ii polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp twist vorinostat inhibit twist lead activ oncogeneinduc senesc oncogen driven nonsmal cell lung cancer burn tf dobromilskaya i tran pt rudin cm mol cancer res jan we recent demonstr basic helixloophelix transcript factor twist cooper mutant kras induc lung adenocarcinoma transgen mous model inhibit twist model led krasinduc senesc in current studi show silenc twist kras mutant human nsclc cell line well egfr mutat driven cmet amplifi nsclc cell line result dramat growth inhibit either activ latent oncogeneinduc senesc program case apoptosisthes find suggest silenc twist oncogen driver depend nsclc repres novel promis therapeut strategi tag remagdepreotid bcll betain bim blood test cd cd chemotherapi chfr cholin cox cyclooxygenas detect diet ecadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat her her hierarch model histon deacetylas immun system inflamm kras lung cancer matrix metalloproteinas metastasi model mutat neuregulin nonsmal cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp twist vorinostat associ dietari intak cholin betain lung cancer risk ying j rahbar mh forman mr gorlova oy plos one feb evid human anim research indic cholin metabol pathway may activ varieti diseas includ cancer we report result casecontrol studi lung cancer case control assess associ cholin betain dietari intak lung cancer our result suggest cholin betain intak especi higher betain intak may protect lung cancer mitig advers effect smoke tag remagdepreotid bcll betain bim blood test cd cd chemotherapi chfr cholin cox cyclooxygenas detect diet ecadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat her her hierarch model histon deacetylas immun system inflamm kras lung cancer matrix metalloproteinas metastasi model mutat neuregulin nonsmal cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp vorinostat therapeut effect remagdepreotid nonsmal cell lung cancer vivo vitro yu f lv m yuan x lv z int j clin exp pathol this studi show remagdepreotid inhibit prolifer invas a cell spca cell treatment mbq remagdepreotid via tail vein signific suppress vivo cancer growth induc apoptosi cancer cell these find demonstr remagdepreotid induc apoptosi nsclc cell direct kill nsclc cell provid evid radiotherapi nsclc tag remagdepreotid bcll bim blood test cd cd chemotherapi chfr cox cyclooxygenas detect ecadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat her her hierarch model histon deacetylas immun system inflamm kras lung cancer matrix metalloproteinas metastasi model mutat neuregulin nonsmal cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp vorinostat impact epiderm growth factor receptor kras mutat clinic outcom resect nonsmal cell lung cancer patient ragusa m vannucci j crin l puma f am j clin oncol jan surgeri yield best result nonsmal cell lung cancer nsclc patient epiderm growth factor receptor egfr downstream factor kirsten rat sarcoma viral oncogen homolog kras variabl mutat nsclc such mutat predict clinic respons tyrosin kinas inhibitor this studi evalu incid correl egfr kras mutat clinicopatholog paramet outcom resect stage i iii nsclc egfr kras mutat frequent adenocarcinoma prognost factor surviv egfr mutat could use identifi patient suitabl adjuv treatment target therapi result potenti improv outcom',\n",
       "  'NN'),\n",
       " ('thank much janin help mom liver enzym rise fast past day there possibl isnt due cancer also gallbladd inflamm symptom dead ultrasound today indic possibl inflammationi possibl opdivo caus inflamm the reason i ask inde inflamm increas liver enzym possibl liver isnt stress cancer may time give opdivo work thank ilan',\n",
       "  'NN'),\n",
       " ('doe suggest fingolimod combin anoth dmt', 'VBZ'),\n",
       " ('euretina award lectur this issu ophthalmologica includ text euretina lectur francin beharcohen md phd deliv th euretina congress barcelona spain in present stress need better understand corticosteroid mechan action order optimis use treatment ocular inflammatori condit she cite research indic glucocorticoid may induc retin cell death pathway undetect classic toxicolog test she add combin low dose glucocorticoid togeth antagonist mineralocorticoid receptor hold promis therapeut strategi treat ocular inflamm f beharcohen toward optim use ocular corticosteroid euretina award lectur ophthalmologica volum issu earli treatment me secondari brvo provid best result patient macular oedema me relat branch retin vein occlus brvo receiv intravitr dexamethason implant within first month condit onset achiev greater rapid longerlast visual improv morpholog improv receiv implant later stage diseas accord result multicentr cobalt studi among brvo patient me less three month mean improv bestcorrect visual acuiti bcva letter letter six month respect follow initi inject dexamethason implant over month treatment period receiv one inject patient receiv three inject yh yoon et al dexamethason intravitr implant earli treatment retreat macular edema relat branch retin vein occlus the multicent cobalt studi ophthalmologica volum issu bevacizumab ranibizumab show similar efficaci rop the find retrospect studi suggest bevacizumab ranibizumab similar efficaci treatment type retinopathi prematur rop affect zone the retrospect studi includ eye patient all initi diseas regress although four patient receiv bevacizumab two receiv ranibizumab show reactiv p eye bevacizumab group ranibizumab incomplet vascularis p the mean spheric equival refract one year myopic bevacizumab group d ranibizumab group d p s kimyon et al comparison bevacizumab ranibizumab treatment type retinopathi prematur affect zone ophthalmologica volum issu',\n",
       "  'JJ'),\n",
       " ('i look st lidwinai read articl comment i year old diagnos year ago so symptom year went cancun walk outsid pyramid heat altitud that symptom increas mononucleosi ive lyme diseas twice diagnos drop feet associ ms may leg brace i first person penn med chester counti pa fda approv ocrevus infus may i truli believ help i infus twice year also prayer has prevent my diseas progress on stress never good god bless anyon diagnos famili member',\n",
       "  'NN'),\n",
       " ('are altern biolog humira what side effect associ medic', 'JJ'),\n",
       " ('congratul as guy i dont good jpouch suggest except jpouchorg women health section have talk insur compani id ask one insur compani nurs coordin assign mayb assist get new doc even better get surgeon approv network coverag keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('shock i know this time portion error involv i told last month secondari insur aetna technic it secondari certain thing otherwis secondari medicaid what im error infus place wait last minut verifi insur sinc inform wrong need note doctor couldnt get approv done time order medicin no medicineno infus there good thing delay i havent feel good past day infus wasnt best idea also realiz i infus suit per last insur hope come home infus would much easier i dont date yet complet i call time see status im still wait everi time i ocrevus infus i problem i dont understand i think infus site yet time i hope best this rd infus i think strike your',\n",
       "  'NN'),\n",
       " ('hello i wonder anyon know anyth problem ive develop gilenya ive sinc earli april start lot headach etc settl somewhat howev i got phone call yesterday let know last blood test i friday th show white blood cell count it seem want anoth blood test two month time see continu drop usual blood test three month apart my question anyon els problem mean ill chang med over past three year ive gone copaxon tecfidera gilenya anyway merri christma and a happi new year',\n",
       "  'VBP'),\n",
       " ('age f swedish i diagnos stage iv nsclc lpa egfr exon last june main tumor left lung one met right lung in addit mani ground glass opac nodul lung both tumor surgic remov mri brain petct sept show chang afatinib mg start oct ct dec show chang afatinib lower mg jan ct april show chang my onkologist termin afatinib keep survey ct scan everi month i read dr west propos algorithm manag asymptomat multifoc bac understand i treat afatinib diffus progress but i taken month standard protocol stop medic progress thank laken',\n",
       "  'VBN'),\n",
       " ('cnw telbec merck nyse mrk known msd outsid canada unit state announc today keytruda pembrolizumab monotherapi indic treatment metastat nonsmal cell lung cancer nsclc adult whose tumour high pdl express egfr alk genom tumour aberr prior system chemotherapi treatment',\n",
       "  'JJ'),\n",
       " ('year day sinc i start remicad it done wonder control crohn symptom i dont think ever abl i still ongo issu fistula abscess there under problem secondari crohn like chronic fatigu kidney stone psoriasi but i still go faith everi week get juic i guess call iv drug user speak altern someth i want go back the year prior remicad fill pain surgeri weight loss depress probe worri loss friend anxieti etc i dont want go back and ive i know newli diagnos feel all i say advanc everi day treatment crohn coliti better chanc get thru hope discov caus closur email this blogthi share twitter share facebook share pinterest no comment post comment newer post older post home subscrib post comment atom search this blog blog archiv novemb octob septemb august normal you might be a crohni get out crohni style remicad day miss famili tripagain you might be a crohni juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb pageview follow follow if wish receiv updat pleas enter email my blog artistslain shop my collect crohn leav seat down facebook vote top for past year healthlin vote one of the top crohn blog gutsi writer drug price comparison benandbreakfastcom logo design disclaim the inform blog experi blogger this blog inform intend heal treat prevent cure crohn diseas diseas as definit caus crohn diseas current cure all us suffer differ experi crohn by mean i medic expert profession pretend one if decid take advic blog risk pleas alway check medic profession anyth blog i sell person contact inform comment follow compani i put inform spam list i respons privaci practic advertis blog comment i hand take respons smile laughter result read blog vern pictur window theme theme imag mammuth power blogger',\n",
       "  'JJR'),\n",
       " ('my husband stage b adeno nsclc he right lung remov tumor gone had round cisplatinalimta adjuv a month treatment adeno lymph node show near origin tumor sightlik lurker his last rad treatment monday he scan month realli posit hes manag mani symptom herb oil',\n",
       "  'NN'),\n",
       " ('ocrevus near third per dose rituxan made companygenentech repli with quot the follow user say thank agat howi jeani z jendi parsi stillstannd sunshin',\n",
       "  'IN'),\n",
       " ('the center biosimilar recap top news week octob rituximab is effect treat cutan lupus erythematosus studi find current treatment cutan lupus erythematosus cle common focus photoprotect topic therapi corticosteroid antimalari drug immunosuppress drug more recent bcell deplet therapi rituximab shown promis treat system lupus erythematosus though feasibl treat cle rituximab well describ biosimilar rheumatolog roundup octob with launch high anticip product thus far biosimilar experi releas key new data multipl biosimilar product octob memor month biosimilar stakehold studi new patient treat with ctp discontinu treatment more often a recent populationbas studi examin prescrib util ctp versus refer infliximab infliximabnav patient found discontinu switch common among patient began therapi biosimilar biosimilar filgrastim prove noninferior refer pbcm a recent studi present annual scientif meet british blood transfus societi held brighton unit kingdom octob sought determin impact introduc biosimilar filgrastim sold unit kingdom zarzio number patient abl achiev target cd yield peripher blood stem cell mobil pbcm as humira biosimilar advanc abbvi upadacitinib outperform adalimumab treat ra the arriv biosimilar adalimumab european market caus enthusiasm among seek greater patient access lower cost treatment rheumatoid arthriti ra howev abbvi maker refer adalimumab humira reveal oral janus kinas inhibitor upadacitinib outperform placebo adalimumab phase studi largest studi date patient with ibd find switch ctp safe effect while realworld data deriv norswitch studi reassur feasibl switch patient inflammatori diseas refer infliximab remicad biosimilar ctp sold inflectra remsima ambigu data patient inflammatori bowel diseas ibd rais question among clinician switch indic crohn diseas ulcer coliti the top biosimilar articl week octob the center biosimilar recap top news week octob the top biosimilar articl week octob the center biosimilar recap top news week octob administ nivestym home is effect wellreceiv patient a recent studi provid insight feasibl athom administr biosimilar filgrastimpf recent approv nivestyman option potenti reduc patient burden associ hospit administr',\n",
       "  'NN'),\n",
       " ('im sure im navig site correct i know im look hope i diagnos adenocarcinoma stage novemb lung liver brain bone i whole brain local radiat late decemb i start tarceva it physic emot roller coaster i tri keep mind go far forward difficult my natur problem solv and one i cant',\n",
       "  'JJ'),\n",
       " ('if youv diagnos multipl sclerosi ms overwhelm learn various type may treatment prognosi take time below youll find descript type ms along short descript treatment avail ms categor four type name type describ treat bodi each type also mild moder sever symptom ms befor receiv diagnosi probabl note laundri list symptom didnt make lot sens these ms symptom may includ follow prolong doubl vision loss vision partial complet loss vision typic occur one eye time tingl pain throughout bodi numb limb typic one side bodi problem bladder bowel function dizzi exhaust slur speech tremor unsteadi gait these symptom easili associ serious health condit may test ms requir make sure accur diagnosi made the differ type ms there four main type ms clinic isol syndrom cis primaryprogress ms ppms relapsingremit ms rrms secondaryprogress ms spms when review differ type ms import rememb ms unpredict diseas vari signific person person also rare type ms primari type provid fair comprehens view diseas cours ms may take live advertis clinic isol syndrom cis though clinic isol syndrom cis consid first ms type differ ms involv first episod singl incid symptom to diagnos cis symptom must caus process found ms inflamm demyelin central nervous system the symptom also must last hour the chanc cis lead type ms vari anywher depend upon whether brain lesion consist ms found via mri if two area damag central nervous system found occur differ time occurr second attack diagnosi ms like follow the nation ms societi nmss describ cis two three time common women men seventi percent peopl diagnos cis age year averag year primaryprogress ms ppms primaryprogress ms ppms affect approxim peopl ms it character disabl begin accumul slowli right onset there may minor remiss seldom occur often temporari the nation ms societi nmss state ppms character differ point time either activ occasion relaps andor evid new mri activ activ well progress evid diseas worsen object measur chang time without relaps new mri activ without progress peopl primaryprogress ms difficulti walk need assist everyday activ ppms appear equal men women median age onset year relapsingremit ms rrms relapsingremit ms rrms common form multipl sclerosi about peopl ms initi diagnos peopl rrms go unpredict cycl exacerb remiss diseas progress symptom depend area brain spinal cord ms damag symptom come go other appear never come back no two peopl alik exacerb durat symptom experi intens length level partial remiss the multipl sclerosi associ america msaa state averag relaps form ms women three time like men develop disord the median age onset rrms year secondaryprogress ms spms relaps remit mser transit secondaryprogress ms spms year first diagnos this steadili progress phase ms character nerv damag loss place inflammatori process seen relapsingremit ms spms symptom board rrms spms symptom slowli progress without relaps if relaps occur usual temporari entir remit as primari progress ms nation ms societi nmss state spms character differ point time either activ relaps andor evid new mri activ activ well progress evid diseas worsen object measur chang time without relaps without progress benign ms there fifth type ms kind ms exhibit symptom never benign ms occur onefifth ms case treatment ms there cure ms regardless stage ms goal treatment prevent disabl manag symptom speed recoveri process attack there also quit medic option avail may slow progress ms treatment exacerb corticosteroid plasmapheresi use ms flareup corticosteroid decreas inflamm this includ oral prednison iv methylprednisolon plasmapheresi remov plasma blood the blood mix albumin transfus back bodi this typic done symptom new respond steroid see also treat ms ms symptom and treatment multipl sclerosi care sleep problem ms you might also like how doe ms affect bodi treatment slow ms progress there medic therapi known slow progress ppms suffer rrms suffer quit option beta interferon inject reduc frequenc sever relaps glatiram acet copaxon inject prevent immun system attack myelin dimethyl fumar tecfidera oral medic reduc amount relaps fingolimod gilenya also oral medic reduc amount relaps treatment manag symptom a larg part ms treatment manag symptom physic therapi may help strengthen stretch muscl in addit physic therapist may abl show perform adl easier muscl relax help suffer muscl spasm muscl stiff other oral medic may use depend type symptom note antidepress depress next page debra offer advic make sens differ type ms',\n",
       "  'NN'),\n",
       " ('brand name zykadia whi medicin prescrib ceritinib use treat nonsmal cell lung cancer nsclc spread nearbi tissu part bodi patient alreadi treat least one chemotherapi medic improv whose condit worsen ceritinib class medic call kinas inhibitor it work block action abnorm protein signal cancer cell multipli this help slow stop spread cancer cell are other use medicin this medic may prescrib use ask doctor pharmacist inform how medicin use ceritinib come capsul take mouth it usual taken empti stomach day either least hour hour eat meal snack take ceritinib around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take ceritinib exact direct do take less take often prescrib doctor your doctor may decreas dose ceritinib tell stop take ceritinib period time treatment this depend well medic work side effect may experi be sure tell doctor feel treatment ceritinib what special precaut i follow befor take ceritinib tell doctor pharmacist allerg ceritinib medic ingredi ceritinib capsul ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take be sure mention follow antacid anticoagul blood thinner warfarin coumadin jantoven beta blocker atenolol tenormin labetalol normodyn metoprolol lopressor toprol xl nadolol corgard propranolol inder carbamazepin carbatrol epitol equetro tegretol teril certain medic human immunodefici virus hiv acquir immunodefici syndrom aid atazanavir reyataz indinavir crixivan nelfinavir viracept ritonavir norvir kaletra saquinavir inviras corticosteroid cyclosporin gengraf neoral sandimmun dihydroergotamin dhe migran diltiazem cardizem dilacor tiazac ergotamin ergomar fentanyl abstral actiq durages fentora subsi ketoconazol nizor medic control blood pressur medic indigest heartburn ulcer cimetidin tagamet duexi esomeprazol nexium famotidin pepcid lansoprazol prevacid nizatidin axid omeprazol prilosec pantoprazol protonix rabeprazol aciphex ranitidin zantac nefazodon methadon dolophin methados phenytoin dilantin phenytek pimozid orap quinidin rifampin rifadin rimactan rifat sirolimus rapamun tacrolimus astagraf prograf telithromycin ketek verapamil calan covera isoptin verelan mani medic may interact ceritinib sure tell doctor medic take even appear list your doctor may need chang dose medic monitor care side effect tell doctor herbal product take especi st john wort tell doctor ever diabet high blood sugar heart failur irregular heartbeat qt prolong irregular heart rhythm lead faint loss conscious seizur sudden death liver heart diseas tell doctor pregnant plan becom pregnant breastfeed you use birth control prevent pregnanc treatment least week treatment talk doctor birth control method work ceritinib may harm unborn babi if becom pregnant treatment ceritinib call doctor immedi tell doctor breastfeed you breastfe take ceritinib surgeri includ dental surgeri tell doctor dentist take ceritinib know may experi hyperglycemia increas blood sugar take medic tell doctor immedi follow symptom take ceritinib extrem thirst frequent urin extrem hunger blur vision troubl think concentr breath smell like fruit tired what special dietari instruct i follow do eat grapefruit drink grapefruit juic take medic what i if i forget take dose take miss dose soon rememb howev within hour next dose skip miss dose continu regular dose schedul do take doubl dose make miss one what side effect medicin caus ceritinib may caus side effect tell doctor symptom sever go away nausea diarrhea vomit constip stomach pain heartburn difficulti swallow fatigu rash chang vision some side effect serious if experi symptom list special precaut section call doctor immedi pain right upper part stomach unusu bruis bleed dark urin yellow skin eye decreas appetit flulik symptom itch short breath fever chill sore throat ongo cough congest sign infect chest pain discomfort chang heartbeat heart palpit dizzi lightheaded faint ceritinib may caus side effect call doctor unusu problem take medic if experi serious side effect doctor may send report food drug administr fda medwatch advers event report program onlin web phone what i know storag dispos medic keep medic contain came tight close reach children store room temperatur away light excess heat moistur bathroom unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin takeback program talk pharmacist contact local garbagerecycl depart learn takeback program communiti see fdas safe dispos medicin websit web inform access takeback program it import keep medic sight reach children mani contain week pill minder eye drop cream patch inhal childresist young children open easili to protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach web what other inform i know keep appoint doctor laboratori your doctor may order certain lab test check bodi respons ceritinib do let anyon els take medic ask pharmacist question refil prescript it import keep written list prescript nonprescript overthecount medicin take well product vitamin miner dietari supplement you bring list time visit doctor admit hospit it also import inform carri case emerg this report medic inform consid individu patient advic becaus chang natur drug inform pleas consult physician pharmacist specif clinic use the american societi healthsystem pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field the american societi healthsystem pharmacist inc make represent warranti express impli includ limit impli warranti merchant andor fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos the entir monograph drug review thorough understand drug action use side effect the american societi healthsystem pharmacist inc endors recommend use drug the inform substitut medic care ahf patient medic inform copyright the american societi healthsystem pharmacist inc eastwest highway suit bethesda maryland all right reserv duplic commerci use must author ashp',\n",
       "  'NN'),\n",
       " ('hello i approach year survivor anniversari januari stage lung cancer liver spine lymph met alk after chemo crizotinib stabl start alectinib april due acquir resist crizotinib the initi dose mgday alectinib super toxic so much dose reduct labwork went mg alectinib per day past year stay stabl well brain mri last week show new brain met mm left cerebellum primari lung tumor stabl x cm a new enlarg cm prevascular heart area lymph node discov june ct scan stabl septemb scan still new so question patient nd line tki therapi develop brain met lymph node enlarg consid acquir resist nd line drug i view entir patient forum target therapi video present cleveland clinic my radiat oncologist want stereotact radiat brain met this rd time brain radiat twice previous i sbrt brain met st time met nd time met one am wonder mani time im go brain radiat remedi i live ongo emerg brain met i go request onc rebiopsi see new resist mutat may present guid new rd line drug that decid would best next step didnt rememb doctor video mention go ahead stay alectinib brain met lymph node develop thank by way also big thank you host patient confer post entir video help inform this grace forum import valuabl',\n",
       "  'NN'),\n",
       " ('on nov am chucksan wrote my wife noriko diagnos august stage squamous lung cancer nsclc she petct scan novemb st schedul infus opdivo nivolumab month month diagnosi she previous gone thru two combo regimen fail chemo there similar immunolog fda approv drug lung cancer keytruda merck opdivo keytruda origin develp melanoma test number type cancer fda approv last year lung cancer her oncologist dr howard jack west md came said cancel infus the petct scan show wasfre cancer remiss he origin estim mayb month these new immunolog drug also call check point inhibitor pd name seem better success mani previous chemo type drug there mani new clincal trail test simialr drug mani show lot promis she ecstat there hope even stage lung cancer thank brystolmey squibb area seattl swedish hospit cancer institut dr west entir staff no need fli across countri region seek best cancer center two nearest larg metro citi near mani time larg hospit cancer section univeristi teach medic hospit check oncologist special specif type cancer be sure access latest clinic trail drug recent fda approv mani time lead edg succes treatment of cours less stage surgeri raditaion success pleas stay far away altern clinic doctor product good food suppliment great general health none cure cancer regardless mani phoni testimoni see site same goe mexico mani foreign bogus clinic push coffe enema nonsens cure big buck medic phyician mds top us medic univers there is hope chuck httpwwwcancerorgtreatmenttreatmentsandsideeffectstr atmenttypesimmunotherapycancerimmunotherapyimmunecheckpointinhibitor targetblank relnofollowhttpwwwcancerorgtreatmenttreatmentsandsideeffectstr targetblank relnofollowhttpwwwcancerorgtreatmenttreatmentsandsideeffectstr httpwwwcancerresearchorgcancerimmunotherapyimpact allcancerslungcanc targetblank relnofollowhttpwwwcancerresearchorgcancerimmunotherapyimpact targetblank relnofollowhttpwwwcancerresearchorgcancerimmunotherapyimpact httpswwwgooglecomsearchnewwindowrlzcahpztenususqimmunotherapycancertreatmentsaxvedahukewjdgoxqahuqmmkhwkdafwqqiipgeoagbiwbih all prais creator bless im truli happi wife remiss i eould like add mani mani year cone im also opdivo scan last week show mm nodul upper right lobe my oncologist other discuss case tumor board meet week ive opdivo almost yr prior immunotherapi i permatrex caboplatin yr month without treatment tumor increas fro cm that doctor decid immuno i know decis week move forward im keep faith heal becaua god ultim healer take care let staynin mm prayer elli',\n",
       "  'NN'),\n",
       " ('a mainten dmt one keep take treatment work pill everi day inject time week infus month most ms treatment categori the kind treatment someth may need anoth treatment year later dont keep the three treatment fit categori lemtrada hsct cladribin they seem much effect mainten treatment the jc virus john cunningham virus about half popul carri time adult general harmless for peopl immunosuppress treatment jc virus give pml horribl demylin diseas kill peopl leav sever disabl it seem frequent peopl tysabri although still rare also small number peopl got take gilenya tecfidera i think',\n",
       "  'VBP'),\n",
       " ('crohn diseas also call ileiti enter affect part gut mouth way anus in major case howev lower part small intestin ileum affect symptom unpleas they includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain common felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain the level pain vari individu depend inflamm gut most common pain felt lowerright side abdomen ulcer gut ulcer raw area gut may bleed if bleed patient might notic blood stool mouth ulcer these common symptom diarrhea this rang mild sever sometim may mucus blood pus the patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit there may time appetit low weight loss this result loss appetit anemia a loss blood lead anemia rectal bleed anal fissur the skin anus becom crack lead pain bleed other possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas while ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum the crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need highcalori liquid formula especi growth affect most patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol some peopl feel like eat in sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement the aim control inflamm correct nutrit problem reliev symptom there cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previous treatment recur symptom some peopl long period even year without symptom this known remiss howev usual recurr as period remiss vari much hard know effect treatment it imposs predict long period remiss go best food crohn diseas flareup eat right food help peopl manag symptom crohn diseas find read medic crohn diseas antiinflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor general treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol antidiarrh fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ they reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect some studi suggest use biolog reduc chanc person need abdomin surgeri within year percent befor introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid there differ type biolog drug individu react differ a doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri the major crohn diseas patient may need surgeri point when medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov some crohn diseas patient may requir one oper live in case colectomi need whole colon remov the surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma a pouch collect fece doctor say patient stoma carri lead normal activ life if surgeon remov diseas section intestin connect intestin stoma need the patient doctor need consid surgeri care it appropri everyon the patient bear mind oper diseas recur most peopl crohn diseas live normal activ live hold job rais famili function success caus the exact caus crohn diseas unclear thought stem abnorm reaction immun system the theori immun system attack food good bacteria benefici substanc unwant substanc dure attack white blood cell build line gut buildup trigger inflamm the inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close relat condit if ident twin crohn diseas twin percent chanc a bacterium virus may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi a doctor ask person sign symptom a physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth the follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut a long thin flexibl telescop endoscop goe esophagus stomach ct scan barium enema xray reveal chang insid bowel complic if symptom sever frequent likelihood complic higher the follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut there may also persist iron defici food absorpt problem slight higher risk develop bowel cancer relat coverag what stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year for reason doctor usual classifi crohn differ stage learn read what expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read crohn diseas surgeri what know while surgeri cannot cure crohn diseas help reduc person symptom prevent lifethreaten complic in articl learn differ type crohn diseas surgeri prepar expect recoveri read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd all refer avail refer tab refer this content requir javascript enabl baumgart m dogan b rishniw m weitzman g bosworth b yantiss r berg d cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni relat deplet clostridial crohn diseas involv ileum the ism journal retriev httpwwwnaturecomismejjournalvnabsismejahtml crohn diseas nd american societi colon rectal surgeon retriev httpswwwfascrsorgpatientsdiseaseconditioncrohnsdiseas crohn diseas caus april retriev httpwwwnhsukconditionscrohnsdiseasepagescausesaspx epidemiolog ibd march cdc retriev httpswwwcdcgovibdibdepidemiologyhtm leena halm paulina paavolasakki ulla turunen maarit lappalaccinen martti frkkil kimmo kontula june world journal gastroenterolog retriev httpswwwncbinlmnihgovpmcarticlespmc lichtenstein g r loftus e v isaac k l regueiro m d gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev httpgiorgguidelinemanagementofcrohnsdiseaseinadult what crohn diseas nd cleveland clinic retriev httpsmyclevelandclinicorghealtharticlescrohnsdiseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian what crohn diseas medic news today medilexicon intl dec web jan httpswwwmedicalnewstodaycomarticlesphp apa nordqvist c decemb what crohn diseas medic news today retriev httpswwwmedicalnewstodaycomarticlesphp pleas note if author inform provid sourc cite instead recommend relat news latest news alzheim blood test detect brain damag year symptom test blood level protein brain cell leak faulti die detect peopl alzheim diseas year symptom emerg how immun system use chao prevent diseas new research find chaotic swing concentr certain protein key regul immun respons prevent chronic diseas reprogram immun cell attack cancer tumor macrophag immun cell eat pathogen cell debri often ineffect cancer cell how coopt attack tumor common food addit may impact gut bacteria increas anxieti emulsifi mani food product a new studi ask whether chemic might impact physiolog psycholog stool transplant super donor could cureal new research suggest fecal transplant super donor could cure host condit rang irrit bowel syndrom alzheim',\n",
       "  'NN'),\n",
       " ('ocrelizumab reduc progress upper extrem impair patient primari progress multipl sclerosi find phase iii random oratorio trial show author edward j fox clyde markowitz angela applebe first publish novemb research articl httpsdoiorg abstract background upper extrem ue impair common primari progress multipl sclerosi ppms object this exploratori analysi examin effect ocrelizumab confirm progress cp confirm improv ci ue impair patient oratorio method patient ppms receiv ocrelizumab mg placebo everi week week the ninehol peg test hpt administ baselin bl everi week thereaft prespecifi exploratori endpoint includ chang hpt time proport patient cp hpt analysi popul includ intentiontotreat itt patient subgroup stratifi bl hpt time expand disabl status scale post hoc analys includ proport patient achiev sever threshold cp proport achiev ci hpt result among itt patient ocrelizumab signific reduc chang hpt time week risk cp hpt time hand risk sever hpt progress versus placebo numer trend also favour ocrelizumab versus placebo respect achiev ci consist direct trend observ subgroup analys conclus ocrelizumab reduc risk ue disabl progress may increas possibl improv versus placebo ppms dave bexfield activems',\n",
       "  'NNS'),\n",
       " ('i happi youlong may continu samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergiesintoler take humira g prednison reduc week',\n",
       "  'JJ'),\n",
       " ('hi blueberri these two reason option i think one import consider hing question symptomat mother if symptom signific may push decis favor establish chemo regimen carboalimta tend welltoler prove effect signific percentag patient immunotherapi hand extrem effect smaller percentag patient often effect treatment take longer manifest anoth consider question chemo vs trial whether choos chemo first disqualifi patient trial later although trial mention list previous treatment exclus factor list firstlin therapi trial one shouldnt overemphas import factor though sinc mani trial immunotherapi agent even particular combin might avail someth similar jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('a random phase trial niraparib mainten therapi initi chines patient extens diseasesmallcel lung cancer edsclc accord inform poster present iaslc th world confer lung cancer toronto canada niraparib parp inhibitor effect patient brca mutat ovarian cancer well patient non brca mutat ovarian cancer respond platinumbas chemotherapi sclc cell demonstr high level parp express sensit platinumbas chemotherapi suggest target dnarepair pathway may effect approach the aim studi evalu niraparib mainten therapi edsclc the random doubleblind phase zl trial enrol approxim patient ed sclc demonstr respons platinumbas chemotherapi relat articl fda grant acceler approv nivolumab small cell lung cancer copd may not affect surviv patient with small cell lung cancer lurbinectedin receiv fda orphan drug status recurr smallcel lung cancer to elig trial patient need achiev complet partial respons prior platinumbas chemotherapi regimen requir complet cycl etoposid plus cisplatin carboplatin patient random assign receiv niraparib placebo mainten set niraparib dose mg daili patient baselin bodi weight least kg baselin platelet count least l patient lower baselin bodi weight platelet count administ mg daili patient continu mainten therapi diseas progress intoler toxic stratif paramet includ gender lactas dehydrogenas level prophylact cranial irradi the coprimari end point trial progressionfre surviv pfs assess independ central radiolog review overal surviv the secondari end point includ investigatorassess pfs safeti toler qualiti life read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'NN'),\n",
       " ('could new symptom result stop gilenya it known rebound effect', 'NN'),\n",
       " ('hi galen tough call make one reason rebound effect would concern mani peopl convert jcv year i think convers rate around per year there reason think ocrevus effect class tysabri detail remain seen time howev lot reason believ pml risk much much lower have consid drug rituximaub are avail area happi send link detail wife tecfidera i alway wonder next move either becom aggess dmt move tecfidera in situat i would go ocrevus person base ton studi paper i read base real medic train wife also jcv like i think dr least passiv good question follow om well',\n",
       "  'NN'),\n",
       " ('unfortun insur decid med take order you might need tri remicad humira st much much quicker respons time entyvio all med patientcopay assist card manufactur our uc sever determin med work dose work id wager flare whole lot sever past one iv steroid sometim need just make sure your test recent pathogen caus like c diff respond steroid often red flag verifi infect infect worsen steroid help hang get better post edit ipoop am gmt',\n",
       "  'JJ'),\n",
       " ('ruth bader ginsburg lung cancer httpswwwmsncomenusnewsusruthbaderginsburg read more answer answer share rob experi squamous cell carcinoma l year ago oh no im back round four time brand new med yey bodi heard opdivo read more comment gregpwn question invas squamous ce year ago it seem like everi day new type immunotherapi use have doctor suggest type immunotherapi some type cancer suit better treatment other curious read more answer answer share gregpwn question invas squamous ce almost year ago what biggest issu your face week have serious problem let let hear answer answer share gregpwn question hodgkin diseas year ago have found treatment taken littl pep step mayb your strong abil use our blog post today issu take look httpbit',\n",
       "  'NN'),\n",
       " ('miapi neuro correct retic cladribin present time it yet approv nice present use offlabel your neuro may ask sign disclaim obtain dmt present time',\n",
       "  'JJ'),\n",
       " ('ive complet full cours inject form cladribin veri easi toler high recommend i continu work day take shot home night the drug clear day dose effect last year',\n",
       "  'JJ'),\n",
       " ('hard believ one year ago wife i receiv diagnosi cancer go two week potenti pneumonia stage iv lung cancer indescrib but bless wonder oncolog team support famili friend and dark time first week fill fear might happen wonder wife i also bless found site straightforward honest inform care peopl let know alon journey this site comfort wife continu trail treatment so year later one success chemo treatment two unsuccess one behind us midst clinic trial dont yet know outcom her cancer bit diagnos seem trade initi bone metastes liver one adren but still great health otherwis wonder strong attitud move onward toward colleg graduat son may wed daughter juli we lucki time work manag side effect treatment effect cancer know driver mutat potenti target therapi still go tri trial drug work i want thank everyon site have place read latest method see stori other go issu ask question know other travel along road certain help i go emot high low love one deal cancer so mark first year thank much everyon grace wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl all stabl addl growthoff trial start gemzarlarg tumor reduct',\n",
       "  'NN'),\n",
       " ('how much oral cladribin cost compar intraven outof patent intraven cladribin such wast public money',\n",
       "  'NN'),\n",
       " ('youll like fine stress worri go aggrav crohn symptom there thing like stress worri worth risk upset crohn id ask is good mrmsmrs colon answer no dont i dont know get premed time remicad infus antihistamin benadrylclaritin tylenol refus preme i would definit insist preme get infus as youd slight increas risk infus reaction moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa there two certainti life pay tax prednison side effect',\n",
       "  'NN'),\n",
       " ('i soooooo happi i actual problem get rituxan cover that i end ocrevus im hope i switch easili pleas keep touch often email jami or facebook jami koralstarr',\n",
       "  'NN'),\n",
       " ('notsosicklygirl im pretti sure posit respons due remicad sinc i put iv steroid remicad day littl improv then right remicad great so im assum remicad one trick and yes i diagnos via colonoscopi confirm biopsi i also stool test show inflamm well blood test show high inflammatori marker ipoop i agre i think need tri med help unfortun doctor hasnt mention combin therapi sure mention next time speak thing taken turn though third infus didnt see good respons first two infus it diarrhea right time day infus day ago i hope delay respons there occasion blood time',\n",
       "  'RB'),\n",
       " ('sinc seem like us consid ask ocrevus it avail i sure insur situat short term it could effect amount risk my wife use tecfidera right',\n",
       "  'JJ'),\n",
       " ('is friday session someth longawait subgroup analysi actrim httpwwwactrimsorgforumindexphpprogramfullprogram friday februari pm pm talk efficaci ocrelizumab patient ppms without t gadoliniumenhanc lesion baselin phase iii placebocontrol trial jerri wolinski the univers texa health scienc center houston',\n",
       "  'NN'),\n",
       " ('human prescript drug label item code sourc ndc rout administr intraven dea schedul activ ingredientact moieti ingredi name basi strength strength ustekinumab ustekinumab ustekinumab mg ml inact ingredi ingredi name strength edet disodium mg ml histidin mg ml histidin monohydrochlorid monohydr mg ml methionin mg ml polysorb mg ml sucros mg ml product characterist color yellow colorless light yellow score shape size flavor imprint code contain packag item code packag descript ndc vial singleus box ml vial singleus ndc vial singleus box ml vial singleus market inform market categori applic number monograph citat market start date market end date bla bla',\n",
       "  'NN'),\n",
       " ('my yearold wife nsclc adenocarcinoma surgic resect lower middl lob right lung six year ago follow adjuv cisplatin cancer return one year later lung shes alimta avastin everi four week three year progress dure time blood pressur alway high even medic six month ago decid take hiatus due chemo brain while hiatus tia complic she saw hypertens specialist chang medic brought blood pressur normal kept four month hiatus start sign progress put back alimta alon everi three week dose reduc avastin due tia after two infus symptom cough wet rail sound exhaledifficulti catch breath fatigu grew wors current hospit treat possibl pneumonia fever infect wait cultur ct show growth someth pulmonologist want bronchoscopi rule caus cancer if growth cancer oncologist opinion alimta longer work want switch taxoter bu veryt reluct return avastin my question sinc blood pressur control go back avastin sinc doublet alimta avastin kept progress free three year reluct move onto someth els is possibl avastin synerget effect alimta avastin alon keep progress free in case oncologist want go taxoter order knock effect wife reluct due hair loss oner side effect ive post cancergrac sever time past six year extrem grate respons help enorm chart cours treatment thank',\n",
       "  'NN'),\n",
       " ('the food drug administr fda approv combin use keytruda pembrolizumab plus carboplatin either paclitaxel nabpaclitacel treat patient metastat squamous nonsmal cell lung cancer nsclc diseas account percent lung cancer accord merck manufactur immunotherapi agent the agenc base approv result phase keynot trial recent present intern associ studi lung cancer th world confer lung cancer the trial random patient receiv either mg keytruda patient placebo patient first day cycl for first four cycl patient also receiv carboplatin either paclitaxel nanoparticl albuminbound nabpaclitaxel patient follow median month the keytruda regimen prolong median overal surviv month month vs month median progressionfre surviv month month vs month keytruda surviv benefit consist regardless pdl express among patient treat agent in addit keytruda regimen demonstr superior respons rate percent vs percent compar placebo reduc risk diseas progress death percent grade higher side effect occur percent patient treat keytruda includ neutropenia percent anemia percent thrombocytopenia percent diahrrea percent this keytruda fifth approv lung cancer space the drug also approv treat certain type melanoma head neck cancer classic hodgkin lymphoma urotheli carcinoma microsatellit instabilityhigh msih solid tumor gastric cancer cervic cancer today approv expand current lung cancer indic includ combin treatment patient squamous cell carcinoma type lung cancer particular difficult treat said roger m perlmutt md phd presid merck research laboratori approv fda potenti mean keytruda use improv surviv patient debilit diseas',\n",
       "  'JJ'),\n",
       " ('i repeat femal canada ivig pentasa uccrohn test posit map antibodi mycobacterium pg remiss flare year current deal perian abscess fistula rvf wait stelara',\n",
       "  'NN'),\n",
       " ('i realiz rather late respons convers origin id like share father experi hope may use other contempl wbrt at age diagnos stage egfr exon delet nsclc adenocarcinoma liver bone brain metastas he brain lesion rang mm mm size asymptomat his first oncologist recommend wbrt father reluct concern late cognit effect radiat especi older patient we request second opinion lung cancer specialist major teach hospit decis made defer wbrt favor tarceva a shortinterv brain mri week done dramat respons week tarceva all lesion decreas size enhanc longer visibl mri my father subsequ consult neurooncologist author aforement paper httpswwwncbinlmnihgovpubm well neurosurgeon seem agreement wbrt would last resort least father case there probabl mani factor affect decis proceed wbrt i want share father stori sinc posit respons tkis without need brain radiat to judi bmjs son jcs mother i wish best hope good respons treatment long time hope',\n",
       "  'NN'),\n",
       " ('marci i slight differ pair convent chemotherapi taxol carboplatin it appear doctor believ pemetrex altima better drug combin mainten therapi i near two year mainten therapi last infus cycl ad target therapi drug tarceva taxol carboplatin this doctor understood tarceva would ineffect squamous cell non small cell lung cancer taxol carboplatin kept knock back tumor steff reveal secret convent chemotherapi sideeffect onc present occur time period infus if present good idea record time sideeffect onset hour infus i also success take sideeffect mitig medic hour schedul sideeffect onset my chemo nurs gave advic work in case i experienc one sleepless night even infus like steroid along intens hunger my nausea symptom start hour infus didnt happen i took antinausea medic hour project start my troubl sideeffect joint pain start hour infus last sever day mani toler altima carboplatin well so hope sideeffect minim stay cours tom',\n",
       "  'NN'),\n",
       " ('hi bh i dont see problem continu antibiot alimta when wife receiv combin alimta tarceva use bactrim treat skin toxic on hand given lung mass clot may want discuss oncologist whether actual need antibiot it possibl imag clinic factor point simultan case pneumonia it unreason return alimta last success mom previous experienc although mani oncologist would prefer switch someth new there isnt right wrong answer the problem keytruda immunotherapi tend take longer chemotherapi show antitumor effect effect subset patient want discuss issu doctor well jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('i diagnos stage ib adenocarcinomaat first surgial remov one lobe right lung all well no chemo requir year later march found metatic brain that made stageiv i gobsmack i thought gone cyberknif chemo rest my first chemo also carboplantinalimta last test show evid diseas said immedi temporari anyway im alimta mainten side effect arent bad the carboplantin almost kill im still happi alimta side effect minim compar now youi suspect say dad minim hes tell doc everyth side effect i learn hard way one must stay hydrat i dont like water plus doc might prescrib thing like neulasta help deal side effect but doc cant help deal one tell what go you possibl keep journal symptom go doc speak someon told stage iv learn live cancer you knock live life knock pleas post progress report know im pull dad',\n",
       "  'NN'),\n",
       " ('alt compos il receptor fusion protein mutant form il it target share il il pathway activ immun cell nivolumab prevent tumor cell evad the combin two differ effect might work synergist elimin cancer cell note dr rolfo dr smit signific invari toxic hamper use il cytokin immunotherapi therapeut dose but author new studi report subcutaneouslyinject g alt per kg week week four week cycl month safe drive nivolumabassoci advers event rate the author report doselimit toxic alt plus nivolumab identifi maximum toler dose in posthoc analysi studi particip experienc partial respons suggest reassert control relaps icirefractori lung cancer note lead studi author john m wrangl md medic univers south carolina charleston coauthor what uniqu trial two complet differ type drug never combin human trial demonstr drug safe administ said senior studi author mark p rubinstein phd medic univers south carolina press releas relat articl time report palliat care need lead more appropri endoflif care nsclc osimertinib improv qualityoflif global health status nonsmal cell lung cancer the posthoc analysi suggest alt might salvag ici refractori nsclc dr rubinstein suggest no dualimmunotherapi nonpdpdl ici yet approv us food drug administr nsclc more effect immunotherapi regimen bring clinic benefit patient lung cancer resurrect clinic benefit resist emerg repres huge unmet need note the abil alt reinduc immunotherapeut respons pdrelaps refractori nsclc stimul surg renew interest cytokin combin treatment cancer injectionsit reaction flulik symptom common affect patient respect two patient experienc grade toxic lymphocytopenia fatigu anoth patient experienc grade heart attack no grade toxic patient death report the studi fund altor bioscienc nation institut health nih univers south carolina holl cancer center phase trial enrol ongo studi author report there reason caution as dr rolfo dr smit point osimertinib durvalumab show similar earli promis later demonstr troubl rate advers event but even express optim the studi laid foundat clinic investig use il agonist combin pd pdl inhibitor immunotherapybas treatment improv outcom patient nsclc tumor wrote combin treatment futur immunotherapi refer',\n",
       "  'VBP'),\n",
       " ('hello i enjoy read ur ms stori i ms almost yrs may i suggest anoth anoth exercis youwhen i diagnos back balto md john hopkin neurologist benjamin brook md told best exercis ms swim i take advis first anoth attack arm hand numb month then i join gym indoor outdoor pool that it took time get adjust water water comfort soul brain muscl dont worri get overh swim i didnt like get hair wet though so i took deep water jog class that i love you exercis ur arm leg stomach get chlorin ur hair i want suggest mayb would like tri i spms stage i copaxon i inj year neuro switch gilenya i use rollat help balanc issu i enjoy read ur stori my best give pool tri u may like stay away warm therapeut pool alsomi best vicki',\n",
       "  'NN'),\n",
       " ('in articl reduc cost enhanc qualiti care ms kister corboy urg neurologist part improv afford ms medic the unafford ms medic driven outrag price way tie benefit medic provid the experi share includ simpl strategi lower cost without diminish qualiti care the one impact use rituximab forerunn ocrelizumab like fda approv avail ridicul high price the biggest barrier implement rituximab use insur carrier deni coverag fda approv ms neurologist afraid legal action prescrib nonfda approv product drug compani incred good market product glossi ad promot brand bond entic mani promin neurologist speaker fee dinner firstauthorship new england journal articl studi didnt design conduct analyz biogen roch alreadi busi creat fals distinct ocrelizumab rituximab lucenti avastin frighten neurologist believ would harm patient risk litig use rituximab offlabel prescrib neurologist time legal risk ocrelizumab proven superior safer rituximab data exist studi roch biogen would afraid conduct the swedish kaiser permanent neurologist negoti medic center allow use rituximab high activ patient natalizumab option use rituximab increas dramat sweden kaiser permanent high favor efficacysafeti profil high patient satisfact becom clearer pharma tri pressur swedish govern halt use rituximab met outrag neurologist swedish health care author review extens use rituximab ms deem scientif sound legal i urg neurologist stand patient swedish neurologist done help patient get access rituximab editor note for addit inform see recent articl rituximab multipl sclerosi a retrospect observ studi safeti efficaci salzer j svenningsson r alp p et al',\n",
       "  'NN'),\n",
       " ('octob increas proport treatmentchang limit interpret result initi iqwig evalu shall continu crizotinib xalkori avail sinc secondlin treatment patient advanc nonsmallcel lung cancer high activ enzym anaplast lymphoma kinas crizotinib alreadi undergon dossier evalu use the gba limit decis manufactur submit anoth dossier the iqwig assess second dossier for patient elig treatment chemotherapi contain new result these data cannot interpret meaning for patient manufactur present new data the result first dossier evalu therefor remain unchang read iqwig press releas german',\n",
       "  'JJ'),\n",
       " ('my question i open lung biopsi tumor less cm how know wait see especi doctor realli push surgeon background jan diagnos nsclc stage right lower lobectomi mutat egfr exon detect i declar cure treatment quarterlybiannu ct scan follow review in sept mm tumor detect medic oncologist prescrib tarceva mg base previous occur the tumor reduc sizestabl aug small perifissur nodul mm mm well mm mammari lymph nodul progress jan nodul still less cm oncologist want biopsi remov the tumor situat cannot easili radiat biopsi pulmonologist my impress surgeon find tumor small difficult open biopsi use hand feel tumor small becaus oncologist want doesnt want wait surgeon will i dont much confid especi read dr west talk adenoma in situ potenti treatment lung cancer how know go oncologist is worth open lung biopsi tumor small even surgeon hesit',\n",
       "  'NN'),\n",
       " ('hello all ive gilenya almost month suppress neutrophil dramat has anyon els experienc as well ive notic red spot tini quarter size hand feet they arent blister rais itchi hurt they tend go away week come back spot still hand feet ive schedul see dermatologist wont awhil i dont know natur symptom medic im also take medic ani thought',\n",
       "  'VBD'),\n",
       " ('sth i cladribin week ago veri simpl procedur day intect secondari effect realli pill given think rrms think pharma money make inyect differ situat eg advanc inject patent cheaper internet full scari stuff peopl report thing sometim could ms drug by way hair lost case least yet still keep frizzi hair doe work earli day guess my hope let see i fingolimod think good stop relaps noth start spms take bad place secondari effect lymphocit low lymphopenia get wors time rebound effect stop twice immun system back normal attack come back in opinion drug stop spms beast would go sth caus troubl realli go throughin case spms start yesr but older younger noon predict take care xxx',\n",
       "  'JJ'),\n",
       " ('i first infus ocrelizumab next week', 'JJ'),\n",
       " ('antibodi arent foregon conclus biolog some never get antibodi biolog even without concurr immunomodul therapi some get antibodi quick best concurr immunomodul therapi i believ highest odd antibodi format earli biolog treatment alreadi year havent alreadi got antibodi like wont get it easi test antibodi unless becom problem there reason discontinu med remicadeinfliximab oldest ucapprov biolog percent human protein percent mous protein as general littl higher odd antibodi format rest the rest percent human like entyvio dont even recommend immunomodul concurr treatment current clinic guidelin even worst case scenario antibodi drug dose increas counter act mani case and antibodi format one medic doesnt predispos one alway develop antibodi everi medic it isol one med some food thought least i wouldnt fixat antibodi moder ulcer coliti john minor flare uc proctosigmoid rx remicad mgskgwks mgs mp g lialda mgs pred with uc ive becom poopninja sli sightunseen insan urgenc demand post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('in term healthcar medicin oral medic ms still consid infanc come onto market five year ago oral medic ms savior mani they provid relief inject i talk last week provid hope research futur when i first diagnos oral treatment seem like still thought figment medic imagin but year later hit market cheer sigh relief mani patient the first scene gilenya gilenya believ work prevent certain type white blood cell cross bloodbrain barrier by believ reduc inflamm damag nerv cell gilenya seem answer mani mser prayer shot but soon mani began take report side effect came this unusu drug often side effect but high profil drug side effect high profil well one main side effect report heart issu within first hour take first dose and sad individu experienc worst side effect possibl pass away within hour take first dose this led regul chang includ eeg prior start medic monitor hour hospit receiv first dosag gilenya also known caus vision breath liver problem individu prompt group urg fda use restrict medic there alway two side everi coin though peopl report wonder relief symptom abl thing havent done year next emerg aubagio aubagio believ work inhibit function specif immun cell believ present ms patient happi anoth oral option besid gilenya prove research still march forward when take aubagio one requir liver enzym check regular aubagio could damag liver there also side effect well flush hair loss hair thin among other i aubagio year copaxon i experienc major hair loss least i thought major i relaps take well clear bodi tell time switch the last oral medic make way world tecfidera tecfidera formal known bg formul specif peopl ms use germani higher dose treat acut flare up psoriasi year it thought inhibit immun cell may specif antioxid properti might protect damag brain spinal cord the main side effect report mani individu take tecfidera flush in individu sad pass away pml prompt stringent warn label jc virus test patient take tecfidera as i mention one medic i far aubagio i experienc i would consid extrem hair loss clean shower floor everi day major relaps take as possibl side effect i didnt notic anyth els i love idea abl take oral medic ms instead inject bodi differ plan if i need transit tysabri futur i definit look one oral option anyth els like medic come plenti side effect what import rememb alway weigh risk versus benefit what toler side effect to put plain medic work will put order get benefit if medic make feel hot make skin look like tomato hour flush youv relaps free year import or youv test posit jc virus level risk ok those definit tough question answer littl honesti get real done husband cent the one oral medic tri aubagio didnt work her hair fell relaps take includ subtl lesion brain it may awesom thing peopl unfortun i person never notic differ hair i know it frustrat watch frustrat if like your read want stay connect join lissm communiti',\n",
       "  'NN'),\n",
       " ('as jimmi carter pembrolizumab human monoclon antibodi umab mysteri although detail get technic if love one get cancer i high recommend undergradu immunolog erridg afford introduct subject just dont get discourag inform unlik understand keep read use googl encount new vocabulari new concept',\n",
       "  'IN'),\n",
       " ('i diagnos nsclc jan had chemo continu opdivo chemo actual honest i havent chang thing lifestyl still drink eat i wantwhatev mayb im deathproof my point your either go live not sure anyth outsid treatment dictat outcom',\n",
       "  'JJ'),\n",
       " ('i tell near four year ago near year type diabet know two year i background retinopathi macular edema dme hit right eye this blue vision acuiti drop due locat leakag close fovea laser rule that left antivegf viabl option one thing i say work thank god my vision restor next four month it still the caveat antivegf inject eylea perman solut in case persist dme requir sinc i averag inject per year inject free pleasant hey maintain good vision id happi go everi morn',\n",
       "  'JJ'),\n",
       " ('i dont know dr woolmor i differ neuro i first diagnos i saw i think move somewher els diseas modifi drug prescrib number clinic signific relaps certain time i think two year general start inject drug like betaferon copaxon if dont work side effect problem may move anoth treatment gilenya taken capsul day i dont know much tysabri given hospit everi month ani treatment depend ms affect time you may need physiotherapi help eye specialist avail qe i name treatment i need year im sure other think avail qe',\n",
       "  'NN'),\n",
       " ('thank fg i havent around yr femal dx uc dx chang crohn coliti current total colectomi oct previous use remicad humira stelara imuran mp apriso asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam prednison im glutenfre supp vsl calmag vit d krill oil ezf',\n",
       "  'NN'),\n",
       " ('ncot i technic remiss surgeri i start entyvio i still perian diseas two fistula after year entyvio fistula close ive fine ever sinc i got scope everi way last week diseas activ inflamm seen anywher so id say entyvio work pretti darn well wait work difficult part especi your feel sick i fortun i wasnt realli sick i start yearold male diagnos crohn age ileostomi april revis surgeri june current med entyvio nexium past med humira remicad cimzia imuran mp mtx everi asa',\n",
       "  'JJ'),\n",
       " ('as turn multipl sclerosi doesnt exempt us relentless life when feel like your stuck fugu state one bad thing anoth begin wish could throw flag appeal univers throw damn bone alreadi but flag univers suppos benevol rot real bitch come make pour rain it make start think life test might fail it make think life unfair it make forget grate greater sin none i lost anoth felin famili past week i want downplay go highbrow circl life play elton john song inspir help find beauti long life well live i quit simpli feel way even littl bit when i lost cat roger may entir dynam hous chang all sudden littl vocal social potstirr gone hous went quiet ivan littlest kitti kind step roger void he talk he snuggl spent everi bedtim perform nighttim ritual circl head head but hand forehead pet squawk whole time it like didnt want lone he make sure i ok okh cat probabl none sentient intent felt like matter right i knew someth wrong i led believ minor issu a chronic clog anal gland gross i need keep eye he happi play eat take care like perfect healthi littl kitti exact like roger complet fine wasnt i saw diarrhea live room floor i somehow caught put carrier without fall face adrenalin amaz thing i bare stand without fall postprednison haze i manag catch littl guy shove carrier i call nephew alex panic he came immedi took ivan emerg vet i sure ivan go ok i didnt even tri go along ive bad shape i knew stress trip wouldnt good ridicul dysfunct bodi the steroid last week give usual backlash i could bare walk the lemtrada leg cramp back vengeanc those steroid basic got one day offic im piss prednison that feel complet reason complet irrat time i shape go pranc cold night emerg vet it ok though alex would handl he text vet told doc thought ivan would ok his vital realli good he seem perfect healthi except clog anal gland they plan clean send home antibiot it good i caught got go fine until went clean behind rectal exam they realiz didnt clog anal gland he giant tumor i see extend outsid bodi they call explain even i chose oper would like never abl go bathroom without difficulti keep clean he would like terribl pain he wouldnt last long like ivan year old i couldnt believ i hear i alreadi walk away idea anyth serious wrong this wasnt happen but after telephon convers vet decid done i want drive ivan went sleep i wasnt strong enough roger went sleep i alreadi hospit time roger first pet death i wasnt even remot prepar would hit know i didnt know i didnt think i could bear let ivan go without see one time alex solv problem drive minut back hous get drive back emerg vet i held ivan pur loud sound like warm tini littl lawn mower arm i kiss talk held tight littl heart stop i didnt want let go gone he look peac like asleep like tini littl black sleep kitten i want hold forev go four cat three strang go three cat two like kind seismic shift the two left fred owen kinda quiet they keep bit in last day sinc ivan gone though glu side i know theyr cat but know somehow they know im ok it probabl sound crazi i think miss ivan sinc thursday night went ive midst anoth famili crisi complet unrel again univers work mysteri way i need someon els i need focus someth realli import wasnt someon i love i love even physic wasnt ideal stress isnt bodi friend we know ive basic night three day catch sleep day i havent realli seen much daylight sinc thursday night it feel strang three day pajama three day wake sun go mayb univers know shes i need focus someth wasnt fail bodi poor sweet kitti i need use famili i the crisi sinc pass thing get back normal i may actual sleep tonight dark wake sun tomorrow im sure im go feel tomorrow most postprednison postlemtrada bodi asshol i would kind love go outsid breath air feel cold see snow i know soon i type word might high unlik im go shape thing tomorrow mayb i and im mayb later week im get better patienc thing even i resist everi fiber i miss ivan i miss work bodi i miss outsid kind i miss new fuck life lesson learn everi time i turn around i miss spontan smile take work bodi grant i miss love winter im sure i start go rabbit hole thing i miss i how littl pound fur ball incred impact grown woman human life i honest idea i miss core i hope hes cozi wherev',\n",
       "  'JJ'),\n",
       " ('on tysabri everi six month head everi year headc spine', 'NN'),\n",
       " ('present annual ectrim confer london septemb quot efficaci safeti siponimod secondari progress multipl sclerosi result placebo control doubleblind phase iii expand studi l kappo a baror b cree r fox g giovannoni r gold p vermersch s arnould t sidorenko c wolf e wallstroem f dahlk neurolog clinic policlin depart medicin clinic research biomedicin biomed engin univers hospit basel switzerland neuroimmunolog unit montreal neurolog institut hospit mcgill univers montreal qc canada multipl sclerosi centr univers california san francisco san francisco ca mellen centr treatment research multipl sclerosi neurolog institut cleveland clinic cleveland oh unit state blizard institut bart the london school medicin dentistri queen mari univers london london unit kingdom depart neurolog st josefhospitalruhrunivers bochum bochum germani univers lill depart neurolog lill citi franc novarti pharma ag basel switzerland lycali sprl brussel belgium background there high unmet need treatment delay disabl progress secondari progress multipl sclerosi spms siponimod baf oral activ select modul sphingosinephosph receptor subtyp expand largest randomis control studi spms date object expand phase multicentr randomis doubleblind placebocontrol studi design evalu efficaci safeti toler siponimod treatment spms designmethod patient spms defin progress increas disabl month durat absenc independ relaps age year expand disabl status scale edss score enrol elig patient randomis receiv either mg daili siponimod follow initi dose titrat start mg match placebo the eventdriven studi design allow blind core studi stop prespecifi number confirm disabl progress cdp event occur the primari efficaci outcom time month cdp measur edss the key secondari outcom time confirm worsen baselin time foot walk test t lesion volum chang baselin safeti assess includ report advers event ae serious ae sae clinic notabl laboratori abnorm patient complet core phase offer receiv openlabel siponimod extens phase result overal patient randomis countri baselin demograph diseas characterist previous report repres patient popul spms overal patient complet core studi median time studi core studi complet month major patient particip year there cdp event patient could maxim contribut one event primari endpoint ae report sae patient conclus top line efficaci safeti result expand studi present the result larg control studi recruit activ spms popul without superimpos relaps determin siponimod delay disabl progress spms contribut better understand natur histori spms wellcontrol trial set disclosur fund sourc this studi support novarti pharma ag basel switzerland ludwig kappo institut univers hospit basel receiv last year use exclus research support steer committe advisori board consult fee actelion addex bayer healthcar biogen idec biotica genzym lilli merck mitsubishi novarti ono pharma pfizer recepto sanofi santhera siemen teva ucb xenoport speaker fee bayer healthcar biogen idec merck novarti sanofi teva support educ activ bayer healthcar biogen csl behr genzym merck novarti sanofi teva royalti neurostatus system gmbh grant bayer healthcar biogen idec european union merck novarti roch research foundat swiss ms societi swiss nation research foundat amit baror particip speaker meet sponsor receiv consult fee amplimmun biogen idec diogenix genentech sanofigenzym glaxosmithklin novarti ono pharma teva neurosci recepto inc roch merckemd serono receiv grant support amplimmun biogen idec diogenix genentech sanofi genzym glaxosmithklin novarti ono pharma teva neurosci recepto inc roch merckemd serono bruce cree receiv person compens consult abbvi biogen idec emd serono medimmun novarti genzymesanofi aventi teva neurosci contract research support includ clinic trial acorda biogen idec emd serono hoffman la roch medimmun teva neurosci robert fox receiv compens serv consult speaker allozyn avanir biogen idec novarti questcor teva pharmaceut industri institut work receiv research support novarti gavin giovannoni steer committe member daclizumab trial abbvi steer committe member bg daclizumab trial biogenidec receiv consult fee advisori board meet honoraria speak physician summit consult fee advisori board meet steer committe oral cladribin trial merckserono steer committe member fingolimod siponimod trial novarti steer committe member laquinimod trial teva consult fee advisori board meet genzymesanofi honoraria speak sever medic educ meet steer committe member ocrelizumab trial roch consult fee relat dsmb activ synthon bv cochief editor multipl sclerosi relat disord elsevi ralf gold receiv compens serv consult speaker bayer healthcar biogen idec merck serono novarti teva neurosci institut work receiv research support bayer healthcar biogen idec merck serono novarti teva neurosci patrick vermersch receiv honoraria consult fee biogen idec genzymesanofi bayer novarti merck serono gsk almiral research support biogen idec genzymesanofi bayer merck serono sophi arnould tatiana sidorenko erik wallstroem frank dahlk employe novarti christian wolf partner lycali sprl he serv consult novarti also receiv compens serv consult tobbb desitin investitionsbank berlin keyrus synthon mylan teva',\n",
       "  'NN'),\n",
       " ('thank kati repli thank thought treatment reason choic have start treatment yet i also offer ocrevus said would abl offer month said clinic trial i go ask next appoint said littl side effect one your comment help confus dont worri i feel better talk peopl understand give opinion help thank',\n",
       "  'JJ'),\n",
       " ('has anyon experi treat met amplif if met level hard get approv insur my mother get conflict respons two differ doctor whether met level warrant treatment she current tagrisso progress steadi month look next step',\n",
       "  'NN'),\n",
       " ('sorri took id finish similar i dxd may rrms biggi cluster episod within space three day iv steroid hospit job i made great recoveri no last affect easi dismiss diagnosi so i ms no big deal hasnt affect ill fine three month later i anoth partial paralysi episod usual hospit admitt steroid i left crutch i unsteadi by decemb i use rollat occas march i need wheelchair distanc when i met neuro june year confirm id suspect not rrms ppms i diagnosi last year believ neuro dxd ppms allow chanc use dmds even sinc chang diagnosi allow continu tecfidera request well dont knowit might good good luck gilenya',\n",
       "  'NN'),\n",
       " ('paul so question would person opinion b cell deplet therapi dr martin duddi neurologist so b cell deplet therapi depend kind approach from scientif point view realli interest thing there lot reason might work ms your kind pragmat person look data realli great data i think kind take regardless drug work so look look virtual stop new mri activ six month relaps i suppos one thing wait see good brain shrinkag know campath alemtuzumab sort year three four five saw maximum effect so ocrelizumab come good brain shrinkag top stop new lesion come that power combin ad fact seem work relaps form potenti progress form absenc relaps so yeah kind excit time two thing togeth i think show move deal peopl ms when speak peopl progress diseas theyv felt left long know everi new stori seem relaps diseas here two big new stori progress diseas paul so i want also ask kind timelin might see ocrelizumab avail patient dr martin duddi at minut european regul i think theyr halfway process my understand that like reach decis middl next year if goe usual thing come nice year wed drug kind avail nhs probabl still gut two year httpsshiftmsmsreport httpswwwfacebookcomshiftm httpswwwinstagramcomshiftdotm httpstwittercomshiftm',\n",
       "  'NN'),\n",
       " ('hey jana i hope new diagnosi welcom rather scari my diagnosi chang life i final answer hope feel sorri hear bladder issu i capoxon daili inject busi migrat gilenya clone my medz effect anymor in rsa i live cannot choos medic neuro choos go plan i realli hope medic effect i diagnos year ago third treatment my wish would could lot older diagnosi difficult i diagnos it suck want activ social bodi play well idea pleas ask want know peopl awesom support i great help past site ask answer happi easter mser',\n",
       "  'NN'),\n",
       " ('marlo ive ever type treatment sinc i diagnos i round lemtrada evid diseas activ sinc it quick simpl problem free ive talk neurologist i would i ever relaps cladribin would probabl next choic i couldnt anoth round lem probabl much help want lemmi talk friend request im happi share contact detail pm xx',\n",
       "  'NN'),\n",
       " ('cimzia common crohn diseas i would assum similar humira regard side effect i certain you ask crohnsforum healingwel dont get answer moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa there two certainti life pay tax prednison side effect',\n",
       "  'NN'),\n",
       " ('i use visual multipl sclerosi journey a rather complic journey foreign countri direct destin everchang i dont speak languag late i visual multipl sclerosi complex maze kind like one pictur various place make way see light shine but mani place find continu make way maze light hard see seem gone entir im feel muddl im tri like hell hold shit togeth posit look forward msdoesnthavem beth late gotten bit much i realiz recent mobil taken real turn wors sinc last relaps juli mobil alway issu begin i mean troubl walk one first symptom weird feel leg that legsnotleg feel confus i enjoy walk around reservoir highland park have sit one quarter mile lap be super confus i sudden couldnt easi thing like freak walk easili anymor walk alway issu ampyra help to honest hasnt help much late i live fear stop time ive ever done accid forget second dose exampl leg becom complet useless almost immedi im terrifi test life would like without especi i big thing go work come week requir physic present schedul place offic id liar i didnt admit mess head big time after relaps i unsteadi feet result vertigo i final gave got cane i accept unsteadi impact life i troubl even get offic i valet park right across street i feel home bound antsi i rare left hous beyond go work i id becom instant frustrat awkward learn walk cane sorri stanley i know tri to honest leg drag like dead tree stump cane doesnt whole lot make leg walk better i rememb first appoint the great scott ms specialist said reason believ i wouldnt even need cane i he said get aggress treatment that i want soon progress would slow id start feel bit better tysabri turn miracl wait i day light corner maze i allow hope i would feel better but relaps happen ive never quit made back stage even felt like million round highdos steroid made fat miser i still back prerelaps level abil buy stanley felt like give it felt like failur but i buy i use best abil i almost dont hate much i thought i would at least i cane peopl clear see probabl tri mow without look like complet asshol that kind nice i havent seen tgs sinc i start use cane im almost embarrass tell stanley im afraid mayb hell disappoint i dont know it strang for girl word without right one describ feel the closest i get feel shame on outsid i make joke use stanley accessori emphas import point convers bang ground definit thing i occasionallyi cannot deni but insid i resent shit stanley i feel like hes outsid sign i fail im stuck ten feet maze hes help get next light corner i troubl walk feet fifti feet my leg start liter drag like inanim object i stumbl foot everi i cant turn head walk without lose bear ive come reli stanley kind thing but hes semieffect walk distanc chore i realiz late simpl fact kept walk much im stuck dark corner maze i cant see way one simpl fact am i disabl or i semiabl or i abl uncomfort abl im life full awkward discomfort i feel like im quit one thing quit would walker help im sure that seem like anoth awkward thing carri around get car anoth devic doesnt make leg work better give someth lean stanley pretti good job i guess i could get rollat also allow sit get exhaustedbut im im carri backpack full water drug comput collaps reset rollat doesnt realli seem practic should i get wheel chair a transport chair a motor scooter but i can walk i cant walk far i dont know deal realiti i tri build life around realiti go place limit walk possibl this also mean progress life progress maze slow dramat ive got desir social im tire littl walk i given day i never sure much walk involv get point a point b back outsid world ive got bare enough energi get offic back home then im home ive got bare enough energi take care home thing like laundri cat care go bathroom shower involv mani stair step i live alon two stori hous it unavoid peopl suggest i consid thing like move somewher i dont step sell home make new one somewher els without challeng daytoday life ive even thought drastic thing like sell hous move mom thing would mean i didnt work hard tri hard everi day job that meant someon fulli abl someon semiabl i all thought make feel sick stomach instant this i know right thing i cant give yet i still keep stumbl way maze tri get next area maze littl light shine the idea get middl place light shine i final understand diseas way make bearabl drive ive lost much i use think made i unwil give even littl bit and yet live gray area entir disabl kind make life pretti freak complic walk kind import part life i guess i never thought much of cours i didnt most peopl simpl activ without even think i see the great scott april week third ocrevus infus april im go talk im go tell i think im get wors im happi im go tell im sure patient i treatment given everi six month doesnt seem make better ive definit gotten wors see im nowher near im walk damn cane so that physic realiti even tgs cant deni im go tell hope i dont burst tear front everpres intern i know im suppos look bright side believ peopl i i realli realli much time when leg cant carri much one handicap space anoth becom littl bit harder keep when technic can walk cant walk far like halfpregn im abl im crippl im somewher feel like im write worri anyon i know dip dive part ms life i know much experienc i taught youv reassur i believ over reassur i get better i believ work daili maze get better i would hard time ralli silli thing like win busi work make money peopl im readi give silli thing like yet im ive met new peopl late some begin journey bit farther along i much deal life silli job thing like rais kid famili the thing make better know women most women get it help anyth im complet sure so mayb ive decid complet honest shithol maze game im play mayb help someon els feel less crazi im write usual i name fear rambl someth i dread let loos like whiniest annoy pessimist friend never want take away littl bit power when i talk sudden seem smaller less scari almost silli im write dispel gigant huge way enorm fear i write they less power it like magic there gonna epic meet april i hit the great scott it make great blog post meet tgs usual result favorit blog post sinc i find complet delight i clear calm recount much suck ask realli still believ miracl drug actual right one and i introduc stanley',\n",
       "  'NN'),\n",
       " ('hi bfarz congratul great scan report glad stick tagrisso continu keep cancer control if mixtur indol bac adenocarcinoma alway possibl invas compon becom aggress although long histori slowno growth make less like with slowgrow cancer difficult determin whether treatment that work well indol natur cancer jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('hey barbz how feel it hard say stelara work ive dose far my mouth throat ulcer clear that definit posit i like fistula small larg bowel caus excess diarrhea weight loss tpn alreadi gain pound i dont know stelara abl fix probabl look surgeri unfortun cant live tpn fentanyl forev',\n",
       "  'NN'),\n",
       " ('janin quick question direct read indol cancer elder especi malign pleural effus thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('not sure whether add post start new one may end my heart break read post see pain grief horribl diseas caus the roller coaster natur treatment scan setback take toll dh sail first round folfoxavastin even work day rd round then everyth hit like brick wall after visit hospit final day overnight home nausea vomit diarrhea final bay i grate final abl eat sandwich week hold noth but still incred worri sleep day hope med new norm scare tire impati still tri pray cant even imagin round day yet new ct show shrink tumor',\n",
       "  'JJ'),\n",
       " ('has anyon experi stop rebif outright need wean im due back neuro th june i know im go come rebif i cant handl side effect im person im miser cri time feel anxious constant physic discomfort top mental side i never use feel bad i start fact i deal quit well situat im current holiday australia month week i feel im go abl relax enjoy trip i dont come aw drug has anybodi experi stop take bat make thing wors my neuro told gilenya next step actual never want go rebif first place i refus tecfidera read bad stori side effect put rebif thank much advanc',\n",
       "  'NN'),\n",
       " ('the topdown approach trend therapi recommend use mani gasteroenteroligist start stronger med much much earlier within treatment process extinguish control uc spread extent sever that produc best qualiti life control fast let move remiss forget uc you could tri small adjust next month much along get past flare bms day put highend moder flare lowend sever flare humira perfect reason recommend symptom if your feel pretti good bms day your realli forget bm day like remiss would whole lot better qualiti life stronger treatment say well bms day least better trap best whole lot better what good save trumpcard sleev joker your best tri treatment option get remiss there mani biolog avail mani new treatment develop you end rope tri humira moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('angi randal chicago mom live multipl sclerosi i excit introduc angi optimist inform websit well strong ms how mani year live ms ive ms year what medic use im tysabri month infus ive one year great result knock wood do natur therapi treatment fight ms i tri eat clean diet most carbgluten free exercis regular get lot sleep i think rest key ms how ms affect mother there certain precaut ive take part life ive modifi ive abl figur new normal motherhood i definit make health prioriti also daughter what someth ms wish peopl knew that end world when i first diagnos i assum worst i thought life would never that true degre ms diseas even year ago medic treatment advanc much new treatment option come everi year im abl live full activ life diseas i tri demonstr other blog well strong ms i start blog show peopl ani advic someon whos newli diagnos i know overwhelm begin id suggest coupl thing find neurologist trust interview find someon realli confid seek other thrive diseas see attribut success learn take control situat find medic treatment option work be posit this hard begin go best asset throughout ms journey what think futur ms treatment it feel like everi day new medic horizon alway give hope im excit ocrelizumab the effect drug suppos high infus everi month seem ideal',\n",
       "  'NN'),\n",
       " ('this weekend post alemtuzumab work peopl fingolimod beg question how transit peopl fingolimod onto someth els we debat natalizumab alreadi look post aspect highlight fingolimod natalizumab racehors drug they keep cell trap stop enter brain as kill drug diseas form cell accumul time they starter order race brain stop drug diseas rebound peopl there mani limod trial ongo take fingolimod siponimod what measur place drug suppli stop end trial how rebound go prevent even progress everi want call ms trial these drug kill drug trap drug fingolimod trap diseasecaus cell lymphoid tissu natalizumab trapdiseas caus cell blood they stop diseas process diseas caus cell accumul trap whilst drug treatment place howev see cell racehors wait run brain starter order wait go the gate open theyr remov drug cell escap get brain diseas activ occur whilst peopl view progress ms differ diseas i think dumb view import danger view it clear mani peopl activ lesion come go progress cours carri if look patholog peopl progress ms activ lesion it clear peopl progress ms benefit immuneinhibit howev i think also case racehors drug allow accumul damag cell peopl progress ms extent drug convert subclin relaps patholog relapsingact ms timebomb tick drug stop this hors line wait go stop drug relaps occursthi sometim call rebound call resum synchron relaps case dont like word reboundbut damag ever name call need avoid doe happen sure drk case report pleas drk say here md davion jb et al two case relaps primari progress multipl sclerosi fingolimod withdraw j neurol',\n",
       "  'NN'),\n",
       " ('hi i stage lc spread bone spine neck went chemo next opdivo noth i thrill i got yet noth week treatment dose it appear work treat i would certain tri mean time readi last appear help buddi hope the opdivo shrunk tumor like magic depend pd protein tcell',\n",
       "  'NN'),\n",
       " ('janin thank respons i appreci knowledg expertis forum bring address aw ill unfortun diseas hit peopl age everyon experi differ i find help hear peopl stori mayb experi i share mother help similar situat through forum other ive learn lot cours diseas diagnosi treatment often undertaken patient much younger mother the differ i see test treatment regimen pursu come goal involv given mother advanc age frailti famili decis make process driven primarili goal maintain improv qualiti life follow goal extend time for younger patient abl toler i think revers usual true with goal mind come question offlabel use last line set often time especi case cancer doctor abl prescrib offlabel treatment insur pick tabwhich depend argument present i feel much uncertainti test tm could leav larg popul benefit tagrisso im interest hear opinion circumst condit would consid offlabel prescript last line treatment inconclus tm test result by seek offlabel use tagrisso keep goal treatment mother ill we continu monitor condit month liquid biopsi chose treatment pay greatest dividend correspond goal hope one test come back posit issu famili chi',\n",
       "  'NNS'),\n",
       " ('oral medic so much easier inject needl i inject type med didnt work i horribl inject medicin i would frequent miss time bruis i i gilenya year bright idea switch someth strong tecfidera now month i go back gilenya it okay though i well gilenya flare up often',\n",
       "  'VBP'),\n",
       " ('do want honest answer the nhs leagu leagu ahead healthcar system it incred cost effici still get high qualiti drug surgeri treatment guy sorri blunt make laugh i see american terrifi social medicin go describ cant pick doctor want doctor arent insur network fight fight stay x drug insur compani want switch drug cheaper instead cant even get x drug first place specialist ibd doctor within mile small rural town forth i wouldnt feel sorri us when lose nhs feel sorri us becaus whatev replac much much wors ps what extrem limit choic ive remicad humira past vedolizumab i chang hospit doctor i want what i miss american get forprofit privatis healthcar system post edit nicecupoftea am gmt',\n",
       "  'JJ'),\n",
       " ('wow realli realli suck i sorri i cant even imagin frustrat cd gastroparesi fibro arthriti gerd med remicad for thing i besought lord thrice depart he said my grace suffici thee strength made perfect weak most glad therefor i rather glori infirm i take pleasur infirm reproach necess persecut distress i weak i strong cor',\n",
       "  'JJ'),\n",
       " ('it much rechalleng rather isnt clear afatinib isnt best option slow rate growth cancer use instanc stereotact radiat area control there isnt lot inform go one cannot confid afatinib isnt option next best would osimertinib erlotinib fewer side effect penetr brain better chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       "  'JJ'),\n",
       " ('yet anoth chapter begin ms histori tri keep diseas bay yesterday i infus rituxan seventh attempt therapi ive tri interferon rebif copaxon tysabri i fail get clinic trial lemtrada after five year relat bliss follow stem cell transplant creep return i move aubagio steadi ship somewhat so rituxan slight modifi form expect approv late year fda ocrevus aka ocrelizumab ocrevus soon recogn therapi progress multipl sclerosi rituxan logic choic whi in month prior stem cell transplant i began precipit slide without relaps perhap precursor secondari progress ms the transplant stop dramat long i relaps familiar uneb slide restart aubagio help nip i felt i need get aggress and ocrevus still month away i took shot get rituxan offlabel i initi deni insur compani ms specialist doc talk around the first transfus went pretti well although i slight allerg reaction coupl hour red face itchi a littl extra benadryl prednison clear thing went smooth although i pretti dopey insert joke took six hour amf adventur predict next infus two week six month ish ill keep folk abreast progress although mayb that bad word use how success lack progress that sound like dave bexfield activems',\n",
       "  'NNS'),\n",
       " ('my termin ileum inflam long time due ibd the inflamm colon push back ileum complet erod away ic valv now food dump straight colon ileum without stop this caus pain cramp diarrhea gas malabsorpt nutrient my gi say i lifelong ic valv syndrom along small intestin bacteri overgrowth he said common uc told problem crohn patient biopsi say uc joanna diagnos proctiti spread pancol append ileocec valv syndrom mg simponi everi week mg imuran daili mg nicotin patch mg welchol algaec magnesium curcumin vsl fish oil dao oral ironvenof may scope clinic remiss ic valv anymor due inflamm small intestin former known bananagirl',\n",
       "  'JJ'),\n",
       " ('thank i agre i know better liter dont eat month avoid bathroom trip care littl one got excit i felt amaz but i know better sinc take nd dose humira yesterday today better less bathroom trip still semi liquid stool i alway stay away crohn avoid food crab weak unfortun ive tri i seem alway go back but week feel amaz abl go w kid worri i need tri harder',\n",
       "  'NN'),\n",
       " ('i absolut idea self respect neurologist would offer someon rrms betainterferon rather option first line dmd the betainterferon estim reduct relaps now your say rebif success year i see youd want chang but first dmd would neurologist offer tecfidera gilenya either would give relaps reduct some peopl given lemtrada first dmd now that bold side effect serious yet expect outcom regard ms excel i would definit go back neurologist ask choic certain oral therapi rather inject it realli stronger option fit lifestyl suit individu plus effect drug and opinion havent given enough option sue',\n",
       "  'NN'),\n",
       " ('hi steve you correct valu use tarceva adjuv postsurgeri set clear establish evid longterm treatment tarceva may benefici there thorough discuss use tarceva set gracecast video of cours state discuss possibl lung cancer alreadi cure surgeri radiat chemo there way know although i tend strong support obtain second opinion see discuss reason oncologist differ assess avail data im sure get differ answer assum initi opinion wrong as far develop resist sooner certain concern howev thirdgener egfr inhibitor avail treat egfr inhibitor resist diseas research continu develop new treatment agent jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('daybyday partner need go emot rollercoast went postdiagnosi he much stuck shockdeni phase need move forward in respect also suffer ms need see life must go this take time time you cant forc subtl i understand matern crave ocrevus may best dmt pregnanc recommend you discuss dmt pregnanc plan neuro may drug eg would fit better plan whilst may genet factor contract ms part stori there factor involv so whilst risk pass ms margin increas definit',\n",
       "  'NN'),\n",
       " ('i ppms tri ocrvea i one dose split thank god i bad reaction got sick bed whole week read post day ago hug use just receiv denial assist dmt i tecfidera past year inform i assist futur i enough get toward end month appoint neurologist end march the request med refil issu heard weekend ani suggest i go talk look ocrevus patient infus cover medicar just take read post day ago hug use answer sign view previous answer a mymsteam member said call biogen make tecfidera they help cost i live post day ago hug use i tecfidera then tysabri mani mris r talk ocrevus has anyon experi drug post day ago hug use answer sign view previous answer a mymsteam member said just start take ocrevus week ago take second half i seem okay long enough realli know',\n",
       "  'JJ'),\n",
       " ('the impact hurrican sandi resid midatlant northeastern midwestern unit state devast msaa staff deepli sadden tragic loss life well destruct person possess home busi caus storm power outag gas shortag loss basic servic continu disrupt live million peopl effect particular urgent individu disabl with mind hope follow inform may help member ms communiti need for individu either lost medic lost power abl keep medic cold requir follow pharmaceut inform may assist specif note list provid msaa individu pharmaceut compani msaa updat list inform becom avail aubagio program name ms one one phone websit wwwmsonetoonecom avonex program name ms activesourc phone websit wwwavonexcom storm note avonex lost improp store result hurrican sandi replac cost betaseron program name betaplus phone websit wwwbetaseroncom storm note betaseron lost improp store result hurrican sandi handl case case basi copaxon program name share solut phone websit wwwcopaxonecom storm note copaxon lost improp store result hurrican sandi handl case case basi repres note copaxon left without refriger one month room temperatur extavia patient servic program phone websit wwwextaviacom storm note extavia lost improp store result hurrican sandi handl case case basi gilenya patient servic program phone websit wwwgilenyacom storm note gilenya lost improp store result hurrican sandi handl case case basi rebif program name ms lifelin phone websit wwwmslifelinescom tysabri program name ms activesourc phone websit wwwtysabricom storm note tysabri lost improp store result hurrican sandi replac cost sent direct infus center to see full list pharmaceut assist program contact inform pleas visit httpswwwmymsaaorgaboutmssourc the american red cross salvat armi communiti food bank state offic emerg disast center organ unit methodist committe relief set throughout countri assist peopl crisi contact inform servic avail telephon inform search internet to follow specif contact servic american red cross wwwredcrossorg red cross salvat armi wwwsalvationarmyusaorg state offic emerg manag httpwwwfemagovregionaloperationsstateofficesandagenciesemergencymanag unit methodist committe relief deliv health sanit kit well homerepair casemanag servic wwwumcororg articl unit methodist committe relief help disast httpwwwumcororgumcorresourcesnewsstoriesoctoberhowtohelpdothisnotthat fbi tip page avoid disast relief donat scam httpwwwicgovmediaaspx new jersey new york among state sever affect hurrican sandi to follow state servic may assist new jersey nj state offic emerg httpwwwstatenjusnjoem nj disast center provid link feder state disast center resourc httpdisastercentercomnewjersynewjersyhtm communiti food bank new jersey food resourc coordin fema food new york new york state offic emerg httpwwwdhsesnygovoem new york disast center httpdisastercentercomnewyorknewyorkhtm american red cross new york httpwwwnyredcrossorg nyc food bank also help relief effort httpwwwfoodbanknycorg for inform assist individu ms famili member member ms communiti may contact msaa helplin email msaa',\n",
       "  'NN'),\n",
       " ('last week discuss inject medic this week let discuss oral medic option avail oral medic didnt hit market recent befor peopl ms stuck inject option clear ideal as patient would hear oral medic option someday futur didnt know would actual happen until eventu gilenya approv fda current three oral medic market approv relaps remit ms let take closer look medic gilenya gilenya new class medic call sphingosin phosphat receptor modul that mouth scientist think work keep certain white blood cell lymph node therebi make imposs cross blood brain barrier get central nervous system make cell cannot get central nervous system reduc inflamm damag nerv cell in sever studi done gilenya shown effect gilenya cut relaps compar avonex one year studi it also prevent relaps compar placebo two year period the fda approv use gilenya relaps remit ms there sever side effect associ gilenya headach slow heart beat weak fatigu infect elev liver enzym diarrhea note an uncommon side effect macular edema swell area retina respons central vision gilenya also known slow heart rate signific especi first month treatment an individu also might feel realli tire heart palpit chest pain feel dizzi usual someon experi symptom disappear within first day two treatment in fda updat regul around patient first dose gilenya it requir individu ecg receiv first dose six hour first dose is also recommend first dose taken medic observ this due patient unfortun pass away late take first dose gilenya as far i know definit link gilenya tecfidera tecfidera also known dimethyl fumar oral medic taken twice day specif develop peopl relaps remit ms a similar chemic compound call fumaderm use germani mani year treat flare psoriasi the specif way tecfidera work still unknown scientist think activ certain pathway bodi help protect nerv cell damag inflamm in one studi two year period peopl take tecfidera experi relaps compar peopl placebo group tecfidera approv fda use relaps remit ms common side effect tecfidera includ flush stomach pain nausea diarrhea side effect seem present begin treatment dissip treatment progress there case pml report patient take tecfidera actual pml rare dead brain diseas happen individu take immunosuppress medic in order develop pml individu must posit jc virus first routin blood test monitor jc virus status recommend take ms med aubagio aubagio also known teriflunomid pyrimidin synthesi inhibitor it work reduc number white blood cell central nervous system decreas inflamm overal protect nerv peopl ms in sever studi aubagio proven effect placebo reduc relaps reduc disabl progress show decreas brain lesion aubagio approv fda use relaps remit ms common side effect aubagio includ headach nausea hair loss diarrhea elev liver test like symptom numb tingl hand feet less common serious side effect includ elev blood pressur increas risk infect liver damag while take aubagio need regular blood test monitor liver function blood cell count aubagio also associ sever birth defect neither women man take aubagio pregnanc plan aubagio remain bodi two year discontinu medic special treatment may need remov drug system your plan becom pregnant usual take medic requir individu effect birth control method i took aubagio year unfortun i went treatment alreadi activ diseas state two relaps take medic i like i could take pill instead daili inject previous copaxon i soon experienc side effect lot hair loss irregular blood cell count due relaps i eventu chang medic the arriv oral medic welcom relief mani ms patient they repres constant advanc research develop hope futur bring mani option tabl',\n",
       "  'NN'),\n",
       " ('thank repli label intraven cladabrin avail nhs hospit even hospit tend favour mitox also mavenclad ocrelizumab dispos rrms progress ms would favour case delet repli repli mousedoctor wednesday novemb pm iv clad sub cut clad avail use sub cut easier maven v ocrelizumab good drug you talk pwms find suit i person think moa similar delet repli repli mousedoctor wednesday novemb pm i believ stay away mitox cancer risk',\n",
       "  'JJ'),\n",
       " ('yes i us ani doctor avail make comment thank diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('i poor experi gilenya in i well tysabri pml risk high my doc switch gilenya i relaps next month i put back tysabri despit high pml risk never fulli recov two relaps subsequ learn i sustain perman heart damag gilenya when pml risk went roof earli doctor refus tysabri i desper stabil ms i travel us germani lemtrada i look way get wors after rough month heavi fatigu ms start stabil improv i stun ms never realli improv get major relaps might recov loss back total new thing improv i deal long time immens fatigu cognit problem pain issu jump muscl eye sight pupil stop constrict oh relief sunni day so mani i would strong urg consid lemtrada time chang i would happi talk lemtrada read blog first year lem lemtradablogspotcom fellow member tracyd also lemtrada blog lemtrada strongest medicin fight back ms if spare week life get medicin basic wait work day year later but dont take pill everi day medicin bodi week keep work keep ms bay best wish search right treatment take care emma',\n",
       "  'JJ'),\n",
       " ('i diagnos stage a adenocarcinoma i enrol clinic trial tecentriq initi treatment week apart follow surgeri the patholog report show posit lymph node negat treatment i continu treatment prevent recurr no major side effect my sisterinlaw small cell chemo went remiss evid diseas month cancer back spread bone liver brain so i would take drug',\n",
       "  'JJ'),\n",
       " ('doctor i togeth decid begin copaxon mg copaxon mg year gilenya year surviv viral enceph drug almost immedi joint began stiffen becam pain much lift use hand difficult it feel like i arthriti joint the nurs ms clinic inform report side effect now tri detox bodi',\n",
       "  'NN'),\n",
       " ('apolog gilenya', 'NN'),\n",
       " ('hi i thought cladribin relaps remit ms peopl sp still relaps as far i understand idea work lymphocyt target bad bit immun system attack myelin relaps but peopl whove know meanwhil tri research drug might eas anxieti either youll decid drug cope one way carol said tri get stress stress ms realli dont go well togeth sue',\n",
       "  'NN'),\n",
       " ('i would make appoint gi asap technic inflectra isnt ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra i idea honesti but better nd rd infus i would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('hi im new shift ms im need advic regard treatment when i diagnos i put tecfadera gave terribl side effect i move aubagio which fail miser i relaps month year so i got letter say i could move gilenya tysabri lemantra but i psoriasi neuro look one would treat he ask dermatologist that possibl i heard say im probabl go give gilenya my question i say im keen choic im worri side effect macular oedema i virtual lost sight eye due optic neuriti i lose licens i live farm mile anywher can i ask differ one the ms nurs sent inform treatment letter im lean toward tysabri but like i say i dont know choic ani help would great i feel confus im worri progess i need relaps stop thank',\n",
       "  'NN'),\n",
       " ('hi jacki ive heard correl per se take afatinib progress tarceva hasnt shown effect stop cancer progress vice versa if tm mutat acquir tarceva afatinib there good chanc tagrisso efficaci correl time unknown the mechan resist tagrisso new much understand yet you didnt ask i wont hesit tri guess els may help think bonus this video excel explan nsclc specialist today patient whove begun show progress tarceva httpcancergraceorglunggcvllucombinationsotheroptionsegfracquiredresist all best janin',\n",
       "  'NN'),\n",
       " ('fda accept prioriti review supplement biolog licens applic sbla eylea treatment diabet retinopathi patient regeneron report second quarter financi oper aug the compani recent submit supplement biolog licens applic sbla eylea treatment diabet retinopathi regeneron pharmaceut inc nov vein occlus diabet macular edema dme well design treatment diabet retinopathi patient dme regeneron report fourth quarter full year financi feb initi phase studi treatment diabet retinopathi patient without diabet macular edema dme regn pdgfrbeta unit state secur and exchang commiss visual acuiti defin total number letter read correct earli treatment diabet retinopathi studi etdr chart standard chart use download doc visual acuiti defin total number letter read correct earli treatment diabet retinopathi studi etdr chart standard chart use regeneron report first quarter financi oper may in march us food drug administr fda approv eylea treatment diabet retinopathi patient diabet sec file regeneron pharmaceut inc report oneyear data phase panorama studi treatment non prolif diabet retinopathi patient without diabet macular edema sec file regeneron pharmaceut inc apr the compani expect expand ocular program includ addit indic diabet retinopathi dr excess regeneron pharmaceut inc form k may diabet retinopathi patient diabet macular edema dme sponsor diabet retinopathi clinic research network',\n",
       "  'NN'),\n",
       " ('hi im travel spain month student visa im remicad everi week no intern health insur ive call cover biolog remicad my statesid health insur reimburs i need know cost doe anyon know cost either follow medic per mg vial spain remicad remsima inflectra someon must taken medic spain without insur i cant find inform anywher els internet thank',\n",
       "  'NN'),\n",
       " ('on jul am mikeandcarolyn wrote hi laura thank repli are take doxycyclin day take my husband take morn empti stomach water he take tarceva pm do take togeth also time take ondansatron take are use lotion cleaner tha work thank agian in christ carolyni havent yet start chemo i also take doxycyclin twice day the instruct leaflet say alway taken meal full glass water prevent irrit eosophagus also taken even food least two hour bed the direct also say taken upright posit hope help x',\n",
       "  'IN'),\n",
       " ('i diagnos crohn month ago remicad sinc april my insur recent switch inflectra cuz yay i first inflectra infus past friday felt sinc today i nauseat lighthead i hold wall support cuz i feel like im go fall it intens rn husband offer take er i dont know reaction inflectra crohn symptom i havent other ive felt general weak fatigu sinc infus usual im tire rest day mayb hour never long i feel kind like i i adjust imuran i start novemb ani idea',\n",
       "  'JJ'),\n",
       " ('sorri delay repli i difficulti figur repli post in repli question biopsi m negat taken progress tarceva i watch video youtub dr west show promis tagrisso negat m patient also mention two trial recruit negat m patient ani addit comment',\n",
       "  'NN'),\n",
       " ('click receiv ms news via email the stori show written ms patient name laura to fulli understand titl blog post pleas read laura entir stori make sens cost effect in ms treatment when i question explan given fair predict negoti payment insur go pay much would signific reduc amount eventu paid for increas bill clinic provid paid per year real cost treatment base today price still stagger amount consid i continu mental struggl whether amount money worth big pictur consid age factor is fair treatment cost affect health care dollar cost like take sizeabl chunk avail moni how much treatment affect escal cost health insur ms chronic diseas known cure i could conceiv continu treatment remaind life amass treatment cost million dollar fortun entir cost treatment cover privat health care insur along patient assist program tysabri cost i paid noth pocket year i imagin type bill part drive cost health insur i pay lot everyon els just i think i angri frustrat ms treatment cost often anoth remind escal bill usual form notic insur tell much bill actual paid today remind came differ way write dr gavin giavanonni bart ms blog written ms doctor research depart neuroimmunolog blizard institut bart the london school medicin dentistri unit kingdom in particular articl talk nice nation institut health care excel uk one function nice set price healthcar treatment includ drug cost nice decid consid fair price pay drug look option treat patient decid would cost effect govern health care system the blog author also concern afford access drug polici nice affect treatment post observ recent confer anoth groundshift poster oratorio studi result ocrelizumab ppms this studi first studi show dmt slow rate disabl progress ppms this one signific thing happen field ms last year despit i concern nice may view ocrelizumab treatment ppms favour nice alway assess costeffect use increment cost model for ppms costeffect ocrelizumab compar alreadi ie best support care their write think treatment cost i also wonder i could put price might cost provid support care compar money spent drug for i would need much way help money could spent someon els but pictur could chang quick ms progress i treatment i found depend health care servic activ daili live would amount money take care i nurs facil in averag daili cost nurs home care day just think money would save somewher someon decid cost effect tysabri show health care money would better spent put nurs home read question bart ms blog make concern us cost effect model might what need control drug cost us in way insur compani alreadi form often deni treatment author certain drug reimburs the topic cost effect one core point list north american registri care research multipl sclerosi narcrm project major initi us part canada look link patient clinic data togeth health care econom core will identifi inform collect databas regard disabl util health care resourc employ help better understand whether use expens therapi worthwhil econom standpoint save fewer hospit less disabl longer employ span decreas util health care resourc unlik system uk help cost live hous transport medic care peopl need due financi demand live chronic ill dont broad rang assist us my health insur would pay live cost pay drug be financi respons leav littl choic i continu treatment despit escal cost linger question best avoid futur care need i would pay resourc in meantim i hope next bill i open doesnt caus requir treatment choke price well laura httpinsidemystorycom ms view news provid educ inform resourc servic affect ms',\n",
       "  'NN'),\n",
       " ('hi janin sorri late repli i ask echo make sure chf insist pleas thoracentesi make sure cancer mom thoracentesi biopsi fluid show cancer she also echocardiogram done last thursday normal age accord cardiologist the fluid visibl echo pleura so suspicion right heart fail due fluid overload everytim cancer back mom alimta week ago schedul anoth infus wednesday her breath improv usual alimta remark better even one session time worrisom keep finger cross work so glad see husband remain ned met friend yesterday whose mother remain ned year initi treat stage diagnosi that gave hope thank write take care bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('i recent start gilenya due major issu side effect i stop day it suggest i take tecfidera i wonder anyon experi two best wish sarah',\n",
       "  'VBP'),\n",
       " ('februari roch today announc us food drug administr fda accept compani new drug applic ndas grant prioriti review entrectinib treatment adult paediatr patient neurotroph tropomyosin receptor kinas ntrk fusionposit local advanc metastat solid tumour either progress follow prior therapi initi therapi accept standard therapi treatment peopl metastat rosposit nonsmal cell lung cancer nsclc these ndas base result integr analysi pivot phase ii startrk phase i startrk phase i alka trial data phase iib startrkng studi the fda expect make decis approv august read roch press releas',\n",
       "  'NNS'),\n",
       " ('how long remicad ive almost year curious work fellow crohni', 'VBP'),\n",
       " ('hi gate lemtrada experi inspir i go ask move gilenya lemtrada noth work far copaxon tysabri gilenya i tri get lemtrada next appoint ive decid sure read good report thank updat i hope i happi lemtrada',\n",
       "  'JJ'),\n",
       " ('hey everybodi wonder anybodi thought dealt fertil issu duringaft melanoma treatment my husband went braf inhibitor unabl go sperm bank beforehand accord sideeffect drug make person infertil befor got sick hope kid someday i turn hes mid right still middl cancer treatment he high tumour burden still sure keytruda work although thing look cautious optimist symptom stabl even slight improv and even keytruda work know chanc complet respond pretti low consid serious diseas but still have think futur stay posit right so i find wonder whether ever kid situat stabil has anybodi els dealt someth like what i wonder i go like get egg frozen someth i dont even realli know mean our sex life nonexist month low testosteron lot pain killer hes unabl go hormon replac therapi pretti sure tradit way wouldnt work us anyway',\n",
       "  'RB'),\n",
       " ('by youv read anyth blog know i daili writer ive written journal year i stack stack paper book full scribbl these day i use actual app i journal anyth phone comput ipad along precious aka therapist cheryl i dont much hope remain quasisan without daili journal write cathart it someth i i need i want i cant so imagin happi make guy tell like read someth ive written it beyond anyth i could ever wish i start put person write blog i need communiti i need find peopl like i could learn real peopl real ms bound much better manag diseas i present i great doctor i realli shock day the great scott clear one best among ms specialist still doesnt quit get i know everi time ask when last walk mile maribeth i resist throttl most i like i need big brain unless ms cant possibl understand feel like you empath listen love help im grate around thing consist everi singl day but also need communiti so i found one prop httpwwwtrippingonaircom origin inspir take write public you check she win award stuff one person favorit ms blogger all said i still write journal thing i need deal write first foremost thing privat believ i keep thing privat not much but small topic after infus new goo ocrevus newbi i found struggl write musion my newest infus would next logic blog post i went bed tire bone juic abl sleep so i i usual happen i wrote journal this morn id read i wrote last night made realiz i need share well it best descript i could give i felt infus so im repeat verbatim edit there probabl million writer mistak includ i first apolog marathon long blog post folk get whole thing might super human peopl general like short pithi post tip hack whatev that oh well gotta so it infus day today big number i havent blog yet want talk im alreadi bed late get maximum rest attempt shower and get offic tomorrow brain overdr probabl tini pinch steroid inject bloodstream today make sleep elus it would notabl i accomplish amaz feat i mention id hope get littl boost i got ocrevus last time realli first time im feel unrealist optimist i stupid thing thing like email entir staff tell im go focus get offic infus day number bag i may may commit offic tomorrow the first day big near hour day allegheni general infus center not smart i no arent smart beth i feel like i need kick ass hit restart i gave day big infus day number two stop believ bodi simpli cant oper outsid world regular slight abil challeng human today hour i feel like i tri harder make happen stop brain undermin everi singl littl thing life the trick figur without tri hard i kick back relaps or fall or end hospit it realli difficult determin line my nose still bit purpl it liter plain nose face one might say push far without realiz dire consequ how far far i honest dont know scare but there feel come the feel good day i havent one quit hasnt long ive forgotten feel like it specif symptom it i feel feet hit floor morn i walk littl easier it sudden burst energi it lighten bolt look back day realiz werent pop advil like skittl it like slow realize pain sudden quit pain it feel light a feel safeti a feel peac it never last long least late but good place those day ms quiet the thing i alway fail realiz good day constant nois head somehow it usual run loop brain daili i cant i cant i cant i cant i cantwhat alway alway alway alway alway hurt hurt hurt hurt hurt i wont i wont i wont i wont i wont repeat that voic allow ms put veil life make everyth slight less vivid slight less clear slight less appeal slight less possibl i dont know stop voic im probabl stupid give kind clear line person sand test to forc action to present actual date take shower leav hous on the same day believ work work allow scare it sound inspir like much bullshit it could actual be hard i might get shower tomorrow feel like limb sudden made cook pasta i might fall feet hit floor i get bed the world around could sudden spin like craze whir bird i might throw i might someth entir brand fuck new like abl see right one side entir bodi sudden go complet numb ani could happen that crazi ass mess diseas actual bodi and entir uniqu differ us we relat us strang club call multipl sclerosi digit friend it help know someon els similar thing happen one timebut goe far your ms ms look face make kind friend everi day complet utter surpris i liter idea minut minut second second moment moment central nervous system cook girl friday immun system i accept i almost two year mess im shock i still havent accept listen here bottom line everi day complet utter surpris even peopl dont ms my unpredict almost better normal i mean mine name their call life holi shit that scariest diseas also chang moment moment i use one normal know i felt i thought i knew life would chang million differ reasonsi plan i reason smart i work hard made import plan i would tell good kind love human i would happi littl place world thing would go way they part easi myth believebut i didnt know none us first fuck clue what go happen day week we think i know mayb i look name diseas face accept chao i begin accept diseas isnt alway ugli it facet eccentr like i think i know go it go destroy it simpli that exist but mayb there mayb diseas teacher mayb i learn stop think teacher mindless dolt start listen or mayb i cant i honest dont know point person evolut i idea what go happen next and neither anyon els this might sound crazi that part make feel better that i know fact gospelaccordingtobethtruth we never know we never known it alway complet crap shoot and still will i shower go work offic tomorrow triumph gauntlet i threw the truth i dont know i know i tri that i know certain post script my origin plan over ambiti my day start today phone call am call call call pm i still hadnt shower brush teeth i make import thing happen call didnt feel like failur i suck accept i over ambiti it good thing becaus i final shower around pm shower kick mshave ass i never would abl get done i got done today i attempt go offic earli shower i foolish plan day rough infus experi i know take time new goo make magic im head but im final physic clean im go offic tomorrow babi step still step right direct im give much need pass hold commit today in end im tri im tri hard that enough',\n",
       "  'IN'),\n",
       " ('leo wow touch choic i know opdivo fda approv treat small lung cell recurr follow convent chemotherapi ive abl find inform advantag pair opdivo yervoy offer im sure medic oncologist abl provid data full disclosur ive experienc immunotherapi treatment two repeat convent chemotherapi taxol carboplatin my experi repeat convent therapi affect tumor elimin reduc size third elimin stubborn tumor my repeat radiat actual precis radiat cyberknif fri stubborn tumor it look like three small tumor i know folk whove precis radiat fri multipl tumor good result you might includ precis radiat potenti treatment id get precis radiat answer radiat oncologist stay cours tom',\n",
       "  'JJ'),\n",
       " ('diet supplement chang life got steroid first time four year i still need remain medic though im vedolizumab well mesalazin azathioprin it proven best treatment i radic chang approach nutrit i remain ill wingman proctiti need fix get bad fast realli realli unpleas i mistook terribl flair ive alway found mesalazin enema effect though administr isnt pleasant the nhs dont want medic drug cost fortun immunomodul particular unfortun diseas individu unpredict well understood follow protocol see diseas give medic still see diseas give stronger medic were told diet isnt big part i believ year now i think dont yet enough inform tell patient anyth els i saw nutritionist told asid avoid trigger tri vsl diet noth all i say goe bodi singl greatest impact sever diseas unfortun ibd still mani question mark lucki drug sometim help us avoid danger procedur remov mani variabl manag constant balanc act anyway good luck',\n",
       "  'NN'),\n",
       " ('is one patient bridg fingolimod', 'NN'),\n",
       " ('it strang coupl day im final abl start take high dose biotin if read thread biotin mani most show biotin walk speed increas seven second this accord neurolog test doctor howev ive state i still stand biotin help besid notic weak leg hip area hand also give problem sinc i problem hand time anyway i havent paid much attent yesterday i realiz much wors it got think mayb i start take biotin might improv biotin vitamin in opinion could hurt tri howev im doctor need check doctor so ive put univers possibl companion life the intent signific partner fall love mayb i readi despit ms i gave univers know full well i cant alon ive made mani mistak so somebodi wrote via letgo the websit like ebay sell stuff who pick somebodi site like then googl plus somebodi sent email tri pick the guy cute pictur i said i could email backandforth could hurt so thing call hang like googl chat and chat backandforth coupl day all fine littl weird call honey babe realli nice dont even know i dont like but yesterday wrote i realli love context friend kind way said my repli peopl dont talk like i block note univers i know i said chanc meet im go date site ridicul im go mention guy told govern incub children rais armi like clone war star war yesterday i get email mom say awar new drug call ocrevus it recent came multipl sclerosi suppos good i call mom im like hi nice meet know anyth dont rememb i rituxan sister drug switch ocrevus wasnt cover insur i switch get cover then mother final goe oh yeah sound familiar it funni proof doesnt read blog defens get live version time day via phone happi friday',\n",
       "  'NN'),\n",
       " ('did quick search longterm outcom ra patient treat rituxan didnt find mention uptick cancer im wonder though compar rituxamab ocrelizumab might direct comparison certain differ appl orang mayb tri compar macintosh appl golden delici appl what i mean although rituxamab ocrelizumab erad cd cell someon differ mechan action it possibl differ account ocrelizumab higher efficaci may also contribut possibl peril safeti profil after ocrelizumab ra trial halt due opportunist infect patient death wherea rituxan use success safe treat ra year this would seem indic differ bodi react two drug this may similar tysabri dramat higher risk pml compar t cell drug tysabri mechan action certain lead higher risk pml compar drug like gilenya keep t cell cns so higher risk pml tysabri on differ note dr g would will interview wheelchair kamikaz blog post would love talk therapeut lag implic treat progress ms patient we could short telephon interview i call i run transcript blog post therebi allow explain theori straight hors mouth we could also talk topic inclin i think would tremend valu reader would give theori wider exposur among patient popul certain deserv thank everybodi involv blog ms communiti',\n",
       "  'VBZ'),\n",
       " ('it seem condit autoimmun inflammatori uc possibl remicad may treat know certain valid point concern wait see hope best unfortun us even autoimmun diseas categori isnt enough moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g lialda x rowasa im speed i poop realli realli bad',\n",
       "  'JJ'),\n",
       " ('alain thank comment yup bionx system i want look i see rl kit dl tour slight differ price i cant figur differ do one that use inform possibl adjust weaker leg i see batteri fit boom i shorten consider accomod fivefootnoth frame i see also mount rear tube dont know would affect ride weight one side instead center boom so good thing research ani info give i thank take glad ocrevus posit result must joy finger cross continu be thank dream big never give up',\n",
       "  'NN'),\n",
       " ('ann im sorri hear lung cancer diagnosi broken femur ordeal go thru are met leg bone vertebra new sinc begin treatment i assum recent pet scan follow recent one serv base line my mom receiv session carboalimtakeytruda lung cancer recurr she continu keytruda near year it work well great candid keytruda pdl level she evid diseas near year keep finger cross receiv latest ct result hour like tom said weird thing pop earli treatment immunotherapi pet scan show activ area that organ light activ as tom said activ leg could due activ heal process but time tell my mom wait see program she wait see prior initi diagnosi see lung nodul grew wait see scan hope show cancer return it horribl part diseas but great hand immunotherapyit great thing lot peopl give time get work in meantim continu regular appoint i assum get blood test report side effect troubl issu they keep close eye thing new plan attack ifwhen need take care steff',\n",
       "  'NN'),\n",
       " ('appar peopl spms use ocrevus interest possibl hasnt mention articl appear medic period ms diagnos avonex copaxon member ms board sinc repli with quot the follow user say thank howi jeani z sunshin',\n",
       "  'IN'),\n",
       " ('thank pennstat kimba im sorri jump thru hoop get ocrevus i know frustrat i hope work im sorri ms neuro die yes scari start new med especi read report marco post',\n",
       "  'NN'),\n",
       " ('i dont think fact right biogen ms the rather deep pipelin ms space poach back one exstaff run earli ms develop pipelin biogen ms compani give you also need rememb take big slice ocrelizumab sale ip came biogen via idec',\n",
       "  'NN'),\n",
       " ('lancet jan oral fingolimod primari progress multipl sclerosi inform phase randomis doubleblind placebocontrol trial lublin f miller dh freedman ms cree ba wolinski js weiner h lubetzki c hartung hp montalban x uitdehaag bm merschhemk m li b putzki n liu fc hring da kappo l inform studi investig author inform the corinn goldsmith dickinson center multipl sclerosi icahn school medicin mount sinai new york ny usa electron address queen squar ms centr ucl institut neurolog london uk the ottawa hospit research institut univers ottawa ottawa on canada multipl sclerosi center univers california san francisco ca usa univers texa health scienc center houston houston tx usa brigham women hospit harvard medic school boston ma usa univers pari salptrir hospit aphp center clinic investig pari franc depart neurolog medic faculti heinrichhein univers dsseldorf germani hospit universitari vall dhebron barcelona spain vu univers medic center amsterdam netherland novarti pharma ag basel switzerland novarti pharmaceut corpor east hanov nj usa depart medicin clinic research biomedicin biomed engin univers hospit univers basel switzerland background no treatment approv primari progress multipl sclerosi fingolimod oral sphingosin phosphat receptor modul effect relapseonset multipl sclerosi assess primari progress multipl sclerosi we assess safeti efficaci fingolimod patient primari progress multipl sclerosi method in inform multicentr doubleblind placebocontrol parallelgroup studi patient primari progress multipl sclerosi recruit across centr countri random alloc computergener block receiv oral fingolimod placebo least month maximum year patient initi assign fingolimod mg per day placebo cohort howev protocol amend nov patient switch mask manner fingolimod mg wherea placebo continu match placebo from onward patient assign receiv fingolimod mgday placebo cohort key inclus criteria age year clinic diagnosi primari progress multipl sclerosi year diseas progress two follow criteria posit brain mri posit spinal cord mri posit cerebrospin fluid addit elig criteria includ diseas durat year object evid disabl progress previous year patient studi investig mask group assign we use novel primari composit endpoint base chang baselin expand disabl status scale edss timedwalk test ninehol peg test assess time month confirm disabl progress studi particip treat least year all randomis patient took least one dose studi drug the primari efficaci analysi includ patient cohort assign placebo cohort the safeti analysi includ patient cohort this studi regist clinicaltrialsgov number nct the studi close find patient random assign sept aug fingolimod mg placebo cohort fingolimod mg placebo cohort the efficaci analysi set n consist patient random alloc fingolimod mg placebo baselin characterist similar across group repres primari progress multipl sclerosi popul women mean age year sd mean edss sd free gadoliniumenhanc lesion by end studi month confirm disabl progress occur patient fingolimod placebo group respect result kaplanmei estim ci patient fingolimod group versus patient placebo group risk reduct hazard ratio ci p safeti result general consist studi fingolimod patient relapseonset multipl sclerosi lymphopenia occur patient fingolimod group versus none placebo group bradycardia five versus one firstdegre atrioventricular block three versus six serious advers event occur patient fingolimod group placebo group includ macular oedema six versus six basalcel carcinoma versus nine interpret the antiinflammatori effect fingolimod slow diseas progress primari progress multipl sclerosi therapeut strategi primari progress multipl sclerosi might need differ approach use relapseonset multipl sclerosi fund novarti pharma ag',\n",
       "  'NN'),\n",
       " ('heeeey fellow chroni im julian australia melbourn year old this first time post im desper need advic approach befor start remicad take azathiorpin allopurinol my gastro doctor told sever case crohn diseas base inflamm via colonoscopi crp level around mark faecal calprotectin littl my result chang treatment doctor consid remicad battl sever malnutrit nasti common symptom crohn diseas i put remicad desper oh miracl drug it month im almost complet remiss scope crp faecal calprotectin level back normal clear i experienc littl side effect remicad consid lucki for first coupl month doctor recommend take remicad mp prevent bodi build antibodi sooner combo effect liver level doctor want mri liver found mild case psc primari scleros cholang form liver diseas my doctor took mp liver level went straight back normal stay remicad alon it truli work wonder cant thank far but cant help think scari side effect take medic long term which bring back titl thread im almost complet remiss scope result clear normal symptom i hope could talk doctor lower dose minim risk long term use remicad anoth altern someon give anyon repli would great appreci god bless everyon battl terribl diseas',\n",
       "  'NNS'),\n",
       " ('hi sorri hear go shock diagnosi as other said give time come term when i diagnos almost year ago i denial i attitud i forget might go away it best part year i got relaps i put lot stress definit tri avoid i put betaferon year i diagnos help control i gileni sinc septemb ms stabl sinc it good dmt easi take compar inject if need anymor info gilenya let know take care x',\n",
       "  'VBP'),\n",
       " ('over cours inform total durat year month includ extens phase edss deterior fingolimod effect suppress diseas activ cours studi clear contradict',\n",
       "  'JJ'),\n",
       " ('you would stop natalizumab would transit onto anoth therapi the latter could oral cladribin ocrelizumab fingolimod etc or jcvnegat stay natalizumab',\n",
       "  'NN'),\n",
       " ('it fallaci argument impli work someon els know mean work convers side effect list experienc someon know reason someon whose medic histori circumst unfamiliar go experi orlando less enlighten amongst us perhap could expand sourc claim are refer paper jone et al httpbrainoxfordjournalsorgcont and six year rounder view emerg this doesnt say lemtrada gilyena bad put context around it broad good in journal therapeut advanc drug safeti sage recent paper entitl benefit versus risk latest therapi multipl sclerosi perspect review there prelicens articl httpwwwncbinlmnihgovpmcarticlespmc and forth the point context everyth alemtuzumab good drug right circumst patient meet right criteria there plenti thing make patient unsuit likewis gilenya i believ recent post admin advoc particular cours action have good even best dom',\n",
       "  'NN'),\n",
       " ('kw sinc neuro doesnt prescrib inject littl comment regard say older drug approv noth els avail there legitim question came market today would get fda approv certain question you ask good question long peopl recommend stay tysabri jcv negat biogen doesnt make treatment recommend decis doctorpati domain vari individu circumst one popular fals internet rumor biogen doesnt recommend stay tysabri beyond two year i call biogen told biogen make treatment recommend so rumor fals you ask long peopl stay tysabri jcv negat standard length time the jc virus caus pml if jc virus cannot get pml but fals negat test happen in word jcv antibodi titer threshold negat rang indetermin posit negat btw even negat peopl found jc viremia present and coupl peopl test jcv negat get pml i believ obvious posit rememb jc virus alon caus pml test negat fals negat pleas ask neuro ok out approx chanc test negat jcv get pml quit small keep mind get test everi month tysabri chanc fluke test test negat actual posit diminish to test may unlik subsequ consecut test a negat test sever time row would suffici proof i negat fall stat peopl taken tysabri develop pml die result pml again check doctor doe risk chang time jcv negat interest question time element age exposur peopl chang jcv jcv noth unusu get older exposur possibl infect jcv unknown origin everi type jcv but cannot get pml jcv remain second ask tysabri med mser put fail therapi yes often case alway treatment philosophi come play some neuro want aggress right away stop ms track soon possibl other neuro prefer wait see ms get bad go higher risk higher reward dmt like tysabri obvious patient person risk profil factor can sleep decis make it got pass sleep test neuro perhap neuro see suspect ms high activ want treat aggress be sure ask talk lean toward tysabri third outofpocket cost biogen copay assist program almost everyon qualifi toward medicin anoth infus it use make less k per year even higher im sure just call biogen fill straight with insur copay biogen pay they also assist toward infus cost be sure call biogen ask assist program state allow ive heard coupl fourth come tysabri trigger relaps yes mean instanc but techniqu mitig elimin develop it use long washout standard go anoth medicin howev found shorter wash period less like relaps occur last i would say tysabri tremend effect slow diseas progress my wife tysabri sinc except period market due pml concern she remark good health jcv posit sinc first test jcv develop year ago the major techniqu derisk pml sinc jcv extend time dose the theori tysabri diminish satur time allow immun surveil jc virus so far last fall zero case pml mser go week infus case pml control group number standard dose week so appear though extend time dose benefici trial ongo neuro chang clinic practic data publish peerreview adopt possibl peopl high activ ms may abl go beyond week also littl need go beyond week first two year tysabri whether jcv negat pml risk low first two year treatment im sure seen chart estim pml risk if might want googl bart ms research blog find pml risk chart if go site also pleas check charcot project they seek viral caus ms need consider support tysabri risk pml ms also huge risk treat effect treatment decis doctorpati make togeth those opt fda approv med educ ldn lowdos naltrexon imo last thought ocrelizumab new impress med phase trial like get fda approv late thereabout some neuro may choos med like tysabri know present littl risk pml first two year plan switch ocrelizumab becom avail may want stick tysabri proven superb track record effect littl pml risk patient remain jcv in patient ive seen spoken regular year infus center side effect tysabri larg nonexist that person observ pleas discuss side effect doctor other tysabri hope offer experi thread also mani mser jcv choos remain tysabri accept risk pml tysabri halt diseas progress just thought best',\n",
       "  'JJS'),\n",
       " ('reallif observ studi denmark compar clinic diseas activ individu treat natalizumab versus fingolimod individu began treatment either drug first secondlin treatment juli march prospect record danish ms treatment regist two group propens score match',\n",
       "  'NN'),\n",
       " ('hertfordshir england pittsburgh pa tokyo prnewswir mylan nv nasdaq myl fujifilm kyowa kirin biolog co ltd today announc european commiss ec grant market author hulio product code fkb biosimilar abbvi humira adalimumab indic the author follow adopt posit opinion committe medicin product human use chmp conclud develop program includ analyt function clinic immunogen data demonstr biosimilar refer product humira the ec approv hulio appli european union eu member countri european econom area eea member state norway iceland liechtenstein mylan plan launch hulio across various market europ oct mylan fujifilm kyowa kirin biolog partner earlier year fujifilm kyowa kirin biolog nonexclus royalti bear licens abbvi mylan sublicens use sale hulio european countri mylan presid rajiv malik comment were pleas decis european commiss grant market author hulio this fourth product mylan bring market area complex generic biosimilar proud leader market format weve made great progress fujifilm kyowa kirin biolog look forward continu import collabor we delight hulio receiv approv european commiss said dr yoshifumi torii fujifilm kyowa kirin biolog presid ceo the ec approv hulio mark signific mileston in cooper mylan continu commit effort bring high qualiti afford biosimilar patient throughout european countri mylan europ presid jacek glinka ad biosimilar repres huge opportun europ drive better patient access high qualiti valu medic support healthcar system across region deliv ongo excel care face age popul increas stretch resourc hulio indic indic humira includ adult rheumatoid arthriti ankylos spondyl axial spondyloarthr without radiograph evid ankylos spondyl psoriat arthriti psoriasi hidraden suppurativa crohn diseas ulcer coliti uveiti children polyarticular juvenil idiopath arthriti age older enthesitisrel arthriti age older plaqu psoriasi age older crohn diseas age older hidraden suppurativa age older uveiti age older humira world bestsel biolog medic it brand sale approxim billion europ month end june accord iqvia about adalimumab adalimumab inject biolog medic inhibit tumour necrosi factor tnf this caus inflamm autoimmun diseas rheumatoid arthriti plaqu psoriasi crohn diseas ulcer coliti by specif bind tnf adalimumab block activ therebi reduc inflamm diseas symptom about mylan mylan global pharmaceut compani commit set new standard healthcar work togeth around world provid billion peopl access high qualiti medicin innov satisfi unmet need make reliabl servic excel habit what right what easi impact futur passion global leadership we offer grow portfolio market product around world includ antiretrovir therapi peopl treat hivaid global depend we market product countri territori we one world largest produc activ pharmaceut ingredi everi member approxim strong workforc dedic creat better health better world one person time learn mylancom we routin post inform may import investor websit investormylancom about fujifilm kyowa kirin biolog fujifilm kyowa kirin biolog establish fujifilm corpor presid kenji sukeno hereinaft fujifilm kyowa hakko kirin co ltd presid coo masashi miyamoto hereinaft kyowa hakko kirin march compani develop manufactur market biosimilar it pipelin includ adalimumab biosimilar hulio biosimilar antivegf human monoclon antibodi bevacizumab product code fkb drug use treat rang cancer includ colorect nonsmal cell lung cancer fujifilm kyowa kirin biolog establish centus biotherapeut ltd joint ventur develop commerci fkb astrazeneca plc by merg technolog advanc product qualiti control analysi fujifilm develop mani year photograph film busi proprietari technolog knowhow kyowa hakko kirin accumul biopharmaceut rd manufactur fujifilm kyowa kirin biolog creat revolutionari product process reduc cost product biosimilar through partnership compani develop manufactur reliabl high qualiti costcompetit biosimilar product commerci product time manner with strategi fujifilm kyowa kirin biolog aim hold lead posit expand biosimilar market you learn busi fujifilmkyowakirinbiologicscom forwardlook statement mylan this press releas includ statement constitut forwardlook statement includ regard mylan plan launch hulio across various market europ oct these statement made pursuant safe harbor provis privat secur litig reform act becaus statement inher involv risk uncertainti actual futur result may differ materi express impli forwardlook statement factor could caus contribut differ includ limit success clinic trial partner abil execut new product opportun regulatori legal impedi partner abil bring product market risk inher product develop scope time outcom ongo legal proceed includ govern investig impact proceed partner busi action decis healthcar pharmaceut regul chang healthcar pharmaceut law regul inth unit state abroad impact competit strategi competitor third parti delay prevent product introduct effect chang partner custom supplier relationship custom purchas pattern chang thirdparti relationship chang econom financi condit busi mylan partner uncertainti matter beyond control manag risk detail mylan file secur exchang commiss mylan undertak oblig updat statement revis chang date releas',\n",
       "  'NNS'),\n",
       " ('so anoth year end still new treatment approv progress ms surpris same old stori what happen great ocrelizumab big talk no action the monke song lyric too much talk enough action someth go but',\n",
       "  'VBP'),\n",
       " ('ocrevus potenc bomb bomb blow patient face upper respiratori fatal infect probabl the side effect drug way intens rtx accord patient descript is reason intens patient suffer question i doubt',\n",
       "  'JJ'),\n",
       " ('it look like ocrelizumab first approv treatment ppms although idea date yet httpswwwmstrustorgukazocrelizumab',\n",
       "  'NN'),\n",
       " ('new diabet diabet retinopathi research indic peopl type diabet intens control blood sugar level landmark a ction c ontrol c ardiovascular r isk d iabet accord trial eye studi cut risk diabet retinopathi half followup analysi call accord followon eye studi accordion conduct four year stop intens blood sugar control regimen requir accord trial this studi send power messag peopl type diabet worri lose vision said dr emili chew studi coauthor deputi director nation eye institut divis epidemiolog clinic applic wellcontrol glycemia blood sugar level posit measur last effect eye health pleas note howev cautionari issu unresolv causat factor relat blood sugar glycem control group origin accord studi discuss reader evalu care discuss physician about research diabet care this new diabet retinopathi research entitl persist effect intens glycem control retinopathi type diabet action control cardiovascular risk diabet accord followon studi publish juli edit diabet care peerreview journal publish month american diabet associ ada diabet care journal health care practition intend increas knowledg stimul research promot better manag peopl diabet the author emili chew md nation eye institut action control cardiovascular risk diabet followon accordion eye studi group action control cardiovascular risk diabet followon accordion studi group some explan terminolog the accord trial the accord trial involv studi site across north america enrol particip type diabet the purpos accord trial test three treatment strategi reduc risk cardiovascular diseas among peopl longstand type diabet maintain nearnorm blood sugar level intens glycem control improv blood lipid level lower ldl bad cholesterol triglycerid rais hdl good cholesterol lower blood pressur editor note the treatment phase glycem blood sugar control portion accord plan last year stop year due increas death among particip intens glycem control group analys thus far determin specif caus increas death howev benefit intens glycem therapi must weigh potenti risk notabl increas risk death observ accord trial the accord trial eye studi analyz subset trial particip receiv laser photocoagul vitrectomi prolif diabet retinopathi data begin year four studi accord sponsor nation heart lung blood institut collabor nation institut diabet digest kidney diseas nation institut age nation eye institut center diseas control prevent you read accord trial the nation institut health clinic trialsgov the accordion followon eye studi accordion followup assess diabet retinopathi progress peopl particip accord accordion reassess diabet retinopathi approxim four year intens glycem control portion studi end eight year enrol accord by time averag ac see explan percent intens therapi group percent standard therapi group howev diabet retinopathi advanc percent particip intens therapi group sinc enrol accord compar percent standard therapi group accordion fund nation heart lung blood institut part nation institut health type diabet type diabet former call adultonset type ii noninsulin depend follow characterist it usual occur age affect individu diabet it occur pancrea produc enough insulin insulin defici bodi cell abl use insulin correct effici insulin resist condit present glucos continu rise bloodstream suffici level insulin avail open cell allow glucos enter initi manag weight loss physic activ effect meal plan for individu suffic period time diseas progress howev oral medic insulin may also requir primari risk factor includ increas age ethnic background africanamerican latino nativ american asian famili histori obes you learn what is diabet the ac test the ac blood test also known glycat hemoglobin hemoglobin ac hbac primari tool use diagnos diabet prediabet monitor blood glucos control peopl type type diabet this test enabl health care provid diagnos diabet treat complic occur diagnos prediabet prevent delay develop type diabet you read establish ac level use diagnos diabet prediabet diabet signific ac test about research excerpt intens diabet treatment prevent damag vision unit press intern intens treatment diabet help prevent damag blood vessel retina often lead blind accord longterm studi nation institut health research use aggress treatment maintain glycem control blood lipid level blood pressur cut risk develop diabet retinopathi half report the research stop portion focus glycem control year plan year test increas death among particip though patient treat blood pressur blood lipid level continu rest intend test period tight control condit improv health patient reduc risk cardiovascular diseas the treatment howev reduc progress retinopathi onethird for new studi research reexamin patient took part origin accord studi measur progress particip retinopathi four year treatment conclud while measur blood glucos particip receiv intens standard care remain similar end previous studi percent particip seen advanc retinopathi less half percent receiv standard treatment whose condit progress more diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age what person diabet retinopathi may see retinopathi general term describ damag retina the retina thin lightsensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls these electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif general term mean grow increas rapid rate produc new tissu cell when term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina nonprolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild nonprolif retinopathi at earli stage small area balloonlik swell occur retina tini blood vessel moder nonprolif retinopathi as diseas progress blood vessel nourish retina becom block sever nonprolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina the damag retina signal bodi produc new blood vessel prolif retinopathi at advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreous transpar gel fill interior eye becaus new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreous scar tissu develop tug retina caus damag even retin detach more studi diabet care condens excerpt articl summari conclus full articl avail onlin our result show intens glycem control confer endur protect progress diabet retinopathi even though glycat hemoglobin level similar year random year cessat clinic trial this first studi peopl type diabet year durat establish cardiovascular diseas unlik newli diagnos particip unit kingdom prospect diabet studi ukpd demonstr effect this phenomenon call metabol memori legaci effect studi type diabet the accordion find demonstr similar legaci effect intens glycemia control progress retin diseas peopl establish type diabet moreov effect occur respons median year intens glycem control observ peopl type diabet addit cardiovascular risk factor whose mean diabet durat year whose initi mean hbac these observ suggest glucos lower reduc progress retin diseas relat late cours diabet retina respond relat shortterm chang glucos level whether even shorter period glucos lower could achiev similar longterm effect eye either type type diabet remain unknown in summari studi result provid evid intens glycem control benefici reduc progress diabet retinopathi legaci effect evid peopl type diabet the addit accordion retin result prior find demonstr posttreat benefit intens glycemia control progress eye kidney nerv diseas',\n",
       "  'NNS'),\n",
       " ('in regard last comment cours insensit downplay human tragedi but biogen built busi around ms franchis show major crack tecfidera sale way tysabri pressur ocrevus news take anoth pillar ms platform would nice start direct research find caus cure diseas that moneymak busi model better keep patient shackl obscen expens drug profound impact immun system longterm consequ complet unknown',\n",
       "  'VBP'),\n",
       " ('updat i saw ibd specialist yesterday first followup colonoscopi may nd week ago let rewind say i stress appoint afraid ibd specialist would give option i didnt like bulli pick one i wait test result honest look surgeri i tri drop mg mg prednison last monday aw i horribl withdraw symptom start bleed that defeat i knew bad sign i went back mg stabil actual badhav bms everi day requir dulcolax though much blood my tenesmus much better i havent taken bentyl week im still fatigu manag live life despit italbeitmi hous messi someth gotta give it great symptom improv sinc im depend prednison humira cortifoam realli cant consid win here thing consid discuss treatment plan i tpmt normal can metabol mp imuranso drug becam option i antibodi humirabut my humira serum level low ibd specialist crinkl nose said that anyth becaus humira level low i wouldnt wait amount time start new biolog that decid so option discuss a humira imuran b remicaid imuran i dont antibodi c stelara imuran d entyvio imuran e divert colostomi temp i heal f perman colostomi we discuss pros con treatment i wait patient ibd specialist finish make flow chart explain everyth i ask question gave input my first question am i candid jpouch and i knew answer would no correct i immedi elimin option divert colostomi state i go surgeri i would choos perman surgeri sinc that ultim i want though i disappoint jpouch option i happi ibd specialist said surgeri is good option sinc i never shown inflamm outsid colon said chanc develop diseas elsewher mayb surgeri i would need take med anymor woot ultim i want medfre diseasefre life encourag i could live life i want live ostomybar complic but im readi surgeri yet i told ive research read peopl stori im encourag even peopl complic tend happi surgeri i afraid recoveri time i see peopl feel better immedi activ within week surgeri howev im troubl get excit i want feel good im still struggl imagin life ostomi i scare complicationsif didnt turn way i plan ibd specialist total understood i told i like humira i think help mei much wors steroid aloneand i like i side effect i want tri ad mpimuran see help wean prednison so humira imuran first choic she said ok problem we elimin remicaid altogeth respons wasnt goodi still use rowasa enema if humira imuran doesnt allow get prednison chose stelara imuran next drug therapi most stelara work quick entyvio but i consid go straight ostomi humira imuran fail it realli depend thing go someth click visit when i got car leav i didnt cri feel scare confus i felt reliev becaus surgeri isnt sound bad i start posit vision life ostomi my famili go vacat june th i ask keep thing stabl i return i want enjoy ibd specialist said of cours told add imuran dont worri drop prednison i get back i appreci i blood drawn monitor june nd i see ibd specialist june th blood drawn i need get flu shot pneumonia vaccin i nervous get plane also go disneyland rememb measl outbreak mg prednison humira imuran on handmi immun system relentless im physic pretti strong right chanc good i fine but suggest stay healthi travel appreci so think guy yr femal dx uc dx chang crohn coliti current humira apriso uceri foam enema prednison buproprion synthroid start humira feb mgweek previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri im glutenfre supp vsl calmag vit d krill oil ezf iron',\n",
       "  'JJ'),\n",
       " ('osimertinib demonstr better clinicallymeaning efficaci wellcharacter safeti profil compar platinum pemetrex among patient epiderm growth factor receptor egfr tmposit advanc nonsmal cell lung cancer nsclc follow progress egfrtyrosin kinas inhibitor tki treatment accord result present intern associ studi lung cancer iaslc th annual world confer lung cancer austria osimertinib potent irrevers central nervous system cnsactiv egfrtki select sensit egfrm tm resist mutat osimertinib indic treatment patient locallyadvanc metastat egfr tmposit nsclc the author present result aura nct trial phase openlabel random studi assess efficaci safeti osimertinib versus platinumbas chemotherapi plus pemetrex among patient egfr tmposit advanc nsclc four hundr nineteen patient random either receiv osimertinib patient platinumpemetrex patient sixtyfour percent patient femal asian never smoker cns metastas egfr exon delet patient treat osimertinib median progressionfre surviv pfs month compar month patient treat platinumpemetrex the object respons rate orr also improv among patient treat osimertinib compar platinumpemetrex median durat respons month osimertinib month platinumpemetrex relat tumor node metastasi classif th edit chang grade higher advers event ae report patient treat osimertinib treat platinumpemetrex the common ae group treat osimertinib diarrhea rash the author conclud result establish new standard care patient refer',\n",
       "  'NN'),\n",
       " ('diagnos nsclc adenocarcinoma stage brain met march cyber knife ck brain met march resolv start tarceva april lobectomi novemb ned neck march ck anoth mm brain met januari recurr two brain met mm previous treat march octob multipl small lung nodul lung two bit larger mm pet activ lung two activ lymph node plus two brain met mm mm march liquid biopsi detect egfr tm april bronchoscopi lymph node fail may march except two lung nodul mm larger one brain met stabl mm anoth one mm new small met close optic nerv june the plan tri tagrisso label one two month hope would help progress brain neck otherwis carboalimta ck litt howev brain met grow i schedul fraction ck juli brain met close optic nerv laser interstici thermal therapi litt mm brain met today i receiv tagrisso unfortun abl echo wednesday i good health otherwis my question should i start tagrisso tomorrow saturday i want wait anymor btw i stop tarceva mg i abl echocardiogram wednesday be doctor still feel i slow progress i take big risk tri give tagrisso chanc abl establish tm status the place could actual abl tissu biopsi one lymph node locat aorta pulmonari arteri my option start chemo i reluct thank faith this topic modifi year month ago faithaboveal this topic modifi year month ago faithaboveal',\n",
       "  'NN'),\n",
       " ('over past week warn issu side effect two ms treatment first us food drug administr warn slight risk serious worsen ms symptom someon use diseasemodifi therapi gilenya fingolimod stop use the fdas alert said worsen symptom could result perman disabl alert fail provid detail rare problem about week later fda issu anoth warn this one lemtrada alemtuzumab the risk sever stroke may involv tear arteri neck head in case howev fda specif mani stroke report peopl treat lemtrada occur in near year sinc fda approv lemtrada alemtuzumab treat relaps ms identifi worldwid case ischem hemorrhag stroke cervicocephal arteri dissect these case report fda advers event report system faer databas occur within day administr drug patient ms ten case occur us three occur europ the fda went say didnt enough inform fulli assess individu risk factor occurr advers event within one day lemtrada administr suggest associ kneejerk reaction unsurpris quick respons news social media site some came peopl treat lemtrada report among suffer stroke follow treatment their comment generat other mani along line i wish id known treatment now im sure i want use treatment but other caution restraint say side effect everi medic these writer also remind us sever side effect much frequent report lemtrada i wrote gilenya warn day issu similar advis diseasemodifi treatment possibl side effect serious other we use treatment alway eye wide open fulli inform risk ms treatment benefit outweigh risk short i wrote post bring everyon date experi lemtrada im eight month past round two im pleas say posit we know know dmts carri certain level risk it us consult neurologist make serious riskbenefit analysi start treatment we proceed believ benefit outweigh risk we also must will accept risk problem occur one thing we need sure read beyond headlin warn receiv be sure read full alert get complet pictur magnitud concern if think probabl run higher risk incur serious disabl time get automobil use medic that design prevent disabl becom wors a version post first appear one column ms news today websit',\n",
       "  'NN'),\n",
       " ('my thought mom i hope scan show posit result growth shrinkag my mom first round keytruda wchemo cocktail last friday i hope abl share updat us throughout treatment i sure benefit mani forum as fellow caregiv i hope find way care face stress take care',\n",
       "  'NN'),\n",
       " ('repli post hippopostr remicad one sever biolog there two type approach medic there bottom therapi take lighter drug mesalmin work way the top approach doctor prescrib biolog first line treatment avoid complic futur i remicad lifesav i struggl year find right medic put remiss medic if still unsur talk child doctor see think i hope help',\n",
       "  'NN'),\n",
       " ('im hope four cycl carboplatin etoposid year sinc treatment im high risk resist chemo i know that alway possibl radiat consid primari therapi time they reach radiat oncologist input treatment interest consult expert seem move away onli immun therapi carboetoposid tecentriq immun therapi leg will see i land radiationinfo provid help',\n",
       "  'NN'),\n",
       " ('video dr alic shaw join grace discuss control brain metastas patient molecular driven advanc nonsmal cell lung cancer read lung cancer video librari control brain metastas patient molecular driven advanc nsclc laura giannini program director in februari laura join the global resourc advanc cancer educ program coordin a nativ italian laura year experi work nonprofit sector she spent last year live work south east asia latin america europ usa oversaw manag develop educ program disast affect area she fluent english spanish italian love work peopl differ background cultur laura hold ba read laura giannini program director alic shaw md phd grace faculti alic t shaw director center thorac cancer paula okeeff endow chair thorac oncolog massachusett general hospit she also associ professor medicin harvard medic school she receiv ab biochemistri harvard md phd degre harvard medic school she resid intern medicin massachusett general hospit complet fellowship hematologyoncolog danafarbermassachusett general hospit she complet postdoctor work laboratori dr read alic shaw md phd grace faculti karen reckamp md ms grace faculti karen reckamp md ms associ professor depart medic oncolog therapeut research citi hope comprehens cancer center cohccc she receiv medic degre univers chicago master degre clinic investig ucla she complet resid train intern medicin barnesjewish hospit hematologyoncolog fellowship david geffen school medicin ucla read karen reckamp md ms grace faculti matt hiznay live forum moder patient advoc matt hiznay fiveyear survivor metastat alkposit nonsmal cell lung cancer he born youngstown ohio grew small town poland ohio matt graduat poland seminari high school john carrol univers bachelor scienc degre magna cum laud read matt hiznay live forum moder patient advoc janet freemandaili patient advoc live forum moder janet freemandaili writer scienc geek lung cancer patientactivist she receiv diagnosi advanc nonsmal cell lung cancer may becam metastat despit chemotherapi radiat after learn genom test precis medicin onlin patient communiti join clinic trial rosposit lung cancer evid diseas four year read janet freemandaili patient advoc live forum moder john cherol live forum moder patient advoc john cherol diagnos januari stage iv egfr lung cancer age he start gilotrif afatinib acquir resist month luckili blood test show develop tm mutat start tagrisso april year hes also treat nine brain met gamma knife cleveland clinic read john cherol live forum moder patient advoc heather wakele md grace faculti dr wakele assist professor medicin stanford univers divis oncolog colead lung cancer diseas manag group her focus clinic research lung cancer patient particular interest antiangiogenesi agent dr wakele princip investig ongo intern lung cancer intergroup trial e investig potenti role bevacizumab addit adjuv chemotherapi resect earlystag nonsmal cell lung cancer read heather wakele md grace faculti rachel sanborn md grace faculti after graduat oregon health scienc univers medic degre dr rachel sanborn complet resid intern medicin univers illinoi chicago then return portland fellowship hematolog medic oncolog oregon health scienc univers she boardcertifi medic oncolog intern medicin read rachel sanborn md grace faculti boon wilder goodgam md grace faculti boon wilder goodgam md grew uganda father taught nation medic school he move texa age complet high school he earn undergradu degre univers texa austin mechan engin complet medic school baylor colleg medicin houston read boon wilder goodgam md grace faculti page first previous next last search form search featur content grace live yoga therapi present power yoga build resili video grace excit bring new seri surviv cancer congratul fantast year meet ami bickleman execut director video grace celebr year in recognit would like introduc staff board member deepli involv bring grace life in video introduc ami happi holiday make impact grace onehop articl onehop wine partner grace holiday donat purchas wine coffe gift grace latest video articl lung cancer video librari immunotherapi stage lll nsclc the pacif trial imfinzi video dr karen kelli associ director clinic research uc davi comprehens cancer center met grace bring updat lung cancer video librari in video dr kelli discuss lung cancer video librari tumor mutat burden current status video dr sandip patel associ professor medicin moor cancer center uc san diego health join grace offer updat lung cancer video librari in video dr patel discuss lung cancer video librari evolv standard molecular test advanc nsclc video dr sandip patel associ professor medicin moor cancer center uc san diego health join grace offer updat lung cancer video librari in video dr patel discuss',\n",
       "  'NN'),\n",
       " ('i adenocarcinoma lung brain metsi gefitinib month progress bit brain dr wakele switch tagresso sinc past month have done gamma knife surgeri twice brain but side effect overal minimalsom nauseafeel tire etc major i continu live full busi day work exercis medit walksand focus import thing life i live mumbai india glad mayo connect jump post shalia thank share inform us it hearten read success withgamma knife surgeri it wonder read full busi life',\n",
       "  'NN'),\n",
       " ('hello grace it sinc i post i sad report lost wife maria june near year battl stage iv nsclc i say enough good thing inspir care receiv dr hens team northshor univers health system near chicago dr sequist massachusett general hospit boston mention support guidanc receiv grace everyon tremend give us univers in maria case diagnos stage iv multipl site spread yet beat ill long time thank larg part year month respons tarceva our son actual thank genentech memori servic now i new question regard wife brother mexico also diagnos egfr exon del stage iv nsclc three year ago brain met he two year stint afatinib progress tm negat reli radiat combin carboplatin pemetrex fight diseas his foundat one report came im wonder grace team treatment thought base clinic experi mutat identifi follow cours review detail treatment suggest provid report alter identifi egfr exon del eadel pikca ek crebbp truncat exon rb truncat exon tp rw addit find microsatelit status msstabl tumor mutat burden tmblow mutsmb no report alter identifi kras alk braf met ret erbb ros thank you thought may dan',\n",
       "  'NN'),\n",
       " ('great news congrat babi girl so happi well uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc lglutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison in remiss',\n",
       "  'JJ'),\n",
       " ('in us dumb sometim rituxan wasnt approv insur cost rough year technic not approv ms theyll approv ocrelizumab year approv the basic drug then question higher health care price fall patient not fair system so great work well that suppos hope continu feel better',\n",
       "  'NN'),\n",
       " ('ocrelizumab it anoth monoclon antibodi i wish would look anoth direct ann last edit stillstannd am there come time silenc betray mlk repli with quot the follow user say thank suzeq',\n",
       "  'NN'),\n",
       " ('expert analysi from ecco a mg dose tofacitinib twice daili signific improv remiss',\n",
       "  'JJ'),\n",
       " ('hi i wonder experi nivolumab my fatherstag iv rcc found progress sutent doctor consid possibl option i appreci feedback',\n",
       "  'NN'),\n",
       " ('good hear i hope med bring dread steroid best luck year old femal diagnos uc age was remiss entyvio imuran combo dcd imuran flare month current moderatesever flare fail entyvioremicadesteroid refractivetacrolimuslialdauceri current med cortifoam x per day xeljanz just start daili probiot vsl',\n",
       "  'NN'),\n",
       " ('i offer gilenya secondlin treatment probabl i live long distanc hospit tysabri month infus would inconveni expens i understand mani peopl stop ty coupl year risk viral complic no issu gilenya a daili pill a bit perform start involv day hospit thereaft regular monitor realli breez',\n",
       "  'NN'),\n",
       " ('firefrau get neurologist talk data brain atrophi drug if want treat need fulli understand potenti drug alter cours brain atrophi alreadi start lemtrada best avail drug prevent brain atrophi assum given brain atrophi start i know much data ocrevus effect progress ms like alter cours brain atrophi alreadi begun you neurologist abl clear explain benefit risk drug make inform choic',\n",
       "  'NN'),\n",
       " ('thank post your post great insight helpful i also worri cd come back cellsul month hsct btw i i dont know mitig inhibitor i think md refer dmts trap lymphocyt lymph node fingolimodnatalizumab ps correct wrong obrigado lui',\n",
       "  'NN'),\n",
       " ('weve success stori xeljanz noth els work fail remicad entyvio etc see suzyq husband stori wwwhealingwellcomcommunitydefaultaspxfm what scare surgeri weve number poster done live excel afterward without medic worri futur flare it good thing consid serious fail mani treatment i worri somebodi say want avoid surgeri cost poster die due put way long chironjoseph month back moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc',\n",
       "  'NN'),\n",
       " ('hello greet everyon newbi i diagnos nsclc decemb lung mass discov pet scan done workup gyn malign i symptom a mass cm r lung hilar mediatin node supraclvicular node gastrohepat node it adenocarcinoma mutat pdl the gastrohepat node turn neuroendocrin tissu still stage iv onward got port mri brain negat three cycl carboalimtakeytruda did ok third treatment i develop dermatomyos this rare paraneoplast syndrom come under malign case felt autoimmun side effect keytruda everyth stop i hospit coupl time got high dose iv steroid mycophenol iv gammaglobulin revers effect keytruda sever month rehab later i got better still muscl issu myopathi much better anyway my last cat scan ned except mass stabl believ pseudotumor my second opinion oncologist nci cancer center also feel see need furthur treatment time either dont realli question wonder anyon els seen overwhelm respon immunotherapi gotten ned my oncologist optimist i may prolong respons my gyn cancer i surgeri also seem ned i guess i skeptic grate none less nil desperandum',\n",
       "  'NN'),\n",
       " ('hi helen thank question individu encourag discuss treatment option healthcar team the ms societi canada provid list clinic us offer ocrelizumab infus there number import consider one mind consid travel abroad medic treatment click read consider detail thank dr k',\n",
       "  'NN'),\n",
       " ('have tri antihistamin itch i know itch isnt allerg reaction i sometim hot itchi hand feet scratch rub doesnt help stop itch antihistamin it counterintuit work i take loratadin tesco brand tri differ one find suit the burn sensat i i touch area upper lip that may side effect gilenya either way mild enough ignor',\n",
       "  'NN'),\n",
       " ('hi my name barri i stage four metastat melanoma my last pet scan show cancer behav that good news i opdivo month you see profil thing go well despit fact i stage four anyway im deal pain swell knee joint my cancer doctor sent rheumatologist he prescrib methotrex said would take minimum three week least i would even notic benefit i reach threeweek mark yet i friend tell wonder cbd oil so one night knee realli bother i decid i would give tri i right swell weak pain spread left wrist right shoulder elbow right ankl and seem wors i wonder experi methotrex cbd oil my cancer doctor say like spread joint swell pain still respons opdivo said stay bodi month i hope i aggrav cbd oil what experi',\n",
       "  'NN'),\n",
       " ('dear jim onthemark thank much kind word onthemark wife mainten energi activ i most attribut amaz spirit focus resourc when first found diagnosi look said i plan live mani year yet i learn get great idea head never stand way the carboplatin hit pretti hard plummet rbcs almost quit point need transfus wbcs enough need neulasta but outsid worst day treatment still pretti much everyth normal the opdivo probabl difficult effect caus coliti nonetheless took whatev medic need still travel israel midst opdivo treatment and year later went galapago still hike faster i did i mention amaz we lucki call diagnosi near earli stage one could get base initi ct scan pulmunologist thought stage a main lung tumor coupl lymph node two bone metastas just past call oligometastat but second effect treatment clinic trial drug kept cancer bay year virtual effect rbc wbc energi level improv expens neuropathi still present great reduc finish drug the gemzar work well allow neuropathi improv expens phlebiti port put problem basic whatev need get life i incred lucki spous and i take mani deep breath today i teach cell biolog today i talk cell receptor like egfr mutat caus cancer wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met tumor growth liver met stabl all stabl addl growthoff trial gemzar tumor reduct stabl',\n",
       "  'NN'),\n",
       " ('hiya i lumbar punctur done show band in initi stage diagnosi begin treatment ms extrem activ particular within first month after start gilenya howev ive signific flareup sinc',\n",
       "  'NN'),\n",
       " ('dr steinman said worth risk nhe thank chart it illumin i found tonightehealthm independ site compil fda advers report drug accord site august peopl pml take tysabri httpwwwehealthmecomdstysabripro phalopathi seriouslywher outrag cheer husband dx rrms dx dual jugular vein stenosi ccsvi httpccsviinmsblogspotcom top harryz famili elder post join tue may pm locat london on canada contact contact harryz icq re updat tysabriaugust quot post harryz tue aug seriouslywher outrag cheer mind boggl isnt a german websit show total tysabri pml relat case now see real number like ive said past biogen market depart great job sweep negat data tysabri proverbi carpet amaz compani protect immens incom danger drug harri top erinc famili elder post join sat jun pm locat montreal re updat tysabriaugust quot post erinc wed aug year i diagnos i got impress littl symphoni pwms',\n",
       "  'NN'),\n",
       " ('eylea inj yrs left eye prob inj right eye st inj felt like blue cover rip eyelash skin also dot heavi handedconsequ pain ndandrd inj veri pain afterward eye swollen red crusti visit ask what wrong time told go see gphave sinc oct seen gps clinic doc clinic consult one given differ dri eye drop noth today saw differ gp think bleathar caus st inj right eye ignor gp rang oncal ophthalm clinic ask seen urgent app morn sound unbeliev true sinc oct new team doc concern anyth give inj gpsaid carri inj known one doc actual ask got blethar repli say dont know tell said go gp last gp one someth may add eyelid eye still swollen sinc oct droop one side stilliv bad experi last myh nervous next inj janthey also mix date inject consult obnoxi loud wouldnt letm speak didnt even want look eyehop get sort morn',\n",
       "  'VBN'),\n",
       " ('as age eye age us accord vision council america industri trade organ american age older type visual impair vision loss decreas eye function make life challeng limit person independ mobil impair vision put risk serious health condit well accid fall senior vision eye problem percent like involv motor vehicl accid exampl so import awar age may affect vision symptom signal serious eye condit seek help ophthalmologist eye specialist here rundown condit look cataract cloudi eye lens photo credit scienc photo librarygetti imag accord nation eye institut half senior age suffer cataract common caus blind world cataract involv cloud len this area eye made most water protein person age protein eye may start collect cloud vision some peopl develop cataract result smoke side effect diabet unfortun everyon develop cataract age cataract arent prevent theyr high treatabl surgeri the surgeri quick relat painless typic perform outpati basi it involv replac cloud len artifici intraocular len agerel macular degener amd photo credit nucleus medic artgetti imag this chronic eye diseas affect million american age older accord american academi ophthalmolog macular degener lead caus vision loss among american the condit character damag macula part eye that necessari see object clear there two form diseas dri macular degener wet macular degener the major senior dri macular degener caus gradual thin macula about percent patient develop wet form diseas abnorm blood vessel may leak blood fluid retina caus damag central vision treatment dri macular degener limit though nutrit supplement often slow progress diseas for wet macular degener patient treat inject drug bevacizumab ranibizumab aflibercept stop growth blood vessel laser eye surgeri also shown effect diabet eye diseas photo credit medicalonlinealami also known diabet retinopathi chronic condit caus diabet around million american diabet retinopathi accord nation eye institut diabet retinopathi caus damag blood vessel lightsensit area back eye at first condit caus minor vision problem difficulti see distanc but diabet progress vision loss may eventu lead blind laser treatment use treat diabet retinopathi some patient may vitrectomi surgeri gellik matter remov middl eye the procedur follow laser surgeri remov blood scar tissu form eye some doctor may give patient medic inject ranibizumab reduc inflamm stop growth blood vessel all treatment may slow vision loss cant cure diabet retinopathi fulli restor vision presbyopia farsighted photo credit neinihgov start around age eye begin lose focus condit that known presbyopia the age eye natur part get old affect near everyon but presbyopia make daili activ read work comput especi challeng fortun mani individu eyeglass contact lens usual trick they correct improv vision doctor increas strength prescript need time glaucoma damag optic nerv photo credit bsip saalami glaucoma refer collect eye condit eventu damag optic nerv often alway result increas pressur eye known intraocular pressur glaucoma lead loss peripher vision time caus total blind left untreat it estim million american glaucoma million accord nation eye institut the optic nerv damag glaucoma known silent thief sight prevent lower intraocular pressur topic eye drop surgeri dri eye syndrom photo credit getti imag for vision remain clear eye must suffici lubric mani senior experi dri eye low tear product though condit larg benign great impact vision caus person experi eye discomfort includ sting burn there isnt cure dri eye salin lubric drop artifici tear help reliev discomfort keep vision clearer there also prescript drug help manag condit',\n",
       "  'NN'),\n",
       " ('dear jaquetap pleas let husband tri opdivo could pleasant surpris i notic side effect got appetit back etc and help stabilis mani metastasi similar radiat chore daili drive cancer centr park wait treatment help the opdivo certain close year dont give religi ask lord support good luck margo',\n",
       "  'NN'),\n",
       " ('tri get canada wont budg pancol uc sinc sept averag bmsday time respons remiss therapi salofalkasa enema oral g clinic trial drug fail therapi entyvio antimadcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       "  'NN'),\n",
       " ('there old say medicin when hear hoof beat think hors zebra the logic behind adag common answer usual correct one this well good hors us zebra sometim get lost shuffl i ros lung cancer mean cancer driven mutat ros gene there explos research current underway examin genet caus cancer ros rare account percent lung cancer in fact wasnt march drug fda approv specif ros posit lung cancer xalkori crizotinib drug save life two year i went confer two year ago focus acquir resist target medicin the afternoon session broke mutat type egfr alk ros us zebra tickl pink see eight peopl ros sinc none us ever met anoth one we better take pictur i dont think ever mani ros er room sinc i quest track other rare mutat along way i met sever other equal driven form connect gather us zebra dazzl realli that term group zebra it start inform seri text messag kept tack peopl at point one us said might less unwieldi form facebook group and this group becom place us share treatment journey discuss clinic trial exchang advic symptom manag pool knowledg as month went told doctor group realiz wealth inform amass it wheel start turn there ton excit research happen cancer day small group us concern would get overlook we rare breed zebra stick togeth someon group suggest approach bonni j addario lung cancer foundat ask would creat studi us it long shot group peopl advanc cancer lose ask when situat like face absolut terrifi dire diagnosi prognosi nice someon will listen concern it even hearten offer help it love surpris take step support but exceed rare wonder actual put muscl money behind plan help reach goal that exact bonni j addario foundat over past month subset ros group number peopl around globe particip confer call foundat creat connect research health care provid stakehold investig mutat ultim creat ros repositori serv research treatment mutat you read incred patientdriven initi lung cancer foundat websit httpwwwlungcancerfoundationorgpatientsro if someon know ros cancer pleas follow link answer onlin survey diseas this easi step understand ros cancer httpwwwlungcancerfoundationorgpatientsrossurvey i beyond excit part initi empow part group patient speak heard have metastat lung cancer realli suck i met amaz peopl and realli overlook dazzl zebra tori tomalia mani thing mom wife theatr artist mediocr cook buffi fan stinki chees aficionado she also unfortun repeat visitor cancerland stay tune continu adventur facebook facebookcomlungcancerblogg twitter twittercomlillytnin blog a lil lytnin strike lung cancer lillytninblogspotcom',\n",
       "  'NN'),\n",
       " ('help lay person ms i went fingolimod start ocrelizumab in articl i tri understand better drug i know everyon differ etc',\n",
       "  'NN'),\n",
       " ('hello after rebif year quit signific relaps ive given option move cladribin option lemtrada i dont think anxieti could handl potenti side effect i wonder anyon els tablet form i realis new wonder side effect effect thank',\n",
       "  'NN'),\n",
       " ('i recent ask question i like start either tecfidera gilenya soon the nurs i spoke said come drug gradual wait around month tri conceiv hope help',\n",
       "  'NN'),\n",
       " ('i understand fear regard switch pill fwiw pill market show theyr better slow progress interferon none caus depress flulik symptom have tri gilenya tecfidera i team gilenya but dont forget pill arent option there also tysabri month infus hsct lemtrada rememb peopl ms stop med end relaps far like wont end one especi consid your look rebif tysabri ty known rebound effect basic guarante quit your gonna relaps mayb call neurologist offic let know want seen sooner sometim folk cancel last minut snap earlier appoint good luck let us know goe',\n",
       "  'NN'),\n",
       " ('excit news ocrelizumab offer expand access program locat particip primari progress multipl sclerosi ocrelizumab grant prioriti review design announc expand access program ocrelizumab particip with primari progress multipl sclerosi the primari object expand access program eap provid ocrelizumab treatment elig particip primari progress multipl sclerosi ppms commerci avail unit state us indic ppms an eap enabl particip receiv investig medic yet approv unit state food drug administr fda this program nontradit studi placebo group enrol given activ medic it follow strict protocol develop consult fda through ocrelizumab eap enrol particip receiv studi medic given everi six month via two infus separ two week the studi sponsor cover cost programspecif medic procedur perform program outsid cost standardofcar medic procedur',\n",
       "  'NN'),\n",
       " ('you said gene mutat egfr l correct there second line tki tarceva mutat afatinib has suggest theyr also find immunotherapi hasnt work well egfr mutat this read ive done im sure someon may info also clinic trial specif mutat could check not know your locat youll check locat trial good luck matter treatment come next take care judi httpsclinicaltrialsgovctshowncttermnsclcandlmutationrank ps i medic profession two time lung cancer survivor advoc stage iiia adeno dx srs chemo carboalimta x ned local recurr surgeri remov lrl cm involv pleura chemo carboalimta x ned',\n",
       "  'VBD'),\n",
       " ('as usual i beg differ ob dr gi made sweep statement unsubstanti unfair rich peopl still abl get misleadin suggest work doesnt i miss trick he isnt oracl nice tri protect nhs rape well us die this drug kill seven peopl withdrawn treatment rheumatoid arthriti hasnt triall proper thorough sp patient how could the good research seanchai provid evid but patient die ocrelizumab arm unexpect system inflammatori syndrom that could chanc still hope larger studi assur sever rheumatoid arthriti trial ocrelizumab termin overal benefit risk profil ocrelizumab favor realli mean patient die unexpect high ocrelizumab dose arm trial and cladribin phase iii trial test cladribin multipl sclerosi publish new england journal medicin day fingolimod result report despit similar effect compar fingolimod increas frequenc neoplasm sever infect death compar placebo led negat report fda emea approv profil cladribin chemotherapeut drug use rare leukemia it purin analog interfer dna synthesi usual cell metabol easili blood cell act cytotox drug cell sorri id upset nice agre ocrelizumab we need fight actual cure like insur polici nowaday aint worth paper written',\n",
       "  'JJ'),\n",
       " ('well turn i c diff infect could reason remicad wasnt work onc i get control in current take vancomycin antibiot treat im hope remicad still work if doesnt work ill move anoth med like entyvio mark thank insight ill make sure mention doctor possibl under infectionsparasit test order find',\n",
       "  'IN'),\n",
       " ('long term efficaci safeti ustekinumab refractori crohn diseas patient multicentr experi conclusionin cohort refractori cd patient receiv longterm ustekinumab therapi patient continu ustekinumab treatment loss respons intoler surgeri good safeti profil sourc alimentari pharmacolog therapeut',\n",
       "  'JJ'),\n",
       " ('ive scan post first i want commend keep togeth you seem calm level head im twice age scare rabbit what go second im glad hospit get fluid care lug iv around pain there alway garbag near i hope get better remi work i strong suspect femal canada ivig pentasa uccrohn test posit map antibodi mycobacterium pg remiss flare year current deal perian abscess fistula rvf wait stelara',\n",
       "  'NN'),\n",
       " ('in us amjevita pharmacolog class adalimumab use for amjevita adalimumabatto inject use treat symptom prevent progress moder sever activ rheumatoid arthriti ankylos spondyl it use children year age older juvenil idiopath arthriti this medicin also use treat psoriat arthriti type arthriti caus pain swell joint along patch scali skin area bodi psoriat arthriti usual occur skin condit call psoriasi adalimumabatto may use alon combin medicin eg methotrex adalimumabatto inject also use treat symptom activ crohn diseas patient help medicin eg infliximab it also use treat moder sever ulcer coliti patient treat medicin eg azathioprin corticosteroid mercaptopurin work well this medicin may also use treat moder sever chronic plaqu psoriasi skin diseas red patch white scale dont go away this medicin avail doctor prescript befor use amjevita in decid use medicin risk take medicin must weigh good this decis doctor make for medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use adalimumabatto inject treatment juvenil idiopath arthriti children year age howev safeti efficaci establish children younger year age juvenil idiopath arthriti safeti efficaci establish use children geriatr appropri studi perform date demonstr geriatricspecif problem would limit use adalimumabatto inject elder howev medicin may caus serious infect cancer often elder may requir caution patient receiv adalimumabatto inject breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when take medicin especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use medicin follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adenovirus vaccin anakinra bacillus calmett guerin vaccin live cholera vaccin live infliximab influenza virus vaccin live measl virus vaccin live mump virus vaccin live poliovirus vaccin live rilonacept rotavirus vaccin live rubella virus vaccin live smallpox vaccin tofacitinib typhoid vaccin varicella virus vaccin live yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use medicin make sure tell doctor medic problem especi blood problem eg aplast anemia pancytopenia thrombocytopenia histori congest heart failur guillainbarr syndrom histori infect fungal bacteri histori leukopenia low number white blood cell multipl sclerosi optic neuriti eye problem psoriasi skin diseaseus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd granulomatosi polyangiitisus caution may increas chanc get new cancer diabet hepat b histori opportunist infect histori tuberculosi histori ofmay increas chanc side effect infect activeshould use patient condit tuberculosi activeshould treat first receiv medicin proper use amjevita this medicin given shot skin adalimumabatto may sometim given home patient need hospit clinic if use medicin home doctor nurs teach prepar inject medicin be sure understand use medicin this medicin come medic guid patient instruct read follow instruct care ask doctor question if use medicin home shown bodi area shot given use differ bodi area time give child shot keep track give shot make sure rotat bodi area this help prevent skin problem this medicin avail form you may use prefil sureclick autoinjector prefil syring to use autoinjector syring first gather item need clean flat surfac use cloth towel welllight area wash hand soap water use medicin remov carton syring pen refriger place cloth allow minut syring autoinjector warm room temperatur do warm medicin way do remov needl cover prefil syring autoinjector allow medicin reach room temperatur remov immedi use check liquid syring autoinjector use view window it clear colorless if cloudi discolor particl float use syring autoinjector check amount liquid autoinjector close fill line seen window the fill line show full dose medicin if autoinjector full amount liquid use call pharmacist if liquid clear place clean flat surfac do shake medicin check expir date prefil syring autoinjector make sure date pass do use medicin date pass choos inject site bodi eg thigh abdomen stomach area clean inject site fresh alcohol wipe let dri remov cap needl cover readi inject inject full amount medicin within minut cap cover remov use differ bodi area time give shot keep track give shot make sure rotat bodi area do inject skin area red bruis tender hard if psoriasi inject rais thick red scali skin patch skin lesion you might small amount blood liquid inject site press hold dri clean cotton ball inject site second rub throw away use syring autoinjector hard close contain needl cannot poke punctureresist keep contain away children pet dose the dose medicin differ differ patient follow doctor order direct label the follow inform includ averag dose medicin if dose differ chang unless doctor tell the amount medicin take depend strength medicin also number dose take day time allow dose length time take medicin depend medic problem use medicin for inject dosag form autoinjector prefil syring for crohn diseas adultsat first week milligram mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a mainten dose mg given week everi week thereaft childrenus dose must determin doctor for juvenil idiopath arthriti children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year ageus dose must determin doctor for plaqu psoriasi adultsat first milligram mg inject skin mg week initi dose everi week thereaft childrenus dose must determin doctor for psoriat arthriti rheumatoid arthriti ankylos spondyl adult milligram mg inject skin everi week your doctor may adjust dose need childrenus dose must determin doctor for ulcer coliti adultsat first week milligram mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a mainten dose mg given week everi week thereaft childrenus dose must determin doctor miss dose if miss dose medicin take soon possibl howev almost time next dose skip miss dose go back regular dose schedul do doubl dose storag keep reach children do keep outdat medicin medicin longer need ask healthcar profession dispos medicin use store refriger do freez protect medicin direct light keep medicin suppli origin packag readi use also travel store medicin cool carrier ice pack store room temperatur day precaut while use amjevita if use medicin long time import doctor check progress child regular visit this allow doctor see medicin work proper decid whether continu use blood test may need check unwant effect you child need skin test tuberculosi start use medicin tell doctor anyon home ever posit reaction tuberculosi skin test adalimumabatto temporarili lower number white blood cell blood may increas chanc get infect it also lower number platelet necessari proper blood clot if occur certain precaut take especi blood count low reduc risk infect bleed if avoid peopl infect check doctor immedi child think get infect get fever chill cough hoars lower back side pain pain difficult urin check doctor immedi child notic unusu bleed bruis black tarri stool blood urin stool pinpoint red spot skin be care use regular toothbrush dental floss toothpick your medic doctor dentist nurs may recommend way clean teeth gum check medic doctor dental work done do touch eye insid nose unless wash hand touch anyth els meantim be care cut use sharp object safeti razor fingernail toenail cutter avoid contact sport situat bruis injuri could occur do take medicin unless discuss doctor use abatacept orencia anakinra kineret togeth medicin may increas risk serious side effect this medicin may caus unwant effect may occur month year medicin use a small number peopl includ children teenag use type medicin develop certain type cancer eg leukemia some patient also develop type cancer call lymphoma talk doctor child unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss also check doctor right away skin red scali patch rais bump fill pus adalimumabatto may caus serious allerg reaction includ anaphylaxi anaphylaxi lifethreaten requir immedi medic attent check doctor right away child rash itch swell face throat leg feet troubl breath chest pain receiv medicin check doctor right away child one symptom short breath swell face finger feet lower leg sudden weight gain these may sign heart condit call congest heart failur chf some peopl use medicin develop lupuslik symptom treatment got better medicin stop check doctor right away child start chest pain short breath joint pain rash cheek arm sensit sun do live vaccin immun child treat adalimumabatto your child vaccin need current begin use adalimumabatto be sure ask child doctor question the needl cover autoinjector prefil syring contain dri natur rubber deriv latex may caus allerg reaction peopl sensit latex tell doctor child latex allergi start use medicin amjevita side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor immedi follow side effect occur more common bodi ach pain chill cough diarrhea difficulti breath ear congest fever general feel discomfort ill headach joint pain loss appetit loss voic muscl ach pain nausea pain tender around eye cheekbon shiver sneez sore throat stuffi runni nose sweat tight chest troubl breath troubl sleep unusu tired weak vomit less common abdomin stomach pain bleed gum nose bloat swell face arm hand lower leg feet chest pain dizzi eye pain faint fast slow irregular heartbeat general feel tired weak hoars lower back side pain pain difficult urin rapid weight gain ring ear sore ulcer white spot lip mouth tingl hand feet unusu bleed bruis unusu weight gain loss incid known blind blister peel loosen skin blueyellow color blind blur vision darkcolor urin decreas vision diarrhea eye pain general feel tired weak itch joint muscl pain lightcolor stool red skin lesion often purpl center red irrit eye red scale crust skin stomach pain continu yellow eye skin some side effect may occur usual need medic attent these side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question more common bleed blister burn cold discolor skin feel pressur hive infect inflamm itch lump numb pain rash red scar sore sting swell tender tingl ulcer warmth inject site rash incid known hair loss thin hair other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'NN'),\n",
       " ('hi everyon drug seem promis im sure i understood fulli would block relaps good brain got hope understood happi lol httpswwwucsfedunewsnewmultiplesclerosisdrugocrelizumabcouldhaltdiseas',\n",
       "  'NNS'),\n",
       " ('yes link work hi sonia i tri look far ahead yes shot atv ocrevus might good thing tke care georg',\n",
       "  'VBP'),\n",
       " ('tuesday march pm san francisco kgo on good day watch sarah warto climb stair might guess suffer multipl sclerosi but short birth daughter year ago symptom kick it effect abil walk that probabl biggest issu mother newborn child i want get run around warto said now shes wait potenti approv new drug could chang cours diseas possibl life stephen hauser md ucsf help overse test drug it develop bay areabas genentech clinic name ocrelizumab hauser say abl disrupt symptom less sever form multipl sclerosi call relaps ocrelizumab abl near complet stop diseas activ peopl relaps remit form multipl sclerosi hauser said he say even abl reduc symptom much damag form diseas call progress ultim rob patient abil move so peopl relaps ms spectacular news and peopl progress ms door final open hauser said',\n",
       "  'JJ'),\n",
       " ('clinic relaps experienc individu switch rituximab individu switch fingolimod within year natalizumab cessat',\n",
       "  'NN'),\n",
       " ('tuvigin gilenya trademark own pharma compani novarti perhap tuvigin followon drug gilenya patemt expir',\n",
       "  'NN'),\n",
       " ('abstractpurpos reviewwith rapid evolv complement advanc target therapi inflammatori bowel diseas addit safeti side effect concern emerg it purpos review consid various risk biolog therapi inflammatori bowel diseas discuss mitig strategiesrec findingstwo recent approv monoclon antibodi vedolizumab ustekinumab janus kinas inhibitor small molecul tofacitnib introduc number novel safeti risk consider we review clinic trial realworld safeti data date agent well review sourc current gastroenterolog report',\n",
       "  'NN'),\n",
       " ('hi everyon i ulcer coliti sinc i year old i hid symptom month i embarrass scare got horribl stand anymor i almost surgeri remicad done realli well far problem sinc i made tshirt quot made smile hospit one thing made smile time i still tri pay medic bill year thought mayb peopl would like shirt quot spread word ulcer coliti mayb make smile let know think and like one mayb consid buy one if you would like one for crohn let me know pleas link item your sell fundrais healingwel rule allow even good caus post edit by moder ipoop am gmt',\n",
       "  'VBD'),\n",
       " ('jayle present drug ppms ocrevus present approv use nhs this decis review review conclud sometim next year there potenti treatment pipelin live hope',\n",
       "  'NN'),\n",
       " ('hi maceyma i dublin well i know mean worri brain inflamm i dmts tysabri gilenya side effect i attend st vincent tysabri closley monitor i would imagin beaumont as far i know risk gileni bad i would let nurseneurologist know concern see drug decid closley monitor i sent friend request let know question hard decid med pick ann mari x',\n",
       "  'NN'),\n",
       " ('speaker david greco md associ neurologist preregistr requir contact organ regist read categori connecticut tag event food free genentech ms multipl sclerosi patient educ program treatment waterburi ct ms educ event about ocrevus courtyard marriott ticket oct pm speaker david greco md associ neurologist preregistr requir contact organ regist',\n",
       "  'NN'),\n",
       " ('thank marco post the final some ppms love post made also help httpwwwmsworldorgforumshowthrsomeppmslov i spoke genentech patient advocaci today ocrevus manufactur switzerland avail end next week april us not sure insur coverag formulari right i understand someth call honeymoon period newli approv drug perhap one know someth here articl ny time approv includ price httpwwwnytimescomhesocrevushtml i agre marco final some ppms love and result look good rrms hope safeti profil continu good time anoth choic patient doctor consid good alan',\n",
       "  'NN'),\n",
       " ('hi linea my wife lorlatinib week criz work well brain met problem my question lorlatinib usual associ stabl diseas clear chest are figur also median os pfs prev resist rob',\n",
       "  'JJ'),\n",
       " ('hi daxi id circumspect interpret clinic trial egfr inhibitor sinc mum uncommon variant variant known respond signific better second generat tki therapi like afatinib first third generat least first line treatment this differ exon mutat respond best osimertinib third generat first line so i would read much studi focus mum initi mutat i would also wonder brain met aros mum taken afatinib without know mutat present hard make infer my inclin would tri rechalleng afatinib see chang rate growth if slow thing afatinib also penetr blood brain barrier it noteworthi mum rate progress chang taken afatinib bar use afatinib either alon combin jim suggest post sinc alreadi access osimertinib might best cours point avail chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       "  'JJ'),\n",
       " ('connect friend famili the internet sew doll make cloth great grand daughter play cat charli jelli joan yr old greatgrand mom dxed uc fail med liadaasacolmpremicad humira have entyvio year much improv less trip potti less accid i abl gain back lbs supplement tumericvitb vitcd reuteri pearl dao need',\n",
       "  'NN'),\n",
       " ('hi jenni sorri hear tough time cladribin i start cladribin last augustseptemb due second dosag later year so far good though have new episod latest mri decemb show new diseas activ i lucki suffer ill winter cold so relat plain sail the downsid month blood checksnot ideal terribl fear needl what hospit my consult the royal london one lead research treatment realli keen choos option emma x',\n",
       "  'NN'),\n",
       " ('hey guy i flare back june due antibodi entyvio i gotten mg bump back mg i start taper august i current mg we taper slower time mg week i howev feel like i realli harder time time around i also think thyroid may my hair fall profus tongu swollen normal regular period day late thing like fatigu crossov symptom those end need endocrinologist ask pcp gi referr also think i would benefit yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mgs pred',\n",
       "  'VBD'),\n",
       " ('whtc radio roch immunotherapi tecentriq given older drug avastin chemotherapi improv surviv advanc lung cancer patient percent combin without tecentriq accord interim result late stage trial releas wednesday but surviv benefit tecentriq plus chemotherapi avastin chemotherapi combin brief summari data becam avail wednesday the phase iii studi involv peopl nonsquam nonsmal cell lung cancer nsclc whose cancer spread yet receiv chemotherapi more detail data trial present next month annual meet american societi clinic oncolog roch conduct sever tecentriq lung cancer trial expect announc summer result trial drug combin alimta carboplatin the tecentriqavastinchemo combin also show surviv advantag patient egfr alk mutat first treat drug target genet marker yet receiv chemotherapi compani said it also show patient whose cancer spread liver live median month receiv fourdrug combin compar month given avastin chemotherapi an estim american diagnos lung cancer year nsclc account percent case accord american cancer societi',\n",
       "  'JJ'),\n",
       " ('redhil biopharma ltd announc posit toplin safeti efficaci result first phase iii studi rhb crohn diseas map us studi the studi success met primari endpoint key secondari endpoint toplin result intenttotreat itt popul demonstr superior rhb placebo achiev remiss week defin crohn diseas activ index cdai valu less primari endpoint studi the proport patient meet primari endpoint signific greater rhb group compar placebo vs p the studi also success met key secondari endpoint demonstr consist benefit crohn diseas patient treat rhb patient treat rhb also achiev statist signific greater respons week defin decreas cdai baselin compar placebo vs p patient treat rhb also experienc statist signific benefit achiev earli remiss defin remiss week vs p patient receiv rhb also experienc statist signific benefit durabl remiss week defin continu remiss throughout period vs p demonstr improv placebo at week treatment remiss rhb arm continu favor placebo vs p an analysi mainten remiss week subject note remiss week also demonstr statist signific benefit rhb placebo vs p rhb found general safe well toler toplin result demonstr activ placebo treatment group experienc similar low rate serious advers event treatment emerg advers event lead studi drug discontinu indic posit safeti profil rhb the compani continu assess addit exploratori endpoint data becom avail includ mucos heal map status qualiti life assess subpopul analys pharmacokinet addit data expect come month comment you need login leav comment epgonlineorg monitor collect advers event report ani advers event report nation report agenc andor manufactur learn zone an epgonlineorg learn zone lz area site dedic provid detail selfdirect medic educ diseas condit procedur inflammatori bowel diseas knowledg centr the inflammatori bowel diseas ibd knowledg centr contain key inform relat epidemiolog pathophysiolog crohn diseas ulcer coliti highlight preval impact unmet need under inflammatori process drive ibd consid key inflammatori pathway chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician migrain knowledg centr the migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option fluid manag are uptod latest evid effect procedur fluid manag chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria acut advanc heart failur what effect treatment acut heart failur can defin advanc heart failur discov load relat content news journal articl clinic trial guidelin news phase iii imun studi stelara show continu efficaci year crohn diseas jj janssen cilag the janssen pharmaceut compani johnson johnson announc new threeyear data phase iii imun studi demonstr ad month ago addit data phase iii mapus studi rhb confirm benefit crohn redhil biopharma redhil biopharma report addit posit data map us studi first phase iii studi rhb ad month ago success phase iii studi map us studi rhb treatment crohn diseas redhil biopharma ltd redhil biopharma ltd announc posit toplin safeti efficaci result first phase iii studi rhb ad month ago chmp recommend approv extens indic xeljanz ulcer coliti pfizer the committe medicin product human use chmp adopt posit opinion recommend chang term ad month ago fda advisori committe recommend xeljanz treat ulcer coliti pfizer pfizer announc posit outcom fda gastrointestin drug advisori committe gidac meet met discuss pfizer supplement ad month ago load view news item journal articl safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthesitisrel arthriti psoriasi crohn diseas object to evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthesitisrel arthriti ad month ago novel therapi treatment strategi patient inflammatori bowel diseas this articl review current treatment option strategi provid updat status drug develop program new therapeut agent inflammatori bowel diseas ibd ad month ago review articl predictor respons vedolizumab ustekinumab inflammatori bowel diseas aim to summaris current data predictor respons vedolizumab ustekinumab ibd patient ad month ago safeti efficaci pharmacokinet vedolizumab patient simultan exposur antitumour necrosi factor aim to explor outcom patient coexpos antitnf vedolizumab ad month ago phase ii evalu antimadcam antibodi pf treatment crohn diseas report opera studi this phase ii randomis doubleblind placebocontrol clinic trial design evalu efficaci safeti pf fulli human monoclon antibodi bind human mucos addressin cell adhes molecul ad month ago load view journal articl item clinic trial impact medic treatment sexual function patient with crohn diseas the investig propos month studi compar sexual function treatment patient crohn diseas initi therapi antitnf drug treatment perian fistula intestin crohn ad month ago studi to test whether pf is safe and improv diseas symptom in patient with crohn diseas opera adult crohn diseas clinic activ despit convent treatment elig studi patient may receiv one three dose pf experiment drug placebo inact drug ad month ago the impact antitnf exposur vedolizumab effect vedolizumab new medic use treatment crohn diseas ulcer coliti it work block specif white blood cell alpha beta lymphocyt migrat area inflamm ad month ago a multicent random doubleblind placebocontrol studi abt induct symptomat endoscop remiss subject with moder sever activ crohn diseas who have inadequ respond are intoler immunomodul antitnf therapi to determin efficaci safeti multipl dose abt subject moder sever activ crohn diseas histori inadequ respons intoler immunomodul antitumor necrosi factor ad month ago personalis antitnf therapi crohn diseas pant the primari object studi investig mechan underli primari nonrespons pnr loss respons lor advers drug reaction adr antitnf drug patient activ lumin crohn diseas ad month ago load view clinic trial item guidelin third european evidencebas consensus diagnosi manag ulcer coliti part current manag the guidelin condens two paper second describ current therapeut manag treatment activ diseas mainten medic induc remiss ad month ago third european evidencebas consensus diagnosi manag ulcer coliti part definit diagnosi extraintestin manifest pregnanc cancer surveil surgeri ileoan pouch disord the guidelin condens paper st detail definit classif diagnosi imag patholog manag special situat eim pregnanc cancer surveil surgeri ileoan pouch disord uc ad month ago consensus guidelin eccoespghan medic manag pediatr crohn diseas the object guidelin provid state art guidanc medic treatment long term manag children adolesc cd individu therapi base risk benefit base thorough review ad year ago crohn diseas manag crohn diseas chronic inflammatori diseas main affect gastrointestin tract the diseas may progress peopl proport may develop extraintestin manifest',\n",
       "  'NN'),\n",
       " ('i never know someth i take help i stop take if thing go south i know help happen occas i switch cytoxan ocrevus last year i feel punki two day infus',\n",
       "  'NN'),\n",
       " ('summari a studi base john hopkin univers compar two treatment strategi peopl newli diagnos onsetdiagnosi past receiv minim treatment relapsingremit form ms the studi recruit approxim center nationwid one option escal approach patient start take lesspow therapi option switch potent therapi diseas activ continu the approach involv start stronger therapi potenti effect also carri potenti greater risk signific advers effect the tradit versus earli aggress therapi multipl sclerosi treatm trial fund patientcent outcom research institut pcori detail rational there unmet need identifi specif treatment strategi relapsingremit phase ms prevent delay reduc longerterm disabl particular unclear whether peopl experi diseas activ tradit firstlin diseasemodifi therapi includ inject oral medic treatm trial switch differ firstlin therapi escal immedi higherefficaci therapi therapi greater effect possibl side effect deliv via infus the treatm trial one two studi fund pcori help inform treatment decis around whether peopl ms would benefit earli possibl riski aggress therapi the studi determin effect earli intens versus escal approach treatment relapsingremit multipl sclerosi deliverm elig detail investig seek particip diagnos relapsingremit ms age year particip elig month exposur one ms diseasemodifi therapi prior treatment rituximab ocrelizumab alemtuzumab mitoxantron cladribin experiment aggress therapi further enrol criteria avail contact elig particip divid two group base whether show characterist may make higher risk longterm disabl within group particip random assign either tradit earli aggress therapi particip neurolog specialist choos therapi within categori appropri those deem low risk disabl initi random assign tradit therapi experi ongo diseas activ interest switch therapi random assign differ tradit therapi earli aggress therapi studi particip rang month depend enrol date studi relat activ occur around particip standard visit local health care provid the primari outcom measur time sustain disabl progress determin expand disabl status scale edssplus combin outcom includ chang either edss time foot walk test mobil leg function ninehol peg test measur upper extrem function investig also monitor symptom fatigu mobil cognit track brain mri scan also patient report outcom particip report percept condit obtain gain better understand full impact treatment contact to learn enrol criteria studi find elig particip pleas email team john hopkin connect particip site area site enrol follow citi current activ site pleas see studi list clinicaltrialsgov birmingham al phoenix az los angel ca sacramento ca san francisco ca washington dc newark de gainesvill fl miami fl tampa fl chicago il kansa citi ks louisvill ky boston ma worcest ma baltimor md second site ann arbor mi detroit mi rochest mn bill mt great fall mt hackensack nj teaneck nj new york ny rochest ny stoni brook ny cincinnati oh columbus oh dayton oh westervill oh portland or danvill pa pittsburgh pa nashvill tn dalla tx round rock tx salt lake citi ut norfolk va burlington vt seattl wa download brochur discuss issu think consid enrol ms clinic trial pdf without particip research studi ms research would come standstil read',\n",
       "  'JJ'),\n",
       " ('the main tumor lung rest lymph node one left arm pit chest stabl grow supraclavicular lymph node act kick origin clinic studi done went st week week carboplatin nabpaclitaxelabraxan chemo pemrolizumab immunolog week nabpaclitaxelabraxan chemo fli color speak advers reaction drug littl hair loss fact grew back thicker littl neuropathi feet reach base ankl word one other would envious would like punch light take bottl extra medic nausea vomit prescrib diarrhea loss appetit etc at least get call phase ii yes much type weather i nice warm water bed i stay time front f bedroom tv laptop smartphon side diagnos oct fact know biopsi lung cancer pet scan etc dec th start treatment think indi everi week everi week octdec start week trip till nid april miss session delay one land ditch jan th rainsleet weather probabl highway snowplow get head home immun count would treatment do harm besid made death father june th make enough red blood cell transfus everi week mother die dec th acut myocardi infract near blockag sepsi cdiff stage acut onset kidney diseas besid full right side stroke nurs home sinc dec i sat watch die slowli dec hour comfort care dnr advanc life sustain support surgeri aliv blockag would possibl made done damag good just hope best well first round one chemo similar nabpaclitaxelabraxan how come along olgamari jump post wow you amaz what book lesson everyon say keep fight i think say keep live good luck',\n",
       "  'NN'),\n",
       " ('onli day i get find latest pet scan im somewhat nervous tarceva dosag lower i peopl i live i truli sit talk everyth im thank peopl i god i tri give worri him it hard brave front karley sometim these scan irrit i use worri im year day im worri someth beyond control anyway enough worri chris draft fabul past sunday took karley stephen i jaguar game it much fun cold raini lost blast i thank god peopl went they amaz if want donat good lung cancer caus donat wwwteamdraftorg thank continu prayer pleas pray good scan friday i feel like i realli need prayer right god bless corinthian love patient kind love envi boast arrog rude it insist way irrit resent rejoic wrongdo rejoic truth love bear thing believ thing hope thing endur thing',\n",
       "  'VBG'),\n",
       " ('ive follow thread sinc begin i firm believ ginger root tea relief arthriti pain shoulder i easili see get juic fiber heat use could much better ive use mani herbal remedi time work dont ginger cinnamon two work ginger work great i give cinnamon due blood get thin bruis easili but gingeri wonder stuff i never notic much chang uc due find interest follow it bit amaz talk real herbalistnot anoth moron like myselfthat everi weed everyon lawnshav medicin purpos we dont know thank share ginger researchi shall continu watch diagnos med triamteren hctz remicad infus wk interv mesalaminemg x day donnat tab x dayhyoscyamin sulfat odt hour neededomeprazol mg capsul daylatanoprost op drop eye potassium mg x day metfonidazol mg x dayciprofloxacin hcl mg x day lorazepammg xday need prednison mg week',\n",
       "  'JJ'),\n",
       " ('my mother diagnos nsclc chemo year start work she stage iv pleural effus addit small nodul right lung chemo result stabil tumor resolv nearbi earli stage lymph node metastasi she otherwis healthi keep weight exercis she well chemo high blood pressur chemo start work so almost year opdivo first month sign concern now near year pet scan go lung biopsi concern area pancrea arm pit we terrifi sinc believ immunotherapi go solut next great breakthroughso question i cannot seem find anywher peopl situat go back onto chemo drug treatment immunotherapyand type possibl set back typic occurr the oncologist said earli immunotherapi sometim look worst get better ani thought share i find difficult find anyth posit inform immunotherapyfor find drug work due individu histolog option ani help offer famili would grate hear pleas pray everyth us god bless thank',\n",
       "  'NN'),\n",
       " ('brand name mekinist whi medicin prescrib trametinib use alon combin dabrafenib tafinlar treat certain type melanoma type skin cancer cannot treat surgeri spread part bodi it use combin dabrafenib treat prevent return certain type melanoma surgeri remov affect lymph node trametinib also use combin dabrafenib treat certain type nonsmallcel lung cancer nsclc spread nearbi tissu part bodi it use combin dabrafenib treat certain type thyroid cancer spread nearbi tissu part bodi cannot treat therapi trametinib class medic call kinas inhibitor it work block action abnorm protein signal cancer cell multipli this help stop spread cancer cell are other use medicin this medic may prescrib use ask doctor pharmacist inform how medicin use trametinib come tablet take mouth it usual taken day empti stomach least hour hour meal take trametinib around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take trametinib exact direct do take less take often prescrib doctor do stop take trametinib without talk doctor your doctor may adjust dose trametinib depend respons treatment side effect experi talk doctor feel treatment ask pharmacist doctor copi manufactur inform patient what special precaut i follow befor take trametinib tell doctor pharmacist allerg trametinib medic ingredi trametinib tablet ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take tell doctor ever lung diseas breath problem diabet bleed problem blood clot coliti inflamm colon stomach problem high blood pressur heart eye liver kidney diseas medic condit tell doctor pregnant plan becom pregnant you becom pregnant take trametinib you use birth control prevent pregnanc treatment trametinib month final dose talk doctor birth control method work if becom pregnant take trametinib call doctor trametinib may harm fetus tell doctor breastfeed plan breastfe you breastfe take trametinib month final dose know medic may decreas fertil women talk doctor risk take trametinib what special dietari instruct i follow unless doctor tell otherwis continu normal diet what i if i forget take dose take miss dose soon rememb howev less hour next schedul dose skip miss dose continu regular dose schedul do take doubl dose make miss one what side effect medicin caus trametinib may caus side effect tell doctor symptom sever go away dri skin sore mouth tongu dri mouth vomit loss appetit chang abil tast food tired some side effect serious if experi symptom stop take trametinib call doctor immedi unusu bleed bruis bloodi black tarri stool cough vomit blood materi look like coffe ground noseble sever diarrhea stomach pain nausea fever chill rapid irregular pound heartbeat difficulti breath chest pain swell face arm leg ankl feet dizzi lightheaded weak short breath leg pain swell tender red warmth sever headach cough blur vision chang vision includ see halo blur outlin around object color dot loss vision eye pain dri red swollen eye rash red skin pimpl wart reddish bump bleed heal chang size color mole itch blister ulcer sore skin nail tingl burn red swell peel flake blister sore palm hand sole feet frequent urin increas thirst trametinib may increas risk develop new skin cancer cancer talk doctor risk take medic trametinib may caus side effect call doctor unusu problem take medic if experi serious side effect doctor may send report food drug administr fda medwatch advers event report program onlin web phone what i know storag dispos medic keep medic contain came tight close away moistur light reach children do place tablet contain daili week pill box store refriger freez do remov desicc small packet includ medic absorb moistur bottl it import keep medic sight reach children mani contain week pill minder eye drop cream patch inhal childresist young children open easili to protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach web unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin takeback program talk pharmacist contact local garbagerecycl depart learn takeback program communiti see fdas safe dispos medicin websit web inform access takeback program what i case overdos in case overdos call poison control helplin inform also avail onlin web if victim collaps seizur troubl breath cant awaken immedi call emerg servic symptom overdos may includ follow vision problem what other inform i know keep appoint doctor laboratori your doctor order certain lab test treatment see safe receiv trametinib check bodi respons trametinib your doctor also check skin chang begin treatment everi month treatment month treatment your doctor also check blood pressur time time need do let anyon els take medic ask pharmacist question refil prescript it import keep written list prescript nonprescript overthecount medicin take well product vitamin miner dietari supplement you bring list time visit doctor admit hospit it also import inform carri case emerg this report medic inform consid individu patient advic becaus chang natur drug inform pleas consult physician pharmacist specif clinic use the american societi healthsystem pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field the american societi healthsystem pharmacist inc make represent warranti express impli includ limit impli warranti merchant andor fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos the entir monograph drug review thorough understand drug action use side effect the american societi healthsystem pharmacist inc endors recommend use drug the inform substitut medic care ahf patient medic inform copyright the american societi healthsystem pharmacist inc eastwest highway suit bethesda maryland all right reserv duplic commerci use must author ashp',\n",
       "  'NN'),\n",
       " ('nope i never wear glove honest i think empti pouch sanitari wipe butt least see your i cours wash hand im done differ preostomi day yearold male diagnos crohn age happi humira year august fail remicad cimzia imuran mp mtx ileostomi april began entyvio juli med except nexium',\n",
       "  'NN'),\n",
       " ('i regret take drug it recent found peopl stop take gilenya risk sever exaccerb the thing white blood cell count drop low enough have to stop take my count low may fortun come back my neurologist want month blood test im kind terrifi i cant afford lose function',\n",
       "  'NN'),\n",
       " ('merck spent time turn offpat drug sciv onpat oral prepar went lower hang fruit first earli relaps diseas plenti mri activ relaps facilit posit outcom detect at time clariti oracl ms undertaken entir understand who know ema look littl harder suspect cancer risk misinterpret lymphopenia advers effect effect movectro may obtain licens patent life would longer trial progress ms obvious followon project now differ stori i would surpris compani spend hundr million develop mavenclad progress diseas may chang heart work we trial design chariot ms ill post next week first collabor meet taken place howev yet fund we trial less million let know know somebodi abl will chip big our current offer peopl progress ms entir compassion plausibl rational howev limit data total transpar peopl sign consent understood do luck well know ocrelizumab requir year mani hundr patient show effect fat chanc detect differ control arm atm what i say treatment except well toler the biotin trial allow inclus peopl dmt yes prepar includ peopl cladribin we dont know whether memori cell brain affect contrari drug dont penetr cns cladribin certain potenti at time howev dont even know degre memori b cell peripher deplet first anecdot evid suggest work well way data preliminari we encourag peopl progress ms lps cours year order obtain neurofila level howev mandatori',\n",
       "  'FW'),\n",
       " ('thank comment im type employ quit physic current wait seen medic doctorsi want get rid ive downplay pain i high pain toler point i tear time day it incred hard focus anyth els i appoint ms specialist come i think i need tell everyth even cost employ im role dismiss believ i cannot perform inher duti im med may effect role ive gilenya month first dmd sinc diagnosi i guess small victori ive nil side effect yay',\n",
       "  'NN'),\n",
       " ('i confus pdl inhibitor from websit tecentriq respond therapi show complet respons no data long term bc free opdivo patient complet respons data longterm bc free keytruda overal respons rate complet respons no data long term bc free i may miss someth seem lot smoke littl fire three primari phl inhibitor market',\n",
       "  'NN'),\n",
       " ('hi cannedi thank ask i feel lot better week ago fever cough i take tagrisso after day take tumor went cm cm susan',\n",
       "  'JJ'),\n",
       " ('veri bad sometim dead infect happen patient take infliximabdyyb most peopl infect take drug lower immun system like methotrex steroid drug if infect take antibiot recent past mani infect talk doctor tb tuberculosi seen patient start infliximabdyyb these patient expos tb past never got infect you test see expos tb start infliximabdyyb lymphoma cancer happen peopl take infliximabdyyb drug like this dead case talk doctor a rare type cancer call hepatosplen tcell lymphoma hstcl happen infliximabdyyb drug like these case dead almost case peopl use drug like one along certain drug azathioprin mercaptopurin most time happen treatment crohn diseas ulcer coliti also case male teenag young men talk doctor use infliximabdyyb see also entyvio it use methotrex prevent problem patient moder bad rheumatoid arthriti it use treat crohn diseas it use treat psoriat arthriti it use treat plaqu psoriasi it use treat ankylos spondyl it use treat ulcer coliti it may given reason talk doctor what i need tell doctor befor i take infliximabdyyb if allergi infliximab part infliximabdyyb if allerg mous protein talk doctor if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if heart failur weak heart if take drug abatacept anakinra if take take anoth drug like one if breastfeed do breastfe take infliximabdyyb this list drug health problem interact infliximabdyyb tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take infliximabdyyb drug health problem do start stop chang dose drug without check doctor what thing i need know i take infliximabdyyb tell health care provid take infliximabdyyb this includ doctor nurs pharmacist dentist this medicin may lower abil bone marrow make blood cell bodi need this lead bad sometim dead bleed problem infect tell doctor right away sign infect like fever chill bad sore throat ear sinus pain cough sputum chang color sputum pain pass urin mouth sore wound heal bruis bleed feel tire weak do get weaken bacteria like bcg bladder cancer use infliximabdyyb talk doctor have skin check tell doctor skin chang like new wart skin sore reddish bump bleed heal chang color size mole if hepat b carri virus infliximabdyyb caus virus becom activ this lead bad sometim dead liver problem you test hepat b start infliximabdyyb you need watch sign hepat take infliximabdyyb sever month stop talk doctor rare peopl use drug like one nervous system problem sometim problem gone away call doctor right away burn numb tingl feel normal chang eyesight dizzi seizur weak arm leg veri bad sometim dead liver problem happen infliximabdyyb call doctor right away sign liver problem like dark urin feel tire hungri upset stomach stomach pain lightcolor stool throw yellow skin eye abnorm heartbeat heart attack high low blood pressur stroke happen within hour infus sometim heart attack dead loss eyesight also happen within hour infus talk doctor if older use infliximabdyyb care you could side effect use care children talk doctor if use child make sure child date vaccin tell doctor pregnant plan get pregnant you need talk benefit risk use infliximabdyyb pregnant if use infliximabdyyb pregnant tell babi doctor your babi may higher chanc get infect least month birth your babi doctor also need decid babi get vaccin certain vaccin may caus infect lead bad health problem death given within month birth how medicin infliximabdyyb best taken use infliximabdyyb order doctor read inform given follow instruct close it given infus vein period time you may chanc get infect wash hand often stay away peopl infect cold flu have blood work check told doctor talk doctor this medicin may affect certain lab test tell health care provid lab worker take infliximabdyyb talk doctor get vaccin use vaccin infliximabdyyb may rais chanc infect what i i miss dose call doctor find see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign lupus like rash cheek bodi part sunburn easi muscl joint pain chest pain short breath swell arm leg sign high low blood pressur like bad headach dizzi pass chang eyesight weak side bodi troubl speak think chang balanc droop one side face blur eyesight chest pain pressur veri bad back pain pale skin swollen gland night sweat a big weight loss loss eyesight black tarri bloodi stool a skin lump growth fast slow heartbeat red scali patch bump pus fill fever chill itch hive chest pain pressur short breath drug given other drug may given avoid heart failur happen infliximabdyyb well heart failur gotten wors peopl alreadi tell doctor heart diseas call doctor right away short breath big weight gain heartbeat normal swell arm leg new wors a bad skin reaction stevensjohnson syndrom toxic epiderm necrolysi may happen it caus bad health problem may go away sometim death get medic help right away sign like red swollen blister peel skin without fever red irrit eye sore mouth throat nose eye what side effect infliximabdyyb all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away headach upset stomach throw belli pain feel tire weak flush irrit shot given sign common cold these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw infliximabdyyb if need store infliximabdyyb home talk doctor nurs pharmacist store consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area this medicin come extra patient fact sheet call medic guid read care read time infliximabdyyb refil if question infliximabdyyb pleas talk doctor pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'JJ'),\n",
       " ('question point treat advanc cancer say keytruda type drug ipilimumab time it seem like would need',\n",
       "  'NN'),\n",
       " ('juhi kund lungev scienc writer last weekend close oncolog profession includ superstar lung cancer research mani member lungev scientif advisori board gather chicago attend annual meet american societi clinic oncolog asco this year confer domin studi focus immunotherapi diseas treatment leverag bodi natur immun respons the field immunotherapi burst option the breakthrough new approach diseas manag flow research treatment lung cancer below i summar highlight asco confer immunotherapi immunotherapi found effect tumor cell express high level protein pdl howev pdl alway reliabl biomark tend fluctuat time area tumor may express pdl area also tumor make pdl protein still respond immunotherapi with mind research work optim biomark use predict patient benefit immunotherapi they found measur tumor mutat burden tmb number mutat tumor dna may promis approach predict patient respons immunotherapi sometim tmb may use conjunct pdl level provid guidanc cancer treatment one import phase clinic trial look bevacizumab anticanc drug known reduc tumor abil promot blood vessel growth requir feed cancer patient advanc nonsquam nonsmal cell lung cancer nsclc the initi result show ad atezolizumab immunotherapi drug bevacizumab carboplatinpaclitaxel two chemotherapi drug often use doublet treatment decreas cancer progress increas overal surviv compar regimen without immunotherapi while research need studi also rais hope patient egfrposit alkposit nsclc the trial result note patient shown progress egfr tyrosin kinas inhibitor tki alk tki respond well combin approach bevacizumab doublet chemotherapi atezolizumab anoth key phase clinic trial studi effect ad immunotherapi agent current recommend firstlin treatment advanc squamous nsclc research found immunotherapi drug pembrolizumab ad doublet chemotherapi patient saw signific increas overal surviv this studi like result chang current guidelin firstlin treatment patient advanc squamous nsclc mani differ clinic studi underway determin optim combin lung cancer treatment includ immunotherapi chemotherapi target therapi radiat also research conduct identifi optim sequenc treatment enhanc patient surviv rate qualiti life nonsmal cell lung cancer driver mutat lot progress also happen nsclc driver mutat in phase clinic trial patient advanc nsclc posit retfus promis result drug loxo select target retfus protein addit studi plan develop treatment option small cell lung cancer excit around rovat continu lungev scientif advisori board member david carbon md phd ohio state univers present phase clinic trial result show protein dll found high level small cell lung cancer sclc tissu healthi tissu could first target therapi advanc sclc the result show rovat bind dll improv overal surviv sclc patient whose cancer return chemotherapi in addit scientist explor potenti immunotherapi sclc data phase clinic trial suggest pembrolizumab may effect sclc patient progress chemotherapi whose tumor posit pdl protein earli detect and final progress liquid biopsi continu field earli detect when someon develop cancer blood often contain piec mutat dna escap die tumor cell tumor dna found blood often call circul dna ctdna plasma cellfre dna plasma cfdna recent liquid biopsi test becom avail analyz ctdna determin whether patient cancer type cancer the result studi present asco suggest techniqu may also use detect earlystag lung cancer the research develop circul cellfre genom atlas ccga aim understand liquid biopsi use earli detect complement ct screen more research underway hope develop techniqu use lifesav tool earli detect lung cancer in presidenti address asco presid dr bruce johnson mention close abl treat half patient nsclc target therapi immunotherapi initi treatment we encourag progress saw asco year confid next year bring even juhi kund ma scienc writer lungev categori earli detect immunotherapi mutat nonsmal cell lung cancer nsclc small cell lung cancer',\n",
       "  'NN'),\n",
       " ('for consid stelara great far it instantan infus mood chang happi energi i kid i think happen took lot pain bodi im bent stomach area im feel sick i cant drop pred yet mg i take omoperzol i work everi day i new life sinc infus poop mushi bloodi sometim no urgenc onli one accid sinc start i would recommend fail humira entyvio mp remicad uc sinc mayo clinic say chronscol dx chronic lyme no biolog work took rafaximin sibo work awesom take asacol hd',\n",
       "  'NN'),\n",
       " ('hi yui welcom i havent read suggest i apolog redund if hasnt done alreadi id suggest emerg bag car offic desk etc i alway undi wipespad ziplock bag chang pant imodium bottl ensur time well im love remiss i carri undi imodium purs there alway anxieti diseas prepar help anxieti come along flare for i never ate morn i go id get hour work empti give imodium time workbas flexibl alway readi dash run toilet it would seem easi enough take steroid doubl edg sword unend list side effect happen immedi caus signific damag if hes troubl get flare control may want tri entocort nonsystem steroid mean absorb gut caus less like chang side effect still happen great advic imagardnerdont momma uccrohn test posit map antibodi mycobacterium pg remiss chronic fistula fail setonsit pure tortur start stelara may mg imuran current stelara ivig occas',\n",
       "  'NN'),\n",
       " ('hi everyon i diagnos year ago ms i first went gilenya made foggi i couldnt drive work next i tri copaxon got use give shot mri neurologist said thought wasnt help so im rd month tecfidera manag med well decemb i get anoth mri i experienc lot bladder problem learn manag well although annoy i want know anyon experienc problem bowel yuck i know pretti subject sometim i feel like i dont muscl power empti bowel way it constip just feel enough strength i need anyon els issu thank much',\n",
       "  'JJ'),\n",
       " ('opdivo case miracl drug thought id post shoutout whod seen previo post',\n",
       "  'NN'),\n",
       " ('check livewithcanc opdivo long time', 'NN'),\n",
       " ('hi dane life welcom forum i diagnos lung cancer april due delay lab took end june oncologist decid put keytruda i third treatment week ago there serious side effect far i littl tire weaker mild joint pain occasion i cough lot fluid dr say that tumorcanc caus keytruda my appetit goodeven put weight i problem drive hour treatment good luck journey us',\n",
       "  'JJ'),\n",
       " ('it great see other posit result opdivo nivolumab my wife continu well she opdivo everi week next infus go everi week the cts show problem blood result continu slowli improv this august th year surviv sinc diagnosi stage squamous cell lung cancer treatment thru swedish hospit cancer institut seattl they access new clinic trial drug thank god current year issuesid effect might might due opdivo swell knee discomfort knee ankl similar arthriti she see rheumatologist soon see due arthriti mayb side effect opdivo your best hope go best largest cancer treatment center closet metropolotan citi us access clinic trial stay far far away altern medicin phoni clinic cure mexico germani countri sourc stay away slick well advertis tv center locat across countri all the best chuck',\n",
       "  'NN'),\n",
       " ('natalizumab exposur sinc nhs england gave us permiss switch highrisk natalizumab patient fingolimod continu derisk natalizumabtr popul we hope prevent anyon centr get pml despit mser prepar stop natalizumab simpli well drug the follow import headlin data slide mser regard risk base three identifi pml risk factor jcv serostatus durat treatment previous exposur immunosuppress in addit appear titr level antijcv antibodi also play role risk see need incorpor futur risk model we develop simpl infograph help integr inform you download print infograph inform plavina et al use jc virus antibodi index stratifi risk progress multifoc leukoencephalopathi natalizumabtr patient multipl sclerosi en multipl sclerosi i therapeut object in mser treat natalizumab presenc antijcv antibodi jcv ab prior use immunosuppress is increas durat natalizumab treatment especi greater year known risk factor progress multifoc leukoencephalopathi pml with polyomavirus higher level antibodi correl increas viral burden increas diseas risk it known whether jcv ab level correl pml risk natalizumabtr mser the object analysi examin associ jcv ab index jcv antibodi level measur use stratifi jcv dx select assay pml risk natalizumabtr mser method analys involv jcv ab index data jcv ab mser enrol clinic studi clinic practic a crosssect analysi jcv ab index data mser without pml first perform assess potenti relationship jcv ab index known risk factor natalizumab treatment durat vs month infus prior is use p valu calcul use wilcoxon rank sum test the associ jcv ab index pml assess use avail longitudin data odd ratio or estim generalis estim equat logit link the predict probabl use updat current pml risk estim jcv ab mser highlow ab index appli bay theorem result jcv ab index data avail natalizumabtr pml mser least month prior pml diagnosi nonpml jcv ab mser jcv ab index found associ number natalizumab infus p prior is use p signific associ pml risk p estim or least high versus low jcv ab index jcv ab mser updat pml risk estim longitudin stabil jcv ab index present conclus risk pml jcv ab negat natalizumabtr mser low per in jcv ab mser low jcv ab index risk pml severalfold lower risk current attribut jcv ab mser utilis jcv ab index allow clinic meaning stratif pml risk jcv ab natalizumabtr mser the figur bottom tabl deriv tabl present data differ way rather per thousand absolut risk you realis figur deriv relat small number ie case pml but data confirm anyon els i assum case emerg data set updat the implic data mani mser well natalizumab low titr low index may choos stay natalizumab rather switch in mser high risk elect stay natalizumab start month mri monitor earli sign pml the idea behind latter strategi detect pml earli washout natalizumab it clear pml pick asymptomat phase manag quick mser much better highlight slide coi multipl',\n",
       "  'JJ'),\n",
       " ('interest articl compar opdivo keytruda httpblogssciencemagorgpipelinearchiveskeytrudavsopdivo nocontest',\n",
       "  'NN'),\n",
       " ('london merck commit advanc patient care offer therapeut option help address unmet medic need peopl ms focus efficaci dose durabl safeti said luciano rossetti global head research develop merck biopharma busi we look forward share addit data rebif cladribin tablet scientif communiti year ectrim congress oral present includ comparison clariti clariti extens studi sought examin durat clinic outcom respons cladribin tablet result solar studi examin effect ad highdos cholecalciferol vitamin d rebif therapi patient rrms poster present report clinic magnet reson imag outcom patient treat cladribin tablet rebif patientreport outcom patient treat rebif sever health econom outcom research present highlight key issu face peopl ms includ pregnanc outcom in addit data present mercksponsor satellit symposium reimagin ms treatment journey take place wednesday septemb bst hall a excel the panel session featur distinguish expert ms debat whether unmet need ms care remain consid ideal ms therapi might look like review current potenti futur therapi on thursday septemb merck hold fourth annual grant multipl sclerosi innov gmsi award symposium up million award one research support work aim improv understand ms ultim benefit patient the symposium take place south galleri excel bst for inform data present pleas review ectrim websit also visit merck booth year congress learn compani program commit advanc ms care about cladribin tablet cladribin tablet oral small molecul prodrug select period target lymphocyt thought integr patholog process ms cladribin tablet current clinic investig approv use unit state canada europ about rebif rebif interferon betaa diseasemodifi drug use treat relaps form multipl sclerosi ms similar interferon beta protein produc human bodi the efficaci rebif chronic progress ms establish interferon thought help reduc inflamm the exact mechan unknown rebif approv europ us regist countri worldwid rebif proven delay progress disabl reduc frequenc relaps reduc mri lesion activ area rebif administr rebismart electron autoinject devic approv us rebidos singleus dispos pen manual multidos inject pen rebislid rebif also administ autoinjector rebiject ii manual inject use readytous prefil syring these inject devic approv countri',\n",
       "  'NN'),\n",
       " ('safe food a uniqu person definit honest lifechang concept need i quick learn safe food diagnosi nine year ago short i began experienc symptom ibd i quick learn certain food i could toler often regardless nutrit valu food item becam thing i reli heavili while luck faith brat diet banana rice applesauc toast give certain categori like dairi gluten sugar i most live realm carb safeti cracker rice pasta bread roll these safe food essenti certain time safe food especi paramount i need function human whether go work run groceri store think straight there seem general better chanc retain energi food less chanc rush bathroom eat food near anyth els i tri dure crohn diseas flare year i alway return version carb life stomach ruin i wasnt keep much els insid i often felt like eat terribl horribl good bad thing i forc mani time i wish skip food altogeth my safe food rare let year i endless amount gratitud i final abl add food varieti life i switch remicad infus march by august although still play dose frequenc infus i good day bad one first time year my ibd becam stabl anytim previous i found i new flexibl i abl eat i enter chapter life i sometim even enjoy food someth differ mani year i abl fill plate diet thing sound good thing i interest tri thing actual nutrit valu i began meal plan luxuri i never i realli enjoy i knew might last i focus benefit exist back safe food in septemb husband i went second round invitro fertil success result current pregnanc first child dure first trimest i experienc morn sick form daili nausea period vomit bowel gone confus my regular bowel movement transit back diarrhea time day due hormon pregnanc meant everyth i gotten use year chang realli quick i realiz fair quick i feel queasi like stomach upset i reach thing ive alway known safe food carb at first i felt concern would safeti food default diet mean babi wasnt get enough nutrient both gi ob doctor reassur mom first trimest goal eat whatev whenev the babi take babi need unabash lot come prenat vitamin your take the doctor said import thing i need focus stay hydrat luckili life ibd made pro i found fascin safeti diet one i default often last nine year serv beyond ibd flare i didnt expect util strategi pregnanc time life i grate option understand thing general keep gut calm with ibd chronic ill surgeri time life safe food offer secur relief',\n",
       "  'JJ'),\n",
       " ('hello i reach thought appreci expertis thank i back anoth question could cancer journey in treatment cancer type lung cancer diseas learn treatment scleroderma my sisterinlaw diagnos year ago stage adenocarcinoma would consid oligiomestast diseas she round cancer journey just diagnos cancer type lung cancer diseas learn biolog ok alectinib i psoriasi along stage iv nsclc alk posit i take alectinib nsclc is ok take biolog like cosentyx stelara cancer journey in treatment cancer type lung cancer diseas learn neuropathi autoimmun hi year prior diagnosi small cell lung cancer i suffer small fiber neuropathi sure autoimmun relat cancer journey just diagnos cancer type lung cancer diseas learn progess tagrisso ive tagrisso sinc juli i great initi respons visibl cancer shrink point longer detect cancer journey in treatment',\n",
       "  'NN'),\n",
       " ('awesom give us hope femal canada ivig pentasa entyvio infusionsno respons discontinu uccrohn test posit map antibodi mycobacterium pg remiss flare almost yearsin bad way due abx treatment gone wrong sigh',\n",
       "  'JJ'),\n",
       " ('to david wilson i also extrem pain head ach found anesthet i reaction chang type anesthet eylea inject i discomfort',\n",
       "  'NN'),\n",
       " ('yes everyon els say stop basic imposs start bodi antibodi recogn protein foreign humira good second option it work fast well i develop reaction job realli well',\n",
       "  'NN'),\n",
       " ('oh nice approv ocrevus', 'IN'),\n",
       " ('pffft said exact thing blog year ago advic partner oncologist lol say must kid word melbourn renown neuro ongo immunomodul suppress associ indefinit use tysabri gilenya etc mab unlik hsct associ cancer d pre aus rituximab ocrelizumab partner oncologist sorta gave blank look let dwell ah stop snarki boo thank entri instead d',\n",
       "  'JJ'),\n",
       " ('no i havent regular mris doctor follow until i havent seen doc sinc had brain mri lesion that i went ms doc last week they send blood jc virus test back yet i my ms seem flare month time month my friend took gilenya start just heart attack doc said drug contribut heart attack he start tecifedera say seem work fine he i cant swallow big pill tec capsul huge he said got stuck throat entir day im afraid drug pml risk what mean day regim tysabri whi know tec concern',\n",
       "  'JJ'),\n",
       " ('hey nicol i issu ocrevus infus mild allerg reaction handl easili bit iv benedryl i think im start feel tini bit better sinc second half dose late may i slip relaps i without tysabri day pre ocrevus i serious come back im still feel great but honest i cant rememb last time i could say i felt great im year two diagnosi start lose patienc wait everyon i talk ms longer tell first year worst i know that long time wait but somehow give tini bit hope thank kind word write if i didnt id probabl lose what left mind alway nice someon els like read hang let know ocrevus infus goe',\n",
       "  'NN'),\n",
       " ('deputi billi kelleh ask minist busi enterpris innov number local enterpris offic client counti case dublin dublin citi dn laoghairerathdown fingal south dublin year tabular form make statement matter view answer billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number local enterpris offic support job counti case dublin dublin citi dn laoghairerathdown fingal south dublin year tabular form make statement matter view answer written answer question busi minist busi enterpris innov share i propos take question nos togeth the local enterpris offic leo firststopshop provid advic guidanc financi assist support wish start grow busi detail number leo support client number job microenterpris support leo shown follow tabl counti basi includ four leo dublin pleas note relev detail avail result annual employ survey leo client complet q leo no leo client no leo client carlow cavan clare cork citi cork south cork w n doneg dublin citi dlr fingal dublin south galway kerri kildar kilkenni laoi leitrim limerick longford louth mayo meath monaghan offali roscommon sligo tipperari waterford westmeath wexford wicklow grand total leo total job ft pt total job ft pt carlow cavan clare cork citi cork south cork w n doneg dublin citi dlr fingal dublin south galway kerri kildar kilkenni laoi leitrim limerick longford louth mayo meath monaghan offali roscommon sligo tipperari waterford westmeath wexford wicklow grand total department staff recruit question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number addit staff appoint depart state agenc bodi aegi depart estim cost hire addit staff depart state agenc bodi tabular form make statement matter view answer written answer question busi minist busi enterpris innov share my depart consid overal alloc resourc need ongo basi workforc plan process the need addit post consid conjunct budget revis estim take account deliveri urgent busi prioriti cannot met current staff resourc this exercis undertaken context expans respons across depart light brexit global challeng grow number prioriti face depart includ signific increas number employ permit applic in regard total addit critic post identifi meet depart prioriti the overal cost approv addit staf request associ prioriti area identifi depart this inform set follow tabl grade number addit post princip offic assist princip offic administr offic execut offic cleric offic total estim cost it note posit may need review later year next cycl workforc plan undertaken particular respect demand employ permit in relat offic depart addit pay budget alloc offic director corpor enforc odc workplac relat commiss wrc the odc alloc addit pay budget assist transit offic statutori agenc identif specif post requir part ongo work underway progress transit odc agenc status the wrc alloc addit pay provid addit resourc support extens function includ sector employe gain access servic the agenc come within remit depart carri workforc plan exercis earli stage identifi follow addit posit cost associ agenc number addit post estim cost competit consum protect commiss enterpris ireland health safeti author ida ireland nation standard author ireland econom competit question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov view latest report nation competit council ireland competit challeng timelin implement recommend public view answer written answer question busi minist busi enterpris innov share improv ireland competit ensur ireland attract locat busi key econom prioriti govern by highlight competit challeng economi face identifi action address issu within control nation competit council make valuabl contribut regard i welcom council recent report ireland competit challeng in report nccs messag clear while ireland overal competit perform remain posit risk ireland prosper increas room complac the threat pose brexit evolv global trade tax landscap mean must enhanc competit posit make economi resili withstand extern shock i share council view improv competit need sustain public financ continu invest infrastructur talent drive innov product across sector economi moreov sever initi train across govern enhanc competit perform includ the review sme polici design assess sme busi ecosystem rang support offer smes undertaken depart conjunct oecd the develop industri strategi respond challeng opportun aris impact digit technolog the develop sector strategi enterpris ireland client base the futur growth loan scheme allow busi borrow year support capit invest enhanc competit my depart depart taoiseach also prepar futur job programm crossgovern initi strong focus improv product publish februari this initi propos concret ambiti action enhanc product competit ensur well posit adapt transform chang economi face year ahead alongsid competit challeng ncc made submiss futur job initi highlight key action govern we reflect find competit challeng content nccs submiss futur job initi finalis work permit data question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number employ permit grant noneea worker year occup sector tabular form view answer billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number applic work permit receiv year number applic remain process decemb year tabular form view answer written answer question busi minist busi enterpris innov share i propos take question nos togeth the inform request deputi regard number employ permit grant noneea worker year list occup sector set tabular form the employ permit section depart use intern standard occup classif soc code system classifi worker occup categori purpos collect calcul dissemin data sinc the follow tabl set inform request deputi regard number applic accept year number applic remain process decemb year tabular form applic accept applic remain process decemb the figur applic remain process decemb approxim occup sector work permit elig question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov occup sector high skill elig occup list inelig categori employ list respect tabular form view answer written answer question busi minist busi enterpris innov share the employ permit system manag oper high skill elig occup list hseol inelig categori employ list icel occup list hseol high skill job profession posit medicin ict scienc financ busi occup list icel general occup lower skill requir eg person servic trade oper evid enough irisheea worker fill vacanc everi job labour market employ cannot find worker may elig employ permit in order ensur employ permit scheme respons chang econom circumst labour market condit occup list review twice year keep pace rapid labour market chang proactiv identifi address shortag aris ireland leader eu wide link labour market intellig econom migrat polici guid research undertaken sola expert group futur skill need govern strategi well public consult process a review list underway present expect finalis end januari the review commenc public call submiss stakehold interest group request chang list submiss receiv respect rang occup submiss relev research data examin comprehens inform employ permit system avail depart websit wwwdbeigovi attach no hseol attach no icel person injuri claim question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov provid data detail suppli period view answer written answer question busi minist busi enterpris innov share the detail request deputi oper matter person injuri assess board piab piab independ statutori agenc i minist permit execut function interfer way day day oper function piab howev order assist deputi i set follow tabl relev inform publish piab annual report year annual report publish yet tabl applic piab year applic receiv total motor claim receiv total public liabil claim receiv total employ liabil claim receiv sourc data piab annual report tabl award made award accept year award made number accept award sourc data piab annual report medic aid applianc provis question billi kelleh share billi kelleh question deputi billi kelleh ask minist health person detail suppli receiv new wheelchair make statement matter view answer written answer question health minist health share as servic matter refer hse direct repli deputi home help servic provis question billi kelleh share billi kelleh question deputi billi kelleh ask minist health satisfi level qualiti servic provid home care compani detail suppli behalf hse plan ensur action taken immedi resolv care issu experienc person make statement matter view answer written answer question health minist state depart health share as servic matter i ask health servic execut respond direct deputi soon possibl medicin product avail question billi kelleh share billi kelleh question deputi billi kelleh ask minist health decis refus person detail suppli allergi prevent form pain relief obtain lidocain patch review matter urgenc make statement matter view answer written answer question health minist health share medicin play vital role improv health irish patient secur access exist new innov medicin key health servic object howev challeng safe sustain manner treatment must appropri proportion clinic decisionmak prescrib base patient need sound medic evid lidocain medic plaster licens localis relief postshingl pain adult this patch licens use ireland it reimburs communiti drug scheme sinc clinic concern aros usag increas signific point plaster use ireland entir uk nation health servic in situat import appropri clinician review usag hse medicin manag programm mmp review use plaster the review estim prescrib licens indic from septemb follow clinic review hse introduc new reimburs approv system patch support appropri use patient care under arrang patient gp consult appli mmp reimburs approv behalf patient if applic refus clinician may submit appeal mmp make clear clinic case patient inform patient practition hse mmp websit hseieyourmedicin the outcom applic appeal reimburs lidocain patch matter mmp treat clinician the deputi appreci minist health i cannot interven individu case the decis introduc new reimburs approv process particular treatment matter hse howev i fulli support object hse medicin manag programm hospit group question michael mcgrath share michael mcgrath question deputi michael mcgrath ask minist health posit relat spend revenu alloc matern director southsouthwest hospit group make statement matter view answer written answer question health minist health share as servic matter i ask health servic execut respond direct soon possibl hospit group question michael mcgrath share michael mcgrath question deputi michael mcgrath ask minist health view request capit budget million matern director southsouthwest hospit group enabl second oper theatr open cork univers matern hospit deal servic improv make statement matter view answer written answer question health minist health share as health servic execut respons deliveri healthcar infrastructur project i ask hse respond direct relat matter hospit procedur question gerri adam share gerri adam question deputi gerri adam ask minist health number person undergon cataract surgeri year cost surgeri year view answer gerri adam share gerri adam question deputi gerri adam ask minist health hse locat cataract surgeri perform view answer gerri adam share gerri adam question deputi gerri adam ask minist health number person counti await cataract surgeri length time wait view answer written answer question health minist health share i propos take question nos inclus togeth improv access hospit treatment key prioriti govern wait list figur decemb publish last week ntpf show consider improv made number patient wait inpati day case procedur fallen peak juli this repres reduct overal number patient wait procedur over period wait list cataract reduc repres reduct furthermor number patient wait month almost halv sinc juli the impact particular noteworthi one consid improv wait list particular specialti focus inpatientdaycas action plan includ number wait month cataract procedur fallen sinc juli my depart work close ntpf hse finalis schedul care access plan inpatientsdaycas outpati in regard ntpf hse continu work close hospit group invit propos improv access patient wait hospit procedur the number person treat cataract the ntpf direct role commiss patient treatment at time procur treatment carri hse role ntpf administr payment hospit the expenditur ophthalmolog annual financi statement finalis the hse locat cataract surgeri perform children univers hospit templ street galway univers hospit letterkenni general hospit mater misericordia univers hospit royal victoria eye ear hospit sligo region hospit south infirmaryvictoria univers hospit st vincent univers hospit univers hospit limerick univers hospit waterford nenagh hospit louth counti hospit the inform request deputi regard number person counti await cataract surgeri set document follow link cataract vaccin programm question john curran share john curran question deputi john curran ask minist health age children may previous vaccin meningococc b diseas entitl vaccin hse make statement matter view answer john brassil share john brassil question deputi john brassil ask minist health hse undertaken cost analysi provis mening b vaccin children born octob consid make statement matter view answer john brassil share john brassil question deputi john brassil ask minist health hse establish number person affect mening b strain relat recent mening outbreak number person recent die due mening affect mening b strain make statement matter view answer john brassil share john brassil question deputi john brassil ask minist health plan extend mening b vaccin children born octob make statement matter view answer john brassil share john brassil question deputi john brassil ask minist health plan establish public awar campaign encourag uptak mening b vaccin booster programm make statement matter view answer risn shortal share risn shortal question deputi risn shortal ask minist health catchup mening b programm provid children estim cost provid programm make statement matter view answer written answer question health minist health share i propos take question nos inclus togeth the nation immunis advisori committe niac independ committe royal colleg physician ireland compris expert number specialti includ infecti diseas paediatr public health make recommend vaccin polici ireland it recommend base preval relev diseas ireland intern best practic relat immunis all relev appropri inform taken account decid make chang state immunis programm niac submit recommend depart consider on foot recommend niac primari childhood immunis schedul amend includ introduct mening b vaccin babi born octob this chang immunis schedul took effect decemb the first dose vaccin administ children reach two month age second dose administ four month third final dose twelv month mening b diseas common babi age year old time administr vaccin immunis programm take account all vaccin administ primari childhood immunis schedul provid free charg ireland second countri europ make men b vaccin avail free charg part nation immunis programm a vaccin protect meningococc c diseas men c vaccin given month it also note adolesc routin offer men c vaccin first year secondari school parent strong advis ensur children immunis accord vaccin programm other vaccin protect form mening septicaemia includ routin child vaccin programm hib vaccin pneumococc vaccin pcv there plan introduc catchup programm men b vaccin older children those medic card elig vaccin administ gp free charg howev purchas vaccin cover medic card scheme eleven case meningococc diseas notifi health protect surveil centr hpsc sinc last week decemb three death among case this due increas incid meningococc diseas last two week the eleven case notifi compar case time period last year in total meningococc case notifi compar provision data strain type identifi indic differ strain organ circul all age group affect rang infant elder two case notifi relat mening b none three death attribut strain diseas member public advis includ alreadi vaccin concern show symptom contact gp first instanc ensur medic expertis sought medicin product avail question john curran share john curran question deputi john curran ask minist health plan ensur drug pembrolizumab made avail person detail suppli make statement matter view answer written answer question health minist health share the hse statutori respons medicin price reimburs decis accord health price suppli medic good act as minist health i statutori power function relat reimburs medicin in addit section health act preclud direct hse provid treatment person servic individu confer elig individu it would inappropri comment particular circumst individu patient in ireland major patient access medicin public fund communiti drug scheme in line act nation framework agre industri compani would like medicin reimburs hse must appli new medicin ad reimburs list reimburs licens indic grant market authoris european medicin agenc ema health product regulatori author hpra hse decis medicin reimburs taxpay made object scientif econom ground advic nation centr pharmacoeconom ncpe pembrolizumab market authoris irelandth eu number indic the hse approv reimburs pembrolizumab follow indic monotherapi treatment advanc unresect metastat melanoma adult monotherapi firstlin treatment metastat nonsmal cell lung carcinoma nsclc adult whose tumour express pdl tumour proport score tps egfr alk posit tumour mutat monotherapi treatment adult patient relaps refractori classic hodgkin lymphoma chl fail autolog stem cell transplant asct brentuximab vedotin bv transplantinelig fail bv it note first part last indic reimburs hse alreadi reimburs anoth immunotherapi similar efficaci nivolumab lower cost patient transplantinelig fail bv receiv reimburs support pembrolizumab nivolumab market authoris subgroup patient the hse drug group review indic monotherapi treatment local advanc metastat urotheli carcinoma adult elig cisplatincontain chemotherapi whose tumour express pdl combin posit score cps the follow indic current health technolog assess ncpe combin pemetrex platinum chemotherapi firstlin treatment metastat nonsquam nsclc adult whose tumour egfr alk posit mutat monotherapi treatment local advanc metastat urotheli carcinoma adult receiv prior platinumcontain chemotherapi no reimburs applic receiv date follow indic monotherapi treatment recurr metastat head neck squamous cell carcinoma hnscc adult whose tumour express pdl tps progress platinumcontain chemotherapi howev hse approv reimburs nivolumab treatment recurr metastat squamous cell cancer head neck adult progress platinumbas therapi in octob committe medicin product human use chmp european medicin agenc committe respons human medicin adopt posit opinion recommend chang term market authoris pembrolizumab includ new indic follow monotherapi adjuv treatment adult stage iii melanoma lymph node involv undergon complet resect the hse commiss rapid review assess indic there indic pembrolizumab approv european union time clinic trial various immunotherapi includ pembrolizumab ongo global rang possibl indic may receiv market authoris eu next number year each indic consid reimburs market authoris grant applic receiv department staff data question barri cowen share barri cowen question deputi barri cowen ask minist health number employe depart number profession qualifi organis detail suppli number relev profession qualif number profession qualif tabular form view answer barri cowen share barri cowen question deputi barri cowen ask minist health number employe depart authoris engag procur number profession qualifi organis detail suppli number relev profession qualif number profession qualif tabular form view answer written answer question health minist health share i propos take question nos togeth the number employe depart end decemb term headcount my depart hold record profession qualif held employe some employe may member profession organis person capac pay membership fee the depart would record membership the depart pay corpor membership institut public administr in three individu annual membership charter account ireland one individu membership charter institut manag account reimburs depart various member staff engag procur good servic depart alongsid main duti these staff abid procur guidelin procedur laid offic govern procur act advic appropri the staff involv would requir profession qualif procur order undertak work',\n",
       "  'NN'),\n",
       " ('i clinic trial john hopkin hospit baltimor maryland combin use opdivo lag i test pdl negat howev cea level continu decreas treatment my next ct scan earli feb',\n",
       "  'NN'),\n",
       " ('hi sorri late repli i away vacat the implant last month in case last month i next implant month affect previous shot wore but one month wait period also i could manag read write drive work without difficulti it littl discomfort overal i hear numer doctor websit ozurdex elimin remain fluid effici perman case rvo i keep finger cross',\n",
       "  'NN'),\n",
       " ('video dr vamsidhar velcheti cleveland clinic join grace discuss updat lung cancer video librari in video dr velcheti discuss gilotrifafatanib squamous non small cell lung cancer',\n",
       "  'NN'),\n",
       " ('home ms inform public ms research updat gilenya fingolimod gilenya fingolimod in section main articl fdaapprov medic experiment medic new direct ms research close note trial phase investig drug treatment approv longterm treatment ms pdf refer fdaapprov medic new data compani novarti pharmaceut corp oral medic mg capsul taken daili approv relaps form ms previous tysabri next laquinimod gilenya first class immunomodulatori drug call spreceptor modul it similar structur natur occur compon cellsurfac receptor white blood cell white blood cell produc immun system fight infect diseas gilenya block potenti damag t cell leav lymph node lower number blood tissu it may reduc damag cns enhanc repair damag nerv within brain spinal cord although gilenya approv relapsingremit ms rrms clinic trial continu evalu role ms the month inform trial evalu effect gilenya relat placebo delay time sustain disabl progress patient ppms as present fdaapprov medicin ppms import studi field the enrol ppms patient inform trial complet trial data analysi complet novarti announc decemb unfortun primari outcom studi met gilenya show signific differ placebo combin disabl measur a novel primarycomposit disabl endpoint use trial base increas disabl measur expand disabl status scale edss foot timedwalk test tfw hole peg test hpt other key endpoint format new lesion percentag brainvolum chang pbvc brain atrophi shrink reduct brain volum detail result trial present spring gilenya prevent accumul disabl patient ppms greater placebo furthermor pbvc differ gilenya placebo group unsurpris given agent success reduc relaps new mri lesion rrms patient fewer new mri lesion seen gilenyatr patient the safeti result general consist medic prior ms trial it certain disappoint gilenya signific slow diseas progress ppms these find like tysabri spms import implic understand progress diseas doubt allow research refin studi move forward anoth ongo gilenya clinic trial studi evalu safeti efficaci two dose fingolimod versus copaxon this month trial compar market dose gilenya onehalf dose use copaxon comparison annual ms relaps sever mri measur diseas the goal studi requir fda assess lower dose medic may equal effect reduc number relaps patient relaps form ms this studi expect report data previous tysabri next laquinimod',\n",
       "  'NN'),\n",
       " ('it choic dont want treat ms im post say effect treatment rrms spms relaps lemtrada cladribin hsct as i said ocrezilumab way treatment ppms larg doubleblind placebocontrol trial shown drug realli work that scienc',\n",
       "  'NN'),\n",
       " ('eylea us net product sale total revenu nongaap net incom nongaap net incom per share dilut gaap net incom gaap net incom per share dilut busi highlight eylea aflibercept inject intravitr inject in first quarter net sale eylea unit state increas million million first quarter net sale first quarter negat impact decreas distributor inventori net sale first quarter benefit increas distributor inventori exclud chang inventori under demand eylea unit state increas year year bayer healthcar llc commerci eylea outsid unit state in first quarter net sale eylea outsid unit state million compar million first quarter in first quarter regeneron recogn million share net profit eylea sale outsid unit state repay million develop expens the target date fda decis supplement bla us regulatori approv eylea treatment diabet macular edema dme august applic market approv european union japan eylea dme also submit in februari compani report posit two year result phase vistadm trial treatment dme dure first quarter compani supplement bla us regulatori approv eylea treatment macular edema follow branch retin vein occlus brvo accept fda target date fda decis supplement bla octob in februari compani initi phase trial eylea combin regn antibodi platelet deriv growth factor receptor beta pdgfrbeta coformul intravitr inject treatment neovascular agerel macular degener wet amd in januari compani enter licens collabor agreement bayer healthcar joint develop commerci outsid unit state regn includ combin eylea treatment ocular diseas disord in may compani enter research collabor licens agreement avalanch biotechnolog inc discov develop commerci novel gene therapi product treatment ophthalmolog diseas monoclon antibodi regeneron fifteen fulli human monoclon antibodi generat use compani velocimmun technolog clinic develop includ eight collabor sanofi highlight latestag antibodi pipelin includ alirocumab compani antibodi target pcsk proprotein convertas subtilisinkexin type lower ldlcholesterol ldlc current evalu global phase odyssey program the odyssey program expect enrol patient current includ clinic trial alirocumab combin lipidlow agent monotherapi all trial odyssey program studi everi two week dose alirocumab except choic i choic ii studi everi four week dose all trial odyssey program includ choic i choic ii fulli enrol except patient odyssey outcom studi data nine phase trial expect avail mid along data previous announc odyssey mono trial form basi compani initi global regulatori file five abstract alirocumab present american colleg cardiolog meet march these includ first present data posit phase odyssey mono trial data oneyear openlabel treatment heterozyg famili hypercholesterolemia patient data test alirocumab milligram mg dose everi four week patient statin in addit april compani sanofi report posit result first phase studi alirocumab japanes patient sarilumab compani antibodi target ilr rheumatoid arthriti current continu enrol global phase sarilra program the sarilra phase program consist studi expect enrol approxim adult moderatetosever rheumatoid arthriti achiev adequ result treatment agent data first posit phase trial sarilra program mobil present upcom medic confer dupilumab compani antibodi target ilr alpha allerg diseas current phase b test dure first quarter posit phase data dupilumab treatment moderatetosever atop dermat present annual meet american academi allergi asthma immunolog aaaai the compani expect phase b data dupilumab treatment atop dermat becom avail second quarter a phase b trial dupilumab asthma ongo phase trial nasal polyposi addit indic dupilumab clinic develop evalu human genet initi in januari compani announc launch new human genet initi via newli creat wholli own subsidiari regeneron genet center llc rgc rgc leverag deidentifi clinic molecular data human volunt medic relev associ blind fashion design preserv patient privaci rgc perform sequenc genotyp generat deidentifi genom data the object rgc expand use human genet discov valid genet factor caus influenc rang diseas major unmet medic need prospect improv drug discoveri develop process in januari compani also announc rgc geising health system one largest integr health system unit state serv approxim million resid enter research collabor focus studi genet determin human diseas the aim collabor build highthroughput platform discov valid genet factor caus influenc rang diseas major unmet medic need first quarter financi result product revenu net product sale million first quarter compar million first quarter eylea net product sale unit state million first quarter compar million first quarter arcalyst net product sale million first quarter compar million first quarter total revenu total revenu increas million first quarter compar million first quarter total revenu includ collabor revenu million first quarter compar million first quarter collabor revenu increas primarili due increas compani net profit commerci eylea outsid unit state higher reimburs antibodi develop cost sanofi collabor revenu first quarter also includ million sale mileston earn bayer healthcar refer tabl summari collabor revenu research develop rd expens gaap rd expens million first quarter compar million first quarter the higher rd expens first quarter princip due increas rd activ primarili relat compani antibodi collabor sanofi higher rd headcount higher noncash sharebas compens expens in first quarter rdrelat noncash sharebas compens expens million compar million first quarter sell general administr sga expens gaap sga expens million first quarter compar million first quarter the increas primarili due higher expens connect contribut notforprofit organ assist patient chronic diseas condit higher noncash compens expens in first quarter sgarel noncash sharebas compens expens million compar million first quarter cost collabor manufactur gaap cost collabor manufactur million first quarter compar million first quarter cost collabor manufactur increas primarili due royalti payabl third parti commenc may pursuant licens settlement agreement connect sale eylea outsid unit state cost collabor manufactur also includ cost produc commerci suppli eylea bayer healthcar zaltrap sanofi incom tax expens the compani current pay expect pay near futur signific cash incom tax gaap incom tax expens million first quarter compar million first quarter the effect tax rate first quarter compar first quarter the effect tax rate first quarter negat impact expir end feder tax credit increas research activ ii loss incur foreign jurisdict rate lower feder statutori rate iii recent enact new york state tax legisl this tax legisl reduc compani new york state incom tax rate zero percent effect howev also result onetim charg relat compani reduc relat defer tax asset first quarter the effect tax rate first quarter includ impact the american taxpay relief act enact januari retroact extend various expir tax provis includ credit increas research activ as result first quarter compani recogn benefit full year feder research tax credit nongaap net incom exclud incom tax expens nongaap gaap net incom the compani report nongaap net incom million per basic share per dilut share first quarter compar nongaap net incom million per basic share per dilut share first quarter the compani report gaap net incom million per basic share per dilut share first quarter compar gaap net incom million per basic share per dilut share first quarter the decreas gaap net incom result primarili compani higher effect tax rate first quarter describ cash posit at march cash market secur total billion compar billion decemb regeneron record net product sale eylea unit state outsid unit state eylea net product sale compris sale bayer healthcar countri japan sale santen pharmaceut japan copromot agreement japanes subsidiari bayer healthcar the compani recogn share profit includ percentag sale japan eylea sale outsid unit state within bayer healthcar collabor revenu statement oper this press releas use nongaap net incom nongaap net incom per share financi measur calcul accord us general accept account principl gaap the compani believ present nongaap measur use investor exclud applic noncash sharebas compens expens fluctuat period period base factor within compani control compani stock price date sharebas grant issu ii noncash interest expens relat compani convert senior note sinc deem use evalu compani oper perform iii incom tax expens sinc compani current pay expect pay near futur signific cash incom tax due primarili util net oper loss tax credit carryforward therefor gaap incom tax expens deem use evalu compani oper perform manag use nongaap measur plan budget forecast assess histor perform make financi oper decis also provid forecast investor basi howev limit use nongaap financi measur exclud certain expens recur natur furthermor compani nongaap financi measur may compar nongaap inform provid compani ani nongaap financi measur present regeneron consid supplement substitut measur financi perform prepar accord gaap a reconcili compani gaap nongaap result includ tabl press releas confer call inform regeneron host confer call simultan webcast discuss first quarter financi oper result thursday may am to access call dial us intern a link webcast may access event present page regeneron websit wwwregeneroncom a replay confer call webcast archiv compani websit avail day about regeneron pharmaceut regeneron lead sciencebas biopharmaceut compani base tarrytown new york discov invent develop manufactur commerci medicin treatment serious medic condit regeneron commerci medicin eye diseas colorect cancer rare inflammatori condit product candid develop area high unmet medic need includ hypercholesterolemia oncolog rheumatoid arthriti asthma atop dermat for addit inform compani pleas visit wwwregeneroncom forwardlook statement this press releas includ forwardlook statement involv risk uncertainti relat futur event futur perform regeneron actual event result may differ materi forwardlook statement word anticip expect intend plan believ seek estim variat word similar express intend identifi forwardlook statement although forwardlook statement contain identifi word these statement concern risk uncertainti includ among other natur time possibl success therapeut applic regeneron product product candid research clinic program underway plan includ without limit regeneron human genet initi unforeseen safeti issu result administr product product candid patient includ serious complic side effect connect use regeneron product candid clinic trial likelihood time possibl regulatori approv commerci launch regeneron latestag product candid new indic market product includ without limit eylea treatment diabet macular edema macular edema follow branch retin vein occlus alirocumab sarilumab dupilumab ongo regulatori oblig oversight impact regeneron research clinic program busi includ relat patient privaci determin regulatori administr government author may delay restrict regeneron abil continu develop commerci regeneron product product candid compet drug product candid may superior regeneron product product candid uncertainti market accept commerci success regeneron product product candid abil regeneron manufactur manag suppli chain multipl product product candid coverag reimburs determin thirdparti payer includ medicar medicaid unanticip expens cost develop produc sell product abil regeneron meet sale financi project guidanc chang assumpt under project guidanc includ without limit relat eylea us net product sale incom tax oblig potenti licens collabor agreement includ regeneron agreement sanofi bayer healthcar cancel termin without product success risk associ third parti intellectu properti pend futur litig relat thereto a complet descript materi risk found regeneron file us secur exchang commiss includ form k fiscal year end decemb form q quarter period end march ani forwardlook statement made base manag current belief judgment reader caution reli forwardlook statement made regeneron regeneron undertak oblig updat public forwardlook statement includ without limit financi project guidanc whether result new inform futur event otherwis this press releas andor financi result attach press releas includ amount consid nongaap financi measur sec rule as requir regeneron provid reconcili measur contact inform manisha narasimhan phd peter dworkin investor relat corpor communic',\n",
       "  'JJ'),\n",
       " ('the us food drug administr fdaapprov ventana alk df cdx assay accur select patient elig receiv anakinas lymphoma kinas alk tyrosin kinas inhibitor treatment compar anoth common use immunohistochemistri ihc assay a ihc assay studi publish journal thorac oncolog shown for studi research sought compar wide use ihc assay lung adenocarcinoma sampl fluoresc situ hybrid fish ihc ventana alk df cdx assay optiview amplif kit standard ihc test clone a perform lung adenocarcinoma nextgener sequenc perform sampl inconsist result fish ihc result show fdaapprov ihc assay sensit specif posit predict valu negat predict valu a ihc assay sensit specif posit predict valu negat predict valu these find suggest high degre fals posit a ihc assay nextgener sequenc perform sampl fish ihc data differ nextgener sequenc confirm fish data suggest low proport patient alk rearrang negat alk protein express level low percentag patient without detect alk rearrang alk protein expressionposit relat durvalumab plus tremelimumab activ lung cancer the studi also demonstr respons rate alk inhibitor fishnegativeihc analysisposit case respons rate fishpositiveihc analysisneg case refer',\n",
       "  'NN'),\n",
       " ('i know i disappoint ever optimist i hashimoto crohn i realli realli feel like give go my liver deal normal fine anyway i start mp dx crohn summer yay tri fail asa azathioprin mp remicad methotrex humira various diet had surgeri feb subtot colectomi end ileostomi first thing put remiss year had second surgeri th juli revers stoma connect ileum rectum offici flare the fun never begin',\n",
       "  'NN'),\n",
       " ('hello friend my mom plan go nivolumab opdivo ipilimumab yervoy near futur doe anyon suggest complementari care expect side effect etc doe anyon know good scientif studi combin probiot supplement checkpoint inhibitor best ovcadaught',\n",
       "  'VBD'),\n",
       " ('thank much inform i felt alon long time i would like hear stori similar mine sound like alkorg good start i alectinib also well nice meet',\n",
       "  'NN'),\n",
       " ('even hope everyon well ive result recent mri i new lesion show im current rebif mcg last year now ive pretti stress coupl year lose husband follow year dad diagnos bowel cancer this year ive go pip renew stop bit rubbish im go put new activ speak ms nurs think may time switch med this first new lesion ive sinc rebif could stress that caus med becom less effect the nurs mention possibl chang either gilenya tysabri said i mayb bit read ask around peopl experi i go hospit see neurologist so anyon experi either im sure mani tell experi start side effect wear kind thing xx',\n",
       "  'NN'),\n",
       " ('hi five welcom grace im sorri hear stepmom diagnosi your post rais question may affect futur treatment decis was treatment alimta effect stop alimta due progress cancer progress later has shown progress keytruda grow slowli rapid with stage iv diseas usual expect evid diseas disappear although small number patient achiev status instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept you want get maximum benefit treatment move anoth line therapi and immunotherapi keytruda patient dont show benefit immedi patient deriv longlast benefit treatment so base youv said i wouldnt assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress it would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question ive rais well tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('honest way cancer patient sinc diseas like cancer uc knack come back seem go dormant seem disappear word cure touchi remiss prefer cure gone never come back demolish im complet rid diseas remiss im symptom diseas seem suspend which i feel accur depict uc patient get versus total endal cure i feel though word disservic uc communiti mani us get remiss dream seem almost imposs worst day achiev remiss throw cure word around isnt excel idea opinion i know word but uc life whether your current symptom that real realiti need mental prepar it better hope best expect worst expect best trash worst educ awar realiti diseas patient statist key also cure nonsens typic spam buzzword so i understand aspect well year old femal diagnos decemb ulcer pancol spent decemberfebruari hospit treatment remicad sever liver damag stop treatment immedi prednison caus sever weight gain well swollen feet leg becom nonrespons valcyt kill cmv infect tacrolimus bridg biolog medic entyvio current dose',\n",
       "  'JJ'),\n",
       " ('inform compil susan well courtney review jack burk md msaa chief medic offic articl summari shingl caus reactiv varicella zoster virus vzv virus caus varicella chickenpox the reactiv virus caus pain rash cluster fluidfil blister postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain the shingl vaccin zostavax recommend use peopl year older reduc risk shingl the shingl vaccin live attenu vaccin could issu member ms popul medic may modul suppress immun system could pose risk live vaccin individu ms consid shingl vaccin discuss risk benefit doctor pleas note portion articl also appear msaa articl vaccin safeti ms shingl herp zoster overview shingl caus reactiv varicella zoster virus vzv virus caus varicella chickenpox this usual occur decad initi chickenpox infect the reactiv virus caus pain rash cluster fluidfil blister shingl contagi blister dri virusfil fluid transmit chickenpox someon previous expos virus come close contact open rash other symptom shingl includ fever headach chill upset stomach last week month even year postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain area rash occur this chronic debilit pain vari mild sever disrupt one sleep mood activ daili live phn reduc one qualiti life potenti lead social withdraw depress even suicid report scar anoth potenti longterm complic shingl rare case shingl infect lead pneumonia hear problem blind brain inflamm enceph death while peopl one episod shingl second third episod possibl for older individu ms risk shingl complic great without ms individu ms take immunosuppress medic associ risk becom even greater everyon risk shingl great increas get older particular age the risk develop phn caus continu chronic pain complic shingl increas age likelihood experienc longer last sever pain phn addit individu compromis suppress immun system also like experi complic shingl the shingl vaccin accord center diseas control prevent cdc vaccin shingl also known herp zoster zoster recommend use peopl year older reduc risk shingl this includ everyon age group contraind well peopl previous episod shingl andor chronic medic condit the specif chronic medic condit list cdc includ kidney failur diabet rheumatoid arthriti chronic pulmonari diseas the shingl vaccin approv food drug administr fda market brand name zostavax the shingl vaccin given one dose subcutan skin arm common side effect vaccin includ red sore swell itch shot site headach after receiv vaccin individu may around infant young children pregnant women peopl weaken immun system report made someon get chickenpox anoth person receiv shingl vaccin some peopl may develop chickenpoxlik rash near inject site if occur simpli precaut rash cover disappear the shingl vaccin contain thimeros preserv contain mercuri sometim use vaccin no serious advers event seen shingl vaccin test approxim peopl without ms age older the vaccin appear effect least six year may last longer while older individu may get vaccin age appear effect peopl year studi found shingl vaccin reduc risk shingl percent older adult reduc risk phn percent also reduc sever durat pain associ phn the safeti shingl vaccin difficult judg individu ms the current data support use reassur complet vaccin fulli investig ms the shingl vaccin thorough investig ill includ patient whose immun system may compromis diseas drug use treat diseas the shingl vaccin live attenu vaccin issu individu ms mani vaccin use virus inactiv ie kill virus chanc infect anyon the shingl vaccin contain live virus attenu mean strength reduc point cant infect someon healthi uncompromis immun system as mani individu various health condit larg number individu ms take medic may modul suppress immun system a livevirus vaccin may conceiv abl infect someon whose immun system fulli function result either ill medic given treat ill in addit fdaapprov longterm diseasemodifi therapi ms larg dose extend use steroid frequent prescrib treat ms relaps also suppress immun system less common treatment consid evalu safeti shingl vaccin includ experiment treatment ms studi clinic trial ms patient offlabel treatment methotrex imuran azathioprin hematopoiet stem cell transplant hsct antivir medic guidelin shingl vaccin safeti accord extens report advisori committe immun practic harpaz r et al differ treatment need consid shingl vaccin may consid safe individu this report origin nation center immun respiratori diseas divis viral diseas part center diseas control prevent to follow general guidelin as remind individu strong advis consult physician safeti shingl vaccin doctor need look person situat casebycas basi individu get shingl vaccin wait includ anyon ever lifethreaten sever allerg reaction gelatin antibiot neomycin anoth compon shingl vaccin an individu weaken immun system hivaid diseas affect immun system someon take medic weaken immun system peopl immunosuppress therapi includ highdos corticosteroid mg per day prednison equival last two week wait least one month discontinu therapi anyon moder sever acut ill includ anyon temperatur degre fahrenheit higher usual wait recov get vaccin individu may receiv vaccin includ anyon minor acut ill cold may vaccin peopl receiv shortterm corticosteroid therapi less two week lowtomoder dose less mg per day prednison equival topic given via nasal skin inhal administr longterm alternateday treatment low moder dose shortact system corticosteroid consid suppress immun system enough caus concern vaccin safeti therapi lowdos methotrex equal less mgkgweek azathioprin equal less mgkgday consid suppress immun system enough caus concern vaccin safeti special group circumst peopl previous shingl may vaccin although need wait rash clear peopl normal immun system anticip immunosuppress pleas see next bullet point without prior shingl vaccin receiv vaccin soon possibl immun intact vaccin administ least day initi immunosuppress therapi although expert advis wait one month accord msaa chief medic offic jack burk md most ms drug consid immunosuppress consid immunomodul affect immun system differ nonetheless recommend patient consult doctor regard cdc recommend for exampl recommend gilenya fingolimod immun day start gilenya in regard individu receiv recombin human immun mediat immun modul especi antitumor necrosi factor agent adalimumab infliximab etanercept safeti efficaci shingl vaccin administ concurr unknown if possibl administ vaccin initi therapi patient immun status assess physician determin relev risk benefit otherwis vaccin defer least one month stop medic this categori would includ ms medic tysabri natalizumab well mani experiment therapi present clinic trial lemtrada alemtuzumab former campath daclizumab also known zenapax rituxan rituximab ocrelizumab ofatumumab also known arzerra individu take one drug advis talk doctor assess risk benefit shingl vaccin conjunct type diseasemodifi therapi peopl receiv blood product includ antibodycontain blood product may receiv shingl vaccin time list includ intraven immun globulin ivig plasma exchang would also fall categori specifi report patient receiv type treatment advis consult physician get shingl vaccin experi individu undergo hematopoiet stem cell transplant hsct limit consid casebycas basi patient immun status assess physician determin relev risk benefit shingl vaccin approv administ least two year month transplant antivir medic may interfer replic livevirus vaccin anyon take zovirax acyclovir famvir famciclovir valtrex valacyclovir regular discontinu medic least hour administr shingl vaccin possibl these medic use least day vaccin addit note shingl vaccin accord cdc shingl vaccin may given simultan vaccin includ flu vaccin each vaccin must administ use separ syring differ inject site if vaccin administ time shingl vaccin may still given time vaccin provid inactiv vaccin if receiv anoth live attenu vaccin addit shingl vaccin time patient need wait least four week shingl vaccin receiv differ live attenu vaccin the shingl vaccin recommend anyon receiv varicella chickenpox vaccin howev chickenpox vaccin becom avail unit state virtual peopl receiv vaccin chickenpox young receiv shingl vaccin for reason the cdc state healthcar provid need inquir one varicella vaccin histori sinc virtual person recommend age group least next decad receiv chickenpox vaccin addit cdc note anyon older without contraind get vaccin regardless whether rememb chickenpox studi show percent american age chickenpox patient need ask histori chickenpox blood test antibodi insur coverag resourc the follow inform provid cdcs websit the shingl vaccin avail pharmaci doctor offic to find local facil offer vaccin pleas visit wwwzostavaxcom all medicar part d plan cover shingl vaccin costshar vaccin vari medicar part b cover shingl vaccin medicaid may may cover vaccin most privat health insur plan cover vaccin peopl age cover peopl age the merck vaccin patient assist program provid free vaccin elig adult usual individu without insur for inform pleas visit wwwmerckcommerckhelpsvaccineshomehtml call vaccin inform statement avail spanish languag pleas see wwwimmunizeorgvi interest individu may also go cdcs websit inform shingl visit httpwwwcdcgovvaccinesvpdvacshinglesdefaulthtm for inform vaccin ms pleas refer msaa articl vaccin safeti ms for more inform in addit msaa websit individu may call msaa inform ms treatment question msaa client servic depart may email refer much inform articl obtain center diseas control cdc prevent harpaz r et al recommend advisori committe immun practic acip nation center immun respiratori diseas center diseas control prevent',\n",
       "  'JJ'),\n",
       " ('today i met oncologist rd trip juic bar anoth mg bag opdivo nivo two week ago right nd infus i full bodi check dermatologist i fast appear lesion back right hand i bit panic she punch biopsi mole was difficult wait four day patholog came back prais lord negat evil enemi mel i kinda supris base high risk patholog so not sure i think i ned primari lmph node tumor disect well suspici growth remov the onc said probabl wont anoth petct scan month stay biweek opdivo infus month check dermatologist lymph node check everi month also i seem much issu opdivo slug i feel bit tire day mild nausea my blood work look great last three preinfus check it seem like long road sinc novemb deal devil mel start but nice see time thing go way sinc follow forum group i see new member come anxieti fear road front like i i want say find comfort much life road mel realli help wick month peac',\n",
       "  'NN'),\n",
       " ('my husband diagnos sclc februari almost year ago he coupl pretti larg tumor right lung inoper lymph node involv well he began chemo treatment week diagnosi use carboplatin etoposid he cycl day start second cycl also began radiat tumor treatment day straight day then low dose brain radiat treatment pci it last februari juli you correct tether statement practic live cancer center the cancer metastas liver undergon two cycl chemo along one new immunotherapi drug tecentriq he liver tumor gone remain smaller he tecentriq time toler fair well they found spot rib bone stop chemo continu tesentriq ad drug call zometa bone strength he get scan everi month instead everi like begin the decis ultim famili cours would recommend treatment our famili bless still us almost year appear grim situat begin im sure right it veri hard would take cours know go he i say yes i tell honest truth he hospit time low sodium need blood transfus got sepsi top hes alway strong man a brick mason a weaker person may abl endur hes endur i realli believ strength import type treatment but side effect usual someth help though it hard road go i would recommend ani extra time get bless everi day find new immunotherapi drug help sclc despit extrem rough journey alway hope everyon respond differ could easier time husband take care best luck if near md anderson facil husband i would strong recommend i hope share stori help keep us updat',\n",
       "  'NN'),\n",
       " ('cochran databas syst rev apr cd treatment diseasemodifi drug peopl first clinic attack suggest multipl sclerosi filippini g del giovan c clerico m beiki o mattoscio m piazza f fredrikson s tramacer i scalfari a salanti g author inform scientif direct fondazion ircc istituto neurologico carlo besta via celoria milan itali cochran itali depart diagnost clinic public health medicin univers modena reggio emilia via del pozzo modena itali univers turin divis neurolog aou san luigi gonzaga region gonzol orbassano torino itali depart clinic neurosci karolinska institutet stockholm sweden depart epidemiolog biostatist kermanshah univers medic scienc kermanshah iran depart medicin divis brain scienc centr neurosci wolfson neurosci laboratori imperi colleg london du cane road london uk w nn institut social prevent medicin ispm univers bern finkenhubelweg bern switzerland background the treatment multipl sclerosi chang last year the advent diseasemodifi drug mid herald period rapid progress understand manag multipl sclerosi with support magnet reson imag earli diagnosi possibl enabl treatment initi time first clinic attack as diseasemodifi drug associ advers event patient clinician need weigh benefit safeti various earli treatment option take inform decis object estim benefit safeti diseasemodifi drug evalu studi randomis nonrandomis treatment first clinic attack suggest ms compar either placebo treatment assess relat efficaci safeti diseasemodifi drug accord benefit safeti estim benefit safeti diseasemodifi drug evalu studi randomis nonrandomis treatment start first attack earli treatment compar treatment start second attack anoth later time point delay treatment search method we search cochran multipl sclerosi rare diseas cns group trial regist medlin embas cinahl lilac clinicaltrialsgov who trial registri us food drug administr fda report search unpublish studi decemb select criteria we includ randomis observ studi evalu one drug monotherapi adult particip first clinic attack suggest ms we consid evid alemtuzumab azathioprin cladribin daclizumab dimethyl fumar fingolimod glatiram acet immunoglobulin interferon betab interferon betaa rebif avonex laquinimod mitoxantron natalizumab ocrelizumab pegyl interferon betaa rituximab teriflunomid data collect and analysi two team three author independ select studi extract data the primari outcom disabilityworsen relaps occurr least one serious advers event ae withdraw studi discontinu drug ae time convers clinic definit ms cdms defin poser diagnost criteria probabl discontinu treatment dropout reason record secondari outcom we synthes studi data use randomeffect metaanalys perform indirect comparison drug we calcul odd ratio or hazard ratio hr along relat confid interv ci outcom we estim absolut effect primari outcom we evalu credibl evid use grade system main result we includ randomis trial eight openlabel extens studi ole four cohort studi publish the overal risk bias high report ae scarc the qualiti evid associ result rang low low earli treatment versus placebo first month followup there small nonsignific advantag earli treatment compar placebo disabilityworsen fewer fewer particip disabilityworsen interferon betaa rebif teriflunomid relaps fewer fewer particip relaps teriflunomid earli treatment associ fewer particip least one serious ae fewer particip earli treatment averag time fewer like withdraw studi due ae this result most driven studi interferon beta b glatiram acet cladribin associ signific withdraw ae earli treatment decreas hazard convers cdms hr ci compar activ intervent first month followup indirect comparison interferon betaa rebif teriflunomid show differ reduc disabilityworsen or ci we found differ includ drug respect hazard convers cdms interferon betaa rebif teriflunomid associ fewer dropout ae compar interferon betab cladribin glatiram acet or rang substanti uncertainti earli versus delay treatment we find evid differ earli delay treatment disabilityworsen maximum five year followup fewer particip earli treatment fewer there import variabl across intervent earli treatment interferon betab consider reduc odd particip disabilityworsen three five year followup or ci or ci the earli treatment group fewer particip relaps fewer fewer compar late treatment maximum five year followup earli treatment decreas hazard convers cdms followup year ie five year followup hr ci we draw conclus longterm serious ae discontinu due ae inadequaci avail data includ ole cohort studi author conclus veri lowqual evid suggest small uncertain benefit earli treatment compar placebo reduc disabilityworsen relaps the advantag earli treatment compar delay disabilityworsen heterogen depend actual drug use base lowqual evid lowqual evid suggest chanc relaps lower earli treatment compar delay earli treatment reduc hazard convers cdms compar either placebo treatment delay treatment short longterm followup lowqual evid suggest earli treatment associ fewer particip least one serious ae compar placebo veri lowqual evid suggest compar placebo earli treatment lead withdraw treatment discontinu due ae differ drug shortterm benefit safeti uncertain studi indirect comparison avail longterm safeti earli treatment uncertain inadequ report unavail data',\n",
       "  'NN'),\n",
       " ('hi galatea im base republ irelandim lucki consult alreadi patient rituximab happi tri best luck gilenyai hope transit goe well',\n",
       "  'NN'),\n",
       " ('hi gina there encourag evid tagrisso cross blood brain barrier fair well although most anecdot evid so surpris husband doctor switch irinotecan establis track record cns diseas im sorri troubl toler jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('from explor forum one thing clear patient symptom but i find cross road start biolog without certainti i fact crohn in short sinc i flare year sever rlq pain nausea vomit diarrhea loos wateri each flare resolv week steriod diet modif i take lialda mainten still experi rlq pain almost daili nausea vomit i eat sinc i lost approx lbs last colon egd scope non specif inflamm noth impress biopsi my last major flare june lialda month time wbc count k ct show enter ileus small bowel possibl coliti my old gi somewhat lean ibd reluct start treatment i felt best get second opinion current gi fair certain base histori ct find i like crohn small bowel access scope he feel best start entyvio i continu symptom rlq pain low grade temp nausea vomit eat say patient stori so question forum anyon els diagnos base symptom non specif lab imag even though safer biolog come risk cours expens want what best famili',\n",
       "  'VBZ'),\n",
       " ('sorri delay respons well overal uc isnt bad peopl ive seen i havent blood present bms sort sinc first true flare back septemberoctob accord gi improv saw overal entyvio first drug actual truli help not count devil tictac i absolut notic massiv qualiti life improv sinc go entyvio januari one main motiv get surgeri due descript ion doctor gave they basic said i surgeri recoveri time good no drug infus essenti uc well i dont larg intestin anymor as i look around i notic lot peopl jpouch still uc forum page now i know lot peopl help other still diseas i wonder im tri get truli accur pictur life postop i mean would someon longer larg intestin still entyvio meslaminewhen i tri ask person never respond doe uc truli go away surgeri one asterisk kind situat quotehow bad diseas has reach point potenti complic wouldnt wors right symptom liveabl as i mention earlier diseas isnt detremen other i lot problem still i still go i feel i i alway fatigu screw sleep cycl lot drug i onprednison primari offend where i cusp i year old i graduat colleg month ago tri start profession career i even hire process posit right if i got would year solid train graduat academi a flare would devast would ultim result either resign laid ada wouldnt protect given sworn posit appar my doctor parent feel best i surgeri done truli mean uc drug flare up etc behind good i realli want surgeri see qualiti life go backward',\n",
       "  'JJ'),\n",
       " ('hi vvd welcom grace i sorri hear mom diagnosi her type cancer often refer mucin bac great deal inform avail site search term bac tend spread beyond lung mom case bulki adren gland suspici could noncanc caus some instanc bac slow grow much treatment need start immedi although mucin form bac tend grow faster in regard treatment produc tumor stabil mom case good result if symptom blood cough etc improv also good sign respons chemo followup scan help assess result treatment status cancer if point cancer appear grow signific option although patient get good respons immunotherapi respond well long time would certain option especi sinc mom cancer egfralk negat sinc lower percentag patient respond well immunotherapi dr west also note even patient egfr negat may receiv benefit tarceva point may option in addit type lung cancer though rare seen individu oncologist often dr west estim oncologist treat patient mucin bac last coupl decad experi bac seen patient mucin bac past decad two httpcancergraceorgforumsindexphptopicmsgmsg with mind mom might want seek second opinion oncologist experienc mucin bac continu next post jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('june the us fda today approv coba egfr mutat test v bloodbas companion diagnost cancer drug tarceva erlotinib hydrochlorid this first fdaapprov bloodbas genet test detect epiderm growth factor receptor egfr gene mutat nonsmal cell lung cancer patient such mutat present approxim percent nonsmal cell lung cancer nsclc lung cancer lead caus cancerrel death among men women us though common men number death lung cancer women increas accord nation cancer institut estim american diagnos lung cancer die diseas year nsclc common type lung cancer nsclc tumor may shed tumor dna patient blood make possibl detect specif mutat blood sampl test tumor dna use blood sampl also call liquid biopsi approv liquid biopsi test make possibl deliv high individu health care patient said alberto gutierrez phd director offic in vitro diagnost radiolog health fdas center devic radiolog health liquid biopsi also potenti allow physician identifi patient whose tumor specif mutat least invas way possibl for detail go httpwwwfdagovnewseventsnewsroompressannouncementsucmhtm',\n",
       "  'NN'),\n",
       " ('consecut use gilenya lemtrada caus diseas activ ms patient case report suggest httpsmultiplesclerosisnewstodaycomhighmsactivityseenpatientafterconsecutiveuseimmunotherapiescasereportutmsourcemultiplesclerosisutmcampaignfebrssnonusemailcampaignutmmediumemailutmtermbfbadaefeb httpswwwncbinlmnihgovpubm obrigado',\n",
       "  'NN'),\n",
       " ('the colon part bodi digest system the digest system remov process nutrient vitamin miner carbohydr fat protein water food help pass wast materi bodi the digest system made esophagus stomach small larg intestin the colon larg bowel first part larg intestin feet long togeth rectum anal canal make last part larg intestin inch long the anal canal end anus open larg intestin outsid bodi enlarg anatomi lower digest system show colon organ gastrointestin stromal tumor occur colon see pdq summari gastrointestin stromal tumor treatment inform see pdq summari unusu cancer childhood treatment inform colorect cancer children health histori affect risk develop colon cancer anyth increas chanc get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk doctor think may risk colorect cancer risk factor colorect cancer includ follow have famili histori colon rectal cancer firstdegre relat parent sibl child have person histori cancer colon rectum ovari have person histori highrisk adenoma colorect polyp centimet larger size cell look abnorm microscop have inherit chang certain gene increas risk famili adenomat polyposi fap lynch syndrom hereditari nonpolyposi colorect cancer have person histori chronic ulcer coliti crohn diseas year have three alcohol drink per day smoke cigarett be black be obes older age main risk factor cancer the chanc get cancer increas get older enlarg polyp colon some polyp stalk other inset show photo polyp stalk sign colon cancer includ blood stool chang bowel habit these sign symptom may caus colon cancer condit check doctor follow a chang bowel habit blood either bright red dark stool diarrhea constip feel bowel empti way stool narrow usual frequent gas pain bloat full cramp weight loss known reason feel tire vomit test examin colon rectum use detect find diagnos colon cancer the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit past ill treatment also taken digit rectal exam an exam rectum the doctor nurs insert lubric glove finger rectum feel lump anyth els seem unusu fecal occult blood test fobt a test check stool solid wast blood seen microscop a small sampl stool place special card special contain return doctor laboratori test blood stool may sign polyp cancer condit there two type fobt guaiac fobt the sampl stool special card test chemic if blood stool special card chang color enlarg a guaiac fecal occult blood test fobt check occult hidden blood stool small sampl stool place special card return doctor laboratori test immunochem fobt a liquid ad stool sampl this mixtur inject machin contain antibodi detect blood stool if blood stool line appear window machin this test also call fecal immunochem test fit enlarg a fecal immunochem test fit check occult hidden blood stool a small sampl stool place special collect tube special card return doctor laboratori test barium enema a seri xray lower gastrointestin tract a liquid contain barium silverwhit metal compound put rectum the barium coat lower gastrointestin tract xray taken this procedur also call lower gi seri enlarg barium enema procedur the patient lie xray tabl barium liquid put rectum flow colon xray taken look abnorm area sigmoidoscopi a procedur look insid rectum sigmoid lower colon polyp small area bulg tissu abnorm area cancer a sigmoidoscop insert rectum sigmoid colon a sigmoidoscop thin tubelik instrument light len view it may also tool remov polyp tissu sampl check microscop sign cancer enlarg sigmoidoscopi a thin light tube insert anus rectum lower part colon look abnorm area colonoscopi a procedur look insid rectum colon polyp abnorm area cancer a colonoscop insert rectum colon a colonoscop thin tubelik instrument light len view it may also tool remov polyp tissu sampl check microscop sign cancer enlarg colonoscopi a thin light tube insert anus rectum colon look abnorm area virtual colonoscopi a procedur use seri xray call comput tomographi make seri pictur colon a comput put pictur togeth creat detail imag may show polyp anyth els seem unusu insid surfac colon this test also call colonographi ct colonographi biopsi the remov cell tissu view microscop pathologist check sign cancer certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the stage cancer whether cancer inner line colon spread colon wall spread lymph node place bodi whether cancer block made hole colon whether cancer cell left surgeri whether cancer recur the patient general health the prognosi also depend blood level carcinoembryon antigen cea treatment begin cea substanc blood may increas cancer present stage colon cancer key point after colon cancer diagnos test done find cancer cell spread within colon part bodi there three way cancer spread bodi cancer may spread began part bodi the follow stage use colon cancer stage carcinoma situ stage i stage ii stage iii stage iv after colon cancer diagnos test done find cancer cell spread within colon part bodi the process use find cancer spread within colon part bodi call stage the inform gather stage process determin stage diseas it import know stage order plan treatment the follow test procedur may use stage process ct scan cat scan a procedur make seri detail pictur area insid bodi abdomen pelvi chest taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area insid colon a substanc call gadolinium inject patient vein the gadolinium collect around cancer cell show brighter pictur this procedur also call nuclear magnet reson imag nmri pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell chest xray an xray organ bone insid chest an xray type energi beam go bodi onto film make pictur area insid bodi surgeri a procedur remov tumor see far spread colon lymph node biopsi the remov part lymph node a pathologist view tissu microscop look cancer cell this may done surgeri endoscop ultrasoundguid fine needl aspir biopsi complet blood count cbc a procedur sampl blood drawn check follow the number red blood cell white blood cell platelet the amount hemoglobin protein carri oxygen red blood cell the portion blood sampl made red blood cell carcinoembryon antigen cea assay a test measur level cea blood cea releas bloodstream cancer cell normal cell when found higher normal amount sign colon cancer condit there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl colon cancer spread lung cancer cell lung actual colon cancer cell the diseas metastat colon cancer lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi the follow stage use colon cancer stage carcinoma situ enlarg stage colon carcinoma situ abnorm cell shown mucosa colon wall in stage abnorm cell found mucosa innermost layer colon wall these abnorm cell may becom cancer spread nearbi normal tissu stage also call carcinoma situ stage i enlarg stage i colon cancer cancer spread mucosa colon wall submucosa muscl layer in stage i colon cancer cancer form mucosa innermost layer colon wall spread submucosa layer tissu next mucosa muscl layer colon wall stage ii enlarg stage ii colon cancer in stage iia cancer spread muscl layer colon wall serosa in stage iib cancer spread serosa spread nearbi organ in stage iic cancer spread serosa nearbi organ stage ii colon cancer divid stage iia iib iic stage iia cancer spread muscl layer colon wall serosa outermost layer colon wall stage iib cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum stage iic cancer spread serosa outermost layer colon wall nearbi organ stage iii stage iii colon cancer divid stage iiia iiib iiic enlarg stage iiia colon cancer cancer spread mucosa colon wall submucosa may spread muscl layer spread one three nearbi lymph node tissu near lymph node or cancer spread mucosa submucosa four six nearbi lymph node in stage iiia cancer spread mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread one three nearbi lymph node cancer cell form tissu near lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa cancer spread four six nearbi lymph node enlarg stage iiib colon cancer cancer spread muscl layer colon wall serosa spread serosa nearbi organ cancer spread one three nearbi lymph node tissu near lymph node or cancer spread muscl layer serosa four six nearbi lymph node or cancer spread mucosa submucosa may spread muscl layer cancer spread seven nearbi lymph node in stage iiib cancer spread muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread one three nearbi lymph node cancer cell form tissu near lymph node muscl layer serosa outermost layer colon wall cancer spread four six nearbi lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread seven nearbi lymph node enlarg stage iiic colon cancer cancer spread serosa colon wall nearbi organ cancer spread four six nearbi lymph node or cancer spread muscl layer serosa spread serosa nearbi organ cancer spread seven nearbi lymph node or cancer spread serosa nearbi organ one nearbi lymph node tissu near lymph node in stage iiic cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum cancer spread four six nearbi lymph node muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread seven nearbi lymph node serosa outermost layer colon wall nearbi organ cancer spread one nearbi lymph node cancer cell form tissu near lymph node stage iv enlarg stage iv colon cancer the cancer spread blood lymph node part bodi lung liver abdomin wall ovari stage iv colon cancer divid stage iva ivb ivc stage iva cancer spread one area organ near colon liver lung ovari distant lymph node stage ivb cancer spread one area organ near colon liver lung ovari distant lymph node stage ivc cancer spread tissu line wall abdomen may spread area organ recurr colon cancer recurr colon cancer cancer recur come back treat the cancer may come back colon part bodi liver lung treatment option overview key point there differ type treatment patient colon cancer seven type standard treatment use surgeri radiofrequ ablat cryosurgeri chemotherapi radiat therapi target therapi immunotherapi new type treatment test clinic trial treatment colon cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient colon cancer differ type treatment avail patient colon cancer some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial some clinic trial open patient start treatment seven type standard treatment use surgeri surgeri remov cancer oper common treatment stage colon cancer a doctor may remov cancer use one follow type surgeri local excis if cancer found earli stage doctor may remov without cut abdomin wall instead doctor may put tube cut tool rectum colon cut cancer this call local excis if cancer found polyp small bulg area tissu oper call polypectomi resect colon anastomosi if cancer larger doctor perform partial colectomi remov cancer small amount healthi tissu around the doctor may perform anastomosi sew healthi part colon togeth the doctor also usual remov lymph node near colon examin microscop see whether contain cancer enlarg resect colon anastomosi part colon contain cancer nearbi healthi tissu remov cut end colon join resect colon colostomi if doctor abl sew end colon back togeth stoma open made outsid bodi wast pass this procedur call colostomi a bag place around stoma collect wast sometim colostomi need lower colon heal revers if doctor need remov entir lower colon howev colostomi may perman enlarg colon cancer surgeri colostomi part colon contain cancer nearbi healthi tissu remov stoma creat colostomi bag attach stoma after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiofrequ ablat radiofrequ ablat use special probe tini electrod kill cancer cell sometim probe insert direct skin local anesthesia need in case probe insert incis abdomen this done hospit general anesthesia cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu this type treatment also call cryotherapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi chemoembol hepat arteri may use treat cancer spread liver this involv block hepat arteri main arteri suppli blood liver inject anticanc drug blockag liver the liver arteri deliv drug throughout liver onli small amount drug reach part bodi the blockag may temporari perman depend use block arteri the liver continu receiv blood hepat portal vein carri blood stomach intestin the way chemotherapi given depend type stage cancer treat see drug approv colon rectal cancer inform radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer the way radiat therapi given depend type stage cancer treat extern radiat therapi use palliat therapi reliev symptom improv qualiti life target therapi target therapi type treatment use drug substanc identifi attack specif cancer cell without harm normal cell type target therapi use treatment colon cancer includ follow monoclon antibodi monoclon antibodi made laboratori singl type immun system cell these antibodi identifi substanc cancer cell normal substanc may help cancer cell grow the antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus they may use alon carri drug toxin radioact materi direct cancer cell there differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form this may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell this stop cancer cell grow divid cetuximab panitumumab egfr inhibitor angiogenesi inhibitor angiogenesi inhibitor stop growth new blood vessel tumor need grow zivaflibercept vascular endotheli growth factor trap block enzym need growth new blood vessel tumor regorafenib use treat colorect cancer spread part bodi gotten better treatment it block action certain protein includ vascular endotheli growth factor this may help keep cancer cell grow may kill it may also prevent growth new blood vessel tumor need grow see drug approv colon rectal cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell pembrolizumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv colon rectal cancer inform new type treatment test clinic trial inform clinic trial avail nci websit treatment colon cancer may caus side effect for inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show condit chang cancer recur come back these test sometim call followup test checkup treatment option colon cancer for inform treatment list see treatment option overview section stage carcinoma situ treatment stage carcinoma situ may includ follow type surgeri local excis simpl polypectomi resect anastomosi this done tumor larg remov local excis use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage i colon cancer treatment stage i colon cancer usual includ follow resect anastomosi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage ii colon cancer treatment stage ii colon cancer may includ follow resect anastomosi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iii colon cancer treatment stage iii colon cancer may includ follow resect anastomosi may follow chemotherapi clinic trial new chemotherapi regimen surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iv recurr colon cancer treatment stage iv recurr colon cancer may includ follow local excis tumor recur resect without anastomosi surgeri remov part organ liver lung ovari cancer may recur spread treatment cancer spread liver may also includ follow chemotherapi given surgeri shrink tumor surgeri radiofrequ ablat cryosurgeri patient cannot surgeri chemoembol hepat arteri radiat therapi chemotherapi may offer patient palliat therapi reliev symptom improv qualiti life chemotherapi andor target therapi monoclon antibodi angiogenesi inhibitor immunotherapi clinic trial chemotherapi andor target therapi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about colon cancer for inform nation cancer institut colon cancer see follow colorect cancer home page colorect cancer prevent colorect cancer screen test detect colorect cancer polyp unusu cancer childhood treatment cryosurgeri cancer treatment drug approv colon rectal cancer target cancer therapi genet test hereditari cancer syndrom for general cancer inform resourc nation cancer institut see follow about cancer stage chemotherapi you support peopl with cancer radiat therapi you support peopl with cancer cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment colon cancer it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq adult treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq adult treatment editori board pdq colon cancer treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypescolorectalpatientcolontreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('hello fellow mser hope everyon happi well quick question anyon take cocodamol allevi pain top medic take gabapentin pregabalin omeprazol citalopram betahistin dihydrochlorid gilenya baclofen answer respons keep em clean much appreci fluffyolli xx',\n",
       "  'NN'),\n",
       " ('that took stop usual peopl take stop matter long develop antibodi it mean tri infus bodi reject like allerg reaction virus could get pretti sick i think yes almost alway elev onc bodi make ton extra antibodi hang bloodstream patrol infliximab view foreign invad as humira your probabl fine probabl shouldnt remicad for thing i besought lord thrice depart he said my grace suffici thee strength made perfect weak most glad therefor i rather glori infirm i take pleasur infirm reproach necess persecut distress i weak i strong cor',\n",
       "  'NN'),\n",
       " ('marlondagg yes pleas keep us updat ocrevus treatment a minidiari speak benefit challeng etc',\n",
       "  'NN'),\n",
       " ('dear janin thank much link prompt respons we town visitor see mom sorri i didnt acknowledg repli earlier have go link hope discuss result mom onc next week mom chemo appoint i keep updat thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('result phase studi pembrolizumab chemotherapi pemetrex platinumbas drug found combin result signific longer overal surviv os progressionfre surviv pfs compar chemotherapi alon reduc risk death patient metastat nonsquam nonsmal cell lung cancer nsclc these data present american associ cancer research confirm earlier phase studi find lead author leena gandhi md new york univers perlmutt cancer center nyu langon health new yok said data unequivoc alter clinician treat type nsclc befor studi firstlin therapi advanc nsclc lack target mutat egfr alk platinumbas chemotherapi patient tumor proport score program death ligand pdl greater pembrolizumab replac cytotox chemotherapi dr gandhi also author phase studi said small number trial meant daili practic pattern didnt chang number small make definit conclus with patient phase studi howev estim rate os month pembrolizumabchemotherapi group compar placebochemotherapi group median pfs month pembrolizumabchemotherapi group month placebochemotherapi group the median os yet reach pembrolizumabchemotherapi group further rate advers event almost ident two arm similar advers event grade higher relat articl immunotherapi lung cancer are combin regimen path forward time report palliat care need lead more appropri endoflif care nsclc osimertinib improv qualityoflif global health status nonsmal cell lung cancer these result incred clear cut dr gandhi said it earli look clear differ there question result studi there noth wait alter treatment regimen pd pdl inhibitor chemotherapi mount evid suggest pd pdl inhibitor effect treatment nsclc said for instanc data present confer nivolumab ipilimumab advanc nsclc checkmat clinicaltrialsgov identifi nct found combin signific prolong pfs compar platinumdoublet chemotherapi alon the keynot studi clinicaltrialsgov identifi nct allow crossov pembrolizumab monotherapi patient demonstr diseas progress the benefit combin shown patient level pdl express even pdl tumor proport score less dr gandhi said although greatest respons rate group differ found patient tumor proport score greater pembrolizumab combin group vs placebo combin group',\n",
       "  'VBP'),\n",
       " ('ifit would the rituximab trial show profg other put trial cd target antibodi produc plasma cell best choic cd option cd may better the extens data say ocrelizumab still work still worsen it show time brain clear relaps trial extens studi the two year lost time placebo interferon caught cant think better exampl say dump crab',\n",
       "  'JJ'),\n",
       " ('an fyi read long articl includ research datamethod etc i often skip lot middl part least first read conclus discuss that clinic research discuss implic patient use often break taken induct therapi carbotaxolava person watch close ct scan physic check onc everi week so progress start caught earli enough treat chanc recoveri platinum base chemo toxic chemo this good option peopl want need break recov go vacat sit couch without feel sick on hand oncologist andor arent comfort break continu treatment may discuss that fine the recent research show anyon pdl express benefit checkpoint inhibitor immunotherapi pembrolizamub pembro shown longer last efficaci cytotox agent aka chemo if health system requir use chemo progress allow use immunotherapi alimta alon much much common avaistin alon mani peopl use alimta avaitin data ecog trial matur dont know best keep us post best luck janin this repli modifi month ago catdand forum moder this repli modifi month ago catdand forum moder',\n",
       "  'NN'),\n",
       " ('howd go are still give humira time decid go surgeri rout valli said will abl j pouch i boyfriend i still want feel sexi around he say thing dont matter if cant creat pouch life like afterward mani uc patient candid jpouch you wont know absolut sure colectomi after colectomi want sure crohn diseas theyll look larg intestin greater detail remov ensur truli uc case as crohn patient arent elig jpouch long odd crohn want sure possibl moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa uc unimagin crapnado post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('i sure avastin much differ lucenti eylea the basic it avastin come larger phial suitabl cancer treatment instead small one eye treatment the manufactur drug far refus produc smaller amount suitabl eye treatment this mean anoth compani transfer drug smaller phial may increas risk contamin thus infect in fact actual happen avastin use lucenti eylea develop also i heard patient treatment chang avastin one drug longer work they mention tv mani million nhs safe is head',\n",
       "  'JJ'),\n",
       " ('repli post lvkiefer i coliti crohn was remicad entyvio neither seem work they tri imuran made death ill it medicin i react bad im consid allerg it caus vomit diarhea simultan kind like bad symptom crohn coliti amp some folk done great im noton',\n",
       "  'NN'),\n",
       " ('hello i femal live the netherland i diagnos june bilater internuclear ophthalmoplegia migran nausea sensori symptom mri show nonenhanc brain lesion one brainstem lumbar punctur reveal presenc oligoclon band ino resolv i still mild sensori symptom fatigu month followup mri end aug show chang lesion loadvolum start mg copaxon end septemb question nr dr recommend mri month copaxon start i also mayb rebaselin month copaxon start right reach therapeut level becaus lesion found month i know whether creat cop start work question would i good candid cladribin alemtuzumab question i also vit d defici what would good supplement dose dr recommend iuday isnt bit low can vit d benefici impact diseas thank beforehand repli best regard mp',\n",
       "  'NN'),\n",
       " ('lialda effect mild crohn some studi show much effect placebo i think appli modsever cd it pretti effect uc it worth shot i person never success cd gastroparesi fibro arthriti gerd med remicad for thing i besought lord thrice depart he said my grace suffici thee strength made perfect weak most glad therefor i rather glori infirm i take pleasur infirm reproach necess persecut distress i weak i strong cor',\n",
       "  'NN'),\n",
       " ('zyklon wrote wed feb now point patient b t jc virus level high doctor suggest stop veri limit choic time either continu drug high risk go drugfre patient a start ocrevus low pml risk dont forget risk immun reconstitut inflammatori syndrom iri case prove fatal lethal multipl sclerosi relaps after natalizumab withdraw httpnneurologyorgcontentlong natalizumab dramat reduc relaps patient activ multipl sclerosi ms may induc progress multifoc leukoencephalopathi pml a rebound ms immun reconstitut inflammatori syndrom iri describ natalizumab withdraw even absenc pml veri data concern potenti sever neuropatholog event avail we report case yearold patient ms develop fulmin relaps month stop natalizumab lead death despit intens care immunosuppress therapi radiolog neuropatholog find provid interest data regard natur rebound the man death provid interest data scienc how comfort',\n",
       "  'NN'),\n",
       " ('my ms specialist say ocrelizumab avail juli', 'VBD'),\n",
       " ('after i stop take gilenya i take year i bad rebound effect month and moment i start relaps everi month my ms becam agress but rememb everi case differ just take care good luck',\n",
       "  'IN'),\n",
       " ('hi my dad diagnos stage iv nsclc bone metastasi sept he start take irressa nov in feb progress iressa enter azd trial current nd egfr inhibitor azd work well stabl it close two year sinc start take azd amaz also wor eventu progress azd explor option i understand immunotherpi drug effect egfr mutat patient also singl agent like keytruda combin agent just wonder option current avail right mani thank fischer',\n",
       "  'NN'),\n",
       " ('hi christina i suggest speak macular societi there tel email contact websit i thought csr wetmd separ condit although like brvo caus damag problem macular i dont know treatment eg brvo give steroid implant wetmd suffer cant benefit i suppos possibl incred unlucki develop two separ condit or mayb one eventu trigger to csr ten year treatment sound odd i dont know anyth stress make wors there lot drs dont seem know respond differ there often clear path lucenti specif formul eye like eyelea unlik avastin although expens general prefer whole bodi perspect also load dose proper inj check when i inj i often got central blurri day would go other blurri would come later oedema return worsen person lucenti known treatment csr sight worsen notic i would give go there peopl may person experi share use i suspect best wish go forward x',\n",
       "  'NN'),\n",
       " ('hi tamara i dont facebook either tri that anoth stori tagrisso target therapi taken oral everyday for egfr mutant effect drug also fast act some peopl get pain relief within day the outcom data date excel the common side effect fatigu constip edema your friend would benefit oz organ beet juic yuck work keep liver happi for constip check petrasolc citrus fiber lot crucifer veggi thank check michell yesterday pm repli swollen lymph node i worri rower michell repli tomm topic nsclc group hi tom thank check im sit airport watch plane get deic kci head fla forget cancer our first trip sinc diagnosi beach instead acupunctur i get ct result next week take page bob book news samegood news glad hear treatment gone well far i saw articl post anoth forum cbd contraind immunotherapi publish studi cant find link phone thought might want potenti explor the airpark express bus driver morn name ned hope sign pray anoth great outcom let hippi protocol roll michell',\n",
       "  'NN'),\n",
       " ('hi im i diagnos rrms th bday ugh one year ago im gilenya i almost constant headach month ive read line peopl ms get headach my neurologist doesnt seem care headach i feel like brain actual hurt if i go pick someth fast horribl i much anxieti ridicul i worri day work headach get bad i alway form headach how know ms someth els it truli exhaust pretend ok i go home work sleep everi day i guess part life tri stay posit have lot life happi im scare futur hold thank support pam',\n",
       "  'NN'),\n",
       " ('how is my ms i probabl start updat current health status sort page regard current state ms the whole oscillopsianystagmusvertigo vision thing remain number one terribl symptom everi singl day of cours day much wors other symptom becom part baselin i impress alway go t symptom life i definit learn better live doesnt realli make less miser debilit although dizzi vision thing sort becom part new normal main symptom might actual hear complain often fatigu it heavi sinc begin i relaps realli impact life pretti negat way now i realli think i never sit deep depress vision noth feel steadi no alway i almost alway feel complet defeat sever fatigu i never want anyth sit stare wall i alway exhaust everyth i even brush teeth stuff i would consid fun requir mental battl decid i fact muster energi move even medic like nuvigil armodafinil ritalin methylphenid what if not just ms when i first got colorado coupl month ago i want tri see general physician possibl someth els ms contribut abund level fatigu hemochromatosi run famili mayb i check or anemia there mani possibl symptom associ thing alreadi caus ms whole time i develop health condit total mask ms like everyon i ever saw assum new occurr symptom ms thing i never get test someth actual hope result would come back posit i mean yeah posit would mean someth ms life i treat meant get tri someth ms warrant tri past could ticket relief a new neurologist well i saw physician assist ran lab check stuff negat hemochromatosi anemia idea vitamin d b look fine damn at point refer neurologist one want touch learn i ms wouldnt want mess risk su sent neurologist someth like right that probabl reason sometim that feel i cant ever seem get opinion anyon neurologist cours alway go see noth ms so yeah i admit i realli wasnt motiv call make appoint i run low nuvigil neurologist offic back california return call messag call pharmaci regard refil i went ahead made appoint that appoint today i prepar whole find new doctor game plagu mani peopl live chronic ill you know game i talk set appoint get appoint realiz doctor complet quack doesnt want hear anyth suggest actual spent even littl time educ diseas make inform decis regard treatment find anoth new doctor start whole process that game well surpris noth like actual pretti awesom she went histori refil prescript wrote new one set ampyra i abl get ahold like year sent referr mri brain cervic spine talk littl ocrevus ocrelizumab even brought latest ms research topic learn latest ectrim european committe treatment and research multipl sclerosi noth like i expect i worri i would see neurologist graduat didnt realli know anyth ms whatev whole paragraph introduct function anatomi brain textbook dedic ms the thing rememb spent year medic school read book actual total qualifi ms specialist expert hmmm sound like i issu newli graduat doctor think step god nope i dont think i anyway simpl fact even knew ectrim gave level comfort usual take coupl year build medic profession i pretti happi',\n",
       "  'NN'),\n",
       " ('marion im look tri get mother prescrib keytruda offlabel seem pulmonari embol disqualifi everi trial ive look go next for anyon interest look like ucsf keytruda trial specif cholangiocarcinoma patient that enrol httpsclinicaltrialsgovctshownct bostonguy i know pleural effus increas result ag breath improv soon go trial as pulmonari embol though your right might side effect cancer thank info wish best mom',\n",
       "  'NN'),\n",
       " ('wife lumbar punctur posit leptomengen metatsi again nsclc alk posit began new alectinib therapi have seen mark improv day memori balanc gait along posit weight gain this drug alectinib much easier toler crizotinib ceritinib veri hope smoother day awhil not mani studi us point anyon know prognosi alectinib long efficaci pertain central nervous system pleas let know',\n",
       "  'VBP'),\n",
       " ('hi sharon where about aus im cq just thought id let know time frame jc test youv given max ive come back week month but may depend live ive tysabri year june im jc ocrevus would also first choic son im expect wait becom avail this happen insid year ty next best moment i feel quit fluy ish hrs ty lot ive spoken experi noth one patient know call gogo juic if week post diagnosi flaresymptom lead diagnosi eas i hope well keep us post carolin',\n",
       "  'NN'),\n",
       " ('eylea indic treatment neovascular wet agerel macular degener amd macular edema follow retin vein occlus rvo diabet macular edema dme diabet retinopathi dr patient dme eylea dosag administr import inject instruct for ophthalm intravitr inject eylea must administ qualifi physician a micron steril filter needl gaug inch ml luer lock syring gaug inch steril inject needl need eylea avail packag follow vial kit inject compon filter needl syring inject needl see how suppli neovascular wet agerel macular degener amd the recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day month first week month follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day month addit efficaci demonstr patient eylea dose everi week compar everi week see clinic studi some patient may need everi week month dose first week month although effect recommend everi week dose regimen patient may also treat one dose everi week one year effect therapi patient assess regular macular edema follow retin vein occlus rvo the recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day month see clinic studi diabet macular edema dme the recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day month first inject follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day month addit efficaci demonstr patient eylea dose everi week compar everi week see clinic studi some patient may need everi week month dose first week month diabet retinopathi dr patient dme the recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day month first inject follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day month addit efficaci demonstr patient eylea dose everi week compar everi week see clinic studi some patient may need everi week month dose first week month prepar administr eylea inspect visual prior administr if particul cloudi discolor visibl vial must use the glass vial singl use eylea avail packag follow vial kit inject compon filter needl syring inject needl see how suppli use asept techniqu carri follow prepar step prepar intravitr inject follow medic devic singl use micron steril filter needl gaug inch ml steril luer lock syring mark measur ml steril inject needl gaug inch remov protect plastic cap vial see figur clean top vial alcohol wipe see figur remov gaug inch micron filter needl ml syring packag attach filter needl syring twist onto luer lock syring tip see figur push filter needl center vial stopper needl complet insert vial tip touch bottom bottom edg vial use asept techniqu withdraw eylea vial content syring keep vial upright posit slight inclin eas complet withdraw to deter introduct air ensur bevel filter needl submerg liquid continu tilt vial withdraw keep bevel filter needl submerg liquid see figur b ensur plunger rod drawn suffici back empti vial order complet empti filter needl remov filter needl syring proper dispos filter needl note filter needl use intravitr inject remov gaug inch inject needl packag attach inject needl syring firm twist inject needl onto luer lock syring tip see figur when readi administ eylea remov plastic needl shield needl hold syring needl point check syring bubbl if bubbl gentl tap syring finger bubbl rise top see figur to elimin bubbl expel excess drug slowli depress plunger plunger tip align line mark ml syring see figur b inject procedur the intravitr inject procedur carri control asept condit includ surgic hand disinfect use steril glove steril drape steril eyelid speculum equival adequ anesthesia topic broadspectrum microbicid given prior inject immedi follow intravitr inject patient monitor elev intraocular pressur appropri monitor may consist check perfus optic nerv head tonometri if requir steril paracentesi needl avail follow intravitr inject patient instruct report symptom suggest endophthalm retin detach eg eye pain red eye photophobia blur vision without delay see patient counsel inform each vial use treatment singl eye if contralater eye requir treatment new vial use steril field syring glove drape eyelid speculum filter inject needl chang eylea administ eye after inject unus product must discard dosag form strength inject mg ml clear colorless pale yellow solut singledos glass vial intravitr inject contraind ocular periocular infect eylea contraind patient ocular periocular infect activ intraocular inflamm eylea contraind patient activ intraocular inflamm hypersensit eylea contraind patient known hypersensit aflibercept excipi eylea hypersensit reaction may manifest rash pruritus urticaria sever anaphylacticanaphylactoid reaction sever intraocular inflamm warn precaut endophthalm retin detach intravitr inject includ eylea associ endophthalm retin detach see advers reaction proper asept inject techniqu must alway use administ eylea patient instruct report symptom suggest endophthalm retin detach without delay manag appropri see dosag administr patient counsel inform increas intraocular pressur acut increas intraocular pressur seen within minut intravitr inject includ eylea see advers reaction sustain increas intraocular pressur also report repeat intravitr dose vascular endotheli growth factor vegf inhibitor intraocular pressur perfus optic nerv head monitor manag appropri see dosag administr thromboembol event there potenti risk arteri thromboembol event ate follow intravitr use vegf inhibitor includ eylea ate defin nonfat stroke nonfat myocardi infarct vascular death includ death unknown caus the incid report thromboembol event wet amd studi first year combin group patient treat eylea compar patient treat ranibizumab week incid eylea group compar ranibizumab group the incid dme studi baselin week combin group patient treat eylea compar control group baselin week incid combin group patient treat eylea compar control group there report thromboembol event patient treat eylea first six month rvo studi advers reaction the follow potenti serious advers reaction describ elsewher label',\n",
       "  'NN'),\n",
       " ('revscott stomach upset recognis side effect tuvigingilenya howev tuvigingilenya immunosuppress would leav expos runofthemil bug may harder shift',\n",
       "  'NN'),\n",
       " ('it week prednison snack werewolf perfect descript i havent crave like ever even i get period all i want beef potato chocol specif peanut mms i gain lbs i recent lost intent prior diagnos uc sort vigor exercis help combat nogo shake everyth make run toilet i also moon face i wasnt sure i order new glass week ago fit fine i pick look small face i know thatll go away ugh hope humira i start today let ditch prednison soon leftsid coliti dx current mg prednison mg humira biweek saccharomyc boulardii xday wheat glutenfre g lialda month caus migrain stop work budesonid mg week noth',\n",
       "  'DT'),\n",
       " ('had laser time help lot pain faith levothyroxin mcg dicyclomin mg need clonazepam lamict duave two year humira two year simponi wait start entyvio need tb med least mont had second load dose entyvio still entyvio isoniazid mg latent tb finish one year isoniazid latent tb yeah',\n",
       "  'VBP'),\n",
       " ('upal basu roy mph phd director translat research programdirector patient forc lungev septemb end bang the th world confer lung cancer host toronto summer unoffici end new york us food drug administr approv anoth drug dacomitinib lung cancer i sure i miss thing this year world confer lung cancer world lung fond refer biggest world lung ever convenedov deleg countri attend more import meet showcas number practicechang scientif presentationstoo mani list therefor i go tri categor theme chang horizon practicechang scienc pertin entir patient journey screen treatment present as may awar lung cancer screen use lowdos comput tomographi ldct avail us individu high risk develop lung cancer this howev case europ part world result nelson trial europ disclos meet soon chang this trial set determin benefit ldct lung cancer screen enrol patient clear demonstr benefit ct screen men high risk lung cancer the benefit even pronounc women the studi reinforc populationlevel benefit ldct also lay groundwork addit studi look gender differ lung cancer in term lung cancer therapi excit news alkposit lung cancer a clinic trial brigatinib alk inhibitor current approv patient progress crizotinib show drug work realli well firstlin settingeven patient brain metastas soon alkposit lung cancer patient may new firstlin treatment option lungev scientif advisori board member dr scott antonia present updat result pacif trial test immunotherapi chemotherapi radiat chemoradi stage iii nonsmal lung cancer patient nsclc the new result show ad checkpoint inhibitor durvalumab chemoradi provid clear surviv benefit stage iii nsclc patient this big news given stage iii patient uniqu subset nsclc patient treatment option last least small cell lung cancer sclc may score big win result impow clinic trial show addit immunotherapi drug atezolizumab standard chemotherapi regimen sclc benefici the standard care sclc chemotherapi past year inde big deal collabor key chang of cours chang isnt possibl without collabor lung cancer complex diseas requir multipl stakehold tabl come solut the biggest impact collabor highlight oncogenedriven patient group rosder alk posit egfresist ret renegad exon mutat group apart provid support patient caregiv increas awar diseas patient group acceler research rais fund research help patient enrol oncogenespecif clinic trial provid tissu biospecimen creat new mous model studi uniqu subtyp lung cancer as lungev scientif advisori board member dr david carbon point plenari talk scienc matter first step develop effect therapi robust basic scienceand develop mous model studi uniqu subtyp lung cancer first phase test new drug creation new therapi treatment paradigm the scientif communiti also hard work creat new drug subset lung cancer hard treat one subset lung cancer mutat exon egfr her gene these mutat respond standard egfr tyrosin kinas inhibitor work scientif advisori board member dr john heymach show drug poziotinib may use rare subtyp lung cancer in addit scientist creat new drug entrectinib ropotrectinib rosposit lung cancer these drug show promis patient previous treat crizotinib never receiv ros inhibitor i think lungev scientif advisori board member dr juli brahmer plenari present quot no patient left behind communiti strive i left year world lung feel certain take step direct dr basu roy lungev director translat research programsdirector patient forc categori clinic trialsresearch person medicin research',\n",
       "  'JJ'),\n",
       " ('hello everyon hope your great day im year old male i diagnos ms year ago i avoid take medic i afraid side effect problem minor each problem i i reli steroid right i optic neuriti blind spot eye it worst im activ like work i lower eye blind steroid help my neru ophthalmologist told steroid help time i forgot exact i took mri exam couldnt find caus they know caus ms optic neuriti about week ago i start ms medic call gilenya my vision still goe bad ive worri sinc happen is chanc stop vision remain perfect',\n",
       "  'NN'),\n",
       " ('veri bad sometim dead allerg reaction happen docetaxel inject nonalcohol formula do take docetaxel inject nonalcohol formula ever allerg reaction docetaxel inject nonalcohol formula drug polysorb the risk death may rare happen docetaxel inject nonalcohol formula rais peopl liver problem peopl get high dose drug the risk also rais peopl certain type lung cancer treat platinumbas chemo drug past this medicin must given peopl high bilirubin level liver problem rais liver enzym if health problem question talk doctor this medicin may caus swell keep fluid bodi tell doctor swell weight gain troubl breath this medicin may lower abil bone marrow make blood cell bodi need this lead need blood transfus bad sometim dead bleed problem infect tell doctor right away sign infect like fever chill sore throat bruis bleed feel tire weak this medicin must given peopl low white blood cell count talk doctor have blood work check told doctor talk doctor use docetaxel inject see also kisqali it use treat cancer what i need tell doctor befor i take docetaxel inject if allergi docetaxel part docetaxel inject nonalcohol formula if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if liver diseas rais liver enzym if low white blood cell count if take drug atazanavir clarithromycin indinavir itraconazol ketoconazol nefazodon nelfinavir ritonavir saquinavir telithromycin if take voriconazol if breastfeed plan breastfe this list drug health problem interact docetaxel inject nonalcohol formula tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take docetaxel inject nonalcohol formula drug health problem do start stop chang dose drug without check doctor what thing i need know i take docetaxel inject tell health care provid take docetaxel inject nonalcohol formula this includ doctor nurs pharmacist dentist avoid drive task action call alert clear eyesight see docetaxel inject nonalcohol formula affect you may chanc get infect wash hand often stay away peopl infect cold flu you may bleed easili be care avoid injuri use soft toothbrush electr razor if upset stomach throw loos stool diarrhea hungri talk doctor there may way lower side effect your doctor may start drug help swell talk doctor get vaccin use docetaxel inject nonalcohol formula may either rais chanc infect make vaccin work well rare bone marrow problem call myelodysplast syndrom mds happen patient treat docetaxel inject nonalcohol formula a type leukemia also rare happen if question talk doctor hair loss common docetaxel inject nonalcohol formula most time normal hair growth come back sometim hair growth gone back normal talk doctor some peopl felt tire weak docetaxel inject nonalcohol formula this may last day sever week call doctor sign bad caus problem daili live go away rare lung problem happen docetaxel inject nonalcohol formula call doctor right away sign lung breath problem like short breath troubl breath cough fever this medicin caus sever bowel problem neutropen enterocol this problem dead sometim earli first day sign happen call doctor right away stomach pain without fever tender stomach diarrhea if older use docetaxel inject nonalcohol formula care you could side effect this medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take docetaxel inject nonalcohol formula if pregnant get pregnant take docetaxel inject nonalcohol formula call doctor right away how medicin docetaxel inject best taken use docetaxel inject nonalcohol formula order doctor read inform given follow instruct close it given infus vein period time a steroid drug like dexamethason given docetaxel inject nonalcohol formula lower side effect talk doctor tell doctor steroid drug use doctor told what i i miss dose call doctor find see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign infect like fever chill bad sore throat ear sinus pain cough sputum chang color sputum pain pass urin mouth sore wound heal sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign liver problem like dark urin feel tire hungri upset stomach stomach pain lightcolor stool throw yellow skin eye dizzi pass a fast heartbeat a heartbeat feel normal a burn numb tingl feel normal veri bad headach chang hear muscl pain weak ani skin reaction this medicin may caus tissu damag drug leak vein tell nurs red burn pain swell blister skin sore leak fluid drug go bodi this medicin may caus certain eye problem call cystoid macular edema cme you may need eye exam use docetaxel inject nonalcohol formula call doctor right away chang eyesight like blur eyesight loss eyesight what side effect docetaxel inject all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away upset stomach throw mouth irrit mouth sore feel tire weak hair loss chang nail dri skin chang tast chang sens smell constip not hungri joint pain flush eye red more tear weight loss heartburn these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw docetaxel inject if need store docetaxel inject nonalcohol formula home talk doctor nurs pharmacist store consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area some drug may anoth patient inform leaflet check pharmacist if question docetaxel inject nonalcohol formula pleas talk doctor nurs pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'JJ'),\n",
       " ('hello my mom whole brain radiat multipl met brain lung cancer egfr exon t m negat end two month ago she start tagrisso first line therapi due evid leptomening diseas unfortun develop symptom suggest interstiti lung diseas tagrisso she respond well drug brain lung six week my question sinc drug long progess diseas develop brain thank',\n",
       "  'NN'),\n",
       " ('david i want tri sway one way regard continu keytruda i want let know common first dose keytruda see swell look like growth cancer my mom current experienc although symptom swellinggrowth her ct show thicken around area tumor backsid trachea her pulmonologist scope trachea took biopsi he report see swell scar tissu much els the biopsi came back negat cancer so point assum coupl thing this may swell due immun system attack area could also mass tcell bunch attack tumor there may cancer cell area biopsi get my mom finish th keytruda treatment keytruda chemo keytruda ct thicken th treatment cell pdl mutat whatev decid i wish best it look like youv quit journey take care steff',\n",
       "  'NN'),\n",
       " ('danield i got carboplatin alimta avastin my tumor shrank half they stay stabl went mainten avastin when stop chemic treatment tumor made ground gain matter week i sick chemotherapi first week everi three week',\n",
       "  'JJ'),\n",
       " ('by jay hancock kaiser health news nov sherees hickson multipl sclerosi flare spasm leg symptom get wors she could still walk take care son six year doctor diagnos diseas attack central nervous system earlier symptom slur speech vision problem resolv treatment other linger tire sometim still fell this summer doctor switch ocrevus drug approv delay progress diseas clinic trial better older medicin genentech south san franciscobas subsidiari swiss pharma giant roch make ocrevus it one sever drug multipl sclerosi deliv intraven hospit clinic such medicin becom increas expens group price mani case well year hospit deliv drug often take cut upcharg drug ad hefti fee infus clinic hickson receiv first two ocrevus infus outpati two week apart juli august and bill came patient sherees hickson singl mother work health aid train medic coder live girard ohio becaus ms left disabl work medicar also medicaid backup total bill two ocrevus infus taken outpati caresourc hickson medicar managedcar plan paid discount hickson got bill balanc calcul share hospit insur reimburs continu read',\n",
       "  'NN'),\n",
       " ('for opdivo side effect', 'NN'),\n",
       " ('hello i ask communiti anybodi expereinc tarceva overcom problem my mother year old diagnos nsclc egfr mutat she prescib tarceva mg june she sever rash itch swallow joint pain went away month but month treatment start develop nausea lack appetit i wouldnt say realli lack appetit sinc alway hungri want eat couldnt she lost tast everi food bodi regist food tri consum includ water juic milk she couldnt eat anyth due hunger becam weak so doctor stop medic two week start gain back abil eat then put mg take day develop symptom so doctor suggest take tarceva month also antibiot day h pylori dure time regain abil eat start enjoy food couldnt eat month anyway doctor reduc drug mgday she start take day ago i see symptom cannot take food the sight food make nauseat cannot eat we tri sever nausea medicin none realli help anybodi kind problem tarceva ani way i feel like die cancer shell die hunger i confus sure pleas let know anybodi kind expereinc tarceva',\n",
       "  'NN'),\n",
       " ('i start gilenya midfebruari i dont think i experienc sideeffect but i know everyon differ i think sever peopl post say felt bad start drug have tri put gilenya search box',\n",
       "  'NN'),\n",
       " ('i suspect md mean multipl use case ocrelizumab i think ocrelizumab may becom standard treatment ms a treatment two infus year effect good risk profil',\n",
       "  'NN'),\n",
       " ('mari if take moment analyz worst case scenario ms tumor stroke that good news less bad also consid nervous breakdown first exacerb trust judgement slow move diseas cours found earli enough respond correct now first breath pamper small way i cant live onedayatatim philosophi obsess i make today good you youv got time next appoint pass take opportun nice thing then becom offici recogn ms pick fight yet pick someth start swing om perfect often time enough but may want explor mani pharmaceut option peopl didnt year ago i found aubagio agreeabl middl hsct see thread if i werent i would use ocrelizumab there option keep head fight like mofo faith optim creat physiolog feedback loop heal good luck mar',\n",
       "  'NN'),\n",
       " ('from multipl sclerosi trust announc nice approv ocrevus rrms certain restrict',\n",
       "  'NN'),\n",
       " ('ikhlaq yes alectinib proven effect brain mani peopl alectinib effect rest bodi sinc leptomening diseas lepto cancer line brain difficult treat alectinib would lead choic treatment sinc new treatment mani oncologist still want use radiat area caus symptom if brother symptom brain met outsid line stereotact radiat may still option move alectinib again new drug without much research direct lepto alk patient oncologist may info may need introduc idea this excel exampl partner one treatment busi medic oncologist treat mani type cancer may know new practic promis isnt written standard practic flow chart the follow quot along articl nation institut health may help talk brother onc addit alectinib report activ alk nsclc patient leptomening diseas httpswwwncbinlmnihgovpmcarticlespmc in case awar new confer video target therapi lung cancer patient forum held cleveland oh coupl week ago httpcancergraceorglungtargetedtherapiesinlungcancerpatientforumpresentationsandhandout keep us post best luck brother janin',\n",
       "  'NN'),\n",
       " ('hello so mani time ive start post havent sure ask today here full stori upon father diagnosi nsclc rib hip back brain liver kidney metastasi began chemo treatment radiat brain rib at first respons within two month chemo almost back normal self hed put weight oxygen even back volunt air forc base we full hope then chemo stop work the oncologist put immunotherapi tecentriq as soon start treatment lost appetiteweight becam weak slept lot these seem like side effect treatment howev day ago new scan confirm treatment wasnt work tumor grow multipli his oncologist said next cours treatment would radiat new tumor brain start new chemoimmuno combo treatment unfortun day later home nurs worri contract pneumonia call paramed take hospit while hospit doctor said wasnt kick pneumonia increas becam weaker couldnt sit get bed lot pain the doctor said probabl coupl month recommend hospic we contact oncologist confirm hospic inpati best cours action trust knew best decid today make move hope would take best care get home we let hospic feel made wrong choic how know give what right i live amsterdam stay mom dayton oh care father thought best i dont know provid enough he need full time care how know go',\n",
       "  'NN'),\n",
       " ('i dont get i feel relat great last six week week start plaquenil two week last remicad ach went away i felt like thing manag noth seem bring back ach lack sleep stress food thought solut now i wake today day anoth dose remicad i feel like total junk everyth oppress sore sick ach i dont get noth differ to top i plan see rheumi thursday blood work result sinc wouldnt talk phone wait week i realli need discuss issu im major snow storm come morn offic hour away im first appoint i call today reschedul basic told i allow reschedul they refus even tell next appoint i offic like ive cancel two day notic now thank listen i guess i low toler thing feel crappi',\n",
       "  'JJ'),\n",
       " ('for first time sinc diagnosi i includ pharmaceut inform event initi i rather apprehens found silli attend one close proxim not i glean good bit inform present i also made import ms warrior contact this even i plan travel morgantown order hear posit effect lemtrada ms infus unfamiliar i never consid infus part diseas treatment friend told anoth newer drug read major news paper so ocrevus event pop somewher close i consid attend lectur well dure recent doctor visit explain three medic treatment multipl sclerosi infus highest list time that make sens evid expens timeinvas method it requir entir day complet infus least happen twice year inject least effect new excit oral drug second infus suppos bomb so origin drug choic beta seron practic dinosaur world ms combat i actual find rather excit mean ms research medic investig definit progress option explor daili basi give hope mysteri solv sooner later occur to make work though drug compani need help weed best worst yes comrad mean human guinea pig agre go trial test result final result along way i usual fair game jump experi at point i realli anyth lose but end goal around long possibl my son senior high school next year we colleg attend career explor driver licens hes interest acquir becaus pretti much save life begin horribl medic journey i owe best hang around long possibl these big pharm event help the i learn better life decis even though i realli not relish idea infus treatment i do need learn it myourjob ms advoc learn it easi get excit learn process it equal disturb learn realiti said quest not tri sad sack i need share warn label drug i hear tonight they warn but warrior super hero and super hero bold go man gone dont allow follow word frighten shake dive research serious infus reaction lemtrada caus serious infus reaction may caus death serious infus reaction may happen receiv hour longer receiv lemtrada you receiv infus healthcar facil equip staff train manag infus reaction includ serious allerg reaction urgent heart breath problem you watch receiv hour longer receiv lemtrada if serious infus reaction happen receiv lemtrada infus may stop tell healthcar provid right away follow symptom serious infus reaction infus left healthcar facil swell mouth throat troubl breath weak fast slow irregular heartbeat chest pain rash to lower chanc get serious infus reaction healthcar provid give medicin call corticosteroid first infus treatment cours you may also given medicin infus tri reduc chanc reaction treat happen certain cancer receiv lemtrada may increas chanc get kind cancer includ thyroid cancer skin cancer melanoma blood cancer call lymphoprolif disord lymphoma call healthcar provid follow symptom may sign thyroid cancer',\n",
       "  'NN'),\n",
       " ('roch ocrevus ocrelizumab addit report case progress multifoc leukoencephalopathi pml rais neurologist alarm despit analyst concern most physician familiar treat pml said event negat affect medic uptak multipl sclerosi ms despit contrari market opinion the fda advers event report system faer list three case pml ocrevus far follow one report case pml june expert discuss potenti addit effect ocrevus biogen tysabri natalizumab though ultim conclud case like due latter carryov effect',\n",
       "  'NN'),\n",
       " ('hello my father suffer stg nsclc tripl negat pdl last month he yrs old sinc perform score doctor advis chemo carboplatinpaclitaxel keytruda immunotherapi cycl it help reduc pleural effus reduc tumor increas appetit pain signific howev week ago doctor found new lesion c c cervic vertebra now doctor say diseas progress keytruda need immedi stop need put paclitaxel ps given tarceva due lack option has anyon els boat im confus lot posit effect start keytruda cervic lesion new go make devoid treatment option whatsoev can continu keytruda coupl cycl scan he alreadi palliat radiat cervic lesion fyi pleas advis i help father surviv diseas long possibl thank sudipto',\n",
       "  'NN'),\n",
       " ('hey guy ive take tecfidera two year bad relaps offer cladribin lemtrada fingolimod i chosen cladribin found isnt actual avail area yet idea just wonder anyon els wait cladribin avail area thank jemma',\n",
       "  'NN'),\n",
       " ('anoth reason i wont take ocrelizumab progress ms ever becom avail', 'NN'),\n",
       " ('hi sameen welcom grace i sorri hear progress mother cancer one line therapi tagrisso known effect lung cancer tm mutat efficaci clear nontm posit diseas it isnt safe tri certain easili toler therapi chemotherapi realli question whether help if followup scan show signific progress typic option would chemotherapi sinc shes alreadi tri immunotherapi target therapi if doesnt want tri anoth chemotherapi option continu weaken point doctor doesnt feel someth toler unfortun want look palliat therapi keep comfort possibl there time patient improv result palliat therapi general good choic make patient comfort possibl my best wish mother comfort jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('ad previous comment check full data present atrophi measur use mtr sensit mri techniqu purpos classic mri techniqu use alemtuzumab ocrelizumab trial hard compar appl orang',\n",
       "  'NN'),\n",
       " ('as report current intern associ studi lung cancer th world confer lung cancer abstract pl the new england journal medicin antonia et al phase iii pacif trial shown signific improv overal survivala coprimari endpointwith durvalumab imfinzi vs placebo chemoradiotherapi unresect stage iii nonsmal cell lung cancer nsclc an earlier report trial support approv durvalumab set februari basi improv progressionfre surviv studi detail in intern doubleblind trial patient random may april receiv durvalumab mgkg intraven iv n iv placebo everi week n month consolid patient unresect stage iii nsclc without progress cycl definit platinumbas chemoradi random perform day receipt chemoradiotherapi stratifi accord age sex smoke histori the primari endpoint progressionfre surviv assess blind independ central review overal surviv overal surviv as data cutoff march median followup overal surviv month overal surviv month durvalumab group vs placebo group p median overal surviv reach confid interv ci monthsnot reach vs month confid interv ci monthsnot reach the stratifi hazard ratio hr overal surviv durvalumab vs placebo p the overal surviv benefit durvalumab observ across prespecifi subgroup updat analysi show median progressionfre surviv vs month stratifi hr ci after discontinu studi treatment durvalumab group placebo group receiv addit anticanc therapi median time death distant metastasi month durvalumab group vs month placebo group stratifi hr ci new brain metastas found vs patient investigatorassess median time second progress death month vs month stratifi hr ci safeti profil safeti profil similar previous report grade advers event occur durvalumab group vs placebo group advers event led treatment discontinu vs patient common caus pneumon group vs advers event special interest occur vs grade vs serious advers event occur vs patient advers event led death vs the investig conclud this trial show surviv advantag durvalumab therapi concurr chemoradi therapi patient stage iii unresect nsclc no new safeti signal identifi the studi fund astrazeneca the content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       "  'NN'),\n",
       " ('we thank drs bhatia puri comment articl the random clinic trial rct remain design refer evalu theoret effect treatment when sampl size suffici rct ensur compar treat control group an addit advantag margin causal estim ie treatment effect entir treat popul vs entir control popul nevertheless well establish rcts perform optim circumst overrepresent treatmentadher patient low frequenc morbid etc result nonrepres conclus reallif practic observ studi close repres reallif treatment effect treat control patient often noncompar due lack random we compar fingolimod vs natalizumabtr patient clinic radiolog outcom year no studi compar outcom patient make work origin strengthen perceiv impress natalizumab clinic superior least patient aggress diseas we agre safeti complianc data would strengthen research data unavail as conclud articl rct need object compar natalizumab fingolimod barbin l rousseau c jousset n et al compar efficaci fingolimodvsnatalizumab a french multicent observ studi neurolog zwarenstein m treweek s what kind random trial need cmaj for disclosur pleas contact editori offic',\n",
       "  'NN'),\n",
       " ('id like tri cladribin i cant claim much progress id like feel normal i sang verdi requiem semipro choir we stand still minut now im home exhaust set we sang twice extrem activ realli drain thigh muscl im sure cladribin would help extrem urinari urgenc problem i less minut reach toilet that cloth i mri come sometim if there activ i shall plead cladribin',\n",
       "  'NN'),\n",
       " ('repli post ltrish hi trish my yearold son start stelara crohn treatment he initi infus one mainten dose feel well he side effect point he take stelara methotrex previous humira month develop antibodi prevent happen we deni insur first time approv appeal send best wish good health success new medic',\n",
       "  'JJ'),\n",
       " ('so i start g yesterday year tec c anyway soon tell far littl tire anywaysi want bring i havent seen anyon mention thread i vision ekg first dose appoint home nurs came vision ekg nurs doctor came hous yesterday hour monitor this arrang gilenya go program they said option home test avail area i said hell yeah i live somewhat rural ks mile south kansa citi so like i live huge metropoli anyon els start g home option',\n",
       "  'NN'),\n",
       " ('avengr i think i address earlier post mayb we much common except i spent last year read everyth avail appli clinic trial foster relationship other clinic trial statesfl i miss last trial fight ms decad even though dxd rrms key qualifi lem state depend insur carrier either must rrms relaps form ms payer becom bias us older patient they want us deem progress declin coverag dmd i dont think tysabri discuss lem i taken drug lem requir infus first month particip year clinic trial it reset immun system first day ms trait unlearn tysabri suppress immun system reset carri risk pml lem halt revers progress ms particip trial no risk pml tysabri requir continu month infus foreverthat slow progress ms ses serious drug howev common one lem thyroid relat easili detect manag use month blood test paid full genzym common rx drug lem research done right use approv drug take after lem diminish chanc ses ocrelizumab still year away approv my best friend wc bound horribl disabl i fight by tht third year post lem walk milesday felt well she round infus setback still benefit great this short cheat sheet top head i think hit major point talk neuro better yet find someon speed current best ms therapi she tell tell think i wish best matter decid',\n",
       "  'NN'),\n",
       " ('we talk oncologist husband pet scan last week he keytruda sinc midnovemb also got one lowdos yervoy three week ago next one tomorrow mix result most met shrunk fact one near spine put husband wheelchair hospit last novemb disappear there one small new spot elsewher spine the spot adren gland look brighter scan his liver look littl wors blood work so mix bag the oncologist think new spot spine well brighter spot adren gland could due introduct yervoy sinc might led addit inflamm she say hard tell scan the liver issu might also yervoy he go back blood work week half monitor liver close he also get anoth pet scan three month bar worsen symptom meantim get clearer idea whether drug realli work she said overal meet posit im still pretti sad i hope better news everyth shrunk but i guess keep play wait game',\n",
       "  'NN'),\n",
       " ('i agre say fingolimod empti blood hope peopl well this import altern peopl gene mean igg job proper',\n",
       "  'JJ'),\n",
       " ('hello everyon hello coliti everyon thread i research topic i interest potenti get umbil cord stem cell therapi done coliti clinic got panama i got touch stem cell institut panama quot k umbil cord stem cell treatment includ hotel accommod transport two peopl one thing i though interest doctor i contact said i need stop remicad stem cell treatment i read stop entyvio im actual entyvio as us i went function doctor last week said perform umbil cord stem cell therapi patient the umbil cord come frozen cold pack it done via infus he said multipl treatment need quot k first one k second one he also said stem cell regul fda one need fda approv that probabl qualiti control difficult i problem find clinic conduct stem cell therapi umbil cord i couldnt find mani peopl tri i hope post someon done would share experi former cfsme fibromyalgia suffer symptomfre year fibromyalgia complet gone immunizelab painrelief develop uc past treatment chines herb ayurveda acupunctur medit med prednison almost kill mesalamin hydrocortison enema noth hospit sever pancol remicad help stop work current entyvio',\n",
       "  'NN'),\n",
       " ('look honest answet happen stage lung cancer spread brain bone spine spinal fluidcan actual tarceva help',\n",
       "  'NN'),\n",
       " ('veg wrote perhap first thing test jvc marker someth like excus ignor youll know whether rule drug list yes i think norm plan start gilenya tecfidera testif jcvirus posit prior startup just saw week anoth rrms drug approv eu zinbryta daklizumab seem potenti danger sideeffect i guess time tell posit i mention case jcv posit explor option hope get well',\n",
       "  'NN'),\n",
       " ('hi fano i dont know i would make connect low albumin crizotinib ineffecaci as dr west said it may well crizotinib actual associ direct caus decreas albumin level hasnt identifi yet low albumin level common enough cancer especi mild decreas albumin doesnt realli set alarm bell and patient dont rush emerg room low albumin level side effect caus visit er tend one get attent httpcancergraceorglungtopiclowalbuminlevelspost jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('im sorri i continu understand ocrelizumab trial chang dogma regard ppms reinforc alreadi knew near decadeold rituxan ppms trial while encourag appear subgroup ppms patient anticd drug moder effect name younger less disabl enhanc lesion popul repres greater ppms popul the dont appear like see benefit drug the ocrelizumab trial clear frontload patient like respond base inform glean previous rituxan trial strang trial statist underpow prove disprov efficaci patient without enhanc lesion i hate read nefari intent may none seem like gross oversight like conscious decis part drug manufactur muddi water come get drug approv ive seen reason believ ocrelizumab less effect rituxamab treat ppms rituxamab would appear much friendlier safeti profil it clear reason ocrelizumab develop rituxamab due soon come patent decis near blew drug compani face ocrelizumab lupus crohn trial halt patient death the ms trial prove save grace deem ms patient higher toler risk due morbid natur diseas my neurologist other practic routin use rituxamab treat ppms patient rate success would expect given statist accru anticd ppms drug trial these doctor seem quit disgruntl fact ocrelizumab see much hype rituxan alreadi avail albeit label may safer agent grant progress battl ppms herald ocrelizumab appear least shroud sort reason concern reason develop potenti frighten side effect profil appear clever manipul trial data effect as person like ppms i yearn day real reason hope provid us drug compani andor research at best ocrelizumab seem small increment step one mere replic efficaci alreadi exist drug honest sorri im come over cynic critic work dr g put ocrelizumab it seem much research group involv truli cuttingedg outsid box bang ocrelizumab drum detour discov long sought black swan forev alter ms treatment paradigm',\n",
       "  'NN'),\n",
       " ('a month back i ask neuro shingrix she didnt get answer nmss say the cdc recommend shingrix nonliv vaccin prevent herp zoster shingl relat complic the vaccin given two dose separ month recommend zostavax previous approv vaccin shingl shingrix approv adult year older whether prior episod herp zoster dose zostavax chronic medic condit unless specif reason individu get adult vaccin influenza pneumococc pneumonia vaccin no studi shingrix done peopl ms howev two clinic studi shingrix increas immunemedi condit the cdc indic person take lowdos immunosuppress therapi go begin take immunosuppress medic take shingrix it import discuss vaccin healthcar provid treat ms ensur appropri my next ocrevus infus octob i tri get shot earli juli',\n",
       "  'NN'),\n",
       " ('insomniacoffeelov they offer tysabri option well gilenya i went ocrevus bit aggress suspect i may devic diseas help i sinc ocrevus immunosuppress good luck gilenya i hope goe well',\n",
       "  'NN'),\n",
       " ('hi all just finish round cisplatinalimta chemo boy cisplatin realli joke yeow still held whop lb weight throughout even got last infus go me anyway first scan tumor drop cm suv max went lymphnod suv drop well so go right direct least next meet surgeon im told want anoth biopsi lymphnod he want make sure longer cancer commit surgeri this may dumb question butif activ wouldnt cancer also tumor still activ can remov activ tumor safe lymphnod i knowask surgeon stufflol i cring idea cut live cancer i know done alll time butfreak littl bad experi mom surgeryling i guess anywaythey tentat schedul week taxolcarboradi treatment pend surgeon determin or i say definit surgeri lol tomi read blog receiv treatment i know consid lowdos chemo given radiat ani idea low was half dose less ugghhhif i get thrush straight week im gonna extrem grouchi oncologist keep tell wont bother much heh',\n",
       "  'NN'),\n",
       " ('fightermclaudepa i would echo word i think know horribl enemi fight win courag tenac help eventu overcom this forum will abl make differ alway show messag we capitul sharingsearch i liter brown fluid drawn left plural caviti show rbc norm im also work year votrient month go opdivo progress how much longer i surviv for us question the day come scourg beaten each done fighterm made huge differ cours qualiti messag view ncivet',\n",
       "  'NN'),\n",
       " ('if husband activ bleed sever symptom cannot wait around get person prefer i one eylea inject horribl circumst i prep povidon iodin i allerg i endur itch want scrach etc month but heal leak found i could wait month next inject my problem see antivegf inject prepar inject click expand dcukmod said pleas dont think suggest anyth option op husband refus get bed attent hospit mean noth would happen i also state took assess medic condit account my suggest safeti net suggest get someth done situat zero look like serious potenti in world i would beat door seen asap talk i recognis everyon react way experi other might find accept even unpalat endur sometim heavili compromis situat better problem ignor conscious unconsci click expand thank there danger may get bed treatment we day still depress refus get we appoint laser tuesday next week inject follow week he hasnt said wont attend lot depend see if treatment doesnt need discuss prognosi may get okay i ask pal clarifi happen we appoint diagnost consult i cancel rearrang later date buy us time my plan get treatment start make enquiri referr elsewher i dont want delay treatment would good know option thank support this unbear im desper tri hold togeth',\n",
       "  'JJ'),\n",
       " ('diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r negat m alk kras ros pd pdl met treatment st carboplatinpemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrexedavastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question is tagrisso good altern m negat never smoker if altern current treatment yale dr roggerio lilenbaum can suggest suitabl clinic trial ct mass ny can suggest doctor second opinion',\n",
       "  'NN'),\n",
       " ('befor fmt less blood stool start get form frequenc now there lot blood especi morn stool mushi piec frequenc hard realli call progress dx leftsid uc fulmin flare sinc start fmt clinic trial feb dx wmycobacterium avium paratuberculosi map sept stop amat week due intoler med other entyvio everi week low dose naltrexon mg bedtim natur ferment current status linger rectal bleed otherwis healthi',\n",
       "  'NN'),\n",
       " ('hello that sound like pretti unhelp way given diagnosi ms were given pointer neurologist drug thought consid apart ignor inject and contact detail ms nurs run option someon knowledg the incred thoughtless doctor make want shout swear of cours overwhelm it may expect diagnosi even still hit like hammer forehead i would anticip emot bit place next daysweeksmonth mayb longer dont feel constrain see posit accept ms crap and best imo fight big stick ie strong diseas modifi drug in term diseas modifi drug dmds side effect balanc benefit the point dmd reduc number sever relaps and dmds vari wide efficaci but balanc effect come potenti side effect the first dmds market initi inject betainterferon copaxon these join variant type interferon copaxon essenti though come milder side effect averag relaps reduct rate ad group aubagio day pill in opinion i give aubagio bodi swerv still got relaps reduct rate come long list possibl side effect these drug categori mild effect and youv told ignor option the next group categori more effect gilenya cladribin tecfidera they tablet relaps reduct rate they possibl side effect serious other side effect seem resolv drug stop gilenya tecfidera daili pill cladribin aka mavenclad taken year period time year i would expect cladribin tecfidera best option group the last categori veri effect lemtrada ocrevus tysabri these infus averag relaps reduct rate signific wors potenti side effect lemtrada taken year run risk attach includ develop autoimmun thyroid diseas tysabri month infus also risk particular rare brain virus call progress multifoc leukoencephalopthi pml but develop antibodi virus call john cunningham virus jcv posit the risk quit well manag regular blood test real consider the newest categori ocrevus taken everi month iv infus signific much less serious potenti side effect this would probabl safest best option group have look httpswwwmstrustorgukaboutmsmstreatmentsmsdecisionsaid this decis aid goe lot detail various drug benefit mean take possibl side effect if given contact detail ms nurs id talk himher well famili andor friend decis make like also affect close famili if youv given access ms nurs tri phone neurologist secretari ask get touch nurs talk option someon understand theyr fair essenti i use think pretti bad show bad old day i given four video four inject avail film made drug compani told watch pick one time improv term number drug avail interperson term youv told avoid pick one other i wish best luck choic drug if chose lower risk categori drug would cours still potenti move one effect categori drug but mani peopl face activ ms head straight effect drug get hold hope avoid potenti disabl futur for part ive unlucki dmds i side effect drug ive tri copaxon stop work ive ms year start relaps year relaps stop go give copaxon anoth whirl simpli that option becaus ive spent near year dmd free im quit bad disabl this reason i would definit start decent dmd soon peopl bad experi mani drug i sue',\n",
       "  'NN'),\n",
       " ('love articl alway as person live ms year diagnos year i know share diseas modifi therapi even particip clinic trial i fail five therapi four t cell deriv therapi copaxon therapi i recent start ocrevus ocrelizumab this first b cell deriv therapi im hope one for worth risk as therapi frank drug take your take risk qualiti life matter right',\n",
       "  'VBD'),\n",
       " ('my headach mild i start problem vision sometim difficult read focus eye one tarcet i still use pazopanib mg per day i stop complet headach turn way wors it like biggest tumor start grow sooner later need plan it possibl radiat pazopanib keytruda compin could kill tumor cm i cant count i see medic reason surgeri wouldnt possibl effect biggest tumor as long reason oper tumor i think continu tri find somepodi will oper biggest tumor start grow wait tumor caus emerg would give poor chang surviv of cours new tumor appear chang everyth far hasnt happen i need talk neurosurgeon like i miss someth last time i short interact surgeon i ok possib die surgeri yes know statist good heatcar i diseas rare doctor dont know anyth hard feel disappoint i know i advantac us dont get fight hard by way univers hospit treat first still doenst recommend surgeri asp i mean surgeri one patient year tki main tumor remov',\n",
       "  'NNS'),\n",
       " ('look recommend manag side effect tagrisso diarrhea current take mg tri imodium caplet they didnt help much now i use lomotil',\n",
       "  'JJ'),\n",
       " ('repli post coop thank inform everyon sinc i last post son start wean prednison weve seen doctornutritionist natur remedi my son high dose liquid turmer heavi duti probiot digest enzym sbi protect immun health hes also iron still were tri go gluten free start slow not easi teenag boy start small chang recent test result pretti good inflamm test normal no longer anem vitamin d low surpris we live mn much sun next step see gastro dr still recommend remicad we pursu need he pass get last blood test needl phobia isnt get better but wont stop us biologicsif need hes pretti well i honest dont know prednison supplement dietari chang will find soon prednison done goe back feel wors good luck everyon deal diseas it hard know help hear other experi',\n",
       "  'VBP'),\n",
       " ('first line treatment monthsstandard chemo progress second line treatment monthscrizotinib symptom improv remark ct scan show slight progress mass liver determin work third line treatment monthsopdivoorigin symptom return cough fatigu breath difficulti pend ct scan determin work question is possibl return crizotinib opdivo is data suggest would either effect could result serious problem',\n",
       "  'JJ'),\n",
       " ('well near breakdown boat load stress final given solid diagnosi rrms last mri show sign activ also told im go start ocrevus treatment januari buzz even come close today good day',\n",
       "  'NN'),\n",
       " ('del egfr wt egfr lr the water case two drug loos bound drug make noncoval interact henc trap water one constraint compact aris exon delet taken togeth structur interact may account increas activ afatinib exon delet result subsequ improv overal surviv observ pool analysi lux lux these model consist emerg preclin clinic data regard preferenti activ afatinib egfr',\n",
       "  'NN'),\n",
       " ('a nod ema convinc doubter cladribin benefici riskbenefit profil would send messag generic use could give drug truli global potenti in situat trial anoth induct treatment would potenti redund term safeti efficaci howev test generic cladribin versus ocrelizumab peopl relaps ms health econom outcom could interest',\n",
       "  'JJS'),\n",
       " ('i shot lucenti eye laser surgeri one eye await appoint eye so far goodi notic improv sight',\n",
       "  'NN'),\n",
       " ('post past follow mix respons year ago my mother law stage nsclcstart iressa first line biopsi egfr posit this back juli was month mix respons attempt get aura trial back nov she reject previous receiv kidney transplant certain antirejectionimmunosuppress med they three round carboplatinpemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia they stop pemetrex stop work due complicationscanc progress tube insert assist fluidseem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far i know result came back negat t mutat this yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil various antirejectionimmunosuppress med kidney transplant novemb sound like without posit t mutat option limit dr plan tri three round pemetrex see respons the next option taxoter dr said much stronger could side effect just wonder option immunosuppress current cours dr want get touch transplantkidney dr discuss option just wonder idea i send along so three year anniversari diagnosi juli year appreci time',\n",
       "  'NN'),\n",
       " ('hi there this certain place get weve sclc truli one worst there noth wrong feel howev feel certain noth offens voic howev i want correct someth regard tecentriq clinic trial data general oftentim youll read studi report headlin seem big deal dont get peopl excit so studi tout major breakthrough report month improv pfs os whatev those baselin statist report across kind diseas medic howev practic mean prolong peopl live month rather mean peopl doesnt work subpopul sclc patient prolong life signific mani case even longer time period studi that immunotherapi seem work produc durabl respons distinct popul peopl usual eventu stop work doesnt help peopl so husband tumor right genet profil chanc may well lifesav but much new treatment terribl diseas much uncertainsom peopl dont right sign genet test somehow work peopl right sign arent help it crap shoot best luck everyth',\n",
       "  'NN'),\n",
       " ('cheer stumbler post repli im concern daili pill self inject i done year anyway im gilenya moment look forward hear anymor opinion i mske final decis',\n",
       "  'NN'),\n",
       " ('thank info neda what theori gilenya fail stop progress diseas sequest b tcell lymph node also thought fail rituxan intrathec trial progress patient it reduc bcell activ brain effect i understand decreas neurofila level therefor pull plug do think need better medic monoclon antibodi medic destroy bcellsplasma cell brain how cladribin fit pictur progress ms brain access lower b t cell',\n",
       "  'NN'),\n",
       " ('laura said lot question pleas dont post anyth realli person forum first thing first you need regist gp your resid near exet befor i obvious dont know whether youll need medic insur access nhs check soon i knowledg whys wherefor pleas research make decis im ppms idea gilenya dr drs name remov moder royal devon exet hospit excel high thought i believ all best tippi x',\n",
       "  'VBZ'),\n",
       " ('jacobosantamartabarr studi httpsclinicaltrialsgovctshownct present recruit evalu whether ocrevus slow progress primari progress ppms secondari progress spms ms',\n",
       "  'JJ'),\n",
       " ('hi sharonk i thank son recov time if dont mind i express opinion treatment option first i would choos gilyena near effect tysabri ocrevus also case pml report europ gilyena vast greater number case report usa so give paus also btw case pml tecfidera report europ much greater usa also the biggest favor son educ use research site httpmultiplesclerosisresearchbternativehtml second i would serious consid wait ocrevus begin tysabri difficult get the reason ms often rebound vengeanc come drug what tysabri keep certain destruct cell enter cns those cell still circul blood stream when tysabri remov cell rush caus major flareup ms the protocol switch tysabri ocrevus guess game right for peopl go fine i believ but mani pleasant that i would give serious thought wait ocrevus there ms drug i would even consid tysabri ocrevus poor effect andor aw side effect combin jmho the option i might consid year old son would stem cell transplant legitim well respect institut ps i spent year studi ms treatment behalf wife ms she one first patient receiv tysabri earli trial continu extrem well today she jc virus posit consid ocrevus best wish sharon your son fortun pleas consid ocrevus it virtual effect tysabri without pml risk true littl risk tysabri first two year treatment but littl like ride tiger safe long stay get safe quit tricki there drug i would even come close consid effect treat ms but jmho pleas understand some peopl develop neutral antibodi particular drug may limit option case reason one approv drug may okay',\n",
       "  'NN'),\n",
       " ('i mp felt great month later i hospit day cyclosporin i even met surgeon i i left hospit mp cyclosporin anoth month i probabl would fine i didnt stop mp i hate stuff i could never sleep i keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('hello i new came across place look advic new treatment i diagnos rrms i ok rebif time recent mri activ lesion i also suffer dizzi spell weak left hand worst terribl fatigu memori loss difficulti concentr it got point peopl work dont know i ms say i look like someon taken batteri i tri hard let peopl notic get harder i also random symptom find hard say normal ms caus anyway i went hospit today med look due mri result the advic neurolagist go mavenclad gilenya i read everyth i could find also look i sure choos i like idea maveclad year treatment total day year i know i still need monitor seem ideal someth said bother i sure they said gilenya tablet daili mean i stop effect wear mavenclad revers not sure problem seem final also say treatment need year what happen year noth mention anywher cours expect ms stay remiss i think thing i need email ms nurs she say would yreat wirh mevenclad would work gilenya coupl altern the side effect th gilenya seem wors i drawn mavenclad just realli hard make decis i know none tell choos help know might other shoe least understand im deal thank read post would appriciat advic similar situat also anyon mavenclad treatment i know start seen post anyon start thank',\n",
       "  'NN'),\n",
       " ('im start entyvio tomorrow late afternoon the nurs said plan hour my dad want come bc would feel better i told like im get chemotherapi anyth im embarrass goe id rather sit read whatev it make feel less big deal but im let come along bc i know parent thing im wonder i shouldnt make plan next day compar infus i feel like might less side effect is tri optimist i kind feel like go breez has anyon experi experi side effect',\n",
       "  'JJ'),\n",
       " ('hi larri standard chemo pretti hard i got carboplatin alimta avastin i sick first week treatment okay shape week i friend get chemoan immunotherapi someth current i think sick first week treatment seem work best luck wife',\n",
       "  'NN'),\n",
       " ('see believ and regeneron pharmaceut want peopl see like retin diseas togeth intouch solut compani hascreat virtual augment realiti app call in my eye allow viewer experi blurri wavi line black patch caus differ type retin diseas the app avail itun googl app store use without vr goggl work two mode in stori mode viewer look around doctor offic full degre see three patient wait choos patient open person stori along video life like birthday parti picnic shown specif retin eye diseas view the three diseas featur neovascular agerel macular degener wet amd diabet macular edema dme macular edema follow retin vein occlus mefrvo the second view live mode engag phone camera allow viewer see whatev field vision three differ retin condit free daili newslett like stori subscrib fiercepharma biopharma fastgrow world big idea come along daili our subscrib reli fiercepharma mustread sourc latest news analysi data drug compani make sign today get pharma news updat deliv inbox read go subscrib now the app includ brand regeneron treatment eylea origin meant tool sale rep use eye specialist physician howev work began idea grew broaden app use caregiv famili friend anyon retin diseas it easi talk retin diseas clinic perspect term letter chart number gain challeng like daytoday experi retin diseas natali mancuso senior product manag market ophthalmolog regeneron said interview realli immers someon experi creat empathi we want make sure get folk engag order drive action educ brent scholz vice presid execut creativ director intouch also note import empathi call app bridg understand when patient first encount vision problem go doctor grip worri thought thing like abl drive lose independ scholz said it pretti emot thing doctor great deal fact patient told us tend talk clinic dont alway seem fulli understand whatth patient feel what stake regeneron midst slowdown eylea superstar ed that drive compani top line sinc us launch late the compani recent offer expect singledigit percentag growth fall short invest communiti predict forecast med expans rate',\n",
       "  'NN'),\n",
       " ('i saw ms nurs yesterday ask cladribin question we cannot prescrib we teach hospit part formal trial so i cannot they obvious will prescrib offticket would requir cooper oncolog well my problem hospit i could move also teach hospit the person tell would prescrib neurolog nurs visit wife week away yet a move london question geoff',\n",
       "  'NN'),\n",
       " ('hi adam happi new year i diagnos uc month ago im still struggl diseas cant say i remiss yet sinc longer deal would like ask sun although i live us year im origin south america no histori famili big side diseas inde first time i heard i diagnos so im still illiter topic howev one issu i alway heard told run sun in word sun peopl diseas autoimmun diseas becaus autoimmun diseas trigger skin cancer even remiss take medic may caus skin cancer case right remicad imuran ani feedback provid be south america rais sun cours i never crazi one whole day sun without protect devast thank',\n",
       "  'NN'),\n",
       " ('i wonder anyon ever combin two biolog humira stelara exampl cant find data notion i guess requir cooper compet compani product unlik test',\n",
       "  'JJ'),\n",
       " ('janin thank repli we tri thing oncologist staff suggest either work knock wife we tie citrucel imodium store brand combo see may help citrucel mention dr harman post link us could provid info chemo link layman version pro con chemo lung cancer some would give us understand expect need go chemo rout the oncologist mention alimta one drug want use she also mention anoth drug start c want combin alimta moment cannot think name found i written thank jkcath',\n",
       "  'NN'),\n",
       " ('today day i start gilenya i sure know feel anoth day anoth medic life multipl sclerosi ms like in i took part phase three clinic trial gilenya still went name fingolimod time i trial coupl week liver react to fair i taken lot tylenol day blood test i later found i assign higher dose med trial still doctor standoffish place back onto med sinc hit market but recent like mani ms i funnel med tire side effect i final decid worth risk trial error shop right med one thing i realli never expect i diagnos diseas i alway figur doctor would set protocol drug treatment ms taught realiti bit differ the truth everyon differ we respond differ medic way it isnt easi decis figur medic proven effect we must also consid toler amount type side effect bodi the first medicin i tri rebif it fair toler i abl take medicin time everi time i would take ibuprofen go sleep earli dosag even five year pass i becam tire sleep three even week i becam tire flu everi monday wednesday friday night most i becam tire tire began realiz year son life fill tire version countless bedtim stori goodnight kiss went miss i sad time chang almost two year ago i began tecfidera again drug suppos i took medic religi reward prevent new lesion brain spine this medicin differ i longer inject fatigu flu three night week in way tecfidera felt like cold glass water on hand side effect my experi med sever stomach pain turn red multipl time day see also relaps ms med for multipl sclerosi best ms treatment center ms treatment center you might also like ms walk again deal with side effect i told side effect would lessen time didnt i told eat protein fat i took pill would help the problem life becam balanc act eat right food order get past side effect two year life yield pound weight gain without valid way lose pound i becam depress felt overrun worn i need free terribl side effect it amaz daili stomach ach burn skin sensat mind day pile next page libbi experi tri new med deal with side effect eat past med work well use i began feel tunnel vision view life happi encroach for first time mani year i felt terrifi my big decis quit came month ago i shop mall husband son i done everyth right i eaten hearti breakfast low carb one day eat right wasnt enough my husband look i knew look well said honey need get someth eat your turn red not i thought i knew true the burn began drip way scalp peopl alreadi begun stare we rush healthiest thing could find pick crpes i accident chosen wrong kind i want capres crpe one i actual chose cover can mushroom absolut worst in meantim i look like oompa loompa i flush i almost purpl i face continu reaction shove terribl food throat i sat tabl frozen verg tear my husband get worri tri get talk my head reel i told everi doctor i seen past two year side effect oftentim i would turn red offic right eye i search help none seem concern they fluf like small tradeoff lose abil walk see how could i argu logic still i empti shred yet i word left husband want desper speak my bodi burn i tire eat time often stuff like tabl front for second i even thought mayb bodi meant live world mayb i suppos live that thought terrifi get dark i never want give someth aw terribl horribl wrong as i look one set worri eye i realiz husband son see see also relaps ms med for multipl sclerosi best ms treatment center ms treatment center you might also like book everi mser should read the time come i final said i need quit tecfidera now i drop tecfidera i see easi step away tri someth new but i thick wasnt i felt to i run short option to idea tri gilenya clinic trial result riski honest still might look though i realiz thing gotten pretti dark i dark person natur thing realli pile feel trap i felt i write today remind allow thing get dark turn around start walk toward light i pride person never give person never quit sometim though quit one thing way continu anoth in case med i chose come run life rail my life import med my life worth risk tri someth scari new',\n",
       "  'NN'),\n",
       " ('aw lorrain that crap what shame youv stop tysabri im exact posit current dmd either tysabri gave rais liver enzym i stop take then tecfidera i presum drug cant take jcv status gave deplet lymphocyt i stop ive alreadi bad side effect avonex fail copaxon ie start relaps given histori fact im disabl ms year i dont think anoth dmd possibl differ posit im sure you get anoth dmd even one that got wors relaps reduct rate like beta interferon copaxon have alreadi tri what gilenya is possibl or one super drug bear risk lemtrada hsct cladribin have got ms nurs if get onto herhim see what avail otherwis appoint set see neurologist if get hisher secretari get one sort you shouldnt left adrift raft even someth isnt good tysabri better noth hope youll abl get someth sort sue',\n",
       "  'NN'),\n",
       " ('grouseman wrote the dose schedul sound similar wife current trial attempt irinotecan erbitux without avastin placebo they drop fu previous folfiri ad erbitux she think still get avastin base previous experi she still ace inhibitor use avastin use though bp usual low begin she infus monday noth day get hit problem i dont know use higher dosag erbitux she toler well rash came week right away think subsid prior yesterday infus i cours interest ucsd trial i contribut research class drug particular ci dacomitinib i still believ despit failur dacomitinib erlotinib big pfizer nsclc trial archer dacomitinib still superior egfr famili inhibitor the ucsd trial look promis we know egfr inhibitor becom resist one lay pathway divert make tumor resist revert egfr inhibitor becom effect so i wonder also dose schedul concentr use trial isnt work similar hit tumor hard relax enabl tumor slide altern signal pathway mani question hope trial answer i wonder would consid use dacomitinib arm crowd fund trial also regard grouseman good point question grouseman thank first i wish wife good result trial in term point i think mechanist goal delay resist via puls dose much mind you rais interest question dacomitinib the final trial protocol written yet i discuss pi i think intent focus use lmw egfr inhibitor better dose control pk cetuximab pk quit variabl peopl long halflif i big fan altern dose schedul general strong scientif basi tri cheer dk',\n",
       "  'NN'),\n",
       " ('i think descript protocol give cladribin websit omidm', 'JJ'),\n",
       " ('have ppms go mexico may hsct rituxan part process was go check i could replac rituxan ocrevus base info mayb worth',\n",
       "  'NN'),\n",
       " ('ive interest intraocular sustain drug deliveri system year i particip clinic trial sever deliveri system this articl describ recent develop technolog design deliv fluocinolon acetonid treat patient uveiti sustain period approach less invas current avail surgic implant system at a glanc the surgic implant fluocinolon acetonid intravitr implant mg effect treat chronic uveiti howev requir surgic placement caus cataract format elev intraocular pressur a less invas mg fluocinolon acetonid intravitr implant deliv inject pend fda approv treatment uveiti the origin intravitr fluocinolon acetonid implant fluocinolon acetonid insolubl lipophil synthet corticosteroid the first surgic implant fluocinolon acetonid intravitr implant i evalu prototyp look like elong cylind we implant eye patient sever panuv abl control inflamm it predict deliveri system could releas drug year deem practic develop would way design studi assess well system work everyon involv includ mani patient investig would long gone time drug deplet i also involv clinic evalu nextgener devic surgic implant fluocinolon acetonid intravitr implant mg retisert bausch lombval design releas drug rough year the us fda approv implant base result two phase studi the implant indic treatment patient chronic uveiti affect posterior segment eye ie intermedi posterior panuv i still find drug deliveri system use i use patient either intoler system medic unilater diseas usual macular edema system find opportun for improv the surgic implant mg fluocinolon acetonid intravitr implant effect caus cataract format elev intraocular pressur iop it import note cataract occur within year virtual everi phakic patient receiv implant in fact whether sustain drug deliveri system steroid administ frequent enough long enough time period caus cataract the rise iop implant although control often requir glaucoma procedur anoth drawback addit mg fluocinolon acetonid intravitr implant must surgic implant or what less invas option avail that under idea develop threeyear inject fluocinolon acetonid intravitr implant mg eyepoint pharmaceut use compani durasert technolog clinic evalu a fluocinolon acetonid intravitr implant mg name iluvien alimera scienc approv fda treatment diabet macular edema dme patient previous treat cours corticosteroid clinic signific rise iop alimera scienc licens right dme indic eyepoint former psivida retain licens right develop implant use patient uveiti meanwhil alimera seek approv european union use iluvien treatment noninfecti posterior uveiti licens agreement eyepoint pilot studi befor new indic ad drug clinic test requir i perform pilot investigatoriniti studi ii inject mg fluocinolon acetonid intravitr implant patient posterior uveiti i first provid inject fluocinolon acetonid intravitr implant two releas rate treat patient intermedi posterior panuv the studi later modifi includ gday implant commerci avail version in pilot trial implant place eye patient noninfecti intermedi posterior panuv the primari endpoint chang status uveiti studi eye we look rate recurr time status patient untreat fellow eye comparison eye inflamm eye none eye receiv implant recurr inflamm year time period wherea patient less sever affect fellow eye receiv implant signific recurr ultim wors visual acuiti base result ii decid proceed phase trial undertaken center unit state europ india phase trial patient enrol control phase trial chronic uveiti recurr inflamm least year least one eye dure year enrol either two separ recurr requir treatment treat system immunosuppress steroid least month least two inject local therapi patient random assign receiv either inject mg fluocinolon acetonid intravitr implant sham procedur the treatment administ clinic result the primari endpoint recurr uveiti studi eye within month a secondari endpoint recurr uveiti within year other outcom measur includ recurr uveiti fellow eye year at month uveiti recur treatment eye compar sham group this differ statist signific at year recurr rate shamtreat eye treat eye at year fewer treat eye untreat eye lost line visual acuiti in word twice mani patient shamtreat group line greater loss discuss base result phase trial eyepoint submit new drug applic nda fda januari fluocinolon acetonid intravitr implant mg durasert threeyear posterior uveiti the nda includ data two phase studi achiev primari efficaci endpoint month the safeti profil patient treat implant consist safeti profil steroid treatment consid standard care diseas dexamethason intravitr implant mg ozurdex allergan fluocinolon acetonid intravitr implant mg the fda given compani target date novemb respons nda follow observ base experi clinic trial record recurr inflamm in ii i observ recurr inflamm patient year implant we seen recurr year weve also patient recurr i believ latter case much cure diseas patient overal diseas activ decreas time iop respons iop respons steroid general quit low phase studi at month three eye implant group end need surgeri address iop elev compar two patient shamtreat group there minim differ two group experi patient develop iop respons tend earli if havent develop one end year odd wont problem addit therapi whether patient requir addit system local therapi anoth import question get potenti reduct treatment burden in group receiv implant patient need system therapi wherea patient receiv sham inject requir therapi that twice mani patient need addit system therapi receiv implant the need local therapi intraperiocular steroid inject also much greater sham group compar treatment group figur size comparison year inject fluocinolon acetonid intravitr implant mg left surgic implant fluocinolon acetonid intravitr implant mg right draw comparison although surgic implant mg fluocinolon acetonid intravitr implant inject mg fluocinolon acetonid intravitr implant contain drug use similar sustainedreleas technolog place anatom locat par plana insert quit differ the mg implant small cylindr polyimid tube inject gaug needl injector releas drug one end the surgic implant mg implant lamin coat silicon polyvinyl alcohol figur the mg implant releas drug semiperm membran port one advantag surgic implant drug deliveri devic come play vitrectom eye stay place doesnt move around also aphak eye inject implant tend move field vision lodg vitreous base could potenti migrat front eye caus problem cornea anoth inject treatment option patient uveiti dexamethason intravitr implant mg that implant indic treatment noninfecti posterior uveiti last week month often use instanc sever inflamm look ahead the hope inject mg fluocinolon acetonid intravitr implant achiev fda approv later year becom viabl option physician want provid longterm therapi patient uveiti officebas procedur retisert packag insert waterford ireland bausch lomb revis decemb iluvien packag insert alpharetta ga alimera scienc revis novemb alimera scienc receiv accept file obtain approv iluvien noninfecti posterior uveiti indic europ press releas alimera scienc januari httpinvestoralimerasciencescomindexphpnewsreleasesnewsreleasedetailsalimerasciencesreceivesacceptancefilingobtainapprov access june eyepoint pharmaceut product pipelin httpeyepointpharmacompipelin access june pilot studi fluocinolon acetonid intravitr insert fai treat intermedi posterior panuv iluvien clinicaltrialsgov clinicaltrialsgovctshownct access june jaff gj lin p keenan rt ashton p skalak c stinnett ss inject fluocinolon acetonid longact implant noninfecti intermedi uveiti posterior uveiti panuv twoyear result ophthalmolog safeti efficaci inject fluocinolon acetonid intravitr insert clinicaltrialsgov clinicaltrialsgovctshownct access june safeti efficaci studi fluocinolon acetonid intravitr fai insert subject chronic noninfecti posterior uveiti clinicaltrialsgov clinicaltrialsgovctshownct access june jaff gj american uveiti societi winter meet park citi utah jan glenn j jaff md retina surgeon duke eye center durham north carolina member retina today editori advisori board financi disclosur consult eyepoint pharmaceut tag fluocinolon acetonid implant retisert implant uveiti relat news research test stem cellbas retin implant dri amd with encourag result physician research usc roski eye institut collabor california institut show firstinkind stem cellbas retin gensight biolog announc toplin result phase clinic trial gs patient leber hereditari optic neuropathi lhon gensight biolog announc phase studi gs raavnd patient leber hereditari optic neuropathi lhon fail meet primari endpoint sh treatextendstop protocol wet amd longterm outcom a retrospect chart review perform eye patient neovascular agerel macular degener amd treat intravitr antivascular endoth',\n",
       "  'CC'),\n",
       " ('i rituxan sure doctor due sever i round mg separ week first two next month cd absolut zero prior th yes like say i switch ocrevus despit first line work fda approv ms like get vig rituxan didnt provid old',\n",
       "  'JJ'),\n",
       " ('ncot httpjamajamanetworkcomarticleaspxarticleid httpwwwadaorgenscienceresearchscienceinthenewscannabisandperio pancol uc sinc sept averag bmsday time respons remiss therapi salofalkasa enema oral g clinic trial drug fail therapi entyvio antimadcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       "  'NN'),\n",
       " ('as nsclc survivor id like add side effect abnorm especi cisplatin alimta he bare finish wbr wasnt long ago jim said still work i carboalimta fatigu extrem sometim i would tri make someth eat go lay when hit need rest i couldnt push it month chemo i start get energi back howev i still year get fatigu easili day unfortun call new normal person learn adjust differ is still take folic acid daili stop alimta this suppos done month complet alimta is steroid he realli tri eat varieti food probabl stay away spici acid eat smaller meal time day could make differ energi level wish best take care judi stage iiia adeno dx srs chemo carboalimta x ned local recurr surgeri remov lrl cm involv pleura chemo carboalimta x ned',\n",
       "  'VBD'),\n",
       " ('im love gilenya no relaps sinc i went i various cognit issu though', 'JJ'),\n",
       " ('fda accept supplement biolog licens applic sbla tecentriq combin chemotherapi firstlin treatment peopl metastat nonsquam nsclc egfr alk genom tumor aberr httpswwwgenecommediapressreleasesfdaacceptsgenentechssupplementalbiol',\n",
       "  'NN'),\n",
       " ('last night ocrevus approv ms primari progress relaps form ms given infus everi month this first treatment approv primari progress ms huge breakthrough',\n",
       "  'IN'),\n",
       " ('sep oa novel therapi met ret braf oral abstract oa activ crizotinib met ros posit nsclc result ac trial deni morosibilot nathali cozic mauric prol josian otto julien mazier pierrejean souquet rastislav bahleda mari wislez sophi de guibert bertrand menneci christo chouaid renaud sabati suzanna bota radj gervai vroniqu verriel vroniqu haddad gilbert ferretti frdriqu nowak cline mahier ait oukhatar gill vassal',\n",
       "  'NN'),\n",
       " ('repli post mentinga i sorri experi i feel embarress go restroom anyon near terribl inconveni i wish i answer could make better my husband said thing insensit i dont think person understand hurt word especi joke topic selfconsci in welcom nd son after birth i spiral insan infect i skin infect need medic attent one requir hospit i recent start switch remicad entivyo hope help occur skin infect howev two week ago i got shower notic small red circl spot arm i think either eczema psoriasi come back my husband time decid say skin issu anyon know i absolut hurt crush i selfconsci look especi skin issu i sinc dianos uc i told comment hurt explain apolozi similar spous doesnt eras insecur caus comment thank littl coconut oil clear spot i alway rememb remark time tinest flaw skin i current see therapist help work emot my uc much stress induc two littl one stress common theme person life i also work full time life constant insan perhap see therapist dont alreadi help channel emot some person dont understand sometim want feel taken consider i dont know youv watch nail httpswwwyoutubecomwatchvedhdahrog great video show sometim men tend want fix problem instead listen if youd ever like penpal email communiti everyth',\n",
       "  'NNS'),\n",
       " ('ladybug wrote i terribl hair loss start aubagio diet i cut hair short i stop aubagio start take gilenya biotin my hair grow veri fast fill thin patch i know aw feel my hair long i dread wash id golf ball size ball hair hand time good luck that realli good know ladybug yes ive cut hair short mean shower doesnt get block quick how much biotin take',\n",
       "  'VBP'),\n",
       " ('hateucyou may right i realli posit ask that thing work anyway bleed miracl i got approv first place humira i dont think option avail i realli dont approv biolog huge deal expect grate thatwhich i samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergiesintoler current reduc pred g wait start humira next week',\n",
       "  'JJ'),\n",
       " ('i well opdivo stop work i would like use yervoy boosterbut onc say insur wont pay strong i hear differ count could i feedback coleridg',\n",
       "  'NN'),\n",
       " ('hi deb im keytruda stage melanoma god sent yrs ago treatment melanoma immunotherapi i keytruda yr least anoth yr go the treatment easi toler take hrs start finish side effect toler far one ive fatigu bone ach brain fog so far side effect stop immunotherapi immuno rash im prednison hope back treatment wks i work full time yr im take time concentr fight i heard lot great result immunotherapi lung cancer keep expand trail immunotherapi cancer dont respond convent chemo good luck mom hug jeanni',\n",
       "  'NN'),\n",
       " ('so yesterday morn im sit i get call insur expedit review ancillari servic aka infus deem necessari therefor review conduct usual standard time per polici wtf i thought problem didnt order drug turn never got author get drug administ author go doctor my first step start i call insur compani they told never expedit i shouldnt receiv phone call deni to get expedit i need call doctor offic request i call doctor offic wonder thank god howev never start author process so go back infus center find this took seven phone call backandforth final got answer send form get review expedit soon possibl great i thought on complet differ thing i decid refil everi day medicin i get messag say pleas contact pharmaci insur card file expir not know meant i decid make phone call they inform system say i longer elig insur emblem health sinc i state health insur i first renew new york state medicaid onc that approv system updat updat file emblem health well reason i receiv notic discontinu medicaid error month i got straighten immedi fix guess screen werent updat insur compani elig i sit phone anoth hour contact state find i truli still elig they need verifi recertif year actual done system need updat howev insur isnt quit easi either expedit updat insur screen compani as end day yesterday still wasnt done iron middl i get call author depart tell ancillari servic author the pharmaci call said pharmaci servic inelig order medicin someth doesnt come right i legal respons price ocrevus would i like wait insur fix order i told pleas order medicin i get done i know i elig everyth fine i liter phone differ part insur entir day yesterday it good thing i dont fulltim job fulltim job can imagin i cant make stuff',\n",
       "  'NN'),\n",
       " ('oh yeah ive talk peopl whove done much i im entyvio thought zeljanz doctor read studi say low rate especi compar placebo good good remicad humira entyvio i guess',\n",
       "  'IN'),\n",
       " ('health news octob ben hirschler london reuter frustrat delay new medicin reach countri small grow number patient turn onlin broker bill legal version dalla buyer club while regul warn risk buy drug onlin amsterdambas social medwork see network trust supplier fill gap market latest drug diseas cancer migrain multipl sclerosi now look rais profil expand sign former eu commission neeli kroe supervisori board secur million euro million new fund social impact ventur capit fund like ron woodroof aid patient movi dalla buyer club patient cannot get drug want local healthcar system use organ selfimport medicin abroad but woodroof smuggl drug across mexican border social medwork custom place order onlin legal long prescript doctor letter state drug strict person use in past month group regist dutch ministri health medicin intermediari suppli patient they includ british migrain suffer senti bera recent use system buy aimovig new month migrain inject amgen novarti first improv class drug target chemic involv trigger attack my qualiti life poor i thought worth tri work brilliant bera said as yet aimovig approv use within britain state health servic though bera hope soon reput mean one social medwork topsel despit price tag euro two autoinjector a spokeswoman britain medicin healthcar product regulatori agenc confirm formal restrict import medicin person use in past inform drugbuy network help suppli cheap generic version treatment hiv hepat c but dutch group charg fee around percent claim organ focus newli approv brand drug file photo pharmaceut tablet capsul arrang tabl photo illustr shot septemb reuterssrdjan zivulovicfil photo with custom countri lineup includ new cancer drug usapprov yet avail elsewher well medicin chronic disord roch new multipl sclerosi treatment ocrevus founder sjaak vink say internet mean patient increas awar may wait month even year novel drug follow first approv elsewher we realli need bridg gap situat ridicul said interview vink said inspir found organ delay european avail merck cos innov cancer immunotherapi keytruda today group custom australia middl east asia well major european market franc itali germani britain drug delay could worsen brexit disrupt suppli line given relat speedi us approv current fewer custom america although spike us demand last year mitsubishi tanab pharma amyotroph later sclerosi drug radicutradicava approv first japan',\n",
       "  'NN'),\n",
       " ('if meet someon tell multipl sclerosi ms hmm best thing first say hello dont feel sorri dont tell sister next door neighbour cousin cure ms certain dont assum know diseas ive know i ms sinc probabl five year beforehand accord neurologist i suffer illinform respons quit time career person ms have ms terribl thing trial irrit sometim littl bit much it depend diseas go person situat regard theyr cope weather like larg varieti thing i ms i would never assum i know anoth person experi know im well current medic gilenya i know peopl bad i also know peopl medic ive theyr extrem wherea i ok rather extrem well i think best thing meet person ms let lead convers some peopl happi talk ms situat other bore talk still other dont want discuss that thing peopl theyr differ ms peopl experi differ when diseas differ symptom depend bodi damag happen still happen symptom quit differ some peopl ms suffer optic neuriti i problem eye ms apart short sight other peopl suffer pain wherea i would say i suffer pain i fall and that one thing peopl ms agre fall peopl without ms i also like talk peopl happili launch so meet person ms say hi mayb talk weather start see convers goe',\n",
       "  'NN'),\n",
       " ('wow i surpris noth post gilenya sinc march doe mean everyon take great without major side affect everyon move someth els reason i recent start gilenya i still bit nervous would like hear other experi thank advanc',\n",
       "  'NN'),\n",
       " ('it fair common peopl dose mgkg everi week i didnt fight insur get week dose if insur deni doc abl appeal howev dose would pretti difficult get approv that said flare week like switch everi week get solid remiss if ad immunomodul mp take month work up week doesnt work id move simponi entyvio also option given sever pancol id worri could lose colon entyvio take full effect depend liber insur xeljanz jak inhibitor rather biolog might also option the advantag xeljanz would take week tell work',\n",
       "  'NN'),\n",
       " ('montalban x et al ocrelizumab versus placebo primari progress multipl sclerosi n engl j med',\n",
       "  'VBD'),\n",
       " ('zolgensma per patient gene therapi the first cart cell therapi novarti kymriah gileadkit yescarta launch europ spark gene therapi luxturna also approv europ late year novarti deal spark market luxturna europ therefor forefront groundbreak rd behind cell gene therapi also look lead revolut price reimburs requir make commerci success the next step process launch zolgensma avexi gene therapi spinal muscular atrophi sma file fda ema set gain approv region first half novarti hit headlin suggest price zolgensma could around bn mark would make easili expens biopharma product ever the compani say price would justifi base fact patient requir one infus gene therapi rather longterm treatment requir sma treatment avail biogen spinraza the compani argu current ten year cost care sma type patient spinraza addit care cost somewher novarti ceo vas narasimhan say compani explor novel reinsur model third parti would underwrit catastroph case child one rare condit ar first peanut allergi treatment potenti dead allergi food everyday substanc rise around world current therapi help prevent lifethreaten anaphylaxi result now us biotech compani aimmun look set bring first treatment market end year there million peanut allergi suffer us similar number europ analyst say market could eventu worth bn annual the fda grant ar fast track design peanut allergi septemb breakthrough therapi design peanut allergi age june aimmun therapeut submit drug fda decemb howev compani like mani other merci us govern shutdown mean mani fda staff unpaid leav threaten drug approv timelin drag longer in europ compani expect file european medicin agenc ema first half epidiolex lead flower therapeut cannabinoid market the last month seen huge growth interest therapeut potenti cannabi author allow regul access new generat product a hand legitim compani pioneer product led gw pharma ukheadquart firm work area sinc late gw pharma gain histor approv drug epidiolex fda june last year becom first ever prescript medicin deriv cannabi epidiolex first medicin base high purifi plantderiv cannabidiol cbd lack high associ marijuana first new categori antiepilept drug a the oral solut treat seizur associ lennoxgastaut syndrom lgs dravet syndrom patient two year age older two difficulttotreat epilepsyrel condit analyst believ gw pharma success commercialis drug us major global market add indic could blockbust treatment hand worth bn year the compani wait novemb could launch product howev activ ingredi cbd need reschedul us law similar chang requir europ compani look set launch later year final regulatori approv q the compani rapid establish european corpor infrastructur led chief oper offic chris tovey hire staff medic affair market access market select candid strong epilepsi specialist diseas experi mayzent latest addit competit ms market novarti mayzent siponimod expect launch us q multipl sclerosi eu launch follow later year the compani say latest trial result first studi secondari progress ms show meaning result it success vital novarti bn franchis gilenya face increas competit analyst predict peak sale bn ultomiri alexion followup soliri alexion brace patent expiri blockbust soliri eculizumab use treat paroxysm nocturn haemoglobinuria pnh myasthenia gravi hit revenu around bn the followup ultomiri alxn secondgener pnh therapi npv bn the drug match soliri efficaci trend toward superior improv dose it gain earlier expect fda approv decemb takhzyro postmerg takeda debut launch takeda chief execut christoph weber stake reput compani bn bn takeov shire need demonstr combin compani market muscl the first test shire new blockbusterinwait takhzyro gain ema approv novemb rare diseas hereditari angioedema hae the eu regul clear takhzyro lanadelumab prevent treatment hae patient age base clinic data show drug reduc hae attack typic swell area bodi abdomen face feet genit hand throat versus placebo analyst predict drug could make bn peak sale make one brightest prospect shire pipelin eu approv follow green light us august takhzyro first antibodi approv hae market hand exist treatment includ shire three exist product cinryz firazyr kalbitor collect made bn sale first nine month year almost sale come us market main suppli constraint cinryz recent year someth combin compani aim address the compani maintain takhzyro potenti expand hae prevent market particular intern market easier administ drug it given subcutan inject take less minut deliv everi two week around fewer inject product hae prevent it earli us takeup encourag accord shire q sale come at moment shire big competitor hae csl haegarda product subcutan medicin launch last year tri steal market share cinryz administ intraven twice week analyst bernstein recent predict takhzyro eventu domin hae prophylaxi market share lentiglobin tdt gene therapi first europ gene therapi compani bluebird bio cours gain approv first product year europ expect approv ahead us the cambridg massachusettsbas firm file gene therapi lentiglobin tdt ema last year treatment adolesc adult patient transfus depend thalassemia tdt non genotyp pivot data two studi sever inherit blood condit suggest gene therapi could transform care diseas provid cure mani patient in one recent present studi seven eight patient longer need longterm blood transfus continu show normal level haemoglobin bluebird say decis file europ first part thank lentiglobin accept ema prime fast track design allow earli discuss data requir trial design groundbreak therapi analyst william blair forecast lentiglobin could eventu hit global peak revenu tdt would depend efficaci harder treat genotyp patient sever thalassemia the analyst predict drug price around per treatment level compar favour cost convent stem cell therapi unlik fellow boston mabas gene therapi compani spark therapeut bluebird led ceo nick lesch opt market product europ well us it regulatori market market access team alreadi place europ advanc discuss contin payer includ valuebas payment system daurismo new wave aml treatment after mani year new therapi treatment acut myeloid leukaemia aml set rapid chang thank wave rival product arriv market these includ pfizer daurismo first smoothen smo receptor inhibitor approv blood cancer the fda clear daurismo glasdegib late novemb use combin lowdos cytarabin patient newlydiagnos aml age frail treat intens chemotherapi the fda also approv abbvi roch venclexta venetoclax cytarabin hypomethyl agent azacitidin decitabin exact indic ad option patient popul take total number new drug aml last coupl year seven decad stagnat phase data submit support daurismo market applic show combin daurismo cytarabin reduc risk death compar cytarabin alon patient the smallmolecul drug block part sonic hedgehog pathway also target cancer drug includ roch erivedg vismodegib novarti odomzo sonidegib basal cell carcinoma smaller patient popul aml analyst credit suiss predict approv aml could make glasdegib product addit upsid pfizer also get approv indic myelodysplast syndrom mds acut lymphoblast leukaemia all chronic myeloid leukaemia cml solid tumour meanwhil venclexta latest approv add grow momentum behind abbvi roch bcl inhibitor also file approv previous untreat aml patient inelig intens chemotherapi go along exist indic chronic lymphocyt leukaemia cll evaluatepharma predict could becom near bn product provid also pick approv aml indic like multipl myeloma vitrakvi novel addit immuneoncolog market earlier year merck comsd becam first compani secur approv tissu agnost drug pd inhibitor keytruda pembrolizumab back cancer harbour biomark known microsatellit instabilityhigh msih merckmsd look gain domin posit checkpoint inhibitor immunooncolog io keytruda remain room growth market via new io agent this particular case consider percentag patient dont respond exist io treatment vitrakvi larotrectinib gain fda approv late novemb treat solid tumour neurotroph tyrosin receptor kinas ntrk gene fusion caus product trk famili protein drive tumour growth this first us product approv loxo oncolog market partner bayer becom second compani get fda back drug treat cancer base specif genet mutat rather locat bodi in europ market applic larotrectinib submit ema last august set potenti approv mid analyst oppenheim predict annual sale vikrakvi grow bn thank impress result clinic trial ntrk fusion rare loxo estim around new case advanc ntrk fusion cancer us year big challeng loxo bayer encourag oncologist test identifi patient may elig vitrakvi launch premium price tag per year howev bayer offer refund patient dont see benefit drug within three month at moment companion diagnost ntrk fusion patient need identifi genom profil techniqu immunohistochemistri genet sequenc approach tend avail specialist centr the compani say critic screen patient age advanc solid tumour action genom insight improv care inclus clinic trial loxo brought drug market ahead main rival entrectinib roch latestag test could submit approv end year erleada next generat prostat cancer treatment johnson johnson gain fda approv erleada februari got go ahead europ first treatment nonmetastat castrationresist prostat cancer crpc erleada apalutamid first drug clear strength metastasisfre surviv mfs trial endpoint use fda cancer drug approv analyst believ drug could achiev peak sale around bn face fierc competit like pfizer astella establish xtandi around prostat cancer case castrationresist patient show evid cancer spread time castrationresist diagnosi in patient nonmetastat crpc high unmet need delay develop metastas progress advanc prostat cancer erleada approv data spartan studi involv patient nonmetastat crpc receiv either erleada placebo top hormon therapi gonadotropin releas hormon gnrh analogu surgic castrat the median mfs patient take erleada month compar month placebo arm jj need drug hit ground run exist prostat cancer blockbust zytiga face generic competit us account around half drug bn revenu it also give jj legup look set big market tussl pfizer astella xtandi product also file approv us eu nonmetastat crpc strength mfs data prosper trial buvid advanc opioid depend treatment opioid addict surg us sinc prescript drug oxycontin vicodin becam common remedi number condit last year american die overdos opioid about peopl diagnos opioid depend us almost one million receiv treatment while problem acut europ nevertheless still signific grow issu across contin now grow need treatment help wean depend patient prescript drug street drug mani transit new opioid depend treatment market year cam market camurus compani headquart lund sweden cam inject solut slowli releas buprenorphin common drug use treat opioid addict bodi elimin need daili dosag well risk substanc make way onto black market the product gain ema approv novemb fda approv decemb camurus current prepar launch drug first european market earli januari expect substanti sale treatment although take three six month ramp in long term us market share number patient treat bn annual sale expect the us market treatment opioid addict current domin indivor suboxon film place tongu day the advantag treatment cam patient get continu treatment without run risk miss dose without visit clinic inject while treatment today taken daili dose use longact inject expect increas come year compar similar treatment market indivior drug advantag flexibl inject volum lower taken week well month administ differ part bodi upadacitinib risankizumab twin anti inflamm blockbust make the world biggest sell drug humira lost market exclus europ biosimilar competit abbvi well awar impend us patent expiri the good news compani one two potenti blockbust like gain approv upadacitinib abbvi ra risankizumab comarket boehring ingelheim psoriat arthriti crohn diseas inflammatori condit humira reach revenu around bn mean abbvi soon larg hole revenu fill it see upadacitinib key compon posthumira portfolio predict drug could eventu hit sale bn year risankizumab ad anoth bnbn peak abbvi present new data risankizumab candid psoriasi upadacitinib atop dermat suggest potenti lucrat dermatolog franchis way it announc file upadacitinib us europ decemb file risankizumab expect earli year three studi interleukin inhibitor risankizumab psoriasi present firm case drug ahead possibl regulatori approv it also unveil midstag data jak inhibitor upadacitinib atop dermat ad anoth clinic win earlier success rheumatoid arthriti for risankizumab new data could import help abbvi differenti il inhibitor clutch new psoriasi treatment novarti lilli jj other jostl space increas crowd market the analysi concentr patientreport outcom data two studi compar risankizumab jjs bnayear ilil inhibitor stelara ustekinumab one tnf inhibitor humira adalimumab current biggestsel drug world revenu bn the analysi show patient risankizumab symptomfre year treatment compar stelara group there also signific improv abbvi drug humira qualiti life measur stelara anxieti depress risankizumab better compar drug came keep patient work without loss product caus skin disord meanwhil phase b result upadacitinib show drug abl improv skin lesion itch patient moderateto sever atop dermat eczema across dose test sustain treatment effect week upadacitinib alreadi phase trial atop dermat pick breakthrough design btd fda indic earlier year abbvi five trial go rheumatoid arthriti file indic end year the new data atop dermat put cours addit indic drug analyst predict could unlock billion dollarplus market although abbvi isnt oral jak inhibitor develop eye particular prize lilli alreadyapprov olumi baricitinib pfizer pf rival abbvi upadacitinib gilead galapago filgotinib abbvi castoff look like biggest competit threat it also phase trial atop dermat risankizumab almost inevit go tough time claw market share increas competit moderatetosever psoriasi market sever new inject potenti also new oral therapi tyk inhibitor bristolmy squibb other outcom data could help abbvi persuad prescrib plump drug assum get regulatori approv likewis upadacitinib face competit ra atop dermat particular filgotinib final see rapid increas uptak humira biosimilar across europ anoth factor temper demand new agent ant term price competit therapi area',\n",
       "  'JJ'),\n",
       " ('you three inject cladribin adjac day one two three month later depend lymphocyt count a year later go process that cladribin licens treatment ms australia bart provid peopl ms hospit below link reliabl inform cladribin ms it contain link scientif paper publish subject httpmultiplesclerosisresearchblogspotcomsupposetherewastherapyforallhtml',\n",
       "  'NN'),\n",
       " ('excerpt osimertinib improv progressionfre surviv compar standard first line therapi patient egfr mutat nonsmallcel lung cancer nsclc accord latebreak result flaura trial present today esmo congress madrid egfr mutat present around nsclc western popul rise asian popul egfr inhibitor superior chemotherapi first line treatment patient howev despit high respons rate good progressionfre surviv patient invari develop resist drug erlotinib gefitinib in major patient resist mediat tm mutat go full articl if your wonder whether stori appli cancer case love one invit use ask cancer common servic',\n",
       "  'JJ'),\n",
       " ('on jan pm maryd wrote hi i stage iv lung cancer met brain adrenaldiagnos juli i i start chemotherapi right away target radiat i determin stabl three week later spread brain after complet whole brain radiat seven tumor i final place nivolumab i steadi slow size reduct last two year bare side effect immunotherapi in truth i suffer radiat nausea vomit lung adren short term memori loss brain radiat this difficult i nurs i write everyth downand retrac step often they would use cyber knife four tumor all said opinion make immunotherapi first line treatment possibl combin treatment nivolumab kick i wish best momfor mari d said make immunotherapi first line treatment pleas aee keytruda pembrolizumab merck it immunolgi drug simialr nivolumab opdivo fda approv firstlin treatment',\n",
       "  'NN'),\n",
       " ('hi i year old woman i recent diagnos wet macular degener one eye dri at first western eye said extrafovi choroid neovascular outer rim readi inject yesterday second privat opinion guy call kashif qureshi london eye hospit harley street told extrem urgent i inject day i rush western eye first eylea inject yesterday afternoon wow i didnt know expect realli scarey i bad reaction probabl first one im ok today last night inject frighten the doctor saw gave lot posit feedback inject im live hope i also someth call charl bonnet syndrom hallucin i ask privat doctor said hope would get less less inject kick it nice site hear fellow suffer gotta strong',\n",
       "  'NN'),\n",
       " ('doe mean give opdivo anymor but tri sbrt cryo met start recognit done local easili cryo jaw bone met drlittup anoth idea go dr lugnani spain cryoablat jaw bone met inject',\n",
       "  'JJ'),\n",
       " ('it control tbh most peopl delay remicad coupl week without issu chanc okay it much easier said done tri spend next week panick if remicad truli put deep remiss hold quit last infus month even year depend person diseas dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('i respond well anyth right hope ask nonchemo option like rfa radiotherapi etc chemo far i start ec joy move abraxan avastin work port problem forc break gemcitabin carboplatin joy eribulin joy cape i thought work pain gone joy keep everyth cross vinorelbin would interest know tnbc peopl anyth differ i might abl ask hope rest luck treatment xxx',\n",
       "  'NN'),\n",
       " ('thank suggest i was told dri eye also told use otc eye drop but culprit gilenya i stop take symptom slowli disappear month later i back normal actual fell pretti good last week spite major stress go sinc septemb last year neuro decid i must dmd decid aubagio one i take well good patient i start last week now like omg how i suppos live feel like the headach gone oh i still slight one time motrin stop light sensit back blueey curs type',\n",
       "  'NN'),\n",
       " ('hi my dad year old found suspect lung cancer follow ct scan it confirm i got asap moffitt cancer center tampa after pet scan confirm stage nsclc my hope opdivoyervoy clinic trial offer heartbroken find day ago pet scan qualifi clinic trial wasnt whole tumor could safe remov need qualifi the inch mass lung press bit right ventricl heart they gone result pet scan ct show look contain one lung metastasi adren possibl fluid surround one lung he needl biopsi set next thursday brain mri yesterday no result i feel thing move slow moffitt call day said want get anoth clinic trial research sole it combin keytruda vorinostat phase iii i cannot find info combin someth gut doesnt feel right i think cancer hit aggress stage possibl chemo option keytruda togeth research to trial seem like let see long extend life rather let hit aggress hope shrink tumor make year mental i process tri get baptist md anderson jacksonvill live orlando second opinion this seem like move slow they made appoint second opinion im tri get move has anyon heard keytruda vorinostat test togeth and i right feel like might best first line treatment dad point i child im best i parent dad i want make wrong decis look signific help i determin help beat thank help lisa',\n",
       "  'NN'),\n",
       " ('there sever drug target pd checkpoint to make immunotherapi effect combin drug the combin respond stronger respons also side effect the follow combin clinic trial approv combin checkpoint inhibitor checkpoint inhibitor eg opdivo plus yervoy combin checkpoint inhibitor immun modul like ox ido etc antibodi combin checkpoint inhibitor cytotox chemotherapi drug combin checkpoint inhibitor radiat combin target drug on hand checkpoint like tim lag target togeth pd there immun cell kill cancer nk cell macrophag the cd antibodi remov dont eat signal cancer cell result macrophag engulf agonist tlr receptor activ immun cell innat immun system dendrit cell macrophag they combin checkpoint inhibitor the cancer vaccin get success they also use immunotherapi engin t cell til develop differ cancer chemokin cytokin adjuv immunotherapi the problem immunosupress address treg m macrophag n neutrophil to trial combin clinic studi requir sever year need hang littl longer combo get approv',\n",
       "  'NN'),\n",
       " ('i sorri i appreci good news good news alreadi gone path seem second alemtuzumab treatment cycl put one back track i wonder guilti approach switch strategi get natalizumabfingolimodalemtuzumab the neuro need discuss strategi move forward mayb profg comment it disturb neuro wont prescrib approv drug howev surpris i know plenti risk avers wait see neuro if would interest see centr uk prescrib dont i guess could done freedom inform see ms drug prescrib centr we done compani pharma find prescrib',\n",
       "  'NN'),\n",
       " ('conner i keep finger cross see success i follow journey close surgeri recommend son turn day we desper altern solut famili year old diagnos ulcer coliti fall tri uceri lialda remicad canasa entyvio everi week imuran sinc june still remiss',\n",
       "  'JJ'),\n",
       " ('i understand feel tire constant fight want give ive havent gone thru half youv thru i know there noth anyon say make feel better i want offer support note that differ feel sorri one want feel piti other i didnt know quit say bull post i sleep i still dont but support forum that come deris other theyr feel isnt cool imo i think forum perfect place say cant say someth nice say noth uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc lglutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       "  'NN'),\n",
       " ('remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom havent found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas firstlin approach biolog therapi work block certain chemic caus inflamm intestin most biolog crohn diseas block protein call tumor necrosi factor tnf other biolog block immun cell call integrin other act protein call interleukin il interleukin il this biolog therapi stop inflamm gut antitnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week the three antitnf biolog humira remicad cimzia humira humira selfadminist treatment follow initi demonstr healthcar profession if doctor decid handl inject theyll give set pen dosagecontrol medic insid youll also given instruct mani inject take first day after initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flareup it may also help maintain remiss prevent symptom return remicad given direct bloodstream this allow work immedi reliev symptom it administ medic facil experienc healthcar profession close monitor side effect treatment remicad doesnt taken everi day after three starter dose patient often see benefit six dose per year the downsid remicad must given intraven medic facil twohour period cimzia cimzia administ small inject the inject either given doctor offic home if choos receiv treatment doctor offic option receiv treatment powder form the powder mix steril water inject the option use prefil syring the syring contain medic that alreadi mix measur dose these use home doctor offic if choos treatment youll get packag two syring instruct give treatment after first three dose given everi two week abl take cimzia everi four week the two antiintegrin biolog crohn tysabri entyvio tysabri this type biolog prevent inflammationcaus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week it take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl havent respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar serious side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml this result virus test advanc ani physician prescrib tysabri crohn warn patient risk they also explain enrol prescrib program call touch this program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas havent respond well intoler reason cant take tnf blocker immunomodul corticosteroid it work similar tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gutspecif doesnt appear risk pml entyvio given doctor care intraven infus it given minut first day therapi it repeat week two week six everi eight week thereaft if improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient uptod immun stelara the third class biolog il il agonist stelara drug class approv treat adult moder sever crohn havent respond well enough convent therapi the drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession the follow dose given via inject skin everi eight week either healthcar provid selfadminist patient train side effect although benefit often far outweigh risk biolog therapi present serious side effect the process biolog therapi reduc bodi abil fight infect this caus tuberculosi infect includ brain infect there also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen tcell lymphoma this type cancer often fatal becaus biolog therapi work differ other side effect may caus also vari ask doctor thorough explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm your doctor discuss option benefit risk help find effect treatment in case biosimilar generic version biolog drug may avail manag crohn also save money your doctor tell option',\n",
       "  'NN'),\n",
       " ('electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move the major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect it import replac miss electrolyt becom rebalanc how done depend sever imbal if minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi an mri scanner larg tube contain power magnet you lie insid tube scan mris help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimus astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes common caus scar surgeri less common scar due activ inflammatori bowel diseas adhes fibrous band form tissu caus pain blockag intestin post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit a bowel resect surgic procedur part larg small intestin remov post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit a hemicolectomi involv surgeri remov right left portion colon',\n",
       "  'FW'),\n",
       " ('dear strike avonex first prescript drug i hate after everi inject i felt i flu a year later gilenya approv didnt make feel sick but wasnt slow diseas progress i three relaps take i took month final relaps involv depth percept i couldnt manag walk stair my ms nurs told copaxon doesnt mani side effect daili inject and isnt effect newer drug accord clinic trial i tysabri no advers effect and i havent relaps sinc i receiv tysabri infus half year anyhow stumbler state earlier mani option avail pleas check neurologist ms nurs benefit versus risk good luck',\n",
       "  'NN'),\n",
       " ('march about checkmat checkmat phase random openlabel studi evalu combin opdivo mgkg plus yervoy mgkg versus sunitinib patient previous untreat advanc renal cell carcinoma rcc in intermedi poorrisk studi popul patient receiv opdivo mgkg plus yervoy mgkg everi three week four dose follow opdivo mgkg everi two week patient receiv sunitinib mg daili four week follow two week everi cycl the recommend dose opdivo plus lowdos yervoy combin opdivo mgkg follow yervoy mgkg infus intraven minut day everi three week four dose after complet four dose combin opdivo administ intraven mg everi two week minut mg everi four week minut diseas progress unaccept toxic the coprimari efficaci outcom measur trial overal surviv object respons rate complet respons partial respons progressionfre surviv determin independ radiograph review committe irrc intermedi poorrisk patient patient includ regardless pdl status about renal cell carcinoma renal cell carcinoma rcc common type kidney cancer adult account death worldwid year clearcel rcc preval type rcc constitut patient rcc approxim twice common men women highest rate diseas north america europ global fiveyear surviv rate diagnos metastat advanc kidney cancer bristolmy squibb advanc oncolog research we lead scientif understand io extens portfolio investig compound approv agent our differenti clinic develop program studi broad patient popul across type cancer clinicalstag molecul design target differ immun system pathway our deep expertis innov clinic trial design posit us advanc ioio iochemotherapi iotarget therapi io radiat therapi across multipl tumor potenti deliv next wave therapi sens urgenc we also continu pioneer research help facilit deeper understand role immun biomark patient tumor biolog use guid treatment decis throughout journey we understand make promis io realiti mani patient may benefit therapi requir innov part also close collabor lead expert field our partnership academia govern advocaci biotech compani support collect goal provid new treatment option advanc standard clinic practic about opdivo opdivo program death pd immun checkpoint inhibitor design uniqu har bodi immun system help restor antitumor immun respons by har bodi immun system fight cancer opdivo becom import treatment option across multipl cancer opdivo lead global develop program base bristolmy squibb scientif expertis field immunooncolog includ broad rang clinic trial across phase includ phase varieti tumor type to date opdivo clinic develop program enrol patient the opdivo trial contribut gain deeper understand potenti role biomark patient care particular regard patient may benefit opdivo across continuum pdl express',\n",
       "  'NN'),\n",
       " ('my thought also negat we know fda ema consid use ocrevus nice need approv use nhs accord professor giovannoni say i quot uk patient may disappoint may hard nhs fund everyon get drug like expens i would expect narrow group peopl elig mean either postcod lotteri treatment depend live narrow group peopl ie peopl primari secondari ms weve poor relat ms famili mani year deserv treatment the nhs get fund get privat prescript drug peopl abl afford exampl drug sativex approv nhs england cost month privat prescript dont think mani us could afford hate think much ocrevus would cost ok sum i think restrict use disappoint mani peopl peopl year donat hundr even thousand pound find treatment hope cure find dont live right area medic insur wealthi enough dont get treatment i one donat money peopl get one afford regard mike',\n",
       "  'IN'),\n",
       " ('thought prayer come way jake hope thing work well give us updat soon your abl my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran jakeb regular member join dec post post pm gmt so surgeri end uncov sort disturb news i form small bowel cancer small tumor uncov the fortun part think remov tumor chemotherapi take care the issu i like due cancer they still remov cm jejunum i less half small bowel remain they want continu tpn i leav recoveri help offset loss nutrient also see oncologist least isnt urgent mind pain excruti yesterday got control much better today walk coupl time without huge issu pain also made feel good all mix bag thing i tri err side posit the cancer thing reason didnt realli shake much i think i come expect anyth day thank constant support if insight happen would great help sure year old crohn sinc medicin remicad restart methotrex supplement vitamin d zinc b multivitamin clo veteran member join feb post post pm gmt jake i dont insight i want know i sorri go thru you thought prayer in i remicad awhil i issu short moment calm in june i partial obstruct they scope everyth look good except soft tissu inflammationstrictur area sigmoid we sure would go away they sent home i return day excruci pain that happen time june juli in august i ill kept in septemb i end colostomi i reliev pain gone my surgeon said inflam area atrophi predysplasia they believ got mine surgeri the follow year find cancer scope they check yearand everi year go forward it challeng road travel i believ sometim lucki listen close bodi get sign symptom alert ing us someth need seen i send posit thought way pleas let us know goe hug clo symptom start diagnosi diagnos uc diverticul hosp fistula dx chang crohn develop new skin rash eye problem pain joint hospx new specialistsaid wors case hes seen hosp mm strictur stricturplasti mm colostomi med remicad methtrexatefol acid vit d calcium probiot turmer omega post edit clo pm gmt eruditepaul regular member join jan post post pm gmt i would agre clo said the follow statist the cumul incid smallbowel cancer cd diagnosi year year year the expect incid base iowa white seer rate year year year wwwgastrojournalorgarticlesfulltext howev danish studi show calcul lifetim risk o year develop small andor larg bowel cancer patient crohn diseas compar danish popul ns post edit eruditepaul pm gmt',\n",
       "  'NN'),\n",
       " ('jayle my neurologist told type ms three progress like walk stair ppms progress one escal it ppms never stop whatev angl escal if rise slow progress slow quick remain quick have said also said ocrevus might help yet drug approv canada prescrib he set anoth mri six month put lifetim wait list one mri per year continu collect paycheck lol',\n",
       "  'NN'),\n",
       " ('thank jennif share stori rais spirit realist hope would abl share target therapi current long after year success pharmaceut career manufactur qualiti regulatori sole breadwinn famili minor children one colleg i lost job due reorgan nov soon i solid offer one work dec i accept one dec senior level major pharma compani anoth state start date first week januari i alway struggl depress high anxieti due high job demand lot travel at time i would short breath doctor i would attribut anxieti i i thought reason i start feel short breath i furious continu job hunt nov my symptom escal day accept job offer end emerg room xray ct scan fluid test thoracentesi confirm i malign pleural effus involv left lung later dec i diagnos stage nonsmal cell lung cancer egfr ive mutat i start target therapi tagrisso day ago alreadi feel better symptom except cough although less frequent remain my enorm dread replac much hope thank target therapi great medic team md anderson cancer center summit medic nj howev i struggl ad fear without job health insur first time life famili especi children without mean insur dread cancer i answer confirm avenu i famili surviv i keep push live healthi happi long life new normal i take great solac stori survivor site would love connect',\n",
       "  'NN'),\n",
       " ('this exact kind thing im talk who romantic i seen anyth sort everyon say freakin hard wasi someon ask question i answer best abil base experi becaus i say im happi i surgeri that romantic i guess eye one say theyr happi theyr remicad remiss mariann age dx pancol famili histori uc symptom start short i quit smoke tri everi drugeven remicad cyclosporinetri dietsnoth work step jpouch surgeri laparoscop restor proctocolectomi w temporari divert loop ileostomi step take surgeri ileostomi revers no uc drug veri happi jpoucher post edit byebyeuc am gmt',\n",
       "  'NN'),\n",
       " ('i know ino result relaps involv brain stem posterior fossa this high alarm my sister similar progress quit fast year edss edss her neuro want switch look anoth help she stabl gilenya if i would place i tri everyth chang high effect therapi caus young ladi chang cladribin alemtuzumab ive answer q without read switchswitchswitch q vitd recommend iu daili pleas write email vitamin d council',\n",
       "  'NN'),\n",
       " ('i think depend bodi type bit i alway hard time gain weight even coliti mine gone within month lower dose some report longer i think facial hair bother i final shave bit now i dont issu either it get better moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start antibodi gone everi week down mgs pred',\n",
       "  'VBD'),\n",
       " ('ok mri monday year lemtrada st round i havent relaps wahoo but mobil hasnt realli improv am i reli drug much should i top run home singl hand work full time should i find hour week swim walk i top hour day monday friday pleas find cure jcv put back tysbari',\n",
       "  'JJ'),\n",
       " ('i cannot express much medic help when i first prescrib i terrifi review super pain i sever psoriasi cover bodi i given citratefre inject pen when i say i felt noth i mean noth i thought i hadnt inject yet but prick my psoriasi onli week treatment gone onli white scar wreck bodi remain this medic incred liter chang life my skin doesnt flake ooz doesnt get super red irrit doesnt sting everi movement like start medicin the best part go websit sign humira card copay onli dollar five fricken dollar when the medic origin cost this compani amaz i near loss word effect painless citratefre formula report star post month ago rate humira adalimumab crohn diseas mainten report i took humira remicad lower immun system i develop tb i start humira one shot hurt begin take feel like stomach crucifi top needl feel like spin went back remicad feel better ask doctor remicad humira less pain work better humira',\n",
       "  'NN'),\n",
       " ('hi andrey current cure ms rather medic help manag various aspect diseas under diseas cours dmt symptom manag general wellb strategi benefici type ms ocrevus approv treatment earli primari progress ms ppms adult age base find clinic trial oratorio earli ppms defin diseas durat length time year sinc diagnosi level disabl addit magnet reson imag mri featur characterist inflamm indic activ diseas peopl outsid age rang edss score studi safeti efficaci ocrelizumab unknown health canada unabl provid author new drug assess safeti efficaci without clinic trial data individu interest ocrelizumab age encourag speak neurologist diseas modifi therapi dmt target inflamm peopl progress ms inflammatori activ general benefit therapi peopl progress ms health care team great deal manag diseas includ rehabilit symptom manag dr k',\n",
       "  'NN'),\n",
       " ('chezi now i understand bad moon due pediod probabl yeah good bad day im glad never got relaps sinc i start gilenya least',\n",
       "  'NN'),\n",
       " ('paulmorrison i om month i didnt realli get medit part line either i sure benefit gilenya diet i presum gilenya ms stabilis addit lesion month mris also claim gilenya box my problem om take meat fat end eat lot rice bread make fat accord mother internet anyway good luck give fag good anyth i gave gasper use nicorett quick mist it actual work howev get addict spray good luck',\n",
       "  'JJ'),\n",
       " ('hi ladychelli i diagnos i son we actual current tri babi number my first piec advic havent alreadi talk doctor best handl ms tri becom pregnant pregnant well i take gilenya first plan action stop take could safe conceiv my pregnanc son wonder i experi hard ms symptom my biggest piec advic prepar labor keep communic doctor plan right ms remain strong activ possibl wish best pregnanc journey if question pleas dont hesit reach cali multiplesclerosisnet team member',\n",
       "  'NN'),\n",
       " ('hi coco studi shown around half peopl egfr tm posit respond well tagrisso even number peopl remain less real efficaci stabil drug it probabl tagrisso best option inde option nhs i would push i hope respond treatment all best janin',\n",
       "  'NN'),\n",
       " ('the neuro bart blog seem favour fingolimod stop relaps tysabri so might stop gap treatment also httpmultiplesclerosisresearchblogspotcomclinicspeakswi',\n",
       "  'NN'),\n",
       " ('the definit spms rrms arent straightforward if lot accumul disabl still relaps peopl put one categori my neuro say label help im dmd i still relaps spite ms year plenti accumul disabl if relaps realli sound like give serious thought go onto dmd lot tri im happi gilenya though i know peopl hate',\n",
       "  'NN'),\n",
       " ('repli post ahainlin the mental fear wors bite i fail remi went humira it work well year i anxious inject burn trust thought go feel like way wors realiti you i alway inject right bed that way hurt i could go sleep move around just tri quiet brain much possibl',\n",
       "  'NN'),\n",
       " ('thank forum took mom univers hospit gene test result given us today the result read ros rearrang intron addit find say tumor mutat burden tmblow mutsmb the therapi identifi ceritinib crizotinib how therapi differ one anoth no therapi identifi tumor mutat also understand ros identifi bodi report say unclear oncogen rearrang present it say activ ros rearrang present fusion i read old articl written dr west said patient ros rearrang respond favor alimta well patient ros respond alimta wait tri crizotinib later resort mom test report also state patient ros rearrang exhibit longer progress free surviv alimta as mom still respond alimta pleural effus week breathless appetit return result treat import inform chang treatment consid point her onc order test hope discuss result onc mom next visit variant also identifi none hold signific much known scientif literatur time report said one variant ros lv if could point articl inform ros pertin result could share input i would grate thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('rotherhamdav thank share feedback ill gilenya but didnt start gilenya yet still wait call',\n",
       "  'NN'),\n",
       " ('i suppos wait anxious intermedi result phase clinic trial pd inhibitor opdivo keytruda are also clinic trial pdl inhibitor tecentriq my wife keytuda metastat tnbc sinc month well',\n",
       "  'NN'),\n",
       " ('hi grumpyman im tecfidera nurs said didnt work could tri gilenya even lemtrada im assum appli tecfidera sound scari side effect soon wear within month scari seizur must plain wrong polish version give inform need fix asap ask ms nurs get soon possibl dont know long stay activ system may mean need time dmd good luck carol x',\n",
       "  'NN'),\n",
       " ('hi i hope im includ describ good condit well i wasnt daignos lobg ago was saudi year old highschool student girl lost sight graduat highschool finish uni move scotland alon stay year studi english volunt citizen advic studi return countri or mayb cant rememb done transplant eye plan eye have job ny countri even shift dure time i describ i treatment nd vitamin i anxious but month ago i start gilenya in i develop atrophi in scotland i hate mention abyon i smoke short time im still disabl no one know i suffer ms famili manag work',\n",
       "  'NN'),\n",
       " ('hi sunday thank repli sorri hear tagrisso work do oncologist think acquir anoth mutat alongsid tm mean tagrisso work rather tm mutat chang have pleural effus drain had build thank best luck treatment would clinic trial immunotherapi',\n",
       "  'NN'),\n",
       " ('from read i believ main sideeffect problem relat avastin problem dose split use syring intend inject bodi use inject eye there appar number lawsuit take place regard issu schmidtlawcomavastin there issu well one least ive found relat much drug get bloodstream long stay despit similar visual outcom mani headtohead compar trial bevacizumab ranibizumab aflibercept wet amd signific differ molecular structur agent result differ pk pharmacokinet profil system exposur intravitr inject the result report show differ among three main intravitr vegf inhibitor system pk pharmacodynam may provid biolog plausibl potenti differ system safeti risk this paper also provid informt bevacizumab bival monoclon antibodi ranibizumab monoval monoclon antibodi fragment aflibercept fusion protein bjobmjcomcontentear',\n",
       "  'JJ'),\n",
       " ('i copi unrel comment sake discuss spam unnecessari a recent studi found gilenya halt grey matter atrophi httpwwwsciencedirectcomsciencearticlepiisx gilenya less effect tysabri delay progress httpsonlinelibraryectrimscongresseuectrimsactrimsectrimsjwilliamlbrowntheeffectofdiseasemodifyingtreatmentsonconversiontohtmlfmediaspeak the risk assess hazard ratio convert spms among patient treat inject followup year gilenya followup year tysabri followup year lemtrada followup year compar match untreat patient the higher hazard ratio lesser risk what thought',\n",
       "  'JJ'),\n",
       " ('the european commiss approv twicedaili mg dose tofacitinib citrat combin methotrex adult patient',\n",
       "  'NN'),\n",
       " ('ps read post sound like could come prednison entyvio pred changevc hormon hormon disrupt caus temporari hairloss ad',\n",
       "  'NN'),\n",
       " ('consumpt least mgd dietari longchain polyunsatur fatti acid lc pufa link decreas risk diabet retinopathi older patient type diabet accord research publish jama ophthalmolog aleix salavila dpharm phd lipid clinic endocrinolog nutrit servic institut dinvestigacion biomdiqu barcelona spain colleagu conduct prospect studi within predim prevencin con dieta mediteranea trial determin mediterranean diet one supplement extra virgin oliv oil nut vs control diet effect primari cardiovascular prevent between research recruit individu year age previous diagnosi type diabet the primari studi outcom incid diabet retinopathi requir laser photocoagul vitrectomi antiangiogen therapi in total n particip met target lc pufa recommend near new event document year followup after adjust age sex intervent group lifestyl clinic variabl particip meet lc pufa recommend baselin mgd compar fulfil recommend mgd show relat reduc risk incid sightthreaten dr conclud dr salavila this associ slight stronger year updat lc pufa intak the research note target lc pufa intak mgd easili achiev week serv oili fish',\n",
       "  'JJ'),\n",
       " ('oh wow that aw couldnt get earlier deterior that disgrac make want fight ill keep eye ocrelizumab though like lemtrada scare',\n",
       "  'NN'),\n",
       " ('we read interest find le berr et al report first case combin biolog agent tofacitinib manag inflammatori bowel diseas ibd the recent approv small molecul tofacitinib treatment ulcer coliti multipl small molecul therapeut pipelin make co mbinat increas attract approach tri close therapeut gap ibd furthermor lack immunogen offer advantag biolog agent potenti allow sequenti therapi httpswwwcghjournalorgarticlesfulltextrssy sourc clinic gastroenterolog hepatolog',\n",
       "  'NN'),\n",
       " ('vanessa hello i copaxon daili inject never issu as regard gilenya i declin treatment your right dont rock boat feel listen gut instinct ive studi copaxon safe option never negit report i awar alway stand correct otherwis best luck whatev decid upon jane',\n",
       "  'NN'),\n",
       " ('thank post cladribin sew chick due start short would mind call talk concern thank',\n",
       "  'NN'),\n",
       " ('that great news keytruda seem promis what kind side effect son jump post olga sat nov pm forum person stori updat topic p thailand dx yrs old repli view re year old thiland dx march hi keytruda approv asp approv cancer peopl get label oncologist find benefici we receiv news prescrib boy us jump post arojussi sat nov pm forum person stori updat topic jussi finland dx repli view re jussi finland dx i fifth dose mri i keytruda moth jump post phura sat nov pm forum person stori updat topic p thailand dx yrs old repli view re year old thiland dx march for countri use approv drung understad could pls suggets hi rojussi thank much suggest can keytruda use kid did approv kd do link inform keytruda kid hi martinbub thank much suggets',\n",
       "  'NNS'),\n",
       " ('hello hope well daughter optic neuriti hospit april neurologist recommend two drug either copaxon ocrevus unsur can pleas tell cours medic good luck',\n",
       "  'VBP'),\n",
       " ('i still fair new crohn i offic diagnos june week hospit bowel blockag sepsi i remicad year stop work i develop antibodi i put humira it didnt seem anyth gi took i anyth methotrex coupl month the diseas still activ noth sever far my gi want tri stelara has anyon doe bad side effect trish',\n",
       "  'JJ'),\n",
       " ('hi thank repli updat i complet two month half alectinib far improv tumor size start shrink yet slow progress someth better noth excit thing side effect like fatigu diarrhea last blood test show effect far kidney liver tumor marker go bad symptom gone away cough short breath except im heavi activ thank god next scan nd apr let know wish healthi life',\n",
       "  'NN'),\n",
       " ('in us renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class infliximab use for renflexi infliximababda inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi it use children treat crohn diseas ulcer coliti infliximababda inject monoclon antibodi work enhanc improv immun system this medicin avail doctor prescript befor use renflexi in decid use medicin risk take medicin must weigh good this decis doctor make for medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use infliximababda inject treatment crohn diseas ulcer coliti children year older howev safeti efficaci establish children younger year appropri studi perform relationship age effect infliximababda inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximababda inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatricspecif problem would limit use infliximababda inject elder howev elder patient like infect may requir caution patient receiv infliximababda inject breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when receiv medicin especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use medicin follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenovirus vaccin type live adenovirus vaccin type live alefacept anakinra bacillus calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza virus vaccin live ixekizumab measl virus vaccin live mump virus vaccin live natalizumab paclitaxel phenytoin poliovirus vaccin live quinidin rilonacept rituximab rotavirus vaccin live rubella virus vaccin live sarilumab sirolimus smallpox vaccin tacrolimus tocilizumab tofacitinib typhoid vaccin ustekinumab varicella virus vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use medicin make sure tell doctor medic problem especi aspergillosi fungus infect histori blastomycosi fungus infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungus infect histori coccidioidomycosi fungus infect histori diabet guillainbarr syndrom nervous system disord histori hepat b activ histori histoplasmosi fungus infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungus infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet bloodus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copdus caution may increas chanc get new cancer tuberculosi histori ofus caution patient may need addit tuberculosi therapi proper use renflexi a doctor train health profession give medicin it given needl place one vein this medicin come medic guid it import read understand inform be sure ask doctor anyth understand you may also receiv medicin help prevent possibl unwant effect inject precaut while use renflexi it import doctor check progress regular visit make sure medicin work proper blood test may need check unwant effect infliximababda may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat your bodi abil fight infect may reduc use infliximababda it import call doctor first sign infect check doctor right away fever chill cough flulik symptom unusu tired weak serious skin reaction occur use medicin check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak this medicin may increas chanc lupuslik syndrom liver diseas call autoimmun hepat check doctor right away dark browncolor urin fever chill general feel discomfort ill weak joint pain lightcolor stool nausea vomit rash cheek arm wors sun sever tired upper rightsid stomach pain yellow eye skin a small number peopl includ children teenag use medicin develop certain type cancer this common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light some teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen tcell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pus skin use medicin may increas risk get skin cancer eg melanoma merkel cell carcinoma if chang growth skin tell doctor right away while treat infliximababda immun vaccin without doctor approv live virus vaccin given infliximababda your child vaccin must current use infliximababda talk child doctor question women if babi receiv infliximababda make sure babi doctor know use medicin you need wait month give certain vaccin babi talk babi doctor question you need skin test tuberculosi start use medicin tell doctor anyon home ever posit reaction tuberculosi skin test it import heart check close receiv infliximababda call doctor right away short breath swell ankl feet sudden weight gain do take medicin unless discuss doctor this includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximababda use medicin togeth infliximababda may increas chanc serious unwant effect renflexi side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur more common accumul pus black tarri stool blur vision chest pain chill cough diarrhea difficulti swallow breath dizzi faint lightheaded get sudden lie sit posit fever general feel discomfort ill headach hive itch rash muscl pain stiff pain joint lower back side pain difficult urin pound ear puffi swell eyelid around eye face lip tongu slow fast heartbeat sore throat sore ulcer white spot lip mouth stuffi runni nose swollen gland swollen red tender area infect tight chest unexplain bleed bruis unusu tired weak weight loss yellow skin eye less common crack skin corner mouth sore red around fingernail toenail vagin burn itch discharg white patch mouth throat tongu rare abdomin stomach pain claycolor stool confus cough sometim produc pink frothi sputum dark bloodi urin difficult fast noisi breath dri mouth faint loss conscious fast irregular breath general feel discomfort ill weak increas sweat loss appetit nausea pain tender swell foot leg pale skin blue lip fingernail pinpoint red spot skin sever constip sunken eye swollen pain tender lymph gland armpit vomit incid known blister peel loosen skin bloodi nose chang mental status difficulti speak heavier menstrual period muscl ach weak new mole chang size shape color exist mole mole leak fluid bleed numb tingl finger face feet red irrit eye red scale crust skin red skin lesion often purpl center seizur some side effect may occur usual need medic attent these side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question more common acid sour stomach belch discomfort upset pain stomach ear congest heartburn indigest loss voic nasal congest pain tender around eye cheekbon other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'JJ'),\n",
       " ('poor thing i think hope you havent tri biolog entyvio might work realli well even simponi humira besid point may normal symptom lower dose prednison may clear know i hate say though go forev know get one uti cold throw whole situat back action who time energi everi year it cant get easier older either last time i flare cold month flare i surgeri are still take vsl comoder ulcer coliti diagnos pancol laryngopharyng reflux migrain battl extrem exhaust current med step one jpouch surgeri complet step two complet step complet',\n",
       "  'NN'),\n",
       " ('my yo first remicad infus day ago after day sever serum sick her fever shot blood pressur realli low she spent hrs picu it scare needless say wont abl take we hope last effect time tell her symptom serum sick fever chill sever joint pain hive swollen hand red eye dri mouth',\n",
       "  'NN'),\n",
       " ('ive heard lot talk recent new oral therapi tecfidera approv fda last spring multipl sclerosi it third oral drug aim treat diseas in one mani articl announc news new york time wrote while selfinject medicin like avonex biogen copaxon teva enter market still use major treat patient newer oral drug make inroad in addit tecfidera two oral drug gilenya novarti approv aubagio sanofi approv septemb im still inject therapi copaxon i consid new drug great progress ms world i think back i diagnos time one therapi avail one i betaseron two year switch new avonex onceaweek inject sound much appeal everyotherday inject but i suffer horribl side effect therapi i felt like i flu make difficult work full time take care babi boy singl mother when copaxon hit market i eager tri id done research knew sideeffect profil much differ therapi id struggl five year it daili inject i know lot peopl hard time but i decid i would rather give shot everi day mean bodi toler without miser flulik side effect ive take daili inject daili dose hope i like call ever sinc im symptom free ill stick pun intend inject therapi the oral therapi new proof work well inject drug isnt convinc enough not yet anyway i admit take pill twice day sound like nice chang ive year but say goe broken dont fix as ms patient advoc i opportun speak mani other share diseas a lot patient newli diagnos idea therapi best alway person decis patient make guidanc neurologist i encourag everyon type therapi matter long theyv ms even theyr current symptom free whi someth slow diseas if one therapi isnt work tri differ one that what nice far weve come past year patient lot choic but still need dont cure the fda remind us press releas new drug tecfidera no drug provid cure multipl sclerosi import varieti treatment option avail patient said russel katz md director divis neurolog product fdas center drug evalu research multipl sclerosi impair movement sensat think profound impact person qualiti life so let stick therapi work us best stay healthi get cure',\n",
       "  'NN'),\n",
       " ('repli post supersmal thank share experi ive decid start take entyvio start first infus next week i definit keep eye side effect finger cross i see improv',\n",
       "  'NN'),\n",
       " ('the past week discuss various type treatment multipl sclerosi includ inject medic oral medic this week discuss infus medic there four medic categori two approv recent tysabri novantron lemtrada ocrevus let take closer look tysabri tysabri monoclon antibodi design prevent damag immun cell enter bloodstream cross blood brain barrier brain spinal cord it approv fda use ms tysabri consid immuno suppress medic use combin medic affect immun system it given via infus month hospit local infus center doctor offic usual infus take around hour individu must observ hour afterward make sure complic reaction medic tysabri usual consid medic tri success there serious rare risk take tysabri immno suppress medic pml pml progress multifoc leukoencephalopathi potenti fatal brain infect caus jc virus if take medic suppress immun system take tysabri longer period time two year test posit jc virus risk get pml increas while take tysabri monitor everi six month via blood test jc virus pml tricki spot symptom similar symptom ms clumsi vision chang weak one side bodi person chang problem cognit think memori orient lead confus if ever experi symptom think may pml import call doctor immedi other side effect tysabri includ headach fatigu chestabdomin discomfort diarrhea depress rash joint pain tysabri also caus liver damag monitor detect blood test just anoth reason keep regular appoint blood work although mani warn potenti side effect mani patient review medic call liquid gold they find help symptom immens novantron novantron antineoplast anticanc medic dna reactiv agent mean caus damag dna it approv fda use ms novantron work stop prolifer b cell t cell macrophag play role immun respons thought involv ms it indic peopl secondari progress ms progress relaps ms worsen relaps remit ms novantron given via infus take minut due potenti damag heart shouldnt take mg lifetim limit treatment year befor start take novantron youll heart test look problem call left ventricular eject fraction lvef if clinic signific reduct reduct lvef take novantron also neutrophil count cellsmm shouldnt take novantron clear slowli bodi liver function impair well therefor need test proper liver function prior start novantron common side effect novantron includ nausea temporari hair thin temporari bluegreen urin urinari tract airway infect uneven heart rate weight gain chest paintight more serious side effect includ heart diseas liver damag therapyrel acut leukemia tral lemtrada lemtrada monoclon antibodi focus cd protein surfac immun cell caus deplet lymphocyt it approv fda use ms origin use approv much higher dose treatment chronic lymphocyt leukemia it abil target immun cell lead scientist test potenti treatment ms lemtrada given infus five consecut day first three consecut day year later there serious side effect associ lemtrada a rare bleed condit rare kidney condit lifethreaten infus reaction increas risk cancer autoimmun thyroid disord yike more common less sever side effect includ rash headach fever nasal congest nausea urinari tract infect fatigu insomnia upper respiratori tract infect herp viral infect hive itch thyroid gland disord fungal infect pain joint extrem back diarrhea sinus sore mouth throat tingl dizzi abdomin pain flush vomit prior start medic individu vaccin varicella thyroid function test monitor everi three month receiv full cbc urinalysi month month last infus skin exam year monitor melanoma ocrevus ocrevus newest medic scene it approv fda earli use primari progress ms first medic approv primari progress ms ocrevus monoclon antibodi target cd posit b lymphocyt these lymphocyt contribut nerv damag ms ocrevus given via infus infus center doctor offic the initi dose split two week in first infus mg infus two week later anoth mg each infus take least hour after first two dose get one infus everi six month take least hour prior first dose need screen hepat b as medic mani potenti side effect fatigu cough fever short breath nausea headach possibl infus relat reaction may occur well these may includ throat irrit headach flush mild fever rash dure clinic trial sever individu develop abnorm growth tissu link growth medic still known it clear medic strong mani includ caveat tri other first when decid one medic individu decis you talk mani peopl want end medic affect come bodi biolog youll never truli know someth work work tri ive tysabri two year befor start medic i read numer patient review it seem like one person love next hate continu page page i final realiz i need tri when i first start i would infus i would exhaust like spend rest day couch noth exhaust as infus went exhaust lessen eventu i got point i i walk infus center get infus go day almost like noth happen',\n",
       "  'JJ'),\n",
       " ('robino wrote what amaz drop cea number sound like opdivo work splendid thank robino',\n",
       "  'NN'),\n",
       " ('mine recommend ocrevus due age immun system good age virginia repli with quot the follow user say thank agat howi jeani z sunshin',\n",
       "  'JJ'),\n",
       " ('sorri lab be forc doctorshop youv alreadi got doctor your perfect happi suck massiv ive was forc find new gp i move three year ago the current one good gp i still miss old one sometim plus lot lax prescrib stuff i know shouldnt reason want stay gp yeah as gi ive seven year look forward day leav if replac isnt good ill make decis whether switch hospit i hope find good gi quick dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('hi greg my father ask consid nivolumabthey actual want start next week yes side effect pretti bad is hard decis have start treatment find i hope good rita',\n",
       "  'NN'),\n",
       " ('hello i crohn sever year start take remicad befor take tb skin test come posit gi went ahead sinc chest xray clear i pneumonia infect anoth bout shingl due suppress immun system but medicin work crohn in past month i notic slight swell neck doc suggest ct scan rule lymphoma the scan show i swollen lymph node doc advis remov lymph node biopsi luckili came back negat lymphoma sent analysi a week later i receiv diagnosi mycobacterium tuberculosi appar dormant reactiv due suppress immun system has anyon gone tb treatment remicad ani help advic appreci thank',\n",
       "  'NN'),\n",
       " ('barryb your neuro anybodi favor feed hope condit remain stabl ms chronic progress march even dmts except possibl lemtrada cladribin rituximab stem you right tell adio favor anoth like bart treat like matter good luck sewingchick fampyra help tremend abl lift leg it work like magic i take day within half hour i transit weak serious foot drop mobil disabl abl walk fair normal gait i use activ ingredi even year patent time releas product approv it dmt effect type ms it work help damag nerv conduct impuls effici the drug compani give patient free day trial work everyon it high effect one third user particip clinic trial it effect medic i ever taken',\n",
       "  'IN'),\n",
       " ('ive got agre ipoop longterm pred simpli isnt viabl option i didnt feel bad surgeri either i mg pred which i felt quit good wasnt actual thing heal colon the patholog report show i sever chronic acut inflamm throughout colon as test could get pred summer still okay i tend alway flare wors winter acut flareup year happen autumn winter dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('i almost finish first month gilenya increas sever leg pain weak along daili headach last hour i worri i also increas fatigu weak i havenotcheck neuro yet',\n",
       "  'NN'),\n",
       " ('ms long character diseas brain white matter immun cell destroy myelin this demyelin believ respons neuron death lead irrevers disabl individu ms howev first time team research identifi subtyp diseas mcms featur neuron loss demyelin brain white matter in studi publish lancet neurolog research observ mcms part neuron becom swollen look like typic ms lesion indic white matter myelin loss mri the team find support concept neurodegener demyelin occur independ ms underscor need sensit mri imag techniqu evalu brain patholog real time monitor treatment respons patient diseas this studi open new arena ms research it first provid patholog evid neuron degener occur without white matter myelin loss brain patient diseas comment bruce trapp cleveland clinic lead investig studi this inform highlight need combin therapi stop disabl progress ms within studi research remov brain spinal cord autopsi individu die ms accord studi visual examin cerebr hemispher slice carri identifi brain without area cerebr whitematt discolor indic demyelin lesion refer mcms brain cerebr whitematt discolor demyelin lesion refer typic ms their observ reveal brain white matter demyelin the research also compar microscop tissu characterist brain spinal cord individu mcms tradit ms also individu without neurolog diseas although mcms tradit ms patient typic ms lesion spinal cord cerebr cortex latter group ms lesion brain white matter despit mcms brain reduc neuron densiti cortic thick hallmark brain degener also observ tradit ms the import research twofold the identif new ms subtyp highlight need develop sensit strategi proper diagnos understand patholog mcms said daniel ontaneda cleveland clinic coauthor studi ontaneda conclud we hope find lead new tailor treatment strategi patient live differ form ms more multipl sclerosi identifi new subtyp multipl sclerosi neurodegen diseas manag multipl sclerosi us fda assess cladribin tablet potenti treatment ask expert emerg therapi multipl sclerosi part ii stem cell futur research world multipl sclerosi day note editor sourc trapp bd vigno m dudman j et al cortic neuron densiti cerebr white matter demyelin multipl sclerosi retrospect studi lancet neurolog doisx epub ahead print httpsnewsroomclevelandclinicorgclevelandclinicresearchersdiscovernovelsubtypeofmultiplesclerosi',\n",
       "  'NNS'),\n",
       " ('art rena it seem earli say receiv ocrevus improv if i understand literatur ocrevus decreas progress pleas let us know ocrevus help mom hope',\n",
       "  'VBP'),\n",
       " ('i just took one bf sit cuz i high anxieti start someth newand see i feel okay hour okay dinner i take two uc sinc mayo clinic say chronscol dx chronic lyme no biolog work now stelara love ittook rafaximin sibo work awesom',\n",
       "  'NN'),\n",
       " ('risk small realli much small risk will takeperson id rather take risk relaps relaps been gilenya year problem one flare old symptom that cours mileag may',\n",
       "  'NN'),\n",
       " ('in recent year excit develop treat lung cancer through genet test tumor sampl doctor identifi specif type lung tumor prescrib treatment design target immunotherapi also emerg treatment option certain type lung cancer these advanc made treatment effect often fewer side effect type lung cancer there two major type lung cancer nonsmal cell lung cancer nsclc small cell lung cancer sclc nsclc account percent lung cancer includ adenocarcinoma common form lung cancer unit state among men women squamous cell carcinoma larg cell carcinoma sclc tumor account remain percent lung cancer unit state they tend grow quick nsclc tumor tumor classifi stage stage base whether cancer local lung local advanc spread nearbi lymph node lung area metastat spread part bodi treatment option print email share tweet lungev lung cancer helplin cancer care partner lungev nation lead lung cancerfocus nonprofit organ provid lungev lung cancer helplin call lung view cancer care resourc help better cope lung cancer editor heather wakele md associ professor depart medicin divis oncolog stanford univers stanford cancer institut listen surgeri surgeri sometim combin chemotherapi common treatment option tumor confin lung advanc surgic techniqu allow doctor make much smaller incis remov tumor section lung affect cancer use videoassist thoracoscop surgeri vat surgeon insert tube call thoracoscop chest this devic light tini camera connect video monitor radiat therapi in case surgeri possibl mani local advanc cancer radiat therapi sometim use either alon combin chemotherapi these treatment may also use surgeri shrink tumor surgeri help prevent cancer come back recur extern beam radiat common use treat lung cancer standard extern beam radiat use machin direct beam multipl beam radiat tumor the use ct computer tomographi mri magnet reson imag pet positron emiss tomographi scan allow radiat oncologist accur target tumor shape radiat beam size dimens tumor help spare healthi tissu a newer form radiat call sbrt stereotact radiat stereotact ablat radiat therapi sabr sometim use treatment earlystag lung cancer instead surgeri sbrt deliv higher dose radiat shorter period time approach minim impact healthi tissu in patient high risk surgeri sbrt shown curat rate close expect rate surgeri ongo research tri determin patient could type focus radiat instead surgeri chemotherapi chemotherapi long effect treatment lung cancer continu one import element treatment mani patient chemotherapi extrem effect treat sclc also use treat nsclcs chemotherapi help patient earli stage cancer remov surgeri combin radiat local advanc cancer it also import part treatment patient advanc stage lung cancer chemotherapi drug approv fda treatment lung cancer includ cisplatin platinol carboplatin paraplatin these common medic use treat lung cancer most treatment approach includ either cisplatin carboplatin combin anoth chemotherapi drug pemetrex alimta pemetrex use combin chemotherapi cisplatin initi treatment advanc nonsquam nsclc pemetrex also approv use alon treat advanc nonsquam nsclc anoth chemotherapi given pemetrex use adenocarcinoma lung activ squamous cell lung cancer small cell lung cancer gemcitabin gemzar other these drug use treat nsclc either combin cisplatin carboplatin initi treatment singl drug chemotherapi given this drug work type nsclc paclitaxel taxol nabpaclitaxel abraxan docetaxel taxoter these drug form taxan chemotherapi given combin cisplatin carboplatin nsclc docetaxel frequent given alon later line therapi advanc stage lung cancer etoposid etopopho vepesid etoposid use combin cancer medic treatment sclc target treatment to destroy cancer cell target therapi focus specif cell mechan thought import growth surviv tumor these medic caus differ often less sever side effect chemotherapi research discov mutat gene call epiderm growth factor receptor egfr caus develop growth spread lung cancer approxim ten percent peopl lung cancer egfr mutat present tumor egfr inhibitor target therapi given pill form often use treat type lung cancer today four medic approv treatment option unit state lung cancer patient gene mutat erlotinib tarceva other the us food drug administr fda first approv use erlotinib lung cancer in erlotinib approv initi treatment patient nsclc spread part bodi certain type egfr mutat piec miss call delet egfr gene afatinib gilotrif in fda approv afatinib initi treatment metastat nsclc patient egfr gene mutat delet treat success erlotinib gefitinib iressa in juli fda approv gefitinib initi treatment patient nsclc whose tumor harbor specif type egfr gene mutat detect fdaapprov test osimertinib tagrisso in novemb fda approv osimertinib treatment patient nsclc whose tumor specif egfr gene mutat start regrow treatment erlotinib afatinib gefitinib if resist develop one drug tumor start grow newer egfrinhibitor drug call osimertinib tagrisso often work shrink cancer stop grow anoth gene mutat found lung cancer refer alk four target treatment fdaapprov option peopl whose cancer mutat crizotinib xalkori this treatment approv fda treat metastat nsclc tumor alk gene mutat crizotinib block mutat alk gene stop growth tumor in clinic trial found effect chemotherapi addit crizotinib approv treat peopl metastat nsclc tumor mutat ros gene ceritinib zykadia this medic approv peopl metastat alkposit lung cancer cannot toler crizotinib whose cancer continu grow treat crizotinib in approv newli diagnos patient alk posit lung cancer alectinib alcensa alectinib approv decemb patient lung cancer alreadi treat crizotinib as result larg clinic trial novemb alectinib approv given firstlin treatment choic prior treatment brigatinib alunbrig in april brigatinib approv patient alreadi treat crizotinib in june fda approv target therapi dabrafenib trametinib administ combin patient nsclc mutat braf ve gene detect fdaapprov test there gene mutat seen nsclc target therapi option may avail as gene mutat tend common adenocarcinoma type nsclc import patient adenocarcinoma discuss valu genet test oncologist becaus gene cancer cell evolv tumor may becom resist target therapi treatment medic meet challeng studi clinic trial cut off blood suppli tumor anoth approach destroy cancer cell chang blood suppli tumor need grow blood vessel grow sever way process depend presenc substanc call vascular endotheli growth factor vegf produc tumor normal cell this substanc stimul blood vessel penetr tumor suppli oxygen miner nutrient feed growth bevacizumab avastin monoclon antibodi work stop vegf stimul growth new blood vessel when combin chemotherapi bevacizumab shown like shrink tumor help patient certain type nsclcsuch adenocarcinomato live longer ramucirumab cyramza also use treat nsclc a monoclon antibodi target vegf receptor help stop format new blood vessel ramucirumab often given chemotherapi drug docetaxel later line therapi anoth treatment stop work immunotherapi our immun system constant work keep us healthi it recogn fight danger infect virus grow cancer cell in general term immunotherapi use immun system treatment cancer in march fda approv immunotherapi nivolumab opdivo treatment metastat squamous nsclc unsuccess treat chemotherapi nivolumab work interf molecular brake known pd prevent bodi immun system attack tumor two addit drug categori approv octob atezolizumab tecentriq pembrolizumab keytruda pembrolizumab drug categori approv firstlin initi treatment lung cancer in februari fda approv immunotherapi durvalumab imfinzi treatment patient stage iii nsclc whose tumor unabl surgic remov whose cancer progress treatment chemotherapi radiat treatment approach be studi the effect combin immunotherapi treatment nsclc studi mani clinic trial one promis approach pair nivolumab ipilimumab yervoy immunotherapi current approv fda treatment metastat melanoma anoth area ongo research combin immunotherapi chemotherapi firstlin treatment option in fda approv use pembrolizumab combin chemotherapi firstlin treatment metastat nsclc addit effect potenti side effect ad radiat therapi immunotherapi current studi introduct manag treatment side effect print email share tweet the import clinic trial clinic trial standard measur worth new treatment qualiti life patient receiv treatment for reason doctor research urg peopl cancer take part clinic trial your doctor guid make decis whether clinic trial right here thing know often peopl take part clinic trial gain access benefit new treatment befor particip clinic trial fulli inform risk benefit trial includ possibl side effect most clinic trial design test new treatment standard treatment find whether new treatment ad benefit you stop take part clinic trial time reason listen all cancer treatment caus side effect it import report side effect experi health care team help manag report right awaydont wait next appoint do improv qualiti life allow stick treatment plan it import rememb patient experi side effect patient may experi side effect list side effect chemotherapi the side effect chemotherapi depend type dose drug given length time use includ fatigu tire hair loss diarrhea constip increas risk infect white blood cell easi bruis bleed chang memori think peripher neuropathi numb tingl hand feet side effect radiat therapi treatment chang skin includ dryness swell peel red blister if reaction occur contact health care team appropri treatment prescrib it especi import contact health care team open skin pain area could indic infect infect treat oral antibiot topic antibiot cream side effect target therapi target therapi drug dont effect bodi chemotherapi drug still caus side effect some potenti side effect target therapi includ rash diarrhea liver problem elev liver enzym problem blood clot wound heal high blood pressur side effect immunotherapi immunotherapi travel bloodstream help prompt immun respons becaus trigger attack healthi cell well cancer cell certain side effect may experienc includ fatigu decreas appetit digest tract symptom the manag potenti side effect discuss later next section booklet manag digest tract symptom nausea vomit avoid food strong odor well over sweet greasi fri high season food nibbl dri cracker toast these bland food easi stomach have someth stomach take medic may help eas nausea mani effect medic nausea vomit develop recent year talk doctor whether may right diarrhea drink plenti water ask doctor use drink gatorad provid electrolyt well liquid electrolyt bodi salt must stay balanc cell work proper overthecount medicin loperamid imodium ad other prescript drug avail diarrhea use necessari if diarrhea bad enough need medicin discuss doctor nurs choos food contain solubl fiberfor exampl bean oat cereal orang flaxse highpectin food peach appl orang grapefruit banana apricot also help avoid diarrhea loss appetit to help maintain weight eat small meal throughout day that easi way take protein calori tri includ protein everi meal to keep feel full earli avoid liquid meal take small sip unless need liquid help swallow drink liquid meal focus liquid nutrit valu be physic activ sometim take short walk hour meal help feel hungri keep highcalori highprotein snack hand hardboil egg peanut butter chees ice cream granola bar liquid nutrit supplement pud nut can tuna trail mix if struggl maintain appetit talk health care team whether appetitebuild medic could right manag fatigu fatigu extrem tired help sleep one common side effect mani cancer treatment if take medic doctor may lower dose drug long make treatment less effect if experienc fatigu talk doctor whether take smaller dose right there number tip reduc fatigu take sever short nap break take short walk light exercis possibl tri easier shorter version activ enjoy ask famili friend help task find difficult tire save energi thing find import there also prescript medic may help modafinil your health care team provid guidanc whether medic right approach individu circumst manag pain there number option pain relief includ prescript overthecount medic it import talk member health care team take overth counter medic determin safe interfer treatment treatment option communic with your health care team print email share tweet listen as manag lung cancer import rememb consum health care the best way make decis health care educ diagnosi member health care team includ nurs social worker patient navig here tip improv communic health care team start health care journal have health care journal notebook allow keep health inform one place you may want write name contact inform member health care team well question doctor keep diari daili experi cancer treatment you separ journal notebook differ section help keep organ prepar list question befor next medic appoint write question concern becaus doctor may limit time ask import question first specif brief possibl bring someon appoint even journal prepar list question concern alway help support go appoint the person accompani serv second set ear he may also think question ask doctor rememb detail symptom treatment may forgotten write doctor answer take note help rememb doctor respons advic instruct if cannot write answer ask person accompani if mobil devic use take note write note help review inform later record visit doctor allow record convers doctor give chanc hear specif inform share famili member friend incorpor health care profession team your oncologist oncolog nurs essenti member health care team health care profession help manag diagnosi treatment make sure oncologist know medic condit pain experienc consult primari care physician specialist need rememb thing overcommun manag treatment side effect faq print email share tweet cancer care free support servic program oncolog social worker provid emot support peopl cancer love one these profession help cope challeng cancer diagnosi guid resourc cancer care offer free counsel profession oncolog social worker understand challeng face peopl cancer caregiv we work oneonon develop strategi cope treatment side effect oncolog social worker also help communic doctor member medic care team health care issu import support group provid care environ share concern other similar circumst support group member come togeth help one anoth provid insight suggest way cope at cancercar peopl cancer famili particip support group person onlin telephon financi help offer cancer care number organ assist cancerrel expens transport treatment child care home care to learn cancer care help pleas call us hope visit wwwcancercareorg wwwlungcancerorg listen frequent ask question q my breath affect surgeri chemotherapi what i a when surgeri reduc size lung cannot take much air some medic also chang lung function lead short breath ani time difficulti breath report doctor he prescrib pulmonari lung rehabilit therapi this therapi may includ exercis train energyconserv techniqu breath strategi nutrit counsel improv lung function q my lung cancer ret gene mutat are drug studi type tumor a ret protein send signal cell tell divid matur special perform specif function when mutat ret gene signal get stuck caus uncheck cell growth in discov mutat ret gene mutat link lung cancer three medic approv fda peopl type cancer ret mutat cabozantinib cometriq vandetanib caprelsa peopl thyroid cancer sunitinib sutent kidney cancer pancreat cancer gastrointestin stromal tumor gist talk doctor lung cancer clinic trial peopl ret gene mutat ask whether recommend prescrib medic label use prescript drug legal treat cancer drug approv fda q what happen treatment stop work a if happen discuss altern treatment option doctor their recommend base uniqu situat includ factor relat overal health note sever drug latephas clinic trial intend use initi lung cancer treatment becom less effect stop work q i stage a lung cancer surgic remov my doctor say i dont need chemo type treatment should i get second opinion a if cancer truli stage a treatment surgeri recommend howev import get ct scan everi six month first two year surgeri check recurr new cancer after first two year doctor recommend frequent get ct scan communic with your health care team print email share tweet resourc cancer care hope american cancer societi cancernet cancer support communiti lungcan lungcancerorg hope the lung cancer allianc nation cancer institut to find out about clinic trial emergingm',\n",
       "  'NN'),\n",
       " ('my mother diagnos stage nsclc septemb she efgr tm histori she first tarceva carboplatinalimta plus tarceva tagrisso progress tagrisso start decemb she tri one round keytruda pdl express due extrem cough rule pneumon ct scan done right second round keytruda scan show larg growth exist tumor new growth the oncologist thought would better switch chemo tri control growth soon possibl immunotherapi tend take week month effect by cancer could grown much so round docetaxol noth cancer continu progress now round navelbin ct scan show mix result some tumor slight smaller other remain grew tini bit she continu navelbin much clearer progress show but option mom the oncologist thought would worth shot retri tagrisso still tm posit the oncologist think higher chanc tagrisso work retri type immunotherapi she said egfr posit patient good result immunotherapi mother rare case egfr posit high pdl express',\n",
       "  'NN'),\n",
       " ('also i spent yearyear half wallow seem get wors wors when i final got rear someth activ i start feel differ almost immedi the first coupl week i exhaust i built strength got better i honest bother ms month year sinc first dx i take vitamin d vitamin b energi gilenya i most stop klonopin i work fireplac technician requir walk stand kneel lift cognit abil all year patient ms i never stop move i licens residenci builder i come fact bodi cant use matter hard i push i dont mean complain kinda strang year i went build hous troubl walk time im wallow im angri i fear i stop ill die but bodi work never good day never i realli hope g work prms suck all ms suck onli mser get prms pain it never end never you honest dont choic bodi say mean one guy told i ms lotto that didnt make happi not funni i laugh',\n",
       "  'IN'),\n",
       " ('hi jeanni most often patient begin standard dosag most clinic trial shown dose toler patient specifi dosag shown efficaci onc maximum toler dose establish earlyphas clinic trial lower dosag dont tend test but oncolog much art scienc certain room individu if oncologist feel lower dose would minim side effect particular patient dose recommend unless cancer appear progress fast rate reason start low rais dose drug welltoler respons less anticip although tough determin sinc patient achiev differ level respons stage iv diseas even stabil without tumor shrinkag good result as far side effect larger dose taken less frequent doesnt tend well studi either number patient given puls tarceva eg mg everi four day seem experi signific side effect receiv mg per day jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'JJ'),\n",
       " ('hi kempten i think initi question would slight progress lung mass compar overal size has thought continu tagrisso bit confirm progress determin rate growth dr west often state often make sens stay welltoler treatment even face slow progress bad brake better brake of cours local doctor best abl judg question if origin percentag exon mutat unchang seem indic exon posit portion cancer progress sinc would expect percentag rise either way specul sinc unfortun dont understand resist progress well yet there discuss treat tarceva failur tagrisso that use tagrisso firstlin set even context isnt good evid yet efficaci dr ramalingam state two month ago tagrisso studi first line therapi set see shut t escap resist mechan proactiv improv outcom patient the approach shown promis earli result studi larg clinic trial this trial compar tagrisso direct tarceva iressa we still learn mechan resist observ patient treat tagrisso first line set it possibl subset patient use iressa tarceva receiv tagrisso might benefici earli time make firm statement issueth present avail data base laboratori experi confirm patient httpcancergraceorgtopictagrissofirstlineandthentarcevatherapypost continu jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa this repli modifi year month ago jimc forum moder this repli modifi year month ago jimc forum moder',\n",
       "  'NN'),\n",
       " ('hi bettina i year diagnos rebif tysabri fingolimod i came fingolimod nov prepar start ivf janfeb year i worst relaps i ever slap bang middl first ivf tri mri show least new activ lesion neuro realli want stop ivf go straight lemtrada leav ivf anoth year i didnt want at one point appoint got frustrat threw hand air walk say would get someon els make see sens i agre i would least meet ms nurs start lemtrada much understand want babi interest said isnt unheard women babi lemtrada treatment i understand say feel selfish want babi well i alway pretti bad relaps luckili recov well my husband also ms huge decis come treatment ivf despit relaps i i happi i stuck gun i want i older alreadi much older want i start famili way wait anoth year pregnanc kind ms breast feed deliv also offer protect relaps we lucki enough nd round ivf work i due late jan my neuro want start lemtrada within week deliveri i havent decid yet i cant imagin i would want leav newborn day even though i come home night soon ms throw us mani mani curv ball great hear peopl didnt i honest believ go gut you alway find someon disagre decis i cant tell mani time iwe call selfish tri babi ms didnt stop us good luck decis i realli interest get whichev way choos go dont mind share cours hayey xx',\n",
       "  'NN'),\n",
       " ('my neuro say ocrelizumab old drug rituxumab revampt not much chang realli rituxumab move patent new version ocrelizumab pharma get money yet doctor bart blog seem excit ocrelizumab moyna',\n",
       "  'VBP'),\n",
       " ('mapesg how get trial ulcer coliti sinc juli pred mg upadacitinib clinic trial sinc octob colazid g entyvio vedolizumab sinc januari stop oct lost respons azathiporin mg stop due clinic trial',\n",
       "  'JJ'),\n",
       " ('longterm treatment diseasemodifi therapi dmts appear lessen risk diseas worsen relapsingremit multipl sclerosi rrms patient year followup studi suggest but therapi seen benefit progress secondari progress multipl sclerosi spms the studi onset secondari progress multipl sclerosi influenc current relaps multipl sclerosi therapi publish multipl sclerosi journal experiment translat clinic diseasemodifi therapi dmts treatment aim reduc ms progress relapsingremit form diseas spms research conduct retrospect analysi patient regist group research treatment multipl sclerosi gitem registri valencia spain out initi patient clinic diagnos ms receiv treatment firstlin dmts interferon beta biogen avonex among brand name glatiram acet sold teva copaxon treatment dmts began patient experienc least one relaps previous year two relaps within previous three year rrms patient follow median year patient fail respond treatment given secondlin therapi name immun suppress novantron mitoxantron cyclophosphamid select secondlin dmts tysabri natalizumab gilenya fingolimod studi particip evalu regular everi three six month chang expand disabl status scale edss score relaps rate side effect decis stop treatment progress spms confirm patient previous edss score greater experienc sixmonth worsen edss greater without evid relaps research wrote continu read',\n",
       "  'NN'),\n",
       " ('hi see inject silicon tini amount silicon oil use lubric insid needl although use needl contain silicon henc class action usa im uk appar occasion use needl i got small silicon bubbl first inject eylea subsequ problem inject the elea inject almost complet cure small amount wetamd i one eye i person ok live small floater occasion appear',\n",
       "  'JJ'),\n",
       " ('repli post justmari i remicad sinc ever sinc hospit claim im remiss base studi blood work result despit fals claim i still occasion bloodi stool frequent symptom side effect mouth sore psoriasi abdomin cramp etc so final switch hospit new gi want switch stalera much newer far appear effect i havent start first stalera treatment yet i see natur remedi like healthi diet correct vitamin supplement exercis littl pot may abl make differ without biolog system so far i feel much better i remicad if i experi less symptom ill probabl keep treatment if aint broke dont fix',\n",
       "  'NN'),\n",
       " ('i said gp refer doctor bart second opinion ms neurologist refer talk cladribin want find might help',\n",
       "  'NN'),\n",
       " ('glad hear contentprof ive well go next infus week pancol dx fall current imuran lialda entyvio',\n",
       "  'NN'),\n",
       " ('do peopl know medic stori ive tysabri four year four month ive gone downhil pretti steadili time nervous move gilenya less power lot side effect common i chang coupl year ago i didnt we make mistak just christma i told pml risk gone right i one dose tysabri i scare rebound relaps i long tysabri first dose gilenya im start gilenya day still nervous side effect physic deterior i get still hope go cladribin end i know i month gilenya i tri still hope get better physic state rather wors one but im sort get lift put hous hope best plan worst',\n",
       "  'JJ'),\n",
       " ('if youv fail remicadeinfliximab humiraadalimumab consid entyviovedolizumab xeljanztofacitinib as beav said simponigodlimumab yet anoth tnfalphablock sister medic humira remicad moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc',\n",
       "  'NN'),\n",
       " ('hi i follow site sinc april i diagnos rrms i thought stroke im yo femal sinc time i sever relaps tri differ med didnt agre second one leav bed ridden week my last relaps june i develop sever vertigo i still havent fulli recov complet numb right side go hospit iv steroid i refus take oral on plus side led start fingolimod i found give issu i number symptomat medssom work dont mobil come goe ive reduc hour work i kept fall asleep home sudden one could wake i readi come i realli good doctor ms nurs i contact time im one tell peopl what go complain i experi someth differ realli say someth ask my biggest issu annoy moment addit deal random stuff current constip odd accid like bus stop get bus bladder issu i go abl pass urin utter wet recent new year eve front mother the urologist want self catheris i cant bring it alway nice read peopl deal dealt regular basi tri get and im one get random symptom deal x',\n",
       "  'NN'),\n",
       " ('fernando did find stelara help periann crohn do also fistula julia', 'NN'),\n",
       " ('mollymop im sorri small chang i dont know much fund drug bc i live usa i hope get approv btw i wrote previous messag i saw kindl chang word i fix messag i dont know anyth kadcyla my experi abraxaneavastin combo month stop bc kick butt even though still work i use vinorelbin year cap year gemcitabin month still work i toxic reaction couldnt breath letrozoleibr finish th cycl im hair ive lost mine x it didnt bother much nd time im happi best luck ff',\n",
       "  'NN'),\n",
       " ('leogirl i gilenya neuro month mris there chang diseas activ past mris move annual mri head spine seem littl long i new lesion without clinic symptom past like know go noggin',\n",
       "  'NN'),\n",
       " ('my mother prednison almost four year polumyalgiarheumatica we found recent reason horribl back pain could hard walk extend use prednison the mri show actual crack spine we still shock this cannot revers even though peopl feel fine realli top world end result devast so deal even pain even associ polymyalgia she never recov everyon differ pleas look con medicin take bewar regret for inflammatori condit i copd chest pain also i shoulder pain due lift heavi object last year i start prednison mg x two day back i shall take day i felt much better second day today third day i feel much better my copd symptom improv much also reduc swell shoulder magic i taken shoulder pain improv much now i rais hand degre imposs two day back my breathless due smoke relat copd get cure improv upto three day go i shall updat ajit review for crohn diseas mainten i take mg x day along humira everi two week the combin work well im healthier ive year the signific sideeffect anxieti i told side effect ive pentasa year year stretch i complet anxieti went away entir it wasnt i went back pentasa i made connect fionafir for crohn diseas mainten was diagnos year emerg surgeri mass colon due build scar tissu inflamm after coupl month mg x day frequenc flare up great reduc onli notic symptom one weight gain elev liver function test my dosag reduc x day liver function normal weight gain still issu diet stress level seem import factor control flare up',\n",
       "  'NN'),\n",
       " ('week three gilenya i felt aw limb leaden utter exhaust day i also bad hayfeav weather hot sunni i contact wonder ms nurs see could relaps bodi becom use new med i previous copaxon my ms nurs thought most like combin new need hayfeav hot weather this turn correct by end week three week four i feel much better mile recumb trike ride next day mile nordic walk follow day anoth mile cycl activ easi terrain this follow quieter day even ive book club board game group',\n",
       "  'NN'),\n",
       " ('ive opdivo year apart itchi rash i feel good scan result today lymph node cant seen new growth anywher work well easi treatment far compar chemo dream i wish dad best luck hope opdivo good',\n",
       "  'NN'),\n",
       " ('if know someon may relaps go hard time thing could buy friend multipl sclerosi we like comfort super soft blanket luxuri spa robe sheerl slipper cotton pajama we need sleep hot steam eye mask cute silk one essenti oil mani heal properti make life easier alexa echo product assist shop entertain remind relax a box set favorit televis show alf anyon tri audibl get two free audiobook not glamor help shower chair cool vest squatti potti friend rave obvious gift never need text hug visit favor appreci welcom do favorit gift idea you also may enjoy read one step closer ms cure ocrevus show promi e new step diagnos ms stay connect modern day ms facebook twitter instagram pinterest pleas watch share ms awar video',\n",
       "  'NN'),\n",
       " ('hi hammer so sorri learn sister diagnosi hope intrathec chemo forestal progress that glaze stare portray one mani symptom wife experienc if look one last photo togeth see i wish famili best hope miracl sister bob sept wife beth year old nonsmok dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mgwk sept lost beth',\n",
       "  'NN'),\n",
       " ('until i read post i thought felt gilenya made ms wors i start gilenya june first month two bad past month symptom gotten progress wors major exacerb begin novemb had week solumedrol ten day oral prednison felt littl better everi day seem im littl numb feet gone knee left armhand day face im go see dr begin next week i want drug it stop slow worsen symptom go tri ocrevus',\n",
       "  'JJ'),\n",
       " ('im current gilenya ive pretti much relaps free sinc i start take seven year ago the drug recommend spms interferon beta mitoxantron theyr peopl still relaps ive taken betaferon caus depress interferon beta wouldnt option i dont like sound mitoxantron side effect if hang relapsingremit label keep drug im happi ill let neurologist use label regardless i feel condit as appoint i think see neurologist year your take prescrib medic you also see ms nurs year six month appoint neurologist it sometim sound like pwms get left devic theyr medic i suppos get see neurologist someth serious happen',\n",
       "  'JJ'),\n",
       " ('i headach sinc i small child progress got wors year old teenag i link ton ms symptom age eventu diagnosi have eye check recent i find ms eye constant chang i three differ prescript i also rule allergi trigger headach mine main tension headach environment i end take advil sinus pill work like charm the gilenya caus frequent headach i well notic first month lot headach get better though i pill bit longer ms pain long stay kind far rest diet stress figur work definit speak gp possibl medic eas pain headach also make sure get rest sleep issu right manag full night sleep without wake i see sleep apnea specialist enjoy everi day come dont stress futur present tackl issu soon aris take time figur work',\n",
       "  'NN'),\n",
       " ('and rememb often combinationtherapi best often singl medic get us rather take multipl medic simultan order achiev remiss you might need remicad imuranmp mesalamin achiev remiss it often take less medic sustain remiss initi achiev remiss expect med reduc your sustain remiss moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc',\n",
       "  'NN'),\n",
       " ('the fingolimod failur typic would first inject mani peopl need third round inject get maximum benefit ensur deplet alemtizumab',\n",
       "  'NN'),\n",
       " ('hi vender the way i understand ms basic involv demyelin neurodegener nerv brain andor spinal cord the various symptom fatigu bladder issu eye issu etc seem span across differ type ms although everyon regardless ms type exact symptom weird diseas huh there differ cours diseas take though the nation ms societi recent modifi descript four type ms cours prms fall activ ppms relaps i ppms take dmds relaps acut inflammatori event here chart nmss show four cours httpwwwnationalmssocietyorgwhatismstypesofm it seem littl confus hope get feedback use gilenya wish good luck take care',\n",
       "  'NN'),\n",
       " ('i nerv pain relat damag begun initi attack caus lose use domin arm hand month after sever dose solumedrol pt i regain motor function lost fine motor skill the last damag begin chronic pain eventu includ arm hand affect leg side final ms hug the associ symptom distinct nerv pain cannot improv typic pain medic pregabalin antiseizur low dose antidepress med help prior i suffer spastic bladder featur sear pain help gabapentin i found secret pain reduc year suffer i experienc whole bodi pain syndrom describ gilenya four year back pain list possibl se i i learn experi lot ms nerv damag dmd stir pot mayb pot stir',\n",
       "  'JJ'),\n",
       " ('hey im ocrevus ive first two half infus im much better i most symptom disappear lessen tremend i walk fast without use walker my cog fog gone along spastic cog fog swallow issu ms hug it lessen fatigu tingl i use numb ting head toe i get occasion tingl feet leg use bad numb ting burn felt heavi theyr pretti much back normal i slight infus reaction first half itchi scalp took care i reaction second half i recent came shingl pain i know ocrevus lower immun system probabl trigger i recommend get vaccin i believ vaccin given week prior infus lemtrada also immunosuppress when i go lemtrada neuro actual given med shingl take week lead short i got ms specialist decid ocrevus i never took med ive also heard posit thing lemtrada well decid dmt alway difficult let know question best luck',\n",
       "  'NN'),\n",
       " ('i hope know cidp isnt hereditari you pass children as far recoveri goe cidp littl year seem unfortun diseas take sometim abat go becaus type nerv damag cidp mani medic profession consid two three year mark time heal symptom still present three year may stay us mani year the good news newer treatment alway come this forum full discuss newer treatment there hsct rituximab ocrelizumab mani list forum post along link neurolog report cover addit treatment option here booklet may offer help info cidp teen httpgelbbnkgprnuuwpenginenetdnasslcomwpcontentuploadsteenyoungadultpdf it way earli say like would get wors futur kid give time see heal mayb anoth year two least',\n",
       "  'NN'),\n",
       " ('good morn ive updat i check read post i last round chemo rough go one i lower left lobectomi septemb follow round cisplatinalimta went st scan follow lobectomi chemo get readi radiat unfortun found new total new nodul lower right mm upper left mm i schedul anoth biopsi next thursday larger one at point radiat start earli februari hold till know go',\n",
       "  'JJ'),\n",
       " ('no one say humira affect it might get remiss give old self back someth anyon promis truth crohn complex diseas even peopl remiss intestin still ongo issu fatigu ib joint problem etc id say youv got luxuri time give humira go may one lucki one if make decis think care go humira dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'RB'),\n",
       " ('just follow histori origin post should read articl havent i would even print share drinsur provid i deni coverag the shame stori rituximab multipl sclerosi httpsneuroimmunologywordpresscomtheshamefulstoryofrituximabinmultiplesclerosi rituximab vs ocrelizumab multipl sclerosi httpsneuroimmunologywordpresscomrituximabvsocrelizumabinmultiplesclerosi',\n",
       "  'NN'),\n",
       " ('hi molli molop yes maam ive experi laser eye treatment retinopathi plenti treatment so mani treatment ive lost count probabl sever variat laser i diagnos retinopathi joslin clinic assur id total blind within two year refer ophthalmologist boston confirm diagnosi prognosi told treatment theori work laser photocoagul i volunt guinea pig my first laser treatment modifi weapon grade rubi fix strength durat i return everi month burn year video joslin site lay oper tabl shirt tie one followup treatment summer my latest laser treatment decemb greenargon as far pain discomfort ive never much ive found locat burn make big differ rubi laser least pain the time ive felt brief short pain doctor need aim close nerv high power i doubt requir case becaus thousand burn ive i dont real estat avail futur treatment if i found place trust opinion skill doctor i would agre treatment my decis year ago award mani year good vision life befor i agre i research i never heard laser i sot advic doctor scientist includ nasa turn one relat charg apollo space mission use rubi laser mark land site moon messag email want talk',\n",
       "  'NN'),\n",
       " ('the dose schedul sound similar wife current trial attempt irinotecan erbitux without avastin placebo they drop fu previous folfiri ad erbitux she think still get avastin base previous experi she still ace inhibitor use avastin use though bp usual low begin she infus monday noth day get hit problem i dont know use higher dosag erbitux she toler well rash came week right away think subsid prior yesterday infus i cours interest ucsd trial i contribut research class drug particular ci dacomitinib i still believ despit failur dacomitinib erlotinib big pfizer nsclc trial archer dacomitinib still superior egfr famili inhibitor the ucsd trial look promis we know egfr inhibitor becom resist one lay pathway divert make tumor resist revert egfr inhibitor becom effect so i wonder also dose schedul concentr use trial isnt work similar hit tumor hard relax enabl tumor slide altern signal pathway mani question hope trial answer i wonder would consid use dacomitinib arm crowd fund trial also regard grouseman',\n",
       "  'NN'),\n",
       " ('im get readi start stelara sometim sept i also wonder fistula etc it strang didnt let stay the last drug studi offer indic i success close would continu provid drug seem rather cruel take get sick femal canada ivig pentasa entyvio infusionsno respons discontinu uccrohn test posit map antibodi mycobacterium pg remiss flare almost yearsin bad way due abx treatment gone wrong sigh',\n",
       "  'JJ'),\n",
       " ('today us food drug administr fda approv pembrolizumab keytruda combin pemetrex alimta platinum firstlin treatment patient metastat nonsquam nonsmal cell lung cancer egfr alk genom tumor aberr pembrolizumab previous grant acceler approv indic may base improv overal respons rate progressionfre surviv patient random pembrolizumab administ pemetrex carboplatin compar pemetrex carboplatin alon keynot studi keynot this recent approv repres fulfil postmarket commit demonstr clinic benefit product this action base result keynot random multicent doubleblind activ control studi enrol patient receiv firstlin treatment metastat nonsquam nsclc in keynot patient random receiv pembrolizumab placebo combin pemetrex investig choic either cisplatin carboplatin everi week cycl follow pembrolizumab placebo pemetrex treatment pembrolizumab continu diseas progress unaccept toxic maximum month the primari efficaci outcom measur overal surviv progressionfre surviv assess blind independ committe review use respons evalu criteria solid tumor version key result the trial demonstr statist signific improv overal surviv patient random pembrolizumab chemotherapi hazard ratio hr confid interv ci p prespecifi interim analysi median overal surviv reach time data cutoff pembrolizumabpluschemotherapi arm month chemotherapi arm the trial also demonstr improv progressionfre surviv patient random pembrolizumab plus chemotherapi hr ci p the median progressionfre surviv month patient receiv pembrolizumab plus chemotherapi month receiv chemotherapi alon the overal respons rate signific higher vs p pembrolizumabpluschemotherapi arm the median respons durat month month respect the common advers reaction report patient keynot fatigueasthenia nausea constip diarrhea decreas appetit rash vomit cough dyspnea pyrexia the recommend pembrolizumab dose schedul nonsquam nsclc mg intraven infus minut everi week this second fda approv use real time oncolog review pilot program enabl fda review team begin analyz data applic submiss the content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       "  'NN'),\n",
       " ('repli post cianphillip hi jami i know look confirm unfortun i diagnos didnt eat microwav process food follow year dure time i steroid work first time next flare didnt work even mg day my symptom final improv i ramp mg per day i naturapath alergen free liquid diet didnt work i took bunch chines herb enter coat peppermint work didnt then azacol never work even highest dose mercapterpurin mp work coupl year liver enzym test start come back danger rang i stop most recent ive remicad work year stop my current flare remicad cant treat steroid make super sugar sensit requir insulin inject etc i take hand pro prebiot everi day eat sour krout pickl live cultur unsweeten goat kefir garlic fish oil much i toler there year i stay away milk nut black red pepper etc think culprit follow year eat without incid except spici food still hurt pretti consist all say i convinc treatment diet contraint addit offer minim benefit sometim enough assist remiss none consist as mention previous poster regard one mani treatment untreat placebo group improv respond treatment if math right may feel free correct possibl posit outcom could spontan eg placebo leav higher placebo efficaci treatment surpris i havent fact check number mirror experi treatment kind in experi i made correl connect mani diet chang medic long run turn causat',\n",
       "  'NN'),\n",
       " ('in review literatur found date pembrolizumab pd pdli inhibitor show signific surviv benefit chemotherapi given monotherapi part combin therapi metastat squamous nonsquam nsclc nonsmal cell lung cancer that statement research write the new england journal medicin also present new data iaslc th world confer lung cancer toronto canada septemb base data merck sharp dohm maker pembrolizumab add treatment pembrolizumab combin chemotherapi result signific longer overal surviv os progressionfre surviv pfs compar chemotherapi alon squamous nsclc accord articl kaplanmei estim rate surviv year pembrolizumabcombin arm placebocombin arm though trial conclud estim conclus date decis report second interim result occur efficaci boundari primari hypothes overal surviv progressionfre surviv met investig wrote they origin set goalpost interim analysi occur event diseas progress death occur relat articl in headtohead battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient with stage iii nsclc despit promis trial result skeptic rais red flag about anlotinib efficaci heavili treat nsclc in doubleblind phase trial research run keynot trial random assign untreat metastat squamous nsclc patient receiv either mg pembrolizumab salin placebo cycl patient patient respect all patient also treat carboplatin either paclitaxel nanoparticlealbumin bound nabpaclitaxel first cycl patient receiv paclitaxel also receiv premed glucocorticoid antihistamin patient allow crossov certain circumst patient switch placebo pembrolizumab diseas progress patient receiv subsequ pd pdl inhibitor prescrib outsid trial pdl express status assess use agil technolog pdl ihc c pharmdx assay tumor imag schedul week everi week week everi week thereaft as result use tool patient exclud trial could provid tumor sampl determin pdl status os pfs respons rate durat respons calcul use blind independ central review radiolog imag a pdl tumor proport score greater seen patient regardless patient pdl express level overal surviv benefit observ across pembrolizumabcombin group in group median os followup month compar month placebocombin group hazard ratio death confid interv ci p median pfs month month respect hazard ratio diseas progress death ci p the risk death lower risk diseas progress death lower pembrolizumabcombin group placebocombin group author wrote but ad in patient pdlposit tumor current avail data permit determin whether pembrolizumab plus chemotherapi greater efficaci pembrolizumab alon respons rate howev higher among individu receiv pembrolizumabbas regimen compar rate observ placebo regimen patient place subgroup defin pdl tumor proport score and outcom improv across categori pdl tumor proport score pembrolizumabchemotherapi group make studi author question use pdl biomark guid drug select advers event ae similar across treatment group although treatment discontinu pembrolizumabcombin group occur frequent placebocombin group vs respect there death due ae pembrolizumabbas arm aerel death placebobas arm read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'VBP'),\n",
       " ('weve arriv heavi hitter go back first instal ibd academi back basic rememb inflammatori bowel diseas fundament autoimmun disord immun system mistak attack bodi tissu to inhibit counteract reaction immunomodul biolog use dampen autoimmun respons a serious concern use medic t lymphocyt white blood cell center autoiummun widespread bodi target induc systemat local immunosuppress mean gut isnt part bodi affect regular blood test usual done check liver kidney bone marrow function suppress effect drug immun system patient immunomodul andor biolog also encourag receiv year flu vaccin avoid live vaccin medic becaus mani cell molecul involv autoimmun key player familiar refer back dive mechan util various immunosuppress medic key vocab intestin mucosa tissu line gi tract made endotheli cell attack white blood cell autoimmun reaction basi ibd t lymphocyt t cell type white blood cell central immun respons ibd autoimmun disord antibodi protein circul blood follow product immun system respons foreign particl detect bodi may produc bodi creat artifici use drug cytokin signal protein essenti communic cell involv inflammatori respons may proinflammatori antiinflammatori interleukin class cytokin involv modul immun respons develop t lymphocyt tnf tumor necrosi factor alpha proinflammatori cytokin central regul immun function target multipl biolog therapi autoimmun disord integrin receptor t cell allow interact cell bodi madcam protein express endotheli cell small blood vessel intestin mucosa immunomodul drug modul andor weaken immun system order dampen inflammatori respons may use conjunct biolog dual therapi combin therapi increas chanc induc maintain remiss thiopurin azathioprin imuran oral mercaptopurin mp purinethol oral mechan action prevent activ t lymphocyt keep attack intestin mucosa caus inflamm may take three month work therefor patient often steroid new medic kick methotrex subcutan sc inject mechan action addit act cellular level like thiopurin methotrex may also inhibit proinflammatori cytokin like il interleukin tnf bloodstream tradit use treat rheumatoid arthriti lupus use crohn patient fail becom toler thiopurin hasnt shown effect uc must use caution women childbear age due risk birth defect miscarriag cyclosporin oral mechan action prevent t lymphocyt produc cytokin multipli tradit use prevent reject follow organ transplant use patient sever uc much rapid onset action thiopurin take two week begin work tacrolimus oral topic mechan action also prevent t lymphocyt make cytokin multipli tradit use prevent reject follow organ transplant use patient sever uc fistul crohn use topic activ crohn diseas around mouth perian area skin pyoderma gangrenosum biolog drug name end mab stand monoclon antibodi biolog antibodi design bind inhibit inflammatori factor molecular target involv immun respons ibd antibodi foreign protein immun system produc antidrug antibodi biolog caus drug stop work mani ibd patient switch anoth biolog form antibodi one list order fda approv oldest newest antitnf mechan action bind block excess tnf bloodstream order prevent attack healthi cell gut see figur remicad infliximab infus everi week fda approv treat crohn diseas ulcer coliti adult children two biosimilar essenti generic avail renflexi infliximababda inflectra infliximabdyyb also treat rheumatoid arthriti plaqu psoriasi psoriat arthriti ankylos spondyl humira adalimumab sc inject everi week fda approv treat crohn diseas adult children ulcer coliti adult also treat juvenil adult rheumatoid arthriti plaqu psoriasi psoriat arthriti ankylos spondyl hidraden suppurativa panuv cimzia certolizumab pegol sc inject everi week fda approv treat crohn diseas adult also treat rheumatoid arthriti psoriat arthriti ankylos spondyl simponi golimumab sc inject everi week fda approv treat ulcer coliti adult also treat rheumatoid arthriti psoriat arthriti ankylos spondyl excess amount tnfalpha caus immun system mistaken attack healthi cell gi tract lead inflammationth under caus crohn symptom janssen biotech inc remicad belong class biolog medic known tnfblocker remicad bind tnfalpha block action janssen biotech inc antiintegrin indic patient respond lost respons antitnf tysabri natalizumab infus everi week mechan action bind integrin receptor t cell block interact madcam protein blood vessel intestin mucosa prevent t cell migrat blood stream attack intestin mucosa also block t cell interact vcam protein endotheli cell elsewher bodi associ increas risk rare brain infect call progress multifoc leukoencephalopathi pml especi use conjunct anoth immunosuppress drug fda approv treat adult crohn diseas also treat multipl sclerosi entyvio vedolizumab infus everi week mechan action also bind integrin receptor t cell block interact madcam prevent t cell migrat gut doesnt affect vcam shown caus pml first current biolog target gutfocus inflammatori pathway fda approv treat adult crohn diseas ulcer coliti target gut specif inflammatori mechan use exclus ibd antiinterleukin stelara ustekinumab sc inject everi week mechan action target proinflammatori factor il il interleukin prevent activ t lymphocty fda approv treat adult crohn diseas also treat plaqu psoriasi psoriat arthriti note dose list baselin guidelin medic follow induct stage treatment base individu respons schedul may adjust frequent dose no individu class biolog shown effect treat case ibd it current unknown given patient respond one biolog anoth becaus seri molecular interact lead activ ibd inflammatori cascad complic web trigger interact mani mani potenti molecular target new treatment in addit target pathway common mani autoimmun disord research also attempt develop new biolog gutspecif mechan immunosuppress entyvio medic work way safer overal suppress immun system local manner make patient less suscept certain infect comparison older general immunosuppress the immun respons lead intestin inflamm activ inflammatori bowel diseas consist varieti proinflammatori factor includ cytokin tna interleukin well activ multipl type white blood cell main various t cell each molecul associ cell receptor repres potenti target ibd therapi the top section figur show target associ drug intestin mucosa antitnf antiinterleukin the bottom section show target border blood vessel antiintegrin imag taken danes s vuitton l peyrinbiroulet l biolog agent ibd practic insight natur review gastroenterolog hepatolog page doinrgastro while we strong advoc be involv in decis regard your treatment make sure that you onli take medic as prescrib by your doctor and under hisher supervis come next ibd academi surgeri ostomi sourc sciencedirect cytokin httpswwwsciencedirectcomtopicsneurosciencecytokin sciencedirect interleukin httpswwwsciencedirectcomtopicsneuroscienceinterleukin sciencedirect tumor necrosi factor alpha httpswwwsciencedirectcomtopicsimmunologyandmicrobiologytumornecrosisfactoralpha biorad what antibodi immunoglobulin httpswwwbioradantibodiescomimmunoglobulinantibodyhtml crohn coliti foundat immunomodul httpwwwcrohnscolitisfoundationorgresourcesimmunomodulatorshtml crohn coliti uk azathioprin mercaptopurin httpseuwestamazonawscomfilescrohnsandcolitisorgukpublicationsazathioprineedbfebpdf neurath m thiopurin ibd httpswwwncbinlmnihgovpmcarticlespmc swaminath a taunk r lawlor g use methotrex inflammatori bowel diseas a user guid httpswwwncbinlmnihgovpmcarticlespmc segal r yaron n tartakovski b methotrex mechan action rheumatoid arthriti httpswwwncbinlmnihgovpubm harding k mage c pharmacolog cyclosporin tacrolimus httpswwwuptodatecomcontentspharmacologyofcyclosporineandtacrolimus american cancer societi monoclon antibodi treat cancer httpswwwcancerorgtreatmenttreatmentsandsideeffectstreatmenttypesimmunotherapymonoclonalantibodieshtml bendtzen k tumor necrosi factoralpha inhibitor induct antibodi autoantibodi autoimmun diseas httpswwwuptodatecomcontentstumornecrosisfactoralphainhibitorsinductionofantibodiesautoantibodiesandautoimmunediseas jannsen biotech how remicad work httpswwwremicadecomcrohnsdiseasehowdoesremicadework merck co renflexi prescrib inform httpwwwmerckcomproductusapicircularsrrenflexisrenflexispipdf pfizer inflectra prescrib inform httplabelingpfizercomshowlabelingaspxidsectionmedguid abbvi learn humira work moder sever crohn diseas httpswwwhumiracomcrohnshowhumiraworksforcrohn ucb live cd httpswwwcimziacomlivingwithcd jannssen biotech explor inject experi simponi offer httpswwwsimponicom biogen tysabri mechan action httpswwwtysabrihcpcomenushomeaboutmechanismofactionhtmlcidppcbngtyhcpbrandedvexactmoagclidckhcqlkitocfvdygqodtsnzagclsrcd fda highlight prescrib inform tysabri httpswwwaccessdatafdagovdrugsatfdadocslabelslblpdf takeda pharmaceut entyvio mechan action httpswwwentyviohcpcommechanismofact jannsen biotech stelara httpswwwstelarahcpcomcrohnsdiseasemechanismofact danes s vuitton l peyrinbiroulet l biolog agent ibd practic insight kristen weiss sander proud ostom third generat girl gut diagnos ibd she passion patient educ encourag chronic ill knowledg part healthcar team kristen credit constant exampl support strong women famili determin thrive crohn diseas use ibd journey empow other',\n",
       "  'JJR'),\n",
       " ('my sisterinlaw diagnos year ago stage adenocarcinoma would consid oligiomestast diseas she round cancer journey just diagnos cancer type lung cancer diseas learn biolog ok alectinib i psoriasi along stage iv nsclc alk posit i take alectinib nsclc is ok take biolog like cosentyx stelara cancer journey in treatment cancer type lung cancer diseas learn neuropathi autoimmun hi year prior diagnosi small cell lung cancer i suffer small fiber neuropathi sure autoimmun relat cancer journey just diagnos cancer type lung cancer diseas learn progess tagrisso ive tagrisso sinc juli i great initi respons visibl cancer shrink point longer detect cancer journey in treatment cancer type lung cancer diseas learn pancoast about four month ago i start pain neck shoulder upper arm left side had cervic shoulder upper arm mri cancer journey cancer type lung cancer head neck cancer',\n",
       "  'NN'),\n",
       " ('hi folk i surpris neurologist suggest i think join year studi new drug ocrelizumab i plegridi year although i havent relaps last mri show new lesion spinal cord im due screen studi come friday i know peopl studi uk i wonder anyon els consid alreadi accept studi thank',\n",
       "  'VBD'),\n",
       " ('just clariti im pretti sure wont let gilenya alreadi low lymphocyt count gilenya would lower even',\n",
       "  'JJ'),\n",
       " ('did offer mavenclad it definit worth consid along side option the final choic definit your ms nurs help choos though',\n",
       "  'IN'),\n",
       " ('repli post zepolv you came right place youll see peopl differ degre crohn you sympathi get young age i got ulcer coliti around age noth help i eventu proctocollectomi thought problem i got crohn it bad uc still aw was remicad two year noth now tri entyvio i hope work good luck',\n",
       "  'NN'),\n",
       " ('hi i new forum i diagnos ms sinc i im ive mani med help slow progress diseas i current process set get start gilenya ive test jc virus came back negat im lower chanc get pml side affect im still kind nervous though is anyon els take med id love hear experi',\n",
       "  'NN'),\n",
       " ('hi jihm i us get eylea chang doc thank inform gave forum regard silicon now i wonder would explain doc diagnos bubbl silicon is test if like i think i would prove perman irrit bubbl center vision silicon i avastin inject pleas let us know legal action come along if i would known i could gotten fda approv eye inject eylea i would refus avastin eyesight precious medic profess avoid anyth risk eyesight i hope turn well eylea inject help',\n",
       "  'NN'),\n",
       " ('doesnt entyvio sort financi assist program i think ive seen talk forum year oldfemal diagnos decemb ulcer pancolitiscmvanemialiv damag remicad fail prednison fail respons valcyt tacrolimus bridg biolog entyvio current dose uceri x iron infus blood transfus current case studi memberpati ut southwest dalla tx',\n",
       "  'NN'),\n",
       " ('whi read httpmultiplesclerosisresearchblogspotcomresearchspeakrituxumabvsfingolimodhtml mayb read',\n",
       "  'NN'),\n",
       " ('i year survivor nsclc came upon site accid i first diagnos i went conventi rout remov right lung chemotherapi appear cancer free return i egfr mutat oral target therapi sinc i remain first line drug tarceva gilotrif i cancer check today growth my tumor small i stage oper i symptom except side effect med i dont know anyon els around long nsclc interest hear other still',\n",
       "  'NN'),\n",
       " ('i diagnos stage nsclc april i went radiat chemo i ned small nodul grew small amount a biopsi show cancer cell i opdivo sinc septemb the nodul smaller less solid hope someday gone i minor side effect joint pain tire coupl day follow treatment this noth compar chemo',\n",
       "  'JJ'),\n",
       " ('i didnt mean scare want give inform i given genetech there post facebook ocrevus page two member develop cancer lung brain pancreat year someon suggest call drug compani mani given inform i list i opt go infus i schedul stay tecfidera least inform good luck',\n",
       "  'NN'),\n",
       " ('anoth updat i three infus i seem wick headach within twentyfour hour afterbut settl but i still get weird headach morn i get move around day i go day feel heavi head my walk general ok still balanc problem general weak thing way better gilenya i dont know i onceif i turn jcv posit lemtrada not avail new zealandto expens either i still progress as i definit good i use avonex',\n",
       "  'NN'),\n",
       " ('first deserv much respect admir choos serv countri im sorri hear youv diagnos good news advanc treatment option there reason regul proper would abl continu full capac militari servic i would question right choic mesalamin the mesalamin famili drug consid antiqu therapi quit time were initi treat prednison chanc this would residu effect make seem like mesalamin might help what type diagnost confirm diagnosi did upper lower scope biopsi i would recommend followup even second opinion treatment plan anoth gi might necessari good luck go forward militari servic keep us post progress my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran',\n",
       "  'NN'),\n",
       " ('adjuv treatment erlotinib associ improv diseasefre surviv versus chemotherapi chines patient epiderm growth factor receptormut stage iiia nonsmallcel lung cancer indic phase ii trial result',\n",
       "  'NN'),\n",
       " ('fingolimod slow progress diseas measur combin disabl measur compar placebo',\n",
       "  'NN'),\n",
       " ('in olympus trial rituximab trial patient ppms negat result halt progress but suggest potenti decreas progress younger patient ppms younger yrs old especi inflammatori lesion so rituximab ocrelizumab ppms older inflammatori lesion i hold excit final ocrelizumab result ppms',\n",
       "  'NN'),\n",
       " ('i question about two week ago left side face went numb appar reason numb sens week ago start feel like consist high someth i curious one experienc in past mani diagnos read more repli view appreci ms hug author andis creat apr im lean site journalnot visit neuro rather bug staff i cant handl stress bring lol ive sharp pain rib cage one side time second take breath away complet i ask told lingo read more repli view appreci feel like im die author lizzybel creat jun went beach day i awesom time day bare keep eye open serious choos fun complet exhaust work yesterday took nap hoursgot upat went back bed hour today work still fight read more repli view appreci doe happen anyon els author scottj creat jun so im avid i avid energi drinker coffe connoisseur i recent thought amount caffin i take doe caffin effect anyon els trigger symptom im tri nail caus symptom elimin mani variabl possibl read more repli view appreci inabl use finger author luigi creat jun amongal symptomsof multipl sclerosisi toconstantlycompar toa symptom muchth applicantin usingth fingersof thehandto write typeor actionaft minutesi feel asharp painin fingersmiddl ringand littl fingerswith subsequentin tous themthes finger read more repli view appreci frustrat author dag creat jun when i straggl multitud symptom almost unheard male ms kind tri explain symptom doctor wont listen fustrat but i got doctor would hear i hospit unabl speak wright have ms discov read more repli view appreci ocd author amylm creat jun is connect ms ocd impulsecontrol disord i know depress link ms i wonder mental health issu well for past year i follow neurologist possibl ms i possibl lesion read more repli view appreci wonder neuro take next appoint author andis creat jun so i take rough pill day includ gilenyawel i decid around th last month i fed take pill i quit so far almost week everyth gilenya i feel fine i still get migrain noth wors i read more repli view appreci bladder cramp author lizzybel creat jun been bladder cramp urinalysi negat anyon bladder spasm is precursor incontininc ugh read more repli view appreci what constitut relaps author jtsokolov creat jun hello i diagnos ms week ago my symptom start tingl right hand went right arm leg left leg well what realli scare go dr work tingl get intens translat tight read more repli view appreci first symptom newli diagnos author sgandotra creat jun i diagnos past april mri spinal tap the symptom i sever fatigu ive lot stress late notic im lie still tri sleep upper bodi sometim entir bodi random spasm without warn everi minut read more repli view appreci summer come author scottj creat may im partial concern heat issu arriv soon becaus im pretti new i wonder kind thing other done stay cool least help reduc relaps read more repli view appreci menstrual cycl author americaninhongkong creat jun hi im wonder anyon els see tight connect ms symptom menstrual cycl month read more',\n",
       "  'NN'),\n",
       " ('in may novarti announc fda approv gilenya first diseasemodifi therapi f treatment children adolesc less year age relaps form multipl sclerosi rms make first diseasemodifi therapi indic patient this approv expand age rang gilenya previous approv patient age year older rms gilenya grant breakthrough therapi design fda decemb pediatr indic read entir articl',\n",
       "  'NN'),\n",
       " ('just simponi did mesalamin asacol lialda pentasa immunomodul azathioprinemp anyth often biolog like simponi plus class med simultan combat flare simponi plus immunomodul sometim plus mesalamin moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa is unpatriot wipe bumm georg washington bill there tp stall your otherwis direstraight i think georg would understand',\n",
       "  'NN'),\n",
       " ('my neurologist recommend i add lyrica sea medic provid addit relief nerv pain i concern weight gain side effect what experienc post year ago hug use answer sign view previous answer a mymsteam member said littl weight gain watch eat cut back sweet post year ago hug use who take gabapentin tell experi i wwas tri take someth would caus fatigu i dont much pain anyway ive take mertazapin sleep i think caus bad morn fatigu it either gilenya ms fatigu heat the mertazapin low dose want altern mertazapin gabapentin bed i experi take gabapentin edit origin post month ago hug use answer sign view previous answer a mymsteam member said a mymsteam member i drove road three year time thousand mile day tractor trailer never caus fall asleep read post month ago hug use pain armshand finger doe anybodi suffer pain arm hand finger prepar food eat late i terribl achi feel arm burn pin needl hand electr shock pin needl befor pain tollarobl bad ani suggest ms famili post year ago hug use answer sign view previous answer a mymsteam member said i get pain left shoulder arm lr my doc think rotat cuff post year ago hug use do troubl sleep what help post year ago hug use answer sign view previous answer a mymsteam member said awok friday morn wonder wonder im feel pretti good gymnasium post month ago hug use baclofen anybodi take baclofen if like side effect my doc want take mg time day i read web i figur id ask expert thank post year ago hug use answer sign view previous answer a mymsteam member said it make number go i take need post year ago hug use what myth ms wish other would stop believ post year ago hug use answer sign view previous answer a mymsteam member said will tri find a mymsteam member post month ago hug use gabapentin i gabapentin still confus yesterday saw ms nurs recommend mg three time day mg i describ new symptom hot feet feel like cover sweat dri i touch i dont think i suffer sideeffect post year ago hug use answer sign view previous answer a mymsteam member said i take mgs gabapentin daili i nerv pain back constant among place come go it anti seizur medic also read post year ago hug use feel low so i finish lemtrada infus yesterday came home hospit around slept night suffer ach pain overyour bodi woke today feel numb lower half remind relaps symptom the treatment manag mean easi ride today im feel low isol i feel partner understand serious i go im fed like i feel im fight alon read',\n",
       "  'NN'),\n",
       " ('sorri guy i got bit end first post im crohn mirowpl good luck entyvio i mean i know experi isnt encourag one ever i seen lot peopl say got remiss scifig ha yeah i wouldnt want gut prettier that i think whole i would still pick clinic remiss hand would annoy symptom explan if case i would start think possibl caus think i pin thing onto crohn per usual cm no right technic i crohn ileocolilti vast bulk diseas colon howev termin ileum affect well i remov along colon henc neo new termin ileum report goe ive tri imuran mp ive mp near year as far i tell mp done noth except make burn easier sun i dont good luck med edit tom thank im certain stelara avail id ask gi while inflamm isnt widespread seem stubborn treatmentresist on plus side im ill entir colon inflam i dont feel entir healthi either i dont think immun system attack bit digest system thyroid eye etc sorri im get bit time go bed i think post edit nicecupoftea pm gmt',\n",
       "  'NN'),\n",
       " ('thank much respond i tri search pharmaceut assist medicar websit could find page referenc i keep look make phone call head littl clearer i appreci help hope well ocrevus',\n",
       "  'NN'),\n",
       " ('i surgeri jan th choicecould went humira remi choos bc fact lower immunitymi colon respond pred alway doneboth surgeon gastrofor year agre mesurgeon said bad inflam colonim yo want life normal put uc monster yearsextrem happi got surgeryno anxietyno medslif goodso happi made choic wasnt emerg patientrecoveri oktook life slow let bodi healhop best u',\n",
       "  'JJ'),\n",
       " ('hello folk thank f lab scifig bull i know mean well i certain wouldnt disagre i lone but nobodi get admit psychiatr ward loneli particular nhs one i liter suicid look plan internet i dont think understand withdrawn depress make someth overcom willpow if i could eg made convers staff local cafe like regular i would done as end i struggl even place order without want cri it bit vicious circl way depress make lone depress also make imposs socialis or gain pleasur i mean brother girlfriend friend wasnt alon but wasnt enough protect issu obvious lifelong tendenc toward depress at rate guess still hasnt seen doctor folk yep but i grant leav afternoon a staff member told yesterday i inform patient ie not section i basic could go whenev i want thought sound bit good true complet non surpris i desper need cloth thing also i would rather like see market squar it pretti christma tree cover light id rather go guy sound dubious an occup therapist knock door ask i need anyth yes toilet roll desper im use paper towel ridicul i actual ran last night ask nurs girl overheard said could give which realli nice unfortun wasnt near enough fault anyway ot mention someth standard issu i let know i crohn diseas go x day standard issu wasnt near enough anyway im get tire would like write patient time may long phone in meantim i took photo earlier i upload later later everyon p dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('now current data concept pseudoprogress concern mani oncologist side equat wait long immuno work mistak here recent articl dr jack west cancer grace differ cancer differ pseudoprogress rate in melanoma fair signific in lung cancer percent httpcancergraceorglungdeathbypseudoprogressionknowingw hentocutyourlosseswithimmunotherapymor along think here quot lung cancer present dr eddi garon say one import issu address issu pseudoprogress someth peopl immunotherapi field talk long time effect immunotherapi may immun cell infiltr tumor result rather get smaller tumor would actual get larger that could certain happen short period time i would say date someth weve seen lot lung cancer our colleagu melanoma certain report signific issu patient initi growth tumor imag afterward shrink we certain sever intrigu anecdot sort individu patient peopl describ sort increas tumor volum get better i would say actual quit uncommon lung cancer so dilemma continu roll dice there progress continu move onto next line treatment in case first scan two round keytruda show mix result progress shrinkag hint perhap new thing sinc pd express high perform status continu zero oncologist i decid keep go anoth three infus rescan he said convent wisdom would tell us move someth els so buck convent wisdom full understand risk next scan two week five infus total clem',\n",
       "  'NN'),\n",
       " ('two isati cool pill am went back sleep hour work no headach far feel fine thank listen my husband im sure even though doesnt say probabl sick hear never end talk supplement medic poop day i feel i diari listen i hate burden i got week florastor pill day i gave i didnt stop i follow someth that hard sometim it gave much diarreah night i thought first coupl day wow im better nope the week i rotat antibiot no luck either uc sinc mayo clinic say chronscol dx chronic lyme no biolog work now stelara love ittook rafaximin sibo work awesom',\n",
       "  'NN'),\n",
       " ('it much rechalleng rather isnt clear afatinib isnt best option slow rate growth cancer use instanc stereotact radiat area control there isnt lot inform go one cannot confid afatinib isnt option next best would osimertinib erlotinib fewer side effect penetr brain better',\n",
       "  'NN'),\n",
       " ('brand name tafinlar whi medicin prescrib dabrafenib use alon combin anoth medic trametinib mekinist treat certain type melanoma type skin cancer cannot treat surgeri spread part bodi it also use along trametinib treat prevent return certain type melanoma surgeri remov affect lymph node dabrafenib also use combin trametinib treat certain type nonsmal cell lung cancer nsclc spread nearbi tissu part bodi it also use treat certain type thyroid cancer spread nearbi tissu part bodi respond previous treatment dabrafenib class medic call kinas inhibitor it work block action abnorm protein signal cancer cell multipli this help stop spread cancer cell are other use medicin this medic may prescrib use ask doctor pharmacist inform how medicin use dabrafenib come capsul take mouth it usual taken twice day empti stomach hour hour meal take dabrafenib hour apart around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take dabrafenib exact direct do take less take often prescrib doctor do stop take dabrafenib without talk doctor swallow capsul whole open break crush your doctor may adjust dose temporarili perman stop treatment depend respons treatment side effect experi talk doctor feel treatment your doctor pharmacist give manufactur patient inform sheet medic guid begin treatment dabrafenib time refil prescript read inform care ask doctor pharmacist question you also visit food drug administr fda websit web manufactur websit obtain medic guid what special precaut i follow befor take dabrafenib tell doctor pharmacist allerg dabrafenib medic ingredi dabrafenib capsul ask pharmacist check medic guid list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take be sure mention follow clarithromycin biaxin prevpac dexamethason gemfibrozil lopid ketoconazol midazolam nefazodon rifampin rifadin rifam rifat rimactan warfarin coumadin jantoven your doctor may need chang dose medic monitor care side effect mani medic may also interact dabrafenib sure tell doctor medic take even appear list tell doctor ever diabet glucosephosph dehydrogenas gpd defici genet condit bleed problem eye problem heart failur heart problem liver kidney diseas medic condit know medic may decreas fertil men women dabrafenib may temporarili perman stop sperm product howev assum cannot get someon els pregnant tell doctor pregnant plan becom pregnant plan father child you partner becom pregnant take dabrafenib if partner becom pregnant take dabrafenib call doctor dabrafenib may harm fetus know dabrafenib may decreas effect hormon contracept birth control pill patch ring implant inject you use anoth method birth control prevent pregnanc partner treatment dabrafenib week final dose talk doctor birth control method work tell doctor breastfeed plan breastfe you breastfe take dabrafenib week final dose surgeri includ dental surgeri tell doctor dentist take dabrafenib what special dietari instruct i follow unless doctor tell otherwis continu normal diet what i if i forget take dose take miss dose soon rememb howev less hour next schedul dose skip miss dose continu regular dose schedul do take doubl dose make miss one what side effect medicin caus dabrafenib may caus side effect tell doctor symptom sever go away headach joint muscl back pain nausea diarrhea constip loss appetit cough runni nose sore throat hair loss tired some side effect serious if experi symptom call doctor immedi chang skin new wart skin sore red bump bleed heal chang size color mole rash red skin pimpl fever faint dizzi lightheaded weak chill decreas urin swell hand feet ankl lower leg frequent urin increas thirst eye pain red swollen eyelid sensit light blur vision vision chang includ see halo blur outlin around object color dot swell pain red peel skin palm sole feet ongo pain begin stomach area may spread back unusu bleed bruis bloodi black tarri stool cough vomit blood materi look like coffe ground chest pain short breath swell hand feet ankl lower leg fast irregular pound heartbeat yellow skin eye dabrafenib may increas risk develop new skin cancer cancer talk doctor risk take medic dabrafenib may caus side effect call doctor unusu problem take medic if experi serious side effect doctor may send report food drug administr fda medwatch advers event report program onlin web phone what i know storag dispos medic keep medic contain came tight close reach children store room temperatur away excess heat moistur bathroom it import keep medic sight reach children mani contain week pill minder eye drop cream patch inhal childresist young children open easili to protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach web unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin takeback program talk pharmacist contact local garbagerecycl depart learn takeback program communiti see fdas safe dispos medicin websit web inform access takeback program what i case overdos in case overdos call poison control helplin inform also avail onlin web if victim collaps seizur troubl breath cant awaken immedi call emerg servic what other inform i know keep appoint doctor laboratori your doctor order certain lab test treatment check bodi respons dabrafenib your doctor check skin chang everi month treatment month treatment do let anyon els take medic ask pharmacist question refil prescript it import keep written list prescript nonprescript overthecount medicin take well product vitamin miner dietari supplement you bring list time visit doctor admit hospit it also import inform carri case emerg this report medic inform consid individu patient advic becaus chang natur drug inform pleas consult physician pharmacist specif clinic use the american societi healthsystem pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field the american societi healthsystem pharmacist inc make represent warranti express impli includ limit impli warranti merchant andor fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos the entir monograph drug review thorough understand drug action use side effect the american societi healthsystem pharmacist inc endors recommend use drug the inform substitut medic care ahf patient medic inform copyright the american societi healthsystem pharmacist inc eastwest highway suit bethesda maryland all right reserv duplic commerci use must author ashp',\n",
       "  'NN'),\n",
       " ('the fda grant prioriti review design supplement biolog licens applic sbla tecentriq atezolizumab use combin carboplatin etoposid frontlin treatment patient extensivestag small cell lung cancer essclc the sbla base phase impow studi ad tecentriq standard upfront carboplatin etoposid signific prolong surviv patient essclc the fda action date decis sbla march after median followup month median overal surviv os impow month tecentriq arm compar month placebo arm percent reduct risk death os event occur percent tecentriq arm percent control arm median progressionfre surviv pfs month tecentriq group compar month placebo tecentriq associ higher sixmonth pfs rate percent vs percent doubl month pfs rate percent vs percent compar placebo it year sinc new initi treatment option extensivestag small cell lung cancer deliv clinic meaning surviv benefit sandra horn md chief medic offic head global product develop genentech roch manufactur tecentriq said statement we work close fda bring tecentriqbas regimen peopl difficulttotreat type lung cancer soon possibl ad horn the global doubleblind random placebocontrol phase impow trial evalu efficaci safeti firstlin tecentriq adjunct therapi standard care combin carboplatin etoposid treatmentnav patient essclc result studi present th world confer lung cancer the result simultan publish new england journal medicin all patient receiv four day cycl carboplatin auc mgmlmin iv day one mgm etoposid iv day patient also random receiv either concurr tecentriq mg iv day patient placebo patient induct phase treatment follow mainten therapi tecentriq placebo accord previous random assign everi three week progress diseas loss clinic benefit investigatorassess pfs os intentiontotreat popul serv primari endpoint secondari endpoint includ object respons rate orr durat respons safeti age demograph smoke status repres diseas median age year rang tecentriq placebo group major male percent vs percent respect white percent vs percent former smoker percent vs percent the tecentriq arm includ patient percent brain metastas percent liver metastas placebo group consist percent percent respect the median durat treatment tecentriq month median dose receiv the investig saw major differ orr arm percent vs percent respect median durat respons vs month tecentriq demonstr superior month percent vs percent month percent vs percent eventfre rate eighteen patient treat concurr tecentriq ongo respons compar patient control arm the safeti profil regimen appear consist previous report safeti profil individu agent new find observ the common grade treatmentrel ae among tecentriq placebo arm includ neutropenia percent vs percent respect anemia percent vs percent decreas neutrophil count percent vs percent thrombocytopenia percent vs percent leukopenia percent vs percent immunerel advers event ira common tecentriq compar placebo percent vs percent the common grade ira among tecentriq placebo arm includ rash percent vs percent respect hepat percent vs percent infusionrel reaction percent vs percent pneumon percent vs percent coliti percent vs percent tecentriq approv fda indic nonsmal cell lung cancer urotheli carcinoma this articl origin appear onclivecom fda grant atezolizumab regimen prioriti review frontlin sclc',\n",
       "  'NN'),\n",
       " ('mayb im paranoid i read incid time time news not surgeri also care home gynecologist abus thing this isol incid when i die i want cremat no cut open none uc sinc was remicad success made step back azathioprin current mg azathioprin wellbutrin mg zoloft mg ccherbal need algaec scope show inflamm scar dexa scan show decreas bone densiti new dexa scan still wait result',\n",
       "  'NN'),\n",
       " ('dear coleridg sinc joint inflamm pain anticip side effect immun therapi emerg long actual end therapi probabl talk first oncologist report he may want see either doctor need understand opdivo bring printout side effect manufactur might help well timelin treatment prior joint issu manag painwhat work doesnt etc post high dose interleukin treatment year ago i sharp pain shoulder joint initi diagnos frozen shoulder the physic therapist indic i would need therapi long year i believ think problem lay around hospit total four week howev frozen shoulder disappear within three month fifth month past last hd il dose i free cancer lung howev six week post last dose i still big mess get smaller earlier scan to ideal success immun therapi meant immun system revv taught counter rcc sinc rcc cancer develop way evad immun system like year lie quiet wait immun system complet uninterest proof system learn rccmore like vaccin antibiot action',\n",
       "  'NN'),\n",
       " ('cherish other interest it took bit effort get go persist help here i this argument crib bart ms websit i sent neurologist cladribin least effect treatment mayb hsct alemtuzimab the clariti oracl ms trial use oral cladribin posit sipe et al cladribin treatment chronic progress multipl sclerosi lancet beutler et al the treatment chronic progress multipl sclerosi cladribin proc nat acad sci usa stelmasiak et al effect parenter cladribin relaps rate patient relaps form multipl sclerosi result year doubleblind placebocontrol crossov studi mult scler j giovannoni et al a placebocontrol trial oral cladribin relaps multipl sclerosi nejm giovannnoni et al sustain diseaseactivityfre status patient relapsingremit multipl sclerosi treat cladribin tablet clariti studi posthoc subgroup analysi lancet neurol leist et al effect oral cladribin time convers clinic definit multipl sclerosi patient first demyelin event oracl ms phase randomis trial lancet cladribin safe dmt safer high efficaci dmts unlik alemtuzumab daclizumab caus secondari autoimmun it doesnt caus pml it much safer mitoxantron penetr spinal fluid plasma concentr blood aug cancer res mar it work kill b tlymphocyt decreas inflamm cns six subcutan inject cladribin one year give equival plasma concentr use clariti oracl ms trial j clin oncolog everyon ms need antiinflammatori treatment even progress ms patient cladribin get brain kill lymphocyt neuroprotect slow progess it induct treatment consist mgyear subq inject within month it requir singl wbc count st three nd three inject cladribin safe effect ms patient it relat low cost i think could help slow progress diseas can prescrib is anyth i get go dr k schmierer spearhead cladribin effort bart help he even look neuro recent attend asn meet vancouv my doctor agre worth tri drk sent protocol us i almost month st dose i blood work done wife gave inject also take antivir day prevent infect the inject ridicul easi toler even though ml subq inject no ill rash inj site problem i get blood work monday next dose later next week i dmds year im us put cost credit card st vial insur hasnt agre cover yet hope find supplier drug much difficult i imagin veri opaqu price avail ps im also take mg simvastatin day mayb also slow thing',\n",
       "  'VBG'),\n",
       " ('how mani year cladribin neda includ those alemtuzumab neda valu two year post treatment prof g pleas elabor cladribin figur im pretti sure alemtuzumab fare better cladribin trial',\n",
       "  'JJ'),\n",
       " ('im sorri horribl infus im lucki infus reaction ocrevus latest infus two week ago unev i know case peopl i start ocrevus last fall latest infus first full infus the two half dose negat effect i actual felt pretti good afterward howev full dose absolut level physic mental i bad day exhaust weak unsteadi rave b everyon around after coupl day i start feel back usual self week i actual feel better i infus i found i start ocrevus posit effect fatigu i feel way week everyon react differ medic i know experi could differ mine i hope feel better possibl good coupl rough day',\n",
       "  'JJ'),\n",
       " ('greet my stepmom stage iv lung cancer met liver it also metastas bone surgic remov octob she asymptomat perform status she st line treatment alimta year recent finish four round second line treatment keytruda ani idea rd line treatment might appar clinic trial avail thank',\n",
       "  'NN'),\n",
       " ('even treatment k one time year ms treatment k year everi year die i think closer k treatment nw cost compar dmds typic would pay year the stem cell therapi speed recoveri chemotherapi treatment curat portion look ms therapi find mani root chemotherapi agent a person theori could go intens chemotherapi regimin effect there reput clinic around world offer similar treatment consider less cost this clinic push stem cell treatment cure your articl uniform extrem bias almost pharmacut payrol most ms treatment also associ sever advers event includ death mani one year efficaci flare no stop under caus ocrevus new treatment reformul rituxan big pharma pull trial sinc run patent this prove therapi avail research done stall maxim profit expens patient exploit collus insur industri it would countri best interest fund non pharmacut trial actual find effect open sourc therapi instead fda assur billion dollar barrier big pharma navig afford treatment reach market',\n",
       "  'NN'),\n",
       " ('is acid reflux medic taken hour period tarceva i told i cannot take prilosec longer is interact new inform thank repli this topic modifi year month ago elizoc this topic modifi year month ago elizoc',\n",
       "  'NN'),\n",
       " ('i medicar u medicar supplement insur part b medicar pay infus supplement pick rest i found medicar prescript part d pay much pill inject biolog drug tier insur price extrem wait u hit donut hole mayb would qualifi program humira help offset cost anyway infus drug ra tocilizumab actemra abatacept oriencia infliximab remicad rituximab rituxan golimumab simponia aria i think certolizumab cimzia i remicad orencia ithink month doctor go make chang put actemra know i hope help good luck i wish well',\n",
       "  'VBP'),\n",
       " ('hello everyon i diagnos rrms last week hooray coupl month test etc i got lab back today i jcv negat relief sinc im consid tysabri i question would appreci tip pointer my ms specialist recommend i go tysabri right gate im realli sure i didnt think ask visit spent lot time highlight efficaci also said prescrib inject theyr effect pill she warn pml risk order jcv ratio test at time unsur jcv status recommend gilenya second choic depend i felt jcv risk came back so ive come back jcv negat i admit easier decis make i pretti sure recommend i go tysabri first statist long peopl recommend typic stay tysabri jc negat ive seen pml risk factor laid year tysabri chang geometr time jcv i havent seen thing jcv is thing are quantifi risk factor jcv i realiz cours jcv status could chang still requir monitor second ive seen suggest tysabri pretti highpow drug peopl seem put fail therapi i didnt think ask visit much inform come would purpos recommend drug first time aggress lesion load ani thought welcom i suspect lesion load case even though prior incid ive real reason believ anyth wrong third i insur im curious outofpocket cost i realiz vari across board im tri prepar could impact wallet what peopl typic pocket cost privat employerbas insur extent general fourth hard data suggest come tysabri trigger serious relaps ive seen scare stori im sure think last anyon jcv gotten pml tysabri im sure ill question that thank read',\n",
       "  'JJ'),\n",
       " ('i experienc floater inject go yrs week apart they disappear field vision bottom eye sever day sometim week even two after inject larg floater shape like oliv slice dark rim bright whiteneon center remain i still day it beyond annoy get doubl size i bend brighter sunshin even sunglass my doctor switch lucenti right away i report fda ask much inform it took long time nobodi seem eager forthcom i dealt drug manufactur compound lab i lot number vial info silicon oil use coat needl manufactur syring now i wait fda run databas see whether report remain silicon droplet have wait month i not give somebodi compound lab mess i convinc',\n",
       "  'NN'),\n",
       " ('centenarian wrote eye wrote if lot doctor prescrib fingolimod offlabel socal spms would find work well mani case mani misdiagnos anyway socal rrms one studi it laugh do harm i think peopl start see one statist shall make free or least inexpens so dont think good thing studi done doctor stop prescrib ineffect potenti harm drug time tell good thing everybodi doesnt think one studi last word think good doctor feel oblig everyth someon els book i reckon doctor think word last it shouldnt you neednt continu beat poor anim alreadi dead doctor often let inform person make decis sometim even agre regardless studi done other conclud i think play import role besid drug gatekeep in case fentanyl doctor dont seem much control anyway',\n",
       "  'NN'),\n",
       " ('hello it realli disappoint ocrevus make person prone risk breast cancer cancer well my mom die pancreat cancer i first mcg infus second mcg infus i realli side effect infus except mild flush left facial cheek subsid drive home i pleas just nervous chanc develop ca i would need has anyon ocrevus year what thought worri thank blue satin',\n",
       "  'NN'),\n",
       " ('predictor function vision chang follow cataract surgeri provis studi joshua barbosa varun chaudhari marko popov michael mak kaela gusenbau s mohammad mohaghegh p evalu iophthalmolog mobil applic tool increas patient knowledg satisfact cataract surgeri mirian m dang harri dang porcin cataract creation use formalin microwav treatment ophthalmolog wet lab robert w machuk sourabh arora morley kutzner karim f damji applic lean think cataract surgeri patient safeti waitlist resourc adrienn duimer edith imber carla servic hamza khan analysi intraocular len power calcul formula flat cornea henri chen michell ceniza n kevin wade intraocular len fractur complic laser posterior capsulotomi harmanjit singh iqbal ike k ahm diamond tam sarah l kwan acut present unidentifi intraocular foreign bodi munir iqbal rookaya mather practic pattern among cataract surgeon the ottawa hospit nima noordeh michael myle intracapsular cataract extract buphthalm eye case report andr vicent ana cabugueira vanessa lemo livio costa duart amado nuno marqu joao feijao glaucoma econom analysi medic vs surgic manag open angl glaucoma a canadian perspect hamza n khan adrienn duimer chronic prostaglandin analogu treatment persist depress intraocular pressur follow washout eddi y liu vlad diaconita jillian belros cindi hutnik surgic manag uveiti glaucoma hyphema ugh syndrom moness masri tessa a weinberg xavier m camposml chris rudniski jay chingchieh wang iqbal ike k ahm ocular surfac diseas among patient topic glaucoma drug therapi a systemat review literatur nima mohammadshahi helena zakrzewski ali hafez cindi hutnik posturalinduc chang intraocular pressur treat glaucoma patient jeremi a murphi paul art marcelo nicolela lesya shuba vection respons earli stage glaucoma martin j steinbach longitudin rate neuroretin rim retin nerv fibr layer chang glaucoma patient control a studi convent anatom accur indic jaym r vianna vishva m danthurebandara glen sharp ann belliveau donna hutchison marcelo nicolela balwantray chauhan the correl retin nerv fiber layer thick axial length use optic coher tomographi oct bassam n alkhalaf how old old glaucoma a compar analysi elder middleag patient antoni clark christoph kranemann catherin birt hot topic the effect oral inhal corticosteroid intraocular pressur patient ocular hypertens control glaucoma edward b moss yvonn m buy darana yuen stephani a low graham e trope rd prize cos award excel research poster the interact primari human trabecular meshwork cell metal alloy candid microinvas glaucoma surgeri wendi wan wang kelsey watson jeffrey dixon hong liu amin rizkalla cindi m hutnik trabeculectomi subconjunctiv ranibizumab prospect random control clinic trial mohammad hamid paul harasymowycz mark lesk daniel desjardin veronica flore fawzia djafari gisel li paradigm shift slt topic medic glaucoma vlad diaconita david schulz jillian belros yufeng nanci n chen dariusz gozdzik dania jamal eddi y liu monali malvankar cindi hutnik util discern instrument assess qualiti internet websit peripher iridotomi paul huang ammar mahmood kevin j warrian patrick gooi the relationship ophthalm characterist util valu glaucoma diabet retinopathi dr patient seramelisa thoma william hodg cindi hutnik monali malvankar complic year surviv canaloplasti glaucoma faisal almobarak excis fibrot capsul glaucoma drainag devic mitomycin c oneyear result without ologen flix bernier turmel paul harasymowycz util discern instrument assess qualiti internet websit trabeculectomi ammar mahmood paul huang kevin j warrian patrick gooi hot topic screen glaucomat damag ganglion cell complex spectral domain oct a pilot studi ghada seyam harmanjit singh paul harasymowycz neuroophthalmolog assess qualiti neuroophthalmolog referr tertiari practic cindi t lam edward margolin uveiti the multifoc electroretinogram may predict function retin deterior patient birdshot chorioretinopathi adrian c tsang paul a bastianelli john hamilton stuart g coupland chloe gottlieb dissemin chronic mucocutan candidiasi present endogen candida albican endophthalm qianqian wang simon frdric dufresn mariejos aubin multipl evanesc white dot syndrom masquerad myopic choroid neovascular membran keyvan koushan',\n",
       "  'NN'),\n",
       " ('in us inflectra ixifi remicad renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class tumor necrosi factor inhibitor use for infliximab infliximab inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi it also use children treat crohn diseas ulcer coliti infliximab inject monoclon antibodi work enhanc improv immun system infliximab avail doctor prescript befor use infliximab in decid use medicin risk take medicin must weigh good this decis doctor make for infliximab follow consid allergi tell doctor ever unusu allerg reaction infliximab medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use infliximab inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform relationship age effect infliximab inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximab inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatricspecif problem would limit use infliximab inject elder howev elder patient like infect may requir caution patient receiv infliximab inject pregnanc pregnanc categori explan all trimest b anim studi reveal evid harm fetus howev adequ studi pregnant women or anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetus breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when receiv infliximab especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use infliximab follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenovirus vaccin type live adenovirus vaccin type live alefacept anakinra bacillus calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza virus vaccin live ixekizumab measl virus vaccin live mump virus vaccin live natalizumab paclitaxel phenytoin poliovirus vaccin live quinidin rilonacept rituximab rotavirus vaccin live rubella virus vaccin live sarilumab sirolimus smallpox vaccin tacrolimus tocilizumab tofacitinib typhoid vaccin ustekinumab varicella virus vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use infliximab make sure tell doctor medic problem especi aspergillosi fungus infect histori blastomycosi fungus infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungus infect histori coccidioidomycosi fungus infect histori diabet guillainbarr syndrom nervous system disord histori hepat b activ histori histoplasmosi fungus infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungus infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet bloodus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copdus caution may increas chanc new cancer congest heart failur moder severeshould given patient condit tuberculosi histori ofus caution patient may need addit tuberculosi therapi proper use infliximab a doctor train health profession give infliximab it given needl place one vein it must given slowli needl remain place least hour infliximab come medic guid read follow instruct care ask doctor question you may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut while use infliximab it import doctor check progress regular visit make sure infliximab work proper blood test may need check unwant effect infliximab may caus infus reaction includ heart attack stroke chang blood pressur heart rhythm problem eg arrhythmia receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat your bodi abil fight infect may reduc use infliximab it import call doctor first sign infect check doctor right away fever chill cough flulik symptom unusu tired weak serious skin reaction occur use infliximab check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximab may increas chanc lupuslik syndrom liver diseas call autoimmun hepat check doctor right away dark browncolor urin fever chill general feel discomfort ill weak joint pain lightcolor stool nausea vomit rash cheek arm wors sun sever tired upper rightsid stomach pain yellow eye skin a small number peopl includ children teenag use infliximab develop certain type cancer this common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light some teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen tcell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pus skin use infliximab may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer if chang growth skin abnorm vagin bleed pelvic pain tell doctor right away while treat infliximab immun vaccin without doctor approv live virus vaccin given infliximab your child vaccin must current use infliximab talk child doctor question women if babi receiv infliximab make sure babi doctor know use infliximab you need wait month give certain vaccin babi talk babi doctor question you need skin test tuberculosi start use infliximab tell doctor anyon home ever posit reaction tuberculosi skin test it import heart check close receiv infliximab call doctor right away short breath swell ankl feet sudden weight gain do take medicin unless discuss doctor this includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab use medicin togeth infliximab may increas chanc serious unwant effect infliximab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur more common chest pain chill cough dizzi faint fever flush red face headach hive itch rash muscl pain nasal congest nausea runni nose sneez sore throat stomach pain tight chest troubl breath unusu tired weak vomit less common back pain bloodi cloudi urin crack skin corner mouth diarrhea difficult pain urin frequent urg urin pain tender around eye cheekbon sore irrit mouth tongu sore red around fingernail toenail vagin burn itch discharg white patch mouth tongu rare abscess area infect contain pus black tarri stool blood urin stool bone joint pain constip feel full hernia lump abdomen stomach irregular pound heartbeat pain rectum pain spread abdomen stomach left shoulder pinpoint red spot skin stomach pain sever swollen pain gland tendon injuri unusu bleed bruis unusu weight loss yellow skin eye incid known bloodi nose burn tingl numb pain hand arm feet leg chang mental status claycolor stool continu vomit dark bloodi urin difficulti speak difficulti swallow fast heartbeat general feel tired weak heavier menstrual period hoars inabl move arm leg itch puffi swell eyelid around eye face lip tongu lightcolor stool loss appetit loss bladder control lower back side pain muscl spasm jerk extrem noisi breath painless swell neck armpit groin pale skin red scale crust skin red sore itch skin seizur sensat pin needl sever muscl weak sudden progress slow irregular breath sore welt blister stab pain sudden loss conscious sudden numb weak arm leg unpleas breath odor upper right stomach pain vomit blood other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'NN'),\n",
       " ('avengr i live socal progress ms consid it dose methotrex among option it offer tisch ms center nyc i went cladribin use bart protocol i thought less intrus i like get past bloodbrain barrier knock leucocyt activ good slow progress the dose ms much lower leukemia it equival lower dose use success clariti optimizem clinic trial it super easi dose i even work next day ill effect rash headach ml subq dose day done year felt much better interferon shot bit trickier dose copaxon the packag insert cladribin internet make scari read but paracelsus say sola dosi facit venenum the hard part get neuro prescrib find special pharmaci would sell most place cool ship iv cancer drug use offlabel ms patient home i help dr k bart talk neurologist send protocol my neurologist current prescrib lemtrada agre cladribin worth tri it took convinc read send journal articl be prepar get offlabel treatment prog ms i think possibl slow progress easi toler relat inexpens i paid mg vial retail my insur hasnt agre cover monitor leucocyt level import safeti i went x l st dose i took second will check level novemb sorri long comment i think safe easi may help spms i think treatment like would good type ms patient they good human data safeti efficaci now treat ms even relaps mistak ani nerv damag smolder inflamm isnt come back better save',\n",
       "  'VBP'),\n",
       " ('i generic mg tablet generic budesonid prescrib case i need away home i week trip come toward end year wonder i use rescu medic instead pred the instruct say take twice day i find post ipoop state if dont respond budesonid within week need much stronger cousin prednison in addit age pill i also say uceri help coupl year ago i uceri tablet lie around doe realli take week budesonid help not ideal i recent scope unabl see doctor januari i call dont even biopsi result almost month the doctor mention humira prednison i could long time mayb i take per budesonid day start earli symptom i want plan place case i wait till januari i confess recent i borrow mg tab pred illeg so shoot i abl go groceri store walk dog celebr big birthday famili friend it worth one day it necessari wean day i anyway end mg coupl day with pred pill new uceri foam realli bad symptom never return could temporari so i continu beg small suppli pred use i hand hope friend extra pred i even know dog take mg diagnos leftsid inflamm three doctor opinion uc like crohn indetermin current gm lialda per day cant toler night choic generic rowasa cortison retent enema canasa option us medicar',\n",
       "  'NN'),\n",
       " ('repli post croninstc honest diet differ everyon chron diseas for i tight intestin i low fiber diet i also develop lactos intoler diseas howev thing affect diseas i also nsaid nonsteroid antiinflammatori drug remicad infus everi month taken two differ steroid get inflamm control stress anxieti also play major role whether stomach good bad day chron diseas chronic diseas diet cure it import find diet best affect individu order help get diseas remiss diet alon',\n",
       "  'NN'),\n",
       " ('not complet probabl relev i went gilenya cladribin i four week washout period the follow post washout tysabri natalizamub lemtrada alemtuzumab read comment end see answer washout gilenya fingolimod lemtrada they dont recommend long washout httpmultiplesclerosisresearchblogspotcomreboundonwithd',\n",
       "  'JJ'),\n",
       " ('hello im one peopl buri head sand come find thing ill post im go crap time anyway i dx year ago done bad year i copaxon year stop i start bad reaction caus stress i go lot emot thing divorc associ issu point i toller copaxon well i put onto anoth inject gave month gave aw headach last year i gilenya start well year bit nightmar i get everi littl bug go around pretti much feel ill time far year ive spent month sign work debilit fatigu bug sat flat unabl anyth last month ive urinari tract infect wont go away pill noth shift ive shingl month medic isnt shift top horrid year yesterday left hand side face swell templ halfway neck new bulbous head go mild annoy pain oh bottom spine also pain start yesterday well im want find whether other gilenya find get disproportion amount ill virus infect and whether anyon think gilenya might factor apart ms i normal keep well avoid bug go around time type i sat tender shingl rash bum sat slight forward help back pain head tilt right help swollen face bit oh i think i vent apolog anyon inform view gilenya id appreci feedback im tempt stop take gradual cours i would talk gp get appoint lotteri neurologist plus i valu inform real life experi thank',\n",
       "  'NN'),\n",
       " ('hahahahaha thing ive worri sinc ms thing pronounc drug correct even list let alon top i pronounc tysabri teesabri much amus annoy partner neuro never fail correct lol pronounc ocrelizumab o drug im crazi enough even attempt i understand would concern correct pronounci though',\n",
       "  'NN'),\n",
       " ('increas cancer risk mention literatur address somewhat offhand dr chin genentech articl this optim howev temper concern increas cancer risk in three trial cancer rate twice high among receiv ocrevus among respect control group patient rate malign ocrelizumab treatment remain within epidemiolog report clear relationship bcell suppress malign establish said chin also reassur patient genentech work understand rate numer higher httpsmultiplesclerosisnewstodaycomhistoryofocrevusdefiantideatogamechangingmultiplesclerosistherapi can anyon explain within epidemiolog report mean i cant seem get past doubl cancer rate three trial doubl we enough cancer famili right thank gallow humor attempt cant help',\n",
       "  'NN'),\n",
       " ('hi thank much repli jimc we tri get brain met resolv cyberknif one radiologist suggest cyberknif done scan check said got differ met left side well got line mening said cyberknif option go wbr plus said go cyberknif later wbr control line brain my question switch alecensa avoid radiat alecensa penetr brain barrear or must wbr is possibl cyberknif wbr how cope side effect wbr anyth help like medicin what expect wbr term complet resolut brain met without cyberknif i know i sound bit silli everi case differ still chanc brother age good spirit happi cyberknif dont want go wbr will wait repli thank much time kind regard',\n",
       "  'NN'),\n",
       " ('and coliti research pleas keep updat go process well it nice although crappi someon go exact thing timelin of cours long dont mind give updat diagnos summer left side coliti current mg azathioprin mg taper prednison three dose entyvio anucort suppositori i glutamin probiot',\n",
       "  'NN'),\n",
       " ('hope awesom the first thing onc said start alectinib target therapi alk treatment resist might becom problem i sent articl integr medic oncologist im start wonder pharma compani would arrang group discount number us wiling travel clincal trial what find guy ok take deworm ani updat',\n",
       "  'NN'),\n",
       " ('just quick updat cladribin had second dose today day felt fine major ses far the inject quick hurt lil bit inject would so far good',\n",
       "  'NN'),\n",
       " ('i ms regimen it includ water vitamin d omega diet exercis medit stress free live prescript medic i feed head bodi good stuff i could alway better i pizza day i lot combat diseas after take copaxon tecfidera year avail im realli interest slow progress unless cours find way go back way disabl set im go yet anoth mri mayb take gilenya doctor supervis cours i appreci everybodi comment and thank trip blog this stuff actual part stuff i combat diseas thank well je',\n",
       "  'JJ'),\n",
       " ('been gilenya last year the first dose monitor unev but loweredborderlin lymphocyt count ongo initi month higher liver enzym count normal i absolut issu gilenya conveni use i relaps sinc start gilenya brain mri contrast month later start no new lesion tspine mri contrast recent week no new lesion good luck',\n",
       "  'NN'),\n",
       " ('my husband stage iv nsclc micro brain met liver met spine met treat photon radiat egfr exon lr tagrisso start decemb lost tm june carboplatinalimta ad septemb chemo combo start due pain tagrisso reach area ie pleural effus caus rib pain sneez problem spasm abdomin area all sinc went away start system chemo he finish cycl start mainten alimta by way stabl point neck brain he toler combo well littl issu also side note treat sbrt radiat septemb one liver met primari lung mass treat sbrt radiat juli everyth shrunk andor disappear pain on chemo combo delay everi week due low platelet the oncologist mention carboplatin may improv platelet my question data regard stop carboplatin cycl go whole distanc cycl far effect i know cycl time visit learn later visit my comment oncologist i concern carboplatin stop would progress sooner he said protocol stop cycl go mainten risk allerg reaction stay carboplatin thank',\n",
       "  'NN'),\n",
       " ('articl multipl sclerosi cladribin tablet ad ifn activ relaps ms the onward studi xavier montalban thoma p leist bruce a cohen et al',\n",
       "  'JJ'),\n",
       " ('my mom diagnos month ago stage iv lung cancer met bone she start carboplatin alimta keytruda still progress then gemzar cycl still spread spine then radiat lung spine weaken dose taxol put hospit week uti bronchiti now get pain medicin right and home nyar option',\n",
       "  'NN'),\n",
       " ('fdaapprov dmts warn safeti manag strategi mose brand samkoff alemtuzumab lemtrada prescrib inform warn serious sometim fatal autoimmun condit immun thrombocytopenia antiglomerular basement membran diseas serious lifethreaten infus reaction possibl increas risk malign includ thyroid cancer melanoma lymphoprolif disord recommend safeti manag strategi recommend monitor lemtrada avail lemtrada rem program requir patient healthcar facil enrol prescrib pharmaci certif premed corticosteroid prior first three infus cours administ antivir agent herpet prophylaxi start first day continu minimum month complet dose cd lymphocyt count cell per microlit whichev occur later obtain thyroid function test prior init treamtn everi month month last infus monitor complet blood count month month last infus consid delay treatment patient activ infect infect fulli resolv do administ live viral vaccin follow treatment cours daclizumab zinbryta prescrib inform warn hepat injuri includ liver failur autoimmun hepat immunemedi disord includ skin reaction lymphadenopathi noninfecti coliti immunemedi disord acut hypersensit infect includ upper respiratori tract infect urinari tract infect viral infect depress suicid recommend safeti manag strategi recommend monitor zinbryta avail zinbryta rem program prior start treatment obtain baselin serum transaminas alt ast total bilirubin level test transaminas level total bilirubin month dose follow transaminas level total bilirubin month least six month last dose if patient develop clinic sign symptom suggest hepat dysfunct measur serum transaminas total bilirubin interrupt discontinu treatment appropri use caution use medic hepatotox drug includ nonprescript product dimethyl fumar tecfidera prescrib inform warn lymphopenia recommend safeti manag strategi recommend monitor recent cbc month start treatment annual clinic indic fingolimod gilenya prescrib inform warn bradycardia andor atrioventricular conduct first dose infect macular edema decreas pulmonari function liver injuri elev serum hepat transaminas hypertens recommend safeti manag strategi recommend monitor recommend screen white blood cell count serum transaminas determin serum bilirubin determin serum varicella zoster antibodi test patient histori chicken pox baselin ecg ophthalmolog evalu observ bradycardia least hour first dose hour puls bp obtain ecg prior dose nad end observ period if problem occur continu monitor overnight repeat firstdos monitor higher risk patient monitor overnight ophthalmolog evalu month treatment event new visual symptom obtain pft clinic indic monitor bp treatment women childbear potenti use contracept treatment two month stop treatment glatiram acet copaxon glatopa generic equival mg dose prescrib inform copaxon prescrib inform glatopa warn lipoatrophi skin necrosi recommend safeti manag strategi recommend monitor site rotat essenti monitor interferon ba avonex prescrib inform warn hepat hematolog abnorm depress iinject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mos first year q mos thereaft thyroid function test q mos first year year thereaft monitor mood chang educ site rotat sc ifn interferon ba rebif prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mos first year q mos thereaft thyroid function test q mos first year year thereaft monitor mood chang educ site rotat sc ifn interferon bb betaseron prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mos first year q mos thereaft thyroid function test q mos first year year thereaftermonitor mood chang educ site rotat sc ifn interferon bb extavia prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mos first year q mos thereaft thyroid function test q mos first year year thereaft monitor mood chang educ site rotat sc ifn pegyl interferon ba plegridi prescrib inform warn hepat injuri depress suicid seizur anaphylaxi allert reaction inject site reaction congest heart failur decreas peripher blood count autoimmun disord recommend safeti manag strategi recommend monitor monitor liver function encourag report depress sx suicid ideat use caution patient seizur disord teach inject techniqu site rotat monitor patient signific cardiac hx monitor complet blood count consid discontinu new autoimmun disord occur mitoxantron novantron prescrib inform warn cardiac toxic acut myelogen leukemia like occur cumul dose mgm recommend safeti manag strategi recommend monitor baselin lvef repeat lvef prior dose treatment termin lvef continu monitor cardiac function complet treatment ocrelizumab ocrevus prescrib inform warn infus reaction potenti life threaten includ pruriti rash urticaria erythema bronchospasm throat irrit oropharyng pain dyspnea pharyng laryng edema flush hypotens pyrexia fatigu headach dizzi nausea tachycardia infect includ respiratori tract infect herp potenti pml hepat b reactiv possibl increas immunosuppress effect immunosuppress use prior ocrelizumab risk malign includ breast cancer may increas recommend safeti manag strategi recommend monitor premed corticosteroid antihistamin observ one hour follow infus administ vaccin least week prior administr ocrelizumab liveattenu live vaccin treatment bcell replet femal patient follow recommend breast cancer screen protocol natalizumab tysabri prescrib inform warn progress multifoc leukoencephalopathi hypersensit reaction hepatotox includingacut liver failur enceph mening caus herp simplex varicella zoster virus recommend safeti manag strategi recommend monitor touch safeti monitor program risk factor pml antibodyposit jc virus prior treatment immunosuppress yrs tysabri antibodi test repeat everi six month monitor continu six month end treatment collabor pml consortium pml registri nind teriflunomid aubagio prescrib inform warn infect elev serum hepat transaminas black box warn fetal death malform black box warn skin reaction blood pressur increas respiratori effect recommend safeti manag strategi recommend monitor pretreat evalu infect pregnanc renal failur peripher neuropathi interstiti pulmonari diseas hypertens white blood cell count serum transaminas determin serum bilirubin determin dure treatment blood pressur monitor serum transaminas determin',\n",
       "  'NN'),\n",
       " ('thank jim prompt respons thought agre still think continu tagrisso may make sens although would also prefer hold later would great appreci dr creelan thought dilemma best',\n",
       "  'JJS'),\n",
       " ('my husband xeljanz month he still full remiss appar side effect he start feel better almost right away bleed stop month month felt confid work had colonoscopi month start xeljanz show total remiss hope work take mg mg morn mg even spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       "  'NN'),\n",
       " ('hi i temporari ileostomi i think i metr small bowel left suppos metr straight i think crohn come back go kill i i last flare year ago i dont want die im write keep get everi hour half throughout night im wit end i repeat i dont want die i tri azathioprin remicad mercaptopurin bodi reject drug remicad last chanc thought would grate appreci',\n",
       "  'NN'),\n",
       " ('i carboplatin alimta avastin gave neulasta arm pro combat flu like symptom steroid take day treatment neausa that help lot nausea bodi ach fatigu first week treatment month later i remiss year later back i start opdivo that work im clinic trial work side effect speak i stage nsclc year still roll along keep faith motto alway someth new come pike',\n",
       "  'NN'),\n",
       " ('hi ive neuro appoint i found i new lesion suspect relaps septemb ive tecfidera year clear work anymor my neuro suggest i go either cladribin fingolimod lemtrada prefer cladribin becaus new arent mani experi peopl take cladribin onlin i wonder whether anyon experi could share thank much',\n",
       "  'JJ'),\n",
       " ('is entyvio medic uc mayb addinv second med get true remiss moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa showerthought most peopl surpris see blood toilet paper uc patient surpris isnt paul a regular member join oct post post yesterday pm gmt thank respons overal qualiti life improv i hope better result the biopsi show inflamm doc think may ib i lialda year entyvio i recent stop see would make differ i alway wonder medicin actual anyth greenuc regular member join sep post post yesterday pm gmt have ever tri probiot there research ib probiot the one come mind s boulardii l rhamnosus gg has gg varieti lot trial error requir everyon differ httpswwwncbinlmnihgovpmcarticlespmc httpswwwoptibacprobioticscouklearninglabblogsboulardiiprobioticgetsibshealthclaimcanada diagnos moder sever uc septemb medic lialda pill dailyrowasa need diet limit carb sugar alcohol high protein high fat diet dbwithuc veteran member join feb post post yesterday pm gmt i would tri probiot diet mod ib light use immodium ib med neither lialda entyevo affect symptom one bit inflamm gone they antiinflammatori some folk ibslik gi symptom inflamm managedtr it suck got antiinflammatori wont touch matter much time give good luck ischem coliti scope perf colon cm colonileocec resect iv antibsepsi dx mod uc pancol rx lialda x major flare wantibsinus rx mg pred taper mp histol remiss rttran wors sigmoid rx rowasa hydrocort curr softform stool urgenc lialda x no pred probiot vitdc',\n",
       "  'NN'),\n",
       " ('just read wiki ocrelizumab list drug work similar way triall sonia x',\n",
       "  'NN'),\n",
       " ('hi sew chick i sorri cladribin work i follow messag sinc may i treatment royal london hospit octob blood test novemb came back lymphocyt meant i treatment i seen improv far sure chang i still take anti viral tablet may tri contact hospit see inform i tie posit moment would like know hve good experi cladribin wish well better luck futur',\n",
       "  'NN'),\n",
       " ('the lung pair coneshap breath organ found chest the lung bring oxygen bodi breath take carbon dioxid breath each lung section call lobe the left lung two lobe the right lung slight larger three a thin membran call pleura surround lung two tube call bronchi lead trachea windpip right left lung the bronchi sometim also affect lung cancer small tube call bronchiol tini air sac call alveoli make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset there two type lung cancer small cell lung cancer nonsmal cell lung cancer this summari small cell lung cancer treatment see follow pdq summari inform lung cancer nonsmal cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen there two main type small cell lung cancer these two type includ mani differ type cell the cancer cell type grow spread differ way the type small cell lung cancer name kind cell found cancer cell look view microscop small cell carcinoma oat cell cancer combin small cell carcinoma smoke major risk factor small cell lung cancer anyth increas chanc get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past this import risk factor lung cancer the earlier life person start smoke often person smoke year person smoke greater risk lung cancer be expos secondhand smoke be expos asbesto arsenic chromium beryllium nickel soot tar workplac be expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut have famili histori lung cancer be infect human immunodefici virus hiv take beta caroten supplement heavi smoker older age main risk factor cancer the chanc get cancer increas get older when smoke combin risk factor risk lung cancer increas sign symptom small cell lung cancer includ cough short breath chest pain these sign symptom may caus small cell lung cancer condit check doctor follow chest discomfort pain a cough doesnt go away get wors time troubl breath wheez blood sputum mucus cough lung hoars troubl swallow loss appetit weight loss known reason feel tire swell face andor vein neck test procedur examin lung use detect find diagnos stage small cell lung cancer the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi these test help diagnos diseas plan check treatment monitor diseas time chest xray an xray organ bone insid chest an xray type energi beam go bodi onto film make pictur area insid bodi enlarg xray chest xray use take pictur organ bone chest xray pass patient onto film ct scan cat scan brain chest abdomen a procedur make seri detail pictur area insid bodi taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog a microscop use check cancer cell sputum mucus cough lung biopsi the remov cell tissu view microscop pathologist check sign cancer the differ way biopsi done includ follow fineneedl aspir fna biopsi lung the remov tissu fluid lung use thin needl a ct scan ultrasound imag procedur use find abnorm tissu fluid lung a small incis may made skin biopsi needl insert abnorm tissu fluid a sampl remov needl sent laboratori a pathologist view sampl microscop look cancer cell a chest xray done procedur make sure air leak lung chest enlarg fineneedl aspir biopsi lung the patient lie tabl slide comput tomographi ct machin take xray pictur insid bodi the xray pictur help doctor see abnorm tissu lung a biopsi needl insert chest wall area abnorm lung tissu a small piec tissu remov needl check microscop sign cancer bronchoscopi a procedur look insid trachea larg airway lung abnorm area a bronchoscop insert nose mouth trachea lung a bronchoscop thin tubelik instrument light len view it may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi a bronchoscop insert mouth trachea major bronchi lung look abnorm area a bronchoscop thin tubelik instrument light len view it may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi a surgic procedur look organ insid chest check abnorm area an incis cut made two rib thoracoscop insert chest a thoracoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer in case procedur use remov part esophagus lung if certain tissu organ lymph node cant reach thoracotomi may done in procedur larger incis made rib chest open thoracentesi the remov fluid space line chest lung use needl a pathologist view fluid microscop look cancer cell mediastinoscopi a surgic procedur look organ tissu lymph node lung abnorm area an incis cut made top breastbon mediastinoscop insert chest a mediastinoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer light electron microscopi a laboratori test cell sampl tissu view regular highpow microscop look certain chang cell immunohistochemistri a test use antibodi check certain antigen sampl tissu the antibodi usual link radioact substanc dye caus tissu light microscop this type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the stage cancer whether chest caviti spread place bodi the patient age gender general health for certain patient prognosi also depend whether patient treat chemotherapi radiat for patient small cell lung cancer current treatment cure cancer if lung cancer found patient think take part one mani clinic trial done improv treatment clinic trial take place part countri patient stage small cell lung cancer inform ongo clinic trial avail nci websit stage small cell lung cancer key point after small cell lung cancer diagnos test done find cancer cell spread within chest part bodi there three way cancer spread bodi cancer may spread began part bodi the follow stage use small cell lung cancer limitedstag small cell lung cancer extensivestag small cell lung cancer after small cell lung cancer diagnos test done find cancer cell spread within chest part bodi the process use find cancer spread within chest part bodi call stage the inform gather stage process determin stage diseas it import know stage order plan treatment some test use diagnos small cell lung cancer also use stage diseas see general inform section other test procedur may use stage process includ follow mri magnet reson imag brain a procedur use magnet radio wave comput make seri detail pictur area insid bodi this procedur also call nuclear magnet reson imag nmri ct scan cat scan a procedur make seri detail pictur area insid bodi brain chest upper abdomen taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell a pet scan ct scan may done time this call petct bone scan a procedur check rapid divid cell cancer cell bone a small amount radioact materi inject vein travel bloodstream the radioact materi collect bone cancer detect scanner there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl small cell lung cancer spread brain cancer cell brain actual lung cancer cell the diseas metastat small cell lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi the follow stage use small cell lung cancer limitedstag small cell lung cancer in limitedstag cancer lung start may spread area lung lymph node collarbon extensivestag small cell lung cancer in extensivestag cancer spread beyond lung area lung lymph node collarbon place bodi recurr small cell lung cancer recurr small cell lung cancer cancer recur come back treat the cancer may come back chest central nervous system part bodi treatment option overview key point there differ type treatment patient small cell lung cancer six type standard treatment use surgeri chemotherapi radiat therapi immunotherapi laser therapi endoscop stent placement new type treatment test clinic trial treatment small cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient small cell lung cancer differ type treatment avail patient small cell lung cancer some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial some clinic trial open patient start treatment six type standard treatment use surgeri surgeri may use cancer found one lung nearbi lymph node becaus type lung cancer usual found lung surgeri alon often use dure surgeri doctor also remov lymph node find cancer sometim surgeri may use remov sampl lung tissu find exact type lung cancer after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi the way chemotherapi given depend type stage cancer treat see drug approv small cell lung cancer inform radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer the way radiat therapi given depend type stage cancer treat extern radiat therapi use treat small cell lung cancer may also use palliat therapi reliev symptom improv qualiti life radiat therapi brain lessen risk cancer spread brain may also given immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi some type immun cell t cell cancer cell certain protein call checkpoint protein surfac keep immun respons check when cancer cell larg amount protein attack kill t cell immun checkpoint inhibitor block protein abil t cell kill cancer cell increas they use treat patient advanc smallcel lung cancer there two type immun checkpoint inhibitor therapi ctla inhibitor ctla protein surfac t cell help keep bodi immun respons check when ctla attach anoth protein call b cancer cell stop t cell kill cancer cell ctla inhibitor attach ctla allow t cell kill cancer cell ipilimumab type ctla inhibitor pd inhibitor pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell pembrolizumab nivolumab type pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv small cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell endoscop stent placement an endoscop thin tubelik instrument use look tissu insid bodi an endoscop light len view may use place stent bodi structur keep structur open an endoscop stent use open airway block abnorm tissu new type treatment test clinic trial inform clinic trial avail nci websit treatment small cell lung cancer may caus side effect for inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show condit chang cancer recur come back these test sometim call followup test checkup treatment option stage for inform treatment list see treatment option overview section limitedstag small cell lung cancer treatment limitedstag small cell lung cancer may includ follow combin chemotherapi radiat therapi chest radiat therapi brain may later given patient complet respons combin chemotherapi alon patient cannot given radiat therapi surgeri follow chemotherapi surgeri follow chemotherapi radiat therapi radiat therapi brain may given patient complet respons prevent spread cancer brain clinic trial new chemotherapi surgeri radiat treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail extensivestag small cell lung cancer treatment extensivestag small cell lung cancer may includ follow combin chemotherapi radiat therapi brain spine bone part bodi cancer spread palliat therapi reliev symptom improv qualiti life radiat therapi chest may given patient respond chemotherapi radiat therapi brain may given patient complet respons prevent spread cancer brain clinic trial new treatment chemotherapi immunotherapi immun checkpoint inhibitor use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail treatment option recurr small cell lung cancer for inform treatment list see treatment option overview section treatment recurr small cell lung cancer may includ follow chemotherapi immunotherapi immun checkpoint inhibitor radiat therapi palliat therapi reliev symptom improv qualiti life laser therapi stent placement keep airway open andor intern radiat therapi palliat therapi reliev symptom improv qualiti life clinic trial new chemotherapi treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about small cell lung cancer for inform nation cancer institut small cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv small cell lung cancer tobacco includ help quit cigarett smoke health risk how quit secondhand smoke cancer for general cancer inform resourc nation cancer institut see follow about cancer stage chemotherapi you support peopl with cancer radiat therapi you support peopl with cancer cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment small cell lung cancer it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq adult treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq adult treatment editori board pdq small cell lung cancer treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypeslungpatientsmallcelllungtreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('hifrancishannon work like beauti two year stop one year three relaps went back time half dose everi day lymphocyt ive take half dose four year ms progress start go one year half dose spms fingolimod stop ms case i hope better luck be care rebounf effect take care xxx',\n",
       "  'NN'),\n",
       " ('medic use multipl sclerosi ms modifi diseas cours treat relaps also call attack exacerb manag symptom along essenti compon comprehens ms care medic help peopl manag ms enhanc comfort qualiti life modifi diseas cours the follow us food drug administr fdaapprov diseasemodifi agent pdf brochur reduc diseas activ diseas progress mani peopl relaps form ms includ relapsingremit ms well progress form ms peopl experi relaps inject medic avonex interferon betaa betaseron interferon betab copaxon glatiram acet extavia interferon betab glatiram acet inject glatiram acet generic equival copaxon mg mg dose glatopa glatiram acet generic equival copaxon mg dose plegridi peginterferon betaa rebif interferon betaa zinbryta daclizumab oral medic aubagio teriflunomid gilenya fingolimod tecfidera dimethyl fumar infus medic lemtrada alemtuzumab novantron mitoxantron ocrevus ocrelizumab tysabri natalizumab follow treatment plan doctor establish best possibl strategi manag ms earli ongo treatment diseasemodifi therapi support ms coalit includ nation ms societi this evidencebas consensus diseasemodifi therapi pdf summari pdf may use discuss treatment option healthcar provid advoc insur access coverag this paper last updat adher diseasemodifi medic key element treatment effect for help manag cost medic read patient assist program offer pharmaceut compani under certain circumst healthcar provid may use medic treat ms fda approv diseas also call offlabel use over past decad sever medic use offlabel ms manag relaps ms relaps caus inflamm central nervous system damag myelin coat around nerv fiber this damag slow disrupt transmiss nerv impuls caus symptom ms most relaps gradual resolv without treatment for sever relaps involv loss vision sever weak poor balanc exampl interfer person mobil safeti overal abil function neurologist recommend treatment corticosteroid the common treatment regimen threetofiveday cours highdos intraven corticosteroid reduc inflamm end relaps quick this regimen may may follow slow taper oral prednison corticosteroid believ longterm benefit diseas medic option includ highdos intraven solumedrol methylprednisolon highdos oral deltason prednison hp acthar gel acth manag symptom a wide varieti medic use help manag symptom ms below common symptom ms medic use treat symptom',\n",
       "  'NN'),\n",
       " ('im still midst decisionmak process i set lemtrada end last year new neuro point essenti lastlin treatment present youv gone onto cant move onto anyth els caus perman chang immun system this ok number new drug potenti come onlin next year would mean one wouldnt elig i keen tackl thing strong dmt rrms activ i also awar fact one need play long game at present decis kind like pop i guess probabl go tysabri month see work andor jvc status increas im mo becom high risk stay work move onto either gilenya lemtrada it tough call incred stress i feel much just rememb bodi decis i know sound obvious ive peopl tri influenc one way anoth theyr scare certain risksbut theyr experienc ill cant necessarili understand mean go',\n",
       "  'NN'),\n",
       " ('hi all a brief updat mom progress seek opinion she round paclitaxel carbo dosag drop sinc nd round due low white blood cell count cea drop rd infus she abl cope side effect pet scan done th round also shown satisfactori improv near tumor shrunk size activ howev cea valu also stabil reincreas th round she th round next week primari doctor suggest paus afraid bodi cannot cope accumul toxic we also consult nd opinion privat sector suggest test action mutat braf ret met exon skip anoth got negat result here summari treatment far cea begin alimta carbo round cea drop alimta mainten round cea increas keytruda round cea increas paclitaxel carbo round cea drop go her physic status still good moment less cough better pet scan result compar time end keytruda treatment howev seem situat could go wors soon given rise cea valu run option i queri is still worth seek tri anoth immunotherapi though doctor govern privat sector suggest option it seem pdl inhibitor avail area ctla is still chemotherapi canshould tri even reus her doctor refus suggest think realli need and i could find much inform onlin regard rd th line chemo treatment best regard mike',\n",
       "  'NN'),\n",
       " ('shortterm assess intravitr dexamethason implant use enhanceddepth imag optic coher tomographi optic coher tomographi angiographi patient retin vascular diseas abstractintroductionto evalu shortterm efficaci safeti intravitr dexamethason implant idi patient macular oedema associ diabet retinopathi dr retin vein occlus rvo use enhanceddepth imag optic coher tomographi edioct estim effect dexamethason choroid retin vascular network use oct angiographi octamethodsfifteen eye patient macular oedema secondari diabet drn retin vein occlus rvon treat intravitr inject sustainedreleas idi primari efficaci end point chang best correct visual acuiti central macular thick cmt secondari end point chang choroid thick choroid retin vascular network determin octaresultscmt signific reduc baselin h inject p httplinkspringercom sourc advanc therapi',\n",
       "  'NN'),\n",
       " ('my mom diagnos septemb nsclc she realli sick time couldnt breath lose weight mental she slept time after workup spend week hospit pleural effus pulmonari embol came home hous plurex cathet she drain ccs first onc effus blood clot gone start feel better she qualifi immunotherapi due pl percentag she went keytruda three month felt well enough go home the tumor shrink start grow the doctor took keytruda put carboplatin pematrex shes six month befor last appoint doctor said would take carboplatin stabl mainten pemetrex we would find said next set scan taken last monday well latest scan result can anyon give word wisdom what would suggest i feel like tri get studi im readi give fight i know isnt either her last scan juli btw lungsairway unremark for exampl right lower lobe subpleur mass adjac atelectasi slight increas measur x cm previous x cm right posterior upper lobe opac measur x cm unchang masslik subpleur consolid medial basal right lower lobe measur cm unchang slight decreas focus interstiti thickeningconsolid medial basal segment left lower lobe no new suspici nodul pleurapericardium unchang right pleural nodular thicken predomin along lower lobe unchang small locul right pleural effus increas size nodul right obliqu fissur measur x cm previous x cm no left pleural effus mediastinumthorac node increas adenopathi for exampl paratrach measur x cm previous x cm paraesophag measur x cm previous x cm right supradiaphragmat measur x cm previous x cm thank obvious discuss doctor i hope get thought go i tell scan report im go let doctor tell i cant work hard slept my sibl arent much help my mother medic issu sister doesnt get involv',\n",
       "  'NN'),\n",
       " ('i much better interact mom doctor today regard clinic trial recent advanc sclc care advis even though still firstlin treatment wouldnt bad idea get understand secondlin fast diseas recur andor spread there lot new develop avail clinic trial even exist drug offlabel use pick rout go depend lot specif characterist tumor for exampl attract rout vs standard chemo isnt effect first line opdivoyervoy offlabel clinic trial particular effect cancer high tumor mutat burden tmb keytruda offlabel clinic trial particular effect high pdl express rovat clinic trial particular effect high dll express so question test specif characterist usual done sclc inde patholog report got didnt test rather random pick secondlin treatment id like opt one that like work so liter test order biopsi send away lab is advis proactiv would biopsi painfuldamag worth just sure go',\n",
       "  'NN'),\n",
       " ('rtp veri good point my wife i eat meal home thank most effort it start tri scd diet im strict adher anymor chang way eat complet no sugar process food almost dairi grain complex carbsstarch we save money cook home overal health proven cholesterol test weight loss marker much improv m dx sept sulfasalazin work year current flare year g sulfasalazin g canasa mg iron supplement paleoscd base diet sever month humira so far good',\n",
       "  'NN'),\n",
       " ('accord nation cancer institut patient diagnos nonsmal cell lung cancer nsclc year percent chanc aliv year later for patient stage iv diseas describ cancer spread distant site beyond origin tumor statist drop percent now univers colorado cancer center studi publish journal thorac oncolog tell much optimist stori for stage iv nsclc patient whose tumor test posit rearrang gene alk alk nsclc treat uchealth univers colorado hospit median overal surviv year this mean popul instead percent patient aliv year diagnosi percent patient aliv year diagnosi what show develop good target therapi alkposit lung cancer even patient stage iv diseas well mani mani year say jose pacheco md investig cu cancer center studi first author studi detail of patient current studi percent neversmok median age year almost patient initi treat drug crizotinib earn fda approv august treat alk nsclc previous avail colorado academ medic center set clinic trial import treatment crizotinib patient current studi show evid worsen diseas percent transit anoth alkinhibitor common brigatinib alectinib ceritinib mani studi report shorter overal surviv patient stage iv alk nsclc treat crizotinib these studi lower surviv outcom larg part lower percentag patient receiv nextgen alk inhibitor progress crizotinib patient get nextgen alk inhibitor phase clinic trial mani center access pacheco say combin therapi also factor anoth factor influenc surviv use pemetrexedbas chemotherapi alk lung cancer often addit target therapi alk inhibitor patient undergo chemotherapi sometim radiat howev mani chemotherapi choos often unclear specif chemotherapi success specif cancer stage patient characterist a studi cu cancer center investig d ross camidg md phd also senior author current studi suggest pemetrex work especi well alk form diseas we tri use main pemetrexedbas chemotherapi alk lung cancer pacheco say it possibl shorter surviv studi may associ use nonpemetrex base chemotherapi interest exist brain metastas time diagnosi predict shorter surviv a lot new alk inhibitor develop crizotinib get brain well work similar brain compar outsid brain and care surveil patient see develop brain met instead wait symptom treat monitor develop metastas imag brain see someth new sometim treat caus symptom pacheco say the predict factor shorter surviv number organ found carri cancer time diagnosi benefit target therapi at point year one longest median surviv ever report nsclc subpopul stage iv diseas pacheco say it show benefit target therapi chang surviv lot patient and i think suggest type nsclc may becom much chronic condit rather termin diseas learn',\n",
       "  'NN'),\n",
       " ('what time take prednison mayb best take dose am how long humira dose if awhil mayb time consid move anoth biolog get remiss best way fix sleep issu i never slept well i mp it one reason i stop medic i find pepto bismol tablet realli help gas diarrhea keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri total hip replac thank prednison current condit chronic pouchiti not bad i thought would current med stelara',\n",
       "  'NN'),\n",
       " ('so sound like trawl find paper counter valu cladribin cladribintabletten bei schubfrmig multipl skleros noch ein purinanalogon oder echt therapeutisch innov s schmidt nervenarzt oct doi howev articl german i go comment take read german vocabulari good enough howev mayb drk may flick we deal alot differ european languag within group azaothiaprin anti prolif cell recent shown inhibit rate relaps level found beta interferon way less expect clad httpmultiplesclerosisresearchblogspotcomcheapaschipsazathioprineisbetterhtml it also induct therapi',\n",
       "  'NN'),\n",
       " ('oh man bought hous great hous crash we put contract got one post uc diagnosi i shudder think bathroom didnt get there us i accid get bed bathroom congrat yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mgs pred',\n",
       "  'VBD'),\n",
       " ('i doc keep mind i would want research breast feed take steroid these enorm dose short term realli number insomnia blurri vision due high blood sugar mood chang longer term affect bone strength my doc recommend take antacid counter digest effect i learn go close zero sugar possibl steroid white rice flour count categori can pump freez get babi week steroid as ongo treatment i ocrevus would recommend get go time brain mean dilli dalli around less effect drug cost ocrevus fall categori efficaci scari side effect wise treatment pleas oh pleas give permiss not supermom sleep nutrit exercis medit key your child rememb made feel tri focus your allow process diagnosi tear anger frustrat etc take requir readjust new symptom pop educ dont depend sole neurologist hesh much time read new develop',\n",
       "  'JJ'),\n",
       " ('the fda issu complet respons letter crl tie manufactur prefil syring ask info suppli process in addit want regeneron complet usabl studi evalu singl inject eylea prefil syring approxim patient part preapprov process regeneron said expect complet studi andget inform fda earli expect process delay launch eylea prefil syring it may target date potenti approv eylea npdr free daili newslett like stori subscrib fiercepharma biopharma fastgrow world big idea come along daili our subscrib reli fiercepharma mustread sourc latest news analysi data drug compani make sign today get pharma news updat deliv inbox read go subscrib now the news came tarrytown new yorkbas regeneron report eylea hit primari endpointin phase trial patient take eylea everi everi week interv moder sever sever diabet retinopathi without treatment one third patient develop visionthreaten complic diabet macular edema within one year regeneron said relat an undervalu indic regeneron eylea could help weather novarti threat analyst it said first trial npdr show reduct visionthreaten complic develop diabet macular edema moder sever sever diabet retinopathi lead caus vision impair blind among workingag adult eylea abl reduc complic even everi fourmonth dose moreov abl revers anatom sever diseas georg d yancopoulo regeneron chief scientif offic said statement this import regeneron foundat drug assault treatment eylea generat billion sale regeneron last year withabout us sale come patient wet agerel macular degener amd with new drug candid threaten eylea lock indic compani test blockbust drug area',\n",
       "  'JJ'),\n",
       " ('if parasit worm fungus bacteria etc easili overwhelm someon compromis immun system doesnt data show signific number peopl get overhwelm parasit worm fungus bacteria etc the data show modest elev risk certain specif infect post read like noth scare tactic as skin cancer issu anybodi med get regular skin check can show link remicad actual tripl risk more recent studi show increas risk i dont think tripl what real concern skin cancer isnt basal cell carcinoma squamous cell carcinoma melanoma im sure good data whether remicad increas risk melanoma as black box warn also wellunderstood there reason longer put boy young men combo therapi i dont think appli sinc born your exact boy as huff post link tell us number risk without quantifi look like scare tactic and tell us risk undertr uc crohn diseas or better yet tell us risk aspirin otc taken hundr million peopl or tell us risk prednison',\n",
       "  'NN'),\n",
       " ('quot link bart blog in short pwppms unfortun miss relaps phase diseas they simpli unlucki new lesion occur clinicallyeloqu site caus relaps bring attent neurologist earlier cours diseas they present lost reserv capac the good news posit trial ocrelizumab let hope regul payer allow pwppms access ocrelizumab this remind bart blog year back say possibl pwppms fact rrms symptom mild never investig possibl ms for i feel true i year weird symptom either bad enough see doctor last short time i didnt bother see doctor i see doctor put anxieti and anxieti medic note everyth put anxieti in fact extent i believ suffer anxieti believ i hypochondriac after mani year i stop go see doctor altogeth even though i suffer pin needl numb patch swallow problem dizzi pain especi fatigu it bad case shingl face scalp final got doctor long stori short final got dx ms i wonder mani dx ppms also similar histori odd unexplain symptom could mild episod rrms sorri longer i meant pat xx',\n",
       "  'NN'),\n",
       " ('lancet neurolog decemb free access paper tipsheet revis mcdonald criteria diagnosi ms pdf aan practic guidelin current american academi neurolog clinic practic guidelin relat tool includ patient physician summari select guidelin addit tool new guidelin ad regular clinic tool inject anxieti a sixsess program call selfinject anxieti train siac develop david c mohr phd darci cox psyd univers california san francisco ucsf behavior medicin research center bmrc shown effect help peopl overcom fear learn selfinject the siac patient workbook counselor manual download inform program develop valid manual counselor pdf patient workbook pdf siac background valid refer pdf health insur appeal letter abstract templat health insur appeal letter develop societi report coverag denial limit receiv direct peopl ms healthcar profession societi medic advisor determin treatment need address review approv templat letter as new therapi evid emerg letter may develop dissemin below sampl health insur appeal letter diseas modifi therapi aubagio avonex avonex follow st demyelin event betaseron betaseron appeal follow st demyelin event copaxon mg copaxon mg gilenya glatopa lemtrada novantron ocrevus plegridi rebif rebif follow st demyelin event rituxan tecfidera tysabri symptom manag rehab ampyra clean intermitt cather cool vest erectil dysfunct drug ivig lyrica neurontin neuropsycholog evalu plasmapheresi power oper vehicl provigil rehabilit inform patient appeal right avail ssdi claim privat disabl resourc guidebook webinar assist healthcar profession collabor ms patient process file claim ssdi ssi pdf privat longterm disabl benefit pdf the new ms list social secur disabl webinar physic activ resourc physic activ peopl multipl sclerosi pdf yoga program peopl ms a focus peopl mild symptom ms pdf wheel mobil seat mobil evalu person multipl sclerosi pdf talk with your patient about wheel mobil pdf how choos mobil devic that right you pdf custom wheel mobil patient wtih ms a guid mobil option prescript document pdf mental health webinar we invit month network learn call mental health profession work peopl live ms famili view call schedul the call interact look provid present case request offer topic interest us if topic interest case discuss pleas reach andrea arzt previous webinar multipl sclerosi what you need know about diseas adapt life ms emot challeng cope strategi cognit dysfunct ms recognit assess treatment profession challeng what they didnt teach us school webinar also avail ce credit wake ahec mswhat you need know diseaseadapt life ms ms cognit dysfunctionprofession challeng clinic studi measur inform frequent use clinic measur includ descript administr score method psychometr properti literatur citat test form provid possibl ccsvi read latest inform ccsvi',\n",
       "  'VBZ'),\n",
       " ('the question long i remiss lot like old one piec string how long piec string well depend it depend use whether fray worn similar long might go relaps stage remiss stage multipl sclerosi ms at moment i seem happili remiss stage ms like less year i say less i brief interlud relaps brief time these call pseudoexacerb mean bodi feel fragil ms symptom jump hit this may caus much stress get hot infect over fatigu peopl ms intens cold thing when caus goe away go back feel version good i work hard reduc chanc stress life i tri adopt easi go attitud life go flow much i i make sure i keep cool hot weather attack seem part south australia moment air condit shade friend i tri overdo thing i i know i rest bodi forgiv these thing may take mere minut work anyon ms may take day anyth pseudoexacerb go away becom full relaps good thing a full relaps could lead brain forgotten work proper memori cognit almost switch overal muscl weak terribl feel bleuhh this current remiss i joy i much hope particular piec string longer length journey moon back is current medic posit life attitud increas level exercis sometim bodi love healthier diet work harder fix damag part bodi i love write life brain frizzl i wouldnt abl write book thing like one photo i havent mri year one would indic much damag done central nervous system and gp indic would good i went saw neurologist see well im medic prescrib back wonder drug becam avail australia afford cost this drug gilenya tablet i take everi day rather inject drug avonex i use inject thigh muscl week the avonex work ok help symptom gilenya work much much better so go back origin question long remiss last the answer who know gilenya may go work well forev i may never anoth relaps at moment im love i work tri keep happen bodi abl walk drive car brain abl less thing i want this happi ms stori i hope other happi ms stori id glad hear and stori happi share sometim write bad thing take bad away',\n",
       "  'RB'),\n",
       " ('alimta usual administ anoth chemo drug potenti immunotherapi like keytruda i carboplatinalimtakeytruda as lexiecat say oncologist make recommend signific advanc lung cancer treatment last two year the treatment tailor individu produc best outcom the best news longer one size fit approach lung cancer the social worker cancer center understand reimburs work best wish prayer friend michell',\n",
       "  'JJ'),\n",
       " ('ani thought potenti use gingertumer extract tinctur year oldulc pancolitisdiagnos decemb admit month half hospit care due extrem symptom treatment given prednison remicad tacrolimus valcyt blood transfus celebrex neurontin pantoprazol bentyl entyvio',\n",
       "  'NNS'),\n",
       " ('ok thank folk i know i sure hear result knowledg learn much valuabl learn the thing i want know ncot what mean say i luxuri time versus make decis i get well you say think care go humira whi tell know pleas i make ok i stand go br time least i accid happen i antibiot first time month get sicker my tummi hurt time energi zero i work full time dont know much longer i joint leg hurt bad see i avascular necrosi go along crohn stuff i think joint better measur intestin health anyth els tell know humira pleas',\n",
       "  'VBP'),\n",
       " ('hi emili happi new year famili i happi learn husband well we know devast lmd know husband remain stabl hope improv provid much hope other diagnosi my hope husband continu improv saralb good fortun best wish all bobbeth sept wife beth year old nonsmok dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mgwk sept lost beth',\n",
       "  'JJ'),\n",
       " ('i diagnos nsclc januari was put carboplatin abraxan surviv ok earli put gemzarwhich noth thing look realli bad insur final approv opdivo septemb last year in case amaz a met brain vanish latest scan show noth inert nodul lung lung scare appar nonact nodul lymph node i feel great my weight remain steadi month blood count pretti good littl low rbc heck the downsid realli bad rash itch like hell but i told gp doctor death rash decid i went rash i go everi two week opdivo chemo oncologist recent told rest life mainten i recent request return work month i work difficult high tech posit i feel well enough resum what im say your lucki work itll dramat improv outlook qualiti life good luck god bless',\n",
       "  'NN'),\n",
       " ('melibu not diagnos seem trend i unexplain symptom sinc i diagnos when i read medic record thing like tridgemeni neuralgia bladder urgenc panic attack hand tingl i realli wonder someth neurolog wasnt question what realli make angri due intens headach i request mri told i dont need one im hypochondriac lo behold found lesion old top addit new one hit hard lemtrada would next drug choic gilenya isnt help stop progress',\n",
       "  'NN'),\n",
       " ('i viibryd year half soon start medic mg i start ach pain joint i didnt think anyth i recent ankl surgeri attribut discomfort as pain joint spread i becam concern i crohn diseas arthriti relat crohn diseas so pain inflamm increas i went see gi dr felt crohn arthriti start humira well didnt help joint pain inflamm continu progress get wors so i refer primari rheumotologist start heavi dose prednison still diagnosi crohn arthriti this bring',\n",
       "  'VBG'),\n",
       " ('anyon experienc fever take mekinisttafinlar my sister fever spike wouldnt come call doc said side effect chemo possibl sign wont abl toler chemo had give decadron steroid fever so far bring temp doc told us give even chemo dose see oncologist friday just wonder anyon els experienc afraid fever someth',\n",
       "  'JJ'),\n",
       " ('i would like ask long keytruda infus take in leaflet minut all ppl i know take keytruda minut my father take minut is possibl isnt wrong mani thank veronika',\n",
       "  'JJ'),\n",
       " ('hi kaitlyn thank much check blog so glad abl connect congrat pregnanc i humira decadei stay throughout entir first pregnanc son current month im time around current wks pregnant i would high recommend stay medicationa dont want chanc put greater risk postpartum flare my son pictur healthh thrive beauti rare even get sniffl the vaccin babi wont get rotavirus isnt concern the humira stay babi system first six monthsmi son didnt even cold mayb month i kept low profilew go target instanc week feel free contact direct blog question happi help guid',\n",
       "  'NN'),\n",
       " ('i year old male recent diagnos ms my last year rough i suffer chronic pain due bad vasectomi octob that left tri various medic includ high dose gabapentin sometim spring i start notic numb sensat left handfing sinc i car crash summer doctor ascrib possibl neck injuri prolaps in august i vasectomi revers sever hour oper full narcosi a week oper left shoulder neck start hurt lot an mri confirm prolaps neck i sent hospit full ms survey unfortun took sever month dec ms less fact the oligoclon band csf still miss though on dec strong attack start went emerg unit after mani hour wait gave solumedrol as result attack i sensat chang hand feet left quit weak i push like crazi start dmt final last week approv ocrevus first infus two day i cant wait start fight back ms it slowli eat away myelin probabl year in hindsight probabl mild attack marchapril set numb left hand then nd attach august follow surgeri and final rd attack decemb anyon attack per year experi dmt i cours research like crazi complic diseas i start look will ocrevus suffici stop power halt diseas attack that tough question i know anoth way would ask whether anyth i add increas chanc i current vitamin b c d fish oil calcium linol acid chronic pain i order ginkgo biloba magnesium flax seed oil let know think thank',\n",
       "  'NN'),\n",
       " ('he schedul see ent dr today fiberopt laryngoscopi nasolaryngoscopi show complic tumor insid throat neck area the swell growth part lung cancer treat lymph node shrunk start show symptom step backward taken clinic studi but got put anoth chemo immunolog togeth chemo drug docetaxel taxoter pemrolizumab get st combo chemo drug sinc april alon area stabil supraclavicular lymph node act the neck ct show noth new seen report yet blood test done get stud way go back biopsi lymph node ask realli suggest tri stay posit hope well chemo real side effect except lose littl hair neuropathi feet brace cold night went high low lower it rain day time tell god us guid us noth easi far surviv right mind go around circl wait thing come though hope dont go astray wish warmer weather get thing done trip indi the sya best laid plan mice men',\n",
       "  'NNS'),\n",
       " ('durham ncbusi wirejan aeri pharmaceut inc nasdaqaeri ophthalm pharmaceut compani focus discoveri develop commerci firstinclass therapi treatment patient openangl glaucoma retina diseas diseas eye today announc us food drug administr fda review investig new drug applic ind ar dexamethason intravitr implant effect allow aeri initi human studi treatment macular edema due retin vein occlus rvo the ind submit decemb aeri expect initi phase clinic studi later first quarter ar bioerod implant design releas steroid dexamethason sixmonth sustain period the method administr common use intravitr inject the potenti benefit ar compar steroid product includ sixmonth durat efficaci improv administr due smaller needl size possibl better safeti profil due lower peak drug level ar first indstag treatment aeri retina pipelin import mileston compani said vicent anido jr phd chairman chief execut offic aeri this quarter also plan file ind second retina product bioerod implant contain rho kinaseprotein kinas c inhibitor ar develop wet agerel macular degener diabet macular edema these product demonstr potenti two enabl platform deliv drug back eye bioerod polym technolog licens dsm print manufactur technolog licens envisia as advanc new treatment second signific therapeut area eye care continu pursu goal build next major ophthalm pharmaceut compani about aeri pharmaceut inc aeri ophthalm pharmaceut compani focus discoveri develop commerci firstinclass therapi treatment patient openangl glaucoma retina diseas diseas eye aeri first product rhopressa netarsudil ophthalm solut oncedaili eyedrop approv us food drug administr fda reduct elev intraocular pressur iop patient openangl glaucoma ocular hypertens launch unit state april in clinic trial rhopressa common advers reaction conjunctiv hyperemia cornea verticillata instil site pain conjunctiv hemorrhag more inform rhopressa includ product label avail wwwrhopressacom aeri advancedstag product candid rocklatan netarsudillatanoprost ophthalm solut fixeddos combin rhopressa widelyprescrib pga prostaglandin analog latanoprost achiev month primari efficaci endpoint two phase registr trial mercuri mercuri also show safeti efficaci throughout month mercuri aeri submit rocklatan new drug applic nda may juli fda set pdufa prescript drug user fee act goal date complet fdas review rocklatan nda march aeri continu focus global expans develop addit product candid technolog ophthalmolog includ wet agerel macular degener diabet macular edema more inform avail wwwaeriepharmacom forwardlook statement this press releas contain forwardlook statement purpos safe harbor provis privat secur litig reform act we may case use term predict believ potenti propos continu estim anticip expect plan intend may could might explor pursu word convey uncertainti futur event outcom identifi forwardlook statement forwardlook statement includ statement regard intent belief project outlook analys current expect concern among thing expect regard commerci manufactur rhopressa rocklatan futur product candid includ time cost aspect commerci launch rhopressa rocklatan futur product candid commerci market manufactur suppli manag capabl strategi success time cost ongo anticip preclin studi clinic trial rhopressa respect regulatori approv outsid unit state addit indic rocklatan futur product candid includ statement regard time initi complet studi trial statement press releas regard expect clinic trial ar ar result clinic trial time abil request obtain maintain fda regulatori author approv action respect applic rhopressa rocklatan futur product candid includ expect time time regulatori andor review file applic rhopressa rocklatan futur product candid potenti advantag rhopressa rocklatan futur product candid plan pursu develop addit product candid technolog within beyond ophthalmolog plan explor possibl use exist proprietari compound beyond glaucoma includ develop retina program abil protect proprietari technolog enforc intellectu properti right expect regard strateg oper includ abil inlicens acquir addit ophthalm product product candid technolog by natur forwardlook statement involv risk uncertainti relat event competit dynam industri chang factor beyond control depend regulatori approv econom environment circumst may may occur futur may occur longer shorter timelin anticip we discuss mani risk greater detail head risk factor quarter annual report file secur exchang commiss sec in particular fda approv rhopressa constitut fda approv rocklatan assur receiv fda approv rocklatan ar ar futur product candid fda approv rhopressa also constitut regulatori approv rhopressa jurisdict outsid unit state assur receiv regulatori approv rhopressa jurisdict outsid unit state our receipt prescript drug user fee act pdufa goal date notif rocklatan constitut fda approv rocklatan new drug applic nda assur fda complet review pdufa goal date march fda requir chang addit data must made receiv approv nda ever fda approv nda in addit accept ind discuss press releas constitut fda approv ar outcom later clinic trial ar may suffici submit nda fda receiv fda approv forwardlook statement guarante futur perform actual result oper financi condit liquid develop industri oper may differ materi forwardlook statement contain press releas ani forwardlook statement make press releas speak date press releas we assum oblig updat forwardlook statement whether result new inform futur event otherwis date press releas view sourc version businesswirecom httpswwwbusinesswirecomnewshomeen contact media tad heitmann investor ami bavishi keyword unit state north america north carolina industri keyword health clinic trial other health general health sourc aeri pharmaceut inc copyright busi wire pub amdisc am httpwwwbusinesswirecomnewshomeen',\n",
       "  'JJ'),\n",
       " ('thank poppi nssg keith so i took step email cleveland clinic yesterday see appoint they email back offer consult dr daniel fish colorect surgeon i googl much came my current colorect dr kann oschner new orlean you googl read bio oschner websit oschner current rank nation gastroenterolog dr kann special ibd particular crohn i like plus i trust ibd specialist dr shah googl quit resum oschner best region houston hour drive away water right still quit far mayo jackson almost hour drivei would fli may well go cleveland case i assum dr kann offer colostomi thought would ok case i appreci treat individu he conced diseas could come back odd would favorthat reason never guarante i like given option abl weigh base person experi goal dr shah dr kann offer diplomat although dr shah moment pushycontrol tri so anyway im pretti comfort i wonder cleveland might say if might appeal option and outcom might better base hospit except level care cleanli but oschner rank pretti high specialti experi visit dr shah locat hospit colonoscopi staff compet facil clean ive made trip mani time everyth familiarwhich make much less stressfuland proxim i live make followup care much simpler keithar consid jpouch remov my goal surgeri get ibd medic except i think id rather continu oral mesalamin so chronic pouchiti neccesit antibiot also stelara would satisfi is ostomi realli bad whi choos keep pouch post edit plucki pm gmt',\n",
       "  'JJ'),\n",
       " ('european union clear tofacitinib ulcer coliti european union clear tofacitinib ulcer coliti the jak inhibitor indic adult moder sever activ ulcer coliti fail respond adequ intoler therapiesintern approv sourc medscap medic news headlin',\n",
       "  'NN'),\n",
       " ('your welcom spanish lesson i feel like i havent written long time most i mani downward spiral i dont want complain place how soul decid dimens one experi depth detail it like i got derail i made wrong turn back i want turn around what hell happen how i f thing did i realiz fragil happi took grant spit face luck god then ill get moment light get mad melodramat symptom infus werent bad lot ms patient a lot wors besid im still lucki i got privat room infus i access great doctor i amaz insur im suppos inspir get togeth but i write i dive spiral take medic marijuana candi later today i woke sing opera style kermit voic song yesterday i made coffe belt feel like mayb steroid high final kick i got energi i think iron coincident yesterday i feel like i futur friend blah blah blah last day laugh sing yesterday it realli funni then i open email anoth long rider i burst tear sing realiz roller coaster may complet yet and so i wait want scienc solumedrol corticosteroid infus day gram day stop relaps track super power antiinflammatori shut activ lesion veri hard adren should taken light dramat cut effect relaps you tast soon iv goe tast like suck penni i felt burn vein first time time mix salin i didnt feel anyth most peopl say get energi love buzz get laundri done organ cracki behavior i slept hour that could also ativan gave anoth strong anti anxieti medic turn i freak medic procedur i dont trust medic industri complex healthi fear die pain human error rapid heart rate shallow breath good heal shut soon i walk it kind pleasant i put black cloth red lipstick go get blanket pillow pull watercolor lay color i pass a littl scienc rituxin rituximab produc compani call genentech i fair certain genentech name evil corpor scifi show i may guest star the i get medic world exact like marvel comic rock star doctor crazi billionair mad scientist the world hologram i project weird shit sorri carri rituxin monoclon antibodi drug use blood cancer it chemo an immunosuppress act kill half immun system the immun system made t cell b cell all ms drug act t cell general though react bodi so fact b cell modul effect ms chang way scientist think ms but rituxin use treat ms pretti success sinc it stop lesion stop relaps help peopl rrms regain lost function whi isnt use ask and exact drug also act b cell come year name ocrelizumab mayb patent rituximab year would cheaper generic option made compani peopl could actual get afford help instead pay year just rumor so ocrelizumab drama continu ocrelizumab new brother rituxin basic exact drug coupl littl twerk patent price hearsay rituxin though use cancer year then rheumatoid arthriti lupus ms autoimmun diseas it safe success ocrelizumab howev seem lot instanc cancer most breast cancer rituxin didnt bunch problem cancer would they realli allow drug prescrib patient face disabl they couldnt make big enough profit spend year million develop slight wors version caus cancer start push super expens evil twin frighten mass i dont know all i know shit head super scari i make decis i educ enough make i tend turn everyth super dramat plot line start amus i start believ i realli know noth except i read ugh breakdown point i get infus rituxin my doctor rock star got insur cover i think in word favorit ms blogger wheelchair kamikazi rogu prescrib rituxin it hard get prescrib hard get approv it still cancer med ms med it still chemo it still scari it infus might make feel sick they still kill half immun system im sensit thing bodi kill it unpleas it feel like poison point poison my new band name heheh rituxin last month then get kill half immun system can i live indefinit half immun system i think i dont want tri i fond immun system even though abus relationship it hurt ill alway take back it chop hand i kill half start eye eye world goe blind or i lose feel nippl the infus get rid numb make abl finish ride then immun system i get marriag counselor tri learn gentl i wont kill stop eat brain i want go natur rout i dont want part system i want believ i strict diet medit i strangl ms i want faith slow deliber process i control but super honest i dont think i much faith i dont realli like much control i tri natur remedi i tri use cranberri juic cure bladder infect bunch sex week piss razor blade sleep bathtub i took ass dr pill i want wholist peac but i anxieti ridden i want get back hors liter figur there battl insid time that like trigger ms that i want focus ride or rather not focus i want simpl goal what next mile look like how i find water hors how i keep safe how i control anim how i stop focus someth bigger how i help peopl can i simpl task day day accomplish what ident i accomplish small goal everi day this mile just cover mile keep everyon healthi safe fed but isnt simpl ever there peopl opinion there peopl want scare hors there peopl want talk mission there diseas creep slowli make numb bare use hand the univers conspir anymor but yesterday lucki yesterday pretti success troubl seem far away now im bloat head achey want crawl hole but i readi count yesterday yet i dramat steroid roller coaster mood swing i would rather count pleasur laugh add im glad i laugh hallway hospit get woken depress spiral interview guy got addict porn couldnt get anymor one guy kept refer limp noodl i laugh hard i final got bed ive rambl i dont know i melodramat repress thing but i bare feel hand i get exhaust type fix typo existenti feel exhaust i cant even fathom futur my chicken destroy hillsid aunt flo got town i gotta go get feminin product im slowli peak hole like groundhog day unless infus next week scare back insid my hors safe wait i realli miss littl camper im super thank nanci davi racetoerasem peopl i want support ride end help tremend she call doctor behalf got treatment stuff roll they research rituxin prescrib i hope peopl start donat i get back realli go find cure shes like beauti heiress ring leader medic genius find cure cost i cant think anyth better contribut way i remind tell medic marijuana candi next time ps right i wrote enough faith natur curesand i got phone call woman ms run anim sanctuari me futur she beat ms without drug diet disciplin prayer she got number friend read blog contact the convo seem like fate seem crazi i serious doubt call exact right time i wont go i feel reinvigor natur heal depart feel like i lot meditationthink it weird figur stuff loud hope someon els think lifedeath drugsnaturopath faithvoid kind stuff help thank dian zac',\n",
       "  'NNP'),\n",
       " ('have stool sampl taken test pathogen last two year but yeah two year look like uc less like infecti coliti i would ask anoth colonoscopi biopsi i dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('i back long break mom diagnos adenocarcinoma lung septemb age she treat pneumonia month thoracentesi procedur one suspect cancer tumor nodul fluid the er doc order biopsi fluid drain determin stage lung cancer mom alimta sinc short trial tarveva she usual goe almost year symptom cancer reoccur it alway manifest fluid lung suspect pneumonia in novemb admit hospit short breath treat lasix sent home after two hospit stay determin cancer back she put alimta within week breath better finish week x session alimta last april mom start breathless three week ago pcp thought could pneumonia he put amoxicillin chest xray her onc said xray show sign cancer last ct octob clear this past week mom breathless worsen visit pcp taken er yesterday they treat lasix start erythromycin rocephin they get ct morn there enough fluid settl base tap the xray show lung plump fluid one doc said anoth said show condens the onc review ct doesnt think progress restart chemo mom hospit might let go home tomorrow depend breathless improv i write ask test way determin cancer back that way put back alimta thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan this topic modifi year month ago catdand forum moder this topic modifi year month ago catdand forum moder',\n",
       "  'NN'),\n",
       " ('hi carolin thank ive done bit research lemtrada definit readi yet ive recent read lot peopl go still bad relaps yep hes say much i think thing settl bit worri happen futur great hear peopl like still wonder lifew heap convers someon line said thank rucat thank that brilliant i littl concern cancer risk allevi lot angst i wish could see neurologist i realli like hit hard attitud hi temagami thank much detail repli how ocrevus he actual get sort program new neurologist appar ocrevus approv tga pbs yet abl patient ocrevus hope june think one so even though day gilenya major issu i think probabl go ocrevus he keen infus doesnt like take tablet im keen ocrevus ad amount relaps protect i actual point dr jelnick hes bit reluct right nowbut get bit older wrap head around bit i think open definit let express point i think hes still bit denial concentr abl go first solo us adventur plan diagnosi guess might feel emot impact bit he gp ms nurs mate hope enough support outsid us need thank support',\n",
       "  'NN'),\n",
       " ('lorri i would like clarifi observ i made when i said lmc progress rapid i mean week like month my wife diagnos may pass away septemb of cours case exact alik i would set horizon month possibl gradual deterior i pray take longer when i suggest contact hospic mean put hospic right away there numer factor consid we chose fight puls dose tarceva long see posit result contrari oncologist recommend month i found difficult make hospic decis i felt like give time realiz tarceva longer work great difficulti even swallow pill hospit hospic becam logic altern right way go what i realli meant number choic come hospic home nurs home dedic facil get duck line reason ok condit dont want go shop thing turn wors your oncologist hesh good assist make decis appropri cours action all said i hope pray i said never come bear mom next valeri harper bobbeth sept wife beth year old nonsmok dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mgwk sept lost beth',\n",
       "  'VBZ'),\n",
       " ('hi guy im due start ocrelizumab earli feb ive think last week there hard data new just year worth america i exactlti consult told googl is anyon els reluct tale someth that got kuch histor data',\n",
       "  'JJ'),\n",
       " ('im read sometim wait best treatment but defin longer wait my mom histori in juli abnorm spot chest xray pnuemonia in petscan confirm small nodul right lung definit cancer lot littl sparkl throughout lung she biopsi nodul confirm adenocarcinoma mom switch care roswel park anoth biopsi left lung ground glass sparkl came back inconclusiveneg in octob wedg resect upper lower right lobe remov nodul tini margin check lymph node chest one calcifi none cancer the surgeon said kind adenocarcinoma old subset longer use bac multifoc adenocarcinoma limpid featur they stage iib egfr posit she went thru round chemo cisplatinalitma end feb all quiet everi month told ned back octob oncologist said area watch right lung tini he didnt realli give us much grow biopsi in februari said littl chang extend next appt month went back month inform nodul one mm one mm one mm all slowli chang all grown sinc octob anywher mm i gather see scan the plan month goe pet scan confirm figur nodul good biopsi retest genet mutat they talk tarceva treatment noth definit it small slow grow treat wait',\n",
       "  'NN'),\n",
       " ('good luck hope work had tri pentasa asacol neither much btw origin prescrib general gastro consult wasnt clear go mine most small bowel endoscopi clear visual show stuff biopsi wasnt till mri show load strictur small bowel i got proper diagnosi sent crohn specialist immedi took mesalazineasacol useless stuff comment start path tri thing get onto biolog case humira',\n",
       "  'NN'),\n",
       " ('pinki glad hear sorri hear none drs see fit give anyth pain relief i would serious see get anoth pain mgt dr board i sure awar two type pain mgt dr one inject procedur pain medic the also rx pain med warrant it sound much like saw one rx medic your surgeon rx pain med probabl two week believ need pain med longer week i think farther get shoulder surgeri better cervic done that lot surgeri recov worker compens insur bear deal mean stress if i rememb correct ra i assum humira i except i crohn diseas help i issu end taken keep us post susi moder chronic pain psoriasi forum',\n",
       "  'NN'),\n",
       " ('ocrevus ocrelizumab pass phase trial fasttrack fda us author suppos approv th decemb year approv ema european author appar usual follow fdas lead pass nice criteria but myth dream realiti i discuss ms nurs last month perhap youll believ bart blog httpmultiplesclerosisresearchblogspotcomresearchspeakec even forum httpswwwmssocietyorgukmsresearchtreatmentsinthepipelineocr it cure slow halt progress and that good enough give hope becaus quit honest hope thing keep go day pretti short suppli but nice wont approv seem bother the dmt siponimod that far along approv path httpswwwmssocietyorgukmsresearchtreatmentsinthepipelinesipo i know drug without side effect potenti serious one i awar but five half year ago i holiday lisbon like normal person im edss i spend lot life watch mobil independ digniti disappear toilet im ask much longer i even go limit mobil i price i pay retain i quit high price i dont relish prospect life wheelchair contempl mighthavebeen and i realli sympathis come late peopl forum i realli i wish could i wish discoveredtrial year ago none us would unfortun wasnt if turn fals hope i think im paraphras dr jelinek better fals hope hope jo x',\n",
       "  'NN'),\n",
       " ('i also simular problem ive type year i bleed eye i mani laser treatment vitrectomi eye i stick rule work exercis even though im disabl a healthi diet plenti red veg fruit lutein eye vitamin and keep control blood sugar especi sinc use freestyl libra eye improv',\n",
       "  'NN'),\n",
       " ('i found fatigu get wors wors well i spoke neurologist ldn she said let wait see infus i first ocrevus infus today so far good',\n",
       "  'NN'),\n",
       " ('my neuro told i couldnt tri to get pregnant take gilenya i stop take gilenya month start get pregnant lymphocyt are back normaal medic your system so it shouldnt keep start famili i guess it take bit plan but ask your neuro know detail',\n",
       "  'NN'),\n",
       " ('i believ ms reason isnt quit right imo for mani peopl start rr later age say older and mani peopl remain rr live never becom progress and peopl diagnos initi rr younger diagnosi alter ppms within year general pp diagnos year chang mri remiss phase there seem differ within categori ppms rrsp varieti the pp tend relaps mayb odd spot get temporarili wors real relaps and fact dmds either dont work dont work well henc ocrevus scandal work ppms well rrms cant despit dmds avail i think scandal then peopl like definit rr least year then decid im progress year ago earlier summer i seem like mildish most sensori relaps then last month i proper motor function relaps treat day high dose steroid i complet remiss symptom ive year made slight improv so much rehab neurologist went back note year ago astound improv right leg foot drop he said hes seen hundr case foot drop never seen improv year a medic miracl so think i dmd and i question whether id qualifi classifi sp said start talk activ diseas inact equal mani neurologist pwms prefer use word advanc oppos divid us categori so yes essenc i think initi question isnt ms correct load argument back forth within sue',\n",
       "  'NN'),\n",
       " ('i wait long time someth come around approv fda treat ppms i go wait ocrevus neurologist call suggest i get lemtrada infus i infus januari if look find real world result may abl find someth web uk i believ ocrevus use month good luck',\n",
       "  'NN'),\n",
       " ('secondgener alk inhibitor ceritinib to overcom resist crizotinib potent alk inhibitor develop the secondgener alk inhibitor ceritinib grant acceler approv fda second thirdgener inhibitor current evalu ceritinib fold potent crizotinib alk inhibit includ sever resistanceconf mutat includ leumet glyala ilethr sertyr result phase ascend trial clinicaltrialsgov identifi nct suggest ceritinib inde overcom crizotinib resist to definit establish ceritinib standard option crizotinibresist set perform random trial compar ceritinib standard care singleag chemotherapi alk posit patient fail prior crizotinib platinumbas chemotherapi alic shaw md phd massachusett general hospit boston one ascend investig told cancer therapi advisor the multicent intern openlabel trial random assign patient alk rearrang stage iiib iv nsclc receiv ceritinib chemotherapi pemetrex docetaxel all patient progress treatment chemotherapi crizotinib patient allow crossov ceritinib progress chemotherapi the overal respons rate substanti higher ceritinib ci compar ci chemotherapi the diseas control rate ceritinib chemotherapi dure median followup month ceritinib treatment signific prolong pfs month ci compar month ci chemotherapi hr p though os data matur half requir event yet occur time interim analysi death occur among patient receiv ceritinib patient receiv chemotherapi hr ci p all subgroup analys includ age sex race perform status diseas burden smoke histori previous respons crizotinib favor ceritinib patient brain metastas baselin respect also improv pfs ceritinib compar chemotherapi suggest ceritinib cns activ gastrointestin gi toxic includ diarrhea nausea vomit occur frequent ceritinib chemotherapi encourag data present suggest ceritinib dose mg per day food similar exposur ceritinib mg fast signific reduc gi toxic author note despit high rate gi toxic discontinu rate ceritinib due advers event patientreport outcom also higher chemotherapi it greater antitumor activ compar chemotherapi led improv score diseaserel symptom signific longer time symptom deterior greater benefit overal health status dr shaw said the median time symptom deterior month ceritinib compar month chemotherapi accord questionnair data score composit pain dyspnea cough similar arm yet individu score dyspnea cough sore mouth dysphagia peripher neuropathi alopecia chest pain other favor ceritinib the investig note questionnair analysi often noninterpret low number patient remain chemotherapi group',\n",
       "  'NN'),\n",
       " ('this articl remind daunt decis in us slow progressionprob spms on tysabri trustworthi doc suggest ocrevus not sure i agre though famili histori breast cancer it hard make decis',\n",
       "  'VBD'),\n",
       " ('dear tamara im sorri friend my father took tagrisso month he diagnos lung cancer stage iv juli took tarceva iressa tagrisso hes live realli well without collater damag year on last decemb went hospit unfortun pass away week ago he heart issu besid kidney lung failur doctor say mayb caus tagrisso if friend take tagrisso mayb would good talk cardiologist i hope friend continu fight cancer dear dad i wish good luck best wish',\n",
       "  'JJ'),\n",
       " ('newpml risk number it becom common with patient global treat natalizumab longer period time estim per in patient test posit antibodi jcv clinic histori immun suppress treatment natalizumab receiv dose number pml case per httpwwwncbinlmnihgovpubm husband dx rrms dx dual jugular vein stenosi ccsvi httpccsviinmsblogspotcom top harryz famili elder post join tue may pm locat london on canada contact contact harryz icq re updat tysabriaugust quot post harryz sun aug pm with patient global treat natalizumab longer period time estim per in patient test posit antibodi jcv clinic histori immun suppress treatment natalizumab receiv dose number pml case per httpwwwncbinlmnihgovpubm quot i recal ago reader realli nasti thing say i state tysabri go danger drug long term was remind risk pml i alarmist tri scare peopl hmmmwhat scari risk problem continu escal harri',\n",
       "  'RB'),\n",
       " ('a linger question topic i find strang ocrevus cd blocker akin rituxan even map treatment nmosd although rituxan extens use diseas anyon idea what doubleneg ab nmosd doe exist or figment one imagin one hope better guidelin monitor cd cell count frequent endpoint pitfal variat endstag diseas earli onset diseas pregnanc vs dmds nmosd character pauciti data we need better data also data collect hope open share research mani mind work topic instead select refer ganesh a practic current how treat neuromyel optica neurolog clinic practic',\n",
       "  'JJ'),\n",
       " ('paul what would say current symptom dave bexfield mser expert founder activ mser well that interest first right treatment that biggest chang occur i would say first two month i went walk bare hundr metr i could put even metr and year one i could hike mayb two mile rest my longest hike mayb two half mayb three mile one day but unfortun happen even though i ideal candid treatment i start backslid year four that would i notic i wasnt quit well last studi updat i could metr unaid quit and unfortun im back use walker littl bit frustrat im better pretti much everi area cognit fine vision fine i dont fatigu im someon ms actual pretti well leg arent great so i start new treatment i start aubagio wasnt realli cut year i went rituxan right im rituxan i might switch ocrevus insur compani say sure so well see would i oh hell yeah i mean save life cure least case join shiftm communiti httpsshiftm watch video httpsshiftmsmsreport httpswwwfacebookcomshiftm httpswwwinstagramcomshiftdotm httpstwittercomshiftm',\n",
       "  'NN'),\n",
       " ('my mother pass away due stage iv non small cell adenocarcinoma ultim leptomengi carcinomatosi i includ date clear timelin on march i realiz mom act odd best way i could describ space letharg i didnt think much i thought mayb take mani sleep pill night someth on march call told fallen due poor balanc need get xray wrist thought broken we went walk clinic thought possibl copd get enough oxygen caus fog that case we follow primari order chest xray everyth clear i knew someth wrong insist brain mri that day everyth chang they found multipl stop count lesion brain need admit hospit immedi find caus point know primari cancer they unsur type cancer sinc chest xray clear after test nodul lung found broncoscophi confirm stage iv non small cell adenocarcinoma poor differenti whi chest xray clear lung cancer she bit linger cough noth alert she multipl chest xray came back clear she incontin problem sinc least octob i wonder relat coincid she impati day develop plan care began whole brain radiat end total session by end april come fog bit seem littl bit like she began chemo wth mixtur carboplatin alimta avastin everi',\n",
       "  'NN'),\n",
       " ('no worri eye line the thing happen abl see one eye sever month onc i vitrectomi could see i bit cross eye sever week eventu eye line affect one got strength back',\n",
       "  'NN'),\n",
       " ('my son age dx stage atyp poor differenti nec neuroendocrin carcinoma treatment last resort oncologist abl get compassion care opdivo it miracl hundr tumor gone other manag cant get rid constant brain metastatsi anyon success w avastin',\n",
       "  'NN'),\n",
       " ('ocrevus great news dave wish best', 'JJS'),\n",
       " ('ive gilenya sinc neuro put part clinic trial i visual problem ive take werent caus drug in fact i havent side effect sinc earli stage trial im much happier gilenya i betaferon',\n",
       "  'NN'),\n",
       " ('doe anyon know stelara help pay medicar peopl remicad stop help soon i went medicar yo woman dx crohn back never heard year ago current remicad dure gallbladd surgeri liver biopsi reveal cirrhosi along hepat encelapathi esophag varic insur prevent see liver specialist concern great arthriti fibro need hope',\n",
       "  'NN'),\n",
       " ('thank support everyon it help peopl gone plucki great hear your well yay get prednison hope work way system quick i know took month feel anywher close normal i stop diagnos ulcer coliti in remiss lialda prednison no respons entyvio remicad azathioprin opt threestep j pouch surgeri complet step one subtot colectomi ileostomi may complet step two protocolectomi ileal pouch anal anastomosi loop ileostomi januari',\n",
       "  'NN'),\n",
       " ('there folk crohn board lengthi remiss without anyth special im talk year they werent strong med follow particular diet but im sure mind could found someth took kept remiss long pat back accord short post cos bed it adventur vedolizumab land tomorrow',\n",
       "  'NN'),\n",
       " ('have consid go roch instead they could lower price drug rrms ppms roch make drug expect httpswwwbiopharmadivecomnewsmostimpressivedruglaunchrocheocrevus the nhs point costeffect limit health budget pay drug mean anoth drug oper doesnt get done somewher els henc need health funder use robust health econom model everi drug if health funder increas budget everi time drug compani ask drug compani go continu rais price drug current futur quick becom becom unsustain roch need demonstr ocreluzimab generat right health outcom everi dollar spent compar next best drug nhss list fund if roch cant justifi price base health outcom need drop price keep drop',\n",
       "  'NN'),\n",
       " ('hi paul ocrevus isnt avail yet there lot debat whether nice allow ppms patient receiv nhs modest benefit peopl there group facebook peopl america experi like ocrevus work',\n",
       "  'NN'),\n",
       " ('hi i didnt work i bad reaction longer take either i feel gilenya wors tecfidera howev everyon react differ trial error process hope whatev prescrib worka happi tell consult talk option',\n",
       "  'NN'),\n",
       " ('as i suspect letter neurologist confirm i meet amend criteria relaps remit multipl sclerosi she honest said shock neither radiologist local hospit neuro radiologist larger local hospit identifi spinal lesion latest mri despit fact appreci previous scan ive ask consid diseas modifi treatment i would like opt i appoint ms nurs th januari it look like tecfidera lemtrada ocrevus ani opinion im nervous look side effect ive print dvla form told car insur said didnt need know travel insur alreadi screen ms disclos cis previous life insur told i need write lifestyl chang medic condit theyll note polici is anyon els i need tell do i actual need tell life insur compani could refus continu cover sorri question btw',\n",
       "  'IN'),\n",
       " ('im sorri hear dad my husband sclc brain met cycl chemo also wbrt he tecentriq immunotherapi his doctor said could possibl add month he hasnt side effect side effect advanc stage cancer spread brain unless one tumor remov surgic im sure whole lot done besid add littl time i know peopl disagre im go husband doctor said research i done i hope work dad get much time possibl',\n",
       "  'JJ'),\n",
       " ('prednison good temporari water retent insati appetit lead weight gain best reduc salt intak limit bloat eat healthi fill snack some unavoid though make sure take extra calcium potassium pred wast bodi light exercis joint also help reduc bone loss no chanc get xeljanz stelara offlabel sound horribl stay pred month await offici approv new med do plan b xeljanz work moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa offic standdown the man held hostag hour pain within bathroom kept bowel sound like misunderstand',\n",
       "  'NN'),\n",
       " ('i squamous cell i left lower lobe remov no lymph node involv no overrid marker tri chemo gave april tumor growth site lobectomi surgeri anoth surgeri could get tri opdivo now duravalumab the tumor grow slowli i unrel cough squamous hard one treat best regard',\n",
       "  'NN'),\n",
       " ('im probabl one list statist i surgeri hospit readmit due blockagekink i realli doubt mine due biolog my gi biolog month prior surgeri keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('my husband diagnos stage nsclc he given radiat chemo went remiss short time his month pet scan show lung lymph node he went opdivo well pop colon cancer total unrel it happen cancer famili got they oper remov tumor cancer colon stage treatment need but sinc treatment lung cancer progress it lymph node chest neck abdomen his oncologist decid continu opdivo put oral chemo drug afatinib is anyon familiar my sister law california took cancer free year ani feedback i get i would realli appreci',\n",
       "  'NN'),\n",
       " ('the produc lucenti eylea claim surplus money gain use research better eye treatment drug the produc avastin interest cancer treatment rather eye care and low cost would anyth left research',\n",
       "  'NN'),\n",
       " ('i use gilenya introduct state last year lemtrada approv gilenya stop gap measur like dmts lemtrada i realli cannot offer anyth except conveni i kept get wors that feel get wors end i start take lemtrada i wrote quick synopsi tysabri lemtrada entri check research',\n",
       "  'NN'),\n",
       " ('no i didnt regret i daignos just start take gilenya ive normal still i start gilenya insist speciali develop atrophi but still fine fun life hate fact im take alway',\n",
       "  'RB'),\n",
       " ('my wife otherwis healthi year old non smoker stage iv nsclc egfr treat brain met diagnos oct after round carbotaxol switch tarceva last month no progress seen date month ago scan began show hazi describ ground glass in addit experienc warfarin failur last month small pe now dalteparin her breath becom big problem one seem know address has anyon experienc acut short breath find resolut',\n",
       "  'JJ'),\n",
       " ('the way i look colon huge part overal immun system health affect much bowel system far ive read howev im go path medicin mesalamin enema immunosuppres probiot ad remicad entyvio well tri diet thing like gluten free low process sugar etc doesnt work im wait surgeri you smart move get hung opinion but alway prefer keep organ theyr reason my favorit quot colleg roommat sometim get bear sometim bear get',\n",
       "  'NN'),\n",
       " ('home ms inform public ms research updat ms research updat in updat main section fdaapprov medic experiment medic new direct ms research close note trial phase investig drug treatment approv longterm treatment ms pdf refer viewdownload pdf order copi written compil stephen krieger md michell fabian md includ addit materi margaret m mccormick rn bsn mscn review jack burk md edit susan courtney this year ms research updat publish joint multipl sclerosi associ america msaa consortium multipl sclerosi center cmsc intern organ ms nurs iomsn msaa great appreci support cmsc iomsn assist product public the ms research updat provid import new data approv experiment treatment ms valuabl resourc entir ms communiti pleas note updat give overview research behind approv experiment medic therapi longterm treatment multipl sclerosi it includ inform symptommanag medic therapi for addit inform ms symptom symptom manag well msaa program servic pleas visit mymsaaorg call question msaa client servic depart may also email addit pleas note due time nation intern ms confer studi data confer could includ write inform public includ data present confer well import updat occur earli pleas visit msaa websit mymsaaorg futur summari confer highlight to learn consortium multipl sclerosi center cmsc pleas visit mscareorg they may also contact via phone via email for inform intern organ ms nurs iomsn pleas visit iomsnorg introduct coauthor michell fabian md stephen krieger md this year streamlin ms research updat refin emphas numer experiment drug current investig longterm treatment multipl sclerosi ms entir new clinic trial data approv diseasemodifi therapi dmts also includ pleas note order keep annual research updat current date histor background complet trial approv dmts longer includ view chart give overview approv dmts this edit msaa ms research updat print standalon issu reflect incred divers scope research progress ms there nonetheless far much ongo research ms therapeut cover this therefor complet list studi result could includ this inform base wide rang sourc includ extens journal literatur ms manag review ongo clinic trial paper present major nation intern confer these includ confer host american academi neurolog aan consortium multipl sclerosi center cmsc america european committe treatment research multipl sclerosi actrim ectrim more year pass sinc unit state food drug administr fda approv betaseron interferon betab first diseasemodifi therapi ms begin mstreatment era the watch wait approach ms therapi becom thing past favor proactiv strategi prevent msdiseas activ disabl prefer treatment often start person diagnos clinic isol syndrom cis this defin singl attack appear one symptom characterist ms high risk develop ms diseas caus symptom appar the use mri scan identifi lesion characterist ms expedit diagnosi numer studi multipl type dmts confirm earli treatment time cis benefici long term the past two year seen approv new formul copaxon glatiram acet dose three time per week versus daili well new type interferon call plegridi peginterferon betaa dose everi two week a new agent given seri infus year lemtrada alemtuzumab approv fda end with success research initi expand number approv medic choic diseasemodifi therapi grown complex in expert member organ multipl sclerosi coalit msc includ multipl sclerosi associ america msaa collabor develop write paper summar current evid support fdaapprov dmts longterm treatment multipl sclerosi the object provid evid effect medic provid support broad access approv therapi peopl ms unit state ultim goal enabl individu ms medic profession select appropri medic avail this profession paper titl the use diseasemodifi therapi multipl sclerosi principl current evid avail msaa websit anyon review it written expressli medic profession high detail scientif style this paper profession may access go mymsaaorgmscdmtful follow releas profession paper member organ msc collabor develop summari written readerfriend style better serv broader ms communiti this paper avail msaa websit well titl the use diseasemodifi therapi multipl sclerosi principl current evid summari this summari direct correl differ section found within profession version simplifi inform highlight main point incorpor common use terminolog in addit summari follow extens glossari assist term specif describ ms process this paper approv dmts valuabl counterpart research updat focus summar new emerg data cover avail therapi well emerg treatment still develop this paper ms communiti may access go mymsaaorgmscdmtsummari pleas note author report recent studi result avail time public while everi effort made provid meaning time balanc inform medic keep length inform equal medic possibl pleas know differ length text way consid favorit toward one product addit refer cite newer studi result as symptommanag drug fall scope report inform specif symptom ms treatment manag symptom pleas visit mymsaaorg select symptom ms inform for inform trial phase pleas refer page reader may also note studi involv progress form ms highlight mention progress ms appear bold type this present approv dmts relaps form ms author public want also bring studi progress ms reader attent editor note initi studi result therapeut agent investig consid preliminari sinc addit studi andor evalu may need prove safeti efficaci agent msaa endors recommend specif product therapi reader advis consult physician make chang medic diet exercis treatment regimen fdaapprov medic this ms research updat cover inform year earli must begin sober note regard failur two high anticip clinic trial progress ms by test approv medic relaps ms progress diseas possibl extend use wellknown medic progress ms may rigor explor unfortun discuss success relaps ms alway predict similar efficaci progress diseas we begin unsuccess studi move numer posit avenu ongo ms research relaps progress form ms new data tysabri natalizumab gilenya fingolimod experiment medic administ oral laquinimod also known nerventra monoclon antibodi medic about monoclon antibodi monoclon antibodi deriv cell ident clone singl cell replic they produc anim tissu common laboratori mice human monoclon antibodi antibodi nonhuman speci common mous whose protein sequenc modifi increas similar antibodi produc natur human monoclon antibodi extrem power effect specif direct toward certain part system leav part system untouch this desir tri impact structur complex immun system the name monoclon antibodi end mab includ natalizumab tysabri alemtuzumab lemtrada alreadi approv ms sever monoclon antibodi shown promis ms review section daclizumab zinbryta rituxan rituximab ocrelizumab ofatumumab also known arzerra vatelizumab new sp receptor modul data present sever investig oral agent ongo clinic trial mechan similar gilenya isol lymphocyt damag myelin lymph node these agent welltoler reduc lesion relat rrms it hope agent ozanimod rpc siponimod baf ponesimod maintain potenti improv efficaci safeti gilenya howev research continu remain vigil regard cardiovascular side effect bradycardia slow heart rate ozanimod former rpc siponimod baf ponesimod other therapeut strategi masitinib also known kinavet masivet ibudilast tcelna former tovaxin tetracyclin antibiot statin new therapi investig the earlier list approv experiment drug fraction mani treatment current studi some follow among excit potenti therapi investig these brief snapshot high technic concept warrant indepth explan futur pilot clinic trial encourag antilingo lingo protein central nervous system whose role halt myelin prevent surviv neuron the cell make organ bodi receiv instruct regard grow ceas grow without sort cellular check balanc tissu could grow without restraint seen malign antilingo biib agent potenti remyelin properti anim studi show block protein respons stop growth myelin it shown promot spinal cord remyelin axon integr anim model ms eae the first trial experiment antilingo stimul myelin repair human phase i trial involv healthi adult volunt peopl relaps secondaryprogress ms complet in trial intraven iv dose antilingo well toler serious advers event headach frequent advers event report the first phase ii trial antilingo call renew launch the studi recruit patient newlydiagnos ms involv visual pathway optic neuriti evalu drug effect remyelin result present spring the primari outcom renew assess recoveri opticnerv function measur speed nerv conduct visual signal this studi evalu test call full field visual evok potenti ffvep particip treat antilingo compar placebo patient treat least five six dose antilingo show percent improv opticnerv conduct latenc delay speed visual signal week compar placebo further recoveri opticnerv conduct observ last studi visit week statist signific percent improv togeth data demonstr evid treatment effect continu improv observ week follow last studi dose the studi show effect secondari endpoint includ chang thick retin layer optic nerv neuron axon measur optic coher tomographi oct visual function measur test vision call lowcontrast letter acuiti antilingo general welltoler studi note two patient hypersensit allerg reaction time infus one patient liver function test abnorm resolv drug discontinu taken togeth result provid encourag indic antilingo appear safe may facilit remyelin though meaning clinic outcom need assess larger trial to end second larger phase ii trial synergi look drug combin avonex the studi recruit approxim patient rrms spms examin degre patient improv disabl antilingo sinc agent reduc relaps prevent new mri lesion studi antilingo potenti remyelin therapi need util new endpoint prove efficaci these includ measur recoveri improv physic visual cognit function assess effect ms result provid clinic inform drug efficaci neuroprotect repair within central nervous system cns the result also address two fundament question are effect seen optic neuriti studi replic area nervous system and doe translat improv function patient ms either short long term other experiment treatment investig potenti foster remyelin myelin repair includ agent earli stage develop still experiment name gsk rhigm proofofprincipl data expect agent amilorid phenytoin sodium channel blockad the accumul salt potassium within cell ms lesion may possibl contribut cellular injuri neurodegener breakdown nerv this hypothesi would suggest block certain channel cell buildup molecul prevent neurodegener also prevent this strategi test data present look use amilorid potassiumspar diuret approv treatment high blood pressur congest heart failur this medic may potenti provid neuroprotect activ the effect amilorid studi peopl ppms use mri marker neurodegener outcom measur neuroprotect patient ppms underw mri scan amilorid treatment standard dose use high blood pressur period three year research found signific reduct develop brain atrophi well slow develop disabl treatment phase this suggest amilorid may exert neuroprotect effect patient ppms becaus amilorid readili cross bloodbrain barrier gain access cns precis mechan result clear this pilot studi first effort peopl ms focus neuroprotect use amilorid support investig drug potenti neuroprotect agent ms a phase ii trial studi agent optic neuriti initi data expect this studi similar principl renew studi antilingo discuss attempt foster protect repair optic nerv acut phase optic neuriti it worth note strategi success studi antiseizur medic phenytoin brand name dilantin also work modul sodium channel a phase ii clinic trial assess whether phenytoin could neuroprotect acut optic neuriti aon the studi compris peopl aon random within two week symptom onset receiv either phenytoin mg per kg daili placebo three month the primari outcom aon studi evalu structur retin nerv fiber layer rnfl macular volum mv six month visual function opticnerv imag visualevok potenti also measur of origin particip follow studi end in patient averag adjust affect eye rnfl thick six month higher activ group versus placebo result percent protectivetreat effect adjust mv macular volum show percent protectivetreat effect vision general recov well signific differ visual outcom treatment group this intrigu studi may broad implic found administr wellknown relat safe drug seem neuroprotect period direct follow optic neuriti both amilorid phenytoin may also repres potenti combin strategi conjunct immunemodul diseasemodifi therapi idebenon catena sovrima this experiment drug similar coenzym q initi develop treat alzheim diseas cognit defect coenzym q produc within bodi necessari cell grow remain healthi this substanc also work antioxid help prevent injuri oxid process it explor ms oxid stress postul play role death myelinproduc cell link ms progress oxid bodi natur metabol oxygen when disturb occur process oxid stress result caus damag bodi cell tissu oxid stress believ contribut factor mani diseas includ affect nerv immun system a doubleblind placebocontrol phase iii clinic trial idebenon sponsor nation institut neurolog disord stroke recruit particip ppms littl moder disabl the trial began juli schedul complet septemb extens trial continu mis this therapeut vaccin potent activ innat immun system provid immedi defens infect result longlast protect immun as side note help explain type immunesystem defens innat natur immun respons nonspecif it type memori react way time encount foreign entiti virus bacteria mis primarili test cancer acquir infect goal enhanc inher capabl person immun system fight diseas a phase iii studi evalu safeti toler ivadminist mis peopl either ppms spms present interim result this openlabel doseescalationconfirm trial show mis welltoler identifi clinic dose evalu moreov doseconfirm portion studi eight patient spms treat mis week show improv a phase ii studi spms plan complet late transderm administr peptid a small polish studi individu rrms evalu efficaci safeti transderm skin patch administr two dose level three myelin peptid mbp plp mog versus placebo in lowerdos group receiv mg three peptid annual relaps rate one year reduc percent compar placebo progress measur expand disabl status scale edss slight lower indic disabl worsen may slight improv addit percent relapsefre versus percent placebo group the treat group also show decreas gadoliniumenhanc lesion volum tlesion volum the treatment safe welltoler this approach use combin peptid may pursu futur studi il modul secukinumab ain cjm il one sever cytokin produc immun system cytokin small protein may stimul inhibit function cell il appear major inflammatori compon ms secukinumab human monoclon antibodi il a preliminari studi administ ain intraven infus small number patient psoriasi rheumatoid arthriti uveiti variabl result a proofofconcept trial rrms enrol patient show reduct gadoliniumenhanc mri lesion compar placebo a larger phase ii trial plan enrol approxim patient relaps ms design studi present ectrim fall cancel favor clinic develop cjm also target il administ subcutan inject the design phase ii trial present ectrim fall to date individu ms receiv experiment treatment sb firategrast oral agent thought reduc number activ white blood cell enter brain it work via similar mechan tysabri it posit result phase ii trial use gadoliniumenhanc lesion primari outcom atl oral agent affect vla system molecular mechan util tysabri it via novel mechan action fall class antisens oligonucleotid previous use ms the result phase ii trial publish note atl decreas emerg new activ brain lesion compar placebo two month treatment approxim rrms patient as develop path agent still consid pixantron pix investig altern effect cardiotox drug novantron mitoxantron mix treatment aggress rrms spms in phase iii studi patient aggress diseas result present show pixantron effect novantron less cardiotox although via differ mechan action rituximab ocrelizumab pixantron shown studi reduc b cell percent accord studi abstract pixantron structur similar novantron drug similar immunosuppress properti anim studi howev author state pixantron less toxic heart srcrh stabil neuropeptid also known aimspro in phase ii doubleblind placebocontrol studi peopl spms present srcrh welltoler given subcutan inject twice week four week result signific improv sever secondari endpoint these endpoint includ ms function composit msfc time foot walk tfw mean hole peg test hpt larger longerterm studi warrant given promis result howev new trial present conduct new direct ms research new therapeut approach vitamin electrolyt vitamin d biotin salt stem cell biomark genet studi the microbiom ms close note in summari futur diseasemodifi therapi dmts ms continu promis term new inform current approv dmts excit result emerg therapi advanc genet biomark studi hold promis futur possibl person decis ms therapi precis biologicallydriven manner more ever field ms research reli upon will particip patient clinic trial we recogn ethnic racial genet cultur divers ms communiti divers clinic trial popul lack in data six random placebocontrol trial use examin baselin characterist clinic outcom white black asian hispan popul the result challeng interpret due incred low number nonwhit particip clinic trial turn make clinic trial result hard interpret real world the field ms research need divers popul recruit clinic trial truli know medic global effect ms despit setback unsuccess trial progress ms ongo clinic trial ppms spms well investig neuroprotect remyelin repair offer great promis treatment progress ms goal revers damag caus diseas in recent year arsenal ms therapi grown consider way along new therapi come host new challeng risk requir vigil thought approach medic select manag as clinician numer complex treatment option offer patient need patient educ awar becom crucial now ever age empow highlyinform patient true particip ms care collabor treatment team we hope updat valuabl part process for inform clinic trial pleas visit wwwclinicaltrialsgov for inform ms treatment pleas contact msaa visit mymsaaorg',\n",
       "  'NN'),\n",
       " ('read help ive given option copaxon inject caus problem find inform cladribin much appreci',\n",
       "  'NN'),\n",
       " ('fecal microbiota profil predict ustekinumab respons crohn fecal microbiota profil predict ustekinumab respons crohn data patient fecal microbiota use predict respons ustekinumab therapi crohn diseas research reportreut health inform sourc medscap patholog headlin',\n",
       "  'NN'),\n",
       " ('decemb clomipramin approv antidepress show potenti treat peopl progress multipl sclerosi ms diseas form treatment protect nerv various process thought under progress ms earli research show the lab anim studi focus alreadyapprov treatment titl systemat screen generic drug progress multipl sclerosi identifi clomipramin promis therapeut publish journal natur communic a varieti therapi exist peopl relapsingremit ms rrms mark exacerb flare but fewer exist peopl progress ms one ocrevus ocrelizumab approv primari progress diseas among reason mark differ under process under two type ms the mechan caus damag progress ms alway relapsingremit ms this latter requir differ therapeut approach simon faissner research hotchkiss brain institut univers calgari canada studi first author said press releas progress ms involv sever aspect neurodegener accompani ironmedi neurotox immun cell activ oxid stress an effect treatment essenti need address mechan read more ms view news provid benefici multipl sclerosi educ inform resourc servic',\n",
       "  'NN'),\n",
       " ('hi welcom tecentriq brand name atezolizumab use certain type nonsmal cell lung cancer origin fda approv here excerpt email sent lungev recent a big win small cell lung cancer sclc result impow clinic trial show addit immunotherapi drug atezolizumab standard chemotherapi regimen sclc benefici the standard care sclc chemotherapi past year inde big deal if want inform googl tecentriq small cell lung cancer ignor entri nonsmallcel general dont recommend dr googl sinc new treatment may way get info let us know question may support bridget o',\n",
       "  'NN'),\n",
       " ('sorri pred truli aw remind temporari i hope humira longterm ticket clubremiss while pred tri limit salt intak reduc bloat water retent there prevent limit salt limit up calcium potassium intak pred wast two thing system if light weightbear exercis slow calcium wast ive pred number time year dure worst flare i lost pound weight due flare regain pound weight due insati pred appetit a week ceas pred i notic coupl pound disappear water retent howev major weight gain sustain due increas calor intak id eat big meal minut later id starv like i hadnt eaten day long tri eat fill low calor thing exampl airfil thing like bowl butterfre popcorn waterfil thing like bowl soup broth you fill stomach youll free bit the longer chronic ill easier get uc real rough bodi caus dramat weight loss pred caus dramat weight gain loos hair thing entir control we fret thing let go at one remicad infus i spoke nice ladi crohn year she say keep two set cloth one larger size one smaller size shes flare well got tire throw rebuy cloth differ size overandov feel well prioriti els worri cannot control noth make uc wors moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you might uc leav hous wear sock return none emerg tp post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('the thorac surgeon describ incis rib inch spread rib insert hand feel tumor i pretti clear thoracotomi i ask vat robot surgeri respons would use whatev mean necessari would remov littl tissu possibl would remov anyal nodul this hospit origin lobectomi lowest lobe right lung use da vinci robot system while surgeon first use system i find surgeri first time system use facil the surgeon perform move differ facil surgeri would perform differ doctor typic heart lung surgeri daili experienc accord nurs i spoke offic oncologist insisit tissu remov part wonder cya sinc never test new area use either pet biopsi start tarceva option discuss i diagnos cardsup i clear describ tumor locat isnt describ report it look close spinal column surgeon suggest close heart the report say slight increas right upper lobe nodul current measur x cm stabl subpleur nodul anterior right upper lobe measur mm stabl mm right intern mammari chain lymph node who one call request second opinionconsult ucla citi hope usc within drive distanc do i choos one call ask second opinion consult is way ask dr west second opinion this repli modifi year month ago snickerdoodl this repli modifi year month ago snickerdoodl this repli modifi year month ago snickerdoodl this repli modifi year month ago snickerdoodl',\n",
       "  'NN'),\n",
       " ('this site use inform prolif retinopathi httpwwwdiabeticretinopathyorgukproliferativehtml laser treatment httpwwwdiabeticretinopathyorguklaserdiabeticretinopathyhtml laser treatment profession httpwwwdiabeticretinopathyorguklaserdiabeticretinopathyprofhtml antivegf httpwwwdiabeticretinopathyorguklucentispatientsdrhtm vitrectomi httpwwwdiabeticretinopathyorgukvitreoushemorrhagehtml the nhs requir inform consent treatment if dont feel understand treatment offer ask explan if feel team give correct treatment could tri ask second opinion although balanc delay treatment',\n",
       "  'NN'),\n",
       " ('marlo is oral chemotherapi option peopl ms professor david baker research oh lemtrada anoth name call alemtuzumab yeah and alemtuzumab take apart mab mean monoclon antibodi alem name theyv made tu mean origin made treat cancer so alemtuzumab chemotherapi agent use treat multipl sclerosi believ ms driven effect t cell get t b cell cancer that alemtuzumab use so that one cladribin essenti anoth one mitoxantron anoth one so there lot chemotherapi drug actual use ms work kill activ cell activ cell white blood cell so yeah marlo right join shiftm communiti httpsshiftm watch video httpsshiftmsmsreport httpswwwfacebookcomshiftm httpswwwinstagramcomshiftdotm httpstwittercomshiftm',\n",
       "  'NN'),\n",
       " ('hey everyon i know i quiet late frank hasnt lot news report current trial progress mani new one open late but i continu watch close i expect newsflow increas hit big news engin aacr asco cancer confer especi asco later spring i post blog today talk crowdfund effort new crc trial ucsd it base upon good scientif idea elig kraswt krasmut it dose egfr inhibitor erlotinib high dose day week rest week treatment the hypothesi support data far cmax drive dose may increas activ well decreas skin toxic crc trial tell sure i plan enter need crowdfund use help pay trial start sinc drug almost offpat more detail blog second half httpadventuresinlivingterminallyopti caltrial cheer dk',\n",
       "  'NN'),\n",
       " ('i dont total agre if pharma wont come tabl wont approv occur eg ocrelizumab cladribin tri we havent wait drk perform label treatment a proper studi plan time knockout back get pilot data funder look whilst donald trump build wall tri build bridg move forward',\n",
       "  'NN'),\n",
       " ('apolog open question subject that kind cover ill attempt answer goe depend pwms if treat earli enough choos switch alemtuzumab peopl drop zero recoveri regardless baselin count i guess appli ocrelizumab i last manag print guid offlabel cladribin see dose adjust avoid grade lymphopaenia fulli explain thank is grade lymphopaenia teriflunomid bad thing mayb worth moder benefit teriflunomid offer better option avail i suppos remain option stick crab drug i know much love hahaha httpmultiplesclerosisresearchblogspotcomclinicspeakneurospeaknotallhtmlm',\n",
       "  'NN'),\n",
       " ('straydog i walk lot the burn stab pain littl better today have taken mani percocet longer the gi hospit put entocort said ct scan last week look good were wait follow start new med retri humira cimzia i guess nerv pain heel',\n",
       "  'NN'),\n",
       " ('humira actual gave psoriasi i start lose hair round patch spot head size euro coin dri scabbi skin even bigger size knee all clear week consult put humira',\n",
       "  'NN'),\n",
       " ('ocrevus intend ppms hope approv fda meet march also i believ ppmsspms patient may receiv lemtrada infus',\n",
       "  'NN'),\n",
       " ('nutshel ocrevus stem cell treatment look encourag time tell', 'RB'),\n",
       " ('home ms inform public ms research updat siponimod baf siponimod baf in section main articl fdaapprov medic experiment medic new direct ms research close note approv longterm treatment ms pdf refer experiment medic new sp receptor modul compani novarti oral medic studi sever dose be studi spms previous ofatumumab next ozanimod siponimod drug mechan action similar gilenya like gilenya work sp receptor famili block movement lymph cell lymph node howev siponimod appear interact less receptor gilenya primari action sp sp receptor siponimod relat short halflif compar gilenya mean drug stay bodi long research hope small differ minim cardiac issu in rrms result phase ii dosefind studi siponimod report the trial complex design primari goal determin appropri dose carri forward futur trial approxim peopl particip studi at six month proport relapsefre patient percent mg group percent mg group percent mg group compar percent placebo group after six month arr annual relaps rate lower individu take one three higher dose addit regard mri paramet mg dose reach statist signific versus placebo reduct activ lesion approxim percent some excit news ms research last year surround announc result expand phase iii trial siponimod spms the trial random patient spms siponimod versus placebo ratio two time mani patient given siponimod versus placebo the primari endpoint expand trial time threemonth confirm disabl progress cdp cdp met particip develop increas disabl confirm repeat exam threemonth later this trial abl show small yet statist signific decreas threemonth cdp percent studi drug compar placebo particip siponimod arm also show percent slower decreas brain volum compar placebo howev differ observ two group chang time footwalk relaps decreas group take siponimod overal patient toler drug well though serious advers event infect occur siponimod group previous ofatumumab next ozanimod',\n",
       "  'JJ'),\n",
       " ('infliximab rmc consum medicin inform what leaflet this leaflet answer common question inflectra it contain avail inform it take place talk doctor pharmacist all medicin risk benefit your doctor weigh risk use inflectra benefit expect if concern given medicin ask doctor pharmacist keep leaflet you may need read what inflectra use inflectra contain activ ingredi infliximab inflectra approv biosimilar medicin compar safeti efficaci qualiti inflectra refer product establish infliximab monoclon antibodi produc human mous protein recombin technolog monoclon antibodi protein recognis bind certain special protein bodi infliximab act bind special protein bodi call tumour necrosi factor alpha tnf in peopl diseas crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti psoriasi bodi produc much tnf caus bodi immun system attack normal healthi part bodi inflectra block damag caus much tnf rheumatoid arthriti rheumatoid arthriti inflammatori diseas joint inflectra use reduc sign symptom rheumatoid arthriti prevent damag joint you also given diseasemodifi medicin call methotrex ankylos spondyl ankylos spondyl inflammatori diseas spine inflectra reduc sign symptom ankylos spondyl therebi improv physic function psoriat arthriti psoriat arthriti inflammatori diseas joint psoriasi usual occur associ arthriti often finger toe affect although may occur part bodi inflectra use reduc sign symptom psoriat arthriti improv physic function adult respond well enough previous treatment diseasemodifi antirheumat drug dmard inflectra may given alon combin methotrex psoriasi psoriasi inflammatori diseas skin inflectra use treat patient moder sever psoriasi respond well enough treatment phototherapi convent system treatment treatment appropri crohn diseas crohn diseas chronic inflammatori diseas bowel it may also affect part gut inflectra use treat moder sever crohn diseas adult patient children adolesc patient year old respond well enough treatment inflectra also reduc number abnorm open bowel skin call drain enterocutan fistula common complic crohn diseas ulcer coliti ulcer coliti inflammatori diseas bowel inflectra use treat sign symptom ulcer coliti adult patient children adolesc patient year old respond well enough treatment do give inflectra children crohn diseas ulcer coliti younger year do give inflectra children adolesc diseas your doctor howev may prescrib inflectra anoth purpos ask doctor question inflectra prescrib befor given inflectra when must given do use inflectra allergi mous protein ingredi list end leaflet some symptom allerg reaction inflectra may includ skin rash hive fatigu wheez difficulti breath andor low blood pressur do use inflectra sever infect tuberculosi infect abscess repeat infect repeat infect do use inflectra alreadi take anoth medicin arthriti contain substanc call anakinra if never given inflectra congest heart failur use befor given tell doctor current infect prone infect histori infect inflectra may affect normal immun respons you might get infect easili some case serious infect includ tuberculosi tb sepsi report patient treat inflectra ever close contact tb even treat ever close contact hepat b reactiv hepat b report peopl treat tnf blocker howev report rare live travel area fungal infect call histoplasmosi coccidioidomycosi blastomycosi common ask doctor dont know infect common area live travel these infect caus fungus affect lung part bodi cancer a type blood cancer call lymphoma report patient receiv tnf blocker the report rare frequent expect peopl general cancer lymphoma also report long histori crohn diseas rheumatoid arthriti ankylos spondil psoriat arthriti especi high activ diseas andor take medicin reduc activ bodi natur defenc you may like develop infect lymphoma peopl general even without receiv tnf blocker inflectra pregnant plan becom pregnant like medicin inflectra recommend pregnanc you must use adequ contracept avoid fall pregnant breastfeed like medicin inflectra recommend breastfeed it known whether inflectra pass breastmilk diseas affect nervous system multipl sclerosi seizur experi numb weak tingl sight disturb suffer congest heart failur step must taken monitor chang condit treatment inflectra ongo blood disord histori blood disord schedul receiv vaccin patient receiv inflectra receiv type vaccin your doctor discuss benefit use inflectra potenti risk take given medicin tell doctor take medicin includ buy without prescript pharmaci supermarket health food shop some medicin may affect way medicin work do use inflectra alreadi take anoth medicin arthriti contain substanc anakinra tell doctor alreadi take anoth medicin arthriti contain substanc abatacept tell doctor receiv treatment rheumatoid arthriti ankylos spondil psoriat arthriti psoriasi phototherapi treatment crohn diseas ulcer colliti prevent reject organ transplant tell doctor take inflectra receiv vaccin some vaccin given treat inflectra your doctor pharmacist abl tell given inflectra medicin how inflectra given inflectra avail prescript inflectra given drip vein call infus least hour if abl toler first twohour infus doctor may decid give next inflectra infus period less hour for children adolesc year infus given least hour a period observ follow treatment rheumatoid arthriti the recommend start dose infus mgkg you get addit dose mgkg week first infus everi week if week treatment arthriti respond well enough mgkg dose doctor may decid gradual increas dose maximum mgkg everi week you also take methotrex part treatment ankylos spondyl the recommend start dose infus mgkg you get addit dose mgkg week first infus everi week psoriat arthriti the recommend start dose infus mgkg you receiv addit dose mgkg week first infus everi week inflectra may given alon combin methotrex psoriasi the recommend start dose infus mgkg you get addit dose mgkg week first infus everi week crohn diseas the recommend start dose crohn diseas adult children adolesc year closur fistula adult patient initi infus mgkg follow addit dose mgkg week first infus everi week in case doctor may decid increas dose mgkg ulcer coliti the recommend start dose ulcer coliti adult children adolesc year infus mgkg you get addit dose mgkg week first infus everi week while given inflectra thing must tell doctor nurs pharmacist medicin start upset symptom becom wors tell doctor dentist treat inflectra undergo surgic procedur tell doctor symptom tb persist cough weight loss listless fever infect appear do immedi symptom hepat b upset stomach loss appetit vomit tired dark yellow brown urin yellow eye skin appear you must immedi take inflectra receiv vaccin some vaccin given treat inflectra you continu take adequ contracept measur avoid pregnanc your doctor also advis breastfe thing care tell doctor think infect inflectra may affect normal immun respons there possibl may prone infect you watch close sign infect tell doctor immedi develop skin rash hive your doctor may discontinu inflectra symptom go away begin give medicin symptom resolv appropri treatment if suffer congest heart failur tell doctor immedi condit worsen inflectra unlik make drowsi if tire drive car work machineri side effect tell doctor nurs pharmacist soon possibl feel well given inflectra all medicin side effect sometim serious time you may need medic treatment get side effect general patient rheumatoid arthriti crohn diseas ankylos spondyl psoriat arthriti psoriasi alreadi take sever medicin treat diseas these medicin may caus side effect if get addit side effect new symptom pleas tell doctor ask doctor pharmacist answer question may do alarm follow list possibl side effect you may experi dure infus inflectra follow reaction may occur fever chill itchi hive chest pain low blood pressur high blood pressur short breath these reaction like occur first second infus may also appear six month last infus tell doctor immedi notic follow pain tender chest muscl joint jaw swell hand feet ankl face lip mouth throat may caus difficulti swallow breath fever muscl pain joint pain tired abnorm chest sound rash itch symptom may indic heart failur eg short breath especi exercis lie swell feet tell doctor nurs soon possibl notic follow headach nausea vomit dizzi lightheaded fatigu fever rash hive itch sore throat cough hoars short breath chest pain back pain muscl pain abdomin pain indigest diarrhoea weight loss muscl wast problem urin chang way heart beat exampl notic beat faster flush dri skin increas sweat fluid retent new onset psoriasi main sole feet palm worsen rheumatoid arthriti there rare case peopl take inflectra develop liver problem sign could problem includ jaundic skin eye turn yellow darkbrown colour urin rightsid abdomin pain fever sever fatigu tired you contact doctor immedi develop symptom tell doctor notic effect most side effect mild moder sever other side effect list may also occur patient some side effect may appear six month last infus cancer in clinic studi cancer seen patient receiv tnfblocker includ inflectra patient receiv treatment in children adult treat tnfblocker chanc get lymphoma cancer may increas it note howev patient longstand activ rheumatoid arthriti crohn diseas may alreadi higher risk develop cancer even without tnfblocker make difficult estim risk develop cancer patient nevertheless role tnfblocker develop cancer cannot exclud a rare type cancer call hepatosplen tcell lymphoma hstcl report rare adolesc young adult crohn diseas ulcer coliti receiv inflectra all patient also receiv drug known azathioprin mercaptopurin no case hstcl report patient receiv inflectra hstcl often result death the role tnf blocker develop cancer children adolesc remain unclear talk doctor concern skin cancer melanoma merkel cell carcinoma basal cell carcinoma squamous cell carcinoma report rare patient treat tnfblocker includ inflectra tell doctor notic new skin lesion therapi exist lesion chang appear patient lung diseas call chronic obstruct pulmonari diseas histori heavi smoke may increas risk get cancer treat inflectra after inflectra stop tell doctor immedi notic follow side effect even occur sever week stop treatment inflectra skin rash hive frequent infect symptom tb persist cough weight loss listless fever infect appear symptom hepat b upset stomach loss appetit vomit tired dark yellow brown urin yellow eye skin appear these symptom may appear sever month last inflectra treatment you continu take adequ contracept measur avoid pregnanc least month last infus inflectra your doctor advis breastfe least month last infus inflectra tell doctor notic effect storag inflectra store c c refriger do use beyond expiri date inflectra vial singl use ani unus portion discard product descript what look like inflectra come white powder glass vial ingredi activ ingredi infliximab rmc mg per vial inact ingredi monobas sodium phosphat monohydr dibas sodium phosphat dihydr sucros polysorb sponsor pfizer australia pti ltd abn wharf road west ryde nsw australia toll free number australian registr number aust r',\n",
       "  'NN'),\n",
       " ('hi dr west we heard much expertis bac lung cancer we would like ask question pleas help to save time i make stori short in juli wife stage ib lung cancer she year old she eastern asian non smoker she right upper lobe remov the singl tumor cm patholog report state cancer adenocarcinoma mix subtyp papillari bronchioloalveolar acinar well differenti viscer pleural invas present all lymph node negat nowher els cancer she finish round cisplatinalimta chemotherapi novemb she follow ct pet scan everi year sinc in februari ct discov new mm nodul right lower lobe then nodul measur mm april pet scan juli ct mm januari pet scan mm februari ct mm june ct two new smaller nodul mm right lower lobe discov june ct we biopsi juli patholog confirm big nodul cancer year her doctor recommend tarceva next therapi given histori i follow question doe wife adenocarcinoma bac featur is lung cancer consid slow grow is tarceva best therapi do think help need schedul appoint see mani thank',\n",
       "  'NN'),\n",
       " ('in decemb new england journal medicin publish spectacular result pair major intern clinic trial led hauser confirm ocrelizumab block inflamm drive diseas the trial known opera i opera ii compar effect safeti ocrelizumab interferon betaa current standard treatment relapsingremit ms ocrelizumab cut annual relaps rate percent reduc disabl percent shrank inflammatori lesion brain percent compar interferon a separ clinic trial known oratorio found ocrelizumab could modest slow advanc primari progress ms resist treatment these phase iii trial shown ocrelizumab antibodi target cd molecul surfac b cell extrem effect relapsingremit ms caus b cell circul blood bound nervous system orchestr inflamm these b cell percent b cell bodi destroy reliabl sever month dose ocrelizumab treatment given infus everi six month the trial sponsor f hoffmanla roch roch compani hold patent ocrelizumab the avail high effect welltoler treatment mean peopl dawn ms treat therapi essenti complet block inflamm myelin caus relaps remiss said hauser chair ucsf weill institut neurosci and optimist outlook mani year even favor today research believ primari progress ms caus percent b cell live protect area within brain tissu ocrelizumab modest effect target hidden b cell but nonetheless first therapi effect primari progress ms hope patient approv ocrelizumab could mean new outlook patient sarah warto one hauser patient diagnos relapsingremit ms colleg student decad ago warto experienc sever bout diseas symptom rang impair depth percept difficulti walk her recent flareup occur shed given birth daughter two year ago i fair sever attack realli limit abil use leg i could walk minut minut like total differ person taken bodi said with ocrelizumab horizon dream futur free relaps especi think second child find better model the approv ocrelizumab mark shift treatment ms sever decad make one overcom mani hurdl just year ago hauser colleagu told nation institut health propos test bcelltarget ms drug lack biolog plausibl at time still wide accept anoth type immun cell known t cell culprit behind ms idea base inaccur mous model diseas in mice research could transmit mslike condit one anim anoth simpli transfer t cell under tissu chang mice close resembl human ms nevertheless research shrug discrep continu reli model when hauser start laboratori harvard univers set find model ms fidel human diseas this work continu move ucsf becom professor chair depart neurolog after mani year setback hauser mid togeth postdoctor fellow luca massacesi claud genain develop new anim model replic behavior tissu chang seen human ms the new model led hauser call first eureka moment saw antibodi tight bound degener myelin protein these antibodi could detect spinal fluid patient ms long use diagnost marker ms yet consid insignific diseas mechan produc b cell rather t cell here clear complicit diseas in new anim model research found could transmit mslike condit one anim anoth transfer antibodi b cell along t cell this paradigm chang field said hauser he team believ antibodi work alongsid t cell key myelin destruct it would anoth coupl year realiz still hadnt hit nail head a second eureka moment as clinicianscientist hauser eager appli laboratori discoveri toward new therapi he colleagu wrote grant nih propos test exist cancer drug rituximab target b cell approv b cell lymphoma they hope ms patient bcell kill drug would stop product antibodi caus inflamm the nih dismiss propos suggest would fund switch tcell therapi we devast said hauser but readi quit in approach genentech maker rituximab month discuss everyon acknowledg low chanc success began preliminari trial would allow test one dose drug becaus antibodi produc direct b cell longliv intermedi cell known plasma cell would direct target drug hauser team believ would take sever dose drug elimin antibodi we hope one dose would see tini littl effect would give us courag embark longer studi said hauser instead saw effect far dramat imagin there almost immedi near complet blockad new inflamm peopl receiv drug said hauser the stun result one dose told two thing first someth like help mani hundr thousand peopl second scienc driven experi wrong said hauser it almost certain antibodi instig nerv damag process wouldv taken longer revers b cell import clinicianscientist crosstalk bench bedsid key solv mysteri ms clinicianscientist like hauser essenti conduit clinicianscientist alway work two area said we want understand deepli possibl caus diseas studi also feel respons drive understand forward better therapi today a year later genentech acquir roch develop ocrelizumab newer bcell target drug design safer easier administ that set drug path clinic studi ultim approv patient my hope ocrelizumab make lifechang differ mani hundr thousand peopl ms today mani may develop ms futur said hauser',\n",
       "  'NN'),\n",
       " ('anyon experi immunitherapykeytruda forigo', 'NN'),\n",
       " ('holtyc hi want add dont get cladribin end dont get cross we tend hook possibl stop ms i believ noth i havent seen anyth hundr percent stop type ms my best advic spend nine year life read ms forget live life noth go stop ms get life adapt new chang ms bring it may sound bit depress i believ that',\n",
       "  'WP'),\n",
       " ('ocrevus use canada hope get soon', 'VBZ'),\n",
       " ('ken as disinterest interest third parti reader i would encourag keep get medicin first seem keep aliv damn good thing im sure famili agre second altruist perspect contribut trial follow if allow continu experi advers issu would forc counsel would continu i say base read entir blog understand path also somewhat detach i realli detach i also fight bca view outsid nb i ethicist simpli reader the altern isnt great therapi doesnt kill may fact make stronger my aunt chemo lung cancer opdivo par cours cancer found way around she pass long i would worri discontinu would give cancer thing seek way back best anon reader',\n",
       "  'JJR'),\n",
       " ('cumul ive pred year i reckon thought id gotten away unfortun effect bone loss take year come least teeth despit thorough brush bone loss subsequ gum recess periodont diseas scare lose teeth i get older i dont want dentur keith best luck new hip i hope give new leas life dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('is safe take vitamin c tarceva i didnt find literatur discuss', 'NN'),\n",
       " ('a treatment combin provision reject peopl certain type lung cancer nhs england the decis review nation institut health care excel nice end march the combin includ four drug immunotherapi atezolizumab tecentriq target drug call bevacizumab avastin plus two chemotherapi carboplatin paraplatin paclitaxel taxol nice review combin patient type lung cancer call nonsquam non small cell lung cancer it assess advanc diseas whose cancer cell carri one two genet fault cancer research uk polici manag rose gray said shame nice provision reject treatment lung cancer surviv lower mani type cancer crucial find new effect treatment option peopl diseas patient cancer current given combin chemotherapi drug combo cost effect the combin atezolizumab signific prolong amount time patient diseas stabl long live clinic trial compar group receiv combin minus atezolizumab but nice said studi compar treatment combin current standard care overal benefit unknown nice also disagre longterm surviv patient genet fault calcul becaus combin couldnt consid costeffect nhs the trial the studi question includ patient non small cell lung cancer receiv one three differ combin drug bevacizumab carboplatin paclitaxel atezolizumab carboplatin paclitaxel atezolizumab bevacizumab carboplatin paclitaxel patient lung cancer remain stabl around one half month longer averag receiv four drug compar receiv bevacizumab carboplatin paclitaxel the fourdrug combin also boost surviv patient live around four half month longer averag take bevacizumab carboplatin paclitaxel side effect slight wors group take four drug they report case symptom rash loss appetit fever the drug the drug combin attack cancer differ way atezolizumab immunotherapi block molecul often found excess surfac cancer cell the molecul call pdl tell immun cell attack cancer cell by block pdl atezolizumab may unveil cancer cell immun system attack destroy bevacizumab target differ molecul call vascular endotheli growth factor vegf help cancer grow blood vessel by attack growth blood vessel drug stop cancer gather food oxygen blood',\n",
       "  'NN'),\n",
       " ('hi guy quick backstori i diagnos im ive one month period remiss time i sever pan coliti i uceri prednison i resist they zero impact condit system side effect im allerg mesalamin saw result imuranmpmercaptopurin in decemb i hospit lost sever amount weight colon inflamm caus blockag etc i start humira time began saw littl relief short live began flare fair quick i start remicad i go th infus i get everi week im doubl dose i feel better almost immedi i go bms day bms howev still alway urgent diarrhea unfortun infus effect last week i begin flare wait next dose my doctor say im max dosag remicad i receiv she opt start mercaptopurin see would work better togeth so question would ditch remicad start new biolog is normal work week is diarrhea still even tho i feel most better normal has anyon els experienc someth similar post edit ucgirl am gmt',\n",
       "  'NN'),\n",
       " ('hi jim thank repli affirm thought option move forward reason just wonder would possibl doctor forum make comment option would consid patient present similar mom given cancer histori i suspicion convers last week onc like consid rechalleng tagrisso issu drug induc pneumon when ask afatinib immunotherapi mention generat tkis immunotherapi could also induc similar side effect given option consid would help control diseas brain bone lung is risk justifi fact viabl treatment option avail on side note mom never line convent iv chemotherapi would viabl option i read literatur chemo tend extend life coupl month tend work well brain leptomening diseas is accur if least worth tri respond clinic respons short run retri tki therapi eg afatinib or wise pursu rechalleng tki immunotherapi therapi i havent thought realli confus look forward help guidanc possibl look forward hear back best hain',\n",
       "  'NN'),\n",
       " ('near half patient ocrelizumab achiev evid diseas activ neda kristina fior associ editor medpag today vancouv the investig bcell monoclon antibodi ocrelizumab beat interferon stifl diseas activ multipl sclerosi year research report in opera i ii trial signific larger proport patient experiment treatment achiev evid diseas activ neda versus respect anthoni traboulse md univers british columbia vancouv report american academi neurolog meet ocrelizumab anticd monoclon antibodi target bcell most avail immunosuppres therapi ms target tcell research theoriz bcell may also play import role ms in fact ocrelizumab would first bcell target therapi use ms some physician current use rituximab offlabel treat condit both rituximab ocrelizumab made rochegenentech test rituximab progress relapsingremit ms promis result decid fund trial research said rituximab chimer ocrelizumab fulli human monoclon antibodi bind tight target older drug infus reaction antidrug antibodi respons may lessen neda rrms in opera i ii neda composit relaps confirm disabl progress new enlarg gadoliniumenhanc t lesion new enlarg t lesion patient random ocrelizumab mg infus everi week interferon beta three time week week investig previous report reduct annual relaps rate ocrelizumab trial compar interferon relat reduct opera i relat reduct opera ii in latest analysi found signific ocrelizumab patient achiev neda compar treat interferon versus opera i versus opera ii that translat relat increas prevent diseas activ p traboulse said when break neda individu compon larger proport ocrelizumab without relaps versus without week confirm disabl progress versus without gadoliniumenhanc t lesion versus without new enlarg t lesion versus ocrelizumab relaps ms extrem import step forward david hafler md yale univers involv studi told medpag today the risk progress multifoc leukencephalopathi seem relat low it appear mri criteria effect treatment yet hafler said ms clinician probabl use firstlin drug long safeti profil remain weve seen raghav govindarajan md univers missouri also involv studi call drug promis relaps ms this chang way think ms diseas told medpag today other medic like natalizumab work t cell predomin thought ms no new ppms data research also report result patient oratorio trial poster session much differ previous report ectrim barcelona traboulse said the drug reduc relat risk week clinic disabl progress hr p the trial enrol younger patient whod shorter durat progress diseas past progress ms trial this first treatment crack open door show progress ms treatabl traboulse told medpag today now know treatment work partial work better explor work improv get bigger impact patient traboulse note everyth effect relaps ms understand mechan better we still struggl figur peopl progress hafler said effect seen oratorio trial modest best we bad need understand ppms vari form yes probabl get approv yes use need better govindarajan said improv abl offer progress ms patient someth shown treat condit cooccur symptom right i provid support said i dont much offer i get wheelchair i give botox spastic i help swallow but medic shown work make differ patient a familiar situat it remain seen whether ocrelizumab beat rituximab slow diseas activ ms although trial isnt like done given rochegenentech manufactur product the compani stranger two compet drug singl condit one offer signific cheaper price rochegenentech manufactur bevacizumab avastin ranibizumab lucenti host ophthalm condit physician long prefer less cost bevacizumab especi studi larg show equal efficaci safeti profil two whether situat aris rituximabocrelizumab remain specul biosimilar rituximab expect introduc eventu point market pressur may forc rochegenentech drop price rituximab traboulse disclos financi relationship biogen hoffmanlaroch genzym serono teva',\n",
       "  'JJ'),\n",
       " ('dear plucki you brave woman i admir i cant get thereyet even though im still abscess blah blah blah stelara realli help not perfect bms form day still urgenc my gi want least month see heal fistula i rd dose day ago and i came virus immedi follow im tri sort life well yesterday i took ferri island spent day beach even public transit home i take immodium urgenc near access clean bathroom im fine today im run tear i knew would happen plus butt pressur pain build againim fear next abscesssurgeri pain would consid divers i upcom crs appoint octob differ crs one ive seen last year im hope theyll lift fix fistula mayb mayb ill respit my gi also made referr mayo that long shot financi perspect fail gi tri map drugsthen i get psycholog strong enough mayb divers my tini support system burnt i realli dont think i could handl perhap youll provid exampl i need my year old mom one frank heartbreakingsh struggl much i think hard say i follow suit femal canada ivig hold uccrohn test posit map antibodi mycobacterium pg remiss chronic perian abscess fistula fail setonsit pure tortur start stelara may mg imuran hope start antimap drug soon had week repriev flaringagain year flare tiresom',\n",
       "  'NN'),\n",
       " ('im go mexico hsct next year current ocrevus do know could replac rituxan ocrevus posthsct just ask sinc would easier stay therapi replac rituxan',\n",
       "  'NN'),\n",
       " ('last infus friday week ago scan next thuesday immunotherapi caus swell hasnt settl scan i immunotherapi littl moth as similar case moth wasnt clear treatment respons rescan six week drug holiday saw respons so i would like keep take avastin cediranib symptom rescan cardiac mri confirm diseas progress like week and discuss continu immunotherapi base scan result',\n",
       "  'NN'),\n",
       " ('eyesright you correct ozurdex treat macular oedema alalex my apolog pleas disregard comment use wet amd',\n",
       "  'JJ'),\n",
       " ('kirkland quebec merck canada inc known msd outsid canada unit state announc provinc british columbia reimburs renflexi infliximab inject public drug plan effect august renflexi infliximab inject approv treatment crohn diseas ulcer coliti adult pediatr patient well fistulis crohn diseas rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi adult we pleas see govern british columbia add renflexi formulari offer effect afford treatment option patient impact diseas said manon lafontain vicepresid patient access merck canada were commit continu work provinc territori throughout canada ensur broader access patient care need for inform renflexi public list pleas consult httpswwwgovbccaassetsgovhealthhealthdrugcoveragepharmacarenewslettersnewspdf about inflammatori bowel diseas inflammatori arthriti around canadian live crohn diseas ulcer coliti two main form inflammatori bowel diseas ibd canada also amongst highest rate childhoodonset ibd world approxim children live diseas sinc crohn diseas canada almost doubl children age the burden condit patient signific qualiti life substanti affect inflammatori arthriti affect canadian everi stage life irrespect gender ethnic it common form includ rheumatoid arthriti ra psoriat arthriti pa ankylos spondyl as about canadian adult one everi ra while affect person age women affect two three time frequent men support elig patient merck offer comprehens patient assist program renflexi elig patient merck harmoni patient assist program indic renflexi tm for inform renflexi includ full product indic clinic data highlight pleas consult product monograph httpwwwmerckcastaticpdfrenflexispmepdf about merck biosimilar for inform merck biosimilar visit wwwmerckbiosimilarsca merck canada inc member canadian biosimilar forum allianc compani repres breadth biosimilar industri collect work increas awar access adopt biosimilar across canada for inform visit wwwcanadianbiosimilarsforumca about merck for centuri merck lead global biopharmaceut compani known msd outsid unit state canada invent life bring forward medicin vaccin mani world challeng diseas through prescript medicin vaccin biolog therapi anim health product work custom oper countri deliv innov health solut we also demonstr commit increas access health care farreach polici program partnership today merck continu forefront research advanc prevent treatment diseas threaten peopl communiti around world includ cancer cardiometabol diseas emerg anim diseas alzheim diseas infecti diseas includ hiv ebola for inform oper canada visit wwwmerckca connect us youtub twitter merckcanada refer renflexi product monograph access juli avail httpwwwmerckcastaticpdfrenflexispmepdf crohn coliti foundat canada the impact inflammatori bowel diseas in canada final report and recommend access juli avail httpwwwcrohnsandcolitiscacrohnsandcolitisdocumentsreportsccfcibdimpactreportpdf ei benchimol cn bernstein a bitton et al trend epidemiolog pediatr inflammatori bowel diseas canada distribut network analysi multipl populationbas provinci health administr databas the american journal gastroenterolog volum page access juli avail httpswwwnaturecomarticlesajgpdf crohn coliti canada are risk access juli avail httpcrohnsandcolitiscaaboutcrohnscolitisareyouatrisk arthriti societi inflammatori arthriti access juli avail httpswwwarthritiscaaboutarthritisarthritistypesaztypesinflammatoryarthr arthriti societi rheumatoid arthriti what rheumatoid arthriti access juli avail httpswwwarthritiscaaboutarthritisarthritistypesaztypesrheumatoidarthr contact dominiqu quirion merck canada inc lesli haber',\n",
       "  'NNP'),\n",
       " ('so glad mom i hope uceri trick hold inflamm mesalamin med if i go med ladder i would entyviobut yes make case insur compani keep advoc research make inform decis i applaud give big hug it tough mom tougher yet make decis pleas continu keep us post best b',\n",
       "  'NN'),\n",
       " ('is acid reflux medic taken hour period tarceva i told i cannot take prilosec longer is interact new inform thank repli this topic modifi year month ago elizoc this topic modifi year month ago elizoc',\n",
       "  'NN'),\n",
       " ('liquid biopsi focus intens research group expert impanel american societi clinic oncolog colleg american pathologist ascocap report march studi multipl cancer type indic ctdna analysi identifi emerg resist mutat month earlier standard radiolog studi creat opportun test whether chang therapi clinic progress could improv outcom advanc genom analysi aid progress blood test sever factor pose challeng avail evid indic patient earlystag cancer harbor less one mutant templat molecul per millilit plasma cancerseek paper author state often beyond limit detect previous report technolog assess multipl mutat simultan yet anoth issu liquid biopsi identif under tissu origin becaus gene mutat drive multipl tumor type liquid biopsi base genom analysi alon general cannot identifi anatom locat primari tumor therefor ascocap panel recogn promis result research thus far caution blood test base ctdna requir much extens broadbas clinic trial use routin practic relat articl liquid biopsi may accur detect genom mutat urotheli carcinoma nsclc tissu rather than liquid biopsi recommend identifi resist mechan there evid clinic util littl evid clinic valid ctdna assay earlystag cancer treatment monitor residu diseas detect author said there evid clinic valid clinic util suggest ctdna assay use cancer screen outsid clinic trial howev nation cancer institut said articl websit last novemb there recent surg research relat liquid biopsi test analyz tumor dna blood call circul tumor dna ctdna sever ctdnabas liquid biopsi test clinic develop in fact us food drug administr fda gave approv bloodbas cancer test first time year ago the coba egfr mutat test v detect epiderm growth factor receptor egfr gene mutat patient nonsmallcel lung cancer help identifi may benefit treatment erlotinib howev fda advis mutat detect blood tumor biopsi perform determin nsclc mutat present approv liquid biopsi test make possibl deliv high individu health care patient alberto gutierrez phd director offic in vitro diagnost radiolog health fdas center devic radiolog health silver spring maryland explain time liquid biopsi also potenti allow physician identifi patient whose tumor specif mutat least invas way possibl the acceler pace research bring new evid support use liquid biopsi varieti way quick address concern as one member ascocap panel alexand lazar md phd fcap depart patholog genom medicin univers texa md anderson cancer center houston said via email the field liquid biopsi move rapid our comment manuscript base literatur time discuss wrote review almost year ago becaus excit work mani field publish literatur support use approach use liquid biopsi result determin therapi posit result clinic feasibl mutat present act upon reason there less certainti regard clinic action negat result see particular mutat howev continu studi publish learn better appli test effect refer',\n",
       "  'VBP'),\n",
       " ('just thought consid entyviosinc gut specif mayb would easier toler i hate throw anoth option though sinc seem bit map i say though real success humira i hope you definit deserv realli good break pleas continu keep us post hug b uc diagnos prob lialdaday rowasa night period anucort supp cortifoam neededneed i would like vsl slipperi elm metamucil capsul tri gluten free',\n",
       "  'JJ'),\n",
       " ('ive follow time ive read everi post i havent comment i ocrevus sinc decemb i like cant say help in fact i problem to summar experienc ocrevus second half first infus caus anaphylact reaction i abl continu medic rate lower bag salin administ concurr medic i immedi headach infus walk somewhat improv declin month swell lower leg feet horribl i start problem regul temperatur day im alway cold night i night sweat i hormon test normal i knew someth ocrevus thing realli start declin i went next infus august i came home infus discov i start menstrual cycl it didnt stop januari year after test done confirm i fibroid uterus cyst ovari the reason i stop week ago i total hysterectomi now im await news patholog see cancer found i find advers event fdas websit httpsfisfdagovhubstreamaaecdabfdfafd list fibroid cyst uterin cancer addit known breast cancer risk all thing report sinc trial start ran septemb report last updat there serious advers reaction i tell lower true number i plan report mine im sure your facebook jami coupl ocrevus page im there lot women discuss thing go like i also rituxan prior o i cant say right i would consid go back ibe tri everi dmd gilenya lemtrada anoth name campath quit frank two scare im go im realli point say medic caus problem diseas i i total understand frustrat',\n",
       "  'NN'),\n",
       " ('your word reson especi today year fistula anniversari crohn termin diseas ive start look assist suicid it possibl get femal canada ivig hold uccrohn test posit map antibodi mycobacterium pg remiss chronic perian abscess fistula fail setonsit pure tortur start stelara may mg imuran hope start antimap drug soon had week repriev flaringagain year flare tiresom',\n",
       "  'NN'),\n",
       " ('bob exact i prescrib imfinzi without pdl test unfortun work i cant emphas enough import biomark test in hind sight i believ biomark test done treatment start nsclc my biomark test done imfinzi show work i end pleural effus',\n",
       "  'NN'),\n",
       " ('sure what meant inflamatori activ sure everyon thatswhi symptoms ask year regular mri scan one year could compar past one see progress ive alway refus decis might scupper chanc get ocrelizumabi still main walk aid stick furnitur home use wheelchair outsideanyway im due see neurologist month il ask',\n",
       "  'NN'),\n",
       " ('thank repli he pleural effus increas sinc first ct first ct done second ct done nodul along major minor fissur along right side nodul right side would pleural effus caus lot pain x cm in addit front right rib area my dad pain first biopsi site strang what could caus sinc didnt pain hes front pain sinc begin possibl nerv damag biopsi pdl result complet find appoint one hour if higher start keytruda if less start keytrudacarboalimta sinc super anxious symptom pain doe sound reason thank input',\n",
       "  'VBD'),\n",
       " ('i experienc diabet macular edema inject arrest i experienc appear complet revers scan shown eye free edema two year treatment inject intimid frighten seem i includ link post i made three year ago tudiabet first inject lucenti cross my heart hope',\n",
       "  'RB'),\n",
       " ('an interest report ocrevus patient i receiv half dose ocrevus august i serious one infect anoth sinc felt like crap in get blood work next round next month look like im actual get pull ocrevus wont take anymor my immunoglobulin level critic low i ivig treatment asap my wonder drug i wait take year wonder my neuro say pull lot patient he think strong dose he suggest go back rituxan use swedish standard mg everi month instead us mg awhil i even',\n",
       "  'RB'),\n",
       " ('my father diagnosi nsclc plural effus over pass year gone carboplatin cycl cisplatin gemcitabin cycl alimta cycl pembrolizumab cycl diseas show progress increas fluid metastat neck lymph node pleas advis chemo treatment immun treatment give tri can also check new drug come trial let particip thank help',\n",
       "  'VB'),\n",
       " ('wellsetonsword cannot describ paini best solut problem reallyi say within year truli think disabl issu so hard keep area clean hour without home bathroom dont want discuss anyth els right nowtoo depress i wonder hot tub chemic harshhot water sure eas painlidocain even cover anymor insur great seton almost year depress crohn med entyvio mp',\n",
       "  'NN'),\n",
       " ('i copaxon year major relaps sever damageaft solumedrol i statrt gilenya help i still somewhat progess wonder lemtradathought lemtrada vs gilenya',\n",
       "  'NN'),\n",
       " ('thank jim thank janin the kidney failur actual occur sixth infus alimta i understand quit rare side effect alimta i doubt theyll prescrib i know option i tell would most requir dialysi i read peopl last lot longer month tagrisso though im hope im one better believ i worri i wont thank jacki',\n",
       "  'NN'),\n",
       " ('thank respons other sore morn i feel lot better i didnt expect work quick i also wasnt sure symptom bad enough given histori uc i alway tend underestim amount pain im i wrong made signific differ no side effect i know feel yet finger cross continu work do mind ask stop take humira enbril thank',\n",
       "  'NN'),\n",
       " ('hi matt in georg om book chapter medic realli worth read wont newer med eg ocrelizumab give good run other avail best wish pipi',\n",
       "  'NN'),\n",
       " ('a trial rituximab would benefici howev patent financ trial may problemat ocrelizumab probabl go approv rrms spms would lead one think rituximab would similar long histori use oncolog transplant autoimmun diseas',\n",
       "  'NNS'),\n",
       " ('actual abl access full paper studi size small patient mix ppms spms least one ppms patient gadolinium enhanc lesion prior undergo hsct paper didnt includ breakdown subset progress free surviv rate would love know patient fare best i didnt see data avail given burgeon hsct medic tourism industri exclud patient progress diseas larger robust studi efficaci hsct patient various form progress ms urgent need if treatment induc year stabil patient otherwis would see disabl progress ms communiti urgent need know info if hsct work patient progress ms display activ inflammatori marker also need shown given moder effect ocrevus even progress patient activ inflammatori marker treatment modal put halt progress year time warrant robust investig',\n",
       "  'VBP'),\n",
       " ('my husband bac mucus mutat he year old i read dr west well known bac my husband suffer bronchorrhea type cancer he th round chemo altima carboplatin get anoth ct scan next week it right lung said stage he percent use right lung there small spot left lung sometim show ct scan didnt show pet scan he doesnt cancer anywher els except right lung the plan treatment two altima infus go keytruda is anyon type lung cancer mucus was anyon success get rid mucus i read much confus inform type lung cancer pleas help understand',\n",
       "  'NN'),\n",
       " ('had mild case psoriasi one patch dandruff scale had psoriat arthriti two year morn stiff swollen small joint knee pain i endur almost two year on doctor advic start stelara after start dosag also prescrib remicaid week howev took almost week pharmaci fill remicaid within day take medicin i felt better slight stop daili celebrex and pharmaci call pickup remicaid i said i dont need within two week i could feel better enough stop celebrex i took second shot week ago at point joint pain gone i almost back normal i abl wear wed ring i remov finger stare swell i back go gym build muscl back life good bobbi',\n",
       "  'NN'),\n",
       " ('osimertinib prolong progressionfre surviv pfs compar earliergener tyrosin kinas inhibitor tkis regardless level pdl tumor expressionamong patient advanc nonsmal cell lung cancer nsclc accord analysi phase flaura trial present iaslc th world confer lung cancer toronto canada result trial demonstr osimertinib prolong pfs compar gefitinib erlotinib patient egfr mutat nsclc the effect pdl express frequent express tumor egfr mutat egfr tkis unknown of patient random assign treatment studi harbor egfr mutat suffici tissu pdl assess the sp ventana immunohistochemistri test use evalu pdl tumor express tumor cell tc stain least consid posit relat articl pembrolizumab plus chemotherapi extend surviv longer than chemotherapi alon studi in headtohead battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient with stage iii nsclc there signific differ median pfs among patient posit versus negat pdl tumor express receiv osimertinib treatment osimertinib result median pfs compar month gefitinib erlotinib among patient whose tumor pdl posit hazard ratio hr ci similar median pfs among patient whose tumor negat pdl express month osimertinib compar month gefitinib erlotinib hr ci the author conclud data support efficaci egfrtki includ osimertinib firstlin treatment egfr mutat advanc nsclc irrespect pdl express read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'VBP'),\n",
       " ('call doc let know get wors year old femal diagnos sever uc remicad mgkg imuran mg librax zofran need calcium vitamin slow fe',\n",
       "  'NN'),\n",
       " ('post past follow mix respons year ago my mother law stage nsclcstart iressa first line biopsi egfr posit this back juli was month mix respons attempt get aura trial back nov she reject previous receiv kidney transplant certain antirejectionimmunosuppress med they three round carboplatinpemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia they stop pemetrex stop work due complicationscanc progress tube insert assist fluidseem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far i know result came back negat t mutat this yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil various antirejectionimmunosuppress med kidney transplant novemb sound like without posit t mutat option limit dr plan tri three round pemetrex see respons the next option taxoter dr said much stronger could side effect just wonder option immunosuppress current cours dr want get touch transplantkidney dr discuss option just wonder idea i send along so three year anniversari diagnosi juli year appreci time',\n",
       "  'NN'),\n",
       " ('takeda announc phase iii visibl trial investig subcutan formul entyvio vedolizumab patient ulcer coliti met primari endpoint the trial test entyvio mainten therapi adult patient moder sever activ ulcer coliti uc respond well entyvio the result show signific patient receiv sc formul vedolizumab achiev clinic remiss week versus placebo in addit safeti data consist known safeti profil entyvio alreadi market intraven form new safeti signal identifi takeda announc yesterday submit entyvio approv crohn diseas japan comment you need login leav comment epgonlineorg monitor collect advers event report ani advers event report nation report agenc andor manufactur learn zone an epgonlineorg learn zone lz area site dedic provid detail selfdirect medic educ diseas condit procedur inflammatori bowel diseas knowledg centr the inflammatori bowel diseas ibd knowledg centr contain key inform relat epidemiolog pathophysiolog crohn diseas ulcer coliti highlight preval impact unmet need under inflammatori process drive ibd consid key inflammatori pathway chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option fluid manag are uptod latest evid effect procedur fluid manag chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria migrain knowledg centr the migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid acut advanc heart failur what effect treatment acut heart failur can defin advanc heart failur discov transplant see inform best practic solid organ transplant expert discuss relat hot topic load relat content news journal articl clinic trial guidelin news phase iii imun studi stelara show continu efficaci year crohn diseas jj janssen cilag the janssen pharmaceut compani johnson johnson announc new threeyear data phase iii imun studi demonstr ad day ago phase iii visibl trial subcutan entyvio show remiss rate ulcer coliti takeda result phase iii visibl clinic trial evalu efficaci safeti investig subcutan sc formul ad day ago addit data phase iii mapus studi rhb confirm benefit crohn redhil biopharma redhil biopharma report addit posit data map us studi first phase iii studi rhb ad day ago phase iii unifi studi stelara posit ulcer coliti janssen biotech janssen biotech announc new data show treatment singl intraven iv dose stelara ustekinumab induc clinic remiss ad month ago success phase iii studi map us studi rhb treatment crohn diseas redhil biopharma ltd redhil biopharma ltd announc posit toplin safeti efficaci result first phase iii studi rhb ad month ago load view news item journal articl safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthesitisrel arthriti psoriasi crohn diseas object to evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthesitisrel arthriti ad month ago novel therapi treatment strategi patient inflammatori bowel diseas this articl review current treatment option strategi provid updat status drug develop program new therapeut agent inflammatori bowel diseas ibd ad month ago review articl predictor respons vedolizumab ustekinumab inflammatori bowel diseas aim to summaris current data predictor respons vedolizumab ustekinumab ibd patient ad month ago safeti efficaci pharmacokinet vedolizumab patient simultan exposur antitumour necrosi factor aim to explor outcom patient coexpos antitnf vedolizumab ad month ago phase ii evalu antimadcam antibodi pf treatment crohn diseas report opera studi this phase ii randomis doubleblind placebocontrol clinic trial design evalu efficaci safeti pf fulli human monoclon antibodi bind human mucos addressin cell adhes molecul ad month ago load view journal articl item clinic trial impact medic treatment sexual function patient with crohn diseas the investig propos month studi compar sexual function treatment patient crohn diseas initi therapi antitnf drug treatment perian fistula intestin crohn ad month ago studi to test whether pf is safe and improv diseas symptom in patient with crohn diseas opera adult crohn diseas clinic activ despit convent treatment elig studi patient may receiv one three dose pf experiment drug placebo inact drug ad month ago the impact antitnf exposur vedolizumab effect vedolizumab new medic use treatment crohn diseas ulcer coliti it work block specif white blood cell alpha beta lymphocyt migrat area inflamm ad month ago a multicent random doubleblind placebocontrol studi abt induct symptomat endoscop remiss subject with moder sever activ crohn diseas who have inadequ respond are intoler immunomodul antitnf therapi to determin efficaci safeti multipl dose abt subject moder sever activ crohn diseas histori inadequ respons intoler immunomodul antitumor necrosi factor ad month ago personalis antitnf therapi crohn diseas pant the primari object studi investig mechan underli primari nonrespons pnr loss respons lor advers drug reaction adr antitnf drug patient activ lumin crohn diseas ad month ago load view clinic trial item guidelin third european evidencebas consensus diagnosi manag ulcer coliti part current manag the guidelin condens two paper second describ current therapeut manag treatment activ diseas mainten medic induc remiss ad month ago third european evidencebas consensus diagnosi manag ulcer coliti part definit diagnosi extraintestin manifest pregnanc cancer surveil surgeri ileoan pouch disord the guidelin condens paper st detail definit classif diagnosi imag patholog manag special situat eim pregnanc cancer surveil surgeri ileoan pouch disord uc ad month ago consensus guidelin eccoespghan medic manag pediatr crohn diseas the object guidelin provid state art guidanc medic treatment long term manag children adolesc cd individu therapi base risk benefit base thorough review ad year ago crohn diseas manag crohn diseas chronic inflammatori diseas main affect gastrointestin tract the diseas may progress peopl proport may develop extraintestin manifest',\n",
       "  'NN'),\n",
       " ('fluconazol overthecount medic uk mani women use thrush it therefor vital inform known take fingolimod',\n",
       "  'NN'),\n",
       " ('result two earlyphas clinic trial present american societi clinic oncolog annual meet provid evid prime immun system attack tumor potenti treatment certain cancer the find also publish june new england journal medicin nejm although preliminari result notabl trial treatment produc substanti tumor shrinkag patient nonsmal cell lung cancer extrem resist immunebas therapi thus far trial leader explain and mani patient tumor respons maintain year i think one excit thing ive seen recent year said d ross camidg md phd lung cancer research univers colorado denver involv either studi a lot progress weve made recent identifi molecular subtyp lung cancer specif target treatment the promis immunotherapi someth actual cut across boundari may chang everi singl treatment paradigm current develop both studi test investig drug target molecul known checkpoint molecul help restrain immun respons dont harm bodi tumor coopt checkpoint molecul weaken immun system abil erad tumor tumor shrinkag also seen patient melanoma kidney cancer previous studi shown cancer respond immunotherapi food drug administr fda approv immunotherapi patient tumor in addit one patient ovarian cancer receiv one investig drug also tumor respons unleash immun respons the two drug test trial monoclon antibodi one target receptor protein known pd surfac activ t cell the drug target bind partner ligand pd call pdl express higher normal level mani tumor cell tumor microenviron respons inflammatori stimuli both agent develop bristolmy squibb primari funder trial in fda approv first checkpoint molecul inhibitor ipilimumab yervoy treat advanc melanoma ipilimumab howev target differ checkpoint molecul ctla surfac activ t cell patient trial also stomach breast colorect castrat resist prostat pancreat tumor grew despit multipl prior treatment near patient enrol trial test pd target agent slight enrol trial test pdl target agent both trial test escal dose drug start low dose if signific side effect seen research increment increas dose patient enrol later the result intrigu number respons also durabl note suzann topalian md john hopkin univers school medicin led trial test pd target agent among patient respond pd target agent follow least one year respons persist least year',\n",
       "  'VBP'),\n",
       " ('i also switch generic start i want see everyon els i still coupl week worth lialda been without issu sinc my day suppli copay i pick script cvs i didnt realiz i switch i got home thought doc renew day im due see soon just start mild flare fun diseas keep us guess i post result i problem generic lgreco new member join sep post post yesterday pm gmt now lialda save card im afraid generic may option move forward for past week ive take half generic half lialda test no notic differ besid frequent bm ive also up fiber diet ucingv regular member join mar post post yesterday pm gmt my employ tri push everyon hsahdhp plan phase ppo start end the big problem cours buy lialda pocket current ppo charg pay i also found i switch generic without notic befor three month ago i pay insur paid so anticip push hsa plan i start look price someon show app call goodrx find place cheapest price this app say pill generic lialda mesalamin dr costco close im pay insur compani mail order walmart can right is big differ price drug walmart differ befor i go buy i sure generic lialda i buy deliveri mechan brand name lialda is mesalamin dr offici generic name lialda deliveri mechan lialda ipoop forum moder join aug post post yesterday pm gmt zydus pharmaceut produc genericlialda genericasacohd wwwzydususacomproductdetailsid wwwzydususacomproductdetailsid moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa told dentist id rather see gasteroenteroligist he said hed take compliment johnnyuc new member join nov post post today am gmt i switch generic month ago blood mucus came back my gi ask anyth chang told take generic lialda he said switch back gone back name brand symptom disappear suppos allow differ formula will pay extra name brand glasw new member join apr post post today pm gmt has anyon lialda remiss success take generic brand i cant afford flare last flare horrif caus perman damag spine due side effect prednison i dont want go humira serious drug dont think take drug without risk ive lialda year keep stabl took asacol flare everi year the releas system lialda differenti work compar asacol they mesalamin work complet differ medicastioj releas system anyway im wari go generic rout i stay lialda caus eventu go broke my insur wont cover much cost lialda stop copay program this realli dishearten say least',\n",
       "  'NN'),\n",
       " ('hello sorri present dmt work treatment decis ms difficult my spous receiv third infus ocrevus i dont believ ocrevus near good medicin tysabri she great deal fatigu ms symptom numb right hand arm stab pain eye the differ profound today i compar disabl progress ocrevus tysabri ill put link to gold standard compar med imo tysabri much superior slow disabl progress ocrevus chart confirm disabl progress httpswwwmedicinesorgukemcimabpng natalizumab tysabri treatment show low cumul probabl confirm disabl worsen edss mileston longterm set httpswwwsciencedirectcomscienc best wish you prayer find best med',\n",
       "  'VBD'),\n",
       " ('learn insur declin entyvio remihumira my doc mention applic appeal declin within three week window from anyon experi long appeal usual take bum consid option realli dont want take remi humira seem affect whole bodi instead gut male proctiti sinc pancol rx asacol x maint mg budesonid gerd mg pantoprazol flare everi month may move immun suppress tbd',\n",
       "  'JJ'),\n",
       " ('hi fighterm l spain treat spanish nation health fail alimta iv week thing put opdivo matter l ask test even said l would pay onco said no point test that get problem stage v tri keep aliv cure thing tri littl bit harder mire peopl may live longer',\n",
       "  'NN'),\n",
       " ('ocrevus ocrelizumab new approv drug treatment patient relaps primari progress form multipl sclerosi ive rituxan sister drug ocrevus year the comparison drug most illustr blog post ocrelizumab versus rituximab rituxan i made error think compani basic drug easi transitionnot last friday i found infus place i receiv rituxan will not ocrevus infus they arent go train my doctor request i get infus done nyc i i start rituxan normal i wouldnt problem i dont drive far step dad take work take long day like infus rituxan infus done two week later done i make sidebar note point forward ocrevus everi six month wherea rituxan alway follow week apart protocol the idea go citi infus begin mess i also get appoint made i call first time i gave inform appoint requir i told comput froze shed call right back ten minut later no call shock i call this time tell i cant make appoint doctor put order comput receiv ocrevus i call doctor assist got voicemail sent email in repli email im told doctor put order soon receiv blood work back blood work when i ask blood work mind happen hour friday im close oclock hour i get ill doctor send prescript blood test tuesday i saw doctor chang ocrevus june alway plan i find blood work veri frustrat on top everyth els insur approv doesnt start order system appoint made all i say wtf my next infus suppos juli im will bet rituxan i dont think readi transit even full week gave',\n",
       "  'VBP'),\n",
       " ('well well well i say i wouldnt updat blog i neutrophil i neutrophil as im sure your alreadi well awar your read i shout emphat anyon everyon within physic digit hear rang not i neutrophil month sinc beauti sweet littl neut return count remain entir time highest a normal neutrophil count fierc celebr bit extrem what also extrem bone pain time i warn bone marrow swell new cell activ would pain sheeeesh i said thousand time anyon listen i still shock neutrophil came back rapid long noth bizarr first day hospit admiss neut count crept plummet back next week haematolog didnt want discharg anc calcul daclizumab clear systemth treatment kick would take least month reach healthi neutrophil count and damag reversibledrug would work mask fashun whilst day leav becaus preced happen doctor idea the theori daclizumab ms treatment interact cvid common variabl immun defici shut neutrophil product like scenario none doctor could confirm certainti actual happen daclizumab tga approv use rrms less year literatur lack i understand incid peopl ms cvid extrem low ms approx cvid approx haematolog came numer occas flat told honest idea immunolog told tri everyth could research like mad idea i would ever recov and height infect i caught whilst neutropen i look reassur ask doctor infecti diseas depart i go die could offer i realli hope most week hospit blur one long horrif day august stand day i liter got life back it start like day basic tri make look present healthi possibl doctor would approv day leav essenti i put cloth brush hair i sick first month big improv i sit bed tri make look nonchal full energi resid came told incred neutrophil count day come back amaz i could cri then consult came told count actual i cri the haematologist want check film eye celebr went lab came back short confirm blood abund fluffi littl white cell even consult haem team rotat ward duti came tell want crack bottl champagn after spend week think i like go die rush elat relief indescrib i went day leav miss call hospit short they left voicemail tell neutrophil count blood taken morn i lay bed listen voicemail time in space hour i gone patient tick everi singl box highest risk categori complet normal we rip sign door tell hospit staff visitor wear mask around stop gcsf inject stimul bone marrow i start eat fruit veget didnt need peel bacteria risk i threw dettol kid im reckless even haematologist seem surpris neutrophil dramat reappear reason flog bodi everi drug imagin final kick for first time sinc i admit plan discharg date went board room it one week away time wed make sure neutrophil stay stabl gcsf start tinker dosag med my picc consist caus noth grief frequent block would flush aspir mean blood often taken peripher point in pic send drug call alteplas line break blood clot of cours noth ever simpl whilst white blood cell behav beauti lead discharg i extrem tachycard haemoglobin drop the haematologist explan haemoglobin level except mayb bone marrow still bit slump we knew like thing caus tachycardia anaemia haematologist worri might infect immunosuppress meant i wasnt show symptom we pull picc line earli case infect sourc tip picc sent test didnt grow anyth it day ive wait get frenemi picc line remov by time came plan day discharg howev new think i either blood clot lung slow intern bleed by haemoglobin drop i given anoth blood transfus haematolog werent over concern possibl intern bleed worri possibl blood clot so i sent nuclear medicin i havent enough radiat exposur how i felt blood transfus hour picc pull need cannul after xray look infect bodi i spect scan for first scan i breath radioact gas second scan i inject radioact dye both scan lung compar radioact gas abl travel dye went if discrep meant i clot probabl wouldnt worn crop top id realis i go scan arm head hour by time i got back ward near pm i complet given discharg day but one doctor came see scan confirm i blood clot i good go home after hospit long strang feel discharg almost anticlimact i reliev overwhelm sad scare someth would happen i would die without constant observ i hadnt good sleep entir time i hospit druginduc insomnia ward nois haematolog ward loudest ward i ever seem lot met call i attest woken middl night iv med blood i slept full hour bed night the greatest but i woke heart race there much normal wake heart rate i start realli freak potenti intern bleed so nice find i didnt one symptom bodi fault i went see gastroenterologist day took one look extens drug chart said go word haematolog i went back monash day methotrex ivig rather sheepish look haem team come let know gastro point i still dapson prophylact drug theyd overlook chart they ran test blood turn dapson caus haemolysi destruct red blood cell also caus methomoglobinemia meant littl amount haemoglobin i wasnt abl proper deliv oxygen around bodi noooooo wonder i felt like shit so unceremoni kick dapson curb could hang zinbryta gilenya tecfidera drug allow nowher near morgan blood club now neutrophil haemoglobin stabl i sloooooowli wean prednisolon like stay methotrex coupl year mtx seem kind wonder drug also good ms mysteri look like coeliac isnt coeliac gut issu i happi stay especi whilst bodi heal recondit not i recollect ive told first meal month infect nonstop vomit this i start massiv dose methylprednisolon start feel bit human the white bag hang top right corner call tpn feed picc line in term nutrit i abl eat like normal person put weight at lowest hospit i weigh kg i feed tube put nose second time idea i would eat normal throughout day night tube would deliv extra calori bodi desper need i bare memori first tube i admiss i unwel bare lucid point i definit could toler second tube i lot pain threw everyth i fed tube last entir hour pull can tell much i enjoy tube the clinic nutrit doctor pretti unimpress threaten put peg tube tube surgic place stomach abdomen haematolog wouldnt let anyon oper without neutrophil henc i also wait surgeri ear long now i longer neutropen gastro float option peg tube last week i laugh shout no dilig consum fat shake protein supplement chocol life tough i much happier my health full time job moment i hospit appointmentstreat methotrexateivig day week decreas next coupl month ill abl go back work the walter eliza hall institut current sequenc exom hope well find defect gene immun system i could potenti start treatment correct just drug i take daili amongst lot i prophylact antibiot antivir antifung prop shitti immun system i use think health solar system ms big bad sun comorbid planet orbit around ms but im start think ms actual planet cvid real sun ms definit take planetari cake big ol jupit cvid bastard given immun system defici antibodi immun system confront like attack shut various function bodi see fit to fair cvid like star distant galaxi first decad life much i couldnt see idea exist it wasnt i began immunotherapi ms cvid becam enrag when i diagnos ms i specialist neurologist year immunotherapi combin cvid later talli specialist team hit if end ologist i probabl one it feel outrag much wrong bodi amount medic intervent i requir stay aliv i felt pretti bloodi shit i hospit i reason adjust fact hand ive dealt im live best life i panic futur fact ive much there mani year left life hope thing go wrong what els happen i turn but i think gp put best week joke i excel get sick said your also incred good get better this post pretti long i havent even touch what happen ms melanoma so i leav anoth blog post thank read end come along ride morgan xxx',\n",
       "  'VBN'),\n",
       " ('the addit pd antibodi pembrolizumab standard firstlin chemotherapi treatmentnav advanc nonsmallcel lung cancer signific improv respons rate progressionfre surviv research report esmo congress copenhagen today pembrolizumab class immunotherapeut anticanc drug call checkpoint inhibitor target mechan tumour use shut bodi immun respons pembrolizumab enabl t cell reactiv accomplish design facilit tumour cell kill said princip investig dr corey langer director thorac oncolog program abramson cancer center univers pennsylvania us in phase ii keynot studi research random patient stage iiibiv chemotherapyna nonsquam nonsmallcel lung cancer receiv four cycl carboplatin pemetrex mgm everi three week without month treatment pembrolizumab mg everi three week after median followup month research observ signific greater object respons rate vs p patient receiv pembrolizumab well chemotherapi compar treat chemotherapi alon while patient select amount pdl express tumour research note higher respons rate around pembrolizumab chemotherapi combin tumour pdl express greater equal particip pembrolizumab arm also experienc improv progressionfre surviv median month vs month although overal surviv rate similar two arm month surviv rate earli landmark assess there higher incid advers event grade sever pembrolizumab arm compar chemotherapi alon arm vs impact treatment discontinu rate pembrolizumab arm compar chemotherapi arm treatmentrel death the common treatmentrel advers event fatigu nausea common patient receiv pembrolizumab anemia common chemotherapi alon arm studi this first random phase ii trial advanc treatmentnav nonsquam nonsmallcel lung cancer assess benefit ad monoclon antibodi target pd standard chemotherapi said langer if benefit confirm ongo phase iii trial result may radic alter treatment paradigm advanc nonsmallcel lung cancer comment studi dr raffael califano consult medic oncolog the christi hospit univers hospit south manchest manchest uk said data combin chemotherapi plus pembrolizumab popul certain encourag reassur see addit pembrolizumab firstlin chemotherapi manag toxic profil doesnt increas incid treatmentrel advers event death notabl progressionfre surviv report standard arm much longer expect near doubl compar histor data could due patient select clinicalmolecular characterist patient enrol studi califano said in order establish strategi adopt clinic practic result investig phase iii random studi similar design adequ power progressionfre surviv robust assess patient report outcom sourc esmo',\n",
       "  'JJ'),\n",
       " ('my condol loss sister i hope allow time griev dont push hard work right uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc lglutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       "  'NN'),\n",
       " ('thank much posit here updat liquid biopsi dad local miami oncologist email the result guardant remark singl mutat detect ros gene rh uncertain signific specif treatment avail i found use crizotinib target ros lung cancer found trial multipl cancer type refer fusion chromosom transloc activ mutat involv ros gene would dad ros mutat count i look ros discuss board saw cholangiocarcinoma patient might experi anyon tell dad kind ros mutat target thank',\n",
       "  'NN'),\n",
       " ('im nifedipin petroleum jelli mix lidocain your doc order get compound pharmaci i anal skin tag pull caus bleed tear sometim this mixtur help lot i also coat whole bottom a d ointment help well thank t diagnos proctiti april sp c diff infect age nov crohn coliti mid transvers mildmoder remiss marchsept flare againfail prednisonebalsalzid wean start humira prednison sinc past med cortifoam canasa rowasabalsalazid prednison',\n",
       "  'NN'),\n",
       " ('happen someon stop take ocrelizumab probabl peopl know answer alreadi sinc rituximab around year rebound similar natalizumab',\n",
       "  'NN'),\n",
       " ('addit result present today show experiment monoclon antibodi ocrelizumab slow progress disabl compar placebo phase iii trial the studi known oratorio involv peopl primari progress ms compar placebo ocrelizumab signific reduc risk progress clinic disabl also reduc time requir walk feet decreas volum brain lesion reduc rate whole brain volum loss week this first largescal clinic trial show posit result peopl primari progress ms genentech member roch group support trial in press releas compani state plan seek market approv fda',\n",
       "  'NN'),\n",
       " ('hi im new forum on decemb th mom diagnos stage iv nsclc tumor patholog nonsquam adenocarcinoma pdl less negat target mutat she spot lung tumor nearbi lymph node tumor left adren gland least potenti brain met the brain met scatter throughout brain sever frontal lobe least one left pariet least one right top cerebellum my father took er major neurolog symptom insist fine despit fact right hand wouldnt function begin entir whirlwind mom handl news exceed well part shes tough nononsens part tumor frontal lobe help respect henc think fine even know right hand wouldnt work she spent week hospit intens steroid reduc swell week inpati rehab help regain right hand function improv balanc etc while still rehab began whole brain radiat she came home finish treatment she toler radiat well better everi day we weigh next step qualiti life mom prioriti she amaz fortun experienc pain far she interest clinic trial im scientist former research i pro clinic trial general philosophi i support mom choic im even go to quot im pain im nauseous i dont feel sick i intend keep way her doc recommend cycl carboplatin pemetrex alimta pembrolizumab keytruda shes debat doe anyon experi treatment regimen will share',\n",
       "  'NN'),\n",
       " ('pcori award m studi compar current drug rehab therapi ms magdalena kegel the nation multipl sclerosi societi report patientcent outcom research institut pcori grant near million fund four research project assess various multipl sclerosi ms therapi clinic effect two grant cover studi compar diseasemodifi treatment look identifi differ effect drug well assess downsid a third fund project evalu drug allevi fatigu fourth assess whether ms patient live rural lowincom area benefit equal well rehabilit provid phone internet access clinicbas rehabilit all project noteworthi patient engag key focus pcorifund research ms patient famili caregiv ms healthcar provid nurs physician contribut design perform studi these pcori award welcom muchneed infus new ms research fund import realworld question treatment strategi effect bruce bebo phd execut vice presid research nation ms societi said news releas pcori delight make new award address crucial evid gap question vital interest peopl us live multipl sclerosi ad joe selbi md mph execut director pcori these studi provid signific new evid help patient famili clinician decid confid therapi avail work best given need prefer the design select four studi came prioriti identifi workshop there peopl ms healthcar provid scientist govern agenc pharmaceut industri repres health insur gather refin question pcori later use fund announc the session identifi number evid gap issu put forward top prioriti workshop particip address four research project the first grant million went studi explor biolog drug rituxan rituximab effect common use diseasemodifi drug peopl relapsingremit ms also also compar side effect drug the studi base karolinska institutet sweden perform partnership healthcar insur provid kaiser permanent southern california anoth million goe project run research team univers alabama birmingham assess whether patient alabama mississippi rural lowincom area benefit much exercisebas rehabilit program deliv via internet telephon therapi provid clinic clinic provid servic area scarc put emphasi altern option three drug often use reliev fatigu peopl ms evalu studi univers california san francisco receiv million the drug symmetrel amantadin provigil modafinil methylphenid known sever brand name includ ritalin rare compar sidebysid final million award trial compar benefit side effect two oral diseasemodifi treatment gilenya fingolimod tecfidera dimethyl fumar again drug never direct compar although general view similar effect side effect might differ the trial led research team base foundat carlo besta neurolog institut itali includ studi site us europ israel the ms grant among grant total million support research various diseas area approv pcori board governor last week',\n",
       "  'JJ'),\n",
       " ('sugarplum i lesion year i feel progress i know lemtrada work stop so i hope ocrevus slow hell i wish best',\n",
       "  'NN'),\n",
       " ('i ask dr week ago ie biolog prevent delay surgeri said evid number surgeri come number peopl respond medic although biolog still year experi guess need time draw firm conclus dx pancol last remiss moder sever leftsid coliti sinc have tri near drug quack option avail current work entyvio sure work',\n",
       "  'NN'),\n",
       " ('hi i ldn almost year to find need know facebook group call ldn research trust there file section inform as ldn immun stimul may work gilenya immun suppress for ldn help fatigu gave endorphin ive still attack group i refer my dose mg some take liquid pill i get mg pill make liquid thus isnt stabl i live long way compound pharmaci good luck research',\n",
       "  'NN'),\n",
       " ('hi mohit welcom grace i sorri hear recent progress father lung cancer though oncologist like continu tarceva even progress combin drug alimta pemetrex often progress signific enough third generat egfr tki tagrisso chosen in addit doctor choos combin afatinib cetuximab effect quit challeng term combin side effect egfrposit patient often overlook standard chemotherapi tend quit effect subgroup patient regimen carboplatin cisplatin combin alimta taxol often use jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('neoadjuv erlotinib tarceva benefit select patient epiderm growth factor receptor egfr mutat nonsmal cell lung cancer nsclc undergo complet resect stage iiian diseas accord random studi compar erlotinib gemcitabin plus cisplatin neoadjuv treatment the find present zhong et al european societi medic oncolog esmo congress abstract lbapr our result suggest promis use biomarkerguid neoadjuv egfr tyrosin kinas inhibitor treatment strategi stage iiian nsclc said yilong wu md tenur professor guangdong lung cancer institut guangzhou china princip investig ctong studi this first studi demonstr progressionfre surviv superior erlotinib gemcitabin plus cisplatin chemotherapi neoadjuvantadjuv set stage iiian egfr mutat nsclc dr wu ad ctong result a total patient center china screen random assign therapi includ intentiontotreat popul the object respons rate orr neoadjuv erlotinib vs gemcitabin plus cisplatin chemotherapi confid interv ci vs ci odd ratio ci p after neoadjuv therapi patient erlotinib group gemcitabinepluscisplatin group underw surgeri median progressionfre surviv signific longer erlotinib month ci vs gemcitabinepluscisplatin chemotherapi month ci hazard ratio ci p overal surviv immatur report said dr wu grade toxic fewer erlotinib arm compar gemcitabinecisplatin arm current treatment strategi resect stage iiian egfr mutat nsclc controversi explain dr wu egfr tyrosin kinas inhibitor shown improv prognosi patient advanc egfr mutant nsclc cisplatinbas doublet chemotherapi neoadjuv treatment stage iiian nsclc give patient year overal surviv benefit said dr wu explain unmet medic need patient popul recent ctong trial publish zhong et al lancet oncolog show first time adjuv gefitinib iressa could improv diseasefre surviv month compar adjuv chemotherapi vs month nn resect nsclc this rais possibl egfr tyrosin kinas inhibitor may play benefici role neoadjuv set subgroup the content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       "  'JJ'),\n",
       " ('wow thank anon i dint know theori prof vollmer i realiz neuro option treat decid take risk leav boy fingolimod realli improv exam result mri',\n",
       "  'NN'),\n",
       " ('cc stelara work matter day if gi will jump hoop get probabl worth consid if one anti tnf stop work anoth pm ulcer coliti next surgeri schedul i problem skin loop i ad setup pm ulcer coliti next surgeri schedul im familiar hollist probabl they go first cut hole stoma go place direct skin it protect leak stay skin pm ulcer coliti humira remicad there cimzia simponi antitnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug pm ulcer coliti unexpect scope result jpouch buckey i think how appoint gi go i know issu complex mine i didnt see post anyth am ulcer coliti next surgeri schedul congratul id recommend get convex wafer new ostomi realli help liquid output as probabl know loop ileo time littl pm ulcer coliti after remicad infus id get test remicad antibodi i symptom i serum sick dont ignor mine got wors i start drop thing memori loss bone joint pain if pm ulcer coliti the superdonor phenomenon fecal microbiota transplant here segment cbc radio quirk quark show httpswwwcbccaradioquirksnotallpoopiscreatedequalandsuperpooperscouldbelifesav they test am ulcer coliti just saw gi hes recommend xeljanz im scare when start thread check box includ signatur i see med have thought ad entyvio either prednison entocort is blood test pm ulcer coliti just saw gi hes recommend xeljanz im scare have antitnf med like remicad you dont anyth list signatur are use rectal med steroid pm ulcer coliti recent takendown friend ive heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi gas diarrhea also caus sibo it easi test ive taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       "  'NN'),\n",
       " ('travel multipl sclerosi doesnt ordeal but bit complex especi bit disabl mobil wise especi diseasemodifi therapi like injectab copaxon rebif avonex betaseron extavia all shot therapi needlesairplaneshmm requir keep eye temperatur cold hot here practic advic activems cull fellow mser travel agent airlin staff cruis line disabl specialist person experienc travel countri six contin mani diagnos mani use walk aid wheelchair i serious get around you here even machu picchu made access general tip a letter doctor state multipl sclerosi good idea i read woman deni extra drink flight look drunk she claim ms now doctor letter might help particular situat still drunk ms i digress keep ms specialist phone number email offhour pager number if travel countri dont forget add countri code dial rememb differ exacerb pseudoexacerb accord nmss websit true exacerb worsen old symptom appear new one last least hour this import stress heat andor fatigu easili happen travel could caus temporari symptom flare clear next day pace you know bodi better anyon if know go allout go put hurt bodi save climb kilimanjaro end holiday recov plane ride and rememb dont everyth guidebook holiday call success choos activ wise build recoveri time check ego you lot tool dispos make travel easierus wheelchair cane trekk pole scooter rollat dispos undergar name is someon stare who bloodi care it probabl wise dont take medic origin label contain come cryptic pill diseasemodifi inject ms med okay sinc label the dude especi custom dont realli like guess pill take tysabri lemtrada rituxan be sure plan around infus date katmandu like infus center use dont underestim import reliabl travel companion when need littl extra assist extra pair ablebodi hand leg godsend mental note bathroom travel intern avoid pass good one there cell phone app help find public potti watch data fee oversea and rememb hustl back natur call she alway tend ring inopportun time if travel remot area particular ventur outsid us nonindustri countri may want ask neurologist prescript oral steroid prednison that way exacerb long trekk trip say nepal dose oral steroid could trim attack symptom big time save vacat note onli previous taken oral steroid awar drug affect dont wait dont save dream trip retir or kid grown or feel better ms unpredict go carp diem seiz day savor moment make vacat unforgett right reason focus instanc make travel enjoy diseas run bull spain an over access bathroomjungl gym seiz day and windi rail plan your trip consid use travel agent special make arrang disabl this especi use requir wheelchair be sure inform agent special need current mobil equip bring need destin seat prefer etc here detail list travel agent around us around us experienc work handicap folk httpwwwdisabledtravelerscomtravelagentshtm for europ sage travel gob trip dozen citi wheelchair access httpwwwsagetravelingcom view accommod onlin make reserv note stair pool access restroom exercis room etc have question email call you dont want stuck go stair bb thought singl level also dont trust handicap access declar what folk think access downright laughabl the best solut sever mobil issu ask pic even video even cant trust area access in peru i cannot count number bathroom wheelchair access despit appearancesovers grab bar galorerequir get chair anywher near toilet stall door often would close brought wheelchair on anoth occas bathroom door open block toilet a room access bathroom isnt folk use wheelchair as one activems discov larger bathroom grab bar especi help exhaust day some hotel shower chair avail shower alreadi equip one better ask sink may may allow roll wheel ask and doorway andor bathroom heck even bedroom may wide enough chair especi travel oversea tape measur minimum requir need the time year travel absolut make differ i prefer travel season less stand line easier get restaur better seat special event temperatur cooler if heat wear travel toasti could turn vacat littl quest ac consid cruis even cruiser ive travel ship extens pre post ms inde one trip near four month took around world host advantag you unpack great fatigu disabl access good especi need mobil aid doctor alway onboard help relaps travel time often night sleep exhaust car ride recommend i like alaska summer caribbean winter europ fall spring note travel agenc special adapt cruis shore excurs want farflung adventur an african safari great travel x mean access ac seat the lodg spectacular kenya i actual slept bed x size bedroom staff cater special need can say multipl sclerosi languag if travel countri dont speak languag download onto phone free a ccessibl travel phrase book pdf lone planet ask access bathroom elev countless essenti disabl got way easier purchas travel insur book trip like aig travel guard most travel insur compani will recogn preexist condit like ms purchas insur within day put deposit trip if miss window ms event void travel insur now meant buy travel insur space i dolt plan travel insur intern wwwtravelinsuredcom purchas day initi deposit rememb initi deposit includ fund trip penni and word warn buy insur compani travel go belli sol so i alway recommend buy insur third parti not travel agentcompani cruis ship wheel athen greec cruis easi access option mser ride camel sahara desert whi hell gear unless need help walk around airport pack trekk pole luggag avoid juggl two pole cane allow aboard airplan trekk pole well tell anyon ask mobil aid ski pole almost alway frown upon forearm crutch problem flight attend may store anoth area plane dont fit overhead bin if happen seat surf bathroom better yet could lucki enough set joint forearm crutch like trick pair develop dick fate httpswwwyoutubecomwatchvimejaogow they fold jiff store seat front the easiest cool vest pack one evapor sinc lightweight uncharg but perform poor humid condit sinc usabl freezer hard find prefer allaround travel vest recharg ice glacier tek vest wwwglaciertekcom room temperatur first line technolog vest wwwfirstlinetechcom one thing watch tsa love search bag carri cool vestshatsscarv hydrat bead avoid someon paw luggag take carri inform screener mari washington if go carri cool vest plane doctor note extrem help could confisc due gel fill evapor vest okay charg on recent trip tsa let gel vest without question although i announc i one send xray a unit airlin secur rep want remind cool vest not actual wear go secur you know gel pack look like scan bodi like bomb strap chest take tell friend break camera film chao i like tini lightweight digit camera cell phone record travel memori photograph audio video the weight save conveni slip pocket invalu i dont like caneseat combo oh sound conveni crummi cane crummi seat get pant littl dirti sit curb must get wheeli bag dont alreadi one no sens burn energi lug around granddad old militaryissu trunk look cool lot sticker the absolut smartest pack advic taken veteran travel make whatev bring fit singl carryon bag especi go travel multipl destin yes includ go oversea three week youll never lose bag far easier handl larger luggag substanti lighter pawn travel companion need bring multipl form walk aid whi if lose cane still trekk pole vice versa also primarili use rollatorwalk bring cane forearm crutch i heard one mser much troubl cobbleston street itali rollat essenti useless the cane although meant slower go save vacat a pair forearm crutch offer three time support singl cane make get around uneven surfac cake walk if need help get around airport massiv hotel museum ask dont shi this vacat dont want spend two day recov amount stubborn pride most facil wheelchair borrow although forewarn youll often get beater on recent trip boston i got overconfid fail bring wheelchair and none avail rent so switch hotel one provid chair guest use weekend it save trip seri short cab ride a person favorit travel companion summertim travel umbrella particular sunsaf umbrella gustbust order wwwinnovagolfcom they handl wind mph provid instant shade relief heat great spectat sport long line outdoor plus come kinda handi rain if need wheelchair travel plane ship fulltim scooter user mser suggest take manual chair possibl you dont worri recharg batteri deal hassl stow chair manual chair brought gate without problem easier tote car if one lightweight remov wheel even better you rent wheelchair easili countri for instanc franc virtual corner pharmaci chair rent qualiti iffi though usual less euro day this made train travel much easier i didnt lug wheelchair public transport i would get chair destin town but cant alway count in itali wheelchair imposs find so dont lug scooter around worri get broken rent one destin compani usual deliv ride direct hotel pick finish dramat lower hassl factor mani cab equip tote scooter thank great tip ruth with carryon bag stack lap i doubl luggag cart trekk bhutan trusti pole cold water cool vest alway recommend on plane in airport if travel person wheelchair sure gatecheck wheel take way actual board plane when leav chair plane entri detach easili remov item take aboard plane person carryon item that includ seat cushion footplat armrest i like bring small stuff sack well stuff everyth wheelchair knicknack stay one place limit risk someth fall bin clunk innoc stranger head and take gear minim risk lose import piec equip it serious suck lose left footplat youv got enjoy entir vacat leg cross even dont tinkl is tsa precheck worth year global entri if fli twice year probabl you get speed secur check wait usual less minut get keep shoe belt liquid stay bag if use wheelchair usual patdown disappoint week last year full monti test hand chair explos residu super quick easi request wheelchair assist book flight bring when check tell ticket agent request assist call someon this person take whoever travel thru securitywithout stand long line right gate if switch plane your fli direct someon wait take next gate if isnt anyon let gate agent know call someon when arriv destin someon take baggag claim rememb take dollar bill tip the wheelchair assist help conserv energi mari oklahoma if travel scooter electr wheelchair best gel cell dri cell batteri if wet cell batteri rariti day airlin remov chair special storag hassl again dont forget remov seat cushion etc pervent get lost belli plane scooter either gate check go check luggag dont forget secur key power pin someth bit stronger rubberband some suggest fish line and set throttl slowest set tape help prevent speedi joyrid how much scooter wheelchair weigh if heavi may allow flight we recommend call ahead check restrict on power chair remov joystick recommend or least point downward those littl bugger stick attent uncanni abil attract errant luggag look care airport chang airplan know far go gate for exampl perth brisban australia domest intern termin actual separ airport not easi transfer mobil impair and alway allow longer time suggest make transfer a notabl except home town melbourn intern domest flight one build mari washington take advantag earli board ask flight attend help need consid use curbsid check luggag porter arriv airport save energi buck usual worth request isl forward seat airplan the closer front airplan less walk anoth reason h ey sometim us mser go lavatori well realli gotta go if front plane avail head rear on intern flight i alway check wwwseatgurucom find seat close toilet sinc number locat various area larg plane also note last row seat may reclin fulli walk aid often store behind seat make retriev cake speak bathroom wouldnt hurt chang cloth carri in fact id consid mandatori sometim bodi dont suppos wear clean cloth lot better wear wet cloth wash airplan lavatori and id suggest hit restroom board now cours dont dehydr advic drink plenti h jetlag may mitig sleep aid make even hour plane trip relat breez but import word caution never drink alcohol take sleep aid dont tri first time airplan onli take companion a unit airlin secur rep warn altitud alcohol ambien danger mix if lot med keep person a friend baggag confisc twicecom goingbecaus drug pack check luggag of cours didnt help matter transfer singapor note hang folk much tylenol actual kilo heroin get pictur her bag delay coupl day fortun stash pill prevent natur critic pick cool swordcan kenya if cant fit check luggag i pretti much guarante confisc doc note and youll cool swordcan stori woe flight attend quick help disabl a travel scooter boon tire leg tsa frown sword cane crossbow wookie at your destin if use wheelchair especi intern museum sight often free go straight front line question ask eiffel tower hour wait bam next elev hord peopl surround mona lisa bam frontrow access even closer ablebodi person sistin chapel access bam back corridor hidden passag vatican when get cafe hotel hang bit ask toilet locat need some well hidden would never find ever at one hotel dinner i befuddl bathroom it around screen closet behind close door also downstair requir new plan stair limit in one case waiter took differ build altogeth get easyaccess toilet if dont see access bathroom ask one cafe hidden behind broom box dont rush you dont cram everyth be select enjoy when get home youll far better memori race clock hit smithsonian museum one dc afternoon take advantag break seek shade drink ici beverag sit the energi save come handi later trust sometim conveni cost littl extra it often money well spent if roll may need scout ahead alter rout find curb cut sinc block nonexist okay found incred easili breakabl souvenir last day trip fit luggag cloth listen implor take larg suitcas and ship home odd high break what ship home cloth toss new treasur bag folk accommod ask a tabl wall perfect stash forearm crutch spot near bathroom uncertain time seat upfront avoid maze diner front line us avoid travesti dont let disabl stop travel ms medic travel advic a small softsid cooler ice park two watch dont accident freez med work great tote medic store carryon backpack wont count extra carryon copaxon avonex betaseron extavia never store temperatur higher degre fahrenheit rebif never see light day degre fahrenheit take cooler alway good idea travel inject even betaseron extavia dont requir refriger never know medic sit hot car hike on oral druggilenya aubagio tecfidera avoid extrem temp in word dont leav roast glovebox hot car expos camp overnight siberia januari and camp siberia januari i recommend see therapist alway keep medic part carryon luggag that one piec luggag cant afford lose it smart prescript drug well letter doctor state multipl sclerosi i person never stop secur boatload potenti subcutan weapon ive pull asid eyeglass screwdriv immedi confisc appropri scold the xray machin use airport harm medic if need call ahead hotel ask portabl refriger put room mini bar most hotel abl honor request when remov item minibar make room med sure later check bill some minibar abil automat charg bill item remov fridg even put back bring coupl digit thermomet record ambient air temperatur put one hotel fridg keep one cooler transport drug do not store medic fridg unless certain wont freez degre if dont thermomet bottl touch water tablespoon nice put coldest part fridg befor add med wait least hour if freez even warmest set find new fridg instead lug around big sharp contain needl might consid needl clipper storag devic these littl gadget clip needl store needl allow store syring safe look one local pharmaci bd safeclip one brand a word caution medic wast usual cant toss trash youll need find place store empti at least wont get poke bring extra dose case someth stupid pooch one inject drop bill gutter and weather caus delay cancel wont stuck without medic have travel tip youd like share fellow activ mser write happi travel',\n",
       "  'NN'),\n",
       " ('hi simplest explan i think relaps month initi b cell deplet treatment autoantigen b cell includ ebv present b cell t cell induc relaps when b cell die ocrelizumab b cell phagocytos macrophag b cell protein enter serum b cell protein taken macrophag instead b cell present t cell enhanc autoreact t cell relaps within month initi treatment question data happen immunolog immun system first week b cell die',\n",
       "  'VBP'),\n",
       " ('hi honeyb lemtrada first line dmt uk mani newli dxd patient shift particular aggress diseas offer if want halt progress ticket i discov earliest use gabapentin solv bladder pelvic pain i switch pregabalin address need pregabalin pain ad gaba back solv puzzl i sinc read gaba direct target lower part spine manag bladder cannabi avail i press see get i seen sever mention help richard prior sad right that correct word spastic root much pain you lucki case are sure present like expect thank tip i took gilenya four year wait lemtrada it caus mani pain ses lemtrada goal i believ i strong advoc state i petit fda approv i know clinic trial patient advic research investig state made compar drug rebif look like placebo your mri encourag dont wait isnt best wish',\n",
       "  'JJ'),\n",
       " ('doe anyon cancer concern know anyon cancer upon use biolog crohn diagnosi year ago xifaxan pentasa sulfasalazin mayb stelara ileocol resect primari diseas focus ileum perian diseas xifaxan remiss year not remiss veri activ firm believ supplement acupunctur pain mgmt',\n",
       "  'NN'),\n",
       " ('drug stelara may eas crohn diseas medic potenti help didnt find relief treatment research say sourc webmd health',\n",
       "  'NN'),\n",
       " ('i think go onto one treatment stop ms track these treatment given twice wont get wors the one i heard lemtrada cladribin mitoxantron anticd possibl hsctbmt you talk neurologist one treatment pm i give name neurologist give treatment if i i would soon',\n",
       "  'NN'),\n",
       " ('hi jc welcom grace im sorri hear mom diagnosi im glad shes well address effus issu impact daili life it true tarceva cross blood brain barrier effect brain metastas system therapi cross barrier one extent anoth the problem concentr drug reach brain met often suffici effect in fact common egfrposit lung canceer first show progress brain becom sanctuari site cancer cell as result standard treatment multipl brain met whole brain radiat it true wbrt side effect like appear time the problem immedi benefit vs delay deterior qualiti life debat mani discuss issu signific neurolog symptom consequ reduct qualiti life caus progress brain met given suffici consider if decis made forego delay wbrt would good close monitor symptom fair short interv followup scan i hope tarceva effect mom long time jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('this realli interest at level would need recov alemtuzumabcladribinefingolimod reason sensibl option my level never great dmf last month i encourag think switch tricki',\n",
       "  'NN'),\n",
       " ('i exhaust near nonsurg option point just got xeljanz author start week im go high expect given histori nonrespons biolog hope nonetheless yo male dxd ulcer coliti tri fail lialda meslamin imuran azathioprin uceri remicad humira entyvio stelara current prednison xeljanz',\n",
       "  'NN'),\n",
       " ('ive thought lot treatment cost past year even rais question ohiohealth i treat tysabri made biogen when i first went new locat januari cost around per month this new medic provid i follow neurologist decid go differ medic practic construct new build infus clinic move initi i shock anger see cost treatment cost enough k per month old build jump per infus new one mean treatment cost would bill year when i check medic record stori i find medic provid charg per treatment increas januari april part increas drug cost remaind infus clinic overhead when i question explan given fair predict negoti payment insur go pay much would signific reduc amount eventu paid for increas bill clinic provid paid per year real cost treatment base today price still stagger amount consid i continu mental struggl whether amount money worth big pictur consid age factor is fair treatment cost affect health care dollar cost like take sizeabl chunk avail moni how much treatment affect escal cost health insur ms chronic diseas known cure i could conceiv continu treatment remaind life amass treatment cost million dollar fortun entir cost treatment cover privat health care insur along patient assist program tysabri cost i paid noth pocket year i imagin type bill part drive cost health insur i pay lot everyon els just i think i angri frustrat ms treatment cost often anoth remind escal bill usual form notic insur tell much bill actual paid today remind came differ way write dr gavin giavanonni bart ms blog written ms doctor research depart neuroimmunolog blizard institut bart the london school medicin dentistri unit kingdom in particular articl talk nice nation institut health care excel uk one function nice set price healthcar treatment includ drug cost nice decid consid fair price pay drug look option treat patient decid would cost effect govern health care system the blog author also concern afford access drug polici nice affect treatment post observ recent confer anoth groundshift poster oratorio studi result ocrelizumab ppms this studi first studi show dmt slow rate disabl progress ppms this one signific thing happen field ms last year despit i concern nice may view ocrelizumab treatment ppms favour nice alway assess costeffect use increment cost model for ppms costeffect ocrelizumab compar alreadi ie best support care their write think treatment cost i also wonder i could put price might cost provid support care compar money spent drug for i would need much way help money could spent someon els but pictur could chang quick ms progress i treatment i found depend health care servic activ daili live would amount money take care i nurs facil in averag daili cost nurs home care day just think money would save somewher someon decid cost effect tysabri show health care money would better spent put nurs home read question bart ms blog make concern us cost effect model might what need control drug cost us in way insur compani alreadi form often deni treatment author certain drug reimburs the topic cost effect one core point list north american registri care research multipl sclerosi narcrm project major initi us part canada look link patient clinic data togeth health care econom core will identifi inform collect databas regard disabl util health care resourc employ help better understand whether use expens therapi worthwhil econom standpoint save fewer hospit less disabl longer employ span decreas util health care resourc unlik system uk help cost live hous transport medic care peopl need due financi demand live chronic ill dont broad rang assist us my health insur would pay live cost pay drug be financi respons leav littl choic i continu treatment despit escal cost linger question best avoid futur care need i would pay resourc in meantim i hope next bill i open doesnt caus requir treatment choke price well laura',\n",
       "  'NN'),\n",
       " ('ive got two stabl ground glass small lesion one mm anoth faint one xmm right lung read peopl experi web on differ forum often state lesion rare grow larg i thought case grow larg call ai grow larger cm question definit rather relat natur life histori lesion can subcentimet ground glass lesion stabl year grow larg usual stay small chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan this topic modifi month week ago onthemark this topic modifi month week ago onthemark',\n",
       "  'NN'),\n",
       " ('stumbler thank respons the full stori lesion origin earlier mri this along new enhanc lesion brain i got start gilenya after gilenya i either new enhanc one brain spinal cord nor i get relaps but cord lesion one mention show hypointens t imag quit concern doe also warrant chang dmt despit new enhanc lesion im sure one',\n",
       "  'NN'),\n",
       " ('i humira inject treat complex perian fistul crohn diseas it great i came remiss reaccur flare infect infliximab reccomend treatment go there period week treatment time i develop excruci lower leg pain bare walk they burn throb even im walk my head ach i feel wors i stop humira i first infliximab infus yesterday feel like ive run bus can anyon relat',\n",
       "  'JJ'),\n",
       " ('have best bowel movement year start remicad load may first wrist pain juli went away came back big time octob poor sleep worst not even consid give remicad i laugh am suppos take someth day next infus januari',\n",
       "  'NN'),\n",
       " ('but drug realli cost effect they provid modest efficaci also work peopl whi use caldribin much effect drug and induct therapi i think time clear cupboard make room effect therapi horizon such ocrelizumab spinimod ozanimond posinmod ofatumumab etc',\n",
       "  'NN'),\n",
       " ('can i mention dmts rrms think im right say for us ppms steadi progress ms symptom yet seem fampyra vari success hope eventu ocrevus approv uk improv lot i person whch lot time balanc rubbish i fall rather often but i exercis stretch resist i keep mobil strong flexibl fit i whatev type ms poppi question mindsetmind matter obvious i bad day non mser but i dont dwell situat i main get life have good mobil vehicl help i take dog run go visit friend meal go shop etc im retir situat bit differ someon young doesnt mean say im plan give time soon so i hope ive help bitit doesnt doom gloom xx',\n",
       "  'NN'),\n",
       " ('hi antonett fick funni mention gilenya i given choic mavenclad gilenya i told mavenclad higher effici rate hi stumbler thank input websit i realli hope effect your truli amanda',\n",
       "  'NN'),\n",
       " ('i diagnos inflammatori arthriti ra septemb year old first i plaquenil never seem help top i develop terribl hive rash went away i stop take next i tri humira that work great month symptom came back now im remicad almost year it work great i get infus everi week no symptom i love remicad it gave life back i slight concern though ive develop anoth rash wont seem go away month deal tri steroid etc etc cross finger remicad caus rash ill cri',\n",
       "  'NN'),\n",
       " ('an articl author topic appear injama neurolog may avail entireti onlin this abstract quot rebound syndrom patient with multipl sclerosi after cessat fingolimod treatment staci ellen hatcher bs emmanuell waubant md phd bardia nourbakhsh md elizabeth crabtreehartman md jennif s grave md phd mas author affili depart neurolog univers california san francisco import the appropri sequenc agent strong immun system effect becom increas import transit requir care balanc safeti protect relaps the case present herein highlight rebound event ceas fingolimod treatment may happen even short washout period week may perpetu despit steroid treatment immedi use fastact immun therapi rituximab object to describ rebound syndrom patient multipl sclerosi ms cessat fingolimod treatment design set particip clinic demograph data extract electron medic record univers california san francisco multipl sclerosi center januari decemb magnet reson imag review ms neurologist jsg ew bn ech rebound syndrom defin new sever neurolog symptom ceas fingolimod treatment develop multipl new enhanc lesion exceed baselin activ we review pubm databas januari decemb similar case sever diseas reactiv ceas fingolimod treatment use search term fingolimod either rebound reactiv particip includ stop receiv fingolimod januari decemb five patient identifi experienc rebound ceas fingolimod treatment exposur each patient receiv treatment oral fingolimod various durat main outcom measur occurr rebound ceas fingolimod treatment result the mean sd age femal patient present case seri year of patient stop fingolimod treatment within year period experienc sever relaps week ceas fingolimod treatment despit vari prior sever relapsingremit cours particip experienc unexpect sever clinic relaps accompani drastic increas new enhanc lesion seen magnet reson imag evidenc median rang increas new gadoliniumenhanc lesion median rang new t lesion new lesion develop persist month despit treatment corticosteroid n initi bcell deplet therapi n in addit patient identifi literatur review report sever relaps consist rebound syndrom similar featur case conclus relev these case provid evid fingolimod rebound syndrom clinic relev frequenc highlight need determin best method sequenc discontinu ms therapi a larg prospect registri populationbas studi would help confirm rebound phenomenon determin contribut factor includ immun biomark increas risk syndrom the entir articl seen',\n",
       "  'JJ'),\n",
       " ('hi i sick recent i think flu i took care dad day i felt sick i afraid i may pass flu virus he cough lot symptom slight high bodi temperatur f sometim chest congest mucus i call pcp she prescrib tamiflu azithromycin i would like know okay take tamiflu azithromycin prevent while chemo he go chemo tomorrow continu three day kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('predict assess pharmacogenet glutathion stransferas gene efficaci platinumbas chemotherapi nonsmal cell lung cancer patient ye huan et al scientif report predict egfr mutat status lung adenocarcinoma ct imag use deep learn wang shuo et al the european respiratori journal jan httpswwwcancergovnewseventscancercurrentsblogearlystagelungcancerbiomark nci januari detect egfr mutat alkro rearrang nonsmal cell lung cancer use malign pleural effus sampl yao yi et al thorac cancer dec nextgener sequenc circul tumor dna detect gene mutat lung cancer implic precis treatment lai jinhuo et al oncotarget therapi perform analysi sire nextgener sequenc panel diagnost set focus nsclc routin sampl pepe francesco et al journal clinic patholog jan race poverti initi implement precis medicin lung cancer kehl kenneth l et al journal nation cancer institut dec genom biomark checkpoint efficaci highway precis medicin lung cancer ghiringhelli francoi et al oncotarget nov clinic util plasmabas digit nextgener sequenc patient advancestag lung adenocarcinoma insuffici tumor sampl tissu genotyp zugazagoitia j et al annal oncolog offici journal european societi medic oncolog dec detect egfr mutat circul tumor dna ctdna retriev plasma interlaboratori qualiti assess czech republ linda capkov et al klinicka onkologi casopi cesk slovensk onkologick spolecnosti inform various databas cdc inform nih resourc cdcauthor public state public health genom program tier tabl epidemiolog studi translationimplement studi evid synthesi guidelin reviewscommentari toolsmethod ethicalleg social issu amd week clip gwas catalog grant support public genet test gtr genet diseas omim pubm review pubm clinic queri pharmgkb from cdc inform databas this databas includ general cdc public health inform specif diseas health relat topic when avail databas display genom inform various cdc web page user also encourag conduct search cdc websit addit inform lung cancer awar a famili health histori lung cancer risk factor lung cancer what lower lung cancer risk go cdc inform databas from cdcauthor genom public databas this databas contain cdcauthor public public health genom includ infecti diseas newborn screen reproduct health genet test cancer chronic diseas birth defect development disabl environment occup health well laboratori bioinformat statist method util genet test analysi genespecif bill medicar claim data lynch juli a et al genet medicin offici journal american colleg medic genet aug consensus report weinman intern confer mesothelioma carbon michel et al journal thorac oncolog offici public intern associ studi lung cancer aug further confirm germlin glioma risk variant rs tp it implic tumor tissu via integr analysi tcga data wang zhaom et al hum mutat jul the microrna famili target multipl nonsmal cell lung cancer prognost marker h cell beasb cell pacurari maricica et al int j oncol aug compar effect research cancer genom precis medicin current landscap futur prospect simond naoko i et al j natl cancer inst jul util epiderm growth factor receptor egfr test unit state case studi t translat research lynch juli a et al genet med aug multiwal carbon nanotubeinduc gene signatur mous lung potenti predict valu human lung cancer risk prognosi guo nanci l et al j toxicol environ health part a a smokingassoci gene signatur lung cancer diagnosi prognosi wan yingwooi et al int j oncol oct chronic occup exposur arsenic induc carcinogen gene signal network neoplast transform human lung epitheli cell stueckl todd a et al toxicol appl pharmacol jun stakehold assess evid cancer genom test insight three case studi deverka patricia a et al genet medicin offici journal american colleg medic genet jul multiwal carbon nanotubeinduc gene express mous lung associ lung patholog pacurari m et al toxicol appl pharmacol aug go cdcauthor genom public databas from state public health genom program databas this databas focus state nation activ integr genom public health program clinic practic get record from tier tabl databas cdc offic public health genom ophg conduct horizon scan systemat research method find follow novel technolog appear literatur identifi track progress genom test move research clinic public health practic as aid organ horizon scan result ophg rank genom test famili health histori applic level evid see detail get record from huge literatur finder databas this databas contain publish literatur genet associ human genom epidemiolog get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from genom health impact scan databas this databas includ publish scientif literatur evidencebas translat genom discoveri improv health care diseas prevent potenti impact popul health get record from from advanc molecular detect clip databas this databas includ publish scientif literatur popular press articl tool databas emerg role pathogen genom hostpathogen interact infecti diseas control prevent it includ inform method evolut pathogen detect diagnosi outbreak epidemiolog transmiss antimicrobi vaccin hostpathogen interact get record from nation institut health web site approv osimertinib necitumumab increas lung cancer treatment option asbestosrel lung diseas from nhlbi health topic site bring precis screen cancer enhanc riskbas lung cancer screen may prevent more death current approach fda approv alectinib alkposit nonsmal cell lung cancer httpswwwcancergovnewseventscancercurrentsblogearlystagelungcancerbiomark nci januari idiopath pulmonari fibrosi from nhlbi health topic site most case lung cancer due smoke howev risk factor includ famili histori noninvas strategi lung cancer test nih research matter march nonsmal cell lung cancer childhood from ncat genet rare diseas inform center small cell lung cancer childhood from ncat genet rare diseas inform center small cell lung cancer adult from ncat genet rare diseas inform center target photoimmunotherapi approach cancer move forward twodrug combin approv lung cancer braf mutat nci juli use gene express diagnos lung cancer more accur with fda approv gefitinib return us market some patient lung cancer from grantom grantom search engin analysi tool grant inform associ publish literatur evidencebas translat genom discoveri improv health care diseas prevent human genom epidemiologyth literatur inform genom health impact scan databas huge literatur finder databaseth grant inform extract grant data pubm record nih report grant inform search diseasecondit environment risk factor gene studi free text simpl analysi perform get record from gwas catalog the catalog qualiti control manual curat literaturederiv collect publish genomewid associ studi get record from nih the genet test registri the genet test registri gtr provid central locat voluntari submiss genet test inform provid the scope includ test purpos methodolog valid evid test use laboratori contact credenti the overarch goal gtr advanc public health research genet basi health diseas search genet test registri lung cancer from nih omim omim comprehens authorit compendium human gene genet phenotyp freeli avail updat daili search omim lung cancer from pubm clinic queri pubm clinic queri util offer pubm search scientif literatur specif clinic research area search pubm clinic queri lung cancer from pharmgkb the pharmgkb pharmacogenom knowledg resourc encompass clinic inform includ dose guidelin drug label potenti clinic action genedrug associ genotypephenotyp relationship search pharmgkb lung cancer from pubm pubm compris million citat biomed literatur medlin life scienc journal onlin book citat may includ link fulltext content pubm central publish web site pubm link genet review articl lung cancer disclaim articl list public health knowledg base select cdc offic public health genom provid current awar literatur news inclus updat necessarili repres view center diseas control prevent impli endors articl method find cdc dhhs assum respons factual accuraci item present the select omiss content item impli endors posit taken cdc dhhs opinion find conclus express origin author item includ updat person quot therein strict way meant repres opinion view cdc dhhs refer public news sourc noncdc websit provid sole inform purpos impli endors cdc dhhs',\n",
       "  'NN'),\n",
       " ('reviv old thread diagnos moder sever pan coliti been everyth remicad amaz new job insur made cost like per infus been humira sinc seem hold remiss for reason year ago gi chang stanc prescrib pain med ibd mayb realiz true thing help peopl live somewhat normal ive norco twice day like year although ive opioid year for im remiss opioid thing allow oper like normal human cramp urgenc diarrhea bleed fatigu gone take although i agre risk addict even taken direct withdraw stop the part realli suck withdraw symptom similar uc symptom ive feel better taper pain med still feel okay bleed return withdraw symptom im go give anoth week see happen like mani mention risk addict opioid well worth altern mani case especi compar side effect biolog steroid',\n",
       "  'VBP'),\n",
       " ('im mesalamin intoler took doctor year half forc tri fail everi mesalamin drug move imuran the thing final convinc i scope show mild proctiti run bathroom time day throw night my doctor kept insist might ib complic uc i dont know anyon ib goe bathroom time day everi day matter eat so scope improv symptom arent mesalamin may blame also consid someth like imuran mp next stop someth els note folk toler rectal mesalamin oral pan coliti current entyvio imuran mg as need bentyl zofran hydrocortison suppositori klonopin tri asa flagyl cipro canasa prednison medrol uceri entocort fodmap scd elimin intermitt liquid diet mesalamin intoler',\n",
       "  'NN'),\n",
       " ('hi i want know stelara effect read', 'NN'),\n",
       " ('great articl prof g howev there seem big disconnect rest team for instanc md dr karl seem thick ocrelizumab caldeibin better therapi brain atrophi low due therapi start latter alem this littl odd ocr complet suppress observ inflam beat alem hand even start late eventu so agre view complet my point hope convinc other cant bring depart board nevertheless i believ promnient ms author err i think aaron boster also',\n",
       "  'NN'),\n",
       " ('paulin arr recent convers cladribin', 'NN'),\n",
       " ('i brain tumor abl remov aa treat avastin current if i right gene drug might option have find i right mutat',\n",
       "  'NN'),\n",
       " ('hey everyon my checkup good he explain goal exact i right year pass he said right leg sinc last time examin said good so hope next year still wors wear he told matur bcell destroy ocrevus stop progress ms brain he said dont realli know occur occur i get anoth brain mri right i see april see improvementdiffer i receiv full dose he said take long sinc turn administ faster pace we sure glad hear unrel ocrev ask i fall last time ask answer short i strang fall bedroom i knelt stood like someon push befor i knew i fallen backward time catch he said common involv equilibrium inner ear whole balanc orient he want care make sure i alway someth grab hold second brain catch posit doesnt allow fall backward strang diseas ms you think youv sudden someth new occur i told month later i experienc weird sensat bathroom i recogn grab hold sink pull bodi forward it took coupl second brain bodi got sync i avoid anoth fall he told would keep happen without warn prepar unexpect after finish increv tackl issu i pcp he agre provid script lyrica xanax he even gave script diabet med sinc doctor hold hostag forc come appoint he agre us time find anoth famili doctor i see decemb well anyon question fire away hope i answer dar rr so never anxious next day next day anxieti each day enough troubl matthew repli with quot the follow user say thank agat howi jeani z stillstannd sunshin',\n",
       "  'JJ'),\n",
       " ('hello i ms a month ago meet criteria ocrevus trial walk meter independ cane i start research i copaxon stop due allerg reaction and tecfidera start walk independ within month i use cane i found coimbra protocol use high dose vitamin it cure lifelong treatment program done protocol train doctor supervis i start octob had small relaps februari left leg start rag like right year scare with doctor approv i up vitamin dosag iu in three day leg back normal that never happen even steroid i stabl sinc octob no new symptom shown stay my exist symptom worsen i decid ale charg health tri rate i go i afraid i would wheel chair decemb this treatment program it not cure here link fb group inform help they pressur simpli point right direct i could gather inform ask question help make inform decis httpswwwfacebookcomgroupsvitamindprotocolnorthamericarefgrouphead if doesnt link correct call coimbra protocol ms autoimmun diseas north america good luck',\n",
       "  'NN'),\n",
       " ('ms preval women childbear age group when young women receiv diagnosi ms frequent question effect diseas childbearingand vice versa studi undertaken past sever decad allow health profession provid answer question download pregnanc deliveri post partum fact sheet pdf next doctor visit effect ms fertil there evid ms impair fertil lead increas number spontan abort stillbirth congenit malform sever studi larg number women repeat demonstr pregnanc labor deliveri incid fetal complic differ women ms control group without diseas effect pregnanc ms befor women ms counsel avoid pregnanc belief might make ms wors over past year mani studi done hundr women ms almost reach opposit conclus pregnanc reduc number ms relaps especi second third trimest effect postpartum period relaps rate tend rise first three six month postpartum risk relaps postpartum period estim these relaps appear contribut increas longterm disabl in studi longterm followup women ms children increas disabl result pregnanc found pregnanc known associ increas number circul protein factor natur immunosuppress addit level natur corticosteroid higher pregnant nonpregn women these may reason women ms tend well pregnanc use corticosteroid medic women use corticosteroid exampl methylprednisolon prednison acut ms relapsess may continu use pregnanc the use prednison woman breastfeed care monitor special concern pregnant patient ms women gait difficulti may find get wors late pregnanc becom heavier center graviti shift increas use assist devic walk use wheelchair may advis time bladder bowel problem occur pregnant women may aggrav women ms preexist urinari bowel dysfunct ms patient may also subject fatigu in general pregnanc appear affect longterm clinic cours ms women ms wish famili usual success assist neurologist obstetrician addit resourc oh babi momentum articl umbil cord blood donat can cord blood use benefit ms research is worthwhil bank umbil cord blood benefit famili member might need umbil stem cell futur treatment get answer resourc get answer pregnanc registri pregnanc registri ms diseasemodifi medic the manufactur fdaapprov diseasemodifi medic establish pregnanc registri monitor pregnanc outcom women take one drug within week becom pregnant pregnant learn more learn more pregnanc ms kara stori part pregnanc ms kara stori part medic manag pregnanc deliveri postpartum none diseasemodifi medic aubagio avonex betaseron copaxon extavia gilenya glatopa lemtrada novantron ocrevus plegridi rebif tecfidera tysabri zinbryta approv use pregnanc women take medic discuss plan becom pregnant prescrib physician for inform treatment consider women men reproduct year refer ms coalit consensus paper use diseasemodifi therapi multipl sclerosi principl current evid women ms usual need special gynecolog care pregnanc labor deliveri usual women special manag need all form anesthesia consid safe women labor deliveri andseem well toler the diseasemodifi drug recommend breastfeed known excret breast milk a woman also review medic take neurologist obstetrician order identifi safe pregnanc breastfeed studi indic increas risk relaps ms associ breastfeed',\n",
       "  'NN'),\n",
       " ('gypsyros same post twice i hope moder delet post ocrevus mean believ ms want someth suspect work good news pleas keep us updat',\n",
       "  'NN'),\n",
       " ('ed ive wonder status sever time sinc last post great see one honest youv inspir as yo woman ppms recent rd ocrevus infus i understand up down wonder follow treatment after wait year diseas modifi medic come along i overjoy immedi signedup soon becam avail i see improv stamina encourag thank share stori my best wish continu progress good health keep faith karen riley',\n",
       "  'NN'),\n",
       " ('the follow statement one present class action lawsuit mani compound pharmaci avastin use syring intend use diabet inject skin in mani case barrel needl syring lubric silicon oil such lubric may suitabl skin inject eye inject i inject wet blood amd far the first avastin without month long bubbl describ my new ret doc us switch eylea next satisfi avastin result when read possibl side effect drug use avastin lucenti eylea hope none side effect serious type it seem say doctor fault you advers get new one the skill techniqu injector everyth i switch longer pain bloodshot eye go bed rest day pleas googl eye inject silicon lubric inform includ class action lawsuit',\n",
       "  'NN'),\n",
       " ('excus reactiv old thread we cross road progress lung adren gland month afatinibcetuximab well multipl brain met stabl sometim presum credit afatinib the plan move carboplatinalimta tagrisso avail yet howev concern control brain met think may less like hold chemo our oncologist suggest continu afatinib low dose get chemo i think combin well studi warn pancytopenia dr christin chung john hopkin sidney kimmel cancer centr httpjournalslwwcomoncologytimesfulltextwarningaboutchemotherapyafatinibcombinationaspx anoth articl seem report benefit accept risk profil combin afatinib paclitaxel luxlung trial i would appreci input cancergrac feasibl combin afatinib chemo thank nj wife asian dx adenocarcinoma b egfr iressa great respons asymptomat brain met possibl lepto wbr continu iressa local progress primari tumor focal radiat pet scantumor resolut continu iressa pet show flare primari ct stablemri reappear brain met stabl brain met increas suv slight pleural effus afatinib cetuximab',\n",
       "  'JJ'),\n",
       " ('my wife first scan postiniti opdivo round week exact hope hard realli know goodbad sinc oncologist said opdivo often doesnt show effect anoth month howeverth main lung tumor right middl lung grown small bit new nodul oncologist said could new metastas could initi site inflamm opdivo start work cant tell yet there also two new lesion liver the last two blood test shown increas ast alt liver enzym yet blood chemistri includ bilirubin alp quit normal blood physic sign liver malfunct so increas liver enzym could increas sizenumb liver lesionsmetastas could due initi inflamm kidney lesion caus opdivo cant tell yet unfortun cant opdivo liver enzym high still high week next round start wait week see enzym go if switch someth els moment could possibl come back opdivo one dual immun combo futur luckili new lesion anywher els rest lung fine organ look fine noth new bone it still seem surreal wife look feel great especi lower rbcs first round carboalimta we got back week trip israel stamina endur normal lot walkinghik etc her cough come back occasion although much persist origin so waitand meantim start plan daughter wed juli wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl all stabl addl growthoff trial start gemzarlarg tumor reduct',\n",
       "  'NN'),\n",
       " ('woohoo plucki sound excel so glad good week partial colectomi diverticul sept uc pancol dx march apriso g x day canasa uceri foam supplement zinc lglutamin probiot reuteri peral vsl folic acid coq turmer boswellia start entyvio wed constant flare sinc march reliev prednison',\n",
       "  'NN'),\n",
       " ('read lemtrada ocrelizumab thier suppress immun system make feel interest pursu hsct myleo version whi knock immun system build back instead repeat knock i cant constant immun compromis young children which doctor offer i pleas assist get test fill form submit applic and shes will follow along assist way and afterward im keen see dr sadiq work offer way repar therapi',\n",
       "  'NN'),\n",
       " ('this hilari the i bother read articl floor contradictori realli evid th cd t cell critic ms doe ocrelizumab deplet th mayb work realli couldnt wait paragraph contradict',\n",
       "  'NN'),\n",
       " ('hah other way round it start colon year later move onto thyroid was diagnos hashimoto thyroid levothyroxin appear keep well control i sometim get paranoid hormon funki thing anyway canada mark said a year mine realli struck i symptom blood stool minor sporad along mucus month veri lose stool no urgenc though i thought i colon cancer mayb realli bad stomach bug i afraid go doctor fear would say i cancer i time most peopl seem gone previous symptom diseas struck real got diagnosi but mine start blue id day diarrhoea no bleed mucus urgenc abdomin pain either the thing i chronic constip child teenag but i sort constip late teen simpli eat green stuff first time life increas fibr intak had year perfect poop crohn start never anoth normal poop im exagger by way i would never claim mcdonald healthi meal i suspect slight healthier uk us hfcs never big thing europ i never big soda drinker i usual orang juic meal toothrot coke probabl healthier overal dx crohn summer yay tri fail asa azathioprin mp remicad methotrex humira various diet had surgeri feb subtot colectomi end ileostomi first thing put remiss year had second surgeri th juli revers stoma connect ileum rectum offici flare the fun never begin',\n",
       "  'NN'),\n",
       " ('he listen issu address one he profession kind he lot uc patient research support group uc his staff help kind i pregnant remicad do know monitor care avail i need oper room ob doctor i deliv child he awesom he even follow deliveri want meet littl girl i must say great doctor i move meet i need find anoth one none came close yet about anonymousuc all post annonym uc ulcer coliti peopl anonym submit stori doctor review medic supplement review etc i post stori site theyr differ person stori hope account make sens adam founder ihaveuccom',\n",
       "  'NN'),\n",
       " ('thank janin thank bonus vid it took month progress tarceva never got tri afatinib onc hadnt seen good result patient chemo tri nivo i test posit tm put tagrisso my last scan show complet metabol remiss though primari still visibl scan back mind im awar averag time resist tagrisso month im tenth month obvious patient differ choic go forward limit due chemo induc kidney failur last year i wonder correl done i guess thing look time data avail thank get back janin all best jacki',\n",
       "  'NN'),\n",
       " ('time im hampton road va doctor richmond nssg sound aw but that also mind i thought i would need reason consid surgeri it seem somehow prematur like i want life back intellectu ridicul realli tough shake reason do think fatigu stuff improv bodi continu adjust your expect remain my doctor save troubl bring surgeri bring she abl get remicad approv start im today wait deliv said didnt seem work remain option would entyvio take forev isnt optimist clinic trial surgeri whichsh feltsurgeri might best option qualiti life so im keep everyth cross remi work feel terrifi also littl like relief someon that suggest current situat tenabl dx flare sinc rx lialda gx uceri sometim humira fail xeljanz toler deck remicad wtg approv',\n",
       "  'NN'),\n",
       " ('this old thread tiredofcolonbut entyvio work he undergo jpouch procedur male mid diagnos proctosigmoid uc februari current med lialda gm x daili generic rowasa need perian abscess june fistulotomi decemb doc still say uc crohn specif carbohydr diet start june still go strong happi doesnt depend depend sole think dale carnegi',\n",
       "  'NN'),\n",
       " ('hello i diagnos stage iv metastat lung cancer august i radiat treatment brain tumor result tumor bare detect reduc i also treat chemo alimta cisplatin well keytruda after treatment combo i ongo mainten receiv alimta keytruda i side affect except sensitiveweepi eye drippi nose week everi treatment my md say heard i find odd alway week week i receiv next treatment i recent read cbd oil possibl antitumor effect start take week ago i idea may reduc effect keytruda plan speak chemo pharmacist friday i go next treatment there much conflict inform web must care my oncologist say studi recommend no altern treatment advic far i respond well treatment someth right i hope win battl that sure die exercis medit good us',\n",
       "  'NN'),\n",
       " ('a recent studi relaps remit multipl sclerosi patient treat fingolimod natalizumab alemtuzumab found less like convert secondari progress ms spms compar treat interferon beta glatiram acet the studi publish journal jama set determin associ use type time dmts risk convers spms one thousand five hundr fiftyf rrms patient countri took part studi the result reveal patient initi treat glatiram acet interferon beta lower hazard convers spms match untreat patient initi treatment fingolimod gilenya alemtuzumab lemtrada natalizumab tysabri associ lower risk convers initi treatment glatiram acet interferon beta the probabl convers lower glatiram acet interferon beta start within five year diseas onset versus later when glatiram acet interferon beta escal fingolimod alemtuzumab natalizumab within five year versus later hazard ratio current interferon beta glatiram acet first tier treatment rrms fingolimod second tier drug alemtuzumab natalizumab part top tier drug neurologist prescrib patient depend activ patient ms neurologist suggest drug suit some lower tier drug success rate reduc relaps wherea higher tier drug alemtuzumab show reduc relaps versus placebo research conclud find consid along therapi risk may help inform decis diseas modifi therapi select',\n",
       "  'NN'),\n",
       " ('what amaz drop cea number sound like opdivo work splendid', 'JJ'),\n",
       " ('i rd infus opdivo as predict i tire bodi ach what i didnt expect swell my leg hand tight on top hand small pocket fluid form my hand actual sting burn night time extrem i cant sleep im guess neuropathi i see doctor next thursday ani suggest get relief',\n",
       "  'NN'),\n",
       " ('hi everyon this first post ive manag crohn diet low fodmap this work great symptom control colonoscopi still show multipl ulcer doc worri one particular she want start humira cimzia remicad conjunct azathioprin first month im wonder anyon compar experi med im scare tempt go remicad histori excit inoffic infus instead shot thank info j',\n",
       "  'NN'),\n",
       " ('hello coco im sorri i answer question detail sinc im lay person without physician background as far i understood studi tri predict next mutat instead wait result patient trial they abl scientif method complic i comprehend i guess quit reliabl they found new mutat occur tagrisso therapi they state posit allel cis tran impact effect tagrisso like singl agent combin older tkis the newest generat genet test might abl tell far i know yet done routin pleas take grain salt im profession dont realli know im talk sorri limit inform if i find paper i send link thank kempten',\n",
       "  'JJ'),\n",
       " ('diagnosi adenocarcinoma lung major subtyp nonsmal lung cancer nsclc nowaday trigger mandatori test tumor tissu alter four gene egfr alk ros recent braf if present alter predict sensit specif target drug approv us food drug administr fda work better often longer standard chemotherapi better toler howev mani targetableaction genom alter also known driver nsclc this blog post briefli discuss goal promot molecular test four usual suspect mention some patient alter may benefit fdaapprov drug enrol clinic trial test addit drug drug combin molecular alter nsclc fdaapprov treatment option egfr egfr mutat caucasian patient nsclc asian patient egfr mutat frequent nonsmok most mutat egfr either delet portion gene call exon mutat known lr exon two account egfr mutat rare mutat found exon there four fdaapprov drug target egfr mutat erlotinibtarceva geftinibiressa afatinibgilotrif osimertinibtagrisso drug investig clinic trial mutat exon respond better afatinib erlotinib gefitinib alter exon may respond better osimertinib like drug current trial nazartinibegf poziotinib for patient receiv egfrtarget drug almost inevit medic eventu stop work when happen import conduct new mutat test determin mechan resist drug test perform biopsi resist lesion liquid biopsi via blood test sever known molecular alter lead resist i go detail mani address use relev target drug alk the gene alk involv chromosom transloc becom fuse anoth gene eml the frequenc emlalk transloc nsclc much higher nonsmok account mutat found nonsmok crizotinib xalkori fdaapprov firstlin treatment tumor alk rearrang ceritinib alectinib brigatinib use treatment alkposit cancer develop resist prior treatment alk inhibitor lorlatinib may approv soon ros this gene involv transloc nsclc case ros close relat alk crizotinib fdaapprov drug subtyp other alktarget drug alreadi approv alk subtyp ceritinib lorlatinib shown excel activ ros subtyp well entrectinib rdx pf also trial rostransloc nsclc braf this mutat found nsclc case strong associ smoke histori unlik three mutat ve predomin type braf mutat presenc tumor associ high rate respons combin dabrafenib tafinlar trametinib mekinist approv fda june molecular alter nsclc drug avail clinic trial met amplif a high number copi met gene found newli diagnos nsclc case it frequent alter drive resist egfr inhibitor egfrmut cancer drug trial patient amplifi met crizotinib cabozantinib tivantinib glesatinib mgcd inc met exon skip this particular form met alter metex result product potenti overact met protein it encount nsclc case often older patient particular characterist nonsmok of interest differ type lung cancer pulmonari sarcomatoid carcinoma harbor met exon skip case about metex cancer also contain high number copi metex a number drug might work metexposit tumor avail trial enrol includ crizotinib capmatinib tepotinib merestinib her mutat egfrrel gene found case adenocarcinoma lung often asian patient most nonsmok the common her mutat insert exon the drug dacomimitinb neratinib pyrotinib test trial herposit nsclc egfrtarget drug afatinib could also use subtyp ret this gene alter nsclc case tend form pair rearrang one least five gene partner a number drug cabozantinib vandetanib alectinib loxo blu rxdx test tumor clinic trial ntrk the frequenc gene fusionstransloc involv ntrk gene estim anywher nsclc case identifi mutat drug relev treatment subtyp entrectinib rxdx larotrectinib loxo avail trial alreadi shown good activ includ diseas metastas brain there also relev trial investig drug like dsb tsr whi get test nsclc patient may target mutat egfr alk ros alter account this provid strong rational test multipl mutat patient yet mandat nation comprehens cancer network nccn guidelin howev nccn strong advis broader molecular profil goal identifi rare driver mutat effect drug may alreadi avail appropri counsel patient regard avail clinic trial numer provid offer mutat test test cover health insur plan discuss treat oncologist just recent possibl get free mutat test cancer patient announc fifti hospit abl order test strata oncolog test specif nsclc cover mani rare mutat the strata test process includ match patient potenti relev clinic trial rememb broad molecular profil key compon improv care patient nsclc nccn guidelin',\n",
       "  'NN'),\n",
       " ('i offer opinion person experi use tecfidera well gilenya lemtrada rather comment attack advocaci lemtrada defi evid i dont assum ms patient limit cognit skill instead i believ blind accept choic other may recommend treatment base differ prioriti chief among cost my experi best judgement inform advoc research reput sourc ms societi ms trust ms associ america bart london jama neurolog publish clinic trial result among other the lemtrada clinic trial result i referenc show definit most trial particip orlando friend diseas progress halt revers five year clinic trial the result peer review document submit drug manufactur nation regulatori agenc approv ultim given around globe i think pivot time ms research signific progress made breakthrough solut chang ms landscap treatment paradigm today best practic involv earli intervent efficaci dmt instead older practic treat patient increment stronger dmts begin less effect safer dmts theori i believ respons stay inform seek care ms specialist stay current new innov',\n",
       "  'NN'),\n",
       " ('a combin radiotherapi local system immunotherapi may clinic benefici treat type tumor there urgent need howev develop clinic trial explor novel treatment regimen accord articl publish trend cancer novel immunotherapi enter clinic practic acceler rate clinician sure best combin radiotherapi local tumor radiotherapi shown abil enhanc respons immun checkpoint inhibitor similar ipilimumab nivolumab pembrolizumab tolllik receptor agonist imiquimod this includ agent yet approv investig human use sever preclin model cancer includ breast colorect brain melanoma lung prostat said lead studi author sandra demaria md professor radiat oncolog patholog weill cornel medicin new york new york she said earli data show benefit combin radiotherapi immunotherapi patient melanoma nonsmal cell lung cancer nsclc lymphoid malign dr clinic trial ongo cancer type well produc rather encourag result preliminari report respons seen combin radiat antipd tumor type respons antipd alon signific patient ovarian cancer small intestin adenocarcinoma as data suggest use radiat patient immunotherapi appear general safe benefit patient beyond local control tumor treat physician evalu patient abscop respons data need combin treatment recommend standard care dr demaria told cancer therapi advisor to use radiat purpos generat antitumor immun respons need better understand mechan involv dr demaria said mani unansw question whether greater immun respons trigger high lowdos radiat given sever time differ tumor respond differ vari fraction regimen unfortun clinic studi radiat given base physician prefer standard care use palliat may produc desir effect said dr demaria we need work think critic design clinic studi this multidisciplinari topic base novel partnership among immunologistsimmunotherapist radiat oncologist accord dr demaria process uniqu radiat other cancer treatment chemotherapi target therapi use patient receiv immunotherapi clinician still dont know treatment interact relat new drug combin may be benefici newlydiagnos myeloma patient raquibul hannan md phd assist professor radiat oncolog univers texa ut southwestern dalla said synergist approach radiat immunotherapi promis excit this appli particular stereotact ablat radiotherapi sabr stereotact bodi radiat therapi sbrt we call approach strateg combin sabr immunotherapi isabr ongo clinic trial nct nct design answer question cancer site immunotherapi respons strategi dr hannan told cancer therapi advisor multipl new immunotherapi chang standard care melanoma lung head neck bladder renal cancer the benefit howev may limit malign dr hannan said mani site evalu determin even minim respons immunotherapyradiotherapi combin wherev respons possibl radiat therapi boost respons when respons opportun radiat initi respons this due fact radiat initi tumorspecif respons tumor specif lack checkpoint inhibitor immunotherapi said dr hannan it clinic trial identifi site respons isabr strategi in opinion melanoma rcc first certain site strategi prove synergist refer demaria s coleman cn formenti sc radiotherapi chang game immunotherapi cancer cell',\n",
       "  'VBP'),\n",
       " ('two step forward one huge step back sorri length time updat lot happen my husband first treatment privat avastin inject notic improv week afterward this enough get feet start walk last week see famili his depress start lift his bg level right insulin hes half stone healthi bmi we could afford one round treatment privat transfer nhs we first appoint yesterday consult clinic seen dr consult it absolut nightmar start finish despit warn husband anxieti issu fragil mental state dr complet insensit quit aggress approach i realis cannot sugar coat thing tact way discuss prognosi even though husband seen improv first inject dr seem quit dismiss would see much improv my understand guarante even consult cannot predict repond effect treatment this came crush blow husband retreat bed want talk the diagnosi nonprolif retinopathi left eye sever prolif retinopathi right sever maculopathi eye right impair eye worst the treatment plan eylea inject laser right begin i intend speak pal monday see anyway see sympathet clinician next time i honest dont think husband could go struggl get i wish could afford go whole thing privat has anyon els similar experi',\n",
       "  'NN'),\n",
       " ('have two scan get complet diagnosi though effus automat make stage iv know cancer load start tx prefer onc i know doe health issu ad treatment decis age factor id definit get anoth opinion the good news alimta continu work need take care judi stage iiia adeno dx srs chemo carboalimta x ned local recurr surgeri remov lrl cm involv pleura chemo carboalimta x ned',\n",
       "  'VBN'),\n",
       " ('repli post han youv one flare sent er mesalamin mainten still need prevent medicin general either mp imuran first line then move biolog like humira remicad it sound like imuran didnt work two med shouldnt seen overkil i see mayb tri mp next step understand imuran deriv like much differ good luck one way',\n",
       "  'RB'),\n",
       " ('it littl two full year sinc i offici diagnos multipl sclerosi decemb the content entir blog summat struggl accept even understand inform actual meant serv kind proof crazi shit actual realli happen let face these two rather shitti year i got diagnosi i began go downhil it made wonder mere function know somehow made bodi kick disabl mode like ignor friend i enlighten bodi throw diseas parti entir central nervous system invit limb useless fatigu made live zombi i learn first time life real anxieti feel like i chang complet differ person almost night i stop recogn i look mirror i stop go night almost entir it hard all all life i decemb becam fuck hard you guy alreadi know import understand mental affect diseas unleash understand last week felt downright amaz former outgo seeandbeseen beth girl could handl anyth turn homebound neverwanttobeseen beth live mortal fear somehow abl think let alon walk sometim physic thing most time physic thing id ignor entir mental side happen i tri fail look bright side i swung back forth dire despair insan denial cheryl therapist keep reassur believ would get better we then pain start i get back feet great relaps summer i call mind like titl movi i tri get back kind routin life get offic least day week tri function tri tri harder in middl i start feel intens fire bodi id never felt anyth like i think i fair high toler pain someth differ i would feel creep spine around pm i sit desk i would begin feel desper know head i knew i could reli sandi bff also happen work help get car i get hous daili cat chore get bed the mere physic effort took get hous anoth locat render basic useless bodi riddl fire i got fanci new ergonom chair it amaz comfort didnt help newfound pain id drag home drag bunch stair id lay bed tear entir bodi fire base skull bottom feet fingertip i eat mg ibruprofen everi four hour way much it didnt help even littl bit id start think next day like go it becom pretti consist sometim i woke morn pain alreadi full forc i start feel desper if live kind normal life led kind pain i begin panic how could i i pretti well act normal real world im great pretend i toy idea ask the great scott someth i could take pain the minut thought cross mind i shudder no more drug those word echo head i cannot take singl addit prescript medic i mean point diminish return right i take mani med id list youd probabl hard time believ also pain medic scare im definit type person would inclin abus medic like if one pill help i bet two pill help much i know it good idea i start feel pretti dark i think could probabl tell post throughout i tri keep humor i alway remind peopl much wors i that i grate everi minut everi day think true thing didnt realli help much know peopl suffer doesnt make pain go away pain physic menac presenc like fire burn insid skin nobodi see feel like might consum it doesnt help friend id made onlin suggest i consid tri cannabi pain i mean ive read research ton possibl i truli believ merit i alreadi use homemad cannabi edibl help sleep night i never reveal i get suffic say person make liter angel earth then there one small detail i couldnt get around cannabi isnt legal pennsylvania i know process legal medic cannabi that process take lot time id heard bit hard get card need becom patient get suppli limit number dispensari oh also might suspect the great scott ms specialist medic mmj across board shocker but struggl factual legal hurdl there fact proven year life i freak hate weed i hate make feel i hate smell i hate smoke anyth except short spurt menthol ultra light thirti i drink face five night weekthat fun i found weed basic repel it terribl effect it use thing husband i aliv smoke pot everi day life he knew i hate ethic moral reason simpli fact soon took one hit joint instant becam repel i rememb tell you know call shit dope reason gross and would laugh laugh but i digress suffic say marijuana friend i couldnt realli see becom fundament part life i watch much help mser friend meg particular inspir watch joy face chronicl daili walk instagram note new found joy walk someth fear lost forev but anymor meg credit cannabi give life back you read meg blog she know much medic mmj ms i could ever share check but smile meg face make realli happi haunt time i want smile i want smile without smile feel like intern grimac i rememb tell ms friend i wish i could get benefit relief without high id instant um guess you total well stop ill admit im entir comfort write i havent told mani nonm friend it make feel funni even though im someth complet legal nonpsychoact still bother i havent broken news mom member famili ive told closest friend one i trust im sure feel like dirti littl secret ive use cbd reliev pain hard admit write start realli chang best way i start whole explor look relief pain i inde found relief but i got lot let start begin i start cbd oil cw hemp colorado i seen stori guy cbs sunday morn year ago here link excerpt cnn documentari tell stori charlott this kid seizur week the stori heartbreak interest happi end the cbd oil made stanley brother colorado chang charlott life henc name compani honor it worth squirt pricey nasti tast oil tongu time day see could help pain and it did it took come half hour take oil i felt pain get quiet it didnt disappear immedi got better i start everyday product wasnt strong enough i progress quick everyday advanc much better better enough dive research i discov kind pain degre sever ingest cbd oil effect way get cannabidiol blood stream by time oil ingest process digest system liver etc someth like cbd im fudg number bit reduct concentr distinct i find anoth way get cannabidiol system without use oil mechan cannabidiol concentr would higher this led anoth legal product call cbd shatter shatter crumbl a clear solid break littl piec to get cbd blood stream direct i get vape pen use here anoth hurdl i know i short stint smoker thirti suck liter i hate smoke anyth i know im vape technic smoke feel essenti i inhal vapor come heat cbd shatter vape pen it look much like dab weed concentr devoid thc there psychotrop effect i realli skeptic turn get high i super reliev i found anoth form even high concentr cbd form wax here thingi share info anyon want messag email i dont want im obvious doctor expert anyth relat cbd vape but i tell ive felt happi first time month past week i havent thought take pain medic kind month i buy advil liquigel bulk not anymor there even better aftereffect new practic that constant churn head the fear noth ever the constant if fli around head quit liter hour day even find way dream the ever present sometim crippl anxieti futur could holdit quiet it quiet that anxieti voic still i know it probabl never go away complet i mean diseas chronic degen that kind deal especi one unpredict ms liter thing chang daytoday even minutetominut have yoke hang around unstylish neck difficult busi thing make voic quiet elud complet and im therapi expert ask cheryl cbd vape help it help lot i hate it still feel wrong even though i know i hate tast peopl actual love go figur but im three four time day help maintain calm quiet mind to help keep fire bodi bay even help loosen ridicul spastic muscl prevent move around natur way it helpsnear everyth so my dirti littl secret it realli dirti i wish i knew im judgey most mayb cheryl cure day im tri learn accept thing and yes i discuss entir develop the great scott i alreadi steel medic debat sure ensu but here thing im mac daddi ms drug right ocrevus it life chang experi i told would it justmeh if someth els help want open eye everi day mayb leav hous bit embrac damn cane sorri stanley perhap shower littl often im in research i find littl side vape cbd ive experienc exact zero side effect none it might work forev so im go enjoy last im go deal fact i cant realli carri around might legal doesnt look legal i pain free sever hour interv hell that i ill take i feel like littl tree pictur lot time i tri keep thing light airi i dont often feel light airi i make joke brush bad but i feel dark alon much time even surround peopl love near far a littl ray light seep welcom even i suck lung id eat rock right someon told theyd make feel better you bet',\n",
       "  'JJ'),\n",
       " ('septemb roch face fresh row drug price britain follow decis bodi respons medicin use within state health servic approv drug ocrevus treat high disabl form multipl sclerosi in june nation institut health care excel endors ocrevus relapsingremit ms common type diseas reject rarer sever primaryprogress form ms ocrevus avail treatment primaryprogress ms sever drug relapsingremit ms roch uk general manag richard erwin said monday decis devast news patient read reuter articl',\n",
       "  'NN'),\n",
       " ('love hear great respons i begin opdivo septemb th i hope im lucki thank',\n",
       "  'NN'),\n",
       " ('i let neuro respons privat prescript in india peopl affect ms access ms drug howev prescribingoff label neurologist mayb frighten pharma look favour importan like follow prescrib pattern set licenc drug licenc give comfort adher best practis it interest iran manufactur drug licenc make beta interferon appar i heard i i concret proof treat hearsay make dmf fingolimod so patent what peopl go embargo mayb embargo impos creat cultur howev i believ made movectro i say stop manufactur programm licenc so licenc generic cladribin one countri would help other in quest white knight intent obtain licenc peopl comfort folow accept proceedur may give protect su anyth goe wrong howev throughout attempt amaz peopl power help us along path never want mention correspond never saw academ exercis anyway let see happen movectro get lisenc seen tomorrow post compar oral vers nonor rout',\n",
       "  'IN'),\n",
       " ('i recent diagnos ms first ms attack probabl time i mri reveal one lesion i follow mri month later show chang i told noth wrong over year i similar attack main loss sensat leg over past year happen closer togeth seem much wors durat intens i mri februari reveal extens amount lesion my first appoint neurologist at appoint said high like i ms would want aggress treatment appear quit advanc he feel though necessari complet lumbar punctur everyth indic ms point he took lot blood gave intens cours steroid mg prednisolon day ask return i actual left appoint quit upset he confirm ms my jcv result come back could discuss realli didnt cover anyth he didnt mention type ms i assum rrms he mention i activ lesion seem talk what differ doe matter i dont know my current symptom pain nerv pain constant feel like thing crawl i horribl fatigu leg weak ting numb walk realli difficult headach horribl he pretti much said sinc steroid work noth i is realli case he brief sever medic done pretti much said none good arent strong enough i choic gilenya tysabri lemtrada i decid i dont want gilenya option i start ask question option told anoth patient i would come back three week he seem lean tysabri couldnt realli tell he mention one drug ocrelizumab approv yet expect releas come month he seem want put tysabri possibl switch one could tell anyth new drug studi releas yet cant discuss im confus i concern i need aggress treatment will continu push appoint back back i lean lemtrada appear period week decid treatment begin even i choos next appoint that week i actual start treatment doe anyon recommend idea two drug how even decid someth like',\n",
       "  'JJ'),\n",
       " ('hi spider i dont know ocrevus i know fantast happi i havent chang sxs good bad',\n",
       "  'NN'),\n",
       " ('thank brad wow gilenya long time im glad hear havent problem i hope pump help spastic',\n",
       "  'JJ'),\n",
       " ('hi kim im sorri know ariel progress there good evid cancer form lepto cure wait see essenti wait return the problem wait saw symptom show quick cant alway tamp i imagin radiat area would difficult imposs safe nd time there say cant start tagrisso stop side effect toxic his oncologist right worri may miss opportun benefit tagrisso ultim ariel i wish i could give direct answer i hope ariel well all best janin',\n",
       "  'NN'),\n",
       " ('the purpos studi httpswwwmskccorgcancercareclini al assess safeti combin two drug varlilumab nivolumab patient advanc solid tumor continu grow despit treatment varlilumab investig drug bind protein immun cell call cd make immun system stronger nivolumab form immunotherapi it work attach block molecul call pd shut immun respons it hope bind protein drug combin activ immun system enhanc bodi abil detect destroy cancer cell',\n",
       "  'NN'),\n",
       " ('hi veg i sure i latest edit mine publish there short section discuss fingolimod new promis drug much els the convers i nurs threw whole host possibl side effect i realli hope hear peopl first hand experi rachel',\n",
       "  'NN'),\n",
       " ('tonometri a test measur pressur eye call intraocular pressur your doctor use check glaucoma slit lamp examin a physician optometrist shine vertic slit light across eye look microscop it help find mani eye problem fundoscop exam the doctor give special eye drop widen pupil hell call dilat then shine bright light back eye see retina refract if vision problem doctor place seri lens front eye one time figur prescript correct lens visual acuiti test youll read seri eversmal letter across room this help doctor spot distanc vision problem read upclos help find problem near vision fluorescein angiographi the doctor inject fluoresc dye vein take seri retin imag regular adult eye exam this collect test may includ one mention plus other like eye movement eye treatment contact lens glass they correct common eye problem like nearsighted farsighted astigmat lasik laserassist insitu keratomileusi a doctor creat thin flap cornea he use laser reshap this procedur improv nearsighted excess farsighted astigmat radial keratotomi rk the doctor make seri small incis cornea reshap onc common treatment nearsighted rare use today photorefract keratectomi prk the doctor rub surfac cell cornea use laser improv nearsighted farsighted astigmat the cell grow back eye heal way would youd scratch lasek laser epitheli keratomileusi it similar prk the doctor peel back upper layer cornea cell use later reshap he may replac remov flap afterward artifici tear these eye drop lot like natur tear they help treat dri irrit eye cyclosporin eye drop restasi this antiinflammatori eye drop treat dri eye caus inflamm laser photocoagul a doctor use laser part retina poor circul treat abnorm blood vessel direct it often use diabet retinopathi also seal retin tear cataract surgeri the doctor remov cloudi cataract replac natur len manmad version',\n",
       "  'NN'),\n",
       " ('this effect ocrelizumab reduc brain atrophi take cobin effect stop diseas right also bart say mechan term ppms then combin therapi effect make ms benign diseas for type',\n",
       "  'NN'),\n",
       " ('i curious know would consid tamoxifen women ocrevus famili histori breast cancer',\n",
       "  'NN'),\n",
       " ('yes initi keytruda then month scan mix result follow scan show progress im realli find much info keytruda docetaxel onlin mom thought trial at next appoint theyll also take blood send see mutat so finger cross here hope combo show improv best marci',\n",
       "  'NN'),\n",
       " ('i start gilenya week ago dishow morn day i must taken mistak i flare sinc first week still ongo im progress suffer alot pain time anyway i wouldnt know i bad effect doubl dose im kinda worri',\n",
       "  'NN'),\n",
       " ('for helli i realis i answer half question do i think cladribin might cure for peopl mayb in sens cladribin seem stop deterior someth like half peopl see improv well i think cladribin lemtrada lot cheaper drug take rest life and theyr effect do drug compani want close huge market tecifidera tysabri gilenya etc etc probabl i think cladribin better drug lemtrada effect less side effect cladribin may good drug compani want',\n",
       "  'JJ'),\n",
       " ('caddo tumor test mutat it possibl could qualifi target therapi drug instead tradit chemo for nonsmal cell lung cancer i get opdivo immunotherapi it doesnt work everyon kept cancer stabl year when i tradit chemo i carboplatin avastin alimta',\n",
       "  'NN'),\n",
       " ('a drug fail effect strike larger target lung cancer hit bullsey smaller target present previous untreat form diseas research the univers texa md anderson cancer center report natur medicin their research provid scientif underpin clinic trial way drug poziotinib nonsmallcel lung cancer specif alter call exon insert either epiderm growth factor receptor egfr human epiderm growth factor receptor her there effect treatment patient encourag earli clinic trial result show patient percent egfr exon mutat confirm tumor shrinkag poziotinib treatment say john heymach md professor chair thoracichead neck medic oncolog we need see unpreced respons rate maintain remaind trial scientif find provid basi optim so far patient enrol md anderson origin phase ii trial egfr enrol her arm the drug owner spectrum pharmaceut open multicent phase ii trial approv target therapi egfr mutat improv progressionfre surviv pfs qualiti life patient seen respons rate rang percent among patient exon insert median pfs patient two month so far md anderson clinic trial median pfs reach month about percent patient either egfr her diseas exon insert amount peopl diagnos annual unit state heymach also note patient exon insert never smoke deep dive exon heymach team start focus exon part drug repurpos pipelin open md anderson moon shot program collabor effort acceler develop scientif discoveri lifesav advanc the week identifi problem focus upon lung moon shot i three four exon patient noth offer point heymach said it clinic tell us need we decid deep dive exon postdoctor fellow jacqulyn robichaux phd colleagu test differ target therapi lung cancer cell line exon insert egfr her found cell strong resist drug work shux zhang pharmd phd associ professor experiment therapeut team conduct d model known crystal structur egfr her they found exon insert dramat effect protein bind pocket drug connect block activ these smaller misshapen pocket pose barrier target therapi also suggest structur characterist might make drug effect smaller better robichaux say team hypothes smaller egfr inhibitor high level halogen presenc group molecul help bind drug target receptor might greater activ exon diseas this drew poziotinib egfr inhibitor fail common egfr mutat clinic trial the structur poziotinib publish show small high halogen test panel cell robichaux said resist test show poziotinib time potent cell drug they compar specif poziotinib three target therapi exon mutat common target t hit drug exon mutat time sensit poziotinib resist three drug structur analysi show poziotinib size flexibl allow fit deepli exon bind pocket larger drug either didnt fit lack structur deep connect tumor shrink mous model the team test drug mous model exon diseas compar afatinib secondgener target therapi shown abil inhibit diseas cell line egfr mice treat poziotinib percent reduct diseas burden measur mri treat afatinib percent increas level almost equal untreat control her exon mice percent reduct tumor burden compar percent reduct afatinib separ studi in egfr her poziotinib respons durabl week the team test poziotinib mice egfr tumor develop patient poziotinibtr mice tumor burden reduc half treat afatinib reduct in second studi mice anoth patientderiv egfr exon tumor poziotinib reduc tumor percent eight nine mice day possibl applic cancer heymach team contact spectrum pharmaceut find the compani heymach group cooper provid poziotinib patient compassion use basi prepar launch md anderson clinic trial updat clinic trial result report detail later heymach robichaux colleagu studi resist mechan poziotinib develop way overcom resist egfrher exon insert occur cancer lung cancer robichaux said im investig whether type also might sensit poziotinib md anderson develop intellectu properti relat use poziotinib treatment exon insert cancer coauthor heymach robichaux zhang yasir elamin md alissa poteet moniqu nilsson phd huiy sun emili roarti phd memet altan md charl lu md vassiliki papadimitrakopoulou md thoracichead neck medic oncolog zhi tan experiment therapeut brett carter md radiolog shengwu liu phd shuai li md ting chen phd danafarb cancer institut boston adriana estradaberna phd anh le robert doebel md phd univers colorado cancer center aurora co anna truini sarah goldberg md katerina politi phd yale cancer center yale univers school medicin juli brahmer md sidney kimmel comprehens cancer center john hopkin univers baltimor kwokkin wong md phd laura isaac perlmutt cancer center new york univers in addit initi moon shot fund research also support grant nation cancer institut p ca ro ca includ md anderson lung cancer spore grant p ca md anderson cancer center support grant p ca lung cancer research fund rexanna foundat fight lung cancer exon group david bruton jr chair tumor biolog stade fund egfr inhibitor resist mr mrs william p hallman fund fox lung egfr inhibitor fund christin burg endow lung cancer research univers colorado cancer center burg famili miramount care foundat italian associ cancer research cancer prevent research institut texa nation scienc foundat nation institut general medic scienc spectrum pharmaceut support clinic studi',\n",
       "  'NN'),\n",
       " ('i diagnos stage lung cancer juli was put afatinb juli drug resist appear apr did x rt nodul may hope afatinib long posibl unfortun pleural effus start increas sinc end june stop afatinib put chemo carboplatin alimta on sep tagrisso given free charg compassion scheme i chemo quit even though work cea drop sep oct on sep l pleural effus pe drain xray show lung could reexpand origin posit my onc ask tri practic breath exercis home anoth xray today show didnt help the empti space occupi fluid the problem pe caus cough month onc told live rest life he said far awar treatment method reexpand lung consult lung specilist earli oct he opinin trap lung due tumor entangl lung membran he ask patient wait effect tagrisso pentrat by lung reexpand on oct l pleural effus pe drain no sign reexpansin found in fact situat deterior now i need use oxygen concentr home i grate advic problem overcom mani thank advanc',\n",
       "  'NN'),\n",
       " ('pastglori i ask stop gilenya switch tysabri relaps washout', 'NN'),\n",
       " ('im expert i dont think fail tradit therapi get trial i went citi hope ca lobectomi got tarceva trial without chemo first this back',\n",
       "  'NN'),\n",
       " ('while alway good trump card sleev ask card your save joker in end today qualiti life a given treatment either work regardless use pretti much new uc medicin research biolog mani new novel one work therefor i dont worri run option remi work well sinc sudden fail i still humira simponi entyvio xeljanz soon stelara option choos certain consid point view decid whatev think best',\n",
       "  'JJS'),\n",
       " ('stumbler thank alway im mind whether choos tecfidera instead possibl side effect dont seem harsh main two concern fingolimod',\n",
       "  'NN'),\n",
       " ('well long one expect wait diet work month year if isnt show symptom improv isnt work i think month fair that ill give mesalamin remicad show least improv discontinu our vari respons realli make believ uc umbrella diseas simular symptom perhap us intoler specif food inturn aggrav symptom post edit ipoop pm gmt',\n",
       "  'NN'),\n",
       " ('hi adam read messag i like tecfedira also problem left leg foot drop walk get wors have offer ocrevus last day need get final approv i accept i desper tri anyth improv did accept go berti',\n",
       "  'NN'),\n",
       " ('brand name tecentriq whi medicin prescrib atezolizumab inject use treat certain type urotheli cancer cancer line bladder part urinari tract spread cannot remov surgeri peopl unabl receiv platinumcontain chemotherapi carboplatin cisplatin worsen treatment platinumcontain chemotherapi medic it also use treat certain type lung cancer nonsmal cell lung cancer nsclc spread part bodi worsen treatment chemotherapi medic atezolizumab inject class medic call monoclon antibodi it work block action certain protein cancer cell this help person immun system fight cancer cell help slow tumor growth are other use medicin this medic may prescrib use ask doctor pharmacist inform how medicin use atezolizumab inject come liquid inject vein minut doctor nurs hospit medic facil it usual inject everi week the length treatment depend well bodi respond medic side effect experi atezolizumab inject may caus serious reaction infus medic a doctor nurs monitor care receiv medic if experi follow symptom tell doctor immedi flush fever chill shake dizzi feel faint short breath difficulti breath itch rash back neck pain swell face your doctor may need slow infus delay stop treatment treat medic experi certain side effect be sure tell doctor feel treatment atezolizumab your doctor pharmacist give manufactur patient inform sheet medic guid begin treatment atezolizumab inject time receiv medic read inform care ask doctor pharmacist question you also visit food drug administr fda websit web manufactur websit obtain medic guid what special precaut i follow befor take atezolizumab inject tell doctor pharmacist allerg atezolizumab medic ingredi atezolizumab inject ask pharmacist check medic guid list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take your doctor may need chang dose medic monitor care side effect tell doctor treat infect also tell doctor ever organ transplant lung breath problem diseas affect nervous system myasthenia gravi disord nervous system caus muscl weak guillainbarr syndrom weak tingl possibl paralysi due sudden nerv damag autoimmun diseas condit immun system attack healthi part bodi crohn diseas condit immun system attack line digest tract caus pain diarrhea weight loss fever ulcer coliti condit caus swell sore line colon larg intestin rectum lupus condit immun system attack mani tissu organ includ skin joint blood kidney liver diseas tell doctor pregnant plan becom pregnant you becom pregnant treatment month last dose talk doctor birth control method use treatment if becom pregnant take atezolizumab inject call doctor immedi tell doctor breastfeed your doctor may tell breastfe treatment month last dose what special dietari instruct i follow unless doctor tell otherwis continu normal diet what side effect medicin caus atezolizumab inject may caus side effect tell doctor symptom sever go away back neck joint pain rash itch troubl fall asleep stay asleep extrem tired pale skin feel cold swell arm loss appetit nausea vomit diarrhea constip hair loss deepen voic hoars weight gain some side effect serious if experi symptom call doctor immedi get emerg medic treatment diarrhea abdomin pain bloodi black tarri sticki stool ongo pain begin upper left middl stomach may spread back fever nausea vomit constip stomach bloat swell fever sore throat cough chill flulik symptom frequent urgent difficult pain urin sign infect pink red dark brown urin decreas urin swell leg ankl feet warm red swollen tender leg new worsen cough short breath chest pain cough may bloodi short breath chest pain yellow skin eye extrem tired bleed bruis easili nausea vomit abdomin pain dark color urin decreas appetit headach wont go away unusu headach increas thirst urin vision chang decreas sex drive fast heartbeat increas appetit sudden weight loss feel hot mood chang muscl weak numb tingl hand feet arm leg fever confus chang mood behavior sensit light neck stiff blurri doubl vision vision problem eye pain red dizzi feel faint feel hungri thirsti usual increas urin extrem tired weak breath smell fruiti chang mood behavior decreas sex drive irrit confus forget chest pain short breath irregular heartbeat swell ankl abl exercis like use atezolizumab inject may caus side effect call doctor unusu problem take medic if experi serious side effect doctor may send report food drug administr fda medwatch advers event report program onlin web phone what i case overdos in case overdos call poison control helplin inform also avail onlin web if victim collaps seizur troubl breath cant awaken immedi call emerg servic what other inform i know keep appoint doctor laboratori your doctor order certain lab test treatment atezolizumab inject check bodi respons medic it import keep written list prescript nonprescript overthecount medicin take well product vitamin miner dietari supplement you bring list time visit doctor admit hospit it also import inform carri case emerg this report medic inform consid individu patient advic becaus chang natur drug inform pleas consult physician pharmacist specif clinic use the american societi healthsystem pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field the american societi healthsystem pharmacist inc make represent warranti express impli includ limit impli warranti merchant andor fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos the entir monograph drug review thorough understand drug action use side effect the american societi healthsystem pharmacist inc endors recommend use drug the inform substitut medic care ahf patient medic inform copyright the american societi healthsystem pharmacist eastwest highway suit bethesda maryland all right reserv duplic commerci use must author ashp',\n",
       "  'NN'),\n",
       " ('hi i told ocrelizumab avail australia my cours ms sever i ms year affect primarili hand cognat badder drive etc leg ok i still quit mobil activ creep numb especi hand suggest spms rrms my liver toler gilenya well stop year i tysabri month swap stage ocrelizumab period i jv i ocrelizumab possibl affect spms ppms i add i biotin month definit notic posit affect biotin it appear first drug asid biotin effect progress form ms httpwwwmedpagetodaycommeetingcngdr',\n",
       "  'NN'),\n",
       " ('if alemtuzumab deplet b t cell would effect rituximab ocrelizumab ppms it either mean alemtuzumab doesnt deplet b cell someth els go i dont understand ignor discuss',\n",
       "  'NN'),\n",
       " ('good luck trip home it sevenhour ride felt like odyssey diagnos ulcer coliti in remiss lialda prednison no respons entyvio remicad azathioprin opt threestep j pouch surgeri complet step one subtot colectomi ileostomi may complet step two protocolectomi ileal pouch anal anastomosi loop ileostomi januari',\n",
       "  'NN'),\n",
       " ...]"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parts_of_speech"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('previous stabl natalizumab switch fingolimod', 'NN'),\n",
       " ('on fingolimod sinc decemb way i describ better like feel drunk without drink',\n",
       "  'VBP'),\n",
       " ('appar shingl i red spot left breast appear day ago wasnt sure connect show gp immedi said shingl appar cos i left day late prescrib anyth shingl the gp prescrib useless amitryptilin i probabl wont take even low dose make unbear groggi still entir happi cos stomach pain bad ive lot bloat stuff no fever far i know anyon experi shingl seem like i expect week dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('if docetaxel week x week week claim less harsh efficaci everi week diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('cc stelara work matter day if gi will jump hoop get probabl worth consid if one anti tnf stop work anoth pm ulcer coliti next surgeri schedul i problem skin loop i ad setup pm ulcer coliti next surgeri schedul im familiar hollist probabl they go first cut hole stoma go place direct skin it protect leak stay skin pm ulcer coliti humira remicad there cimzia simponi antitnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug am ulcer coliti unexpect scope result jpouch buckey i think how appoint gi go i know issu complex mine i didnt see post anyth am ulcer coliti next surgeri schedul congratul id recommend get convex wafer new ostomi realli help liquid output as probabl know loop ileo time littl pm ulcer coliti after remicad infus id get test remicad antibodi i symptom i serum sick dont ignor mine got wors i start drop thing memori loss bone joint pain if pm ulcer coliti the superdonor phenomenon fecal microbiota transplant here segment cbc radio quirk quark show httpswwwcbccaradioquirksnotallpoopiscreatedequalandsuperpooperscouldbelifesav they test am ulcer coliti just saw gi hes recommend xeljanz im scare when start thread check box includ signatur i see med have thought ad entyvio either prednison entocort is blood test am ulcer coliti just saw gi hes recommend xeljanz im scare have antitnf med like remicad you dont anyth list signatur are use rectal med steroid pm ulcer coliti recent takendown friend ive heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi gas diarrhea also caus sibo it easi test ive taken test previous also home test sibo happen jpoucher certain antibiot pm ulcer coliti still experienc issu cuffiti sl so doctor say pouchiti chronic person id tri med tri knock id accept diagnosi i dont get much gas unless im treat',\n",
       "  'NN'),\n",
       " ('janssen biotech inc receiv fda approv new biolog stelara treatment crohn',\n",
       "  'NN'),\n",
       " ('i i thought thing would better one year ms talk husband last night i live louisiana im teacher i love summer not anymor depress while everyon go lake suntan im freak ghost vampir also i fail first month jcv blood work so treatment neurologist move ocrevus how have transfus made sick way you cant find info except cancer warn i love write ladi keep nicol',\n",
       "  'JJ'),\n",
       " ('dec basha fowler i diagnos rd week dec egfriv nonsmal cell lung cancer it stage iv tumor top lobe left lung metastas pleural line pleural caviti thank god spread organ brain my oncologist devis target therapi tagrisso i start treatment next day i still roller coaster emot utter panic i lost job nov accept offer full reloc dec state compani overshadow new health challeng be sole breadwinn i realli dont know i famili get are lung cancer survivor could share stori would love connect with health life',\n",
       "  'NN'),\n",
       " ('hi i start gilenya week ago woeful anxieti time period it realli embarrass make feel like loser ive anxieti free long i wonder gilenya could causat i stop contracept pill know caus issu kind thank advanc repli',\n",
       "  'NN'),\n",
       " ('my uncl still go treatment kind chemo keytruda it realli kick butt today birthday hour treatment it doesnt seem help he angri stage i cant realli blame cant anyth he energi he lost weight hair head but thank vomit he treatment round the next treatment month mark they plan anoth scan see treatment anyth has anyon experi success combin it stess depress see way he normal activ social great sens humor it hard aunt primari caregiv get brunt anger i wonder next treatment done keep hope pray miracl he qualiti life time it hard watch feel way',\n",
       "  'NN'),\n",
       " ('my daughter stage adenocarcinoma nsclc ros dx decemb standard chemo xalkori gave posit result the dr want tri opdivo even though test negat pdlthis result mass tripl then dr return chemo carboplatin alimta alimta mainten month the dr recommend new combin unusu growth around previous radiat spot lung i sure combin growth identifi is evid next cours treatment given histori result unknown caus smear ct scan',\n",
       "  'JJ'),\n",
       " ('hi nt toxic would probabl main object combin instanc chemo regimen tougher other though isnt clear data show benefit combin treatment individu case may differ stori it certain possibl portion cancer respond one treatment one factor note increas size pleural effus usual consid strong evid progress warrant chang treatment so realli come extent progress lymph node whether signific enough stop tarceva also although major respons chemo seen first two cycl one cycl two week may earli make accur assess efficaci chemo jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('thank jim thank janin the kidney failur actual occur sixth infus alimta i understand quit rare side effect alimta i doubt theyll prescrib i know option i tell would most requir dialysi i read peopl last lot longer month tagrisso though im hope im one better believ i worri i wont thank jacki',\n",
       "  'JJ'),\n",
       " ('hey ipoop i tri click link didnt work but i went websit click link work bit odd page link full document thepowerofpoopcombriggsprotocol dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('bad lifetim nearsighted os led macular degener left eye went inject avastin year th eylea over time warp distort improv great dark grey spot obscur central vision improv gotten wors on half shot i endur sear pain hour later i mean terribl agon writh pain can imagin direct shot ghost pepper spray would feel like wear pirat patch extrem light sensit ice help tini bit short time i gobbl whatev general pain med i find leftov medicin cabinet hydrocon vicodin etc doesnt help much amount risk seem frequenc pain inject worsen my sympathet ophthalmologist believ sensit antisept iodin insist necessari i make point talk everi session rins rins three time normal rins we cannot realli find secret sometim annoy ach hour sometim excruci ordeal hour look opinion fellow suffer has anyon els doctor figur is agoni go save eye am i endur suffer postpon lose eye year',\n",
       "  'IN'),\n",
       " ('janin have ever heard kras mutat mutat someth anoth kras mutat i friend alk facebook group think peopl group origin kras driver becom egfr alk posit could mistaken thank cathi dx stage iv adeno dec kras gd pdl tumor sampl st line carboplatinalimta alimta mainten work well nd line keytruda didnt work rd line imrt lung radiat gy current watch wait',\n",
       "  'NN'),\n",
       " ('the import metric brain volum loss what brain integr the follow studi found fingolimod affect widespread diffus microgli activ nawm gm are microglia nawm gm go stay activ forev previous damag lesion site constant neda may lead deactiv whi dont use microgli activ nawm gm measur ms activ',\n",
       "  'NN'),\n",
       " ('hello guy i hope well i didnt know post topic excus wrong place i got bad relaps week ago hospit numb arm leg exact they ran examin mri other told i risk develop epilepsi this came blue i never heard thing realt ms never life epilept symptom anyth alik i gilenya found new leisur well they prescrib anoth drug prevent epilepsi make sleepi dizzi night have similar problem i confus right i trust doctor cours mayb i look comfort wish best',\n",
       "  'NN'),\n",
       " ('hi i first scan take tagrisso week the scan show mix result slight progress primari tumor nodul slight increas fluid build but nodul also shrunk my doctor suggest continu tagrisso anoth month sinc old scan use comparison done i still tarceva three week i start tagrisso i told best option next treatment would chemo carbo pemetrex avastin i consid option sinc i read studi avastin proven treat brain metastasi i specif mutat chemo would work effect so far i test posit m i read studi depend test result detect cs cancer cell would resist third line tkis sensit first third line tkis httpclincancerresaacrjournalsorgcontentlong anyon inform detect cs combin tkis i would appreci thought thank sunday',\n",
       "  'NN'),\n",
       " ('nice turn daclizumab mser nhs newsspeak politicalspeak msblog nice publish apprais consult document daclizumab recommend nhs within market authoris treat relaps form multipl sclerosi adult this depress news interest mser england i would expect daclizumab wide prescrib definit unmet need use welldefin cohort patient as i said mani time daclizumab overt immunosuppress therefor ideal switch drug patient high risk pml natalizumab there also signific number patient highlyact diseas fail platform therapi fingolimod contraind would benefit daclizumab these patient littl option treat alemtuzumab what alemtuzumab failur if nhs england dont allow us give third fourth cours alemtuzumab relat larg popul patient i even argu past patient high activ diseas rapid evolv sever ms jcvposit may choos daclizumab alemtuzumab firstlin daclizumab attribut make appeal patient alemtuzumab ie selfadminist immunosuppress what i sincer hope biogen abbvi appeal decis wider ms communiti let nice know disagre assess at end day choic make implement personalis medicin ms realiti not abl prescrib one licens ms therapi simpli disadvantag peopl ms live england the cynic howev think nice simpli ask big discount price daclizumab nhs relat list price this game catandmous well tri test one reason nhs get highcost drug cheaper develop countri countri put place version nice coi multipl',\n",
       "  'IN'),\n",
       " ('you overthink just ask see accept first if say yes discuss youd like go would suit if want talk crohn listen i wouldnt mention honest ditto unsympathet ex dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('thank clo i dunno much longer i go like ive excruci pain hour codein didnt touch upper left pain hard describ stab gnaw id say like someth chew away insid skin area ultra tendersensit i got book anoth onlin appoint gp today one time it ive neck anoth load paracetamol codein time ibuprofen drink cup tea think pain slowli get better ever sinc utter nonsens start alway much wors night pretti easi bear daytim im past point depress im hollow tired drug eyebal although i dont feel particular sedat debilit pain i havent tri ici wrap yet gonna get pharmaci later buy whatev stuff i pain sparkleplenti if wasnt late antivir day ago im almost certain late will ask gp anyway also next entyvio infus th april month away judg last night im gonna readi month',\n",
       "  'JJ'),\n",
       " ('neurolog jul ee abstract read full text paper diseas modifi drug boyko an boyko ov cladribin tablet potenti role key exampl select immun reconstitut therapi multipl sclerosi degen neurol neuromuscul dis may abstract read full text paper sedal l winkel a la j et al current concept multipl sclerosi therapi degen neurol neuromuscul dis sep abstract read full text paper hendin b naismith rt wray se et al treatment satisfact signific improv patient multipl sclerosi switch interferon beta therapi peginterferon betaa everi week patient prefer adher jul abstract read full text paper sacc f lanzillo r signori a et al determin therapi switch multipl sclerosi treatmentnav patient a reallif studi mult scler jul epub ahead print abstract metz c winkelmann a loebermann m et al immunogen predictor respons singl dose trival season influenza vaccin multipl sclerosi patient receiv diseasemodifi therapi cns neurosci ther jul epub ahead print abstract houtchen mk bove r a case genderbas approach multipl sclerosi therapeut front neuroendocrinol jul pii s epub ahead print abstract setayeshgar s kingwel e zhu f et al use new oral diseasemodifi therapi multipl sclerosi british columbia canada first fiveyear mult scler relat disord jul epub ahead print abstract cascion m tenenbaum n wendt j et al treatment retent fingolimod compar inject multipl sclerosi therapi africanamerican patient a subgroup analysi random phase studi mult scler relat disord jul epub ahead print abstract read full text paper zhang y salter a cutter g et al clinic trial multipl sclerosi mileston ther adv neurol disord jul abstract read full text paper romeo mal martinelli v dalla costa g et al assess role innov therapeut paradigm multipl sclerosi treatment respons acta neurol scand jul epub ahead print abstract mirabella m prosperini l lucchini m et al safeti efficaci dimethyl fumar multipl sclerosi italian multicent realworld studi cns drug jul epub ahead print abstract naegelin y rasenack m andelova m et al shorten washout week switch natalizumab fingolimod risk diseas reactiv multipl sclerosi mult scler relat disord jul epub ahead print abstract read full text paper lucchetta rc tonin fs borba hhl et al diseasemodifi therapi relapsingremit multipl sclerosi network metaanalysi cns drug jul epub ahead print abstract alnajashi ha alshamrani fj freedman ms toler discontinu rate teriflunomidetr patient a realworld clinic experi neurosci riyadh jul abstract reen gk silber e langdon dw best method communic clinic trial data improv understand treatment patient multipl sclerosi valu health jul abstract rasmussen pv magyari m moberg jy et al patient awar famili plan repres major knowledg gap multipl sclerosi mult scler relat disord jun epub ahead print abstract read full text paper schreiber k kant m pfleger c et al high treatment adher satisfact motiv healthrel qualiti life fingolimod patient relapsingremit multipl sclerosi result month multicent openlabel danish studi patient prefer adher jun abstract read full text paper oshima y tanimoto t yuji k et al drugassoci progress multifoc leukoencephalopathi multipl sclerosi patient mult scler jul epub ahead print abstract yamout bi sahraian ma ayoubi ne et al efficaci safeti natalizumab extend interv dose mult scler relat disord jul epub ahead print abstract robertson d aungst a collier r et al patient perceiv chang sexual dysfunct initi natalizumab multipl sclerosi mult scler j exp transl clin jun abstract read full text paper zecca c bellavia g brambilla l et al atyp postinject reaction delay onset follow glatiram acet mg need titrat cns drug jul abstract drug develop cohen ja comi g arnold dl et al efficaci safeti ozanimod multipl sclerosi doseblind extens random phase ii studi mult scler jul epub ahead print abstract read full text paper gold j marta m meier uc et al a phase ii baselin versus treatment studi determin efficaci raltegravir isentress prevent progress relaps remit multipl sclerosi determin gadoliniumenhanc mri the inspir studi mult scler relat disord jun epub ahead print abstract de ang f planton d chataway j pharmacotherapi secondari progress multipl sclerosi overview cns drug jun abstract uitdehaag bmj disabl outcom measur phase iii clinic trial multipl sclerosi cns drug jun epub ahead print abstract read full text paper econom murley c yang f gyllensten h et al dispos incom trajectori workingag individu diagnos multipl sclerosi acta neurol scand jul epub ahead print abstract famili landfeldt e castelobranco a svedbom a et al the longterm impact multipl sclerosi risk divorc mult scler relat disord jul epub ahead print',\n",
       "  'NN'),\n",
       " ('i thought anoth reason peopl pick hsct cladribin there lot descript person experi hsct gazillion facebook exampl there equival fund stori cladribin mayb that peopl favour hsct what think humbug',\n",
       "  'NN'),\n",
       " ('repli plan i offici ocrevus view post by penkalet sorri dave i forgot rituxan sorri dave i forgot rituxan fyi i saw doc yesterday ask patient feel better year o say realli but patient',\n",
       "  'NN'),\n",
       " ('research evalu macular pigment distribut pattern prognost marker diseas progress individu macular telangiectasia type part retrospect cohort studi they analyz eye individu singlecent studi measur pigment optic densiti dual wavelength fundus autofluoresc independ grader blind assign eye mpod distribut class increas loss macular pigment they defin bestcorrect visual acuiti read acuiti total scotoma size funduscontrol perimetri microperimetri break ellipsoid zone optic coher tomographi en face measur function morpholog outcom paramet evalu eye baselin month after mean review period month sd month research found chang mpod class compar baselin morpholog function deficit limit area mpod loss at followup record signific decreas mean va read acuiti well signific increas mean scotoma size ez break eye assign mpod class paramet remain stabl class eye research wrote result indic mpod distribut might serv prognost marker diseas progress function impair individu mactel sourc mller s issa pc heeren tfc et al macular pigment distribut prognost marker diseas progress macular telangiectasia type am j ophthalmol jul epub ahead print widefield oct map detect earli glaucomat structur progress investig evalu potenti use serial analysi combin widefield optic coher tomographi map detect structur progress individu earli glaucoma part retrospect observ studi they analyz individu earli primari openangl glaucoma minimum threeyear followup involv serial spectraldomain oct measur subject divid nonprogressor n progressor group n base serial stereo disc photographi redfre photographi investig generat serial combin widefield oct map integr parapapillari retin nerv fiber layer macular ganglion cellinn plexiform layer map serial spectraldomain oct softwar glaucoma specialist assess structur progress detect abil serial widefield oct map earli glaucomat eye compar sensit rnfl gcipl guid progress analys gpas main outcom measur includ diagnost abil serial widefield oct map earli glaucomat structur progress ninetyfour individu mean sd age year percent women includ serial widefield oct map analysi show good agreement detect structur progress two glaucoma grader widefield oct thick map widefield oct deviat map map show earli glaucomat structur progress detect abil compar rnfl gcipl gpas sensit widefield oct thick map percent widefield oct deviat map percent rnfl gpas percent gcipl gpas percent p specif widefield oct thick map percent widefield oct deviat map percent rnfl gpas percent gcipl gpas percent p investig determin serial combin widefield oct map integr rnfl gcipl map perform well detect structur progress earli glaucomat eye they ad confirm independ prospect studi might provid greater confid conclus sourc lee wj kim tj kim yk et al serial combin widefield optic coher tomographi map detect earli glaucomat structur progress jama ophthalmol jul epub ahead print visual outcom intraop complic postvitrectomi cataract surgeri scientist analyz visual outcom rate intraop complic phacoemulsif surgeri prior par plana vitrectomi part retrospect multicent databas studi they includ eye underw phacoemulsif june march eight site unit kingdom studi eye classifi vitrectom prior ppv group nonvitrectom depend vitreous state time cataract surgeri they exclud eye multipl intraocular surgeri histori ocular diseas known caus cataract progress increas risk intraop complic phacoemulsif main outcom measur includ logmar visual acuiti rate intraop complic time interv cataract surgeri eye prior ppv group n compar nonvitrectom group wors preoper logmar va vs p younger longer axial length nonvitrectom group n poorer mean vision vs four week p postop time point measur week smaller proport eye achiev postop va logmar snellen percent vs percent four week p the rate posterior capsular ruptur differ prior ppv percent nonvitrectom percent group incid zonular dialysi percent vs percent drop nuclear fragment percent vs percent higher prior ppv group p the mean time interv ppv cataract surgeri day scientist found signific va improv postvitrectomi cataract surgeri eye exhibit wors mean postop vision logmar unit higher rate zonular dialysi drop nuclear fragment similar rate posterior capsul ruptur compar eye without prior ppv sourc soliman mk hardin js jaw f et al a databas studi visual outcom intraop complic postvitrectomi cataract surgeri ophthalmolog juli epub ahead print antivegf therapi dme realworld outcom research assess realworld visual acuiti outcom antivascular endotheli growth factor therapi diabet macular edema they perform retrospect analysi vestrum health retina databas aggreg longitudin electron medic record geograph demograph divers sampl case us retina specialist particip includ dme eye underw month antivegf inject within four month first inject januari march followup data prior march the eye divid three group base initi intravitr antivegf agent aflibercept bevacizumab ranibizumab these eye subdivid three cohort length followup six month cohort mutual exclus research assess va outcom number treatment cohort stratifi result baselin va a total dme eye includ in month cohort eye initi treat aflibercept mean month improv letter ci letter p inject averag similar outcom bevacizumab eye letter ci letter p averag inject ranibizumab eye letter ci letter p averag inject the mean number corticosteroid macular panretin laser treatment session similar group in month cohort stratifi baselin va aflibercept group final mean letter gain lost wors better bevacizumab group final mean letter gain lost wors better letter ranibizumab group final mean letter gain lost wors better research conclud realworld va outcom follow antivegf therapi dme meaning inferior note random control trial they ad eye better baselin va gain fewer letter compar wors baselin va initi choic antivegf agent didnt correl visual outcom sourc ciulla ta bracha p pollack j et al realworld outcom antivascular endotheli growth factor therapi diabet macular edema unit state ophthalmolog retina juli epub ahead print will eye sponsor feasibl studi implant devic rp will eye hospit receiv us fda approv begin earli feasibl studi implant retina implant alpha am subretin devic individu blind due retin pigmentosa manufactur retina implant ag reutlingen germani devic design replac nonfunct absent photoreceptor cell lost rp deterior a surgic implant alpha am chip stimul remain compon visual system restor limit function vision blind rp individu compani say the ri alpha am investig devic unit state receiv ce mark approv europ read glauko enter into d western therapeut institut agreement glauko corp enter research develop collabor agreement d western therapeut institut japanes biotechnolog compani under agreement glauko dwti conduct joint research develop novel intraocular product treat glaucoma use compound dwtis proprietari rock inhibitor compound librari one dwtis fundament technolog potenti design synthes new compound read essilor launch wavefront aberromet essilor instrument launch wam wavefront aberromet anterior chamber analysi visual need assess base shackhartmann wavefront technolog essilor say devic design fast effect spacesav fulli automat wavefront aberromet built eas navig larg touch screen wam provid seven detail measur second eye the compani say devic help simplifi screen condit cataract glaucoma keratoconus learn review ophthalmolog onlin publish review group divis jobson medic inform llc jmi campus boulevard newtown squar pa to subscrib jmi newslett manag subscript click to chang email address repli email write chang address subject line make sure provid us old new address to ensur deliveri pleas sure add address book safe sender list click want receiv futur email review ophthalmolog onlin advertis for inform advertis email newslett creativ advertis opportun review ophthalmolog pleas contact sale manag jame henn michel barrett news to submit news contact editor send email fax news',\n",
       "  'VBZ'),\n",
       " ('hi beachgirl i gain weight gilenya remain constant loss gain', 'NN'),\n",
       " ('hi ive gilenya near three year i annual scan mayb depend hospit kim', 'NN'),\n",
       " ('comprehens discuss side effect across current singl combo immuno drug i start separ dolm se thread sinc opdivo a littl someth everyon stat chart graph oh httpstcowanikuugh',\n",
       "  'NN'),\n",
       " ('the drug caus apoptosi slow kill rather burst ocrelizumab alemtuzumab explain low administr reaction ray',\n",
       "  'NN'),\n",
       " ('a macular hole small break macula part eye respons detail central vision note macular hole differ macular degener although symptom similar how eye work light pass cornea front eye focus len onto retina the retina delic tissu line insid eye the retina convert light electr signal travel along optic nerv brain the brain interpret signal see world around light object look direct focus onto tini area retina call macula back eye the macula mm across respons detail central vision colour vision it provid vision need read recognis face drive car see colour clear activ requir detail fine vision the rest retina give side vision peripher vision about macular hole no one know exact macular hole develop peopl other the jelli vitreous fill space insid eyebal chang get older it becom wateri move away back eye toward centr when happen space left behind fill fluid produc eye the chang vitreous usual caus problem vision although may increas floater flash vision floater usual appear small darkish fleck like strand cotton littl spider web move littl around field vision ani signific increas new floater flash examin eye care profession ophthalmologist optometrist in peopl vitreous jelli firm attach retina macula as vitreous shrink pull macula caus small tear this start macular hole fluid seep hole caus sight becom blur distort over time hole get bigger caus vision problem if optometrist find suspect macular hole ask referr ophthalmologist ideal retin surgeon soon possibl macular hole usual affect one eye though per cent chanc eye also get hole stage symptom macular hole peopl macular hole probabl chang central part vision these chang rang straight line look wavi earli stage small blank patch centr vision late stage peopl may first notic troubl read small print distort look print page there number differ stage macular hole these stage usual class size hole layer eye affect this import know earli stage possibl macular hole may heal without treatment this mean sometim ophthalmologist simpli want regular monitor small hole decid offer treatment howev case macular hole get bigger distort vision treatment need treatment attempt stop hole develop stage central vision lost prevent macular hole there noth done prevent macular hole diet exercis thought contribut problem there evid take kind medicin vitamin help fix macular hole in case best treatment surgeri have eye test least everi two year best way help ensur eye issu detect earli treatment macular hole most macular hole requir surgeri the eye surgeon normal want oper macular hole within six month found the longer hole left larger normal becom harder success close hole in case surgeri stop vision problem get wors most peopl notic improv vision case gain suffici vision allow drive read it rare howev perfect vision restor there two main stage treatment surgeri remov vitreous insert gas eye a recoveri period gas push retina back place hole close surgeri macular hole macular hole surgeri call vitrectomi general perform local anaesthet the eye surgeon remov vitreous jelli eye leav space gas insert the surgeon also normal peel away fine membran across back eye a gas insert eye help edg macular hole close togeth after period usual week gas gradual absorb bodi replac natur fluid made eye recoveri surgeri over hole close surgeri while gas place normal vision poor when gas absorb fluid taken place sight improv in mani peopl may take sever month improv occur howev other oper main effect stop sight becom wors patient previous cataract surgeri may start notic gradual blur vision sever month due begin cataract format the symptom macular hole it uncommon macular hole eye even rare case hole doesnt close peopl good vision eye postur until recent peopl macular hole surgeri requir spend signific period oper head face downward this known postur howev becom increas common postur unnecessari there may situat still need the surgeon explain whether postur requir long if surgeon decid need postur need plan thing oper probabl need help afterward stay face sever day difficult may made difficult problem arthriti it import discuss surgeon medic problem may affect abil postur in case may possibl get short term help social servic tip postur usual minut everi hour need spent face although surgeon may recommend otherwis time postur usual allow thing eat use bathroom appli postsurgeri eye drop it necessari lie complet flat mani peopl postur whilst sit chair tri differ postur posit help avoid stiff boredom for exampl sit tabl lean forward onto tabl sit armchair lean onto small stool lie bed prop pillow either side stop roll onto back prepar postur prepar go hospit import expect start postur soon return home befor go hospit consid thing housework ensur home clear trip hazard shop food prepar eg prepar frozen meal arrang deliveri meal social servic talk surgeon rent postur tabl head rest cut face you also contact foundat inform obtain it may take week deliv sure leav enough time make sure postur furnitur aid right place live alon arrang someon stay consid need postur exampl keep thing may need frequent close eg tissu drink book phone help drink consid use straw entertain watch tv may possibl radio music close if use laptop comput tablet ipad still abl use face complic macular hole surgeri there two main complic associ oper cataract a cataract cloud len insid eye if havent previous cataract remov eye macular hole almost certain cataract form month year macular hole surgeri the cataract usual remov normal way start affect vision mani peopl eventu develop cataract even dont macular hole macular hole surgeri may make cataract form somewhat earlier if alreadi cataract form mani surgeon perform macular hole surgeri cataract surgeri time retin detach when eye surgeon remov vitreous jelli peel membran retina small chanc retina may detach back eye if happen usual step taken reattach retina soon possibl sometim surgeri you talk surgeon possibl complic manag vision loss macular hole surgeri normal help maintain good vision rare second oper may need help close hole if unsuccess central vision general lost happen untreat macular hole peripher side vision remain normal if sight eye still good peopl adjust quit quick maintain normal activ if vision eye poor extra help may need when manag vision loss key prioriti maintain qualiti life independ contact low vision organis help work assess individu need determin aid technolog help there mani excel solut help live well low vision review macular hole fact sheet order face sheet macular diseas foundat australia develop comprehens rang public macular degener diabet eye diseas macular diseas you order resourc subscrib foundat newslett find free educ session come contact macular diseas foundat australia discuss low vision need receiv free inform low vision telephon helplin mactel curious poor understood disord blood vessel suppli central part retina see contentmaculartelangiectasiasthashimfbqordpuf mactel curious poor understood disord blood vessel suppli central part retina see contentmaculartelangiectasiasthashimfbqordpuf',\n",
       "  'NN'),\n",
       " ('oh i feel like someth what tri cladribin one therapi use other exhaust unfortun alway side effect i could toler and doc great respons peopl put cladribin i betaseron avonex copaxon tysabri gilenya plegridi name and i year most side effect i would alway stop are better med i research lot sometim think better practic self heal diet moder exercis medit thing like and sometim prednison lol ive readin lot heal gut gluten i feel like med treat symptom root caus ms i tri figur year ive boutsflar up sever alway heal though overload diet nutrit rid complet stress which im concern take cladribin it first time i abl feel better hope med still work i becom concern know i put someth bodi that toxic mess immun system bit hope reduc overact part immun system that caus flare up but i physic better gerrrrr sorri long vent it nice talk someon get im new shiftm still tri get use thank lend ear',\n",
       "  'IN'),\n",
       " ('fingolimod ineffect ppms phase trial data may improv futur studi stephani sutherland even failur studi inform fingolimod diseasemodifi treatment relapsingremit multipl sclerosi',\n",
       "  'NNS'),\n",
       " ('wow i tire fatigu whatev want call i want even move on top vision realli suck make feel realli dizzi usual i mean either way i tri push actual get stuff done like minor chore final get work done blog it might look like much first i final merg old blog one all post old blog part websit tri visit old url mattsmscom redirect mayb sound like minor chang updat technic crap pain took forev get done noth work so i slowli time organ menu updat articl write new one if ever want read older articl way back i first diagnos ms found toward bottom right blog navig blog archiv like i alway written blog as far fatigu i dont feel like anyth caus random wave sucki know but cours cant fatigu doesnt suck enough i also felt realli antsyrestless a horribl combin feel like die thirst go bathroom realli bad so part bodi want move i lie i cant shut i feel compel get back this result liter sit desk stare floor hour wish i could sleep even though i tire even flip tv i cant turn brain so instead i sit i count hour till i go sleep night at night i take tylenol pm melatonin i admit i sleep realli well i get much go bathroom everi hour dream vivid unfortun i wake morn right back extrem fatigu like i got hour sleep coffe noth ritalin noth nuvigil make feel antsi and yes i tri provigil anyth day my doctor doesnt prescrib adderal i sort lost it horribl stuck problem seem solut although much fatigu suck hard compar vision the dizzi caus make everyth feel imposs even type right i keep hit wrong key hit backspac it take time long write although partial i think fine motor skill get wors but fatigu kill everi ounc motiv i might abl work motiv anyth and cherri top back kill it seem i strain muscl lower back everi time i arch bend back kill i feel like i alway keep straight pain take sometim like today pain radiat knee awesom i ibuprofen effect kill pain scissor mow entir lawn technic grass shorter i still need finish job right tool my second hope final round lemtrada sometim septemb suppos it schedul end septemb neurologist move new locat i transfer new center make sure i system insur good i schedul i hate schedul i want i know worst behind knock wood we talk ocrelizumab approv end year hope doesnt knock ass like lemtrada i realli look peopl react finger cross i know better better as get closer lemtrada infus i anoth video hope make habit might easier sinc type get harder time tell all i know stare comput screen make horribl dizzi somewhat cross eye feel this sort destroy option i though i actual career someday lemtrada work hospit might great idea immun compromis ugh had hard time fall asleep last night i stress day could i career i start feel better ugh i hate know',\n",
       "  'VBP'),\n",
       " ('nutshel i sorri unsur it tough choic first pill get easier howev feel still might want consid tecfidera instead gilenya you realli shouldnt stop gilenya start realli need convinc tecfidera hand stop feel work well even though feel great still lot go cant see howev like never know i realli dont know wife someth stronger tecfidera good mayb shouldnt anyth there way know sure in famili go date decid someth tri look back in coupl week ectrim find year mayb give unless amaz new research pr problem go gilenya',\n",
       "  'JJ'),\n",
       " ('how bad mine get chronic degre flare yearsmayb the worst go time day vomit time a nurs pick bathroom floor the pain bad i cri scream famili i want die what save usual ivig within hour i went time week later i go time day last year i develop fistula diseas chang uc cd humiraivig stelara help bowel up monday i go normal time day all form now im regress possibl due new food i excit tri or ivig destroy stelara connorar togta post edit u b tough am gmt',\n",
       "  'NN'),\n",
       " ('aug mcnv diabet retinopathi patient dme dupix dupilumab inject atop dermat adult eylea aflibercept inject receiv fda approv macular oct baselin measur earli treatment diabet retinopathi studi etdr chart primari endpoint studi compar regeneron pharmaceut inc nov phase eylea panorama studi treatment diabet retinopathi fulli enrol us regulatori submiss expect regeneron submit biolog licens applic fda vegf visual acuiti measur score base total number letter read correct earli treatment diabet retinopathi studi etdr eye chart pipelin a power research develop engin famili hypercholesterolemia hofh aflibercept vegftrap aflibercept vegftrap nonprolif diabet retinopathi npdr without dme sec file regeneron pharmaceut inc phase eylea panorama studi treatment diabet retinopathi fulli enrol us regulatori submiss expect aflibercept inject treatment diabet macular edema feb patient diabet macular edema said georg d yancopoulo md ph dme common complic diabet retinopathi dr sec file regeneron pharmaceut inc diabet grow diseas worldwid dme major caus vision loss peopl diabet retinopathi we hope abl offer new antipdgfrbeta sep efficaci evalu use earli treatment diabet retinopathi scale etdr bcva patient random one three unit state secur exchang commiss form k jan nasal polyp eylea diabet retinopathi without diabet macular edema fasinumab ngf pain regn rsv respiratori syncyti',\n",
       "  'NN'),\n",
       " ('i new forum i want share experi crohn diseas biolog psoriasisi put humira back crohn diseas my doctor tri everi kind medic could possibl tri crohn diseas noth work after multipl hospit stay sever surgeri final got approv humira i would inject pen everi week onc i month i began develop rash leg slowli got bigger eventuali spread foot befor long spread leg feet my doctor told psoriasi gave steroid cream help eventu spread bodi includ scalp hair began fall i sevral bald patch depress angri i decid take humira within coupl week everyth began clear within month complet gone i didnt give doctor chanc upset either i show pictur couldnt dismiss later i place remicad infus everi week needless say i issu i humirapsoriasi i hate i use cortison itch steroid cream inflamm red good lotion cerava best lotion i found psoriasi thank everyon allow share experi',\n",
       "  'NN'),\n",
       " ('hi my question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl weekson face bodi stop take zykadia dermatologist gave medicin rash sudden swear headach and take dexa get normal ct scan report today say there mm hyperdens lesion area punctat calcif target like fashion within right parietaltempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema this caus effac ipsilater later ventricl subfalcin herniat along mid line shift no patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right parietaltempor lobe whole brain radiat suggest my question we scare radiat cyberknif option or gammaknif which option best he shouldnt stop take zykadia or need stop zykadia day till radiat stop zykadia jump nivolumab as zykadia result better except brain lesion if need carri zykadia avoid brain lesion zykadia doesnt cross brain barrier can get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       "  'NN'),\n",
       " ('my apolog momordica notic post i seen a person may awar someth back mind thrown face like respiratori therapist wife well yes shocker slap face consid neither specialist crystal ball tell futur also right say fair enough mention concern speak absolut anoth thing opinion anyway i glad hear otherwis wife receiv excel care oncologist care it make true differ doesnt you mention treatment tri i see opdivo keytruda mention were discuss it could right base type mutat you amaz love person care wife as caregiv i know fear grip exhaust take prayer dream it import take good care right rememb wear wont abl proper look let alon wife below i leav link inform caregiv it inform varieti topic some probabl alreadi know i hope may find inform help httpwwwcancercaencancerinformationcancerjourneyifyoureacaregiverregionab pleas take care jodi',\n",
       "  'NN'),\n",
       " ('i avastin uk time noth els licens myopic macular degener i given option it work well restor lost vision gave extra year use sight eye when i second bleed two year later lucenti licenc myopic macular degener lucenti never effect in opinion option peopl help for avastin prefer option novarti bayer make lucenti eyelea exploit nhs patient long i wonder though fight ensur potenti save plough back massiv overstretch eye clinic instead cover overspend elsewher nhs',\n",
       "  'NN'),\n",
       " ('the lung pair coneshap breath organ chest the lung bring oxygen bodi breath they releas carbon dioxid wast product bodi cell breath each lung section call lobe the left lung two lobe the right lung slight larger three lobe two tube call bronchi lead trachea windpip right left lung the bronchi sometim also involv lung cancer tini air sac call alveoli small tube call bronchiol make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset a thin membran call pleura cover outsid lung line insid wall chest caviti this creat sac call pleural caviti the pleural caviti normal contain small amount fluid help lung move smooth chest breath there two main type lung cancer nonsmal cell lung cancer small cell lung cancer see follow pdq summari inform lung cancer small cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen there sever type nonsmal cell lung cancer each type nonsmal cell lung cancer differ kind cancer cell the cancer cell type grow spread differ way the type nonsmal cell lung cancer name kind cell found cancer cell look microscop squamous cell carcinoma cancer begin squamous cell thin flat cell look like fish scale this also call epidermoid carcinoma larg cell carcinoma cancer may begin sever type larg cell adenocarcinoma cancer begin cell line alveoli make substanc mucus other less common type nonsmal cell lung cancer pleomorph carcinoid tumor salivari gland carcinoma unclassifi carcinoma smoke major risk factor nonsmal cell lung cancer anyth increas chanc get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past this import risk factor lung cancer the earlier life person start smoke often person smoke year person smoke greater risk lung cancer be expos secondhand smoke be expos asbesto arsenic chromium beryllium nickel soot tar workplac be expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut have famili histori lung cancer be infect human immunodefici virus hiv take beta caroten supplement heavi smoker older age main risk factor cancer the chanc get cancer increas get older when smoke combin risk factor risk lung cancer increas sign nonsmal cell lung cancer includ cough doesnt go away short breath sometim lung cancer caus sign symptom it may found chest xray done anoth condit sign symptom may caus lung cancer condit check doctor follow chest discomfort pain a cough doesnt go away get wors time troubl breath wheez blood sputum mucus cough lung hoars loss appetit weight loss known reason feel tire troubl swallow swell face andor vein neck test examin lung use detect find diagnos stage nonsmal cell lung cancer test procedur detect diagnos stage nonsmal cell lung cancer often done time some follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi these test help diagnos diseas plan check treatment monitor diseas time chest xray an xray organ bone insid chest an xray type energi beam go bodi onto film make pictur area insid bodi enlarg xray chest xray use take pictur organ bone chest xray pass patient onto film ct scan cat scan a procedur make seri detail pictur area insid bodi chest taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog a procedur pathologist view sampl sputum mucus cough lung microscop check cancer cell thoracentesi the remov fluid space line chest lung use needl a pathologist view fluid microscop look cancer cell if lung cancer suspect biopsi done one follow type biopsi usual use fineneedl aspir fna biopsi lung the remov tissu fluid lung use thin needl a ct scan ultrasound imag procedur use locat abnorm tissu fluid lung a small incis may made skin biopsi needl insert abnorm tissu fluid a sampl remov needl sent laboratori a pathologist view sampl microscop look cancer cell a chest xray done procedur make sure air leak lung chest enlarg fineneedl aspir biopsi lung the patient lie tabl slide comput tomographi ct machin take xray pictur insid bodi the xray pictur help doctor see abnorm tissu lung a biopsi needl insert chest wall area abnorm lung tissu a small piec tissu remov needl check microscop sign cancer an endoscop ultrasound eus type ultrasound may use guid fna biopsi lung lymph node area eus procedur endoscop insert bodi an endoscop thin tubelik instrument light len view a probe end endoscop use bounc highenergi sound wave ultrasound intern tissu organ make echo the echo form pictur bodi tissu call sonogram enlarg endoscop ultrasoundguid fineneedl aspir biopsi an endoscop ultrasound probe biopsi needl insert mouth esophagus the probe bounc sound wave bodi tissu make echo form sonogram comput pictur lymph node near esophagus the sonogram help doctor see place biopsi needl remov tissu lymph node this tissu check microscop sign cancer bronchoscopi a procedur look insid trachea larg airway lung abnorm area a bronchoscop insert nose mouth trachea lung a bronchoscop thin tubelik instrument light len view it may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi a bronchoscop insert mouth trachea major bronchi lung look abnorm area a bronchoscop thin tubelik instrument light len view it may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi a surgic procedur look organ insid chest check abnorm area an incis cut made two rib thoracoscop insert chest a thoracoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer in case procedur use remov part esophagus lung if certain tissu organ lymph node cant reach thoracotomi may done in procedur larger incis made rib chest open mediastinoscopi a surgic procedur look organ tissu lymph node lung abnorm area an incis cut made top breastbon mediastinoscop insert chest a mediastinoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer enlarg mediastinoscopi a mediastinoscop insert chest incis breastbon look abnorm area lung a mediastinoscop thin tubelik instrument light len view it may also cut tool tissu sampl may taken lymph node right side chest check microscop sign cancer in anterior mediastinotomi chamberlain procedur incis made besid breastbon remov tissu sampl lymph node left side chest anterior mediastinotomi a surgic procedur look organ tissu lung breastbon heart abnorm area an incis cut made next breastbon mediastinoscop insert chest a mediastinoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer this also call chamberlain procedur lymph node biopsi the remov part lymph node a pathologist view tissu microscop look cancer cell one follow laboratori test may done studi tissu sampl molecular test a laboratori test check certain gene protein molecul sampl tissu blood bodi fluid molecular test check certain gene chromosom chang occur nonsmal cell lung cancer immunohistochemistri a test use antibodi check certain antigen sampl tissu the antibodi usual link radioact substanc dye caus tissu light microscop this type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the stage cancer size tumor whether lung spread place bodi the type lung cancer whether cancer mutat chang certain gene epiderm growth factor receptor egfr gene anaplast lymphoma kinas alk gene whether sign symptom cough troubl breath the patient general health for patient nonsmal cell lung cancer current treatment cure cancer if lung cancer found take part one mani clinic trial done improv treatment consid clinic trial take place part countri patient stage nonsmal cell lung cancer inform ongo clinic trial avail nci websit stage nonsmal cell lung cancer key point after lung cancer diagnos test done find cancer cell spread within lung part bodi there three way cancer spread bodi cancer may spread began part bodi the follow stage use nonsmal cell lung cancer occult hidden stage stage stage i stage ii stage iii stage iv after lung cancer diagnos test done find cancer cell spread within lung part bodi the process use find cancer spread within lung part bodi call stage the inform gather stage process determin stage diseas it import know stage order plan treatment some test use diagnos nonsmal cell lung cancer also use stage diseas see general inform section other test procedur may use stage process includ follow mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area insid bodi brain this procedur also call nuclear magnet reson imag nmri ct scan cat scan a procedur make seri detail pictur area insid bodi brain abdomen lymph node taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg pet positron emiss tomographi scan the patient lie tabl slide pet machin the head rest white strap help patient lie still a small amount radioact glucos sugar inject patient vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan a procedur check rapid divid cell cancer cell bone a small amount radioact materi inject vein travel bloodstream the radioact materi collect bone cancer detect scanner pulmonari function test pft a test see well lung work it measur much air lung hold quick air move lung it also measur much oxygen use much carbon dioxid given breath this also call lung function test bone marrow aspir biopsi the remov bone marrow blood small piec bone insert hollow needl hipbon breastbon a pathologist view bone marrow blood bone microscop look sign cancer there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl nonsmal cell lung cancer spread brain cancer cell brain actual lung cancer cell the diseas metastat lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi the follow stage use nonsmal cell lung cancer occult hidden stage in occult hidden stage cancer cannot seen imag bronchoscopi cancer cell found sputum bronchial wash sampl cell taken insid airway lead lung cancer may spread part bodi stage in stage abnorm cell found line airway these abnorm cell may becom cancer spread nearbi normal tissu stage may adenocarcinoma situ ai squamous cell carcinoma situ scis stage i in stage i cancer form stage i divid stage ia ib stage ia the tumor lung centimet smaller cancer spread lymph node stage ib the tumor larger centimet larger centimet cancer spread lymph node the tumor centimet smaller one follow found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node stage ii stage ii divid stage iia iib stage iia the tumor larger centimet larger centimet cancer spread lymph node one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon stage iib the tumor centimet smaller cancer spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node one follow found the tumor larger centimet larger centimet there one separ tumor lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart stage iii stage iii divid stage iiia iiib iiic stage iiia the tumor centimet smaller cancer spread lymph node side chest primari tumor the lymph node cancer around trachea trachea divid bronchi also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow found the tumor larger centimet larger centimet there one separ tumor lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart cancer may spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow found the tumor larger centimet there one separ tumor differ lobe lung primari tumor the tumor size cancer spread follow trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiib the tumor centimet smaller cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon the tumor may size cancer spread lymph node side chest primari tumor the lymph node cancer around trachea trachea divid bronchi also one follow found there one separ tumor lobe differ lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiic the tumor may size cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow found there one separ tumor lobe differ lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iv stage iv divid stage iva ivb in stage iva tumor may size cancer may spread lymph node one follow found there one tumor lung primari tumor cancer found fluid around lung heart cancer spread one place organ near lung brain liver adren gland kidney bone sac around heart lymph node near lung in stage ivb cancer spread multipl place one organ near lung recurr nonsmal cell lung cancer recurr nonsmal cell lung cancer cancer recur come back treat the cancer may come back brain lung part bodi treatment option overview key point there differ type treatment patient nonsmal cell lung cancer ten type standard treatment use surgeri radiat therapi chemotherapi target therapi immunotherapi laser therapi photodynam therapi pdt cryosurgeri electrocauteri watch wait new type treatment test clinic trial chemoprevent radiosensit new combin treatment nonsmal cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient nonsmal cell lung cancer differ type treatment avail patient nonsmal cell lung cancer some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial some clinic trial open patient start treatment ten type standard treatment use surgeri four type surgeri use treat lung cancer wedg resect surgeri remov tumor normal tissu around when slight larger amount tissu taken call segment resect enlarg wedg resect lung part lung lobe contain cancer small amount healthi tissu around remov lobectomi surgeri remov whole lobe section lung enlarg lobectomi a lobe lung remov pneumonectomi surgeri remov one whole lung enlarg pneumonectomi the whole lung remov sleev resect surgeri remov part bronchus after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment onc day sever day radiat machin aim larger usual dose radiat direct tumor by patient posit treatment less damag nearbi healthi tissu this procedur also call stereotact externalbeam radiat therapi stereotax radiat therapi stereotact radiosurgeri type extern radiat therapi use treat lung cancer spread brain a rigid head frame attach skull keep head still radiat treatment a machin aim singl larg dose radiat direct tumor brain this procedur involv surgeri it also call stereotax radiosurgeri radiosurgeri radiat surgeri for tumor airway radiat given direct tumor endoscop the way radiat therapi given depend type stage cancer treat it also depend cancer found extern intern radiat therapi use treat nonsmal cell lung cancer chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi the way chemotherapi given depend type stage cancer treat see drug approv nonsmal cell lung cancer inform target therapi target therapi type treatment use drug substanc attack specif cancer cell target therapi usual caus less harm normal cell chemotherapi radiat therapi monoclon antibodi tyrosin kinas inhibitor two main type target therapi use treat advanc metastat recurr nonsmal cell lung cancer monoclon antibodi monoclon antibodi therapi cancer treatment use antibodi made laboratori singl type immun system cell these antibodi identifi substanc cancer cell normal substanc blood tissu may help cancer cell grow the antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus they may use alon carri drug toxin radioact materi direct cancer cell there differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form this may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell this stop cancer cell grow divid cetuximab necitumumab egfr inhibitor tyrosin kinas inhibitor tyrosin kinas inhibitor smallmolecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid some tyrosin kinas inhibitor also angiogenesi inhibitor effect there differ type tyrosin kinas inhibitor epiderm growth factor receptor egfr tyrosin kinas inhibitor egfr protein found surfac insid certain cell includ cancer cell epiderm growth factor attach egfr insid cell send signal tyrosin kinas area cell tell cell grow divid egfr tyrosin kinas inhibitor stop signal stop cancer cell grow divid erlotinib gefitinib afatinib osimertinib type egfr tyrosin kinas inhibitor some drug work better also mutat chang egfr gene kinas inhibitor affect cell certain gene chang certain chang alk ros gene caus much protein made block protein may stop cancer grow spread crizotinib use stop protein made alk ros gene ceritinib alectinib brigatinib use stop protein made alk gene dabrafenib use stop protein made braf gene trametinib use stop protein made mek gene see drug approv nonsmal cell lung cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell nivolumab pembrolizumab atezolizumab durvalumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv nonsmal cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell photodynam therapi pdt photodynam therapi pdt cancer treatment use drug certain type laser light kill cancer cell a drug activ expos light inject vein the drug collect cancer cell normal cell fiberopt tube use carri laser light cancer cell drug becom activ kill cell photodynam therapi caus littl damag healthi tissu it use main treat tumor skin line intern organ when tumor airway pdt given direct tumor endoscop cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu carcinoma situ this type treatment also call cryotherapi for tumor airway cryosurgeri done endoscop electrocauteri electrocauteri treatment use probe needl heat electr current destroy abnorm tissu for tumor airway electrocauteri done endoscop watch wait watch wait close monitor patient condit without give treatment sign symptom appear chang this may done certain rare case nonsmal cell lung cancer new type treatment test clinic trial this summari section describ treatment studi clinic trial it may mention everi new treatment studi inform clinic trial avail nci websit chemoprevent chemoprevent use drug vitamin substanc reduc risk cancer reduc risk cancer recur come back for lung cancer chemoprevent use lessen chanc new tumor form lung radiosensit radiosensit substanc make tumor cell easier kill radiat therapi the combin chemotherapi radiat therapi given radiosensit studi treatment nonsmal cell lung cancer new combin new combin treatment studi clinic trial treatment nonsmal cell lung cancer may caus side effect for inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show condit chang cancer recur come back these test sometim call followup test checkup treatment option stage for inform treatment list see treatment option overview section occult nonsmal cell lung cancer treatment occult nonsmal cell lung cancer depend stage diseas occult tumor often found earli stage tumor lung sometim cure surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage treatment stage may includ follow surgeri wedg resect segment resect photodynam therapi electrocauteri cryosurgeri laser surgeri tumor near bronchus use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage i nonsmal cell lung cancer treatment stage ia nonsmal cell lung cancer stage ib nonsmal cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi extern radiat therapi includ stereotact bodi radiat therapi patient cannot surgeri choos surgeri a clinic trial chemotherapi radiat therapi follow surgeri a clinic trial treatment given endoscop photodynam therapi pdt a clinic trial surgeri follow chemoprevent use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage ii nonsmal cell lung cancer treatment stage iia nonsmal cell lung cancer stage iib nonsmal cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi pneumonectomi chemotherapi follow surgeri surgeri follow chemotherapi extern radiat therapi patient cannot surgeri a clinic trial radiat therapi follow surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iiia nonsmal cell lung cancer treatment stage iiia nonsmal cell lung cancer remov surgeri may includ follow surgeri follow chemotherapi surgeri follow radiat therapi chemotherapi follow surgeri surgeri follow chemotherapi combin radiat therapi chemotherapi radiat therapi follow surgeri a clinic trial new combin treatment treatment stage iiia nonsmal cell lung cancer cannot remov surgeri may includ follow chemotherapi radiat therapi given period time one follow extern radiat therapi alon patient cannot treat combin therapi palliat treatment reliev symptom improv qualiti life intern radiat therapi laser surgeri palliat treatment reliev symptom improv qualiti life chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab a clinic trial new combin treatment for inform support care sign symptom includ cough short breath chest pain see pdq summari cardiopulmonari syndrom nonsmal cell lung cancer superior sulcus often call pancoast tumor begin upper part lung spread nearbi tissu chest wall larg blood vessel spine treatment pancoast tumor may includ follow radiat therapi alon surgeri chemotherapi radiat therapi follow surgeri a clinic trial new combin treatment some stage iiia nonsmal cell lung tumor grown chest wall may complet remov treatment chest wall tumor may includ follow surgeri surgeri radiat therapi radiat therapi alon chemotherapi combin radiat therapi andor surgeri a clinic trial new combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iiib stage iiic nonsmal cell lung cancer treatment stage iiib nonsmal cell lung cancer stage iiic nonsmal cell lung cancer may includ follow chemotherapi follow extern radiat therapi chemotherapi radiat therapi given separ treatment period time chemotherapi radiat therapi given separ treatment period time dose radiat therapi increas time chemotherapi radiat therapi given separ treatment period time chemotherapi alon given treatment chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab extern radiat therapi alon patient cannot treat chemotherapi extern radiat therapi palliat therapi reliev symptom improv qualiti life laser therapi andor intern radiat therapi reliev symptom improv qualiti life clinic trial new extern radiat therapi schedul new type treatment a clinic trial chemotherapi radiat therapi combin radiosensit clinic trial target therapi combin chemotherapi radiat therapi for inform support care sign symptom cough short breath chest pain see follow pdq summari cardiopulmonari syndrom cancer pain use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail newli diagnos stage iv relaps recurr nonsmal cell lung cancer treatment newli diagnos stage iv relaps recurr nonsmal cell lung cancer may includ follow combin chemotherapi combin chemotherapi target therapi monoclon antibodi bevacizumab cetuximab necitumumab combin chemotherapi follow chemotherapi mainten therapi help keep cancer progress target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor osimertinib gefitinib erlotinib afatinib target therapi anaplast lymphoma kinas alk inhibitor alectinib crizotinib ceritinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor pembrolizumab without chemotherapi laser therapi andor intern radiat therapi tumor block airway extern radiat therapi palliat therapi reliev symptom improv qualiti life surgeri remov second primari tumor surgeri remov cancer spread brain follow radiat therapi whole brain stereotact radiosurgeri tumor spread brain cannot treat surgeri a clinic trial new drug combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail progress stage iv relaps recurr nonsmal cell lung cancer treatment progress stage iv relaps recurr nonsmal cell lung cancer may includ follow chemotherapi target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor erlotinib gefitinib afatinib osimertinib target therapi anaplast lymphoma kinas alk inhibitor crizotinib ceritinib alectinib brigatinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor nivolumab pembrolizumab atezolizumab a clinic trial new drug combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about nonsmal cell lung cancer for inform nation cancer institut nonsmal cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv nonsmal cell lung cancer target cancer therapi laser cancer treatment photodynam therapi cancer cryosurgeri cancer treatment tobacco includ help quit secondhand smoke cancer for general cancer inform resourc nation cancer institut see follow about cancer stage chemotherapi you support peopl with cancer radiat therapi you support peopl with cancer cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment nonsmal cell lung cancer it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq adult treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq adult treatment editori board pdq nonsmal cell lung cancer treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypeslungpatientnonsmallcelllungtreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('that exact i took oral thrush week back gilenya i went hike exert lot effort pass shall i concer',\n",
       "  'NN'),\n",
       " ('i alecensa month progress side effect i experienc begin gone great drug',\n",
       "  'JJ'),\n",
       " ('so glad recoveri go well i curious whether diagnos osteoporosi osteonecrosi unfortun husband osteoporosi year prednison shock radiologist actual misread initi dexa said everyth normal endocrinologist caught gis dont know t score i didnt doubl check radiologist conclus so i curious whether case porosi preced necrosi spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       "  'NN'),\n",
       " ('robbi ask alan hes look forward ectrim robbi what look forward professor alan thompson neurologist well i think ectrim extraordinari event it get bigger everi year ms meet so meet interest result announc so i like i like go main lectur get real summari thing earli lectur day i also like listen result trial so know go interest trial present main interest progress ms im look result progress know there go trial discuss saturday i think go suggest posit result trial secondari progress ms would amaz i mean last year barcelona result posit trial primari progress ms ocrelizumab that go process licens so second drug progress would fantast robbi there actual noth apart relaps remit drug professor alan thompson at moment none we mani drug relaps remit ms weve noth progress ms so realli great breakthrough i plug progress ms allianc i involv that rais profil progress encourag earli trial progress ms definit trial but would basic two definit posit trial progress would fantast join shiftm communiti httpsshiftm watch video httpsshiftmsmsreport httpswwwfacebookcomshiftm httpswwwinstagramcomshiftdotm httpstwittercomshiftm',\n",
       "  'NN'),\n",
       " ('i inform it lung cancer keytruda prove better chemotherapi wherea case opdivo but keytruda select patient express pdl tumor',\n",
       "  'NN'),\n",
       " ('congratul great respons keytruda i diagnos stage non smallcel lung cancer march opdivo i start later year fda approv i happili stabl two half year im treatment pretti well i side effect muscl joint pain cours aw fatigu much better diagnosi i start i brain tumor lung tumor pulmonari embol ive come long way i feel lucki thank i think need think posit hope treatment work well i also think opdivo miracl drug i wish work well everybodi lisa',\n",
       "  'NN'),\n",
       " ('i remicad month far crohn goe work great inflamm last colonoscopi i humira previous develop fair sever muscl pain colonoscopi discov humira work anyway switch remicad now i develop muscl pain much wors this start six day prior last infus everi day got wors it got i could hard walk within hour start infus pain start decreas even total gone it three week six week cycl muscl pain start alreadi on top doctor offic call today inform latest blood work my anti bodi level high even though i six week cycl remicad left system i appoint see gi next week nurs told think option readi talk doctor one option go four week schedul remicad as much i like remicad i cant see go four vs six week help much seem like sooner later muscl pain return the option switch entyvio sterlara ive done research realli cannot see one better has anyon experienc muscl pain remicad switch either drug good result gone someth els',\n",
       "  'NNS'),\n",
       " ('thankyou much md this antijcv treatment market mani year ago gilenya tecfidera tysabri etc releas immunosuppress drug pml known sever side effect pharma could derisk tysabri gilenya almost complet',\n",
       "  'VBP'),\n",
       " ('hi pinkperfect just repli previous messag seen i think lucenti talk tri eylea hadnt work avastin',\n",
       "  'JJ'),\n",
       " ('natalizumab aidan said like fingolimod disrupt passag lymphocyt cns the question drug cure ms sinc theori immun attack would caus diseas',\n",
       "  'JJ'),\n",
       " ('checkpoint immunotherapi especi pd checkpoint pathway proven effect sever cancer type unfortun major patient still dont respond immunebas approach therefor day asco mani talk poster discuss dealt strategi overcom resist immunotherapi combin well novel agent may hold synergist potenti exist approach in renal cell carcinoma rcc common form kidney cancer laurenc albig md phd gustav roussi univers parissaclay discuss two poster describ studi use immunotherapi combin the first focus combin pd checkpoint immunotherapi pegilodecakin form immunemodul interleukin cytokin also known am among patient respond repres object respons rate the median progressionfre surviv year month oneyear overal surviv rate the combin treatment also associ clonal expans t cell blood patient thus indic potenti use biomark respons the second involv cxcr inhibit via xp combin axinitib tyrosin kinas inhibitor common use treat advanc kidney cancer the cxcr receptor promot tumor blood vessel growth well recruit myeloidderiv suppressor cell mdscs regulatori t cell treg suppress anticanc immun respons elev express cxcr often found rcc tumor associ poor patient outcom by block cxcr tyrosin kinas activ combin treatment led one complet respons ten partial respons patient addit stabl diseas translat diseas control rate albig end question right combin move forward larger clinic trial wonder perhap combin involv cxcr pd blockad might prove effect brian shuch md yale school medicin follow albig discuss two poster present focus potenti use biomark advanc rcc patient treat pd immunotherapi one show killer t cell among abund tumorinfiltr immun cell treatment infiltr m macrophag associ durabl clinic benefit immunotherapi the studi also found wherea number tumor mutat relat low associ improv outcom presenc certain type mutationsknown indelsthat involv insert delet dna segment posit signific impact overal surviv patient the provid evid impact gut microbiometh bacteria live within person digest systemon immunotherapi effect in addit prospect analysi specif gut fingerprint abl predict patient would benefit pd checkpoint immunotherapi shown transplant either akkermansia muciniphila bacteroid salyersia abund human patient respond mice improv respons this led shuch suggest potenti benefit profil even modul microbiom patient prior immunotherapi ask regul antibiot andor diet patient undergo treatment would benefici anoth focus day immunotherapi strategi patient advanc hpvassoci cancer head neck cancer cervic cancer one approach led discuss christian hinrich md nation cancer institut nci involv use patient exist t cell metastat tumor after identifi isol t cell within patient recogn hpvspecif antigen hinrich team expand reinfus back patient follow treatment chemotherapi aldesleukin recombin interleukin of eighteen patient metastat cervic cancer treat five patient respond two complet respons remain ongo month year month year sinc infus in noncerv cancer cohort consist eleven patient two experienc respons one patient anal squamous cell carcinoma scc anoth scc head neck hinrich conclud share team find posttreat engraft t cell target hpv oncoprotein correl posit patient respons jame gulley md phd nation cancer institut also led gave talk treat hpvassoci cancer immunotherapi gulley approach involv m bifunct fusion protein simultan target two immunosuppress pathway pdl immun checkpoint tgfb receptor of seventeen patient hpvassoci cancer six respond includ two whose tumor complet elimin five twelv patient known hpvposit tumor respond one complet the diseas control rate respect hpvassoci hpvposit patient cohort import gulley note immun activ seen across cervic anal head neck cancer type respons durabl ongo may breast cancer especi tripleneg breast cancer tnbc anoth tumor type hard treat hasnt proven vulner singl agent checkpoint immunotherapi effect combin strategi desper need patient popul to end kari wisinski md univers wisconsin carbon cancer center discuss poster present combin pembrolizumab radiat heavili pretreat metastat tnbc patient wisinski explain approach involv import immunolog respons known abscop effect wherebi irradi one tumor stimul immun activ metastat lesion elsewher bodi of seventeen patient three partial respons while respons rate may seem signific appear improv compar trial evalu pd immunotherapi heavili pretreat tnbc patient respons rate observ accord wisinski even impress howev metastat lesion entir elimin three patient partial respons this import vast major cancerrel death due secondari metastat tumor two respons last half year week weekswhil last respons remain ongo almost one year week anoth immunotherapi strategi evalu tnbc addit cancer highlight timothi yap phd mbbs univers texa md anderson cancer center in studi conduct yap led memori sloan ketter margaret callahan md phd former cri postdoctor fellow combin nivolumab ico agonist jtx while respons rate combin werent high other mention produc sever respons patient advanc gastric cancer nonsmal cell lung cancer tnbc furthermor callahan yap team found tumor reduct coincid emerg ico cd t cell popul thus may identifi potenti biomark respons a trial investig valu target anoth import immunerel pathwaycdwa present branimir i sikic md stanford univers school medicin cd act dont eat signal protect normal cell macrophagemedi cell eat phagocytosi cancer cell howev use trick protect well by block cd receptor research hope would promot destruct tumor cell macrophag of eight patient ovarian fallopian tube cancer receiv cdtarget hufg two partial respons especi promis given patient treat six line prior therapi a trial combin hufg rituximab rituximabrefractori nonhodgkin lymphoma shown promis includ multipl complet respons discuss depth later asco addit trial combin hufg pd immunotherapi plan adi diab md univers texa md anderson cancer center showcas promis activ nktr design provid sustain signal interleukin pathway combin pd immunotherapi as firstlin treatment patient metastat melanoma combin led object respons rate diseas control rate even patient pdlnegat tumor benefit respond sever patient experienc complet respons includ one patient pdlnegat tumor the combin also benefici firstlin treatment patient kidney cancer rcc among patient twelv respond addit eight saw diseas stabil there also sever complet respons patient popul among biomark associ posit respons increas t cell natur killer cell prolifer blood increas killer t cell tumor tumor initi pdlnegat increas pdl express within three week treatment also associ posit respons in sarcoma anoth hardtotreat tumor type benefit oncolyt virus combin well cellbas immunotherapi present the first studi led sandra dangelo md memori sloan ketter reveal benefit combin pd immunotherapi oncolyt virus tvec patient metastat sarcoma produc respons patient second pilot studi involv creat tcrengin t cell target cancerassoci nyeso antigen patient liposarcoma while six month sinc first patient treat eight far receiv infus custom t cell four respond addit three stabl diseas the final patient yet assess final updat axicel cdtarget car t cell immunotherapi nonhodgkin lymphoma present moffitt cancer center frederick lock md in phase zuma clinic trial object respons rate patient complet respons median overal surviv yet reach interest lock team found respons deepen time he show patient partial respons eventu becam complet respond surviv curv partial respond complet respond seem merg threemonth mark group similar progressionfre surviv rate point addit patient remain respons threemonth mark likelihood maintain respons oneyear mark day asco featur import updat cancer immunotherapi sure check blog tomorrow read recap',\n",
       "  'NN'),\n",
       " ('jimc is normal i still tumor pain palliat radiat it day alreadi i finish radiat is radiat suppos help shrink tumor reduc pain how long take notic symptomat improv thank kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('i usual would mild flare year worst year ever i sick i origin put remicad i lot side effect eventu built antibodi then i start humira i pen the shot dont hurt i stomach i take mgs everi two week ive humira month i say im ucb symptom free which ive never abl say thank humira save colon give life back',\n",
       "  'NN'),\n",
       " ('eagleim glad got sort i ask onc genet test sampl she said nothat done metatast wha butit spread lymphnod isnt still metatast local metatast mayb i dunno i think right give durvamulab regardless pdl level anyway im happi hear tagrisso work well',\n",
       "  'NN'),\n",
       " ('among paramet b cell patient ms produc elev level il and mani info il target b cell treatment multipl sclerosi recent advanc remain challeng doi these data identifi il import target modul autoimmun respons chronic inflamm il control th immun vivo inhibit convers convent t cell foxp regulatori t cell doi pnas i dindt find info ocrelizumab act il onli interact bcell il',\n",
       "  'JJ'),\n",
       " ('thank zoe i would stop take gilenya danger i see neurologist februari talk i see plus even i stop take month gilenya actual leav bodi system',\n",
       "  'NN'),\n",
       " ('chuck i wasnt upset dismiss i upset ridicul yes i friend high place cancer field wasnt threat what understand opdivo cure cancer it work month your wife outlier i sincer hope remain at point opdivo stop work the cancer mutat that wasnt mutagen opdivo would kill wed happi cancerfreemeanwhil harm tri thing like ursol acid it natur supplement oncologist said sure and fwiw i spirit crystal homeopath weird stuff but scientif studi show promis unharm substanc given doctor appov it cant hurt i go die i know i go fight tri find way delay and i head direct possibl ration deter other look nontox drug may help us at point wife stop respond opdivo look trial data i realli realli hope im wrong folk need creativ look thing may help',\n",
       "  'NN'),\n",
       " ('rilonacept use treat symptom rare genet condit famili cold autoinflammatori syndrom fcas mucklewel syndrom mws fcas mws inflammatori disord bodi develop certain symptom without known caus virus bacteria ill these symptom includ fever chill fatigu joint pain more serious symptom may involv bone joint central nervous system deaf vision loss mental impair major organ kidney rilonacept may treat prevent symptom famili cold autoinflammatori syndrom fcas mucklewel syndrom mws howev medic cure inherit condit rilonacept may also use purpos list medic guid serious sometim fatal infect may occur treatment rilonacept call doctor right away sign infect fever chill sore throat flu symptom easi bruis bleed noseble bleed gum loss appetit nausea vomit mouth sore unusu weak you use medic allerg rilonacept type infect befor use rilonacept tell doctor activ chronic infect histori tuberculosi recurr infect high cholesterol triglycerid make sure current vaccin start treatment rilonacept tell doctor medic use especi drug treat arthriti psoriasi crohn diseas ankylos spondyl do receiv live vaccin use rilonacept the vaccin may work well time may fulli protect diseas avoid come contact anyon recent receiv live vaccin there chanc virus could pass you use medic allerg rilonacept type infect to make sure rilonacept safe tell doctor condit activ chronic infect histori tuberculosi recurr infect high cholesterol triglycerid type fat blood make sure current vaccin start treatment rilonacept use rilonacept may increas risk develop certain type cancer talk doctor specif risk fda pregnanc categori c it known whether rilonacept harm unborn babi tell doctor pregnant plan becom pregnant use medic it known whether rilonacept pass breast milk could harm nurs babi do use medic without tell doctor breastfeed babi do give medicin child younger year old without medic advic basicdescript back top rilonacept side effect get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat serious sometim fatal infect may occur treatment rilonacept call doctor right away new sign infect fever chill sore throat flu symptom easi bruis bleed noseble bleed gum nausea vomit loss appetit mouth sore unusu weak call doctor serious side effect bloodi black tarri stool cough blood vomit look like coffe ground wheez chest tight troubl breath pain burn urin headach neck stiff increas sensit light purpl spot skin andor seizur convuls other common side effect may includ cold symptom stuffi nose sneez cough sore throat nausea stomach pain diarrhea numb ting feel pain swell red itch warmth blister bleed irrit medicin inject this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda back top rilonacept interact do receiv live vaccin use rilonacept the vaccin may work well time may fulli protect diseas avoid come contact anyon recent receiv live vaccin there chanc virus could pass live vaccin includ measl mump rubella mmr bacillus calmettegurin bcg oral polio rotavirus smallpox yellow fever varicella chickenpox zoster shingl oral typhoid vaccin nasal flu influenza vaccin tell doctor medic use start stop use treatment rilonacept especi adalimumab humira certolizumab cimzia etanercept enbrel fingolimod gilenya golimumab simponi infliximab remicad leflunomid arava blood thinner warfarin coumadin jantoven this list complet other drug may interact rilonacept includ prescript overthecount vitamin herbal product not possibl interact list medic guid back top rilonacept dosag follow direct prescript label do use medicin larger smaller amount longer recommend rilonacept inject skin you may shown use inject home use exact prescrib doctor do self inject medicin fulli understand give inject proper dispos use needl syring your first dose may given two inject time differ place bodi rilonacept powder medicin must mix liquid diluent use if use inject home sure understand proper mix store medicin use differ place stomach thigh upper arm time give inject your care provid show best place bodi inject medic do inject place two time row while use rilonacept may need frequent blood test doctor offic each singleus vial bottl medicin one use throw away one use even still medicin left inject dose use dispos needl throw away use needl punctureproof contain ask pharmacist get one dispos keep contain reach children pet store unmix powder medicin refriger protect light do freez keep vial origin contain readi mix medicin after mix rilonacept diluent store room temperatur use within hour protect light seek emerg medic attent call poison help line overdos symptom may includ sever form side effect list medic guid call doctor instruct miss appoint rilonacept inject',\n",
       "  'VB'),\n",
       " ('this second go round avonex long stori the first time almost five year ago i dont rememb experi i three month feel like ive pretti good howev last three week ive lot troubl walk i lot stiff thigh much pain my dw think fault avonex i dont agre has anyon els type problem take avonex i go neuro tomorrow i would like know talk i think ive progress spms dxd first symptom avonex copaxon tecfidera gilenya current dmts start aubagio back avonex it hard beat person never give babe ruth',\n",
       "  'NN'),\n",
       " ('bffj new studi come everi day the mechan ctla inhibit clear indic ipilimumab type igg antibodi caus treg deplet but also costimulatori molecul ox gitr httpwwwnaturecomicbjournalvnfullicbahtml all manipul immun system care btw one inspir friend wrote pm wife pdl express take keytruda coupl time got strong overactiv t cell develop cytokin releas syndrom could lethal all lung cell inflam without infect cytokin attack lung tissu sever peopl die begin car t cell trial now need immun suppressor overcom syndrom',\n",
       "  'IN'),\n",
       " ('my husband xeljanz month still full remiss no appar side effect feel he knew within two week help good luck he take mg day mg morn afternoon spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       "  'JJ'),\n",
       " ('tumor keep get smaller look like mg pazo enough keep keytruda effect last summer i certain i would dead point',\n",
       "  'NN'),\n",
       " ('im sorri your go i dont much add i hope figur get relief soon diagnos hospit current sever proctiti current med flortistor entyvio sinc august pred mg',\n",
       "  'NN'),\n",
       " ('chicagopembrolizumab led superior overal surviv os among patient previous untreat advancedmetastat nonsmallcel lung cancer nsclc without egfr alk mutat pdl tumor proport score tps greater equal platinumbas chemotherapi regimen accord data present plenari session american societi clinic oncolog annual meet sunday june data keynot studi previous demonstr firstlin pembrolizumab therapi led signific prolong progressionfre surviv pfs os among patient metastat nsclc studi particip target alter pdl tps greater equal keynot keynot clinicaltrialsgov identifi nct author evalu efficaci pembrolizumab among patient lower tps in phase studi research random assign patient receiv pembrolizumab mg everi week investig choic chemotherapi includ paclitaxel plus carboplatin pemetrex plus carboplatin option pemetrex mainten therapi nonsquam histolog relat articl prophylact cranial irradi reduc incid brain metastas nsclc pembrolizumab chemotherapi combin signific improv pfs nsclc overal patient assign arm tps greater equal greater equal respect the median followup month at time analysi patient pembrolizumab arm continu therapi versus patient receiv pemetrex mainten therapi os signific improv among patient tps treat pembrolizumab month compar month among patient receiv chemotherapi hazard ratio hr ci p among patient tps pembrolizumab led os month versus month chemotherapi arm hr ci p among patient tps patient pembrolizumab arm os month compar month among patient treat chemotherapi hr ci p moreov patient receiv pembrolizumab experienc lower rate treatmentrel grade advers event compar chemotherapi vs pfs outcom still investig the author conclud data confirm potenti extend role pembrolizumab monotherapi standard firstlin treatment pdlexpress advancedmetastat nsclc read cancer therapi advisor coverag american societi clinic oncolog asco meet visit confer page refer',\n",
       "  'NN'),\n",
       " ('inform provid the nation multipl sclerosi societi import research progress occur offer new lead toward vision world free ms the societi mobil peopl resourc everyon affect ms live best live stop ms track restor lost end ms forev we continu pursu promis path uncov solut wherev opportun exist special focus progress ms nervous system repair lifestylewel genesenviron the result previous societi invest continu mount commit grow research fund even in societi invest million new ongo research project initi here brief summari signific research progress initi includ link detail stop ms posit result report three phase trial experiment therapi call ocrelizumab genentech member roch group show posit impact relaps ms first time largescal trial modest impact primari progress ms the societi collabor conven scientif workshop set research prioriti understand comorbid medic condit impact ms sever clinic trial outcom explor implic program develop find solut address comorbid may slow progress increas lifespan qualiti life peopl ms a new studi uncov gene variat link respons ms therapi may open new treatment approach research toward import goal person medicin ms the first generic version daili copaxon glatiram acet brand glatopa sandoz novarti compani develop collabor momenta pharmaceut approv fda distribut began sandoz june addit generic therapi expect soon scientist univers virginia uncov evid previous unrecogn network vessel facilit immun system activ brain the team show evid network lymphat vessel mice peopl further research need understand whether lymphat vessel play role ms whether present new opportun stop ms diseas activ result publish phase trial daclizumab highyield process zinbryta relaps ms show could signific reduc relaps rate diseas activ observ mri scan cours year biogen abbvi appli regulatori agenc us europ obtain market approv treat peopl ms the john dystel prize ms research went prof alastair compston univers cambridg drive breakthrough therapeut immunolog genet focus area progress ms a clinic trial cofund societi repurpos oral epilepsi therapi call phenytoin show promis protect nervous system neuroprotect lead strategi slow stop progress while disappoint result announc major trial tysabri natalizumab secondari progress ms gilenya fingolimod primari progress ms learn trial advanc understand process lead progress inform futur clinic trial design a studi found ms progress faster continu smoke cigarett compar quit ms diagnosi this may explain part societyfund studi show mice expos smoke show increas inflamm oxid stress the ms outcom assess consortium rd annual meet fda ad new clinic trial data partner global effort develop tool provid sensit way detect benefit potenti treatment slow revers ms progress the intern progress ms allianc held scientif meet ms pathophysiolog fund new collabor network plan grant grown member societi pharmaceut particip industri forum restor and repair learn more ms view news help provid educ inform person affect ms keep current multipl sclerosi news inform optingin websit click thank',\n",
       "  'NN'),\n",
       " ('thank repli i two differ opthomogi appoint today second opinion one advis vitrectomi suggest danger much blood eye atm complic happen gone suggest start inject first see goe reduc blood vessel said right eye sick left littl better finger cross ill tri stay posit polli alway your experi make feel bit confid im wish i came goodluck futur cheer',\n",
       "  'NN'),\n",
       " ('waynexxl i glad fine come gilenya one drug realli bad rebound come that usual within month otherwis relaps hit time my wife follow om care also take tecfidera the jcv risk low drug the case basic peopl would got anyway part that stop tysabri switch gilenya tecfidera becam jcv posit like problem impact switch tecfidera doesnt known pml issu lymphocyt level stay problem extend period time given risk profil benefit i wouldnt choos aubagio first choic it one option wife opt toward tecfidera aubagio actual realli good valu peopl fail drug doesnt seem like case jelinek book doesnt rule use dmts one reason say consid use side effect my earlier drug flu like symptom etc might impact abil exercis etc on tecfidera wife none first week realli miser she doesnt even know taken track care pillbox',\n",
       "  'NN'),\n",
       " ('the develop treatment multipl sclerosi past year success translat medicin in timelin articl tintor et al chart major develop discuss implic current futur patient manag mar tintor angela vidaljordana jaum sastregarriga natur review neurolog review articl assess treatment outcom multipl sclerosi trial clinic set in clinic trial outcom measur might determin whether drug worthi develop clinic might guid import treatment decis here tur colleagu help clinician research navig maze option clinic neuroimag patientreport composit outcom measur multipl sclerosi carmen tur marcello moccia frederik barkhof jeremi chataway jaum sastregarriga alan j thompson olga ciccarelli natur review neurolog scienc societi the tension earli diagnosi misdiagnosi multipl sclerosi the benefit earli treatment multipl sclerosi ms place pressur physician make diagnosi earli therebi increas risk misdiagnosi consider consequ patient healthcar system solomon corboy examin problem ms misdiagnosi includ probabl caus associ risk discuss tension earli diagnosi misdiagnosi might address andrew j solomon john r corboy natur review neurolog review articl autolog haematopoiet stem cell transplant treatment multipl sclerosi autolog haematopoiet stem cell transplant produc strike result patient aggress multipl sclerosi small trial in review muraro et al provid overview procedur detail evid high efficaci multipl sclerosi provid recommend clinic use futur trial paolo a muraro roland martin giovanni luigi mancardi richard nichola maria pia sormani riccardo saccardi natur review neurolog review articl treatment decis multipl sclerosi insight realworld observ studi realworld observ studi potenti answer question multipl sclerosi ms treatment random control trial cannot trojano colleagu discuss pitfal necessari safeguard observ studi insight studi provid treatment decis patient ms maria trojano mar tintor xavier montalban jan hillert toma kalincik pietro iaffaldano tim spelman maria pia sormani helmut butzkueven natur review neurolog review articl diseasemodifi therapi infecti risk multipl sclerosi the rang immunomodulatori therapi treat multipl sclerosi ms widen mark recent year ms treatment becom effici this improv efficaci accompani increas risk treatmentassoci infect in review winkelman et al discuss mode action current avail ms therapi detail specif infect associ treatment they consid inform influenc daili clinic use ms therapi minim associ infecti risk alexand winkelmann micha loebermann emil c reising hanspet hartung uwe k zettl natur review neurolog review articl myeloid cell target medic multipl sclerosi in review mishra yong consid myeloid cell monocyt macrophag microglia dendrit cell contribut patholog multipl sclerosi ms the author also consid current multipl sclerosi treatment might direct indirect affect cell manoj k mishra v wee yong natur review neurolog review articl aggress multipl sclerosi propos definit treatment algorithm a subset patient multipl sclerosi ms demonstr rapid accumul disabl symptom refractori standard diseasemodifi therapi rush colleagu present criteria identifi patient socal aggress ms outlin efficaci various therapi group patient the author emphas need act quick patient propos treatment algorithm aid clinic decisionmak carolina a rush heather j maclean mark s freedman natur review neurolog review articl defin score respons ifn multipl sclerosi as rang therapeut option multipl sclerosi ms continu expand abil select appropri treatment patient becom increas import in review sormani de stefano assess studi attempt classifi patient ms basi respons ifn treatment the author also discuss develop use score system combin differ clinic mri marker aid definit earli respons drug maria pia sormani nicola de stefano natur review neurolog review articl b cell antibodi multipl sclerosi pathogenesi therapi increas evid support role b cell antibodi pathogenesi multipl sclerosi ms here meinl colleagu discuss proinflammatori contribut bcell signal ms consid potenti target autoantibodi the bcell respons various ms therapi also summar markus krumbholz tobia derfuss reinhard hohlfeld edgar meinl natur review neurolog review articl fingolimod potenti novel therapi multipl sclerosi onli moder effect therapi current avail treatment multipl sclerosi ms new treatment ms neuroprotect properti well antiinflammatori effect need fingolimod could one potenti treatment in articl akta et al examin under biolog action prospect new therapi review data phase ii phase iii oral fingolimod clinic trial provid updat emerg field sphingosinephosph receptormedi therapi ms',\n",
       "  'NN'),\n",
       " ('updat i saw ibd specialist yesterday first followup colonoscopi may nd week ago let rewind say i stress appoint afraid ibd specialist would give option i didnt like bulli pick one i wait test result honest look surgeri i tri drop mg mg prednison last monday aw i horribl withdraw symptom start bleed that defeat i knew bad sign i went back mg stabil actual badhav bms everi day requir dulcolax though much blood my tenesmus much better i havent taken bentyl week im still fatigu manag live life despit italbeitmi hous messi someth gotta give it great symptom improv sinc im depend prednison humira cortifoam realli cant consid win here thing consid discuss treatment plan i tpmt normal can metabol mp imuranso drug becam option i antibodi humirabut my humira serum level low ibd specialist crinkl nose said that anyth becaus humira level low i wouldnt wait amount time start new biolog that decid so option discuss a humira imuran b remicaid imuran i dont antibodi c stelara imuran d entyvio imuran e divert colostomi temp i heal f perman colostomi we discuss pros con treatment i wait patient ibd specialist finish make flow chart explain everyth i ask question gave input my first question am i candid jpouch and i knew answer would no correct i immedi elimin option divert colostomi state i go surgeri i would choos perman surgeri sinc that ultim i want though i disappoint jpouch option i happi ibd specialist said surgeri is good option sinc i never shown inflamm outsid colon said chanc develop diseas elsewher mayb surgeri i would need take med anymor woot ultim i want medfre diseasefre life encourag i could live life i want live ostomybar complic but im readi surgeri yet i told ive research read peopl stori im encourag even peopl complic tend happi surgeri i afraid recoveri time i see peopl feel better immedi activ within week surgeri howev im troubl get excit i want feel good im still struggl imagin life ostomi i scare complicationsif didnt turn way i plan ibd specialist total understood i told i like humira i think help mei much wors steroid aloneand i like i side effect i want tri ad mpimuran see help wean prednison so humira imuran first choic she said ok problem we elimin remicaid altogeth respons wasnt goodi still use rowasa enema if humira imuran doesnt allow get prednison chose stelara imuran next drug therapi most stelara work quick entyvio but i consid go straight ostomi humira imuran fail it realli depend thing go someth click visit when i got car leav i didnt cri feel scare confus i felt reliev becaus surgeri isnt sound bad i start posit vision life ostomi my famili go vacat june th i ask keep thing stabl i return i want enjoy ibd specialist said of cours told add imuran dont worri drop prednison i get back i appreci i blood drawn monitor june nd i see ibd specialist june th blood drawn i need get flu shot pneumonia vaccin i nervous get plane also go disneyland rememb measl outbreak mg prednison humira imuran on handmi immun system relentless im physic pretti strong right chanc good i fine but suggest stay healthi travel appreci so think guy yr femal dx uc dx chang crohn coliti current humira apriso uceri foam enema prednison buproprion synthroid start humira feb mgweek previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri im glutenfre supp vsl calmag vit d krill oil ezf iron',\n",
       "  'NN'),\n",
       " ('congratul great respons keytruda i diagnos stage non smallcel lung cancer march opdivo i start later year fda approv i happili stabl two half year im treatment pretti well i side effect muscl joint pain cours aw fatigu much better diagnosi i start i brain tumor lung tumor pulmonari embol ive come long way i feel lucki thank i think need think posit hope treatment work well i also think opdivo miracl drug i wish work well everybodi lisa',\n",
       "  'NN'),\n",
       " ('remind start entyvio pill cam i think entyvio realli slow act perhap enough time rule complet i start entyvio august januari dose i final felt like someth diagnos wcrohn med synthroid allergi med b liquid probiot fish oil turmer migrain med prn vicodin prn gall bladder remov start entyvio have tri sulfasalazin asacol entocort imuranallerg humira remicad serious joint painfatigu stop dose mp cimzia pentasa mtx arava joint pain',\n",
       "  'NN'),\n",
       " ('result phase studi pembrolizumab chemotherapi pemetrex platinumbas drug found combin result signific longer overal surviv os progressionfre surviv pfs compar chemotherapi alon reduc risk death patient metastat nonsquam nonsmal cell lung cancer nsclc these data present american associ cancer research confirm earlier phase studi find lead author leena gandhi md new york univers perlmutt cancer center nyu langon health new yok said data unequivoc alter clinician treat type nsclc befor studi firstlin therapi advanc nsclc lack target mutat egfr alk platinumbas chemotherapi patient tumor proport score program death ligand pdl greater pembrolizumab replac cytotox chemotherapi dr gandhi also author phase studi said small number trial meant daili practic pattern didnt chang number small make definit conclus with patient phase studi howev estim rate os month pembrolizumabchemotherapi group compar placebochemotherapi group median pfs month pembrolizumabchemotherapi group month placebochemotherapi group the median os yet reach pembrolizumabchemotherapi group further rate advers event almost ident two arm similar advers event grade higher relat articl immunotherapi lung cancer are combin regimen path forward time report palliat care need lead more appropri endoflif care nsclc osimertinib improv qualityoflif global health status nonsmal cell lung cancer these result incred clear cut dr gandhi said it earli look clear differ there question result studi there noth wait alter treatment regimen pd pdl inhibitor chemotherapi mount evid suggest pd pdl inhibitor effect treatment nsclc said for instanc data present confer nivolumab ipilimumab advanc nsclc checkmat clinicaltrialsgov identifi nct found combin signific prolong pfs compar platinumdoublet chemotherapi alon the keynot studi clinicaltrialsgov identifi nct allow crossov pembrolizumab monotherapi patient demonstr diseas progress the benefit combin shown patient level pdl express even pdl tumor proport score less dr gandhi said although greatest respons rate group differ found patient tumor proport score greater pembrolizumab combin group vs placebo combin group',\n",
       "  'NN'),\n",
       " ('hi sue discuss neuro rrspms definit i told recent improv ask sure ms progress he said sure anyon last damagedis caus relaps otherwis return normal remiss definit progress ms he also said mani peopl progress diseas relaps remiss dmds my ms activ lot relaps never offer dmd yrs confus i realli lot think didnt think elig treatment go find candid cladribin lisa',\n",
       "  'VBD'),\n",
       " ('this weekend post alemtuzumab work peopl fingolimod beg question how transit peopl fingolimod onto someth els we debat natalizumab alreadi look post aspect highlight fingolimod natalizumab racehors drug they keep cell trap stop enter brain as kill drug diseas form cell accumul time they starter order race brain stop drug diseas rebound peopl there mani limod trial ongo take fingolimod siponimod what measur place drug suppli stop end trial how rebound go prevent even progress everi want call ms trial these drug kill drug trap drug fingolimod trap diseasecaus cell lymphoid tissu natalizumab trapdiseas caus cell blood they stop diseas process diseas caus cell accumul trap whilst drug treatment place howev see cell racehors wait run brain starter order wait go the gate open theyr remov drug cell escap get brain diseas activ occur whilst peopl view progress ms differ diseas i think dumb view import danger view it clear mani peopl activ lesion come go progress cours carri if look patholog peopl progress ms activ lesion it clear peopl progress ms benefit immuneinhibit howev i think also case racehors drug allow accumul damag cell peopl progress ms extent drug convert subclin relaps patholog relapsingact ms timebomb tick drug stop this hors line wait go stop drug relaps occursthi sometim call rebound call resum synchron relaps case dont like word reboundbut damag ever name call need avoid doe happen sure drk case report pleas drk say here md davion jb et al two case relaps primari progress multipl sclerosi fingolimod withdraw j neurol',\n",
       "  'NN'),\n",
       " ('a major research question multipl sclerosi ms determin person ms progress diseas cours respond treatment research attend american academi neurologyaan meet address crucial question look new emerg biomark ms biomark signatur found bodi object measur indic health reveal presenc progress diseas the biomark interest ms right neurofila protein found nerv cell import mainten cell structur when damag occur protein releas cerebrospin fluid blood it measur cerebrospin fluid blood marker indic brain damag ms in recent year research look level protein peopl diagnos ms found neurofila level associ ms moreov higher level serum neurofila present activ brain lesion diseas activ magnet reson imag outcom research built earlier find present result look neurofila biomark ms dr baror univers pensylvania dr calabresi john hopkin hospit dr kuhl univers basel dr sormani univers genoa evalu level neurofila blood cerebrospin fluid peopl ms treat differ diseasemodifi therapi for exampl dr baror measur level neurofila cerebrospin fluid withdrawn peopl treat ocrelizumab relapsingremit ms understand go brain they found treatment ocrelizumab reduc level white blood cell neurofila suggest neurofila might predict biomark effect treatment similar dr kuhl dr calabresi show individu ms treat fingolimod natalizumab lower level neurofila blood compar peopl take mockdrug dr thebault group dr freedman univers ottawa analyz blood serum cerebrospin fluid small group individu aggress ms receiv bone marrow transplant lower level neurofila found blood serum cerebrospin fluid receiv treatment again encourag result although preliminari depict potenti neurofila monitor respons treatment togeth research identifi biomark easili obtain inexpens reliabl correl diseas progress the use biomark measur lab still new clinic field might requir time implement standard practic this said result present meet promis could hold great potenti fill critic gap clinic have question biomark ms leav',\n",
       "  'NN'),\n",
       " ('it much rechalleng rather isnt clear afatinib isnt best option slow rate growth cancer use instanc stereotact radiat area control there isnt lot inform go one cannot confid afatinib isnt option next best would osimertinib erlotinib fewer side effect penetr brain better chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       "  'JJ'),\n",
       " ('hi amay my mom standard chemo cocktail adenocarcinoma chemo keytruda recurr year later after session keytruda chemo went keytruda year as tom said pretti common growth earli scan this growth attribut mani thing lot time inflamm this mom case at first glanc ct show look like cancer growth cancer cell found growth deem inflammationswel tumor attack immun system this growth slowli start reced still present small year later although alway want hear evid diseas take time get i keep finger cross good news tomorrow take care steff',\n",
       "  'NN'),\n",
       " ('our daughter live bay area progress ms she start ocrevus she declin fast she need doctor special progress diseas at ucsf seem slip communic slat can suggest advis',\n",
       "  'NN'),\n",
       " ('marc thank compliment regard healthnewsrevieworg recent stori ocrevus joy victori i multimedia team launch podcast seri explor certain diseas tripl perspect patient healthcar provid journalist wed like ms wonder would will share thought patient perspect if pleas email thank michael',\n",
       "  'NN'),\n",
       " ('in us inflectra ixifi remicad renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class tumor necrosi factor inhibitor use for infliximab infliximab inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi it also use children treat crohn diseas ulcer coliti infliximab inject monoclon antibodi work enhanc improv immun system infliximab avail doctor prescript befor use infliximab in decid use medicin risk take medicin must weigh good this decis doctor make for infliximab follow consid allergi tell doctor ever unusu allerg reaction infliximab medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use infliximab inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform relationship age effect infliximab inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximab inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatricspecif problem would limit use infliximab inject elder howev elder patient like infect may requir caution patient receiv infliximab inject pregnanc pregnanc categori explan all trimest b anim studi reveal evid harm fetus howev adequ studi pregnant women or anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetus breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when receiv infliximab especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use infliximab follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenovirus vaccin type live adenovirus vaccin type live alefacept anakinra bacillus calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza virus vaccin live ixekizumab measl virus vaccin live mump virus vaccin live natalizumab paclitaxel phenytoin poliovirus vaccin live quinidin rilonacept rituximab rotavirus vaccin live rubella virus vaccin live sarilumab sirolimus smallpox vaccin tacrolimus tocilizumab tofacitinib typhoid vaccin ustekinumab varicella virus vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use infliximab make sure tell doctor medic problem especi aspergillosi fungus infect histori blastomycosi fungus infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungus infect histori coccidioidomycosi fungus infect histori diabet guillainbarr syndrom nervous system disord histori hepat b activ histori histoplasmosi fungus infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungus infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet bloodus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copdus caution may increas chanc new cancer congest heart failur moder severeshould given patient condit tuberculosi histori ofus caution patient may need addit tuberculosi therapi proper use infliximab a doctor train health profession give infliximab it given needl place one vein it must given slowli needl remain place least hour infliximab come medic guid read follow instruct care ask doctor question you may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut while use infliximab it import doctor check progress regular visit make sure infliximab work proper blood test may need check unwant effect infliximab may caus infus reaction includ heart attack stroke chang blood pressur heart rhythm problem eg arrhythmia receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat your bodi abil fight infect may reduc use infliximab it import call doctor first sign infect check doctor right away fever chill cough flulik symptom unusu tired weak serious skin reaction occur use infliximab check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximab may increas chanc lupuslik syndrom liver diseas call autoimmun hepat check doctor right away dark browncolor urin fever chill general feel discomfort ill weak joint pain lightcolor stool nausea vomit rash cheek arm wors sun sever tired upper rightsid stomach pain yellow eye skin a small number peopl includ children teenag use infliximab develop certain type cancer this common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light some teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen tcell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pus skin use infliximab may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer if chang growth skin abnorm vagin bleed pelvic pain tell doctor right away while treat infliximab immun vaccin without doctor approv live virus vaccin given infliximab your child vaccin must current use infliximab talk child doctor question women if babi receiv infliximab make sure babi doctor know use infliximab you need wait month give certain vaccin babi talk babi doctor question you need skin test tuberculosi start use infliximab tell doctor anyon home ever posit reaction tuberculosi skin test it import heart check close receiv infliximab call doctor right away short breath swell ankl feet sudden weight gain do take medicin unless discuss doctor this includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab use medicin togeth infliximab may increas chanc serious unwant effect infliximab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur more common chest pain chill cough dizzi faint fever flush red face headach hive itch rash muscl pain nasal congest nausea runni nose sneez sore throat stomach pain tight chest troubl breath unusu tired weak vomit less common back pain bloodi cloudi urin crack skin corner mouth diarrhea difficult pain urin frequent urg urin pain tender around eye cheekbon sore irrit mouth tongu sore red around fingernail toenail vagin burn itch discharg white patch mouth tongu rare abscess area infect contain pus black tarri stool blood urin stool bone joint pain constip feel full hernia lump abdomen stomach irregular pound heartbeat pain rectum pain spread abdomen stomach left shoulder pinpoint red spot skin stomach pain sever swollen pain gland tendon injuri unusu bleed bruis unusu weight loss yellow skin eye incid known bloodi nose burn tingl numb pain hand arm feet leg chang mental status claycolor stool continu vomit dark bloodi urin difficulti speak difficulti swallow fast heartbeat general feel tired weak heavier menstrual period hoars inabl move arm leg itch puffi swell eyelid around eye face lip tongu lightcolor stool loss appetit loss bladder control lower back side pain muscl spasm jerk extrem noisi breath painless swell neck armpit groin pale skin red scale crust skin red sore itch skin seizur sensat pin needl sever muscl weak sudden progress slow irregular breath sore welt blister stab pain sudden loss conscious sudden numb weak arm leg unpleas breath odor upper right stomach pain vomit blood other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'JJ'),\n",
       " ('hello i would like know doctor use combin immunotherapi tki drug egfr patient how combin two immunotherapi drug combin immunotherapi chemo will combin therapi increas respons rate egfr patient my dad recent ct scan show progress tagrisso he diagnos leptomening metastasi nov his brain mri dec still show stabl i dont feel comfort immunotherapi alon ive heard respons rate egfr patient end sever health condit requir hospit kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('i schedul neuro appoint yesterday us im current stabl gilenya his view cladribin said hed put cladribin heartbeat he strong advoc lemtrada he quit patient arewer lemtrada he optimist cladribin get approv near futur fda well see goe',\n",
       "  'NN'),\n",
       " ('the trial failur gave result rememb compound licens australia russia may well europ merck submit document ema approv howev fda ema approv movectro i sure i would sun i part programm sure get when fingolimod goe generic cladribin patent deriv dead arriv it depend stack better mayb peopl pay can look forward day fingolimod goe generic although i sure the landscap may inde chang is us have novarti lost extens case what australia you sling mud like help know sling help right sling otherwis come across troll what behaviour would like chang howev i would like understand what posit tri defend upset mayb get name like mudsling rather hide behind anaonym dish dirt',\n",
       "  'NN'),\n",
       " ('lung cancer lead caus cancer death men women unit state respons million death worldwid year advanc target molecular therapi improv outcom patient egfr driven tumor approxim peopl north america whose tumor driven mutat kras general consid inelig therapi the presenc mutat usual found codon eg kras gd associ poor prognosi surviv poor respons egfr inhibit patient nonsmallcel lung cancer nsclc howev new research two group work independ scotland vienna show signal erbb famili member necessari surviv prolifer kras driven tumor tyrosin kinas inhibitor tkis block multipl erbb specif afatinib neratinib produc antitumor respons egfr one four erbbfamili receptor tyrosin kinas found upstream kras g protein gtpase activ part erkmek pathway cell kras normal activ respons signal upstream receptor tyrosin kinas egfr erbb her activ mutat kras thought confer independ upstream regul howev studi show gmutant kras continu requir input egfrerbb famili receptor order drive lung cancer explain daniel j murphi phd lead investig oncogeneinduc vulner group univers glasgow institut cancer scienc cruk beatson institut cancer research scotland relat articl biomarkerbas blood test may extend reach ct screen certain lung cancer role braf mutat nonsmal cell lung cancer still emerg evolv bevacizumab plus erlotinib may be new standard care nonsmal cell lung cancer patient kras driven tumor general respons egfrspecif inhibitor use treat lung cancer erlotinib gefitinib these studi found kras mutat tumor progress increas express nonegfr erbb ligand depend altern erbbfamili signal surviv in vienna studi inhibit erlotinib genet inactiv egfr led mutat kras adenocarcinoma overexpress erbbfamili receptor thus work around loss egfr signal restor downstream growth factor activ use public avail data set biopsi human tumor vitro model mous model moll colleagu demonstr nonegfr erbb signal activ appear necessari surviv human mous kras driven lung adenocarcinoma afatinib inhibit tumor growth',\n",
       "  'NN'),\n",
       " ('new diabet diabet retinopathi research indic peopl type diabet intens control blood sugar level landmark a ction c ontrol c ardiovascular r isk d iabet accord trial eye studi cut risk diabet retinopathi half followup analysi call accord followon eye studi accordion conduct four year stop intens blood sugar control regimen requir accord trial this studi send power messag peopl type diabet worri lose vision said dr emili chew studi coauthor deputi director nation eye institut divis epidemiolog clinic applic wellcontrol glycemia blood sugar level posit measur last effect eye health pleas note howev cautionari issu unresolv causat factor relat blood sugar glycem control group origin accord studi discuss reader evalu care discuss physician about research diabet care this new diabet retinopathi research entitl persist effect intens glycem control retinopathi type diabet action control cardiovascular risk diabet accord followon studi publish juli edit diabet care peerreview journal publish month american diabet associ ada diabet care journal health care practition intend increas knowledg stimul research promot better manag peopl diabet the author emili chew md nation eye institut action control cardiovascular risk diabet followon accordion eye studi group action control cardiovascular risk diabet followon accordion studi group some explan terminolog the accord trial the accord trial involv studi site across north america enrol particip type diabet the purpos accord trial test three treatment strategi reduc risk cardiovascular diseas among peopl longstand type diabet maintain nearnorm blood sugar level intens glycem control improv blood lipid level lower ldl bad cholesterol triglycerid rais hdl good cholesterol lower blood pressur editor note the treatment phase glycem blood sugar control portion accord plan last year stop year due increas death among particip intens glycem control group analys thus far determin specif caus increas death howev benefit intens glycem therapi must weigh potenti risk notabl increas risk death observ accord trial the accord trial eye studi analyz subset trial particip receiv laser photocoagul vitrectomi prolif diabet retinopathi data begin year four studi accord sponsor nation heart lung blood institut collabor nation institut diabet digest kidney diseas nation institut age nation eye institut center diseas control prevent you read accord trial the nation institut health clinic trialsgov the accordion followon eye studi accordion followup assess diabet retinopathi progress peopl particip accord accordion reassess diabet retinopathi approxim four year intens glycem control portion studi end eight year enrol accord by time averag ac see explan percent intens therapi group percent standard therapi group howev diabet retinopathi advanc percent particip intens therapi group sinc enrol accord compar percent standard therapi group accordion fund nation heart lung blood institut part nation institut health type diabet type diabet former call adultonset type ii noninsulin depend follow characterist it usual occur age affect individu diabet it occur pancrea produc enough insulin insulin defici bodi cell abl use insulin correct effici insulin resist condit present glucos continu rise bloodstream suffici level insulin avail open cell allow glucos enter initi manag weight loss physic activ effect meal plan for individu suffic period time diseas progress howev oral medic insulin may also requir primari risk factor includ increas age ethnic background africanamerican latino nativ american asian famili histori obes you learn what is diabet the ac test the ac blood test also known glycat hemoglobin hemoglobin ac hbac primari tool use diagnos diabet prediabet monitor blood glucos control peopl type type diabet this test enabl health care provid diagnos diabet treat complic occur diagnos prediabet prevent delay develop type diabet you read establish ac level use diagnos diabet prediabet diabet signific ac test about research excerpt intens diabet treatment prevent damag vision unit press intern intens treatment diabet help prevent damag blood vessel retina often lead blind accord longterm studi nation institut health research use aggress treatment maintain glycem control blood lipid level blood pressur cut risk develop diabet retinopathi half report the research stop portion focus glycem control year plan year test increas death among particip though patient treat blood pressur blood lipid level continu rest intend test period tight control condit improv health patient reduc risk cardiovascular diseas the treatment howev reduc progress retinopathi onethird for new studi research reexamin patient took part origin accord studi measur progress particip retinopathi four year treatment conclud while measur blood glucos particip receiv intens standard care remain similar end previous studi percent particip seen advanc retinopathi less half percent receiv standard treatment whose condit progress more diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age what person diabet retinopathi may see retinopathi general term describ damag retina the retina thin lightsensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls these electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif general term mean grow increas rapid rate produc new tissu cell when term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina nonprolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild nonprolif retinopathi at earli stage small area balloonlik swell occur retina tini blood vessel moder nonprolif retinopathi as diseas progress blood vessel nourish retina becom block sever nonprolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina the damag retina signal bodi produc new blood vessel prolif retinopathi at advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreous transpar gel fill interior eye becaus new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreous scar tissu develop tug retina caus damag even retin detach more studi diabet care condens excerpt articl summari conclus full articl avail onlin our result show intens glycem control confer endur protect progress diabet retinopathi even though glycat hemoglobin level similar year random year cessat clinic trial this first studi peopl type diabet year durat establish cardiovascular diseas unlik newli diagnos particip unit kingdom prospect diabet studi ukpd demonstr effect this phenomenon call metabol memori legaci effect studi type diabet the accordion find demonstr similar legaci effect intens glycemia control progress retin diseas peopl establish type diabet moreov effect occur respons median year intens glycem control observ peopl type diabet addit cardiovascular risk factor whose mean diabet durat year whose initi mean hbac these observ suggest glucos lower reduc progress retin diseas relat late cours diabet retina respond relat shortterm chang glucos level whether even shorter period glucos lower could achiev similar longterm effect eye either type type diabet remain unknown in summari studi result provid evid intens glycem control benefici reduc progress diabet retinopathi legaci effect evid peopl type diabet the addit accordion retin result prior find demonstr posttreat benefit intens glycemia control progress eye kidney nerv diseas',\n",
       "  'JJ'),\n",
       " ('gumbi thank dont worri im surpris either the day ill surpris someth work i dont think cimzia approv treatment crohn uk anoth thing i check but id rather tri stelara least someth differ antitnf as map treatment yeah i would consid i posit map havent mani antibiot cours coupl i taken didnt make differ fact metronidazol flagyl posit horribl a stoma wouldnt necessarili stop diseas it crohn arent guarante that said far stoma liter thing year given break crohn but i get stoma come back i dont see im better posit i onc im torn',\n",
       "  'JJ'),\n",
       " ('the biolog price competit innov act bpci act sign law march part afford care act the bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product a total evid approach taken fda evalu biosimilar approv the result clinic trial import data preclin work also consid onc biosimilar approv use fda approv addit indic condit base concept call extrapol data if data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct for instanc clinic trial biosimilar filgrastimsndz studi effect safeti clinic trial whose particip treat breast cancer when approv grant fda filgrastimsndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth bloodform cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac bloodform stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastimsndz current twelv biosimilar approv fda treatment specif condit in fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas these drug list order approv infliximabdyyb inflectra origin product infliximab remicad etanerceptszz erelzi origin product etanercept enbrel adalimumabatto amjevita origin product adalimumab humira infliximababda renflexi origin product infliximab remicad adalimumabadbm cyltezo origin product adalimumab humira infliximabqbtx ixifi origin product infliximab remicad in septemb fda approv bevacizumabawwb mvasi treatment five type cancer nonsquam nonsmal cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumabawwb approv indic origin drug bevacizumab avastin could reach us market soon patent bevacizumab expir in decemb fda approv trastuzumabdkst ogivri treatment peopl herposit breast cancer herposit gastric cancer her growthpromot protein found surfac cancer cell the origin drug trastuzumab herceptin patent expir',\n",
       "  'NN'),\n",
       " ('hi i mris everi month sinc februari in octob i met neurologist blue said jc virus level risk zone pml i need come gilenya i took last one today wait month mri due st cours lemtrada point next year noon seem know i could everyth lengthi time look first time year could interest i felt like i nag everi time i question next mri im risk level i feel justifi keep top i also special blood test courier denmark everi month pml check stop year say i need mri scan keep express concern led believ pml slow progress notic earli better chanc deal not much hope spot month later good luck keep strong x',\n",
       "  'NN'),\n",
       " ('new fda approv zykadia ceritinib alkposit nsclc whi i think it poor choic initi treatment the fda approv new therapi approxim patient nsclc molecular marker known alk rearrang the cancer journey just diagnos in treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey in treatment cancer type lung cancer diseas learn target therapi imprecis medicin whi keytruda pembrolizumab chemo pdl nsclc isnt readi prime time let start say im fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi chemotherapi immunotherapi is immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu in fact cancer journey in treatment cancer type lung cancer diseas learn target therapi firstlin treatment symptom secondlin treatment death pseudoprogress know when cut your loss immunotherapi among mani novel concept manag immunotherapi potenti pseudoprogress this unusu phenomenon patient scan cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi secondlin treatment immunotherapi view more communiti forum local therapi metastat lung cancer who what whi when how hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer who cancer journey just diagnos in treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ros procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva tm negat progress year tarceva tissu biopsi show tm negat ani suggestionsexperi next step onc suggest i move afatinib opdivo pdl test cancer journey in treatment cancer type lung cancer diseas learn lung cancer general lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc has anyon inform obtain use vaxira cuban drug stage advanc nsclc not sure us citizen still travel cancer journey in treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva my wife come long way stage iv lung cancer sinc she develop acquir resist tarceva gene sequenc biopsi cancer journey just diagnos in treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       "  'NN'),\n",
       " ('thank i diagnos nsclc stage iv met bone one brain lesion hip lesion egfr exon gs ga februari i know exon rare on tarceva sinc mid march look like i progress t blood least negat my physician consid new biopsi find place is data suggest exon common mutat t perhap compar exon there seem choic progress rare mutat current standard next step med t negat thank',\n",
       "  'NN'),\n",
       " ('i fail remicad cimzia humira entivyo sigh insur wont cover stelara experiment unsubstanti are sure experiment the fda approv stelara last year crohn if appeal decis probabl good chanc win appeal id get gis offic involv appeal also state insur regul keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri total hip replac thank prednison current condit chronic pouchiti not bad i thought would current med stelara',\n",
       "  'JJ'),\n",
       " ('howevervot count start higher leav predict go close look thing less affluent area vote much higher number predict swing leavei entyvio infus tomorrow shouldnt realli stay night watch proctiti pan coliti mani well year flare yrs med help raw sauerkraut mezav xl x day march pseudomembran coliti treat flagyl thing harder sinc cours pred intoler aza mp oct start entyvio far good respons',\n",
       "  'NNS'),\n",
       " ('holtyc i understand concern father there may option progress variant ms slight improv none the nation institut clinic excel nice determin drug suppli nhs base effect valu money there lot research go httpswwwmssocietyorgukresearchexploreourresearchemergingresearchandtreatmentsexploretreatmentsintrialsresulttypelistsortrelevancepageresult howev futur look answer the follow interest httpmultiplesclerosisresearchblogspotcomcladribineforpeoplewithprogressivehtml if father londonbas well could ask refer bart team see treat offlabel',\n",
       "  'VBP'),\n",
       " ('thank jonock that use can post link buy also help symptom take care ulcer coliti sinc juli pred mg upadacitinib clinic trial sinc octob colazid g entyvio vedolizumab sinc januari stop oct lost respons azathiporin mg stop due clinic trial',\n",
       "  'JJ'),\n",
       " ('novarti today announc posit result phase iii expand studi show oral oncedaili baf siponimod signific reduc risk confirm disabl progress compar placebo peopl secondari progress multipl sclerosi spms spms form ms character continu worsen neurolog function time independ relaps toplin result expand present nd congress european committe treatment research multipl sclerosi ectrim london uk baf investig select sphingosinephosph sp receptor modul initi first interpret data expand studi show treatment baf reduc risk threemonth confirm disabl progress compar placebo p the risk reduct sixmonth confirm disabl progress greater support robust data a consist reduct risk threemonth confirm disabl progress across predefin subgroup a signific differ favor baf compar placebo month annual relaps rate percent chang brain volum chang baselin volum t lesion brain lesion identifi tweight magnet reson imag scan the differ chang baselin time foot walk test tfw signific baf general safe well toler profil compar drug class there avail treatment option delay diseas progress spms high unmet need effect therapi accept safeti profil peopl condit said vasant narasimhan global head drug develop chief medic offic novarti novarti global leader understand role sp receptor modul treatment ms posit result expand studi continu ongo effort innov meet need patient these data posit stride forward unserv diseas area look forward evalu next step health author expand largest random control studi spms date patient enrol expand repres general spms popul they must diagnos spms also demonstr progress disabl two year prior studi the major patient nonrelaps spms the mean age studi entri year patient median expand disabl status scale edss score correspond use walk aid novarti complet full analys expand data evalu next step consult health author the full studi result includ data primari secondari endpoint submit public about expand studi the expand studi random doubleblind placebocontrol phase iii studi compar efficaci safeti baf versus placebo peopl secondari progress ms spms it largest random control studi spms date includ peopl spms countri at time studi individu enrol expand mean age year live ms approxim year patient receiv diagnosi spms also demonstr progress disabl two year prior studi they also expand disabl status scale edss score inclus median score correspond use walk aid patient random receiv either mg baf placebo ratio respect the primari endpoint studi time threemonth confirm disabl progress measur edss versus placebo secondari endpoint includ delay time sixmonth confirm disabl progress base edss versus placebo time confirm worsen least baselin time foot walk test tfw t lesion volum annual relaps rate arr safeti toler baf peopl spms about baf siponimod baf siponimod investig select modul specif type sphingosinephosph sp receptor the sp receptor common found surfac specif cell resid central nervous system cns respons caus cns damag drive loss function secondari progress ms spms invitro studi show baf enter brain bind specif receptor may prevent activ harm cell help reduc loss physic cognit function associ spms about multipl sclerosi multipl sclerosi ms chronic disord central nervous system cns disrupt normal function brain optic nerv spinal cord inflamm tissu loss the evolut ms result increas loss physic eg walk cognit eg memori function there three type ms relapsingremit ms rrms secondari progress ms spms primari progress ms ppms spms character gradual worsen neurolog function time this lead progress accumul disabl independ relaps sever affect patient abil carri everyday activ it usual follow initi phase rrms account approxim ms diagnos quarter peopl rrms eventu go develop spms within year initi rrms diagnosi rise threequart year there remain high unmet need effect safe treatment help delay disabl progress spms ms affect around peopl us about novarti multipl sclerosi the novarti multipl sclerosi ms portfolio includ gilenya fingolimod sp modul indic relaps form ms also develop pediatr ms extavia interferon betab subcutan inject approv us treatment relaps form ms in europ extavia approv treat peopl relapsingremit ms secondari progress ms spms activ diseas peopl singl clinic event suggest ms in addit baf siponimod develop spms investig compound includ ofatumumab omb fulli human monoclon antibodi develop relaps ms ofatumumab target cd current investig two phase iii pivot studi in us sandoz divis novarti market glatopa glatiram acet inject mgml first generic version teva copaxon mg disclaim the forego releas contain forwardlook statement identifi word continu investig continu ongo effort stride forward look forward next step develop investig similar term express impli discuss regard potenti market approv baf omb potenti new indic label gilenya extavia regard potenti futur revenu baf gilenya extavia omb glatopa you place undu relianc statement such forwardlook statement base current belief expect manag regard futur event subject signific known unknown risk uncertainti should one risk uncertainti materi under assumpt prove incorrect actual result may vari materi set forth forwardlook statement there guarante baf omb approv sale market particular time neither guarante gilenya extavia submit approv addit indic label market particular time nor guarante baf gilenya extavia omb glatopa commerci success futur in particular manag expect regard product investig compound could affect among thing uncertainti inher research develop includ unexpect clinic trial result addit analysi exist clinic data unexpect regulatori action delay govern regul general compani abil obtain maintain proprietari intellectu properti protect general econom industri condit global trend toward health care cost contain includ ongo price pressur unexpect safeti qualiti manufactur issu risk factor refer novarti ag current form f file us secur exchang commiss novarti provid inform press releas date undertak oblig updat forwardlook statement contain press releas result new inform futur event otherwis about novarti novarti pharmaceut corpor offer broad rang medicin cancer cardiovascular diseas endocrin diseas inflammatori diseas infecti diseas neurolog diseas organ transplant psychiatr diseas respiratori diseas skin condit locat east hanov nj novarti pharmaceut corpor affili novarti ag provid innov healthcar solut address evolv need patient societi headquart basel switzerland novarti offer diversifi portfolio best meet need innov medicin eye care costsav generic pharmaceut novarti global compani lead posit area in group achiev net sale usd billion rd throughout group amount approxim usd billion usd billion exclud impair amort charg novarti group compani employ approxim fulltimeequival associ novarti product avail countri around world for inform pleas visit httpwwwnovartiscom novarti twitter sign follow novarti httptwittercomnovarti for novarti multimedia content pleas visit wwwnovartiscomnewsmedialibrari for question site requir registr pleas contact copaxon regist trademark teva pharmaceut industri ltd novarti media relat central media line email',\n",
       "  'JJ'),\n",
       " ('amap therapi magic bullet everyon much higher success rate biolog can citat pleas for uc crohn possibl dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('well year wife diagnosi as previous updat i need start thank everyon dedic compass pass site cancer journey in emot rocki path deal cancer inde bless place get clear focus inform peopl care much affect i remain deepli grate year ago i first start read stage nsclc i afraid wife might even make long despit persist call mani way everi cancer everi patient uniqu statist still fear now odd place everyth seem stabl good moment cancer still lurk around corner gemzar seem hold thing bay moment next ct scan next week alway apprehens weach new ct keep keyboard finger cross wife feel realli good bit headach ach coupl day treatment noth like carbo my wife amaz strength energi complet cochair huge fundrais gala synagogu continu x week esl tutor adult we continu communiti chorus so keep score basic treatment line effect line treatment ineffect one appar new metastas number month dure year son graduat colleg daughter got engag marri weve gone israel galapago quebec taken number small trip la toronto denver the time also includ father death year ago unfortun fall section famili almost exact year ago one graph speak your site remain bright spot world fog fear wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met tumor growth liver met stabl all stabl addl growthoff trial gemzar tumor reduct stabl',\n",
       "  'NN'),\n",
       " ('guysssss updat ive work realli hard get healthi back shape sinc colectomi oct i cannot believ month alreadi as i previous wrote hardest part heal process wean darn prednison a coupl month ago i sign fatloss program week time i lost lbs competitioni proud then famili took vacat hawaii i found outim pregnant crazi right at one point thread i thought life id never well i would never abl workout id never anoth child im glad i wrong surgeri gave back life life good ostomi yr femal dx uc dx chang crohn coliti current total colectomi oct previous use remicad humira stelara imuran mp apriso asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam prednison im glutenfre supp vsl calmag vit d krill oil ezf post edit plucki pm gmt',\n",
       "  'NN'),\n",
       " ('hey everyon i crohn small illieum i believ that what call lol i alreadi humira remicad i crohn sinc i im remicad stop work doctor switch stelara i get infus first time yesterday remaind time im i take shot first shot week sinc i infus yesterday i wonder long take stelara kick anyon experi side effect reach remiss anyth tell help thank',\n",
       "  'NN'),\n",
       " ('hi fano in addit great inform alreadi provid janin write i review anoth post dr west deal valu pdl test differ respons eventu approv keytruda opdivo he point although opdivo seem efficaci pdlnegat patient approv use patient keytruda that due differ clinic trial led drug approv differ mechan action agent also note addendum post dr west soften stanc whether secondlin taxoter docetaxel clear superior opdivo set he also state feel patient get opportun treatment immunotherapi agent point jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('hello friend i seek advic behalf mother she gilotrif month this first line treatment stage iv nsclc adenocarcinoma egfr exon neversmok her respons initi posit recent medic seem less effect diseas shown progress given advanc age januari opt liquid biopsi test tm genet marker use genestrat test the test unfortun came back negat i realiz tissu biopsi conclus determin mutat depend site sampl falseneg still possibl use method with greater chanc develop drug resist due tm mutat possibl posit enough circul tumor detect current sampl method find tm mutat easter egg hunt leav candid could potenti benefit my question even though result tm mutat may negat new medic tagrisso still work germlin egfr genet marker it would go far label treat tagrisso despit inclus result tm what possibl drawback prescrib egfr chanc tm what step would need prescrib tagrisso secondlin treatment offlabel use treat egfr patient given condit tradit chemotherapi would overwhelm sincer chi this topic modifi year month ago chidog this topic modifi year month ago chidog',\n",
       "  'NN'),\n",
       " ('sth i cladribin week ago veri simpl procedur day intect secondari effect realli pill given think rrms think pharma money make inyect differ situat eg advanc inject patent cheaper internet full scari stuff peopl report thing sometim could ms drug by way hair lost case least yet still keep frizzi hair doe work earli day guess my hope let see i fingolimod think good stop relaps noth start spms take bad place secondari effect lymphocit low lymphopenia get wors time rebound effect stop twice immun system back normal attack come back in opinion drug stop spms beast would go sth caus troubl realli go throughin case spms start yesr but older younger noon predict take care xxx',\n",
       "  'VBD'),\n",
       " ('i diagnos stage adenocarcinoma dec one met hipbon anoth met hipbon discov may treat i vat ull remov lung tumor radiat met im current ned take tarceva sinc may hope stay ned due side effect first worst horribl acid reflux dosag reduc mg mg i otherwis healthi year old femal nonsmok struggl side effect tarcevath reflux continu frequent diarrhea horribl fatigu depress rash eye sore nose alway terribl sore constant runni hair fall stop grow food doesnt tast mouth alway sensit my doctor casual ask i want stop medic hasnt realli entertain much discuss pros con im scare i know high recurr stage lung cancer idea success other medic stay ned i also wonder other taken break medic my doctor impli one start medic cannot stop develop resist onetim chanc opportun i grow weari cumul effect side effect also know could much wors cours grate ned will i need improv chanc stay way',\n",
       "  'RB'),\n",
       " ('repli post david remicad stelara sever other they possibl side effect deal infect sinc your knock immun system most side effect ive arent warn odd took remicad imuran dx decad ago after i develop abnorm lymph respons develop tumor lymph node i realli heart believ imuran blame while i scare lymphoma tumor remov everyth benign thank i move humira work sever year i got great remiss year i recent fail humira becam hypotens blood pressur drop we believ plummet bp exampl time odd reaction humira i quit humira month bo return normal i start stekara no ill effect thus far got load infus keep finger cross work magic make well',\n",
       "  'JJ'),\n",
       " ('hi patterson welcom whatnext i glad found us im also glad alreadi ask question my cancer adenocarcinoma nonsquam cell non small cell i cant specif relat opdivo control cancer past year i hope youll similar result keytruda',\n",
       "  'JJ'),\n",
       " ('has oncologist talk dental health beyond ask mouth sore oncologist busi peopl patient mani question cancer treatment we miss ask import area affect overal wellb wallet if treat system cancer treatment like affect oral health tip good oral hygien here tip take care mouth fight cancer these tip help newli diagnos lung cancer patient treatment make dental appoint soon possibl learn lung cancer get good clean fix lurk dental problem soon cancer treatment may make difficult deal dental issu futur keep dentist inform treatment some treatment limit dentist dental problem for exampl avastin bevacizumab dental hygienist dentist go need gentl gum you cannot dental surgeri extract unless stop take drug xgeva denosumab anoth drug increas risk necrosi jaw good dental hygien import ever when i chemo i notic teeth becam coat icki feel much easili the better clean teeth like prevent tooth decay need invas dental procedur you may need chang dental care product use mani cancer treatment make mouth sensit harsh spici flavor a minti toothpast i use year burn mouth i first start take tarceva erlotinib you find mani product made sensit mouth pharmaci i got good result switch gentl fruitflavor dental product made children your dentist also prescrib mild toothpast higher fluorid a simpl salin rins help meal lighten brush techniqu consid use electr toothbrush water flosser you dilig tooth clean effort scrub mouth clean hard teeth gum in case i brush vigor found easier correct problem use electr toothbrush i make sure i softest manual toothbrush i find hand time electr toothbrush need recharg i travel alon leav home my dental hygienist recommend water flosser caution use gentl set watch reced gum unfortun gum tissu worn away gone forev if gum start reced talk dentist soon possibl a gentler touch may enough stave futur damag keep mouth moist saliva protect mouth well make easier swallow food my dentist say dri mouth lead caus sudden widespread tooth decay rule one cancer treatment stay hydrat help there also sever product market dri mouth use seem issu the enjoy solut special kind candi contain sugar my dentist strong recommend suck xylitol hard candi stimul saliva suppress bacteria caus tooth decay you worth invest a friend lung cancer talk quandari decid whether worth spend money expens dental care dont know long abl benefit invest anyon ever toothach know get need dental care unpleas result i rememb think diagnosi wast money acquir anyth new includ cloth yarn knit hobbi eyeglass my new oncologist told you get new glass peopl need get thing even use week qualiti life import dental health right eyeglass part live best life',\n",
       "  'NN'),\n",
       " ('damn anoth two week gone sinc februari post appoint doctor visit even new consult ad with crohn diseas journey ive felt differ start stelara i followup gi dr s past week i got explain everyth the week stelara infus urgenc bowel pain flare ive spent time spare bathroom read second offic symptom run wild late i mention ive diagnos fibromyalgia i would like take time write blog focus specif im still research she ask perian diseas luckili abscess fistula fissur ouch she told stelara could take week effect around time first selfinject medic the stelara needl differ humira pen i use past automat button small needl dont see the stelara shot normal needl style patient watch needl go skin ill inject time year i home luckili around time inject time i expect feel better around month ill anoth followup dr s gi see i maintain and later week i met plastic surgeri anoth followup appoint take blood pressur temperatur event plastic surgeri depart as per usual temperatur littl high i seem alway lowgrad fever i blame immunocompromis alway keep constant feel cold run fever when went check blood pressur thought i suffer heart attack my blood pressur skyrocket high even sit wait area good minut they hook right arm nut he told high heart attack rang someth would take er immedi the nurs shock went tell doctor then tri left arm right arm they time ask id ever valv blood pressur issu i told i hadnt there wasnt issu left arm right after redo decid possibl fluke couldnt explain log medic chart the doctor dr r look ganglion cyst surgeri scar reason followup my cyst area still tender rang movement nonexist i babi left hand still use much i avoid certain movement send shoot pain nerv grip still weak the doctor look scar move wrist thumb around uncomfort he almost seen surpris said doesnt look like come back almost insinu yet end the doctor told i would probabl still pain tender i could wear brace help he told want see three month make sure wasnt come back see im still nerv pain i mention i take gabapentin unrel nerv pain help hand now hand rememb i couldnt get mri septum pierc i call va reschedul outsid sourc would perform nose ring i talk ladi appoint happen day she told would call back didnt i call va week hear noth i told anoth repres i talk lunch i call later afternoon transfer around time told i would talk primari care team so i call primari care when i talk nurs told primari care hard time schedul outsid visit sinc musculoskelet issu perhap could set referr while i nurs phone i mention rib issu never resolv in januari i xray rib see primari care sinc area inflamm one singl rib i mention primari care doctor dr c felt around left side rib note swollen area see ganglionectomi after xray i got letter state lung clear real answer when i ask nurs littl confus kept bring right side breast never pain relat pleas note pain unrel the breast nerv pain like electr shock happen sporad send shock outsid right breast whi i still dont know answer nerv pain the leftsid rib pain swell like lump near bottom rib left side sometim feel larger normal feel sore touch alway spot compar right side noth lump swell rib i express nurs told would ask dr c return call when call back dr c told xray clear know nodul sort one rib she told i would need new consult general surgeri find need remov my luck need surgeri ill get ahead knock wood finger cross i dont ill general surgeri consult upcom week im sure itll requir appoint scan sort whether anoth xray mri sometim i feel like i live va and i visit va im constant call ive alreadi appoint year futur appoint alreadi plan i call va anoth matter week prescript i went onlin print current medic list medic crohn diseas pill i take daili imuran mental health medic lexapro mark discontinu i call request mark activ i mention gi last visit i need refil imuran soon like forgotten i havent seen mental health sinc invas privaci i worri theyd make anoth visit let refil prescript luckili easi fix activ status back normal otherwis past week ive gotten insomnia i thought perhap problem help melatonin mirtazapin ive late night late alway anoth appoint it could be wors blog alway anoth appoint it could be wors blog sometim i fall asleep i wake middl night restless sometim i cant fall asleep bodi crash sometim ive even face hair late either ive share social media stori daili activ ive home day pajama im va i hope help explain lack imag post usual i bunch throughout i think i less hand oneand singl selfi my bodi hurt back stomach head hand time pretti unev i make medic bottl wreath hoard mess medicin bottl last coupl year you may seen alreadi social media i keep bottl like i wristband procedur i decid make wreath offic read real offic i still ton i thought creat one va mayb gi would like one i also sign lexington take step walk year crohn coliti i particip i drop ball last year forgot regist i made sure regist earli year it held whitak ball park lexington septemb you join my team without donat donat cure for ibd donat page youd like instead i prefer donat go toward cure ibd goe research unlik fundrais page i know i mention last post start new job i go first day i learn rope expect everyth job complet differ id told two interview compani i thank opportun i continu look elsewher it harder look think health job search i think hour job feel appoint avail doctor visit happen littl time advanc detail job requir well worri wellb bodi feel everi singl day if werent hand difficult id phlebotomi if i could choos i i would love focus write journal i know i matter find right fit think crohn fibromyalgia everyth els wrong for i suppos ill focus get well for it could be wors thank read keep my crohn journey pleas like it could be wors blog facebook and alway inform youd like offer infus current struggl andor issu i open ear ill happili take tip offer cure ibd for continu donat cure crohn coliti i encourag donat toward team page cure ibd fund we rais alloc ibd research cure that right to donat wwwcureforibddonordrivecomcampaignicbwblog ibd news today column welcom it could be wors a column mari horsley previous post it could be wors februari stelara infus ganglionectomi pain ganglionectomi entyvio the last goodby hello colonoscopi crohn diseas essenti emerg kit wego health nomin',\n",
       "  'NN'),\n",
       " ('childhood soft tissu sarcoma diseas malign cancer cell form soft tissu bodi soft tissu sarcoma occur children adult have certain diseas inherit disord increas risk childhood soft tissu sarcoma the common sign childhood soft tissu sarcoma painless lump swell soft tissu bodi diagnost test use detect find diagnos childhood soft tissu sarcoma if test show may soft tissu sarcoma biopsi done there mani differ type soft tissu sarcoma fat tissu tumor bone cartilag tumor fibrous connect tissu tumor skelet muscl tumor smooth muscl tumor socal fibrohistiocyt tumor peripher nervous system tumor pericyt perivascular tumor tumor unknown origin blood vessel tumor certain factor affect prognosi chanc recoveri treatment option childhood soft tissu sarcoma diseas malign cancer cell form soft tissu bodi soft tissu bodi connect support surround bodi part organ the soft tissu includ follow fat a mix bone cartilag fibrous tissu muscl nerv tendon band tissu connect muscl bone synovi tissu tissu around joint blood vessel lymph vessel soft tissu sarcoma may found anywher bodi in children tumor form often arm leg trunk chest abdomen enlarg soft tissu sarcoma form soft tissu bodi includ muscl tendon fat blood vessel lymph vessel nerv tissu around joint soft tissu sarcoma occur children adult soft tissu sarcoma children may respond differ treatment may better prognosi soft tissu sarcoma adult see pdq summari adult soft tissu sarcoma treatment inform treatment adult have certain diseas inherit disord increas risk childhood soft tissu sarcoma anyth increas risk get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk child doctor think child may risk risk factor childhood soft tissu sarcoma includ follow inherit disord lifraumeni syndrom famili adenomat polyposi fap rb gene chang smarcb ini gene chang neurofibromatosi type nf werner syndrom other risk factor includ follow past treatment radiat therapi have aid acquir immun defici syndrom epsteinbarr virus infect time the common sign childhood soft tissu sarcoma painless lump swell soft tissu bodi a sarcoma may appear painless lump skin often arm leg trunk there may sign symptom first as sarcoma get bigger press nearbi organ nerv muscl blood vessel may caus sign symptom pain weak other condit may caus sign symptom check child doctor child problem diagnost test use detect find diagnos childhood soft tissu sarcoma the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit past ill treatment also taken xray an xray type energi beam go bodi onto film make pictur area insid bodi mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area bodi chest abdomen arm leg this procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen the child lie tabl slide mri scanner take pictur insid bodi the pad child abdomen help make pictur clearer ct scan cat scan a procedur make seri detail pictur area insid bodi chest abdomen taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen the child lie tabl slide ct scanner take xray pictur insid abdomen ultrasound exam a procedur highenergi sound wave ultrasound bounc intern tissu organ make echo the echo form pictur bodi tissu call sonogram the pictur print look later if test show may soft tissu sarcoma biopsi done one follow type biopsi usual use core needl biopsi the remov tissu use wide needl this procedur may guid use ultrasound ct scan mri incision biopsi the remov part lump sampl tissu excision biopsi the remov entir lump area tissu doesnt look normal a pathologist view tissu microscop look cancer cell an excision biopsi may use complet remov smaller tumor near surfac skin this type biopsi rare use cancer cell may remain biopsi if cancer cell remain cancer may come back may spread part bodi an mri tumor done excision biopsi this done show origin tumor may use guid futur surgeri radiat therapi the placement needl incis biopsi affect success later surgeri remov tumor if possibl surgeon remov tumor found involv plan biopsi in order plan best treatment sampl tissu remov biopsi must larg enough find type soft tissu sarcoma laboratori test tissu sampl taken primari tumor lymph node area may cancer cell a pathologist view tissu microscop look cancer cell find type grade tumor the grade tumor depend abnorm cancer cell look microscop quick cell divid highgrad midgrad tumor usual grow spread quick lowgrad tumor becaus soft tissu sarcoma hard diagnos tissu sampl check pathologist experi diagnos soft tissu sarcoma one follow laboratori test may done studi tissu sampl molecular test a laboratori test check certain gene protein molecul sampl tissu blood bodi fluid a molecular test may done procedur biopsi help diagnos type cancer molecular test check certain gene chromosom chang occur soft tissu sarcoma revers transcriptionpolymeras chain reaction rtpcr test a laboratori test cell sampl tissu studi use chemic look chang express certain gene when gene express make specif protein need structur function monitor bodi tissu organ this test done order identifi type tumor cytogenet analysi a laboratori test cell sampl bone marrow blood amniot fluid tumor tissu view microscop look chang chromosom fluoresc situ hybrid fish type cytogenet analysi immunocytochemistri a test use antibodi check certain antigen marker sampl cell the antibodi usual link enzym fluoresc dye caus cell marker becom visibl microscop this type test may use tell differ differ type soft tissu sarcoma there mani differ type soft tissu sarcoma the cell type sarcoma look differ microscop the soft tissu tumor group base type soft tissu cell first form this summari follow type soft tissu sarcoma fat tissu tumor liposarcoma this rare cancer fat cell liposarcoma usual form fat layer skin in children adolesc liposarcoma often low grade like grow spread slowli there sever differ type liposarcoma myxoid liposarcoma usual low grade respond well treatment the cell myxoid liposarcoma certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos myxoid liposarcoma tumor cell check genet chang pleomorph liposarcoma usual high grade like grow spread quick less like respond well treatment bone cartilag tumor bone cartilag tumor mix bone cell cartilag cell bone cartilag tumor includ follow type extraskelet mesenchym chondrosarcoma this type bone cartilag tumor often affect young adult occur head neck extraskelet osteosarcoma this type bone cartilag tumor rare children adolesc it like come back treatment may spread lung fibrous connect tissu tumor fibrous connect tissu tumor includ follow type desmoidtyp fibromatosi also call desmoid tumor aggress fibromatosi this fibrous tissu tumor low grade like grow slowli it may come back nearbi tissu usual spread distant part bodi rare tumor may disappear without treatment desmoid tumor sometim occur children chang adenomat polyposi coli apc gene chang gene caus famili adenomat polyposi fap fap inherit condit mani polyp growth mucous membran form insid wall colon rectum genet counsel discuss train profession inherit diseas possibl need gene test may need dermatofibrosarcoma protuberan this rare tumor deep layer skin found children adult the cell tumor certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos dermatofibrosarcoma protuberan tumor cell check genet chang fibrosarcoma there two type fibrosarcoma children adolesc infantil fibrosarcoma also call congenit fibrosarcoma this type fibrosarcoma found children age year younger it often occur infant may seen prenat ultrasound exam this tumor often larg fast grow rare spread distant part bodi the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos infantil fibrosarcoma tumor cell check genet chang a similar tumor seen older children it transloc often seen younger children adult fibrosarcoma this type fibrosarcoma found adult the cell tumor genet chang found infantil fibrosarcoma see pdq summari adult soft tissu sarcoma treatment inform inflammatori myofibroblast tumor this fibrous tissu tumor occur children adolesc it like come back treatment rare spread distant part bodi a certain genet chang found half tumor lowgrad fibromyxoid sarcoma this slowgrow tumor affect young middleag adult the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos lowgrad fibromyxoid sarcoma tumor cell check genet chang the tumor may come back mani year treatment spread lung line wall chest caviti lifelong followup need myxofibrosarcoma this rare fibrous tissu tumor found less often children adult scleros epithelioid fibrosarcoma this rare fibrous tissu tumor come back spread place year treatment longterm followup need skelet muscl tumor skelet muscl attach bone help bodi move rhabdomyosarcoma rhabdomyosarcoma common childhood soft tissu sarcoma children year younger see pdq summari childhood rhabdomyosarcoma treatment inform smooth muscl tumor smooth muscl line insid blood vessel hollow intern organ stomach intestin bladder uterus leiomyosarcoma this smooth muscl tumor link epsteinbarr virus children also hiv diseas aid leiomyosarcoma may also form second cancer survivor inherit retinoblastoma sometim mani year initi treatment retinoblastoma socal fibrohistiocyt tumor plexiform fibrohistiocyt tumor this rare tumor usual affect children young adult the tumor usual start painless growth skin arm hand wrist it may rare spread nearbi lymph node lung peripher nervous system tumor peripher nervous system tumor includ follow type ectomesenchymoma this rare fastgrow tumor nerv sheath protect cover nerv part brain spinal cord occur main children ectomesenchymoma may form head neck abdomen perineum scrotum arm leg malign peripher nerv sheath tumor this tumor form nerv sheath some children malign peripher nerv sheath tumor rare genet condit call neurofibromatosi type nf this tumor may low grade high grade malign triton tumor these rare fastgrow tumor occur often children nf pericyt perivascular tumor pericyt tumor form cell wrap around blood vessel pericyt tumor includ follow type myopericytoma infantil hemangiopericytoma type myopericytoma children younger year time diagnosi may better prognosi in patient older year infantil hemangiopericytoma like spread part bodi includ lymph node lung infantil myofibromatosi infantil myofibromatosi anoth type myopericytoma it fibrous tumor often form first year life there may one nodul skin usual head neck area myofibroma nodul sever skin area muscl bone myofibromatosi these tumor may go away without treatment tumor unknown origin tumor unknown origin place tumor first form known includ follow type alveolar soft part sarcoma this rare tumor soft support tissu connect surround organ tissu it common found limb occur tissu mouth jaw face it may grow slowli may spread part bodi time diagnosi alveolar soft part sarcoma may better prognosi tumor centimet smaller tumor complet remov surgeri the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos alveolar soft part sarcoma tumor cell check genet chang clear cell sarcoma soft tissu this slowgrow soft tissu tumor begin tendon tough fibrous cordlik tissu connect muscl bone anoth part bodi clear cell sarcoma common occur deep tissu foot heel ankl it may spread nearbi lymph node the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos clear cell sarcoma soft tissu tumor cell check genet chang desmoplast small round cell tumor this tumor often form abdomen pelvi tissu around test may form kidney desmoplast small round cell tumor may also spread lung part bodi the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom in order diagnos desmoplast small round cell tumor tumor cell check genet chang epithelioid sarcoma this rare sarcoma usual start deep soft tissu slow grow firm lump may spread lymph node extraren extracrani rhabdoid tumor this rare fastgrow tumor soft tissu liver peritoneum it usual occur young children includ newborn occur older children adult rhabdoid tumor may link chang tumor suppressor gene call smarcb this type gene make protein help control cell growth chang smarcb gene may inherit pass parent offspr genet counsel discuss train profession inherit diseas possibl need gene test may need extraskelet myxoid chondrosarcoma this rare soft tissu sarcoma may found children adolesc over time tend spread part bodi includ lymph node lung the cell tumor usual genet chang often transloc part one chromosom switch place part anoth chromosom in order diagnos extraskelet myxoid chondrosarcoma tumor cell check genet chang the tumor may come back mani year treatment perivascular epithelioid cell tumor pecoma benign cancer pecoma may found children inherit condit call tuber sclerosi they occur stomach intestin lung femal reproduct organ genitourinari organ primit neuroectoderm tumor pnet extraskelet ewe tumor see pdq summari ewe sarcoma treatment inform synovi sarcoma synovi sarcoma common type soft tissu sarcoma children adolesc synovi sarcoma usual form tissu around joint arm leg may also form trunk head neck the cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom larger tumor greater risk spread part bodi includ lung children younger year whose tumor centimet smaller better prognosi undifferenti unclassifi sarcoma these tumor usual occur muscl attach bone help bodi move undifferenti pleomorph sarcoma malign fibrous histiocytoma highgrad this type soft tissu tumor may form part bodi patient receiv radiat therapi past second cancer children retinoblastoma the tumor usual found arm leg may spread part bodi see pdq summari osteosarcoma malign fibrous histiocytoma bone treatment inform malign fibrous histiocytoma bone blood vessel tumor blood vessel tumor includ follow type epithelioid hemangioendothelioma epithelioid hemangioendothelioma occur children common adult year age they usual occur liver lung bone they may either fast grow slow grow in third case tumor spread part bodi quick see pdq summari childhood vascular tumor treatment inform angiosarcoma soft tissu angiosarcoma soft tissu fastgrow tumor form blood vessel lymph vessel part bodi most angiosarcoma skin those deeper soft tissu form liver spleen lung they rare children sometim one tumor skin liver rare infantil hemangioma may becom angiosarcoma soft tissu see pdq summari childhood vascular tumor treatment inform see follow pdq summari inform type soft tissu sarcoma includ summari childhood rhabdomyosarcoma treatment ewe sarcoma treatment unusu cancer childhood treatment gastrointestin stromal tumor certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the part bodi tumor first form the size grade tumor the type soft tissu sarcoma how deep tumor skin whether tumor spread place bodi the amount tumor remain surgeri remov whether radiat therapi use treat tumor the age sex patient whether cancer diagnos recur come back stage childhood soft tissu sarcoma key point after childhood soft tissu sarcoma diagnos test done find cancer cell spread part bodi there three way cancer spread bodi cancer may spread began part bodi after childhood soft tissu sarcoma diagnos test done find cancer cell spread part bodi the process use find cancer spread within soft tissu part bodi call stage there standard stage system childhood soft tissu sarcoma in order plan treatment import know type soft tissu sarcoma whether tumor remov surgeri whether cancer spread part bodi the follow procedur may use find cancer spread sentinel lymph node biopsi the remov sentinel lymph node surgeri the sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor it first lymph node cancer like spread primari tumor a radioact substanc andor blue dye inject near tumor the substanc dye flow lymph duct lymph node the first lymph node receiv substanc dye remov a pathologist view tissu microscop look cancer cell if cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node this procedur use epithelioid clear cell sarcoma pet scan a pet scan procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell this procedur also call positron emiss tomographi pet scan petct scan a procedur combin pictur pet scan comput tomographi ct scan the pet ct scan done time machin the pictur scan combin make detail pictur either test would make there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl soft tissu sarcoma spread lung cancer cell lung soft tissu sarcoma cell the diseas metastat soft tissu sarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi recurr progress childhood soft tissu sarcoma recurr childhood soft tissu sarcoma cancer recur come back treat the cancer may come back place part bodi progress childhood soft tissu sarcoma cancer respond treatment treatment option overview key point there differ type treatment patient childhood soft tissu sarcoma children childhood soft tissu sarcoma treatment plan team health care provid expert treat cancer children treatment childhood soft tissu sarcoma may caus side effect eight type standard treatment use surgeri radiat therapi chemotherapi observ hormon therapi nonsteroid antiinflammatori drug target therapi immunotherapi new type treatment test clinic trial gene therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient childhood soft tissu sarcoma differ type treatment avail patient childhood soft tissu sarcoma some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment becaus cancer children rare take part clinic trial consid some clinic trial open patient start treatment children childhood soft tissu sarcoma treatment plan team health care provid expert treat cancer children treatment overseen pediatr oncologist doctor special treat children cancer the pediatr oncologist work health care provid expert treat children soft tissu sarcoma special certain area medicin these may includ pediatr surgeon special train remov soft tissu sarcoma the follow specialist may also includ pediatrician radiat oncologist pediatr hematologist pediatr nurs specialist rehabilit specialist psychologist social worker childlif specialist treatment childhood soft tissu sarcoma may caus side effect for inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment may includ physic problem chang mood feel think learn memori second cancer new type cancer some late effect may treat control it import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform eight type standard treatment use surgeri surgeri complet remov soft tissu sarcoma done possibl if tumor larg radiat therapi chemotherapi may given first make tumor smaller decreas amount tissu need remov surgeri this call neoadjuv therapi the follow type surgeri may use wide local excis remov tumor along normal tissu around amput surgeri remov part limb appendag cancer arm hand lymphadenectomi remov lymph node cancer moh surgeri a surgic procedur use treat cancer skin individu layer cancer tissu remov check microscop one time cancer tissu remov this type surgeri use treat dermatofibrosarcoma protuberan it also call moh micrograph surgeri hepatectomi surgeri remov part liver a second surgeri may need remov remain cancer cell check area around tumor remov cancer cell remov tissu need if cancer liver hepatectomi liver transplant may done liver remov replac healthi one donor after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu this type radiat therapi may includ follow stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment onc day sever day radiat machin aim larger usual dose radiat direct tumor by patient posit treatment less damag nearbi healthi tissu this procedur also call stereotact externalbeam radiat therapi stereotax radiat therapi intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer the way radiat therapi given depend type stage cancer treat whether tumor complet remov surgeri extern intern radiat therapi use treat childhood soft tissu sarcoma chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi combin chemotherapi use one anticanc drug the way chemotherapi given depend type cancer treat most type soft tissu sarcoma respond treatment chemotherapi see drug approv soft tissu sarcoma inform observ observ close monitor patient condit without give treatment sign symptom appear chang observ may done complet remov tumor possibl no treatment avail the tumor like damag vital organ hormon therapi hormon therapi cancer treatment remov hormon block action stop cancer cell grow hormon substanc made gland bodi circul bloodstream some hormon caus certain cancer grow if test show cancer cell place hormon attach receptor drug surgeri radiat therapi use reduc product hormon block work antiestrogen drug block estrogen tamoxifen may use treat desmoidtyp fibromatosi nonsteroid antiinflammatori drug nonsteroid antiinflammatori drug nsaid drug aspirin ibuprofen naproxen common use decreas fever swell pain red in treatment desmoidtyp fibromatosi nsaid call sulindac may use help block growth cancer cell target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat kinas inhibitor type target therapi block enzym call kinas type protein there differ type kinas bodi differ action alk inhibitor may stop cancer grow spread crizotinib may use treat inflammatori myofibroblast tumor tyrosin kinas inhibitor tkis block signal need tumor grow imatinib use treat dermatofibrosarcoma protuberan pazopanib may use treat desmoidtyp fibromatosi type recurr progress soft tissu sarcoma it studi mani type newli diagnos soft tissu sarcoma type recurr soft tissu sarcoma sorafenib may use treat desmoidtyp fibromatosi new type tyrosin kinas inhibitor studi loxo entrectinib infantil fibrosarcoma trametinib epithelioid hemangioendothelioma other type target therapi studi clinic trial includ follow mtor inhibitor type target therapi stop protein help cell divid surviv mtor inhibitor use treat desmoplast small round cell tumor studi treat perivascular epithelioid cell tumor pecoma epithelioid hemangioendothelioma sirolimus temsirolimus type mtor inhibitor therapi angiogenesi inhibitor type target therapi prevent growth new blood vessel need tumor grow angiogenesi inhibitor cediranib sunitinib thalidomid studi treat alveolar soft part sarcoma epithelioid hemangioendothelioma bevacizumab studi blood vessel tumor histon methyltransferas hmt inhibitor target therapi drug work insid cancer cell block signal need tumor grow hmt inhibitor tazemetostat studi treatment epithelioid sarcoma malign peripher nerv sheath tumor extraren extracrani rhabdoid tumor extraskelet myxoid chondrosarcoma synovi sarcoma heatshock protein inhibitor block certain protein protect tumor cell help grow ganetespib heat shock protein inhibitor studi combin mtor inhibitor sirolimus malign peripher nerv sheath tumor cannot remov surgeri antibodydrug conjug made monoclon antibodi attach drug the monoclon antibodi bind specif protein receptor found certain cell includ cancer cell the drug enter cell kill without harm cell lorvotuzumab mertansin antibodydrug conjug studi treatment rhabdomyosarcoma malign peripher nerv sheath tumor synovi sarcoma see drug approv soft tissu sarcoma inform immunotherapi immunotherapi treatment use patient immun system fight diseas substanc made bodi made laboratori use boost direct restor bodi natur defens diseas interferon type immunotherapi use treat epithelioid hemangioendothelioma it interfer divis tumor cell slow tumor growth new type treatment test clinic trial this summari section describ treatment studi clinic trial it may mention everi new treatment studi inform clinic trial avail nci websit gene therapi gene therapi studi childhood synovi sarcoma recur spread cannot remov surgeri some patient t cell type white blood cell remov gene cell chang laboratori genet engin attack specif cancer cell they given back patient infus patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show child condit chang cancer recur come back these test sometim call followup test checkup treatment option childhood soft tissu sarcoma for inform treatment list see treatment option overview section newli diagnos childhood soft tissu sarcoma fat tissu tumor liposarcoma treatment liposarcoma may includ follow surgeri complet remov tumor if cancer complet remov second surgeri may done chemotherapi shrink tumor follow surgeri radiat therapi surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi bone cartilag tumor extraskelet mesenchym chondrosarcoma treatment extraskelet mesenchym chondrosarcoma may includ follow surgeri complet remov tumor radiat therapi may given andor surgeri chemotherapi follow surgeri chemotherapi without radiat therapi given surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi extraskelet osteosarcoma treatment extraskelet osteosarcoma may includ follow surgeri complet remov tumor follow chemotherapi a clinic trial target therapi radiat therapi surgeri without chemotherapi see pdq summari osteosarcoma malign fibrous histiocytoma bone treatment inform fibrous connect tissu tumor desmoidtyp fibromatosi treatment desmoidtyp fibromatosi may includ follow surgeri complet remov tumor treatment surgeri may includ follow observ chemotherapi radiat therapi antiestrogen drug therapi nonsteroid antiinflammatori drug nsaid therapi if tumor complet remov surgeri treatment may includ follow observ treatment option possibl radiat therapi radiat therapi chemotherapi tumor cannot remov surgeri a clinic trial target therapi a clinic trial target therapi radiat therapi surgeri without chemotherapi treatment desmoidtyp fibromatosi come back may includ follow observ possibl surgeri later time chemotherapi dermatofibrosarcoma protuberan treatment dermatofibrosarcoma protuberan may includ follow surgeri complet remov tumor possibl this may includ moh surgeri radiat therapi surgeri radiat therapi target therapi imatinib tumor cannot remov come back a clinic trial target therapi radiat therapi surgeri without chemotherapi fibrosarcoma infantil fibrosarcoma treatment infantil fibrosarcoma may includ follow surgeri remov tumor possibl follow observ surgeri follow chemotherapi chemotherapi shrink tumor follow surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi a clinic trial target therapi tyrosin kinas inhibitor adulttyp fibrosarcoma treatment adulttyp fibrosarcoma may includ follow surgeri complet remov tumor possibl inflammatori myofibroblast tumor treatment inflammatori myofibroblast tumor may includ follow surgeri complet remov tumor possibl chemotherapi steroid therapi nonsteroid antiinflammatori drug nsaid therapi target therapi alk inhibitor a clinic trial target therapi radiat therapi surgeri without chemotherapi lowgrad fibromyxoid sarcoma treatment lowgrad fibromyxoid sarcoma may includ follow surgeri complet remov tumor a clinic trial target therapi radiat therapi surgeri without chemotherapi myxofibrosarcoma treatment myxofibrosarcoma may includ follow surgeri complet remov tumor a clinic trial target therapi radiat therapi surgeri without chemotherapi scleros epithelioid fibrosarcoma treatment scleros epithelioid fibrosarcoma may includ follow surgeri complet remov tumor a clinic trial target therapi radiat therapi surgeri without chemotherapi skelet muscl tumor rhabdomyosarcoma see pdq summari childhood rhabdomyosarcoma treatment smooth muscl tumor leiomyosarcoma treatment leiomyosarcoma may includ follow chemotherapi a clinic trial target therapi radiat therapi surgeri without chemotherapi socal fibrohistiocyt tumor plexiform fibrohistiocyt tumor treatment plexiform fibrohistiocyt tumor may includ follow surgeri complet remov tumor a clinic trial target therapi radiat therapi surgeri without chemotherapi peripher nervous system tumor ectomesenchymoma treatment ectomesenchymoma may includ follow surgeri chemotherapi radiat therapi malign peripher nerv sheath tumor treatment malign peripher nerv sheath tumor may includ follow surgeri complet remov tumor possibl radiat therapi surgeri chemotherapi tumor cannot remov surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi a clinic trial target therapi tumor cannot remov surgeri a clinic trial target therapi histon methyltransferas inhibitor a clinic trial antibodydrug conjug it clear whether give radiat therapi chemotherapi surgeri improv tumor respons treatment malign triton tumor malign triton tumor may treat rhabdomyosarcoma includ surgeri chemotherapi radiat therapi a regimen target therapi radiat therapi surgeri without chemotherapi studi pericyt perivascular tumor infantil hemangiopericytoma treatment infantil hemangiopericytoma may includ follow chemotherapi infantil myofibromatosi treatment infantil myofibromatosi may includ follow combin chemotherapi tumor unknown origin place tumor first form known alveolar soft part sarcoma treatment alveolar soft part sarcoma may includ follow surgeri complet remov tumor possibl radiat therapi surgeri tumor cannot complet remov surgeri target therapi angiogenesi inhibitor a clinic trial target therapi angiogenesi inhibitor children a clinic trial target therapi radiat therapi surgeri without chemotherapi clear cell sarcoma soft tissu treatment clear cell sarcoma soft tissu may includ follow surgeri remov tumor possibl radiat therapi surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi desmoplast small round cell tumor there standard treatment desmoplast small round cell tumor treatment may includ follow surgeri complet remov tumor possibl chemotherapi follow surgeri chemotherapi target therapi mtor inhibitor radiat therapi epithelioid sarcoma treatment epithelioid sarcoma may includ follow surgeri remov tumor possibl chemotherapi surgeri radiat therapi surgeri a clinic trial target therapi histon methyltransferas inhibitor extraren extracrani rhabdoid tumor treatment extraren extracrani rhabdoid tumor may includ follow a combin surgeri remov tumor possibl chemotherapi radiat therapi a clinic trial target therapi histon methyltransferas inhibitor extraskelet myxoid chondrosarcoma treatment extraskelet myxoid chondrosarcoma may includ follow surgeri remov tumor possibl radiat therapi a clinic trial target therapi radiat therapi surgeri without chemotherapi a clinic trial target therapi histon methyltransferas inhibitor perivascular epithelioid cell tumor pecoma treatment perivascular epithelioid cell tumor may includ follow surgeri remov tumor observ follow surgeri target therapi mtor inhibitor tumor certain gene chang cannot remov surgeri a clinic trial target therapi radiat therapi surgeri without chemotherapi primit neuroectoderm tumor pnetextraskelet ewe tumor see pdq summari ewe sarcoma treatment synovi sarcoma treatment synovi sarcoma may includ follow surgeri radiat therapi andor chemotherapi may given surgeri chemotherapi a clinic trial gene therapi a clinic trial target therapi radiat therapi surgeri without chemotherapi a clinic trial target therapi histon methyltransferas inhibitor a clinic trial antibodydrug conjug undifferentiatedunclassifi sarcoma these tumor includ undifferenti pleomorph sarcoma malign fibrous histiocytoma highgrad there standard treatment tumor treatment may includ follow a clinic trial target therapi radiat therapi surgeri without chemotherapi see pdq summari osteosarcoma malign fibrous histiocytoma bone treatment inform treatment malign fibrous histiocytoma bone blood vessel tumor angiosarcoma soft tissu treatment angiosarcoma may includ follow surgeri complet remov tumor a combin surgeri chemotherapi radiat therapi angiosarcoma spread target therapi bevacizumab chemotherapi angiosarcoma began infantil hemangioma a clinic trial target therapi radiat therapi surgeri without chemotherapi epithelioid hemangioendothelioma treatment epithelioid hemangioendothelioma may includ follow surgeri remov tumor possibl immunotherapi interferon target therapi thalidomid sorafenib pazopanib sirolimus tumor like spread chemotherapi total hepatectomi liver transplant tumor liver a clinic trial target therapi trametinib metastat childhood soft tissu sarcoma treatment childhood soft tissu sarcoma spread part bodi diagnosi may includ follow chemotherapi radiat therapi surgeri may done remov tumor spread lung stereotact bodi radiat therapi tumor spread lung for treatment specif tumor type see treatment option childhood soft tissu sarcoma section use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail recurr progress childhood soft tissu sarcoma treatment recurr progress childhood soft tissu sarcoma may includ follow surgeri remov cancer come back first form spread lung surgeri follow extern intern radiat therapi radiat therapi alreadi given surgeri remov arm leg cancer radiat therapi alreadi given chemotherapi target therapi pazopanib a clinic trial new chemotherapi regimen without target therapi pazopanib a clinic trial check sampl patient tumor certain gene chang the type target therapi given patient depend type gene chang use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about childhood soft tissu sarcoma for inform nation cancer institut childhood soft tissu sarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv soft tissu sarcoma target cancer therapi for childhood cancer inform general cancer resourc see follow about cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer a guid parent cancer children adolesc stage cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment childhood soft tissu sarcoma it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq pediatr treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq pediatr treatment editori board pdq childhood soft tissu sarcoma treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypessofttissuesarcomapatientchildsofttissuetreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('hi jaquar i dont understand choic seem one form betaferon ie plegridi avonex whi arent offer option such copaxon anoth inject similar relaps rate plegridi avonex often give peopl less side effect or tecfidera daili pill much better relaps reduct rate or fingolimod anoth pill or better still tysabri given month infus reduct relaps rate perhap could talk various option ms nurs neurologist and tri figur reason your offer two option dont count two option realli drug deliv differ form sorri i dont seem answer question precis i experi avonex copaxon tecfidera tysabri unfortun im one rare peopl seem various side effect mean i cant take avonex tecfidera tysabri copaxon stop work so i cant give much help experi drug i think option open and mind drug best relaps reduct rate possibl depend system toler regard side effect sue',\n",
       "  'NN'),\n",
       " ('hi kmallori my neuro also recommend ocrevus i blood draw today i also concern medicar approv side effect im spms fatigu balanc issu promin symptom moment of cours could chang frequent cog fog rear ugli head worst time has anyon experienc infus side effect ocrevus it new im apprehens earli adopt treatment ani feedback would much appreci i havent use dmd sinc stop tecfidera year ago thank roger',\n",
       "  'NN'),\n",
       " ('i dont mean scare anyon check respons thread titl quit ty ocrevus cancer concern i develop gynecolog cancer year tysabri i advis go back immunosuppress medic fear cancer relaps until oncologist said no way neurologist thought ocrevus might possibl ad oncologist would pleas actual oncologist pleas ms drug except copaxon interferon i cant toler so yeah wise consid cancer risk on hand i relaps year i could forget ms now im ask choos cancer ms',\n",
       "  'NN'),\n",
       " ('first thank much help histolog we hear highunaccept risk pneumon go specif tagrissoazd immunotherapi i read articl said pdls lower risk pneumon pds due method action i see opdivopd tecentriqpdl advertis egfr patient progress chemo egfr target therapi that wife ani inform whether aforement higher risk go tagrisso immunotherapi true risk lower go pdltecentriq onli option us point appear chemo applic trialsegf asp hm recruit immunotherapi appear toxic sequenti treatment egfr inhibitor tagrisso immunotherapi stage iv nsclc adeno egfr mutat tarceva help carboavastinalimta month avastin mainten month afatanib month clovisco month tagrissoazd month progress',\n",
       "  'NN'),\n",
       " ('antibodi nivolumab pembrolizumab target program cell death protein pd well ipilimumab target cytotox tlymphocyt antigen ctla may promis patient small cell lung cancer sclc accord studi publish the oncologist there major chang last year i dont know month within next year hope see checkpoint inhibitor approv said lead studi author leora horn md msc associ professor medicin clinic director thorac oncolog program vanderbiltingram cancer center nashvill tennesse preliminari data shown promis respons rate nivolumab alon nivolumab ipilimumab singl agent pembrolizumab durabl respons low toxic profil there multipl clinic trial includ ongo phase studi compar nivolumab topotecan second line therapi mainten studi firstlin platinumbas therapi nivolumab nivolumabipilimumab phase trial pembrolizumab follow platinumbas chemotherapi said dr horn she colleagu note patient respond firstlin chemotherapi though sclc aggress lung cancer subtyp patient eventu relaps there approv agent beyond secondlin research hope soon chang they report identif molecular target sclc may point combin immun checkpoint inhibitor new target therapi the toxic profil agent nonsmal cell lung cancer nsclc signific lower chemotherapi differ anticip sclc if approv major chang especi patient recurr extens stage diseas limit treatment option said dr horn hossein borghaei do chief thorac oncolog associ professor depart hematologyoncolog fox chase cancer center philadelphia pennsylvania said move new era treatment sclc general though particular immunotherapi accord dr borghaei mani potenti activ treatment investig sclc clinic landscap could chang soon it hard estim surviv improv immunotherapi dr borghaei told cancer therapi advisor we mani disappoint i think base seen immunotherapi agent far diseas limit data sclc i hope see improv surviv m catherin pietanza md colleagu recent report th congress european societi medic oncolog esmo rovalpituzumab tesirin rovat antibodi drug conjug adc may promis patient relaps firstlin therapi preliminari data suggest posit overal respons rate orr accept side effect relat ipilimumab combin appear ineffect treatment sclc in phase b sclc trial found wa orr clinic benefit rate the studi includ patient research found common advers event ae fatigu experienc grade the research note respons durabl trend toward improv overal surviv os',\n",
       "  'NN'),\n",
       " ('hi roadtrip sorri hear pain thank inquir updat pain come uc my stori differ though pleas bear updat we learn lot past year sinc i first post i overtaken excruci disabl joint pain most hand wrist couldnt write hold cup even lie still i tini us advers reaction remicad i ultim diagnos antitnf induc lupus took year recov help oral prednison well awar downsid work along neuro pt get joint esp wrist hand function regain strength muscl wast prior unfortun develop th month mark remicad go great remi recov worst flare ever seem inconceiv stop as ive said i known would unfold id still remicad regret despit month miseri recov advers effect remi extinguish flare got new qualiti life in fact i think stay month stop infus so bought time enough overcom next big bad uc flare flatten i couldnt function after research option i readi start entyvio octob i happi report ive great ever sinc uc total quiet onli two downsid it seem there vulner respiratori infect the extra intestin joint painsproblem accompani uc mani us evid i mang emerg flarelik it make sens sinc entyvio gutspecif the benefit live i distinguish ibd relat joint pain inc inflammatori arthriti distinct occur remicad excruci wrist hand pain tell realli wreak havoc system caus polyneurophathi need stop i realiz get know bodi better time i get pain wrist hand weird swell wrist hand inc swollen finger blue knee swell bad i couldnt walk bit need cortison inject plus round oral pred calm i think expect get joint pain ibd without system anti inflammatori effect remicad mainten med my smart rheumatologist key guid unfamiliar terrain along experienc neurologist had lot blood lab definit expert diagnos rather gi case want get evalu other expertis would happi provid detail lesson learn itd help wish well cope feel like unend set challeng sinc ive uc close year pleas forgiv i havent updat profil ive line also reach thoreau usual respond there post lengthi thread parallel track disabl pain desper effort sensemak differ manifest recoveri timelin itd good know recoveri post remicad best wish regular ibd relat pain it possibl iv push solumedrol remi infus could help may worth tri uc yrs for flare i use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mos due joint pain antitnf induc lupus neuropathi on entyvio sinc oct far ok',\n",
       "  'NN'),\n",
       " ('tofacitinib manag ulcer coliti refractori antitnf antiintegrin therapi we report patient activ ulcer coliti primari nonrespons three biolog infliximab adalimumab vedolizumab differ mechan action refus surgic treatment favor respons tofacitinib clinic endoscop remiss no advers event observ use agent this case illustr difficulti may face regard identif express proper mechan action involv pathogenesi ulcer coliti patient import anoth treatment option differ mechan action lik sourc arquivo de gastroenterologia',\n",
       "  'NN'),\n",
       " ('well done i alway think peopl surgeri deserv medalit cannot easi samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergiesintoler take humira have final come prednison yay',\n",
       "  'NN'),\n",
       " ('the gist asian peopl nonsmal cell lung cancer nsclc whose tumor common mutat egfr gene call del might better surviv treat drug afatinib instead chemotherapi that conclus recent clinic trial test afatinib volunt patient boehring ingelheim report posit data prespecifi subgroupanalysi pivot phase iii luxlung trial afatinib asian nonsmal cell lung cancer nsclc patient the trial show patient common type egfr mutat exon delet del live signific longer receiv firstlin treatment afatinib compar chemotherapi the compani note overal surviv result prespecifi asian subgroupanalysi consist overal del popul luxlung previous report asian phase iii luxlung trial patient del mutat live median one year longer start treatment afatinib rather standard chemotherapi guangdong academi medic scienc guangdong general hospit vicepresid princip investig luxlung trial yilong wu said afatinib first treatment demonstr signific overal surviv benefit nsclc patient del mutat common egfr mutat more half world lung cancer case occur asia therefor egfr test nsclc patient import order identifi patient elig target therapi',\n",
       "  'NN'),\n",
       " ('hi bfarz congratul great respons tarceva i hope scan result show tagrisso effect as tarceva mani lung cancer drug case patient respond number year point patient drop statist due lack continu followup sinc tagrisso relat new certain case i hope becom one outlier patient respons particular durabl as discuss dr west post lepid predomin adenocarcinoma still often refer bac type lung cancer aggress also slow grow among least threaten case ever label lung cancer at diagnosi possibl determin aggress particular patient cancer passag time help answer question from histori youv describ cancer appear slowgrow respons tarceva may long respons tagrisso well at present progress secondlin tagrisso treat standard chemo agent perhap immunotherapi dont realli good tki address progress also mention oncologist face singl site progress radiat site continu tki as far biopsi check new mutat isnt progress suffici size biopsi may need chang therapi and sinc tagrisso resist mutat target therapi biopsi may provid usabl inform that said point doctor feel biopsi need liquid biopsi use bodili fluid rather tissu may recommend but hope tagrisso effect long time jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('httpsumolymozo i submit link biotin researchclin studi show may help peopl progress form multipl sclerosi i write perspect take medicin excerpt past blog post mind explain doctor notic i get mg pill i take time day ace pharmaci httpshighdosebiotinnet i complet th month somewher middl th month i neurologist check back decemb time walk i second faster i ever walk offic what mean it mean noth one time maintain mark improv in simpler term i part clinic trial biotin second would seen improv person progress ms what second mean effect life not one bit when i get tire doesnt matter fast i walk difficulti walk the daili struggl i fall frustrat havent chang walk second faster hasnt made differ you read post httpwwwmultipleexperiencesorghighdosebiotininmultiplesclerosismonth has chang anyth no long run hasnt i still struggl day except im sit howev ive written post biotin past im realli start think chang leg is due biotin im pretti convinc drug make walk better origin i wasnt sure mani new thing i start around time i start rituxan ms version ocrelizumab come march physic therapi alpha lipoic acid also studi help ms see studi link httpwwwmultipleexperiencesorgalphalipoicacidandmultiplesclerosi onc sinc im vacat realli abl take advantag good day stretch realli make see differ when leg strong fatigu matter ani part isnt fatigu im walk much better doe last sure i noth day someon bid like i said yesterday post realist though no multipl sclerosi come take soon bodi fatigu stage get easier easier will i stop take biotin absolut not there definit differ go even differ five minut day day hour five hour hour it definit worth get ani multipl sclerosi patient i hope check studi top page past blog they honest take biotin one thing i would agre take month see differ pleas patient tri httpwwwmultipleexperiencesorghighdosebiotinwithprogressivemsapatientsreview rememb biotin vitamin wors case youll great hair nail',\n",
       "  'NN'),\n",
       " ('adher treatment plan best possibl strategi manag multipl sclerosi ms continu diseasemodifi medic doctor recommend import part plan becaus take diseasemodifi medic long period time challeng import understand role diseasemodifi therapi overal ms treatment plan awar obstacl often interfer adher plan whi earli treatment import ms expert recommend anyon diagnos relaps form ms consid begin treatment soon possibl becaus associ risk lemtrada zinbryta general recommend peopl alreadi inadequ respons two diseasemodifi therapi novantron also general reserv peopl diagnos secondaryprogress ms inadequ respons treatment some peopl diagnos clinicallyisol syndrom cis first episod neurolog damag may benefit medic well the possibl benefit medic includ reduct number new lesion shown magnet reson imagn mri reduct number exacerb also call relaps attack flareup reduct progress disabl probabl reduct futur diseas activ improv qualiti life individu diagnos primari progress ms talk healthcar provid start treatment ocrevus medic approv us food drug administr fda treatment primari progress ms start treatment earli diseas particular import research indic perman damag may occur central nervous system cns even person experienc symptom all avail medic effect earli diseas activ inflammatori later diseas general progress neurodegen addit detail outlin ms coalit consensus diseasemodifi treatment ms whi peopl reluct start treatment absenc symptom a person whose symptom disappear may see reason start treatment howev research show diseas caus signific irrevers damag cns even arent experienc symptom time fear needl some avail medic given inject skin muscl infus vein mani peopl hate needl howev manufactur medic offer support program help becom comfort effect tool avail help selfinject anxieti some oral medic also approv use ms expens all medic expens insur coverag vari consider one insur plan anoth howev manufactur offer financi assist program help ensur anyon whose physician prescrib medic access fear side effect each medic side effect peopl particular whose ms symptom mild remiss may hesit take medic may make feel wors rather better howev physician nurs support program offer manufactur medic give tip strategi reduc side effect make manag most side effect diminish time whi peopl stop take medic the diseasemodifi medic design longterm use recommend peopl continu medic unless side effect sever medic clear work better treatment becom avail howev mani peopl stop medic period week month reason im feel better it import rememb diseasemodifi medic design reduc under diseas activ they dont treat symptom cure diseas make peopl feel better fact may abl feel work but diseasemodifi medic import invest futur work behind scene help slow diseas the side effect make feel wors diseas some peopl problem side effect other whatev side effect experienc best manag collabor healthcar team drug manufactur support program peopl experi intoler side effect dont improv time talk doctor medic option i taken medic i exacerb anyway none medic abl cure ms complet stop progress most peopl continu experi occasion exacerb even take medic faith if doctor determin mani relaps develop expect number new lesion offer treatment option mayb someth els would work better sinc take month medic begin work system switch frequent one drug anoth leav unprotect long period time your best strategi give medic take suffici time doctor abl evalu effect my insur stop cover medic i take the pharmaceut manufactur nation ms societi avail help sort insur issu if insur compani longer cover medic take call assist soon possibl order avoid interrupt treatment if solut found problem physician may recommend differ medic cover insur i longer afford copay medic insur compani rais lower copay without notic this anoth situat manufactur societi may abl assist do stop medic without check see either resourc help if question concern issu sure contact societi manufactur medic take',\n",
       "  'NN'),\n",
       " ('melissag countri patient mavenclad switch interferon rebif betaseronbetaferon much experi process go fingolimod start treatment cladribin howev patient switch fingolimod cladribin week major problem i believ main issu fingolimod cessat quit tricki if decid chang therapi im sure neurologist want monitor white blood cell count a period longer week without treatment would suffic cessat effect gilenya',\n",
       "  'NN'),\n",
       " ('in recent month spastic go bonker especi right leg now i found might spastic later someth done beyond daili stretch enter baclofen other dmt current ocrevus i take med supplement vitamin d daili ambien need viagra need fiber chew stool soften enter pictur occas but right leg cooper straighten get stiffer neuro said time tri baclofen muscl relax i start mg x day help tri mg made loopi so im somewher around day slight higher dose night it help much do folk baclofen experi advic i know common ms med dave bexfield activems',\n",
       "  'VBZ'),\n",
       " ('i never understood comprehens guy antivegf treatment piss retina communiti much they dont realli make money of cours compar intravitr inject vitrectomi nonsens if i primari ppvs resid manag postop care dont think id abl one graduat most resid get cours isnt enough practic skill real world as comprehens doc i allow treat without piss subspecialist dri eye do i refer anyth requir otc artifici tear cornea glaucoma do i refer slts micropuls mig glaucoma should i treat medic plastic can i offer epil blepharoplasti i attend lectur aao oculoplast liter said comprehensivist pleas refer us simpl bleph you where draw line i went comprehens ophthalmolog offer comprehens care i think ridicul patient refer doctor manag routin problem manag glaucoma manag dri eye manag intravitr inject refract obvious patient extrem complex need care specialist simpli need month eylea run mill wet amd isnt rare million diseas process cant handl generalist',\n",
       "  'JJ'),\n",
       " ('ibutilid antiarrhythm heart medic correct certain condit irregular heart rhythm ibutilid use help keep heart beat normal peopl certain heart rhythm disord atrium upper chamber heart allow blood flow heart ibutilid use peopl atrial fibril atrial flutter ibutilid may also use purpos list medic guid ibutilid caus lifethreaten irregular heart rhythm your heart rate constant monitor use electrocardiograph ecg sometim call ekg problem treat quick you receiv medic allerg ibutilid if possibl tell doctor taken heart rhythm medic within past hour receiv ibutilid to make sure ibutilid safe tell doctor congest heart failur fda pregnanc categori c it known whether ibutilid harm unborn babi tell doctor pregnant it known whether ibutilid pass breast milk could harm nurs babi tell doctor breastfeed babi in emerg situat may possibl tell caregiv health condit pregnant breast feed make sure doctor care afterward know receiv medicin basicdescript back top ibutilid side effect get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat tell caregiv headach chest pain sever dizzi short breath lighthead feel like might pass common side effect may includ mild headach nausea this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda back top ibutilid interact follow doctor instruct restrict food beverag activ tell doctor taken heart rhythm medic within past hour this includ amiodaron disopyramid dofetilid dronedaron procainamid quinidin sotalol tell doctor medicin use start stop use treatment ibutilid especi citalopram fingolimod lumefantrin mifepriston saquinavir antibioticazithromycin clarithromycin erythromycin cancer medicinearsen trioxid degarelix nilotinib toremifen vandetanib vemurafenib medicin treat mental illnessiloperidon pimozid thioridazin ziprasidon this list complet other drug may interact ibutilid includ prescript overthecount medicin vitamin herbal product not possibl interact list medic guid back top ibutilid dosag ibutilid inject vein iv a healthcar provid give inject ibutilid caus lifethreaten irregular heart rhythm your heart rate constant monitor use electrocardiograph ecg sometim call ekg problem treat quick cardiac emerg equip also kept nearbi case need treat heart monitor may continu sever hour stop receiv ibutilid sinc medic given healthcar profession medic set overdos unlik occur becaus receiv ibutilid clinic set like miss dose',\n",
       "  'JJ'),\n",
       " ('i diagnos year ago ppms tomorrow i see doc get mri result i go ocrevus becom avail',\n",
       "  'NN'),\n",
       " ('congrat youv much i imagin deck life good gear thank continu post uc yrs for flare i use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mos due joint pain antitnf induc lupus neuropathi on entyvio sinc oct far ok',\n",
       "  'NN'),\n",
       " ('hi jennyo sorri hear footdrop speak ms nurs havent alreadi may abl offer physio help im interest read say feel never quit know new symptom drug relat simpli ms relat often seem stress relat though twin wonder side effect worth drug posit effect almost drug tackl symptom never caus ive spent last six year tri deciph spider web lifestori see anysom kind pattern might lead bloodbrain barrier damag henc eventu ms feel new round think much closer ever gut bio must start thing go pist keep your keep support health howev import control process noth els support drug sort posit way bodi less els deal make sens ive tri sort altern therapi copaxon drug seem remind day ms give sore inject site inflamm spinal cord mris look differ year neurologist pat back copaxon work well actual made differ keep us uptod cladribin seem effect drug im serious consid back lemtrada seem best bunch tackl awri immun system hold onto hear doesni tough treg cell tell immun system start fight must good here wish best',\n",
       "  'JJS'),\n",
       " ('hello grace team you may recal wife diagnos egfrexon del poor differenti nsclc septemb she tarceva experienc two brain met we switch tagrisso unconfirm suspicion wastm then progress miliari micronodul lung may we switch carboplatinalimta midmay cycl alimta mainten we learn week progress miliari spread lung difus inumer micronodul we got tini fine needl biopsi one nodul outsid lung the path report negat target mutat also indic cancer longer egfr posit we confirm mutat sclc i question would unusu cancer lose egfr status we consid path analysi fals read cancer remain egfr rechalleng tarceva avastin we month use tki is view long one wait increas chanc success tki rechalleng ie long take cancer sensit tki thank much fedback',\n",
       "  'NN'),\n",
       " ('new mattress theyv come along way past year last year i bought one purpl mattress comfort mattress ive ever urlwwwonpurplecomurl mayb pcp give script muscl relax happen futur keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('i got approv humira work put remiss came back remicad didnt work stelara didnt work simponi seem work bit bit bring home seem like peopl fail biolog get result feelinglesscrappi new member join oct post post yesterday am gmt i start xeljanz week ago work better medic i longer urgenc i i previous difficulti longer second wait time poop regardless i want im poop less x day massiv improv x good day normal time day diarrhea push ive blood stool grand total x sinc i start take less number time id bleed day i lot pain gas i first start take lessen lot overal im happi thank god work ramess new member join jun post post yesterday am gmt did tri med humira entyvio remicad stelara didnt work either just tri see likelihood work none other feelinglesscrappi new member join oct post post yesterday pm gmt i taken year taken due sever weight gain possibl futur complic brought stool day around day lot urgenc prednison imuran allerg reaction pentasa noth gave headach humira noth entyvio work somewhat decreas stool anywher near enough still bleed often mesalamin suppositori caus serious pain put point i worri caus fissur work pretti well overal i abl forc take feelinglesscrappi new member join oct post post yesterday pm gmt my diagnosi sever ulcer pancol in order i start prednison continu take take first pentasa imuran move onto humira final i use suppositori entyvio time move onto xeljanz now i wait colon heal bit doctor start remov polyp caus said theyr precancer i also told medic last option surgeri remov colon would also take care polyp i hope inform help xeljanz work well ramess new member join jun post post yesterday pm gmt ah im surpris doctor didnt tri biolog ive one avail none work enough simponi help enough im tri xeljanz',\n",
       "  'NN'),\n",
       " ('local consolid therapi surgeri andor radiat proven prolong surviv patient oligometastat ie three fewer metastas nonsmal cell lung cancer nsclc whether patient greater metastat burden would also benefit known the answer may found two new clinic trial combin local consolid therapi novel system treatment combat metastat nsclc in two trial patient first receiv immun checkpoint inhibitor nivolumab ipilimumab lonestar trial tyrosin kinas inhibitor osimertinib northstar trial patient random assign receiv mainten therapi studi drug local consolid therapi follow mainten therapi weve shown local consolid therapi benefit nsclc patient oligometastat diseas expand paradigm includ patient polymetastat diseas said daniel gomez md associ professor depart radiat oncolog the univers texa md anderson cancer center our hope combin local consolid therapi immunotherapi osimertinib extend surviv patient metastat diseas anywher bodi build promis find dr gomez colleagu hope combin local consolid therapi immun checkpoint inhibitor thirdgener egfr epiderm growth factor receptor inhibitor osimertinib extend surviv patient metastat nsclc beyond seen studi modal separ the surviv benefit local consolid therapi demonstr recent phase ii trial no patient oligometastat nsclc receiv firstlin therapi random assign receiv local consolid therapi mainten therapi the median progressionfre surviv durat patient receiv local consolid therapi month signific longer patient receiv mainten therapi month p this first random control trial establish local consolid therapi slow diseas progress nsclc patient limit metastat diseas said dr gomez trial princip investig immun checkpoint inhibitor also shown benefit patient metastat diseas the pd program cell death protein inhibitor nivolumab approv us food drug administr fda treat sever type cancer includ previous treat metastat nsclc furthermor combin nivolumab ctla cytotox t lymphocyt antigen inhibitor ipilimumabalreadi approv fda treat metastat melanomai investig treatment metastat nsclc clinic trial no the egfr inhibitor osimertinib also shown promis nsclc in march fda approv osimertinib treatment patient metastat nsclc egfr tm mutat one main gatekeep resist egfr inhibitor tm point mutat dr gomez said it shown patient develop resist way treat osimertinib diseas respond new clinic trial the northstar lonestar trial differ previous trial local consolid therapi use novel agent also includ patient oligometastat diseas also patient polymetastat diseas dr gomez said both trial recent began enrol patient metastat nsclc northstar dr gomez md anderson princip investig multiinstitut northstar trial no enrol patient previous untreat recurr stage iiib iv nsclc amen potenti curat treatment treatmentnav patient must tumor harbor egfr exon delet lr mutat wherea patient recurr diseas must egfr tm mutat aros treatment egfr inhibitor erlotinib gefitinib afatinib patient previous treat osimertinib anoth thirdgener tyrosin kinas inhibitor elig trial all patient trial receiv osimertinib week those whose diseas progress induct therapi random assign receiv osimertinib mainten therapi local consolid therapi follow osimertinib mainten therapi all patient continu mainten therapi diseas progress unaccept toxic effect occur dr gomez colleagu compar progressionfre surviv patient receiv local consolid therapi patient lonestar the lonestar trial no enrol patient stage iv nsclc treatment nave undergon one line chemotherapi target therapi patient whose diseas classifi adenocarcinoma must wildtyp egfr alk patient nsclc subtyp need test egfr alk status mutat rare subtyp patient undergon system immunotherapi diseas inelig trial all patient receiv two week cycl nivolumab ipilimumab then patient whose diseas progress random assign receiv mainten therapi nivolumab ipilimumab local consolid therapi follow mainten therapi nivolumab ipilimumab all patient continu mainten therapi year the princip investig md andersonon trial john heymach md phd professor chair depart thoracichead neck medic oncolog the trial coprincip investig dr gomez stephen swisher md professor depart thorac cardiovascular surgeri head divis surgeri the research compar overal progressionfre surviv patient receiv local consolid therapi determin local consolid therapi in northstar lonestar trial multidisciplinari treatment team determin approach local consolid therapi whether patient treat surgeri radiat depend tumor locat extent diseas in patient modal use treat lesion patient better suit hybrid approach lesion resect other irradi certain lesion tend better suit surgeri versus radiat therapi dr gomez said we prefer use surgeri lung lesion resect lobectomi singl brain metastasi domin brain metastasi adren gland lesion resect relat modest risk other metastas general treat radiat the surgeon radiat oncologist use whichev surgic radiat techniqu like achiev treatment goal lung lesion may resect open thoracotomi video robotassist thoracoscopylaparoscopi goal resect grossli negat surgic margin for radiat therapi stereotact bodi radiat therapi common modal use although modal intensitymodul radiat therapi proton therapi avail the goal radiat therapi ablat diseas whether use surgeri radiat main point aggress dr gomez said we think treat mani lesion possibl key prolong surviv patient metastat nsclc for inform contact dr daniel gomez to learn clinic trial patient lung cancer visit wwwclinicaltrialsorg further read gomez dr blumenschein gr lee jj et al local consolid therapi versus mainten therapi observ patient oligometastat nonsmallcel lung cancer without progress firstlin system therapi multicentr randomis control phase studi lancet oncol skoulidi f papadimitrakopoulou va target gatekeep osimertinib egfr tm mutationposit nonsmal cell lung cancer clin cancer res oncolog march volum issu',\n",
       "  'NN'),\n",
       " ('novarti basel switzerland announc us fda ema file accept siponimod new drug develop treat secondari progress multipl sclerosi adult',\n",
       "  'NN'),\n",
       " ('the breast cancer risk ocrellizumab still undefin the confid interv term risk still cross ie yet sure risk what would recommend women ocrelizumab enrol standard breast cancer screen appropri women meant selfexamin breast month taught encourag there lot onlin content regard follow exampl httpswwwyoutubecomwatchvunjbwxncvi httpswwwyoutubecomwatchvsdupuejor httpswwwyoutubecomwatchvlxjiqgwhw',\n",
       "  'IN'),\n",
       " ('right i bring combo specif antipd combin keytruda opdivo exampl i skim abstract seem combo antipd monoclon tabl post quick skim seem similar',\n",
       "  'JJ'),\n",
       " ('immunerel advers event ira relat treatment nivolumab associ better surviv among patient advanc nonsmal cell lung cancer nsclc accord retrospect studi present iaslc th world confer lung cancer toronto canada this largest studi date aim evalu whether develop ira predict nivolumab efficaci pretreat nsclc patient investig wrote pdpdl inhibitor prolong surviv patient advanc nsclc caus develop ira the aim studi determin nivolumab efficaci associ ira defin advers event immunolog mechan requir monitor intervent relat articl pembrolizumab plus chemotherapi extend surviv longer than chemotherapi alon studi in headtohead battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient with stage iii nsclc this multicent retrospect studi includ patient advanc nsclc median age year male ira grade develop patient patient experienc grade grade event ira signific associ prolong median progressionfre surviv pfs month compar month patient experi ira p correspond hazard ratio hr ci p multivari analysi the number ira develop also associ prolong pfs patient least ira ira demonstr median pfs month respect this compar month patient sign ira p overal surviv os also better among patient ira the median os month ira compar month without ira p correspond hr ci p multivari analysi patient least ira ira median os month month respect compar median os month patient ira p accord investig result studi suggest develop ira strong predictor surviv outcom nsclc patient receiv nivolumab line set read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'NN'),\n",
       " ('this awesom thank test subject butt hope bless continu femal canada ivig pentasa uccrohn test posit map antibodi mycobacterium pg remiss flare year current deal perian abscess fistula rvf wait stelara',\n",
       "  'NN'),\n",
       " ('hi kelyb congratul good respons treatment although i wish cost treatment side effect assum that caus symptom describ in forum would tough guess may caus tagrisso sinc common symptom wide rang possibl caus if havent alreadi done would good review medic doctor pharmacist sinc drug interact side effect common your doctor also may want order blood work follow find caus if defin caus tagrisso dose reduct certain option mani patient respond well egfr tki suffer debilit side effect quit well lower dose lessen side effect such patient seem particular sensit tkis term respons toxic at time way know symptom caus particular drug reduc dose hold drug period time see symptom lessen good luck find relief symptom jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('slide anoth talk jerri wolinski alreadi avail breakdown data ocrelizumab talk lot data trial httpsactrimsconfexcomactrimsmeetingappcgipap',\n",
       "  'NN'),\n",
       " ('had first ever abnorm pap await biopsi wbc tysabri link abnorm pap im wonder gilenya well anyon els been g four year',\n",
       "  'VBP'),\n",
       " ('ive read cladribin i gong see neurologist whether i short at bart seem think better ms drug whisper dare drug compani prefer other make money that seem post say anyway mayb im read bias way i want tri drug httpmultiplesclerosisresearchblogspotcomsupposetherewa',\n",
       "  'JJ'),\n",
       " ('cnw astrazeneca canada today announc health canada approv imfinzi durvalumab treatment patient local advanc unresect nonsmal cell lung cancer nsclc whose diseas progress follow platinumbas chemoradi therapi crt with approv imfinzi becom first approv immunooncolog therapi follow crt patient set review health canada acceler approv framework imfinzi grant notic complianc condit nocc base data phase iii pacif trial demonstr imfinzi extend progressionfre surviv patient near one year month versus placebo ii patient diagnos stage iii set lung cancer spread part bodi treat intent cure cancer combin surgeri radiat therapi andor chemotherapi despit major eventu cancer spread over past twenti year research improv outcom patient result signific benefit iii imfinzi first therapi abl delay progress lung cancer patient the approv imfinzi base posit progressionfre surviv pfs data phase iii pacif trial imfinzi demonstr improv median pfs near one year month compar placebo repres per cent reduct relat risk progress death vs placebo patient regardless program deathligand pdl status iv the pacif trial ongo evalu overal surviv os unresect stage iii nsclc detail interim result pacif trial publish onlin new england journal medicin nejm overal incid sever advers event compar patient receiv imfinzi compar patient receiv placebo in patient receiv imfinzi common advers reaction greater equal patient cough pneumon radiat pneumon upper respiratori tract infect rash v discontinu concurr crt due advers reaction regardless causal occur per cent patient receiv imfinzi vs per cent patient receiv placebo vi quot health canada approv imfinzi herald new era treatment stage iii unresect lung cancer despit often dead prognosi attempt treat patient intent cure diseas we long await new therapeut option offer hope postchemoradi therapi with imfinzi proven approv treatment may signific improv outcom patient within diseas set dr rosalyn juergen medic oncologist juravinski cancer centr this approv mark signific mileston great proport lung cancer patient effect treatment option follow curativeint chemoradi the progressionfre surviv rate seen imfinzi unpreced impact diseas set benefici treatment offer patient last two decad dr rob elmaraghi medic oncologist simco muskoka region cancer centr over last three year immunotherapi major develop treatment metastat lung cancer arriv imfinzi revolut treatment stage iii unresect nonsmal cell lung cancer imfinzi delay recurr lung cancer median near addit year it first immunotherapi stimul immun system address residu microscop diseas left undetect chemotherapi radiat this give hope patient watch wait recurr major case dr mari florescu clinic investig assist clinic professor depart medicin universit de montral health canada approv imfinzi welcom news patient live stage iii unresect nonsmal cell lung cancer give better chanc surviv health canada approv first step we call stakehold work togeth public fund need shem singh execut director lung cancer canada about lung cancer stage iii advanc nsclc lung cancer lead caus cancer death men women canada common diagnos cancer accord canadian cancer societi ccs approxim canadian diagnos lung cancer this repres around per cent new cancer case vii stage iii nonsmal cell lung cancer nsclc repres approxim per cent new nsclc diagnos approxim per cent patient unsuit surgeri viii in canada averag per cent peopl diagnos nsclc like live five year diagnosi follow crt ix stage iii nsclc divid three stage iiia iiib iiic defin size locat tumour much cancer spread local possibl surgeri x while patient diagnos set treat intent cure cancer major patient benefit chemoradi therapi per cent experi progress metastat diseas xi for inform lung cancer visit wwwlvngca about imfinzi durvalumab imfinzi fulli human monoclon antibodi bind pdl block interact pdl pd cd counter tumour immuneevad tactic releas inhibit immun respons imfinzi alreadi grant notic complianc condit nocc canada treatment patient local advanc metastat urotheli carcinoma bladder cancer diseas progress follow platinumcontain chemotherapi whose diseas progress within month receiv platinumcontain chemotherapi neoadjuv adjuv surgeri xii clinic studi imfinzi ongo includ mystic neptun pearl phase iii trial imfinzi studi stline treatment monotherapi andor combin tremelimumab antictla monoclon antibodi potenti new medicin treatment metastat nsclc the poseidon trial investig imfinzi without tremelimumab combin chemotherapi similar patient popul about astrazeneca approach immunooncolog immunooncolog io therapeut approach design stimul bodi immun system attack tumour at astrazeneca medimmun biolog research develop arm io portfolio anchor immunotherapi design overcom antitumour immun suppress we believ iobas therapi offer potenti lifechang cancer treatment major patient about astrazeneca astrazeneca global innovationdriven biopharmaceut busi primari focus discoveri develop commerci primari specialti care medicin transform live our primari focus three import area healthcar cardiovascular metabol diseas oncolog respiratori inflamm autoimmun astrazeneca oper countri innov medicin use million patient worldwid in canada employ employe across countri astrazeneca canada headquart locat mississauga ontario for inform pleas visit compani websit wwwastrazenecaca refer astrazeneca canada inc imfinzi durvalumab product monograph may ii ibid iii denton eve matthew conron improv outcom lung cancer the valu multidisciplinari health care team journal multidisciplinari healthcar pmc apr avail httpswwwncbinlmnihgovpmcarticlespmc iv astrazeneca canada inc imfinzi durvalumab product monograph may v ibid vi ibid vii canadian cancer statist access april avail httpwwwcancercaencancerinformationcancertypelungstatisticsregionon viii zhao q wang z huang w wang q yu s zhou t li b phase iii studi cisplatin pemtrex vinorelbin plus concurr late cours acceler hyperfraction radiotherapi patient unresect stage iii nonsmal cell lung cancer oncotarget httpdoiorgoncotarget ix auperin a le pechoux c rolland e curran w furus k fournel p metaanalysi concomit versus sequenti radiochemotherapi local advanc nonsmallcel lung cancer journal clinic oncolog may httpascopubsorgdoifulljco x the nation comprehens cancer network nccn nccn clinic practic guidelin oncolog nonsmal cell lung cancer version avail httpswwwnccnorgprofessionalsphysicianglspdfnsclpdf access januari xi bradley jd paulus r komaki r master g blumenschein g schild s bogart j choy h standarddos versus highdos conform radiotherapi concurr consolid carboplatin plus paclitaxel without cetuximab patient stage iiia iiib nonsmallcel lung cancer rtog a randomis twobytwo factori phase studi the lancet oncolog httpwwwthelancetcomjournalslanoncarticlepiisfulltext xii astrazeneca canada inc imfinzi durvalumab product monograph may sourc astrazeneca for inform michell marchion senior manag corpor communic astrazeneca canada tel x email',\n",
       "  'NN'),\n",
       " ('hi ami chose copaxon diagnos realli easi fit day work well year howev got bad lipotrophi sever condit inject site switch tecfidera tecfidera tablet day much pleasant daili inject see ms nurs everi month blood test care white blood cell count go appoint make sure ask question need much know alreadi offer infus lemtrada tysabri big gun may offer first line treatment inject rebif avonex copaxon tablet tecfidera gilenya aubagio feel nervous ask someon accompani rememb your decis cant make decis day ask time think good luck carol x',\n",
       "  'NN'),\n",
       " ('hey amanda is mavenclad clone medic gilenya', 'NN'),\n",
       " ('avengr i know edgarleroy cladribin us hes post it may doctor differ us state offer differ drug hes ski offpist way one do mind ask found scari cladribin it seem one milder ms drug side effect',\n",
       "  'NN'),\n",
       " ('my mom diagnos nsclc approv keytruda she small tumor lung even smaller hard visibl one liver everyth els came back clear the keytruda first treatment what expect side effect i know cancer differ i would love hear someon taken is even possibl could shrink liver tumor oper lung lead remiss she obvious stage iv i know serious im worri much time i left my question never told size spot lung liver this may dumb question size matter give indic advanc she doesnt ask question appoint im tri learn much possibl thank advanc help provid',\n",
       "  'NN'),\n",
       " ('hello eyesight thank posit like i realli want abl keep read this along abl drive would wors nightmar at present left eye fine i dread thing happen one had second inject eyelea last week lucenti appear help fact made thing seem wors just hope eyelea stabilis like other report i black disc told bubbl scari went coupl hour hope goe well x',\n",
       "  'NN'),\n",
       " ('potenti treatment nonrespond dr ariyan studi cours first exampl treat melanoma immunotherapi combin approach combin ipilimumab nivolumab recent becam firstlin treatment advanc melanoma clinic studi report object respons rate ipilimumab nivolumab compar ipilimumab monotherapi although median pfs combin superior ipilimumab nivolumab alon month month respect still month our best immunotherapi today combin ipilimumab pd inhibit still room make improv dr ariyan said nevertheless ili like take place pd inhibitor combin ipilimumab firstlin treatment advanc melanoma as dr ariyan coauthor wrote littl role limb infus ctla blockad firstlin treatment invas natur ili need hospit my hope futur abl use treatment patient otherwis respond dr ariyan said the next step look combin peopl fail tradit immunotherapi ad relat articl obes associ with improv melanoma outcom immunotherapi metastat melanoma in clinic can vismodegib induc melanoma patient treat basal cell carcinoma grow interest chemoimmunotherapi there current push test various chemotherapi immunotherapi mous studi clinic trial treat rang cancer type said gordon freeman phd professor medic oncolog danafarb cancer institut boston massachusett for advanc melanoma phase trial found improv overal surviv combin ipilimumab dacarbazin compar dacarbazin alon ipilimumab paclitaxel carboplatin current evalu treatment nonsmal cell lung cancer nsclc smallcel lung cancer in the us food drug administr fda approv combin ipilimumab pemetrex carboplatin nsclc research also evalu target therapi mek kinas inhibitor treatment colorect cancer antiandrogen therapi treatment prostat cancer antiangiogenesi therapi treatment kidney cancer combin pd inhibit precis target agent may advantag nontarget drug pemetrex nonspecif kill divid cell thus could hinder product t cell immunotherapi act dr freeman explain',\n",
       "  'VBP'),\n",
       " ('my first ever infus schedul day thank share i appreci know expect ive never dmt recent dxd ill start ocrevus soon im look forward',\n",
       "  'RB'),\n",
       " ('mike hello david so weve good day today ms life ectrim morn think good piec work that happen today inform think peopl know professor david baker neurologist well i think probabl interest thing that happen today news first time theyv shown drug affect progress ms so drug call siponimod shown slow rate disabl accumul peopl secondari progress ms that first time that happen and phase three trial mean theyr probabl readi go regul may far becom real drug so i think probabl one highlight meet but other one thing i realli realli interest studi sweden so know there drug come along call ocrelizumab pretti effect diseas modifi drug there drug call ocrelizumab that probabl regul moment but interest thing problem drug general cost kind influenc whether peopl get access so theyv sweden theyv use like cheap version ocrelizumab theyv got thousand peopl whove given access drug obvious look like work now interest thing look long peopl drug actual take coupl year wherea pharmaceut compani want take everi six month forev might so kind realli good news could mean effect might take drug long long time reduc side effect and also suggest know doctor will tri thing outsid box good thing i think drug may benefit peopl ms theyr use theyr produc market ms pharmaceut compani nevertheless use say epilepsi drug might valu multipl sclerosi so one highlight like stick man like great mike on topic think might risk move away big pharmaceut compani move sort generic area might less acceler term fund that come kind treatment professor david baker definit definit and i think worri i guess there go burst bubbl mani year pharmaceut industri invest heavili ms drug one neurolog diseas treatment avail that pharmaceut compani make money but eventu happen drug theyr protect patent patent run generic come along now what happen histor drug biolog difficult manufactur straight chemic first chemic come patent could potenti mean price plummet therefor pharmaceut compani may show less interest and that kind potenti good thing term get access drug there restrict ration cost could bad thing pharmaceut compani may disinvest ms so could well happen join shiftm communiti httpsshiftm watch video httpsshiftmsmsreport httpswwwfacebookcomshiftm httpswwwinstagramcomshiftdotm httpstwittercomshiftm',\n",
       "  'JJ'),\n",
       " ('on apr pm ilex wrote for opdivo side effect youi develop serious rash besid thatnada zilch but rash realli realli bad but tumor shrank i recov earlier nastier chemo abl go back work',\n",
       "  'NN'),\n",
       " ('hi five welcom grace im sorri hear stepmom diagnosi your post rais question may affect futur treatment decis was treatment alimta effect stop alimta due progress cancer progress later has shown progress keytruda grow slowli rapid with stage iv diseas usual expect evid diseas disappear although small number patient achiev status instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept you want get maximum benefit treatment move anoth line therapi and immunotherapi keytruda patient dont show benefit immedi patient deriv longlast benefit treatment so base youv said i wouldnt assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress it would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question ive rais well tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('nil kochhenriksen depart clinic epidemiolog clinic institut aarhus univers aarhus denmarkth danish multipl sclerosi registri neurosci centr rigshospitalet univers copenhagen copenhagen denmark melinda magyari the danish multipl sclerosi registri neurosci centr rigshospitalet univers copenhagen copenhagen denmarkth danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark finn sellebjerg the danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark per soelberg srensen the danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark the danish multipl sclerosi registri neurosci centr copenhagen univers hospit rigshospitalet blegdamsvej dk copenhagen denmark background natalizumab fingolimod approv treatment activ relapsingremit multipl sclerosi rrms denmark respect there random headtohead studi compar two drug object to compar clinic efficaci natalizumab fingolimod method data danish rrms patient start first secondlin treatment natalizumab fingolimod juli march prospect record danish multipl sclerosi ms treatment regist the two treatment arm propens score match baselin covari use nearest neighbour method result propens score match left rrms case treatment group the ontreat annual relaps rate confid interv ci natalizumab ci fingolimod the adjust relaps rate ratio ci p mean time first relaps year respect p there differ chang expand disabl status scale edss conclus we found differ clinic diseas activ natalizumab fingolimodtr rrms patient reallif observ studi howev lack magnet reson imag mri data propens score match may conceal higher efficaci natalizumab',\n",
       "  'JJ'),\n",
       " ('peg ivig infus suppos last day i surpris done hour i learn quicker infus meant side effect the nurs decid make go faster even though doctor order way this year ago i wonder could ocrevus repli with quot the follow user say thank agat howi jeani z jendi stillstannd',\n",
       "  'JJ'),\n",
       " ('best luck next week solomon i wish best possibl outcom my ileostomi definit prefer i i sometim use find empti bag bit pain i miss empti bag abl get go without worri stool pass butt burn becom absolut excruci kept control anal itchingleakag that said i hadnt revers i think i would constant wonder i suspect would tri beat given jpouch go dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('surgeri recoveri slow immunomodul dont heal fast so time requir step instead two step surgeon call you would med enough time prior nd surgeri i step i wouldnt want two step condit step tough recov i wouldnt want combin presurgeri condit how entocort similar steroid they nonsystem mayb one cycl knock flare keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('the fingolimod secondari progress eae i may comment i see full paper i may unless i confirm realli secondari progress model i suspect relaps progress relaps drive worsen synchronis line graph look secondari progress i ask last two nod paper publish japan australia raw data got nowher it import despit said abstract harvard group report model respons quick t cell immunosuppress fingolimod may work in progress system great like fingolimod great primari progress ms will tri spms i doubt siponimod develop then vitro fingolimod activ agent use hundr time sp bind efficaci know cell killer food thought if sp eae use',\n",
       "  'NN'),\n",
       " ('longish post question end i start lower back pain around l lumbar vertebra along tingl equal leg week ago this tingl new addit residu peripher neuropathi feet cisplatin end year ago i lul vat adenocarcinoma lung yesterday i start gentl lumbar stretch yoga pose i found web i much mobil comfort today yesterday still pain lower back tingl leg when stand i get dull ach leg all symptom complet new aros simultan i realiz lower back pain extrem common i probabl worri noth ive never nowaday whenev i get ailment i wonder could cancer return this whole subject im guess pretti common it hard know realli ration concern inevit i mean cancer recurr real possibl still resect lung adenocarcinoma even act one hand hand everi one age process ongo cancer without i abdomin chest ct scan without contrast show evid metastasi week ago refer bone area said specif focal destruct lytic sclerot osseous lesion abdomen pelvi the question i standard ct scan chestabdomenpelvi also imag spine way rule metastat spread spine sourc pain second way pain result cancer lower back nervous system i sure spine includ term abdomen pelvi the second question general come grip cancer risk confront general health problem post diagnosi chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan this topic modifi year month ago catdand forum moder this topic modifi year month ago catdand forum moder',\n",
       "  'NN'),\n",
       " ('yeah my buddi stan got he go help film video blog hes go drive jeep feed water hors i ride i excit we alreadi went tulsa trade car jeep problem check we drive back last night sky orang distanc i explain stan farmer burn field late make room new growth so decid go find fire it fun we took jeep crazi eeri dirt road follow orang glow sky final crest littl hill acr acr acr burn grass we got right next turn light we got film the smoke realli strong probabl good us a truck pull trailer water guy stand back drove us they keep eye fire probabl thought dork take pictur beauti we made video tie high line hitch hors tree soon post video everyon know tie cow hitch it nice partner i havent given ms updat awhil basic i fine i take dri cordycep mushroom powder it mushroom medicin gilenya made i figur activ ingredi one strongest ms medicin might help not say anyon tri i medicin right i i i also take turmer powder black pepper curcumin activ ingredi turmer super potent antiinflammatori i make smoothi morn dump powder i still take liquid d liquid methyl b i think liquid get absorb better i take lot pill supplement i worri ill overload pee i tri space day someday i better other it learn curv i still hard time chang diet we eat steak haha im tri put much pressur i get road i confid i road routin itll easier eat anti inflammatori simpl diet that i go take',\n",
       "  'NN'),\n",
       " ('my husband xeljanz month he still full remiss appar side effect he start feel better almost right away bleed stop month month felt confid work had colonoscopi month start xeljanz show total remiss hope work take mg mg morn mg even spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       "  'JJ'),\n",
       " ('i like post updat possibla work name wife i use clinic trial drug see former post coupl week next ct scan done but meantim i want say today mark good moment my wife ayso soccer refere number year boysgirl year old game one two game week howev ever sinc cancer diagnosi year half ago refere first due carboalimta treatment lower red blood cell reduc stamina consider nonrespons opdivo treatment side effect persist cough return work clinic trial initi treatment the possibla treatment howev side effect hair neuropathi pain numb time seem affect blood cell energi level great so today year half back refere ayso game afternoon two us went kayak hour morn so mileston return hope ct scan coupl week continu show reduct lung tumor liver metastas one day one step forward time wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl all stabl addl growthoff trial start gemzarlarg tumor reduct',\n",
       "  'NN'),\n",
       " ('veri good news pediatr fingolimod result ani idea effect children the result much better transform studi',\n",
       "  'NN'),\n",
       " ('saw current gi doc today i say ma rn kind concern megot back room quick i could lay i step scale inde i lost lbs day i freak hungri afraid eat as thing i want discuss doc answer q should i consid use immunomodul along humira a sinc i spike fever dont know option right q i need pain med im run hydrocodon will prescrib refer pain manag specialist a he prescrib hydrocodon pill he order chest xray slew bloodurinefec test i go labcorp pick test suppli he told next time i spike i go er and fact i ever feel offpanicki due pain mental anguish etc dont hesit go er i ask at point i admit and said wouldnt admit right hed alreadi done i told first hospit i day time i left i poop normal feel fine my diseas never act like wateri d solid wast never taken long see relief symptom after i finish doctor famili went qdoba dinner i got kidsiz burrito bowlbeen crave rice bean i glad i ate though would made sick eat much so far i dont regret eatng i look forward finish bowl morn i appoint local gi doc monday sinc i good experi current gis offic today im sure i want switch my current doc better credenti local gi hes easi talk toi establish relationship marnetc what thinkshould i go see local gi say or cancel stick current gi yr femal diagnos hospit current apriso ampm rowasa enema pm mg prednison mg ammg pm liquid diet current wait approv start humira previous fail remicaid previous use asacol lialda delzicol pentasa cortenema canasa entocort uceri im glutenfre supp vsl calmag vit d krill oil',\n",
       "  'NN'),\n",
       " ('i read page couldnt read much jack seem like know jackwagon doesnt listen anyth anyon say anyway ask question ill go ahead tri answer anyway yes hinder growth see blood mean nowher close remiss unless hemmi someth alik yes serious flare hit lose muscl mass fast i weigh lbs squat lbs set rep flare land hospit day week sever anemia hemoglobin i abl squat set i weigh lbs point yes diseas hit fast i diagnos year jan went prednison lialda enema got back normal april in may i back full blown flare prednison wouldnt control i went imuran remicad entyvio age i colon remov jpouch procedur noth help i sever anem couldnt much constant pain etc the navi would perform medic anyway inflamm marker anyth show theyd investig flare etc wouldnt matter previous record show probiot sound great just probiot help low amount user least forum you talk like know whole lot surgeri requir ever came havent even met surgeon let alon diagnos i doubt realli know would like wont youd boat all best luck ps attitud especi militari youd get absolut rock',\n",
       "  'NN'),\n",
       " ('i found cm liaison brain surgeri day radiat spot remov tumor month later mri found mm tini abnorm tumor i go last day treatment radiat monday would complet day i hope isnt anymor cell brain sinc lung nsclc far negat ct scan i pet scan follow call surveil scan make sure im ned i feel great lung specialist said im elig keytruda said data that say im readi i dont know that good thing bad oncologist say i dont need chemo keytruda i guess i wait till anoth tumor come back i wonder alway come backugggh common denzil give perk knowledg i look forward hear u r say time lol',\n",
       "  'JJ'),\n",
       " ('i know i mention elus articl state appl peel excel natur tnfa inhibitor it actual came right said appl peel i think per day gave tnfa inhibit dose remicad that mani appl peel day would leav ruin i suffer hour last night eat small portion kale dinner sad fibrous veggi bowel longer get along use friend fell year ago dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('mousedoctorsaturday juli pm howev pharma get burneda posit result ocrelizumab ppms siponimod spmsno reward may ask bother or mayb pharma get burn ocrelizumab ppms littl late mani mayb tri harder better result ppms earlier would onto better gold mine',\n",
       "  'NN'),\n",
       " ('hello lesion brain spine neruo told last mri result two day ago lesion left side brain grew bigger he said could possibl grow black hole dead spot anyon explain which reason want chang medicin tecfidera copaxon gilenya work therefor chang medicin scare tri anoth one due side effect long fda approv read post day ago hug use answer sign view previous answer a mymsteam member said flipsid i nd round lemtrada septemb you said year sinc nd round long start feel read post day ago hug use be assert doctor i passiv person realli believ i need becom assert doctor i realiz ms mani unknown etc perhap doctor may less say but first neurologist i met diagnosi prescrib tecfidera told look ms internet learn actual start appoint i think go tell mistaken i ms but look mri tone chang oh definit read post day ago hug use answer sign view previous answer a mymsteam member said it old school medicin say ms pain everyon differ everyon lesion differ effect degre read post day ago hug use infus center want see anyon get infus done moor cancer center la jolla think experi im go start infus decemb i could use kind feed back lead start date thank much love post day ago hug use answer sign view previous answer a mymsteam member said thank much respons a mymsteam member post day ago hug use had mri august found new spot spine had anoth mri head today head full lesion alreadi what spine spot mean bladder bowel last month gait becom have brace made drop foot next week post day ago hug use answer a mymsteam member said i brain cervicalthorac lesion just mean symptom differ area bodi for exampl handsfingertip feel read edit origin post day ago hug use what best medicaid plan option cook counti resid have insur cover tysabri infus doctor rush univers medic center experi hope i give idea six blue cross communiti famili health plan countycar health plan incook counti harmoni health plan illinicar health meridian health plan molina healthcar nextlevel health cook counti resid just want sure i cover much ppo ive pay read post day ago hug use answer sign view previous answer a mymsteam member said ive got get decis made soon possibl i take advic give email joshuakerouac gmail truli read post day ago hug use tattoo ms i want get tattoo repres diseas anyway wonder anyon got one diagnos good idea',\n",
       "  'NN'),\n",
       " ('hey ladi man i miss guy want catch pretti distract thing go well over relish feel better mani waysi drink pedialyt day still felt dehydr i drink normal amount fluid even cup coffe i feel fine i rosacea ive perior dermat mouth ulcer extraintestin issuesbut current skin gorgeous i done noth even moistur my perirect fistula nonissu sitz bath i around cook light housework stand feet talk someon long i want i alway sit lay take break lean thing and i alway pain especi toilet i use dread vacum carri groceriesput away simpl task wore but anymor i tri take easi i love abl live life peopl impress posit outlook truli i believ i canand live full life ostom on hand at night i get emot i fan scar particular bikini scarswel go i still look differ i tri figur bag i like base sampl arriv past coupl day hard suppos chang bag often luckili leak yet but i find empti lot kind process cumbersom point i feel awkward wonder i realli live ostomi foreveri shed tear worri frustrat i hot mess wonder i ever get hang ostom i feel dishevel hair fell due stelara grow back stick everywher i move i dont even know alot cloth i need buy belt ostomi underwear i dont fluck know buy onlin cannot tri whyyyyi cant somebodi say need and save drain task onlin research i nap would nice an ostomi personalshopp my home health nurs came today help chang bag might one sensura mio pieceit fit stoma i mm bagflang heavi fold nice i tri biggerbulki two piec ostomi nurs rightit heavi postop still tender i use barrier spray seal past powder i tri deodorantlubric bravo today good i tri m my nurs today said skin look good relief area tender i wasnt sure someth wrong im start wean prednison i drop mg mg today readi i dont want feel bad oh i didnt mention hemoglobin fell hospit i end anoth iron infus discharg friday i felt littl light head hereandther hope anemia clear quick im bleed toddler think bag cool reassur my husband coach low point incred support i didnt know mani peopl louisiana husband collaps surgeri found ton support around uspeopl bring meal groceri mow lawn care pet even give us money i lose faith world i tire struggl silenc but faith god mankind renew and i never repay peopl help us time need i never miss opportun pay forward i see way i help serious i tear eye right i grate love guy yr femal dx uc dx chang crohn coliti current stelara apriso prednison wean previous use remicad humira imuran mp asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam im glutenfre supp vsl calmag vit d krill oil ezf post edit plucki pm gmt',\n",
       "  'NN'),\n",
       " ('i want give updat post novemb my son rd infus ocrelizumab april everyth still stabil sinc start ocrelizumab no side effect even infus short infus got flue infect brother father came visit us day infus all high temperatur day tire week be ocrelizumab made differ equal sick wish well ing',\n",
       "  'VBG'),\n",
       " ('front neurol nov abstract read full text paper siddiqui mk khurana is budhia s et al systemat literatur review network metaanalysi cladribin tablet versus altern diseasemodifi treatment relapsingremit multipl sclerosi curr med res opin nov epub ahead print abstract read full text paper lublin fd cofield ss cutter gr et al longterm followup random studi combin interferon glatiram acet multipl sclerosi efficaci safeti result year mult scler relat disord nov abstract gerber b cowl t chen g et al the impact treatment adher clinic econom outcom multipl sclerosi real world evid alberta canada mult scler relat disord nov abstract eagl t stuart f chua as et al treatment satisfact across inject infus oral diseasemodifi therapi multipl sclerosi mult scler relat disord nov abstract eriksson i car t piehl f et al persist dimethyl fumar relapsingremit multipl sclerosi populationbas cohort studi eur j clin pharmacol nov epub ahead print abstract read full text paper moccia m palladino r carotenuto a et al a year retrospect cohort studi compar interferon formul relapsingremit multipl sclerosi mult scler relat disord nov epub ahead print abstract thelen j bruce a catley d et al baselin predictor dmt reiniti among patient multipl sclerosi follow micbt intervent j behav med nov epub ahead print abstract zimmer a coslovski m abraham i et al adher fingolimod multipl sclerosi investigatoriniti prospect observ singlecent cohort studi patient prefer adher oct',\n",
       "  'JJ'),\n",
       " ('kleo i eight far next due dec i never seen scan never offer show time wait doctor comment let talk till run thing say nod head give thumb if concern question bring get soon possibl as long feel good happi way treatment goingnow week infus thing took differ direct cough congest advic get medic help there one thing come mind last infus never took water even got home thing water pm cough start way think stupid move part water play big factor cough clear congest loosen thank good i wonder order pet instead regular ct way could answer question at stage let doctor interpret let tell cours action and also want miss xmas basket durvalumab',\n",
       "  'NN'),\n",
       " ('brand name portrazza import warn necitumumab inject may caus serious lifethreaten problem heart rhythm breath your doctor order certain test infus infus least week final dose check bodi respons necitumumab tell doctor ever lower normal level magnesium potassium calcium blood chronic obstruct pulmonari diseas copd high blood pressur heart rhythm problem heart problem if experi follow symptom call doctor immedi chest pain short breath dizzi loss conscious fast irregular pound heartbeat keep appoint doctor laboratori talk doctor risk receiv necitumumab inject whi medicin prescrib necitumumab inject use gemcitabin gemzar cisplatin treat certain type nonsmallcel lung cancer nsclc spread part bodi necitumumab inject class medic call monoclon antibodi it work help immun system slow stop growth cancer cell are other use medicin this medic may prescrib use ask doctor pharmacist inform how medicin use necitumumab inject come liquid given intraven vein hour doctor nurs medic facil it usual given certain day everi week the length treatment depend well bodi respond medic side effect experi your doctor may need stop delay treatment experi certain side effect it import tell doctor feel treatment necitumumab you may experi symptom fever chill short breath difficulti breath receiv follow dose necitumumab especi first second dose tell doctor healthcar provid experi symptom treatment if experi reaction necitumumab doctor may stop give medic time may give slowli your doctor may prescrib medic help prevent reliev symptom your doctor tell take medic receiv dose necitumumab what special precaut i follow befor receiv necitumumab inject tell doctor pharmacist allerg necitumumab medic ingredi necitumumab inject ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take your doctor may need chang dose medic monitor care side effect tell doctor pregnant plan becom pregnant you becom pregnant receiv necitumumab inject you use effect birth control prevent pregnanc treatment necitumumab inject least month final dose medic talk doctor birth control method work if becom pregnant receiv necitumumab inject call doctor immedi necitumumab inject may harm fetus tell doctor breastfeed plan breastfe you breastfe receiv necitumumab month final dose plan avoid unnecessari prolong exposur sunlight wear protect cloth sunglass sunscreen necitumumab inject may make skin sensit sunlight what special dietari instruct i follow unless doctor tell otherwis continu normal diet what side effect medicin caus necitumumab inject may caus side effect tell doctor symptom sever go away acn dri crack skin diarrhea vomit weight loss sore lip mouth throat vision chang red wateri itchi eye red swell around fingernail toenail itch some side effect serious if experi symptom call doctor immedi get emerg medic treatment leg pain swell tender red warmth sudden chest pain tight weak numb arm leg slur speech rash difficulti swallow cough blood necitumumab inject may caus side effect call doctor unusu problem receiv medic if experi serious side effect doctor may send report food drug administr fda medwatch advers event report program onlin web phone what i case overdos in case overdos call poison control helplin inform also avail onlin web if victim collaps seizur troubl breath cant awaken immedi call emerg servic symptom overdos may includ follow headach vomit nausea what other inform i know ask pharmacist question necitumumab inject it import keep written list prescript nonprescript overthecount medicin take well product vitamin miner dietari supplement you bring list time visit doctor admit hospit it also import inform carri case emerg this report medic inform consid individu patient advic becaus chang natur drug inform pleas consult physician pharmacist specif clinic use the american societi healthsystem pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field the american societi healthsystem pharmacist inc make represent warranti express impli includ limit impli warranti merchant andor fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos the entir monograph drug review thorough understand drug action use side effect the american societi healthsystem pharmacist inc endors recommend use drug the inform substitut medic care ahf patient medic inform copyright the american societi healthsystem pharmacist inc eastwest highway suit bethesda maryland all right reserv duplic commerci use must author ashp',\n",
       "  'NN'),\n",
       " ('repli plan i offici ocrevus view post by activems even much differ rtx even much differ rtx ocrevus i hope placebo effect good enough give bump in hour afterward i felt pretti darn good rememb i',\n",
       "  'VBP'),\n",
       " ('cancer run famili i diagnos stage iv lung cancer septemb came complet shock i healthi activ yearold wife mother two young girl sinc ive learn anyon lung get lung cancer ive also learn import find doctor medic team trust i want peopl around commit find cure diseas research and i found md anderson my lung cancer symptom i symptom lung cancer diagnosi i felt pressur chest i assum relat stress due recent move i thought return regular fit routin would help feel better i went jog new neighborhood surpris i felt unusu breath i assum i virus possibl walk pneumonia i went local walkin clinic the doctor took xray chest told i collaps lung need go emerg room right away i spent four day hospit i underw test fluid drain around left lung i told i like ovarian cancer due enlarg cyst one ovari we found later size within normal rang noth symptom my husband i left hospit question answer my lung cancer diagnosi the next day friend recommend go anoth local hospit seek answer i still fluid around lung need drain after test doctor recommend exploratori surgeri when i woke surgeri famili visibl upset the surgeon told i stage iv adenocarcinoma type lung cancer i mass upper left lobe lung anoth lower left lobe nodul chest belli my prognosi good my first question much time i left the surgeon said two week nine month the oncologist want genet test tumor say might chang treatment plan we wait two long week result ultim i test posit alk genet mutat link lung cancer my husband i knew want get best care possibl set appoint md anderson we immedi made plan fli houston meet new doctor whi i came md anderson lung cancer treatment at md anderson met dr vincent lam the first thing told us give hope he said job keep aliv cure found need stay strong keep fight then recommend drug call crizotinib one first target therapi develop alkposit lung cancer we felt realli comfort dr lam trust expertis he agre partner local oncologist knoxvill that husband i start call medic ateam they communic work togeth ensur i get best treatment i start take crizotinib twice daili and though kept cancer stabl i felt nauseous exhaust time i kept get sick white blood cell count low dr lam suggest switch new target therapi drug call alectinib he said new research indic strong possibl new drug would prevent cancer spread longer period time we trust dr lam got local oncologist onboard within day start alectinib i began feel normal i energi back abl exercis could play daughter the best part new target therapi made cancer disappear i refer radiat oncologist dr daniel gomez suspici spot chest medic team advis wait six week start radiat therapi alectinib took care my life today i take alectinib pill twice day two year the side effect ive experienc sun sensit achi feet morn but i get move pain goe away i return md anderson everi day scan appoint dr lam eventu lung cancer build resist drug my ateam plan place happen as right result wonder ive what call complet metabol respons ive shown evid diseas sinc novemb request appoint md anderson onlin call',\n",
       "  'NN'),\n",
       " ('toxicmegacolon typic high fever associ are still fever discontinu simponi least i think discontinu i know high fever lower temp fever thereaft i hadnt thought seem possibl fever',\n",
       "  'NN'),\n",
       " ('bumppleas read folk want inform regard iron zamboni research husband dx rrms dx dual jugular vein stenosi ccsvi httpccsviinmsblogspotcom top paulmur famili member post join thu mar pm quot post paulmur sat feb pm as ive said various forum i dxd ironoverload hemochromotosi month dxd ms first exacerb i found lesion brain spine typic ms i suffer ms symptom contant main lot fatigu depress fog brain tingl anyway i mention context i absolut believ iron causat factor effect perhap ive alway ccsvi fact signific iron level start rise age also i think rr part rrms stress vasodilat right perhap one trigger among other could caus stenosi reach tip point would start reflux then perhap time stenosi retriet enough recoveri just thought top lucki famili elder post join wed dec pm locat usa contact contact lucki icq websit quot post lucki sat feb pm just keep thing interest i borderlin anem whole life i diagnos ms age no exacerb first year diseas then pregnanc terribl anemia chomp ice nine month straight time after born i start avonex year rebif tysabri i constant anem exacerb slow progress year i fought procrit bandaid i dmds await test ccsvi ultrasound posit reflux ijv im back borderlin anem sinc i stop drug year ago i still progress how someon like fit equat top mshusband famili elder post join sun jan pm locat pittsburgh pa usa contact contact mshusband icq quot post mshusband sat feb pm you still iron blood lucki whether lot littl top marcstck famili elder post join tue jan pm contact contact marcstck icq websit quot post marcstck sat feb pm the problem associ iron deposit ccsvi ms iron deposit seen mani neurolog condit none associ ccsvi here link pertin studi httpwwwncbinlmnihgovpubm httpwwwsciencedirectcomscienceo c httpwwwajnrorgcgicontentabstract httpemedicinemedscapecomarticleoverview also nerv cell releas iron damag die iron deposit ms may effect rather caus marc wwwwheelchairkamikazecom top cece famili elder post join mon jan pm contact contact cece icq quot post cece sat feb pm marcstck wrote also nerv cell releas iron damag die iron deposit ms may effect rather caus it seem like could cascad iron releas nerv cell die caus damag area howev truth scienc ultim emerg although sometim take long time arthur silverstein autoimmun a histori earli struggl recognit top paulmur famili member post join thu mar pm quot post paulmur sat feb pm marc i know iron went haywir due genet propens happeni dont believ aspect health relat ccsvi ms but perhap hh appear ccsvi condit may caus lesion i i think fact iron deposit appear diseas may mean set factor could add result i havent ccsvi imag for i know lesion caus hh alon top bethr famili elder post join sun dec pm quot post bethr sun feb paulmur wrote marc i know iron went haywir due genet propens happeni dont believ aspect health relat ccsvi ms but perhap hh appear ccsvi condit may caus lesion i i think fact iron deposit appear diseas may mean set factor could add result i havent ccsvi imag for i know lesion caus hh alon my lesion form iron level peak like mention elsewher i one gene hemochromatosi enough rais iron level when i drop level iron phlebotomi normal level easi i wasnt particular overload doctor standard tired fatigu disappear instant hour i didnt know whether laugh cri i could free two year ago doctor taken notic high iron level got they slight normal ferritin measur now i find i porphyria a rare genet diseas yeah right doctor dont test rare my point rare it preval scottish irish northern european bloodlin porphyria carrier react iron drug love give contracept alcohol make brain strang thing like ms there must heap genet interact go porphyria carrier never show sign mix iron pill much dairi produc beef whamoyou ms take drug big pharma would crumbl sort my son diagnosi autismadhd my niec diagnosi depress brother diagnosi stuf liver my sister i diagnos ms it fix phlebotomi cessat drugscontracept care diet no money big pharma hmmmmm bad packag food industri put mani addit food chemic cocktail day everi breakfast food pack extra iron everyth high preserv nitrat sulphit i pretti healthi i hit iron built decad whammi my sister inject iron teenag got ms much earlier i year',\n",
       "  'VBP'),\n",
       " ('repli post car good luck i hope help symptom much mine side effect reaction as fyi i talk gi next day all level good blood test prior doesnt think allerg reaction actual entyvio mayb someth packag inwho know those kind reaction happen time sound like i go probabl tri stelara next definit keep us post entyvio goe cross finger toe i know good',\n",
       "  'NN'),\n",
       " ('this third differ type medic i ask opdivo i start week ago my first treatment trial drug also immuntherapthi drug pleas excus spell i could stay caus made cancer go per cent first time percent second time im wonder one els opdivo canser gone thank mari',\n",
       "  'NN'),\n",
       " ('yeah your fine i tri azathioprin remicad combin aza entyvio aza prednison still nd step novemb jpouch happi result grow pain adapt up down',\n",
       "  'JJ'),\n",
       " ('young patient whose live blight aggress blood cancer offer new hope experiment immunotherapi drug of take part new trial experienc consider shrink tumour typic remain symptomfre near eight month the drug nivolumab one new generat smart medicin interfer abil cancer shield immun system known checkpoint inhibitor alreadi prove effect melanoma danger form skin cancer one type lung cancer scientist found take part experiment drug trial use nivolumab experienc shrinkag tumour gerri broomeap the new studi look nivolumab abil tackl classic hodgkin lymphoma patient fail respond treatment reboot immun system use transplant stem cell taken bone marrow a total patient took part phase ii trial rang age hodgkin lymphoma develop lymph system affect immun system blood cell call blymphocyt in peopl uk diagnos diseas of classic form ill most affect young adult earli older peopl patient suffer hodgkin lymphoma took part phase ii trial ed uthman flickr result checkmat trial present annual meet european haematolog associ copenhagen denmark due publish journal the lancet oncolog jonathan pearc chief execut lymphoma associ said it vital innov treatment develop made avail lymphoma patient we want everyon affect lymphoma receiv best possibl treatment care option improv outcom qualiti life patient better',\n",
       "  'NN'),\n",
       " ('veri bad sometim dead infect like tuberculosi shingl fungal infect bacteri viral infect happen patient take xeljanz tofacitinib tablet the risk greater also take drug suppress immun system like methotrex corticosteroid if get bad infect doctor may stop xeljanz tofacitinib tablet infect control call doctor right away fever chill sweat cough muscl ach short breath sputum chang color sputum red warm swollen pain blister skin weight loss belli pain loos stool diarrhea pain pass urin pass urin often feel tire weak tb tuberculosi seen patient start xeljanz tofacitinib tablet these patient expos tb past never got infect you test see expos tb start xeljanz tofacitinib tablet lymphoma skin cancer type cancer happen peopl treat xeljanz tofacitinib tablet talk doctor if kidney transplant take drug work immun system greater risk problem certain white blood cell grow control call posttranspl lymphoprolif disord caus epstein barr virus talk doctor use xeljanz see also otezla it use treat rheumatoid arthriti it use treat psoriat arthriti it use treat ulcer coliti what i need tell doctor befor i take xeljanz if allergi tofacitinib part xeljanz tofacitinib tablet if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if liver diseas if anemia if infect low white blood cell count if take rifampin if take drug abatacept adalimumab anakinra certolizumab etanercept golimumab infliximab rituximab secukinumab tocilizumab ustekinumab vedolizumab if take drug use suppress immun system like azathioprin cyclosporin there mani drug ask doctor pharmacist sure if breastfeed do breastfe take xeljanz tofacitinib tablet least hour last dose this list drug health problem interact xeljanz tofacitinib tablet tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take xeljanz tofacitinib tablet drug health problem do start stop chang dose drug without check doctor what thing i need know i take xeljanz tell health care provid take xeljanz tofacitinib tablet this includ doctor nurs pharmacist dentist some viral infect like herp zoster becom activ xeljanz tofacitinib tablet tell doctor ever viral infect like herp zoster talk doctor hepat b c test may done a hepat b c infect may get wors care talk doctor have blood work check told doctor talk doctor high cholesterol happen xeljanz tofacitinib tablet if question talk doctor you may need skin check take xeljanz tofacitinib tablet talk doctor if drink grapefruit juic eat grapefruit often talk doctor this medicin may affect certain lab test tell health care provid lab worker take xeljanz tofacitinib tablet make sure date vaccin treatment xeljanz tofacitinib tablet talk doctor get vaccin use xeljanz tofacitinib tablet may either rais chanc infect make vaccin work well you may chanc get infect wash hand often stay away peopl infect cold flu if high blood sugar diabet talk doctor you may like get infect this medicin may use drug treat health condit if also take drug talk doctor risk side effect may happen if older use xeljanz tofacitinib tablet care you could side effect this medicin may caus fertil problem this may affect abl children it known go back normal if question talk doctor if abl get pregnant talk doctor you may need use birth control prevent pregnanc take xeljanz tofacitinib tablet time last dose if pregnant get pregnant take xeljanz tofacitinib tablet call doctor right away how medicin xeljanz best taken use xeljanz tofacitinib tablet order doctor read inform given follow instruct close take without food to gain benefit miss dose keep take xeljanz tofacitinib tablet told doctor health care provid even feel well what i i miss dose skip miss dose go back normal time do take dose time extra dose see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign liver problem like dark urin feel tire hungri upset stomach stomach pain lightcolor stool throw yellow skin eye sign infect like fever chill bad sore throat ear sinus pain cough sputum chang color sputum pain pass urin mouth sore wound heal warm red pain skin sore bodi shingl chang color size mole a skin lump growth feel tire weak chang bowel habit night sweat short breath muscl pain weak slow heartbeat a heartbeat feel normal tear stomach bowel wall happen certain peopl take xeljanz tofacitinib tablet call doctor right away swell pain stomach bad get wors go away call doctor right away throw blood throw look like coffe ground upset stomach throw go away black tarri bloodi stool veri bad sometim dead lung problem happen xeljanz tofacitinib tablet call doctor right away lung breath problem like troubl breath short breath cough new wors what side effect xeljanz all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away headach loos stool diarrhea sign common cold runni nose sore throat stuffi nose these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw xeljanz store origin contain room temperatur store dri place do store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin this medicin come extra patient fact sheet call medic guid read care read time xeljanz tofacitinib tablet refil if question xeljanz tofacitinib tablet pleas talk doctor pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'NN'),\n",
       " ('no pml brain viral infect occur clinic trial ocrevus treatment deplet b immun cell associ rare pml general immunosuppress medic exposur a higher rate cancer seen ocrevus vs placebo rebif although still infrequ unclear ocrevus truli caus malign random find trial the prescrib inform recommend routin breast cancer screen',\n",
       "  'JJ'),\n",
       " ('hi lamn i hope mom well tagrisso long time it great say yes flaura trial tagrisso demonstr efficaci brain most anti cancer treatment penetr blood brain barrier most lung cancer specialist want give tagrisso first tri see shrink elimin brain met tri radiat howev brain met caus symptom radiat may better quicker surer choic it difficult say next step for one thing time mom need anoth treatment may option avail mutat form treatment cancer way work around treatment this known acquir resist research work address mutat your mom may good fit promis trial drug test posit pdl express immunotherapi would choic egfr dont usual benefit immunotherapi chemotherapi effect singl agent like alimta may side effect work long time best luck mom janin',\n",
       "  'NN'),\n",
       " ('the surgeon actual one think best plan action surgeri the issu primari crohn doc and main surgeon vacat week come back monday the mid level ibd fill doc one reluct surgeri i sure miss half small bowel i sorri i didnt distinct separ aspect there surgeri team ibd team charg care surgeri team lead care inpati the plan attack surgeri depart charg care i go get picc line weekend sometim start tpn feed still npo give bowel rest bit my main ibd doc surgeon go meet monday discuss meet discuss surgeri it sound like surgeri team think need done need get done i think may end semi fast track depend want i still inpati there seem plan place least strang antisurgeri ibd doc i total get take isnt necessari three area seem inflamm caus issu year old crohn sinc medicin remicad restart methotrex supplement vitamin d zinc b multivitamin',\n",
       "  'NN'),\n",
       " ('post past follow mix respons year ago my mother law stage nsclcstart iressa first line biopsi egfr posit this back juli was month mix respons attempt get aura trial back nov she reject previous receiv kidney transplant certain antirejectionimmunosuppress med they three round carboplatinpemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia they stop pemetrex stop work due complicationscanc progress tube insert assist fluidseem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far i know result came back negat t mutat this yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil various antirejectionimmunosuppress med kidney transplant novemb sound like without posit t mutat option limit dr plan tri three round pemetrex see respons the next option taxoter dr said much stronger could side effect just wonder option immunosuppress current cours dr want get touch transplantkidney dr discuss option just wonder idea i send along so three year anniversari diagnosi juli year appreci time',\n",
       "  'JJ'),\n",
       " ('i glad find forum my dad exon insert switch kadcyla he took four round carboplatin pemetrex pembrolizumab although show improv round cancer spread round would love know peopl pyrotinib poziotinib clinic drug',\n",
       "  'JJ'),\n",
       " ('consid cladribin httpmultiplesclerosisresearchblogspotcomsupposethereistherapyformsthatishtml i st dose last month easi toler probabl safer effect fingolimod it offlabel generic publish data show good efficaci send email dr k websit dose info',\n",
       "  'NN'),\n",
       " ('never test best knowledg certain want oversuppress immun system i believ part fear unknown say take tnfalphablock remicadehumira madcamblock simultan entyvio youd suppress abil bodi call immun attack block tnfalpha also suppress bodi respons follow immun attack block madcam prevent wbcs exit circulatori system if also simultan immunomodul azathioprinempmtx there less wbc start so bodi weak abil call follow attack would leav youi there necessari infect beat sepsi uti bronchiti uti etc might need oozi bubbl roll around lol not sure cumul immun suppress abil med honest i know got sepsi due combin mp also potent allopurinol combo requir everyotherweek blood monitor durat precaut moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa my review yelp trip advis terribl night uncomfort bed aw food least drug good hospit',\n",
       "  'JJ'),\n",
       " ('my dad go cycl keytrudacarboalimta monday his pain hard understand cant seem verbal easili either i dont blame some moment ok other much last night didnt sleep at all hes pretti fatigu week take nap day without pain med yesterday might contribut lack sleep night wish someth mom i could help we feel helpless moment like ani comment experi would super appreci if none that ok just felt need vent',\n",
       "  'NN'),\n",
       " ('bristolmy squibb compani nyse bmi today announc committe medicin product human use chmp european medicin agenc adopt posit opinion recommend approv opdivo nivolumab plus lowdos yervoy ipilimumab combin includ firstlin treatment patient intermedi poorrisk advanc renal cell carcinoma rcc this recommend review european commiss ec author approv medicin european union eu there remain high unmet medic need patient advanc renal cell carcinoma said arvin yang md phd develop lead melanoma genitourinari cancer bristolmy squibb we encourag today posit opinion chmp look forward potenti bring first immunooncolog combin therapi appropri rcc patient across eu the chmp recommend base posit data phase checkmat clinic trial stop earli follow plan interim analysi show combin opdivo mgkg plus yervoy mgkg demonstr signific increas overal surviv os decreas risk death intermedi poorrisk patient regardless pdl express level compar current standard care sunitinib hazard ratio hr confid interv ci p median os patient treat opdivo plus lowdos yervoy yet reach ci estim ne compar month patient treat sunitinib opdivo plus lowdos yervoy also deliv durabl respons higher object respons rate ci p n versus sunitinib ci n median durat respons durabl opdivo plus lowdos yervoy yet reach ci ne among respond patient compar month sunitinib ci ne the overal safeti profil consist prior studi opdivo combin lowdos yervoy',\n",
       "  'NN'),\n",
       " ('dear friend i wonder youd minut share thought hope i week make decis next cours actionmedicin here littl background info im year old marri children age diagnos stage iv adenocarcinoma lc march egfr posit tm posit exon extens metastes brain bone rib spine femur etc lymphat system inumer nodul lung scatter throughout lobe firstlin treatment tarceva work brilliant month produc neartot respons all notic sign cancer gone within week after month progress began lung bone brain secondlin treatment tagrisso work well month respons wasnt dramat tarceva but still extrem effect my brain met clear still gone bone show extens heal lung dramat improv no new met anywher last weekat month mark tagrissomi scan show progress lung brain bone still clear im most asymptomat energi level decent my breath isnt perfect good enough no notic symptom except littl short breath especi morn ive time ive tagrisso my question my oncologist recommend chemo rd round treatment he recommend pemetrexid alimta carboplatin do agre i would like preserv abil work fulltim i and id like keep abil remain activ husband father long possibl in experi sever side effect pemetrexid alimta carboplatin if believ i look someth differ pleas share also im hesit abandon tagrisso yet do think im foolish wait next scan',\n",
       "  'JJ'),\n",
       " ('emd serono inc maker cladribin tablet oral formul cladribin announc today receiv complet respons letter crl unit state food drug administr fda the fda issu crl complet review applic howev situat fda abl approv applic without addit inform the announc disappoint member ms communiti hope see anoth option ad list avail diseasemodifi therapi longterm treatment ms accord emd serono fda found substanti evid cladribin tablet effect indic clariti studi cla ri bine t ablet treat ms oral y while effect question fda look improv understand safeti risk overal benefitrisk profil this requir either addit analysi present avail data addit studi conduct the drug compani plan request endofreview meet fda dure meet emd serono would find proceed data complet ongo clinic studi cladribin tablet could suffici answer fdas question safeti emd serono note remain commit complet ongo studi cladribin tablet continu seek fda approv drug three ongo studi near complet toplin result initi primari outcom studi expect end first half the safeti data studi provid valuabl addit safeti data fda consid background inform cladribin investig oral drug studi longterm treatment relaps form multipl sclerosi ms it submit unit state food drug administr fda approv receiv fast track status juli fast track status reduc fdas review time month six decis expect novemb howev agenc extend review time three month decis anticip februari while cladribin tablet approv earlier year australia russia trade name movectroi european regul issu negat opinion regard whether benefit outweigh risk merck serono divis merck kgaa plan appeal negat decis came committe medicin product human use chmp european medicin agenc this reject issu septemb prior fda extend review period drug for inform cladribin tablet relat studi pleas see msaa onlin news articl fda extend review period oral cladribin anyon question may call msaa helplin speak consult written susan well courtney msaa senior writer creativ director review dr jack burk msaa chief medic offic',\n",
       "  'NN'),\n",
       " ('hi merile i hope your feel alright dr weiss say blog post cisplatin vs carboplatin want start brawl meet thorac oncologist good way start cisplatin vs carboplatin debat cisplatin lover feel cisplatin slight effect carboplatin carboplatin lover argu carboplatin equival even cisplatin slight edg efficaci small differ inadequ compens dramat higher toxic httpcancergraceorglungintroductiontofirstlinetherapyforadvancednsclc for adeno nsclc mani oncologist prefer alimta side effect profil less toxic howev partner drug often use taxol ani cytotox drug shown effect nsclc fine except gemcitabin toxic use concurr radiat it import wait follow scan radiat inflamm caus radiat look like cancer ct pet too radiat continu work time treatment stop most specialist like wait least month complet radiat scan sometim radiat scar make difficult know even longer more wait i know better get wrong impress cancer grow im sorri your go hope gone all best janin',\n",
       "  'NN'),\n",
       " ('im sorri loss im reader year wonder surgeri went condol joseph famili friend mom year old daughter diagnos apriso pill xs day pill x daili purinethol mpmg daili everi other day chewabl vitamin remicad start stop second infusionstart cimzia back remicad stop augustremiss acheiv flare simponi simponi stop rd dose chang reinduct remicad methotrexa',\n",
       "  'NN'),\n",
       " ('obvious issu balanc concern enorm cost strict glucos control term demand patient time energi vigil worri seldom taken account uncrit prais everlow blood sugar level mani medic journal articl littl weight given tripl sever hypoglycemia incid strict control regimen death hypoglycemia occur even disrupt patient social work life abil hold driver licenc import consider throw onto scale whatev physiolog valu lower blood sugar level case discount influenc genet continu autoimmun caus contribut etiolog complic also even good blood sugar level gambl sinc peopl fail pay dividend a friend mine exampl alway better blood sugar control i blind dialysi age so patient pay heavi price good blood sugar valu invest may bring benefit addit metabol memori oper patient high blood sugar level year may continu generat new complic even though patient achiev perfect blood sugar control in case exampl sinc i type diabet year first home glucomet becam avail i long histori hyperglycemia caus mani decad later four laser photocoagul treatment retinopathi even though ac fourrang last decad so use strict control case mani other situat perhap use it realli fine linedraw exercis would accept life constant sever hypoglycemia incid undermin job social life legal right drive car return delay onset endstag renal failur year year onset year the answer depend prioriti life some healthi peopl choos smoke would rather live pleasur cigarett risk cancer heart diseas earli death diabet variat approach life perhap peopl would rather avoid hypoglycemia regiment life entir take risk other would answer question want calibr complic risk lifestyl valu high individu',\n",
       "  'NN'),\n",
       " ('i rebif i first diagnos year i coupl minor elaps gave new lesion right frontal lobe horn then i couldnt tell feet hot cold i knew someth happen couldnt tell hot cool anyway turn i yet anoth lesion nero chang gilenya i nurs doctor come hous watch first hour i took first dose everyth great gilenya great ive problem sinc relaps kind i feel much freer shot howev find antidepress taken gilenya they stop take mine doesnt go well medic i celexa so cours i stop didnt give anyth substitut the withdraw crazi took forev find good one i could take the come depress bad i almost went back rebif thank god i takecymbalta seem work realli well meit take get use i love gilenya im glad i the side effect absolut none i person love good luck question dont hesit ask',\n",
       "  'NN'),\n",
       " ('hey i total feel pain i start humira month ago bowel obstruct bad joint pain hand shoulder hip gi doc sent referr rheumatologist cant seen januari def recommend get referr sooner rather later wait pretti long sometim best luck',\n",
       "  'VBD'),\n",
       " ('repli post car i entyvio sinc april it help crohn immens i remicad got shingl twice stop had mp long time flare food poison decemb i couldnt recov entyvio around octnov start experienc itch everywher thought mayb allergi dri skin final realiz side effect entyvio earlier month bloodwork normal gi told keep eye i will deal itch normal stool i went infus today allerg reaction flush heart race dizzi blood pressur heart rate skyrocket had stop infus midway take benadryl took hour get back near normal the gi staff said wouldnt reccomend anoth entyvio infus doctor still proceed give heavi dose steroid attempt counteract inpati set have see next option nowposs humira but perhap tri see bodi toler just keep eye sure effect especi itch mayb earli indic reaction i miss good luck',\n",
       "  'JJ'),\n",
       " ('a recent studi show golimumab simponi effect salvag therapi refractori crohn patient fail antitnf like humira remicad so could worth tri link golimumab studi academicoupcomjcagarticlesuppl year old femal issu began juli capsul endoscopi late march show suspect crohn ileocol after colonoscopi april offici diagnos ulcer pancol w backwash ileiti current med remicad apriso x daili canasa mg suppositori night b inject month iu vit d week remiss',\n",
       "  'JJ'),\n",
       " ('thank janin i wonder thing my t m mutat disappear tagrisso therapi origin egfr exon mutat still detect can i assum go back tarceva might trick i also got ct result neck pelvi veri happi no met seen anywher lung tumor irradi decjan continu shrink nice so deal noth els hide singl visibl mass cerebellum mm mm month ago i see onc tomorrow discuss would make sens test theori tarceva might effect i wait srs brain lesion find onc lesion gone wont know time thank repli i treasur input alway kempten',\n",
       "  'NN'),\n",
       " ('thank bang drum natalizumab biogen must tough time roch take lead ocrelizumab two decad rituximab went market take pharma ineffici asid id realli like see somebodi nail diseas antiebv treatment rituximabocrelizumab chanc',\n",
       "  'NN'),\n",
       " ('hi caringinsc i termin rcc kidney stage iv i diagnos i multipl differ treatment variabl rate success at present i triall opdivo nivolumab yet seen possibl treatment kidney cancer i mani metastasi spine back shoulder bone hip rib skul liver lung etc i start opdivo octob last year infus everi week after three month treatment ct scan show remark result boni metastasi stabilis tumor liver shrunk hard visibl lung tumor stabilis except new tumor pop overal good result notic side effect i still opdivo next scan toward end april i would advis go nivolumab give remark result cheerio margo',\n",
       "  'NN'),\n",
       " ('ive entyvio nine month sinc ive medicin i experi crohn system everi week half even around bed time at time i diarrhea empti i feel fine i longer concern go eat leav hous emerg diarrhea howev last two week plus ive fight cold symptom although i mayb littl better i begin wonder i ever get cold after read experi other i wonder entyvio complic recoveri',\n",
       "  'NN'),\n",
       " ('lucenti ranibizumab made human antibodi fragment it work keep new blood vessel form retina sensori membran line insid eye in peopl certain type eye disord new blood vessel grow retina leak blood fluid lucenti use treat wet form agerel macular degener lucenti also use treat swell retina caus diabet blockag blood vessel import inform you receiv lucenti allerg ranibizumab type infect around eye befor receiv lucenti tell doctor glaucoma histori blood clot stroke call doctor sudden vision problem eye pain irrit discharg bleed eye swell around eye see flash light floater vision sudden numb weak bodi sudden sever headach problem speech balanc the time month inject import medic effect call doctor instruct miss appoint receiv lucenti inject befor take medicin you receiv lucenti allerg type infect around eye to make sure lucenti safe tell doctor glaucoma histori blood clot stroke it known whether lucenti harm unborn babi tell doctor pregnant plan becom pregnant it known whether ranibizumab pass breast milk could affect nurs babi tell doctor breastfeed how lucenti given lucenti given inject eye your doctor use medicin numb eye give inject you receiv inject doctor offic clinic set for short time inject eye check period make sure inject caus side effect lucenti usual given everi month for peopl macular degener after receiv first inject doctor may chang inject schedul everi month follow doctor dose instruct care the time month inject import medic effect to sure lucenti help condit caus harm effect eye need check regular basi do miss followup visit doctor lucenti dose inform usual adult dose macular degener mg via intravitr inject month approxim day use neovascular wet agerel macular degener amd usual adult dose diabet retinopathi dme diabet retinopathi dme mg via intravitr inject month approxim day macular edema follow rvo mg via intravitr inject month approxim day use diabet macular edema dme diabet retinopathi dme macular edema follow retin vein occlus rvo usual adult dose macular edema dme diabet retinopathi dme mg via intravitr inject month approxim day macular edema follow rvo mg via intravitr inject month approxim day use diabet macular edema dme diabet retinopathi dme macular edema follow retin vein occlus rvo what drug affect lucenti other drug may interact ranibizumab includ prescript overthecount medicin vitamin herbal product tell health care provid medicin use medicin start stop use see also dosag inform detail what happen i miss dose call doctor instruct miss appoint receiv lucenti inject what happen i overdos sinc medicin given healthcar profession medic set overdos unlik occur what i avoid receiv lucenti this medic may caus blur vision be care drive anyth requir abl see clear lucenti side effect get emerg medic help sign allerg reaction lucenti hive difficult breath swell face lip tongu throat call doctor eye pain red swell around eye blur vision tunnel vision eye pain see halo around light increas sensit light discharg bleed eye see flash light floater vision sudden numb weak especi one side bodi sudden sever headach problem speech balanc common lucenti side effect may includ',\n",
       "  'NN'),\n",
       " ('hello juliemari gosh load health problem deal i realli hope aubagio work',\n",
       "  'NN'),\n",
       " ('recruit apr elig cancer histiocyt sarcoma juvenil xanthogranuloma langerhan cell histiocytosi lymphoma recurr central nervous system neoplasm recurr malign solid neoplasm refractori central nervous system neoplasm refractori malign solid neoplasm intervent ros patient receiv x ensartinib countri usa children oncolog group philadelphia pa nct a studi of oral pf a cmethepatocyt growth factor tyrosin kinas inhibitor in patient with advanc cancer status recruit elig cancer alkposit nonsmal cell lung cancer nsclc cmet depend nsclc ros marker posit nsclc system anaplast largecel lymphoma advanc malign except leukemia intervent pf crizotinib rifampin itraconazol countri usa state australia republ korea note this origin trial crizotinib it expand time includ new arm nct nation lung matrix trial multidrug phase ii trial nonsmal cell lung cancer status not yet recruit elig cancer nonsmal cell lung cancer nsclc squamous cell carcinoma adenocarcinoma intervent ros patient receiv crizotinib countri unit kingdom uk nct ceritinib trametinib patient with advanc alkposit nonsmal cell lung cancer nsclc status recruit elig cancer stage iiibiv ros phase alk nonsmal cell lung cancer nsclc intervent ceritinib trametinib countri univers california san francisco expand access to experiment drug nct expand access entrectinib cancer with ntrk ros alk gene fusion status avail elig cancer advanc cancer ntrk ntrk ntrk ros alk gene fusion and unabl particip ongo entrectinib rxdx clinic trial intervent entrectinib countri contact ignyta call startrk',\n",
       "  'NN'),\n",
       " ('yes rubyroo stumbler sth someth too tyre write long word rubyroo ms start gilenya dose stop progresson may stop relaps fight get cladribin atm moment',\n",
       "  'NN'),\n",
       " ('hello everyon i remicad year final develop antibodi i tri entyvio coupl year ago advers reaction i larg bowel resect end colostomi octob my crohn diseas symptom improv sinc surgeri howev eye jointmuscl pain inflamm poor i stop remicad antibodi my gi wonder howev said well tri humira cimzia stelara it one prefer it like crap shoot lol should i toss name cup draw one ani suggest would great appreci i develop crohn small intestin besid remicad i mg prednison daili thank much juli',\n",
       "  'NN'),\n",
       " ('check mavenclad compar term perform mention much better safeti profil more info httpsmultiplesclerosisnewstodaycomargentinaapprovesmavencladforrelapsingm of two offer uniqu risk if your consid pregnanc pretti sure youd tysabri certain period wash system wherea wont problem lemtrada',\n",
       "  'NN'),\n",
       " ('i realli enough year ive ms start suffer bad decemb i went work marri home noth marriag broke i lost home job car came symptom i muddl last month live famili purpos life suffer daili symptom brain fog anxieti weak fatigu balanc tremor eyesight self catheteris back pain togeth thing prevent life realli cant battl thing purpos i feel get wors let even one day finish five day cours methylprednisolon yesterday feel aw eyesight wors everyth feel amplifi probabl one week last year i felt posit eas gone everi day battl i dont see point happi end sight keep take gilenya citalopram mirtazipin vit magnesium b respit i want leav place',\n",
       "  'NN'),\n",
       " ('hey brian im singlepay theori i know practic lessthanperfect system i brother live montral mani reader great britain my brother bad experi canadian healthcar system most term lack access certain kind doctor long wait period certain procedur the folk great britain ms patient strict guidelin drug receiv ocrevus receiv approv great britain deem costeffect whether that good thing i guess still need determin also quit sure singlepay would chang medic research model it certain would upend thing without financi incent i think would see slowdown research overal by mean i defend current system i think total piec crap i suppos sort publicpriv hybrid system might work well i know switzerland healthcar system publicpriv work well much smaller countri as i state previous comment what realli need manhattan project style massiv effort direct exclus find caus cure varieti diseas fund i think would public would mean rais tax anethema tax cut zealot seem upper hand last year it confound conundrum one thing certain system stand result cure anytim soon especi diseas like ms patient turn custom life thank comment',\n",
       "  'NN'),\n",
       " ('my mom diagnos stage nsclc oct she done mani round radiat went chemo maintain chemo while maintain chemo tumor start grow lung brain they readi diagnos now say last option opdivo she second opdivo treatment today my concern lost pound two week she bare want eat has anyon els love one go similar circumst start opdivo treatment success certain amount time i feel like i see sign afraid ask doctor i dont want upset',\n",
       "  'NN'),\n",
       " ('if go transit anoth antitnf i would strong consid stelara first it seem get best review rival remicad effect i experi',\n",
       "  'NN'),\n",
       " ('crohn diseas also call ileiti enter affect part gut mouth way anus in major case howev lower part small intestin ileum affect symptom unpleas they includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain common felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain the level pain vari individu depend inflamm gut most common pain felt lowerright side abdomen ulcer gut ulcer raw area gut may bleed if bleed patient might notic blood stool mouth ulcer these common symptom diarrhea this rang mild sever sometim may mucus blood pus the patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit there may time appetit low weight loss this result loss appetit anemia a loss blood lead anemia rectal bleed anal fissur the skin anus becom crack lead pain bleed other possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas while ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum the crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need highcalori liquid formula especi growth affect most patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol some peopl feel like eat in sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement the aim control inflamm correct nutrit problem reliev symptom there cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previous treatment recur symptom some peopl long period even year without symptom this known remiss howev usual recurr as period remiss vari much hard know effect treatment it imposs predict long period remiss go best food crohn diseas flareup eat right food help peopl manag symptom crohn diseas find read medic crohn diseas antiinflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor general treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol antidiarrh fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ they reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect some studi suggest use biolog reduc chanc person need abdomin surgeri within year percent befor introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid there differ type biolog drug individu react differ a doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri the major crohn diseas patient may need surgeri point when medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov some crohn diseas patient may requir one oper live in case colectomi need whole colon remov the surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma a pouch collect fece doctor say patient stoma carri lead normal activ life if surgeon remov diseas section intestin connect intestin stoma need the patient doctor need consid surgeri care it appropri everyon the patient bear mind oper diseas recur most peopl crohn diseas live normal activ live hold job rais famili function success caus the exact caus crohn diseas unclear thought stem abnorm reaction immun system the theori immun system attack food good bacteria benefici substanc unwant substanc dure attack white blood cell build line gut buildup trigger inflamm the inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close relat condit if ident twin crohn diseas twin percent chanc a bacterium virus may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi a doctor ask person sign symptom a physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth the follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut a long thin flexibl telescop endoscop goe esophagus stomach ct scan barium enema xray reveal chang insid bowel complic if symptom sever frequent likelihood complic higher the follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut there may also persist iron defici food absorpt problem slight higher risk develop bowel cancer relat coverag what stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year for reason doctor usual classifi crohn differ stage learn read crohn diseas surgeri what know while surgeri cannot cure crohn diseas help reduc person symptom prevent lifethreaten complic in articl learn differ type crohn diseas surgeri prepar expect recoveri read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read what expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd all refer avail refer tab refer this content requir javascript enabl baumgart m dogan b rishniw m weitzman g bosworth b yantiss r berg d cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni relat deplet clostridial crohn diseas involv ileum the ism journal retriev httpwwwnaturecomismejjournalvnabsismejahtml crohn diseas nd american societi colon rectal surgeon retriev httpswwwfascrsorgpatientsdiseaseconditioncrohnsdiseas crohn diseas caus april retriev httpwwwnhsukconditionscrohnsdiseasepagescausesaspx epidemiolog ibd march cdc retriev httpswwwcdcgovibdibdepidemiologyhtm leena halm paulina paavolasakki ulla turunen maarit lappalaccinen martti frkkil kimmo kontula june world journal gastroenterolog retriev httpswwwncbinlmnihgovpmcarticlespmc lichtenstein g r loftus e v isaac k l regueiro m d gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev httpgiorgguidelinemanagementofcrohnsdiseaseinadult what crohn diseas nd cleveland clinic retriev httpsmyclevelandclinicorghealtharticlescrohnsdiseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian what crohn diseas medic news today medilexicon intl dec web feb httpswwwmedicalnewstodaycomarticlesphp apa nordqvist c decemb what crohn diseas medic news today retriev httpswwwmedicalnewstodaycomarticlesphp pleas note if author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom a recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus this japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist can halt cellular age new drug combo show promis in first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer whi immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       "  'NN'),\n",
       " ('no mysteri cladribin it reject approv fda ema safeti efficaci concern in particular increas cancer risk note major concern option like gilenya tecfidera becam avail better safeti record it approv russia australia',\n",
       "  'JJ'),\n",
       " ('hi hain i think suggest reason as say simpli establish treatment lmc risk may accept circumst sinc mom afatinib coupl week i expect hadnt scan start tagrisso that rais possibl improv due afatinib might two best option point good luck whichev chosen jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('by christina bennett ms in addit today excit plenari session american societi clinic oncolog asco annual meet sever highimpact clinic trial result report keynot practic chang abstract an interim analysi phase iii keynot trial show fourmonth longer median overal surviv os metastat squamous nonsmallcel lung cancer nsclc patient receiv pembrolizumab plus tradit chemotherapi compar receiv placebo plus chemotherapi squamous nonsmal cell lung cancer orphan almost step child develop chemoimmunotherapi metastat lung cancer said charu aggarw md mph assist professor medicin the hospit the univers pennsylvania this first time actual see upfront use immunotherapi combin chemotherapi squamous lung cancer for keynot total particip untreat metastat squamous nsclc enrol random receiv either pembrolizumab plus chemotherapi placebo plus chemotherapi at time interim analysi particip random pembrolizumab plus chemotherapi arm placebo plus chemotherapi arm particip stratifi pdl status median os month pembrolizumab plus chemotherapi arm month placebo plus chemotherapi arm the median progressionfre surviv pfs month pembrolizumab plus chemotherapi arm compar month placebo plus chemotherapi alon arm these data suggest pembrolizumab plus chemotherapi becom new standard care firstlin treatment metastat squamous nsclc across differ level pdl express said studi investig lui pazar md phd professor medicin hospit universitario de octubr not pfs benefit signific overal surviv benefit hazard ratio there doubt mind benefit patient need adopt start today avail said dr aggarw about safeti profil dr aggarw said overal toxic profil seem manag adept manag immunerel toxic sinc use agent clinic keynot frontlin pembrolizumab monotherapi gain traction abstract interim result phase ii keynot trial show respons rate advanc clear cell renal cell carcinoma rcc patient receiv pembrolizumab monotherapi frontlin set three patient achiev complet respons partial respons the median progressionfre surviv month median overal surviv reach keynot singlearm openlabel design enrol particip advanc clear cell nonclear cell rcc elig patient measur diseas per recist criteria prior system therapi karnofski perform status greater equal particip receiv pembrolizumab dose mg iv everi three week onli data cohort a particip present the frequenc advers event special interest consist seen pembrolizumab monotherapi tumor type said lead investig david f mcdermott md director biolog therapi cutan oncolog program beth israel deaco medic center treatmentrel advers event grade occur patient treatmentrel grade advers event occur patient discontinu due treatmentrel advers event report patient said one patient die treatmentrel pneumon naomi haa md associ professor medicin hospit univers pennsylvania describ keynot realli import studi ipilimumab nivolumab combin fda approv recent firstlin treatment kidney cancer there high respons rate combin there also lot toxic singl agent pembrolizumab impress respons rate less toxic she continu the complet respons rate high singl agent pembrolizumab ipilimumab nivolumab combin clear cant rescu peopl later ad second agent perhap spare peopl toxic i think realli import first step answer id like see someth futur would includ singl agent immun checkpoint inhibitor compar arm combin immun checkpoint inhibitor trial erdafitinib new hope advanc urotheli cancer abstract in phase ii studi blc particip metastat unresect urotheli carcinoma treat erdafitinib oral panfibroblast growth factor receptor fgfr inhibitor respons rate three percent patient complet respons partial respons these result come month fda grant breakthrough therapi design erdafitinib patient metastat urotheli cancer this realli excit trial comment dr haa as solid tumor i think there grow awar differ subset urotheli cancer might benefit immun checkpoint inhibitor other might benefit altern treatment pathway the trial enrol advanc urotheli carcinoma patient fgfr alter treat median cycl erdafitinib particip prior treatment immun check point inhibitor elig this clinic trial erdafitinib met primari object achiev object respons rate percent said studi present arlen siefkerradtk md professor depart genitourinari medic oncolog divis cancer medicin the univers texa md anderson cancer centerth median pfs month median os averag followup month month ten percent particip discontinu treatment result side effect serious treatmentrel advers event this trial impress respons rate peopl pretti heavili pretreat interest patient respond drug resist immun checkpoint inhibitor said dr haa anoth cart drive forward abstract the investig cart product lisocabtagen maraleucel relapserefractori nonhodgkin lymphoma nhl show durabl respons accord result phase i transcend nhl trial lisocabtagen maraleucel anticd car tcell the overal respons rate patient core data set patient met studi inclus criteria complet respons month in trial lisocabtagen maraleucel evalu two dose schedul singl dose vs twodos across dose level patient achiev month timepoint remain remiss last followup this anticd car tcell remark efficaci group high refractori aggress bcell nonhodgkin lymphoma patient said caron jacobson md discuss studi dr jacobson medic director immun effector cell therapi program danafarb cancer institut the median overal surviv reach popul note jeremi abramson md clinic director center lymphoma massachusett general hospit near patient achiev complet respons remain aliv year these outcom far superior would anticip convent therapi larg chemorefractori dlbcl popul about toxic dr abramson said i think strike lisocabtagen maraleucel shown low manag toxic profil low rate sever crs cytokin releas syndrom neurotox percent percent respect we continu therefor evalu product outpati administr',\n",
       "  'NN'),\n",
       " ('my mum yearsivstagesmal meta lymph nodesegfrexongx month st line afatinib first reduct last three month slow progress pemetrex monotherapi month quit signific progress sinc finish afatinib liquid biopsi tm done outcom even origin mutat show tissu biopsi would problemat also one month ago lesion brain detect first consid brain metastasi now doctor say might rather meningeom still quit sure want observ month i think realli good chanc mum tm posit given long time slow progress afatinib as best next step i see tri osimertinib even without confirm tm mutat i alreadi order form tagrix afford the oncologist suggest erlotinib rather unusu st line afatinib promis much longterm success followup luxlung trial show patient took st generat tki erlotinib afatinib therapi month i read result studi osimertinib patient tm negat pfs osimertinib month so seem noth lose even turn mum tm negat can anyon give advicecom thank',\n",
       "  'NN'),\n",
       " ('hi folk just want report month mark year ocrevus infus i still walk albeit far year ago and brain mri show chang well my neuro said best case scenario i expect happi i see decemb th i notic small increas strength right leg especi foot toe an unexpect improv otherwis that updat',\n",
       "  'NN'),\n",
       " ('stelara next humira doesnt work im sure work', 'NN'),\n",
       " ('seem like use inform what stelara xeljanz both seem like good potenti option now know what go least treat hope way get better what uceri someth similar would help i know much hate steroid perhap dont even want consid even dread prednison comoder ulcer coliti current med step one jpouch surgeri complet step two complet step complet give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       "  'JJ'),\n",
       " ('soy that lb limit rough youll still take easi week everyth moder i suffer setback pt last week overdo inflam scar tissu ive mean ask kid laid hospit need recov keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('good point guy lemm give info been simponi almost year i feel noth i take shot month increas also noth i feel start cbd oil went remiss week last flex sig i past flare week i start cbd i felt wasnt gonna much show prove true current ad simponi doc order week done absolut noth in past remicad year entyvio humira simponi last month',\n",
       "  'NN'),\n",
       " ('hi leogirl my last mri back februari blood test month later i question i given date next mri august i got call neurologist begin octob told jc virus level risk zone want come gilenya final mri januari gilenya month plan book hospit lemtrada i feel fair month im good frustrat sometim i gilenya year awesom slight gut come hey onward upward x',\n",
       "  'NN'),\n",
       " ('hang i agre suck start entyvio thursday i hold much hope sinc noth els work either surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia condit afib high blood pressur gout crohn edema cellul heart issu ost openia medic entyvio eliqui verapamil quinipril labetalol furosemid atorvastatin alluporinol vitamin',\n",
       "  'NN'),\n",
       " ('im entyvio due fail remicad well gi i good discuss xeljanz recent ibd center mass general boston sever patient well hes recommend last option surgeri they good feedback regard efficaci patient safeti hope help f diagnos feb leftsid uc steroidrefractori fail mesalamin intoler remicad partial respons short remiss fallwint flare sinc feb current tacrolimus supp x daili wait start entyvio zoloft most dairi free avoid carrageenan like plagu',\n",
       "  'NN'),\n",
       " ('hello it sinc i post my mom age nsclc stage adeno egfr alk negat continu okay diagnos earli gone carboalimta alimta mainten month chemo break day tarceva due progress her perform status last year great we would like find may candid target therapi immunotherapi so need repeat bio marker test the challeng remain tissu test will need repeat biopsi get tissu how effect blood test process detect mutat thank alway guidanc semon',\n",
       "  'NN'),\n",
       " ('guy i need quick help cours treatment seem normal ive remicad mayb month help fistul crohn it fine week infus i start get mild symptom most stomach nois modest pain sometim littl diarrhea noth bowl shatter anyway weekend i start experi modest pain right cheek around area abscess when i reach quit swollen i could feel like golfbal size dens area i rest i took coupl hot bath calm bit still better i call doc i go remicad infus tomorrow i worri perhap area around seton interior somewher gotten infect i symptom my doc told reschedul remicad week hes put flagyl doe seem right i hate im put remicad work i know one week go turn two perhap im also scar crapless sorri bad word frank enough ive develop anoth abscess i cant live im also tri get colorect surgeon unfortun shes surgeri week ani thought appreci',\n",
       "  'NN'),\n",
       " ('not everyon say humira shot hurt ice spot first say help if your familiar comfort inject pen there also simponi ask im sure there whole lot differ humira simponi brand moder ulcer coliti john minor flare uc proctosigmoid rx remicad mgskgwks mgs mp g lialda mgs pred taper all time i assum game of throne someth got toilet first morn household mani sibl',\n",
       "  'JJ'),\n",
       " ('new fda approv zykadia ceritinib alkposit nsclc whi i think it poor choic initi treatment the fda approv new therapi approxim patient nsclc molecular marker known alk rearrang the cancer journey just diagnos in treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey in treatment cancer type lung cancer diseas learn target therapi imprecis medicin whi keytruda pembrolizumab chemo pdl nsclc isnt readi prime time let start say im fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi chemotherapi immunotherapi is immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu in fact cancer journey in treatment cancer type lung cancer diseas learn target therapi firstlin treatment symptom secondlin treatment death pseudoprogress know when cut your loss immunotherapi among mani novel concept manag immunotherapi potenti pseudoprogress this unusu phenomenon patient scan cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi secondlin treatment immunotherapi view more communiti forum local therapi metastat lung cancer who what whi when how hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer who cancer journey just diagnos in treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ros procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva tm negat progress year tarceva tissu biopsi show tm negat ani suggestionsexperi next step onc suggest i move afatinib opdivo pdl test cancer journey in treatment cancer type lung cancer diseas learn lung cancer general lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc has anyon inform obtain use vaxira cuban drug stage advanc nsclc not sure us citizen still travel cancer journey in treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva my wife come long way stage iv lung cancer sinc she develop acquir resist tarceva gene sequenc biopsi cancer journey just diagnos in treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       "  'RB'),\n",
       " ('with degre arthrit pain definit biolog i get humira inject although crohn mainten keep inflammatori arthriti bay my brother also humira arthriti could live without sound like realli need new gi doctor total differ group steroid caus last health problem show later life ive issu blame steroid use i much younger it take toll bodi im surpris rheumi isnt suggest biolog year crohn resect abcess fistula arthriti chronic hive dri eye humira antihistamin muro vitamin b vitamin d life good',\n",
       "  'NN'),\n",
       " ('access march fabian m pregnanc set multipl sclerosi continuum minneap minn multipl sclerosi other demyelin diseas kappo l gold r miller dh et al efficaci safeti oral fumar patient relapsingremit multipl sclerosi multicentr randomis doubleblind placebocontrol phase iib studi lancet montalban x hemmer b rammohan k et al efficaci safeti ocrelizumab primari progress multipl sclerosisresult placebocontrol doubleblind phase iii oratorio studi abstract proceed european committe treatment research multipl sclerosi ectrim congress octob barcelona spain kappo l weinshenk b pozzilli c et al interferon betab secondari progress ms combin analysi two trial neurolog hartung hp gonsett r knig n et al mitoxantron progress multipl sclerosi placebocontrol doubleblind randomis multicentr trial lancet langergould am anderson we armstrong mj et al the american academi neurolog top five choos wise recommend neurolog willi ma fox rj progress multipl sclerosi continuum minneap minn multipl sclerosi other demyelin diseas birnbaum g stop diseasemodifi therapi progress multipl sclerosisa prospect studi neurolog supplpp kister i spelman t alroughani r et al are stabl ms patient stop diseasemodifi therapi dmt increas risk relaps disabl progress compar patient continu dmts a propensityscor match analysi msbase registr abstract mult scler j suppl polman ch reingold sc banwel b et al diagnost criteria multipl sclerosi revis mcdonald criteria ann neurol solomon aj klein ep bourdett d undiagnos multipl sclerosi challeng misdiagnosi ms neurolog solomon aj klein e disclos misdiagnosi multipl sclerosi harm continuum minneap minn multipl sclerosi boissi ar ford pj a touch ms therapeut mislabel neurolog rudick ra miller ae multipl sclerosi multipl possibl continu problem misdiagnosi neurolog',\n",
       "  'NN'),\n",
       " ('care preoper plan help reduc complic cataract patient diabet help deal problem occur said francesco bandello md febo xxxiv congress escr copenhagen denmark diabet risk factor cataract associ ocular comorbid predispos complic compromis cataract surgeri outcom particular critic need accur stage treat exist diabet eye diseas status condit strong predict visual outcom cataract surgeri stress there clear evid phacoemulsif caus diabet retinopathi dr diabet macular oedema dme exacerb condit well control said dr bandello professor ophthalmolog univers vitasalut milan itali howev clinic signific dme prolif diabet retinopathi pdr stabilis cataract surgeri reduc risk acceler ad accur stage requir comprehens ophthalmolog examin includ optic coher tomographi possibl fluorescein angiographi standardis echographi treatment option pdr includ panretin photocoagul prp andor antivascular endotheli growth factor antivegf therapi from drcrnet protocol s howev know antivegf therapi better prp stabilis improv visual acuiti eye pdr panretin cryopexi phacoemulsif combin vitrectomi endolas photocoagul may consid select case said dr bandello therapeut option dme includ antivegf agent corticosteroid various laser approach use either monotherapi combin base safeti issu dr bandello recommend use antivegf agent firstlin intervent patient glaucoma low cardiovascular risk profil recent histori cardiovascular event a corticosteroid howev would prefer patient elev risk cardiovascular event histori vitrectomi poor respons previous antivegf therapi expect poor complianc repeat inject special consider preoper patient also evalu treat diabet keratopathi presenc affect accuraci intraocular len iol power calcul in addit special consider iol select it best choos iol larg diamet squareedg bluelight filter optic len facilit visualis treatment peripher retina reduc posterior capsular opacif caus chromat discrimin defect provid addit photoprotect in addit hydrophil iol anterior chamber iol avoid said dr bandello poor dilat pupil intraop miosi also like patient diabet surgeon prepar manag problem in addit prepar zonular instabl capsul damag eye previous vitreoretin surgeri sinc eye moderatetosever dr andor dme risk persist macular oedema dr progress cataract surgeri consid diabet dme common caus poor vision cataract surgeri dr bandello suggest surgeon consid intravitr administr antivegf agent corticosteroid intraop control prevent progress condit vegf concentr aqueous humour predict risk postop macular oedema tend increas phacoemulsif although result larg randomis control trial need provid evidencebas recommend posit clinic outcom report sever studi patient diabet receiv intravitr inject antivegf agent end cataract surgeri base multimod mechan action corticosteroid also play import therapeut role manag dme there also report improv best correct visual acuiti central macular thick eye dme receiv sustainedreleas dexamethason implant ozurdex allergan cataract surgeri howev larger prospect randomis control trial also need establish benefit approach dr bandello said he also note patient diabet increas risk develop cystoid macular oedema cataract surgeri francesco bandello',\n",
       "  'NN'),\n",
       " ('that great new ks glad hear stelara work i look forward post truli help us sinc youv issu actual resolv lol diagnos left side uc vit d vit c multivitamin previous tri coloz lialda asipro sulfasalazin rowasa canasa hydrocortison enema imuran humira fail made symptom wors step surgeri step surgeri step surgeri ks veteran member join sep post post am gmt buckeyecrohni said thank repli keith i anyth yet i appoint gastro late next week i dont know psc throw wrench my gastro dr jpouch it nice hes abl understand issu sinc live i take immodium everyday sinc surgeri i consist time day way better time day surgeri ill start new thread necessari appoint next week i learn much nice peopl i appreci us ibder stick togeth buckey i think how appoint gi go i know issu complex mine i didnt see post anyth keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('i diagnos ms year ago primari symptom nerv pain this manifest trigemin neuralgia sensat burn feet ankl feel like im wear boot made lava two size small ive near antiepilept drug treat nerv pain gabapentin zonisamid carbamazepin pregabalin zonisamidenow take levetiracetam topiram week ago i start aubagio failur inject tecfidera fingolimod sinc nerv pain got steadili wors point im go mind pain there possibl reason got wors current pain med lose efficaci ms got wors aubagio make wors seen ms nurs last week howev noth suggest allevi im end rope i cant sleep i cannot get comfort posit lay i cannot see way there antiepilept left tri sodium valproat im keen take that ever hear back neuro ive start hurt way distract pain feet im sure i carri ani advicehelp would grate reciev sarah',\n",
       "  'JJ'),\n",
       " ('hello tim softi have look httpswwwmstrustorgukaboutmsmstreatmentsmsdecisionsaid the decis aid divid diseas modifi drug dmds group moder more and high effect it make life bit easier research think drug you could also look forum httpsshiftm lot person experi written equal search specif drug your consid youll get person view search just awar subject view you dont tend given free choic among drug id expect someon recent diagnos activ ms offer beta interferon copaxon aubagio andor tecfidera you might also offer gilenya mavenclad softi tim hand youll probabl also offer gilenya mavenclad aka cladribin lemtrada andor ocrevus dmds suppos reduc sever number relaps person with increas efficaci come higher risk side effect but take dmd give side effect although think treatment bit like insur polici you may relaps without dmd drug like less theyll less sever and less relaps equal less disabl progress it costbenefit scenario each neurologist like prefer one drug anoth equal may set prescrib centr dmds but familiar group drug name plus way take your less like utter confus time come choos drug you also talk ms nurs just sure opt drug a oppos drug b c happi choic it bodi risk sue',\n",
       "  'NN'),\n",
       " ('i idea fda probabl useless fbi billion market replac generic seem like wish think one idea i havent investig canada mavenclad avail would treat yank',\n",
       "  'NN'),\n",
       " ('jimc thank prompt respons is possibl ask input dr west thank kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('a happi report have infus side effect fatigu less remicad though skin reaction i get solumedrol iv entyvio otherwis taper prednison month ago no sign uc flare began juli hope best us use entyvio uc yrs for flare i use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mos due joint pain antitnf induc lupus neuropathi now take entyvio',\n",
       "  'IN'),\n",
       " ('just chime biolog i went entyvio end march didnt take month start improv it almost immedi slow steadi improv th dose i pretti free symptom except mild one i still spot linger microscop inflamm visual dr saw inflammt last colonoscopi howev i know drain diseas fulli understand desir rid good luck uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc lglutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       "  'NN'),\n",
       " ('home ms inform public ms research updat laquinimod also known nerventra laquinimod also known nerventra in section main articl fdaapprov medic experiment medic new direct ms research close note approv longterm treatment ms pdf refer experiment medic administ oral compani teva neurosci inc activ biotech oral medic taken daili dose tbd be studi rrms ppms previous gilenya next rituxan although exact mechan action unknown laquinimod immunomodul appar effect cytokin small protein may stimul inhibit function cell interleukin immunesystem signal chemic it enhanc tregulatori cell activ reduc thinflammatori tcell activ it also appear reduc whitebloodcel penetr cns in addit immunomodulatori action laquinimod increas level brainderiv neurotroph factor bdnf possibl contribut neuroprotect protect nerv myelin damag ms patient bdnf protein found brain help support nerv develop the phase iii allegro studi individu rrms show compar placebo laquinimod reduc annual relaps rate percent progress disabl percent it also effect sever mri outcom includ reduct brain atrophi percent the bravo phase iii trial anoth global month doubleblind studi particip it design evalu laquinimod efficaci safeti toler versus placebo in august sponsor announc studi fail achiev primari goal reduc annual relaps rate although trend seen direct data adjust differ mri characterist start studi becaus effect laquinimod relaps modest seen diseasemodifi therapi rrms drug consid approv unit state in result two separ analys pool data phase iii allegro bravo trial studi laquinimod present the first analysi compar expect risk disabl progress given particular relaps rate seen pool data in analysi effect laquinimod reduc risk disabl progress larger predict the second analysi examin relationship relaps disabl look disabl progress relaps relapsefre patient two trial about onethird patient progress relapsefre suggest two outcom measur mediat differ pathway sinc laquinimod may effect disabl relaps new trial look primarili laquinimod disabilityprev impact design this month trial the efficaci safeti toler laquinimod subject with relaps remit multipl sclerosi concerto design compar two dose laquinimod includ mg dose higher test prior phase iii studi placebo look confirm diseas progress cdp primari outcom this first modern rrms trial priorit prevent disabl prevent relaps the trial began enrol patient expect run furthermor base effect disabl prior trial laquinimod also studi ppms trial arpeggio began this trial primarili evalu effect laquinimod brain atrophi secondarili clinic outcom it design enrol approxim peopl anticip run end although concerto arpeggio trial design studi mg dose laquinimod evalu prior trial along higher dose januari teva announc decis discontinu higher dose laquinimod ongo studi eight patient highdos arm concerto arpeggio trial cardiovascular event versus none lowerdos placebo arm decis made continu studi lower mg dose event occur in may announc state concerto primari endpoint time cdp met encourag result seen secondari endpoint previous gilenya next rituxan',\n",
       "  'NN'),\n",
       " ('about month first symptom onset dx begin june year i began experienc skin numb lose feel finger thought oh weird i come trial work wasnt stress thought weird made appoint pcp she though hrm odd let blood work send neurologist blood work came back fine except increas vit ok done was month neuro appoint time develop lhermitt go neuro like oh i know exact lhermitt caus inflamm spinal cord could caus lot thing yes ms one let get pictur c spine went week later came back show lesion she said yeah that good let look brain had done day want see back follow morn stat brain mri that show lesion sent lp had done week result trickl follow month saw new neuro ms center end august like yeah ms well cis high chanc develop full blown ms no evid i ever flare start gilenya earli octob so symptom onset june dx aug dmt octob',\n",
       "  'IN'),\n",
       " ('i th entyvio infus week ago been prednison coupl month can cheat restrict food list everi without consequ even starbuck yay drink coffe everi morn sweeten creamer i wont say yet im remiss close still canasa everi night partial colectomi diverticul sept uc pancol dx march apriso g x day canasa uceri foam supplement zinc lglutamin probiot reuteri peral vsl folic acid coq turmer boswellia start entyvio wed constant flare sinc march reliev prednison',\n",
       "  'JJ'),\n",
       " ('i need clarif previous blog mention need everyon includ progress diseas dmt hope maintain hand function doe includ progress patient non enhanc mri scan here usa ocrevus offer i wonder risk versus benefit',\n",
       "  'NN'),\n",
       " ('well stabl meant bloodi pain bms day i couldnt sleep night i lost lbs i tramadol regular keep pain bay i still went work work surgeri went europ day just littl difficult my hemoglobin also around regular i need somethingso dramat end realli i tri remicad entyvio but year half diagnosi surgeri i went couldnt ever realli get pred i got week initi pred dose got remiss lialda rowasa then came back i went azathioprin thing seem improv got wors remicad stori it rollercoast never i actual get remiss',\n",
       "  'JJ'),\n",
       " ('prescript galor there spate news regard exist propos ms drug much negat side sever drug reject european regulatori agenc anoth seen specter dead side effect continu rise although much malign ms activist communiti mani drug prescrib ms fact improv qualiti life mani patient take although exorbit expens target root caus diseas remain unknown help portion ms popul approv drug shown reduc rate relaps rrms patient though much question whether actual slow insidi progress diseas the inject crab drug copaxon rebif avonex betaseron demonstr clinic trial signific reduc relaps rate one third patient take copaxon relat mild side effect profil three compound form beta interferon often make take suffer flulik symptom day two dose for patient work though signific drop relaps rate substanti lessen impact diseas live unfortun decad use still clear whether drug influenc progress disabl a recent report great britain challeng notion crab drug posit impact progress studi seem support claim drug least someth slow progress a newer generat ms drug includ tysabri rituxan approv fda gylenia offer mark uptick efficaci reduct relaps rate ms symptom well proport patient popul benefici unfortun along increas efficaci come increas sever potenti side effect includ dead brain infect cancer these drug noth address under caus ms work profound alter work complex littl understood human immun system consequ longterm yet seen still sometim dramat improv experienc patient take drug led mani extrem retic give in case tysabri i person know sever patient sever year drug test posit virus caus pml ghast brain infect still refus come tysabri posit impact live unlik ms voic internet im unwil label current crop ms drug snake oil simpli posit influenc live mani patient certain noth cure diseas i doubt abil signific impact progress ms i know enough patient whose live remain relat product larg part due medic i cant help recogn valu the actual financi cost drug mindboggl price newli approv gylenia first oral medic approv ms come almost per year i abhor fact ms turn goos continu lay golden egg mani pharmaceut compani appar posit effect compound shouldnt ignor befor introduct crab drug ms known among physician diagnos adio diseas one littl could done combat the advent drug matter flaw least put arrow quiver tri fight ms unfortun drug current approv ms shown work patient suffer relaps remit form diseas us suffer progress form remain shut even nomin effect treatment veri drug even trial use progress ms patient recent least attent turn plight suffer spms ppms okay enough bloviat current state ms drug here rundown latest news regard ms pharmaceut the fact mani articl link come financi websit speak volum sad state affair regard ms big busi biogen maker tysabri releas month report rate pml devast brain infect patient take drug when first start tysabri therapi patient unit state enrol what call touch program design care track sign infect the risk pml infect result tysabri therapi long tout the statist releas earlier month show infect rate patient take tysabri less two year fall well within figur start rise dramat patient surpass month mark the incid pml longterm therapi state per trend suggest longer patient tysabri higher risk infect after first introduc tysabri quick withdrawn market threat pml becam known it reintroduc second half therefor major patient take yet reach danger zone as i state previous mani patient loath stop tysabri experienc sometim dramat relief ms symptom drug as pml count increas mani patient tysabri grappl difficult decis the european medicin agenc ema committe medicin product human use chmp recommend approv oral drug fampyra north america call ampyra ampyra approv fda drug thus far approv strict symptomat relief ms the compound increas walk speed approxim patient take some patient ampyra also report overal increas muscl strength in recommend drug chmp said convinc fampyra small effect walk speed meaning benefit patient the effect speed could link meaning improv better coordin balanc stamina increas rang action the committe view medicin uncertain benefit outweigh side effect includ pain dizzi paraesthesia unusu sensat like pin needl problem balanc well symptom similar multipl sclerosi could impair patient abil walk the committe also note lack adequ longterm data medicin benefit safeti well data group patient elder patient epilepsi heart problem the chmp conclud benefit fampyra outweigh risk recommend refus market author the chmp also recommend approv experiment oral ms medic cladribin market giant drug compani merck cladribin use iv form anticanc agent sinc mid known possibl sever side effect reformul oral form name movectro drug went full trial regimen use rrms patient shown reduc rate ms relaps possibl imped speed diseas progress in decid drug chmp concern medicin safeti an increas number patient cancer observ trial movectro may indic increas risk cancer time increas dose the committe also note benefit appropri dosag treatment fulli establish patient expect use medicin therefor point time chmp opinion benefit movectro outweigh risk recommend refus market authoris the drug fda approv later year interest see fda follow european cousin decis the chmp recommend approv oral ms drug gylenia formal known fingolimod fti this drug alreadi approv fda hit market sometim first half year gylenia power drug great alter work human immun system the compound trap immun system t cell lymphat system therebi keep central nervous system rest bodi well as one neurologist told tysabri keep cop certain neighborhood gylenia keep lock polic station while mani patient relish thought give inject month infus simplic painfre action take daili oral tablet mechan drug give paus it believ neurologist care prescrib drug interest gylenia test possibl neuroprotect agent drug may doublebarrel effect it would wonder scienc could isol gylenia neuroprotect properti develop compound shield nerv cell ms diseas process develop seem far futur as ms patient i find incred frustrat million upon million dollar spent research develop market pharmaceut compound absolut noth actual cure diseas effect turn patient indentur servant big pharma unfortun medic research model evolv high dysfunct beast one often ignor real patient benefit favor possibl huge financi gain the aberr immun reaction seen ms essenti symptom yet undiscov diseas caus if even fraction research dollar spent big pharma drug design suppress modul immun system instead spent find unknown caus might actual road cure damn diseas one hope belief fervent ccsvi advoc hold forth vascular abnorm prove vital import part ms diseas process at least may investig ccsvi final wrench focus ms research away concept autoimmun onto model ms diseas immun system gone awri signifi greater ill still hidden long last bring hidden ill light this post repost per mentor wheelchair kamikaz',\n",
       "  'NN'),\n",
       " ('my mom year old detect lung cancer th march she lr mutat goe tarceva day ago on fisrt two day tarceva headach felt vomot vomit after symptom gone mild diarrhea day the th day tarceva felt pain insid like someon tri scrape someth organ said the symptom last hour gone when pain gone felt realli good fesh from th day tarceva mom uncomfort feel she look fesh good appetit we read tarceva resist realli worri mom side effect mean start resist could pleas tell symptom could help know tart time tarceva resist mani thank',\n",
       "  'NN'),\n",
       " ('larri i glad ride well walk great veronica i e trike i love yesterday i didnt feel like go ride i trick self told go short trip lot power fun so i went mn easi ride i felt pretti good end great hour ride otherwis i routin yoga medit walk mn morn mn even concentr tell bad leg push hill knee kick hill i done year i see improv thank also ocrevus i feel slow pretti good monster list inflamm part ani one good experi ocrevus rixitan the best alain',\n",
       "  'NN'),\n",
       " ('the thing doesnt realli matter fed i when go someth like last relaps tell minor set back it hiccup it cant last forev but week go your still feel start think mayb inde last forev there lot wait involv one multipl sclerosi particular one young ms like im ms month old im practic ms babi ive share wait month first i wait get approv tysabri then i got approv i wait th th infus i told id feel betterand didnt then i went month flush start ocrevus two month feel like utter excrement i could bare get bed but i got tell amaz new drug would one get back road feel like thing didnt i month feel sudden energet felt awesom then nowher i relaps two half month first ocrevus infus i land hospit four day then i wait entir focus i could get get back home i could feel better then i got home final but feel better part didnt realli happen i mean it get better better mean occasion throw oppos everi time i ingest food feel like im drunk time versus time could argu would correct i better i but better better nah im back wait next great hope that would novemb i find look forward novemb i get second full dose ocrevus hope mayb magic dose help feel better morebut littl voic back brain whisper then might this diseas requir long game i never develop to diseas ok entir life turn upsid promis better come go without relief told would come so focus next milepost the next thing might get over activ diseas control first time sinc whole crazi ride start mayb get back normal normal probabl never mayb establish new normal diseas doesnt affect everi part everi breath everi second everi day i experienc mser friend they much older ms year i assur come i believ but sometim make feel stupid believ fairi tale i make back work last week i made offic two day row it felt awesom final leav hous id liar i didnt admit hard hell i practic forc front door i dont look like i forgot wear real cloth put makeup i usual enjoy felt like put disguis someon imperson old i happi i realli i also scare death what id use good hour day get hous offic what i ran good hour id make home what i use one handi portabl puke bag time privaci home public among peopl look leadership im suppos inspir inspir leader offic i afraid everi minut everi hour i outsid home who i becom im back home week rest take longago schedul week vacat i think i obvious need rest ya know get tire somuchrest rest wear rest faulti bodi never feel rest matter mani hour ive abl stay unconsci though i know best thing i feel anyth rest nobodi pressur everyon peer team colleagu boss support would expect situat like the one person isnt cooper probabl i higher expect ive allow believ this life new life this one wait period anoth thing i need deal wait get beyond i tell i love quieter slower life much like anyth els ive impos i might like i dont realli want i like quiet slow im term these decid term im sure whos term im work ms term accept i struggl whole phase grief thing i rememb well i went husband die almost year ago it use frustrat hell realiz i go phase didnt happen nice plan consecut order they happen all time sometim complet order when think phase start happen willi nilli onc youv experienc grief know noth grief tidi you cannot control you let thing wait peopl tell abl see side your griev realli cant when move new life almost like surpris when happen you realli cant put finger onc happen wonder never notic took the feel see grief rear view mirror shock it like old childhood friend sudden move away your sad youv spent much time togeth start feel comfort guy never realli good friend you know wont miss friend grief much thought would never realli gone you alway feel linger edg life most happi back remind could go away poof just like there silver line it pretti obvious one realli the silver line ive done i i thought id never get sort normal life back one i went poof i i actual made life i realli start love i we transit go live sudden forc acknowledg plan focus anyth moment realli kind lie noth gold stay ponyboy curti taught i preteen it might gold anymor learn get great joy silver bronz sometim even get platinum my slow strang life might chang might it might one day feel like real until there alway novemb also hot anymor i cant even believ im say i almost turn furnac tonight i thought better but i almost it gorgeous sleep weather i better get noth gold stay icon line one favorit childhood book the outsid se hinton refer poem robert frost natur first green gold her hardest hue hold her earli leaf flower but hour then leaf subsid leaf so eden sank grief so dawn goe day noth gold stay robert frost',\n",
       "  'VBD'),\n",
       " ('immunotherapi checkpoint inhibitor antiprogram cell death pd program deathligand pdl pembrolizumab nivolumab anticytotox tlymphocyt antigen ctla ipilimumab highdos interleukin il dual immunomodul dual checkpoint inhibit ctla inhibitor plus pd inhibitor signaltransduct inhibitor braf vraf murin sarcoma viral oncogen homolog b inhibitor patient test posit braf v mutat vemurafenib dabrafenib mek inhibitor trametinib cobimetinib kit inhibitor multikinas inhibitor sorafenib combin therapi signaltransduct inhibitor braf inhibitor plus mek inhibitor dabrafenib plus trametinib vemurafenib plus cobimetinib chemotherapi palliat local therapi two approachescheckpoint inhibit target mitogenactiv protein kinas mapk pathwaydemonstr improv progressionfre surviv pfs overal surviv os random trial antipd monotherapi pembrolizumab nivolumab demonstr improv efficaci outcom better safeti profil compar treatment use singleag antictla ipilimumab investig choic chemotherapi the combin antipd antictla immunotherapi nivolumab ipilimumab also prolong pfs os compar ipilimumab combin associ signific toxic becaus rapid develop new agent combin remain question patient physician encourag consid clinic trial initi treatment time progress clinic trial address follow issu optim dose combin immunotherapi decreas toxic preserv efficaci how select patient benefit combin immunotherapi versus monotherapi the role pdl express biomark efficaci the role mainten therapi the valu sequenc therapi immunotherapi target therapi intralesion therapi talimogen laherparepvec tvec tvec genet modifi herp simplex virus type hsv oncolyt therapi approv local intralesion inject unresect cutan subcutan nodal lesion patient melanoma recur initi surgeri tvec design replic within tumor caus lysi produc granulocytemacrophag colonystimul factor gmcsf releas antigen togeth viral deriv gmcsf may promot antitumor immun respons howev exact mechan action unknown the approv tvec us food drug administr fda base data demonstr shrinkag lesion howev improv os effect viscer metastas improv qualiti life shown evid tvec in multin random openlabel trial nct patient random assign intralesion tvec subcutan gmcsf least month inject lesion level evid iidiv elig patient stage iiib iiic iv melanoma unresect bidimension measur lesion the primari endpoint durabl respons rate drr complet respons cr partial respons pr last month assess independ review the studi stratifi site first recurr presenc liver metastas diseas stage previous nonadjuv system treatment the median patient age year rang year patient baselin eastern cooper oncolog group ecog perform status ps score stage iii diseas stage iv diseas ma mb mc previous therapi melanoma receiv patient the first dose administ plaqueform unit pfuml maximum ml lesion combin subsequ dose administ pfuml ml inject lesion combin inject volum base size lesion inject viscer lesion allow in patient treat tvec confid interv ci drr versus ci patient receiv gmcsf subgroup analysi suggest differ drrs tvec versus gmcsf may greater earlierstag diseas treatmentnav diseas patient stage iiib iiic drr tvec versus gmcsf versus respect patient stage iv ma diseas versus respect patient stage iv mb diseas versus respect patient stage iv mc diseas patient treat tvec gmcsf firstlin therapi drr versus howev patient receiv treatment secondlin therapi greater drr versus the median durat exposur tvec week month patient expos year the common advers event ae tvec group fatigu chill pyrexia nausea influenzalik ill inject site pain the rate discontinu result toxic tvec versus gmcsf group of ten death patient treat tvec eight death consid result pd salmonella infect one myocardi infarct none consid relat therapi base find investig precaut tvec live attenu hsv may caus lifethreaten dissemin herpet infect it contraind immunocompromis pregnant patient healthcar provid close contact avoid direct contact inject lesion biohazard precaut prepar administr handl provid label detail prescrib inform treatment cycl lesion size provid fda label immunotherapi checkpoint inhibitor antipd pdl the pd pathway key immunoinhibitori mediat tcell exhaust blockad pathway lead tcell activ expans enhanc effector function pd two ligand pdl pdl two antipd antibodi pembrolizumab nivolumab approv fda basi improv os random trial pembrolizumab evid pembrolizumab previous treat patient a total patient unresect metastat melanoma diseas progress within week last dose ipilimumab braf v mutat posit previous treatment braf inhibitor random assign one two dose pembrolizumab mgkg mgkgeveri week the trial exclud patient autoimmun diseas condit requir immunosuppress histori sever immunerel advers event ira treatment ipilimumab the median age year male ecog ps ecog ps eighteen percent patient tumor braf v mutat posit elev lactat dehydrogenas ldh mc diseas brain metastas undergon two therapi advanc diseas the primari outcom measur overal respons rate orr accord respons evalu criteria in solid tumor recist version criteria assess blind independ central review level evid iidiv the orr determin independ central review ci p mgkg arm consist one cr prs patient median followup month patient minimum month followup among patient object respons ongo respons rang month month respons rate mgkg arm similar consist respons patient respons seen patient without braf v mutat the approv dose mgkg administ intraven iv infus minut everi week pembrolizumab discontinu ae patient treat mgkg consid drugrel ae investig the common ae mgkg versus mgkg arm fatigu vs pruritus vs rash vs other common ae includ cough nausea decreas appetit constip arthralgia diarrhea the frequent serious ae occur total patient treat pembrolizumab includ renal failur dyspnea pneumonia cellul addit clinic signific ira includ pneumon coliti hypophys hyperthyroid hypothyroid nephriti hepat the fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat treat patient a multicent intern trial keynot nct random assign patient metastat melanoma ratio receiv pembrolizumab mgkg iv q week q week four cycl ipilimumab mgkg q week patient stratifi ecog ps vs line therapi firstlin vs secondlin pdl express posit vs negat the primari endpoint pfs os level evid iia approxim patient receiv previous system therapi advanc melanoma braf v mutat present patient approxim receiv previous braf inhibitor treatment the studi enrol patient braf v mutat high ldh level symptomat rapid progress diseas receiv anti braf therapi could provid rapid clinic benefit approxim patient pdlposit tissu sampl at time second interim analysi os result cross prespecifi efficaci boundari two pembrolizumab group superior os ipilimumab group prespecifi onesid alpha level the data monitor safeti board dmsb recommend studi result unblind pembrolizumab made avail patient diseas progress ipilimumab group the median durat followup time second interim analysi month patient death median os reach treatment group the year estim surviv patient receiv pembrolizumab everi week hazard ratio hr death compar ipilimumab group ci p patient receiv pembrolizumab everi week hr death compar ipilimumab ci p patient treat ipilimumab benefit seen across subgroup except patient pdlnegat tumor howev sinc subset small patient ci wide definit conclus could drawn studi grade ae consid relat studi drug pembrolizumab everi week pembrolizumab everi week ipilimumab rate studydrug discontinu result toxic pembrolizumab everi week pembrolizumab everi week ipilimumab the one death result cardiac arrest occur ipilimumab group patient type diabet mellitus caus metabol imbal associ ipilimumabinduc diarrhea nivolumab evid nivolumab previous treat patient acceler approv base plan noncompar interim analysi first patient receiv nivolumab least month followup multicent openlabel trial checkmat nct random assign patient nivolumab mgkg q week investig choic chemotherapi either dtic mgm iv q week combin carboplatin area curv plus paclitaxel mgm q week fda label level evid iiidiv patient requir unresect metastat melanoma progress treatment ipilimumab braf v mutationposit braf inhibitor the trial exclud patient autoimmun diseas condit requir immunosuppress histori sever ira treatment ipilimumab median age patient year patient male ecog ps patient braf v mutat present patient mc diseas elev ldh histori brain metastas receiv two system therapi previous metastat diseas orr os coprimari endpoint orr ci four crs prs assess recist criteria independ central review among patient respons ongo respons durat month respons seen patient without braf v mutat safeti analysi base patient nivolumab discontinu ae patient serious ae occur patient grade grade ae occur patient the common ae rash cough upper respiratori tract infect peripher edema other import ae includ ventricular arrhythmia iridocycl increas amylas lipas dizzi neuropathi the fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat patient a total patient unresect stage iii stage iv melanoma without braf mutat random assign doubleblind multicent trial receiv nivolumab mgkg q week dticmatch placebo q week dtic mgm q week nivolumabmatch placebo q week the primari endpoint os level evid ia the trial conduct center europ israel australia canada south america countri dtic standard firstlin treatment patient without braf mutat the dmsb note potenti differ os safeti review on june abbrevi report unplan interimdatabas lock review show signific differ os favor nivolumab the dmsb recommend studi unblind allow patient dtic receiv nivolumab the intend sampl size approxim patient total patient enter result doubleblind portion studi crossov amend show median os reach nivolumab group month ci dtic group the os rate year ci nivolumab group ci dacarbazin group the hr death ci p the common ae nivolumab group fatigu pruritus nausea diarrhea in nivolumab group patient discontinu studi treatment ae compar patient discontinu studi treatment dtic group ae potenti immunolog etiolog occur includ gastrointestin hepat pulmonari renal endocrin skin howev major resolv delay studi treatment glucocorticoid administr per manag guidelin nivolumab no death attribut drugrel ae either group chang dose regimen nivolumab metastat melanoma in popul pharmacokinet respons analysi doseexposurerespons analysi flat dose mg nivolumab everi week consid pharmacokinet equival dose regimen mgkg clinic safeti efficaci two dose appear similar across bodi weight tumor type melanoma nonsmal cell lung cancer renal cell carcinoma the dose regimen approv fda monotherapi chang mgkg mg iv everi week diseas progress intoler toxic the dose regimen mgkg iv nivolumab combin ipilimumab remain unchang therapi ipilimumab complet regimen chang mg dose everi week diseas progress intoler toxic anticytotox tlymphocyt antigen ctla ipilimumab ipilimumab human monoclon antibodi bind ctla therebi block abil downregul tcell activ prolifer effector function ipilimumab demonstr clinic benefit prolong os random trial approv fda two prospect random intern trial one previous untreat treat patient support use ipilimumab evid ipilimumab previous treat patient a total patient previous treat unresect stage iii stage iv diseas hlaaposit enter threearm multin random doubleblind doubleplacebo trial a total patient random assign receiv ipilimumab mgkg q week dose glycoprotein gp peptid vaccin one hundr thirtyseven patient receiv ipilimumab mgkg q week dose patient receiv gp vaccin patient stratifi baselin metastas previous receipt nonreceipt il therapi eightytwo patient metastas brain baselin level evid ia the median os month among patient receiv ipilimumab alon month among receiv ipilimumab gp vaccin compar month patient receiv vaccin alon hr ipilimumab alon vs gp alon p hr ipilimumab plus vaccin vs gp alon p an analysi year show among patient treat ipilimumab treat ipilimumab treat ipilimumab vaccin aliv compar patient receiv vaccin grade grade ira occur patient treat ipilimumab these ira often includ diarrhea coliti endocrinerel event eg inflamm pituitari these event requir cessat therapi institut antiinflammatori agent corticosteroid four case infliximab antitumor necrosi factoralpha antibodi there drugrel death seven death associ ira previous untreat patient a multicent intern trial random assign patient untreat metastat diseas adjuv treatment allow ratio receiv ipilimumab mgkg plus dtic mgm placebo plus dtic mgm week follow dtic alon everi week week patient stabl diseas object respons doselimit toxic effect receiv ipilimumab placebo everi week thereaft mainten therapi the primari endpoint surviv patient stratifi accord ecog ps metastat stage approxim patient ecog ps remaind patient ecog ps approxim patient stage mc diseas level evid ia the median os month ci ipilimumabdt group versus month ci placebodt group estim surviv rate ipilimumabdt group year year year hr death p placebodt group rate year year year the common studydrugrel ae classifi immun relat grade grade ira seen patient treat ipilimumab plus dtic versus patient treat placebo plus dtic common event hepat enterocol no drugrel death occur clinician patient awar immunemedi advers reaction may sever fatal earli identif treatment includ potenti administr system glucocorticoid immunosuppress accord immunemedi advers reaction manag guid provid manufactur necessari highdos il il approv fda basi durabl crs eight phase i ii studi phase iii trial compar highdos il retreat provid assess relat impact os conduct evid highdos il base pool analysi patient eight singl multiinstitut trial institut conduct highdos il demonstr cr rate with median followup time surviv patient least year median durat crs reach least month strategi improv therapi activ area investig dual immunomodul tcell coexpress sever receptor inhibit tcell function preclin data earli clinic data suggest coblockad two inhibitori receptor ctla pd may effect blockad either alon this led phase iii trial nct compar singl agent combin dual checkpoint inhibit ctla inhibitor plus pd inhibitor evid ipilimumab plus nivolumab previous untreat patient in intern random doubleblind trial checkmat previous untreat patient unresect stage iii iv melanoma random assign ratio arm nivolumab alon mgkg q week plus placebo arm nivolumab mgkg q week plus ipilimumab mgkg q week dose follow mg nivolumab q week arm ipilimumab alon mgkg q week dose plus placebo pfs os coprimari endpoint the studi power compar combin nivolumab plus ipilimumab ipilimumab monotherapi nivolumab monotherapi ipilimumab monotherapi studi power compar combin ipilimumab plus nivolumab nivolumab patient stratifi accord tumor pdl status assess central laboratori immunohistochem test posit vs negat indetermin braf mutat status v mutationposit vs wildtyp american joint committe cancer stage level evid iia characterist baselin includ patient ecog ps elev ldh braf mutat mc diseas a minor patient pdlposit tumor the prospect defin coprimari analysi pfs occur patient least month followup treatment nivolumab alon combin ipilimumab result signific longer pfs ipilimumab alon result consist across prespecifi stratif factor median pfs month ci nivolumab month ci nivolumab plus ipilimumab month ci ipilimumab the prospect specifi coprimari analysi os occur month with death rate os time point nivolumab group combin group ipilimumab group hr death combin vs ipilimumab ci p hr death nivolumab vs ipilimumab ci p in descript analysi minimum followup month follow data found os rate nivolumab group patient treat combin ipilimumab group the median os reach combin arm ci monthsnot reach median os singleag nivolumab ipilimumab group month ci reach month ci respect the hr death combin versus ipilimumab ci p nivolumab versus ipilimumab hr ci p ae highest combin arm need monitor care grade treatmentrel ae occur patient nivolumab group patient ipilimumab group patient combin group the frequent reason treatment discontinu diseas progress two monotherapi arm nivolumab ipilimumab the frequent reason discontinu combin group toxic four therapyrel death report attribut neutropenia nivolumab group colon perfor ipilimumab group liver necrosi autoimmun myocard combin ipilimumab nivolumab analys pdl express level associ os year indic level express alon poor predict biomark os signaltransduct inhibitor studi date indic braf mek mitogenactiv erkextracellular signalregul kinas activ kinas inhibitor singl agent combin signific impact natur histori melanoma although appear provid cure braf inhibitor vemurafenib vemurafenib oral avail small molecul select braf kinas inhibitor approv fda patient unresect metastat melanoma test posit braf ve mutat treatment vemurafenib discourag wildtyp braf melanoma data preclin model demonstr braf inhibitor enhanc rather downregul mapk pathway tumor cell wildtyp braf upstream ras mutat evid vemurafenib previous untreat patient the approv vemurafenib support intern multicent trial brim nct screen patient previous untreat stage iiic iv melanoma braf v mutat identifi patient via coba braf v mutat test patient random assign receiv either vemurafenib mg po bid dtic mgm iv q week coprimari endpoint rate os pfs at plan interim analysi dmsb determin os pfs endpoint met prespecifi criteria statist signific favor vemurafenib recommend patient dtic group allow cross receiv vemurafenib level evid iia iidiii a total patient evalu os although median surviv yet reach vemurafenib data immatur reliabl kaplanmei estim surviv curv os vemurafenib arm clear superior dtic arm the hr death vemurafenib group ci p the surviv benefit vemurafenib group observ prespecifi subgroup exampl age sex ecog ps tumor stage ldh geograph region the hr tumor progress vemurafenib arm ci p the estim median pfs month vemurafenib arm versus month dtic arm twenti patient non braf ve mutat braf vk braf vd four patient braf vk mutat respons vemurafenib ae requir dose modif interrupt patient receiv vemurafenib receiv dtic the common ae vemurafenib cutan event ie arthralgia fatigu cutan squamous cell carcinoma scc keratoacanthoma develop patient treat simpl excis the common ae dtic fatigu nausea vomit neutropenia refer pdq summari support palliat care inform cope cancer previous treat patient a total patient braf ve braf vk mutat enrol multicent phase ii trial vemurafenib administ mg po bid of enrol patient stage mc diseas elev ldh level all patient receiv one previous therapi advanc diseas median followup month level evid iiidiv an independ review committe irc report respons rate ci eight patient achiev cr median durat respons per irc assess month ci most respons evid first radiolog assess week howev patient respond receiv therapi month dabrafenib dabrafenib oral avail small molecul select braf inhibitor approv fda patient unresect metastat melanoma test posit braf ve mutat detect fdaapprov test dabrafenib braf inhibitor recommend treatment braf wildtyp melanoma vitro experi suggest may paradox stimul mapk signal result tumor promot evid dabrafenib an intern multicent trial break nct compar dabrafenib dtic a total patient unresect stage iii iv melanoma braf ve mutat random assign ratio dabrafenib mg po qd dtic mgm iv q week il allow previous treatment advanc diseas the primari endpoint pfs patient could cross time progress diseas confirm blind irc level evid iidiii with event hr pfs ci p the estim median pfs month dabrafenib versus month dtic os data limit median durat followup crossov the pr rate cr rate patient receiv dabrafenib versus pr rate cr rate receiv dtic the frequent ae patient treat dabrafenib cutan find ie hyperkeratosi papilloma palmarplantar erythrodysesthesia pyrexia fatigu headach arthralgia cutan scc keratoacanthoma occur patient basal cell carcinoma occur four patient mycosi fungoid occur one patient new melanoma occur two patient mek inhibitor trametinib trametinib oral avail smallmolecul select inhibitor mek mek braf activ mek mek protein turn activ mapk preclin data suggest mek inhibitor restrain growth induc cell death braf mutat human melanoma tumor braf activ mek mek protein turn activ mapk in trametinib approv fda patient unresect metastat melanoma braf ve vk mutat determin fdaapprov test evid trametinib a total patient screen braf mutat result elig patient braf ve braf vk one mutat one previous treatment biolog chemotherapi allow howev previous treatment braf mek inhibitor permit patient random assign ratio receiv trametinib mg qd iv chemotherapi either dtic mgm q week paclitaxel mgm q week crossov patient random assign chemotherapi allow therefor primari endpoint pfs the investigatorassess pfs month patient receiv trametinib versus month chemotherapi group hr pfs death ci p a radiolog review blindedtotreat arm result similar outcom median os reach ae lead dose interrupt occur patient trametinib group chemotherapi group ae lead dose reduct occur patient receiv trametinib receiv chemotherapi the common ae includ rash diarrhea nausea vomit fatigu peripher edema alopecia hypertens constip cardiomyopathi interstiti lung diseas central serous retinopathi retinalvein occlus uncommon serious ae associ trametinib onstudi cutan sccs observ refer pdq summari support palliat care inform cope cancer cobimetinib cobimetinib smallmolecul select mek inhibitor approv fda use combin braf inhibitor vemurafenib refer combin therapi signaltransduct inhibitor section summari inform kit inhibitor earli data suggest mucos acral melanoma activ mutat amplif ckit may sensit varieti ckit inhibitor phase ii phase iii trial avail patient unresect stage iii stage iv melanoma harbor ckit mutat multikinas inhibitor sorafenib the multikinas inhibitor sorafenib activ vascular endotheli growthfactor signal rafmekerk pathway this agent minim activ singl agent melanoma treatment two larg multicent placebocontrol random trial carboplatin paclitaxel without sorafenib show improv chemotherapi alon either firstlin treatment secondlin treatment combin therapi signaltransduct inhibitor secondari resist braf inhibitor monotherapi patient braf v mutat may associ reactiv mapk pathway therefor combin signaltransduct inhibitor block differ site pathway site multipl pathway activ area research braf inhibitor plus mek inhibitor dabrafenib plus trametinib evid dabrafenib plus trametinib previous untreat an intern doubleblind phase iii trial without crossov random assign previous untreat patient unresect stage iiic stage iv melanoma braf ve vk mutat receiv combin dabrafenib mg po bid plus trametinib mg po qd dabrafenib plus placebo the primari endpoint investigatorassess pfs the protocol includ prespecifi interim analysi os time analysi primari endpoint patient stratifi baselin ldh braf genotyp level evid idiii median pfs month combin versus month dabrafenib plus placebo the hr death progress ci p updat data time final analysi os reveal median pfs month combin versus month dabrafenib plus placebo the hr pfs death ci p unadjust multipl test a prespecifi final analysi os conduct event median os month dabrafenibplustrametinib group event versus month dabrafenibplusplacebo group event the hr ci p perman discontinu studi drug report patient combin patient treat dabrafenib the incid grade grade ae similar group incid combin incid dabrafenib pyrexia occur frequent combin treat immedi temporari cessat studi drug either group prophylact glucocorticoid may prevent recur episod hyperprolif cutan event includ cutan sccs consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor rare serious ae includ decreas eject fraction chorioretinopathi previous untreat an intern openlabel phase iii trial random assign previous untreat patient metastat melanoma braf v mutat receiv standard dose either combin dabrafenib plus trametinib vemurafenib firstlin therapi the primari endpoint os level evid iia an interim analysi os plan final event occur per protocol dmsb use adjust efficaci boundari actual event side p efficaci p futil the dmsb recommend stop efficaci interim analysi consid final analysi os a protocol amend issu allow crossov combin therapi arm a total patient combin arm vemurafenib group die hr ci p median os patient treat vemurafenib month median reach combin therapi arm vemurafenib plus cobimetinib evid vemurafenib plus cobimetinib previous untreat an intern phase iii trial random assign patient previous untreat unresect stage iiic stage iv melanoma braf v mutationposit melanoma receiv combin vemurafenib mg po qd cobimetinib mg po qd day follow day rest period vemurafenib plus placebo the primari endpoint investigatorassess pfs crossov time pfs allow patient stratifi stage geograph region two interim analys os prespecifi first specifi time analysi primari endpoint level evid idiii median pfs month combin versus month patient treat vemurafenib plus placebo the hr death progress ci p the first interim analysi os immatur event arm therefor median surviv reach either studi group rate withdraw therapi caus ae similar group rate found patient treat combin rate found patient treat vemurafenib six death attribut ae combin group three death attribut ae vemurafenibon group the incid grade grade ae similar group incid rate found patient treat combin rate found patient treat vemurafenib alon rare serious ae includ chorioretinopathi retin detach decreas eject fraction qt prolong hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor chemotherapi dtic approv basi orr phase iii trial indic orr rare crs observ an impact os demonstr random trial when use control arm recent registr trial ipilimumab vemurafenib previous untreat patient metastat melanoma dtic shown inferior os temozolomid oral alkyl agent hydrolyz activ moieti dtic appear similar dtic iv administr random phase iii trial primari endpoint os howev trial design superior sampl size inadequ prove equival the object respons rate dtic nitrosourea carmustin lomustin approxim respons usual shortliv rang month although longterm remiss occur limit number patient attain cr a random trial compar iv dtic temozolomid oral agent os month dtic versus month temozolomid hr ci while data suggest similar dtic temozolomid benefit surviv demonstr either dtic temozolomid therefor demonstr similar result approv temozolomid fda level evid iia an extend schedul escal dose temozolomid compar dtic multicent trial european organis research treatment cancer eortc eortc nct random assign patient no improv seen os pfs temozolomid group dose schedul result toxic standarddos singleag dtic level evid iia two random phase iii trial previous untreat patient metastat melanoma result fda approv vemurafenib ipilimumab includ dtic standard therapi arm both vemurafenib braf v mutant melanoma ipilimumab show superior os compar dtic two separ trial other agent modest singleag activ includ vinca alkaloid platinum compound taxan attempt develop combin regimen incorpor chemotherapi eg multiag chemotherapi combin chemotherapi tamoxifen combin chemotherapi immunotherapi demonstr improv os a publish data metaanalysi random trial surviv inform compar chemotherapi biochemotherapi ie chemotherapi plus interferon alon il report impact os level evidenceiia palliat local therapi melanoma metastat distant lymph nodebear area may palliat region lymphadenectomi isol metastas lung gastrointestin tract bone sometim brain may palliat resect occasion longterm surviv although melanoma relat radiationresist tumor palliat radiat therapi may allevi symptom retrospect studi shown symptom relief shrinkag tumor radiat therapi may occur patient follow multipl brain metastas bone metastas spinal cord compress the effect dosefraction schedul palliat melanoma metastat bone spinal cord unclear highdoseperfract schedul sometim use overcom tumor resist refer pdq summari cancer pain inform treatment option under clinic evalu unresect stage iii stage iv recurr melanoma immunotherapysingl agent combin immunomodul target therapysingleag combin therapi signaltransduct inhibitor includ pk phosphoinositid kinas akt protein kinas b inhibitor cdk cyclindepend kinas addit braf mek inhibitor antiangiogenesi agent preclin data suggest increas vascular endotheli growth factor product may implic resist braf inhibitor target therapi specif melanoma popul in smaller subset melanoma activ mutat may occur nras neuroblastoma ras viral vras oncogen homolog ckit melanoma aris chronic sundamag skin acral mucos melanoma cdk cyclindepend kinas wherea gnaq frequent mutat uveal melanoma drug develop target pathway activ mutat current clinic trial',\n",
       "  'JJ'),\n",
       " ('i resect surgeri noth normal anymorelol yes i gain back lbs sinc jan i yr old male might differ bit weight gain i weigh lbs i ft use athlet but i also use weight i work regular i lost almost muscl mass my wife say arm leg like tooth pick i hope continu help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqu',\n",
       "  'JJ'),\n",
       " ('thank everyon i dread row mum last night like row crept blue upset unexpect like row also someth complet stupid petti surfac but relev thread im gonna talk ill tri make long i show parent capsul endoscopi report my mum squirm inflammationulc said urgh horribl told i basic told guy far i could tell i exhaust medic option basic either live crohn go back stoma they sympathet wasnt caus row went garden centr mum nice afternoon but got back got wine i dont think actual alcohol shes one two tier one ive notic i go drink often even so far last night there issu i know long experi mum deep denial drink day die and time shes right drunk bit annoy but sometim get aw argument state seem spoil argument so last night she ask im come easter sunday im keen idea now feel famili gather noth remot new surpris mum i alway feel like physic crap eat larg meal virtual alway this someth i think peopl realli dont understand my famili perk eat massiv meal drink alcohol get ever louder shriekier wherea i get tired lower want go lie so mum argu say i dont alway feel like crap cite one two exampl i didnt appear obvious collaps now i cant rememb brought brother first mum but somebodi turn ridicul argument ill brother i think know crohn well sinc i mention time time but hes diseas longer ive mine hes also far milder form im close brother hes never given sympathi diseas ive never given sympathi we dont fight anyth like like two polit acquaint one anoth anyway mum tri tell brother ill well despit fact hes never surgeri never hospitalis never biolog seem remiss vast major time alway work fulltim two kid play sport goe holiday eat anyth etc but yeah hes ill one dont get wrong im sure problem nobodi reach middl age acquir problem along way but i proper lost temper i would never tell brother face lucki diseas i told mum howev quit drunk hard enough get shes sober sometim never mind drunk i end proper sob meltdown someth ive coupl year my dad join fun start get verbal aggress both parent desper tri get leav sever minut then mum gave went upstair i left sob hallway my dad volt face said i wasnt safe drive like he becam gentler went made cup tea i calm enough drive home yeah proper grim night i felt proper upset i got home well way longer i intend sorri folk i read repli in fact i read last night obvious wasnt much fit state repli thank everyon post erudit paul yeah possibl pill cam get stuck strictur that crohn tend give patient dummi pill first dissolv case get stuck i dummi pill never saw pass i abdomin xray couldnt see pill i given goahead go ahead swallow real pill clo sparkleplenti i pill cam load dose entyvio sinc th infus due th infus next week im sure that enough time entyvio kick ill ask gi noodlesnoodl i think sure tysabri approv crohn yet anoth thing ask gi nssg i long cours entocort last year it actual help mg but steroid work highest dose stop work i even fulli come med im done steroid liter stick plaster beav i certain travel london treatment necessari i get hour train second seem quit fast i dont know i look symptom achalasia i occasion get feel food stuck find someth quit hard swallow time anyway id better go guy ive got hospit appoint get ill let know goe sorri yet anoth hideous long post alway look shorter white box dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('hi dillerlil welcom there previous convers ocrevus use forum search function magnifi glass top left use term ocrevus locat',\n",
       "  'NN'),\n",
       " ('befor gelinya everi year coupl year i start gilenya three month ago not look forward think',\n",
       "  'NN'),\n",
       " ('im contractor new york i know anxieti feel morn day can i make job without go pant i total accid surgeri i know fun i never humira i know take mani week kick pred i mani mani time how mani mgs pred u yea nasti flare bms hope humira help sooner later again tell dr everyth go thru keep check let us know post edit timechamp am gmt',\n",
       "  'NN'),\n",
       " ('i switch copaxon gilenya i sever allerg reaction copaxon inject reaction would caus temp go i one time i couldnt breath gilenya amaz i year th unchang mri it realli easi rememb take i notic side effect person i like small lesion load moment minor symptom compar it realli chang life better take one pill instead copaxon shot also refer i betaseron first year ms copaxon year gilenya gilenya best far',\n",
       "  'NN'),\n",
       " ('nivolumab monotherapi combin ipilimumab show encourag respons surviv rate among patient recurr small cell lung cancer sclc checkmat studi accord announc bristolmy squibb checkmat ongo phase openlabel trial evalu safeti efficaci differ dose schedul singleag nivolumab nivolumab plus ipilimumab advanc metastat solid tumor the sclc cohort checkmat includ patient diseas progress prior line treatment includ firstlin platinumbas chemotherapi regimen in analysi treatment nivolumab mgkg plus ipilimumab mgkg associ confirm object respons rate ci includ complet respons partial respons eleven percent patient treat nivolumab monotherapi achiev object respons rate investig observ respons regardless platinum sensit prior line therapi relat rovalpituzumab tesirin activ recurr small cell lung cancer median durat respons month ci reach combin arm reach singleag nivolumab arm the estim year overal surviv rate combin nivolumab alon no new safeti signal observ longer followup durat refer',\n",
       "  'VBP'),\n",
       " ('agerel macular degener amd amrd term appli age chang without obvious precipit caus occur central area retina macula peopl age year older amd progress chronic diseas central retina lead caus vision loss worldwid most visual loss occur late stage diseas pathophysiolog amd characteris appear drusen macula accompani choroid neovascularis wet amd geograph atrophi dri amd the two form amd differ pathophysiolog progress dri amdgeograph atrophi ga the characterist lesion dri amd soft drusen chang pigment hypopigment andor hyperpigment retin pigment epithelium rpe atrophi rpe becom extens time the dri form advanc caus vision loss without turn wet form the end stage dri form involv whole macula becom affect ga evolv dri amd common form amd occur case progress visual loss usual gradual eventu area partial complet atrophi rpe this may may involv fovea those dri amd chanc per year develop choroid neovascularis wet amd patient extrem larg drusen higher chanc amd convert wet form within five year wet amdneovascular amdexud amd in wet type amd new blood vessel grow choriocapillari retina they spread rpe they fragil easili leak blood vessel dont initi grow macula start side retina grow toward centr for take day grow macula other take week they reoccur sometim mani year later the consequ abnorm vessel growth haemorrhag scar format disciform scar wet amd account case amd advanc case wet amd definit consid advanc present progress vari month three year untreat becom sever visual impair within approxim two year the end point type amd scar format known disciform macular degener approxim patient wet amd one eye also develop condit second eye within five year classif sever there sever classif scheme base presenc sever characterist featur amd name drusen pigmentari irregular ga neovascularis these classif system moder good predict progress high precis detail the agerel eye diseas studi are trial develop simpler classif system prove clinic use no amd none small drusen earli amd multipl small intermedi drusen abnorm rpe intermedi amd extens intermedi one larg drusen ga involv fovea advanc amd ga involv fovea featur wet amd idiopath polypoid choroidopathi this variant amd consist neovascularis primarili locat within choroid it share featur amd involv macula seen agegroup share common nongenet risk factor smoke hypertens share common genet risk factor howev contrast amd polypoid choroidopathi seen younger age group amd often occur nasal macula polypoid neovascular complex may leak bleed less like invad retina epidemiolog amd common caus sever visual impair older adult develop world amd respons two third registr visual impair uk the estim preval amd uk year age age year there around new diagnos uk year about case dri amd wet amd account advanc amd preval increas line age popul amd common peopl caucasian ethnic women like men develop amd worldwid million peopl amd risk factor amd multifactori diseas environment genet compon play role develop sever risk factor link amd increas age main risk factor smoke risk factor newonset amd progress advanc diseas risk increas number packyear smoke synergist effect genet factor there also seem relationship gene respons treatment famili histori sever gene associ risk develop dri amd sibl affect peopl four time greater chanc develop diseas concord ident twin presenc amd one eye great increas risk develop develop visual impair second eye within four year all cardiovascular risk factor also associ wet amd some studi suggest associ amd cumul eye damag ultraviolet light peopl lightcolor eye like develop dri amd peopl diet high fat cholesterol high glycem index food low antioxid green leafi veget may like develop amd obes bmi greater increas risk time ethnic affect risk amd uncommon nativ african nativ australian it common caucasian there grow evid high cumul lifetim exposur sunlight also increas risk develop amd present symptom amd caus painless deterior central vision typic person age patient may initi asymptomat retin sign may detect incident routin eye test general symptom reduct visual acuiti notic particular near vision loss decreas contrast sensit abil discern differ shade size colour object appear differ eye abnorm dark adapt difficulti adjust bright dim light there may central dark patch visual field notic night clear within minut eye adapt photopsia percept flicker flash light light glare visual hallucin charl bonnet syndrom these occur sever visual loss caus visual hallucin often report unless specif ask dri amd symptom visual deterior tend gradual a common present difficulti read initi smallest size print later larger print peopl may notic visual deterior one eye affect visual loss becom appar second eye becom affect when ga bilater involv fovea patient may complain deterior central vision scotoma person may describ black grey patch affect central field vision normal left eye medic galleri mikael hggstrm via wikimedia common dri armd nation eye institut nih via wikimedia common wet amd symptom the common symptom typic onset exud amd central visual blur distort most patient complain straight line appear crook wavi visual deterior may develop quick a person may sudden becom unabl read drive see fine detail facial featur express vision may sudden deterior profound central visual loss event bleed this may preced accompani shower floater as dri amd exud amd occur second eye patient may sudden becom awar visual loss fundus photo wet amd show bleed retina eye site sacramento examin examin may reveal normal decreas visual acuiti associ distort amsler grid see separ examin eye articl fundus examin reveal drusen discret yellow deposit macular area may becom paler larger confluent patient progress exud amd late diseas macular scar may develop resembl thick yellow patch macular area area sharpli demarc hypopigment hyperpigment peripher retina sometim seen repres ga rpe macular sign wet amd includ welldemarc red patch repres intraretin subretin subrp haemorrhag fluid there may patchi pigment differenti diagnosi painless loss vision caus refract error cataract some corneal diseas eg fuch endotheli dystrophi posterior vitreous detach retin detach retin arteri occlus retin vein occlus central serous retinopathi cerebrovascular diseas includ amaurosi fugax transient ischaem attack stroke some drug chemic includ methanol chloroquin hydroxychloroquin isoniazid thioridazin isotretinoin tetracyclin ethambutol pituitari tumour central nervous system tumour papilloedema macular hole primari openangl glaucoma central visual loss occur late optic atrophi condit caus similar retin sign observ amd includ diabet maculopathi macular degener associ high myopia greater dioptr atroph neovascular chang usual occur younger age amd differ natur histori respons treatment rare inflammatori syndrom caus choroid neovascularis exampl ocular histoplasmosi there usual sign activ previous uveiti central serous retinopathi macular telangiectasia macular dystrophi usual inherit often symmetr type membranoprolif glomerulonephr investig secondari care investig aim confirm diagnosi assess extent diseas possibl intervent keep record order measur treatment effect diseas progress slitlamp biomicroscopi identifi drusen pigmentari exud haemorrhag atroph chang affect macula look characterist area area pallor sharpli defin scallop edg this also help detect retin thicken elev due neovascular amd colour fundus photographi use record appear retina fluorescein angiographi use neovascular amd suspect order confirm diagnosi assess lesion fluorescein dye inject intraven photograph retina taken serial detect abnorm vasculatur leakag capillari indocyanin green angiographi may use visualis choroid circul provid addit inform fluorescein angiographi ocular coher tomographi produc highresolut crosssect threedimension imag retina the guidelin the royal colleg ophthalmologist state test mandatori diagnosi monitor respons therapi reveal area ga may clinic visibl biomicroscopi manag suspect agerel macular degener if amd suspect refer person urgent assess ideal seen within one week referr urgent referr particular import peopl present distort rapidonset visual loss suggest wet amd refer one follow choic depend local referr pathway a fasttrack macular clinic medic retina clinic treatment centr a local district general hospit eye servic an optometrist option seen within one week optometrist abl refer direct ophthalmologist advis person either delay one week seen ophthalmologist symptom worsen whilst wait seen attend eye casualti soon possibl seek immedi medic attent expedit urgent specialist assess manag dri agerel macular degener there treatment prevent progress dri amd although lifestyl adjust may slow progress manag consist main counsel smoke cessat visual rehabilit nutrit supplement expect benefit coexist visual impair cataract refractori error appropri manag although cochran review found possibl conclud avail data whether cataract surgeri benefici harm peopl amd there current consider interest implant len system endstag diseas see advic support peopl diagnos amd receiv inform condit secondari care howev consid offer inform if person develop worsen symptom develop symptom second eye either present soon possibl eye casualti similar urgent walkin hospit eye clinic present soon possibl gp urgent rereferr made specialis servic inform secondari care treatment what done slow progress explain mani peopl sever sight loss experi visual hallucin consid regist sightimpair registr voluntari provid access benefit help if appropri inform access low vision servic see signpost relev organis exampl the macular societi provid support comprehens inform amd live amd print audio format the royal nation institut blind peopl provid inform support includ contact detail local support group visual impair citizen advic provid advic avail benefit drive mani peopl amd abl drive depend sever diseas vision fulfil requir dvla it person legal respons check whether eyesight good enough drive registr sight impair sever sight impair normal rule hold drive licenc if uncertainti fit drive advis person contact dvla lifestyl advic advis smoker stop smoke reduc risk amd progress peopl exist diseas encourag person eat healthi balanc diet rich leafi green veget fresh fruit like improv concentr macular pigment fundus there firm evid help slow progress amd sensibl unlik harm patient may advis take dietari supplement consult ophthalmologist this would typic peopl intermedi amd one eye advanc amd one eye the are trial followup work are conclud specif dietari supplement may reduc risk progress patient the supplement wide sold are formula consist mg vitamin c iu vitamin e mg lutein mg zeaxanthin mg zinc mg copper there evid support use supplement peopl less intermedi amd evid use primari prevent they riskfre zinc supplement caus small increas risk hospitalis due genitourinari condit there possibl small increas risk heart failur associ vitamin e supplement patient diabet mellitus a number studi look use statin ginkgo biloba extract contain flavonoid terpenoid antioxid properti slow diseas progress howev studi inconclus these treatment option use uk visual rehabilit this mainstay manag patient dri amd it revolv around maximis remain visual function assist person maintain independ life long possibl it may involv refract check make sure remain vision best low visual aid clinic referr help person make remain sight the servic may includ provis train use optic aid magnifi advic light tactil aid electron aid nonopt aid low vision servic may provid social servic communiti optometrist eye depart voluntari sector a person need regist sight impair access low vision servic in fact access low vision servic person develop serious visual difficulti give chanc adapt sever affect the servic may also provid advic benefit concess support group peopl sight impair see separ sever partial sight impair articl manag wet agerel macular degener intravitr inject antivascular endotheli growth factor antivegf agent current standard care treatment carri ophthalmologist special interest retin macular problem intervent treatment take place either theatr design treatment clean room local anaesthet antivegf inhibitor vegf proangiogen growth factor also stimul vascular permeabl major role patholog neovascular amd sinc antivegf therapi becom avail substanti improv prognosi peopl affect neovascular amd antivegf drug includ ranibizumab bevacizumab aflibercept the antivegf drug administ intravitr inject usual given month three month variabl time thereaft depend respons treatment followup may beyond two year most patient maintain vision current level third gain improv vision howev respond therapi patient understand risk associ intravitr inject instruct report symptom suggest endophthalm without delay pegaptanib current recommend nation institut health care excel nice treatment neovascular amd ranibizumab aflibercept recommend manufactur provid discount agre patient access scheme follow circumst appli eye treat bestcorrect visual acuiti no perman structur damag central fovea lesion size less equal disc area greatest linear dimens there evid recent presum diseas progress blood vessel growth indic fluorescein angiographi recent visual acuiti chang it recommend treatment ranibizumab continu peopl maintain adequ respons therapi bevacizumab develop system treatment colorect cancer it cheaper whilst current licens intraocular use wide use around world account price studi suggest ranibizumab bevacizumab similar efficaci',\n",
       "  'IN'),\n",
       " ('hi all i crohn coliti humira sinc i final wean prednison end februari remiss now i mild inflamm inch transvers colon everyth els normal i uceri day still see blood littl pain my doc think humira isnt realli work i didnt last long steroid he mention remicad next i think entyvio do crohn patient use entyvio risk get small bowel inflamm entyvio work colon i never small bowel inflamm dont want either is remicad still gold standard crohn thank t diagnos proctiti april sp c diff infect age nov crohn coliti mid transvers mildmoder remiss marchsept flare againfail prednisonebalsalzid wean start humira prednison sinc past med cortifoam canasa rowasabalsalazid prednison',\n",
       "  'NN'),\n",
       " ('i remicad yrs stop work tri humira reaction today i get first dose cimzia i eat disord i afraid weight gain caus anyon els plus i heard caus hair loss im worri question pleas let know new member forum ps i crohn',\n",
       "  'JJ'),\n",
       " ('jussi you tri bring bp by substitut pazopanib help hypotens or tri make sure deliveri opdivo deliv heart tumor by treat low bp how long month dose cediranib revert hypotens youv mention',\n",
       "  'NN'),\n",
       " ('if ocrevus want share inform id interest know treatment made feel did notic changesodd sensat new symptom old symptom vanish got somewhat better ms diagnos avonex copaxon member ms board sinc repli with quot the follow user say thank howi jeani z jendi stillstannd sunshin',\n",
       "  'JJ'),\n",
       " ('diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r negat m alk kras ros pd pdl met treatment st carboplatinpemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrexedavastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question is tagrisso good altern m negat never smoker if altern current treatment yale dr roggerio lilenbaum can suggest suitabl clinic trial ct mass ny can suggest doctor second opinion',\n",
       "  'NN'),\n",
       " ('hi birki i diagnos april adenocarcinoma i quit surpris i quit smoke year go thought i safe radiat surgeri rule luckili i candid immunotherapi i go third treatment tuesday there side effect noth serious i current receiv keytruda i think one newer immunotherapi drug the oncologist said take nine week get good idea cancer respond hang birki i keep date event evolv',\n",
       "  'NN'),\n",
       " ('on oct am jskoziol wrote hello close halloween im great my weight health i diagnos stage nsclc jan opdivo case miracl drug thought id post shoutout whod seen previo post my wife noriko diagnos august stage squamous nsclc petct scan novemb st schedul infus opdivo nivolumab month month diagnosi she previous gone thru two combo regimen fail chemo the oncologist dr jack west came said cancel infus the petct scan show wasfre cancer remiss she ecstat there hopeeven stage lung cancer thank brystolmey squibb area seattl swedish hospit cancer institut all best youjskozio keep spirit great progress chuck',\n",
       "  'VBD'),\n",
       " ('wednesday april et vancouv april prnewswirefirstcal qlt inc nasdaq qlti news tsx qlt news announc today enter exclus worldwid co develop licens agreement retinagenix llc develop activ synthet retinoid product treatment degen retin diseas under term agreement qlt respons develop commerci product use ocular human diseas retinagenix particip research support codevelop collabor elig receiv upfront payment us million payment upon achiev certain develop approv sale mileston well singl digit royalti net sale we excit make announc today said bob butchofski presid chief execut offic qlt this collabor first step forward strategi access develop commerci promis new technolog eye qlts core area therapeut expertis we plan progress first drug candid retinagenix collabor clinic within next month degen diseas retina affect mani peopl worldwid lead vari degre irrevers blind said marco northland chairman retinagenix we believ administr synthet retinoid could revers defect retinoid cycl patient we believ qlts expertis retin diseas drug develop provid strong foundat success collabor about synthet retinoid drug synthet retinoid drug use biochem strategi restor visual function retin degener well age retina genet diseas eye leber congenit amaurosi lca retin pigmentosa aris gene inactiv subsequ disrupt metabol pathway these pathway advers affect natur age process may play role age visual deficit includ agerel macular degener retinagenix preclin studi demonstr oral administ synthet retinoid drug caus longlast restor retin function about qlt inc qlt global biopharmaceut compani special develop treatment eye diseas well dermatolog urolog condit we combin expertis discoveri develop commerci innov drug therapi two uniqu technolog platform photodynam therapi atrigel creat product visudyn eligard for inform visit web site wwwqltinccom about retinagenix llc retinagenix privat held earli stage seattl wa base compani develop commerci synthet retinoid treatment retin diseas retinagenix spinoff univers washington cofound david a saperstein md krzysztof palczewski phd two intern recogn leader treatment retin diseas biochemistri vision respect marco a northland season entrepreneur snip',\n",
       "  'JJ'),\n",
       " ('just want give updat they start scan less frequent everi month get see everyth work mom scan last month everyth stabl doctor said normal tumor small becom he told thing keep go way could possibl go less treatment schedul year keytruda amaz this drug noth short miracl famili origin told may live see year wouldnt surviv month without treatment it year half cancer progress so mani prayer answer there hope',\n",
       "  'NN'),\n",
       " ('franck s paterka m birkenstock j zipp f siffrin v witsch e phenotyp antigen unexperienc th cell inflam central nervous system experiment autoimmun encephalomyel j neuroimmun pharmacol nov epub ahead print multipl sclerosi chronic dissemin inflamm central nervous system thought driven autoimmun t cell genet associ studi multipl sclerosi larg number studi anim model diseas support role effectormemori t helper cell howev mechan under relaps remiss chronic progress multipl sclerosi anim model experiment autoimmun encephalomyel clear in particular scarc inform role central nervous systeminvad naiv t helper cell process by appli twophoton laser scan microscopi could show vivo antigen unexperienc t helper cell migrat deep parenchyma inflam central nervous system experiment autoimmun encephalomyel independ antigen specif use flow cytometr analys central nervous systemderiv lymphocyt found antigenspecif former naiv t helper cell becam activ inflamm central nervous system encount correspond antigen there debat ongo valu eae there number immun modul go increas difficult develop new one go go head head current dmt do need moreof cours howev term basic scienc much need eae understand basic biolog could probabl get idea use less sever model this basi rs central part eu law come use anim research somebodi coupl day ago extol virtu german ethic piec work take view favour i know mani peopl read one could pose question often need reinvent wheel new technolog tell us someth essenti believ know alreadi when cell see target get activ it clear cell arriv cns antigenspecif shown thirti year ago we know migrat marker make import natalizumab fingolimod we know previous antigen sensitizi pool import eae induct we spend vast amount time work immun cell go eg lung spleen brain cell goe tissu die make new one go elsewher or move cns live anoth day',\n",
       "  'NN'),\n",
       " ('i gilenya sinc begin no issu except lymphocyt count drop worrisom zone now i get test everi month make sure dont stay low so far count keep come back otherwis issu',\n",
       "  'VBP'),\n",
       " ('hi mohit welcom grace i sorri hear recent progress father lung cancer though oncologist like continu tarceva even progress combin drug alimta pemetrex often progress signific enough third generat egfr tki tagrisso chosen in addit doctor choos combin afatinib cetuximab effect quit challeng term combin side effect egfrposit patient often overlook standard chemotherapi tend quit effect subgroup patient regimen carboplatin cisplatin combin alimta taxol often use jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('stelara still fair new crohn treatment this might get lot repli ive done research time work answer psoriasi board for psoriasi seem week reach strong therapeaut level the good news stelara seem get rave review crohn patient it seem best med come along sinc remicad i hope good success my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran',\n",
       "  'NN'),\n",
       " ('this real game changer cyndi zagieboylo presid ceo nation ms societi summari the us food drug administr approv ocrevus ocrelizumab genentech member roch group treatment primari progress ms relaps ms base clinic trial show signific benefit ms relaps progress this first therapi specif approv treat primari progress ms potenti safeti issu identifi fda includ infus reaction infect there may increas risk malign peopl take ocrevus ocrevus taken iv infus everi six month more inform ocrevus avail genentech ocrevus ampm eastern addit detail frequent ask question detail the us food drug administr approv ocrevus ocrelizumab genentech member roch group use treatment primari progress ms relaps ms make first therapi treatment primari progress multipl sclerosi ocrevus avail firstlin treatment mean recommend approv label peopl tri ms therapi take ocrevus test children comment as first therapi specif approv treat primari progress ms repres signific mileston said kathi costello ms anpbc mscn associ vice presid healthcar access nation ms societi we grate final diseasemodifi treatment peopl primari progress ms also import new option peopl relaps ms said bruce bebo phd execut vice presid research nation ms societi we hope first mani new treatment approv peopl progress ms about ocrevus ocrevus monoclon antibodi bind molecul cd surfac immun cell call b cell reduc number certain b cell circul blood b cell sever function includ make antibodi believ play role immunesystemmedi damag brain spinal cord tissu ms ocrelizumab administ intraven infus everi month the first dose given two infus two week apart subsequ dose given singl infus potenti benefit primari progress ms the oratorio studi involv peopl primari progress ms compar ocrevus inact placebo met primari endpoint show treatment ocrevus signific reduc risk progress clinic disabl compar placebo peopl compar placebo ocrevus also reduc time requir walk feet decreas volum brain lesion relaps ms in opera i opera ii studi involv peopl relaps ms compar ocrelizumab interferon betaa rebif emd serono pfizer ocrevus signific reduc annual relaps rate compar rebif two year total peopl relaps ms in addit ocrevus signific delay confirm progress disabl edss scale compar rebif ocrevus also signific reduc activ inflamm observ mri scan total damag mri scan compar rebif potenti risk prescrib inform medic guid pdf ocrevus includ sever warn precaut ocrevus caus wide varieti infusionrel reaction frequent itchi skin rash irrit throat flush face fever headach symptom in rare case lifethreaten infus reaction occur frequent first infus occur hour infus as precaut peopl administ steroid antihistamin infus monitor least one hour infus ocrevus increas risk infect includ respiratori tract infect herp infect ocrevus administr delay peopl activ infect vaccin live liveattenu vaccin recommend treatment b cell repopul follow treatment there may increas risk malign cancer includ breast cancer peopl take ocrevus individu use ocrevus follow standard breast cancer screen guidelinesth clinic trial result ongo monitor trial particip indic imbal number cancer occur individu treat ocrevus compar interferon relaps remit trial placebo primari progress trialth number small know sure relat direct ocrevus this imbal requir continu care observ evalu data larger number individu pml although case pml progress multifoc leukoencephalopathi serious brain infect occur clinic trial pml observ peopl take relat medic condit typic symptom divers progress day week includ progress weak one side bodi clumsi vision disturb chang think memori orient person hepat b virus reactiv although case hepat b virus reactiv report peopl take ocrevus occur peopl take similar medic befor initi treatment ocrevus individu blood test detect hepat b virus for inform peopl ms contact genentech ocrevus ampm eastern for peopl qualifi genentech plan offer patient assist program genentech access solut access httpwwwgenentechaccesscom comment price the approv ocrevus excit mileston peopl primari progress ms encourag new option peopl relaps form diseas the nation ms societi applaud genentech leadership set wholesal acquisit cost list price ocrevus per year near percent current market averag ms treatment the continu escal price ms diseasemodifi therapi creat barrier peopl ms get lifechang medic through action ocrevus genentech chang industri dynam peopl access lifechang treatment need live best live we encourag compani follow suit creat drug price trend keep patient first resourc read press releas fda download prescrib inform read fda snapshot describ clinic trial ocrevus read detail clinic trial ocrevus two paper publish decemb issu new england journal medicin ocrelizumab versus placebo primari progress multipl sclerosi dr xavier montalban other ocrelizumab versus interferon betaa relaps multipl sclerosi dr stephen hauser other ocrevus trademark genentech member roch group rebif regist trademark merck kgaa emd serono inc faq about fda approv ocrelizumab brand name ocrevus primari progress relaps form ms q what ocrevus a ocrevus ocrelizumab genentech member roch group monoclon antibodi bind molecul cd surfac immun cell call b cell reduc number certain b cell circul blood b cell sever function includ make antibodi believ play role immunesystemmedi damag brain spinal cord tissu ms q what type ms ocrevus approv treat a the fda approv ocrelizumab treatment adult primari progress ms relaps ms q will everyon primari progress ms benefit ocrevus a we dont know sinc like clinic trial ocrevus trial primari progress ms limit characterist peopl could particip the trial includ peopl age edss expand disabl status scale scale assess neurolog function use clinic trial score mean abl walk help walker bilater crutch devic side evid immun protein test spinal fluid oligoclon band it possibl predict specif individu respond treatment the use ocrevus clinic practic help determin like benefit q will ocrevus help peopl secondari progress ms longer experienc relaps a we dont know so far clinic trial ocrevus involv peopl relaps form ms primari progress ms result announc posit trial popul there data yet whether ocrevus may effect peopl secondari progress ms longer experienc relaps q how ocrelizumab taken a ocrevus administ intraven vein infus everi month at begin treatment two dose separ day after singl infus everi month q when ocrelizumab avail prescript a accord genentech peopl may talk ms doctor take ocrevus the compani expect suppli therapi avail two week around week april access medic also depend issu relat individu health insur q how effect ocrevus primari progress ms a the oratorio studi involv peopl primari progress ms compar ocrevus inact placebo met primari endpoint show treatment ocrevus signific reduc risk progress clinic disabl compar placebo peopl compar placebo ocrevus also reduc time requir walk feet decreas volum brain lesion q how effect ocrelizumab relaps ms a in opera i opera ii studi involv peopl relaps ms compar ocrelizumab interferon betaa rebif emd serono pfizer ocrevus signific reduc relaps rate compar rebif two year total peopl relaps ms in addit ocrevus signific delay confirm progress disabl edss scale compar rebif ocrevus also signific reduc activ inflamm observ mri scan total damag mri scan compar rebif q should individu relaps ms switch current therapi ocrevus a the decis whether take ocrevus made collabor ms doctor take account varieti factor includ effect therapi current use potenti risk benefit well cost lifestyl factor import question consid discuss doctor term ocrevus includ how i current therapi what toler risk known side effect what toler risk advers consequ might emerg longerterm use how medic choic affect abil plan becom pregnant q if i take anoth diseasemodifi therapi ms long i wait start ocrevus a there washout wait time current establish recommend switch anoth therapi ocrevus therefor decis wait proceed need made collabor ms doctor q what potenti side effect ocrevus a prescrib inform pdf ocrevus includ sever warn precaut ocrevus caus wide varieti infusionrel reaction frequent itchi skin rash irrit throat flush face fever headach symptom in rare case lifethreaten infus reaction occur frequent first infus occur hour infus as precaut peopl administ steroid antihistamin infus monitor least one hour infus ocrevus increas risk infect includ respiratori tract infect herp infect ocrevus administr delay peopl activ infect vaccin need administ least week prior start ocrevus vaccin live liveattenu vaccin recommend treatment b cell repopul follow treatment pml although case pml progress multifoc leukoencephalopathi serious brain infect occur clinic trial pml observ peopl take relat medic typic symptom divers progress day week includ progress weak one side bodi clumsi vision disturb chang think memori orient person hepat b virus reactiv although case hepat b virus reactiv report peopl take ocrevus occur peopl take similar medic befor initi treatment ocrevus individu given blood test detect hepat b virus although longterm safeti data avail medic work similar fashion medic deplet b cell longterm safeti ocrevus unknown time q is risk malign ocrevus a there may increas risk malign cancer includ breast cancer peopl take ocrevus individu use ocrevus follow standard breast cancer screen guidelin the clinic trial result ongo monitor trial particip indic imbal number cancer occur individu treat ocrevus compar interferon relaps remit trial placebo primari progress trial the number small know sure relat direct ocrevus this imbal requir continu care observ evalu data larger number individu q has ocrevus proven effect diseasemodifi therapi a ocrevus compar rebif interferon betaa emd serono pfizer in two phase iii studi total peopl relaps ms peopl relapsingremit ms secondaryprogress ms experienc relaps ocrevus signific reduc relaps rate two year compar rebif ocrevus compar clinic trial diseasemodifi therapi q how long would person take ocrevus a there specifi time limit take ocrevus like diseas modifi medic ocrevus would like continu person ms stabl experienc advers event new safeti issu could ascrib medic q will peopl take ocrevus get special medic test monitor a your doctor need run blood test prior start medic test hepat b infect for individu relaps ms ms doctor might like new baselin mri prior start new medic this discret doctor individu use ocrevus follow standard breast cancer screen guidelin q will ocrevus help mobil prevent get wors revers progress disabl a base result clinic trial ocrevus like signific revers individu disabl may help stabil in oratorio trial primari progress ms treatment ocrevus signific reduc risk progress clinic disabl this reduc risk progress mean peopl take ocrevus trial less like demonstr worsen disabl peopl take placebo ocrevus also reduc time requir walk feet decreas volum brain lesion this mean group peopl take ocrevus trial lower risk progress improv ft walk speed reduc volum brain lesion howev possibl predict one individu respond therapi q will ocrevus reduc diseas activ relaps ms a as group peopl take ocrelizumab trial fewer relaps fewer new enlarg lesion mri less risk disabl worsen peopl take rebif interferon betaa howev possibl predict one individu respond therapi q can i continu take supplement ocrevus biotin vitamin d vitamin b etc a yes howev essenti ms doctor know prescript overthecount medic supplement vitamin take q what vaccin ocrevus can i flu shot pneumonia shot vaccin shingl a individu wait week vaccin begin therapi ocrevus ani vaccin live liveattenu virus recommend treatment ocrevus b cell repopul follow treatment individu speak doctor whether shot consid avail inactiv form q how often i mri ocrevus a your ms doctor guid often mri need the revis recommend consortium ms center task forc standard mri protocol clinic guidelin diagnosi followup multipl sclerosi suggest brain mri approxim month switch new treatment routin brain mri everi month year relaps ms current recommend regard frequenc mri primari progress ms q will immun system suppress compromis i take ocrevus will i like catch ordinari infect i take medic a ocrevus increas risk infect includ respiratori tract infect herp infect q can i continu medic i ocrevus ampyra baclofen bladder medic a you continu take ms symptom manag medic howev essenti ms doctor know prescript overthecount medic supplement vitamin take q will i need spinal tap start ocrevus a no q what i longer live home can i still get ocrevus i live assist live facil nurs home a whether live home facil affect abil ocrevus howev insur coverag may impact access medic q what differ relapsingremit ms secondari progress ms primari progress ms a relapsingremit ms rrms character clear defin attack new increas neurolog symptom these attack also call relaps exacerb follow period partial complet recoveri remiss secondari progress ms spms follow initi relapsingremit cours mani peopl diagnos rrms eventu transit spms cours progress worsen neurolog function accumul disabl time primari progress ms ppms character worsen neurolog function accumul disabl onset symptom without earli relaps remiss relaps form ms phrase includ rrms well progress ms individu continu experi relaps q is ocrevus like help disabl primari progress ms mild versus sever a it known benefit use ocrevus the studi involv peopl primari progress ms includ individu age score edss disabl scale minim disabl abl walk help walker bilater crutch devic side it possibl predict specif individu respond treatment q is better take earlier later treat progress ms a in oratorio trial primari progress ms averag time diagnosi particip year it known medic work peopl primari progress ms longer period time q is better take ocrevus earlier later treat relaps ms a in general earli consist treatment diseasemodifi therapi recommend read howev yet specif known whether better use ocrevus earlier later known whether better use ocrevus diseasemodifi therapi q is point ocrevus work a there known point time ms therapi may stop work effect each individu respond differ given therapi respons treatment must assess regular ms doctor q what ocrevus cost a the list price announc per year howev price ocrevus individu ms depend provis insur coverag degre individu elig program design assist outofpocket cost q what nation ms societi respons post price ocrevus a the approv ocrevus excit mileston peopl primari progress ms encourag new option peopl relaps form diseas the nation ms societi applaud genentech leadership set wholesal acquisit cost list price ocrevus per year near percent current market averag ms treatment the continu escal price ms diseasemodifi therapi creat barrier peopl ms get lifechang medic through action ocrevus genentech chang industri dynam peopl access lifechang treatment need live best live we encourag compani follow suit creat drug price trend keep patient first q will health insur cover ocrevus a coverag depend individu insur plan for peopl qualifi genentech plan offer patient assist program genentech access solut access httpwwwgenentechaccesscom q where i get inform support genentech provid help peopl gain access ocrevus a physician peopl ms contact genentech inform access genentech access solut access httpwwwgenentechaccesscom q is ocrevus rituximab therapi use treat cancer a no ocrevus deriv rituximab both rituximab ocrevus work deplet b cell howev two medic base publish report ocrevus manufactur differ rituximab ocrevus most human rituximab equal part mous human these monoclon antibodi bind specif overlap area molecul immun b cell call cd cell there also differ way rituximab ocrevus induc death cd b cell whether differ meaning term potenti effect ms term safeti difficult say time q are therapi develop progress ms a yes the societi close watch clinic trial could lead treatment peopl progress form ms for exampl posit result recent announc trial baf siponimod secondari progress ms in addit studi includ the mssmart trial test three therapi may nerveprotect properti secondari progress ms ms societi uk the sprintm trial ibudilast oral antiinflammatori agent ongo peopl secondari progress primari progress ms thank uniqu collabor nih neuronext network medicinova nation ms societi the msstat studi get underway univers colleg london multicent trial test whether repurpos cholesterollow therapi slow cours secondari progress ms societi provid fundingth societi also interest well research identifi exercis dietari approach help peopl ms live best live the societi support sever clinic trial investig dietari intervent symptom manag potenti modifi diseas process q base trial result still need invest addit research progress ms a yes we need continu invest research find solut progress ms this trial first success mani disappoint we welcom develop must remain focus find better solut treat form progress ms we continu leadership intern progress ms allianc fund research progress ms research program encourag compani commit develop treatment progress form ms',\n",
       "  'NN'),\n",
       " ('the identif molecular target treat nonsmal cell lung cancer nsclc chang treatment landscap diseas among common seen mutat alter epiderm growth factor receptor egfr chromosom transloc anaplast lymphoma kinas alk gene howev mutat braf also found nsclcs braf mutat nsclc repres emerg target entiti among scenario oncogenedriven nsclc anoth import brick pickax molecular wall nsclc alessandro leonetti md univers hospit parma itali colleagu wrote recent review braf nsclc braf protein kinas known play role mapkerk pathway involv cell growth prolifer surviv differenti braf mutat discov cancer greater incid certain tumor includ melanoma papillari thyroid carcinoma in nsclc braf mutat general occur exclus egfr mutat alk rearrang the frequent activ braf mutat braf ve occur lung adenocarcinoma patient braf ve mutat found differ clinic paramet compar non ve mutat overal braf mutat common occur current former smoker braf ve mutat common seen light never smoker addit braf mutat includ braf ve mutat occur common women furthermor patient found braf ve mutat like shorter diseasefre overal surviv rate relat articl bevacizumab plus erlotinib may be new standard care nonsmal cell lung cancer gefitinib plus platinumdoublet chemotherapi may improv overal surviv egfr posit nsclc keynot pembrolizumab improv overal surviv nonsmal cell lung cancer if prognost impact attribut aggress histolog architectur like micropapillari one frequent associ braf ve mutat remain assess dr leonetti colleagu wrote review target braf two potent braf inhibitor vemurafenib dabrafenib approv us food drug administr fda treatment advanc metastat melanoma v mutat howev major patient treat inhibitor eventu develop resist drug some research explor addit mek inhibitor overcom acquir resist braf inhibit melanoma specif two phase trial combin braf mek inhibitor untreat diseas shown respons rate median overal surviv approach year accord dr leonetti colleagu given strong result observ braf inhibit treatment braf mutat metastat melanoma perspect translat success braf inhibit tumor type harbor braf mutat rais interest clinician howev result differ solid tumor type mix emerg posit data nsclc result basket studi look braf ve nonmelanoma show among patient nsclc object respons patient reduct tumor size similar retrospect studi vemurafenib treatment patient braf mutant nsclc show patient ve mutat diseas respons rate',\n",
       "  'NN'),\n",
       " ('hello ive diagnos year current i gilenya far pretti good i rebif two half year i simpli got tire give shot day week next day feel like flu gilenya come pill one time day fear make sure i rememb i take day cant take two one day monitor first dose drop heart rate blood pressur i experi lot side flareup difficult experi your lot stress life basic i think trial error find work best gilenya work i would jump next option i pass infus take much time i small children i dont lot year use gilenya ive issu good luck whatev choos rememb nobodi find work best good luck god bless',\n",
       "  'NN'),\n",
       " ('as final decad th centuri approach congress unit state made special eff ort acceler medic research recogn paramount import neurolog diseas design decad brain purpos funnel fund time talent treatment ill affect nervous system multipl sclerosi benefit enorm eff ort explos drug trial occur period mani decad advanc sprang incred power new technolog sophist techniqu ad mri allow detect ms plaqu earlier accur ever that led rapid diagnosi diseas in averag time person first symptom ms definit diagnosi year use mri technolog reduc time six month now plaqu caus symptom could often seen immedi the power rapid painless mri scan provid inform incalcul bless doctor patient alik studi seri mri scan time show ms plaqu actual develop permit research track burden diseas total plaqu area individu patient at time mri scan gave research faster sophist way test drug treat ms the benefit new drug seen mri scan seen patient research treatment ms thus great acceler most diseas yield secret painstak laboratori work research scientist laboratori work ms show us mani essenti aspect diseas a key culprit ms white blood cell call t cell although mani detail sequenc event process still remain learn know t cell becom activ leav bloodstream enter brain tissu damag myelin fatti tissu insul protect nerv fiber this t cell identifi character detail recent discoveri also emphas myelin target destruct ms often under nerv cell neuron axon damag well thought account perman disabl ms caus dure americanl project discov decod gene human bodi focus attent role gene mani diseas a monument studi peopl ms includ ident twin rear mile apart differ famili clear demonstr gene play role determin get ms although appear singl ms gene seem someth fundament us ie someth gene make one person suscept develop ms anoth this yet anoth clue caus diseas of cours sophist technolog limit medicin there quantum leap comput well dure decad brain comput scientist built inform superhighway wove internet faster better communic data analysi brought ms doctor research world togeth increas power coalit larg databas assembl track analys thousand patient histori clarifi diseas variat respons treatment characterist pattern ms began emerg ms clinic research laboratori link share evalu new find the symptom ms never amen therapi tizanidin introduc manag spastic use intrathec baclofen pump sever spastic becam wide avail it deliv medic direct spinal cord reliev intens muscl stiff ness spasm improv made medic bladder manag eg tolterodin fatigu modafinil treatment sexual problem longneglect aspect ms took major leap forward introduct sildenafil better known viagra similar medic gabapentin introduc treat mani pain symptom rang sever face pain trigemin neuralgia burn pain limb other drug develop rapid pace research also reveal mani way ms alter mind slow think affect memori new drug donepezil use treat problem alzheim diseas test ms refin rehabilit exercis physic therapi also benefit peopl ms these mani new treatment mark enhanc way physician calm symptom improv qualiti life year research drug treat actual diseaseand symptomscam fruition beta interferon b betaseron introduc beta interferon avonex introduc mid glatiram acet copaxon arriv late in mitoxantron novantron approv treat ms especi use slow chronic progress form diseas none therapi abl retard two year new centuri variat beta interferon rebif also introduc the cours ms could alter reduc diseas activ prevent mani attack nataluzimab tysabri first whole new class drug call monoclon antibodi signific suppress relaps ms sever larg trial treatment began widespread use delay procedur develop minim serious infect patient develop treatment drug progress thus remark throughout histori ms untreat diseas then one decad research develop drug suppress attack alter cours ms mani drug test these includ oral cladribin may well first oral diseasemodifi therapi approv ms two new monoclon antibodi rituximab rituxan alemtuzumab campath destroy immun cell regul ms attack fingolimod drug block cell enter nervous system further studi clarifi valu treatment whatev ultim role near drug test the histori ms still written accomplish fight ms last decad preced centuri let us hope new centuri see victori sourc loren a rolak md willek van eeckhoutt ireland multipl sclerosi me unauthor use andor duplic materi without express written permiss blog author andor owner strict prohibit excerpt link may use provid full clear credit given willek van eeckhoutt ireland multipl sclerosi me appropri specif direct origin content',\n",
       "  'JJ'),\n",
       " ('new fda approv zykadia ceritinib alkposit nsclc whi i think it poor choic initi treatment the fda approv new therapi approxim patient nsclc molecular marker known alk rearrang the cancer journey just diagnos in treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey in treatment cancer type lung cancer diseas learn target therapi imprecis medicin whi keytruda pembrolizumab chemo pdl nsclc isnt readi prime time let start say im fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi chemotherapi immunotherapi is immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu in fact cancer journey in treatment cancer type lung cancer diseas learn target therapi firstlin treatment symptom secondlin treatment death pseudoprogress know when cut your loss immunotherapi among mani novel concept manag immunotherapi potenti pseudoprogress this unusu phenomenon patient scan cancer journey just diagnos in treatment cancer type lung cancer diseas learn firstlin treatment target therapi secondlin treatment immunotherapi view more communiti forum local therapi metastat lung cancer who what whi when how hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer who cancer journey just diagnos in treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ros procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva tm negat progress year tarceva tissu biopsi show tm negat ani suggestionsexperi next step onc suggest i move afatinib opdivo pdl test cancer journey in treatment cancer type lung cancer diseas learn lung cancer general lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc has anyon inform obtain use vaxira cuban drug stage advanc nsclc not sure us citizen still travel cancer journey in treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva my wife come long way stage iv lung cancer sinc she develop acquir resist tarceva gene sequenc biopsi cancer journey just diagnos in treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       "  'NN'),\n",
       " ('hi just quick question usual long patient need wait resum tagrisso lung radiat day week or week thank kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('the weather hasnt conduc ride late cold windi scatter snow everi three four day i get one pretti good ride mile includ short hill most flat trail i keep weight work twice week yoga twice week occasion walk ellipt session though lot go realli need better weather i occasion attend men ms group meet went one week ago ive watch one guy diagnos year ago declin rapid aggress case ms he start rituxan sometim last year disabl alreadi diminish near wheel chair bound walk cane impress recoveri ive ever person wit he readili emphas push hard physic person i notic lot small improv also taken togeth improv strength balanc endur i realli hope ocrevusrituxan therapi work guy later larri',\n",
       "  'NN'),\n",
       " ('bizarr exampl work crizotinib xalcori billion usd cancer drug it start oxindol sutentlik lead cmet kinas sugen the pk properti lead terribl inject site precipit unpredict metabol a new aminopyridin lead came hts kalamazoo pharmacia bought sugen the compani eventu cocrystal lead activ site cmet combin structur info oxindol seri help dramat improv aminopyridin seri this time lead fair potent good pk properti poor target select this consid plus compet second seri exquisit cmet select eventu shelv pfizer pharmacia merger the origin research team most laid pfizer transfer san diego former agouron project manag stay there project languish eventu shelv amid postmerg chao later biologist pfizer tri find medchem support alk sinc bind site cmet alk somewhat similar cmet seri rescreen bingo crizotinib taken clinic without modif sinc anim pk data potenc alk good poor select activ cmet consid plus so perfect ration oldfashion structurebas drug design done perfect ration way wrong kinas repurpos smart biologist take advantag offtarget activ oh cmet project manag pfizer took credit republish research sugen colleagu without put name public she enorm promot becam pfizer fellow went start biotech compani',\n",
       "  'NN'),\n",
       " ('so i flex sig last tuesday got result back infect cmv etc howev activ coliti despit therapeut level humira system result said diffus chronic activ coliti mild activ surfac eros my doctor initi recommend remicad sinc i short initi respons humira howev verifi insur remicad simponi entyvio cover she said lt look like cimzia thing cover hope know week is common drug use ive never heard are side effect anyon experi i feel like im go round round get nowher',\n",
       "  'RB'),\n",
       " ('i havent seen anyth post durvalumab wonder im look right place site immunotherapi well side effect would love hear i infus oncologist put hold rash clear seem next start date end nov hope rash doesnt return',\n",
       "  'JJ'),\n",
       " ('am alectinib tyrosin kinas inhibitor tki just notic small print ingredi list protein powder amino acid tyrosin mg per serv yike so i deliber ingest i strive inhibit differ thing needless say i come screech halt drink protein shake so question should avoid food ad tyrosin tki therapi thank alk have alectinib sinc april prior month crizotinib chemo prior dont drug hand list right reason chang med crizotinib alectinib size progress primari lesion later left upper lobe discoveri brain met stereotact lung radiat oct stereotact brain radiat jan resolv met lung lesion stabl date howev size reduct sinc alectinib quarter cts unabl tell lung lesion scar tissu diagnos age feb stage iv nsclc met never smoker healthi except hypothyroid year synthroid activ nd hand smoke asbesto radon alway organ white femal etc etc etc',\n",
       "  'JJ'),\n",
       " ('thank everyon kind repli it help know other gone know like eyesight emot point view i spoke gp monday sign coupl week i dont get anxious work plus hope current haemorrhag drain bit second lot laser today surgeon unabl complet session said view quit hazi place recent bleed least manag he said could also see laser last week look good becaus current bleed delay next laser week allow hope clear he said know stage i would need vitrectomi i suppos depend current bleed clear he reassur second time i go lose sight he said vision good retina look healthi undamag asid neovascularis reassur i dont think im entir go convinc ive told stabl appar version condit call florid happen rapid sinc last screen septemb i switch vegetarian vegan diet bg control general health run improv rapid result i feel super healthi energis seem sad consequ happen my dsn told carri lifestyl level control better long term i follow appoint eye clinic next friday see im thank everyon',\n",
       "  'NN'),\n",
       " ('busi wire fda approv atezolizumab combin genentech member roch group today announc us food drug administr fda approvedatezolizumab tecentriq combin avastin bevacizumab paclitaxel carboplatin chemotherapi initi firstlin treatment peopl metastat nonsquam nonsmal cell lung cancer nsclc egfr alk genom tumor aberr this tecentriq regimen demonstr signific surviv benefit initi treatment metastat nonsquam nonsmal cell lung cancer said sandra horn md chief medic offic head global product develop today approv support combin approach tecentriq lung cancer vision develop medicin improv outcom patient complex diseas this approv base result phase iii impow studi show tecentriq combin avastin chemotherapi help peopl live signific longer compar avastin chemotherapi median overal surviv os versus month hazard ratio hr percent ci p intentiontotreat wildtyp ittwt popul the safeti profil tecentriq combin consist observ previous studi genentech work fda postmarket commit pmcs better understand character potenti effect tecentriqrel antidrug antibodi ada neutral antibodi nab across studi an analysi ada impow studi show impact efficaci tecentriq tecentriq also approv fda treat peopl metastat nsclc diseas progress follow platinumcontain chemotherapi progress appropri fdaapprov target therapi tumor egfr alk genet alter for qualifi genentech offer patient assist program peopl take tecentriq genentech access solut doctor contact genentech access solut read',\n",
       "  'NN'),\n",
       " ('the new england journal medicin jeancharl soria md phd gustav roussi cancer campus univers parissud colleagu phase iii flaura trial shown signific progressionfre surviv benefit thirdgener epiderm growth factor receptor egfr tyrosin kinas inhibitor tki osimertinib tagrisso vs standard egfr tkis previous untreat advanc egfr mutant nonsmal cell lung cancer nsclc osimertinib select inhibit egfr tkisensit egfr tm resist mutat studi detail in the doubleblind trial patient site countri advanc egfr exon delet lr mutat random decemb march receiv osimertinib mg daili n standard tki treatment consist gefitinib iressa mg daili erlotinib tarceva mg daili n the standard tki select trial site except unit state site use erlotinib random stratifi accord tumor egfr mutat status exon delet lr race asian nonasian read perspect studi suresh s ramalingam md treatment continu diseas progress unaccept side effect withdraw consent treatment beyond diseas progress permit set continu clinic benefit a protocol amend allow patient standard tki group cross osimertinib blind confirm diseas progress postdiseas progress document tmposit mutat status the primari endpoint investigatorassess progressionfre surviv osimertinib show efficaci superior standard egfr tkis firstlin treatment egfr mutationposit advanc nsclc similar safeti profil lower rate serious advers event jeancharl soria md phd tweet quot for osimertinib vs standard tki group median age year vs femal asian white vs never smoker one patient world health organ perform status vs adenocarcinoma histolog metastat diseas vs viscer metastas vs central nervous system cns metastas exon delet lr mutat in standard tki group patient receiv gefitinib receiv erlotinib progressionfre surviv at data cutoff median durat total treatment exposur month osimertinib group vs month standardtki group patient continu receiv studi treatment median progressionfre surviv month osimertinib group vs month standardtki group hazard ratio hr p a consist benefit osimertinib observ across predefin subgroup includ asian hr confid interv ci nonasian patient hr ci patient exon delet hr ci lr mutat hr ci accord smoke histori hr ci never smoke hr ci median progressionfre surviv vs month among patient cns metastas hr p vs month among without cns metastas hr p object respons observ vs patient odd ratio p the median durat respons vs month data overal surviv immatur interim analysi matur the surviv rate month vs hr p nonsignific interim analysi after diseas progress osimertinib group standardtki group receiv first subsequ anticanc therapi standardtki group receiv osimertinib osimertinib in emegfremmut lung cancer osimertinib signific improv progressionfre surviv vs standard efgr tki treatment the benefit observ across examin subgroup includ among asian nonasian patient accord egfr mutat type advers event advers event grade occur osimertinib group vs standardtki group common osimertinib group decreas appetit chang qt interv observ vs patient fatal case torsad de point prolong qt interv either group interstiti lung diseas report vs serious advers event occur vs serious advers event includ qt prolong one osimertinib patient interstiti lung diseas six osimertinib four standardtki patient advers event led dose interrupt vs dose reduct vs discontinu treatment vs advers event led death patient osimertinib group pneumonia respiratori tract infect cerebr infarct myocardi infarct pulmonari embol intestin ischemia patient patient standardtki group sepsi patient pneumonia endocard cognit disord pneumonia peripher arteri occlus dyspnea hemoptysi diarrhea gastrointestin hemorrhag respiratori failur circulatori collaps death specifi none death osimertinib group one death standardtki group due diarrhea consid possibl relat studi treatment the investig conclud osimertinib show efficaci superior standard egfr tkis firstlin treatment egfr mutationposit advanc nsclc similar safeti profil lower rate serious advers event disclosur the studi fund astrazeneca for full disclosur studi author visit wwwnejmorg refer soria jc ohe y vansteenkist j et al osimertinib untreat egfrmut advanc nonsmallcel lung cancer n engl j med relat articl osimertinib a new standard care initi treatment egfrmut nsclc suresh s ramalingam md dr ramalingam professor hematolog medic oncolog emori univers school medicin winship cancer institut atlanta mutat in epiderm growth factor receptor egfr gene discov these mutat local common',\n",
       "  'NN'),\n",
       " ('hi peopl just curious i told begin tysabri administ month i other six week infus wether i find i start feel wors come week four five mayb reason month i still feel wonder drug mani say leastbut i function unlik tri gilenya',\n",
       "  'NN'),\n",
       " ('hi nell i worri chemo i imag grandmoth underw treatment throat cancer i diagnos stage iv didnt see point treatment then someth chang sheer determin set i start chemo know expect there urgenc get chemo start right away due lymph node involv my port went next day it blur the medic team great job get us prepar side effect minim my tumor start shrink pretti quick first dose carboalimtakeytruda now im take oral target therapi feel much better whatev decid group help pull weve theredon michell',\n",
       "  'NN'),\n",
       " ('atlanti wonder april your get ocrevus ms diagnos avonex copaxon member ms board sinc repli with quot the follow user say thank howi jeani z jendi sunshin',\n",
       "  'IN'),\n",
       " ('ok thank make feel littl better remicad i ask gi the thing mention humira or i go i see come wednesday so far crohn thing seem like go disabl the thing i lower stress level i read i work high stress job manag i might consid retir anyon got thought remicad versus humira get high stress environ',\n",
       "  'NN'),\n",
       " ('on nov am melissa wrote my husband stage four nslc cure onli chemo qualifi last night said feel death take bodi he said doesnt think make april he still doesnt look sick is possiblepleas read thru post chucksan wife experi my wife remiss sinc last nov year stage nsclc squamous cell in aug doctor said mayb month after uncessess chemo doubl treatment went clinic trial jan year later fda approvedimmunolgi drugcal opdivo nivolumab there two other keytruda terentriq these new type drug mani case offer improv possbl remiss there new drug time test the outlook stage lung cancer improv dramat previous year there hope get second opinion happi oncologist my wife new doctor knowledg access clinic trial drug most doctor local smaller cancer clinic dont look best lung cancer treatment closest larg metro citi cancer clinic hopsit mani connect med school all the best',\n",
       "  'JJS'),\n",
       " ('hi my mom diagnos stage iv nsclc egfr earli decemb in januari start iressa fine month then mom start show terribl stomach symptom at first thought side effect iressa symptom got bad mom unabl eat blood test show elev liver enzym iressa stop then found mom esophag thrush and h pylori infect due prolong steroid use my mom quadrupl therapi omeprazol amoxicillin clarithromycin dyflucan get much better iressa almost month dure part treatment mom omeprazol twice day my mom onc say iressa wont work mom take ppi twice day my mom gi doctor said could attempt stop ppi antibiot done said gastriti usual take anoth week complet resolv the gi doctor said could tri decreas ppi day take pepcid twice day my mom onc say mom need stay omeprazol twice day recommend mom tri alimta interim gastriti resolv im look inform take tki omeprazol peopl experi alimta pemetrex term side effect ani account experi would help',\n",
       "  'NN'),\n",
       " ('md prof g drk i resend email brazilian associ multipl sclerosi abem health initi msbrain health possibl adopt countri use cladribin altern shortag dmts mani citi i hope soon get touch face brazil found similar problem peru',\n",
       "  'NN'),\n",
       " ('hi all i wonder anyon take fingolimod kind side effect i particip clinic studi right diagnos month ago rrms i take pill month notic hair fall much frequent i brought neurologist said wasnt side effect i curious anyon els experienc issu besid ive stomach bowel problem pretti common let know thought',\n",
       "  'VBD'),\n",
       " ('i read studi claim botox work treatment depress they posit first doubt efficaci well come hang hollywood im pretti sure shit aint werkin there lot depress frozen actress realli im smile ok i basic forgotten i ms last month i get certifi dive hang friend explor basic best time ever my bodi love sun love swim ocean make hand feel normal boat mean i dont run i dont get ting leg yay but back realiti i got word doctor white blood cell start come aliv mean bcell wake start eat brain time go back vampir land get infus so here latest ms drug news rant i drug call rituxan it around year it high effect safe it blood cancer wide prescrib autoimmun diseas long time my insur doesnt want cover i month due i search infus center there new drug call ocrevus ocrelizumab i first heard dinner doctor nanci davi race eras ms peopl they herald ocrevus closest thing cure ever super excit this last year the fda approv march th public use so read bunch articl paper blog thought rituxan first drug work bcell ocrevus second all ms drug work tcell honest i dont realli know mean illustr similar drug they manufactur compani rituxan never put clinic trial ms rituxan came patent compani allow start make generic version price went befor happen genentech start develop ocrevus same compani make drug basic mechan action diseas to fair rituxan chimer molecul mean dna part human part anim mous so peopl could allerg reaction mous part drug if reaction it usual happen first coupl time get monitor give iv steroid case ocrevus human believ better toler but one ocrevus longer year peopl develop cancer tumor rituxan increas cancer peopl take year whi wouldnt stick safe drug alreadi work rather abandon start scratch cuzmoney after last infus i got bill my insur didnt want pay medicin use label my doctor wrote letter say import i receiv time went back forth final agre pay time next time now i suppos get week two my insur cover i get pharmaci my doctor work hospit give medicin bought pharmaci so i want doctor give infus cours i would pay pocket the infus last hour hook iv machin i go twice next coupl week if i bad reaction happen shit show team surround deal so order insur cover bill i go infus center mayb hour away stranger without doctor cuzmoney everyon want bill asshol this american medic industri complex and tell next time i switch ocrevus new breakthrough drug which isnt breakthrough mechan year old drug expens higher cancer rate cuzmoney link httpwwwhealthnewsrevieworgfakebreakthroughfakenewsonephysicianresearcherstakeawaynewscoveragemsdrugocrevus httpwwwwheelchairkamikazecomleadingmsclinicissuescautionaryhtml appar europ get rituxan ms pretti freeli way less expens so someon social health care countri need marri next month time next infus sweden leader i think prescrib rituxan soanyon here cherri blossom marri other thought what i noth what would happen i get medic hamster wheel live life doe anyon just eat healthi stay drug you never know go happen ms anyway mayb i super mild form drug noth anyway mris give radiat drug throw everyth wack not sure denial fda approv form treatment that studi id will particip just live sea play music go dive swim eat healthi happi that sound like much better treatment ill need rememb terri wahl protocol modifi paleo diet exercis etc shes ditch drug treat diseas lifestyl chang it damn hard though i well awhil fell mayb worth anoth go she finish first clinic trial confirm plan improv mood cognit function depress it doesnt say anyth diseas progress mobil though here link httpwwwmsviewsandrelatednewsblogspotcomamultimodalnonpharmacologichtmlutmsourcefeedburnerutmmediumfeedutmcampaignfeedablogspotfygjvstusviewsmsnew well i thought thing drug futur ill leav move xx',\n",
       "  'JJ'),\n",
       " ('hi larri husband start tagrisso today he alreadi chemo radiat summer immunotherapi stage stop hope help what side effect wife drug help confus start happen',\n",
       "  'JJ'),\n",
       " ('hi adam i follow past two year we live palo alto son diagnos he great remicad built antibodi he start entyvio hes load phase not sure want go im wonder uc manag lialda alon i dont want add drug all frighten he doesnt want stay drug i dont want either i agre stress huge need get colleg veri concern long term affect med he say hed rather colon obvious issu strict diet tough colleg student yes drink alcohol do feel dr young stanford best how ucsf thank your inspir',\n",
       "  'NN'),\n",
       " ('hey guy i flare back june due antibodi entyvio i gotten mg bump back mg i start taper august i current mg we taper slower time mg week i howev feel like i realli harder time time around i also think thyroid may my hair fall profus tongu swollen normal regular period day late thing like fatigu crossov symptom those end need endocrinologist ask pcp gi referr also think i would benefit yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mgs pred',\n",
       "  'VBD'),\n",
       " ('thank steff tom my mom non small cell adenocarcinoma start alimtacarbokeytruda next week we still wait gene test come back target therapi may still option im happi know standard practic i still feel like i research clinic trial special food eat someth help it go hard sit back let oncologist follow plan wait see happen the doctor answer goal treatment well respond toler treatment when i mention second opinion consult research hospit ego kick blew i dont understand goal treatment slow growth reduc cancer spread gain month life etc what understand thank',\n",
       "  'JJ'),\n",
       " ('hi everyon realli big deal progress noth tea sympathi far i worri deafen silenc ocrelizumabocrevus we talk neuro let them know we know what come assum approv medic get use idea someth progress cheer dave',\n",
       "  'NN'),\n",
       " ('as leav lung cancer awar month thought might like review lung cancer headlin weve seen obr far import perhap controversi juli receiv anoth draft recommend us prevent servic task forc uspstf screen time lung cancer aim primarili heavi smoker if adopt standard care medic practic peopl atrisk annual low dose comput tomographi ct screen could save live find lung cancer sooner still treatabl but without controversi read find pipelin hit some talkedabout drug pipelin lung cancer pdpdl next generat immunotherapi merck mk bristol myerssquibb nivolumab roch mpdla theyr class compound design disabl program death protein call pd pdl prevent immun system spot attack cancer cell in european cancer congress ecc present septemb earli stage trial patient nonsmal cell lung cancer nsclc whose tumor treat mpdla saw tumor shrink the respons rate smoker even encourag compar patient never smoke roch pdl inhibitor call potenti game changer lung cancer first target drug show activ difficulttotreat group smoker nonsmok at world confer lung cancer wclc octob bristol myersquibb releas addit surviv data earli stage studi pretreat patient nsclc nivolumab show extend live lung cancer patient fortytwo percent treat patient aliv year two year merck mk show posit result earli data small trial also present wclc out patient studi whose cancer stop respond earlier round treatment immunesystem respons mk patient experienc tumor shrinkag in august eli lilli co said necitumumab imcf combin standard chemotherapi agent extend overal surviv latestag studi patient squamous form nsclc spread part bodi the compani plan seek us approv necitumumab firstlin treatment and lilli ramucirumab improv surviv latestag trial stomach cancer latestag trial lung cancer then there ariad ap good chanc approv alkdriven lung cancer novarti two promis new compound auy ldk might also treat alkmut lung cancer the list lung cancer therapi pipelin doesnt end screen those atrisk smoke account lung cancer evid year annual screen peopl histori smoke might save live in juli uspstf recommend current former smoker histori smoke pack day year well quit within last year get annual screen low dose comput tomographi ct expert said annual death lung cancer could avoid guidelin adopt the task forc weigh benefit earli cancer detect risk patient those risk includ exposur radiat ct scan number fals posit scan might turn could lead overtr patient some expert also concern screen recommend might send wrong messag peopl ie okay smoke in septemb two new studi publish new england journal medicin made good case task forc recommend research found annual lung cancer screen low dose ct scan could success detect malign tumor spread part bodi and annual screen three year period use ct scan caught earli stage lung cancer chest xray improv abil accur detect cancer year year the current draft recommend sync american societi clinic oncolog asco nation comprehens cancer network nccn organ recommend lung cancer screen low dose ct scan atrisk sinc may with afford care act play medicar insur would cover scan elig patient without copay deduct the public comment period end august final recommend task forc expect time ecigarett kid fda twice mani us middl high school student use electron ecigarett mimic tradit cigarett deliv nicotin vapor year center diseas control prevent cdc said septemb the govern report warn increas use hookah cigar ecigarett yet subject fda regul flavor like fruit candi gateway young peopl lifelong addict use stronger tobacco product the public health threat seen troublesom uspstf recommend august physician counsel teen adolesc danger tobacco smoke routin offic visit antismok advoc public health group said fda hasnt move fast enough issu regul addit tobacco product air that could kill you anoth carcinogen offici identifi lead caus lung cancer year air breath in octob world health organ who offici classifi air pollut human carcinogen the risk who said breath secondhand smoke air pollut would classifi among group human carcinogen cancercaus substanc like tobacco smoke asbesto ultraviolet radiat news report came around world yearold girl jiangsu provinc youngest person record china diagnos lung cancerth countri air pollut blame culprit fda activ let forget sever fda approv year lung cancer boehring ingelheim gilotrif afatinib approv juli patient late stage metastat nsclc whose tumor express specif type epiderm growth factor receptor egfr gene mutat detect fdaapprov test on may coba egfr mutat test roch becam first fdaapprov companion diagnost detect egfr gene mutat intend use tarceva erlotinib roch drug expand use firstlin treatment patient nsclc whose cancer metastas egfr gene mutat',\n",
       "  'NN'),\n",
       " ('hello ive ms year offici new consult believ show syptom year diagnosi ive inject bad side effect im tecfidera moment use flush wasnt much issu ms control could still anyth want ive stop kickbox im ive relaps nerv painfatigu emot stuff etc ms doctor advis consid chang medic option first stay drug isnt good doctor mention aubagiogilenyalemtrada mavenclad two tablet two infus ive told consid chang ive tri research would best honest im total confus anybodi give advis medic side effect etc would grate thankyou read post',\n",
       "  'NN'),\n",
       " ('lorri we similar journey my husband also lepto he finish wbr pulsedos tarceva he start intrathec chemo depocyt friday do mind tell kind chemo mom best wish mom emili',\n",
       "  'NN'),\n",
       " ('g edan depart neurolog chu renn renn franc there two contrast treatment regimen ms induct versus escal the rational behind escal therapi treatment start safe drug move aggress one ongo treatment fail in escal approach interferon beta glatiram acet teriflunomid bg regard firstlin drug immunosuppress mitoxantron natalizumab fingolimod alemtuzumab ocrelizumab secondlin one intens immunosuppress autolog bone marrow transplant highdos cyclophosphamid thirdlin one the key success escal therapi defin upfront patient exact suboptim respons threshold nextlevel therapeut option introduc given immunosuppress current avail present potenti serious side effect induct strategi general reserv patient activ aggress diseas in patient acknowledg risk earli disabl neurolog function lost cannot regain this diseaseinher risk assum outweigh associ use power immunosuppress this treatment strategi involv use immunosuppress minimum amount time need gain adequ control diseas activ onc diseas control achiev treatment switch mainten therapi better toler drug a randomis studi demonstr induct mitoxantron follow mainten treatment afford better diseas control monotherapi interferon beta natalizumab also effect propens result rebound inflammatori diseas activ withdraw more recent mere day cours intraven perfus alemtuzumab found bring longterm clinic benefit earli relaps ms patient this approach may use conserv mean use high effect therapi whilst minimis exposur attend safeti risk disclosur dr edan report grant person fee bayer merck teva pharma novarti person fee biogenidec sanofi lfb',\n",
       "  'NN'),\n",
       " ('gilenya made feel amaz techfidera howev didnt agre stop itgood luck im sure make best choic x',\n",
       "  'NN'),\n",
       " ('did anyon els gain weight gilenya thank respons i realli appreci ani inform med help i know everyon differ help thank',\n",
       "  'NN'),\n",
       " ('lol im go give talk american healthcar the peopl seem go er constant get c diff infect c diff infect board american ive never case c diff life yes stool cultur done everi time ive hospitalis incident i didnt visit ae first time year diagnosi you carri terrifi social medicin i carri get vedolizumab infus safe knowledg i civilis system treat whenev i fall ill matter littl money i that it call progress edit sorri i lost temper bit i dont mean tar american brush i know mani reason peopl arent terrifi bogeyman simpli struggl get best care system like i struggl mine post edit nicecupoftea am gmt',\n",
       "  'NN'),\n",
       " ('i think start chariti reason idea pay cladribin ani money rais use support ms research project your chariti could bypass ineffici say ms societi spend larg proport money administr',\n",
       "  'NN'),\n",
       " ('whi ocrelizumab you cant revers ocrelizumab therefor would need confid diagnosi would test wait result',\n",
       "  'NN'),\n",
       " ('im well inflectra biosimilar remicad shrug leftsid coliti dx current inflectra imuran mg saccharomyc boulardii xday wheatfre g lialda month caus migrain stop work budesonid mg week noth mg humira week week develop antibodi',\n",
       "  'NN'),\n",
       " ('mous dr ocrelizumab show reduct but possibl infect compar say dmt copaxon and copaxon better protect without infect i miss someth biotin polysaccharid a psa gut bacteria',\n",
       "  'FW'),\n",
       " ('the american societi breast surgeon asbr week releas recommend genet test hereditari breast cancer the societi say genet test made avail patient person histori breast cancer in contrast guidelin nation comprehens cancer network nccn recommend test hereditari mutat breast cancer patient depend varieti factor includ famili medic histori age diagnosi ancestri for peopl havent receiv breast cancer diagnosi asbr recommend follow nccn guidelin test support new asbr guidelin contend follow narrow guidelin test breast cancer patient lead patient hereditari mutat miss howev other express concern new guidelin could lead overtreat whether increas screen would save live realli unknown oti brawley john hopkin univers baltimor told washington post it known increas cost and pretti assum increas number women get prophylact surgeri shrink dispar africanamerican like die cancer white american but gap narrow accord feb report american cancer societi ac in black men percent higher risk death cancer white men excess risk fallen percent excess risk fell percent percent black women period j leonard lichtenfeld act chief medic offic ac explain npr declin lung cancer due fall smoke rate africanamerican play major role mortal improv i cant say smoke decreas dramat black communiti fact good news told npr immunotherapi glioblastoma a trial test immunotherapi patient recurr glioblastoma found start checkpoint inhibitor keytruda pembrolizumab prior surgeri diseas live longer receiv drug surgeri longer typic patient recurr glioblastoma the result publish feb natur medicin for patient random receiv keytruda surgeri median length surviv day compar day patient start keytruda surgeri continu drug surgeri complet previous attempt use checkpoint inhibitor patient glioblastoma larg unsuccess the research hypothes give drug presurgeri set tumor still present allow activ immun cell associ tumor frederick lang md anderson cancer center houston involv studi told stat this studi realli infus hope back field checkpoint inhibitor may effect use correct way',\n",
       "  'RB'),\n",
       " ('thank jim i hope get month tagrisso kempten', 'JJ'),\n",
       " ('your brother stage lung cancer lung liver spine rib shoulder it metastis spread usallytoo latefor surgeri radiat what exact chemo long this import know he might better target chemo immunolog drug opdivo keytruda tercentiq give us much detail info citi treat top cancer center hospit local oncologuist my wife stage squamous cell one lung spine rib lymph node brain year ago month chemo radiat help she got clinic trial drug opdivonivolumab two year later fda approv anoth month she remiss evid diseas month total month origin diagnosi back pain these new drug lead edg cancer posit respons extend lfe even remiss my wife patient good result there hope but brother must act make sure top cancer clinic usual larg metro citi also oncologist special lung cancer sometim ask find best lung cancer doctor ask second opinion great idea reason wife still aliv our first doctor general medic oncologist access clinic trial drug some drug also test along second drug combo opdivoepacadostat also keytrudaepacadostat these drug also quit efect stage melanoma there areoth combosb test encourag result see post info wife battl lung cancer be sure brother biomark aka dna mutat test test see pd pdl that let oncologist know drug might work best import oncologist hasnt done test get second opinion if oncologist never heard epacadostat need chang i realli question radiat stage all best chuck',\n",
       "  'JJ'),\n",
       " ('breakfast scientif session vitreoretin lymphoma dean eliott diabet retinopathi current investig therapi allen ho mysteri antivegf switch case mysteri case david chow antivegf switch case keyvan koushan antivegf switch case geoff william antivegf switch case geoff william antivegf switch case keyvan koushan mysteri case john galic mysteri case sohel somani codevelop accredit symposium multidisciplinari care diabet macular edema bayer sponsor symposium codevelop bayer plan achiev scientif integr object balanc multidisciplinari care diabet macular edema david maberley alic yy cheng peter j lin refresh break scientif session ocular manag trauma dean eliott medic manag pvr dean eliott an individu approach posttraumat exploratori vitrectomi children young adult theodor stappler molecular design novel ocular tamponad theodor stappler panel discuss manag complex retin detach',\n",
       "  'NN'),\n",
       " ('in compars treatment low cost antivascular endotheli growth factor vegf drug bevacizumab avastin expens altern aflibercept eylea ranibizumab lucenti cost effect diabet macular edema new studi found aflibercept ranibizumab time expens bevacizumab approv treatment cancer frequent repackag label treatment retin vascular diseas diabet macular edema dme caus swell retina macula abnorm blood vessel growth common caus vision loss among peopl diabet retinopathi vegf stimul growth abnorm blood vessel antivegf drug administ intravitr inject',\n",
       "  'NN'),\n",
       " ('minnietoti constant fatigu issu us chronic diseas my gi pcp told caus blood work look good doesnt mean feel great you bodi take time recov sinc flare take get back normal hope also keep mind mental fatigu issu well blood test confirm this bad wors physic fatigu the best thing i done recent month ago i start see therapist his first question take long i decid need help he said chronic ill caus anxieti depress host issu make diseas wors he bless help get current ordeal encourag file long term disabl you make need drastic discuss help look thing differ import i hope help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio g medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqui xanax er',\n",
       "  'NN'),\n",
       " ('my year old husband diagnos stage octob had two round chemo lobectomi rib resect remov cm upper right lobe tumor he recov well surgeri follow radiat complet april ct scan radiat discov tumor adren gland had adrenalectomi june next ct april came back good recent octob show lesion spleen one lymph node lung had pet scan confirm activ doctor say biopsi need so suggest treatment carboplatinum almita keytruda he tp stk mutat im hope work seen top oncologist univers chicago sudden i feel dont lot answer im consid second opinion ani advic',\n",
       "  'NN'),\n",
       " ('thank janin so mom current hospit recov slowli pneumon discharg day soon onc lung resolv i still curious doctor forum opinion term next treatment option eg resum tagrisso lower dose previous mg daili week or tri one treatment i propos eg afatinib immunotherapi other im sure there evidencedbas treatment choic moment want get good opinion prior discuss option mom primari oncologist on side note recent brain mri show signific reduct tumor lepto diseas month start tagrisso numer spot spot she also asymptomat term headach brain symptom sinc start treatment given worth rechalleng tagrisso lower dose look forward hear back thank advanc best hain',\n",
       "  'NN'),\n",
       " ('hi cathi i betaseron inject i tire side effect lump inject sight anyway next appt neurologist i go ask ocrevus whether fit best luck decis',\n",
       "  'NN'),\n",
       " ('i diagnos w sever ra general practition discov blood test alway common well mtx pillsa wk yrs arava daili i also enbrel humira actemra orencia zeljanz one work didnt i final start remicad infus the first day i slept hrs day later chang yesterday the miracl day one singl pain flare up pain free omg i happi i cri today good yesterday im hope good luck rest',\n",
       "  'VBP'),\n",
       " ('have diagnosi chang coliti crohn happen quit regular youv done amaz well consid wrong diagnosi medic that pretti much useless i think youv certain made right decis progress humira remicad would first choic humira proven effect therapi it hard say youv done well your first dose humira experienc syptom you might need time drug reach strong therapeaut level youll like need stay cours wait awhil longer if thing dont improv come week youll need see gi like updat bloodwork diagnost done in meantim tri switch low residu diet it give thing chanc calm if thing get realli bad gi might suggest short cours prednison patch better assess humra takn hope your feel better soon',\n",
       "  'NN'),\n",
       " ('bethani you may want look tessalon perl prescript cough suppress my mom took stent trachea made cough like crazi it help quit bit i dont recal make sleepi as far treatment goe mom first round treatment week lobectomi month diagnosi as mention everyon differ she wait long take ra med system start surgeri for recurr began treatment week two test came back except pet side effect everyon is differ first time mom platinum base chemo radiat week she felt pretti good throughout entir treatment typic lack energi also realli bad acid reflux control cocktail med for recurr carboalimta keytruda immunotherapi everi week first session fine second session start typic side effect chemo even though second bout chemo much tougher made minim help continu main caregiv dad disabl now keytruda okay despit short breath may may caus keytruda the side effect itchi skin use counter excema cream help bit dont know help thought id share take care steff',\n",
       "  'NN'),\n",
       " ('home ms inform public ms research updat zinbryta daclizumab zinbryta daclizumab in updat main articl introduct fdaapprov medic experiment medic new direct ms research close note approv diseasemodifi therapi ms pdf refer fdaapprov medic new data withdrawn from market compani biogen abbvi mg given via subcutan inject month approv rms voluntarili withdrawn market march previous ocrevus next tecfidera in earli march biogen abbvi announc voluntari worldwid withdraw zinbryta relaps ms the move came european medicin agenc rais new safeti concern relat report inflamm brain surround tissu inflammatori enceph meningoenceph among peopl take immunemodul therapi becaus previous identifi risk medic general reserv use peopl experienc inadequ respons two ms medic to minim potenti confus disrupt care individu take zinbryta fda work close medic manufactur ensur medic withdraw market as ms research updat publish manufactur zinbryta plan medic avail need april peopl take zinbryta told contact doctor instruct stop zinbryta switch medic immedi tell new unexplain symptom the withdraw zinbryta underscor fact clinic trial matter larg rigor perform cannot identifi safeti issu may emerg medic move widespread use follow approv fda regulatori agenc countri at time clinic trial reveal safeti consider prompt medic fdaapprov indic note general use patient satisfactori respons least two medic similar would appear postapprov surveil system work well flag rare serious condit may associ use zinbryta previous ocrevus ocrelizumab next tecfidera dimethyl fumar',\n",
       "  'NN'),\n",
       " ('nice assess ocrelizumab primari progress ms ppms decid whether prescrib nhs england wale scotland northern ireland carri separ apprais what mean peopl ms there current licens treatment ppms the ms trust fulli commit support peopl ms get best appropri treatment hope ocrelizumab made avail peopl ppms we undertaken survey peopl ppms specialist ms health profession gather view nice apprais gather near respons we submit formal respons nice explain think ocrelizumab made avail nhs cladribin approv scotland the scottish medicin consortium smc approv mavenclad cladribin treatment activ relaps remit ms read decis read cladribin nhs england updat account care there fix definit account care broad speak areabas model healthcar provis perhap better describ integr care organis work togeth meet need local popul account care aim improv popul health tackl caus ill wider determin health some form account care involv local author third sector alongsid nhs organis work toward object a king fund brief state develop account care england hold promis differ way work nhs emphasi place popul system rather organis there public concern account care contract legal challeng launch challeng shift annual budget popul rather payment servic use model nhse announc consult contract arrang account care organis if youd like know account care complex hous common librari produc brief paper recent govern announc blue badg scheme consult elig the depart transport current consult elig blue badg the dft look clarifi regul guidanc ensur equal issu address pariti physic nonphys disabl the consult propos consid automat rout blue badg anyon pip score chang word current regul focus difficulti physic nonphys experienc journey rather physic act walk the consult open',\n",
       "  'JJ'),\n",
       " ('op final better type googl humira lupus first thread came yes i recent diagnos humira induc lupus i year old male diagnos crohn diseas earli i went year larg resect done ileostomi year first surgeri i probabl one first peopl radic resect also abl talk doctor tri perform reanastomosi so coupl year initi diagnosi cut crohn anoth year iliostomi i even close stabl i live short bowel syndrom year i deem flare look back event trigger seri smaller event made life overwhelm i becam overwhelm sick crap brain inde rough part three month bout seem like flu yet i immedi shepherd toward remicaid i fail interferon gold test twice pass third tri when six month infus countless respiratori tract infect later i swap humira i complain remicaid didnt seem realli help anyth my neuropathi start remicad quick start journey painstak slow process two job countless doctor endless lost hour accentu fear pain five year life unfold like final better describ although i go cleveland clinic test ana they also found i b i regular treat b due pernici anemia much colon resect am i mad gastroenterologist feel better situat well hell yes here guy whos treat humira collect everi time pass go year colonoscopi egd five year i tell problem ach joint neuropathi swell finger ankl etc last colonoscopi even three month ago meet prior day i get scope i say guy check everyth take mani sampl test everyth i mean mind numb pain lyrica ive swallow get even littl relief i get less pride sensit bullcrap last five year worn so i slight disagr constitut test everyth give stori xyz isnt part special darn last time i check i thought treat autoimmun diseas scope everi year make excus i need answer so sound touch lash im sent book colonoscopi appoint im still realli shaken ai tell nurs i want see gastroenterologist dr g doesnt seem like want work she book scope appoint anyway say call back see anoth doctor a coupl day pass i get call good old dr g tell cant test doesnt know send sampl well i thought ith time drew blood actual sent lab hes confus it chines menu man frickin order everi test sun bill paid im good whatev test could possibl cost then end convers high hand remark tri outsmart said matter fact anyon ive ever heard well arent go cleveland clinic mayb answer im lay bed cant sleep wonder i ever deserv and yes later i get answer gastroenterologist schmuck real a class he knew i constant pain yet i complain well im doctor i must sucker paint im go clinic tomorrow im go file complaint im go gather medic record facil tell complianc offic seal record i know ever would trail first thing good doctor chang offici record im go somewher els see gastro doc understand im belli ach caus even greater harm im mad i could spit these past five year humria great poor old butthol cost neuropathi ive watch tooth tooth cap i lost teeth past five year time life humria great crohn otherwis live hell pain neuropathi thousand dollar hour wast one measli blood test if your humira photo aural sensit teeth fall ankl finger look like stuf sausag take humira poison',\n",
       "  'NN'),\n",
       " ('hello everyon father diagnos stage nsclc met bone brain he tarceva month felt better within coupl week take tarceva scan two month show mix respons pretti much stabl diseas lung brain growth bone after anoth biopsi find tm mutat egfrlrmutationhi doctor switch tagrisso anyway hope would work better brain he anoth scan approx week tagrisso result pretti much stabl diseas brain growth bone after made switch tagrisso start feel littl worst everi week wasnt anyth dramat someth i famili member notic seem tire appetit also got worst it could side effect due tagrisso main concern reason tagrisso might effect tarceva he weak fragil first start tarceva actual abl gain back weight month take lose weight sinc take tagrisso i understand tagrisso suppos work egfr patient even without tm i also saw earlier studi indic respons rate tmnegat patient around make whole thing confus i could wrong i think mani studi trial shown first gen tkis like tarceva iressa high respons rate egfrexon patient someth rang question make sens someon stop tagrisso go back tarceva condit continu deterior given fact doesnt tm origin respond oktho perfectto tarceva sorri long post advic great appreci',\n",
       "  'NN'),\n",
       " ('updat decemb signific research advanc made offer new lead toward vision world free ms the societi research portfolio project activ manag societi invest million new ongo research project initi around world we support collabor innov conven thought leader leverag new technolog data invest train ensur robust futur workforc learn diseas funder peopl live ms this year first therapi specif primari progress ms approv fda progress occur mani approach identifi solut peopl live ms today ultim lead prevent cure here brief summari signific research progress initi aim stop ms track restor function end ms forev stop ms toward new therapi new understand fda approv ocrevus ocrelizumab peopl primari progress ms relaps ms the societi fund earli laboratori clinic work b cell therapi led first diseas modifi treatment progress ms in largest clinic trial yet children adolesc ms oral fingolimod gilenya reduc annual number relaps two year compar treatment interferon betaa avonex after two year fingolimod experienc relaps compar avonex group the trial also show benefit measur mri side effect similar seen adult popul this therapi isnt current approv treatment pediatr ms result phase trial oral ibudilast mn medicinova inc peopl progress form ms suggest signific slow rate brain atrophi shrinkag link cognit physic disabl ms an intern studi report longterm outcom bone marrowderiv stem cell transplant hsct peopl differ form ms after year still experienc progress worsen symptom eight death occur earli develop procedur improv patient select transplant techniqu reduc mortal those best outcom tend younger relaps ms less disabl use fewer ms therapi prior procedur addit research need better understand might benefit procedur compar benefit power immunemodul therapi avail the mcdonald criteria diagnosi ms revis hope speed diagnosi reduc chanc misdiagnosi an intern panel conven auspic intern advisori committe clinic trial ms sponsor nation ms societi european committe treatment research multipl sclerosi the panel publish revis the lancet neurolog onlin decemb avail free registr n small studi conduct oregon health scienc univers antioxid lipoic acid shown reduc rate brain tissu loss atrophi compar placebo secondari progress ms the societi agre help fund larger phase clinic trial evalu whether lipoic acid safe effect treatment progress ms a clinic trial unit kingdom began societi cofund test abil statin cholesterolreduc drug slow secondari progress ms restor what been lost myelin repair well rehabilit scientist cincinnati children hospit medic center fund societi nih report experiment therapi mir promot growth nerveinsul myelin improv function mice mslike diseas the team continu test similar molecul lab necessari step test peopl ms gladston institut research collabor show blood coagul factor call fibrinogen may enter brain ms inflamm hinder myelin repair in lab model reduc fibrinogen enhanc myelin repair suggest may futur strategi develop therapi repair myelin damag caus ms research queen univers belfast report immun cell call treg play role promot myelin repair pinpoint protein appear respons offer potenti target stimul myelin repair robin franklin phd lead scientist univers cambridg focus stimul brain repair mechan select recipi barancik prize innov ms research two studi research univers illinoi urbanachampaign shepherd center atlanta provid evid even peopl moder sever movement issu may benefit exercis intern studi show highintens aerob train improv cognit better standard exercis this research show import physic activ enabl peopl form ms live best live healthier diet lifestyl associ lower level disabl analysi survey involv peopl ms enrol narcom registri further studi need determin healthi lifestyl actual reduc ms symptom whether symptom interfer abil engag healthi dietlifestyl the societi fund sever studi diet approach advanc well solut research amsterdam report peopl ms healthi control show improv work memori brain activ connect part brain interact one anoth treatment repetit transcrani magnet stimul rtms this devic generat electromagnet puls stimul brain activ rtms may futur role cognit rehabilit peopl ms studi need the john dystel prize ms research went alan j thompson md dean univers colleg london faculti brain scienc pioneer research way address symptom improv qualiti life peopl ms leader driver intern progress ms allianc end ms explor risk factor understand prevent ms a largescal studi sweden suggest teen experi head trauma lead concuss especi signific like develop ms this find mean teen experi concuss develop ms research denmark boston fund part nation ms societi report newborn low blood level vitamin d increas risk develop ms later life ad grow evid low vitamin d level potenti risk factor ms new studi us germani fund part nation ms societi add mount evid potenti role intestin bacteria play brain inflamm under ms this offer hope probiot approach may develop test help reduc ms activ the societi support intern ms microbiom consortium project advanc research research collabor and leadership the intern progress ms allianc launch three collabor network award focus find breakthrough progress ms cofund leadership societi engag strateg plan addit activ acceler pace progress ms research research paper publish societyl initi focus well research patient cohortsregistri stem cell therapi clinic measur track ms progress benefit therapi the societi conven tykeson fellow confer build collabor cement commit promis young investig find solut ms with fund societi intern ms microbiom consortium began recruit particip effort identifi influenc good bad gut bacteria ms sever initi around world track peopl ms better understand diseas under patholog identifi driver progress make progress toward person medicin respond therapi best pcori patient center outcom research institut made new commit million studi compar benefit risk ms therapi rehabilit includ two studi compar earli aggress treatment vs gradual escal key question treat ms read yearend progress societi strateg plan avonex regist trademark biogen gilenya regist trademark novarti ag ocrevus trademark genentech member roch group',\n",
       "  'JJ'),\n",
       " ('ive ask neuro come decid i move next get low liver function result whilst gilenya claribin tecfidera suggest lean toward cladribin id interest hear anyon take work',\n",
       "  'NN'),\n",
       " ('after burdensom process insur first infus schedul we drove hour pour rain husband i tens got cleveland thursday night to make matter even better husband pack bag hotel car notic flat tire i cant even make stuff it funni he chang tire hotel park lot rain yuck i sat bed we got infus center friday morn littl bit wait earli i got seat nice littl reclin sat row across anoth row reclin there five other get infus got ocrevus except one man got rituxan i one get initi first dose anoth ladi get second half first dose other get six month dose the nurs calm help ton i nervous they put iv gave oral med consist tylenol benadryl they also gave small dose solumedrol iv then let spousesdriversvisitor come there wait hour ocrevus come pharmaci when arriv effici get start quick everyon about two minut start i got flush sat quick i ask nurs medicin would make hot assur i hadnt even time get medicin yet tri relax i realiz i small moment panic i sat back breath good they check vital everi minut record my bp temp great whole way my lip tongu start tingl i wasnt sure i say someth wonder anxieti side effect i went ahead told nurs one super concern wasnt bad enough stop med after increas ocrevus final time i notic face itch said someth husband point i break i ask let nurs know by time nurs arriv i hive face neck chest they quick deal they stop ocrevus administ iv benadryl pepcid someth els i cant rememb onc took effect hive disappear wait bit start ocrevus other loopi super sleepi benadryl i fine fwiw i didnt notic anyon els issu medicin all went well i havent notic major differ yet hour i tire i got back hotel we go go dinner i didnt feel like get readi go order pizza deliveri instead we much better drive home today im thank i got get medicin even though i feel like i complain time sinc diagnos i know fortun i hive super easi deal seem like easi trade treatment i feel right one just want share first experi dmt happen ocrevus well rest odd trip it certain one book',\n",
       "  'NN'),\n",
       " ('i year rebif im ttecfidera the miseri nusea wer horribl i restart due vomit i feel great i primperan nausea take capsul thin slice toast peanut butter i feel like i think willbfb ine time my neurologist told im better gilenya next',\n",
       "  'JJ'),\n",
       " ('older biolog humira remicad cheapest biolog insur tri get first reason in fact biosimilar closest thing generic biolog remicad ie inflectra also humira newer biolog like entyvioxeljanzstelara two three time cost remihumira there justifi reason might prefer xeljanz theyr safer simpl pill etc moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you never realli appreci youv got gone toilet paper good exampl nealzi regular member join apr post post pm gmt so week dosag remicad cost insur ml i hadnt yet gotten approv doubl dose move week gi i decid switch xeljanz actual work wherea remicad zippo the estim cost insur day suppli xeljanz mg pill bottl theyv told compar appl appl timefram week that k xeljanz vs remicad sure resist fact take month updat approv overal formulari someth get fda approv formulari whole preauthor appeal appeal process fortun pfizer interim servic hold free believ month suppli go approv given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post pm gmt we bcbs maryland also massachusett approv xeljanz the appeal handl quick although approv one pill day instead four our doctor offic realli top thing didnt take longer week recollect there downsid follow direct doc offic also call insur make sure went spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week curious crapper regular member join may post post pm gmt remicad cash price approxim per mg bottl so could extrapol whatev dosag get then factor cost infus if get hospit set cost usual lot clinic home infus servic the cash price list xeljanz month suppli mg day would ra patient get the cash price uc would doubl around k month these cash price though depend insur provid decid bill cover thing could make differ feelinglesscrappi new member join oct post post pm gmt i bcbs my doctor get approv bcbs didnt approv first dr explain current qualiti life approv nealzi regular member join apr post post am gmt veri help respons thank ill let know bcbs approv process differ side fda approv im week preauthor process bit longer readi taper mg pred monday st time sinc last year most hope continu sever pancol patient given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post am gmt blue cross blue shield maryland massachusett approv xeljanz us we appeal the whole process fast less two week i believ primarili i think doctor offic knew you feel free call doc offic also insur direct make sure realli submit correct specialti pharmaci spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post am gmt suzyq long spous prednison i see long took get wonder ive mg sinc april gis direct drop everi day so far good energi touch slow return eat still hook im current monday go day mg day assum xeljanz take uc ill get stuck whatev level i get stuck see spous experi im think either i need extend taper mayb suzyq spous pred high level year given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post pm gmt im realli glad hear xeljanz may work he steroid almost constant time diagnos even though full remiss octob xeljanz our lesson process gis understand prednison taper especi longterm he start feel quit ill oppos usual prednison lousi feel mg short breath memori issu usual also neuropathi seem get wors at point saw endocrinologist said taper correct may take longer shouldnt feel sick so went back slowli taper mg everi four week point went onto hydrocortison some depend toler feel lousi associ worri onc get mg may want go slower some peopl get low everi day see feel you alway go back level didnt feel lousi adjust thing go spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post pm gmt great advic one cut mg pred pill mani way dot powder thank i felt short breath occasion heart palpit like one week sluggish glad i ask year wow i cant imagin im pray uc symptom stay bay i taper cautious optimist thank share suzyq given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred andrina veteran member join aug post post pm gmt stewiecat said i start notic improv coupl week xeljanz im doubledos x mg twice per day seem dose guidelin uc interest im take x mg i spoke pharmacist said dose uc i guess outcom im glad i fewer pill swallow uc sinc suzyq regular member join sep post post pm gmt nealzi there mg prednison tablet end need slowli taper spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week feelinglesscrappi new member join oct post post pm gmt i think prednison taper depend person length time prednison i year last mg done month i felt fine nealzi regular member join apr post post am gmt feelinglesscrappi that good know im drop mg start tomorrow path month day rough taper mg complet xeljanz hold mg',\n",
       "  'NN'),\n",
       " ('i avastin inject myopic md uk work and i would dismiss old technolog i would dismiss anyth els proven time work well bicycl exampl we problem repackag us reason done correct done correct have work mani year drug develop i find research cost argument interest yes pharma need make profit cost manufactur distribut plough back develop paid salari year but case i find argument disingenu avastin came first lucenti simpli cut version avastin molecul made antibodi there theoret reason smaller peptid might better i dont think i seen heard benefit realis practic though peopl undoubt better one rather seem cut way as quit lot develop cost lucenti alreadi spent avastin i realli dont think justifi extra lucenti rd if manufactur packag avastin intraocular use submit registr everyon would happi they could charg quit lot readi use dose everyon know registr cost money must recoup would also pay confid put syring manufactur like buy origin manufactur spare expens motor vehicl sure qualiti safeti but novarti argument seem avastin prescrib macular diseas regist uk unsuit registr regist elsewher to unpleas dog manger attitud and seem shot foot take chanc make profit sell avastin intraocular shot lower profit lucenti still signific revenu stream',\n",
       "  'NN'),\n",
       " ('have blood test done check level humira trough what dose take often befor give humira switch someth els make sure your give humira best chanc work and often mean increas dose andor increas frequenc inject it also may mean combin immunomodul like imuran mp methotrex onli consid humira failur necessit switch as entyvio doesnt work colon it work small bowel colon data far seem show work quit well uc fair well crohn but i id max option humira give switch someth els whether entyvio remicad other',\n",
       "  'NN'),\n",
       " ('hi jim touch reason higher dosag post all clinic trial new drug set first find highest safe dose drug test efficaci this way drug get best possibl chanc show whether work manner test then drug test dose efficaci signific toxic profil bad statist drug may approv govern agenc control drug in us fda onc fda approv drug goe market drug compani littl reason spend million dollar test lower dose may turn lead less incom at point doctor patient manipul dosag individu circumst aris i think doctor patient would agre find least dosag need would great thing know that difficult point find mass i keep hope aliv figur one circumst requir doctor fiddl dose patient abl tri treatment without excess possibl sever advers event no one oncologist say oncologist didnt get baselin mri one question ask would mri chang treatment plan until system anticanc treatment would treat brain met so mri begin system treatment common case one need brain radiat begin system treatment today alectinib would first option alk nsclc non symptomat brain met so non symptomat brain met alectinib would excel first choic thus mri wouldnt chang treatment plan later i get want know i also get need cut medic cost minimum without chang treatment option i hope help all best janin',\n",
       "  'NN'),\n",
       " ('hi my brother diagnos mar nsclc iv alk cis alimta alimta maintain xalkori ceritinib wbr octob lmd straight blood clot lung start blood thinner still oxygen from last two month alectinib effect diseas progress liver pancrea he got tumour bike duct bilirubin shoot start take steroid bilirubin reduc lft shoot doctor ercp suggest litr oxygen oxygen must drop alreadi seem imposs normal expect way ani exampl patient success ercp oxygen one use nivolumab good effect liver met heard good alk ani exampl suggest come situat kind regard',\n",
       "  'NN'),\n",
       " ('hi omegafemal i fingolimod year although may stop relaps stop rapid declin now although spms i still activ diseas process get cladribin i think cladribin good choic may stop bit beastlemtrada may wors secondari effectsnoth effect abit gambl',\n",
       "  'NN'),\n",
       " ('so vitamin d i suggest liquid drop buy vitamin d vitamin k k need absorpt are take antispasmod med like dicyclomin i bad last year antispa med help margin still worth i intens aw perian diseas fistulafissuresthrombos hemorrhoidsincontin biolog dont work even stelara made hair fall fair warn i colectomi octob im way better mine crohn coliti wean prednison spark lot extraintestin issu due inflamm jointmuscl pain skin condit mouth ulcer rectum bleed i decid tri charlott web cbd oil advanc formula help alotit also increas appetit chill expens i use hsa supplement i also take thorn stress b complex bought amazoncom help adren recov long term highdos prednison i believ help i also take gnc calciummagnesium gel capsul krill fish oil cap ezf iron pill gentl tummi vitamin vsl i rememb sinc fridg if im feel lazi i might take vitamin dk drop take least iuday wont see much improv i take iu calciummagnesiumbut i never skip supp vital the calmag help balanc electrolyt protect bone loss also i sick water didnt hydrat i basic live appl juic unflavor pedialytecarri oz yeti cup everywher drank daynight you could also tri electrolyt drop like drip drop need add electrolyt anyth drinkyoul notic feel better good parch pedialyt also make popsicl littl kid babi section walmart cvs tast fcking awesomemi toddler ask treat that i gotbest wish new job i hope stelara work xo',\n",
       "  'NN'),\n",
       " ('ipoop that reason point the way gi explain sinc i tri humira first potenti remicad still may produc signific result had i tri remicad first said would essenti reason tri humira there great chanc would work either she gave quick overview entyvio i never heard somewhat disappoint never even came possibl old gi i digress i great intrigu possibl like said focus specif gi tract oppos block wbc entir bodi i think im interest tri entyvio point doe work well imuran sinc today mark one month point first day actual mg u b i think your right give increas humira tri move im get test done friday check humira level bodi see i built antibodi it may show even worth up dosag may show stay system time i may tri benedryl ill give anyth shot buy even one night bliss sleep boy i miss day notsosickgirl is bentyl prescript ion drug otc i may give enema anoth shot i rememb i tri one i couldnt hold i evacu quick ive also tri proctofoam past saw real result either this third round pred i mg week i saw mild improv it mg thing dip i got im stay steadi i never got dose pred nocturn bms occur essenti sinc flare start last june some day i realli dont know i energi what keep go imagin good im go feel much energi ill i start get full night sleep ill abl accomplish anyth day final come after research night entyvio seem like better option that cours pend result upcom humira blood work mayb ill get lucki use iv yet mayb up humira help diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free most dairi free sinc jan flare sinc june signific inflamm doc word post edit ihatepoop pm gmt',\n",
       "  'NN'),\n",
       " ('in everchang world research mani new advanc technolog come these advanc chang way eye doctor look macular degener amd also chang way see macular pucker mp well research start late given doctor understand two condit in articl discuss differ two condit the point articl keep inform latest advanc well answer seek if love one suffer amd mp recommend read articl what is macular degener amd eye condit result damag macula center vision mani peopl suffer condit amd also caus sever vision loss mani elder the damag amd caus curabl condit treatabl case doctor today use varieti treatment method slow stop damag amd caus treatment often begin are vitamin supplement dietlifestyl chang like remov smoke life may progress inject medic like lucenti eylea macugen visudyn these administ offic ophthalmologist what is macular pucker a macular pucker scar tissu form eye macula the macula center retina it one compon eye make eye lightsensit when enough scar tissu build make macula less sensit light may inhibit light filtrat mp epiretin membran give appear wrinkl cellophan macula condit sometim also known cellophan maculopathi so like ask amd mp relat way the answer the two condit differ night day so differ fact take two differ treatment where amd take supplement laser inject treat macular pucker requir treatment earli stage the blurri effect scar tissu macula minim case the condit becom like age the vitreous fluid eye shrink pull away retina that caus blurri vision elder peopl if vision loss mp signific extens procedur like vitrectomi done treat itbut sever case conclus macular degener macular pucker two differ issu present time if blurri vision recommend visit eye care specialist soon possibl see eye doctor reduc risk vision loss ensur great vision long possibl do either condit let hear experi one love dr travi zigler',\n",
       "  'NN'),\n",
       " ('just sat first infus imfinzi jan nd seem well th worst part stick hand darn vein no side effect i blame exclus immuno drug knock wood when i began whirlwind i vow i would face blind i vow i would everyth power resourc combat conquer possibl maintain posit attitud help god i ask self someth i help imfinzi work better least keep cancer metasis anoth area then ill research question like crazi internet weigh find open mind good bad make decis act act my find durvalumab tell less year old nsclc stage pdl blocker research pacif trial success i found fact utter wonder news sinc drug condit then i found doesnt work everyon claim side effect scari at time i know i wont find lot great success stori miracul cure claim scientist decid look thing anyway in complet scientif studi done h lee moffitt cancer center research institut tampa florida usa depart cancer imag metabol h lee moffitt cancer center research institut tampa florida usadepart pharmacolog toxicolog faculti pharmaci mansoura univers egypt exist immunotherapi includ pd blocker what pd blocker pd durvalumab pdl join caus tcell ignor cancer tumor destroy yes it is websit wwwncbinlmnihgovpmcarticlespmc there research avail like imfinzi i know except pacif trial gave result administr drug oppos placebo percentag success failur overal the rest theori due research the websit address i gave earlier scientif research done immunotherapi vitro vivo petri dish mice claim ph level cancer tumor key immunotherapi level success mechan thereof sinc imfinzi durvalumab pdl inhibitor blocker avail test test pd blocker known keytruda pd pdl work hand hand togeth fool tcell kill tumor research state tcell dont activ acid environ tumor claim so mean even pd pdl molecul block fool tcell tcell dont activ due acid condit shouldnt tri adjust ph level they did and it work they call buffer therapi i home tri make immuno work safe maximum rate hope littl side effect so i littl suppli togeth includ ph test strip vehicl buffer tumor ph elixir formula made i take sinc chemo radiat also shown benefit ph buffer far bad news i put least make fascin read i like johnni subject input thanx',\n",
       "  'NN'),\n",
       " ('diagnosi nsclc adenocarcinoma posit r egfr negat m met alk pd pdl kras oncomin test prior treatment carboplatinpemetrex tumor shrinkag tarceva month addit shrinkag signific progress current th cycl opdivo stabil shown third cycl scan possibl futur option the oncologist consid tagrisso even though m negativeegfr posit can comment efficaci tagrisso m negat egfr posit patient can suggest option futur treatment thank advanc',\n",
       "  'NN'),\n",
       " ('submiss consid pbac relat list medicin medicin prepar pharmaceut benefit scheme remain four relat list vaccin nation immunis program major submiss initi submiss resubmiss submiss new medicin submiss includ ceacua the type econom evalu submiss yet unknown submiss medicin who atc group l antineoplast immunomodul agent medicin who atc group m musculoskelet medicin who atc group n nervous system two submiss appear withdrawn the pbac consid minor submiss includ publish agenda outcom the submiss yield outcom recommend reject deferr insofar submiss includ multipl request number outcom exceed number submiss submiss new medicin consid pbac recommend the submiss known includ ceacua yield outcom recommend reject reject medicin who atc group l reject medicin use patient cancer the resubmiss yield outcom recommend insight the reason submiss pembrolizumab keytruda use combin platinumbas chemotherapi pemetrex disodium heptahydr treatment patient egfr wildtyp alk transloc negat nonsquam nonsmallcel lung cancer reject unclear pbac outcom blank it unclear outcom made public four medicin recommend risk share agreement two medicin recommend basi comparison least cost altern no medicin recommend manag access program the pbac consid one submiss new biosimilar medicin the pbac consid one submiss codepend technolog',\n",
       "  'NN'),\n",
       " ('mousedoctorwednesday june but ocrelizumab pirtinduct therapi lol long neuro payer reckon current state affair fact may becom sometim futur year year year year doesnt realli help get infus everi month right indetermin amount time of cours come year time theyv overdos whole bunch ms patient data avail suggest otherwis neuro say ooop didnt know',\n",
       "  'VBP'),\n",
       " ('by ed tobia jan the question quick start diseasemodifi therapi dmt multipl sclerosi ms diagnosi one i frequent see i brows onlin it goe hand hand question dmt best start there mani thing consid make decis recent i ran across studi may help your weigh benefit risk treat dmt the studi recent publish journal american medic associ review record patient diagnos relapsingremit ms rrms ani dmt better none the studi found peopl rrms initi treat glatiram acet copaxon glatopa interferon beta avonex betaferon extavia rebif lower risk percent progress secondari progress ms spms peopl receiv treatment percent those receiv fingolimod gilenya also lower risk percent versus percent natalizumab tysabri percent versus percent alemtuzumab lemtrada percent versus percent the risk move rrms spms lower glatiram acet interferon beta treatment start quick within five year diseas onset addit accord studi treatment newer dmts appear effect slow advanc diseas older glatiram acet interferon beta treatment among patient relapsingremit ms initi treatment fingolimod alemtuzumab natalizumab associ lower risk convers secondari progress ms vs initi treatment glatiram acet interferon beta studi note so messag treat ms quick effect click continu read',\n",
       "  'NN'),\n",
       " ('sorri i said level chang due activ cancer progress take care judi stage iiia adeno dx srs chemo carboalimta x ned local recurr surgeri remov lrl cm involv pleura chemo carboalimta x ned',\n",
       "  'VBD'),\n",
       " ('teva gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation multipl sclerosi societi stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none denni n bourdett md scientif advisori board none gift none fund travel speaker honoraria nation multipl sclerosi societi fund travel consortium ms center paralyz veteran america editori board current neurolog neurosci report section editor present i receiv modest compens serv section editor neurolog member editori board present patent use patent treatment multipl sclerosi cyclic peptid deriv cyclosporin patent pend thyromimet drug stimul remyelin multipl sclerosi publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi pi april present nation ms societi pi april present stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent use patent treatment multipl sclerosi cyclic peptid deriv cyclosporin debiopharma stockstock option research sponsor none stockstock option medic equip materi none legal proceed none ann h cross md scientif advisori board roch member scientif advisori board gift none fund travel speaker honoraria rockpoint give cme talk regard ms medic receiv honoraria speak video webmd academ cme bloomingdal ave ste wayn pa cme talk editori board brain pathologyeditori board ongo editori board journal neuroimmunolog editori board ongo appoint associ editor annal clinic translat neurolog new onlin journal ongo patent one four inventor publish royalti none employ commerci entiti none consult biogen ad hoc consult sanofi aventi genzym ad hoc consult novarti ad hoc consult teva neurosci ad hoc consult gerson lehrman group austin tx consult guidepoint global llc new york new yorkconsult abbvi ad hoc consult emd serono ad hoc consult genentech ad hoc consult speaker bureaus none other activ actrim talk fall ectrimsactrim meet boston spoke american academi neurolog annual meet receiv honorarium free registr one night hotel project knowledg livingston nj fee write case question etcprim educ inc fee give cme talk clinic procedur imag studi none research support commerci entiti roch site pi studi ocrelizumab primari progress ms oratorio backup investig studi site ocrelizumab rrms opera studi began openlabel extens teva neurosci site pi studi vitamin d ad low versus high dose glatiram acet studi fund nation ms societi usa teva contribut freeofcharg copaxon studi particip ongo research support govern entiti nation institut health nind po ns biomark pathogenesi ms from mous human overal princip investig pi project core a renew research support academ entiti none research support foundat societi barnesjewish hospit foundat pi conrad n hilton foundat stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none angela applebe md scientif advisori board none gift none fund travel speaker honoraria travel expens reimburs genzym novarti pharmaceut editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus genzym novarti pharmaceut speaker bureaus other activ none clinic procedur imag studi none research support commerci entiti current involv clinic trial sponsor novarti acorda sanofi aventi opexa therapeut genentechroch biogen research support govern entiti none research support academ entiti none research support foundat societi none stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none philip m skidd md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none diantha b howard ma scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti nihnlm rlm chenmelton coinvestig nihnia r ag subcontract newhouseaisen subcontract coinvestig nihncrr p gm irvin data analyst clinic core research support academ entiti none research support foundat societi none stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none rebecca i spain md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti depart veteran affair bw oregon clinic translat research institut ultr research support academ entiti va portland health care system oregon health scienc univers research support foundat societi nation ms societi conrad hilton foundat medic research foundat oregon race eras ms stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none michell h cameron md scientif advisori board i serv scientif advisori board genzym corpor gift none fund travel speaker honoraria i receiv compens travel consortium multipl sclerosi center i receiv speaker honoraria multipl sclerosi associ america editori board i editori advisori board member compens journal hand therapi patent none publish royalti i receiv publish royalti follow book physic agent rehabilit from research practic th edit elsevi physic rehabilit elsevi physic rehabilit physic therapist assist elsevi employ commerci entiti none consult i provid consult rewalk speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti i receiv research support depart veteran affair rehabilit research develop servic research support academ entiti none research support foundat societi i receiv research support nation multipl sclerosi societi stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none edward kim md scientif advisori board i serv advisori board genzym teva pharmaceut within past year gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi multicent random clinic trial high dose vs low dose vitamin d stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none michel k mass md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none vijayshre yadav md scientif advisori board genentech gift none fund travel speaker honoraria novarti inc honoraria editori board none patent none publish royalti none employ commerci entiti none consult consult bayer advisori meet consult biogen nation advisori committe consult teva ms medic advisori board meet speaker bureaus novarti inc biogen idec other activ none clinic procedur imag studi none research support commerci entiti biogen idec genentech research support govern entiti depart veteran affair primari investig research support academ entiti none research support foundat societi mcdougal foundat research grant fund nation ms societi nanci davi center without wall foundat race eras ms foundat nation institut health stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none ruth h whitham md scientif advisori board i member data safeti monitor board two clinic trial treatment neuromyel optica sponsor chugai pharmaceut co gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none erin e longbrak md phd scientif advisori board genzym teva gift none fund travel speaker honoraria genzym honoraria serv speaker patient event biogen honoraria serv speakerconsult editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureaus none other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti nation institut health ul tr train grant research support academ entiti none research support foundat societi nation ms societi sylvia lawri physician fellowship stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none robert t naismith md scientif advisori board acorda therapeut alkerm gift none fund travel speaker honoraria acorda therapeut speaker honoraria travel commerci alkerm consult travel commerci bayer healthcar consult speaker honoraria travel commerci biogen idec speaker honoraria travel commerci genentech speaker honoraria travel commerci genzym corpor speaker honoraria travel commerci emd serono consult honoraria travel commerci mallinckrodt consult honoraria travel commerci novarti consult honoraria travel commerci pfizer consult honoraria travel commerci teva consult honoraria travel commerci editori board journal watch present associ editor patent none publish royalti none employ commerci entiti none consult none speaker bureaus acorda therapeut commerci biogen idec commerci genzym corpor commerci other activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi nation institut health stockstock optionsboard director compens none licens fee payment technolog invent none royalti payment technolog invent none stockstock option research sponsor none stockstock option medic equip materi none legal proceed none gregori f wu md phd scientif advisori board commerci biogen gift none',\n",
       "  'CD'),\n",
       " ('lucki lucki neurologist prescrib cladribin i one earli peopl drug merck still market year ago australia i first cours pull market i never got finish full treatment even get half cours i still stabl month i ever make wonder ms would gone i got follow cours treatment brilliant drug best i ever yes i got mild lymphopen bad i gilenya i realli hope assess suitabl and i serious hope merck manag get back market bart blog quit right lobbi return it realli wonder drug i cant find neuro prescrib subcutan form licenc ms taken list i also sympathis deterior symptom i wait get electr wheelchair i immobil been right bugger respond treatment i realli hope cladribin trick slow thing all best brog x',\n",
       "  'JJ'),\n",
       " ('you bring excel question im happi provid inform to knowledg public avail data question whether ad tagrisso chemo progress tagrisso help compar chemotherapi alon the closest data question st generat tkis like erlotinib there continu tki improv respons rate oncolog defin patient shrinkag least system call recist howev surviv improv while combin toler rash diarrhea chemo alon in practic i never done i dont knowledg whether insur would pay dr johnson dr sequist world class everi trial differ rule it pretti new trial allow patient continu drug past progress doctor feel help veri trial allow patient stop drug later get back trial although immuno trial weve seen except i think progress brain differ progress rest bodi when cancer grow nonbrain part bodi i assum cancer resist mechan in contrast cancer grow brain well control rest bodi drug simpli isnt get brain outsid trial i sometim radiat cancer brain go back origin drug rest bodi in case st line egfr treatment erlotinib even trial prospect evalu approach',\n",
       "  'NN'),\n",
       " ('thank info word honest im probabl nervous chemo glad i found place ifwhen question come i place ask thank hour ago repli durvalumab eagl repli robert macaulay topic immunotherapi ask biomark test at minimum get pdl test see good candid durvalamb the biomark test realli way go i found treatment i good candid durvalamb sinc pdl test prior start treatment that biomark test done i target therapi day take tagrisso sinc i egfr mutat i b went stage durvalamb the target therapi stop progress cancer revers lymph node base measur ct scan you spot power prayer',\n",
       "  'NN'),\n",
       " ('i diagnos uc year ago total colectomi surgeri revers year last year i offici diagnos crohn i opt surgeri becuas i initi diagnos uc crohn im issu pretti much wors case scenerio i steriod depend mani year quick fix like prednison isnt long term option mp ineffect my doctor say i need go biolog i actual opt surgeri year ago instead go biolog im littl fear side effect lifelong treatment i havent found much info patient jpouch post surgeri result affect biolog i need choos one soon given suggest entyvio remicad humira stelara has anyon jpouch need go biolog affect someon know',\n",
       "  'VBP'),\n",
       " ('final a publish studi offer proof metastat alk lung cancer patient live year thank target therapi this phenomen consid year crizotinib approv us alk nonsmal cell lung cancer alk nsclc us seer databas list averag surviv metastat nonsmal cell lung cancer less one year in studi patient univers colorado one site origin clinic trial crizotinib alk nsclc median overal surviv time diagnosi stage iv diseas month that year over six year surviv woohoo note median surviv group remain aliv even longer patient diagnos crizotinib approv besid find patient stage iv alk posit nsclc prolong overal surviv studi also found brain metastas diagnosi stage iv diseas influenc overal surviv wow brain met arent automat death sentenc have organ involv tumor stage iv present associ wors outcom bummer work prolong benefit pemetrex chemo associ better outcom patient studi chemo target therapi yay cancer research help lung cancer patient live longer you read complet articl',\n",
       "  'NN'),\n",
       " ('sound like caus pred brain fog anxieti et al what backup plan fail humira moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa a screenwrit crohn diseas came icon scene movi alien alien burst guy abdomen ive muse wonder whether uc pain meant',\n",
       "  'JJ'),\n",
       " ('hi johan thank get back touch sorri hear ms progress realli good news start ocrevus licens yet finger cross help im half french love world cup i also love sushi i often wonder ms would better i xyz ultim best right obvious answerr',\n",
       "  'NN'),\n",
       " ('ugh these compani control here recent articl anther pharma ceo said moral requir make much money rais price generic antibiot ayn rand would proud wwwcnncomhealthdrugpricehikemoralrequirementbnindexhtml yo femal diagnos wuc mid transvers uc crohn coliti remiss sinc confirm scope dec current med entyvio asacol hd tab xday capozid day hypertens dexil otc loratadin day multivitamin day minor flare sinc start wk entyvio infus taper predinson steroid enema',\n",
       "  'JJ'),\n",
       " ('i friend facebook it good see still around there treatment suppos approv fda march ocrelizumab avail spring help rrms progress form diseas it good see',\n",
       "  'NN'),\n",
       " ('sent email spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       "  'JJR'),\n",
       " ('thank marco this day i wait it nice drop visit us i got email mssa news ive read everyth i get hand ocrelizumab still cant find inform peopl tysabri switch guess i patient it come in meantim take care you given everyon site much we hope chanc comfort ever need',\n",
       "  'NN'),\n",
       " ('im rn that mother recent diagnos stage iv nsclc i sinc reloc louisiana florida receiv conflict prognosi data louisiana oncologist current florida oncologist dont know expect here current info anyon similar situat i would love hear rt anterior cervic lymph node involv eggr negat alk negat along follow mass inoper radiat recommend multipl rt later trachea largest cm pretrach cm retrocav cm subcarin cm left hilar cm posterior left mid lung x cm rt lower lung mm posterior left lower lung mm medial left upper lung mm posterior left upper lung mm rt mid lung mm mildmoder pericardi effus we start chemo cycl carboalimta my mom wonder lesion chemo palliat worth make differ one oncologist said dont chemo one recommend shes realli confus i i read',\n",
       "  'NN'),\n",
       " ('sorri moa mechan action yes hospit could label cladi believ clad clad avail uk soon mavenclad v sub cut dose similar monitor influenc white cell deplet determin mani dose treat antivir maven v ocrelizumab head headat moment like maven avail us ocrelizumab avail europ in time test mayb real life experi msbase ocelizumab keep b cell noneexist level ever may effect may carri risk death due serious infect occur sle arthriti',\n",
       "  'NN'),\n",
       " ('well scari list cancer i clinic trial ocrevus look long term safeti trial go much longer i older relaps free sinc ocrevus some new sx start summer i see neuro fall ill ask for pml scare cancer it look like mavenclad get fda stamp approv us sometim soon then ill anoth round research when clinic trial ocrevus i access person b cell level hope im someon could spread infus time even month there consider varieti fast b cell popul rebound like influenc cancer risk slow repopul get anoth round ocrevus knock immun system i think tailor frequenc one person rebound rate',\n",
       "  'NN'),\n",
       " ('hello welcom just need clarifi thing i ms year specialist medic qualif you say hospit inpati patient gave steroid discharg how decid ms mri scan brain spine you say dr doctor suggest go ocrevus tecfidera etc get rid bodi symptom reduc chanc relaps are ms neurologist ms nurs need profession help i tecfidera year i struggl walk make better reduc chanc relaps pleas see medic advisor asap need good advic help sorri concern pleas see someon soon need action stabilis bodi berti',\n",
       "  'NN'),\n",
       " ('hello i opdivo sinc aug along yervoy stage iv lung cancer met spine i get opdivo everi week rd week get drug i ct scan round tumor grew liver upper airway kidney so said dr obvious work said soon scan i get anoth nov my wbcs slight elev everi thing els normal i low level pdl protein thought high level opdivo would work good thing sick as seem drug',\n",
       "  'NN'),\n",
       " ('reg it sinc youv got ocrevus have notic anyth posit just read post everyday tri get glimmer hope hope symptom eas moos main that far said stiff let go bit that good hope hear moos',\n",
       "  'VBP'),\n",
       " ('dont worri bio drug take care im entyvio year strong after almost lose pouch good luck',\n",
       "  'NN'),\n",
       " ('i remicad month far crohn goe work great inflamm last colonoscopi i humira previous develop fair sever muscl pain colonoscopi discov humira work anyway switch remicad now i develop muscl pain much wors this start six day prior last infus everi day got wors it got i could hard walk within hour start infus pain start decreas even total gone it three week six week cycl muscl pain start alreadi on top doctor offic call today inform latest blood work my anti bodi level high even though i six week cycl remicad left system i appoint see gi next week nurs told think option readi talk doctor one option go four week schedul remicad as much i like remicad i cant see go four vs six week help much seem like sooner later muscl pain return the option switch entyvio sterlara ive done research realli cannot see one better has anyon experienc muscl pain remicad switch either drug good result gone someth els',\n",
       "  'NNS'),\n",
       " ('that might record discharg glad hear thing go well bit challeng first like i said feel better overal worth feel free ask question keep us post male diagnos sever uc most vegan diet last year tri differ mesalimin treatment prednison uceri mp humira remicad fail also tri gluten free diet mani naturalaltern product success tri myriad probiot includ vsl final opt threestep j pouch surgeri current recuper third surgeri',\n",
       "  'VBP'),\n",
       " ('hi afi welcom grace the evid efficaci afatinib egfr posit patient progress tarceva realli impress the combin afatinib cetuximab seem work better difficult regimen toler signific skin issu diarrhea as dr pennel state in singl complet trial combin publish cancer discoveri dual inhibit egfr afatinib cetuximab kinas inhibitorresist egfrmut lung cancer without tm mutat includ patient egfr mutant lung cancer progress prior tarceva iressa the respons rate whether patient tumor acquir resist mutat tm the averag durat respons month mention paper activ combin brain metastas the skin rash diarrhea combin general sever tarceva iressa alon httpcancergraceorgtopicafatinibcetuximabtocombatacquiredresistanceoftkipost dr west origin post combin found perhap regimen someth discuss wife oncologist jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'JJ'),\n",
       " ('as per janin xalkori recommend first line treatment standard care lung cancer ros after xalkori stop work clinic trial consid option chemotherapi i search clinicaltrialsgov specif ros lung cancer there studi databas look ceritinib lorlatinib cabozantinib respect these tki alk inhibitor not yet recruitinga studi ldk patient with nonsmal cell lung cancer harbor ros rearrang nonsmal cell lung cancer harbor ros rearrang drug ldkceritinib recruitinga studi lorlatinib advanc alk ros rearrang lung cancer with cns metastasi absenc measur extracrani lesion nonsmal cell lung cancer nsclc drug lorlatinib massachusett general hospit boston massachusett unit state recruitingcabozantinib patient with ret fusionposit advanc nonsmal cell lung cancer those with other genotyp ros ntrk fusion increas met axl activ nonsmal cell lung cancer drug cabozantinib there studi list link page janin post look lung cancer solid tumor httpswwwlungcancerfoundationorgpatientsrostrialsandtreat chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan this repli modifi month ago onthemark this repli modifi month ago onthemark',\n",
       "  'NN'),\n",
       " ('there discuss differ thread recent failur opdivo lung cancer so i want clarifi issu first opdivo fda approv advanc lung cancer second line treatment fail platinum base chemo howev bms greedi want use first line therapi patient independ stage pdl status to use instead chemotherapi chemotherapi actual help make tumor immunogen help tumor attract t cell etc anyway broaden patient elig mistak the trial fail show advantag opdivo first line therapi earli stage anoth interest inform issu numer trial report efficaci pembrolizumab keytruda nivolumab opdivo correl express pdl degre for exampl keynot trial patient whose lung tumor high level pdl protein respons rate patient negat pdl also respond what negat posit pdl test this depend lot compani in trial nivolumab cutoff use posit cell biopsi for pembrolizumab cutoff and atezolizumab also test pdl express differ they use differ antibodi differ detect method anoth factor take consider pdl status easili chang tumor tumor mani trick ya know at time pdl express good enough marker exclud patient get pdpdl checkpoint inhibitor',\n",
       "  'NN'),\n",
       " ('remicad best track record fistula heal humira may well work though worth tri sure it shame jump hoop might find humira work best if still option least my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran',\n",
       "  'VBD'),\n",
       " ('the articl link suggest use specif type antidepress tricycl ndris increas surviv lung cancer clinic statist signific way no benefit seen ssris howev ndri mean norepinephrin dopamin reuptak inhibitor one wellbutrin happen medic i take half year it seem like realli easi thing tri extend surviv i thought mayb peopl would interest the articl freeli avail httpswwwncbinlmnihgovpmcarticlespmc chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan this topic modifi week day ago catdand forum moder this topic modifi week day ago catdand forum moder',\n",
       "  'JJR'),\n",
       " ('although advent antivegf therapi explain administ via eye inject lucenti eylea avastin revolution treatment wet agerel macular degener amd still number person respond treatment it nonrespond reduc respond continu pose signific challeng doctor research despit relat success drug treat cure wet amd retin specialist acknowledg need addit intervent treat wet amd effect one promis approach enter sever phase clinic trial earlier year explor treatment wet amd inhibit vascular endotheli growth factor vegf plateletderiv growth factor call pdgf also explain via inject drug fovista new drug candid ophthotech unfortun although innov approach show promis fovista prove effect data two drug phase clinic trial administ combin lucenti analyz the clinic trial result on decemb ophthotech releas follow inform edit length clariti ophthotech corpor today announc prespecifi primari endpoint ie indic success mean averag chang visual acuiti month achiev two pivot phase clinic trial investig superior fovista antipdgf therapi combin lucenti antivegf therapi compar lucenti monotherapi ie use lucenti alon treatment wet agerel macular degener amd the addit fovista month lucenti regimen result benefit measur mean chang visual acuiti month time point we disappoint result trial particular patient afflict wet amd comment david r guyer md chief execut offic ophthotech we thank patient clinic investig staff particip trial we continu analyz data two studi better understand trial result the two clinic trial oph oph intern multicent random doublemask control phase studi evalu safeti efficaci mg fovista administ combin lucenti call fovista combin therapi compar lucenti monotherapi ie lucenti alon in trial patient random one two approxim equals treatment group the two phase trial enrol patient wet amd to better understand result help understand process underli wet amd along current treatment cure what wet agerel macular degener amd look world amd in wet macular degener choroid part eye contain blood vessel nourish retina begin sprout abnorm blood vessel develop cluster macula call choroid neovascular neo new vascular blood vessel the macula part retina provid clearest central vision becaus new blood vessel abnorm tend break bleed leak fluid macula caus lift pull away base this damag fragil photoreceptor cell sens receiv light result rapid sever loss central vision what is angiogenesi angiogenesi term use describ growth new blood vessel play crucial role normal develop bodi organ tissu sometim howev excess abnorm blood vessel develop occur diseas cancer tumor growth amd retin macular bleed substanc stop growth excess blood vessel call antiangiogen antiagainst angiovessel genicdevelop antineovascular antiagainst neonew vascularblood vessel angiogenesi antivegf treatment the focus current antiangiogen drug treatment wet amd reduc level particular protein call vascular endotheli growth factor vegf bind cell inner line blood vessel vascular endotheli cell promot abnorm growth retina macula thus drug classifi antivegf treatment at present drug lucenti eylea avastin administ inject small needl direct eye surfac numb a new approach angiogenesi antipdgf treatment in contrast vascular endotheli growth factor vegf bind cell inner line blood vessel endotheli cell plateletderiv growth factor pdgf bind cell outer line blood vessel pericyt cell pericyt thus vegf pdgf play relat separ role format growth new blood vessel while vegf stimul abnorm blood vessel growth retina macula pdgf stabil matur blood vessel shield innerendotheli cell keep aliv despit antivegf treatment the result the lucenti eylea avastin treatment render ineffect seen person nonrespond reduc respond research theoriz therefor combin antivegf antipdgf treatment target immatur matur blood vessel may effect antivegf treatment alon call monotherapi the antipdgf therapi strip pericyticprotect cell outer blood vessel cover outer protect cell gone inner endotheli cell expos antivegf therapi elimin well current research antipdgf treatment fovista fovista antipdgf drug candid ophthotech potenti treatment wet amd use combin antivegf drug ophthotech unit statesbas biopharmaceut compani special develop novel therapeut treat diseas back eye focus develop therapeut agerel macular degener sinc fovista inject eye via separ needl antivegf drug treatment requir two separ inject pleas note although unsuccess clinic trial report involv fovista combin antivegf drug lucenti simultan clinic trial progress antivegf drug avastin eylea result clinic trial yet releas the durasert insert psivida anoth antipdgf treatment develop durasert sustainedreleas insert biotechnolog compani psivida the compani also develop fdaapprov inject implant iluvien partnership alimera scienc treatment diabet macular edema the sustainedreleas insert design deliv repurpos cancer drug call tki known block action vegf pdgf thus far insert use two preclin anim studi accord psivida ultim goal durasert project effect treat amd sustain basi six month singl inject target vegf pdgf avoid toxic system side effect cancer drug frequent inject current amd antivegf inject about clinic trial most clinic trial design phase base question studi seek answer in phase clinic trial research test new drug treatment small group peopl first time evalu safeti determin safe effect dosag rang identifi possibl side effect in phase clinic trial studi drug treatment given larger group peopl determin effect evalu safeti in phase studi studi drug treatment given even larger group peopl confirm effect monitor side effect compar common use treatment collect inform allow drug treatment use safe in phase studi unit state food drug administr fda approv drug continu studi determin addit inform drug risk side effect benefit optim use visionawar provid updat macular degener research becom avail',\n",
       "  'JJ'),\n",
       " ('i agre wwith ipoop check level in addit may want stool test havent have scope recent if result if hard know thing activ often rectum best rout treat rectal med are how mesalamin it worth throw simpl stuff see get point free symptom stelara offlabel uc avail crohn i think test uc avail soon howev med simponi humira similar remicad action entyvio differ mechan xeljanz both good option current state id like hope get thing manag someth addit your sinc said your bad mayb dose adjust imuran though mg low peopl everi day could get level check see your respond also add rectal steroid andor mesalamin oral mesalamin moder uc current med step jpouch surgeri complet step complet step complet from sick uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       "  'JJ'),\n",
       " ('befor genom analys egfr even exist understood drug like iressa tarceva work laboratori develop evapcd tar get platform identifi clinic respond target agent function level weve use iressa year inde sever year egfr gene mutat discov regular treat patient found sensit iressa as difficult obtain drug us would dispatch patient famili member tokyo could purchas iressa return success treat famili member predic upon evapcd find in report use firstlin iressa later tarceva patient identifi evapcd provid respons rate nagourney ra et al clinic respons egfrtki identifi druginduc cell death human nsclc primari cultur proc asco whi function profil more effect one import aspect function analys biolog rigor that patient favor evapcd result respond tend respond durabl this reflect predict valid biolog measur gene profil one patient show synergi combin tarceva plus avastin round th year egfr tki therapi one would need look long hard clinic program use genedriven therapi select find year survivor were wait for question while i await result patient genom profil i confid found egfr mutat negat alk ros ras braf cmet our experi patient one encount increas frequent reflect abil interrog human biolog level cellular function faster better accur genom platform while genom analysi provid possibl respons evapcd analysi provid probabl respons onc find we answer wait question as alway i appreci thought comment dr robert nagourney intern recogn pioneer cancer research person cancer treatment year he tedx speaker author book outliv cancer practic oncologist tripl board certifi intern medicin medic oncolog hematolog help cancer patient around world nagourney cancer institut long beach california for info go nagourneycancerinstitutecom',\n",
       "  'NN'),\n",
       " ('daze dont worri itll work relaps without steroid treatment take long time calm youll feel better start therapi work start tysabri coupl month ago ive improv dramat life goe ms scari use major newli diagnos patient it isnt wonder may bearabl major us what els go work meet friend your current work catch netflix want the advic i give make note new symptom report ms nurs and spend minut day think ms that time limit ive set',\n",
       "  'NN'),\n",
       " ('remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom havent found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas firstlin approach biolog therapi work block certain chemic caus inflamm intestin most biolog crohn diseas block protein call tumor necrosi factor tnf other biolog block immun cell call integrin other act protein call interleukin il interleukin il this biolog therapi stop inflamm gut antitnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week the three antitnf biolog humira remicad cimzia humira humira selfadminist treatment follow initi demonstr healthcar profession if doctor decid handl inject theyll give set pen dosagecontrol medic insid youll also given instruct mani inject take first day after initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flareup it may also help maintain remiss prevent symptom return remicad given direct bloodstream this allow work immedi reliev symptom it administ medic facil experienc healthcar profession close monitor side effect treatment remicad doesnt taken everi day after three starter dose patient often see benefit six dose per year the downsid remicad must given intraven medic facil twohour period cimzia cimzia administ small inject the inject either given doctor offic home if choos receiv treatment doctor offic option receiv treatment powder form the powder mix steril water inject the option use prefil syring the syring contain medic that alreadi mix measur dose these use home doctor offic if choos treatment youll get packag two syring instruct give treatment after first three dose given everi two week abl take cimzia everi four week the two antiintegrin biolog crohn tysabri entyvio tysabri this type biolog prevent inflammationcaus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week it take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl havent respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar serious side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml this result virus test advanc ani physician prescrib tysabri crohn warn patient risk they also explain enrol prescrib program call touch this program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas havent respond well intoler reason cant take tnf blocker immunomodul corticosteroid it work similar tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gutspecif doesnt appear risk pml entyvio given doctor care intraven infus it given minut first day therapi it repeat week two week six everi eight week thereaft if improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient uptod immun stelara the third class biolog il il agonist stelara drug class approv treat adult moder sever crohn havent respond well enough convent therapi the drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession the follow dose given via inject skin everi eight week either healthcar provid selfadminist patient train side effect although benefit often far outweigh risk biolog therapi present serious side effect the process biolog therapi reduc bodi abil fight infect this caus tuberculosi infect includ brain infect there also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen tcell lymphoma this type cancer often fatal becaus biolog therapi work differ other side effect may caus also vari ask doctor thorough explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm your doctor discuss option benefit risk help find effect treatment in case biosimilar generic version biolog drug may avail manag crohn also save money your doctor tell option',\n",
       "  'NN'),\n",
       " ('hi i havent taken keytruda opdivo similar first mom stage travel anoth organ time standard treatment surgeri but let get far immunotherapi get rid cancer keep stabl long time everybodi experi differ side effect vari time sever two realli when i first start immunotherapi i runni nose eye hour everi morn week went away i knee pain later went away now almost three year take immunotherapi i experienc fatigu i cold time i cant wait subsid also sever heartburn hit year drug i take counter zantac twice day other rash sometim itch diarrhea requir medic calm a peopl gave fever flu symptom infus four episod went away thing report ani short breath abdomin pain diarrhea good luck mom my uncl also zero energi alway cold he also cant tast food everyth tast he lbs right',\n",
       "  'VBD'),\n",
       " ('this year i among advoc patient cancer appli select particip american associ cancer research aacr scientistsurvivor program ssp as part program i attend aacr annual meet held april new orlean the program consist orient day includ excel cancer brief dr carolyn compton sspon session advoc met top research discuss specif topic immunotherapi fda polici present origin poster aacr poster session group project scientif advisor experienc ssp mentor help us explor major aspect cancer research even network event cours attend annual meet cancer research poster creat advoc talk varieti subject includ cancer journey advocaci organ outreach even person research project my poster discuss benefit lung cancer social media lcsm communiti twitter thank fellow lcsm chat core member valuabl suggest feedback i didnt understand everi present actual aacr meet least one present i didnt understand anyth gene edit technic i come away better understand scope cancer research issu imped progress list topic i want explor i love listen research explain cuttingedg work might lead better cancer treatment some fascin session i attend discuss understand cell microenviron might promot inhibit cancer tumor respons therapi insight cancer cell metabol evolut method detect drive mutat cancer cell use epigenet block cancercaus pathway cell engin immun system person treatment the valu cancer care debat patient research regulatori perspect of cours imposs see everyth some fascin poster session i miss touch use virus prime immun respons improv effect therapi combin immunotherapi radiat inhibit dna repair cancer cell use big data inform cancer trial aspect ssp experi stood meet network patient survivor advoc across widerang cancer type be greet name hallway research thank live tweet open plenari session sit front row vice presid joe biden talk cancer moonshot attend plenari session cancer evolut target therapi friend fellow lung cancer advoc linnea olson see scan lung appear big screen have dr jean cui lead chemist pfizer team develop current oral cancer therapi xalkori crizotinib person explain poster newest drug develop treat rosrearrang cancer well alk ntrkrearrang cancer i high recommend cancer patient advoc interest research appli program thank bonni j addario lung cancer foundat support applic aacr scientistsurvivor program you view poster onlin collabor support lung cancer social media lcsm communiti',\n",
       "  'JJ'),\n",
       " ('each day i learn strength sorrow oral head neck cancer patient caregiv i also acquir better understand scienc cancer treatment cancer possibl caus cancer prevent cancer today societi also face address new popul oral head neck cancer patient in past cancer patient older adult avid smoker howev younger adult age diagnos hpvrelat oropharyng cancer as i learn topic i becom increas encourag immunotherapi new target therapi develop address cancer start newslett next mani month websit headandneckorg hnca provid educ seri immunotherapi better educ oral head neck cancer communiti isnt clinic trial potenti futur therapi access treatment due hard work mani volunt support corpor partner head neck cancer allianc hnca expand program our goal becom onestopshop patient love one famili member seek inform oral head neck cancer worldwid take step achiev goal each everi day hnca dedic advanc prevent earli detect treatment rehabilit oral head neck cancer public awar research advocaci survivorship immunotherapi head neck oral caviti what immunotherapi class medic use treat cancer alter individu immun system they act induc enhanc immun respons such medicin use treat human cancer provid addit approach control diseas what isnt unlik standard chemotherapi radiat therapi affect tumor cell well bodi normal cell immunotherapi direct interact host immun system order enhanc person fight cancer the goal approach util bodi natur defens system erad diseas tri minim side effect there number differ type immunotherapi the immun checkpoint inhibitor promin class immunotherapi repres breakthrough cancer care these medic act program cell death receptor block immun checkpoint normal cell ligand bind cell death receptor allow immun respons know harm bodi in cancer cell produc abund amount ligand also bind cell death receptor tcell the ligand protein suppress immun respons therefor allow mutat cell evad bodi immun system destroy grow rapid tumor exampl includ antibodi program cell death protein pathway pd ligand pdl ex nivolumab pembrolizumab antibodi cytotox tlymphocyt associ antigen ctla anoth type immunotherapi date agent shown remark impact upon malign melanoma ctla downregul activ tcell block antibodi tcell remain activ allow attack tumor cell ctla current approv treatment melanoma nonsmallcel lung cancer both antibodi type similar function regul tcell activ contrast base locat variat express time etc a recent trial show impact head neck cancer agent continu studi multipl cancer type singl therapi combin immunotherapi combin cancer therapi it expect medic becom common treatment mani differ cancer these new therapi associ side effect while immunotherapi appear good overal benefittorisk profil common immunerel side effect dermatolog appear similar product they tend mild manag support local care sometim aggress care might need while side effect troublesom compar seen common use chemotherapi mouth pain mucos dri mouth tast chang nausea hair loss damag kidney nerv bone marrow suppress risk factor immunotherapi toxic well character may includ increas risk age gender presenc prior autoimmun condit combin immun therapi increas risk dermatolog side effect may associ increas sever side effect nevertheless side effect profil immunotherapi typic favor chemotherapi andor radiat how minim side effect immunotherapi dose modif delay schedul discontinu therapi often consid goal prevent manag side effect treat dermatolog oral side effect continu immunotherapi greatest effect upon cancer manag may includ skin moistur prevent dehydr reduc local irrit avoid tight fit cloth wear light wick fabric avoid sun exposur wash skin soap water also help to minim oral side effect option includ good basic oral care mouth rins hydrat avoid rough abras food remov sharp potenti irrit dental surfac dermatolog oral treatment local antiinflammatoryimmunosuppress therapi may includ steroid therapi topicalsystem well medic reduc itch hydroxyzin diphenhydramin pain for sever reaction antitnf medic eg infliximab may consid articl contributor includ hnca board member joel epstein md michael moor md erza cohen md cherieann nathan md the articl first seri immunotherapi treatment oral head neck awar week set screen record earli detect key best outcom cancer for oral head neck cancer earli detect also provid treatment opportun less invas best opportun success hnca host th annual oral head neck cancer awar week ohancaw april set record number screen site well individu screen weeklong nationalintern event in april hnca partnership hospit communiti health center dental offic held event worldwid conduct free oral head neck screen the event also offer hnca educ materi recommend individu test examin warrant it goal continu grow deliv qualiti ohancaw educ activ screen as hncas hallmark program ohancaw save hundr live earli detect we thank thousand volunt clinician enthusiast commit time support communiti host ohancaw screen said dr terri day hnca presid in celebr ohancaw th anniversari look forward anoth banner year hnca wish acknowledg lilli oncolog bristolmy squibb merck support ohancaw unfortun individu diagnos oral head neck cancer everi day therefor organ want host screen support event throughout year to regist go wwwheadandneckorg',\n",
       "  'NN'),\n",
       " ('retin vein occlus rvo preval visionthreaten diseas macular edema common complic standard treatment rvoassoci macular edema involv intravitr treatment antivascular endotheli growth factor antivegf agent ranibizumab bevacizumab aflibercept despit success agent clinic trial antivegf agent may administ less frequent clinic practic studi research sought evalu efficaci safeti inject frequenc antivegf drug treat macular edema secondari rvo clinic practic use multicent retrospect openlabel chart review patient year older receiv least intravitr inject antivegf august septemb a total patient year followup antivegf treatment continu receiv antivegf inject data avail year seventeen continu therapi data avail year a total antivegf inject administ ranibizumab bevacizumab aflibercept most patient receiv repeat inject agent n patient switch agent least time studi period in control clinic trial conduct approv ranibizumab administ month month need year by contrast studi patient receiv mean rang antivegf inject year rang year rang year the mean interv inject rang month across first inject the primari end point combin visual anatom respons measur bestcorrect visual acuiti better central retin thick mcm less timedomain optic coher tomographi mcm less spectraldomain optic coher tomographi visit achiev patient first inject in realworld studi mean antivegf inject administ year respons antivegf therapi suboptim mani patient write author more frequent inject may improv outcom patient achiev dri macula even month inject refer jumper jm dugel pu chen s blinder kj walt jg antivegf treatment macular edema associ retin vein occlus pattern use effect clinic practic echo studi report clin ophtalmol doi opth',\n",
       "  'NN'),\n",
       " ('my wife noriko diagnos august stage squamous lung cancer nsclc she petct scan novemb st schedul infus opdivo nivolumab month month diagnosi she previous gone thru two combo regimen fail chemo there similar immunolog fda approv drug lung cancer keytruda merck opdivo keytruda origin develp melanoma test number type cancer fda approv last year lung cancer her oncologist dr howard jack west md came said cancel infus the petct scan show wasfre cancer remiss he origin estim mayb month these new immunolog drug also call check point inhibitor pd name seem better success mani previous chemo type drug there mani new clincal trail test simialr drug mani show lot promis she ecstat there hope even stage lung cancer thank brystolmey squibb area seattl swedish hospit cancer institut dr west entir staff no need fli across countri region seek best cancer center two nearest larg metro citi near mani time larg hospit cancer section univeristi teach medic hospit check oncologist special specif type cancer be sure access latest clinic trail drug recent fda approv mani time lead edg succes treatment of cours less stage surgeri raditaion success pleas stay far away altern clinic doctor product good food suppliment great general health none cure cancer regardless mani phoni testimoni see site same goe mexico mani foreign bogus clinic push coffe enema nonsens cure big buck medic phyician mds top us medic univers there is hope chuck httpwwwcancerorgtreatmenttreatmentsandsideeffectstr httpwwwcancerresearchorgcancerimmunotherapyimpact httpswwwgooglecomsearchnewwindowrlzcahpztenususqimmunotherapycancertreatmentsaxvedahukewjdgoxqahuqmmkhwkdafwqqiipgeoagbiwbih',\n",
       "  'NN'),\n",
       " ('i fortun ive rare doctor critic control never i experienc one mean but day control great doctor rather awe dedic i put toward control compar averag patient i think kater it unfortun percept diabet experi medic profess cast shadow life it interest i use hate loath diabet everi day everi test frustrat and addit frustrat almost daili diabet also scari sad overwhelm you look back post ten year ago see i wrote diabet experi gain tight control lowcarb diet use pump cgm sugar surf techniqu daili review adjust basal rate ratio taken frustrat diabet it still annoy time doesnt caus emot turmoil first year diabet life the night i ate highercarb meal gram i surpris stress give big relat speak bolus go class studi shown insulin potenc vari wide i felt like id inject big dose unknown system sure enough bg went mmoll i correct correct sent mmoll that brief glimps life use like daili basi rare like enough keep track so answer loosen control live consequ tri avail techniqu find work tighten control stick i resist lowcarb year i insist bg variabl wouldnt work and inde lowcarb answer my bg still high variabl compar mani i see i still need monitor close adjust frequent often larg amount even control near tight peopl post but i glad i gave techniqu shot even i realli didnt want tri profound impact life attitud toward diabet seydlitz well ac four rang past decad yet ive four laser photocoagul treatment period youv said mani post blood sugar swing wild there thought glycem variabl import mayb even import high blood sugar caus complic while ac may import ac alon doesnt realli indic whether someon good control id say averag blood sugar standard deviat time rang better measur and hyperglycem memori may true also studi like followup dcct show even temporari period good control benefit reduc complic decad road',\n",
       "  'NN'),\n",
       " ('my father diagnosi nsclc plural effus over pass year gone carboplatin cycl cisplatin gemcitabin cycl alimta cycl pembrolizumab cycl diseas show progress increas fluid metastat neck lymph node pleas advis chemo treatment immun treatment give tri can also check new drug come trial let particip thank help',\n",
       "  'NN'),\n",
       " ('californeadreamin londonlad jolea it devast that i could say absolut unknown result fail way say one path better im still young never kidney lung heart problem far futur treatment life path age treatment ill start tomorrow whatev subsgio tecfidera gilenya ill age even age protect brain part sacrific part idk absolut inhuman i want someth legit treatment vulner patient',\n",
       "  'NN'),\n",
       " ('sorri hear current regim isnt work there seem rhyme reason work differ peopl i agre tri everi variat theme remicad downsid throw mp back mix sinc work who know whether anoth antitnf might next step entyvio peopl work in interim may also want explor anyon area particip stelara clinic trial my husband gi one patient great result quick problem clinic trial may end placebo first and cours big propon xeljanz get label i dont think path choos wrong path sinc still big scienc experi stelara xeljanz may approv next year still drug option time pass spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       "  'JJ'),\n",
       " ('i took x iu day month iu day total vitamin d pretti low ngml no idea i dont realli wanna pay anoth find winter im go take mainten dose iu day test level next spring im bit worri vitamin k part a brief googl inform scienc doesnt clue yet one day might wwwhealthlinecomnutritionvitamindandvitaminksect think i pick vitamin k supplement anyway or multivitamin supplement includ vitamin k dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('hi fellow travel i stage c adenocarcinoma lung cancer i went remiss two year c far tumor in week i start radiat day week chemo time gram cannabi oil day gram vit c iv twice week natur supplement after treatment put remiss i start someth call durvalumab immunotherapi they genet test i tumor proport score tps high pdl express nsclc everi week iv i hope everyon enjoy seasont',\n",
       "  'NN'),\n",
       " ('well turn i c diff infect could reason remicad wasnt work onc i get control in current take vancomycin antibiot treat im hope remicad still work if doesnt work ill move anoth med like entyvio mark thank insight ill make sure mention doctor possibl under infectionsparasit test order find',\n",
       "  'VBP'),\n",
       " ('home ms inform public the motiv the motiv winterspr research news american academi neurolog meet highlight research news american academi neurolog meet highlight in this section american academi neurolog meet highlight tecfidera approv longterm treatment ms american academi neurolog meet highlight written jack burk md edit susan well courtney the american academi neurolog aan th annual meet took place san diego california march this larg medic confer present latest find research treatment neurolog condit includ multipl sclerosi ms while cover studi relat ms would possibl issu the motiv follow import highlight general studi adher diseasemodifi therapi dmt medic reduc risk ms relaps percent increas number individu relapsefre two year women ms children may experi slower rate disabl progress women never pregnant more studi need confirm find diseas factor may play role whether patient becom pregnant the herp zoster vaccin hzv effect ms studi ms patient these patient suffer increas mri damag clinic indic increas ms symptom three month vaccin this studi suggest hzv safe use ms patient fdaapprov diseasemodifi therapi ms pegyl interferon betaa peginterferon betaa chemic modif interferon betaa avonex molecul allow given subcutan skin everi two four week contrast current onceaweek deeper intramuscular inject studi test experiment therapi safeti effect if approv fda would give patient option use singledos autoinjector prefil syring less frequent in previous studi benefit trial patient clinic isol syndrom cis treat betaseron interferon betab placebo two year diagnos clinic definit ms cdms time everyon switch betaseron a followup extens studi eight year show group stabl low disabl level although patient treat immedi betaseron follow cis fewer relaps delay treatment the fdaapprov dose copaxon glatiram acet mg given daili via subcutan inject in gala studi patient receiv either mg dose three time per week subcutan placebo this experiment dose reduc relaps mri lesion compar placebo if fda approv lessfrequ treatment option copaxon may becom avail rebif interferon betaa studi use rebismart inject devic electron autoinjector monitor drug adher electron dose log in german studi found percent adher rate three month initi autoinjector use data small number women becam pregnant within day take tysabri natalizumab suggest advers effect pregnanc outcom the c recommend potenti harm pregnanc stand women recommend get pregnant tysabri the higher dose mg oral aubagio teriflunomid reduc relaps rate disabl mg dose reduc relaps disabl patient fewer relaps prior treatment less disabl take aubagio a fouryear patientsafeti studi oral gilenya fingolimod show unexpect safeti concern well suggest disabl may improv four year treatment those switch gilenya prior week discontinu tysabri lower risk relaps began therapi gilenya week stop tysabri a combin analysi two tecfidera dimethyl fumar bg clinic trial show given twice per day tecfidera reduc relaps disabl also accept safeti profil a higher number patient free diseas activ versus placebotr patient twoyear trial period experiment ms therapi in threeyear extens studi oral drug laquinimod treat patient continu less risk disabl compar placebo also new safeti issu occur lemtrada alemtuzumab drug infus intraven threetof consecut day entir first year effect rebif reduc overal diseas activ advers event includ thyroid platelet problem consist previous studi daclizumab also known zenapax monoclon antibodi given inject shown less diseas mri activ compar placebo one year in select studi particip given week washout period without treatment reiniti drug show evid rebound diseas activ follow washout period ms patient ocrelizumab bcell target monoclon antibodi low diseas mri activ last least week last dose no new safeti concern experienc vitamin d continu link ms optic neuriti treatment vitamin d demonstr posit immunesystem chang decreas inflamm demyelin african american ms tend lower vitamin d level ms disabl studi progress type ms fourteen primaryprogress ms ppms patient involv clinic trial oral drug amilorid potassiumspar diuret may neuroprotect activ preliminari result suggest posit effect mri disabl inform doubleblind multicent studi evalu gilenya fingolimod mg versus placebo ppms patient flexibl durat threetof year it measur timetosustain disabl progress the enrol ppms patient complet a preliminari studi secondaryprogress ms spms patient evalu effect oral statin drug simvastatin preliminari result show posit influenc mri clinic disabl outcom further studi necessari confirm result siponimod baf oral drug class drug gilenya ident a larg studi design spms patient underway a smaller studi relapsingremit ms rrms encourag base relaps mri result other interest paper high dietari salt implic increas autoimmun neuroinflamm mark boost th helper tcell driven autoimmun respons eae experiment diseas similar ms mice th immunesystem cell lymphocyt involv inflamm caus damag myelin nerv ms this thboost properti dietari salt also seen human the theori salt may increas ms inflamm far reach practic dietari implic ms patient glucos level sugar level blood found predictor level disabl ms patient further studi need prove causal relationship ms patient smoke increas sever ms reason includ fact smoke caus damag chang immun system blood pressur regul system ms patient certain genet pattern hladrb increas level spinal cord damag compar ms patient without hladrb this highlight valu examin brain spinal cord microscop link find genet factor chronic cerebrospin venous insuffici ccsvi propos caus ms damag due block venous drainag brain in studi differ found proport ms patient ccsvi compar healthi peopl without ms this studi suggest ccsvi common ms patient general popul walk gait measur ms patient ampyra dalfampridin first take ampyra drug drug reinstat research found walk becam wors patient take drug improv ampyra reinstat tecfidera approv longterm treatment ms written susan well courtney review jack burk md the unit state food drug administr fda announc march approv tecfidera dimethyl fumar bg firstlin therapi longterm treatment relaps form multipl sclerosi ms tecfidera manufactur biogen idec th drug third oral medic approv diseasemodifi therapi dmt longterm treatment ms the approv dosag mg taken pill form twice daili tecfidera may distinct dual mechan action first immunomodul modul affect immun system function exhibit antiinflammatori properti second tecfidera may neuroprotect effect potenti protect nerv axon myelin cover damag the phase iii defin placebocontrol studi enrol patient result show percent reduct proport patient relaps studi period compar placebo percent reduct risk sustain disabl progress least week the phase iii confirm placebocontrol studi enrol patient result show reduct relaps rate percent tecfidera compar placebo in studi compar placebo individu given tecfidera signific reduc diseas activ shown magnet reson imag mri scan the common report side effect flush gastrointestin event diarrhea nausea vomit abdomin pain these occur often begin treatment decreas frequenc first onetotwo month medic reduc whiteblood cell lymphocyt count seen first year treatment lymphocyt diseasefight cell the fda recommend prior start tecfidera annual thereaft still treatment patient given complet blood count monitor abil fight infect for more inform pleas see mymsaaorgnewstecfideraapprov msaa full articl approv tecfidera addit inform tecfidera may found visit wwwtecfideracom biogen idec patient assist program wwwmsactivesourcecom in addit msaa websit mymsaaorg individu may call msaa inform ms treatment question msaa client servic depart may email back',\n",
       "  'NN'),\n",
       " ('hi sunday welcom grace im sorri cancer progress tarceva hope chanc tri tagrisso ill ask oncologist comment question let us know blood test turn all best janin',\n",
       "  'NN'),\n",
       " ('patient treat adalimumab increas risk infect may becom serious lead hospit death these infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria the risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test negat prior treatment consid empir antifung therapi atrisk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker adalimumab postmarket case hepatosplen tcell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumab primarili adolesc young adult male crohn diseas ulcer coliti most case occur patient receiv concomit treatment azathioprin mercaptopurin subcutan routesolut patient treat adalimumabatto increas risk infect may becom serious lead hospit death these infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria the risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test negat prior treatment consid empir antifung therapi atrisk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker includ adalimumab product postmarket case hepatosplen tcell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumab product primarili adolesc young adult male crohn diseas ulcer coliti most case occur patient receiv concomit treatment azathioprin mercaptopurin subcutan routesolut patient treat adalimumabadbm increas risk infect may becom serious lead hospit death these infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria the risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test negat prior treatment consid empir antifung therapi atrisk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker adalimumabadbm postmarket case hepatosplen tcell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumabadbm primarili adolesc young adult male crohn diseas ulcer coliti most case occur patient receiv concomit treatment azathioprin mercaptopurin common use brand name see also stelara in us amjevita cyltezo humira avail dosag form solut therapeut class antirheumat pharmacolog class monoclon antibodi use for humira adalimumab inject use treat symptom prevent progress activ rheumatoid arthriti ankylos spondyl it use children year age older juvenil idiopath arthriti this medicin also use treat psoriat arthriti type arthriti caus pain swell joint along patch scali skin area bodi psoriat arthriti usual occur skin condit call psoriasi adalimumab may use alon combin medicin eg methotrex dmard adalimumab inject also use treat symptom activ crohn diseas patient help medicin infliximab it also use treat moder sever ulcer coliti patient treat medicin eg azathioprin corticosteroid mercaptopurin work well adalimumab inject may also use treat chronic plaqu psoriasi skin diseas red patch white scale go away it also use treat moder sever hidraden suppurativa chronic skin diseas small pain lump skin adult children year age older this medicin also use treat noninfecti intermedi posterior panuv adult children year age older this medicin avail doctor prescript befor use humira in decid use medicin risk take medicin must weigh good this decis doctor make for medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use adalimumab inject treatment juvenil idiopath arthriti noninfecti uveiti children year age older treatment hidraden suppurativa children year age older howev safeti efficaci establish children younger year age juvenil idiopath arthriti noninfecti uveiti children younger year age crohn diseas children younger year age hidraden suppurativa children condit geriatr appropri studi perform date demonstr geriatricspecif problem would limit use adalimumab inject elder howev medicin may caus serious infect cancer often elder may requir caution patient receiv adalimumab inject breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when take medicin especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use medicin follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adenovirus vaccin anakinra bacillus calmett guerin vaccin live cholera vaccin live infliximab influenza virus vaccin live measl virus vaccin live mump virus vaccin live poliovirus vaccin live rilonacept rotavirus vaccin live rubella virus vaccin live smallpox vaccin tofacitinib typhoid vaccin varicella virus vaccin live yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use medicin make sure tell doctor medic problem especi blood problem eg aplast anemia pancytopenia thrombocytopenia histori congest heart failur guillainbarr syndrom histori infect fungal bacteri histori leukopenia low number white blood cell multipl sclerosi optic neuriti eye problem psoriasi skin diseaseus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd granulomatosi polyangiitisus caution may increas chanc get new cancer diabet hepat b histori opportunist infect histori tuberculosi histori ofmay increas chanc side effect infect activeshould use patient condit tuberculosi activeshould treat first receiv medicin proper use adalimumab this section provid inform proper use number product contain adalimumab it may specif humira pleas read care this medicin given shot skin adalimumab may sometim given home patient need hospit clinic if use medicin home doctor nurs teach prepar inject medicin be sure understand use medicin this medicin come medic guid patient instruct use leaflet read follow instruct care ask doctor question if use medicin home shown bodi area shot given use differ bodi area time give child shot keep track give shot make sure rotat bodi area this help prevent skin problem do inject skin area red bruis tender hard if psoriasi inject rais thick red scali skin patch skin lesion this medicin avail form you may use pen prefil syring to use pen syring first gather item need clean flat surfac use cloth towel welllight area wash hand soap water use medicin remov carton syring pen refriger place cloth allow minut syring pen warm room temperatur do warm medicin way do remov needl cover prefil syring pen allow medicin reach room temperatur remov right away use check liquid syring pen use view window it clear colorless if cloudi discolor particl float use syring pen check amount liquid pen close fill line seen window the fill line show full dose medicin if pen full amount liquid use call pharmacist if liquid clear place clean flat surfac do shake medicin check expir date prefil syring pen make sure date pass do use medicin date pass choos inject site bodi eg thigh abdomen stomach area clean inject site fresh alcohol wipe let dri remov cap needl cover readi inject inject full amount medicin within minut cap cover remov you might small amount blood liquid inject site press hold dri clean cotton ball inject site second rub dose the dose medicin differ differ patient follow doctor order direct label the follow inform includ averag dose medicin if dose differ chang unless doctor tell the amount medicin take depend strength medicin also number dose take day time allow dose length time take medicin depend medic problem use medicin for inject dosag form pen prefil syring for crohn diseas adult children year age older weigh kilogram kg moreat first week milligram mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a mainten dose mg given week everi week thereaft children year age older weigh kg less kgat first week mg inject skin divid dose this may given two shot day then week later dose mg given a mainten dose mg given week everi week thereaft children younger year ageus dose must determin doctor for hidraden suppurativa adultsat first week milligram mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a week mainten dose mg given start week children year age older weigh kilogram kg moredos base bodi weight must given doctor at first week mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a week mainten dose mg given start week children year age older weigh kg kgdose base bodi weight must given doctor at first day mg inject skin mg day a mainten dose mg given everi week children younger year age weigh less kguse dose must determin doctor for juvenil idiopath arthriti children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year age weigh less kguse dose must determin doctor for plaqu psoriasi adultsat first milligram mg inject skin mg week initi dose everi week thereaft childrenus dose must determin doctor for psoriat arthriti rheumatoid arthriti ankylos spondyl adult milligram mg inject skin everi week your doctor may adjust dose need childrenus dose must determin doctor for ulcer coliti adultsat first week milligram mg inject skin divid dose this may given four shot day two shot per day day then week later dose mg given a mainten dose mg given week everi week thereaft childrenus dose must determin doctor for uveiti adultsat first milligram mg inject skin mg week initi dose everi week thereaft children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year age weigh less kguse dose must determin doctor miss dose if miss dose medicin take soon possibl howev almost time next dose skip miss dose go back regular dose schedul do doubl dose storag keep reach children do keep outdat medicin medicin longer need ask healthcar profession dispos medicin use store refriger do freez keep medicin origin carton protect light do use frozen thaw if travel may store medicin room temperatur day throw away unus medicin day do store medicin extrem heat cold temperatur throw away use syring pen hard close contain needl cannot poke keep contain away children pet precaut while use humira if use medicin long time import doctor check child progress regular visit this allow doctor see medicin work proper decid whether continu use blood urin test may need check unwant effect you child need skin test tuberculosi use medicin tell doctor anyon home ever posit reaction tuberculosi skin test adalimumab temporarili lower number white blood cell blood may increas chanc get infect it also lower number platelet necessari proper blood clot if occur certain precaut take especi blood count low reduc risk infect bleed if avoid peopl infect check doctor right away child think get infect get fever chill cough hoars lower back side pain pain difficult urin check doctor right away child notic unusu bleed bruis black tarri stool blood urin stool pinpoint red spot skin be care use regular toothbrush dental floss toothpick your medic doctor dentist nurs may recommend way clean teeth gum check medic doctor dental work done do touch eye insid nose unless wash hand touch anyth els meantim be care cut use sharp object safeti razor fingernail toenail cutter avoid contact sport situat bruis injuri could occur do take medicin unless discuss doctor use abatacept orencia anakinra kineret togeth medicin may increas risk serious side effect this medicin may caus unwant effect may occur month year medicin use a small number peopl includ children teenag use type medicin develop certain type cancer eg leukemia some patient also develop rare type cancer call lymphoma talk doctor child unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss also check doctor right away child skin red scali patch rais bump fill pus adalimumab may caus serious allerg reaction includ anaphylaxi lifethreaten requir immedi medic attent check doctor right away child rash itch swell face throat leg feet troubl breath chest pain receiv medicin check doctor right away child one symptom swell face finger feet lower leg sudden weight gain these may sign heart condit call congest heart failur chf some peopl use medicin develop lupuslik symptom treatment got better medicin stop check doctor right away child start chest pain joint pain rash cheek arm sensit sun do live vaccin immun child treat adalimumab your child vaccin need current use adalimumab be sure ask child doctor question the needl cover prefil syring pen contain dri natur rubber deriv latex may caus allerg reaction peopl sensit latex tell doctor child latex allergi use medicin serious skin reaction occur treatment medicin check doctor right away child follow symptom use medicin blister peel loosen skin red skin lesion sever acn skin rash sore ulcer skin fever chill use medicin do take medicin unless discuss doctor this includ prescript nonprescript overthecount otc medicin herbal vitamin supplement humira side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor immedi follow side effect occur more common bodi ach pain cough ear congest gas abdomin stomach pain hoars lightheaded loss voic lower back side pain muscl ach pain nasal congest pain tender around eye cheekbon rapid sometim shallow breath shiver stomach full sunken eye thirst troubl sleep warmth skin wrinkl skin less common abnorm vagin bleed discharg agit arm back jaw pain black tarri stool bleed gum nose blind bloat swell face arm hand lower leg feet blood stool chang bowel habit bloodi cloudi urin blur vision broken bone chang size shape color exist mole chang skin color chest pain tight heavi chill clear bloodi discharg nippl cold hand feet confus constip cough cough spit blood decreas urin decreas vision depress difficulti breath difficulti burn pain urin dimpl breast skin dizzi drowsi eye pain faint fast slow irregular heartbeat fever forget frequent urg urin general feel ill hair loss headach hive itch skin rash increas thirst invert nippl irregular breath irregular puls irrit light color stool loss appetit lump breast arm lump swell abdomen stomach mole leak fluid bleed muscl cramp spasm nausea new mole night sweat blood pressur puls noisi breath numb tingl arm leg face pain red swell arm leg without injuri present pale skin persist nonheal sore skin pink growth puffi swell eyelid around eye face lip tongu rais firm bright red patch red swell breast see hear thing seizur sharp back pain rib shini bump skin slur speech problem swallow sneez sore skin breast heal sore throat sore ulcer white spot lip mouth spit blood stiff neck stomach pain stop heart sudden high fever low grade fever month sweat swell face finger feet lower leg swollen gland swollen neck vein tired troubl breath activ troubl think unconsci unexplain bruis bleed unpleas breath odor unusu tired weak unusu weight gain loss visual disturb vomit vomit blood materi look like coffe ground yellow skin eye incid known blister peel loosen skin diarrhea joint muscl pain pinpoint red spot skin red skin lesion often purpl center red irrit eye red scale crust skin unusu bleed bruis some side effect may occur usual need medic attent these side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question more common bladder pain bleed blister burn cold discolor skin feel pressur hive infect inflamm itch lump numb pain rash red scar sore sting swell tender tingl ulcer warmth inject site pound ear less common abnorm heal decreas height difficulti move difficulti walk dri mouth heartburn indigest loss hear loss strength energi menstrual chang muscl joint stiff tight rigid muscl pain weak pain back rib arm leg shaki leg arm hand feet swell red joint other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'NN'),\n",
       " ('i done research sbs interest enoughsom issu consist labsmonitor ad nutrient arent foreign moment diseas bad i go three time week fluid ad potassium i need add tpn support i i picc receiv i start accept certain thing accept fullfulltim hour week workweek may never option futur though i sure i get back eventu health turn corner i think good answer soon tomorrow roll around main ibd doc main surgeon get togeth i along current team believ surgeri answer much quick i would believ sinc i alreadi admit surgeri floor surgeri team make sens keep surgeri possibl week say i iv steroid tpn make sure diseas calm right prior surgeri i smart peopl charg case sure i think keyword smart much remov i dont believ option anyth removedespeci i keep get admit obstruct low fiber low residu diet year old crohn sinc medicin remicad restart methotrex supplement vitamin d zinc b multivitamin',\n",
       "  'NN'),\n",
       " ('hi i diagnos crohn diseas i ive tri ton medic remicad humira methotrex mp entyvio even stelara some ive allerg reaction other ive stop respond so noth realli put remiss my latest visit gi doctor ive develop fistula connect colon bladder a colonoscopi week later show pretti sever inflamm blood fistula work so gi recommend surgeri ive surgeri abscess first resect from i understand i need part sigmoid colon resect i nervous enough healthi colon rectum use reconnect so colostomi real possibl im make littl nervous if anyon tip insight life colostomi sigmoid resect id realli appreci thank knorb join jan search board messag relat topic fistula surgeri ladi join jun hi i crohn recent start read consid crohn resec well join oct so i diagnos sinc crohn read pain after surgeri crohn mattison join nov i surgeri may resect small read crohn coliti communiti forum thank help monitor crohn coliti communiti the abus report sent ani inform crohn coliti communiti site replac physician advic alway check person physician take action regard health crohn coliti foundat this websit support educ grant rule welcom crohn coliti communiti this websit associ ccfaorg support educ grant abbvi pleas read top rule post messag share stori alway courteous sensit other intend audienc the crohn coliti foundat onlin communiti intend patient caregiv famili friend the communiti intend industri repres advertis individu permit particip site meet crohn coliti communiti brows site see communiti talk find issu import join share stori after feel comfort site regist share thought regular basi stay secur rememb site view anyon internet with except registr person page search engin avail within site to guard privaci follow simpl rule share address phone number detail famili anyth els would feel uncomfort other read if post person email awar may receiv spam email spammer gather address web read react post care if dont agre offend someon post take step back think repli sinc cant talk inperson must recogn may misunderstand stori post pleas sensit other feel ask clarif act search start new topic to keep messag board easi use pleas use search bar locat topic interest start new thread if start new thread pleas use obvious subject head word catch attent other topic archiv day inact to view past topic post click archiv topic within forum stick guidelin to keep site safe everyon pleas post doctor name treatment facil name treatment specif contact inform other without consent link websit uncertain content advertis request fundrais item sale request studi survey andor questionnair particip provoc inform share photo pleas use good tast appropri imag ad photo profil person stori photo jpg format not follow rule crohn coliti communiti moder routin scan messag board delet tasteless post if post inappropri messag pictur use offens languag post multipl occas notifi via email account inactiv report foul play help crohn coliti communiti moder report anyon post inappropri messag pictur click report abus button messag email question concern pleas feel free email us question concern we want feel comfort term condit by post stori question concern inform communiti grant crohn coliti foundat author agent permiss publish reproduc record use stori crohn coliti communiti author agent see fit medium forum manner help crohn coliti communiti mission you agre releas hold harmless crohn coliti communiti liabil third parti may aris releas inform third parti third parti agre text content made person parentguardian shall exclus properti crohn coliti communiti the crohn coliti communiti cannot verifi everi claim made third parti contributor communiti respons authent inform post',\n",
       "  'NN'),\n",
       " ('i start take b d i start gilenya i feel better i tecfidera i dont know tablet respons im go cut tri find',\n",
       "  'VB'),\n",
       " ('first publish werewolf a year avail new generat anticanc drug new zealand driven polit decis much medic one becaus patient advanc melanoma made lot initi public fuss pharmac polit master sought manag demand expens treatment limit state fund advanc skin cancer this week lung cancer patient put posit need mount public high polit campaign qualifi similar state fund lifesav treatment basicallywhi peopl skin cancer qualifi state fund drug lung cancer current no good medic reason exist polit decis contain pharmaceut cost health budget especi babi boomer enter age bracket risk cancer rise spend public health tight constrain big budget defenc item contrast fund demand that anoth stori pharmac meat sandwich caught rise public demand sky high expens drug one hand beehivedriven demand frugal given potenti scale demand recent increas pharmac fund mere drop bucket it also doesnt help pharmac abil make coher decis oversea test result new drug still come chang landscap almost month basi initi pharmac follow trend global market fund opdivo bristol myer squibb bms anticanc drug first gate late testingmarket race keytruda similar drug develop merck sharp dohm msd both drug tend work second level treatment first line respons drug work induc bodi immun system counter cancer cell not everi patient benefit drug relev current biomark involv diagnost test protein call pdl in june bms tri spectacular fail score decis goal opdivo ongo market battl keytruda ala though test result show opdivo provid better result chemotherapi patient rate pdl express rang plus compani share price sank almost overnight news almost simultan msd releas test result keytruda show glow outcom patient rate pdl express rang plus keytruda market profil msds share price rose substanti wake clear though two set test measur appl orang the opdivo test ambiti attempt measur drug first line treatment potenti amid class patient includ earli onset ie plus express tumour diseas the keytruda test confirm drug efficaci later diseas cycl rate express top taken togeth test suggest futur use drug unlik monotherapi administ earli isol instead futur may well combin drug taken togeth drug eg opdivo plus anoth bms drug call yervoy hope expand ambit condit respons expens treatment here bmss ceo giavanni caforio sum new outlook opdivo light recent test owngoal link in firstlin set decid answer two import question everi patient the first question answer studi what role monotherapi and trial tell us role monotherapi like limit small subset patient express pdl high level believ know previous studi report long time ago and second question becom what therefor role combin therapi and remain confid studi look combin therapi first line becom even import and answer question believ studi clear answer definit question use monotherapi pd firstlin set like limit patient express pd high level in word combin may eventu enabl immun system biolog drug deploy far earlier diseas cycl even perhap first line treatment yet repeat caforio main point current opdivokeytruda use first line monotherapi treatment limit patient express pdl protein high level plain miracl cure everyon the testingmarket pattern outlin also help explain pharmac zigzag opdivo keytruda past month right thoughit isnt fierc competit lower price either drug nor much hope pharmac shorten patent term less expens generic replac appear horizon eight year like patent term drug forese lung cancer common form cancer new zealand state fund keytruda late stage treatment option nonsmal cell lung cancer nsclc would high expens pharmac look hope oversea test evid might help target patient would stand benefit drug this genuin problem in us fda guidelin make pdl level precondit treatment perhap process involv still somewhat mysteri there still consensus regard valu pdl express nsclc predict marker respons across board posit pdl predict respons alway guarante lack pdl exclud respons obvious one must conclud pdl one sever mani factor determin likelihood respons to compound pdl problem lack defin criteria pdlposit tumor realli mean the like emerg combin may increas effect scope treatment peopl eliug mention combin price someth els pharmac nervous ponder cancer meanwhil isnt stand still disturb sign segment cancer patient may stand benefit treatment also face potenti relaps given capac cancer develop resist a recent studi came unsettl conclus patient',\n",
       "  'JJ'),\n",
       " ('samuelmanu i follow om diet month while follow diet ms class stabl i could diet could gilenya could fast could who care i havent relaps sinc diagnosi i recent switch wahl protocol still relaps free go anoth mri month see new lesion i also think benefit ms exagger benefit general help sure revers diseas immun system skeptic still i follow religi els got',\n",
       "  'NN'),\n",
       " ('new genet research diabet led team harvard medic school identifi potenti new therapi target runx explain signific reduc abnorm blood vessel growth retina hallmark advanc diabet eye diseas although research conduct vitro explain laboratori studi human retin cell mous retina studi author hope inhibit runx may also help manag abnorm retin blood vessel growth number eye condit wet macular degener retinopathi prematur earlier diseas process abnorm blood vessel chanc develop were hope may opportun chang treatment paradigm condit said coauthor leo a kim md phd instead treat patient abnorm blood vessel form eye may abl give patient eye drop system medic prevent develop first place the research diabet this new diabet research titl identif runx mediat aberr retin angiogenesi translat identif protein chang reduc abnorm blood vessel growth occur retin diseas includ diabet retinopathi publish onlin first april diabet publish american diabet associ diabet present origin research normal abnorm physic process occur diabet mellitus includ laboratori anim human research the author jonathan d lam daniel j oh lindsay l wong dhanesh amarnani cindi parkwindhol angi v sanchez jonathan cardonavelez declan mcguon anat o stemmerrachamimov dean eliott dian r bielenberg tave van zyl lishuang shen xiaowu gai patricia a damor leo a kim joseph f arboledavelasquez harvard medic school boston ma massachusett general hospit boston ma children hospit los angel los angel ca universidad pontificia bolivariana medellin colombia first some terminolog use research here brief explan key term use diabet research angiogenesi describ growth new blood vessel play crucial role normal develop bodi organ tissu howev excess abnorm blood vessel develop also occur diseas cancer tumor growth macular degener diabet retinopathi retin macular bleed in vitro refer process take place test tube cultur dish typic laboratori in vivo refer process take place live human organ neovascular when refer eye diabet retinopathi wet agerel macular degener describ abnorm blood vessel growth retina neo new vascular blood vessel neovascular also featur eye health condit includ retinopathi prematur cancer runx runtrel transcript factor protein human encod runx gene the runx protein activ gene help control develop blood cell vegf a protein call vascular endotheli growth factor stimul abnorm blood vessel growth retina macula about research excerpt research identifi new target abnorm blood vessel growth eye via medic xpress research identifi novel therapeut target retin neovascular abnorm blood vessel growth retina hallmark advanc diabet eye diseas prolif diabet retinopathi transcript factor runx found abnorm retin blood vessel inhibit runx small molecul drug research achiev percent reduct retinopathi preclin mean human clinic trial begun model these find pave way new therapi address diabet retinopathi condit involv abnorm vessel growth within retina current treatment control retin neovascular requir inject larg protein ie lucenti eylea avastin eye patient often month our studi open door novel mode treatment base small molecul could cross biolog barrier such treatment could selfadminist patient elimin need intravitr inject said coauthor joseph f arboledavelasquez md phd in diabet report author studi tissu patient prolif diabet retinopathi they identifi presenc runx diseas blood vessel normal blood vessel next use small molecul drug origin develop cancer therapi inhibit activ runx eye led signific reduct abnorm blood vessel the studi author hope inhibit runx may present target opportun manag retinopathi certain eye conditionsperhap earlier diseas process abnorm blood vessel develop futur studi test whether drug deliv topic eye drop rather inject explor relationship runx vegf factor seem play role angiogenesi more diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age how person diabet retinopathi might see retinopathi general term describ damag retina the retina thin lightsensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls these electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif general term mean grow increas rapid rate produc new tissu cell when term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina nonprolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild nonprolif retinopathi at earli stage small area balloonlik swell occur retina tini blood vessel moder nonprolif retinopathi as diseas progress blood vessel nourish retina becom block sever nonprolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina the damag retina signal bodi produc new blood vessel prolif retinopathi at advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreous transpar gel fill interior eye becaus new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreous scar tissu develop tug retina caus damag even retin detach you learn current treatment diabet retinopathi what treatment are avail diabet eye diseas visionawareorg more about studi journal diabet excerpt studi abstract prolif diabet retinopathi pdr common caus blind develop world work adult popul affect type type diabet mellitus we identifi runtrel transcript factor runx gene upregul cd vascular endotheli cell obtain human pdr fibrovascular membran fvm via transcriptom analysi in vitro studi use human retin microvascular endotheli cell hrmec ie cell inner line blood vessel show increas runx rna protein express respons high glucos wherea runx inhibit reduc hrmec migrat prolifer tube format immunohistochem stain runx show reactiv vessel patientderiv fvm angiogen tuft retina mice oxygeninduc retinopathi oir suggest runx upregul hallmark aberr retin angiogenesi inhibit runx activ ro small molecul result signific reduct neovascular tuft oxygeninduc retinopathi oir support feasibl target runx aberr retin angiogenesi',\n",
       "  'NN'),\n",
       " ('i dont experi entyvio read hasnt well reciev it seem stelara get best review newer antitnf one consist critic entyvio take quit long time work it might good choic recommend homework first my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran',\n",
       "  'NN'),\n",
       " ('welcom entyvio logthread kinaydeingrrl welcom forum i dont see uceri list medic i id strong advis speak gi switch pred uceri bridg uceri might effect prednison certain doesnt work much safer steroid httpsharedsalixcomsharedpiucerispipdf isnt near system it work also havent mention either remicad simponi i know im keep open option event entyvio someday fail someth consid also mayb good probiot could certain help caus arent alreadi one someth id strong think httpwwwncbinlmnihgovpubm mkl i recollect postinfus issu im hope issu resolv pancol dx fall current imuran lialda entyvio',\n",
       "  'NN'),\n",
       " ('hello it realli difficult earli day differenti relaps progress ms one reason relaps remit ms kind name impli youll get complet remiss symptom and also time frame actual spoken the fact rrms alway give complet remiss you might find i never proper feel feet but sort get use chang sensori symptom and forget like abl feel thing proper finger sole feet whatev the problem time take remiss it sometim week often least alway month and much time would pass id forget i problem one day thing would sudden occur i havent spasm leg im even sure long keep diari way ive found keep track even year sinc first symptom i forget i x happen y so i check diari app see x happen caus get y check my diari app near year old i check time even though im progress neurologist tend reluct day definit diagnos someon outset progress one reason diseas modifi drug dmds avail ppms even possibl ocrevus given thumb week so neurologist uncertain diagnos rrms simpli dmds sort cant go back progress diagnosi and cours marker indic exact progress progress often peopl start rr diagnosi could potenti chang month year pp spms so se ask seem straightforward question easi answer question add fact peopl rrms realli sever disabl relaps peopl ppms much gentl progress disabl see winner loser unfortun ms and bloodi unlucki varieti sue',\n",
       "  'NN'),\n",
       " ('we report patient activ ulcer coliti primari nonrespons three biolog infliximab adalimumab vedolizumab differ mechan action refus surgic treatment favor respons tofacitinib clinic endoscop remiss no advers event observ use agent this case illustr difficulti may face regard identif express proper mechan action involv pathogenesi ulcer coliti patient import anoth treatment option differ mechan action like tofacitinibresumo os inibidor das janus kinas jak sido incorporado ao tratamento de doena imunomediada como artrit reumatoid e alm disso tm sido testado tratamento da psoras e doena inflamatria intestinai tanto na retocolit ulcerativa quanto na doena de crohn tofacitinib uma droga grupo das pequena mol cula de uso oral que inib janus kinas e e em menor grau janus kinas esta inibio promov bloqueio de uma srie de citocina prinflamatria que esto envolvida na patognes das doena inflamatria intestinai e desempenham important papel nos processo imun tai como ativao funo e proliferao linfocitaacu httpwwwscielobrscielophpscriptsciarttextpidsl sourc arquivo de gastroenterologia',\n",
       "  'NN'),\n",
       " ('leav behind bs got second infus let final talk infus unfortun wasnt full dose mg this specialti pharmaci order mg two week ill back take half this way would start ocrevus the second infus suppos full dose howev infus basic after find good vein iv your readi rock my problem find vein due excess use steroid odd year vein habit roll collaps shrink difficult find vein iv luckili took twice first start steroid drip thank god mg mg howev let real mg steroid iv joke when steroid pack your sick highest start mg not mention that oral drug the steroid drip take rough half hour the benadryl realli get ive via pill iv drip push iv line the one i didnt reaction pill i would say drip came second slow still like morph drip the push iv line shock ive learn tell take slow help watch though flush line benadryl still remain goe shoot blood for goe right heart lung it almost seiz i cant breath second i cough second later im fine if your expect scari it also make littl dizzi eventu youll tire it like noth youv ever experienc come direct blood push iv line drip dont expect like benadryl take home the medicin easi they usual step drip start slow increas everi half hour goe slow start build i cant say one advers reaction that somebodi offic i person minor reaction my ear would itch like allergi act the first time i rituxan happen stop give littl benadryl start with ocrevus light i paid mind the total drip last hour this morn i woke headach that say anyth raini snowi day ny could weather relat im also prone migrain could truth biggest side effect i last time rituxan steroid that i probabl wont feel mayb tomorrow that ani question feel free ask',\n",
       "  'NN'),\n",
       " ('i year old femal cancer good health on march i diagnos nsclc stage egfr exon four brain met treat cyber knife ck week later eventu resolv i tarceva sinc april i vat lobectomi novemb i ned neck sinc vat two year one mm brain met treat ck januari i continu work recent latest scansmri show progress two brain met previous treat seem come back one mm seem stabl sinc octob the one grown mm mm one lymph node light pet scan suv one lung nodul light grown multipl tini lung nodul mention pet report small show suv i follow cea month gone i three guardant liquid biopsi would pick nf noth els my doctor request anoth liquid biopsi urin test trovagen find i continu egfr tm mutat i got result phone earlier today told egfr came one test tm detect he still want tissu biopsi check tm i offer follow if tm negat laser interstici thermal therapi litt one brain met chemo if tm posit tagrisso how do respons rate compar between tagrisso tm vs chemo carboplatinalimta could i tri tagrisso for one or two month befor chemo and litt doe chemo penetr the brain of cours the tissu biopsi will definit throw more light into the matter but it will take a while he want to start treatment now a multitud thank faith',\n",
       "  'NN'),\n",
       " ('a type monoclon antibodi use cancer detect therapi monoclon antibodi laboratoryproduc substanc locat bind cancer cell a a substanc studi treatment cancer a small piec protein call urokinas enzym dissolv blood clot prevent form it type antiangiogenesi agent type antimetastat agent also call urokinas plasminogen activ upaderiv peptid a aap an enzym normal found healthi kidney it may found high level urin kidney problem it use biomark detect damag kidney caus drug agent it may also use diagnos certain kidney liver disord also call alanin aminopeptidas abarelix listen uhbayrehlix a drug use reduc amount testosteron made patient advanc symptomat prostat cancer treatment option avail it belong famili drug call gonadotropinreleas hormon gnrh antagonist also call plenaxi abca pathway listen pathway describ group protein cell work togeth help remov extra cholesterol certain fat tissu bodi chang abca pathway may lead diseas heart blood vessel drug substanc affect pathway studi prevent treatment diseas abcd rate listen rayt a stage system prostat cancer use abcd a b refer cancer confin prostat c refer cancer grown prostat spread lymph node place bodi d refer cancer spread lymph node place bodi also call jewett stage system whitmorejewett stage system abdomen listen abdohmen the area bodi contain pancrea stomach intestin liver gallbladd organ abdomin listen abdahmihnul have abdomen part bodi chest hip contain pancrea stomach intestin liver gallbladd organ abdomin ultrasound listen abdahmihnul ultruhsownd a procedur use examin organ abdomen an ultrasound transduc probe press firm skin abdomen highenergi sound wave transduc bounc tissu creat echo the echo sent comput make pictur call sonogram also call transabdomin ultrasound abdomin xray listen abdahmihnul exray an xray organ insid abdomen an xray type radiat pass bodi onto film make pictur area insid bodi xray may use help diagnos diseas abdominoperin resect listen abdahmihnohpayrihneeul reesekshun surgeri remov anus rectum part sigmoid colon incis made abdomen the end intestin attach open surfac abdomen bodi wast collect dispos bag outsid bodi this open call colostomi lymph node contain cancer may also remov oper abegrin listen abehgrin a substanc studi treatment type cancer condit abegrin bind protein surfac blood vessel may prevent growth new blood vessel tumor need grow it may also prevent spread cancer it type antiangiogenesi agent type metastasi inhibitor type monoclon antibodi also call etaracizumab human monoclon antibodi medi medi abemaciclib listen uhbehmuhsyklib a drug use treat hormonereceptor posit hr herneg her breast cancer advanc spread part bodi it use aromatas inhibitor postmenopaus women treat hormon therapi it use fulvestr women whose diseas got wors treatment hormon therapi abemaciclib also use alon men women whose diseas got wors treatment hormon therapi previous chemotherapi it also studi treatment type cancer abemaciclib block certain protein may help keep cancer cell grow it type cyclindepend kinas inhibitor also call verzenio aberr crypt foci listen uhbayrunt kript fohsi cluster abnorm tubelik gland line colon rectum aberr crypt foci form colorect polyp one earliest chang seen colon may lead cancer also call acf abi a drug use treat breast cancer come back spread part bodi it also use carboplatin treat advanc nonsmal cell lung cancer patient abl surgeri radiat therapi it also use gemcitabin hydrochlorid treat pancreat cancer spread part bodi it studi treatment type cancer abi form anticanc drug paclitaxel may caus fewer side effect paclitaxel it stop cancer cell grow divid may kill it type mitot inhibitor type antimicrotubul agent also call abraxan nanoparticl paclitaxel paclitaxel albuminstabil nanoparticl formul proteinbound paclitaxel abirateron acet listen abihratehron asehtayt a drug use prednison treat prostat cancer spread part bodi it use patient whose cancer castrat resist respond treatment lower testosteron level whose cancer high risk castrat sensit respond treatment lower testosteron level it also studi treatment type cancer abirateron acet lower amount androgen male hormon testosteron made bodi this may stop growth cancer cell need androgen grow abirateron acet type antiandrogen also call zytiga ablat listen ablayshun in medicin remov destruct bodi part tissu function ablat may perform surgeri hormon drug radiofrequ heat method abnorm listen abnormul not normal describ state condit behavior unusu differ consid normal an abnorm lesion growth bodi may benign cancer precancer premalign like becom cancer malign cancer abo blood group system listen blud groop sistem a system use group human blood differ type base presenc absenc certain marker surfac red blood cell the four main blood type a b o ab for blood transfus abo blood group system use match blood type donor person receiv transfus peopl blood type o donat blood anyon call univers donor peopl blood type ab accept blood donor call univers recipi peopl type a b receiv match blood type o blood abr test listen test a test use detect type hear loss hear loss caus injuri tumor affect nerv involv hear electrod place head certain tone click sound made the electrod measur nerv signal brain react sound also call auditori brain stem respons test baer test brain stem auditori evok respons test abraxan listen uhbraksayn a drug use treat breast cancer come back spread part bodi it also use carboplatin treat advanc nonsmal cell lung cancer patient abl surgeri radiat therapi it also use gemcitabin hydrochlorid treat pancreat cancer spread part bodi it studi treatment type cancer abraxan form anticanc drug paclitaxel may caus fewer side effect paclitaxel it stop cancer cell grow divid may kill it type mitot inhibitor type antimicrotubul agent also call abi nanoparticl paclitaxel paclitaxel albuminstabil nanoparticl formul proteinbound paclitaxel abrikossoff tumor listen ahbreekahsof toomer a rare type soft tissu tumor usual begin schwann cell cell hold nerv cell place it occur anywher bodi usual occur skin head neck especi mouth tongu it may also occur chest breast esophagus stomach intern organ most abrikossoff tumor benign cancer may malign cancer spread quick nearbi tissu they usual occur middleag adult also call granular cell tumor abscess listen abs an enclos collect pus tissu organ confin space bodi an abscess sign infect usual swollen inflam absolut neutrophil count listen absohloot nootrohfil kownt a measur number neutrophil blood neutrophil type white blood cell they help bodi fight infect an absolut neutrophil count may use check infect inflamm leukemia condit the lower person absolut neutrophil count higher risk get infect have absolut neutrophil count less mean high risk get infect cancer treatment chemotherapi may reduc absolut neutrophil count also call anc absolut risk listen absohloot risk a measur risk certain event happen in cancer research likelihood person free specif type cancer given age develop cancer certain period time for exampl woman year age known risk factor breast cancer absolut risk get breast cancer lifetim year mean one everi seven women develop breast cancer absorpt listen ubsorpshun the process take nutrient digest system blood use bodi abt a substanc studi treatment lymphoma type cancer it block enzym keep cancer cell die it type bcl famili inhibitor also call navitoclax abt a substanc studi treatment cancer it type angiogenesi inhibitor abt a substanc studi treatment cancer it belong famili drug call sulfonamid abt a substanc studi treatment sever type cancer abt block action sever growth factor it may also block growth new blood vessel tumor need grow may caus cancer cell die it type receptor tyrosin kinas inhibitor type angiogensi inhibitor also call multitarget receptor tyrosin kinas inhibitor abt abt a substanc studi treatment breast cancer caus mutat chang brca brca gene it also studi treatment type cancer it block enzym involv mani function cell includ repair dna damag dna damag may caus normal cell action uv light anticanc drug radiat use treat cancer abt may caus cancer cell die it type polyadpribos polymeras inhibitor also call parp inhibitor abt veliparib abvd an abbrevi chemotherapi combin use treat hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vinblastin sulfat dacarbazin also call abvd regimen abvd regimen listen rehjihmen an abbrevi chemotherapi combin use treat hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vinblastin sulfat dacarbazin also call abvd abv an abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid also call abv regimen dbve dbve regimen abv regimen listen rehjihmen an abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid also call abv dbve dbve regimen abvepc an abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid prednison cyclophosphamid also call abvepc regimen dbvepc dbvepc regimen abvepc regimen listen rehjihmen an abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma it includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid prednison cyclophosphamid also call abvepc dbvepc dbvepc regimen abxegf a drug use alon anticanc drug treat certain type colorect cancer spread part bodi it use patient whose cancer alreadi treat whose cancer got wors treatment anticanc drug it also studi treatment type cancer abxegf bind protein call epiderm growth factor receptor egfr found normal cell type cancer cell block protein may help keep cancer cell grow abxegf type monoclon antibodi also call panitumumab vectibix ac an abbrevi chemotherapi combin use type therapi treat breast cancer includ breast cancer spread come back it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid also call ac regimen ac regimen listen rehjihmen an abbrevi chemotherapi combin use type therapi treat breast cancer includ breast cancer spread come back it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid also call ac acalabrutinib listen uhkaluhbrootihnib a drug use treat mantl cell lymphoma patient alreadi receiv least one treatment it also studi treatment type cancer acalabrutinib block protein call bruton tyrosin kinas btk may help keep cancer cell grow it type tyrosin kinas inhibitor also call calquenc acapha listen akafuh a mixtur six herb use china prevent treat diseas lung esophag cancer it studi unit state canada prevent lung cancer peopl use smoke acceler partialbreast irradi listen aksehlehrayt parshulbrest ihraydeeayshun a type radiat therapi given part breast cancer acceler partialbreast irradi give higher dose shorter time given standard wholebreast radiat therapi acceler partialbreast irradi may given use intern extern sourc radiat also call partialbreast irradi acceler phase chronic myelogen leukemia listen aksehlehrayt fayz krahnik myehlahjehnus lookeemeeuh a phase chronic myelogen leukemia diseas progress in phase cell blood bone marrow blast cell immatur blood cell acceler radiat therapi listen aksehlehrayt raydeeayshun thayruhpe radiat treatment total dose radiat given shorter period time fewer day compar standard radiat therapi acceleratedfract radiat therapi listen aksehlehraytedfrakshun raydeeayshun thayruhpe radiat treatment total dose radiat divid small dose treatment given day the total dose radiat also given shorter period time fewer day compar standard radiat therapi accol listen akohlayt a drug use prevent treat symptom asthma it block substanc caus inflamm lung it type antiasthmat agent leukotrien receptor antagonist also call zafirlukast ace inhibitor listen inhihbiht a drug use lower blood pressur an ace inhibitor type antihypertens agent also call angiotensinconvert enzym inhibitor acetaminophen listen uhseetuhmihnuhfen a drug reduc pain fever inflamm it belong famili drug call analges acet listen asehtayt a form acet acid acid found vinegar acet acid listen uhseetik asid an acid found vinegar acet acid also use dissolv substanc need make medicin product plastic aceton listen asehton a chemic substanc found natur small amount plant tree volcano forest fire aceton also made bodi fat broken it also found tobacco smoke car exhaust trash landfil in industri aceton use plastic fiber medicin household cleaner glue nail polish remov be expos high level aceton may irrit skin eye nose throat lung it caus headach nausea vomit dizzi confus loss conscious health problem acetyl group listen asehtil groop a small molecul made two carbon three hydrogen one oxygen atom acetyl group ad remov molecul may affect molecul act bodi acetyl listen asehtihlayshun a chemic reaction small molecul call acetyl group ad molecul acetyl protein may affect act bodi acetylcholin listen asehtilkohleen a chemic made type nerv cell it use send messag cell includ nerv cell muscl cell gland cell it releas nerv end carri signal cell side synaps space nerv cell cell acetylcholin help control memori action certain muscl it type neurotransmitt acetylcystein listen asehtilsisteheen a drug usual use reduc thick mucus eas remov it also use revers toxic high dose acetaminophen also call nacetyllcystein nacetylcystein acetyllcarnitin listen asehtil karnihteen a form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product it use mani cell bodi make energi fat also call acetyllcarnitin hydrochlorid alcar acetyllcarnitin hydrochlorid listen asehtil karnihteen hydrohklorid a form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product it use mani cell bodi make energi fat also call acetyllcarnitin alcar acf cluster abnorm tubelik gland line colon rectum acf form colorect polyp one earliest chang seen colon may lead cancer also call aberr crypt foci achlorhydria listen ayklorhydreeuh a lack hydrochlor acid digest juic stomach hydrochlor acid help digest food acid listen asid a chemic give hydrogen ion water form salt combin certain metal acid sour tast turn certain dye red some acid made bodi gastric acid help organ work way an exampl acid hydrochlor acid acid measur scale call ph scale on scale valu neutral ph valu less show increas acid acidbas balanc listen asidbay balunt in medicin state right amount acid base blood bodi fluid keep normal acidbas balanc import bodi work way also call acidbas equilibrium acidbas equilibrium listen asidbay eekwuhlihbreeum in medicin state right amount acid base blood bodi fluid keep normal acidbas equilibrium import bodi work way also call acidbas balanc acidif listen asihdihfihkayshun the process make becom acid an acid substanc give hydrogen ion water form salt combin certain metal acid listen asihdihte describ amount acid substanc an acid chemic give hydrogen ion water form salt combin certain metal acid measur scale call ph scale on scale ph valu neutral ph valu less show increas acid acitretin listen asihtrehtin a substanc use prevent cancer treatment psoriasi it belong famili drug call retinoid acn a substanc studi treatment type cancer acn weaken adenovirus carri p gene tumor cell caus die it type gene therapi also call radp recombin adenovirusp sch acn listen akne a disord skin oil gland hair gland becom inflam acolbifen hydrochlorid listen aykolebihfeen hydrohklorid a substanc studi prevent breast cancer women high risk breast cancer acolbifen hydrochlorid bind estrogen receptor bodi block effect estrogen breast it type select estrogen receptor modul serm acoust listen uhkoostik have sound hear acoust neurofibromatosi listen uhkoostik noorohfybrohmuhtohsi a genet condit tumor form nerv inner ear caus loss hear balanc tumor may also occur brain nerv skull spinal cord may caus loss speech eye movement abil swallow also call neurofibromatosi type nf acquir immunodefici syndrom listen uhkwyerd ihmyoonohdehfihshunse sindrom a diseas caus human immunodefici virus hiv peopl acquir immunodefici syndrom increas risk develop certain cancer infect usual occur individu weak immun system also call aid acquir pure red cell aplasia listen uhkwyerd sel uhplayzhuh a rare disord bone marrow make almost red blood cell it may caus infect certain drug patient disord may also thymoma tumor thymus autoimmun condit lupus erythematosus rheumatoid arthriti acridin carboxamid listen akrihdeen karboksuhmid a substanc studi treatment cancer it type topoisomeras inhibitor also call daca acromegali listen akrohmehguhle a condit pituitari gland make much growth hormon normal growth skeleton finish this caus bone hand feet head face grow larger normal acromegali caus pituitari gland tumor acrylonitril listen akrihlohnytril a substanc use make plastic rubber textil be expos acrylonitril may increas risk develop certain cancer lung brain prostat cancer act an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call act regimen actaxol regimen act regimen listen rehjihmen an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call act actaxol regimen actaxol regimen listen taksol rehjihmen an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call act act regimen actemra listen aktemruh a drug use treat sever lifethreaten cytokin releas syndrom caus type immunotherapi call chimer antigen receptor car tcell therapi it use patient age year older actemra also use treat certain type arthriti condit caus inflamm line arteri it also studi treatment condit actemra bind receptor protein call interleukin il made white blood cell cell bodi this may help lower bodi immun respons reduc inflamm actemra type monoclon antibodi also call tocilizumab acth a hormon made pituitari gland acth act outer part adren gland control releas corticosteroid hormon more acth made time stress also call adrenocorticotrop hormon corticotropin acth regimen listen rehjihmen an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call actt actt regimen sequenti actaxoltrastuzumab regimen actinex listen aktihnex a drug put skin treat growth caus sun exposur a form actinex taken mouth studi treatment prostat cancer actinex antioxid may block certain enzym need tumor growth also call masoprocol ndga nordihydroguaiaret acid actin keratosi listen aktihnik kayruhtohsi a thick scali patch skin may becom cancer it usual form area expos sun face scalp back hand chest it common peopl fair skin also call senil keratosi solar keratosi actinomycin d listen aktihnohmysin a drug use treat ewe sarcoma gestat trophoblast tumor wilm tumor certain type testicular cancer it also use treat rhabdomyosarcoma children it studi treatment type cancer actinomycin d come bacterium streptomyc parvulus it damag cell dna may kill cancer cell it type anticanc antibiot also call cosmegen dactinomycin action studi listen akshun stuhde in cancer prevent clinic trial studi focus find whether action peopl take prevent cancer activas listen aktihvay a form tissu plasminogen activ made laboratori it help dissolv blood clot use treat heart attack stroke clot lung it also studi treatment cancer it type system thrombolyt agent also call alteplas rtpa recombin tissu plasminogen activ activ listen aktihvayt in biolog stimul cell rest state becom activ this caus biochem function chang activ cell activ surveil listen aktiv servayl a treatment plan involv close watch patient condit give treatment unless chang test result show condit get wors activ surveil may use avoid delay need treatment radiat therapi surgeri caus side effect problem dure activ surveil certain exam test done regular schedul it may use treatment certain type cancer prostat cancer urethr cancer intraocular eye melanoma it type expect manag activ daili live listen aktihvihteezdayle lihv the task everyday life these activ includ eat dress get bed chair take bath shower use toilet instrument activ daili live activ relat independ live includ prepar meal manag money shop housework use telephon also call adl acto listen aktos a drug use treat type diabet studi prevent head neck cancer it may abl stop leukoplakia condit affect mouth develop cancer it type thiazolidinedion also call pioglitazon actt an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call actt regimen acth regimen sequenti actaxoltrastuzumab regimen actt regimen listen rehjihmen an abbrevi chemotherapi combin use treat breast cancer it includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call actt acth regimen sequenti actaxoltrastuzumab regimen acupoint listen akyoopoynt a specif spot bodi acupunctur needl may insert control pain symptom also call acupunctur point acupressur listen akyooprehsh the applic pressur local massag specif site bodi control symptom pain nausea it type complementari altern medicin acupunctur listen akyoopunkch the techniqu insert thin needl skin specif point bodi control pain symptom it type complementari altern medicin acupunctur needl listen akyoopunkch needul a stainless steel needl slight thicker human hair acupunctur needl insert skin specif point bodi control pain symptom acupunctur point listen akyoopunkch poynt a specif spot bodi acupunctur needl may insert control pain symptom also call acupoint acupunctur point inject listen akyoopunkch poynt injekshun a procedur drug vitamin herbal extract fluid inject bodi acupunctur point use syring needl acupuncturelik transcutan electr nerv stimul listen akyoopunkcherlik tranzkyootayneeus eelektrihkul nerv stimyoolayshun a procedur mild electr current appli certain acupunctur point spot bodi acupunctur needl may insert control pain symptom skin it studi treatment dri mouth caus radiat therapi cancer also call alten acupuncturist listen akyoopunkchehrist a person train acupunctur therapi use thin needl insert skin specif point bodi control pain symptom acupunctur type complementari altern medicin acustimul listen akyoostimyoolayshun mild electr stimul acupunctur point control symptom nausea vomit acut listen uhkyoot symptom sign begin worsen quick chronic acut bacteri prostat listen uhkyoot bakteereeul prostuhtyti inflamm prostat gland begin sudden get wors quick it caus bacteri infect symptom includ fever chill bodi ach pain lower back genit area burn feel urin problem empti bladder way acut leukemia listen uhkyoot lookeemeeuh a rapid progress cancer start bloodform tissu bone marrow caus larg number white blood cell produc enter blood stream acut lymphoblast leukemia listen uhkyoot limfohblastik lookeemeeuh a type leukemia blood cancer come quick fast grow in acut lymphoblast leukemia mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphocyt leukemia all acut lymphocyt leukemia listen uhkyoot limfohsihtik lookeemeeuh a type leukemia blood cancer come quick fast grow in acut lymphocyt leukemia mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphoblast leukemia all acut myeloblast leukemia listen uhkyoot myehlohblastik lookeemeeuh an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml anll acut myelogen leukemia listen uhkyoot myehlahjehnus lookeemeeuh an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml anll acut myeloid leukemia listen uhkyoot myehloyd lookeemeeuh an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut nonlymphocyt leukemia aml anll acut myeloid leukemia myelodysplasiarel chang listen uhkyoot myehloyd lookeemeeuh myehlohdisplayzhuhreelayt chaynjiz a type acut myeloid leukemia least patient blood bone marrow myeloblast immatur white blood cell patient one follow condit myelodysplast syndrom mds myelodysplasticmyeloprolif neoplasm mdsmpn cell chang certain chromosom similar found mds least cell least two type blood cell abnorm acut myeloid leukemia myelodysplasiarel chang usual occur older adult poor prognosi also call amlmrc acut nonlymphocyt leukemia listen uhkyoot nonlimfohsihtik lookeemeeuh an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia aml anll acut pain listen uhkyoot payn pain come quick sever last relat short time acut promyelocyt leukemia listen uhkyoot prohmyehlohsihtik lookeemeeuh an aggress fastgrow type acut myeloid leukemia mani immatur bloodform cell blood bone marrow it usual mark exchang part chromosom also call apl promyelocyt leukemia acut radiat sick listen uhkyoot raydeeayshun sikn serious ill caus expos high dose certain type radiat usual short period time symptom acut radiat sick usual occur right exposur may happen time may come go symptom includ nausea vomit diarrhea headach dizzi weak fatigu bleed hair loss swell itch red skin skin problem veri larg dose radiat may caus death also call acut radiat syndrom radiat poison radiat sick radiat sick syndrom acut radiat syndrom listen uhkyoot raydeeayshun sindrom serious ill caus expos high dose certain type radiat usual short period time symptom acut radiat syndrom usual occur right exposur may happen time may come go symptom includ nausea vomit diarrhea headach dizzi weak fatigu bleed hair loss swell itch red skin skin problem veri larg dose radiat may caus death also call acut radiat sick radiat poison radiat sick radiat sick syndrom acyclovir listen aysyklohv a substanc use prevent treat cytomegalovirus herp simplex infect may occur bodi immunosuppress it belong famili drug call antivir ad a drug use treat bladder carcinoma situ get better treatment bacillus calmetteguerin bcg it use patient cannot surgeri right away remov part bladder ad given solut cathet place bladder it block certain enzym need cell divis dna repair may kill cancer cell ad type anthracyclin antibiot type topoisomeras inhibitor also call valrubicin valstar adc a substanc made monoclon antibodi chemic link drug the monoclon antibodi bind specif protein receptor found certain type cell includ cancer cell the link drug enter cell kill without harm cell some adc use treat cancer also call antibodydrug conjug adcc a type immun reaction target cell microb coat antibodi kill certain type white blood cell the white blood cell bind antibodi releas substanc kill target cell microb also call antibodydepend cellmedi cytotox antibodydepend cellular cytotox adcetri listen adsehtri a drug use anticanc drug treat system anaplast larg cell lymphoma peripher tcell lymphoma includ angioimmunoblast tcell lymphoma cd posit treat therapi it also use anticanc drug treat stage iii stage iv classic hodgkin lymphoma treat therapi adcetri also use treat certain type hodgkin lymphoma anaplast larg cell lymphoma mycosi fungoid treat therapi it also studi treatment type cancer adcetri contain monoclon antibodi bind protein call cd found lymphoma cell it also contain anticanc drug may help kill cancer cell adcetri type antibodydrug conjug also call brentuximab vedotin sgn adderal listen adehrawl a combin drug use treatment attent deficit hyperact disord adhd narcolepsi sleep disord it type stimul also call dextroamphetamineamphetamin addict listen uhdikshun an uncontrol crave seek use substanc drug alcohol addison diseas listen adihsun dihzeez a rare disord adren gland make enough certain hormon symptom includ weight loss loss appetit nausea vomit diarrhea muscl weak fatigu low blood sugar low blood pressur patchi dark skin most case disord caus immun system problem may also caus infect cancer diseas also call adren insuffici ade an abbrevi chemotherapi combin use treat childhood acut myeloid leukemia aml it includ drug cytarabin arac daunorubicin hydrochlorid etoposid phosphat also call ade regimen ade regimen listen rehjihmen an abbrevi chemotherapi combin use treat childhood acut myeloid leukemia aml it includ drug cytarabin arac daunorubicin hydrochlorid etoposid phosphat also call ade adenin listen adehneen a chemic compound use make one build block dna rna it also part mani substanc bodi give energi cell adenin type purin adenocarcinoma listen adehnohkarsihnohmuh cancer begin glandular secretori cell glandular cell found tissu line certain intern organ make releas substanc bodi mucus digest juic fluid most cancer breast pancrea lung prostat colon adenocarcinoma adenocarcinoma situ listen adehnohkarsihnohmuh sytoo a condit abnorm cell found glandular tissu line certain intern organ uterus cervix lung pancrea colon adenocarcinoma situ occur often cervix may becom cancer spread nearbi normal tissu also call ai adenoid cystic carcinoma listen adehnoyd sistik karsihnohmuh a rare type cancer usual begin salivari gland adenoma listen adehnohmuh a tumor cancer it start glandlik cell epitheli tissu thin layer tissu cover organ gland structur within bodi adenopathi listen adehnahpuhthe larg swollen lymph gland adenosarcoma listen adenohsarkohmuh a tumor mixtur adenoma tumor start glandlik cell epitheli tissu sarcoma tumor start bone cartilag fat muscl blood vessel connect support tissu an exampl adenosarcoma wilm tumor adenosin triphosph listen uhdehnuhseen tryfosfayt a substanc present live cell provid energi mani metabol process involv make rna adenosin triphosph made laboratori studi patient advanc solid tumor see decreas weight loss improv muscl strength also call atp adenosi listen adehnohsi a diseas abnorm chang gland breast adenosi benign condit lobul larger usual adenosquam carcinoma listen adehnohskwaymus karsihnohmuh a type cancer contain two type cell squamous cell thin flat cell line certain organ glandlik cell adenovirus listen adenohvyrus a member famili virus caus infect respiratori tract eye gastrointestin tract form adenovirus caus diseas use gene therapi they carri gene may fix defect cell kill cancer cell adh a benign cancer condit cell normal line breast duct cell look abnorm microscop have adh increas risk breast cancer also call atyp ductal breast hyperplasia atyp ductal hyperplasia adipeg a substanc studi treatment melanoma liver cancer type cancer it break amino acid arginin may block growth cancer cell need arginin grow it type iminohydrolas also call pegyl arginin deiminas adjunct agent listen ajunkt ayjent in cancer therapi drug substanc use addit primari therapi adjunct therapi listen ajunkt thayruhpe anoth treatment use togeth primari treatment it purpos assist primari treatment also call adjunct therapi adjunct therapi listen ajunktiv thayruhpe anoth treatment use togeth primari treatment it purpos assist primari treatment also call adjunct therapi adjust disord listen uhjust disord a condit person respond stress event ill job loss divorc extrem emot action caus problem work home adjuv therapi listen ajoovunt thayruhpe addit cancer treatment given primari treatment lower risk cancer come back adjuv therapi may includ chemotherapi radiat therapi hormon therapi target therapi biolog therapi adl activ daili live the task everyday life basic adl includ eat dress get bed chair take bath shower use toilet instrument activ daili live iadl activ relat independ live includ prepar meal manag money shop housework use telephon also call activ daili live administr listen admihnihstrayshun in medicin act give treatment drug patient it also refer way given dose often given adnex mass listen adneksul a lump tissu near uterus usual ovari fallopian tube adnex mass includ ovarian cyst ectop tubal pregnanc benign cancer malign cancer tumor adolesc listen adohlehs a young person begun puberti yet becom adult dure adolesc child experi physic hormon chang mark transit adulthood adolesc general age year adopt cell therapi listen uhdoptiv sel thayruhpe a type immunotherapi use patient t cell type immun cell help bodi fight diseas cancer in cancer therapi t cell taken patient blood tumor tissu treat laboratori substanc make better abl target patient cancer cell kill larg number treat t cell grown laboratori given back patient help immun system fight cancer type adopt cell therapi includ chimer antigen receptor tcell car tcell therapi tumorinfiltr lymphocyt til therapi also call cellular adopt immunotherapi tcell transfer therapi adotrastuzumab emtansin listen adohtrastoozoomab emtanseen a drug use treat herposit breast cancer spread part bodi it use patient alreadi treat anticanc drug call trastuzumab type drug call taxan it may also use patient whose cancer recur come back adjuv therapi drug it also studi treatment type cancer adotrastuzumab emtansin contain monoclon antibodi call trastuzumab bind protein call her found breast cancer cell it also contain anticanc drug call dm may help kill cancer cell adotrastuzumab emtansin type antibodydrug conjug also call kadcyla tdm adren cancer listen uhdreenul kanser cancer form tissu adren gland two gland locat kidney the adren gland make hormon control heart rate blood pressur import bodi function adren cancer start outsid layer adren gland call adrenocort carcinoma adren cancer start center adren gland call malign pheochromocytoma adren cortex listen uhdreenul kortex the outer part adren gland small organ top kidney the adren cortex make androgen corticosteroid hormon adren gland listen uhdreenul a small gland make steroid hormon adrenalin noradrenalin these hormon help control heart rate blood pressur import bodi function there two adren gland one top kidney also call supraren gland adren insuffici listen uhdreenul insuhfihshense a rare disord adren gland make enough certain hormon symptom includ weight loss loss appetit nausea vomit diarrhea muscl weak fatigu low blood sugar low blood pressur patchi dark skin most case disord caus immun system problem may also caus infect cancer diseas also call addison diseas adren medulla listen uhdreenul mehdooluh the inner part adren gland small organ top kidney the adren medulla make chemic epinephrin adrenalin norepinephrin noradrenalin involv send nerv signal adrenalectomi listen uhdreenulektohme surgeri remov one adren gland small organ top kidney adrenalin listen uhdrehnuhlin a hormon neurotransmitt also call epinephrin adrenocort listen uhdreenohkortihkul have made outer layer adren gland produc steroid hormon there adren gland top kidney adrenocort cancer listen uhdreenohkortihkul kanser a rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort carcinoma cancer adren cortex adrenocort carcinoma listen uhdreenohkortihkul karsihnohmuh a rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort cancer cancer adren cortex adrenocorticotrop hormon listen uhdreenohkortihkohtrohpik hormon a hormon made pituitari gland adrenocorticotrop hormon act outer part adren gland control releas corticosteroid hormon more adrenocorticotrop hormon made time stress also call acth corticotropin adreview listen adrehvyoo a drug contain form radioact iodin call i use find certain type tumor includ pheochromocytoma neuroblastoma radiat i may help show cancer cell bodi adreview type radioconjug also call imibg iobenguan i iodin i metaiodobenzylguanidin adriamycin pfs listen aydreeuhmysin a brand name doxorubicin hydrochlorid use treat mani type cancer adriamycin pfs brand taken market longer avail adriamycin rdf listen aydreeuhmysin a brand name doxorubicin hydrochlorid use treat mani type cancer adriamycin rdf brand taken market longer avail adult progeria listen uhdult prohjeereeuh an inherit disord mark rapid age begin earli adolesc patient may shorter averag health problem loss gray hair harden arteri thin bone diabet thin harden skin they also increas risk cancer especi osteosarcoma type bone cancer adult progeria caus mutat chang gene involv cell divis it type autosom recess gene diseas also call werner syndrom ws adult ricket listen uhdult rihket a condit adult bone becom soft deform dont enough calcium phosphorus it usual caus enough vitamin d diet get enough sunlight problem way bodi use vitamin d symptom includ bone pain muscl weak when condit occur children call ricket also call osteomalacia adult tcell leukemialymphoma listen uhdult tsel lookeemeeuhlimfohmuh an aggress fastgrow type tcell nonhodgkin lymphoma caus human tcell leukemia virus type htlv it mark bone skin lesion high calcium level enlarg lymph node spleen liver also call atll adulter listen uhdultehrunt a substanc ad product list ingredi substanc end product accid product made adulter may food drug product an adulter may caus product harm cheaper make work adulttyp fibrosarcoma listen uhdult fybrohsarkohmuh a type cancer form fibrous connect tissu it occur anywher bodi adulttyp fibrosarcoma may spread nearbi tissu part bodi lung bone it may also recur come back treatment adulttyp fibrosarcoma usual occur young middleag adult also occur children it type soft tissu sarcoma advanc direct listen advan duhrektiv a legal document state person wish receiv medic care person longer abl make medic decis serious ill injuri an advanc direct may also give person spous relat friend author make medic decis anoth person person longer make decis there differ type advanc direct includ live durabl power attorney dpa healthcar resuscit dnr order in unit state law advanc direct may differ state state may allow certain type advanc direct advanc cancer listen advanst kanser cancer unlik cure control treatment the cancer may spread first start nearbi tissu lymph node distant part bodi treatment may given help shrink tumor slow growth cancer cell reliev symptom advanc practic nurs listen advanst prakti a regist nurs addit educ train diagnos treat diseas advanc practic nurs licens state level certifi nation nurs organ in cancer care advanc practic nurs may manag primari care patient famili base practic agreement doctor also call apn np nurs practition advers effect listen adver ehfekt an unexpect medic problem happen treatment drug therapi advers effect may mild moder sever may caus someth drug therapi given also call advers event advers event listen adver ehvent an unexpect medic problem happen treatment drug therapi advers event may mild moder sever may caus someth drug therapi given also call advers effect advil listen advil a drug use treat fever swell pain red prevent bodi make substanc caus inflamm it type nonsteroid antiinflammatori drug nsaid also call ibuprofen motrin ae a substanc made shark cartilag studi abil prevent growth new blood vessel tumor need grow it type antiangiogenesi agent aee a substanc studi treatment cancer it belong famili drug call protein tyrosin kinas inhibitor angiogenesi inhibitor aeg a substanc studi treatment cancer aeg may kill cancer cell block product protein call xiap help cell live longer it also make cancer cell sensit anticanc drug it type antisens oligonucleotid type chemosensit agent also call gem aerob listen ayrohbik in biochemistri reaction need oxygen happen happen oxygen present aerob exercis listen ayrohbik eksers physic activ increas heart rate bodi use oxygen it help improv person physic fit aerob metabol listen ayrohbik mehtabuhlihzum a chemic process oxygen use make energi carbohydr sugar also call aerob respir cell respir oxid metabol aerob respir listen ayrohbik respihrayshun a chemic process oxygen use make energi carbohydr sugar also call aerob metabol cell respir oxid metabol aerodigest tract listen ayrohdyjestiv trakt the combin organ tissu respiratori tract upper part digest tract includ lip mouth tongu nose throat vocal cord part esophagus windpip aerosol listen ayrohsahl in medicin turn liquid drug fine mist inhal afatinib dimal listen ayfatihnib dymayleeayt a drug use treat nonsmal cell lung cancer nsclc spread part bodi it use patient whose cancer certain mutat chang gene call epiderm growth factor receptor egfr it also use treat squamous cell nsclc spread part bodi got wors treatment anticanc drug includ platinum it also studi treatment type cancer afatinib dimal block certain protein made mutat egfr gene may help keep cancer cell grow it may also prevent growth new blood vessel tumor need grow afatinib dimal type tyrosin kinas inhibitor type antiangiogenesi agent also call gilotrif affin listen uhfihnihte in chemistri biolog strength attact two substanc two chemic antigen antibodi affin reagent listen uhfihnihte reeayjent in chemistri biolog compound bind specif substanc protein nucleic acid mani affin reagent antibodi they use analyz tissu sampl help diagnos diseas afinitor listen uhfihnihtor a drug use exemestan treat postmenopaus women advanc breast cancer hormon receptor posit her negat it also use treat advanc renal cell carcinoma type kidney cancer certain type pancreat lung gastrointestin neuroendocrin tumor afinitor also use treat renal angiomyolipoma type benign kidney tumor subependym giant cell astrocytoma type benign brain tumor patient tuber sclerosi it block protein involv cell divis may help keep abnorm cell includ cancer cell grow it may also prevent growth new blood vessel tumor need grow afinitor contain activ ingredi everolimus it type kinas inhibitor type angiogenesi inhibitor afinitor disperz listen uhfihnihtor disperz a drug use treat subependym giant cell astrocytoma type benign brain tumor certain type seizur patient tuber sclerosi afinitor disperz block protein involv cell divis may help keep abnorm cell grow it may also prevent growth new blood vessel tumor need grow it may also help prevent treat seizur patient afinitor disperz contain activ ingredi everolimus it type kinas inhibitor type angiogenesi inhibitor aflatoxin listen afluhtoksin a harm substanc made certain type mold aspergillus flavus aspergillus parasiticus often found poor store grain nut consumpt food contamin aflatoxin risk factor primari liver cancer afp a protein normal produc fetus afp level usual undetect blood healthi adult men women pregnant an elev level afp suggest presenc either primari liver cancer germ cell tumor also call alphafetoprotein afp a substanc studi treatment cancer afp kill cancer cell stop divid it type aminoflavon ag a substanc studi treatment cancer it belong famili drug call angiogenesi inhibitor protein tyrosin kinas inhibitor ag a drug use treat recurr ovarian epitheli fallopian tube primari periton cancer gotten better treatment anticanc drug includ platinum it use help keep cancer come back ag also use patient whose cancer certain mutat chang brca brca gene alreadi treat least two type anticanc drug it also studi treatment type cancer ag block enzym involv mani cell function includ repair dna damag block enzym may help keep cancer cell grow may kill ag type poli adpribos polymeras inhibitor also call parp inhibitor ag rubraca rucaparib camsyl ag a substanc studi treatment cancer it belong famili drug call glycinamid ribonucleotid formyl transferas inhibitor ag a substanc studi treatment cancer it matrix metalloproteinas inhibitor belong famili drug call angiogenesi inhibitor also call prinomastat ag a substanc studi treatment liver cancer it belong famili drug call thymidyl synthas inhibitor also call nolatrex thymitaq aganglion megacolon listen ayganggleeahnik mehguhkohlun a condit certain nerv cell miss muscl layer part larg intestin this caus sever constip blockag larg intestin constip stool becom hard dri difficult pass bowel movement occur less often normal other symptom includ swollen abdomen vomit bloodi diarrhea gas lack energi troubl gain weight aganglion megacolon present birth symptom may appear later child life this condit link increas risk thyroid cancer neuroblastoma also call hirschsprung diseas agc a find abnorm cell pap test the glandular cell come inner part cervix line uterus this find may sign cancer serious condit test may need also call atyp glandular cell agent studi listen ayjent stuhde in cancer prevent clinic trial studi whether take certain medicin vitamin miner food supplement prevent cancer also call chemoprevent studi agerel macular degener listen ayjreelayt makyool deejehnehrayshun a condit slow breakdown cell center retina lightsensit layer nerv tissu back eye this block vision center eye caus problem activ read drive agerel macular degener often seen peopl age also call amd armd macular degener agglutinin listen uhglootihnin a substanc make particl bacteria cell stick togeth form clump mass aggrav factor listen agruhvayt fakter someth make condit wors for exampl tobacco smoke aggrav factor asthma aggress listen uhgrehsiv in medicin describ tumor diseas form grow spread quick it may also describ treatment sever intens usual aggress fibromatosi listen uhgrehsiv fybrohmuhtohsi a type soft tissu tumor form fibrous connect tissu usual arm leg abdomen it may also occur head neck aggress fibromatos usual benign cancer they often recur come back treatment spread nearbi tissu rare spread part bodi they may occur adult children also call desmoid tumor desmoidtyp fibromatosi aggress lymphoma listen uhgrehsiv limfohmuh a type lymphoma grow spread quick sever symptom also call highgrad lymphoma intermediategrad lymphoma aggress system mastocytosi listen uhgrehsiv sistehmik mastohsytohsi a rare condit mani mast cell type white blood cell build certain tissu organ bodi includ bone marrow lymph node bone liver spleen small intestin aggress system mastocytosi may get wors quick caus sever symptom organ damag sometim may becom mast cell leukemia rare type leukemia aggress system mastocytosi usual occur adult also call asm agit listen ajihtayshun a condit person unabl relax still the person may tens irrit becom easili annoy small thing he may eager argument unwil work caregiv make situat better agnogen myeloid metaplasia listen agnohjehnik myehloyd mehtuhplayzhuh a progress chronic diseas bone marrow replac fibrous tissu blood made organ liver spleen instead bone marrow this diseas mark enlarg spleen progress anemia also call chronic idiopath myelofibrosi idiopath myelofibrosi myelosclerosi myeloid metaplasia primari myelofibrosi agonist listen aguhnist a drug substanc bind receptor insid cell surfac caus action substanc normal bind receptor agoraphobia listen agoruhfohbeeuh an intens fear open place situat may hard escap help may avail peopl agoraphobia usual anxious panic attack public place they may also fear alon troubl leav home they usual avoid elev bridg public place agoraphobia type phobia type anxieti disord agranulocyt listen aygranyoolohsit a type white blood cell monocyt lymphocyt agranulocyt agus a term use describ abnorm cell come gland wall cervix lower narrow end uterus these abnorm cell found small number pap smear procedur use detect cervic cancer may sign serious lesion cancer the term use atyp glandular cell also call atyp glandular cell uncertain signific atyp glandular cell undetermin signific aha one group substanc found sever type fruit milk they use skin care product reduc wrinkl soften skin exampl aha glycol acid lactic acid citric acid also call alpha hydroxyl acid fruit acid aicardi syndrom listen aykarde sindrom a rare genet disord mark lack tissu connect left right halv brain seizur lesion back eye retina brain eye abnorm other problem may includ unusu facial featur defect hand spine rib development gastrointestin problem when aicardi syndrom occur almost alway newborn girl peopl aicardi syndrom increas risk certain tumor hepatoblastoma type liver cancer choroid plexus tumor rare tumor form brain aid listen a diseas caus human immunodefici virus hiv peopl aid increas risk develop certain cancer infect usual occur individu weak immun system also call acquir immunodefici syndrom aidsdefin cancer listen dehfyn kanser a type cancer person infect human immunodefici virus hiv high risk develop if person hiv develop one cancer mean aid aidsdefin cancer includ kaposi sarcoma certain type nonhodgkin lymphoma cervic cancer aidsrel cancer listen reelayt kanser a type cancer like occur peopl infect human immunodefici virus hiv aidsrel cancer includ kaposi sarcoma nonhodgkin lymphoma cervic cancer hodgkin lymphoma cancer mouth throat liver lung anus ai a condit abnorm cell found glandular tissu line certain intern organ uterus cervix lung pancrea colon ai occur often cervix may becom cancer spread nearbi normal tissu also call adenocarcinoma situ ajcc stage system listen stayj sistem a system describ amount spread cancer patient bodi use tnm t describ size tumor spread cancer nearbi tissu n describ spread cancer nearbi lymph node m describ metastasi spread cancer part bodi this system creat updat american joint committe cancer ajcc intern union against cancer uicc the ajcc stage system use describ type cancer also call tnm stage system akt a group enzym involv sever process relat cell growth surviv akt enzym help transfer signal insid cell an akt enzym type serinethreonin protein kinas also call protein kinas b akynzeo listen aykinzeeoh a combin two drug use prevent nausea vomit caus chemotherapi it combin netupit palonosetron hydrochlorid akynzeo block action chemic brain may trigger nausea vomit akynzeo type antiemet also call netupit palonosetron hydrochlorid alagill syndrom listen aluhjeel sindrom a rare disord defect small tube carri bile fluid help digest fat liver these small tube may narrow abnorm shape may fewer normal this caus bile build liver may lead cirrhosi scar liver liver damag alagill syndrom also affect part bodi includ heart kidney blood vessel eye face spine it usual occur infant children may inherit alanin aminopeptidas listen aluhneen uhmeenohpeptihday an enzym normal found healthi kidney it may found high level urin kidney problem it use biomark detect damag kidney caus drug agent it may also use diagnos certain kidney liver disord also call aap alanin transferas listen aluhneen tranzfehray an enzym found liver tissu a high level alanin transferas releas blood may sign liver damag cancer diseas also call serum glutam pyruv transaminas sgpt alanosin listen uhlanohseen a substanc studi treatment cancer it belong famili drug call antimetabolit also call sdx albin listen albihnihzum a group genet condit mark littl none pigment melanin skin hair andor eye peopl albin may vision problem white yellow hair reddish violet blue brown eye pale skin albumin listen albyoomin a type protein found blood egg white milk substanc alcar listen allkar a form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product it use mani cell bodi make energi fat also call acetyllcarnitin acetyllcarnitin hydrochlorid alcl an aggress fastgrow type nonhodgkin lymphoma usual tcell type the cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call anaplast larg cell lymphoma alcohol listen alkuhhol a chemic substanc found drink beer wine liquor it also found medicin mouthwash household product essenti oil scent liquid taken certain plant it made chemic process call ferment use sugar yeast there differ type alcohol the type use make alcohol drink call ethyl alcohol ethanol drink regular larg amount alcohol may increas risk certain type cancer cancer mouth throat esophagus breast liver colon rectum alcohol ablat listen alkuhhol ablayshun an inject ethanol alcohol skin direct tumor kill cancer cell ultrasound ct scan use guid needl tumor also call ethanol ablat pei percutan ethanol inject alcohol depend listen alkuhhol deepend a chronic diseas person crave drink contain alcohol unabl control drink a person diseas also need drink greater amount get effect withdraw symptom stop alcohol use alcohol depend affect physic mental health caus problem famili friend work regular heavi alcohol intak increas risk sever type cancer also call alcohol alcohol listen alkuhhawlihzum a chronic diseas person crave drink contain alcohol unabl control drink a person diseas also need drink greater amount get effect withdraw symptom stop alcohol use alcohol affect physic mental health caus problem famili friend work regular heavi alcohol intak increas risk sever type cancer also call alcohol depend aldara listen aldaruh a drug use treat earli basal cell skin cancer it also use treat actin keratosi skin condit may becom cancer genit wart aldara also studi treatment condit type cancer it may help immun system kill abnorm cell includ cancer cell aldara type immun respons modifi also call imiquimod aldehyd listen aldehhid a type chemic substanc made alcohol aldehyd found essenti oil scent liquid taken plant aldesleukin listen aldeslookin a drug use treat melanoma renal cell carcinoma type kidney cancer spread part bodi it also studi treatment type cancer aldesleukin form interleukin made laboratori aldesleukin increas activ growth t lymphocyt b lymphocyt type white blood cell this may help immun system kill cancer cell aldesleukin type biolog respons modifi also call proleukin recombin human interleukin aldosteron listen aldostehron a steroid hormon made adren cortex outer layer adren gland it help control balanc water salt kidney keep sodium releas potassium bodi too much aldosteron caus high blood pressur buildup fluid bodi tissu aldosteron type mineralocorticoid hormon aldrich syndrom listen alldrich sindrom an inherit immun disord occur young boy it caus eczema type skin inflamm decreas number platelet blood cell help prevent bleed frequent bacteri infect peopl aldrich syndrom increas risk develop leukemia lymphoma also call wiskottaldrich syndrom alecensa listen alehsensuh a drug use treat nonsmal cell lung cancer spread part bodi anaplast lymphoma kinas alk posit it also studi treatment type cancer alecensa block certain protein made alk gene block protein may stop growth spread cancer cell alecensa type tyrosin kinas inhibitor also call alectinib alectinib listen uhlektihnib a drug use treat nonsmal cell lung cancer spread part bodi anaplast lymphoma kinas alk posit it also studi treatment type cancer alectinib block certain protein made alk gene block protein may stop growth spread cancer cell alectinib type tyrosin kinas inhibitor also call alecensa alefacept listen uhlehfuhsept a drug use treat certain skin condit studi treatment cutan skinrel tcell cancer tcell nonhodgkin lymphoma alefacept made combin part antibodi protein block growth type t cell it type fusion protein type immunosuppress also call amev alemtuzumab listen alemtoozoomab a drug use treat bcell chronic lymphocyt leukemia it also studi treatment type cancer alemtuzumab bind protein call cd found type immun cell cancer cell this may help immun system kill cancer cell alemtuzumab type monoclon antibodi also call campath alendron sodium listen uhlendrohnayt sohdeeum a drug use treat certain bone condit osteoporosi paget diseas bone it also studi treatment hypercalcemia high level calcium blood bone pain caus cancer alendron sodium slow breakdown bone prevent loss calcium it type bisphosphon also call fosamax alh a benign cancer condit cell normal breast lobul cell look abnorm microscop have alh increas risk breast cancer also call atyp lobular breast hyperplasia atyp lobular hyperplasia alimta listen uhlimtuh a drug use alon cisplatin treat certain type nonsmal cell lung cancer local advanc spread part bodi it also use cisplatin treat malign pleural mesothelioma patient whose cancer cannot treat surgeri it also studi treatment type cancer alimta stop cell use folic acid make dna may kill cancer cell it type folat antagonist also call ly pemetrex disodium aliqopa listen alihkohpuh a drug use treat follicular lymphoma relaps come back treatment least two anticanc therapi it also studi treatment type cancer aliqopa block certain protein may help keep cancer cell grow may kill it type kinas inhibitor also call copanlisib hydrochlorid alk gene listen jeen a gene make protein call anaplast lymphoma kinas alk involv cell growth mutat chang form alk gene protein found type cancer includ neuroblastoma nonsmal cell lung cancer anaplast larg cell lymphoma these chang may increas growth cancer cell check chang alk gene tumor tissu may help plan cancer treatment also call anaplast lymphoma kinas gene alk inhibitor inhihbiht a substanc block activ protein call anaplast lymphoma kinas alk help control cell growth block protein may help keep cancer cell grow spread some alk inhibitor use treat cancer they type target therapi also call anaplast lymphoma kinas inhibitor alkali listen alkuh a chemic dissolv water combin acid form salt make acid less acid alkali bitter tast turn certain dye blue some alkali help bodi work way an exampl alkali sodium hydroxid alkalin listen alkuhlihnihte refer amount alkali an alkali chemic dissolv water combin acid form salt make acid less acid alkalin listen alkuhlihnihzayshun a process lower amount acid solut in medicin alkali sodium bicarbon may given patient lower high level acid blood urin caus certain medicin condit alkaloid listen alkuhloyd a member larg group substanc found plant fungi alkaloid contain nitrogen made laboratori nicotin caffein codein vincristin alkaloid some alkaloid vincristin use treat cancer alkeran listen alkehran a drug use treat multipl myeloma it also use treat ovarian epitheli cancer cannot remov surgeri it also studi treatment type cancer alkeran may kill cancer cell damag dna stop divid it type alkyl agent also call melphalan alkyl agent listen alkuhlayt ayjent a type drug use treatment cancer it interfer cell dna inhibit cancer cell growth all a type leukemia blood cancer come quick fast grow in all mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphoblast leukemia acut lymphocyt leukemia allegra listen uhlehgruh a drug use treat certain allergi symptom it block chemic releas allerg respons caus itch sneez runni nose wheez wateri eye it type antihistamin also call fexofenadin allergen listen alerjen a substanc caus allerg respons exampl includ pollen mold certain food allerg respons listen uhlerjik rehspont a hypersensit immun reaction substanc normal harmless would caus immun respons peopl an allerg respons may caus harm symptom itch inflamm tissu injuri allogen listen alohjehnayik taken differ individu speci also call allogen allogen bone marrow transplant listen alohjehnayik bone mayroh tranzplantayshun a procedur person receiv stem cell cell blood cell develop genet similar ident donor allogen stem cell transplant listen alohjehnayik stem sel tranzplantayshun a procedur person receiv bloodform stem cell cell blood cell develop genet similar ident donor this often sister brother could unrel donor allogen listen alohjehnik taken differ individu speci also call allogen allograft listen alohgraft the transplant organ tissu cell one individu anoth individu speci ident twin allopath medicin listen alohpathik mehdihsin a system medic doctor healthcar profession nurs pharmacist therapist treat symptom diseas use drug radiat surgeri also call biomedicin convent medicin mainstream medicin orthodox medicin western medicin allopurinol listen alohpyoorrihnol a drug lower high level uric acid byproduct metabol blood caus cancer treatment allovectin listen alohvektin a substanc studi gene therapi agent treatment cancer it increas abil immun system recogn cancer cell kill alltran retino acid listen alltranz rehtihnohik asid a nutrient bodi need small amount function stay healthi alltran retino acid made bodi vitamin a help cell grow develop especi embryo a form alltran retino acid made laboratori put skin treat condit acn taken mouth treat acut promyelocyt leukemia fastgrow cancer mani immatur bloodform cell blood bone marrow alltran retino acid studi prevent treatment type cancer also call atra retino acid tretinoin vitamin a acid aloeemodin listen alohehmuhdin a substanc found certain plant includ alo vera it belong famili compound call anthraquinon shown antiinflammatori anticanc effect alopecia listen alohpeeshuh the lack loss hair area bodi hair usual found alopecia side effect cancer treatment aloxi listen uhlokse a drug use prevent nausea vomit caus chemotherapi it also use prevent nausea vomit surgeri aloxi block action chemic serotonin bind certain nerv may trigger nausea vomit block serotonin may help lessen nausea vomit aloxi type serotonin receptor antagonist type antiemet also call palonosetron hydrochlorid alpha emitt radiat therapi listen alfuh eemiht raydeeayshun thayruhpe therapi use radioact substanc give type highenergi radiat call alphaparticl kill cancer cell the radioact substanc inject vein travel blood collect certain tissu bodi area bone cancer this type radiat may caus less damag nearbi healthi tissu alpha emitt radiat therapi use treat prostat cancer spread bone studi treatment type cancer alpha hydroxyl acid listen alfuh hydroksil asid one group substanc found sever type fruit milk they use skin care product reduc wrinkl soften skin exampl alpha hydroxyl acid glycol acid lactic acid citric acid also call aha fruit acid alphaadrenerg antagonist listen alfuhadrehnerjik antaguhnist a substanc relax muscl tissu blood vessel prostat gland improv flow urin blood alphaadrenerg antagonist use treat symptom mani condit benign prostat hyperplasia bph high blood pressur blood circul problem also call alphablock alphablock listen alfuhblahk a substanc relax muscl tissu blood vessel prostat gland improv flow urin blood alphablock use treat symptom mani condit benign prostat hyperplasia bph high blood pressur blood circul problem also call alphaadrenerg antagonist alphafetoprotein listen alfuhfeetohprohteen a protein normal produc fetus alphafetoprotein level usual undetect blood healthi adult men women pregnant an elev level alphafetoprotein suggest presenc either primari liver cancer germ cell tumor also call afp alphalipo acid listen alfuhlihpohik asid a substanc studi abil protect normal cell side effect chemotherapi prevent peripher neuropathi numb tingl burn weak hand feet alphalipo acid made bodi found food organ meat spinach broccoli pea brussel sprout rice bran it also made laboratori alphalipo acid type antioxid chemoprotect agent alphatocopherol listen alfuhtohkahfehrol a nutrient bodi need small amount stay healthi work way it fatsolubl dissolv fat oil found seed nut leafi green veget veget oil alphatocopherol boost immun system help keep blood clot form it also help prevent cell damag caus free radic high reactiv chemic alphatocopherol studi prevent treatment type cancer it type antioxid also call vitamin e alprazolam listen alprayzohlam a drug use treat anxieti disord panic attack it studi treatment nausea vomit caus cancer treatment it type benzodiazepin also call xanax alprostadil listen alprostuhdil a drug use treat impot inabl erect studi treatment sexual problem men surgeri prostat cancer it type vasodil also call pge prostaglandin e alten listen a procedur mild electr current appli certain acupunctur point spot bodi acupunctur needl may insert control pain symptom skin it studi treatment dri mouth caus radiat therapi cancer also call acupuncturelik transcutan electr nerv stimul alteplas listen altehplay a form tissu plasminogen activ made laboratori it help dissolv blood clot use treat heart attack stroke clot lung it also studi treatment cancer it type system thrombolyt agent also call activas rtpa recombin tissu plasminogen activ alter listen alltehrayshun a chang result someth differ origin altern medicin listen allternuhtiv mehdihsin treatment use instead standard treatment standard treatment base result scientif research current accept wide use less research done type altern medicin altern medicin may includ special diet megados vitamin herbal prepar special tea magnet therapi for exampl special diet may use instead anticanc drug treatment cancer altretamin listen altrehtuhmeen an anticanc drug belong famili drug call alkyl agent alum listen alum a chemic substanc contain aluminum sulfat second chemic usual potassium sulfat it use shrink tissu stop bleed boost immun respons vaccin aluminum listen uhloomihnum a metal element found combin element earth crust it also found small amount soil water mani food it use medicin dentistri mani product foil can pot pan airplan side roof high level aluminum bodi harm alunbrig listen uhlunbrig a drug use treat nonsmal cell lung cancer spread part bodi anaplast lymphoma kinas alk posit it use patient whose cancer gotten wors treatment cannot take crizotinib type anticanc drug alunbrig block certain protein made alk gene block protein may stop growth spread cancer cell alunbrig type tyrosin kinas inhibitor also call brigatinib alvaccea vaccin listen vakseen a cancer vaccin made form canarypox virus caus diseas peopl it studi treatment kind cancer the virus chang laboratori make protein call carcinoembryon antigen cea tumor marker alvaccea vaccin may help immun system find kill cancer cell make cea alveolar rhabdomyosarcoma listen alveeohl rabdohmyohsarkohmuh a soft tissu tumor common older children teenag it begin embryon muscl cell cell develop muscl bodi it occur mani place bodi usual occur trunk arm leg also call arm alveolar soft part sarcoma listen alveeohl sarkohmuh a soft tissu tumor common older children teenag it begin soft support tissu connect surround organ tissu alveolar soft part sarcoma usual occur leg also occur arm hand head neck it caus growth new blood vessel help tumor grow spread also call asp alveoli listen alveeoh tini air sac end bronchiol tini branch air tube lung the alveoli lung bloodstream exchang carbon dioxid oxygen carbon dioxid blood pass lung alveoli oxygen lung pass alveoli blood alvocidib listen alvohsihdib a substanc studi treatment sever type cancer it stop cell divid may kill cancer cell it type cyclindepend kinas cdk inhibitor also call flavopiridol hmr alzheim dementia listen altshym dehmenshuh a brain disord usual start late middl age old age get wors time symptom includ loss memori confus difficulti think chang languag behavior person also call alzheim diseas alzheim diseas listen altshym dihzeez a brain disord usual start late middl age old age get wors time symptom includ loss memori confus difficulti think chang languag behavior person also call alzheim dementia amanita phalloid listen amuhnytuh fuhloydeez a type poison mushroom harm effect kidney liver it respons fatal case mushroom poison also call death cap amantadin hydrochlorid listen uhmantuhdeen hydrohklorid a drug use treat infect caus influenza a virus it block abil virus infect cell make virus particl it also use treat symptom parkinson diseas amantidin hydrochlorid type antivir agent amatuximab listen amuhtuksihmab a substanc studi treatment mesothelioma amatuximab bind protein call mesothelin found cancer cell amatuximab may help immun system kill cancer cell it type monoclon antibodi also call antimesothelin monoclon antibodi morab morab ambien listen ambeeun a drug use treat insomnia inabl sleep anxieti it type imidazopyridin sedat hypnot also call zolpidem amd a condit slow breakdown cell center retina lightsensit layer nerv tissu back eye this block vision center eye caus problem activ read drive amd often seen peopl age also call agerel macular degener armd macular degener amd a drug use autolog stem cell transplant patient nonhodgkin lymphoma multipl myeloma amd given togeth granulocytecoloni stimul factor gcsf help move stem cell bone marrow blood the stem cell collect store given back patient amd type chemokin receptor antagonist also call mozobil plerixafor amelanot melanoma listen aymehluhnahtik mehluhnohmuh a type skin cancer cell make pigment melanin skin lesion often irregular may pink red light brown tan gray edg ameluz listen amehlooz a drug use treat actin keratosi skin condit may becom cancer when ameluz taken abnorm cell includ cancer cell expos certain type light becom activ kill cell ameluz contain activ ingredi aminolevulin acid hydrochlorid it type photosensit agent amethopterin listen amehthoptehrin a drug use treat mani type cancer it also use treat rheumatoid arthriti sever psoriasi type skin condit amethopterin stop cell use folic acid make dna may kill cancer cell it may also lower bodi immun respons amethopterin type antimetabolit type antifol also call methotrex mtx rheumatrex trexal amev listen amehveev a drug use treat certain skin condit studi treatment cutan skinrel tcell cancer tcell nonhodgkin lymphoma amev made combin part antibodi protein block growth type t cell it type fusion protein type immunosuppress also call alefacept amg a substanc studi treatment cancer it bind protein call hepatocyt growth factor hgf may caus cancer cell grow block may caus cancer cell die amg type monoclon antibodi also call antihgf monoclon antibodi amg amg a drug use prevent treat certain bone problem it use brand name xgeva prevent bone problem caus multipl myeloma solid tumor spread bone it also use certain patient treat giant cell tumor bone cannot remov surgeri treat hypercalcemia caus cancer get better treatment bisphosphon amg also use brand name prolia increas bone mass certain patient breast cancer prostat cancer high risk break bone it also use treat osteoporosi men postmenopaus women high risk break bone amg also studi treatment condit type cancer it bind protein call rankl keep rankl bind anoth protein call rank surfac certain bone cell includ bone cancer cell this may help keep bone break cancer cell grow amg may also prevent loss calcium bone it type monoclon antibodi also call denosumab amg a drug use treat thrombocytopenia low platelet level patient immun thrombocytopen purpura itp get better treatment itp condit platelet destroy immun system amg bind thrombopoietin receptor caus bone marrow make platelet it type thrombopoietin receptor agonist also call nplate romiplostim amg a substanc studi treatment type cancer it belong famili drug call angiogenesi inhibitor protein kinas inhibitor amh a hormon made ovari femal testicl male amh help form male femal reproduct organ it also help control hormon act ovari make follicl egg grow woman menstrual cycl measur amount amh blood may help diagnos infertil condit polycyst ovarian syndrom menopaus certain type ovarian tumor it may also help determin sex infant sex clear also call antimullerian hormon amifostin listen amihfosteen a drug use help protect kidney patient receiv cisplatin type anticanc drug advanc ovarian cancer it also use help reduc dri mouth patient receiv radiat therapi surgeri head neck cancer amifostin help protect healthi tissu side effect caus certain type cancer treatment it type chemoprotect agent type radioprotect agent also call ethyol amikacin listen amihkaysin an antibiot drug use treat infect it belong famili drug call aminoglycosid antibiot amino acid listen uhmeenoh asid one sever molecul join togeth form protein there common amino acid found protein amino acid sequenc listen uhmeenoh asid seekwent the arrang amino acid protein protein made differ kind amino acid structur function protein determin kind amino acid use make arrang aminobenzo acid listen uhmeenohbenzohikasid a nutrient vitamin b complex bodi need small amount function stay healthi bacteria live intestin need aminobenzo acid surviv aminobenzo acid found grain food anim it studi radiosensit substanc make tumor cell sensit radiat therapi treatment certain skin disord also call paba paraaminobenzo acid aminocamptothecin listen uhmeenohkamptohthehkin an anticanc drug belong famili drug call topoisomeras inhibitor aminoglutethimid listen uhmeenohglootethihmid an anticanc drug belong famili drug call nonsteroid aromatas inhibitor aminoglutethimid use decreas product sex hormon estrogen women testosteron men suppress growth tumor need sex hormon grow aminoglycosid antibiot listen uhmeenohglykohsid anteebyahtik a substanc work mani type bacteria includ streptomycin gentamicin neomycin an aminoglycosid antibiot use treat bacteri infect aminolevulin acid listen uhmeenohlehvyoolihnik asid the activ ingredi drug use treat actin keratosi skin condit may becom cancer it also studi treatment condit type cancer when aminolevulin acid taken abnorm cell includ cancer cell expos certain type light becom activ kill cell it may also help find type cancer cell expos certain type light aminolevulin acid type photosensit agent aminolevulin acid hydrochlorid listen uhmeenohlehvyoolihnik asid hydrohklorid a drug use brand name ameluz levulan kerastick treat actin keratosi skin condit may becom cancer it also use brand name gleolan imag agent surgeri certain type brain tumor aminolevulin acid hydrochlorid also studi treatment condit type cancer when aminolevulin acid hydrochlorid taken abnorm cell includ cancer cell expos certain type light becom activ kill cell it may also help find type cancer cell expos certain type light aminolevulin acid hydrochlorid type photosensit agent aminopterin listen amihnoptehrin an anticanc drug belong famili drug call antimetabolit amiodaron hydrochlorid listen ameeohduhron hydrohklorid a drug use treat certain type abnorm heart rhythm gotten better drug amiodaron hydrochlorid affect electr activ heart it type antiarrhythm agent also call corderon amitriptylin listen amihtriptihleen a drug use treat depress may given treat anxieti sleep disord pain it also studi oral gel form treatment nerv pain caus chemotherapi amitriptylin type tricycl antidepress also call amitriptylin hydrochlorid amitriptylin hydrochlorid listen amihtriptihleen hydrohklorid a drug use treat depress may given treat anxieti sleep disord pain it also studi oral gel form treatment nerv pain caus chemotherapi amitriptylin hydrochlorid type tricycl antidepress also call amitriptylin aml an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia anll amlmrc a type acut myeloid leukemia least patient blood bone marrow myeloblast immatur white blood cell patient one follow condit myelodysplast syndrom mds myelodysplasticmyeloprolif neoplasm mdsmpn cell chang certain chromosom similar found mds least cell least two type blood cell abnorm amlmrc usual occur older adult poor prognosi also call acut myeloid leukemia myelodysplasiarel chang ammonia listen uhmohnyuh a gas made nitrogen hydrogen it strong odor irrit skin eye nose throat lung ammonia made bacteria decay plant anim found water soil air ammonia also made bodi protein break in laboratori ammonia chang liquid use medicin fertil household clean liquid product it also ad cigarett increas effect nicotin bodi ammonium tetrathiomolybd listen uhmohneeum tehtruhthyohmuhlibdayt a substanc studi treatment mani type cancer ammonium tetrathiomolybd remov extra copper bodi remov copper may prevent growth new blood vessel tumor need grow may kill cancer cell ammonium tetrathiomolybd type chelat agent type antiangiogenesi agent amniot fluid listen amneeahtik flooid the clear slight yellow fluid surround protect unborn babi grow pregnanc amniot fluid cushion babi help keep temperatur womb constant it also help grow babi lung digest system bone develop proper amniot fluid contain babi cell substanc sampl amniot fluid may taken check health babi test genet chang may sign genet diseas condit amniot fluid also may use learn sex babi amonafid listen aymohnahfid a substanc studi treatment cancer it belong famili drug call topoisomeras inhibitor intercal agent amoxicillin listen uhmoksihsihlin a drug use treat bacteri infect amoxicillin form penicillin made laboratori it kill certain type bacteria it type antibiot amoxicillinclavulan potassium listen uhmoksihsihlinklavyoolanayt puhtaseeum a drug use treat bacteri infect ad chemic clavulan potassium antibiot amoxicillin increas amount time antibiot stay activ bodi amoxicillinclavulan potassium type combin antibiot also call augmentin amphotericin b listen amfuhtayrihsin a drug use treatment infect caus fungi it type antifung amplimexon listen amplihmekson a substanc studi treatment type cancer includ pancreat lung breast prostat melanoma multipl myeloma it belong famili drug call cyanoaziridin deriv also call imexon ampulla listen ampuhluh a saclik enlarg canal duct ampulla vater listen ampuhluh vahter an enlarg duct liver pancrea point enter small intestin ampulla vater cancer listen ampuhluh vahter kanser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampullari cancer ampullari cancer listen ampuhlayre kanser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampulla vater cancer amput listen ampyootayshun the remov surgeri limb arm leg bodi part injuri diseas diabet cancer amrubicin listen amroobihsin a substanc studi treatment lung cancer it type anthracyclin analog amsacrin listen amsuhkreen an anticanc drug belong famili drug call topoisomeras inhibitor amuvatinib listen amyoovatihnib a substanc studi treatment type cancer it may block certain protein involv cancer cell growth dna repair block protein may make cancer cell sensit anticanc drug radiat therapi amuvatinib type tyrosin kinas inhibitor also call mp amygdalin listen uhmigduhlin a substanc found pit fruit apricot raw nut plant amygdalin use countri treatment cancer shown work human clinic trial it approv use unit state amygdalin sometim call vitamin b amylas listen amihlay an enzym help bodi digest starch amyloidosi listen amuhloydohsi a group diseas protein build certain organ local amyloidosi throughout bodi system amyloidosi amyloidosi may either primari known caus secondari caus anoth diseas includ type cancer multipl myeloma hereditari pass parent children mani organ affect amyloidosi the organ affect may depend whether amyloidosi primari secondari hereditari form anabol steroid listen anuhbahlik stayroyd a type steroid use medicin repair bodi tissu increas appetit growth muscl anabol steroid made laboratori testosteron male hormon anagrelid listen anagrelid a drug use decreas number platelet blood order prevent blood clot anakinra listen anuhkinruh a substanc use treat rheumatoid arthriti studi treatment cancer anakinra block action interleukin il it type interleukin receptor antagonist also call kinaret anal listen aynul have anus the anus open rectum last part larg intestin outsid bodi anal cancer listen aynul kanser cancer form tissu anus the anus open rectum last part larg intestin outsid bodi anal pap smear listen aynul smeer a procedur cell scrape line anus open rectum outsid bodi look microscop it use find cancer chang cell may lead cancer an anal pap smear also show condit cancer infect inflamm also call anal pap test anal pap test listen aynul a procedur cell scrape line anus open rectum outsid bodi look microscop it use find cancer chang cell may lead cancer an anal pap test also show condit cancer infect inflamm also call anal pap smear analgesia listen anuljeezheeuh pain relief analges listen anuljeezik a drug reduc pain analges includ aspirin acetaminophen ibuprofen analog listen anuhlog in chemistri substanc similar ident anoth analysi listen uhnalihsi a process anyth complex separ simpl less complex part anaphylact shock listen anuhfihlaktik shok a sever sometim lifethreaten immun system reaction antigen person previous expos the reaction may includ itchi skin edema collaps blood vessel faint difficulti breath death anaplast listen anuhplastik a term use describ cancer cell divid rapid littl resembl normal cell anaplast larg cell lymphoma listen anuhplastik larj sel limfohmuh an aggress fastgrow type nonhodgkin lymphoma usual tcell type the cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call alcl anaplast lymphoma kinas listen anuhplastik limfohmuh kynay a protein help control cell growth it made anaplast lymphoma kinas alk gene may chang type cancer anaplast larg cell lymphoma neuroblastoma nonsmal cell lung cancer these chang alk gene caus cancer cell grow spread anaplast lymphoma kinas type receptor tyrosin kinas anaplast lymphoma kinas gene listen anuhplastik limfohmuh kynay jeen a gene make protein call anaplast lymphoma kinas alk involv cell growth mutat chang form alk gene protein found type cancer includ neuroblastoma nonsmal cell lung cancer anaplast larg cell lymphoma these chang may increas growth cancer cell check chang anaplast lymphoma kinas gene tumor tissu may help plan cancer treatment also call alk gene anaplast lymphoma kinas inhibitor anuhplastik limfohmuh kynay inhihbiht a substanc block activ protein call anaplast lymphoma kinas alk help control cell growth block protein may help keep cancer cell grow spread some anaplast lymphoma kinas inhibitor use treat cancer they type target therapi also call alk inhibitor anaplast thyroid cancer listen anuhplastik thyroyd kanser a rare aggress type thyroid cancer malign cancer cell look differ normal thyroid cell anastomosi listen uhnastohmohsi a procedur connect healthi section tubular structur bodi diseas portion surgic remov anastrozol listen anastrohzol a drug use treat certain type breast cancer postmenopaus women it also studi treatment type cancer anastrozol lower amount estrogen made bodi this may stop growth cancer cell need estrogen grow anastrozol type nonsteroid aromatas inhibitor also call arimidex anatom listen anuhtahmik have anatomi studi structur plant anim anatomist listen uhnatuhmist a person special train anatomi studi structur anim plant anatomi listen uhnatohme the studi structur plant anim anc a measur number neutrophil blood neutrophil type white blood cell they help bodi fight infect an anc may use check infect inflamm leukemia condit the lower person anc higher risk get infect have anc less mean high risk get infect cancer treatment chemotherapi may reduc anc also call absolut neutrophil count ancestim listen ansestim a substanc caus blood stem cell cell type cell develop chang differ type blood cell increas number action cell blood it studi treatment myelodysplasia ancestim type recombin stem cell growth factor also call rmethuscf recombin human methionyl stem cell factor stemgen ancillari test listen ansihlayrre in clinic trial medic test patient part origin studi design androblastoma listen androhblastohmuh a rare type ovarian tumor tumor cell secret male sex hormon this may caus viril appear male physic characterist femal also call arrhenoblastoma sertolileydig cell tumor ovari androgen listen androhjen a type hormon promot develop mainten male sex characterist androgen ablat listen androhjen ablayshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen depriv androgen suppress androgen depriv listen androhjen dehprihvayshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen suppress androgen receptor listen androhjen rehsept a protein bind male hormon call androgen androgen receptor found insid cell male reproduct tissu type tissu cancer cell in prostat cancer androgen bind androgen receptor insid cancer cell caus cancer cell grow also call ar androgen receptor posit listen androhjen rehsept pahzihtiv describ cell protein bind androgen male hormon cancer cell androgen receptor posit may need androgen grow these cell may stop grow die treat substanc block bind action androgen hormon also call ar androgen suppress listen androhjen suhprehshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen depriv androgenindepend listen androhjen describ abil tumor cell grow absenc androgen hormon promot develop mainten male sex characterist mani earli prostat cancer requir androgen growth advanc prostat cancer often androgenindepend androstanolon listen androhstanuhlon a hormon made testosteron prostat test certain tissu it need develop maintain male sex characterist facial hair deep voic muscl growth high amount androstanolon may increas growth prostat cancer make harder treat also call dht dihydrotestosteron anecdot report listen anekdohtul rehport an incomplet descript medic treatment histori one patient anecdot report may publish place peerreview scientif journal anemia listen uhneemeeuh a condit number red blood cell normal anesthesia listen anestheezhuh a loss feel awar caus drug substanc anesthesia keep patient feel pain surgeri procedur local anesthesia loss feel one small area bodi region anesthesia loss feel part bodi arm leg general anesthesia loss feel complet loss awar feel like deep sleep anesthesiologist listen anestheezeeahlohjist a doctor special train give drug agent prevent reliev pain surgeri procedur anesthet listen anesthehtik a drug substanc caus loss feel awar local anesthet caus loss feel one small area bodi region anesthet caus loss feel part bodi arm leg general anesthet caus loss feel complet loss awar feel like deep sleep anetholtrithion listen anehtholtrythyon a substanc studi treatment cancer angelica root listen anjehlihkuh root the root group herb call angelica it use cultur treat certain medic problem includ gastrointestin problem loss appetit feel full gas angiocept listen anjeeohsept a substanc studi treatment cancer angiocept may prevent growth new blood vessel tumor need grow may kill cancer cell it type vascular endotheli growth factor receptor vegfr inhibitor type antiangiogenesi agent also call ct vegfr inhibitor ct angiofibroma listen anjeeohfybrohmuh a benign cancer tumor made blood vessel fibrous connect tissu angiofibroma usual appear small red bump face especi nose cheek they common patient tuber sclerosi genet disord caus skin lesion seizur mental problem angiofibroma type vascular tumor angiofollicular lymph node hyperplasia listen anjeeohfuhlihkyool limf node hyperplayzhuh a rare disord benign cancer growth form lymph node tissu there two main way angiofollicular lymph node hyperplasia occur local unicentr multicentr unicentr angiofollicular lymph node hyperplasia affect one group lymph node one part bodi usual chest abdomen it may caus symptom multicentr angiofollicular lymph node hyperplasia affect mani group lymph node lymphoid tissu bodi it weaken immun system caus problem infect fever weight loss fatigu night sweat nerv damag anemia peopl angiofollicular lymph node hyperplasia increas risk lymphoma also call castleman diseas giant lymph node hyperplasia angiogenesi listen anjeeohjehnehsi blood vessel format tumor angiogenesi growth new blood vessel tumor need grow this process caus releas chemic tumor host cell near tumor angiogenesi inhibitor listen anjeeohjehnehsi inhihbiht a drug substanc keep new blood vessel form in cancer treatment angiogenesi inhibitor may prevent growth new blood vessel tumor need grow also call antiangiogenesi agent angiogram listen anjeeohgram an xray comput imag ct scan mri blood vessel blood flow bodi a dye may inject cathet small tube arteri vein make blood vessel easier see an angiogram may use check aneurysm bulg blood vessel wall blockag arteri blood clot problem tumor angiographi listen anjeeahgruhfe a procedur xray blood vessel the blood vessel seen inject dye show xray angioimmunoblast tcell lymphoma listen anjeeohihmyoonohblastik tsel limfohmuh an aggress fastgrow type tcell nonhodgkin lymphoma mark enlarg lymph node hypergammaglobulinemia increas antibodi blood other symptom may includ skin rash fever weight loss night sweat angiolymphoid hyperplasia eosinophilia listen anjeeohlimfoyd hyperplayzhuh eeohsihnohfihleeuh a rare benign cancer tumor small blood vessel surround lymphocyt eosinophil type white blood cell angiolymphoid hyperplasia eosinophilia usual form skin especi skin head occur area bodi bone on skin may appear firm pink red bump may itchi pain if tumor bone may caus swell pain angiolymphoid hyperplasia eosinophilia sometim caus injuri often come back treatment angiolymphoid hyperplasia eosinophilia common young middleag adult it type vascular tumor also call epithelioid hemangioma histiocytoid hemangioma angiomyolipoma listen anjeeohmyohlihpohmuh a benign noncanc tumor fat muscl tissu usual found kidney angiomyolipoma rare caus symptom may bleed grow larg enough pain caus kidney failur they common patient tuber sclerosi genet disord benign tumor grow kidney brain eye heart lung skin caus seizur mental problem skin lesion angioplasti listen anjeeohplaste a procedur enlarg open blood vessel becom narrow block plaqu buildup fat cholesterol inner wall blood vessel exampl angioplasti balloon angioplasti laser angioplasti angiosarcoma listen anjeeohsarkohmuh a type cancer begin cell line blood vessel lymph vessel cancer begin blood vessel call hemangiosarcoma cancer begin lymph vessel call lymphangiosarcoma angiostatin listen anjeeohstatin a protein normal made bodi it also made laboratori studi treatment cancer angiostatin may prevent growth new blood vessel tumor need grow it type antiangiogenesi agent angiotensinconvert enzym inhibitor listen anjeeohtensinkunvert enzim inhihbiht a drug use lower blood pressur an angiotensinconvert enzym inhibitor type antihypertens agent also call ace inhibitor angiozym listen anjeeohzim a substanc studi treatment cancer angiozym special type rna made laboratori it stop protein call vascular endotheli growth factor receptor vegfr made this may prevent growth new blood vessel tumor need grow it type angiogenesi inhibitor type ribozym also call rpi anhidrosi listen anhihdrohsi a rare condit sweat gland make littl sweat it affect whole bodi small part bodi anhidrosi may caus sever burn radiat infect inflamm injuri skin it may also caus certain medicin condit affect skin nerv connect tissu sweat gland it may inherit part genet condit develop later life also call hypohidrosi anhydrovinblastin listen anhydrohvinblasteen an anticanc drug belong famili drug call mitot inhibitor anidulafungin listen uhnihdyooluhfunjin a drug use treat infect caus fungi it belong famili drug call antifung anim model listen anihmul mahdul an anim diseas either like diseas human anim model use studi develop progress diseas test new treatment given human anim transplant human cancer tissu call xenograft model anim studi listen anihmul stuhde a laboratori experi use anim studi develop progress diseas anim studi also test safe effect new treatment test peopl animalassist therapi listen anihmuluhsist thayruhpe a type therapi use dog pet improv physic mental health patient certain acut chronic diseas it studi way reliev distress cancer patient undergo treatment pain also call petfacilit therapi aniridia listen anihrihdeeuh a disord person born without part iri color tissu front eyebal aniridia usual affect eye caus eye problem includ sensit light loss vision anll an aggress fastgrow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml annamycin listen anuhmysin a substanc studi treatment cancer it belong famili drug call anthracyclin antibiot anorexia listen anuhrekseeuh an abnorm loss appetit food anorexia caus cancer aid mental disord ie anorexia nervosa diseas anorexia nervosa listen anuhrekseeuh nervohsuh an eat disord mark intens fear gain weight refus maintain healthi weight distort bodi imag peopl anorexia nervosa abnorm loss appetit food tri avoid eat eat littl possibl an the part nervous system control muscl intern organ heart blood vessel lung stomach intestin gland salivari gland sweat gland one part an help bodi rest relax digest food anoth part help person fight take flight emerg also call autonom nervous system involuntari nervous system ansamycin listen ansuhmysin an anticanc drug belong famili drug call antineoplast antibiot antagonist listen antaguhnist in medicin substanc stop action effect anoth substanc for exampl drug block stimul effect estrogen tumor cell call estrogen receptor antagonist antenat listen anteenaytul have time femal pregnant birth occur also call prenat anterior listen anteere in human anatomi front structur structur found toward front bodi anterior mediastinotomi listen anteere meedeeastihnahtohme a procedur tube insert chest view tissu organ area lung breastbon heart the tube insert incis next breastbon this procedur usual use get tissu sampl lymph node left side chest also call chamberlain procedur anterior mediastinum listen anteere meedeeuhstynum the area front part chest lung also call prevascular space anterior pelvic exenter listen anteere pelvik egzentehrayshun surgeri remov urethra lower part uret uterus cervix vagina bladder anterior urethr cancer listen anteere yooreethrul kanser a diseas malign cancer cell found part urethra tube urin leav bodi closest outsid bodi anthracenedion listen anthruhseendyon an anticanc drug belong famili drug call anticanc antibiot anthracyclin listen anthruhsyklin a type antibiot come certain type streptomyc bacteria anthracyclin use treat mani type cancer anthracyclin damag dna cancer cell caus die daunorubicin doxorubicin epirubicin anthracyclin anthraquinon listen anthruhkwihnon a type anticanc drug antiandrogen listen anteeandrohjen a substanc keep androgen male hormon bind protein call androgen receptor found prostat cell cell tissu treatment antiandrogen may stop prostat cancer cell grow exampl antiandrogen use treat prostat cancer flutamid bicalutamid enzalutamid nilutamid antiandrogen therapi listen anteeandrohjen thayruhpe treatment drug block action androgen male hormon bodi androgen testosteron bind protein call androgen receptor found prostat cancer cell cell tissu antiandrogen therapi keep androgen bind receptor may keep cancer cell grow it use treat prostat cancer antiangiogenesi listen anteeanjeeohjehnehsi prevent growth new blood vessel antiangiogenesi agent listen anteeanjeeohjehnehsi ayjent a drug substanc keep new blood vessel form in cancer treatment antiangiogenesi agent may prevent growth new blood vessel tumor need grow also call angiogenesi inhibitor antiangiogen listen anteeanjeeohjehnik have reduc growth new blood vessel antianxieti agent listen anteeangzyehte ayjent a drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress most antianxieti agent block action certain chemic nervous system also call anxiolyt anxiolyt agent antiapoptot listen anteeapoptahtik someth prevent apoptosi apoptosi type cell death seri molecular step cell lead death antibacteri listen anteebakteereeul a substanc kill bacteria stop grow caus diseas antibiot listen anteebyahtik a drug use treat infect caus bacteria microorgan antibodi listen anteebahde a protein made plasma cell type white blood cell respons antigen substanc caus bodi make specif immun respons each antibodi bind one specif antigen the purpos bind help destroy antigen some antibodi destroy antigen direct other make easier white blood cell destroy antigen an antibodi type immunoglobulin antibodi therapi listen anteebahde thayruhpe treatment use antibodi help bodi fight cancer infect diseas antibodi protein made immun system bind specif marker cell tissu monoclon antibodi type antibodi made laboratori use diagnosi treatment in cancer treatment monoclon antibodi may kill cancer cell direct may block develop tumor blood vessel may help immun system kill cancer cell antibodydepend cellmedi cytotox listen anteebahdeedehpend selmeedeeayt sytohtoksihsihte a type immun reaction target cell microb coat antibodi kill certain type white blood cell the white blood cell bind antibodi releas substanc kill target cell microb also call adcc antibodydepend cellular cytotox antibodydepend cellular cytotox listen anteebahdeedehpend selyool sytohtoksihsihte a type immun reaction target cell microb coat antibodi kill certain type white blood cell the white blood cell bind antibodi releas substanc kill target cell microb also call adcc antibodydepend cellmedi cytotox antibodydrug conjug listen anteebahde konjihgut a substanc made monoclon antibodi chemic link drug the monoclon antibodi bind specif protein receptor found certain type cell includ cancer cell the link drug enter cell kill without harm cell some antibodydrug conjug use treat cancer also call adc anticachexia listen anteekuhkekseeuh describ drug effect work cachexia loss bodi weight muscl mass anticanc antibiot listen anteekans anteebyahtik a type anticanc drug block cell growth interf dna genet materi cell also call antineoplast antibiot antitumor antibiot anticanc therapi listen anteekans thayruhpe treatment stop prevent cancer anticarcinogen listen anteekarsihnohjehnik have prevent delay develop cancer anticcr monoclon antibodi mln listen ante mahnohklohnul anteebahde a substanc studi treatment atherosclerosi buildup fat arteri it also studi treatment cancer spread bone anticcr monoclon antibodi mln bind protein call ccr found surfac certain bone cell white blood cell cancer cell anticcr monoclon antibodi mln block action substanc involv keep healthi bone mass it may help keep cancer cell spread grow bone it type monoclon antibodi also call mln anticd immunotoxin listen ante ihmyoonohtoksin a monoclon antibodi link toxic substanc it studi treatment type bcell cancer anticd immunotoxin made laboratori it bind cd protein surfac normal b cell bcell tumor kill cell anticd immunotoxin listen ante ihmyoonohtoksin a monoclon antibodi link toxic substanc it studi treatment type bcell cancer anticd immunotoxin made laboratori it bind cd protein surfac normal b cell bcell tumor kill cell anticd immunotoxin cat listen ante ihmyoonohtoksin a drug use treat hairi cell leukemia came back get better least two system therapi includ treatment purin nucleosid analog type anticanc drug anticd immunotoxin cat contain monoclon antibodi call moxetumomab bind protein call cd found b cell type white blood cell type leukemia cell it also contain bacteri toxin call pe may help kill cancer cell anticd immunotoxin cat type immunotoxin also call cat lumox moxetumomab pasudotox anticd monoclon antibodi listen ante mahnohklohnul anteebahde a substanc studi treatment type leukemia lymphoma anticd monoclon antibodi bind protein call cd found type blood cell type leukemia lymphoma cell anticd monoclon antibodi may help immun system kill cancer cell it type monoclon antibodi anticea antibodi listen ante anteebahde an antibodi carcinoembryon antigen cea protein present certain type cancer cell anticoagul listen anteekohagyuhlunt a substanc use prevent treat blood clot blood vessel heart also call blood thinner anticonvuls listen anteekunvulsunt a drug substanc use prevent stop seizur convuls also call antiepilept antidepress listen anteedeeprehsunt a drug use treat depress antidiarrh listen anteedyuhreeul a substanc use treat diarrhea frequent wateri bowel movement antiemet listen anteeehmehtik a drug prevent reduc nausea vomit antiepcampseudomonasexotoxin fusion protein listen ante soodohmohnuseksohtoksin fyoozhun prohteen a substanc studi treatment certain type head neck cancer antiepcampseudomonasexotoxin fusion protein made link monoclon antibodi fragment toxic protein may kill cancer cell it bind epcam protein surfac epitheli cell type cancer cell also call proxinium vb antiepilept listen anteeehpihleptik a drug substanc use prevent stop seizur convuls also call anticonvuls antiestrogen listen anteeestruhjin a substanc keep cell make use estrogen hormon play role femal sex characterist menstrual cycl pregnanc antiestrogen may stop cancer cell grow use prevent treat breast cancer they also studi treatment type cancer an antiestrogen type hormon antagonist also call estrogen blocker antifibrinolyt agent listen anteefybrihnohlihtik ayjent a type drug help blood clot it prevent breakdown protein call fibrin main protein blood clot antifibrinolyt agent may use help prevent treat serious bleed patient certain condit hemophilia heavi menstrual bleed type vascular tumor they may also use help prevent control bleed surgeri traumat injuri antifol listen anteefohlayt a type drug stop cell use folic acid make dna may kill cancer cell certain antifol use treat type cancer inflammatori condit rheumatoid arthriti also call folat antagonist folic acid antagonist antifung listen anteefungul a drug treat infect caus fungi antigen listen antihjen ani substanc caus bodi make immun respons substanc antigen includ toxin chemic bacteria virus substanc come outsid bodi bodi tissu cell includ cancer cell also antigen caus immun respons these antigen also use marker laboratori test identifi tissu cell antigenpres cell listen antihjenprehz sel a type immun cell boost immun respons show antigen surfac cell immun system an antigenpres cell type phagocyt also call apc antigenpres cell vaccin listen antihjenprehz sel vakseen a vaccin made antigen antigenpres cell apc apc boost immun respons present antigen surfac cell immun system also call apc vaccin antiglobulin test listen anteeglahbyoolin a laboratori test identifi antibodi bind surfac red blood cell platelet destroy this test use diagnos certain blood disord patient make antibodi red blood cell platelet it also use determin blood type also call coomb test antihgf monoclon antibodi amg listen ante mahnohklohnul anteebahde a substanc studi treatment cancer it bind protein call hepatocyt growth factor hgf may caus cancer cell grow block may caus cancer cell die antihgf monoclon antibodi amg type monoclon antibodi also call amg antihistamin listen anteehistuhmeen a type drug block action histamin caus fever itch sneez runni nose wateri eye antihistamin use prevent fever patient receiv blood transfus treat allergi cough cold antihormon therapi listen anteehormon thayruhpe treatment drug surgeri radiat order block product action hormon antihormon therapi may use cancer treatment certain hormon abl stimul growth type tumor antihypertens agent listen anteehypertensiv ayjent a type drug use treat high blood pressur there mani differ type antihypertens agent work differ way lower blood pressur some remov extra fluid salt bodi other relax widen blood vessel slow heartbeat a person may respond better fewer side effect one drug anoth some patient need one antihypertens agent lower blood pressur antiidiotyp vaccin listen anteeihdeeohtip vakseen a vaccin made antibodi see antibodi antigen bind antiidiotyp vaccin stimul bodi produc antibodi tumor cell antiigfr recombin monoclon antibodi mk listen ante reekombihnunt mahnohklohnul anteebahde a substanc studi treatment mani type cancer antiigfr recombin monoclon antibodi mk bind protein call insulinlik growth factor receptor igfr surfac cell this may prevent cell grow igf present it may also kill cancer cell antiigfr recombin monoclon antibodi mk type monoclon antibodi also call mk antiil chimer monoclon antibodi listen ante kymeerik mahnohklohnul anteebahde a drug use treat rare condit call castleman diseas patient hiv human herpesvirus it also studi treatment multipl myeloma antiil chimer monoclon antibodi bind protein call interleukin il made white blood cell cell bodi antiil chimer monoclon antibodi may help reduc inflamm stop growth cancer cell abnorm blood cell it type monoclon antibodi also call cclb cnto siltuximab sylvant antiinflammatori listen anteeinflamuhtore have reduc inflamm antiinflammatori agent listen anteeinflamuhtore ayjent a drug substanc reduc inflamm red swell pain bodi antiinflammatori agent block certain substanc bodi caus inflamm they use treat mani differ condit some antiinflammatori agent studi prevent treatment cancer antilymphocyt globulin listen anteelimfohsit glahbyoolin serum blood contain antibodi bind human t cell antilymphocyt globulin given patient stem cell transplant kill t cell lower risk graftversushost diseas gvhd it also use treat gvhd kidney transplant help keep bodi reject kidney also call antithymocyt globulin antimesothelin monoclon antibodi morab listen anteemehzohtheelin mahnohklohnul anteebahde a substanc studi treatment mesothelioma antimesothelin monoclon antibodi morab bind protein call mesothelin found cancer cell antimesothelin monoclon antibodi morab may help immun system kill cancer cell it type monoclon antibodi also call amatuximab morab antimetabolit listen anteemehtabohlit a drug similar natur chemic normal biochem reaction cell differ enough interfer normal divis function cell antimicrobi listen anteemykrohbeeul a substanc kill microorgan bacteria mold stop grow caus diseas antimicrotubul agent listen anteemykrohtoobyool ayjent a type drug block cell growth stop mitosi cell divis antimicrotubul agent interfer microtubul cellular structur help move chromosom mitosi they use treat cancer antimitot agent listen anteemytahtik ayjent a type drug block cell growth stop mitosi cell divis they use treat cancer also call mitot inhibitor antimullerian hormon listen anteemyoolayreeun hormon a hormon made ovari femal testicl male antimullerian hormon help form male femal reproduct organ it also help control hormon act ovari make follicl egg grow woman menstrual cycl measur amount antimullerian hormon blood may help diagnos infertil condit polycyst ovarian syndrom menopaus certain type ovarian tumor it may also help determin sex infant sex clear also call amh antineoplast listen anteeneeohplastik block format neoplasm growth may becom cancer antineoplast antibiot listen anteeneeohplastik anteebyahtik a type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antitumor antibiot antineoplaston listen anteeneeohplaston a substanc isol normal human blood urin test type treatment tumor aid antioncogen listen anteeonkohjeen a type gene make protein call tumor suppressor protein help control cell growth mutat chang dna antioncogen may lead cancer also call tumor suppressor gene antioxid listen anteeoksihd a substanc protect cell damag caus free radic unstabl molecul made process oxid normal metabol free radic may play part cancer heart diseas stroke diseas age antioxid includ betacaroten lycopen vitamin a c e natur manufactur substanc antiparasit listen anteepayruhsihtik a drug use treat infect caus bacteria parasit it also use treatment cancer antipdgfr alpha monoclon antibodi imcg listen ante alfuh mahnohklohnul anteebahde a drug use doxorubicin treat soft tissu sarcoma cannot treat radiat therapi surgeri it use patient whose cancer alreadi treat anthracyclin type anticanc drug it also studi treatment type cancer antipdgfr alpha monoclon antibodi imcg bind receptor protein call plateletderiv growth factor pdgf found type cancer cell block protein receptor may help keep cancer cell grow prevent growth new blood vessel tumor need grow antipdgfr alpha monoclon antibodi imcg type monoclon antibodi also call antiplateletderiv growth factor receptor alpha monoclon antibodi imcg imcg lartruvo olaratumab antiplateletderiv growth factor receptor alpha monoclon antibodi imcg listen anteeplaytletdehriv groth fakter rehsept alfuh mahnohklohnul anteebahde a drug use doxorubicin treat soft tissu sarcoma cannot treat radiat therapi surgeri it use patient whose cancer alreadi treat anthracyclin type anticanc drug it also studi treatment type cancer antiplateletderiv growth factor receptor alpha monoclon antibodi imcg bind receptor protein call plateletderiv growth factor pdgf found type cancer cell block protein receptor may help keep cancer cell grow prevent growth new blood vessel tumor need grow antiplateletderiv growth factor receptor alpha monoclon antibodi imcg type monoclon antibodi also call antipdgfr alpha monoclon antibodi imcg imcg lartruvo olaratumab antiprogestin listen anteeprohjestin a substanc prevent cell make use progesteron hormon play role menstrual cycl pregnanc antiprogestin may stop cancer cell grow studi treatment breast cancer an antiprogestin type hormon antagonist antipsychot listen anteesykahtik a type drug use treat symptom psychosi these includ hallucin sight sound smell tast touch person believ real real delus fals belief dementia loss abil think rememb learn make decis solv problem most antipsychot block action certain chemic nervous system also call antipsychot agent neurolept agent antipsychot agent listen anteesykahtik ayjent a type drug use treat symptom psychosi these includ hallucin sight sound smell tast touch person believ real real delus fals belief dementia loss abil think rememb learn make decis solv problem most antipsychot agent block action certain chemic nervous system also call antipsychot neurolept agent antiretrovir therapi listen anteerehtrohvyrul thayruhpe treatment drug inhibit abil human immunodefici virus hiv type retrovirus multipli bodi antisens agent listen antees ayjent small piec dna rna bind specif molecul rna this block abil rna make protein work way antisens agent may use block product protein need cell growth they studi treatment sever type cancer also call antisens oligonucleotid antisens cfos listen antees a substanc studi treatment cancer studi treatment rheumatoid arthriti certain skin condit it block product protein call cfos help control cell growth this may kill cancer cell need cfos grow it type antisens oligonucleotid also call cfos antisens oligonucleotid antisens dna listen antees small piec dna bind specif molecul rna block cell abil use rna make protein work way antisens dna may use block product protein need cell growth it studi treatment mani type cancer antisens oligonucleotid listen antees ahlihgohnookleeohtid small piec dna rna bind specif molecul rna this block abil rna make protein work way antisens oligonucleotid may use block product protein need cell growth they studi treatment sever type cancer also call antisens agent antisens oligonucleotid therapi listen antees ahlihgohnookleeohtid thayruhpe treatment antisens oligonucleotid these small piec dna rna bind specif molecul rna this block cell abil use rna make protein work way antisens oligonucleotid studi treatment mani type cancer also call antisens therapi antisens rna listen antees small piec rna bind specif molecul rna block cell abil use rna make protein work way antisens rna may use block product protein need cell growth it studi treatment mani type cancer antisens therapi listen antees thayruhpe treatment antisens oligonucleotid these small piec dna rna bind specif molecul rna this block cell abil use rna make protein work way antisens oligonucleotid studi treatment mani type cancer also call antisens oligonucleotid therapi antisoci listen anteesohshul describ behavior ignor right other practic law societi antitgfbeta monoclon antibodi gc listen ante baytuh mahnohklohnul anteebahde a substanc studi treatment breast cancer spread part bodi it also studi treatment cancer condit antitgfbeta monoclon antibodi gc bind protein call transform growth factorbeta tgfbeta found cancer cell antitgfbeta monoclon antibodi gc may help keep cancer cell grow prevent growth new blood vessel tumor need grow it type monoclon antibodi type antiangiogenesi agent also call fresolimumab gc antithymocyt globulin listen anteethymohsit glahbyoolin serum blood contain antibodi bind human t cell antithymocyt globulin given patient stem cell transplant kill t cell lower risk graftversushost diseas gvhd it also use treat gvhd kidney transplant help keep bodi reject kidney also call antilymphocyt globulin antitrail rmab listen ante a substanc studi treatment type cancer it bind protein call trail r surfac tumor cell this may kill tumor cell antitrail rmab type monoclon antibodi also call hgsetr mapatumumab antitrail r mab hgsetr listen ante a substanc studi treatment type cancer it bind protein call trailr surfac tumor cell may kill tumor cell antitrail r mab hgsetr type monoclon antibodi also call hgsetr lexatumumab antituberculosi listen anteetooberkyoolohsi describ drug effect work tuberculosi contagi bacteri infect usual affect lung antitumor listen anteetoom have stop abnorm cell growth antitumor antibiot listen anteetoom anteebyahtik a type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antineoplast antibiot antivegfr monoclon antibodi listen ante mahnohklohnul anteebahde a substanc bind receptor protein call vascular endotheli growth factor vegf may found type cancer cell this may prevent growth new blood vessel tumor need grow there differ type antivegfr monoclon antibodi studi treatment cancer these substanc type antiangiogenesi agent type monoclon antibodi antivegfr fulli human monoclon antibodi imcb listen ante fule hyoomun mahnohklohnul anteebahde a drug use drug treat colorect cancer nonsmal cell lung cancer spread part bodi it use alon anoth drug treat cancer stomach gastroesophag junction area esophagus connect stomach advanc spread part bodi it also studi treatment type cancer antivegfr fulli human monoclon antibodi imcb bind receptor protein call vascular endotheli growth factor vegf may found type cancer cell this may prevent growth new blood vessel tumor need grow antivegfr fulli human monoclon antibodi imcb type antiangiogenesi agent type monoclon antibodi also call cyramza imcb ramucirumab antivir listen anteevyrul a drug use treat infect caus virus anus listen aynus the open rectum outsid bodi anxieti listen angzyehte feel fear dread uneasi may occur reaction stress a person anxieti may sweat feel restless tens rapid heart beat extrem anxieti happen often time may sign anxieti disord anxiolysi listen angzeeahlihsi a level sedat person relax may awak the person abl answer question follow instruct anxiolysi caus special drug use help reliev anxieti certain medic surgic procedur also call minim sedat anxiolyt listen angzeeohlihtik a drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress most anxiolyt block action certain chemic nervous system also call antianxieti agent anxiolyt agent anxiolyt agent listen angzeeohlihtik ayjent a drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress most anxiolyt agent block action certain chemic nervous system also call antianxieti agent anxiolyt aorta listen ayortuh the largest arteri bodi it carri oxygenrich blood away heart vessel reach rest bodi aortocoronari bypass listen ayortohkoruhnayre bypass surgeri healthi blood vessel taken anoth part bodi use make new path blood around block arteri lead heart this restor flow oxygen nutrient heart also call cab coronari arteri bypass ap a substanc studi treatment soft tissu bone cancer it also studi treatment solid tumor hematolog cancer ap stop cell divid may caus cancer cell die it type mtor inhibitor also call ridaforolimus ap a substanc studi treatment head neck cancer it may kill cancer cell carri anticanc drug tumor it type platinum compound apalutamid listen apuhlootuhmid a drug use treat prostat cancer spread part bodi it use patient whose cancer castrat resist respond treatment lower testosteron level apalutamid bind protein call androgen receptor found prostat cancer cell these protein bind androgen male hormon may caus cancer cell grow apalutamid block protein may keep cancer cell grow it type antiandrogen also call erleada apc a type immun cell boost immun respons show antigen surfac cell immun system an apc type phagocyt also call antigenpres cell apc vaccin listen vakseen a vaccin made antigen antigenpres cell apc apc boost immun respons present antigen surfac cell immun system also call antigenpres cell vaccin apc a vaccin use treat prostat cancer spread part bodi it use patient symptom whose cancer castrat resist respond treatment lower testosteron level apc made patient immun cell treat laboratori gmcsf type growth factor protein found prostat cancer cell apc may help immun system kill prostat cancer cell it type cellular adopt immunotherapi also call proveng sipuleucelt apcf a vaccin made immun system cell taken patient prostat cancer frozen futur use the cell treat laboratori growth factor attach protein call prostaticacid phosphatas pap found prostat cancer cell when apcf inject patient may caus t cell type white blood cell kill tumor cell pap apheresi listen afehreesi a procedur blood collect part blood platelet white blood cell taken rest blood return donor also call pheresi apidra listen uhpeedruh a drug use control amount sugar blood patient diabet mellitus it form hormon insulin made laboratori apidra get blood faster insulin inject skin short meal it type therapeut insulin also call insulin glulisin apl an aggress fastgrow type acut myeloid leukemia mani immatur bloodform cell blood bone marrow it usual mark exchang part chromosom also call acut promyelocyt leukemia promyelocyt leukemia aplast anemia listen ayplastik uhneemeeuh a condit bone marrow unabl produc blood cell aplidin listen aplihdeen a substanc studi treatment cancer it obtain marin organ apn a regist nurs addit educ train diagnos treat diseas apn licens state level certifi nation nurs organ in cancer care apn may manag primari care patient famili base practic agreement doctor also call advanc practic nurs np nurs practition apol listen aypoh a cell protein attach certain molecul cancer cell may kill cell apol studi treatment cancer also call tnfrelat apoptosisinduc ligand trail tumor necrosi factorrel apoptosisinduc ligand apocrin gland listen apohkrin a type gland found skin breast eyelid ear apocrin gland breast secret fat droplet breast milk ear help form earwax apocrin gland skin eyelid sweat gland most apocrin gland skin armpit groin area around nippl breast apocrin gland skin scent gland secret usual odor anoth type gland eccrin gland simpl sweat gland produc sweat apolizumab listen apuhlizyoomab a substanc studi treatment hematolog blood cancer apolizumab bind protein call id found surfac type immun cell cancer cell it may help immun system kill cancer cell it type monoclon antibodi apoptosi listen apoptohsi a type cell death seri molecular step cell lead death this one method bodi use get rid unneed abnorm cell the process apoptosi may block cancer cell also call program cell death appendag listen uhpendij in medicin bodi part arm leg attach main part bodi appendectomi listen apendektohme surgeri remov appendix small fingershap pouch end first part larg intestin appendix listen uhpendix a small fingerlik pouch stick cecum first part larg intestin near end small intestin appetit listen apehtit a desir satisfi physic mental need food sex adventur aprepit listen uhprehpihtunt a drug use drug prevent nausea vomit caus chemotherapi it also use prevent nausea vomit surgeri aprepit block action certain chemic brain may trigger nausea vomit block chemic may lessen nausea vomit aprepit type antiemet type substanc pneurokinin receptor antagonist also call emend aptivus listen aptihvus a drug use anoth drug ritonavir treat patient infect hiv virus caus aid treat antihiv drug aptivus block hiv virus make copi it type antihiv agent type proteas inhibitor also call tipranavir sodium aqueous listen akweeus have water ar a protein bind male hormon call androgen ar found insid cell male reproduct tissu type tissu cancer cell in prostat cancer androgen bind ar insid cancer cell caus cancer cell grow also call androgen receptor ar listen describ cell protein bind androgen male hormon cancer cell ar may need androgen grow these cell may stop grow die treat substanc block bind action androgen hormon also call androgen receptor posit arac a drug use drug treat acut lymphoblast leukemia all acut myeloid leukemia aml chronic myeloid leukemia cml it also use prevent treat type leukemia spread mening three thin layer tissu cover protect brain spinal cord it also studi treatment type cancer arac block cell make dna may kill cancer cell it type antimetabolit also call cytarabin aranesp listen ayruhnesp a drug use treat anemia caus chronic kidney diseas type chemotherapi aranesp form erythropoietin substanc natur made kidney made laboratori it help bone marrow make red blood cell aranesp type antianem type erythropoiesisstimul agent also call darbepoetin alfa arctigenin listen arktihjehnin a substanc found certain plant includ burdock it shown antivir anticanc effect arctigenin belong group substanc call lignan arctiin listen arktin a substanc found certain plant includ burdock it shown anticanc effect arctiin belong group substanc call lignan aredia listen uhrehdeeuh a drug use treat hypercalcemia high blood level calcium caus certain type cancer it also use anticanc drug treat multipl myeloma breast cancer spread bone it also use treat paget diseas bone aredia may help keep bone break prevent loss calcium bone it type bisphosphon also call pamidron disodium areola listen ayreeohluh the area darkcolor skin breast surround nippl arginin listen arjihneen one twenti common amino acid build block protein arginin studi nutrit supplement treatment prevent cancer condit also call larginin arginin butyr listen arjihneen byootuhrayt a substanc studi treatment cancer argon beam coagul ablat listen argon beem cohagyuhlayt ablayshun a procedur destroy tissu electr current pass stream argon gas tissu it use treat endometriosi condit stop blood loss surgeri arimidex listen uhrihmihdex a drug use treat certain type breast cancer postmenopaus women it also studi treatment type cancer arimidex lower amount estrogen made bodi this may stop growth cancer cell need estrogen grow arimidex type nonsteroid aromatas inhibitor also call anastrozol arixtra listen uhrikstruh a drug use prevent blood clot form insid blood vessel leg it studi prevent blood clot cancer patient includ women surgeri cancer reproduct tract it type anticoagul also call fondaparinux fondaparinux sodium armd a condit slow breakdown cell center retina lightsensit layer nerv tissu back eye this block vision center eye caus problem activ read drive armd often seen peopl age also call agerel macular degener amd macular degener armodafinil listen armohdafihnil a drug use treat certain sleep disord narcolepsi it make patient feel alert awak it also studi treatment insomnia fatigu patient treat cancer armodafinil act part brain control sleep wake it type wakefulnesspromot agent also call nuvigil arm a soft tissu tumor common older children teenag it begin embryon muscl cell cell develop muscl bodi it occur mani place bodi usual occur trunk arm leg also call alveolar rhabdomyosarcoma aromasin listen uhrohmuhsin a drug use treat advanc breast cancer earlystag breast cancer estrogen receptor posit er it use postmenopaus women whose cancer alreadi treat tamoxifen it also studi treatment type cancer aromasin lower amount estrogen made bodi this may stop growth cancer cell need estrogen grow aromasin type aromatas inhibitor also call exemestan aromatas inhibitor listen uhrohmuhtay inhihbiht a drug prevent format estradiol femal hormon interf aromatas enzym aromatas inhibitor use type hormon therapi postmenopaus women hormonedepend breast cancer aromatherapist listen uhrohmuhthayruhpist a person practic type complementari medicin call aromatherapi this therapi use plant oil give strong pleasant smell promot relax sens wellb the plant oil usual inhal put skin use wet cloth bath massag aromatherapi listen uhrohmuhthayruhpe a type complementari altern medicin use plant oil give strong pleasant aroma smell promot relax sens wellb heal aromatherapi infus listen uhrohmuhthayruhpe infyoozhun the process heat without boil mixtur water essenti oil scent liquid taken plant releas pleasant aroma aromatherapi infus may also refer process heat herb liquid releas essenti oil inhal oxygen scent aromatherapi infus studi complementari therapi use addit standard treatment reliev pain shorten recoveri time patient undergo colonoscopi aromatherapi massag listen uhrohmuhthayruhpe muhsazh a type complementari altern medicin use rub knead skin plant oil give strong pleasant aroma smell promot relax sens wellb heal aromat listen ayrohmatik have odor often pleasant spici arous listen uhrowzul the state alert readi respond wake sleep arranon listen ayrrahnon a drug use treat tcell acut lymphoblast leukemia tcell lymphoblast lymphoma it use patient whose cancer gotten better recur come back treatment anticanc drug arranon stop cell make dna may kill cancer cell it type antimetabolit also call u nelarabin arrhenoblastoma listen uhreenohblastohmuh a rare type ovarian tumor tumor cell secret male sex hormon this may caus viril appear male physic characterist femal also call androblastoma sertolileydig cell tumor ovari arsenic listen arsnik a poison chemic use kill weed pest also use cancer therapi arsenic trioxid listen arsehnik tryoksid a drug use treat acut promyelocyt leukemia apl certain chromosom abnorm fusion gene call pmlraralpha it use tretinoin newli diagnos patient it use alon patient whose cancer gotten better come back treatment anticanc drug arsenic trioxid also studi treatment type cancer arsenic trioxid damag fusion protein made pmlraralpha fusion gene this may help keep cancer cell grow may kill also call trisenox art therapi listen thayruhpe treatment use make art respons art improv one physic mental emot wellb art therapi sometim use togeth psychotherapi talk therapi arteri embol listen arteereeul embohlihzayshun a procedur blood suppli tumor abnorm area tissu block dure arteri embol small incis cut made inner thigh cathet thin flexibl tube insert guid arteri near tumor abnorm tissu onc cathet place small particl made tini gelatin spong bead inject this block arteri stop flow blood tumor abnorm area tissu arteri embol use treat type liver cancer kidney cancer neuroendocrin tumor it may also use treat uterin fibroid aneurysm condit also call tae transarteri embol arteriogram listen arteereeohgram an xray arteri the person receiv inject dye outlin vessel xray arteriographi listen arteereeahgruhfe a procedur xray arteri the arteri seen inject dye outlin vessel xray arteri listen artuhre a blood vessel carri blood heart tissu organ bodi arthralgia listen arthraljuh joint pain arthriti listen arthryti a diseas caus inflamm pain joint artifici pacemak listen artihfihshul paysmayk an electron devic implant bodi monitor heart rate rhythm it give heart electr stimul beat normal it run batteri long thin wire connect heart also call cardiac pacemak pacemak arzerra listen arzayruh a drug use alon anticanc drug treat certain type chronic lymphocyt leukemia cll it also studi treatment type cancer arzerra bind protein call cd found b cell type white blood cell type leukemia lymphoma cell arzerra may block cd help immun system kill cancer cell it type monoclon antibodi also call humaxcd ofatumumab arzoxifen hydrochlorid listen arzoksihfeen hydrohklorid a substanc studi treatment osteoporosi breast cancer arzoxifen hydrochlorid made laboratori bind estrogen receptor bodi it type select estrogen receptor modul serm also call ly hydrochlorid asbesto listen asbestus a group miner take form tini fiber asbesto use insul heat fire build loos asbesto fiber breath lung caus sever serious diseas includ lung cancer malign mesothelioma cancer found line lung chest abdomen asbesto swallow may caus cancer gastrointestin tract asbestosi listen asbestohsi a lung diseas caus breath particl asbesto group miner take form tini fiber symptom includ cough troubl breath chest pain caus scar perman damag lung tissu asbestosi increas risk lung cancer malign mesothelioma cancer found line lung chest abdomen asch a find abnorm cell pap test it mean abnorm squamous cell tissu line outer part cervix asch may sign highgrad squamous intraepitheli lesion hsil may becom cervic cancer untreat more test may need also call atyp squamous cell cannot exclud highgrad lesion ascit listen uhsyteez abnorm buildup fluid abdomen may caus swell in latestag cancer tumor cell may found fluid abdomen ascit also occur patient liver diseas ascorb acid listen uhskorbik asid a nutrient bodi need small amount function stay healthi ascorb acid help fight infect heal wound keep tissu healthi it antioxid help prevent cell damag caus free radic high reactiv chemic ascorb acid found fruit veget especi citrus fruit strawberri cantaloup green pepper tomato broccoli leafi green potato it watersolubl dissolv water must taken everi day ascorb acid studi prevent treatment type cancer also call vitamin c ascus listen a find abnorm cell tissu line outer part cervix ascus common abnorm find pap test it may sign infect certain type human papillomavirus hpv it may also sign benign cancer growth cyst polyp menopaus women low hormon level more test hpv test may need also call ascus atyp squamous cell undetermin signific ascus a find abnorm cell tissu line outer part cervix ascus common abnorm find pap test it may sign infect certain type human papillomavirus hpv it may also sign benign cancer growth cyst polyp menopaus women low hormon level more test hpv test may need also call ascus atyp squamous cell undetermin signific asept necrosi listen ayseptik nehkrohsi a condit loss blood flow bone tissu caus bone die it common hip knee shoulder ankl it may caus longterm use steroid medicin alcohol abus joint injuri certain diseas cancer arthriti it may also occur point time cancer treatment includ methotrex bisphosphon corticosteroid also call avascular necrosi ischem necrosi osteonecrosi ashkenazi jew listen ashkehnahze jooz one two major ancestr group jewish individu the ancestor ashkenazi jew live central eastern europ eg germani poland russia the group call sephard jew includ whose ancestor live north africa middl east spain most jew live unit state ashkenazi descent asm a rare condit mani mast cell type white blood cell build certain tissu organ bodi includ bone marrow lymph node bone liver spleen small intestin asm may get wors quick caus sever symptom organ damag sometim may becom mast cell leukemia rare type leukemia asm usual occur adult also call aggress system mastocytosi asparaginas listen aspayruhjihnay a drug use treat acut lymphoblast leukemia all studi treatment type cancer it enzym taken bacterium escherichia coli e coli it break amino acid asparagin may block growth tumor cell need asparagin grow also call elspar lasparaginas asparaginas erwinia chrysanthemi listen aspayruhjihnay erwihneeuh krihsanthehmi a drug use anticanc drug treat acut lymphoblast leukemia all it enzym come erwinia chrysanthemi bacterium it use patient cannot take similar drug come e coli bacterium it also studi treatment type cancer it break amino acid asparagin may block growth cancer cell need asparagin grow it may also kill cancer cell also call erwinaz asparla asparla a drug use drug treat acut lymphoblast lymphoma children young adult age month year asparla form drug lasparaginas link substanc call scpeg make drug stay bodi longer lasparaginas enzym taken bacterium escherichia coli e coli it break amino acid asparagin may stop growth cancer cell need asparagin grow asparla type protein synthesi inhibitor also call calaspargas pegol ezn scpeg e coli lasparaginas aspart transaminas listen aspartayt tranzamihnay an enzym found liver heart tissu a high level aspart transaminas releas blood may sign liver heart damag cancer diseas also call serum glutamicoxaloacet transaminas sgot aspergillosi listen asperjihlohsi an infecti fungal diseas occur often skin ear nasal sinus lung peopl suppress immun system aspergillus listen asperjihlus fungi common found soil certain type aspergillus may caus diseas especi peopl suppress immun system aspir aspir pronounc aspihrit refer fluid tissu substanc withdrawn bodi caviti cyst tumor aspir pronounc aspihrayt refer act withdraw fluid tissu substanc needl it also refer accident breath food fluid lung this caus serious problem pneumonia lung problem aspir listen aspihrayshun remov fluid tissu needl also accident breath food fluid lung aspirin listen aspihrin a drug reduc pain fever inflamm blood clot aspirin belong famili drug call nonsteroid antiinflammatori agent it also studi cancer prevent asp a soft tissu tumor common older children teenag it begin soft support tissu connect surround organ tissu asp usual occur leg also occur arm hand head neck it caus growth new blood vessel help tumor grow spread also call alveolar soft part sarcoma assay listen asay a laboratori test find measur amount specif substanc assent process listen uhsent prahs a process requir law children adolesc given easytounderstand inform clinic trial help decid want take part trial the patient given chanc ask question happen trial done ask formal consent enter trial come parent guardian assess listen uhses in healthcar process use learn patient condit this may includ complet medic histori medic test physic exam test learn skill test find patient abl carri task daili live mental health evalu review social support communiti resourc avail patient asset listen aset someth financi valu person own benefit use money jewelri artwork invest real estat car exampl asset assist devic listen uhsistiv deevis a tool help person disabl certain task exampl cane wheelchair scooter walker hear aid special bed assist technolog listen uhsistiv teknahlohje ani devic technolog help disabl person exampl special grip hold utensil comput screen monitor help person low vision read easili comput control talk telephon make sound louder lifter help person rise chair asthenia listen astheeneeuh weak lack energi strength asthma listen azmuh a chronic diseas bronchial airway lung becom narrow swollen make difficult breath symptom includ wheez cough tight chest short breath rapid breath an asthma attack may brought pet hair dust smoke pollen mold exercis cold air stress astrocyt listen astrohsit a larg starshap cell hold nerv cell place help develop work way an astrocyt type glial cell astrocytoma listen astrohsytohmuh a tumor begin brain spinal cord small starshap cell call astrocyt asymmetri listen aysihmehtre lack absenc balanc proport part thing asymptomat listen aysimtohmatik have sign symptom diseas asymptomat inflammatori prostat listen aysimtohmatik inflamuhtore prostuhtyti inflamm prostat gland symptom presenc white blood cell prostat fluid atrt an aggress cancer central nervous system kidney liver occur young children also call attrht atyp teratoidrhabdoid tumor',\n",
       "  'NN'),\n",
       " ('here result quick grace search the first video list latest one date thought it suggest crizotinib lead choic mom case sinc alreadi take alimta well onc probabl want keep long work side effect limit noth take daili pill may eas lot side effect brought week trip cancer center iv infus httpcancergraceorglungtagro this long thread page patient group forum httpcancergraceorgtopicalkorrosnsclcpatientgroup',\n",
       "  'NN'),\n",
       " ('yes correct but hsct superior alemtuzumab natalizumab ocrelizumab cladribin',\n",
       "  'NN'),\n",
       " ('increas risk serious infect involv various organ system site may requir hospit result death tuberculosi frequent dissemin extrapulmonari invas fungal infect may dissemin bacteri eg legionellosi listeriosi viral infect opportunist infect report see infecti complic caution care consid risk benefit prior initi adalimumab therapi patient chronic recur infect evalu patient latent tuberculosi infect prior period adalimumab therapi indic initi appropri antimycobacteri regimen prior initi adalimumab therapi close monitor patient infect includ activ tuberculosi negat tuberculin skin test treatment discontinu adalimumab serious infect sepsi occur consid empir antifung therapi serious system ill occur patient risk invas fungal infect malign lymphoma malign fatal report children adolesc receiv tnf block agent see malign lymphoprolif disord caution aggress usual fatal hepatosplen tcell lymphoma report main adolesc young adult crohn diseas ulcer coliti receiv tnf block agent includ adalimumab most patient receiv combin immunosuppress agent includ tnf block agent thiopurin analog azathioprin mercaptopurin introduct see also stelara biolog respons modifi diseasemodifi antirheumat drug dmard recombin dnaderiv human immunoglobulin g igg monoclon antibodi specif human tumor necrosi factor tnf tnf use humira rheumatoid arthriti adult use manag sign symptom rheumatoid arthriti induc major clinic respons improv physic function inhibit progress structur damag associ diseas adult moder sever activ rheumatoid arthriti use alon combin methotrex nonbiolog dmard juvenil arthriti manag sign symptom moder sever activ polyarticular juvenil idiopath arthriti children use without methotrex psoriat arthriti use manag sign symptom psoriat arthriti improv physic function inhibit progress structur damag associ diseas adult activ psoriat arthriti use alon combin nonbiolog dmard ankylos spondyl manag sign symptom activ ankylos spondyl crohn diseas use reduc sign symptom crohn diseas induc maintain clinic remiss adult moder sever activ diseas inadequ respons convent therapi also use reduc sign symptom diseas induc clinic remiss adult moder sever activ crohn diseas lost respons intoler infliximab ulcer coliti use induc sustain clinic remiss adult moder sever activ ulcer coliti inadequ respons immunosuppress agent corticosteroid azathioprin mercaptopurin efficaci patient lost respons intoler tnf block agent establish plaqu psoriasi manag moder sever chronic plaqu psoriasi adult candid system therapi phototherapi system therapi medic less appropri use patient close monitor regular followup visit clinician humira dosag administr general concomit therapi methotrex nonbiolog dmard corticosteroid nsaia andor analges may continu adult rheumatoid arthriti psoriat arthriti ankylos spondyl methotrex corticosteroid nsaia andor analges may continu pediatr patient juvenil idiopath arthriti aminosalicyl andor corticosteroid may continu adult crohn diseas ulcer coliti azathioprin mercaptopurin methotrex may continu necessari adult crohn diseas azathioprin mercaptopurin may continu necessari adult ulcer coliti see malign lymphoprolif disord caution administr subq inject avail prefil syring prefil inject pen vial preserv free singl use vial institut use use prompt withdraw solut vial administ subq inject everi week everi week administ subq inject thigh abdomen make abdomin inject within cm inch umbilicus rotat inject site give new inject cm inch old site make inject area skin tender bruis red hard scar stretch mark do inject psoriat lesion intend use guidanc supervis clinician may selfadminist clinician determin patient andor caregiv compet safe administ drug appropri train medic followup necessari the initi selfadminist dose made supervis healthcar profession dosag pediatr patient juvenil arthriti subq children year age weigh kg mg everi week children year age weigh kg mg everi week adult rheumatoid arthriti subq mg everi week patient receiv methotrex may obtain addit benefit week dose mg psoriat arthriti subq mg everi week ankylos spondyl subq mg everi week crohn diseas subq mg day four mg inject one day two mg inject per day consecut day follow mg week later day start mainten dosag mg everi week day week mg dose ulcer coliti subq mg day four mg inject one day two mg inject per day consecut day follow mg week later day start mainten dosag mg everi week day week mg dose if clinic remiss achiev week day discontinu adalimumab plaqu psoriasi subq initi mg follow mg everi week mainten dosag start week initi dose prescrib limit adult crohn diseas manufactur state safeti efficaci continu adalimumab beyond year evalu clinic studi plaqu psoriasi manufactur state safeti efficaci continu adalimumab beyond year evalu clinic studi caution humira contraind known hypersensit adalimumab ingredi formul warningsprecaut warn infecti complic increas risk serious infect involv various organ system site may requir hospit result death opportunist infect caus bacteri mycobacteri invas fungal viral parasit opportunist pathogen eg aspergillosi blastomycosi candidiasi coccidioidomycosi histoplasmosi legionellosi listeriosi pneumocystosi tuberculosi report particular patient receiv concomit therapi immunosuppress agent eg methotrex corticosteroid infect frequent dissemin see box warn increas incid serious infect observ concomit use tnf block agent anakinra abatacept see specif drug interact patient year age comorbid condit andor receiv concomit therapi immunosuppress agent eg corticosteroid methotrex may increas risk infect do initi adalimumab patient activ infect includ local infect consid potenti risk benefit drug prior initi therapi patient histori chronic recur opportunist infect patient under condit may predispos infect patient expos tuberculosi resid travel region tuberculosi mycos histoplasmosi coccidioidomycosi blastomycosi endem close monitor patient adalimumab therapi sign symptom infect eg fever malais weight loss sweat cough dyspnea pulmonari infiltr serious system ill includ shock if new infect occur therapi perform thorough diagnost evalu appropri immunocompromis patient initi appropri antiinfect therapi close monitor patient discontinu adalimumab serious infect sepsi develop evalu patient activ latent tuberculosi risk factor tuberculosi prior period therapi when indic initi appropri antimycobacteri regimen treatment latent tuberculosi infect prior adalimumab therapi also consid antimycobacteri therapi prior adalimumab therapi individu histori latent activ tuberculosi adequ cours antimycobacteri treatment cannot confirm individu negat tuberculin skin test risk factor tuberculosi consult tuberculosi specialist recommend decid whether initi antimycobacteri therapi monitor patient includ negat tuberculin skin test activ tuberculosi strong consid tuberculosi patient develop new infect receiv adalimumab especi previous travel countri tuberculosi high preval close contact individu activ tuberculosi failur recogn invas fungal infect led delay appropri treatment consid empir antifung therapi patient risk invas fungal infect develop sever system ill whenev feasibl consult specialist fungal infect make decis regard initi durat antifung therapi when decid whether reiniti tnf block agent therapi follow resolut invas fungal infect reevalu risk benefit particular patient resid region mycos endem whenev feasibl consult specialist fungal infect malign lymphoprolif disord lymphoma malign fatal report postmarket surveil children adolesc receiv tnf block agent particular receiv immunosuppress agent eg azathioprin methotrex concomit malign includ lymphoma case eg hodgkin diseas nonhodgkin lymphoma various malign eg leukemia melanoma solid organ cancer includ rare malign usual associ immunosuppress malign usual observ children adolesc eg leiomyosarcoma hepat malign renal cell carcinoma median time occurr month rang month initi tnf block agent dose fda conclud increas risk malign tnf block agent children adolesc howev strength associ fulli character hepatosplen tcell lymphoma rare aggress usual fatal tcell lymphoma report main adolesc young adult crohn diseas ulcer coliti receiv tnf block agent andor thiopurin analog mercaptopurin azathioprin most patient receiv combin immunosuppress agent includ tnf block agent thiopurin analog unclear whether occurr relat use tnf block agent use tnf block agent conjunct immunosuppress agent in control studi lymphoma report frequent patient receiv adalimumab tnf block agent control patient patient crohn diseas rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi chronic inflammatori diseas especi high activ diseas andor chronic exposur immunosuppress therapi may increas risk lymphoma even absenc tnf block agent therapi may difficult measur ad risk tnf block agent azathioprin andor mercaptopurin acut chronic leukemia fatal report postmarket surveil tnf block agent adult pediatr patient particular receiv immunosuppress agent concomit leukemia common acut myeloid leukemia chronic lymphocyt leukemia chronic myeloid leukemia general occur first year therapi fda conclud possibl associ tnf block agent develop leukemia interpret find complic patient rheumatoid arthriti may increas risk leukemia independ treatment tnf block agent other malign eg breast colorect lung prostat melanoma nonmelanoma skin cancer occur patient receiv adalimumab in control studi tnf block agent adult increas risk malign eg patient copd histori heavi smoke patient wegen granulomatosi receiv concomit cyclophosphamid greater proport malign occur patient receiv tnf block agent compar control patient some immunerel diseas eg crohn diseas shown increas risk cancer independ treatment tnf block agent other eg juvenil idiopath arthriti unknown whether increas risk cancer consid possibl monitor occurr malign follow treatment tnf block agent consid risk benefit tnf block agent includ adalimumab prior initi therapi patient known malign success treat nonmelanoma skin cancer decid whether continu therapi patient develop malign care consid risk benefit agent especi adolesc young adult especi treatment crohn diseas ulcer coliti examin patient particular histori prior prolong immunosuppress therapi histori psoralen uva light puva therapi nonmelanoma skin cancer adalimumab therapi other warningsprecaut sensit reaction anaphylaxi angioedema allerg reaction eg allerg rash anaphylactoid reaction fix drug erupt nonspecifi drug reaction urticaria observ if serious allerg reaction anaphylaxi occur immedi discontinu adalimumab initi appropri therapi the needl cover prefil syring adalimumab contain dri natur rubber latex handl individu sensit latex hbv reactiv increas risk reactiv hbv infect patient chronic carrier virus ie hepat b surfac antigenposit hbsagposit use multipl immunosuppress agent may contribut hbv reactiv screen atrisk patient prior initi therapi evalu monitor hbv carrier sever month therapi safeti efficaci antivir therapi prevent hbv reactiv establish discontinu adalimumab initi appropri treatment eg antivir therapi hbv reactiv occur not known whether adalimumab readminist control reactiv hbv infect achiev caution advis situat nervous system effect new onset exacerb central peripher nervous system demyelin disord eg multipl sclerosi optic neuriti guillainbarr syndrom report rare patient receiv adalimumab tnf block agent exercis caution consid adalimumab therapi patient preexist recentonset central peripher nervous system demyelin disord hematolog effect possibl pancytopenia includ aplast anemia leukopenia thrombocytopenia consid discontinu patient confirm hematolog abnorm cardiovascular effect worsen chf newonset chf report patient receiv adalimumab tnf block agent use caution care monitor patient heart failur immunolog reaction antibodi format possibl format autoimmun antibodi lupuslik syndrom report if manifest suggest lupuslik syndrom develop discontinu adalimumab antibodi adalimumab may develop longterm immunogen remain determin immun patient may receiv inactiv vaccin avoid live vaccin eg measl virus vaccin live mump virus vaccin live rubella virus vaccin live smallpox vaccin typhoid vaccin live oral varicella virus vaccin live yellow fever vaccin see interact psoriasi newonset psoriasi includ pustular palmoplantar psoriasi exacerb exist psoriasi report tnf block agent includ adalimumab most patient experienc improv follow discontinu tnf block agent consid possibl monitor manifest eg new rash new worsen psoriasi particular pustular palmoplantar psoriasi hepat effect sever hepat reaction includ acut liver failur report patient receiv tnf block agent serum alt elev time uln observ patient receiv adalimumab causal relationship clear mani patient receiv concomit therapi drug known increas liver enzym concentr eg methotrex nsaia specif popul pregnanc categori b see pediatr use caution lactat distribut milk small amount appear unlik absorb breastf infant although use nurs women without appar advers effect breastf infant system bioavail milk effect exposur nurs infant unknown potenti absorpt neonat preterm infant also unknown use caution see pediatr use caution pediatr use safeti efficaci use juvenil idiopath arthriti establish pediatr patient safeti efficaci manag juvenil idiopath arthriti establish pediatr patient year age not studi children year age data patient weigh kg limit review vaccin status child administ ageappropri vaccin possibl prior initi adalimumab malign fatal report children adolesc receiv tnf block agent includ adalimumab see malign lymphoprolif disord caution neonat infant expos adalimumab utero may impair immun respons data suggest adalimumab cross placenta clinic import elev concentr infant unknown consid risk benefit administ live vaccin infant expos adalimumab utero safeti live vaccin infant unknown geriatr use no substanti differ efficaci relat younger adult the incid serious infect malign adalimumabtr patient year age higher incid younger adult the overal incid infect malign higher geriatr popul general younger adult use caution common advers effect adult infect eg upper respiratori tract infect sinus inject site reaction headach rash pediatr patient year age infect inject site pain inject site reaction hypersensit reaction eg local allerg sensit reaction rash increas cpk concentr interact humira administ concomit aminosalicyl methotrex dmard corticosteroid immunomodulatori agent eg azathioprin mercaptopurin andor nsaia clinic studi see concomit therapi dosag administr drug metabol hepat microsom enzym becaus increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym drug metabol cyp isoenzym low therapeut index monitor therapeut effect andor serum concentr follow initi discontinu adalimumab adjust dosag need biolog antirheumat agent for abatacept anakinra rituximab tocilizumab see specif drug interact for biolog agent use manag rheumatoid arthriti psoriat arthriti ankylos spondyl crohn diseas ulcer coliti plaqu psoriasi manufactur state data regard concomit use adalimumab insuffici concomit use adalimumab biolog dmard recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect vaccin patient may receiv inactiv vaccin avoid live vaccin see also pediatr use caution no data avail secondari transmiss infect live vaccin adalimumabtr patient specif drug drug interact comment abatacept increas incid infect serious infect without addit clinic benefit report abatacept tnf block agent rheumatoid arthriti concomit use recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect anakinra increas incid serious infect neutropenia without addit clinic benefit report anakinra etanercept anoth tnf block agent rheumatoid arthriti concomit use recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect cyclosporin possibl effect cyclosporin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect concentr cyclosporin follow initi discontinu adalimumab adjust dosag need influenza virus vaccin inactiv antibodi titer adalimumabtr rheumatoid arthriti patient protect albeit lower placebotr patient methotrex decreas adalimumab clearanc dosag adjust necessari natalizumab increas risk progress multifoc leukoencephalopathi pml serious infect avoid concomit use manag crohn diseas pneumococc polysaccharid vaccin no differ antibodi respons adalimumab placebotr rheumatoid arthriti patient rituximab increas risk serious infect report patient receiv rituximab subsequ receiv tnf block agent use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect theophyllin possibl effect theophyllin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect serum concentr theophyllin follow initi discontinu adalimumab adjust dosag need tnf block agent concomit use recommend tocilizumab concomit use studi possibl increas immunosuppress increas risk infect avoid concomit use use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect warfarin possibl effect warfarin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect warfarin follow initi discontinu adalimumab adjust dosag need humira pharmacokinet absorpt bioavail bioavail approxim peak serum concentr achiev hour distribut extent distribut synovi fluid distribut milk small amount appear cross placenta elimin metabol metabol fate undetermin elimin rout unknown halflif week rang day special popul in patient adalimumab antibodi clearanc adalimumab higher clearanc adalimumab lower increas age patient year age stabil storag parenter inject c do freez use solut frozen dure travel store cool carrier ice pack protect light store origin carton time administr action potent antagonist tnf biolog activ has high specif affin tnf tnf bind inactiv lymphotoxin tnf prevent bind tnf cell surfac tnf receptor therebi block biolog activ tnf an immunoglobulin g igg made phage display technolog amino acid sequenc human germlin contain nonhuman compon artifici fuse human peptid sequenc indistinguish structur function natur occur human igg produc recombin dna technolog mammalian cell express system purifi process includ specif viral inactiv remov step advic patient import patient read manufactur patient inform medic guid prior initi therapi time prescript refil import instruct patient andor caregiv regard proper dosag administr adalimumab includ use asept techniqu proper dispos needl syring determin patient andor caregiv compet safe administ drug increas suscept infect import seek immedi medic attent sign symptom suggest infect eg fever fatigu cough warm red pain skin sore bodi muscl ach diarrhea stomach pain short breath weight loss burn urin urinari frequenc develop risk lymphoma includ hepatosplen tcell lymphoma leukemia malign use tnf block agent import inform patient caregiv increas risk cancer develop children adolesc young adult take account clinic util tnf block agent relat risk benefit immunosuppress drug risk associ untreat diseas import prompt inform clinician sign symptom malign eg unexplain weight loss fatigu abdomin pain persist fever night sweat easi bruis bleed swollen lymph node neck underarm groin hepatomegali splenomegali occur import inform clinician new worsen medic condit eg neurolog condit eg demyelin disord heart failur autoimmun disord eg lupuslik syndrom psoriasi cytopenia import alert clinician allergi latex exist import prompt contact clinician manifest allerg reaction eg urticaria facial swell difficulti breath occur import take drug prescrib alter discontinu therapi without first consult clinician import women inform clinician plan becom pregnant plan breastfe import inform clinician exist contempl concomit therapi includ prescript otc drug well concomit ill histori cancer tuberculosi hbv infect chronic recur infect import inform patient import precautionari inform see caution prepar excipi commerci avail drug prepar may clinic import effect individu consult specif product label detail pleas refer ashp drug shortag resourc center inform shortag one prepar adalimumab rout dosag form strength brand name manufactur parenter inject subcutan use mg ml humira avail dispos prefil syring alcohol swab abbott mg ml humira avail dispos prefil syring prefil inject pen alcohol swab singleus vial abbott ahf di essenti copyright select revis may american societi healthsystem pharmacist inc eastwest highway suit bethesda maryland refer abbvi inc humira adalimumab inject prescrib inform north chicago il sep abbvi inc humira adalimumab medic guid north chicago il may weinblatt me keyston ec furst de et al adalimumab fulli human antitumor necrosi factor monoclon antibodi treatment rheumatoid arthriti patient take concomit methotrex the armada trial arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus felson dt anderson jj boer m et al american colleg rheumatolog preliminari definit improv rheumatoid arthriti arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus felson dt anderson jj boer m et al the american colleg rheumatolog preliminari core set diseas activ measur rheumatoid arthriti clinic trial arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus felson dt anderson jj lang mlm et al should improv rheumatoid arthriti clinic trial defin fifti percent seventi percent improv core set measur rather twenti percent arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus sharp jt score radiograph abnorm rheumatoid arthriti radiol clin north am httpwwwncbinlmnihgovpubmeddoptabstractplus rau r adalimumab fulli human antitumor necrosi factor monoclon antibodi treatment activ rheumatoid arthriti initi result five trial ann rheum dis suppl iiii httpwwwncbinlmnihgovpubmeddoptabstractplus httpwwwpubmedcentralnihgovpicrenderfcgitoolpmcentrezartidblobtypepdf abbott laboratori abbott park il person communic amgenpf corpor enbrel etanercept subcutan inject prescrib inform thousand oak ca sep keyston ec kavanaugh af sharp jt et al radiograph clinic function outcom treatment adalimumab human antitumor necrosi factor monoclon antibodi patient activ rheumatoid arthriti receiv concomit methotrex therapi random placebocontrol week trial arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus weinblatt me keyston ec furst de et al longterm efficaci safeti adalimumab plus methotrex patient rheumatoid arthriti armada year extend studi ann rheum dis dec epub ahead print navarrosarabia f arizaariza r hernandezcrus b et al adalimumab treat rheumatoid arthriti cochran databas syst rev cd meas pj gladman dd ritchlin ct et al adalimumab treatment patient moder sever activ psoriat arthriti result doubleblind random placebocontrol trial arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus gladman dd meas pj cifaldi ma et al adalimumab improv joint skinrel function impair patient psoriat arthriti patientreport outcom adalimumab effect psoriat arthriti trial adept ann rheum dis nov epub van der heijd d kivitz a schiff mh et al efficaci safeti adalimumab patient ankylos spondyl result multicent random doubleblind placebocontrol trial arthriti rheum httpwwwncbinlmnihgovpubmeddoptabstractplus bristolmy squibb orencia abatacept prescrib inform princeton nj sep food drug administr center drug evalu research inform healthcar profession tumor necrosi factor tnf blocker market remicad enbrel humira cimzia simponi fda alert rockvill md aug avail fda websit access nov httpwwwfdagovdrugsdrugsafetypostmarketdrugsafetyinformationforpatientsandprovidersdrugsafetyinformationforheathcareprofessionalsucmhtm food drug administr center drug evalu research fda alert inform healthcar profession cimzia certolizumab pegol enbrel etanercept humira adalimumab remicad infliximab rockvill md food drug administr sep avail fda websit access oct httpwwwfdagovdrugsdrugsafetypostmarketdrugsafetyinformationforpatientsandprovidersucmhtm lovel dj ruperto n goodman s et al adalimumab without methotrex juvenil rheumatoid arthriti n engl j med httpwwwncbinlmnihgovpubmeddoptabstractplus targan sr hanauer sb van devent sjh a shortterm studi chimer monoclon antibodi ca tumor necrosi factor crohn diseas n engl j med httpwwwncbinlmnihgovpubmeddoptabstractplus humira adalimumab risk evalu mitig strategi rem from fda websit httpwwwfdagovdownloadsdrugsdrugsafetypostmarketdrugsafetyinformationforpatientsandprovidersucmpdf access oct us food drug administr fda drug safeti communic drug label tumor necrosi factoralpha tnf blocker includ warn infect legionella listeria bacteria rockvill md sep from fda websit access oct httpwwwfdagovdrugsdrugsafetyucmhtm us food drug administr fda drug safeti communic safeti review updat report hepatosplen tcell lymphoma adolesc young adult receiv tumor necrosi factor tnf blocker azathioprin andor mercaptopurin rockvill md apr from fda websit access jul httpwwwfdagovdrugsdrugsafetyucmhtm genentech actemra tocilizumab inject prescrib inform south san francisco ca apr papp k crowley j ortonn jp et al adalimumab moder sever chronic plaqu psoriasi efficaci safeti retreat diseas recurr follow withdraw therapi br j dermatol httpwwwncbinlmnihgovpubmeddoptabstractplus genentech rituxan rituximab inject prescrib inform south san francisco ca apr biogen idec inc tysabri natalizumab inject prescrib inform cambridg ma sep janssen biotech inc simponi golimumab inject prescrib inform horsham pa jan reinisch w sandborn wj homm dw et al adalimumab induct clinic remiss moder sever activ ulcer coliti result randomis control trial gut httpwwwncbinlmnihgovpubmeddoptabstractplus sandborn wj van assch g reinisch w et al adalimumab induc maintain clinic remiss patient moderatetosever ulcer coliti gastroenterolog e httpwwwncbinlmnihgovpubmeddoptabstractplus adalimumab in brigg gg freeman rk yaff sj drug pregnanc lactat refer guid fetal neonat risk th ed philadelphia lippincott william wilkin reinisch w sandborn wj panaccion r et al week efficaci adalimumab patient moder sever activ ulcer coliti fail corticosteroid andor immunosuppress inflamm bowel dis httpwwwncbinlmnihgovpubmeddoptabstractplus abbvi inc humira adalimumab instruct use singleus pen north chicago il jul abbvi inc humira adalimumab instruct use singleus prefil syring north chicago il jan',\n",
       "  'VBP'),\n",
       " ('i dx stage b nsclc one year ago ive done well tradit chemo radiat left cm nodul my doctor imfinzi kill last littl cancer make sick i stop i would like second opinion can doctor contact im local nyc i want gone',\n",
       "  'NN'),\n",
       " ('i complet agre see therapist one best decis i ever made these diseas affect us physic mental well it import mental emot healthi physic healthi especi face major procedur surgeri i actual began see therapist surgeri i truli felt like shell person i she help i decid continu see year later i still session month it great unbias ear listen offer valuabl advic friend famili unabl provid have therapist play big part overal health well stelara juli inflammatoryboweldiseasenet team member',\n",
       "  'NN'),\n",
       " ('it scari time chronic ill signific pain associ time i found generous pain med whenev i admit hospit exacerb reason never will maintain pain relief home at least alway option go er pain get realli bad everi time i done ct scan see horribl insid admit pain relief iv nutrit sound like may easi option pain med restrict get stricter i actual med student mention get tylenol i er last time luckili actual doctor came order substanti pain relief left wonder teach current student pain relief day year old femal husband son diagnos cd januari resect start stelara june current bad flare work tpn fentanyl patch oxycodon hope back work octob past med mp humira remicad cimzia',\n",
       "  'NN'),\n",
       " ('thank step lead hous two room i dont worri much i think i push littl much yesterday tri take pain medic and output scenario make sens my abdomen small i go attempt shower today easi hospit ground level chair rail i dont live big citi kinda hard get lot exercis ive walk hous multipl time still cant stand straight i look littl awkward haha dx sever pancol appear crohn take humira bi week month lialda x day mg prednison mg calcium vit d flare sinc',\n",
       "  'NN'),\n",
       " ('hi everyon i found i jcv i gilenya ish year never tysabri hope i would abl go futur sinc i heard great thing i might want someth stronger gilenya my question isdid gilenya caus jcv anyon random jcv is anyth i need worri',\n",
       "  'NN'),\n",
       " ('electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move the major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect it import replac miss electrolyt becom rebalanc how done depend sever imbal if minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi an mri scanner larg tube contain power magnet you lie insid tube scan mris help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimus astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes common caus scar surgeri less common scar due activ inflammatori bowel diseas adhes fibrous band form tissu caus pain blockag intestin post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit a bowel resect surgic procedur part larg small intestin remov post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit a hemicolectomi involv surgeri remov right left portion colon',\n",
       "  'NN'),\n",
       " ('cc stelara work matter day if gi will jump hoop get probabl worth consid if one anti tnf stop work anoth pm ulcer coliti next surgeri schedul i problem skin loop i ad setup pm ulcer coliti next surgeri schedul im familiar hollist probabl they go first cut hole stoma go place direct skin it protect leak stay skin pm ulcer coliti humira remicad there cimzia simponi antitnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug am ulcer coliti unexpect scope result jpouch buckey i think how appoint gi go i know issu complex mine i didnt see post anyth am ulcer coliti next surgeri schedul congratul id recommend get convex wafer new ostomi realli help liquid output as probabl know loop ileo time littl pm ulcer coliti after remicad infus id get test remicad antibodi i symptom i serum sick dont ignor mine got wors i start drop thing memori loss bone joint pain if pm ulcer coliti the superdonor phenomenon fecal microbiota transplant here segment cbc radio quirk quark show httpswwwcbccaradioquirksnotallpoopiscreatedequalandsuperpooperscouldbelifesav they test am ulcer coliti just saw gi hes recommend xeljanz im scare when start thread check box includ signatur i see med have thought ad entyvio either prednison entocort is blood test pm ulcer coliti just saw gi hes recommend xeljanz im scare have antitnf med like remicad you dont anyth list signatur are use rectal med steroid pm ulcer coliti recent takendown friend ive heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi gas diarrhea also caus sibo it easi test ive taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       "  'NN'),\n",
       " ('tofacitinib receivedexpand approv treat adult moder sever ulcer coliti the drug approv treat rheumatoid arthriti patient psoriat arthriti sourc jama',\n",
       "  'NN'),\n",
       " ('rachschad i sorri ms caus problem regular everi three week suggest trigger doe doctor view ocrevus lemtrada difficult comparison youll find mser one therapi experienc your doctor view best base sideeffect profil patient feedback apprais medic research behind treatment good luck whichev choos i realli hope break horrend cycl',\n",
       "  'NN'),\n",
       " ('my husband decid particip stelara studi wasnt given much hope would work end get xeljanz offlabel game changer put remiss he day away step surgeri it phase mainten studi rumor fda approv uc may horizon the nice thing xeljanz pill know within week whether work spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label it work no uc symptom abl eat almost everyth fresh fruit veget first time year struggl final taper prednison',\n",
       "  'NN'),\n",
       " ('ocrelizumab monoclon antibodi affect action bodi immun system monoclon antibodi made target destroy certain cell bodi this may help protect healthi cell damag ocrelizumab use treat multipl sclerosi relaps progress form ocrelizumab may also use purpos list medic guid what possibl side effect ocrelizumab ocrevus get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat some side effect may occur inject hour later tell caregiv right away feel dizzi sleepi nauseat lighthead feverish sweati itchi red skin rash headach fast heartbeat chest tight troubl breath swell irrit throat call doctor fever chill cough yellow green mucus stab chest pain wheez feel short breath skin warmth red swell skin sore blister pus ooz cold sore fever blister around lip nerv pain tingl burn pain pin needl feel mood behavior chang confus memori problem weak one side bodi problem vision speech walk your ocrelizumab treatment may delay perman discontinu certain side effect common side effect may includ reaction inject respiratori infect affect nose sinus throat lung this complet list side effect other may occur call doctor medic advic side effect you may report side effect fda fda what import inform i know ocrelizumab ocrevus ocrelizumab may caus unpleas side effect medicin inject hour later tell caregiv right away unusu discomfort inject call doctor unpleas side effect dizzi nausea skin rash chest tight troubl breath within hour inject what i discuss healthcar provid receiv ocrelizumab ocrevus you treat ocrelizumab allerg activ infect hepat b tell doctor receiv vaccin within past week to make sure ocrelizumab safe tell doctor type activ infect histori use medicin weaken immun system carrier hepat b schedul receiv vaccin use ocrelizumab may increas risk develop certain type cancer breast cancer ask doctor specif risk it known whether medicin harm unborn babi tell doctor pregnant plan becom pregnant use effect birth control prevent pregnanc use medicin least month last dose it known whether ocrelizumab pass breast milk could affect nurs babi tell doctor breastfeed how ocrelizumab given ocrevus befor start treatment ocrelizumab doctor may perform test make sure hepat b infect ocrelizumab inject vein iv a healthcar provid give inject you may given medic prevent certain side effect ocrelizumab your first dose ocrelizumab split separ infus you receiv infus week apart the follow dose given everi month ocrelizumab must given slowli infus take hour minut complet you watch close least hour receiv ocrelizumab make sure allerg reaction medic if ever hepat b ocrelizumab caus condit come back get wors you need frequent blood test check liver function treatment sever month stop use medicin skin cancer slideshow take skin cancer quiz sundamag skin slideshow pictur what happen i miss dose ocrevus call doctor instruct miss dose ocrelizumab what happen i overdos ocrevus seek emerg medic attent call poison help line what i avoid receiv ocrelizumab ocrevus do receiv live vaccin use ocrelizumab could develop serious infect live vaccin includ measl mump rubella mmr polio rotavirus typhoid yellow fever varicella chickenpox zoster shingl nasal flu influenza vaccin what drug affect ocrelizumab ocrevus tell doctor medicin recent use treat multipl sclerosi other drug may interact ocrelizumab includ prescript overthecount medicin vitamin herbal product tell doctor current medicin medicin start stop use where i get inform ocrevus your pharmacist provid inform ocrelizumab rememb keep medicin reach children never share medicin other use medic indic prescrib everi effort made ensur inform provid cerner multum inc multum accur uptod complet guarante made effect drug inform contain herein may time sensit multum inform compil use healthcar practition consum unit state therefor multum warrant use outsid unit state appropri unless specif indic otherwis multum drug inform endors drug diagnos patient recommend therapi multum drug inform inform resourc design assist licens healthcar practition care patient andor serv consum view servic supplement substitut expertis skill knowledg judgment healthcar practition the absenc warn given drug drug combin way constru indic drug drug combin safe effect appropri given patient multum assum respons aspect healthcar administ aid inform multum provid the inform contain herein intend cover possibl use direct precaut warn drug interact allerg reaction advers effect if question drug take check doctor nurs pharmacist',\n",
       "  'VBP'),\n",
       " ('hi everyon my father age diagnos nsclc egfr alk negat brain mri bone scan clear yesterday ct scan show nodul grown cm cm along small nodul my dad pretti sever pain right rib area take deep breath also pressur first biopsi site take tylenol around clock pain one oncologist order second biopsi check geneticmolecular marker want wait result start treatment biopsi done today result wont back least week a second oncologist want start dad keytrudaalimtacarboplatin come monday my dad extrem anxious want get start asap still contempl wait genet test result come back should wait or start treatment monday help i provid info need',\n",
       "  'NN'),\n",
       " ('these immunolgi drug work cancer differ manner', 'NN'),\n",
       " ('uf difficult one if born wouldnt stuck drug doesnt work i gilenya faf yes stop relaps stop go spms too afraid drug denial get wors chang drug dont work noth stop spms went unoffici spms year later onc spms mani choic avail there stronger drug ask dr ask stop spms person hstc cladribin choic atm xx',\n",
       "  'JJ'),\n",
       " ('my father go petscan tomorrow septemb two cycl abraxanecarbokeytrudahigh dose vitamin c second line treatment his genom test came back two week ago show egfr tmlr high amplif cmet the report recommend osimertinib tagrisso warn high cmet may contribut resist in part world',\n",
       "  'NN'),\n",
       " ('bravo larri i cant see ride much wind i ride forest i ear wind tree top dont feel it like spring last coupl week i done good ride week those regular mile feet gain tomorrow first full dose ocrevus i excit see i improv littl alain',\n",
       "  'NN'),\n",
       " ('hi i new i read post sourc strength inform extrem difficult time my world shatter father diagnos nsclc squamous cell carcinoma stage iv march primari right lung tumour xcm met hilar mediastinum lymph node lot bone he short breath energi appetit distress persist cough whiteyellowish phlegm we fear could stand chemo first high dose iv vitamin c lose carboplatingemzar april follow second infus april we high hope high dose vitamin c alway full energi ate better felt better first two day vitamin c infus petscan april howev show new lesion around neck increas size number lesion bone tumour lung decreas littl onc said treatment fail move keytruda pdl biopsi came back posit had first keytruda infus april so far side effect fatigu reduc appetit still lot cough debilit he take anoro inhal morn relvar inhal sleep strang cough less sleep night i read fighterm post exchang i sad hear without til tumour infiltr lymphocit even pdl high keytruda immunotherapi work as onc said earlier mention til first histopatholog report biopsi mean father doesnt til i would like ask is worth tmb genom sequenc test squamous cell explor possibl line treatment option tmb us malaysia cost usd self paid insur cover onc supplier offer tmb i dont know better scarix oncodna belgium foundat one onc said chanc squamous cell mutat target therapi work low advis us drop tmb what think i afraid keytruda work father option we second keytruda infus may onc advis month instead everi week the day slow watch cough distress i think ct scan instead petscan second keytruda infus confirm pneumon is true pneumon show pet thank much anyon could help us inform sorri long post peggi',\n",
       "  'NN'),\n",
       " ('childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu certain genet condit increas risk childhood rhabdomyosarcoma a sign childhood rhabdomyosarcoma lump swell keep get bigger diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma certain factor affect prognosi chanc recoveri treatment option childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu rhabdomyosarcoma type sarcoma sarcoma cancer soft tissu muscl connect tissu tendon cartilag bone rhabdomyosarcoma usual begin muscl attach bone help bodi move rhabdomyosarcoma common type soft tissu sarcoma children it begin mani place bodi there three main type rhabdomyosarcoma embryon this type occur often head neck area genit urinari organ occur anywher bodi it common type rhabdomyosarcoma alveolar this type occur often arm leg chest abdomen genit organ anal area anaplast this least common type rhabdomyosarcoma children see follow pdq treatment summari inform type soft tissu sarcoma childhood soft tissu sarcoma adult soft tissu sarcoma certain genet condit increas risk childhood rhabdomyosarcoma anyth increas risk get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk child doctor think child may risk risk factor rhabdomyosarcoma includ follow inherit diseas lifraumeni syndrom pleuropulmonari blastoma neurofibromatosi type nf costello syndrom beckwithwiedemann syndrom noonan syndrom children high birth weight larger expect birth may increas risk embryon rhabdomyosarcoma in case caus rhabdomyosarcoma known a sign childhood rhabdomyosarcoma lump swell keep get bigger sign symptom may caus childhood rhabdomyosarcoma condit the sign symptom occur depend cancer form check child doctor child follow a lump swell keep get bigger go away it may pain bulg eye headach troubl urin bowel movement blood urin bleed nose throat vagina rectum diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma the diagnost test done depend part cancer form the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit past ill treatment also taken xray an xray organ bone insid bodi chest an xray type energi beam go bodi onto film make pictur area insid bodi ct scan cat scan a procedur make seri detail pictur area insid bodi abdomen pelvi lymph node taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen the child lie tabl slide ct scanner take xray pictur insid abdomen mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area bodi skull brain lymph node this procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen the child lie tabl slide mri scanner take pictur insid bodi the pad child abdomen help make pictur clearer pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg positron emiss tomographi pet scan the child lie tabl slide pet scanner the head rest white strap help child lie still a small amount radioact glucos sugar inject child vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan a procedur check rapid divid cell cancer cell bone a small amount radioact materi inject vein travel bloodstream the radioact materi collect bone cancer detect scanner enlarg bone scan a small amount radioact materi inject child vein travel blood the radioact materi collect bone as child lie tabl slide scanner radioact materi detect imag made comput screen bone marrow aspir biopsi the remov bone marrow blood small piec bone insert hollow needl hipbon sampl remov hipbon a pathologist view bone marrow blood bone microscop look sign cancer enlarg bone marrow aspir biopsi after small area skin numb bone marrow needl insert child hip bone sampl blood bone bone marrow remov examin microscop lumbar punctur a procedur use collect cerebrospin fluid csf spinal column this done place needl two bone spine csf around spinal cord remov sampl fluid the sampl csf check microscop sign cancer cell this procedur also call lp spinal tap if test show may rhabdomyosarcoma biopsi done a biopsi remov cell tissu view microscop pathologist check sign cancer becaus treatment depend type rhabdomyosarcoma biopsi sampl check pathologist experi diagnos rhabdomyosarcoma one follow type biopsi may use fineneedl aspir fna biopsi the remov tissu fluid use thin needl core needl biopsi the remov tissu use wide needl this procedur may guid use ultrasound ct scan mri open biopsi the remov tissu incis cut made skin sentinel lymph node biopsi the remov sentinel lymph node surgeri the sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor it first lymph node cancer like spread primari tumor a radioact substanc andor blue dye inject near tumor the substanc dye flow lymph duct lymph node the first lymph node receiv substanc dye remov a pathologist view tissu microscop look cancer cell if cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node the follow test may done sampl tissu remov light microscopi a laboratori test cell sampl tissu view regular highpow microscop look certain chang cell immunohistochemistri a test use antibodi check certain antigen sampl tissu the antibodi usual link radioact substanc dye caus tissu light microscop this type test may use tell differ differ type cancer fish fluoresc situ hybrid a laboratori test use look gene chromosom cell tissu piec dna contain fluoresc dye made laboratori ad cell tissu glass slide when piec dna attach certain gene area chromosom slide light view microscop special light this type test use find certain gene chang revers transcriptionpolymeras chain reaction rtpcr test a laboratori test cell sampl tissu studi use chemic look certain chang structur function gene cytogenet analysi a laboratori test cell sampl tissu view microscop look certain chang chromosom certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the patient age where bodi tumor start the size tumor time diagnosi whether tumor complet remov surgeri the type rhabdomyosarcoma embryon alveolar anaplast whether certain chang gene whether tumor spread part bodi time diagnosi whether tumor lymph node time diagnosi whether tumor respond chemotherapi andor radiat therapi for patient recurr cancer prognosi treatment also depend follow where bodi tumor recur came back how much time pass end cancer treatment cancer recur whether tumor treat radiat therapi stage childhood rhabdomyosarcoma key point after childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri there three way cancer spread bodi cancer may spread began part bodi stage childhood rhabdomyosarcoma done three part the stage system base size tumor bodi whether spread part bodi stage stage stage stage the group system base whether cancer spread whether cancer remov surgeri group i group ii group iii group iv the risk group base stage system group system lowrisk childhood rhabdomyosarcoma intermediaterisk childhood rhabdomyosarcoma highrisk childhood rhabdomyosarcoma after childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri the process use find cancer spread within tissu part bodi call stage it import know stage order plan treatment the doctor use result diagnost test help find stage diseas treatment childhood rhabdomyosarcoma base part stage sometim amount cancer remain surgeri remov tumor the pathologist use microscop check tissu remov surgeri includ tissu sampl edg area cancer remov lymph node this done see cancer cell taken surgeri there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl rhabdomyosarcoma spread lung cancer cell lung actual rhabdomyosarcoma cell the diseas metastat rhabdomyosarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi stage childhood rhabdomyosarcoma done three part childhood rhabdomyosarcoma stage use three differ way describ cancer a stage system a group system a risk group the stage system base size tumor bodi whether spread part bodi stage in stage tumor size may spread lymph node found one follow favor site eye area around eye head neck tissu next brain spinal cord gallbladd bile duct uret urethra test ovari vagina uterus rhabdomyosarcoma form favor site better prognosi if site cancer occur one favor site list said unfavor site enlarg tumor size the size tumor may compar size pea cm peanut cm grape cm walnut cm lime cm egg cm peach cm grapefruit cm stage in stage cancer found unfavor site one area describ favor stage the tumor larger centimet spread lymph node stage in stage cancer found unfavor site one area describ favor stage one follow true the tumor larger centimet cancer spread nearbi lymph node the tumor larger centimet cancer may spread nearbi lymph node stage in stage tumor may size cancer may spread nearbi lymph node cancer spread distant part bodi lung bone marrow bone the group system base whether cancer spread whether cancer remov surgeri group i cancer found place start complet remov surgeri tissu taken edg tumor remov the tissu check microscop pathologist cancer cell found group ii group ii divid group iia iib iic iia cancer remov surgeri cancer cell seen tissu taken edg tumor remov view microscop pathologist iib cancer spread nearbi lymph node cancer lymph node remov surgeri iic cancer spread nearbi lymph node cancer lymph node remov surgeri least one follow true tissu taken edg tumor remov check microscop pathologist cancer cell seen the furthest lymph node tumor remov check microscop pathologist cancer cell seen group iii cancer part remov biopsi surgeri tumor remain seen eye group iv cancer spread distant part bodi cancer diagnos cancer cell found imag test there cancer cell fluid around brain spinal cord lung fluid abdomen tumor found area the risk group base stage system group system the risk group describ chanc rhabdomyosarcoma recur come back everi child treat rhabdomyosarcoma receiv chemotherapi decreas chanc cancer recur the type anticanc drug dose number treatment given depend whether child lowrisk intermediaterisk highrisk rhabdomyosarcoma the follow risk group use lowrisk childhood rhabdomyosarcoma lowrisk childhood rhabdomyosarcoma one follow an embryon tumor size found favor site there may tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node the follow area favor site eye area around eye head neck tissu near ear nose sinus base skull gallbladd bile duct uret urethra test ovari vagina uterus an embryon tumor size found favor site there may tumor remain surgeri seen microscop the cancer may spread nearbi lymph node intermediaterisk childhood rhabdomyosarcoma intermediaterisk childhood rhabdomyosarcoma one follow an embryon tumor size found one favor site list there tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node an alveolar tumor size favor unfavor site there may tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node highrisk childhood rhabdomyosarcoma highrisk childhood rhabdomyosarcoma may embryon type alveolar type it may spread nearbi lymph node spread one follow other part bodi near tumor first form fluid around brain spinal cord fluid lung abdomen recurr childhood rhabdomyosarcoma recurr childhood rhabdomyosarcoma cancer recur come back treat the cancer may come back place part bodi lung bone bone marrow less often rhabdomyosarcoma may come back breast adolesc femal liver treatment option overview key point there differ type treatment patient childhood rhabdomyosarcoma children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children treatment childhood rhabdomyosarcoma may caus side effect three type standard treatment use surgeri radiat therapi chemotherapi new type treatment test clinic trial immunotherapi target therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient childhood rhabdomyosarcoma some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment becaus cancer children rare take part clinic trial consid some clinic trial open patient start treatment children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children becaus rhabdomyosarcoma form mani differ part bodi mani differ kind treatment use treatment overseen pediatr oncologist doctor special treat children cancer the pediatr oncologist work health care provid expert treat children rhabdomyosarcoma special certain area medicin these may includ follow specialist pediatrician pediatr surgeon radiat oncologist pediatr hematologist pediatr radiologist pediatr nurs specialist geneticist cancer genet risk counselor social worker rehabilit specialist treatment childhood rhabdomyosarcoma may caus side effect for inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment rhabdomyosarcoma may includ physic problem chang mood feel think learn memori second cancer new type cancer some late effect may treat control it import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform three type standard treatment use surgeri surgeri remov cancer oper use treat childhood rhabdomyosarcoma a type surgeri call wide local excis often done a wide local excis remov tumor tissu around includ lymph node a second surgeri may need remov cancer whether surgeri done type surgeri done depend follow where bodi tumor start the effect surgeri way child look the effect surgeri child import bodi function how tumor respond chemotherapi radiat therapi may given first in children rhabdomyosarcoma possibl remov tumor surgeri rhabdomyosarcoma form mani differ place bodi surgeri differ site surgeri treat rhabdomyosarcoma eye genit area usual biopsi chemotherapi sometim radiat therapi may given surgeri shrink larg tumor after doctor remov cancer seen time surgeri patient given chemotherapi surgeri kill cancer cell left radiat therapi may also given treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell stop grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu these type extern radiat therapi includ follow conform radiat therapi conform radiat therapi type extern radiat therapi use comput make dimension d pictur tumor shape radiat beam fit tumor this allow high dose radiat reach tumor caus less damag nearbi healthi tissu intensitymodul radiat therapi imrt imrt type dimension d radiat therapi use comput make pictur size shape tumor thin beam radiat differ intens strength aim tumor mani angl volumetr modul arc therapi vmat vmat type d radiat therapi use comput make pictur size shape tumor the radiat machin move circl around patient treatment send thin beam radiat differ intens strength tumor treatment vmat deliv faster treatment imrt stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment onc day sever day radiat machin aim larger usual dose radiat direct tumor by patient posit treatment less damag nearbi healthi tissu this procedur also call stereotact externalbeam radiat therapi stereotax radiat therapi proton beam radiat therapi protonbeam therapi type highenergi extern radiat therapi a radiat therapi machin aim stream proton tini invis positivelycharg particl cancer cell kill this type treatment caus less damag nearbi healthi tissu intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer it use treat cancer area vagina vulva uterus bladder prostat head neck intern radiat therapi also call brachytherapi intern radiat implant radiat interstiti radiat therapi the type amount radiat therapi given depend age child type rhabdomyosarcoma bodi tumor start much tumor remain surgeri whether tumor nearbi lymph node extern radiat therapi usual use treat childhood rhabdomyosarcoma certain case intern radiat therapi use chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi chemotherapi may also given shrink tumor surgeri order save much healthi tissu possibl this call neoadjuv chemotherapi everi child treat rhabdomyosarcoma receiv system chemotherapi decreas chanc cancer recur the type anticanc drug dose number treatment given depend whether child lowrisk intermediaterisk highrisk rhabdomyosarcoma see drug approv rhabdomyosarcoma inform new type treatment test clinic trial this summari section describ treatment studi clinic trial it may mention everi new treatment studi inform clinic trial avail nci websit immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biolog therapi biotherapi there differ type immunotherapi vaccin therapi cancer treatment use substanc group substanc stimul immun system find tumor kill vaccin therapi studi treat metastat rhabdomyosarcoma immun checkpoint inhibitor therapi use bodi immun system kill cancer cell two type immun checkpoint inhibitor studi treatment childhood rhabdomyosarcoma come back treatment ctla protein surfac t cell help keep bodi immun respons check when ctla attach anoth protein call b cancer cell stop t cell kill cancer cell ctla inhibitor attach ctla allow t cell kill cancer cell ipilimumab type ctla inhibitor pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell nivolumab pembrolizumab pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat there differ type target therapi mtor inhibitor stop protein help cell divid surviv sirolimus type mtor inhibitor therapi studi treatment recurr rhabdomyosarcoma tyrosin kinas inhibitor smallmolecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid mk cabozantinibsmal tyrosin kinas inhibitor studi treatment recurr rhabdomyosarcoma patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show child condit chang cancer recur come back these test sometim call followup test checkup treatment option childhood rhabdomyosarcoma for inform treatment list see treatment option overview section previous untreat childhood rhabdomyosarcoma the treatment childhood rhabdomyosarcoma often includ surgeri radiat therapi chemotherapi the order treatment given depend bodi tumor start size tumor type tumor whether tumor spread lymph node part bodi see treatment option overview section summari inform surgeri radiat therapi chemotherapi use treat children rhabdomyosarcoma rhabdomyosarcoma brain head neck for tumor brain treatment may includ surgeri remov tumor radiat therapi chemotherapi for tumor head neck near eye treatment may includ chemotherapi radiat therapi if tumor remain come back treatment chemotherapi radiat therapi surgeri remov eye tissu around eye may need for tumor head neck near ear nose sinus base skull near eye treatment may includ radiat therapi chemotherapi for tumor head neck near eye near ear nose sinus base skull treatment may includ chemotherapi radiat therapi surgeri remov tumor for tumor head neck cannot remov surgeri treatment may includ chemotherapi radiat therapi includ stereotact bodi radiat therapi for tumor larynx voic box treatment may includ chemotherapi radiat therapi surgeri remov larynx usual done voic harm rhabdomyosarcoma arm leg chemotherapi follow surgeri remov tumor if tumor complet remov second surgeri remov tumor may done radiat therapi may also given for tumor hand foot radiat therapi chemotherapi may given the tumor may remov would affect function hand foot lymph node dissect one lymph node remov sampl tissu check microscop sign cancer for tumor arm lymph node near tumor armpit area remov for tumor leg lymph node near tumor groin area remov rhabdomyosarcoma chest abdomen pelvi for tumor chest abdomen includ chest wall abdomin wall surgeri wide local excis may done if tumor larg chemotherapi radiat therapi given shrink tumor surgeri for tumor pelvi surgeri wide local excis may done if tumor larg chemotherapi given shrink tumor surgeri radiat therapi may given surgeri for tumor diaphragm a biopsi tumor follow chemotherapi radiat therapi shrink tumor surgeri may done later remov remain cancer cell for tumor gallbladd bile duct a biopsi tumor follow chemotherapi radiat therapi for tumor muscl tissu around anus vulva anus scrotum anus surgeri done remov much tumor possibl nearbi lymph node follow chemotherapi radiat therapi rhabdomyosarcoma kidney for tumor kidney surgeri remov much tumor possibl chemotherapi radiat therapi may also given rhabdomyosarcoma bladder prostat for tumor top bladder surgeri wide local excis done for tumor prostat bladder top bladder chemotherapi radiat therapi given first shrink tumor if cancer cell remain chemotherapi radiat therapi tumor remov surgeri surgeri may includ remov prostat part bladder pelvic exenter without remov rectum this may includ remov lower colon bladder in girl cervix vagina ovari nearbi lymph node may remov chemotherapi given first shrink tumor surgeri remov tumor bladder prostat done intern extern radiat therapi may given surgeri surgeri remov tumor bladder prostat intern radiat therapi given surgeri rhabdomyosarcoma area near testicl surgeri remov testicl spermat cord the lymph node back abdomen may check cancer especi lymph node larg child year older radiat therapi may given tumor cannot complet remov surgeri rhabdomyosarcoma vulva vagina uterus cervix ovari for tumor vulva vagina treatment may includ chemotherapi follow surgeri remov tumor intern extern radiat therapi may given surgeri for tumor uterus treatment may includ chemotherapi without radiat therapi sometim surgeri may need remov remain cancer cell for tumor cervix treatment may includ chemotherapi follow surgeri remov remain tumor for tumor ovari treatment may includ chemotherapi follow surgeri remov remain tumor metastat rhabdomyosarcoma treatment chemotherapi radiat therapi surgeri remov tumor given site tumor first form if cancer spread brain spinal cord lung radiat therapi may also given site cancer spread the follow treatment studi metastat rhabdomyosarcoma a clinic trial immunotherapi vaccin therapi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail refractori recurr childhood rhabdomyosarcoma treatment option refractori recurr childhood rhabdomyosarcoma base mani factor includ bodi cancer come back type treatment child need child treatment refractori recurr rhabdomyosarcoma may includ one follow surgeri radiat therapi chemotherapi a clinic trial target therapi immunotherapi sirolimus ipilimumab nivolumab pembrolizumab a clinic trial target therapi tyrosin kinas inhibitor mk cabozantinibsmal chemotherapi a clinic trial check sampl patient tumor certain gene chang the type target therapi given patient depend type gene chang use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about childhood rhabdomyosarcoma for inform nation cancer institut childhood rhabdomyosarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv rhabdomyosarcoma target cancer therapi for childhood cancer inform general cancer resourc see follow about cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer a guid parent cancer children adolesc stage cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment childhood rhabdomyosarcoma it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq pediatr treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq pediatr treatment editori board pdq childhood rhabdomyosarcoma treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypessofttissuesarcomapatientrhabdomyosarcomatreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('mlgilber okay that longterm concern id heard note realli wasnt higher general risk my origin prescrib neuro extra screen case still decid ocrevus best bet know sfrox seem convinc pml risk i yet find studi patient get pml asid research believ actual got tysabri switch ocrevus not sure that risk hes concern i know get ocrevus insur first drug challeng sinc im alreadi past hurdl im familiar aspect busi side that good thing consid hadnt thought i guess ill find th stumbler that absolut plan just want see peopl mightv experi mayb i miss reasoningpotenti logic behind ultim call think i find new neurologist',\n",
       "  'NN'),\n",
       " ('i rainout work one thursdayth least littl chore would leav breathless i went emerg roomtold happeningthey kept run testsput breath treatmentoxygen etcthey even done brain scanfast forwardi cancerthey sent oncologist testsh told i stage lung cancerit spread lungsther spot brain also wasnt big enough evaluatefast forward i prescrib keytrudai two infus anoth scan skull sinc time period nov jan i also late stage copd',\n",
       "  'NN'),\n",
       " ('vixen i like ocrevus treatment my last neuro apt show improv walk speed im still rigid leg gate i mri june third appt want see well lesion i post im excit see well',\n",
       "  'NN'),\n",
       " ('a major drug compani block access medicin cheapli effect save thousand peopl go blind want launch expens product market ophthalmologist around world initi inject tini quantiti colon cancer drug call avastin eye patient wet macular degener common condit older age lead sever impair eyesight blind they report remark success low cost one phial split use dozen patient but genentech compani invent avastin want use way instead appli licens fragment avastin call lucenti packag tini quantiti suitabl eye higher cost specul us suggest could cost per dose instead less the compani say lucenti specif design eye modif avastin year test prove safe unless avastin approv uk nation institut clinic excel nice univers avail within nhs but genentech declin appli licenc use avastin nice cannot consid in spite grow drug bill nhs apprais probabl approv lucenti next year although nice role look costeffect say cannot apprais drug pass use nhs unless drug refer depart health the depart say hand tie the drug compani hasnt appli licens use it wouldnt refer nice made first move said depart health spokeswoman they need step get licenc if get licens arent new drug condit bad need slow progress blind with avastin mani patient get sight back one two inject avastin first use human eye philip rosenfeld ophthalmologist us awar anim studi carri genentech show potenti eye condit this unlicens use avastin spread across contin entir word mouth one doctor anoth it inject eye consider success professor rosenfeld publish result websit launch us collat experi doctor around world but although evid good regul requir randomis control trial grant licenc general drug compani afford carri prof rosenfeld said real issu drug compani profit this truli wonder drug said this show good drug compani flip side greedi he would like see govern fund clinic trial drug avastin public interest rise drug bill big problem side atlant in uk said david wong chairman scientif committe royal colleg ophthalmologist doctor fight battl persuad primari care trust pay drug stop patient go blind wait nice decid lucenti anoth expens drug call macugen that decis expect end next year about peopl diagnos agerel macular degener uk year from patient point view eye condit deterior quick question wait said professor wong were talk day week rather month the question noth say randomis control trial prove avastin valu he call primari care trust agre pay plan phasingin new drug condit last night genentech said main concern use avastin treat eye condit patient safeti while small singlecentr uncontrol studi avastin perform safeti data patient treat avastin offlabel collect standard organis fashion said spokeswoman compani pharmaceut firm say need launch drug high price hundr million pound spent develop critic point compani calcul also includ market budget',\n",
       "  'VB'),\n",
       " ('mtx imuran take month get optimum therapeaut level hope youll see continu improv mainten i realli wouldnt worri growth point either my daughter diagnos yrs age like diseas least year previous the earli teen time kid go physic matur my daughter way behind first round prednisnon mainten imuran grew year for reason restrict growth seem relat activ inflamm youll get differ view remicad most attest state art drug mani remicad year combin therapi use some endors what call top approach elimin risk undermed give diseas chanc progress damag other would prefer use what necessari resist overkil if go well mtx year get fresh start remicad optim time take med if well mtx choos continu great the one thing i would stay top symptom regular diagnost blood screen good luck hope thing go well keep us post ipoop forum moder join aug post post am gmt glad shes better your right path treatment it seem like good due dilig caution verifi blood work like thing sometim ad anoth month current treatment take reach remiss at time ad anoth med necessari to end id wait labwork see your as far height qualiti life whole aim remiss when shes remiss shell healthiest happiest grow tandem peer like weed doubt when flare bad growth might impact therefor want limit flare sever durat we strive make remiss long flare infrequ mild short possibl she might regain percentag lost growth rebound id blame bone breakag ill shes prednison iv solumedrol longterm cumul long time in end kid kid sometim someth sudden unexpect break bone otherwis innoc play accid i would hesit put remicad mtx isnt enough it prematur say whether remi necessari i believ worri put child remi certain good convers pediatr gasteroenteroligist though moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa even superman couldnt hold back insurmount forc uc urgenc but i bet spiffi spandex short would least hold mess crohnsmum new member join nov post post am gmt hi guy thank much reassur they check albumin esr level well normal blood all normal limit shes week mtx consult happi escal treatment remicad thank support advic i hope maintain remiss futur',\n",
       "  'JJ'),\n",
       " ('well go time i there settl i could take pain pill i could move posit pain remain sever i realli dont know i fever i definit vomit but would start thing progress lot pain my pain also middl left right dead center upper pain so realli doesnt sound like i agre continu better get check wait is bad jennif diagnos crohn diseas suffer sinc current take methotrex mg remicad questran fail humira imuran caus pancreat cimzia',\n",
       "  'NN'),\n",
       " ('the best doctor treat ibd doctor highlytrain specialist ibd ie gastroenterologist they know import diagnost test understand am ulcer coliti dietari intervent induct mainten remiss inflammatori bowel diseas so author conclus the effect dietari intervent cd uc uncertain thus firm conclus regard benefit harm dietari intervent cd uc am ulcer coliti flare long term remiss fecal transplant hi europ hospit play fmt fact hospit start experi but dr said doesnt think miracl cure pm ulcer coliti humira work like charm yearsnow i would save hardearn money see gastroenterologist person bad experi holist doctor well wast ton time money am ulcer coliti doe pred alway lose effect time i mean meaning compar current state inflamm begin would come medic use treat coliti assum am ulcer coliti doe pred alway lose effect time i also think difficult compar inflamm medic prediagnosi inflamm in term symptom diseas extent first flare start pm ulcer coliti ok i back question i conscious last scope sinc went rectum lowest sigmoid colon watch everi time took biopsi bleed make sens think the am ulcer coliti just saw gi hes recommend xeljanz im scare thank ipoop learn microbiolog post sinc role xeljanz expens articl interest see peopl work pm ulcer coliti just saw gi hes recommend xeljanz im scare i love perspect it definit emot rollercoast last drug surgeri and i identifi posit mention post success surgeri pm ulcer coliti just saw gi hes recommend xeljanz im scare fwiw xeljanz biolog press releas pfizer httpswwwncbinlmnihgovpmcarticlespmc i think advantag dont develop antibodi pm ulcer coliti just saw gi hes recommend xeljanz im scare probabl think live vaccin could take switch direct azathioprineentyvio am ulcer coliti just saw gi hes recommend xeljanz im scare ps articl safeti profil xeljanz am ulcer coliti just saw gi hes recommend xeljanz im scare xeljanz shown specif give higher risk get shingl someon take drug but compar infect rate azathioprin actual compar',\n",
       "  'NN'),\n",
       " ('some may rememb had terribl flare gi bleed upper gi track inflam colon took three week hospit stay get stabl enough come home so im remicad hair fall im wonder remicad nurish anyon els loos hair the sever joint pain back know side effect remicad year ago thing happen joint auntkay straydog forum moder join miss key valu enus post post am gmt auntkay glad see post seem like forev but sorri read still issu jeesh i would will bet hair loss result malnutrit malnutrit infect two big culprit hair loss in cp forum one member name seashel written excel post hair loss lot detail if use search featur type chronic pain forum hair loss find post she respond new member lose hair perfor bowel member undernourish doubl whammi hit how long back remicad stop drs usual hesit retri someon stop i ask other health issu take care susi moder chronic pain psoriasi forum auntkay veteran member join apr post post am gmt hi straydog thank take time respond sinc forum mani thing happenedhad take disabl retir due back injuri i back surgeri l fusion a year later sijoint fusion then partici hystorectomi that crohn diseas decid rear ugli head i remicad sinc but woke sleep dragon i becam dehydr gastric bleed land hospit three week not colon inflam upper gi track wasnt even abl toler ice chip the gi decid put back remicad the infus given hospit done incorrect the remicad hung nobodi ever check till bag empti i later night thought heart attack blood pressur shot extrem high chest felt like someon squeez tight felt like someon tri put fist thru chest came gave someth bring bp ekg place heart monit one night woke pool blood i realli thought may get hospit thought crohn lack care would death as see im fighter im still kick onli come home start lose hair witch set back emotionali my husband still fight liver diseas hes tri get list liver transplant auntkay',\n",
       "  'VBZ'),\n",
       " ('dear dr x i prescrib medicin ranibizumab bevacizumab produc novarti would pleas look medic purpos manufactur i request protest object novarti prescrib avastin wet macular degener none medic appli protest compani your sincer etc cc novarti similar bayer applic',\n",
       "  'JJ'),\n",
       " ('howev make decis fact mayb swiss guy work someon like genzym want think alemtuzumab safer merck want think cladribin safer each drug risk drug perman deplet immun system go carri risk howev weight benefit risk control ms proper you knowledg pros con mayb achill heel ocrelizumab if swiss guy one european regul advisor wont get choic take wont get licenc',\n",
       "  'NN'),\n",
       " ('mirowpl thank im sorri stelara hasnt work complet partial better similar entyvio i think work part i tri find',\n",
       "  'NN'),\n",
       " ('convinc pharma lower drug cost within reach i tri stress much instead look posit high cost ms drug make lucrat market i diagnos sinc aubagio tecfidera lemtrada plegridi approv ocrelizumab way there trial done repair restor i sure soar cost one reason pharmaceut compani invest much ms',\n",
       "  'NN'),\n",
       " ('re is mitoxantron good ppms yes yes activ ms ie gdenhanc lesion mri increas t lesion load no due sideeffect profil at bartsm essenti stop use mitoxantron replac offlabel parenter cladribin would like includ rituximab mix even better would get treat licens product ppms moment one show town ocrelizumab',\n",
       "  'NN'),\n",
       " ('the brain lesion treat gamma knife get bad access i em stage nsclc went away chemo lucki i told least problem and yeah everi time i turn around bad month my wife famili prepar die butwent opdivo sept cancer went poof im feel great opdivo kinda allornoth drug work friend shell fine',\n",
       "  'JJ'),\n",
       " ('it control tbh most peopl delay remicad coupl week without issu chanc okay it much easier said done tri spend next week panick if remicad truli put deep remiss hold quit last infus month even year depend person diseas dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('hi the hard data unfortun averag dont realli tell stori given kind work doesntthat make big deal someth like two month averag move mean someth there hope studi keytruda opdivo seem like winner last trial result thing earli stage develop as individu success stori check site facebook sclc group onlin resourc they usual dont publish individu case studi long fact peopl sclc involv earli studi aliveandwel year immunotherapi one i know made year keytruda i believ in facebook group peopl whove made year some extens your also right biomark pd pdl winner nsclc lot debat even relev sclc i believ theyr rare sclc anyway howev ive found go journey mom lot latest think isnt realli publish see snatch onlin often cant find unless save somewher in fashion i came across studi write i longer locat indic tmb tumor mutat burden microsatellit instabl seem relev sclc term immunotherapi efficaci isnt certain investig clinic relev mutat continu clinic studi so yes given uncertainti genet test usual done sclc anyway we got foundat one test interest result one lead expert sclc associ lungev i believ memori sloan ketter offer us free charg genet panel even accur it show mom high microsatellit instabl high tmb doctor said bode well term immunotherapi efficaci quit rare sclc again none certain that smartest peopl diseas believ as mom diagnos almost exact year ago small primari tumor singl brain metastasi caus seizur found issu begin she brain met surgic remov lucki enough possibl treat gamma knife after chemo took care primari tumor quit quick she cycl total tumor basic gone shes cancer free ever sinc suffer side effect treatment except hair loss bloat steroid day bone pain neulasta she opt consolid radiat also isnt standard care sclc either promis studi forwardthink doctor recommend she side effect either continu well the point id like make your right sclc deck stack the stat arent good though theyr better find onlin date howev hope it good realist look someon like mom longterm survivor i live fear wait day scan come back ugli alreadi done much better oddsin fact given averag surviv time diagnosi like month thes alreadi beaten so husband told month inde averag howev doctor tell beat averag might husband how husband anyway side effect symptom what status scan post chemo i wish best luck',\n",
       "  'NN'),\n",
       " ('thank comment onthemark today i found data aura studi httpwwwahdbonlinecomissuesmarchvolseventhannualpayersguidetagrissoosimertinibapprovedforpatientswithnonsmallcelllungcancerandtheegfrtmmut in addit patient adenocarcinoma lung receiv previous treatment egfr mutat metastat nsclc the site extrathorac metastasi includ bone brain liver somat egfr mutat addit tm includ exon delet lr gx si so i guess would mean gx transform tm mayb less frequent common mutat i mum take first pill osimertinib today we see oncologist monday cant lose time if insist erlotinib take anoth coupl day get approv mayb even longer summer time vacat my mum without treatment sinc th may realli long time someon experienc posttki progress her oncologist week vacat substitut suppos decid erlotinib earlier want i hope oncologist approv osimertinib i dont think afford anoth weak treatment if stop osimertinib coupl day take could lower chanc use drug effect treatment later',\n",
       "  'NN'),\n",
       " ('went gilenya due relaps rate am tri join trial lymphocyt count must rebound least low normal anyon post came back time i went week sinc gone that high enough join trial did folk rebound month',\n",
       "  'JJ'),\n",
       " ('onc nonsmallcel lung cancer nsclc spread far wide treat kind balanc act a cure isnt like slow so aim reliev symptom improv qualiti life side effect possibl newer therapi help and lot option today year ago the number tumor overal health come play decid your doctor start test learn nsclc help guid best treatment when target therapi work best cancer come gene chang caus cell grow divid control but mani gene often hard know one blame with nsclc though doctor track culprit when one known chang get target therapi that mean take drug attack cancer cell specif way base gene differ your doctor test look alk gene chang if youll get drug help block alectinib alecensa brigatinib alunbrig crizotinib xalkori ceritinib zykadia lorlatinib lorbrena the common side effect minor chang vision stomach upset throw diarrhea for peopl problem fall milder side efgr gene chang you get differ set drug one afatinib gilotrif dacomitinib vizimpro erlotinib tarceva gefitinib iressa osimertinib tagrisso they slow fast tumor grow spread side effect includ skin rash diarrhea braf gene chang two main drug use one dabrafenib tafinlar trametinib mekinist they work differ way effect they may caus itch hair loss issu other gene chang there grow list gene defect caus nsclc target drug that one reason look clinic trial research test new medicin when immunotherapi make most sens when dont specif gene chang doctor check tumor cell level protein call pdl if high immunotherapi often best place start it use immun system bodi defens germ attack cancer cell youll take pembrolizumab keytruda drug help bodi see cancer cell someth fight like cold virus some typic side effect includ tired cough stomach upset rash joint pain chemotherapi chemo standard treatment dont gene chang high pdl it use drug kill cancer cell it side effect includ hair loss mouth sore stomach upset there sever chemo drug use nsclc for best result doctor give two time if bodi isnt strong enough two even one help you usual get four six cycl chemo take week onc your finish treatment might keep take what call mainten drug this often anoth chemo medicin some research show slow cancer help live longer your doctor may also add drug along chemo med for nonsquam nsclc might also take pembrolizumab immunotherapi drug or might get bevacizumab avastin anoth target drug if may keep take one mainten drug for squamous nsclc doctor might suggest target therapi drug necitumumab portrazza other treatment the brain bone area around lung common place cancer spread youll get specif care base end problem caus in bone may get radiat curb pain when caus fluid build around lung might need thin tube chest drain easili if one place like brain adren gland might surgeri remov tumor chang treatment sometim first therapi tri doesnt work well youd hope but still option if start immunotherapi doctor may suggest chemo if start one set chemo drug might tri anoth add target therapi it depend health far cancer spread want treatment this also want start approach call palliat care earli it aim keep comfort possibl help manag stress',\n",
       "  'JJ'),\n",
       " ('dannibrett ocrevus may approv uk avail america sometim and would involv clinic trial number year noth fresh product line',\n",
       "  'NN'),\n",
       " ('today realiti age global popul urbanis exponenti obes rate emphasi sedentari lifestyl case diabet inevit with upsurg diabet come loss vision caus damag capillari retina back eye this due excess glucos blood patient poor control diabet if youv recent diagnosi feel like candid develop diabet retinopathi consult eye specialist best manag prevent strategi clear healthi vision futur your ophthalmologist provid appropri vision care guidelin follow utmost import if your unclear eye health diabet affect vision here help guid live understand diabet retinopathi so diabet retinopathi affect eyesight often within diseas diabet eye blood oxygen struggl reach blood vessel the retina made vast collect tini nerv allow perceiv colour light surround environ normal healthi eye nerv suppli enough blood within equal tini blood vessel within often within diseas diabet eye blood oxygen struggl reach blood vessel this develop inhibit eye abil job caus damag retina turn loss vision anyon diabet risk develop retinopathi import monitor progress keep diseas incheck posit chang lifestyl the longer durat diabet poorer control blood glucos factor blood pressur greater risk develop complic diseas peopl poor control diabet either type type develop diabet retinopathi the first stage diabet retinopathi call nonprolif diseas process enter prolif phase requir urgent treatment ophthalmologist prolif diabet retinopathi sever damag visual function fortun level diseas far less common particular glucos control improv not diabet place enorm pressur bodi also global public health system import monitor progress keep diseas incheck posit chang lifestyl if feel major risk factor develop diabet retinopathi speak doctor thwart vision loss associ health problem you gain control diabet the healthi chang make bedrock diabet eye diseas prevent manag lifestyl influenc link tobacco use sedentari lifestyl poor diet particular overconsumpt high process food close associ rate progress diabet retinopathi retinopathyrel risk factor ani loss vision requir serious adjust routin diabet retinopathi throw spanner work come manag diabet the sooner retinopathi diagnos effect manag techniqu treatment avert vision loss there way forward despit challeng ahead number selfmanag strategi implement see beyond visual problem the healthi chang make bedrock diabet eye diseas prevent manag ask doctor assist throughout transit phase ensur your right track keep blood sugar blood pressur blood lipid level within target rang one first step take prevent vision loss regular visit healthcar provid healthi diet exercis take medic prescrib doctor factor help achiev goal reach love one support time also help overcom hurdl you even ask famili member close friend join journey healthier lifestyl way youll everyon best interest heart if left untreat diseas progress so dont wait advancedstag symptom like blur vision eyestrain headach appear pay visit eye specialist dont wait late diabet retinopathi progress diseas lead blind left untreat so dont wait advancedstag symptom like blur vision eyestrain headach appear pay visit eye specialist regular eye health check import weapon diabet retinopathi often doesnt present earli warn sign surgic option avail prevent vision loss but cours gain control health maintain blood sugar level import step take the main treatment avail revers prevent loss vision patient diabet retinopathi includ laser photocoagul intravitr inject case vitrectomi studi show longterm visual acuiti result treatment strategi remark patient retain drive vision least one eye but cours gain control health maintain blood sugar level import step take prevent vision loss diabet retinopathi nonetheless cannot stress enough regular eye exam integr diseas manag prevent look futur vision but outlook patient risk alreadi suffer diabet retinopathi isnt murki with advanc technolog laser surgic expertis educ subject well regular screen prompt treatment visual loss diabet dramat improv if youd like gain control diabet help call us fill onlin enquiri form friend team member readi discuss person need eye laser centr ophthalmologist specialis treatment mani eye diseas includ diabet retinopathi our centr employ latest techniqu equip detect manag progress diseas this inform provid educ servic intend serv medic advic anyon seek specif ophthalm advic assist consult optometrist ophthalmologist zheng y he m congdon n the worldwid epidem diabet retinopathi indian journal ophthalmolog p gregg ja callaghan gm hay sc the diabet lifestyl book face fear make chang long healthi life new harbing public yau jw roger sl kawasaki r lamoureux el kowalski jw bek t chen sj dekker jm fletcher a grauslund j haffner s global preval major risk factor diabet retinopathi diabet care pp cundiff dk nigg cr diet diabet retinopathi insight diabet control complic trial dcct medscap general medicin p chew ey ferri fl csaki kg murphi rp agrn e thompson dj reed gf schachat ap the longterm effect laser photocoagul treatment patient diabet retinopathi earli treatment diabet retinopathi followup studi ophthalmolog pp',\n",
       "  'NN'),\n",
       " ('i similar experi i start gilenya put washout effect copaxon i three day finish copaxon first gilenya pill noth happen two week i start peculiar sensori symptom i mild swallow problem cognit issu well ach pain when i rang nurs team panic i told ms effect untreat copaxon system gilenya yet taken effect it settl three week later',\n",
       "  'NN'),\n",
       " ('remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom havent found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas firstlin approach biolog therapi work block certain chemic caus inflamm intestin most biolog crohn diseas block protein call tumor necrosi factor tnf other biolog block immun cell call integrin other act protein call interleukin il interleukin il this biolog therapi stop inflamm gut antitnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week the three antitnf biolog humira remicad cimzia humira humira selfadminist treatment follow initi demonstr healthcar profession if doctor decid handl inject theyll give set pen dosagecontrol medic insid youll also given instruct mani inject take first day after initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flareup it may also help maintain remiss prevent symptom return remicad given direct bloodstream this allow work immedi reliev symptom it administ medic facil experienc healthcar profession close monitor side effect treatment remicad doesnt taken everi day after three starter dose patient often see benefit six dose per year the downsid remicad must given intraven medic facil twohour period cimzia cimzia administ small inject the inject either given doctor offic home if choos receiv treatment doctor offic option receiv treatment powder form the powder mix steril water inject the option use prefil syring the syring contain medic that alreadi mix measur dose these use home doctor offic if choos treatment youll get packag two syring instruct give treatment after first three dose given everi two week abl take cimzia everi four week the two antiintegrin biolog crohn tysabri entyvio tysabri this type biolog prevent inflammationcaus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week it take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl havent respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar serious side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml this result virus test advanc ani physician prescrib tysabri crohn warn patient risk they also explain enrol prescrib program call touch this program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas havent respond well intoler reason cant take tnf blocker immunomodul corticosteroid it work similar tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gutspecif doesnt appear risk pml entyvio given doctor care intraven infus it given minut first day therapi it repeat week two week six everi eight week thereaft if improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient uptod immun stelara the third class biolog il il agonist stelara drug class approv treat adult moder sever crohn havent respond well enough convent therapi the drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession the follow dose given via inject skin everi eight week either healthcar provid selfadminist patient train side effect although benefit often far outweigh risk biolog therapi present serious side effect the process biolog therapi reduc bodi abil fight infect this caus tuberculosi infect includ brain infect there also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen tcell lymphoma this type cancer often fatal becaus biolog therapi work differ other side effect may caus also vari ask doctor thorough explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm your doctor discuss option benefit risk help find effect treatment in case biosimilar generic version biolog drug may avail manag crohn also save money your doctor tell option',\n",
       "  'NN'),\n",
       " ('appar i forget i workshop present student srsli i think i look like i realiz lionel barrymor insan prof leroy the th hour i realli good remind calendar use etc slip away puckish malfunct synaps well i stay talk sister six hour went bed the struggl real i sort laugh sinc i also forgot take tecfidera morn i realiz i need reassess plan cope skill slow hell i think that ill celebr world ms dayslow my sister i talk great deal kind bulldoz whatev need done she i got ms dx cope thingm say well ok get right clinic trial i doubt trial ocrelizumab soon approv save muchoverinflam brain and realli ms gave choic sooo but slow way month relaps start march i remind forcibl yes im sick yes go away yes need find time rest slow hell ive quit fortun feel like i probabl work point need rest perhap ignor enough slip relapsesom yall know feel so world ms day im grate awesom job awesom boss good enough brain enough synaps take slack burn one i sens humor now i need person assist forc sleep andor rest that would perfectest rx ever enjoy day slay demon smile plow obstacl then nap srsli',\n",
       "  'IN'),\n",
       " ('thank share yout stori my dad diagnos treatement he second cycl alimta cisplatin week th cycl keytruda he plan pet end march see tesult nice hear treatment work i hope doctor stop cisplatin second one sinc neuropathi problem leg he side effect i also hope get cbd oil worri interact keytruda if find anyth pleas let know what doctor say long continu keytruda keep us post ina',\n",
       "  'NN'),\n",
       " ('i pretest start gilenya the answer i got along thing made chang mind when give folder differ doctor need see frequent need see i felt like wasnt go i problem go i problem',\n",
       "  'NN'),\n",
       " ('look like this publish today httpswwwmstrustorguknewsnewsaboutmsnicerejectsocrelizumabo whi committe made recommend there current diseasemodifi treatment approv primari progress multipl sclerosi clinic trial result show ocrelizumab slow worsen disabl peopl condit includ loss upper limb function howev plausibl costeffect estim ocrelizumab compar best support care alon much higher nice normal consid accept use nhs resourc scenario present compani therefor ocrelizumab cannot recommend treat earli primari progress multipl sclerosi adult httpswwwniceorgukguidancegidtadocumentsappraisalconsult',\n",
       "  'NN'),\n",
       " ('repli plan i offici ocrevus view post by penkalet great news i realli hope slow great news i realli hope slow beast i think help alain',\n",
       "  'VBP'),\n",
       " ('aah hsct effect safer alemtuzumab ocrelizumab natalizumab i dont think know answer question i hsct novemb talk hematologish live ahsct year she say alemtuzumab good cancer patient diseas',\n",
       "  'JJ'),\n",
       " ('i went remicad entyvio moder success i still take oral lialda folic acid supplement id say im i scale im sorri hear friend crash one thing ive found trial learn school autoimmun diseas trigger stress dure stress bodi produc excess amount wbcs most lab call fals posit complet blood count so destress import case prevent wbcs go site inflamm us colon',\n",
       "  'NN'),\n",
       " ('hi name harri im uk diagnos i high school crohn diseas grow high school six form definit rough fill lot tough experi make post anyon go question queri experi want share ill listen offer help support your anyon look friend similar condit share stori ill alway around listen talk med omeprazol azathioprin mesalazin stelara methotrex humira prednison hydrocortison feel free email ill make sure repli thank read',\n",
       "  'NN'),\n",
       " ('ditto clo high antibodi isnt ideal remi becom less effect odd side effect like joint pain jump lot consid switch anoth tnfalpha block biolog humira simponi moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you might uc leav hous wear sock return none emerg tp',\n",
       "  'NN'),\n",
       " ('dkb i stop take pouchiti didnt work i went biolog cimzia help lot wear day i need switch someth get whole month im still fight evil insur compani stelara what i found enteragam tast difficult handl if i took i ate tast wasnt bad i would also mix citrus flavor drink keith dxd sever pancol june previous med asa predison mp remicad humira simponi cyclosporin twice step jpouch surgeri current condit chronic pouchiti not bad i thought would current med cimzia sulfasalazin rotat antibiot futur med stelara current wait insur approv',\n",
       "  'NN'),\n",
       " ('childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu certain genet condit increas risk childhood rhabdomyosarcoma a sign childhood rhabdomyosarcoma lump swell keep get bigger diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma certain factor affect prognosi chanc recoveri treatment option childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu rhabdomyosarcoma type sarcoma sarcoma cancer soft tissu muscl connect tissu tendon cartilag bone rhabdomyosarcoma usual begin muscl attach bone help bodi move rhabdomyosarcoma common type soft tissu sarcoma children it begin mani place bodi there three main type rhabdomyosarcoma embryon this type occur often head neck area genit urinari organ occur anywher bodi it common type rhabdomyosarcoma alveolar this type occur often arm leg chest abdomen genit organ anal area anaplast this least common type rhabdomyosarcoma children see follow pdq treatment summari inform type soft tissu sarcoma childhood soft tissu sarcoma adult soft tissu sarcoma certain genet condit increas risk childhood rhabdomyosarcoma anyth increas risk get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk child doctor think child may risk risk factor rhabdomyosarcoma includ follow inherit diseas lifraumeni syndrom pleuropulmonari blastoma neurofibromatosi type nf costello syndrom beckwithwiedemann syndrom noonan syndrom children high birth weight larger expect birth may increas risk embryon rhabdomyosarcoma in case caus rhabdomyosarcoma known a sign childhood rhabdomyosarcoma lump swell keep get bigger sign symptom may caus childhood rhabdomyosarcoma condit the sign symptom occur depend cancer form check child doctor child follow a lump swell keep get bigger go away it may pain bulg eye headach troubl urin bowel movement blood urin bleed nose throat vagina rectum diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma the diagnost test done depend part cancer form the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit past ill treatment also taken xray an xray organ bone insid bodi chest an xray type energi beam go bodi onto film make pictur area insid bodi ct scan cat scan a procedur make seri detail pictur area insid bodi abdomen pelvi lymph node taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen the child lie tabl slide ct scanner take xray pictur insid abdomen mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area bodi skull brain lymph node this procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen the child lie tabl slide mri scanner take pictur insid bodi the pad child abdomen help make pictur clearer pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg positron emiss tomographi pet scan the child lie tabl slide pet scanner the head rest white strap help child lie still a small amount radioact glucos sugar inject child vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan a procedur check rapid divid cell cancer cell bone a small amount radioact materi inject vein travel bloodstream the radioact materi collect bone cancer detect scanner enlarg bone scan a small amount radioact materi inject child vein travel blood the radioact materi collect bone as child lie tabl slide scanner radioact materi detect imag made comput screen bone marrow aspir biopsi the remov bone marrow blood small piec bone insert hollow needl hipbon sampl remov hipbon a pathologist view bone marrow blood bone microscop look sign cancer enlarg bone marrow aspir biopsi after small area skin numb bone marrow needl insert child hip bone sampl blood bone bone marrow remov examin microscop lumbar punctur a procedur use collect cerebrospin fluid csf spinal column this done place needl two bone spine csf around spinal cord remov sampl fluid the sampl csf check microscop sign cancer cell this procedur also call lp spinal tap if test show may rhabdomyosarcoma biopsi done a biopsi remov cell tissu view microscop pathologist check sign cancer becaus treatment depend type rhabdomyosarcoma biopsi sampl check pathologist experi diagnos rhabdomyosarcoma one follow type biopsi may use fineneedl aspir fna biopsi the remov tissu fluid use thin needl core needl biopsi the remov tissu use wide needl this procedur may guid use ultrasound ct scan mri open biopsi the remov tissu incis cut made skin sentinel lymph node biopsi the remov sentinel lymph node surgeri the sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor it first lymph node cancer like spread primari tumor a radioact substanc andor blue dye inject near tumor the substanc dye flow lymph duct lymph node the first lymph node receiv substanc dye remov a pathologist view tissu microscop look cancer cell if cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node the follow test may done sampl tissu remov light microscopi a laboratori test cell sampl tissu view regular highpow microscop look certain chang cell immunohistochemistri a test use antibodi check certain antigen sampl tissu the antibodi usual link radioact substanc dye caus tissu light microscop this type test may use tell differ differ type cancer fish fluoresc situ hybrid a laboratori test use look gene chromosom cell tissu piec dna contain fluoresc dye made laboratori ad cell tissu glass slide when piec dna attach certain gene area chromosom slide light view microscop special light this type test use find certain gene chang revers transcriptionpolymeras chain reaction rtpcr test a laboratori test cell sampl tissu studi use chemic look certain chang structur function gene cytogenet analysi a laboratori test cell sampl tissu view microscop look certain chang chromosom certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the patient age where bodi tumor start the size tumor time diagnosi whether tumor complet remov surgeri the type rhabdomyosarcoma embryon alveolar anaplast whether certain chang gene whether tumor spread part bodi time diagnosi whether tumor lymph node time diagnosi whether tumor respond chemotherapi andor radiat therapi for patient recurr cancer prognosi treatment also depend follow where bodi tumor recur came back how much time pass end cancer treatment cancer recur whether tumor treat radiat therapi stage childhood rhabdomyosarcoma key point after childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri there three way cancer spread bodi cancer may spread began part bodi stage childhood rhabdomyosarcoma done three part the stage system base size tumor bodi whether spread part bodi stage stage stage stage the group system base whether cancer spread whether cancer remov surgeri group i group ii group iii group iv the risk group base stage system group system lowrisk childhood rhabdomyosarcoma intermediaterisk childhood rhabdomyosarcoma highrisk childhood rhabdomyosarcoma after childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri the process use find cancer spread within tissu part bodi call stage it import know stage order plan treatment the doctor use result diagnost test help find stage diseas treatment childhood rhabdomyosarcoma base part stage sometim amount cancer remain surgeri remov tumor the pathologist use microscop check tissu remov surgeri includ tissu sampl edg area cancer remov lymph node this done see cancer cell taken surgeri there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl rhabdomyosarcoma spread lung cancer cell lung actual rhabdomyosarcoma cell the diseas metastat rhabdomyosarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi stage childhood rhabdomyosarcoma done three part childhood rhabdomyosarcoma stage use three differ way describ cancer a stage system a group system a risk group the stage system base size tumor bodi whether spread part bodi stage in stage tumor size may spread lymph node found one follow favor site eye area around eye head neck tissu next brain spinal cord gallbladd bile duct uret urethra test ovari vagina uterus rhabdomyosarcoma form favor site better prognosi if site cancer occur one favor site list said unfavor site enlarg tumor size the size tumor may compar size pea cm peanut cm grape cm walnut cm lime cm egg cm peach cm grapefruit cm stage in stage cancer found unfavor site one area describ favor stage the tumor larger centimet spread lymph node stage in stage cancer found unfavor site one area describ favor stage one follow true the tumor larger centimet cancer spread nearbi lymph node the tumor larger centimet cancer may spread nearbi lymph node stage in stage tumor may size cancer may spread nearbi lymph node cancer spread distant part bodi lung bone marrow bone the group system base whether cancer spread whether cancer remov surgeri group i cancer found place start complet remov surgeri tissu taken edg tumor remov the tissu check microscop pathologist cancer cell found group ii group ii divid group iia iib iic iia cancer remov surgeri cancer cell seen tissu taken edg tumor remov view microscop pathologist iib cancer spread nearbi lymph node cancer lymph node remov surgeri iic cancer spread nearbi lymph node cancer lymph node remov surgeri least one follow true tissu taken edg tumor remov check microscop pathologist cancer cell seen the furthest lymph node tumor remov check microscop pathologist cancer cell seen group iii cancer part remov biopsi surgeri tumor remain seen eye group iv cancer spread distant part bodi cancer diagnos cancer cell found imag test there cancer cell fluid around brain spinal cord lung fluid abdomen tumor found area the risk group base stage system group system the risk group describ chanc rhabdomyosarcoma recur come back everi child treat rhabdomyosarcoma receiv chemotherapi decreas chanc cancer recur the type anticanc drug dose number treatment given depend whether child lowrisk intermediaterisk highrisk rhabdomyosarcoma the follow risk group use lowrisk childhood rhabdomyosarcoma lowrisk childhood rhabdomyosarcoma one follow an embryon tumor size found favor site there may tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node the follow area favor site eye area around eye head neck tissu near ear nose sinus base skull gallbladd bile duct uret urethra test ovari vagina uterus an embryon tumor size found favor site there may tumor remain surgeri seen microscop the cancer may spread nearbi lymph node intermediaterisk childhood rhabdomyosarcoma intermediaterisk childhood rhabdomyosarcoma one follow an embryon tumor size found one favor site list there tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node an alveolar tumor size favor unfavor site there may tumor remain surgeri seen without microscop the cancer may spread nearbi lymph node highrisk childhood rhabdomyosarcoma highrisk childhood rhabdomyosarcoma may embryon type alveolar type it may spread nearbi lymph node spread one follow other part bodi near tumor first form fluid around brain spinal cord fluid lung abdomen recurr childhood rhabdomyosarcoma recurr childhood rhabdomyosarcoma cancer recur come back treat the cancer may come back place part bodi lung bone bone marrow less often rhabdomyosarcoma may come back breast adolesc femal liver treatment option overview key point there differ type treatment patient childhood rhabdomyosarcoma children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children treatment childhood rhabdomyosarcoma may caus side effect three type standard treatment use surgeri radiat therapi chemotherapi new type treatment test clinic trial immunotherapi target therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient childhood rhabdomyosarcoma some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment becaus cancer children rare take part clinic trial consid some clinic trial open patient start treatment children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children becaus rhabdomyosarcoma form mani differ part bodi mani differ kind treatment use treatment overseen pediatr oncologist doctor special treat children cancer the pediatr oncologist work health care provid expert treat children rhabdomyosarcoma special certain area medicin these may includ follow specialist pediatrician pediatr surgeon radiat oncologist pediatr hematologist pediatr radiologist pediatr nurs specialist geneticist cancer genet risk counselor social worker rehabilit specialist treatment childhood rhabdomyosarcoma may caus side effect for inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment rhabdomyosarcoma may includ physic problem chang mood feel think learn memori second cancer new type cancer some late effect may treat control it import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform three type standard treatment use surgeri surgeri remov cancer oper use treat childhood rhabdomyosarcoma a type surgeri call wide local excis often done a wide local excis remov tumor tissu around includ lymph node a second surgeri may need remov cancer whether surgeri done type surgeri done depend follow where bodi tumor start the effect surgeri way child look the effect surgeri child import bodi function how tumor respond chemotherapi radiat therapi may given first in children rhabdomyosarcoma possibl remov tumor surgeri rhabdomyosarcoma form mani differ place bodi surgeri differ site surgeri treat rhabdomyosarcoma eye genit area usual biopsi chemotherapi sometim radiat therapi may given surgeri shrink larg tumor after doctor remov cancer seen time surgeri patient given chemotherapi surgeri kill cancer cell left radiat therapi may also given treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell stop grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu these type extern radiat therapi includ follow conform radiat therapi conform radiat therapi type extern radiat therapi use comput make dimension d pictur tumor shape radiat beam fit tumor this allow high dose radiat reach tumor caus less damag nearbi healthi tissu intensitymodul radiat therapi imrt imrt type dimension d radiat therapi use comput make pictur size shape tumor thin beam radiat differ intens strength aim tumor mani angl volumetr modul arc therapi vmat vmat type d radiat therapi use comput make pictur size shape tumor the radiat machin move circl around patient treatment send thin beam radiat differ intens strength tumor treatment vmat deliv faster treatment imrt stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment onc day sever day radiat machin aim larger usual dose radiat direct tumor by patient posit treatment less damag nearbi healthi tissu this procedur also call stereotact externalbeam radiat therapi stereotax radiat therapi proton beam radiat therapi protonbeam therapi type highenergi extern radiat therapi a radiat therapi machin aim stream proton tini invis positivelycharg particl cancer cell kill this type treatment caus less damag nearbi healthi tissu intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer it use treat cancer area vagina vulva uterus bladder prostat head neck intern radiat therapi also call brachytherapi intern radiat implant radiat interstiti radiat therapi the type amount radiat therapi given depend age child type rhabdomyosarcoma bodi tumor start much tumor remain surgeri whether tumor nearbi lymph node extern radiat therapi usual use treat childhood rhabdomyosarcoma certain case intern radiat therapi use chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi chemotherapi may also given shrink tumor surgeri order save much healthi tissu possibl this call neoadjuv chemotherapi everi child treat rhabdomyosarcoma receiv system chemotherapi decreas chanc cancer recur the type anticanc drug dose number treatment given depend whether child lowrisk intermediaterisk highrisk rhabdomyosarcoma see drug approv rhabdomyosarcoma inform new type treatment test clinic trial this summari section describ treatment studi clinic trial it may mention everi new treatment studi inform clinic trial avail nci websit immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biolog therapi biotherapi there differ type immunotherapi vaccin therapi cancer treatment use substanc group substanc stimul immun system find tumor kill vaccin therapi studi treat metastat rhabdomyosarcoma immun checkpoint inhibitor therapi use bodi immun system kill cancer cell two type immun checkpoint inhibitor studi treatment childhood rhabdomyosarcoma come back treatment ctla protein surfac t cell help keep bodi immun respons check when ctla attach anoth protein call b cancer cell stop t cell kill cancer cell ctla inhibitor attach ctla allow t cell kill cancer cell ipilimumab type ctla inhibitor pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell nivolumab pembrolizumab pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat there differ type target therapi mtor inhibitor stop protein help cell divid surviv sirolimus type mtor inhibitor therapi studi treatment recurr rhabdomyosarcoma tyrosin kinas inhibitor smallmolecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid mk cabozantinibsmal tyrosin kinas inhibitor studi treatment recurr rhabdomyosarcoma patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show child condit chang cancer recur come back these test sometim call followup test checkup treatment option childhood rhabdomyosarcoma for inform treatment list see treatment option overview section previous untreat childhood rhabdomyosarcoma the treatment childhood rhabdomyosarcoma often includ surgeri radiat therapi chemotherapi the order treatment given depend bodi tumor start size tumor type tumor whether tumor spread lymph node part bodi see treatment option overview section summari inform surgeri radiat therapi chemotherapi use treat children rhabdomyosarcoma rhabdomyosarcoma brain head neck for tumor brain treatment may includ surgeri remov tumor radiat therapi chemotherapi for tumor head neck near eye treatment may includ chemotherapi radiat therapi if tumor remain come back treatment chemotherapi radiat therapi surgeri remov eye tissu around eye may need for tumor head neck near ear nose sinus base skull near eye treatment may includ radiat therapi chemotherapi for tumor head neck near eye near ear nose sinus base skull treatment may includ chemotherapi radiat therapi surgeri remov tumor for tumor head neck cannot remov surgeri treatment may includ chemotherapi radiat therapi includ stereotact bodi radiat therapi for tumor larynx voic box treatment may includ chemotherapi radiat therapi surgeri remov larynx usual done voic harm rhabdomyosarcoma arm leg chemotherapi follow surgeri remov tumor if tumor complet remov second surgeri remov tumor may done radiat therapi may also given for tumor hand foot radiat therapi chemotherapi may given the tumor may remov would affect function hand foot lymph node dissect one lymph node remov sampl tissu check microscop sign cancer for tumor arm lymph node near tumor armpit area remov for tumor leg lymph node near tumor groin area remov rhabdomyosarcoma chest abdomen pelvi for tumor chest abdomen includ chest wall abdomin wall surgeri wide local excis may done if tumor larg chemotherapi radiat therapi given shrink tumor surgeri for tumor pelvi surgeri wide local excis may done if tumor larg chemotherapi given shrink tumor surgeri radiat therapi may given surgeri for tumor diaphragm a biopsi tumor follow chemotherapi radiat therapi shrink tumor surgeri may done later remov remain cancer cell for tumor gallbladd bile duct a biopsi tumor follow chemotherapi radiat therapi for tumor muscl tissu around anus vulva anus scrotum anus surgeri done remov much tumor possibl nearbi lymph node follow chemotherapi radiat therapi rhabdomyosarcoma kidney for tumor kidney surgeri remov much tumor possibl chemotherapi radiat therapi may also given rhabdomyosarcoma bladder prostat for tumor top bladder surgeri wide local excis done for tumor prostat bladder top bladder chemotherapi radiat therapi given first shrink tumor if cancer cell remain chemotherapi radiat therapi tumor remov surgeri surgeri may includ remov prostat part bladder pelvic exenter without remov rectum this may includ remov lower colon bladder in girl cervix vagina ovari nearbi lymph node may remov chemotherapi given first shrink tumor surgeri remov tumor bladder prostat done intern extern radiat therapi may given surgeri surgeri remov tumor bladder prostat intern radiat therapi given surgeri rhabdomyosarcoma area near testicl surgeri remov testicl spermat cord the lymph node back abdomen may check cancer especi lymph node larg child year older radiat therapi may given tumor cannot complet remov surgeri rhabdomyosarcoma vulva vagina uterus cervix ovari for tumor vulva vagina treatment may includ chemotherapi follow surgeri remov tumor intern extern radiat therapi may given surgeri for tumor uterus treatment may includ chemotherapi without radiat therapi sometim surgeri may need remov remain cancer cell for tumor cervix treatment may includ chemotherapi follow surgeri remov remain tumor for tumor ovari treatment may includ chemotherapi follow surgeri remov remain tumor metastat rhabdomyosarcoma treatment chemotherapi radiat therapi surgeri remov tumor given site tumor first form if cancer spread brain spinal cord lung radiat therapi may also given site cancer spread the follow treatment studi metastat rhabdomyosarcoma a clinic trial immunotherapi vaccin therapi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail refractori recurr childhood rhabdomyosarcoma treatment option refractori recurr childhood rhabdomyosarcoma base mani factor includ bodi cancer come back type treatment child need child treatment refractori recurr rhabdomyosarcoma may includ one follow surgeri radiat therapi chemotherapi a clinic trial target therapi immunotherapi sirolimus ipilimumab nivolumab pembrolizumab a clinic trial target therapi tyrosin kinas inhibitor mk cabozantinibsmal chemotherapi a clinic trial check sampl patient tumor certain gene chang the type target therapi given patient depend type gene chang use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about childhood rhabdomyosarcoma for inform nation cancer institut childhood rhabdomyosarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv rhabdomyosarcoma target cancer therapi for childhood cancer inform general cancer resourc see follow about cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer a guid parent cancer children adolesc stage cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment childhood rhabdomyosarcoma it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq pediatr treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq pediatr treatment editori board pdq childhood rhabdomyosarcoma treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypessofttissuesarcomapatientrhabdomyosarcomatreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('in podcast cancernet editori board member dr brian rini dr jorg garcia discuss new research kidney prostat cancer present european societi medic oncolog congress held octob nineteenth twentythird munich germani transcript music asco your listen podcast cancernet this cancer inform websit produc american societi clinic oncolog known asco world lead profession organ doctor care peopl cancer the purpos podcast educ inform this substitut profession medic care intend use diagnosi treatment individu condit guest podcast express opinion experi conclus the mention product servic organ activ therapi constru asco endors cancer research discuss podcast ongo data describ may chang research progress in podcast cancernet editori board member dr brian rini dr jorg garcia discuss new research kidney prostat cancer present european societi medic oncolog congress held octob nineteenth twentythird munich germani dr rini professor medicin cleveland clinic lerner colleg medicin case western reserv univers dr garcia assist professor medicin cleveland clinic lerner colleg medicin case western reserv univers they also staff member depart solid tumor oncolog cleveland clinic taussig cancer institut asco would like thank dr rini dr garcia discuss research dr rini hello this brian rini cleveland clinic taussig cancer center im professor medicin lead gu program cleveland clinic im join friend colleagu dr jorg garcia dr garcia thank brian im jorg garcia im gu medic oncologist cleveland clinic well dr rini and go talk today highlight genitourinari gu cancer european societi medic oncolog meet took place coupl month ago munich germani it one major cancer meet lot big data start present meet addit main asco meet meet and im go start talk coupl highlight renal cancer dr garcia describ coupl highlight prostat cancer in kidney cancer general speak pretti excit time so year ago went wave vegftarget therapi therapi target blood vessel sort becam standard care and excit frank time wasnt much els avail patient metastat kidney cancer and that realli foundat weve treat diseas last decad more recent weve start use immun stimul agent common call immunotherapi io therapi use across mani mani malign especi kidney cancer and way treat metastat kidney cancer we still use therapi target blood vessel also call vegftarget therapi increas use immun therapi and recent effort actual combin differ modal and probabl largest data present someth call javelin trial so random phase iii trial compar patient metastat kidney cancer gotten prior treatment receiv either sunitinib vegftarget agent that standard care last year combin axitinib anoth vegftarget therapi plus avelumab and avelumab class drug i mention immunotherapeut we also call checkpoint inhibitor mechan work and mani combin studi start report a coupl report third come next month it realli transform way kidney cancer patient treat walk door so mention larg phase iii trial and rational realli differ way attack cancer attack blood vessel tri stimul immun system about patient treat trial patient treat either sunitinib combin therapi and shown thewhat callprogressionfre surviv i usual describ patient long control tumor signific greater combin therapi it almost month i believ one highest ever report diseas compar month sunitinib so signific advantag term diseas control primari end point trial what also look respons rate so talk respons realli patient signific amount tumor shrink scan and seen overal popul receiv combin therapi half patient object respons and peopl degre tumor get smaller if tumor get littl bit smaller dont necessarili call respons if get least smaller that threshold respons so half patient reach threshold high number compar usual percent singleag antiblood vessel drug and import patient complet respons one great thing immunotherapi done kidney cancer chang mindset littl bit realli tri control diseas recogn there subset patient cure diseas and realli hasnt true larg scale ever realli certain time ive and new regimen control diseas longer lead potenti cure diseas the cure part obvious need time pass we need follow patient etc i think certain possibl they report overal surviv result although data call relat immatur meaningwhich good thingthat patient still aliv receiv either regimen so cant quit yet say regimen make patient live longer averag certain benefit term tumor shrinkag diseas control and time data come interest also similar studi involv combin axitinib pembrolizumab that data present meet press releas happen come first day meet show also effect term tumor shrinkag diseas control interest also show surviv benefit so one thing well sort next year relat merit regimen theyr certain ident theyll differ side effect profil differ way help patient differ patient might help etc so good news number regimen like get approv next month come next wave work tri figur best appli patient certain excit data it first combin regimen includ drug like axitinib includ pill inhibit blood vessel the main piec data i want go i privileg present differ trial i present similar one so trial call immot and trial take patient kidney cancer yet treat it random either sunitinib i mention standard therapi anoth combin immun agent antiblood vessel agent the name drug atezolizumab bevacizumab it regimen that shown effect lung cancer cancer and clinic data studi present gu symposium earli and present esmo correl studi some secondari scientif analys often happen larg clinic trial and detail analys done bit complic suffic say look patient tumor look express gene tumor and differ tumor differ biolog they express differ gene and one stori that emerg analysi sampl trial also small prior trial patient tumor rich blood vessel reliant angiogenesi patient tumor reliant t cell immun system effect obvious patient type tumor cell individu tumor and data realli start show trend there differ biolog subtyp kidney cancer and anybodi treat patient know we give group patient drug peopl respond wonder unfortun other dont everywher and mean under tumor differ and larg data set larg analys start sort say we genet basi clinic differ observ patient i think import first step hope toward individu therapi treat everybodi combin treat certain patient one drug certain patient anoth drug patient combin and i mention mani combin come would nice test would allow us choos best combin best patient were yet were i would say unfortun littl way point but data present esmo i think start take step character tumor and last thing ill mention someth call sarcomatoid tumor so word sarcomatoid appli kidney cancer subset mayb tumor general aggress the cell microscop spindl shape that word sarcomatoid mean and theyv alway difficult treat it look like howev immun therapi patient popul particular suscept actual better immun therapi and genet signatur appli specif tumor surpris verywhat wed sayan immun rich environ they character express gene relev immun system so provid biolog basi clinic observ weve made year hope make us smarter and i think immun therapi certain go benefit patient sarcomatoid kidney cancer i think much clear clinic data point toward and esmo data realli provid biolog basi just summar kidney cancer esmo one phase iii trial present javelin axitinib plus avelumab show advantag sunitinib interest biolog data and certain come combo move forward ill ask dr garcia comment kidney cancer data i mention ill describ prostat updat dr garcia thank brian i think that excel overview excit data perhap comment lack biomark inde put lot pressur select patient select therapi patient metastat renal cell carcinoma and i think javelin trial trial also come soon space i think clinician go face challeng decid dual immuneoncolog approach sequenti manner and matter also perhap look combin vascular disrupt agent plus immunotherapi clear need actual look clinic featur patient diseas make treatment decis havent abl pin biomark help us guid best approach patient front dr rini yeah i agre it good problem mani activ drug tri decid one give patient go big challeng move forward dr garcia great so let move briefli review i think probabl excit report esmo munich prostat cancer so similar brian mention obvious lot movement manag patient advanc prostat cancer i think last year chang practic manag patient walk offic metastat prostat cancer that patient either primari tumor resect radiat therapi primari definit treatment time go progress develop system diseas patient never chanc prostat treat either surgeri radiat therapi the latter group uncommon psa screen least north america and see perhap percent patient walk offic metastat diseas so way background standard care men advanc diseas last decad suppress testosteron socal castrat remov testosteron either medic andor surgic orchiectomi most us unit state medic suppress call hormon therapi basic inject receiv various interv suppress function pituitari access testicl patient suppress testosteron therefor diseas get control tradit patient longer live suppress testosteron like develop resist approach and tradit done happen talk chemotherapi you talk novel oral agent abl inhibit signal within prostat cancer cell allow growth signal hormon bodi make specif renal gland with agent abirateron acet agent capabl suppress testosteron product hormon also activ signal within prostat cancer growth so divid patient main group walk offic metastat diseas well call high volum low volum and definit actual process american data call charter data patient high volum diseas specif speak viscer metastas uncommon prostat cancerthat mean lung diseas liver diseaseor men metastas bone one outsid spine andor pelvic region receiv hormon chemotherapi and clear ad docetaxelbas chemotherapi men drastic improv outcom the french last year present data trial call latitud trial look util oral therapi front combin testosteron suppress in case use abirateron acet and trial also specif aim patient metastat diseas high volum featur although definit high volum diseas bit differ american definit didnt includ viscer diseas presenc bone metastas includ gleason score reflect biolog tumor patient and trial also demonstr patient receiv combin abirateron acet suppress testosteron drastic improv outcom we often time tell patient adt hormon suppress abirateron decreas risk die prostat cancer almost with latitud charter data america standard care either use chemotherapi andor abirateron patient popul didnt good sens patient low volum diseas throughout time british also help us littl bit support role chemotherapi patient the british trial call stamped it complex trial statist speak trial basic take signific number patient metastat diseas basic backbon treatment case suppress testosteron androgen depriv therapi add newer treatment time and allow flexibl remov treatment perform ad new treatment becom part use patient this trial actual demonstr coupl year ago addit docetaxelbas chemotherapi patient metastat diseas made peopl live longerspecif reduc risk mortal diseaseand therefor solidifi role docetaxel similar american data they also includ arm includ abirateron data also present last year demonstr signific surviv improv patient metastat diseas so biggest question offer patient low volum metastas so data didnt actual stratifi patient volum diseas actual present esmo year and i think nutshel quit simpl patient lowvolum diseas andor high volum diseasewheth use french definit american definitionregardless volum addit abirateron patient metastat diseas drastic improv outcom reduc relat risk mortal therapi so standard care low volum patient suppress testosteron ad abirateron acet perhap interest data also arm within trial look addit radiat therapi primari tumor men metastat diseas primari tumor treatedmean radiat upfront surgeryand walk offic metastat diseas and random patient standard care time adt suppress testosteron docetaxel combin plus radiat therapi prostat tumor and saw data surviv improv take comer mean high low volum patient howev stratifi volum diseaseth low volum diseas high volum diseaseit clear signific surviv improv men metastat diseas low volum diseas went receiv adp mean suppress testosteron addit docetaxelbas chemotherapi radiat therapi prostat gland there almost differ year surviv hazard ratio risk reduct mortal call tell patient around almost risk reduct mortal get radiat therapi primari tumor so practic see someon low volum metastat prostat cancer primari place standard care becom suppress testosteron addit abirateron acet primari radiat prostat tumor period for high volum patient i would argu standard care remain either suppress testosteron plus docetaxelbas chemotherapi suppress testosteron plus abirateron and i think us practic simpli use combin oral therapi plus suppress testosteron last i know interest provoc trial trial call era look combin particular agent abirateron acet radiopharmaceut agent also approv men advanc castrationresist prostat cancer mean men becom resist lack testosteron go develop progress diseas bone so rational behind combin agent lifeprolong agent and sinc abirateron use prechemotherapi space set radium radionuclid also use particular patient popul thought mayb combin novel oral hormon approach radionuclidebas approach could actual lead better improv outcom castrationresist prostat cancer patient so trial look patient castrationresist diseas never seen chemotherapi random receiv either combin abirateron plus radium abirateron match placebo and primari end point trial look surviv along reduct skelet symptomat event like patient develop symptom boni metastas common site metastas men prostat cancer it specif relat need radiat therapi pain control develop fractur requir orthoped surgeri develop tumor spine push spinal canal possibl lead neurolog symptom that primari end point trial what learn trial realli drastic differ outcom mean abil delay progress diseas there differ surviv group mean ad radium didnt improv outcom what learn combin abirateron radium unfortun increas risk patient popul develop fractur specif either patholog fractur site boni metastas complic area boni diseas lead bone fractur so big issu clinician use combin abi radium sinc trial i think refrain use combin i think import physician understand trial test time use radium castrationresist diseas it aim test combin agent so i think radium remain lifeprolong agent offer patient castrationresist diseas specif patient popul agent label combin oral agent abirateron actual use point this trial result studi chang label radium unit state also european region i think fair say us refrain use combin oral agent whether mean combin radium anoth oral agent ar inhibitor remain seen but clear signific increas patholog fractur almost differ patient combin arm i think us would concern see patient develop complic combin i dont think realli know biolog behind happen i think fair say data confid enough us use clinic practic so summar i think standard care prostat cancer low volum high volum diseas use suppress testosteron oral agent abirateron acet for patient low volum diseas primari tumor place radiat therapi primari tumor standard care the time remain debat so i think us treat patient system therapi road given time probabl includ radiat oncologist offer radiat therapi and second use combin radium abirateron acet someth one support data new trial look combin agent brian i dont know comment thought dr rini sure yeah i mean tell there lot go prostat cancer well i think mayb broaden area think control primari tumor patient whose diseas alreadi spread and dr garcia mention data radiat primari tumor subset patient especi patient low volum sometim call oligometastat diseas there studi ongo look can treat patient aggress either radiat surgic remov primari surgic remov lymph node even radiat metastat site hope window cure prostat cancer patient expand includ low volum patient but i think there lot work done i think patient may benefit i think ongo trial help defin but that total differ concept thought advanc prostat cancer realli certain time weve so id like thank dr garcia excel summari thank tune podcast as tell gu cancersand weve realli given small slice went one meetingbut there lot import studi go a lot import data that come larg phase iii trial chang standard care chang better continu move forward clinic research thank attent dr garcia thank brian thank opportun asco thank dr rini dr garcia learn genitourinari cancer wwwcancernet and podcast use pleas take minut subscrib rate review show appl podcast googl play cancernet support asco conquer cancer foundat fund breakthrough research everi type cancer help patient everywher to help fund cancernet program like donat conquerorgsupport music',\n",
       "  'JJ'),\n",
       " ('excerpt the third generat epiderm growth factor receptor egfr tyrosin kinas inhibitor tki osimertinib effect firstlin treatment egfr mutat nonsmallcel lung cancer nsclc accord latebreak abstract present european lung cancer confer elcc geneva switzerland a second latebreak abstract confirm drug effect patient tm mutat egfr inhibit standard care nsclc patient egfr activ mutat near develop resist develop tm mutat osimertinib potent inhibitor origin egfr mutat exon exon tm the studi present today investig whether use osimertinib firstlin therapi egfr mutat posit nsclc would result favour efficaci due delay tm mediat resist the studi includ patient two phase i expans cohort aura trial local advanc metastat egfr mutat nsclc thirti patient receiv mg day receiv mg day firstlin set the median followup month go full articl do question stori let us know comment if your wonder whether stori appli cancer case love one invit use ask cancer common servic',\n",
       "  'JJ'),\n",
       " ('thank you your english goodbett peopl whose first languag english i realli appreci take time answer question mayb stelara better option i dont think i want chang medic i get back vacat june th case doesnt go well i wouldnt want ruin famili vacat',\n",
       "  'NN'),\n",
       " ('recruit apr elig cancer histiocyt sarcoma juvenil xanthogranuloma langerhan cell histiocytosi lymphoma recurr central nervous system neoplasm recurr malign solid neoplasm refractori central nervous system neoplasm refractori malign solid neoplasm intervent ros patient receiv x ensartinib countri usa children oncolog group philadelphia pa nct a studi of oral pf a cmethepatocyt growth factor tyrosin kinas inhibitor in patient with advanc cancer status recruit elig cancer alkposit nonsmal cell lung cancer nsclc cmet depend nsclc ros marker posit nsclc system anaplast largecel lymphoma advanc malign except leukemia intervent pf crizotinib rifampin itraconazol countri usa state australia republ korea note this origin trial crizotinib it expand time includ new arm nct nation lung matrix trial multidrug phase ii trial nonsmal cell lung cancer status not yet recruit elig cancer nonsmal cell lung cancer nsclc squamous cell carcinoma adenocarcinoma intervent ros patient receiv crizotinib countri unit kingdom uk nct ceritinib trametinib patient with advanc alkposit nonsmal cell lung cancer nsclc status recruit elig cancer stage iiibiv ros phase alk nonsmal cell lung cancer nsclc intervent ceritinib trametinib countri univers california san francisco expand access to experiment drug nct expand access entrectinib cancer with ntrk ros alk gene fusion status avail elig cancer advanc cancer ntrk ntrk ntrk ros alk gene fusion and unabl particip ongo entrectinib rxdx clinic trial intervent entrectinib countri contact ignyta call startrk',\n",
       "  'NN'),\n",
       " ('good luck tomorrow yrs holi moli after i diagnos i enjoy period remiss like two year follow initi diagnosi i symptom free in i suffer flare got control enjoy anoth two year remiss howev i start flare often longer period prednison i lot stress daughter went bitter divorc thing went haywir uc i hospit i thought go take hospit pine box i soooo sick i tri remicad humira condit spiral downhil qualiti life suck big time so i decid someth i got old',\n",
       "  'VBD'),\n",
       " ('gilead galapago announc oral jak inhibitor filgotinib hit goal phase iii trial patient rheumatoid arthriti fail treatment the result good news partner inflammatori condit contend also studi ulcer coliti crohn diseas ankylos spondyl the finch trial filgotinib adult moderatelytosever activ rheumatoid arthriti achiev primari endpoint proport patient achiev american colleg rheumatolog respons acr week filgotinib mg mg dose achiev signific higher acr respons placebo read acr week higher dose compar placebo the news particular fillip galapago saw share rise announc gilead share also john mchutchinson john mchutchison md chief scientif offic head research develop gilead said data show potenti drug candid combin diseas modifi drug help patient activ ra dont respond adequ current biolog these data particular encourag look ahead phase iii result ongo finch trial explor filgotinib popul patient rheumatoid arthriti the first jak inhibitor market pfizer xeljanz tofacitinib alreadi earn excess bn year ra revenu anoth player lilli olumi though held back safeti concern analyst predict showdown filgotinib abbvi rival upadacitinib next decis event jak inhibitor market abbvi look lead race market phase iii data hand show upadacitinib effect abbvi bnayear inject tnf blocker humira adalimumab ra come clinic respons gaug doctor patient the new result filgotinib follow close behind posit result ankylos spondyl last week',\n",
       "  'JJ'),\n",
       " ('hi im advoc year old mom take tarceva sinc januari year i want everyth i make sure overlook anyth would provid best chanc long pfs on tarveca sinc respond well primari tumor shrink x mm januari x mm stabl right hillier node x mm her last ct still show residu nodular pleural carcinomatosi the treatment also complet resolv moderatelarg malign pleural effus no sign metastasi she sensit medic sever reaction mg mg shes realli well asid numb various part bodi come go with treatment improv rapid pace would consid tarveca best treatment someon profil would consid investig combin therapi there recent studi publish uc davi say mani dismiss surgeri advanc stage nsclc howev may benefit overlook my mom treat major research univers hear los angel never evalu surgeri due mpe should patient seek surgic evalu despit mpe andor residu nodular pleural carcinomatosi seen thank john',\n",
       "  'NN'),\n",
       " ('it kind unreal think tumor abl hijack cell bid in anoth immuno arena list i told lead investig oncolyt viral therapi pair checkpoint inhibitor probabl pembrokeytruda expans arm ovarian cancer phase alreadi start dose monotherapi short ph safeti alreadi establish prior trial diseas type a year i would say theyll combo httpwwwgeneluxcomgloncglonc',\n",
       "  'NN'),\n",
       " ('hi coco sorri hear mom i m posit tagrisso work after wait month wonder drug work oncologist team suggest get anoth lung biopsi see new mutat may mom like might acquir anoth mutat but easi figur take time after rebiopsi next treatment option would get chemo enrol clinic trial take care',\n",
       "  'NN'),\n",
       " ('immun checkpoint inhibitor becom approv commerci avail patient previous treat advanc nsclc dr eddi garon medic oncologist ucla summar key data explain current role treatment cancer journey just diagnos in treatment cancer type lung cancer diseas learn molecular test target therapi mainten therapi secondlin treatment are there distinct among current avail oral egfr inhibitor egfr mutationposit nsclc dr greg rieli medic oncologist mskcc consid evid whether clinic signific differ among current avail first second generat oral egfr inhibitor patient egfr mutat cancer journey just diagnos in treatment cancer type lung cancer diseas learn target therapi molecular test mainten therapi should avastin ad egfr tki therapi egfr mutationposit nsclc dr jack west medic oncologist review evid favor ad avastin bevacizumab egfr inhibitor tarceva erlotinib patient lung cancer harbor activ egfr mutat cancer journey just diagnos in treatment cancer type lung cancer diseas learn target therapi firstlin treatment molecular test mainten therapi symptom what mainten therapi advanc nsclc the concept mainten therapi advanc lung cancer emerg past year dr jack west medic oncologist review concept behind treatment option patient cancer journey just diagnos in treatment cancer type lung cancer diseas learn mainten therapi target therapi it possibl live with cancer novemb lung cancer awar month to mark year grace celebr empow lung cancer patient in video linnea duff cancer journey in treatment just diagnos cancer type lung cancer diseas learn target therapi mainten therapi symptom',\n",
       "  'JJ'),\n",
       " ('repli plan i offici ocrevus view post by penkalet great news i realli hope slow great news i realli hope slow beast i think help alain show result forum jump all time gmt the time am',\n",
       "  'NN'),\n",
       " ('home ms inform public the motiv the motiv summerfal research news new drug applic accept treatment pediatr ms confer highlight research news new drug applic accept treatment pediatr ms confer highlight fda accept applic cladribin tablet on juli emd serono inc announc unit state food drug administr fda accept new drug applic nda cladribin tablet oral formul cladribin this investig treatment relaps form ms accept european commiss august canada decemb cladribin current approv treatment relaps ms countri trade name mavenclad in studi cladribin shown reduc diseas activ patient relaps ms includ disabl progress annual relaps rate mri activ potenti advers event includ lymphopenia condit caus abnorm low count white blood cell play role fight infect herp zoster accord msaa ms research updat cladribin select target immun system b cell t cell lead deplet cell this follow distinct pattern reconstitut new cell t cell produc the medic interest dose regimen two annual cours given maximum day two year it develop note approach avoid continu suppress immun system follow first two year treatment need year fda accept gilenya pediatr ms on may novarti announc gilenya fingolimod approv unit state food drug administr fda treatment children adolesc age relaps multipl sclerosi ms this first diseasemodifi therapi dmt approv form diseas age group known pediatr ms near percent diagnos relaps form diseas children experi approxim twotothre time mani relaps individu adultonset ms prior approv diseasemodifi therapi dmts ms approv adult treatment approv specif children adolesc ms the fdas approv gilenya base result phase iii paradigm studi this clinic trial evalu safeti effect gilenya versus avonex interferon betaa children adolesc age relaps ms paradigm first studi compar two ms therapi approv adult children adolesc ms enrol young individu ms studi conduct site countri paradigm doubleblind random multicent phase iii studi durat two year follow fiveyear openlabel extens phase studi particip either given avonex onceweek intramuscular inject gilenya oral pill taken daili compar avonex group take gilenya experienc percent reduct annual relaps rate period two year side effect advers event similar seen clinic trial adult for inform gilenya treat pediatr ms individu may visit wwwgilenyacom call gilenya speak member novarti support team research highlight aan cmsc annual meet the result numer signific studi report annual meet american academi neurolog aan held los angel april annual meet consortium multipl sclerosi center cmsc took place nashvill may post juli msaa provid summari interest find confer topic articl includ updat experiment diseasemodifi therapi dmts continu studi effect safeti approv dmts compar analysi approv dmts new diagnost test strategi well hot topic ms this latter section includ inform stem cell transplant gut microbiom medic marijuana to read full summari pleas see research highlight aan cmsc annual meet for individu without internet access pleas call msaa request print copi to read msaa latest articl onlin pleas visit websit mymsaaorg go latest news for general inform speak train client servic specialist pleas call msaa helplin extens question msaa client servic depart may also email written susan well courtney msaa senior writer review dr jack burk msaa chief medic consult back',\n",
       "  'NN'),\n",
       " ('gilead scienc galapago announc finch global random placebocontrol phase iii studi glpg filgotinib investig select jak inhibitor adult moderatelytosever activ rheumatoid arthriti prior inadequ responseintoler biolog agent achiev primari endpoint proport patient achiev american colleg rheumatolog percent respons acr week also week proport patient achiev acr acr low diseas activ lda dascrp filgotinib general welltoler finch trial new safeti signal compar report previous trial filgotinib treatmentemerg advers event serious advers event most mild moder sever serious advers event occur percent patient placebo mg mg group respect the proport patient discontinu studi drug due treatmentemerg advers event also similar across group two case uncompl herp zoster report filgotinib group two major advers cardiovascular event mace identifi one subarachnoid hemorrhag placebo group one myocardi ischemia filgotinib mg group there one case nonseri retin vein occlus filgotinib mg group report deep venous thrombosi dvt pulmonari embol pe there death malign gastrointestin perfor opportunist infect includ activ tuberculosi comment analyst focus safeti factor trial grow concern janus kinas jak inhibitor class drug includ filgotinib may affect blood clot howev gilead galapago found report deep venous thrombosi dvt pulmonari embol pe come finch far comment you need login leav comment epgonlineorg monitor collect advers event report ani advers event report nation report agenc andor manufactur learn zone an epgonlineorg learn zone lz area site dedic provid detail selfdirect medic educ diseas condit procedur alkalin phosphatas alp lab assess discov overview hypophosphatasia detail requir facilit time accur detect low alkalin phosphatas migrain knowledg centr the migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician acut advanc heart failur what effect treatment acut heart failur can defin advanc heart failur discov psoriasi see inform psoriasi pathophysiolog sign symptom comorbid treatment option allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option atop dermat the atop dermat knowledg centr educ resourc intend healthcar profession provid credibl medic inform epidemiolog pathophysiolog burden atop dermat well diagnost techniqu treatment regimen guidelin recommend chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria load relat content news journal articl clinic trial guidelin news phase iii selectmonotherapi trial abt show benefit week rheumatoid arthriti abbvi abbvi announc new patientreport outcom data ongo phase iii selectmonotherapi trial evalu abt upadacitinib mg ad day ago integr safeti analysi olumi six years lilli incyt eli lilli compani incyt corpor announc find updat integr safeti analysi olumi baricitinib base ad day ago phase iv interim data hp acthar gel show reduc diseas activ rheumatoid arthriti mallinckrodt mallinckrodt report interim data midway point enrol ongo phase iv multicent studi assess ad day ago detail result phase iii finch trial filgotinib rheumatoid arthriti gilead galapago gilead scienc inc galapago nv announc detail result phase iii finch clinic trial filgotinib ad day ago celltrion advanc remsima sc subcutaneou version remsima biosimilar file europ year celltrion inc announc compani complet phase iii clinic trial remsima sc subcutan sc version ad month ago load view news item journal articl updat subcutan methotrex inflammatori arthriti psoriasi the aim articl review avail literatur data sc mtx treatment inflammatori arthriti special emphasi ra psoriasi examin differ oral mtx treatment ad month ago predict respons methotrex rheumatoid arthriti this narrat review seek cover various genotyp phenotyp characterist investig predictor treatment respons mtx ra ad month ago efficaci safeti interleukin antagonist rheumatoid arthriti systemat review metaanalysi rheumatoid arthriti patient high level proinflammatori interleukin augment blockad interleukin receptor extern interleukin receptor antagonist modifi progress diseas ad month ago the emerg role il inhibit patient affect rheumatoid arthriti diabet object we review role il ra td efficaci il block agent control diseas possibl decreas concomit enhanc atherosclerot process ad month ago safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthesitisrel arthriti psoriasi crohn diseas object to evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthesitisrel arthriti ad month ago load view journal articl item clinic trial compar efficaci safeti studi gp enbrel patient with rheumatoid arthriti equira demonstr equival efficaci gp euauthor enbrel patient moder sever activ ra inadequ respons diseas modifi antirheumat drug dmard includ methotrex mtx ad month ago multicent studi evalu certolizumab pegol compar placebo subject with axspa without xray evid as caxspand patient activ axial spondyloarthr without xray evid ankylos spondyl sign inflamm random assign receiv certolizumab pegol czp mg everi two week placebo ad month ago a studi compar abt monotherapi methotrex monotherapi subject with rheumatoid arthriti ra who have not previous taken methotrex selectear this random doubleblind studi compar abt monotherapi methotrex mtx monotherapi mtxnave subject moder sever activ rheumatoid arthriti ad month ago a studi moder sever rheumatoid arthriti particip rabuild the purpos studi determin whether baricitinib milligram mg daili qd superior placebo treatment particip moder sever activ rheumatoid arthriti ad year ago efficaci safeti sarilumab adalimumab monotherapi patient with rheumatoid arthriti sarilramonarch primari object to demonstr sarilumab monotherapi superior adalimumab monotherapi respect sign symptom assess diseas activ score ad year ago load view clinic trial item guidelin updat asaseular manag recommend axial spondyloarthr the assess spondyloarthr intern societyeular recommend provid uptod guidanc manag patient axspa ad month ago spondyloarthr diagnosi manag this guidelin cover diagnos manag spondyloarthr suspect confirm adult year older it aim rais awar featur spondyloarthr provid clear advic ad month ago bsr bhpr guidelin treatment axial spondyloarthr includ ankylos spondyl biolog these guidelin provid evidencebas guidanc uk clinician prescrib biolog adult patient axspa this includ criteria start treatment choic drug assess respons treatment ad month ago bsr bhpr guidelin prescript monitor nonbiolog diseasemodifi antirheumat drug the purpos guidelin provid uptod evidencebas recommend safe use nonbiolog dmard adult year old ad month ago bsr bhpr guidelin prescrib drug pregnanc breastfeedingpart ii analges drug use rheumatolog practic the object guidelin provid evidencebas recommend impli legal oblig clinician follow prescrib drug common use manag multisystem rheumat condit',\n",
       "  'NN'),\n",
       " ('ive never heard anyth reduc life expect regard either rituxamab ocrelizumab obvious drug carri risk primarili opportunist infect i dont think there way quantifi impact life expect logic could even increas life expect success curtail ms diseas activ thus decreas chanc death ms complic of cours conjectur as ms medic patient must determin toler risk balanc potenti reward take drug',\n",
       "  'NN'),\n",
       " ('asian patient alk posit advanc nonsmal cell lung cancer nsclc demonstr improv outcom alectinib compar crizotinib firstlin set accord result phase alesia trial present esmo congress munich germani in global phase alex trial alectinib signific prolong progressionfre surviv pfs compar crizotinib among patient alk posit nsclc without prior treatment hazard ratio hr ci the purpos trial determin asian patient would experi similar benefit seen popul alex trial investig openlabel phase alesia trial random assign asian patient alk posit stage iiib stage iv nsclc receiv alectinib crizotinib all patient receiv prior system treatment patient asymptomat central nervous system cns metastas allow enrol the primari end point pfs assess via investig analysi secondari end point pfs assess independ review committe time cns progress object respons rate orr durat respons dor overal surviv os cns orr qualiti life safeti relat articl atezolizumab combo improv pfs os stage iv nonsmal cell lung cancer resist mechan identifi nsclc progress with firstlin osimertinib brigatinib found more effect alkposit nsclc brain met compar with crizotinib alectinib met primari end point signific improv pfs median yet reach compar month crizotinib hr ci p pfs found similar assess independ analysi hr ci p the os data immatur median arm yet reach the orr higher alectinib compar crizotinib p the dor also longer alectinib median yet reach compar month crizotinib the time cns progress also yet reach alectinib month crizotinib hr ci p grade grade advers event ae less common alectinib rate compar crizotinib the rate serious ae alectinib crizotinib respect discontinu occur patient alectinib crizotinib arm respect discontinu due ae the author conclud alesia studi result consist global alex studi confirm clinic benefit alectinib asian patient advanc alk posit nsclc read cancer therapi advisor coverag esmo meet visit confer page refer',\n",
       "  'VBP'),\n",
       " ('honest i use cannabi i feel cancer fight properti rather i enjoy combin lorlatinib i need speak maker molecul psychoact qualiti i creativ person enjoy xo linnea',\n",
       "  'NN'),\n",
       " ('frustrat inform rituxan when i met new neurologist last month i brought research show minim almost nonexist rise cancer risk ocrevus she knew immedi meant i malign melanoma histori mine let argu keep rituxan who knew melanoma would use linda be kind woman feet hit floor morn devil saysoh crap shes repli with quot the follow user say thank agat cheri howi jeani z jendi stillstannd sunshin',\n",
       "  'JJ'),\n",
       " ('go meal i dont feel good surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia condit afib high blood pressur gout crohn edema cellul heart issu ost openia medic entyvio eliqui verapamil quinipril labetalol clorithidon atorvastatin alluporinol vitamin',\n",
       "  'NN'),\n",
       " ('sent email spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       "  'NN'),\n",
       " ('my husband stage nonsmal cell metastat lung cancer he diagnos august he egfr mutat put tarceva work month time discov cancer metastas hip bone he given radiat hip work well complet took away hip pain put tagrisso',\n",
       "  'NN'),\n",
       " ('ellina allow take oral vitamin c tarceva i bought today mg pill slow releas vit c doxycyclin might use see paper anyway take doxycyclin anyway one affect microbiota there damag oral vit c it act inhibitor glycolysi cancer cell get oxid form via glucos transport reduc form',\n",
       "  'NN'),\n",
       " ('mayb say repress immun system that work suppress bodi natur immun not but cours noth els work take question there show us cabl tv call the monster insid me it parasit i dont know mani episod discuss various parasit worm fungus bacteria larva everyday environ part harmless us normal immun system easili overwhelm someon compromis immun system while previous studi alreadi indic increas risk infect lymphoma evid publish journal american medic associ suggest remicad tripl risk skin cancer anoth black box issu describ cancer occur children young adult began take tnf blocker remicad humira cimzia along immunesuppress medicin mp the fda fix problem updat warn section drug label wwwhuffingtonpostcomrebeccakaplansocialsecurityadministrbhtml patient ibd depend medic antibiot antiinflammatori steroid immunosuppress control inflamm ulcer pain caus diseas while benefici medic caus sever side effect includ nausea vomit heartburn night sweat insomnia hyperact high blood pressur stunt growth children patient immunosuppress risk develop lymphoma tuberculosi kidney liver damag anaphylaxi seizur potenti serious fatal infect',\n",
       "  'NN'),\n",
       " ('uugghh im sorri hear marci im familiar combo suggest heard go back keytruda ad someth els along im unawar result my mom chemo alimta carbo keytruda first infus at time triplet approv month earlier studi shown patient better respons overal if i recal correct dad keytruda first and sinc cancer respond carboalimta throw anoth kind chemo along immunotherapi perhap combin work how feel otherwis',\n",
       "  'JJ'),\n",
       " ('curr neurol neurosci rep sep infect patient receiv multipl sclerosi diseasemodifi therapi grebenciucova e pruitt a author inform multipl sclerosi divis dave depart neurolog clinic neurosci northwestern univers feinberg school medicin chicago il usa multipl sclerosi divis depart neurolog perelman school medicin the univers pennsylvania convent avenu philadelphia pa usa purpos of review this paper system review risk infect associ current diseasemodifi treatment discuss pretreat test recommend infect monitor strategi patient educ recent find asid glatiram acet interferonbeta therapi multipl sclerosi treatment various degre impair immun surveil may predispos patient develop communityacquir opportunist infect some infect rare seen neurolog practic neurologist awar monitor infect educ patient medicationspecif risk of particular interest discuss risk pml associ recent approv b cell deplet therapi ocrelizumab particular switch natalizumab the risk infect associ ms treatment becom one import factor choic therapi balanc overal risk versus benefit continu reevalu treatment',\n",
       "  'NN'),\n",
       " ('thank your repli i think know ulcer coliti thank restat howev state obvious i look i understand mani thread kefir past question look identifi kefir home run success hear detail implement like thing detail make differ if one take kefir combin specif preibot perhap work but one take kefir combin lot sugar fri food process food work this obvious exampl detail much specif prebiot one use kefir work how mani time day take kefir do still requir daili mainten success certain period ie week abl rebal gi track this specif thread kefir realli realli work anoth thread discuss kefir general diagnos pancol march tri drug steroid mesalamin etc current vedolizumab new experiment gut specfic monoclon antibodi current entir colon heal except rectum recto sigmoid are stubborn noth seem work except high dose steroid royalflush new member join jan post post am gmt hi ibdgal kefir milk grain work tremend this one simpl chang done uc medic diet chang attitud chang when i meet someon ib uc etc i tell kefir milk it success rate tri peopl like million still my trek kefir milk start veget fruit smoothi vitamix juic slow mastic juicer i use carrot celeri appl orang etc vari amount stuff told avoid find highqual veget base enzym kefir water kefir milk addit smoothiesjuic daili like i use tonow i skip day kefir i use kefir grain start pack i cant recal brand whole milk i warm milk bit boil hot warm touch mix grain two quart ball jar i cover jar wa towel leav counter hour refriger when im last second jar i warm milk split last jar remain amount two jar continu kefir grain ive use grain month histori lead kefir the vitamix smoothi juic enzym gave lot energi boost immun system i slept better less flare result less trip bathroom kefir multipli success kefir beyond onc i integr kefir milk id say quadrupl success smoothiesjuicingenzym where i stay away spici food donut fast food bad food told avoid kefir milk allow indulg whether conveni hang friend andor timesav meal eg fast food restaur etc i thing time time im stupid kefir get back track quick monthlong flare day pain scale reduc urgenc erad bathroom time reduc least if i go without fast food spici layer bean dip differ bean layer old flare trigger kefir keep everyth balanc speak solid poo quick evacu go back sit time minut get everyth huge drop quantiti tp i use wipe and i go potti i leav go well anywher im memor clean bathroom way locat if im kefir well im stupid i begin bleedflar kefir stop pain bleed discomfort within day two versus week end pain blood urgenc mention poor attitud for amaz so amaz ive uc med year my liver thank blood test keep show probiot i take enzym mlm call tranont call life i buy friend it work lower price get whole food like kefir dosag on averag i take oz per day even at first even kefir middl night littl gas go i chang morn after bodi adjust good i went back even at time ill simpli take coupl big chug throughout day versus one glass even recent i research tri nonthc cbd oil work well a friend year old son chron made massiv differ within week it new add daili routin made posit chang i truli hope help notsosicklygirl forum moder join dec post post pm gmt i friend use post surgeri she huge kefir made long period i guess didnt work well surgeri i done kombucha yogurt person kefir moder uc current med step jpouch surgeri complet step complet step complet from sick uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish mariamaria regular member join aug post post pm gmt doe tast good can use coffe smoothi etc or chug medicin purpos yo dx leftsid ulcer coliti jan current salofalk tablet scd fmt treatment sinc nov remiss sinc june royalflush new member join jan post post am gmt i find kefir milk tast like yogurt i fan plain yogurt i ad drop stevia ad stevia drop two pure vanilla extract after i grew tire pour drop mix drink clean put away take straight after day i grew accustom flavor big issu everi ill get yogurt face reaction ton better clean regard mix i found mix well fruit smoothi i tri veget smoothi i drink coffe i dont know it thick though i doubt would mix well plus im sure hot water would affect kefir uniform charli veteran member join jul post post am gmt do happen know kefir bacteria elimin lactos milk i assum didnt could use anoth base diagnos proctosigmoid uc hiatial hernia w gerd current med lialda gm x daili duloxetin rowasa need vsl occasion one day multivitamin curcumin occasion did scd year lost willpow royalflush new member join jan post post am gmt hi it sinc i research kefir howev stick head kefir consum lactos ferment process therefor lower lactos end product the tangi end product lower amount remain lactos ferment hour aid get remain lactos low possibl shake glass jar coupl time hour period the longer sit room temperatur longer ferment lower remain lactos i recal long ferment recommend hour ive sit lot tangierbitt hour i also recal kefir aid lactos digest like yogurt kefir doesnt produc symptom lactos intoler kefir bacteria help digest lactos i rememb read studi involv small group take kefir fast i think lactos intoler intoler the group report less gas compar drink straight milk they also measur gas particip breath hydrogen mayb show less gas digest tract scienc right when i began kefir i extra gas be guy i found posit side effect to date i milklik side effect kefir milk i lactos intoler howev consum dairi especi milk would wreck gut mrsmith new member join jan post post pm gmt ive never much success kefir i still drink occas never signific effect symptom far i could tell addit whilst consum massiv amount kefir may transient shift balanc gut microbiom realiti nativ gut bacteria specialis surviv colon wherea microorgan found kefir quick outcompet unabl perman colonis gut this true almost everi probiot sourc i investig you need bacteria specialis live gut realist get faecal transplant',\n",
       "  'NN'),\n",
       " ('gotta go hospit blood test guy was meant entyvio infus yesterday guy rang say pharmaci didnt medic bit annoy massiv deal rearrang next monday instead ibd nurs rang say i havent blood test done sinc novemb i sever test done inpati christma i didnt want go phone infus cancel and i go monday ill problem i dont get blood done thank guy phone let know',\n",
       "  'VBP'),\n",
       " ('boot thank repli i love sun make feel great i watch skin id happili sit sun hour sun cream everi minut even though im told everi hour would enough i couldnt give anyway sun best medicin can i ask person question you say gilenya great come neuro believ becom spms i obvious naiv thought work there progress new lesion activ progress that worri i said i thought activ paus want better word thank dont answer person',\n",
       "  'NN'),\n",
       " ('i pentasa year everi time i colonoscopi crohn progress i final end hospit sever inflamm i told gi doc pentasa probabl work back except mp realli altern month ago i switch humira mani side effect pentasa howev',\n",
       "  'NN'),\n",
       " ('hi i newli diagnos rrms consid treatment option i cant see thread mavenclad cladribin wonder anyon experi newli licens drug it seem attract treatment week year year wonder anyon start treatment think i think i current lean toward tecfidera ive read mani help post slight put side effect difficult decid mani thank paula',\n",
       "  'NN'),\n",
       " ('mark cahil lead industri across europ work diabet center america special diabet eye diseas hes base dublin though continu laser lead thing get wors iv told yes jelli pull retina good wait see would mine stop pull bleed wouldnt act vitrectomi laser clear jelli laser work get vessel proper blood vitreous henc vitrectomi laser op risk cours terrifi told i wors risk i didnt vitrectomi allow retina continu pull id eventu disast line im trust god soon ill stabl bleed stop laser doesnt work month done click expand that im dread it one question monday laser haemorrhag go keep tug reopen sure need laser near base abnorm grown vessel pull jelli fall awaywith ive heard mani vitrectomi stori improv vision fix problem make want suggest antivegf instead there hope us stop point futur year get point hope itll minim loss vision hope recoveri stabilis happen soon x',\n",
       "  'NN'),\n",
       " ('that amaz never need dmt i found ocrevus i general ok infus mayb littl tire ok now one time nice i never choic dmt ms pretti intens right gate i think gave great blog post',\n",
       "  'NN'),\n",
       " ('hi i remi imuran year deep remis i take everi week now due infect i week without infus luckili infect gone schedul monday make week i feel scare i might flare as i feel dull ach belli atm i dont know crohn i stress much also i sooo scare i get infus next week remicad wont work antibodi etc ani tip what i ani experi',\n",
       "  'JJ'),\n",
       " ('ask hero hesh ms specialist there mani neurolog diseas do trust noold nuero decis use ocrevus there cure ms differ drug attack differ thing brain that drug work well one person may work anoth if well ocrevus i would stick there mani dmds crapshoot go latest pipelin i first two dose ocrevus last month we one drug time i stick good luck',\n",
       "  'NN'),\n",
       " ('the peopl taller longer abdomen usual experi high output problem sinc tall might reason slower output keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('thank much beav inform use i read post humira doesnt seem suffici studi use around concept have come across find sinc i start humira i think ill regular least year',\n",
       "  'JJ'),\n",
       " ('cnw the competit bureau announc today close investig alleg abus domin janssen inc canadian pharmaceut compani own johnson johnson the bureaus investig consid whether janssen engag conduct shield biolog drug remicad competit biosimilar drug like inflectra renflexi this includ alleg predatori price well conduct could exclud disadvantag biosimilar competitor after care review fact bureau conclud insuffici evid demonstr janssen conduct substanti lessen prevent competit relev market therefor time bureau unabl conclud competit act contraven while biosimilar drug relat new canada like play import role keep health cost futur biosimilar drug provid patient safe effect treatment option price often far lower origin biolog accord although bureau conclud investig continu close monitor canadian biolog biosimilar industri respond develop potenti disrupt competit critic sector economi the bureau hesit take appropri action maintain promot competit pharmaceut industri for detail bureaus investig find pleas consult comprehens posit statement quot biosimilar vital competit pharmaceut industri they offer canadian benefit lower price drug treatment cost upward thousand dollar year the bureau take alleg harm competit serious vigil monitor conduct compani pharmaceut industri matthew boswel interim commission competit quick fact biolog drug deriv live organ tend complex tradit small molecul drug biosimilar drug high similar version origin biolog biolog one fastest grow pharmaceut product segment canada their high cost continu growth usag contribut signific increas pharmaceut expenditur first introduc remicad approv treatment number condit adult condit children includ crohn diseas ulcer coliti there current two approv biosimilar remicad canada inflectra pfizer canada inc approv remicad adult indic renflexi merck canada inc approv remicad indic adult children in conduct investig bureau gather evid obtain inform interview key market particip includ pharmaceut manufactur public privat insur hospit physician infus clinic network trade associ relat product competit bureau statement regard it inquiri alleg anticompetit conduct janssen associ link competit pharmaceut industri the competit bureau independ law enforc agenc ensur canadian busi consum prosper competit innov marketplac wwwcompetitionbureaugcca enquiri complaint stay connect sourc competit bureau',\n",
       "  'NN'),\n",
       " ('decemb by ed tobia there dozen diseasemodifi therapi avail treat ms some shot infus pill some effect other the market intellig compani spherix global insight regular survey treatment use neurologist what influenc select here latest spherix quarter survey show what prescrib new ms patient just half neurologist survey say theyr choos pill first diseasemodifi treatment relaps ms matter level diseas activ newli diagnos patient but half survey neurologist treatment choic influenc level diseas activ if patient diseas activ low percent group prefer pill tecfidera gilenya aubagio thirtynin percent prefer inject copaxon if diseas activ high howev treatment choic one med consid high effici gilenya tysabri ocrevus as someon suffer needl fatigu use avonex mani year follow sever year tysabri infus lemtrada i tell i prefer oral med i think ms patient would but i also prefer kind treatment that like produc best outcom i prefer pill click continu read',\n",
       "  'NN'),\n",
       " ('which recommend product get guy found success id prefer amazon i get is someth keep take stop problem come back how mani mg take best time day take with food thank advanc diagnos pancol march tri drug steroid mesalamin etc current vedolizumab new experiment gut specfic monoclon antibodi current entir colon heal except rectum recto sigmoid are stubborn noth seem work except high dose steroid',\n",
       "  'VBP'),\n",
       " ('ive also fail remicad entyvio ive xeljanz month im normal person last summer i use bathroom x per day lot blood mucus etc not sleep hour time all mg prednison doctor scope recommend xeljanz last resort surgeri while sort xeljanz script insur i admit hospit iv steroid day left hospit feel lot better i wait xeljanz start start mg x per day labor day us last year i start notic improv coupl week noth drastic slow steadi improv start taper prednison goal start met goal day spare im symptomat remiss havent gotten scope confirm clinic remiss i go x morn like i uc mayb later day no blood mucus bloat gas cramp anyth els i for sideeffect one ive increas cholesterol i went low ish total around stabl sinc xeljanz probabl save life good luck i hope xeljanz done',\n",
       "  'NN'),\n",
       " ('who realli want thing normal anyway i never i didnt realli need normalci this normal isnt new normal typic sens normal i live metastat cancer and live well i must say to ive need develop mani strategi work around and ive lot help but definit worth qualiti life realli matter mayb strategi work other learn rememb energi limit import kind tricki move target there day i great energi i deep deep odd tired most day though i wake get go go strong noon after anybodi guess i learn week im longer abl push like i alway old life when im done im done kind like babi and okay i priorit sometim bonus time someth love do love ive alway believ make great sens well there lot thing i love cant anymor yet normal that okay ive discov i love lot thing so im focus time one i still like photographi natur mayb adjust i and im learn new thing thing like write blog i sure time read i love read pretti much anyth i four book go right one fiction two health relat one nonfict naturebas none educ that first short breath huf puf havent realli found good strategi except go slow steadi not like much run spring i determin walk new orthofeet sneaker and there digest system issu when i first start crizotinib i took differ med system could toler imodium went everywher i never knew id bout diarrhea and advanc notic usual pad dispos underwear extra cloth dispos wipe carri backpack everywher that doesnt seem normal becam routin in addit cloth i tri rememb carri food i know i eat case i cant eat avail with queen lorlatinib current target therapi drug digest system issu much less time finger cross lorlatinib brought new challeng ive refer earlier one neuropathi common peopl chemotherapi drug peopl diabet as much i love go barefoot i cannot even hous anyon inkl neuropathi feet start wear shoe slipper all time i learn hard way if hand neuropathi tri acupunctur help tremend i tri ointment cannabinoid oil i havent found someth yet i say give relief neuropathi wear glove work even drive keep feet well pad work best and i dont stand still long period time lot peel veggi thing sure bother im fortun i dont tri work luckili im good sleeper doesnt bother much night oh yes ignor feel tick crawl ankl or mayb probabl neuropathi best check i spend lot time look ankl weight interest problem past year four month after fire fall i decid buy i absolut need cloth then i becam sick i began lose weight by time i start crizotinib march id lost lbs im wasnt ever terribl overweight between cancer take toll radiat number esophagus i month eat much eat most liquid form food etc and far cloth went thank radiat i couldnt stand anyth near neck wear bra so daughter bought size small stretchi pant vneck loos top that prefer wardrob ever sinc i eventu gain weight back crizotinib weight gain common drug i idea i store lorlatinib i began juli everyon i know target therapi drug still clinic trial problem degre i start gain pound week yes one pound per week eeek and simpli i feel better eat i wasnt abl exercis enough but thank stretchi cloth i move medium keep mind fire resolut bought i need i begin feel uncomfort extra weight by januari i gain sinc begin lorlatinib juli januari much pregnanc weight gain from march januari that lb weight gain both pregnanc combin without even tri lose gain back plus final januari trial nurs mention someon success paleo diet i tri i wrote earlier paleo work i immedi lost pound havent gain as long i feel well i as ive learn weight loss cancer treatment and weight gain side effect common i work around eat well wear comfi cloth finallywhil tri understand normal i think mayb greatest lesson greatest bless ive gain journey okay let even ask other thing i couldnt anyth someon els littl i ill that i began truli understand gratitud express grate your grate peopl care want thing make life easier brighter struggl someth life i still want everyth i dont feel bad ask help let someon els i dont energi strength i feel love grate and i like look thing i brighten day late week i go danafarb scan blood work brain mri ekg oncolog appoint dan drive wait patient everi step day i post updat hope weekend the prayersposit energi thought follow cancer journey give strength basebal softbal start children fun time grandpar find joy everyday everi day dan famili littl dachshund dotti matilda nigerian dwarf goat',\n",
       "  'NN'),\n",
       " ('repli post jrwilson thank i final made back read close help my doc basic let pick med i want tri first i go back forth potenti side effect worri whether newer med safe etc humira cimzia remicad option mention also take azathioprin six month im someon hate take medic big deal',\n",
       "  'NN'),\n",
       " ('ani idea ocrelizumab avail europ ppms it isnt fair fda approv drug still wait lose brain',\n",
       "  'NN'),\n",
       " ('hi i mastectomi gilenya my surgeon hold gilenya day happi neutrophil count i reduct white cell kept antibiot drain bit longer usual for anyon interest dose reduct option evid i heard ms research blog the japanes use gilenya found women low bmi unfortun problem often got leukopaenia could manag prolong dose interv often altern day when i suggest neuro contact drug compani basic said recommend paper other found effect strategi it make sens first principl long half life drug also time frame ecgmonitor hold recomm week i use hold day strategi get quicker lift wcc most success whi go troubl i wouldnt know i except relaps current isnt altern i happi chang soon time i work transit without rebound judi',\n",
       "  'NN'),\n",
       " ('hi candycan what mean make ms wors more frequent relaps gilenya more new lesion gilenya ifeelingi like isymptomsi wors sinc start feel like symptom wors without chang frequenc sever relaps number brain lesion someth els did iyouri neuro say gilenya make ms wors base what give impress gilenya icausedi someon els exacerb',\n",
       "  'NN'),\n",
       " ('thank updat ipoop ive wonder uc thank alway us knowledg calm rational i simmer linger inflamm ive load dose entyvio week sinc my next dose next week im realli anxious see push total remiss im form bms day some day i bit mild cramp dull pain lower left mucus blood and i still low energi tired but appetit good im gain weight and i coffe moder overal good oh and im prednison use canada night uceri foam morn post edit flowersg pm gmt',\n",
       "  'NN'),\n",
       " ('im year old woman diagnos stage squamous cell lung cancer month ago it shock im one famili histori get i start smoke i switch ecig year ago they contain nicotin i start lose hair year ago everi time i brush hair i end littl gob brush i ask doctor time i told could caus number thing cancer never mention my cancer doctor said i candid keytruda i treatment far i go everi week receiv keytruda via iv i go nd treatment wednesday is anyon get treatment i numb sinc diagnosi im strong believ lord the day sign birth certif also sign death certif im numb im also peac whatev plan my dad live doesnt get discuss i friend ex sisterinlaw ear bend she also one insist help everi way and everyth els i truli bless',\n",
       "  'NN'),\n",
       " ('hi blueberri great input janin my mother similar situat age stage iv met diagnos feb start chemo switch crizotinib test alk posit she reason well last scan show stabl situat be sure get mother test mutat overal i read peopl done quit well vari durat span sever year as janin point mani option avail mother oncologist help navig toward feasibl option wish best thank dj',\n",
       "  'NN'),\n",
       " ('i usual would mild flare year worst year ever i sick i origin put remicad i lot side effect eventu built antibodi then i start humira i pen the shot dont hurt i stomach i take mgs everi two week ive humira month i say im ucb symptom free which ive never abl say thank humira save colon give life back',\n",
       "  'NN'),\n",
       " ('hi sameen im sorri mother isnt better deep vein thrombosi pericardi effus common symptom lung cancer neither typic side effect tagrisso your mother oncologist would need explain hesh keep mother drug probabl think wors drug drug isnt caus mani side effect normal targisso go work know first week if side effect manag there treatment option that reason enough give drug coupl week show i hope show improv anti cancer treatment comfort care all best janin',\n",
       "  'NN'),\n",
       " ('a year updat analysi demonstr differ overal surviv os among patient local advanc nonsmal cell lung cancer nsclc receiv prophylact cranial irradi pci compar observ alon limit statist power prevent definit conclus overal surviv benefit accord result phase trial present iaslc th world confer lung cancer toronto canada previous result trial show pci prolong diseasefre surviv dfs reduc number brain metastas compar observ the purpos analysi determin decad follow conclus trial use pci prolong os the trial random assign patient stage iii nsclc progress surgeri andor radiat therapi without concurr chemotherapi patient treat pci receiv gy fraction the primari endpoint os secondari endpoint includ dfs neurocognit function qualiti life relat articl impress cns respons with osimertinib compar with standard egfrtki patient with cns metastas baselin pdpdl inhibitor may increas risk hyperprogress diseas nsclc s plus carboplatin may be effect nsclc patient with interstiti lung diseas there differ os pci observ arm median followup year entir cohort year live patient hazard ratio hr ci p the author note current data power detect hypothes differ hr side signific level suggest definit conclus overal surviv cannot drawn data for patient undergo surgeri howev pci result signific prolong surviv compar observ hr ci p dfs remain improv pci compar observ hr ci p includ analysi nonsurg patient p patient observ arm time like develop brain metastas compar individu pci arm p although inform neurocognit function across cohort previous publish suggest pci signific alter overal function year compar observ trend larger declin the pci arm howev demonstr signific greater declin hopkin verbal learn test immedi recal p delay recal p compar observ there insuffici data evalu neurocognit function year updat analysi the author conclud data indic pci continu signific improv dfs reduc brain metastas note studi inadequ power detect os read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'VBP'),\n",
       " ('sorri didnt work i would done place hope steroid kick soon f uc symptom start januari diagnosi juli colonoscopi nd colonoscopi august confirm left side uc intoler mesalamin azathioprin remicad start feb discontinu bc antibodi sever joint pain predison septnov decjan march may juli',\n",
       "  'JJ'),\n",
       " ('stellara imuran painkil requir', 'NN'),\n",
       " ('i diagnos crohn month ago remicad sinc april my insur recent switch inflectra cuz yay i first inflectra infus past friday felt sinc today i nauseat lighthead i hold wall support cuz i feel like im go fall it intens rn husband offer take er i dont know reaction inflectra crohn symptom i havent other ive felt general weak fatigu sinc infus usual im tire rest day mayb hour never long i feel kind like i i adjust imuran i start novemb ani idea',\n",
       "  'NN'),\n",
       " ('six year remicad infus replac prior intak prednison must say quit effect howev year got shingl eye subsequ postherpet neuralgia there still itch almost five year later then august got cellul right arm pain infect requir seven day stay hospit antibiot follow week long iv administr home onc i better i stop remicad long i enjoy remiss ill never return my gi doc suggest entyvio i like wouldnt even heck aint broke dont fix i dont wish tamper immun system bring disast',\n",
       "  'VBD'),\n",
       " ('i never respond antitnf drug i tri simponi without respons probabl wait month move remicad also dud respons rate remicad that highest biolog use treat uc as get sleep id think mg prednison would need sleep aid sinc your abl get sleep get urgenc id say uc treat hope get test result figur way go until uc wellmanag i dont see get sleep unfortun pill stop urgenc reduct inflamm in order reduc need find treatment work one your take dont seem trick moment have tri rectal med how eat earlier mesalamin higher dose pred tri get slower taper necessari stool test perhap bug need treatment comoder ulcer coliti diagnos pancol laryngopharyng reflux migrain battl extrem exhaust current med step one jpouch surgeri complet step two complet step complet',\n",
       "  'JJ'),\n",
       " ('now mavenclad licens defi worth look discuss ms team there risk secondari autoimmun unlik lemtrada lemtrada remain one riskiest option term serious side effect best long term result prevent brain atrophi tysabri riski jcv posit there potenti rebound effect come both lemtrada mavenclad perman chang immun system hope better good luck make choic',\n",
       "  'JJ'),\n",
       " ('hello friend i seek advic behalf mother she gilotrif month this first line treatment stage iv nsclc adenocarcinoma egfr exon neversmok her respons initi posit recent medic seem less effect diseas shown progress given advanc age januari opt liquid biopsi test tm genet marker use genestrat test the test unfortun came back negat i realiz tissu biopsi conclus determin mutat depend site sampl falseneg still possibl use method with greater chanc develop drug resist due tm mutat possibl posit enough circul tumor detect current sampl method find tm mutat easter egg hunt leav candid could potenti benefit my question even though result tm mutat may negat new medic tagrisso still work germlin egfr genet marker it would go far label treat tagrisso despit inclus result tm what possibl drawback prescrib egfr chanc tm what step would need prescrib tagrisso secondlin treatment offlabel use treat egfr patient given condit tradit chemotherapi would overwhelm sincer chi this topic modifi year month ago chidog this topic modifi year month ago chidog',\n",
       "  'NN'),\n",
       " ('purpos to report clinic outcom intravitr dexamethason implant patient retin pigmentosa cystoid macular edema method multicent retrospect case seri eye retin pigmentosa cystoid macular edema underw intravitr dexamethason implant primari outcom measur bestcorrect visual acuiti logmar central macular thick statist analys use twotail comparison wilcoxon signedrank test result there total eye patient mean age year rang mean followup plus sourc retina',\n",
       "  'NN'),\n",
       " ('hey everyon i crohn small illieum i believ that what call lol i alreadi humira remicad i crohn sinc i im remicad stop work doctor switch stelara i get infus first time yesterday remaind time im i take shot first shot week sinc i infus yesterday i wonder long take stelara kick anyon experi side effect reach remiss anyth tell help thank',\n",
       "  'NN'),\n",
       " ('i got luckiest guy aliv i still aliv it start i broke rib that lucki break led xray spot lung discov if i gotten test i symptom might well late it alreadi stage iii back dark age option chemo radiat surgeri i fortun combin chemoupp left lobectomychemo enough leav ned almost five year when i rediagnos cancer alreadi stage iv thousand spot everywher lung target genet treatment avail i test negat two mutat treatabl time my surgeon told get affair order oncologist admit wasnt best person treat wasnt lung cancer specialist what i couldnt even get clinic return phone call i went anoth oncologist anoth system for second time five year i plan funer think i month live while i start chemo i retest genet mutat part research protocol this time i test posit egfr mutat what odd fals negat need get retest reason i finish chemo continu avastin kidney protest spill protein skyrocket blood pressur sometim avastin continu affect cancer cell long bodi in case meant i avastin alon seven month treatment eleven month after i tarceva month sinc cancer spread back hip i radiat hip pain relief i grate effect sinc time i even use wheelchair get around after i back gym everi day my next unbeliev good luck oncologist told cancer progress noth offer besid spot radiat chemo i better inform next day i got sign clinic trial azd tagrisso i first appoint three day trial close new patient i wasnt go let fact trial thousand mile away san diego i live portland get way i tagrisso month without progress i grate everi day my plan keep hang around next treatment i need avail until cure i plan treat lung cancer chronic diseas rather death sentenc this cancer also serious impact qualiti life it better i gone close guard fierc independ person one learn cant alon i share friend famili given i could imagin return that make easier keep open i becom love my prioriti clear i know import peopleth life as result i start share stori first email famili friend blog wwwdannwonsercom i taken one step write book share stori learn find hope joy mean life love come much sharper relief past twelv year here link httpsamzntohgirt if known i first diagnos would know share i complet stranger even miracl fact i still aliv we right track new treatment friend let best continu outrun cancer dann wonser twelveyear stage iv lung cancer survivor still activ treatment he public speaker member nation local committe lung cancer lobbi state feder congress usa lung cancer issu you read dann journey websit he live portland oregon',\n",
       "  'NN'),\n",
       " ('im janet freemandaili cofound the rosder im write post respons comment weve seen recent privat facebook group ros posit ros cancer mani member ros cancer take target therapi crizotinib xalkori tyrosin kinas inhibitor tki it approv us fda alk nonsmal cell lung cancer nsclc ros nsclc mani alk ros nsclc patient longterm stabil evid diseas ned crizotinib toler well some patient suggest might take vacat crizotinib peopl chemo they think could help avoid develop resist crizotinib could allow stay drug longer start take drug later cancer return their oncologist might even agre idea but pleas if crizotinib xalkori work toler consult ros expert stop treatment if doctor tell stop take crizotinib medic reason like sever side effect toxic temporarili surgeri radiat follow advic but dont stop take crizotinib want drug vacat ros cancer rare diseas oncologist seen ros patient usual havent follow fastmov research diseas dr ross camidg dr robert doebel among hand doctor treat dozen ros alk patient crizotinib global consid expert ros nsclc both told think bad idea patient stop take xalkori theyr ned stabl drug below reason gave target therapi chemo tkis inhibit cancer kill for metastat cancer patient cancer cell like remain blood lymphat system bodi dont mean detect themthat say evid diseas instead cancer free if stop treatment stop inhibit cancer cell cancer remain resum growingsometim fast those cell continu mutat there guarante crizotinib effect cancer restart drug vacat tki flare well document egfr alk patient tkis like xalkori what tki flare some patient tkis stop take drug see cancer grow quick week two when restart drug doesnt alway work we dont much evid may happen ned patient stop take tki except one studi in studi egfr nsclc patient evid diseas tarceva tki like xalkori stop take cancer drug all saw cancer return within year while chronic myeloid leukemia cml patient tki gleevec abl stop take tki blood cancer aggress dead lung cancer each patient right make mind treatment in case i evid diseas crizotinib year when i ask stop crizotinib dr camidg told want stop take cancer drug im go expert opinion share click share twitter open new window click share facebook open new window click share reddit open new window click share linkedin open new window click email friend open new window click share googl open new window like like load publish gray connect i diagnos nonsmal cell lung cancer may the cancer becam metastat octob no i never smoke anyth except salmon ive evid diseas sinc januari thank precis medicin clinic trial patient anyon get lung cancer use engin degre mit sbme caltech aeronaut ms engr i enjoy year career aerospac system engin technic translat sort i research scientif engin subject help other understand new gizmo could benefit in time i left i want use skill help other lung cancer increas visibl knowledg lung cancer among dont i also studi brain research enjoy travel write scienc fiction geek sort scienc stuff',\n",
       "  'NN'),\n",
       " ('i cannot express much medic help when i first prescrib i terrifi review super pain i sever psoriasi cover bodi i given citratefre inject pen when i say i felt noth i mean noth i thought i hadnt inject yet but prick my psoriasi onli week treatment gone onli white scar wreck bodi remain this medic incred liter chang life my skin doesnt flake ooz doesnt get super red irrit doesnt sting everi movement like start medicin the best part go websit sign humira card copay onli dollar five fricken dollar when the medic origin cost this compani amaz i near loss word effect painless citratefre formula report star post month ago rate humira adalimumab crohn diseas mainten report i took humira remicad lower immun system i develop tb i start humira one shot hurt begin take feel like stomach crucifi top needl feel like spin went back remicad feel better ask doctor remicad humira less pain work better humira',\n",
       "  'NN'),\n",
       " ('i stage nsclc adenocarcinoma bone metastasi i start carboplatin alimta avastin chemo treatment wonder triplet effect treat bone metastasi well i also receiv zoledron acid everi three week treat bone met there limit public relat effect standard chemo bone metastasi ive found target drug erlotinib gifatinib effect treat bone metastasi i afraid bone met progress would like find i treatment bone met parallel chemo treatment can i probabl add gefitinib triplet ive found one paper discuss combo they observ improv peopl involv trial thank irina',\n",
       "  'NN'),\n",
       " ('kidney stone referr get blast broken i humira develop antibodi humira come im stellara work differ way humira alongsid imuran ensur i dont develop antibodi i honest tri follow reason diet i dont alway succeed i tri hope im long',\n",
       "  'RB'),\n",
       " ('hello i research internet month feel mayb time post dad stori my dad i dont recal ever take advil nevermind go see doctor he start act strang begin august past summer forget thing distant strang moodjust i bad feel told mom take emerg room got wors second week long stori short found night tumor lung brain a biopsi later stage iv metatast melanoma braf mutat our world gone complet upsid my father rock famili one best men world when found august th tumor lung brain never found site melanoma began i found fact uncl grandfath dad side earli stage melanoma caught treat the first plan action craniotomi earli septemb remov larg tumor leav two smaller one he recov surgeri well set back pneumonia put icu day it discov blood clot leg blood thinner depict bleed ulcer put filter blood clot ceas blood thinner he steroid antiseizur medic antibioticsmor pill i ever seen dad even look they anoth mri hospit discov one month surgeri inumer tumor growth brain this octob th he start mekinist tafinlar combo start work well the mri decemb show diseas stabl tumor stabl smaller two grown littl shrunk disappear he gain weight strength back hope the combo target therapi shrunk tumor lung consider we realli look forward januari mri howev i could tell go good base eye chang start go backward cognitivement status behavior we got news last week mri show mani new tumor grow everi area final result progress diseas the medic work brain he stop take start whole brain radiat today day after might chanc take combo ipilimumab nivolumab oncologist say danger chanc take life cancer at point mani tumor brain gro agress i sure much time left doctor seem amaz still us heard term week dont radiat i know one tell much time reason i feel import tri find except i treasur everi day if anyon insight advic wordsi think i need type tri focus thank listen',\n",
       "  'JJ'),\n",
       " ('i day hell saturday ive realli poor chest infect three week due fingolimod immun system weak it wouldnt seem shift even antibiot then last monday i develop numb lower back accompani sever nerv pain then discov i couldnt go number two five day by friday i feel realli poor went doctor gp thought could cauda equina syndrom thing id never even heard basic nerv lower lumber compress lead symptom bladder bowel retent pain eventu becom complet incontin obvious scari fuck my gp rang hospit want direct transfer said wouldnt take symptom didnt exact meet criteria then gp rang ms nurs the royal free she said shed speak one neurologist call back tell whether i need go ae when i final got call back gp told i go ae pm friday night i like fuck sinc i knew exact expect so anyway i took ae saturday morn yesterday begun hellish day wait till seen one doctor wait seen orthopaed doctor wait orthopaed doctor get advic registrar at ish told go blue light ambul addenbrook hospit appar dont cauda equina syndrom treat immedi oper neurosurgeon affect cannot revers when got addenbrook i expect go straight mri scanner wait assess neurosurgeon third neurolog examin day then i wait till pm go actual mri scanner i wasnt allow anyth eat whole time case need oper spinal cord it absolut fuck terrifi i mri pm id enough need get back cambridg last train pm so i decid go pm call say wasnt cauda equina syndrom thing by time i got i fourteen hour feck hospit still closer know heck caus numb thank symptom get better i went gone work yesterday sunday happen everyon utter surpris i need someth normal anyth wasnt doctor nurs blood test mris i want feel like i could blend disappear crazi appar cauda equina thing happen peopl ms anytim signific frighten possibl in fact anoth ladi ms investig thing thing i cant anymor im work pretend ok im this ill seem tarnish everyth life im constant hit invis forc field fatigu my hand continu tremor despit medic i cant think straight task ive eleven year i cant walk without stick even though im i dont rememb day i havent neuropath pain i feel like im alon island one reach im tire drug mris doctor whove read ms text book my life feel like slowli eb away i cant catch flow like water hand i cant see end i want free',\n",
       "  'JJ'),\n",
       " ('could pfizer xeljanz becom challeng abbvi humira tv ad crown the pfizer antiinflammatori drug boast three indic spent million tv ad decemb behind perenni top spender humira million whi it thank xeljanz new indic ulcer coliti it got nod may ad rheumatoid arthriti psoriat arthriti nod last month pfizer unleash torrent ad spend back new indic it spent million introductori ulcer coliti treatment commerci accord data realtim tv ad tracker ispottv humira competitor antitnf drug unlik xeljanz first drug class jak inhibitor clear treat ulcer coliti one reason humira often lead pharma tv ad spend it spread serious cash across drug three indic arthriti psoriasi crohn ulcer coliti industri research veeva unifi clinic oper survey share thought quick survey the first qualifi respond receiv amazon gift card appreci time qualifi survey respond enter draw win amazon gift card complet survey meanwhil pfizer prevnar continu season ad blitz no pneumococc pneumonia vaccin follow eli lilli diabet med trulic no johnson johnson xarelto no drop sight third month row pfizer lyrica drug face patent expir spent million tv ad decemb overal tv ad spend pharma top decemb million fuel part charttopp humira xeljanz million uptick among top novemb finish million octob million humira movement stay what abbvi antiinflammatori drug total estim spend million million novemb number spot seven three arthriti three ulcer colitiscrohn one psoriasi biggestticket ad bodi proof est million humira tv commerci bodi proof xeljanz xr movement move no what pfizer oral rheumatoid arthriti ulcer coliti med total estim spend million million novemb number spot five biggestticket ad a differ direct est million xeljanz tv commerci a differ direct prevnar movement move no what pfizer pneumococc pneumonia vaccin total estim spend million million novemb number spot three biggestticket ad dont miss out life est million prevnar tv commerci dont miss out life trulic movement move no what eli lilli glp diabet drug total estim spend million million novemb number spot three biggestticket ad i can do more est million trulic tv commerci i can do more xarelto movement not list last month what johnson johnson nextgen anticoagul total estim spend million number spot two biggestticket ad select est million xarelto tv commerci select otezla movement move no what celgen oral treatment plaqu psoriasi total estim spend million million novemb number spot two biggestticket ad littl thing est million commerci avail request advertis eliqui movement down no what pfizer bristolmy squibb nextgener anticoagul total estim spend million million novemb number spot three biggestticket ad what next est million eliqui tv commerci what next jardianc movement not list last month what eli lilli boehring ingelheim sglt diabet treatment total estim spend million number spot one biggestticket ad jardianc ask heart jardianc tv commerci jardianc ask heart ozemp movement not list last month what novo nordisk glp diabet med total estim spend million number spot three biggestticket ad oh est million ozemp tv commerci oh latuda movement not list last month what sunovion pharmaceut antipsychot total estim spend million number spot one biggestticket ad lauren stori',\n",
       "  'NN'),\n",
       " ('joan sorri hear diagnosi subsequ ill happi hear success stem cell would love know exact kind improv experienc i think fda realli target clinic offer sameday stem cell infus use adipos deriv materi like noth scam these clinic dont separ expand mesenchym stem cell harvest dose administ like effect if realli anxious give ocrelizumab tri i would suggest talk doctor rituxamab current avail use mechan action newer drug it also appear lot safer use decad pretti good safeti record wish best gratifi know blog help even small way',\n",
       "  'NN'),\n",
       " ('hi diggiti im trawl site look infoexperi differ dmds have copaxon almost year neuro feel longer work well would like switch tecfidera gilenya lemtrada although neuro favour gilenya i concern pregnanc risk i current singl i would hate jepodis small chanc i may ever children did go lemtrada end if find i lean toward tecfidera moment i cant find much info lemtrada mani thank rachel',\n",
       "  'NN'),\n",
       " ('quick question i wonder anyon experi share immuno target therapi sclc a trial shown efficaci keytruda opdivo sclc certain circumst previous hadnt sign work sclc typic isnt even test genet sequenc protein express etc so process get test done pdl tmb genet sequenc has anyon taken keytruda opdivo anyth els sclc ani result share experi anyth share would help',\n",
       "  'NN'),\n",
       " ('well know remicad work well id consid anoth similar biolog within class remicad cimzia humira tnfalphablock biolog develop antibodi one tnfalphablock doesnt mean develop antibodi cimziahumira molecular structur differ enough immun system must start groundup antibodi develop process you might never develop antibodi cimziahumira could increas odd stelara complet differ class biolog complet differ mechan action itd gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa there two certainti life pay tax prednison side effect',\n",
       "  'NN'),\n",
       " ('i agre kevinaki noth seem right how ophthalmologist plan year ahead whatev eye condit may that time span far long know eye respond treatment in past standard regim eylea inject instanc load dose inject first year treatment today regim longer strict follow perhap due costcut main found alway necessari therefor benefici everybodi i know avastin lucenti differ rule principl treatment inde get anoth opinion give i sorri suffer much end save eyesight must sure worth take care let us know we share worri concern rememb mani us gone though traumat time sympathis you alon',\n",
       "  'NN'),\n",
       " ('hi sorri hear experi lucenti i crvo year back vision got wors within week four week first eyelia i improv after eyelia doctor switch ozurdex even better result i nd ozurdex four week back to give idea improv i drive licens eye test yesterday guess i read letter last line well i wish best hope eyelia work',\n",
       "  'NN'),\n",
       " ('new first time post wife diagnos nsclc stage alk mutat now never smoker activ exercis full treatment carboalimta plus year alimta mainten crizotinib year forc ceritinib due brain met balnc issu also time whole brain radiat mistak brain met size reduc stabl was radiat ceritinib bone met shoulder palliat rad bone met hip spine doc read bone scan believ size increas onc believ last scan wife confus short term memori loss notic along fast lost balanc use walker quick long last fatigu onc doc say noth lose tri alectinib point may help bone spine met brain met may caus balanc leg control alectinib start brain mri schedul check size met check alectinib work dont want second guess mayb wbr use ceritinib fear factor i believ last longer expect met alreadi spine rib adren lymph behind retina initi diagnos she respond well everi treatment wear i know could affect wbr fear met spine caus issu also thought thank note till qualiti life pretti good thing consid',\n",
       "  'JJ'),\n",
       " ('im new site i nsclc adenocarcinoma im well i diagnos juli cm mass right lung lymph node pleura i took crizotinib chemo it shrunk tumor stage met exon i pneumonectomi right lung im look long term survivor met exon i know i lucki i thank god great doctor ucsf i wish love hope heal',\n",
       "  'NN'),\n",
       " ('yes studi show wellbutrin effect control induc remiss uc patient sad i read young one get diseas perhap consid entyvio gut specif half hour infus conveni prepar wait week see work wish strength resili',\n",
       "  'NN'),\n",
       " ('im sure awar humira elev blood sugar slight put prednison look i crohn back i lost coupl feet intestin thank bag boy month i quit happi lose bag as soon i certain i go problem i retir made even happier no middl manag problem deal folk want sell us medicar insur but i tend use one use fake local number get us answer block phone number show unannounc home stress reduc my stress pretti low keep tri im sure awar food caus problem gassi plant like cabbag broccoli limit caus problem i found ad miralax coffe morn slight smooth realli help common problem are sure calcium supplement i take mg vit daili calcium citrat potassium citrat this recommend dr a side benefit i kidney stone attack last year',\n",
       "  'VBP'),\n",
       " ('my mother diagnos stage nsclc two year back progress recent lmd tm she treat tagrix mg lmd doe generic work tagrisso effect at stage know lmd control test need done',\n",
       "  'CD'),\n",
       " ('two step forward one huge step back sorri length time updat lot happen my husband first treatment privat avastin inject notic improv week afterward this enough get feet start walk last week see famili his depress start lift his bg level right insulin hes half stone healthi bmi we could afford one round treatment privat transfer nhs we first appoint yesterday consult clinic seen dr consult it absolut nightmar start finish despit warn husband anxieti issu fragil mental state dr complet insensit quit aggress approach i realis cannot sugar coat thing tact way discuss prognosi even though husband seen improv first inject dr seem quit dismiss would see much improv my understand guarante even consult cannot predict repond effect treatment this came crush blow husband retreat bed want talk the diagnosi nonprolif retinopathi left eye sever prolif retinopathi right sever maculopathi eye right impair eye worst the treatment plan eylea inject laser right begin i intend speak pal monday see anyway see sympathet clinician next time i honest dont think husband could go struggl get i wish could afford go whole thing privat has anyon els similar experi click expand bibabe what shame setback the nhs bit lotteri thing could use armouri on upsid gp ask treatment transfer nomin consult want lead husband care a step gp make referr specif see perereson omon team i know person experi i seen someon diabet eyerel hadnt incred impress my gp ask i would like see someon els i know i would like see she made specif enquiri should go rout potenti impact wait time person want see first appoint avail second rerceiv appoint call check see person one team again impact wait time either way journey challeng pleas dont give',\n",
       "  'JJ'),\n",
       " ('thank scohn my dad exon delet i ask stanford oncologist diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('hi skrri nnag lol well notic im sun notic weird floater i hope due gilenya i see small tini sign black fli dreami way danc air stop one area focus real thing it fli far reach place but tini usual small thing like input small dusti spot wall thing like besid im headach im tri co op i take gilenya ive see invis color flater sinc childhood definit shape',\n",
       "  'NN'),\n",
       " ('oxford uk research kennedi institut nuffield depart orthopaed rheumatolog musculoskelet scienc univers oxford work clinician nhs lothian found inject antitnf drug adalimumab dupuytren diseas nodul result reduct cell characterist respons progress dupuytren diseas base laboratori data tumour necrosi factor tnf drive develop myofibroblast cell type caus dupuytren diseas research team explor effect antitnf drug inject direct dupuytren nodul tissu the result far promis our data shown concentr formul adalimumab inject direct diseas tissu may effect target cell respons dupuytren diseas said jagdeep nanchah md phd univers oxford professor hand plastic reconstruct surgeri led studi this bring new hope peopl suffer disabl condit current wait situat deterior watch hand lose function bad enough surgeri and there lengthi recoveri ahead less ideal situat find this randomis trial phase recruit patient dupuytren diseas schedul surgeri edinburgh remov diseas tissu hand two week prior surgeri receiv singl inject vari dose antitnf drug placebo the tissu remov surgeri usual discard analys laboratori the team found adalimumab dose mg formul ml reduc express fibrot marker smooth muscl actin sma type i procollagen week post inject suggest drug could use stop growth diseas caus myofibroblast cell they also found drug safe well toler the find publish line journal ebiomedicin publish the lancet dupuytren diseas common condit hand affect uk popul caus finger curl irrevers palm there current nice approv treatment earli diseas typic peopl told return gp finger becom bent hand function impair the antitnf drug adalimumab humira current licens eu treatment number condit includ rheumatoid arthriti crohn diseas ulcer coliti overal excel safeti profil we delight receiv fund wellcom trust depart health test whether adalimumab work patient earli stage dupuytren diseas said professor sir marc feldmann coauthor former director kennedi institut in conjunct professor sir ravind maini sir marc identifi tnf therapeut target patient rheumatoid arthriti the kennedi institut long histori success translat laboratori find clinic said professor fiona powri director institut this type work requir close collabor laboratori scientist clinic trialist clinician scientist mani year the research continu investig use drug treat dupuytren diseas phase b trial call ridd trial current run oxford edinburgh contact jagdeep nanchah',\n",
       "  'IN'),\n",
       " ('i love everi singl word especi humor humor one thing i appreci right first ocrevus yesterdaynoth like tire rain debacl get sat huge surg nurs vanderbilt ms clinic pros calm also got hive back side lower abdomen itchi yeah i wasnt beauti calm husband help calm let nurs know i kept small lid crazi bc other infus well ask sweet nurs repetit i go die probabl time pros amaz paus the ocrevus benedryl magic hive goneback o home sleep thru observ no one els room issu i read post help i would love hear second dose went youd will share thank',\n",
       "  'JJ'),\n",
       " ('the mechan differ target differ keytruda opdivo target pd checkpoint t cell it sensibl use togeth yervoy target anoth t cell checkpoint ctla the drug target differ molecul combin in lung cancer addit yervoy opdivo increas respons rate two fold ido differ target protein catabol tryptophan product reaction creat immunosuppress environ tumor rational inhibit reaction you mention chemo drug interest thing eg cyclohosphamid high concentr work inhibitor cell divis low concentr work treg immunosuppress cell the mechan complet differ depend cyclohosphamid concentr it mayb case ido inhibitor tri highest toler concentr get desir result i dont know detail concoct',\n",
       "  'NN'),\n",
       " ('the drug i current remicad i use take mp remicad made feel horribl i also tri imuran past i wonder take past perman made sensit sun i rememb i got rash past one doe anyon think entyvio would differ sinc target gut i bought glove drive i wonder im allerg sunscreen ipoop forum moder join aug post post yesterday am gmt how long ago discontinu mp moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa showerthought most peopl surpris see blood toilet paper uc patient surpris isnt',\n",
       "  'NN'),\n",
       " ('vanessa i relaps last i told i need chang medic betaferon work well enough i chang tysabri gilenya i relaps free sinc i gilenya sinc septemb great inject year howev lower immun system i care i get infect i ongo symptom relaps like dmts help stop progress good luck decis ann mari x',\n",
       "  'NN'),\n",
       " ('haha i guess noon use ocrevus ill plan drive hope i feel ok afterward x',\n",
       "  'NN'),\n",
       " ('onc nonsmallcel lung cancer nsclc spread far wide treat kind balanc act a cure isnt like slow so aim reliev symptom improv qualiti life side effect possibl newer therapi help and lot option today year ago the number tumor overal health come play decid your doctor start test learn nsclc help guid best treatment when target therapi work best cancer come gene chang caus cell grow divid control but mani gene often hard know one blame with nsclc though doctor track culprit when one known chang get target therapi that mean take drug attack cancer cell specif way base gene differ your doctor test look alk gene chang if youll get drug help block alectinib alecensa brigatinib alunbrig crizotinib xalkori ceritinib zykadia lorlatinib lorbrena the common side effect minor chang vision stomach upset throw diarrhea for peopl problem fall milder side efgr gene chang you get differ set drug one afatinib gilotrif dacomitinib vizimpro erlotinib tarceva gefitinib iressa osimertinib tagrisso they slow fast tumor grow spread side effect includ skin rash diarrhea braf gene chang two main drug use one dabrafenib tafinlar trametinib mekinist they work differ way effect they may caus itch hair loss issu other gene chang there grow list gene defect caus nsclc target drug that one reason look clinic trial research test new medicin when immunotherapi make most sens when dont specif gene chang doctor check tumor cell level protein call pdl if high immunotherapi often best place start it use immun system bodi defens germ attack cancer cell youll take pembrolizumab keytruda drug help bodi see cancer cell someth fight like cold virus some typic side effect includ tired cough stomach upset rash joint pain chemotherapi chemo standard treatment dont gene chang high pdl it use drug kill cancer cell it side effect includ hair loss mouth sore stomach upset there sever chemo drug use nsclc for best result doctor give two time if bodi isnt strong enough two even one help you usual get four six cycl chemo take week onc your finish treatment might keep take what call mainten drug this often anoth chemo medicin some research show slow cancer help live longer your doctor may also add drug along chemo med for nonsquam nsclc might also take pembrolizumab immunotherapi drug or might get bevacizumab avastin anoth target drug if may keep take one mainten drug for squamous nsclc doctor might suggest target therapi drug necitumumab portrazza other treatment the brain bone area around lung common place cancer spread youll get specif care base end problem caus in bone may get radiat curb pain when caus fluid build around lung might need thin tube chest drain easili if one place like brain adren gland might surgeri remov tumor chang treatment sometim first therapi tri doesnt work well youd hope but still option if start immunotherapi doctor may suggest chemo if start one set chemo drug might tri anoth add target therapi it depend health far cancer spread want treatment this also want start approach call palliat care earli it aim keep comfort possibl help manag stress',\n",
       "  'JJ'),\n",
       " ('u might relaps u spms natalizumab could inhibit relaps one thing i thought also reduct inflamm natalizumablemtradaocrelizumab good forbut someon post i dont know anymor ocrelizumabrituximab extrem effect prevent gad lesion doesnt matter arent make anyway',\n",
       "  'RB'),\n",
       " ('hi sch welcom new site im sorri hear uncl it unusu mix result treatment howev month sinc last scan diagnos would difficult say happen it could alreadi new met horizon alreadi grow larg enough pick scan first diagnos it typic follow someon treatment ct scan everi month give better idea what happen treatment except special situat pet arent realli go tell onc anyth ct cant ct much cheaper if uncl isnt suffer worsen symptom would reason continu keytruda howev overwhelm major peopl egfr mutat dont respond immunotherapi alon would continu combo alimta immunotherapi long side effect manag there mani promis treatment trial mutat exon world below link group specif connect share inform exon egfr often respond treatment a grace member scohn much tune what happen area wife mutat exon if hes avail knowledg respons send messag dashboard httpwwwexongrouporg i hope uncl well all best janin',\n",
       "  'JJ'),\n",
       " ('breakthrough ibd research present crohn coliti congress las vega nv it estim million american live inflammatori bowel diseas ibd includ crohn diseas ulcer coliti current cure diseas studi present crohn coliti congress partnership crohn coliti foundat american gastroenterolog associ las vega nv februari highlight advanc treatment patient ibd jak inhibitor continu expand reach ulcer coliti studi titl the gut select oral administ panjak inhibitor td demonstr favor safeti toler pharmacokinet signal clinic activ subject moderatelytosever activ ulcer coliti wj sandborn univers california san diego et al signific there need effect safe oral therapeut option moder sever ulcer coliti oral jak inhibitor potenti system immunosuppress panjak inhibitor td design broad inhibitor jak pathway potenti advantag ulcer coliti larg topic effect demonstr earli signal efficaci moderatetosever ulcer coliti biolog therapi target immun cell traffick intestin effect signific ibd patient alreadi benefit therapi vedolizumab sever studi present crohn coliti congress highlight biolog also show promis treatment ulcer coliti crohn diseas etrolizumab treatment modul soluabl madcam level serum patient crohn diseas j mcbride genentech inc south san francisco california et al longterm safeti efficaci antimucos addressin cell adhes molecul madcam antibodi shp ulcer coliti an openlabel extens studi turandot ii wj sandborn univers california san diego et al longterm safeti efficaci pharmacokinet antimucos addressin cell adhes molecul madcam monoclon antibodi shp crohn diseas the opera ii studi wj sandborn univers california san diego et al all abstract accept crohn coliti congress publish inflammatori bowel diseas offici journal crohn coliti foundat gastroenterolog offici journal american gastroenterolog associ feb attribut crohn coliti congress request coverag about crohn coliti congress the crohn coliti congress take place feb las vega combin strength nation lead ibd patient organ crohn coliti foundat premier gi profession associ american gastroenterolog associ aga togeth commit conven greatest mind ibd transform patient care the crohn coliti congress mustattend meet ibd profession learn httpcrohnscolitiscongressorg about aga institut the american gastroenterolog associ trust voic gi communiti found aga grown member around globe involv aspect scienc practic advanc gastroenterolog the aga institut administ practic research educ program organ wwwgastroorg like aga facebook follow us twitter amergastroassn check video youtub join aga linkedin crohn coliti foundat the crohn coliti foundat mission cure crohn diseas ulcer coliti improv qualiti life children adult affect diseas the foundat rank third among lead health nonprofit percentag expens devot research toward cure cent everi dollar foundat spend go missioncrit program the foundat consist meet standard organ monitor chariti includ better busi bureaus wise give allianc giveorg american institut philanthropi charitywatchorg',\n",
       "  'NNS'),\n",
       " ('i diagnos uc i everi medic asa mp remicad humira current entyvio i still symptom although better sinc i start entyvio year ago right i go time day urgenc half time my qualiti life better i still happi i colonoscopi last year found dysplasia colon mean i much higher risk develop colon cancer my doctor recommend surgeri i realli worri for surgeri life look like afterward what kind food drink i avoid i love cup coffe enjoy beerwin well toler surgeri i also profession musician trombonist concern length recoveri time anyon els experi deal someth like mani thank i hope move toward healthier life togeth cheer',\n",
       "  'VBP'),\n",
       " ('start stelara fail remicad humira entyvio cimzia short span year cross finger caus i think last option',\n",
       "  'NN'),\n",
       " ('crohn diseas also call ileiti enter affect part gut mouth way anus in major case howev lower part small intestin ileum affect symptom unpleas they includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain common felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain the level pain vari individu depend inflamm gut most common pain felt lowerright side abdomen ulcer gut ulcer raw area gut may bleed if bleed patient might notic blood stool mouth ulcer these common symptom diarrhea this rang mild sever sometim may mucus blood pus the patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit there may time appetit low weight loss this result loss appetit anemia a loss blood lead anemia rectal bleed anal fissur the skin anus becom crack lead pain bleed other possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas while ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum the crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need highcalori liquid formula especi growth affect most patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol some peopl feel like eat in sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement the aim control inflamm correct nutrit problem reliev symptom there cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previous treatment recur symptom some peopl long period even year without symptom this known remiss howev usual recurr as period remiss vari much hard know effect treatment it imposs predict long period remiss go best food crohn diseas flareup eat right food help peopl manag symptom crohn diseas find read medic crohn diseas antiinflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor general treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol antidiarrh fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ they reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect some studi suggest use biolog reduc chanc person need abdomin surgeri within year percent befor introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid there differ type biolog drug individu react differ a doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri the major crohn diseas patient may need surgeri point when medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov some crohn diseas patient may requir one oper live in case colectomi need whole colon remov the surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma a pouch collect fece doctor say patient stoma carri lead normal activ life if surgeon remov diseas section intestin connect intestin stoma need the patient doctor need consid surgeri care it appropri everyon the patient bear mind oper diseas recur most peopl crohn diseas live normal activ live hold job rais famili function success caus the exact caus crohn diseas unclear thought stem abnorm reaction immun system the theori immun system attack food good bacteria benefici substanc unwant substanc dure attack white blood cell build line gut buildup trigger inflamm the inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close relat condit if ident twin crohn diseas twin percent chanc a bacterium virus may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi a doctor ask person sign symptom a physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth the follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut a long thin flexibl telescop endoscop goe esophagus stomach ct scan barium enema xray reveal chang insid bowel complic if symptom sever frequent likelihood complic higher the follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut there may also persist iron defici food absorpt problem slight higher risk develop bowel cancer relat coverag crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read crohn diseas surgeri what know while surgeri cannot cure crohn diseas help reduc person symptom prevent lifethreaten complic in articl learn differ type crohn diseas surgeri prepar expect recoveri read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read what expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read what stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year for reason doctor usual classifi crohn differ stage learn read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd all refer avail refer tab refer this content requir javascript enabl baumgart m dogan b rishniw m weitzman g bosworth b yantiss r berg d cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni relat deplet clostridial crohn diseas involv ileum the ism journal retriev httpwwwnaturecomismejjournalvnabsismejahtml crohn diseas nd american societi colon rectal surgeon retriev httpswwwfascrsorgpatientsdiseaseconditioncrohnsdiseas crohn diseas caus april retriev httpwwwnhsukconditionscrohnsdiseasepagescausesaspx epidemiolog ibd march cdc retriev httpswwwcdcgovibdibdepidemiologyhtm leena halm paulina paavolasakki ulla turunen maarit lappalaccinen martti frkkil kimmo kontula june world journal gastroenterolog retriev httpswwwncbinlmnihgovpmcarticlespmc lichtenstein g r loftus e v isaac k l regueiro m d gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev httpgiorgguidelinemanagementofcrohnsdiseaseinadult what crohn diseas nd cleveland clinic retriev httpsmyclevelandclinicorghealtharticlescrohnsdiseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian what crohn diseas medic news today medilexicon intl dec web feb httpswwwmedicalnewstodaycomarticlesphp apa nordqvist c decemb what crohn diseas medic news today retriev httpswwwmedicalnewstodaycomarticlesphp pleas note if author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom a recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus this japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist can halt cellular age new drug combo show promis in first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer whi immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       "  'NN'),\n",
       " ('upal basu roy mph phd senior director research nonsmal cell lung cancer nsclc common type lung cancer compris diagnos case lung cancer treatment nsclc depend stage diseas in stage iii nsclc primari origin tumor larg cancer spread lymph node center chest lymph node side primari tumor this stage nsclc often refer local advanc lung cancer divid stage iiia iiib iiic base lymph node affect size primari tumor read lung cancer stage in us food drug administr approv immunotherapi drug durvalumab also known brand name imfinzi treatment local advanc stage iii nsclc follow definit chemoradi base result pacif trial unlik immunotherapi approv stage ivmetastat nsclc durvalumab first immunotherapi approv subset nsclc patient we sat patrick ford md mb bch associ professor oncolog john hopkin school medicin discuss result pacif trial mean survivor communiti dr ford expert immunotherapi lung cancer led sever global phase immunotherapi clinic trial we produc webinar convers watch how stage iii nsclc tradit treat what definit concurr chemoradi approxim onethird nsclc patient stage iii local advanc diseas diagnosi stage iii high heterogen treatment may involv surgeri chemotherapi chemoradi definit concurr chemoradi without surgeri the choic treatment patient joint made patient healthcar team includ medic oncologist provid cancer treatment drug surgic oncologist provid cancer treatment surgeri radiat oncologist provid cancer treatment radiat definit concurr chemoradi defin chemotherapyradi therapi combin treatment patient receiv radiat therapi day chemotherapi infus our understand radiat therapi signific advanc past decad now radiat therapi often administ intensitymodul radiat therapi imrtth intens radiat adapt match precis shape size tumor minim damag surround tissu heart lung what pacif trial how result pacif trial chang approach treat stage iii nsclc though stage iii patient respond chemoradi chanc cancer recur quit high the pacif trial design test whether addit immunotherapi drug durvalumab patient complet chemoradi decreas chanc recurr result pacif trial indic patient receiv durvalumab chemoradi higher progressionfre surviv pfs overal surviv os the addit durvalumab almost tripl pfs patient aliv month treatment base high promis result treatment durvalumab becom standard care stage iii patient receiv definit concurr chemoradi while test immunotherapi biomark pdl requir us ongo studi determin patient may deriv benefit other drug how durvalumab work how enhanc chemoradi tradit use alon treatment stage iii nsclc durvalumab human monoclon antibodi block program death ligand pdl protein tumor cell when patient receiv chemoradi treatment lead gradual kill lung cancer tumor antigen releas blood circul attract immun cell cancer howev cancer cell escap immun system produc high level pdl protein durvalumab block pdl unmask cancer cell provid addit attack tumor chemoradi imag courtesi dr ford immunotherapi chemoradi differ immunotherapi har patient immun system fight cancer wherea chemoradi direct kill cancer cell in stage iii nsclc chemoradi follow durvalumab deliv onetwo punch lung cancer what side effect patient expect start durvalumab side effect durvalumab compar pd pdl block antibodi howev unlik immunotherapi durvalumab administ patient complet chemoradi treatment there may residu side effect chemoradi the patient healthcar team discuss best manag residu side effect in general serious side effect durvalumab rare common side effect see clinic manag easili among may fatigu musculoskelet pain chang hormon level decreas appetit nausea accumul fluid caus swell lower leg hand for stage iii nsclc patient may candid chemoradi may use discuss durvalumab may treatment option start treatment we also invit check new free download patient educ booklet stage iii nsclc this educ activ made possibl grant astra zeneca relat read immunotherapi stage iii lung cancer improv cure rate radiat drug dispel myth surround clinic trial cancer dr basu roy lungev senior director research categori clinic trialsresearch immunotherapi nonsmal cell lung cancer nsclc',\n",
       "  'JJ'),\n",
       " ('the colon part bodi digest system the digest system remov process nutrient vitamin miner carbohydr fat protein water food help pass wast materi bodi the digest system made esophagus stomach small larg intestin the colon larg bowel first part larg intestin feet long togeth rectum anal canal make last part larg intestin inch long the anal canal end anus open larg intestin outsid bodi enlarg anatomi lower digest system show colon organ gastrointestin stromal tumor occur colon see pdq summari gastrointestin stromal tumor treatment inform see pdq summari unusu cancer childhood treatment inform colorect cancer children health histori affect risk develop colon cancer anyth increas chanc get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk doctor think may risk colorect cancer risk factor colorect cancer includ follow have famili histori colon rectal cancer firstdegre relat parent sibl child have person histori cancer colon rectum ovari have person histori highrisk adenoma colorect polyp centimet larger size cell look abnorm microscop have inherit chang certain gene increas risk famili adenomat polyposi fap lynch syndrom hereditari nonpolyposi colorect cancer have person histori chronic ulcer coliti crohn diseas year have three alcohol drink per day smoke cigarett be black be obes older age main risk factor cancer the chanc get cancer increas get older enlarg polyp colon some polyp stalk other inset show photo polyp stalk sign colon cancer includ blood stool chang bowel habit these sign symptom may caus colon cancer condit check doctor follow a chang bowel habit blood either bright red dark stool diarrhea constip feel bowel empti way stool narrow usual frequent gas pain bloat full cramp weight loss known reason feel tire vomit test examin colon rectum use detect find diagnos colon cancer the follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit past ill treatment also taken digit rectal exam an exam rectum the doctor nurs insert lubric glove finger rectum feel lump anyth els seem unusu fecal occult blood test fobt a test check stool solid wast blood seen microscop a small sampl stool place special card special contain return doctor laboratori test blood stool may sign polyp cancer condit there two type fobt guaiac fobt the sampl stool special card test chemic if blood stool special card chang color enlarg a guaiac fecal occult blood test fobt check occult hidden blood stool small sampl stool place special card return doctor laboratori test immunochem fobt a liquid ad stool sampl this mixtur inject machin contain antibodi detect blood stool if blood stool line appear window machin this test also call fecal immunochem test fit enlarg a fecal immunochem test fit check occult hidden blood stool a small sampl stool place special collect tube special card return doctor laboratori test barium enema a seri xray lower gastrointestin tract a liquid contain barium silverwhit metal compound put rectum the barium coat lower gastrointestin tract xray taken this procedur also call lower gi seri enlarg barium enema procedur the patient lie xray tabl barium liquid put rectum flow colon xray taken look abnorm area sigmoidoscopi a procedur look insid rectum sigmoid lower colon polyp small area bulg tissu abnorm area cancer a sigmoidoscop insert rectum sigmoid colon a sigmoidoscop thin tubelik instrument light len view it may also tool remov polyp tissu sampl check microscop sign cancer enlarg sigmoidoscopi a thin light tube insert anus rectum lower part colon look abnorm area colonoscopi a procedur look insid rectum colon polyp abnorm area cancer a colonoscop insert rectum colon a colonoscop thin tubelik instrument light len view it may also tool remov polyp tissu sampl check microscop sign cancer enlarg colonoscopi a thin light tube insert anus rectum colon look abnorm area virtual colonoscopi a procedur use seri xray call comput tomographi make seri pictur colon a comput put pictur togeth creat detail imag may show polyp anyth els seem unusu insid surfac colon this test also call colonographi ct colonographi biopsi the remov cell tissu view microscop pathologist check sign cancer certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the stage cancer whether cancer inner line colon spread colon wall spread lymph node place bodi whether cancer block made hole colon whether cancer cell left surgeri whether cancer recur the patient general health the prognosi also depend blood level carcinoembryon antigen cea treatment begin cea substanc blood may increas cancer present stage colon cancer key point after colon cancer diagnos test done find cancer cell spread within colon part bodi there three way cancer spread bodi cancer may spread began part bodi the follow stage use colon cancer stage carcinoma situ stage i stage ii stage iii stage iv after colon cancer diagnos test done find cancer cell spread within colon part bodi the process use find cancer spread within colon part bodi call stage the inform gather stage process determin stage diseas it import know stage order plan treatment the follow test procedur may use stage process ct scan cat scan a procedur make seri detail pictur area insid bodi abdomen pelvi chest taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area insid colon a substanc call gadolinium inject patient vein the gadolinium collect around cancer cell show brighter pictur this procedur also call nuclear magnet reson imag nmri pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell chest xray an xray organ bone insid chest an xray type energi beam go bodi onto film make pictur area insid bodi surgeri a procedur remov tumor see far spread colon lymph node biopsi the remov part lymph node a pathologist view lymph node tissu microscop check cancer cell this may done surgeri endoscop ultrasoundguid fine needl aspir biopsi complet blood count cbc a procedur sampl blood drawn check follow the number red blood cell white blood cell platelet the amount hemoglobin protein carri oxygen red blood cell the portion blood sampl made red blood cell carcinoembryon antigen cea assay a test measur level cea blood cea releas bloodstream cancer cell normal cell when found higher normal amount sign colon cancer condit there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl colon cancer spread lung cancer cell lung actual colon cancer cell the diseas metastat colon cancer lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi the follow stage use colon cancer stage carcinoma situ enlarg stage colon carcinoma situ abnorm cell shown mucosa colon wall in stage abnorm cell found mucosa innermost layer colon wall these abnorm cell may becom cancer spread nearbi normal tissu stage also call carcinoma situ stage i enlarg stage i colon cancer cancer spread mucosa colon wall submucosa muscl layer in stage i colon cancer cancer form mucosa innermost layer colon wall spread submucosa layer tissu next mucosa muscl layer colon wall stage ii enlarg stage ii colon cancer in stage iia cancer spread muscl layer colon wall serosa in stage iib cancer spread serosa spread nearbi organ in stage iic cancer spread serosa nearbi organ stage ii colon cancer divid stage iia iib iic stage iia cancer spread muscl layer colon wall serosa outermost layer colon wall stage iib cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum stage iic cancer spread serosa outermost layer colon wall nearbi organ stage iii stage iii colon cancer divid stage iiia iiib iiic enlarg stage iiia colon cancer cancer spread mucosa colon wall submucosa may spread muscl layer spread one three nearbi lymph node tissu near lymph node or cancer spread mucosa submucosa four six nearbi lymph node in stage iiia cancer spread mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread one three nearbi lymph node cancer cell form tissu near lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa cancer spread four six nearbi lymph node enlarg stage iiib colon cancer cancer spread muscl layer colon wall serosa spread serosa nearbi organ cancer spread one three nearbi lymph node tissu near lymph node or cancer spread muscl layer serosa four six nearbi lymph node or cancer spread mucosa submucosa may spread muscl layer cancer spread seven nearbi lymph node in stage iiib cancer spread muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread one three nearbi lymph node cancer cell form tissu near lymph node muscl layer serosa outermost layer colon wall cancer spread four six nearbi lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread seven nearbi lymph node enlarg stage iiic colon cancer cancer spread serosa colon wall nearbi organ cancer spread four six nearbi lymph node or cancer spread muscl layer serosa spread serosa nearbi organ cancer spread seven nearbi lymph node or cancer spread serosa nearbi organ one nearbi lymph node tissu near lymph node in stage iiic cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum cancer spread four six nearbi lymph node muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread seven nearbi lymph node serosa outermost layer colon wall nearbi organ cancer spread one nearbi lymph node cancer cell form tissu near lymph node stage iv enlarg stage iv colon cancer the cancer spread blood lymph node part bodi lung liver abdomin wall ovari stage iv colon cancer divid stage iva ivb ivc stage iva cancer spread one area organ near colon liver lung ovari distant lymph node stage ivb cancer spread one area organ near colon liver lung ovari distant lymph node stage ivc cancer spread tissu line wall abdomen may spread area organ recurr colon cancer recurr colon cancer cancer recur come back treat the cancer may come back colon part bodi liver lung treatment option overview key point there differ type treatment patient colon cancer seven type standard treatment use surgeri radiofrequ ablat cryosurgeri chemotherapi radiat therapi target therapi immunotherapi new type treatment test clinic trial treatment colon cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient colon cancer differ type treatment avail patient colon cancer some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial some clinic trial open patient start treatment seven type standard treatment use surgeri surgeri remov cancer oper common treatment stage colon cancer a doctor may remov cancer use one follow type surgeri local excis if cancer found earli stage doctor may remov without cut abdomin wall instead doctor may put tube cut tool rectum colon cut cancer this call local excis if cancer found polyp small bulg area tissu oper call polypectomi resect colon anastomosi if cancer larger doctor perform partial colectomi remov cancer small amount healthi tissu around the doctor may perform anastomosi sew healthi part colon togeth the doctor also usual remov lymph node near colon examin microscop see whether contain cancer enlarg resect colon anastomosi part colon contain cancer nearbi healthi tissu remov cut end colon join resect colon colostomi if doctor abl sew end colon back togeth stoma open made outsid bodi wast pass this procedur call colostomi a bag place around stoma collect wast sometim colostomi need lower colon heal revers if doctor need remov entir lower colon howev colostomi may perman enlarg colon cancer surgeri colostomi part colon contain cancer nearbi healthi tissu remov stoma creat colostomi bag attach stoma after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiofrequ ablat radiofrequ ablat use special probe tini electrod kill cancer cell sometim probe insert direct skin local anesthesia need in case probe insert incis abdomen this done hospit general anesthesia cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu this type treatment also call cryotherapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi chemoembol hepat arteri may use treat cancer spread liver this involv block hepat arteri main arteri suppli blood liver inject anticanc drug blockag liver the liver arteri deliv drug throughout liver onli small amount drug reach part bodi the blockag may temporari perman depend use block arteri the liver continu receiv blood hepat portal vein carri blood stomach intestin the way chemotherapi given depend type stage cancer treat see drug approv colon rectal cancer inform radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer the way radiat therapi given depend type stage cancer treat extern radiat therapi use palliat therapi reliev symptom improv qualiti life target therapi target therapi type treatment use drug substanc identifi attack specif cancer cell without harm normal cell type target therapi use treatment colon cancer includ follow monoclon antibodi monoclon antibodi made laboratori singl type immun system cell these antibodi identifi substanc cancer cell normal substanc may help cancer cell grow the antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus they may use alon carri drug toxin radioact materi direct cancer cell there differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form this may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell this stop cancer cell grow divid cetuximab panitumumab egfr inhibitor angiogenesi inhibitor angiogenesi inhibitor stop growth new blood vessel tumor need grow zivaflibercept vascular endotheli growth factor trap block enzym need growth new blood vessel tumor regorafenib use treat colorect cancer spread part bodi gotten better treatment it block action certain protein includ vascular endotheli growth factor this may help keep cancer cell grow may kill it may also prevent growth new blood vessel tumor need grow see drug approv colon rectal cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell pembrolizumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv colon rectal cancer inform new type treatment test clinic trial inform clinic trial avail nci websit treatment colon cancer may caus side effect for inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show condit chang cancer recur come back these test sometim call followup test checkup treatment option colon cancer for inform treatment list see treatment option overview section stage carcinoma situ treatment stage carcinoma situ may includ follow type surgeri local excis simpl polypectomi resect anastomosi this done tumor larg remov local excis use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage i colon cancer treatment stage i colon cancer usual includ follow resect anastomosi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage ii colon cancer treatment stage ii colon cancer may includ follow resect anastomosi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iii colon cancer treatment stage iii colon cancer may includ follow resect anastomosi may follow chemotherapi clinic trial new chemotherapi regimen surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iv recurr colon cancer treatment stage iv recurr colon cancer may includ follow local excis tumor recur resect without anastomosi surgeri remov part organ liver lung ovari cancer may recur spread treatment cancer spread liver may also includ follow chemotherapi given surgeri shrink tumor surgeri radiofrequ ablat cryosurgeri patient cannot surgeri chemoembol hepat arteri radiat therapi chemotherapi may offer patient palliat therapi reliev symptom improv qualiti life chemotherapi andor target therapi monoclon antibodi angiogenesi inhibitor immunotherapi clinic trial chemotherapi andor target therapi use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about colon cancer for inform nation cancer institut colon cancer see follow colorect cancer home page colorect cancer prevent colorect cancer screen test detect colorect cancer polyp unusu cancer childhood treatment cryosurgeri cancer treatment drug approv colon rectal cancer target cancer therapi genet test hereditari cancer syndrom for general cancer inform resourc nation cancer institut see follow about cancer stage chemotherapi you support peopl with cancer radiat therapi you support peopl with cancer cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment colon cancer it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq adult treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq adult treatment editori board pdq colon cancer treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypescolorectalpatientcolontreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('sorri hear diseas still activ ncot you sure challeng case unrel diseas activ ask get stelara xeljanz or ask clinic trial go join there lot new med clinic trial right i would think london area opportun your esophag transit time surpris slow do achalasia symptom feel food stuck esophagus food like mash potato peanut butter your stomach time within reason your small bowel time also slow like esophagus interest i know drug speed transit time i dont know often use',\n",
       "  'NN'),\n",
       " ('recent stress fractur right th metatars bone no traumat event caus appear metastat though i bone met pelvic bone rib due stage alk nsclc wore boot week heal have zometa xgeva past year sinc diagnosi been brigatinib sinc juli year mainten alimta round taxolcarboplatin start treatment i know possibl jaw necrosi femur fractur bisphosphon anyon heard stress fractur or reason bone would heal relat treatment',\n",
       "  'NN'),\n",
       " ('nhs litig unfortun individu when nhs decis lose massiv public court case destroy individu life thing final chang the neurologist financ decid best cours patient whi fingolimod natalizumab approv consensus safe discontinu plan studi pharma paid research god help children prescrib either one drug long term without lack immun surveil ie malign infect current safe exit plan come drug both drug prove bcell tcell downstream effect go field effect i think confirm caus ms insideout outsidein make studi ai astrocyt hot microglia oligodendrocyt neuron function critic move forward research',\n",
       "  'NN'),\n",
       " ('hi my question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl weekson face bodi stop take zykadia dermatologist gave medicin rash sudden swear headach and take dexa get normal ct scan report today say there mm hyperdens lesion area punctat calcif target like fashion within right parietaltempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema this caus effac ipsilater later ventricl subfalcin herniat along mid line shift no patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right parietaltempor lobe whole brain radiat suggest my question we scare radiat cyberknif option or gammaknif which option best he shouldnt stop take zykadia or need stop zykadia day till radiat stop zykadia jump nivolumab as zykadia result better except brain lesion if need carri zykadia avoid brain lesion zykadia doesnt cross brain barrier can get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       "  'NN'),\n",
       " ('no input surgeon howev i entyvio biolog i wish i would tri i think entyvio caus first surgeri colon resect and doctor pro medicin pro biolog antisurgeri even agre possibl when i ask entyvio could caus damag section colon said way know sure possibl i expect say way when conced possibl even sure entyvio harm good and part entyvio begin theybdid clinic trial entyvio clinic diagnos crohn diagnos psc med triedmesalamin imuran mp remicad humira entyvio simponi methotrex surgeri colon resect loop ileostomi surgeri ostomi closur diseas came back right away wors surgeri total proctocolectomi happi stoma back',\n",
       "  'RB'),\n",
       " ('i agre wwith ipoop check level in addit may want stool test havent have scope recent if result if hard know thing activ often rectum best rout treat rectal med are how mesalamin it worth throw simpl stuff see get point free symptom stelara offlabel uc avail crohn i think test uc avail soon howev med simponi humira similar remicad action entyvio differ mechan xeljanz both good option current state id like hope get thing manag someth addit your sinc said your bad mayb dose adjust imuran though mg low peopl everi day could get level check see your respond also add rectal steroid andor mesalamin oral mesalamin moder uc current med step jpouch surgeri complet step complet step complet from sick uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       "  'JJ'),\n",
       " ('dont know tagrisso havent taken but leader tom galli often said battl side effect plain white rice work well im sure hell jump soon give specif hang judi m',\n",
       "  'NN'),\n",
       " ('i take gilenya wouldnt know except dont relaps get new lesion soon tri paus relaps if i come decis drug in abstract way i understand disconnect lesion symptom goe way ie damag invis mri may may pick amongst day day variabl time lead disabl i choos everyth avail om dmd',\n",
       "  'NN'),\n",
       " ('right cimzia likelyofflabel uc prescript ion might get initi insur denial prescrib appeal doesnt mean cannot work uc studi signific enough prescrib again i dont know whole lot cimzia id call talk insur see figur what ask remicad simponi possibl could approv appeal worstcas scenario simponi humira closest peninject remicad iv administ hospit outpati infusioncent not sure matter much',\n",
       "  'JJ'),\n",
       " ('also put cladribin search box site find experi describ detail it pretti bad short i disabl relaps month two first two round cladribin i wonder i gilenya month first dose',\n",
       "  'JJ'),\n",
       " ('floo droe kor ti sone index term fluorohydrocortison acet fludrocortison acet fluohydrison acet fluohydrocortison acet dosag form excipi inform present avail limit particular generic consult specif product label tablet oral acet generic mg pharmacolog categori corticosteroid system pharmacolog veri potent mineralocorticoid high glucocorticoid activ use primarili mineralocorticoid effect promot increas reabsorpt sodium loss potassium renal distal tubul metabol hepat halflif elimin plasma hour biolog hour use label indic adren insuffici primari addison diseas partial replac therapi primari adrenocort insuffici saltlos adrenogenit syndrom treatment saltlos adrenogenit syndrom congenit adren hyperplasia off label use idiopath orthostat hypotens clinic experi suggest fludrocortison conjunct increas sodium intak may benefici treatment idiopath orthostat hypotens kearney lanier addit data may necessari defin role fludrocortison condit base european feder neurolog societi efn guidelin diagnosi manag orthostat hypotens fludrocortison effect recommend firstlin monotherapi manag orthostat hypotens septic shock data two doubleblind placebo control random trial suggest combin hydrocortison plus fludrocortison may benefici patient septic shock refractori initi volum resuscit vasopressor in trial hydrocortison plus fludrocortison improv mortal compar placebo also aid rapid revers shock annan annan note corticosteroid administ treatment sepsi absenc shock septic shock respons fluid resuscit vasopressor some expert use hydrocortison monotherapi without fludrocortison corticosteroid indic rhode sccmesicm annan contraind hypersensit fludrocortison compon formul system fungal infect document allergen crossreact corticosteroid limit howev similar chemic structur andor pharmacolog action possibl crosssensit cannot rule certainti dose adult adren insuffici primari addison diseas oral initi mg daili morn combin hydrocortison cortison usual mainten dose mg daili if hypertens develop dose reduct suggest antihypertens may necessari hypertens remain uncontrol endocrin societi bornstein manufactur label dose prescrib inform may reflect current clinic practic mg daili transient hypertens develop reduc dose mg daili mainten dosag rang mg time week mg daili saltlos adrenogenit syndrom congenit adren hyperplasia oral mg daili the endocrin societi recommend mainten dose rang mg daili combin hydrocortison patient congenit adren hyperplasia due hydroxylas defici speiser orthostat hypotens offlabel use kearney lahrmann lanier oral initi mg daili conjunct highsalt diet adequ fluid intak may increas increment mg per week maximum dose mg daili note dose exceed mg daili may benefici predispos patient unwant side effect eg hypertens hypokalemia septic shock offlabel use note corticosteroid use septic shock respons volum resuscit vasopressor rhode sccmesicm annan oral mg daili via nasogastr tube day combin iv hydrocortison annan annan dose geriatr refer adult dose dose pediatr adren insuffici autoimmun aldosteron defici compon addison diseas replac therapi offlabel dose limit data avail oral mg daili betterl kliegman congenit adren hyperplasia salt loser eg hydroxylas defici offlabel dose limit data avail note use combin glucocorticoid therapi eg hydrocortison concurr sodium replac therapi may requir particular young infant oral infant children adolesc activ grow usual rang mg daili divid dose dose high mgday may necessari aap aap speiser adolesc fulli grown mg daili aap speiser dose renal impair there dosag adjust provid manufactur label use caution dose hepat impair there dosag adjust provid manufactur label use caution administr oral administ without regard food gi upset may take food for septic shock offlabel use administ via nasogastr tube annan annan dietari consider system use mineralocorticoidscorticosteroid may requir diet increas potassium vitamin a b c d folat calcium zinc phosphorus decreas sodium with fludrocortison decreas dietari sodium often requir increas retent sodium usual desir therapeut effect storag store c c f f avoid excess heat the canadian label recommend store c c f f drug interact acetylcholinesteras inhibitor corticosteroid system may enhanc adversetox effect acetylcholinesteras inhibitor increas muscular weak may occur monitor therapi aldesleukin corticosteroid may diminish antineoplast effect aldesleukin avoid combin amphotericin b corticosteroid system may enhanc hypokalem effect amphotericin b monitor therapi androgen corticosteroid system may enhanc fluidretain effect androgen monitor therapi antacid may decreas bioavail corticosteroid oral manag consid separ dose hour budesonid enter coat tablet could dissolv prematur given drug lower gastric acid unknown impact budesonid therapeut effect consid therapi modif antidiabet agent hyperglycemiaassoci agent may diminish therapeut effect antidiabet agent monitor therapi aprepit may increas serum concentr corticosteroid system manag no dose adjust need singl mg aprepit dose for regimen reduc oral dexamethason methylprednisolon dose iv methylprednisolon dose antiemet regimen contain dexamethason reflect adjust consid therapi modif axicabtagen ciloleucel corticosteroid system may diminish therapeut effect axicabtagen ciloleucel manag avoid use corticosteroid premed axicabtagen ciloleucel corticosteroid may howev requir treatment cytokin releas syndrom neurolog toxic consid therapi modif baricitinib immunosuppress may enhanc immunosuppress effect baricitinib manag use baricitinib combin potent immunosuppress azathioprin cyclosporin recommend concurr use antirheumat dose methotrex nonbiolog diseas modifi antirheumat drug dmard permit consid therapi modif bcg intraves immunosuppress may diminish therapeut effect bcg intraves avoid combin bile acid sequestr may decreas absorpt corticosteroid oral monitor therapi calcitriol system corticosteroid system may diminish therapeut effect calcitriol system monitor therapi ceritinib corticosteroid may enhanc hyperglycem effect ceritinib monitor therapi coccidioid immiti skin test immunosuppress may diminish diagnost effect coccidioid immiti skin test monitor therapi corticorelin corticosteroid may diminish therapeut effect corticorelin specif plasma acth respons corticorelin may blunt recent current corticosteroid therapi monitor therapi cypa induc strong may decreas serum concentr corticosteroid system monitor therapi cypa inhibitor strong may increas serum concentr corticosteroid system monitor therapi deferasirox corticosteroid system may enhanc adversetox effect deferasirox specif risk gi ulcerationirrit gi bleed may increas monitor therapi deferasirox corticosteroid may enhanc adversetox effect deferasirox specif risk gi ulcerationirrit gi bleed may increas monitor therapi denosumab may enhanc adversetox effect immunosuppress specif risk serious infect may increas monitor therapi desirudin corticosteroid system may enhanc anticoagul effect desirudin more specif corticosteroid may increas hemorrhag risk desirudin treatment manag discontinu treatment system corticosteroid prior desirudin initi if concomit use cannot avoid monitor patient receiv combin close clinic laboratori evid excess anticoagul consid therapi modif desmopressin corticosteroid system may enhanc hyponatrem effect desmopressin avoid combin diltiazem may increas serum concentr corticosteroid system monitor therapi echinacea may diminish therapeut effect immunosuppress consid therapi modif estrogen deriv may increas serum concentr corticosteroid system monitor therapi fingolimod immunosuppress may enhanc immunosuppress effect fingolimod manag avoid concomit use fingolimod immunosuppress possibl if combin monitor patient close addit immunosuppress effect eg infect consid therapi modif fosaprepit may increas serum concentr corticosteroid system the activ metabolit aprepit like respons effect consid therapi modif hyaluronidas corticosteroid may diminish therapeut effect hyaluronidas manag patient receiv corticosteroid particular larger dose may experi desir clinic respons standard dose hyaluronidas larger dose hyaluronidas may requir consid therapi modif indacaterol may enhanc hypokalem effect corticosteroid system monitor therapi indium capromab pendetid corticosteroid system may diminish diagnost effect indium capromab pendetid avoid combin isoniazid corticosteroid system may decreas serum concentr isoniazid monitor therapi leflunomid immunosuppress may enhanc adversetox effect leflunomid specif risk hematolog toxic pancytopenia agranulocytosi andor thrombocytopenia may increas manag consid use leflunomid load dose patient receiv immunosuppress patient receiv leflunomid anoth immunosuppress monitor bone marrow suppress least month consid therapi modif loop diuret corticosteroid system may enhanc hypokalem effect loop diuret monitor therapi macimorelin corticosteroid system may diminish diagnost effect macimorelin avoid combin mifamurtid corticosteroid system may diminish therapeut effect mifamurtid avoid combin mifepriston may diminish therapeut effect corticosteroid system mifepriston may increas serum concentr corticosteroid system manag avoid mifepriston patient requir longterm corticosteroid treatment serious ill condit eg immunosuppress follow transplant corticosteroid effect may reduc mifepriston treatment avoid combin mitotan may decreas serum concentr corticosteroid system consid therapi modif natalizumab immunosuppress may enhanc adversetox effect natalizumab specif risk concurr infect may increas avoid combin neuromuscularblock agent nondepolar may enhanc advers neuromuscular effect corticosteroid system increas muscl weak possibl progress polyneuropathi myopathi may occur consid therapi modif nicorandil corticosteroid system may enhanc adversetox effect nicorandil gastrointestin perfor report associ combin monitor therapi nivolumab immunosuppress may diminish therapeut effect nivolumab consid therapi modif nonsteroid antiinflammatori agent cox select corticosteroid system may enhanc adversetox effect nonsteroid antiinflammatori agent cox select monitor therapi nonsteroid antiinflammatori agent nonselect corticosteroid system may enhanc adversetox effect nonsteroid antiinflammatori agent nonselect monitor therapi ocrelizumab may enhanc immunosuppress effect immunosuppress monitor therapi pidotimod immunosuppress may diminish therapeut effect pidotimod monitor therapi pimecrolimus may enhanc adversetox effect immunosuppress avoid combin quinolon corticosteroid system may enhanc adversetox effect quinolon specif risk tendon tendon ruptur may increas monitor therapi ritodrin corticosteroid may enhanc adversetox effect ritodrin monitor therapi roflumilast may enhanc immunosuppress effect immunosuppress consid therapi modif salicyl may enhanc adversetox effect corticosteroid system these specif includ gastrointestin ulcer bleed corticosteroid system may decreas serum concentr salicyl withdraw corticosteroid may result salicyl toxic monitor therapi sargramostim corticosteroid system may enhanc therapeut effect sargramostim specif corticosteroid may enhanc myeloprolif effect sargramostim monitor therapi sipuleucelt immunosuppress may diminish therapeut effect sipuleucelt monitor therapi tacrolimus system corticosteroid system may decreas serum concentr tacrolimus system convers discontinu corticosteroid therapi tacrolimus concentr may increas monitor therapi tacrolimus topic may enhanc adversetox effect immunosuppress avoid combin telaprevir corticosteroid system may decreas serum concentr telaprevir telaprevir may increas serum concentr corticosteroid system manag concurr use telaprevir system corticosteroid recommend when possibl consid altern if use togeth employ extra caution monitor close excess corticosteroid effect diminish telaprevir effect consid therapi modif tertomotid immunosuppress may diminish therapeut effect tertomotid monitor therapi thiazid thiazidelik diuret corticosteroid system may enhanc hypokalem effect thiazid thiazidelik diuret monitor therapi tisagenlecleucel corticosteroid system may diminish therapeut effect tisagenlecleucel manag avoid use corticosteroid premed time treatment tisagenlecleucel except case lifethreaten emerg resist cytokin releas syndrom consid therapi modif tofacitinib immunosuppress may enhanc immunosuppress effect tofacitinib manag concurr use antirheumat dose methotrex nonbiolog diseas modifi antirheumat drug dmard permit warn seem particular focus potent immunosuppress consid therapi modif trastuzumab may enhanc neutropen effect immunosuppress monitor therapi urea cycl disord agent corticosteroid system may diminish therapeut effect urea cycl disord agent more specif corticosteroid system may increas protein catabol plasma ammonia concentr therebi increas dose urea cycl disord agent need maintain concentr target rang monitor therapi vaccin inactiv immunosuppress may diminish therapeut effect vaccin inactiv manag vaccin efficaci may reduc complet ageappropri vaccin least week prior start immunosuppress if vaccin immunosuppress therapi revaccin least month immunosuppress discontinu consid therapi modif vaccin live corticosteroid system may enhanc adversetox effect vaccin live corticosteroid system may diminish therapeut effect vaccin live manag dose equival less mgkg mg per day prednison administ less week consid suffici immunosuppress creat vaccin safeti concern higher dose longer durat avoid consid therapi modif warfarin corticosteroid system may enhanc anticoagul effect warfarin monitor therapi test interact corticosteroid may affect nitrobluetetrazollum test bacteri infect produc falseneg result advers reaction frequenc defin cardiovascular cardiac failur cardiomegali edema hypertens central nervous system delirium depress emot labil euphoria hallucin headach increas intracrani pressur insomnia malais nervous person chang pseudotumor cerebri psychiatr disturb psychosi seizur vertigo dermatolog acn vulgari atroph striae diaphoresi erythema hyperpigment maculopapular rash skin atrophi skin rash suppress skin test reaction urticaria endocrin metabol cush syndrom diabet mellitus glycosuria growth suppress hirsut hpaaxi suppress hyperglycemia hypokalemia hypokalem alkalosi impair glucos toler menstrual diseas negat nitrogen balanc gastrointestin abdomin distent esophag ulcer pancreat peptic ulcer hematolog oncolog bruis petechia purpura hypersensit anaphylaxi general local lipoatrophi inject site neuromuscular skelet amyotrophi bone fractur myasthenia myopathi osteonecrosi femor humer head osteoporosi vertebr compress fractur ophthalm cataract exophthalmo glaucoma increas intraocular pressur miscellan wound heal impair warningsprecaut concern relat advers effect adren suppress may caus hypercortisol suppress hypothalamicpituitaryadren hpa axi particular younger children patient receiv high dose prolong period hpa axi suppress may lead adren crisi withdraw discontinu corticosteroid done slowli care anaphylactoid reaction rare case anaphylactoid reaction observ patient receiv corticosteroid immunosuppress prolong use may increas risk infect mask acut infect includ fungal infect prolong exacerb viral infect limit respons kill inactiv vaccin exposur chickenpox measl avoid corticosteroid use cerebr malaria viral hepat close observ requir patient latent tuberculosi tb andor tb reactiv restrict use activ tb fulmin dissemin tb conjunct antituberculosi treatment amebiasi rule patient recent travel tropic climat unexplain diarrhea prior initi corticosteroid use extrem caution patient strongyloid infect hyperinfect dissemin fatal occur kaposi sarcoma prolong treatment corticosteroid associ develop kaposi sarcoma case report note discontinu therapi consid goedert myopathi acut myopathi report highdos corticosteroid usual patient neuromuscular transmiss disord may involv ocular andor respiratori muscl monitor creatin kinas recoveri may delay psychiatr disturb corticosteroid use may caus psychiatr disturb includ euphoria insomnia mood swing person chang sever depress psychot manifest preexist psychiatr condit may exacerb corticosteroid use diseaserel concern cardiovascular diseas use caution patient hf andor hypertens use may associ fluid retent electrolyt disturb hypertens use caution follow acut mi corticosteroid associ myocardi ruptur diabet use corticosteroid caution patient diabet mellitus may alter glucos productionregul lead hyperglycemia gastrointestin diseas use caution patient gi diseas diverticul fresh intestin anastomos activ latent peptic ulcer ulcer coliti abscess pyogen infect due perfor risk hepat impair use caution patient hepat impair includ cirrhosi longterm use associ fluid retent myasthenia gravi use caution patient myasthenia gravi exacerb symptom occur especi initi treatment corticosteroid ocular diseas use caution patient cataract andor glaucoma increas intraocular pressur openangl glaucoma cataract occur prolong use use caution patient histori ocular herp simplex corneal perfor occur use activ ocular herp simplex consid routin eye exam chronic user osteoporosi use caution patient osteoporosi high dose andor longterm use corticosteroid associ increas bone loss osteoporot fractur renal impair use caution patient renal impair fluid retent may occur seizur disord use corticosteroid caution patient histori seizur disord seizur report adren crisi thyroid diseas chang thyroid status may necessit dosag adjust metabol clearanc corticosteroid increas hyperthyroid patient decreas hypothyroid one concurr drug therapi issu drugdrug interact potenti signific interact may exist requir dose frequenc adjust addit monitor andor select altern therapi consult drug interact databas detail inform special popul elder becaus risk advers effect use caution elder smallest possibl effect dose shortest durat pediatr may affect growth veloc growth develop routin monitor pediatr patient other warningsprecaut discontinu therapi withdraw therapi gradual taper dose stress patient may requir higher dose subject stress ie trauma surgeri sever ill monitor paramet blood pressur blood glucos electrolyt weight growth develop children hpa axi suppress pregnanc risk factor c pregnanc consider anim reproduct studi conduct fludrocortison advers event observ corticosteroid anim reproduct studi some studi shown associ first trimest system corticosteroid use oral cleft parkwylli pradat system corticosteroid may also influenc fetal growth decreas birth weight howev inform conflict lunghi hypoadren may occur newborn follow matern use corticosteroid pregnanc monitor when system corticosteroid need pregnanc general recommend use lowest effect dose shortest durat time avoid high dose first trimest leachman lunghi fludrocortison may use treat women pregnanc requir therapi congenit adren hyperplasia primari adren insuffici bornstein speiser patient educ discuss specif use drug side effect patient relat treatment hcahp dure hospit stay given medicin taken befor give new medicin often hospit staff tell medicin how often hospit staff describ possibl side effect way could understand patient may experi nausea vomit insomnia agit have patient report immedi prescrib sign infect sign high blood sugar confus fatigu increas thirst increas hunger polyuria flush fast breath breath smell like fruit sign cush diseas weight gain upper back abdomen moon face sever headach slow heal sign adren gland problem sever nausea vomit sever dizzi pass muscl weak sever fatigu mood chang lack appetit weight loss sign low potassium muscl pain weak muscl cramp abnorm heartbeat sign pancreat sever abdomin pain sever back pain sever nausea vomit sign skin chang acn stretch mark slow heal hair growth sign dvt edema warmth numb chang color pain extrem sever loss strength energi irrit tremor tachycardia confus sweat lot dizzi short breath excess weight gain swell arm leg angina menstrual chang bone pain joint pain vision chang behavior chang depress seizur burn numb feel bruis bleed sever abdomin pain black tarri bloodi stool vomit blood hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note this comprehens list side effect patient consult prescrib addit question intend use disclaim should print given patient this inform intend serv concis initi refer health care profession use discuss medic patient you must ultim reli discret experi judgment diagnos treat advis patient',\n",
       "  'NN'),\n",
       " ('im probabl one list statist i surgeri hospit readmit due blockagekink i realli doubt mine due biolog my gi biolog month prior surgeri keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('re doe anyon know possibl hsct without loss fertil most bmt unit offer egg harvest bank in addit everyon hsct left infertil our haematologist quot figur but general woman hsct will sacrific fertil downsid treatment seldom discuss other option treat earli alemtuzumab failur anticd therapi rituximab ocrelizumab daclizumab pleas note general comment dont necessarili appli specif individu patient',\n",
       "  'NN'),\n",
       " ('im get readi start stelara sometim sept i also wonder fistula etc it strang didnt let stay the last drug studi offer indic i success close would continu provid drug seem rather cruel take get sick femal canada ivig pentasa entyvio infusionsno respons discontinu uccrohn test posit map antibodi mycobacterium pg remiss flare almost yearsin bad way due abx treatment gone wrong sigh',\n",
       "  'JJ'),\n",
       " ('ncot glad pull avoid convers climat chang was wonder xmas but realli thrill entyvio someth that quit drop fecal cal that amaz actual i keep put mine someth take box contain poop post offic kinda throw will monday though honor my last one measur start entyvio last juli now insan dose humirawel see score femal canada ivig hold uccrohn test posit map antibodi mycobacterium pg remiss flare year current deal fistula includ rectalvag vulvodynia caus ibd take mg gabapentin start humira sept mg week start hyperbar oxygen dec',\n",
       "  'NN'),\n",
       " ('you never plan ahead much soon i would definit get ltd coverag post month ago hug use do sensat clitor penil erect stimul this last hour nortriptylin im nerv pain realli help hurt symptom flare post month ago hug use answer sign view previous answer a mymsteam member said paullinuk im sorri i didnt understand say can explain bit pleas thank post month ago hug use relationship issu i love life partner much sometim drive absolut batti my guy good when come take care domest chore thing around hous i never worri make bed wash cloth cook meal sweep take trash easili hinder task i could name dilig now come side i left offic job year ago i work small famili busi read post month ago hug use answer sign view previous answer a mymsteam member said nzrick so actual doesnt work hes construct busi raini season basic shut read post month ago hug use tysabri cladribin struggl choos hi im new site still tri find way round hope im right i offer choic tysabri cladribin struggl choos ive previous copaxon work realli well limit side effect year relaps stop due lipoatrophi run place inject then tecfidera i hate side effect felt like crap develop new lesion then bit read edit origin post month ago hug use answer sign view previous answer a mymsteam member said ive infus tysabri happi i dont work longer one coukd like work post infus my side effect read post month ago hug use has anyon start mavenclad cladribin finish week one gotten nauseat leg pain wonder leg pain due heat wave go never sort of neuropath leg pain past post month ago hug use answer sign view previous answer a mymsteam member said i see famili doc put second week pill veri reliev i went see head nurs work',\n",
       "  'NN'),\n",
       " ('hi i tagrisso month wonder lot fewer side effect i i take gabapentin neuropathi chemo help sleep my mind race continu year i nsclsc year i one happi person tagrisso becom avail i end med avail my toenail fingernail aw thing best wish prayer mom',\n",
       "  'NN'),\n",
       " ('hi blueberri i sorri hear mother diagnosi my wife yo never smoker also diagnos stage iv nsclc last year we current clinic trial anoth type drug process think clinic trial end come lot question anoth coupl thought i sure interim result talk may want ask result trial combin smoker vs nonsmok from oncologist told us thing i read subsequ appear immunotherapi general tend work better smoke relat nsclcs nonsmok opdivo work wife inde work nonsmok you may want see interim result combo show thing as jimc said may also want talk oncologist extent mother nsclc also talk trial coordin term long would want mother trial drug combo general go trial time want work want make sure would long enough know whether combo effect and said could go trial standard cargoalimta need find one treatment negat possibl i also found dr west discuss molecular marker immunotherapi httpcancergraceorglungvalueofpdltest comment i found search cancer grace decid time clinic trial versus convent chemotherapi use the import part ask question oncologist feel comfort possibl make decis i wish al best may mother find effect treatment whatev path take wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl all stabl addl growthoff trial start gemzarlarg tumor reduct',\n",
       "  'NN'),\n",
       " ('across group patient higher baselin nfl level larger t lesion volum baselin r p month nfl level newenlarg t lesion count r p also correl patient higher nfl level lower normal brain volum r p across group baselin correl percentag brain volum chang baselin month month baselin nfl level fingolimod r m p r m p r',\n",
       "  'NN'),\n",
       " ('dear janin thank much inform im happi hope learn clinic trial go moment exon i forgot say i live finland one grandchildren live philadelphia famili therefor trial osimertinib philli mayjuli sound interest i wonder nonus citizen recruit trial access clinic trial would prioriti it seem clinic trial take place us you ask feel i particip clinic trial mainten alimta get dose alimta everi three week when trial end i felt abandon my scan remain stabl two year first break gradual i start feel safe enjoy normal life i trust doctor know time start get treatment howev i cant help feel uneasi know cancer progress luckili slow grow stabl long period chemo session far dear scohn thank tell wife treatment it amaz drug actual design exon prove effect that pharma compani abl find new user group target drug it great gemzar still work option need i ask doctor exon mutat also her gemzar might worth tri thank much encourag wish best luck wife mani month gemzar with heartfelt thank paulina neversmok bac stage iv dx feb cm infiltr detect rul ct scan possibl spicul carcinoma treatment progress dvt no treatment feb diagnos bac rls lll primari tumor diam cm febapr x cisplatin alimta may april mainten alimta clinic trial round alimta week interv primari tumor cm nodul rl ll clean stabl sinc june dec slight progress march x carboplatintaxol stabl march ct guid needl biopsi april dg papillari adenocarcinoma exon may progress treatment juli more progress new nodul enlarg ggos multipl metastas rl spread also lingula x alimta julyaugust good respons decreas ggos reliev symptom cough mucus x alimta octnov slow progress sinc nov cough mucus sob',\n",
       "  'NN'),\n",
       " ('prayer come way im surpris didnt opt entyvio stelara first did mention either decid cimzia hope thing start improv soon keep us post',\n",
       "  'NN'),\n",
       " ('theoret differ continu immunosuppress associ ongo undefin period time rituximab ocrelizumab treatment know concept induct v mainten treatment tell what better safeti wise reconstitut system post induct treatment ongo immuno suppress associ non induct therapi rituximab ocrelizumab',\n",
       "  'NN'),\n",
       " ('readi n farago a f de braud f atmaca a hellmann m d schneider j g spigel d r moreno v chau i hann c l eder j p steel n l pieter a fairchild j antonia s j articl titl thirdlin nivolumab monotherapi recurr sclc checkmat abstract introduct for patient recurr sclc topotecan remain approv secondlin treatment outcom poor checkmat phase multicent openlabel studi nivolumab nivolumab plus ipilimumab sclc advancedmetastat solid tumor previous treat one platinumbas chemotherapi we report result third laterlin nivolumab monotherapi treatment sclc method in analysi patient limitedstag extensivestag sclc diseas progress two chemotherapi regimen receiv nivolumab monotherapi mgkg everi week diseas progress unaccept toxic the primari end point object respons rate secondari end point includ durat respons progressionfre surviv overal surviv safeti result between decemb novemb patient began receiv third laterlin nivolumab monotherapi at median followup month first dose databas lock object respons rate confid interv median durat respons month rang at month patient progressionfre the month month overal surviv rate respect grade treatmentrel advers event occur patient three patient discontinu treatmentrel advers event conclus nivolumab monotherapi provid durabl respons well toler third laterlin treatment recurr sclc these result suggest nivolumab monotherapi effect third laterlin treatment patient popul intern associ studi lung cancer keyword adult cancer chemotherapi control studi age surviv rate major clinic studi overal surviv fatigu cancer recurr cancer growth diarrhea drug safeti drug withdraw monotherapi treatment durat skin manifest cancer stage follow progress free surviv phase clinic trial nausea random control trial pruritus rash drug fatal surviv time immunotherapi multicent studi drug respons phase clinic trial small cell lung cancer decreas appetit sclc nivolumab human male femal prioriti journal articl pd inhibitor thirdlin journal titl journal thorac oncolog volum issu issn publish elsevi inc',\n",
       "  'NN'),\n",
       " ('stelara imuran look like humira fail', 'NN'),\n",
       " ('smellmin without m with mnada m liquid place drop ostomi bag absorb smell i know i forget m empti bagit wake spous dead sleep my friend use m she said smell like normal person it differ everyon fartspass gasoh yes it also make grumbl old man talk sound i put hand muffl itbut that alreadi let ki notic nois it happen much meso big deal dont freak diseas the major peopl abl get control medic clo symptom start diagnosi diagnos uc diverticul hosp fistula dx chang crohn develop new skin rash eye problem pain joint hospx new specialistsaid wors case hes seen hosp mm strictur stricturplasti mm colostomi med remicad methtrex prednisonfol acid vit d calcium pro biotic',\n",
       "  'JJ'),\n",
       " ('i gone gym regular whenev symptom allow leav hous never big problem sure beat run bike street some day abdomin exercis arent possibl but i everyth schedul person trainer class male dxd w uc flare sinc asacol hd mg day start remicad nonrespons dcd start humira nonrespons dcd hydrocortison enema help regress stop start entyvio restart hydrocortison start umass ibdaid diet improv w entyvio hydrocortison ibdaid colonoscopi show clinic remiss',\n",
       "  'JJ'),\n",
       " ('i believ read comment mayb dont note someon ask pronounc drug name that post if someon know other know either anonymousthursday februari pm it would nice guy could post pronounc various ms drug name for eg i would like know emphasi copaxon g sound like gilenya i heard doctor nurs pronounc mani differ way i dont get listen peopl pronounc drug i dont meet peopl ms day day basi',\n",
       "  'NN'),\n",
       " ('hi uc friend my doctor say i medic resist version uc over last three year i tri imuran humira inflectra like remicad the thing work prednison i consid surgeri go talk surgeon friday i wonder saw improv symptom uc exampl arthriti muscl pain surgeri im wonder expect didnt think surgeon would abl help question',\n",
       "  'NN'),\n",
       " ('i would make appoint gi asap technic inflectra isnt ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra i idea honesti but better nd rd infus i would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'RB'),\n",
       " ('i opdivo similar keytruda year so far good', 'NN'),\n",
       " ('hi welcom grace im sorri hear progress tagrisso howev one first question ask how much progress especi target therapi welltoler reluct abandon particular agent face slow limit progress you havent realli state much progress lung progress small locat grown may reason continu tagrisso get maximum benefit drug dr west fond say bad brake better brake tagrisso keep progress slow may better switch anoth regimen may may effect carboplatinalimta tend one besttoler platinum combin therapi lung cancer alimta singl agent often welltoler mani patient extend period time use mainten therapi round platinum doublet side effect nausea tend wellmanag medic there wrong choic sinc pace develop lung cancer treatment increas recent year there good reason get everyth drug benefit new agent becom avail good luck treatment either way jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'JJ'),\n",
       " ('except uc around long modern food chemic one antibiot came along you theori caus uc pleas dont generalis caus uc rant evil modern life connor said uc rare western world befor peopl most got drink contamin milk got uc usual die this nonsens well sever uc sometim kill peopl day steroid modern surgeri yeah but case uc arent sever lifethreaten countless number peopl must learn live mild moder uc life colonoscopi came along must almost imposs get diagnosi dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'RB'),\n",
       " ('well i start gilenya monday sad phone call last friday dash dream turn even though i chicken pox child varicella test result came back negat so i wait minimum week i gilenya i two dose chicken pox vaccin if ms wasnt activ i probabl wouldnt fuss but right the steriod i april worn the spasm roof even baclofen my pain often unbear spasm breath hurt walk even uncoordin spasm im choke everyth includ saliva air and tongu back feel like someon stuck lidocain patch left side the list go biggest annoy still got count lucki start ofcours but doesnt feel like im best place right mental physic im tri feel dishearten like i chang realiti doesnt make easier cope other husband noon els know everyth gotten wors and mum know treatment delay person i keep date i dont want annoy friend and i honest dont think itll good make upset im stuck right i tri keep busi i make card i energi even tri walk i feel i though intermitt foot drop make even harder even i know mani wors i honest i feel like take much run point month ago id manag start enjoy life hard much anyth issu to ms take life sinc last april i im glad i know ive almost taken life past pain noon understood i i cant get head right',\n",
       "  'JJ'),\n",
       " ('thank janin post excel inform it certain make sens investig immunotherapi the e clinic trial janin mention direct test mainten therapi bevacizumab pemetrex combin bevacizumab pemetrex follow carboplatin paclitaxel bevacizumab advanc nonsquam nsclc onthemark',\n",
       "  'NN'),\n",
       " ('catch week top rheumatolog gastroenterolog clinic practic regulatori polici busi news world biosimilar studi examin potenti role biolog treat primari scleros cholang primari scleros cholang psc chronic immunemedi progress biliari diseas close associ inflammatori bowel diseas ibd psc cure case eventu requir patient receiv liver transplant given efficaci biolog treat ibd potenti treat psc drug matter interest healthcar provid review address role antitnf intestin behet diseas intestin behet diseas bd immunemedi chronic inflammatori intestin diseas difficult treat part pathogenesi intestin bd unclear howev data use antitumor necrosi factor antitnf drug accumul treatment inflammatori bowel diseas ibd similar clinic present potenti treat bd agent investig switch between refer infliximab ctp is unlik evok differ ada a new studi publish alimentari pharmacolog therapeut sought test antigen compar refer infliximab biosimilar spanish studi switch biosimilar infliximab ibd is safe effect month research spain biosimilar use encourag way save cost expand access biolog therapi recent report multicent prospect observ studi patient inflammatori bowel diseas ibd switch refer infliximab biosimilar ctp inflectra remsima gastroenterologist recount clinic experi with switch patient biosimilar i see reason healthcar provid intent go back forth needless i see concern i bad thing would happen said jason schairer md effect infliximab treatment cd is associ with improv mental health crohn diseas cd involv physic psycholog social impair negat impact patient qualiti life high level anxieti depress observ patient cd review find that switch biosimilar infliximab patient ibd accept the question whether switch patient refer biolog avail biosimilar subject extens debat especi patient inflammatori bowel diseas ibd indic evid relev clinic outcom switch limit celltrion report posit phase result subcutan inflectra cd celltrion present new research demonstr formul infliximab biosimilar intend subcutan administr compar intraven administ option the phase studi compar subcutan formulationwhich selfadministeredwith fdaapprov intraven formul patient activ crohn diseas cd fda approv jak inhibitor treat ulcer coliti provid altern antitnf agent this week fda approv expand indic janus kinas jak inhibitor tofacitinib xeljanz includ adult moder sever ulcer coliti tofacitinib first oral medicin approv longterm use uc provid altern antitumor necrosi factor antitnf drug must inject infus',\n",
       "  'NN'),\n",
       " ('i would certain tri entyvio xeljanz stelara still tri differ drug you find husband stori search xeljanz site surgeri schedul tri remicad humira entyvio abl get xeljanz miracl drug trick stelara clinic trial uc peopl good luck crohn xeljanz got approv fda uc us summer the challeng drug work differ peopl doesnt work isnt fun spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week',\n",
       "  'JJ'),\n",
       " ('age relat macular degener amd damag occur macula locat back eye direct line sight the macula part eye respons sharp central vision enabl person pinpoint object recogn face this deterior occur older age mani individu name suggest there two type amd the first type dri amd character breakdown macular tissu caus buildup form underneath retin layer call drusen if yellow deposit drusen increas size tissu back eye may cut blood suppli if occur new blood vessel form tend leak this lead second type macular degener wet exud amd both type macular degener lead devast loss vision amd prevent eat approxim cup leafi green veget day boost antioxid help fight free radic take part agerel breakdown macula wear proper uv protect healthi exercis regimen smoke may also decreas risk amd in fact smoke increas amd risk four time there vitamin supplement avail antioxid lutein zeaxanthin shown help filter oxid chemic harm blue light caus damag macula howev import consult eye doctor begin new eye vitamin our ocular health formula eye love use daili patient definit approv us patient dri amd common monitor amsler grid patient given grid monitor vision function if see part grid miss wavi line may indic condit chang if wet amd begin like becom candid antivegf inject antivegf vascular endotheli growth factor drug use stop new blood vessel format track eylea avastin lucenti name drug success use time these drug aim preserv vision case improv sight if your suffer macular degener dont wait begin supplement definit dont delay eye exam we love hear amd especi hear success stori if youv got one post comment one love dr jenna rufino silva age relat macular degener portug ger group print',\n",
       "  'NN'),\n",
       " ('a posit thing pregnant ms symptom better controll babi born symptom come backtalk doctor back therapi babi born good luck pregnanc would start tri babi third month medicin dont want rebound effect like hapen stop fingolimod',\n",
       "  'NN'),\n",
       " ('often lucenti stabilis condit time need fewer inject amd i hope keep vision stabl im glad hear wont problem access eyelea us england my consult gave good advic follow appoint first lucenti inject overlook month fortun harm done vision stabl time told fluid detect scan i inject week after inject i follow clinic longer week alway week i proactiv ensur appoint time futur i took word know clinic i make fuss polit appoint late good luck take day come easier said done i know were need bit tea sympathi good old rant',\n",
       "  'JJ'),\n",
       " ('the us food drug administr fda approv drug lucenti', 'NN'),\n",
       " ('i never particip trial kind howev crizotinib first line treatment diagnos alk posit adenocarcinoma work beauti side effect month time scan show progress i switch alectinib work well even fewer side effect we bless mani option us day',\n",
       "  'JJ'),\n",
       " ('complet infus yesterday along ct headneck torso ultrasound thyroid result today still clean scan far overal side effect minim discuss exit strategi keytruda infus includ next two infus space week apart follow month scan still clear stop that two year calendar time infus equat year actual treatment im thank brilliant scientist accomplish consid i start aggress modular melanoma happi valentin day everyon login regist post repli regist now login re keytruda infus clean scan result billb pm repli re keytruda infus clean scan result scoobi pm repli re keytruda infus clean scan result mmh pm repli re keytruda infus clean scan result billb pm repli re keytruda infus clean scan result bubbl pm repli re keytruda infus clean scan result jbronicki pm repli re keytruda infus clean scan result kst pm repli re keytruda infus clean scan result sing pm repli re keytruda infus clean scan result amcread pm repli re keytruda infus clean scan result chrispl repli re keytruda infus clean scan result texmelanomex pm repli re keytruda infus clean scan result lkb pm repli expandcollaps topic suspect number five possibl insitu almostalic pm repli so go right next stage charact went keliod recoveri three month suspect insitu need look here interest thing share has anyon ever heard stage two insitus side side path report that first one came back this new one two mole merg grow close with cdkna posit i wonder mine get start like galaxi star collid is much inform ssm melanoma birth',\n",
       "  'JJ'),\n",
       " ('my daughter stage adenocarcinoma nsclc ros dx decemb standard chemo xalkori gave posit result the dr want tri opdivo even though test negat pdlthis result mass tripl then dr return chemo carboplatin alimta alimta mainten month the dr recommend new combin unusu growth around previous radiat spot lung i sure combin growth identifi is evid next cours treatment given histori result unknown caus smear ct scan',\n",
       "  'JJ'),\n",
       " ('minnietoti constant fatigu issu us chronic diseas my gi pcp told caus blood work look good doesnt mean feel great you bodi take time recov sinc flare take get back normal hope also keep mind mental fatigu issu well blood test confirm this bad wors physic fatigu the best thing i done recent month ago i start see therapist his first question take long i decid need help he said chronic ill caus anxieti depress host issu make diseas wors he bless help get current ordeal encourag file long term disabl you make need drastic discuss help look thing differ import i hope help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio g medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqui xanax er',\n",
       "  'NN'),\n",
       " ('yes remicad uc medic current im sure option i mercaptopurin im allerg mesalamin lost respons steroid is one im miss the last time blood work remicad i concentr left doctor said i fast metabol i go medicin quicker',\n",
       "  'NN'),\n",
       " ('the lack biomark major obstacl investig myelin repair we use metabol incorpor cholin analog propargylcholin pcho label visual newli synthes myelin cns mice induc experiment autoimmun encephalomyel eae we develop unbias coloc analysi quantifi pcho incorpor specif myelin our find indic pcho inject mice recov eae either spontan follow glatiram acet treatment result signific elev incorpor myelin offer novel strategi assess remyelin anim model remyelin potenti candid drug glaterim acet drug i clue work mechan action shake stick so today mechan infer proremyelin realli happen way recov attack actual studi look remyelin think take dye light myelin we one alreadi call fingolimod bind myelin layer realli well',\n",
       "  'VBP'),\n",
       " ('sinc ocrevus inject recommend done want talk neurologist', 'JJ'),\n",
       " ('in norway rituximab time use label rrms i first infus this anticd monoclon antibodi chimer mous variabl human constant region i read blog may make neutral antibodi probabl toward mous compon titer may becom reduc multipl treatment cycl nevertheless i worri signific risk individu level drug may low efficaci do guy agre luckili ocrelizumab approv norway a report site blog say drug neutral antibodi found is number still date are studi suggest may unsaf switch ritruximab ocrelizumab what anticd brain atrophi',\n",
       "  'JJ'),\n",
       " ('i episod on event smolder progress sinc not mani brain lesion atrophi brain main thin spinal cord ive lot nerv damag accumul disabl here view ms sinc i havent relaps i doubt mani current drug prevent relaps gilenya crab etc would help avail time besid new attack bloodbrain barrier lead relaps someth els go cns lead progress disabl it slowli eat reserv neurolog abil realli notic loss function get drug stop inflammatori attack cns import i believ treat earli possibl effect drug hsct prevent damag recommend',\n",
       "  'NN'),\n",
       " ('repli post saradarrow hi sara i terrifi start humira i hate needl nowher near bad i expect i would recommend son inject stomach i found less pain thigh i also let humira warm minut ice inject site right i inject the thing hard sometim nois pen make inject it sudden surpris sometim make jump bit hold pen tight enough skin make much much easier avoid misfir i also listen music i inject make littl less serious i hope son found good solut work',\n",
       "  'NN'),\n",
       " ('hi updat i receiv copi letter neuro sent gp ive decid take steroid option two day iv next week oral tail two three week he said make substanti differ symptom would worth chang dmd tecfidera gilenya sinc i feel ive deterior sinc relapsepseudo relaps ive decid give go have read steroid thread i wonder worth email ms nurs ask omeprazol possibl sleep tablet avail or i wait i get appoint louis',\n",
       "  'NN'),\n",
       " ('repli post kelliwithchron i ulcer coliti two healthi pregnanc result two healthi boy i remicad pregnanc i classifi high risk meant i got bunch extra free ultrasound piec mind import stress induc ibd i know scari think pass diseas along child but honest i zero famili histroy ibd end uc the chanc increas parent ibd realiti famili histori autoimmun disord children chanc get auto immun disord i told pregnanc i would chanc uc get better stay get wors i would say first i feel better howev stress less i didnt alreadi child i need rest i could rest with second i say stay main father pass away unexpect i pregnant second thank i abl work emot without stress have children brought much joy life howev medic safe pregnanc i would talk gi i lucki gi absolut best giin opinion brother law ob best obagain opinion communic easi pregnanc ob gi talk regular i felt comfort confid decis health babi health there option though i huge support foster children strength life lesson learn could much good children wish best decis',\n",
       "  'NN'),\n",
       " ('so continu give entivio chanc and deal year old symptom sinc octob diagnos januari ibd ulcer coliti pancol current apriso humira uceri valtrex vari have tri almost everi healthfood thing world no help if could cure herb vitamin diet good day bad day lot sleep',\n",
       "  'JJ'),\n",
       " ('dear moder doctor ive read number exit articl publish spanish group silibinin extract milk thistl those paper prove silibinin prolong time tarceva resist recent public prove silibinin reduc brain met lung cancer use concurr systemat treatment i current tarceva two month realli worri possibl brain met i would like tri silibinin worri could interfer tarceva negat way may i pleas ask advis mani thank',\n",
       "  'NN'),\n",
       " ('part train clinician understand import eye health especi age adult one import eye diseas need abl recogn agerel macular degener amd result vision loss it common adult age amd character either dri amd wet amd dri amd common affect patient amd these patient lose vision slowli time wet amd caus sever vision loss blind differenti import some patient start dri amd later develop wet amd test amd includ dilat eye exam fluorescein angiographi optic coher tomographi oct the retina examin abnorm blood vessel sign drusen seen patient amd patient also examin amsler grid look like piec graph paper patient wet amd see line wavi bent both type amd treat combin vitamin miner call are age relat eye diseas studi are formula this formula includ high dose vitamin a vitamin c betacaroten zinc found help patient macular degener smoker encourag stop smoke smoke increas risk amd quit actual slow progress diseas treatment patient wet amd includ vascular endotheli growth factor vegf inhibitor photodynam therapi laser surgeri research also look use stem cell therapi still preliminari phase surgic option also explor most import encourag older patient get regular eye exam the earlier treatment initi amd better sharon m obrien mpas pac practic physician assist health coach ashevill nc',\n",
       "  'JJ'),\n",
       " ('hi sue thank kind wish yes neuro right low lymphocyt general good thing rrms tec ms dmds aim im case unfortun look may scan high level activ lesion neuro said i must high rogu lymphocyt within low count he think i one small number patient experi rebound effect stop tec this also happen stop tysabri gilenya in case i get lemtrada sooner later sort i grate for i tell mani mani ms friend manag ms without dmds success stop dmds choic actual feel better everyon physiolog differ differ reaction experi drug dmds end i follow lot advic georg jelinek hes sensibl extrem httpsovercomingmsorg good luck',\n",
       "  'NN'),\n",
       " ('i found sleep day day treatment not i paclitaxel carboplatin avastin i also go go person get frustrat i cant everyth food anoth issu i treatment one go smell textur food make difficult prepar meal i wonder husband help meal prep cleanup i dont spend much time around food love cold food though chemo make feel differ thing even watch commerci entic anymor i love eat they give info pamphlet hospit sure dont cover littl thing chemo patient goe thru wish best journey live day full potenti hug',\n",
       "  'NN'),\n",
       " ('i first ocrevus infus june after first infus i felt like your describ it last day i didnt reaction infus two week later i felt pretti good im hope i start get full dose one visit decemb i dont reaction rest allow bodi adjust i hope your feel better soon',\n",
       "  'NN'),\n",
       " ('lung cancer awar month opportun focus promis research field recent health expert around globe gather toronto world confer lung cancer in case miss need refresh compil list key find present event know durvalumab found prolong surviv patient stage iii unresect nonsmal cell lung cancer nsclc a phase trial valid drug progressionfre surviv pfs benefit found overal surviv os benefit studi overal surviv durvalumab versus placebo chemoradiotherapi stage iii nsclc patient experienc better pfs brigatinib crizotinib in ongo phase studi research compar efficaci brigatinib crizotinib alkposit local advanc metastat nsclc treat alk inhibitor so far headtohead analysi investig found pfs longer patient treat brigatinib vs crizotinib studi brigatinib vs crizotinib patient alk inhibitorna advanc alk nsclc first report phase trial a phase trial niraparib initi patient extensivediseas smallcel lung cancer edsclc approxim patient edsclc enrol random doubleblind trial the goal studi evalu efficaci niraparib mainten therapi edsclc studi a ph studi niraparib mainten therapi l platinum respons extens diseas small cell lung cancer patient nintedanib surviv benefit coupl pemetrexedcisplatin patient unresect malign pleural mesothelioma mpm in revers observ phase trial nintedanib phase studi demonstr statist signific clinic meaning improv surviv pfs studi nintedanib pemetrexedcisplatin patient unresect mpm phase iii result lumemeso trial whole brain radiotherapi wbrt concurr erlotinib benefit patient nsclc multipl brain metastas wbrt alon in phase studi research enrol particip nsclc least metastat brain lesion random assign receiv either wbrt wbrt plus concurr erlotinib studi phase trial whole brain radiotherapi concurr erlotinib versus wbrt alon nsclc brain metastas relat articl perspect combin immunotherapi nsclc ct screen reduc lung cancer death highrisk asymptomat patient tislelizumab show antitumor activ lung cancer aprepit plus palonosetron dexamethason found effect prevent chemotherapyinduc nausea vomit cinv patient local advanc metastat lung cancer in phase random trial patient local advanc metastat lung cancer administ either aprepit placebo addit palonosetron dexamethason studi phase iii random trial palonosetron dexamethason without aprepit prevent fulldos singleday cisplatinbas cinv lung cancer patient advanc metastat previous treat nsclc may benefit receiv metformin atezolizumab research retrospect explor use metformin patient nsclc random phase oak trial investig atezolizumab treatment advanc metastat previous treat nsclc studi retrospect descript analysi metformin atezolizumab advanc nonsmal cell lung cancer oak trial darbepoetin alfa noninferior placebo os pfs anem patient nsclc receiv myelosuppress chemotherapi the doubleblind random placebocontrol phase studi found darbepoetin alfa signific reduc odd transfus hemoglobin gdl studi a doubleblind random placebocontrol phase noninferior studi darbepoetin alfa anemia advanc nsclc refer iaslc th world confer lung cancer intern associ studi lung cancer septemb access novemb',\n",
       "  'NN'),\n",
       " ('it offici cannabi legal canada so avail prescript readili avail without prescript peopl may start use conjunct replac cancer treatment ctoam want cancer patient love one know fact make lifealt potenti harm decis help cancer patient famili awar option crucial ctoam goal save live improv cancer care everyon check issu ctoam newslett learn myth truth cannabi cancer treatment do want lifesav inform deliv straight inbox sign month newslett the truth about cannabi cancer doe it help harm truth cannabi can not cure cancer there sever pervas conspiraci theori claim cannabi someth els simpl natur cure cancer giant pharmaceut compani hide fact year howev theori key flaw the first giant pharmaceut compani alreadi found cure would huge profit given half us get cancer point live therefor itd best capitalist interest suppress moreov number peopl would need complicit keep secret magnitud would stagger mani decad secret suppos kept doubt least one peopl would come forward truth either hero make money stori the realiti simpl no conspiraci hide cure cancer cannabi otherwis from sciencebas perspect mani clinic studi subject year still evid cancer cure cannabi there studi impli cannabi effect cancer petri dish this mislead even saliva kill cancer petri dish know saliva cant kill cancer person explain alex rolland oncogenom expert ctoam director scientif research truth cannabi can help symptom relat chemotherapi radiat for year cannabi prescrib help allevi nasti side effect chemotherapi radiat shown help reduc nausea increas appetit decreas stress improv sleep truth smoke cannabi may increas chanc develop lung cancer burn plant matter natur releas carcinogen cannabi cigarett rare filter less tight pack allow smoke get lung compar tobacco cigarett further peopl typic hold cannabi smoke lung much longer tobacco cigarett amount tar deposit lung smoke cannabi cigarett roll cannabi approxim four time despit studi current show weak link smoke cannabi develop lung cancer consid whether smoke cannabi potenti risk lung cancer taken account truth cannabi can benefit or harm other cancer treatment chemotherapi radiat remain standard cancer treatment within canadian public healthcar system howev precis oncolog target treatment continu grow popular use cannabi addit impact peopl tend think anyth natur like cannabi interact pharmaceut medicin this isnt true cannabi interact cancer treatment interact benefici harm depend variabl involv if your consid alreadi use cannabi part cancer care import speak cancer care team potenti interact treatment so the current truth smoke cannabi cure cancer help unpleas side effect cancer treatment smoke cannabi may increas risk lung cancer potenti benefit harm differ kind cancer treatment critic open discuss cannabi use care team as time goe depth research subject grow hope well continu uncov full potenti cannabi hold cancer care if youd like know precis oncolog target treatment want speak expert cannabi might impact current cancer treatment contact us today discov what is scientif proven work book your free consult today give us minut feel more confid your cancer treatment option katherin lung cancer success stori yearold katherin diagnos nonsmal cell lung cancer nsclc offer standard chemotherapi ctoam cancer specialist recommend get test egfr mutat a biopsi test reveal katherin egfr posit nsclc this biopsi provid public oncologist base data public oncologist tri first generat egfr inhibitor tarceva unfortun katherin stop respond drug eight month katherin oncologist told standard chemotherapeut drug would provid temporari relief would stop progress diseas while start platinumbas regimen side effect strong ct scan show diseas progress katherin wasnt readi accept reach ctoam consult read katherin lung cancer treatment how improv treatment success reduc stress there doubt youll greater confid whatev action take cancer treatment ctoam second opinion ctoam alway year ahead standard care whi becaus cancer expert spend everi day research latest advanc cancer care weve use target treatment like immunotherapi cancer patient mani year long standard care start use explor rang servic packag discov right fit which ctoam servic packag right with cancer time essenc discov live longer precis oncolog schedul free consult today you noth lose year gain book your free consult cancer expert today if question pleas contact us anytim ctoam cancer care consult scienc support for all thing cancer sign ctoam newslett stay uptod latest advanc cancer treatment diagnost support',\n",
       "  'NN'),\n",
       " ('hi antonett fick funni mention gilenya i given choic mavenclad gilenya i told mavenclad higher effici rate hi stumbler thank input websit i realli hope effect your truli amanda',\n",
       "  'NN'),\n",
       " ('ghadiri m fitzgerald l rezk a li r nyirenda m haegert d giacomini ps baror a antel j reconstitut peripher immun repertoir follow withdraw fingolimo mult scler doi backgroundfollow fingolimod cessat immun reconstitut lack thereof may consequ diseas rebound safeti commenc altern therapi objectiveto examin degre profil peripher blood lymphocyt reconstitut follow fingolimod withdraw method total lymphocyt count tlc cdcd tcell count measur multipl sclerosi ms patient pretreat fingolimod month postcess tcell subset analyz use flow cytometri result at week postfingolimod cessat tlc reconstitut variabl correl age treatment durat pre ontreat tlc despit normal tlc cdcd ratio month naiv subset remain lower effector memori subset higher frequenc compar pretreat druginduc increas ratio regulatori pathogen thcontain central memori popul appear rapid return baselin conclus earli peripher lymphocyt reconstitut fingolimod withdraw remain partial heterogen relat frequenc circul naiv memori tcell subset may recov mani month even clinic laboratori test normal analyz specif compon peripher immun repertoir help defin overal immun status patient to determin whether assess immun measur implic time safeti commenc altern therapi fingolimod immunemigr inhibit agent this mean rebound occur cell come nich suppos held loss sphingosin one phosphat receptor howev examin blood see subset white cell disappear blood also see individu loss white blood cell this studi reiter issu say despit withdraw drug peopl reconstitut immun system this would perhap suggest fingolimod may deplet immun stem cellsprogenitor peopl reconstitut proper this say action simpl blockad migrat i may suggest kill cell we know happen evid literatur the question common issu reconstitut immun system open infect that effector memori cell common consist mechan express ccr sphingosinenephosph one receptor use allow naiv central memori t cell exit lymphoid gland furthermor t cell reconstitut alway memori t cell repopul quicker naiv t cell howev concern individu reconstitut mean may risk infect so leav problem transit fingolimod if wait long start next treatment rebound diseas activ could occur howev may heard suggest fingolimodswitch alemtuzumab mean diseas activ return case fingolimod trap cell lymph gland i think bonemarrow alemtuzumab cant get delet but antibodi quick gone fingolimod keep cell away antibodi howeverwhat lack lymphocyt deplet longterm problemat we seen peopl cell number recov use anoth immun deplet coinon',\n",
       "  'NN'),\n",
       " ('thank let join i diagnos crohn year ago initi i alot pain my circumst chang i lot les stress pretti much symptom free apart diarrohea til i rectovagin fistula now i seton can anyon tell long like i commenc humira short gi ad methotrex doe mean downhil post edit kiwig am gmt',\n",
       "  'NN'),\n",
       " ('thank repli lisa we spent hour today lab work result rutger we keytruda infus didnt begin my mom done readi mind apt infus u imagin stress tire she refus go back went thru we schedul apt bask ridg im glad thing went smooth we prob end go',\n",
       "  'NN'),\n",
       " ('i taken varieti biolog remicad first i develop antidsdna antibodi need stop almost three year then went humira month i develop sever reaction due extrem high antidsdna antibodi mind antibodi differ antibodi remicad then switch simponi year onli coupl flare up joint had stop i develop allergi medic manifest head bottom feet rash i take stelera month i love done joint my back pain gone peripher joint painfre crohn still remiss be mind intestin crohn went remiss remicad stay sinc moder crohn diseas osteoarthr irrit bowel forum cd ankylos spondyl small fiber peripher neuropathi avascular necrosi peripher arteri diseas pulmonari hypertens degen disc diseas asthma sever allergi host medic problem',\n",
       "  'JJ'),\n",
       " ('no one say humira affect it might get remiss give old self back someth anyon promis truth crohn complex diseas even peopl remiss intestin still ongo issu fatigu ib joint problem etc id say youv got luxuri time give humira go may one lucki one if make decis think care go humira dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'RB'),\n",
       " ('meet amit im program manag larg credit card compani male chicago ulcer coliti diagnos marri two kid otherwis healthi human on th drug uc possibl per gi potenti near surgeri decis some amit i sold first web page mortgag broker use netscap my favorit instrument tabla i like read kid novel read school current symptom bm per day abdomin pain bms food intak trigger bm blood stool scope march complet clean full remiss biopsi negat colonoscopi travel abroad flex sig may moder coliti biopsi posit amit ulcer coliti stori i diagnos uc i start mba program work full time it stress kid small requir lot attent stress high i hospit time requir iv steroid seem hospit stay requir new medicin i also visit mayo clinic day univers chicago gi dept my doctor inform last visit i may need surgeri simponi work humira class drug fail tofacitinib market week to chose surgeri would tri anyth avail today fecal transplant drug approv like tofacitinib rate shingl patient serious altern therapi my doctor well vers head dept major hospit still ever address diet anyway previous gi told sinc i med i eat whatev i pleas i still shock would choos empow patient materi httpwwwcrohnscolitisfoundationorglivingwithcrohnscolitisbookstorehtml perhap specif doctor us i ask doctor reduc inflamm turmer respons i lucki there evid prove would help is anyth might ask doctor tri besid surgeri medic are nonallopath clinic healer would recommend someon junctur current take simponi imuran mg lialda canasa tramadol ask get shingrix shot prepar newest medicin approv uc tofacitinib i med surgeri want prepar make decis medic histori initi lialda mesalamin work fine year after st hospit inpati stay imuran ad after anoth stay mp ad blood test period determin caus liver toxic after determin immunosuppress work i introduc biolog next line defens first remicad entyvio simponit hospit stay current w simponi i still take lialda imuran part combo therapi this current regim work i flare month howev last visit doctor mention surgeri it first time ever ask look depress altern humira would chanc work tofacitinib someth i would like feedback anyon site so option increas frequenc simponi i start today humira low success rate tofa citinib littl data surgeri dr believ improv qualiti life after read procedur still go timesday potenti med i convinc written amit submit coliti vent area',\n",
       "  'VBZ'),\n",
       " ('hi the follow diseas modifi drug approv use nhs uk the avail drug may vari england scotland wale northern ireland aubagio teriflunomid avonex interferon beta betaferon interferon beta b brabio glatiram acet copaxon glatiram acet extavia interferon beta b gilenya fingolimod lemtrada alemtuzumab mavenclad cladribin plegridi peginterferon beta rebif interferon beta tecfidera dimethyl fumar tysabri natalizumab i hope help start point tell one recommend neurologist i dont rr i pp i expect contributor help anthoni',\n",
       "  'JJ'),\n",
       " ('there two main group within total white cell popul lymphocyt neutrophil veri broad speak lymphocyt activ viral infect neutrophil bacterialbut everyth immun complex gilenya sequest lymphocyt lymph node instead circul prevent messeng activ cns it said total number actual preserv readi act need less circul thus measur blood test a reduct lymphocyt count may report less expect mani centr toler have said lower count longer risk atyp infect herp zoster shingl common even fear pml some gilenya user reduc total white cell count neutrophil problemat if doesnt respond lower dose may need stop for surgeri want adequ neutrophil number arent fuss lymphocyt that basic answer complic problem i suspect junior doctor didnt experi lymphocyt count abnorm normal gilenya consult later overrid but need clarifi exact count ask full result opportun discuss i manag low white cell count gilenya reduc doseprolong dose interv everi third day but i made activ decis risk infect relaps see post forum help enough happi add requir judi',\n",
       "  'NN'),\n",
       " ('hello guy i write look advic i start take gilenya day ago sinc i got relaps hospit howev i order professor jelinek book start read what i read medicin hit hard doctor share inform howsoev i year old plane child year two definit dont feel like left disabl give birth wors child sort disabl also th day take i got yeast infect i still antibiot can give advic i stop drug i long i guess damag big i afraid anoth relaps i om program one week precis i start right i got hospit i feel a lot better sinc mayb gilenya ani advic would much appreci wish well',\n",
       "  'NN'),\n",
       " ('accord studi publish cancer octogenarian nonagenarian stage iii nonsmal cell lung cancer nsclc receiv cancerdirect care despit evid standard care concurr chemotherapi plus radiotherapi crt improv overal surviv os although nsclc one common diagnos form cancer manag among patient age year older remain larg unstudi for studi investig access nation cancer data base ncdb evalu treatment outcom elder patient newli diagnos advanc nsclc three treatment group identifi patient receiv treatment patient receiv definit radiat patient receiv crt various patient demograph includ age sex race comorbid insur status educ resid incom diseas characterist assess more onequart patient receiv crt compar patient receiv therapi wors os outcom observ among patient receiv treatment hazard ratio hr ci radiat hr ci compar patient receiv crt propens score match baselin variabl show receiv crt associ wors os outcom hr ci relat articl proton therapi may not reduc radiat exposur nonsmal cell lung cancer fda accept supplement new drug applic osimertinib firstlin treatment egfrmut nsclc phase trial sbrt gene therapi prior nivolumab nsclc twoyear os estim ci crt arm ci radiationon arm ci treatment arm p live lowereduc area odd ratio or ci african american or ci associ receiv cancerdirect care refer',\n",
       "  'VBP'),\n",
       " ('but doesnt tecfidera slow rate deterior wherea lemtrada cladribin potenti stop ms deterior peopl see improv symptom i dont understand neurologist prescrib tecfidera gilenya tysabri anymor it seem everyon choos stop ms slow ms whi would anyway choos slow option',\n",
       "  'NN'),\n",
       " ('i complet agre poppi expect diseas modifi drug chang day day symptom wont a dmds purpos reduc number sever relaps if take tecfidera still relaps work but rather swap gilenya youd probabl qualifi tysabri which better drug fewer side effect better averag relaps reduct rate the qualif tysabri activ ms ie still frequent relaps tri fail anoth dmd if your relaps dmd suppos manag side effect would probabl better stick one rather switch differ drug howev say damag caus previous relaps give ongo symptom probabl talk ms nurs deal ongo symptom there could drug therapi treatment aid help sue',\n",
       "  'NN'),\n",
       " ('am from gregorioallegri aml i certain well inform friend oncolog doc mayb well inform tri wwwamlglobalportalcom look clinicaltrialsgov search acut myeloid leukemia make sure get mutat profil aml like nsclc actual complex sever diseas vari genet caus if lucki may target therapi trial join use offlabel eg ponatinib vs certain mutant form flt if target therapi might consid pd checkpoint inhibitor opdivo keytruda ncbinlmnihgov pd inhibitor might better choic target therapi diseas quit advanc tend work almost mutat type it amaz big pharma keep tri chemo drug opinion their effect versus diseas appear superfici investig limit take grain salt i comput chemist oncolog doc ga',\n",
       "  'NN'),\n",
       " ('i sorri hear chemo work dmfan the encourag news immunotherapi opdivo shown great promis shrink lung tumor even tumor spread brain some even tumor disappear i famili member lung cancer met brain small cell lung cancer differ beast it hard even still say may happen everyon react differ so much depend type lung cancer non small small sub type brain health issu treatment alreadi done mani thing it multi factori i know hear frustrat give answer look i sorri the one truli answer question dad doctor know situat best i hope opdivo provid great result dad keep us updat jodi',\n",
       "  'NN'),\n",
       " ('ann im sorri hear lung cancer diagnosi broken femur ordeal go thru are met leg bone vertebra new sinc begin treatment i assum recent pet scan follow recent one serv base line my mom receiv session carboalimtakeytruda lung cancer recurr she continu keytruda near year it work well great candid keytruda pdl level she evid diseas near year keep finger cross receiv latest ct result hour like tom said weird thing pop earli treatment immunotherapi pet scan show activ area that organ light activ as tom said activ leg could due activ heal process but time tell my mom wait see program she wait see prior initi diagnosi see lung nodul grew wait see scan hope show cancer return it horribl part diseas but great hand immunotherapyit great thing lot peopl give time get work in meantim continu regular appoint i assum get blood test report side effect troubl issu they keep close eye thing new plan attack ifwhen need take care steff',\n",
       "  'JJ'),\n",
       " ('azpref might also tri contact fred hutchinson seattl they work seattl cancer care allianc univers washington high regard do amaz research mani biotech compani my husband current undergo immunolog treatment metastat melanoma far hes fine been opdivo sinc june good luck',\n",
       "  'NN'),\n",
       " ('barryb cherish doctor bart prescrib cladribin it part trial give peopl ms want you sign disclaim say want cladribin rather ms drug market but get refer anoth doctor i dont think selfref i got appoint dr schmierer bart actual royal london part bart hospit trust refer neurologist he said i first three set inject cladribin four week washout gilenya i take time i inject three adjac day royal london i blood test check lymphocyt count four week later gp surgeri a week i three lot inject royal london i blood test everi four week go forward monitor lymphocyt thing done gp surgeri my symptom walk two stick lot difficulti lift feet make hard go upstair mean i fall quit bit problem bladder control urgenc frequenc past though got lot better year ago wors coupl week ago gilenya system poor balanc weak arm hand leg twitch night the improv ive seen recent im hope cladribin find easier lift feet i walk upstair lift leg hand stair night last first time ive abl month month bladder fine today hour session physio i manag get back onto chair instead help reduc drug i take stop leg twitch i know sound like small thing import i get wors ive got bit better even i dont see improv cladribin would worth deterior stop but im hope see improv',\n",
       "  'NN'),\n",
       " ('i chose go everyth possibl im gilenya scare ms the possibl rebound effect come risk pml skin cancer stay make constant question decis take but said havent relaps immedi side effect i plan eventu come medic im readi yet',\n",
       "  'RB'),\n",
       " ('i sure avastin much differ lucenti eylea the basic it avastin come larger phial suitabl cancer treatment instead small one eye treatment the manufactur drug far refus produc smaller amount suitabl eye treatment this mean anoth compani transfer drug smaller phial may increas risk contamin thus infect in fact actual happen avastin use lucenti eylea develop also i heard patient treatment chang avastin one drug longer work they mention tv mani million nhs safe is head',\n",
       "  'JJ'),\n",
       " ('hello i new came across place look advic new treatment i diagnos rrms i ok rebif time recent mri activ lesion i also suffer dizzi spell weak left hand worst terribl fatigu memori loss difficulti concentr it got point peopl work dont know i ms say i look like someon taken batteri i tri hard let peopl notic get harder i also random symptom find hard say normal ms caus anyway i went hospit today med look due mri result the advic neurolagist go mavenclad gilenya i read everyth i could find also look i sure choos i like idea maveclad year treatment total day year i know i still need monitor seem ideal someth said bother i sure they said gilenya tablet daili mean i stop effect wear mavenclad revers not sure problem seem final also say treatment need year what happen year noth mention anywher cours expect ms stay remiss i think thing i need email ms nurs she say would yreat wirh mevenclad would work gilenya coupl altern the side effect th gilenya seem wors i drawn mavenclad just realli hard make decis i know none tell choos help know might other shoe least understand im deal thank read post would appriciat advic similar situat also anyon mavenclad treatment i know start seen post anyon start thank',\n",
       "  'NN'),\n",
       " ('electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move the major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect it import replac miss electrolyt becom rebalanc how done depend sever imbal if minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi an mri scanner larg tube contain power magnet you lie insid tube scan mris help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimus astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes common caus scar surgeri less common scar due activ inflammatori bowel diseas adhes fibrous band form tissu caus pain blockag intestin post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit a bowel resect surgic procedur part larg small intestin remov post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit a hemicolectomi involv surgeri remov right left portion colon',\n",
       "  'NN'),\n",
       " ('that im dread it one question monday laser haemorrhag go keep tug reopen sure need laser near base abnorm grown vessel pull jelli fall awaywith ive heard mani vitrectomi stori improv vision fix problem make want suggest antivegf instead there hope us stop point futur year get point hope itll minim loss vision hope recoveri stabilis happen soon x click expand i ask inject i told stage would help would make everyth wors i may need inject line fluid told inject bleed gone month stop inject bleed activ',\n",
       "  'NN'),\n",
       " ('alright sofiagaston i start ocrevus tuesday ive known ms sinc novemb so whether input good i dont know im honesti i suffer none infus relat side effect cant wait get second half infus week tuesday so i guess i cant realli talk good gonna hey i know noth diseas im game pheasant take marlon',\n",
       "  'NN'),\n",
       " ('juhi kund lungev scienc writer last weekend close oncolog profession includ superstar lung cancer research mani member lungev scientif advisori board gather chicago attend annual meet american societi clinic oncolog asco this year confer domin studi focus immunotherapi diseas treatment leverag bodi natur immun respons the field immunotherapi burst option the breakthrough new approach diseas manag flow research treatment lung cancer below i summar highlight asco confer immunotherapi immunotherapi found effect tumor cell express high level protein pdl howev pdl alway reliabl biomark tend fluctuat time area tumor may express pdl area also tumor make pdl protein still respond immunotherapi with mind research work optim biomark use predict patient benefit immunotherapi they found measur tumor mutat burden tmb number mutat tumor dna may promis approach predict patient respons immunotherapi sometim tmb may use conjunct pdl level provid guidanc cancer treatment one import phase clinic trial look bevacizumab anticanc drug known reduc tumor abil promot blood vessel growth requir feed cancer patient advanc nonsquam nonsmal cell lung cancer nsclc the initi result show ad atezolizumab immunotherapi drug bevacizumab carboplatinpaclitaxel two chemotherapi drug often use doublet treatment decreas cancer progress increas overal surviv compar regimen without immunotherapi while research need studi also rais hope patient egfrposit alkposit nsclc the trial result note patient shown progress egfr tyrosin kinas inhibitor tki alk tki respond well combin approach bevacizumab doublet chemotherapi atezolizumab anoth key phase clinic trial studi effect ad immunotherapi agent current recommend firstlin treatment advanc squamous nsclc research found immunotherapi drug pembrolizumab ad doublet chemotherapi patient saw signific increas overal surviv this studi like result chang current guidelin firstlin treatment patient advanc squamous nsclc mani differ clinic studi underway determin optim combin lung cancer treatment includ immunotherapi chemotherapi target therapi radiat also research conduct identifi optim sequenc treatment enhanc patient surviv rate qualiti life nonsmal cell lung cancer driver mutat lot progress also happen nsclc driver mutat in phase clinic trial patient advanc nsclc posit retfus promis result drug loxo select target retfus protein addit studi plan develop treatment option small cell lung cancer excit around rovat continu lungev scientif advisori board member david carbon md phd ohio state univers present phase clinic trial result show protein dll found high level small cell lung cancer sclc tissu healthi tissu could first target therapi advanc sclc the result show rovat bind dll improv overal surviv sclc patient whose cancer return chemotherapi in addit scientist explor potenti immunotherapi sclc data phase clinic trial suggest pembrolizumab may effect sclc patient progress chemotherapi whose tumor posit pdl protein earli detect and final progress liquid biopsi continu field earli detect when someon develop cancer blood often contain piec mutat dna escap die tumor cell tumor dna found blood often call circul dna ctdna plasma cellfre dna plasma cfdna recent liquid biopsi test becom avail analyz ctdna determin whether patient cancer type cancer the result studi present asco suggest techniqu may also use detect earlystag lung cancer the research develop circul cellfre genom atlas ccga aim understand liquid biopsi use earli detect complement ct screen more research underway hope develop techniqu use lifesav tool earli detect lung cancer in presidenti address asco presid dr bruce johnson mention close abl treat half patient nsclc target therapi immunotherapi initi treatment we encourag progress saw asco year confid next year bring even juhi kund ma scienc writer lungev categori earli detect immunotherapi mutat nonsmal cell lung cancer nsclc small cell lung cancer',\n",
       "  'NN'),\n",
       " ('hi wonder anyon heard anyth avail treatment wise alectinib leptomenig diseas alectinib pretti good i see slow chang wife gate eye focus hear well cough my concern alectinib slowli becom ineffectivenot month sinc start treatment we scan schedul week want prepar need thank much i know god bless us thus far keep move forwardthi year sinc diagnos nsclc stage thank',\n",
       "  'NN'),\n",
       " ('i cant speak clinic trial particular i particip clinic trial i think benefit coupl less obvious way number one im much close monitor i would otherwis i relaps treat immedi wherea would like drag week first i trial relaps tend start slowli build come sudden the benefit psycholog i need know im everyth possibl help a coupl caveat if son relaps remit ms control arm approv therapi placebo if progress ms approv therapi may approv live ocrevus progress ms like must placebo control the side affect risk less well known trial for unknown risk trial less scari certain brain damag i choos particip other feel differ there one size fit i person regret particip even though diseas progress zero sinc best luck whatev choos heidi',\n",
       "  'NN'),\n",
       " ('first thank barnsburi share i ask gi also particip trial longest shed seen someon success said year that interest hear long made im two week next infus want post updat transpar ive d week it start salad i atei share someon get sick gave bad gas nausea d coupl day figur i pick littl bug it got better i get period d start also unusu sever timemi period heavi usual hope correl it sinc though ill say doesnt feel uclik it feel like someth go stomach lower gi tract also ive eat kale salad food so best diet choic i also dont fatigu ach pain associ flare im travel next two week general make bit constip well see goe i updat next infus ask bloodwork check inflamm see there notic chang post infus dxd st entyvio infus respond well current entyvio colaz florastor vsl previous apriso hair loss flagyl prednison mesalamin enema tinidazol align lialda imuran allerg asacol ineffect remicad allerg humira ineffect anusol canasa cortifoam',\n",
       "  'NN'),\n",
       " ('sorri guy i got bit end first post im crohn mirowpl good luck entyvio i mean i know experi isnt encourag one ever i seen lot peopl say got remiss scifig ha yeah i wouldnt want gut prettier that i think whole i would still pick clinic remiss hand would annoy symptom explan if case i would start think possibl caus think i pin thing onto crohn per usual cm no right technic i crohn ileocolilti vast bulk diseas colon howev termin ileum affect well i remov along colon henc neo new termin ileum report goe ive tri imuran mp ive mp near year as far i tell mp done noth except make burn easier sun i dont good luck med edit tom thank im certain stelara avail id ask gi while inflamm isnt widespread seem stubborn treatmentresist on plus side im ill entir colon inflam i dont feel entir healthi either i dont think immun system attack bit digest system thyroid eye etc sorri im get bit time go bed i think post edit nicecupoftea pm gmt',\n",
       "  'NN'),\n",
       " ('conner i keep finger cross see success i follow journey close surgeri recommend son turn day we desper altern solut famili year old diagnos ulcer coliti fall tri uceri lialda remicad canasa entyvio everi week imuran sinc june still remiss',\n",
       "  'JJ'),\n",
       " ('i option go studi join studi compar afatinib vs afatinib cetuximab iv rash is benefit combin i consid get tarceva gilotrif studi thank',\n",
       "  'NN'),\n",
       " ('thank lot carm greg livewithcanc concern first mom crazili wellsh done sever round chemo hair loss sideeffect whatsoev shes tire nauseous sick shes shovel snow renov master bedroom xxx everyth normal shes carboplatin etoposid howev yet know chemo work were scan end week nevertheless even assum work chanc firstlin chemo sclc mean that much sclconc typic cours diseas even peopl get complet respons achiev ned firstlin chemo diseas typic come roar back within year point there littl done so that actual im tri figur round plan thatright i option base respons partial respons complet respons in term new treatment your right checkmat there also keynot show thing keytruda my understand doctor prescrib opdivoyervoy keytruda offlabel in addit rovat trial around us howev limit studi seem show efficaci treatment sclc depend certain condit keytruda seem work well pdl express high tmb opdivo high tmb rovat high express dll so ive mom biopsi tissu sent test genet sequenc plus tmb pdl on hand seem commerci avail test dll the hope result point one direct vs other round need mom around long enough new research perhap genet sequenc result prove use im thank day mom well i need face fact diseas year surviv rate unlik cancer stat remain relev almost noth happen new diseas decad unlik nsclc exampl so i want sure everyth keep mom aliv',\n",
       "  'NN'),\n",
       " ('hi jim hope well back report mom ct look good still research xalkori link janin point check i also stumbl upon refer alimta somewhat effect preventingrevers brain met mom met stick one possibl prevent so confus stick alimta thank much support time give unselfish best bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test negat stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr restart alimta on alimta sinc usual ned chemo period less month month recent reoccurr jan alimta jan thru april ned april reoccurr cancer jan restart alimta test posit ros june appt onc discuss futur tx plan',\n",
       "  'NN'),\n",
       " ('tuesday april edt cambridg mass busi wire biogen nasdaq biib present new data demonstr breadth divers market pipelin multipl sclerosi ms therapi th annual meet american academi neurolog aan vancouv canada compani announc today these data support biogen establish portfolio includ mostprescrib oral ms treatment world tecfidera dimethyl fumar demonstr abil differenti product meet distinct need peopl live ms ms complex lifelong diseas affect person differ becaus peopl ms divers treatment need critic varieti therapeut option avail provid robust efficaci differ mechan action also offer flexibl transit anoth treatment need said ralph kern md senior vice presid worldwid medic with world lead ms portfolio grow pipelin biogen continu focus ms care impact greatest number peopl live ms global tecfidera data showcas strong sustain efficaci newli diagnos ms patient reinforc earlier treatment tecfidera critic improv longterm clinic outcom in addit realworld compar effect data show tecfidera associ signific lower annual relaps rate arr relat glatiram acet interferon teriflunomid arr similar tecfidera fingolimod these data support establish combin benefit tecfidera offer includ strong sustain efficaci wellcharacter longterm safeti profil oral conveni with near year clinic experi tysabri natalizumab data highlight realworld evid demonstr proven longterm efficaci safeti particular use earlier cours diseas addit biogen data present highlight impact zinbryta daclizumab hyp cognit outcom target mechan action moa data show caus broad immun cell deplet effect total lymphocyt count revers within approxim eight week upon treatment discontinu highlight biogen aan data present',\n",
       "  'JJ'),\n",
       " ('extendedreleas inject day protein bind plasma bound albumin alpha glycoprotein special popul elder the halflif increas time special popul gender clearanc approxim lower women special popul note cigarett smoke clearanc approxim higher smoker use label indic oral treatment manifest schizophrenia treatment acut mix mania episod associ bipolar i disord monotherapi combin lithium valproat mainten treatment bipolar i disord combin fluoxetin treatmentresist bipolar i depress im extendedreleas zyprexa relprevv treatment schizophrenia im shortact zyprexa intramuscular treatment acut agit associ schizophrenia bipolar i mania off label use chemotherapyassoci acut delay nausea vomit prevent adult data random phase iii studi support use oral olanzapin combin dexamethason palonosetron prevent acut delay chemotherapyinduc nausea vomit chemotherapi nave patient receiv high emetogen chemotherapi navari data random phase ii studi includ chemotherapi nave patient receiv moder highlyemetogen chemotherapi regimen also suggest oral olanzapin combin dexamethason palonosetron may benefici prevent acut delay nausea vomit navari chemotherapyassoci breakthrough nausea vomit adult data random control phase iii studi support use oral olanzapin manag breakthrough nausea vomit associ high emetogen chemotherapi navari base antiemet guidelin american societi clinic oncolog oral olanzapin may use manag breakthrough nausea vomit chemotherapyassoci breakthrough refractori nausea vomit pediatr base pediatr oncolog group ontario pogo guidelin treatment breakthrough prevent refractori chemotherapyinduc nausea vomit oral olanzapin may benefici manag breakthrough refractori nausea vomit if breakthrough nausea vomit occur children receiv acut prophylaxi high emetogen chemotherapi olanzapin may ad antiemet regimen if refractori nausea vomit occur despit use antiemet prophylaxi high emetogen chemotherapi intervent chang ht antagonist addit aprepit unsuccess olanzapin may ad antiemet regimen delirium base nation institut health clinic excel nice nation clinic guidelin centr ncgc guidelin diagnosi prevent manag delirium shortterm cours olanzapin usual week consid treatment delirium individu distress consid risk other verbal nonverb deescal techniqu ineffect inappropri it recommend use antipsychot drug caution patient condit parkinson diseas dementia lewi bodi delusion infest also call delusion parasitosi data limit number patient studi case report suggest olanzapin may benefici treatment delusion infest also call delusion parasitosi bosman freudenmann kenchaiah lim merja addit data may necessari defin role olanzapin condit psychosisagit associ dementia data random doubleblind control trial support use olanzapin treatment psychosi agit relat dementia de deyn meehan schneider street sultzer verhey addit trial may necessari defin role olanzapin condit base american psychiatr associ apa practic guidelin use antipsychot treat agit psychosi patient dementia antipsychot olanzapin may consid treatment agit psychosi certain patient dementia howev evid efficaci modest use limit patient whose symptom danger sever caus signific patient distress due safeti risk associ antipsychot use base world feder societi biolog psychiatri wfsbp guidelin biolog treatment alzheim diseas dementia drug treatment olanzapin behavior psycholog aspect includ hyperact psychosi recommend low dose short durat last option address causat factor use psychosoci intervent posttraumat stress disord data two small random doubleblind placebocontrol trial studi support use mono adjunct therapi olanzapin treatment posttraumat stress disord carey stein addit trial may necessari defin role olanzapin condit base american psychiatr associ apa practic guidelin treatment patient posttraumat stress disord world feder societi biolog psychiatri wfsbp guidelin pharmacolog treatment posttraumat stress disord adjunct olanzapin suggest treatment option patient concomit psychot symptom present firstlin approach ineffect control symptom tourett syndrom data limit number patient studi suggest olanzapin may benefici treatment tourett syndrom children adolesc adult budman mccracken onofrj stamenkov stephen addit data may necessari defin role olanzapin condit base european societi studi tourett syndrom tourett canada guidelin drug therapi includ olanzapin effect recommend manag tourett syndrom improv qualiti life tic pain distress interfer daili function caus sustain social emot problem howev evid support use limit similar base american academi child adolesc psychiatri aacap practic paramet treatment children adolesc tic disord drug therapi includ olanzapin effect recommend manag moder sever tic caus sever impair qualiti life chronic tic disord includ tourett syndrom becaus limit evid risk weight gain metabol side effect aacap guidelin recommend olanzapin use first line medic canadian guidelin recommend avoid use patient overweight baselin childrenadolesc adult contraind there contraind list manufactur label canadian label hypersensit olanzapin compon formul dose adult schizophrenia oral initi mg daili increas mg daili within day thereaft adjust mg daili week interv recommend maximum mgday mainten mg daili dose mg daili use treatmentresist schizophrenia howev support evid limit apa lehman special risk patient initi mg daili recommend patient debilit predisposit hypotens reaction exhibit combin factor may result slower metabol olanzapin eg nonsmok femal patient year may pharmacodynam sensit olanzapin increas dose caution clinic indic extendedreleas inject im note establish toler oral olanzapin prior chang extendedreleas inject maximum dose mg everi week mg everi week patient establish oral olanzapin mg daili initi dose mg everi week dose mg everi week dose mainten dose mg everi week mg everi week patient establish oral olanzapin mg daili initi dose mg everi week dose mainten dose mg everi week mg everi week patient establish oral olanzapin mg daili initi mainten dose mg everi week special risk patient initi mg everi week recommend patient debilit predisposit hypotens reaction exhibit combin factor may result slower metabol olanzapin eg nonsmok femal patient year may pharmacodynam sensit olanzapin increas dose caution clinic indic bipolar i acut mix manic episod oral monotherapi initi mg daili increas mg daili interv less hour mainten mg daili recommend maximum dose mgday combin therapi lithium valproat initi mg daili dose rang mg daili agit acut associ bipolar disord schizophrenia shortact inject im initi dose mg lower dose mg may consid clinic factor warrant addit dose mg may consid howev hour initi dose hour second dose allow dose evalu respons maximum total dose mgday special risk patient consid lower dose mg patient debilit predisposit hypotens reaction may pharmacodynam sensit olanzapin shortact inject iv offlabel rout note the iv rout studi emerg depart patient close monitor respiratori depress chan cole martel taylor the world feder societi biolog psychiatri wfsbp expert consensus panel recommend use intraven medic manag agit except case altern wfsbp garriga monotherapi iv initi mg may provid two addit mg dose minut interv need maximum mg taylor note lower dose mg singl dose studi concomit midazolam chan howev concomit use parenter olanzapin benzodiazepin recommend due potenti excess sedat cardiorespiratori depress depress depress associ bipolar disord combin fluoxetin oral initi mg even adjust toler usual rang mg daili see note treatmentresist depress combin fluoxetin oral initi mg even adjust toler rang mg daili see note note olanzapinefluoxetin combin symbyax when use individu compon fluoxetin olanzapin rather fix dose combin product symbyax approxim dosag correspond follow olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax special risk patient initi mg daili recommend patient predisposit hypotens reaction hepat impair exhibit combin factor may result slower metabol olanzapin eg femal elder nonsmok status may pharmacodynam sensit olanzapin increas dose caution clinic indic chemotherapyassoci acut delay nausea vomit prevent offlabel use oral mg day chemotherapi day follow mg daili day combin dexamethason palonosetron day navari navari chemotherapyassoci breakthrough nausea vomit offlabel use oral mg daili day navari delirium offlabel use oral mg daili day nice delusion infest also call delusion parasitosi offlabel use oral initi mg daili increas gradual base respons toler mgday maximum mgday freudenmann heller addit data may necessari defin role olanzapin condit posttraumat stress disord offlabel use oral initi mg daili adjust dose base respons toler everi week mg daili carey stein tourett syndrom offlabel use initi mg daili increas gradual base respons toler usual dosag rang mg daili pringsheim roessner after initi dosag increment mg week biweek common use dosag adjust clinic trial maximum dosag mgday budman onofrj stamenkov discontinu therapi american psychiatr associ apa canadian psychiatr associ cpa world feder societi biolog psychiatri wfsbp guidelin recommend gradual taper antipsychot avoid withdraw symptom minim risk relaps apa lehman cerovecki cpa addington wfsbp hasan risk withdraw symptom may highest high anticholinerg dopaminerg antipsychot cerovecki when stop antipsychot therapi patient schizophrenia cpa guidelin recommend gradual taper month apa guidelin recommend reduc dose month apa lehman cpa addington continu antiparkinson agent brief period discontinu may prevent withdraw symptom cerovecki when switch antipsychot strategi suggest crosstitr gradual discontinu first antipsychot gradual increas new antipsychot overlap taper maintain dose first antipsychot gradual increas new antipsychot taper first antipsychot abrupt chang abrupt discontinu first antipsychot either increas new antipsychot gradual start treatment dose evid support ideal switch strategi taper rate limit result conflict cerovecki remington dose geriatr refer adult dose shortact im oral consid lower start dose mg daili elder patient may increas clinic indic toler close monitor orthostat blood pressur extend releas im consid lower start dose mg everi week elder patient increas dose caution clinic indic delirium offlabel use oral patient year oral mg daili day nice psychosisagit associ dementia offlabel use shortact im initi dose mg addit dose mg may consid howev least hour initi dose least hour second dose allow dose evalu respons maximum drug exposur mg per episod meehan oral initi mg daili necessari gradual increas base respons toler exceed mg daili in patient without clinic signific respons week taper withdraw therapi in patient adequ respons attempt taper withdraw therapi within month unless symptom recur previous taper attempt assess symptom least month taper least month withdraw therapi apa reus de deyn schneider street sultzer verhey dose pediatr bipolar i acut mix manic episod adolesc year oral initi mg daili adjust mg daili target dose mg daili dose rang mg daili depress associ bipolar i disord combin fluoxetin children adolesc year oral initi mg daili even combin fluoxetin adjust dose need toler safeti dose mg olanzapin combin fluoxetin dose mg studi pediatr refer adult dose note olanzapinefluoxetin combin symbyax schizophrenia adolesc year oral initi mg daili adjust mg daili target dose mg daili dose rang mg daili chemotherapyassoci breakthrough refractori nausea vomit offlabel use infant children adolesc oral mgkgdose daili maximum mgdose necessari may increas mgkgdose daili maximum mgdose flank tourett syndrom offlabel use children adolesc initi mg daili increas gradual base respons toler usual dosag mg daili aacap murphi pringsheim after initi dosag increment mg week biweek use dosag adjust clinic trial maximum dosag mgday mccracken stephen dose renal impair no dosag adjust necessari not remov dialysi dose hepat impair there dosag adjust provid manufactur label except use combin fluoxetin separ compon initi olanzapin dose limit mg daili use caution case hepat liver injuri report olanzapin use reconstitut inject extendedreleas dilut direct final concentr mgml shake vigor mix form yellow opaqu suspens follow reconstitut suspens may store room temperatur use within hour shake vigor resuspend prior administr if foam form let vial stand allow foam dissip use immedi suspens syring suspens may irrit skin wear glove reconstitut inject shortact reconstitut mg vial ml swfi result solut mgml use immedi within hour follow reconstitut discard unus portion do mix diazepam lorazepam haloperidol syring administr shortact inject may administ im iv offlabel rout administ inject subcutan for im administr inject slowli deep muscl for offlabel iv rout administ rapid iv push taylor if dizzi andor drowsi note patient remain recumb examin indic postur hypotens andor bradycardia problem extendedreleas inject for im gluteal inject administ iv subcutan after needl insert muscl aspir verifi blood appear do massag inject site use diluent syring needl provid conveni kit obtain new kit aspir blood occur tablet may administ without regard meal orallydisintegr remov foil blister peel back push tablet foil place tablet mouth immedi upon remov tablet dissolv rapid saliva may swallow without liquid may administ without foodmeal dietari consider tablet may taken without regard meal some product may contain phenylalanin storag inject extendedreleas store control room temperatur exceed c f inject shortact store c c f f excurs permit c c f f freez protect light tablet oral disintegr tablet store c c f f excurs permit c c f f protect light moistur drug interact abirateron acet may increas serum concentr cypa substrat high risk inhibitor monitor therapi abobotulinumtoxina anticholinerg agent may enhanc anticholinerg effect abobotulinumtoxina monitor therapi acetylcholinesteras inhibitor may diminish therapeut effect anticholinerg agent anticholinerg agent may diminish therapeut effect acetylcholinesteras inhibitor monitor therapi acetylcholinesteras inhibitor central may enhanc neurotox central effect antipsychot agent sever extrapyramid symptom occur patient monitor therapi aclidinium may enhanc anticholinerg effect anticholinerg agent avoid combin alcohol ethyl cns depress may enhanc cns depress effect alcohol ethyl monitor therapi alizaprid may enhanc cns depress effect cns depress monitor therapi amifampridin may diminish anticholinerg effect anticholinerg agent anticholinerg agent may diminish therapeut effect amifampridin monitor therapi amisulprid antipsychot agent may enhanc adversetox effect amisulprid manag drug list except monograph discuss detail separ drug interact monograph avoid combin amisulprid may enhanc qtcprolong effect qtprolong antipsychot moder risk avoid combin amphetamin antipsychot agent may diminish stimulatori effect amphetamin monitor therapi anticholinerg agent may enhanc adversetox effect anticholinerg agent monitor therapi antidiabet agent hyperglycemiaassoci agent may diminish therapeut effect antidiabet agent monitor therapi antihepacivir combin product may decreas serum concentr olanzapin monitor therapi antiparkinson agent dopamin agonist antipsychot agent second generat atyp may diminish therapeut effect antiparkinson agent dopamin agonist manag consid use altern antipsychot agent possibl patient parkinson diseas if atyp antipsychot necessari consid use clozapin quetiapin may convey lowest interact risk consid therapi modif azelastin nasal cns depress may enhanc cns depress effect azelastin nasal avoid combin benzodiazepin olanzapin may enhanc adversetox effect benzodiazepin manag avoid concomit use parenter benzodiazepin im olanzapin due risk addit advers event eg cardiorespiratori depress olanzapin prescrib inform provid specif recommend regard oral administr avoid combin blonanserin cns depress may enhanc cns depress effect blonanserin consid therapi modif blood pressur lower agent may enhanc hypotens effect antipsychot agent second generat atyp monitor therapi brimonidin topic may enhanc cns depress effect cns depress monitor therapi bromoprid may enhanc adversetox effect antipsychot agent avoid combin bromperidol may enhanc cns depress effect cns depress avoid combin buprenorphin cns depress may enhanc cns depress effect buprenorphin manag consid reduc dose cns depress avoid drug patient high risk buprenorphin overuseselfinject initi buprenorphin patch butran brand mcghr adult use cns depress consid therapi modif bupropion may enhanc neuroexcitatori andor seizurepotenti effect agent with seizur threshold lower potenti monitor therapi cannabidiol may enhanc cns depress effect cns depress monitor therapi cannabi may decreas serum concentr cypa substrat high risk induc monitor therapi cannabi may enhanc cns depress effect cns depress monitor therapi carbamazepin may decreas serum concentr olanzapin monitor therapi chloral betain may enhanc adversetox effect anticholinerg agent monitor therapi chlormethiazol may enhanc cns depress effect cns depress manag monitor close evid excess cns depress the chlormethiazol label state appropri reduc dose use combin must use consid therapi modif chlorphenesin carbam may enhanc adversetox effect cns depress monitor therapi cimetropium anticholinerg agent may enhanc anticholinerg effect cimetropium avoid combin clarithromycin qtprolong antipsychot moder risk may enhanc qtcprolong effect clarithromycin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi clozapin qtprolong antipsychot moder risk may enhanc qtcprolong effect clozapin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi cns depress may enhanc adversetox effect cns depress monitor therapi cypa induc moder may decreas serum concentr cypa substrat high risk induc monitor therapi cypa inhibitor moder may decreas metabol cypa substrat high risk inhibitor monitor therapi cyproteron may decreas serum concentr cypa substrat high risk induc monitor therapi deferasirox may increas serum concentr cypa substrat high risk inhibitor monitor therapi deutetrabenazin may enhanc adversetox effect antipsychot agent specif risk akathisia parkinson neurolept malign syndrom may increas monitor therapi dimethinden topic may enhanc cns depress effect cns depress monitor therapi domperidon qtprolong agent moder risk may enhanc qtcprolong effect domperidon manag consid altern drug combin if combin monitor qtc interv prolong ventricular arrhythmia patient addit risk factor qtc prolong may even higher risk consid therapi modif doxylamin may enhanc cns depress effect cns depress manag the manufactur diclegi doxylaminepyridoxin intend use pregnanc specif state use cns depress recommend monitor therapi dronabinol may enhanc cns depress effect cns depress monitor therapi droperidol qtprolong antipsychot moder risk may enhanc qtcprolong effect droperidol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi eluxadolin anticholinerg agent may enhanc constip effect eluxadolin avoid combin fluoxetin may enhanc qtcprolong effect qtcprolong agent moder risk monitor therapi flupentixol qtprolong antipsychot moder risk may enhanc qtcprolong effect flupentixol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi fluvoxamin may increas serum concentr olanzapin monitor therapi gastrointestin agent prokinet anticholinerg agent may diminish therapeut effect gastrointestin agent prokinet monitor therapi glucagon anticholinerg agent may enhanc adversetox effect glucagon specif risk gastrointestin advers effect may increas monitor therapi glycopyrrol oral inhal anticholinerg agent may enhanc anticholinerg effect glycopyrrol oral inhal avoid combin glycopyrronium topic may enhanc anticholinerg effect anticholinerg agent avoid combin guanethidin antipsychot agent may diminish therapeut effect guanethidin monitor therapi haloperidol qtprolong antipsychot moder risk may enhanc qtcprolong effect haloperidol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi hydrocodon cns depress may enhanc cns depress effect hydrocodon manag avoid concomit use hydrocodon benzodiazepin cns depress possibl these agent combin altern treatment option inadequ if combin limit dosag durat drug consid therapi modif hydroxyzin may enhanc cns depress effect cns depress monitor therapi iohexol agent with seizur threshold lower potenti may enhanc adversetox effect iohexol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iohexol wait least hour procedur resum agent in nonelect procedur consid use prophylact anticonvuls consid therapi modif iomeprol agent with seizur threshold lower potenti may enhanc adversetox effect iomeprol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iomeprol wait least hour procedur resum agent in nonelect procedur consid use prophylact anticonvuls consid therapi modif iopamidol agent with seizur threshold lower potenti may enhanc adversetox effect iopamidol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iopamidol wait least hour procedur resum agent in nonelect procedur consid use prophylact anticonvuls consid therapi modif ipratropium oral inhal may enhanc anticholinerg effect anticholinerg agent avoid combin itoprid anticholinerg agent may diminish therapeut effect itoprid monitor therapi kava kava may enhanc adversetox effect cns depress monitor therapi lamotrigin may enhanc sedat effect olanzapin monitor therapi levosulpirid anticholinerg agent may diminish therapeut effect levosulpirid avoid combin lithium may enhanc neurotox effect antipsychot agent lithium may decreas serum concentr antipsychot agent specif note chlorpromazin monitor therapi magnesium sulfat may enhanc cns depress effect cns depress monitor therapi mequitazin antipsychot agent may enhanc arrhythmogen effect mequitazin manag consid altern one agent possibl while combin specif contraind mequitazin label describ combin discourag consid therapi modif methotrimeprazin cns depress may enhanc cns depress effect methotrimeprazin methotrimeprazin may enhanc cns depress effect cns depress manag reduc adult dose cns depress agent initi concomit methotrimeprazin therapi further cns depress dosag adjust initi clinic effect methotrimeprazin dose establish consid therapi modif methylphenid antipsychot agent may enhanc adversetox effect methylphenid methylphenid may enhanc adversetox effect antipsychot agent monitor therapi metoclopramid may enhanc adversetox effect antipsychot agent avoid combin metyrosin cns depress may enhanc sedat effect metyrosin monitor therapi metyrosin may enhanc adversetox effect antipsychot agent monitor therapi mianserin may enhanc anticholinerg effect anticholinerg agent monitor therapi minocyclin may enhanc cns depress effect cns depress monitor therapi mirabegron anticholinerg agent may enhanc adversetox effect mirabegron monitor therapi mirtazapin cns depress may enhanc cns depress effect mirtazapin monitor therapi nabilon may enhanc cns depress effect cns depress monitor therapi nitroglycerin anticholinerg agent may decreas absorpt nitroglycerin specif anticholinerg agent may decreas dissolut sublingu nitroglycerin tablet possibl impair slow nitroglycerin absorpt monitor therapi obetichol acid may increas serum concentr cypa substrat high risk inhibitor monitor therapi onabotulinumtoxina anticholinerg agent may enhanc anticholinerg effect onabotulinumtoxina monitor therapi ondansetron may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi opioid analges cns depress may enhanc cns depress effect opioid analges manag avoid concomit use opioid analges benzodiazepin cns depress possibl these agent combin altern treatment option inadequ if combin limit dosag durat drug consid therapi modif orphenadrin cns depress may enhanc cns depress effect orphenadrin avoid combin oxatomid may enhanc anticholinerg effect anticholinerg agent avoid combin oxomemazin may enhanc cns depress effect cns depress avoid combin oxycodon cns depress may enhanc cns depress effect oxycodon manag avoid concomit use oxycodon benzodiazepin cns depress possibl these agent combin altern treatment option inadequ if combin limit dosag durat drug consid therapi modif paraldehyd cns depress may enhanc cns depress effect paraldehyd avoid combin peginterferon alfab may increas serum concentr cypa substrat high risk inhibitor monitor therapi pentamidin system may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi perampanel may enhanc cns depress effect cns depress manag patient take perampanel drug cns depress activ avoid complex highrisk activ particular drive requir alert coordin experi use combin consid therapi modif pimozid may enhanc qtcprolong effect qtprolong agent moder risk avoid combin piribedil antipsychot agent may diminish therapeut effect piribedil piribedil may diminish therapeut effect antipsychot agent manag use piribedil antiemet neurolept contraind use antipsychot neurolept except clozapin recommend avoid combin potassium chlorid anticholinerg agent may enhanc ulcerogen effect potassium chlorid manag patient drug substanti anticholinerg effect avoid use solid oral dosag form potassium chlorid avoid combin potassium citrat anticholinerg agent may enhanc ulcerogen effect potassium citrat avoid combin pramlintid may enhanc anticholinerg effect anticholinerg agent these effect specif gi tract consid therapi modif qtprolong agent highest risk may enhanc qtcprolong effect olanzapin manag consid altern combin patient risk factor eg older age femal sex bradycardia hypokalemia hypomagnesemia heart diseas higher drug concentr like greater risk toxic consid therapi modif qtprolong antidepress moder risk qtprolong antipsychot moder risk may enhanc qtcprolong effect qtprolong antidepress moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qtprolong antipsychot moder risk may enhanc qtcprolong effect olanzapin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk except amisulprid clozapin droperidol flupentixol olanzapin pimozid monitor therapi qtprolong class ic antiarrhythm moder risk may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qtprolong kinas inhibitor moder risk qtprolong antipsychot moder risk may enhanc qtcprolong effect qtprolong kinas inhibitor moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qtprolong miscellan agent moder risk may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk except domperidon monitor therapi qtprolong moder cypa inhibitor moder risk may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qtprolong quinolon antibiot moder risk may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi quinagolid antipsychot agent may diminish therapeut effect quinagolid monitor therapi ramosetron anticholinerg agent may enhanc constip effect ramosetron monitor therapi rimabotulinumtoxinb anticholinerg agent may enhanc anticholinerg effect rimabotulinumtoxinb monitor therapi ritonavir may decreas serum concentr olanzapin monitor therapi rufinamid may enhanc adversetox effect cns depress specif sleepi dizzi may enhanc monitor therapi saquinavir qtprolong antipsychot moder risk may enhanc qtcprolong effect saquinavir manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi secretin anticholinerg agent may diminish therapeut effect secretin manag avoid concomit use anticholinerg agent secretin discontinu anticholinerg agent least halfliv prior administr secretin consid therapi modif select serotonin reuptak inhibitor cns depress may enhanc adversetox effect select serotonin reuptak inhibitor specif risk psychomotor impair may enhanc monitor therapi serotonin modul may enhanc adversetox effect antipsychot agent specif serotonin modul may enhanc dopamin blockad possibl increas risk neurolept malign syndrom antipsychot agent may enhanc serotonerg effect serotonin modul this could result serotonin syndrom except nicergolin monitor therapi sodium oxyb may enhanc cns depress effect cns depress manag consid altern combin use when combin use need consid minim dose one drug use sodium oxyb alcohol sedat hypnot contraind consid therapi modif sulpirid antipsychot agent may enhanc adversetox effect sulpirid avoid combin suvorex cns depress may enhanc cns depress effect suvorex manag dose reduct suvorex andor cns depress may necessari use suvorex alcohol recommend use suvorex drug treat insomnia recommend consid therapi modif tapentadol may enhanc cns depress effect cns depress manag avoid concomit use tapentadol benzodiazepin cns depress possibl these agent combin altern treatment option inadequ if combin limit dosag durat drug consid therapi modif teriflunomid may decreas serum concentr cypa substrat high risk induc monitor therapi tetrabenazin may enhanc adversetox effect antipsychot agent monitor therapi tetrahydrocannabinol may enhanc cns depress effect cns depress monitor therapi tetrahydrocannabinol cannabidiol may enhanc cns depress effect cns depress monitor therapi thalidomid cns depress may enhanc cns depress effect thalidomid avoid combin thiazid thiazidelik diuret anticholinerg agent may increas serum concentr thiazid thiazidelik diuret monitor therapi tiotropium anticholinerg agent may enhanc anticholinerg effect tiotropium avoid combin tobacco smoke may diminish therapeut effect olanzapin tobacco smoke may decreas serum concentr olanzapin monitor therapi topiram anticholinerg agent may enhanc adversetox effect topiram monitor therapi trimeprazin may enhanc cns depress effect cns depress monitor therapi umeclidinium may enhanc anticholinerg effect anticholinerg agent avoid combin valproat product may decreas serum concentr olanzapin monitor therapi voriconazol may enhanc qtcprolong effect qtprolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi zolpidem cns depress may enhanc cns depress effect zolpidem manag reduc intermezzo brand sublingu zolpidem adult dose mg men also receiv cns depress no dose chang recommend women avoid use cns depress bedtim avoid use alcohol consid therapi modif advers reaction oral cardiovascular orthostat hypotens central nervous system drowsi dose depend adolesc adult extrapyramid reaction dose depend adult adolesc akathisia adolesc adult parkinsonianlik syndrom includ akinesia cogwheel rigid extrapyramid syndrom hypertonia hypokinesia make faci tremor dizzi adult adolesc headach adolesc fatigu dose depend adolesc adult insomnia endocrin metabol increas serum prolactin adolesc adult weight gain adult report high adolesc gastrointestin increas appetit adolesc adult xerostomia dose depend adult adolesc dyspepsia adult adolesc constip adolesc adult hepat increas serum ast adolesc decreas serum bilirubin adolesc increas serum alt x uln adolesc adult neuromuscular skelet weak dose depend miscellan accident injuri cardiovascular chest pain peripher edema tachycardia hypertens central nervous system person disord abnorm gait hypertonia restless adolesc fall older adult articul impair endocrin metabol increas gammaglutamyl transferas adolesc adult increas uric acid menstrual diseas includ amenorrhea hypomenorrhea delay menstruat oligomenorrhea breast chang male femal adolesc includ discharg enlarg galactorrhea gynecomastia lactat disord gastrointestin abdomin pain adolesc vomit diarrhea adolesc genitourinari urinari incontin adult older adult sexual disord adolesc anorgasmia delay ejacul erectil dysfunct chang libido abnorm orgasm sexual dysfunct urinari tract infect hematolog oncolog bruis hepat increas liver enzym adolesc increas serum alkalin phosphatas neuromuscular skelet tremor dose depend limb pain adolesc adult arthralgia adult adolesc back pain muscl rigid adolesc dyskinesia ophthalm amblyopia respiratori rhiniti cough nasopharyng adolesc pharyng epistaxi adolesc respiratori tract infect adolesc sinus adolesc miscellan fever inject frequenc alway defin unless otherwis note advers event report placebocontrol trial adult patient extend releas im inject zyprexa relprevv also refer advers reaction note oral therapi cardiovascular hypertens hypotens shortact solut im inject prolong qt interv ecg orthostat hypotens shortact solut im inject central nervous system headach sedat drowsi im inject formul akathisia shortact solut im inject dizzi im inject formul fatigu extrapyramid reaction solut im inject abnorm think auditori hallucin parkinsonianlik syndrom shortact solut im inject restless pain abnorm dream procedur pain sleep disord dysarthria dermatolog acn vulgari endocrin metabol weight gain gastrointestin diarrhea vomit xerostomia increas appetit nausea longact im formula shortact solut inject tooth infect toothach abdomin pain flatul genitourinari vagin discharg hepat increas liver enzym infect viral infect local pain inject site im inject formul abscess inject site neuromuscular skelet arthralgia back pain muscl spasm stiff tremor longact im formula shortact solut inject otic otalgia respiratori cough nasal congest nasopharyng upper respiratori tract infect pharyngolaryng pain sneez miscellan fever postmarket andor case report abdomin distens accommod disturb agranulocytosi alopecia anaphylactoid reaction angioedema ataxia cerebrovascular accid chill coma confus delirium diabet mellitus diabet ketoacidosi diabet coma difficulti micturit dress syndrom dri eye syndrom dysarthria facial edema hangov effect hepat injuri cholestat mix hepat hyperbilirubinemia hypercholesterolemia hyperglycemia hyperlipidemia hypermenorrhea hypertriglyceridemia hypoproteinemia impot increas creatin phosphokinas intestin obstruct jaundic ketosi leukocytosi eosinophilia leukopenia liver steatosi mastalgia mydriasi myopathi nausea neurolept malign syndrom neutropenia osteoporosi pancreat polyuria postinject deliriumsed syndrom priapism pruritus pulmonari edema pulmonari embol respiratori depress cole restless leg syndrom rhabdomyolysi seizur skin photosensit skin rash sleep apnea syndrom obstruct health canada shirani speech disturb stupor suicid tendenc syncop tardiv dyskinesia thrombocytopenia tongu edema transient ischem attack urinari frequenc urinari retent urinari urgenc urticaria vasodil venous thrombosi withdraw syndrom alert us box warn increas mortal elder patient dementiarel psychosi elder patient dementiarel psychosi treat antipsychot drug increas risk death analys placebocontrol trial modal durat week larg patient take atyp antipsychot drug reveal risk death drugtreat patient time risk death placebotr patient over cours typic week control trial rate death drugtreat patient approxim compar rate placebo group although caus death vari death appear either cardiovascular eg heart failur sudden death infecti eg pneumonia natur observ studi suggest similar atyp antipsychot drug treatment convent antipsychot drug may increas mortal the extent find increas mortal observ studi may attribut antipsychot drug oppos characterist patient clear olanzapin approv treatment patient dementiarel psychosi postinject deliriumsed syndrom zyprexa relprevv advers reaction sign symptom consist olanzapin overdos particular sedat includ coma andor delirium report follow inject olanzapin extend releas er olanzapin er must administ regist health care facil readi access emerg respons servic after inject patient must observ health care facil health care provid least hour becaus risk olanzapin er avail restrict distribut program call zyprexa relprevv patient care program requir health care provid health care facil patient pharmaci enrol warningsprecaut concern relat advers effect alter cardiac conduct may alter cardiac conduct lifethreaten arrhythmia occur therapeut dose antipsychot anticholinerg effect may caus anticholinerg effect constip xerostomia blur vision urinari retent use caution patient decreas gastrointestin motil paralyt ileus urinari retent bph xerostomia visual problem includ narrowangl glaucoma relat neurolept olanzapin moder potenc cholinerg blockad richelson blood dyscrasia leukopenia neutropenia agranulocytosi sometim fatal report clinic trial postmarket report antipsychot use presenc risk factor eg preexist low wbc histori druginduc leukoneutropenia prompt period blood count assess discontinu therapi first sign blood dyscrasia absolut neutrophil count mm cerebrovascular effect an increas incid cerebrovascular effect eg transient ischem attack stroke includ fatal report placebocontrol trial olanzapin unapprov use elder patient dementiarel psychosi cns depress may caus cns depress impair physic mental abil patient must caution perform task requir mental alert eg oper machineri drive may moder high sedat comparison antipsychot apa lehman doserel effect observ dyslipidemia doserel increas cholesterol triglycerid note use caution patient preexist abnorm lipid profil compar antipsychot risk dyslipidemia high solmi esophag dysmotilityaspir antipsychot use associ esophag dysmotil aspir risk increas age use caution patient risk aspir pneumonia ie alzheim diseas particular patient year herzig maddalena extrapyramid symptom may caus extrapyramid symptom ep includ pseudoparkinson acut dyston reaction akathisia tardiv dyskinesia risk reaction general much lower relat typicalconvent antipsychot frequenc report similar placebo risk dystonia probabl ep may greater increas dose use convent antipsychot male younger patient factor associ greater vulner tardiv dyskinesia includ older age femal gender combin postmenopaus status parkinson diseas pseudoparkinson symptom affect disord particular major depress disord concurr medic diseas diabet previous brain damag alcohol poor treatment respons use high dose antipsychot apa lehman soaresweis consid therapi discontinu signssymptom tardiv dyskinesia fall may increas risk fall due somnol orthostat hypotens motor sensori instabl complet fall risk assess baselin period treatment patient diseas medic may also increas fall risk hyperglycemia atyp antipsychot associ develop hyperglycemia case may extrem associ ketoacidosi hyperosmolar coma death olanzapin may greater associ hyperglycemia atyp antipsychot use caution patient diabet disord glucos regul monitor worsen glucos control patient risk factor diabet eg obes famili histori baselin fast blood sugar fbs period assess glucos regul compar antipsychot risk hyperglycemia high solmi hyperprolactinemia may caus doserel increas prolactin level clinic signific hyperprolactinemia patient breast cancer prolactindepend tumor unknown clinic manifest increas prolactin level includ menstrual sexual breastrel event multiorgan hypersensit reaction drug reaction eosinophilia system symptom dress potenti serious sometim fatal multiorgan hypersensit reaction dress report symptom may includ cutan reaction rash exfoli dermat eosinophilia fever andor lymphadenopathi system complic eg hepat nephriti pneumon myocard pericard discontinu olanzapin dress suspect neurolept malign syndrom nms use may associ nms monitor mental status chang fever muscl rigid andor autonom instabl orthostat hypotens may caus orthostat hypotens use caution patient risk effect would toler transient hypotens episod cerebrovascular diseas cardiovascular diseas hypovolemia concurr medic use may predispos hypotensionbradycardia suicid ideat the possibl suicid attempt inher psychot ill bipolar disord use caution highrisk patient initi therapi prescript written smallest quantiti consist good patient care temperatur regul impair core bodi temperatur regul may occur caution strenuous exercis heat exposur dehydr concomit medic possess anticholinerg effect weight gain signific weight gain baselin weight observ antipsychot therapi incid vari product doserel chang observ olanzapin monitor waist circumfer bmi compar antipsychot risk weight gain high solmi diseaserel concern cardiovascular diseas use caution patient sever cardiac diseas hemodynam instabl prior myocardi infarct ischem heart diseas hypercholesterolemia dementia us box warn elder patient dementiarel psychosi treat antipsychot increas risk death compar placebo most death appear either cardiovascular eg heart failur sudden death infecti eg pneumonia natur use caution patient lewi bodi dementia parkinson diseas dementia due greater risk advers effect increas sensit extrapyramid effect associ irrevers cognit decompens death apa reus olanzapin approv treatment dementiarel psychosi hepat impair use caution patient hepat diseas impair may increas transaminas primarili alt parkinson diseas use caution patient parkinson diseas antipsychot may aggrav motor disturb apa lehman apa reus renal impair use caution patient renal diseas seizur use caution patient risk seizur includ histori seizur head trauma brain damag alcohol concurr therapi medic may lower seizur threshold elder patient may increas risk seizur increas preval predispos factor concurr drug therapi issu drugdrug interact potenti signific interact may exist requir dose frequenc adjust addit monitor andor select altern therapi consult drug interact databas detail inform special popul adolesc use patient year age may result increas weight gain sedat well greater increas ldl cholesterol total cholesterol triglycerid prolactin liver transaminas level compar adult adolesc patient maintain lowest dose necessari smoker olanzapin level may lower patient smoke smoker may requir daili dose higher nonsmok order obtain equival olanzapin concentr tsuda howev manufactur routin recommend dosag adjust dosag formspecif concern intramuscular formul there two zyprexa formul intramuscular inject zyprexa relprevv extendedreleas formul zyprexa intramuscular shortact extendedreleas im inject zyprexa relprevv postinject deliriumsed syndrom us box warn sedat includ coma delirium includ agit anxieti confus disorient observ follow use zyprexa relprevv event associ inadvert rapid rise serum concentr administ regist health care facil patient continu monitor hour symptom olanzapin overdos symptom develop highest first hour may occur within hour risk syndrom cumul inject recoveri expect hour upon determin alert status patient escort destin drive oper heavi machineri remaind day unexplain death two unexplain death patient receiv zyprexa relprevv report the patient die day receiv appropri dose drug both patient found high blood concentr olanzapin postmortem it unclear death result postinject delirium sedat syndrom pdss fda safeti communic restrict distribut program zyprexa relprevv avail restrict distribut program onli prescrib health care facil pharmaci regist program abl prescrib distribut dispens zyprexa relprevv patient enrol meet condit program shortact im inject zyprexa intramuscular patient remain recumb drowsydizzi hypotens bradycardia andor hypoventil rule close monitor orthostasi prior repeat dose concurr use imiv benzodiazepin recommend fatal report though causal determin phenylalanin some product may contain phenylalanin polysorb some dosag form may contain polysorb also known tween hypersensit reaction usual delay reaction report follow exposur pharmaceut product contain polysorb certain individu isaksson lucent shelley thrombocytopenia ascit pulmonari deterior renal hepat failur report prematur neonat receiv parenter product contain polysorb alad cdc see manufactur label other warningsprecaut discontinu therapi when discontinu antipsychot therapi american psychiatr associ apa canadian psychiatr associ cpa world feder societi biolog psychiatri wfsbp guidelin recommend gradual taper antipsychot avoid physic withdraw symptom includ anorexia anxieti diaphoresi diarrhea dizzi dyskinesia headach myalgia nausea paresthesia restless tremul vomit apa lehman cpa addington lambert wfsbp hasan the risk withdraw symptom highest follow abrupt discontinu high anticholinerg dopaminerg antipsychot cerovecki addit factor durat antipsychot exposur indic use medic halflif risk relaps consid in schizophrenia reliabl indic differenti minor major relaps drug discontinu howev studi medic wellstabil patient discontinu indic patient relaps within month indefinit mainten antipsychot medic general recommend especi patient multipl prior episod episod within year apa lehman iv administr iv administr studi emerg depart set patient close monitor respiratori depress ie puls oximetri chan cole martel taylor monitor paramet mental status vital sign clinic indic blood pressur baselin repeat month antipsychot initi year weight height bmi waist circumfer baselin repeat week initi chang therapi quarter consid switch differ antipsychot weight gain initi weight cbc clinic indic monitor frequent first month therapi patient preexist low wbc histori druginduc leukopenianeutropenia electrolyt liver function annual clinic indic person famili histori obes diabet dyslipidemia hypertens cardiovascular diseas baselin repeat annual fast plasma glucos levelhba c baselin repeat month start antipsychot year fast lipid panel baselin repeat month initi antipsychot ldl level normal repeat year interv frequent clinic indic chang menstruat libido develop galactorrhea erectil ejaculatori function visit first week antipsychot initi dose stabl year abnorm involuntari movement parkinsonian sign baselin repeat week dose stabil least week introduct week signific dose increas tardiv dyskinesia everi month highrisk patient everi month ocular examin year patient year everi year younger patient ada lehman marder extendedreleas im inject sedationdelirium hour dose pregnanc risk factor c pregnanc consider advers event observ anim reproduct studi olanzapin cross placenta detect cord blood birth newport antipsychot use third trimest pregnanc risk abnorm muscl movement extrapyramid symptom ep andor withdraw symptom newborn follow deliveri symptom newborn may includ agit feed disord hypertonia hypotonia respiratori distress somnol tremor effect may selflimit requir hospit the acog recommend therapi pregnanc individu treatment psychiatr medic pregnanc incorpor clinic expertis mental health clinician obstetrician primari health care provid pediatrician safeti data relat atyp antipsychot pregnanc limit routin use recommend howev woman inadvert expos atyp antipsychot pregnant continu therapi may prefer switch agent fetus yet expos consid riskbenefit acog if treatment need woman plan pregnanc treatment initi pregnanc olanzapin may use larsen olanzapin may caus hyperprolactinemia may decreas reproduct function male femal health care provid encourag enrol women year age expos olanzapin pregnanc atyp antipsychot pregnanc registri httpwwwwomensmentalhealthorgpregnancyregistri patient educ discuss specif use drug side effect patient relat treatment hcahp dure hospit stay given medicin taken befor give new medicin often hospit staff tell medicin how often hospit staff describ possibl side effect way could understand patient may experi agit loss strength energi constip dri mouth nausea weight gain increas appetit back pain inject site irrit have patient report immedi prescrib sign infect sign high blood sugar confus fatigu thirst hunger polyuria flush fast breath breath smell like fruit anxieti confus sever fatigu weak sever headach abnorm movement twitch chang balanc difficulti swallow difficulti speak mood chang suicid ideat behavior chang sever dizzi pass bradycardia tachycardia lack sweat seizur drool vision chang memori impair chest pain swell arm leg burn numb feel swollen gland enlarg breast nippl discharg sexual dysfunct amenorrhea sign neurolept malign syndrom fever muscl cramp stiff dizzi sever headach confus chang think tachycardia abnorm heartbeat sweat lot sign tardiv dyskinesia unabl control bodi movement tongu face mouth jaw stick mouth pucker puf cheek hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note this comprehens list side effect patient consult prescrib addit question intend use disclaim should print given patient this inform intend serv concis initi refer health care profession use discuss medic patient you must ultim reli discret experi judgment diagnos treat advis patient',\n",
       "  'NN'),\n",
       " ('i dont keep diari i know i i suppos ive long see up down relaps part i dont feel need except cours come head i neuro doesnt believ the inject stop none slow relaps rate i tri differ one stop tecfidera fingolimod extrem side effect advic ms nurseneuro so im mif say least im forc take terifluonomid consid anyth els im also concern i turn round say i dont want take anymor honest im quit close ill burn bridg neuro thank repli i agre take dmd sarah',\n",
       "  'NN'),\n",
       " ('drug chemo therapi target therapi tarceva result rash sever nail chang fatigu kept cancer bay year switch tagrisso same side effect work month far',\n",
       "  'NN'),\n",
       " ('final after sever year drug rrms tri plegridi tecfidera im final back get ocrevus clinic trial i it work spectacular so im excit amus infus center im i netbook usb silent film lucki lionel barrymor rasputin shirt let see goe and yes i appli reciev copay assistanceocrevuscopaycom your interest',\n",
       "  'JJS'),\n",
       " ('kimberlamb yervoy pdl inhibitor it ctla inhibitor show superior respons opdivo opdivo alon the combin block differ checkpoint cancer escap the combo dont checkpoint like dont opdivo keytruda opdivo tecentriq that would total redund',\n",
       "  'NN'),\n",
       " ('i start stelara past spring humira treatment began fail the first infus load dose went fine i given benadryl first inject i littl inject site redd day later next inject i itch side stomach around inject site week then next inject i extrem itch i guess i thought reaction get better wors time stelara help crohn symptom the final inject i worst reaction immedi it start itch week next went neck face lip swell the rash blister bit i look like chicken pox i seen derm gi immunologist all agre stelara i taken i treat prednison topic cream i antibodi remicad go back i took almost year ago i stelara rash continu i finish prednison cours they wonder stelara reaction trigger anoth type autoimmun skin condit i biopsi next week anyon els reaction like biolog i never skin issu thank amat join nov search board messag relat topic my solut uc prob jamesmadison join mar i diagnos uc in usua read cbd ulcer coliti mskelli join jun i post board regard read humira possibl drug ljkclark join jul has anyon develop drug induc lupus humir read crohn coliti communiti forum thank help monitor crohn coliti communiti the abus report sent ani inform crohn coliti communiti site replac physician advic alway check person physician take action regard health crohn coliti foundat this websit support educ grant rule welcom crohn coliti communiti this websit associ ccfaorg support educ grant abbvi pleas read top rule post messag share stori alway courteous sensit other intend audienc the crohn coliti foundat onlin communiti intend patient caregiv famili friend the communiti intend industri repres advertis individu permit particip site meet crohn coliti communiti brows site see communiti talk find issu import join share stori after feel comfort site regist share thought regular basi stay secur rememb site view anyon internet with except registr person page search engin avail within site to guard privaci follow simpl rule share address phone number detail famili anyth els would feel uncomfort other read if post person email awar may receiv spam email spammer gather address web read react post care if dont agre offend someon post take step back think repli sinc cant talk inperson must recogn may misunderstand stori post pleas sensit other feel ask clarif act search start new topic to keep messag board easi use pleas use search bar locat topic interest start new thread if start new thread pleas use obvious subject head word catch attent other topic archiv day inact to view past topic post click archiv topic within forum stick guidelin to keep site safe everyon pleas post doctor name treatment facil name treatment specif contact inform other without consent link websit uncertain content advertis request fundrais item sale request studi survey andor questionnair particip provoc inform share photo pleas use good tast appropri imag ad photo profil person stori photo jpg format not follow rule crohn coliti communiti moder routin scan messag board delet tasteless post if post inappropri messag pictur use offens languag post multipl occas notifi via email account inactiv report foul play help crohn coliti communiti moder report anyon post inappropri messag pictur click report abus button messag email question concern pleas feel free email us question concern we want feel comfort term condit by post stori question concern inform communiti grant crohn coliti foundat author agent permiss publish reproduc record use stori crohn coliti communiti author agent see fit medium forum manner help crohn coliti communiti mission you agre releas hold harmless crohn coliti communiti liabil third parti may aris releas inform third parti third parti agre text content made person parentguardian shall exclus properti crohn coliti communiti the crohn coliti communiti cannot verifi everi claim made third parti contributor communiti respons authent inform post',\n",
       "  'NN'),\n",
       " ('hi stumbler nice id btw ive got good team specialist doctor nurs they feel like famili sort nice kind i talk nurs discuss carryov report pml henc ill need lumbar punctur whichev i decid chang this gone long time i mani question answer i may say choic gilenya mavenclad lemtrada new one call ocrevus avail next month there report pml around macclesfield south manchest stockport ive remain posit way i dark ginger hair kid wore glass age i say be ging maketh man',\n",
       "  'JJ'),\n",
       " ('i still fair new crohn i offic diagnos june week hospit bowel blockag sepsi i remicad year stop work i develop antibodi i put humira it didnt seem anyth gi took i anyth methotrex coupl month the diseas still activ noth sever far my gi want tri stelara has anyon doe bad side effect trish',\n",
       "  'JJ'),\n",
       " ('frankielideo you good high level understand i would suggest given prefer solv issu forget gilenya cost us maintain daili treatment forev you could select instead lemtrada part nhs get safer effect treatment complet month that way dmt cost requir state your cost relat ms could insur polici provid employ medicar depend age healthcar cost unpredict recent effort unilater social tradit free market base healthcar system repres fulli one sixth nation economi we see cost skyrocket avail declin result btw novel infus requir lemtrada one reason select older dmts',\n",
       "  'NN'),\n",
       " ('hello christina i sorri learn eye problem are uk if eyesright suggest pleas call helplin pm monday friday it difficult advis forum even email you need get answer exact diagnosi hospit consult central serous retinopathi csr also known central serous chorioretinopathi csc cscr eye diseas caus visual impair often temporari usual one eye wet macular degener ofetn describ small bleed back eye often treat antivegf inject eylea lucenti sometim avastin label uk pleas see booklet treatment follow link macularsocietyorgsitesd best wish macular societi',\n",
       "  'NN'),\n",
       " ('one medic ocrevus ocrelizumab approv us food drug administr fda treat primari progress ms well relaps form ms in addit diseasemodifi therapi wide rang symptomat medic rehabilit strategi use manag ppms back top if approv diseasemodifi medic help relaps ms dont work ppms the diseasemodifi medic current avail primarili target inflamm central nervous system cns they shown reduc number acut relaps also call attack exacerb number new lesion also call plaqu magnet reson imag mri scan ppms involv much less inflamm gradual destruct loss nerv fiber as result peopl ppms tend fewer brain lesion also call plaqu peopl relaps ms lesion tend contain fewer inflammatori cell the avail diseasemodifi medic effect slow neural damag occur ppms back top my doctor hasnt told kind ms i recommend i start diseasemodifi therapi whi cant tell diseas cours i will medic harm i ppms your doctor may still unsur diseas cours while physician scientist identifi four cours ms person diseas cours uniqu may fit precis within one anoth it may take time doctor decid cours person ms follow peopl transit inflammatori relapsingremit diseas cours less inflammatori secondaryprogress diseas cours may may continu relaps may doctor determin transit occur this inform would factor decis diseasemodifi therapi would right if doctor determin ppms may recommend start ocrevus medic approv fda treatment ppms well relaps form ms back top my ms keep get wors doe everyon ppms becom sever disabl ms variabl unpredict diseas although ppms character fair steadi progress one person symptom may progress differ rapid someon els symptom becaus spinal cord lesion also call plaqu common brain lesion ppms problem walk common symptom may occur well the medic ocrevus approv treat ppms well relaps form ms this medic may slow progress experienc at time ongo symptom manag rehabilit strategi help stay activ maintain safeti independ enhanc qualiti life back top ive read differ symptom ms caus sinc diagnosi ppms biggest problem walk will i develop symptom well becaus peopl ppms tend spinal cord lesion brain lesion problem walk common in fact onset ppms usual character gradual increas problem gait lesion spinal cord also caus bladder bowel symptom well sexual dysfunct fatigu lesion brain could caus symptom develop includ visual disturb cognit chang mood chang balanc problem tremor among other howev way predict ahead time primari challeng may continu walk',\n",
       "  'NN'),\n",
       " ('on feb am chucksan wrote pleas click name andread post opdivo keytruda also tencentriq good result mayb less patient that much better chemo signific less side effect my wife one lucki gone complet remiss opdivo stage nsclc squamous opioid ok pain plain otc ibuporfen advilmotrin good result mani wife sinc pain caus tumor push bone ibuprofen antiinflammatori drug help wife lot these immunolgi drug work cancer differ manner thank chuck i actual came across post i post felt happi know work stage ever sinc dad diagnos i tell go remiss plain blind hope thank inform appreci spread hope us and share experi it help inde',\n",
       "  'IN'),\n",
       " ('hi quantummechan like im wait ocrevus im ppms yet anyth although im assess suitabl take fampyra st month free expens otherwis like i worri take might negat tri ocrevus if get approv im also experienc gradual symptom it toughdo dont should shouldnt i think ask power neurologist ms nursewhat advis no regret though stumbler wise say it stti stick though grasp run wall walk wheelchair keep sens humour howev difficult essenti get quagmir msand pair good boot keep fight xxx',\n",
       "  'NN'),\n",
       " ('hi diagnos two year ago sinc i copaxon i mri three month ago show small new small lesion i want talk doctor switch gilenya unfortun inject damag skin i big ugli dent leg small one arm the part terrifi gilenya macular edema i would like know feel take develop vision problem macular edema the gilenya websit say stop immedi first sign vision problem ani rebif thank',\n",
       "  'NN'),\n",
       " ('my husband amd one shot lucenti affect eye per doctor eye good dr said folk take care one sever treatment dh lucki',\n",
       "  'NN'),\n",
       " ('who realli want thing normal anyway i never i didnt realli need normalci this normal isnt new normal typic sens normal i live metastat cancer and live well i must say to ive need develop mani strategi work around and ive lot help but definit worth qualiti life realli matter mayb strategi work other learn rememb energi limit import kind tricki move target there day i great energi i deep deep odd tired most day though i wake get go go strong noon after anybodi guess i learn week im longer abl push like i alway old life when im done im done kind like babi and okay i priorit sometim bonus time someth love do love ive alway believ make great sens well there lot thing i love cant anymor yet normal that okay ive discov i love lot thing so im focus time one i still like photographi natur mayb adjust i and im learn new thing thing like write blog i sure time read i love read pretti much anyth i four book go right one fiction two health relat one nonfict naturebas none educ that first short breath huf puf havent realli found good strategi except go slow steadi not like much run spring i determin walk new orthofeet sneaker and there digest system issu when i first start crizotinib i took differ med system could toler imodium went everywher i never knew id bout diarrhea and advanc notic usual pad dispos underwear extra cloth dispos wipe carri backpack everywher that doesnt seem normal becam routin in addit cloth i tri rememb carri food i know i eat case i cant eat avail with queen lorlatinib current target therapi drug digest system issu much less time finger cross lorlatinib brought new challeng ive refer earlier one neuropathi common peopl chemotherapi drug peopl diabet as much i love go barefoot i cannot even hous anyon inkl neuropathi feet start wear shoe slipper all time i learn hard way if hand neuropathi tri acupunctur help tremend i tri ointment cannabinoid oil i havent found someth yet i say give relief neuropathi wear glove work even drive keep feet well pad work best and i dont stand still long period time lot peel veggi thing sure bother im fortun i dont tri work luckili im good sleeper doesnt bother much night oh yes ignor feel tick crawl ankl or mayb probabl neuropathi best check i spend lot time look ankl weight interest problem past year four month after fire fall i decid buy i absolut need cloth then i becam sick i began lose weight by time i start crizotinib march id lost lbs im wasnt ever terribl overweight between cancer take toll radiat number esophagus i month eat much eat most liquid form food etc and far cloth went thank radiat i couldnt stand anyth near neck wear bra so daughter bought size small stretchi pant vneck loos top that prefer wardrob ever sinc i eventu gain weight back crizotinib weight gain common drug i idea i store lorlatinib i began juli everyon i know target therapi drug still clinic trial problem degre i start gain pound week yes one pound per week eeek and simpli i feel better eat i wasnt abl exercis enough but thank stretchi cloth i move medium keep mind fire resolut bought i need i begin feel uncomfort extra weight by januari i gain sinc begin lorlatinib juli januari much pregnanc weight gain from march januari that lb weight gain both pregnanc combin without even tri lose gain back plus final januari trial nurs mention someon success paleo diet i tri i wrote earlier paleo work i immedi lost pound havent gain as long i feel well i as ive learn weight loss cancer treatment and weight gain side effect common i work around eat well wear comfi cloth finallywhil tri understand normal i think mayb greatest lesson greatest bless ive gain journey okay let even ask other thing i couldnt anyth someon els littl i ill that i began truli understand gratitud express grate your grate peopl care want thing make life easier brighter struggl someth life i still want everyth i dont feel bad ask help let someon els i dont energi strength i feel love grate and i like look thing i brighten day late week i go danafarb scan blood work brain mri ekg oncolog appoint dan drive wait patient everi step day i post updat hope weekend the prayersposit energi thought follow cancer journey give strength basebal softbal start children fun time grandpar find joy everyday everi day dan famili littl dachshund dotti matilda nigerian dwarf goat',\n",
       "  'VBP'),\n",
       " ('biosimilar rituximab avastin come roch go give fight cash ocrelizumab i glad swedish neurologist show common sens fight back the price new drug hideous',\n",
       "  'JJ'),\n",
       " ('yes i us ani doctor avail make comment thank diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('hello i want see doctor would tri combin carboalimta tarceva either togeth intercal stage lung cancer egfr mutat my mother respond initi tagrisso part treatment possibl lepto carcinomatosi her cns fine develop possibl pneumon tagrisso stop restart tarceva week the next pet month tarceva show signific reduct size activ primari lung mass progress lymph pleura they stop tarceva start chemotherapi after two week one cycl chemotherapi increas size primari mass pleural effus gone i think cell respond chemo cell respond tarceva her oncologist say studi shown benefit increas toxic combin i read good data pfs combin what thought thank',\n",
       "  'NN'),\n",
       " ('the alesia trial compris treatmentnav patient advanc anaplast lymphoma kinas translocationposit nonsmallcel lung cancer confirm system intracrani efficaci alectinib crizotinib asian popul',\n",
       "  'NN'),\n",
       " ('thank janin onc diagnos back jan underw carboalmita cycl good result next put mainten treatment almita progress cycl she went afatinib onc tagrisso fail put carbotaxol howev side effect harsh opt opdivo i know immunotherapi usual doesnt bode well egfr howev mutat kras includ mutat load high enough may indic good respons i understand chemo probabl safest way go term get good respons fast someth els compat almita efficaci side effect get back taxol would probabl difficult thank much help ilan ps sort radiat treatment option liver met numer mayb target main one thank',\n",
       "  'NN'),\n",
       " ('i fail remicad cimzia humira entivyo sigh insur wont cover stelara experiment unsubstanti yomalenorthwood wisconsin dx crohn sept sb resect laproscop ileocecectomi other medic issu anxieti depress panic attack med cymbalta xanax',\n",
       "  'NN'),\n",
       " ('hi tia i diagnos rrms prescrib avonex it made realiti ms miser i cant help think mani folk poor drug miss dose needl in case i couldnt longer after year copaxon got hard administ inject site degrad my neuro put techdidera i take ever sinc im familiar gilenya side effect i got past first dose techfidera i problem i flash friend ask ive sun warn at first dose i start mg i thought i go visit emerg room the stomach pain intens i warn i thought needl previous med push im great techfidera i would recommend give go caution medic effect us differ give bodi chanc get use just cogniz possibl initi side effect make sure start lower dose i hope help good luck michael',\n",
       "  'NN'),\n",
       " ('dekkor you locat pretti close lucki two good ms center near ucsf stanford my wife diagnos year ago went process go go stanford locat penisula i think given qualiti ms center area main question might want consid are compliementari treament improv odd are treatment horizon may impact decis particular treatment today are diagnost might done default consid refer later in area given effici seem move process like given choic tecfidera gileyna ocrevus let us know offer we went tecfidera we avoid gileyna littl tricki come ocrevus new offici less year sinc full fda approv in term point i would strong recommend order copi overcom ms point i would make sure test jcv may default i would also see mri t mri t the resolut make big differ decid year if didnt t push anoth month there thing consid i would recommend start get familar thing get lot appoint come prepar knowledg here video i would recommend well it long bit dri worth time it reput ms center us',\n",
       "  'NN'),\n",
       " ('for helli i realis i answer half question do i think cladribin might cure for peopl mayb in sens cladribin seem stop deterior someth like half peopl see improv well i think cladribin lemtrada lot cheaper drug take rest life and theyr effect do drug compani want close huge market tecifidera tysabri gilenya etc etc probabl i think cladribin better drug lemtrada effect less side effect cladribin may good drug compani want',\n",
       "  'JJ'),\n",
       " ('vitrectomis eye have slower but equal respons to intravitr antivegf a histori vitrectomi contraind antivegf therapi eye diabet macular oedema dme new research suggest in prospect studi statist signific differ safeti efficaci intravitr ranibizumab vitrectomis nonvitrectomis',\n",
       "  'NN'),\n",
       " ('i kick ass morn new workout i stood feet record minut omg that incred grant feet cant move much that ok tremend amount time in physic therapi one main thing peopl multipl sclerosi peopl cant realli stand anymor put devic either stand strap bar hold it big thing stand feet especi without hold where feet might move cant danc step arm move whole time therefor minut arm move i hold so new spectscular amount time i stand i concret evid ill tell im im pool three day week for pool kind i ton thing pool i never land that type therapi extrem help pool im feet whole time i say anoth huge compon vital pack i take doterra first foremost i sleep better when im sleep i longer stretch sleep im deeper sleep i wake feel rest i havent nap afternoon week my energi level seem much higher i honest believ vitamin game changer work insid support cell bodi natur vitamin miner omega capsul huge differ other noth much chang i go back ocrevus infus wednesday this first full dose infus ill certain blog i still whole heart agre biotin high dosag if your take i would definit speak doctor howev i talk year half i dont think that big chang right bodi today i go back general doctor go emerg room visit last week from doctor decid i realli need see cardiologist regard elev muscular skelet enzym my neurologist seem believ statin prescrib then decis i stay drug i dont buy one actual anyth final ill end endocrinologist see weight still creep indic definit ms relat like believ so proud morn it feel good abl accomplish workout still even ms',\n",
       "  'NN'),\n",
       " ('hi afi welcom grace it good hear opdivo show good result i understand interest readi futur treatment option at point clear well tmnegat egfrposit patient fare tagrisso as dr west wrote month ago third generat egfr tkis may prove offer meaning benefit patient tmnegat acquir resist may need search better option elsewher httpcancergraceorglungtmosivsroci in regard howev new biopsi perform test cancer progress tarceva from post seem genet test done prior treatment at junctur tm mutat would de novo mutat one present start rather one develop treatment if hasnt new biopsi possibl tm mutat present anoth question cancer progress initi therapi carboalimta chang tarceva come prescrib number chemo cycl without evid progress when patient stop treatment theyv respond progress reason consid return treatment in case sinc repeat platinum agent advis due increas toxic return pemetrex alimta could consid jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'JJ'),\n",
       " ('im tri post repli the site problem accept hi daxi your mum relat rare egfr mutat exon gx thought respond better second generat tkis like afatinib st rd generat see egfr exon mutat lung cancer molecular predictor augment sensit afatinib neratinib compar first third generat tkis exon mutat includ gx ex exon delet present egfr mutat lung cancer harbor mutat appear higher sensit second generationtki especi afatinib neratinib first third generationtki base vitro experi well clinic data although current avail vitro diagnost kit detect exon mutat lung cancer harbor exon mutat overlook clinic practic patient tumor best treat afatinib neratinib httpclincancerresaacrjournalsorgcontentclincanresearlyccrfullpdf also pattern resist rare mutat differ usual one exon like mum pick tm mutat so doesnt seem promis look erlotinib osimertinib ill look see i find anyth promis one option might quadrupl therapi impow trial i would tri hard get tissu biopsi chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatinvinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       "  'JJ'),\n",
       " ('thank info word honest im probabl nervous chemo glad i found place ifwhen question come i place ask thank hour ago repli durvalumab eagl repli robert macaulay topic immunotherapi ask biomark test at minimum get pdl test see good candid durvalamb the biomark test realli way go i found treatment i good candid durvalamb sinc pdl test prior start treatment that biomark test done i target therapi day take tagrisso sinc i egfr mutat i b went stage durvalamb the target therapi stop progress cancer revers lymph node base measur ct scan you spot power prayer',\n",
       "  'NN'),\n",
       " ('flik e mab index term avakin infliximab recombin infliximababda infliximabdyyb infliximabqbtx ixifi dosag form excipi inform present avail limit particular generic consult specif product label solut reconstitut intraven inflectra infliximabdyyb mg ea contain polysorb solut reconstitut intraven preserv free remicad mg ea contain polysorb renflexi infliximababda mg ea contain polysorb brand name us inflectra remicad renflexi pharmacolog categori antirheumat diseas modifi gastrointestin agent miscellan immunosuppress agent monoclon antibodi tumor necrosi factor tnf block agent pharmacolog infliximab chimer monoclon antibodi bind human tumor necrosi factor alpha tnf therebi interf endogen tnf activ elev tnf level found involv tissuesfluid patient rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi crohn diseas ulcer coliti biolog activ tnf includ induct proinflammatori cytokin interleukin enhanc leukocyt migrat activ neutrophil eosinophil induct acut phase reactant tissu degrad enzym anim model shown tnf express caus polyarthr infliximab prevent diseas well allow diseas joint heal distribut within vascular compart v l klotz onset action crohn diseas week rheumatoid arthriti day durat action crohn diseas week rheumatoid arthriti week halflif elimin day klotz use label indic ankylos spondyl treatment adult activ ankylos spondyl reduc signssymptom crohn diseas treatment adult pediatr patient year moder sever activ crohn diseas inadequ respons convent therapi reduc signssymptom induc maintain clinic remiss reduc number drain enterocutan rectovagin fistula maintain fistula closur adult plaqu psoriasi treatment adult chronic sever extens andor disabl plaqu psoriasi altern system therapi psoriat arthriti treatment adult psoriat arthriti reduc signssymptom activ arthriti inhibit progress structur damag improv physic function rheumatoid arthriti treatment adult moder sever activ rheumatoid arthriti methotrex reduc signssymptom activ arthriti inhibit progress structur damag improv physic function ulcer coliti treatment adult pediatr patient year remicad moder sever activ ulcer coliti inadequ respons convent therapi reduc signssymptom induc maintain clinic remiss mucos heal elimin corticosteroid use note renflexi inflectra ixifi remsima canadian product approv biosimilar remicad approv use may vari see product label off label use behet syndrom uveiti initi data case seri suggest iv infliximab may play benefici role manag uveiti associ behet syndrom addit control trial need verifi result crohn diseas manag surgic resect data small random doubleblind placebocontrol trial prospect random open trial metaanalysi support use infliximab manag crohn diseas surgic resect demonstr infliximab lower endoscop recurr possibl histolog clinic recurr rate regueiro regueiro singh yoshida base american gastroenterolog associ institut guidelin manag crohn diseas surgic resect american colleg gastroenterolog guidelin manag crohn diseas adult infliximab effect firstlin agent prophylact therapi patient higher risk clinic recurr juvenil idiopath arthriti data random placebocontrol trial support use infliximab treatment juvenil idiopath arthriti jia ruperto ruperto visvanathan addit trial may necessari defin role infliximab condit base american colleg rheumatolog guidelin treatment jia infliximab effect recommend manag patient system jia requir addit therapi due continu diseas activ follow initi therapi pustular psoriasi data noncontrol studi case seriesreport limit number patient support use infliximab treatment pustular psoriasi addit trial may necessari defin role infliximab condit base nation psoriasi foundat npf medic board consensus statement infliximab recommend firstlin treatment option adult pustular psoriasi particular sever acut general form diseas pyoderma gangrenosum initi data suggest infliximab may benefici treatment refractori pyoderma gangrenosum larger control trial need fulli assess efficaci infliximab treatment pyoderma gangrenosum brooklyn ljung regueiro contraind hypersensit infliximab murin protein compon formul dose mgkg patient moder sever heart failur nyha class iiiiv canadian label addit contraind us label sever infect eg sepsi abscess tuberculosi opportunist infect use patient moder sever heart failur nyha class iiiiv dose adult note premed antihistamin h antagonist h antagonist acetaminophen andor corticosteroid may consid prevent andor manag infusionrel reaction renflexi inflectra ixifi remsima canadian product approv biosimilar remicad approv use biosimilar agent may vari consult product label ankylos spondyl iv mgkg week follow mgkg everi week thereaft crohn diseas iv mgkg week follow mgkg everi week thereaft dose may increas mgkg patient respond lose respons if respons week consid discontinu therapi crohn diseas manag surgic resect offlabel use iv mgkg week follow mgkg everi week thereaft armuzzi regueiro singh mgkg everi week regueiro yoshida note administ first infus within week surgeri highrisk patient lichtenstein plaqu psoriasi iv mgkg week follow mgkg everi week thereaft psoriat arthriti without methotrex iv mgkg week follow mgkg everi week thereaft rheumatoid arthriti combin methotrex therapi iv mgkg week follow mgkg everi week thereaft remicad dose rang mgkg repeat week interv ulcer coliti iv mgkg week follow mgkg everi week thereaft dose mgkg studi clinic trial similar efficaci observ dose rutgeert pustular psoriasi offlabel use iv mgkg week follow mgkg everi week week suguira torii dosag adjust heart failur hf weigh risk versus benefit individu patient mild hf nyha class iii no dosag adjust necessari use caution monitor close worsen hf moder sever nyha class iii iv mgkg dose geriatr refer adult dose dose pediatr note premed antihistamin h antagonist h antagonist acetaminophen andor corticosteroid may consid prevent andor manag infusionrel reaction renflexi inflectra ixifi remsima canadian product approv biosimilar remicad approv use biosimilar agent may vari consult product label crohn diseas children year adolesc iv mgkg week follow mgkg everi week thereaft adult patient crohn diseas observ patient respond week unlik respond continu dose consid discontinu therapi ulcer coliti children year adolesc iv remicad mgkg week follow mgkg everi week thereaft juvenil idiopath arthriti offlabel use children year adolesc iv initi mgkg week mgkgdose everi week thereaft combin methotrex induct mainten ruperto altern studi use mgkg start week methotrex induct regimen week repeat dose mgkg week everi week thereaft ruperto visvanathan dose renal impair there dosag adjust provid manufactur label dose hepat impair there dosag adjust provid manufactur label reconstitut reconstitut vial ml steril water inject swfi gaug smaller needl direct swfi toward wall vial swirl vial gentl dissolv powder shake allow solut stand minut total dose reconstitut product dilut ml ns inject add reconstitut infliximab slowli final concentr mgml do dilut reconstitut infliximab solut diluent infus begin within hour prepar see storagest addit inform administr iv the infus begin within hour reconstitut dilut infus least hour infus agent use inlin low protein bind filter micron temporarili discontinu decreas infus rate infusionrel reaction antihistamin h antagonist h antagonist acetaminophen andor corticosteroid may use manag reaction infus may reiniti lower rate upon resolut mild moder symptom guidelin treatment prophylaxi infus reaction note limit adult patient dosag use crohn diseas prospect data popul pediatr indicationsdos avail a protocol treatment infus reaction well prophylact therapi repeat infus publish mayer treatment infus reaction medic treatment hypersensit reaction avail immedi use for mild reaction rate infus decreas mlhour initi normal salin infus mlhour appropri symptomat treatment eg acetaminophen diphenhydramin monitor vital sign everi minut normal after minut infus may increas minut interv toler complet initi increas mlhour mlhour mlhour etc maximum mlhour for moder reaction infus stop slow initi normal salin infus mlhour appropri symptomat treatment monitor vital sign everi minut normal after minut infus may reinstitut mlhour increas minut interv toler complet initi increas mlhour mlhour mlhour etc maximum mlhour for sever reaction infus stop administr appropri symptomat treatment eg hydrocortisonemethylprednisolon diphenhydramin epinephrin frequent monitor vital consult institut polici avail retreat sever reaction done benefit outweigh risk appropri prophylaxi delay infus reaction typic occur day infus treatment consist appropri symptomat treatment eg acetaminophen antihistamin methylprednisolon prophylaxi infus reaction premed acetaminophen diphenhydramin minut prior infus may consid patient prior infus reaction patient sever reaction corticosteroid administr recommend steroid dose may oral prednison mg oral everi hour dose prior infus intraven singl dose hydrocortison mg methylprednisolon mg administ minut prior infus on initi infus begin test dose mlhour minut thereaft infus may increas minut interv toler complet initi increas mlhour mlhour mlhour etc a maximum rate mlhour recommend patient experienc prior mild moder reaction mlhour recommend patient experienc prior sever reaction in patient cutan flush aspirin may consid becker for delay infus reaction premed acetaminophen diphenhydramin minut prior infus on initi infus begin test dose mlhour minut thereaft infus may increas infus hour postinfus therapi acetaminophen day antihistamin day recommend storag store intact vial c c f f may store room temperatur maximum c f month exceed origin expir date return refriger storag the manufactur recommend solut dilut ns infus use within hour prepar howev stabil studi infliximab mgml prepar ns polyvinyl chlorid pvc bag found loss biolog activ store refriger c day ikeda drug interact abatacept antitnf agent may enhanc adversetox effect abatacept an increas risk serious infect concomit use report avoid combin adalimumab may enhanc immunosuppress effect infliximab avoid combin anakinra antitnf agent may enhanc adversetox effect anakinra an increas risk serious infect concomit use report avoid combin azathioprin infliximab may enhanc adversetox effect azathioprin specif risk tcell nonhodgkin lymphoma includ hepatosplen tcell lymphoma may increas infliximab may increas serum concentr activ metabolit azathioprin monitor therapi baricitinib may enhanc adversetox effect biolog diseasemodifi antirheumat drug dmard avoid combin bcg intraves immunosuppress may diminish therapeut effect bcg intraves avoid combin belimumab monoclon antibodi may enhanc adversetox effect belimumab avoid combin canakinumab antitnf agent may enhanc adversetox effect canakinumab specif risk serious infect andor neutropenia may increas avoid combin certolizumab pegol antitnf agent may enhanc immunosuppress effect certolizumab pegol avoid combin coccidioid immiti skin test immunosuppress may diminish diagnost effect coccidioid immiti skin test monitor therapi denosumab may enhanc adversetox effect immunosuppress specif risk serious infect may increas monitor therapi echinacea may diminish therapeut effect immunosuppress consid therapi modif etanercept may enhanc immunosuppress effect infliximab avoid combin fingolimod immunosuppress may enhanc immunosuppress effect fingolimod manag avoid concomit use fingolimod immunosuppress possibl if combin monitor patient close addit immunosuppress effect eg infect consid therapi modif golimumab may enhanc immunosuppress effect infliximab avoid combin leflunomid immunosuppress may enhanc adversetox effect leflunomid specif risk hematolog toxic pancytopenia agranulocytosi andor thrombocytopenia may increas manag consid use leflunomid load dose patient receiv immunosuppress patient receiv leflunomid anoth immunosuppress monitor bone marrow suppress least month consid therapi modif natalizumab immunosuppress may enhanc adversetox effect natalizumab specif risk concurr infect may increas avoid combin nivolumab immunosuppress may diminish therapeut effect nivolumab consid therapi modif ocrelizumab may enhanc immunosuppress effect immunosuppress monitor therapi pidotimod immunosuppress may diminish therapeut effect pidotimod monitor therapi pimecrolimus may enhanc adversetox effect immunosuppress avoid combin rilonacept antitnf agent may enhanc adversetox effect rilonacept avoid combin roflumilast may enhanc immunosuppress effect immunosuppress consid therapi modif sipuleucelt immunosuppress may diminish therapeut effect sipuleucelt monitor therapi tacrolimus topic may enhanc adversetox effect immunosuppress avoid combin tertomotid immunosuppress may diminish therapeut effect tertomotid monitor therapi thiopurin analog antitnf agent may enhanc adversetox effect thiopurin analog specif risk tcell nonhodgkin lymphoma includ hepatosplen tcell lymphoma may increas monitor therapi tocilizumab may enhanc immunosuppress effect antitnf agent avoid combin tofacitinib biolog diseasemodifi antirheumat drug dmard may enhanc adversetox effect tofacitinib avoid combin trastuzumab may enhanc neutropen effect immunosuppress monitor therapi ustekinumab may enhanc immunosuppress effect infliximab avoid combin vaccin inactiv immunosuppress may diminish therapeut effect vaccin inactiv manag vaccin efficaci may reduc complet ageappropri vaccin least week prior start immunosuppress if vaccin immunosuppress therapi revaccin least month immunosuppress discontinu consid therapi modif vaccin live immunosuppress may enhanc adversetox effect vaccin live immunosuppress may diminish therapeut effect vaccin live manag avoid use live organ vaccin immunosuppress liveattenu vaccin given least month immunosuppress avoid combin vedolizumab antitnf agent may enhanc adversetox effect vedolizumab avoid combin advers reaction central nervous system headach gastrointestin abdomin pain crohn diseas rheumatoid arthriti nausea hematolog oncolog anemia adult children adolesc crohn diseas hepat increas serum alt x uln x uln x uln immunolog increas ana titer antibodi develop doublestrand dna antibodi develop immunogen given singl induct dose episod treatment monotherapi mayer infect infect adult crohn diseas children adolesc crohn diseas indic serious infect children adolesc abscess crohn diseas patient fistul diseas respiratori upper respiratori tract infect rheumatoid arthriti children adolesc ulcer coliti sinus cough pharyng miscellan infus relat reaction sever cardiovascular flush children adolesc crohn diseas hypertens central nervous system fatigu pain dermatolog skin rash pruritus gastrointestin dyspepsia genitourinari urinari tract infect hematolog oncolog leukopenia children adolesc crohn diseas indic neutropenia children adolesc crohn diseas hypersensit hypersensit reaction children adolesc crohn diseas indic type iv hypersensit reaction plaqu psoriasi serum sick infect viral infect children adolesc crohn diseas bacteri infect children adolesc crohn diseas candidiasi neuromuscular skelet arthralgia bone fractur children adolesc crohn diseas respiratori bronchiti pneumonia miscellan fever postmarket andor case report acut hepat failur agranulocytosi anaphylaxi autoimmun hepat bradycardia bronchospasm bullous dermat linear iga bryant cardiac arrhythmia cellul cerebrovascular accid cholestasi chronic inflammatori demyelin polyneuropathi coccidioidomycosi constip cytomegalovirus diseas dehydr demyelin diseas central nervous system demyelin diseas peripher dermal ulcer diaphoresi dizzi edema erythema multiform erythemat rash exacerb psoriasi guillainbarr syndrom hemolyt anemia hepat failur hepat injuri hepat hepatotox idiosyncrat chalasani hepatosplen tcell lymphoma main young adult adolesc male herp zoster histoplasmosi hodgkin lymphoma hypotens immun thrombocytopenia increas serum ast interstiti pulmonari diseas intestin obstruct ischem heart diseas jaundic laryng edema leukemia liver enzym disord transient lower respiratori tract infect lupuslik syndrom lymphadenopathi malign lymphoma malign melanoma malign neoplasm malign neoplasm breast malign neoplasm cervix malign neoplasm colon rectum merkel cell carcinoma multipl sclerosi myocardi infarct neuropathi includ multifoc motor nocardiosi nonhodgkin lymphoma opportunist infect optic neuriti pancytopenia pericardi effus pharyng edema pleurisi pneumonia due pneumocysti jirovecii psoriasi includ new onset palmoplantar pustular pulmonari edema pulmonari fibrosi reactiv tuberculosi reactiv hbv sarcoidosi seizur sepsi stevensjohnson syndrom thrombocytopenia thrombophleb thrombot thrombocytopen purpura toxic epiderm necrolysi transvers myeliti tuberculosi urticaria vascul system cutan temporari vision loss alert us box warn serious infect patient treat infliximab increas risk develop serious infect may lead hospit death most patient develop infect take concomit immunosuppress methotrex corticosteroid discontinu infliximab patient develop serious infect sepsi report infect includ follow activ tuberculosi tb includ reactiv latent tb patient tb frequent present dissemin extrapulmonari diseas patient test latent tb infliximab use therapi treatment latent infect initi prior infliximab use invas fungal infect includ histoplasmosi coccidioidomycosi candidiasi aspergillosi blastomycosi pneumocystosi patient histoplasmosi invas fungal infect may present dissemin rather local diseas antigen antibodi test histoplasmosi may negat patient activ infect empir antifung therapi consid patient risk invas fungal infect develop sever system ill bacteri viral infect caus opportunist pathogen includ legionella listeria the risk benefit treatment infliximab care consid prior initi therapi patient chronic recurr infect patient close monitor develop sign symptom infect treatment infliximab includ possibl develop tb patient test negat latent tb infect prior initi therapi malign lymphoma malign fatal report children adolesc patient treat tumor necrosi factor tnf blocker includ infliximab postmarket case hepatosplen tcell lymphoma rare type tcell lymphoma report patient treat tnf blocker includ infliximab these case aggress diseas cours fatal almost patient receiv treatment azathioprin mercaptopurin concomit tnfblocker prior diagnosi the major report infliximab case occur patient crohn diseas ulcer coliti adolesc young adult male warningsprecaut concern relat advers effect autoimmun disord posit antinuclear antibodi titer detect patient negat baselin rare case autoimmun disord includ lupuslik syndrom report monitor discontinu symptom develop cardiovascularcerebrovascular reaction follow infus cerebrovascular accid mi fatal hypotens hypertens arrhythmia report within hour infus transient vision loss also report within hour infus discontinu therapi serious reaction occur hematolog disord hematolog toxic eg leukopenia neutropenia thrombocytopenia pancytopenia report may fatal patient must advis seek medic attent develop sign symptom suggest blood dyscrasia eg persist fever discontinu signific hematolog abnorm confirm use caution patient histori hematolog abnorm hepat reaction sever hepat reaction includ hepat jaundic acut hepat failur cholestasi report treatment reaction occur week year initi therapi case fatal necessit liver transplant discontinu jaundic andor mark increas liver enzym time uln hepat b reactiv hepat b virus hbv occur chronic carrier virus usual patient receiv concomit immunosuppress may fatal evalu hbv prior initi patient monitor sever month follow discontinu treatment hbv carrier interrupt therapi reactiv occur treat appropri antivir therapi resumpt therapi deem necessari exercis caution monitor patient close hypersensit infus reaction acut infus reaction may occur hypersensit reaction includ anaphylaxi may occur within hour infus medic equip manag hypersensit reaction avail immedi use interrupt andor reinstitut slower rate may requir consult protocol pretreat may consid may warrant patient prior infus reaction serum sicknesslik reaction occur may associ decreas respons treatment the develop antibodi infliximab may increas risk hypersensit andor infus reaction concomit use immunosuppress may lessen develop antiinfliximab antibodi the risk infus reaction may increas retreat interrupt discontinu prior mainten therapi retreat psoriasi patient resum schedul mainten regimen without induct dose use induct regimen use cautious retreat patient infect us box warn patient receiv infliximab increas risk serious infect may result hospit andor fatal infect usual develop patient receiv concomit immunosuppress agent eg methotrex corticosteroid may present dissemin rather local diseas activ tuberculosi reactiv latent tuberculosi invas fungal includ aspergillosi blastomycosi candidiasi coccidioidomycosi histoplasmosi pneumocystosi bacteri viral opportunist infect includ legionellosi listeriosi report monitor close signssymptom infect discontinu serious infect sepsi consid risk versus benefit prior use patient histori chronic recurr infect consid empir antifung therapi patient risk invas fungal infect develop sever system ill caution exercis consid use elder patient condit predispos infect eg diabet residencetravel area endem mycos blastomycosi coccidioidomycosi histoplasmosi latent local infect do initi infliximab therapi patient activ infect includ clinic import local infect patient develop new infect undergo treatment monitor close malign us box warn lymphoma malign may fatal report children adolesc patient receiv tnfblock agent includ infliximab half case lymphoma hodgkin nonhodgkin case vari includ malign typic observ popul us box warn postmarket case hepatosplen tcell lymphoma report patient treat infliximab almost patient receiv concurr prior treatment azathioprin mercaptopurin prior diagnosi major report case occur adolesc young adult male crohn diseas ulcer coliti malign occur median month rang month first dose tnf blocker therapi patient receiv concomit immunosuppress the impact infliximab develop cours malign fulli defin as compar general popul increas risk lymphoma note clinic trial howev rheumatoid arthriti alon previous associ increas rate lymphoma use caution patient histori copd higher rate malign report copd patient treat infliximab psoriasi patient histori phototherapi higher incid nonmelanoma skin cancer melanoma merkel cell carcinoma report patient receiv tnfblock agent includ infliximab perform period skin examin patient therapi particular increas risk skin cancer women rheumatoid arthriti higher incid invas cervic cancer period screen continu women treat infliximab tuberculosi us box warn infliximab treatment associ activ tuberculosi may dissemin extrapulmonari reactiv latent infect evalu patient tuberculosi risk factor latent tuberculosi infect tuberculin skin test prior therapi treatment latent tuberculosi initi use patient initi negat tuberculin skin test receiv continu monitor tuberculosi throughout treatment most case reactiv report within first coupl month treatment caution exercis consid use patient expos tuberculosi diseaserel concern demyelin cns diseas use caution patient preexist recent onset cns demyelin disord rare case optic neuriti demyelin diseas includ multipl sclerosi system vascul guillainbarr syndrom report consid discontinu therapi patient develop signific cns reaction heart failur hf use caution patient mild hf nyha class i ii decreas left ventricular function worsen newonset hf report dose mgkg administ patient moder sever hf nyha class iiiiv discontinu therapi onset new worsen symptom in scientif statement american heart associ tnf blocker determin agent may either caus direct myocardi toxic exacerb under myocardi dysfunct magnitud major aha page seizur disord use caution patient histori seizur discontinu signific cns advers reaction develop concurr drug therapi issu drugdrug interact potenti signific interact may exist requir dose frequenc adjust addit monitor andor select altern therapi consult drug interact databas detail inform special popul pediatr malign report among children adolesc receiv tnfblock agent efficaci establish studi evalu infliximab use juvenil idiopath arthriti jia dosag form specif issu polysorb some dosag form may contain polysorb also known tween hypersensit reaction usual delay reaction report follow exposur pharmaceut product contain polysorb certain individu isaksson lucent shelley thrombocytopenia ascit pulmonari deterior renal hepat failur report prematur neonat receiv parenter product contain polysorb alad cdc see manufactur label other warningsprecaut immun patient brought date immun initi therapi live vaccin given concurr data avail concern secondari transmiss live vaccin patient receiv therapi a fatal outcom report infant receiv live vaccin bcg utero exposur infliximab infliximab cross placenta detect infant serum month it recommend wait month follow birth administ live vaccin infant expos infliximab utero monitor paramet monitor improv symptom physic function assess dure infus reaction note monitor vital sign everi minut depend reaction sever normal if serious reaction occur eg cardiovascular cerebrovascular reaction discontinu infus activ latent tb screen prior initi therapi signssymptom infect prior follow therapi cbc differenti signssymptomsworsen heart failur hbv screen prior initi patient hbv carrier sever month follow therapi sign symptom hypersensit reaction symptom lupuslik syndrom lfts discontinu time uln sign symptom malign eg splenomegali hepatomegali abdomin pain persist fever night sweat weight loss psoriasi patient histori phototherapi monitor nonmelanoma skin cancer women screen period cervic cancer the american gastroenterolog associ suggest reactiv therapeut drug monitor guid treatment chang adult patient treat infliximab activ inflammatori bowel diseas feuerstein pregnanc risk factor b pregnanc consider anim reproduct studi conduct infliximab cross placenta detect serum infant month follow utero exposur agranulocytosi report infant expos infliximab utero a fatal outcom report infant receiv live vaccin bcg utero exposur infliximab recommend wait month follow birth administ live vaccin infant expos infliximab utero if biolog agent infliximab need treat inflammatori bowel diseas pregnanc recommend hold therapi week gestat habal health care provid also encourag enrol women expos infliximab pregnanc mothertobabi autoimmun diseas studi contact organ teratolog inform specialist oti patient educ discuss specif use drug side effect patient relat treatment hcahp dure hospit stay given medicin taken befor give new medicin often hospit staff tell medicin how often hospit staff describ possibl side effect way could understand patient may experi nausea vomit abdomin pain common cold symptom flush inject site irrit have patient report immedi prescrib sign infect sign lupus rash cheek bodi part sunburn easi muscl joint pain angina short breath swell arm leg sign sever cerebrovascular diseas chang strength one side greater difficulti speak think chang balanc vision chang angina sign liver problem dark urin fatigu lack appetit nausea abdomin pain lightcolor stool vomit jaundic sign heart problem cough short breath new wors swell ankl leg abnorm heartbeat weight gain five pound hour dizzi pass infus reaction skin eczema excess weight loss burn numb feel sever back pain sever headach difficulti swallow pale skin swollen gland night sweat vision chang blind black tarri bloodi stool mole chang skin growth dizzi pass bradycardia tachycardia seizur extrem weak bruis bleed sever loss strength energi sign stevensjohnson syndrometox epiderm necrolysi red swollen blister peel skin without fever red irrit eye sore mouth throat nose eye hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note this comprehens list side effect patient consult prescrib addit question intend use disclaim should print given patient this inform intend serv concis initi refer health care profession use discuss medic patient you must ultim reli discret experi judgment diagnos treat advis patient',\n",
       "  'NN'),\n",
       " ('a boxer rochdal fought prove british box board control type diabet hold back ring an absolut amaz feel fda assess new treatment retinopathi the use eye inject current use treat diabet retinopathi dme may expand includ treatment diabet retinopathi pend fda review eylea use expand want know your eat go the public go consult whether calori content meal publish restaur menus this come part push halv childhood obes calori consult pioneer type diabet centr open a centr research way type diabet treatment could improv open novo nordisk it pursu innov medicin help treat prevent condit push research boundari labour deputi leader put type remiss after diagnosi type diabet gave wakeup call tom watson lost weight cut sugar starchi carb point abl come diabet medic overcom medic need low carb eton mess member low carb program follow great british bake off seri absolut treat tonight scrumptious low carb eton mess recip my mouth water write',\n",
       "  'RB'),\n",
       " ('hi fighterlif i happi hear keytruda work well this must relief can i ask stage type my mom squamous cell stage she rd treatment far thing go well she side effect except fatigu bit hoars voic time time she horribl cough well treatment requir liquid codein order sleep night she taken codein week cough better thank respond thread i happi hear good news peopl god bless deb',\n",
       "  'JJ'),\n",
       " ('sorri your deal love diseas extra i dont experi next step stelara fail ive everi drug imagin fail sooner later if start canabi let us know work proctocolectomi result transvers colostomi current receiv stelara',\n",
       "  'NN'),\n",
       " ('true enough i guess surgeri realli last option ulcer coliti diagnos meslamin entyvio remicad prednison fail three step pouch surgeri colon remov two go ipoop forum moder join aug post post yesterday am gmt im sure get adjust period surgeri fulli heal youll feel like million buck normal hang moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa showerthought most peopl surpris see blood toilet paper uc patient surpris isnt ks veteran member join sep post post yesterday am gmt i problem skip entyvio go right surgeri i miser didnt want wait anymor i justifi save entyvio futur use i ever develop chronic pouchiti i develop i havent use yet gi prefer stelara entyvio stelara also faster act keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm timechamp veteran member join oct post post yesterday pm gmt lifestyl thing get better everyday adjust just make sure u drink enough get rest walk also where incis below belli button',\n",
       "  'NN'),\n",
       " ('hi sharonk welcom msworld sorri hear son person id vote start tysabri asap it efficaci greater gilenya although individu respond differ diseas modifi therapi aka dmts the risk contract pml extrem low first two year even jcv there member continu year drug despit jcv the higher titer though higher risk a new dmt call ocrevus approv fda yesterday it expect rival tysabri might present anoth option futur besid gilenya son best luck son',\n",
       "  'NN'),\n",
       " ('i wonder decis forc compani bring eyelea lucenti competit price i start avastin move eyelea i move differ health board move hous the biggest differ i found avastin administ consult hospit eyelea administ nurs guess one effici pleasant',\n",
       "  'JJ'),\n",
       " ('speaker scott gold md theresa s patient advoc patient educ dinner discov ocrevus may right choic treat relaps ms preregistr requir contact organ regist',\n",
       "  'NN'),\n",
       " ('in review literatur found date pembrolizumab pd pdli inhibitor show signific surviv benefit chemotherapi given monotherapi part combin therapi metastat squamous nonsquam nsclc nonsmal cell lung cancer that statement research write the new england journal medicin also present new data iaslc th world confer lung cancer toronto canada septemb base data merck sharp dohm maker pembrolizumab add treatment pembrolizumab combin chemotherapi result signific longer overal surviv os progressionfre surviv pfs compar chemotherapi alon squamous nsclc accord articl kaplanmei estim rate surviv year pembrolizumabcombin arm placebocombin arm though trial conclud estim conclus date decis report second interim result occur efficaci boundari primari hypothes overal surviv progressionfre surviv met investig wrote they origin set goalpost interim analysi occur event diseas progress death occur relat articl in headtohead battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient with stage iii nsclc despit promis trial result skeptic rais red flag about anlotinib efficaci heavili treat nsclc in doubleblind phase trial research run keynot trial random assign untreat metastat squamous nsclc patient receiv either mg pembrolizumab salin placebo cycl patient patient respect all patient also treat carboplatin either paclitaxel nanoparticlealbumin bound nabpaclitaxel first cycl patient receiv paclitaxel also receiv premed glucocorticoid antihistamin patient allow crossov certain circumst patient switch placebo pembrolizumab diseas progress patient receiv subsequ pd pdl inhibitor prescrib outsid trial pdl express status assess use agil technolog pdl ihc c pharmdx assay tumor imag schedul week everi week week everi week thereaft as result use tool patient exclud trial could provid tumor sampl determin pdl status os pfs respons rate durat respons calcul use blind independ central review radiolog imag a pdl tumor proport score greater seen patient regardless patient pdl express level overal surviv benefit observ across pembrolizumabcombin group in group median os followup month compar month placebocombin group hazard ratio death confid interv ci p median pfs month month respect hazard ratio diseas progress death ci p the risk death lower risk diseas progress death lower pembrolizumabcombin group placebocombin group author wrote but ad in patient pdlposit tumor current avail data permit determin whether pembrolizumab plus chemotherapi greater efficaci pembrolizumab alon respons rate howev higher among individu receiv pembrolizumabbas regimen compar rate observ placebo regimen patient place subgroup defin pdl tumor proport score and outcom improv across categori pdl tumor proport score pembrolizumabchemotherapi group make studi author question use pdl biomark guid drug select advers event ae similar across treatment group although treatment discontinu pembrolizumabcombin group occur frequent placebocombin group vs respect there death due ae pembrolizumabbas arm aerel death placebobas arm read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       "  'NN'),\n",
       " ('is remicad uc med sometim need multipl med simultan conquer flare have remicadeinfliximab concentr antibodi test see level typic run hour prior nest infus see true minimum concentr httpswwwlabcorpcomtestmenuinfliximabconcentrationandantiinfliximabantibodi moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa is unpatriot wipe bumm georg washington bill there tp stall your otherwis direstraight i think georg would understand',\n",
       "  'NN'),\n",
       " ('ive written space what i mean newli diagnos multipl sclerosi life start mark major diseas event your first mri your first dmt the first time end hospit relaps your first cane your first time wheel around place place these big event they tax brain give someth focus life sudden look feel noth like some event bad some suck but give brain someth handl someth keep thought occupi next crisi hit now shingl experi pass third ocrevus infus bag ive start wait period what happen might happen septemb i see the great scott i feel bit lost im those long languid period time noth much happen im one right i start physic therapi coupl week ago realiz someth probabl shouldnt surpris methat shit hard it someon evalu everi aspect physic life start think serious mess thing realli it your low platform simpl side leg lift realiz hard tri move stupid leg at it your done step pt step pt realiz littl bit activ go take rest day i start day air cool i felt kind ok feel like i could handl i end feel like shit shingl complet demor complet overwhelm how come back someth like how long go take ten side leg lift doesnt feel like your lift dead weight tree trunk happen connect bodi how long i walk feet without feel like im go collaps it almost three year god sake long go take im sure shout answer question comput screen hope i hear loud clear right interweb it go take realli long time beth it go take long your go think never go end it go take long take fuck choic shut i know i realli know as friend ardra said recent comment we that it might help much realli option even help tiniest bit so im i also offici join ms gym for arent familiar free facebook page learn and learn paid membership site the short stori trevor wicken develop program around rebuild neuromuscular pathway help improv ms symptom with ms brain block slow lesion get way normal pathway creat difficulti spastic pain walkingal kind thing it amaz resourc pretti fantast abil benefit trevor experi dedic onlin i join plan follow program one video per day everi day day week i also went back work week staycat i realiz obvious alreadi thing realli difficult simultan one recov shingl one bodi hasnt felt even remot decent month year im total honest i drag offic outsid world it good mental speak exact i need physic yeh much i tire so spent it almost imposs imagin i could accomplish regular life stuff pt ms gym routin everi singl day week you wont surpris learn ive pull i cancel pt work meet friday i love massag afternoon minut i got home i wobbl leg lift the straight truth i got floor damn good possibl i wouldnt abl get i might pull simpl neck pain video someth i settl night i also might this ill spend time summer i hide heat accompani squid bodi effect keep work i continu feel least littl bit like old me squeez pt exercis i start wonder long lasthow long i old life new life how long thing start feel even littl bit normal the simpl truth matter alreadi long enough i almost cant rememb i use fun i forget i day day werent limit stupid leg refus oper like leg i forget feel like plan i forget i use mayb i didnt much anyway or mayb long sinc anyth felt normal i sincer cant rememb while i work i got random email cakebread cellar favorit wine maker napa i visit year ago travel buddi friend mari back littl jaunt napa check wineri someth i would total mari i use take awesom littl adventur throughout year it feel like anoth life but wasnt long ago on particular trip i must sign cakebread mail list i get occasion email news varieti great deal cakebread like thing i find love cheap i click open email read case deal reserv chardonnay without even think i click link order case wine just like i use back drink wine one thing i realli love i havent much wine past year sinc diagnosi coupl reason biggest one insan cocktail prescript medic i take throughout everi day doesnt mix well alcohol im shaki feet without help wine i dont need help land face first concret hardwood but i decid i go drink wine summer if i one glass week still worth if i share friend might lure home promis realli good wine nice porch sit even better i accept realiti visitor would take i like unclean sport bed head certain cover cat hair definit yoga pant tank top i would also accept realiti i dont much talk day isnt relat curs diseas when peopl ask what new i honest say much materi isnt relat damag central nervous system i talk book im read show im watch beyond ive got whole lot materi crappi i feel new drug im consid havoc may wreak bodi i tell younobodi want hear i dont even want talk so i think i lure peopl wine i listen tell live their stori their adventur i long take i stori adventur dont revolv around struggl someth realli easi fall flat face live room some day i also drink glass wine alon sit swing listen breez leav magnific front yard tree twinkl mani set wind chime on day ridicul hot i enjoy solitud without think drug diseas injuri exercis long take drink one glass wine i rememb i use enjoy good glass chardonnay i still even though everi littl thing new life would utter strang foreign old me old me would wonder i dont like center attent anymor old me would wonder i gave makeup semblanc fashion sens old me would wonder action but new me enjoy glass cakebread chard allow enough new me rememb exercis struggl meet rememb attend much keep bodi tri settl kind new normal the new normal arriv good readi i might well enjoy great glass wine i wait',\n",
       "  'NN'),\n",
       " ('after diarrhea number week oncologist schedul colonoscopi determin keytruda caus read more',\n",
       "  'RB'),\n",
       " ('i brvo macular edema i light grey cloud shape like v upper middl vision start right center amsler grid after first avastin shot cloud becam lighter dissip slight my retin specialist said notic blood absorb after second shot cloud move higher seem break coupl week back bad first time the grid line also still wavi edema i see md monday prob get anoth avastin shot eylea my question anyon vision return im disappoint process fuzzi realli affect vision make almost dizzi thank advanc',\n",
       "  'JJ'),\n",
       " ('befor go pump seven year ago ac hover i i victrctami right eye five year ago along subsequ inject my vision improv two year howev new retinologist say first oper either well perform membran regrew my left eye oper victrctami three year ago subsequ eylea inject after year vision improv stabl free inject eighteen month note i may revers vision ratio',\n",
       "  'NN'),\n",
       " ('drug stelara may eas crohn diseas medic potenti help didnt find relief treatment research say sourc healthday relat medlineplus page crohn diseas medicin sourc medlineplus health news',\n",
       "  'NNS'),\n",
       " ('marlo my person opinion cladribin gilenya didnt stop go spms may stop relaps spms case nice better rrms spms beast dont want addit troubl caus dmd hard alreadi if cladribin stop relaps brainer give less secondari effect it gambl need take',\n",
       "  'VBP'),\n",
       " ('hi all due nhs mess i enough gilenya get week i away toward end week see i cant get respons anyon respons suppos care anyon day week without gilenya within nd month start doe big impact have lost x job due gilenya nurs mess i afraid go thank stuart',\n",
       "  'JJ'),\n",
       " ('the first diseasemodifi therapi relapsingremit multipl sclerosi interferon b approv fda the follow year seen rapid expans therapeut option evolv understand diseas enabl develop therapi differ mode action as result complex treatment landscap includ various inject oral drug monoclon antibodi advantag risk this mileston track develop treatment multipl sclerosi interact timelin approv first diseasemodifi therapi latest breakthrough seen unpreced efficaci approv first drug primari progress multipl sclerosi produc support produc support mileston natur research mileston the dawn therapeut era ms charlott ridler natur research mileston the first monoclon antibodi therapi katharin barn natur research mileston the risk natalizumabassoci pml reveal rebecca kelsey natur research mileston oral drug expand therapeut option megan culli natur research mileston high low secondgener monoclon antibodi isobel leak natur research mileston more treatment creat clinic dilemma louis adam all mileston nr neurolog review natur review neurolog perspect treatment multipl sclerosi success bench bedsid the develop treatment multipl sclerosi past year success translat medicin in timelin articl tintor et al chart major develop discuss implic current futur patient manag mar tintor angela vidaljordana jaum sastregarriga natur review neurolog review articl assess treatment outcom multipl sclerosi trial clinic set in clinic trial outcom measur might determin whether drug worthi develop clinic might guid import treatment decis here tur colleagu help clinician research navig maze option clinic neuroimag patientreport composit outcom measur multipl sclerosi carmen tur marcello moccia frederik barkhof jeremi chataway jaum sastregarriga alan j thompson olga ciccarelli natur review neurolog scienc societi the tension earli diagnosi misdiagnosi multipl sclerosi the benefit earli treatment multipl sclerosi ms place pressur physician make diagnosi earli therebi increas risk misdiagnosi consider consequ patient healthcar system solomon corboy examin problem ms misdiagnosi includ probabl caus associ risk discuss tension earli diagnosi misdiagnosi might address andrew j solomon john r corboy natur review neurolog review articl autolog haematopoiet stem cell transplant treatment multipl sclerosi autolog haematopoiet stem cell transplant produc strike result patient aggress multipl sclerosi small trial in review muraro et al provid overview procedur detail evid high efficaci multipl sclerosi provid recommend clinic use futur trial paolo a muraro roland martin giovanni luigi mancardi richard nichola maria pia sormani riccardo saccardi natur review neurolog review articl treatment decis multipl sclerosi insight realworld observ studi realworld observ studi potenti answer question multipl sclerosi ms treatment random control trial cannot trojano colleagu discuss pitfal necessari safeguard observ studi insight studi provid treatment decis patient ms maria trojano mar tintor xavier montalban jan hillert toma kalincik pietro iaffaldano tim spelman maria pia sormani helmut butzkueven natur review neurolog review articl diseasemodifi therapi infecti risk multipl sclerosi the rang immunomodulatori therapi treat multipl sclerosi ms widen mark recent year ms treatment becom effici this improv efficaci accompani increas risk treatmentassoci infect in review winkelman et al discuss mode action current avail ms therapi detail specif infect associ treatment they consid inform influenc daili clinic use ms therapi minim associ infecti risk alexand winkelmann micha loebermann emil c reising hanspet hartung uwe k zettl all nr neurolog review addit review research natur review diseas primer primer multipl sclerosi multipl sclerosi character format demyelin lesion throughout central nervous system lead neurolog dysfunct this primer provid overview immunopatholog diagnosi manag multipl sclerosi massimo filippi amit baror fredrik piehl paolo preziosa alessandra solari sandra vukus maria a rocca natur immunolog review articl reassess b cell contribut multipl sclerosi in focus review baror colleagu discuss latest evid b cell play import antibodyindepend role multipl sclerosi prospect hold therapeut intervent rui li kristina r patterson amit baror advertis featur mileston multipl sclerosi biogen commit advanc field richard rudick michael r edward bernd c kieseier alfr sandrock scientif report articl open fingolimod reduc circul tightjunct protein level vitro peripher blood mononuclear cell migrat multipl sclerosi patient pasqual annunziata chiara cioni gianni masi maristella tassi giusepp marotta sauro severi scientif report articl open dimethyl fumar induc persist chang composit innat adapt immun system multipl sclerosi patient g mont diaz j fraussen b van wijmeersch r huppert v somer natur communic articl open systemat screen generic drug progress multipl sclerosi identifi clomipramin promis therapeut progress multipl sclerosi inflammatori degen diseas central nervous system effect treatment lack the author carri screen identifi oral avail generic medic show antidepress clomipramin reduc patholog mous model simon faissner manoj mishra deepak k kaushik jianxiong wang yan fan claudia silva gail rauw luann metz marcus koch v wee yong all addit review research news comment natur review neurolog news view aan unveil new guidelin ms diseasemodifi therapi follow recent european academi neurolog guidelin pharmacolog treatment multipl sclerosi ms american academi neurolog issu updat practic guidelin diseasemodifi therapi dmts ms the guidelin provid general recommend initi switch stop dmts indic futur research direct stefan bittner frauk zipp natur review neurolog comment unifi understand ms cours requir drug develop the treatment multipl sclerosi ms evolv remark past year this progress enabl advanc research drug develop activ engag scientif communiti regulatori author howev inconsist approach ms diseas cours could negat impact drug develop process timothi coetze alan j thompson natur review neurolog news view multipl sclerosi progress multifoc leukoencephalopathi risk stratif a compel need exist reliabl risk evalu natalizumab associ progress multifoc leukoencephalopathi pml a new report propos refin protocol use updat patientbas data cumul risk evalu provid improv assess annual risk pml patient posit jc virus kalliopi pitarokoili ralf gold natur review neurolog comment cladribin old newcom puls immun reconstitut ms heinz wiendl natur review neurolog news view multipl sclerosi is safe time discontinu therapi ms as yet clear strategi develop discontinu diseasemodifi therapi multipl sclerosi a recent observ studi add new inform inform patient group still assess comprehens sever question need address prospect studi mark s freedman natur review neurolog news view multipl sclerosi dimethyl fumar come age recent publish find endors studi provid year random safeti efficaci data two dose dimethyl fumar dmf multipl sclerosi the report complement result pivot confirm defin trial howev postmarket data clinic practic need complet riskbenefit profil dmf',\n",
       "  'NN'),\n",
       " ('ocrelizumab recommend licens european medicin agenc multipl sclerosi trust httpswwwmstrustorguknewsnewsaboutmsocrelizumabrecommendedlicensingeuropeanmedicinesag',\n",
       "  'IN'),\n",
       " ('the produc lucenti eylea claim surplus money gain use research better eye treatment drug the produc avastin interest cancer treatment rather eye care and low cost would anyth left research',\n",
       "  'NN'),\n",
       " ('most comment dismiss natalizumab spms trial ascend trial negat simpli move one person said spms intract problem best prevent earli effect treatment anoth said what expect ascend anoth negat spms trial could easili predict experi interferon trial how cynic sad these attitud entrench concept therapeut window ms perpetu concept futil tri develop treatment spms i disagre posit prepar go limb hypothesis therapeut window remain open throughout cours ms futil tri develop treatment spms we give peopl ms hope in opinion ascend trial clear posit although studi hit desir primari outcom natalizumab show effect virtual flatten loss upper limb function sure treatment protect upper limb function peopl spms worth explor to quot one spmser now i wheelchair hand arm becom leg click see download pdf what gall oratorio trial ocrelizumab ppms posit is ocrelizumab realli superior natalizumab is ppms differ spms i would argu account the differ ascend oratorio trial explain differ studi popul the ascend spms popul older disabl studi subject edss in word lost meaning reserv capac motor system leg we know studi disabl level edss unilater support bilater support edss good outcom measur year mser level disabl spend mani year level progress higher level disabl in measur speak refer ceil effect edss in comparison ppmser oratorio studi edss less henc level disabl edss scale like move in addit disabl edss reserv capac motor system allow recoveri function get readout two year period in word lower level disabl less therapeut lag for last year i discuss two concept hypothes blog ie therapeut lag lengthdepend the result two studi evid new old strong support relat hypothes therapeut lag state reserv lost specif pathway longer take see treatment effect relat therapi target ms specif mechan this oratorio trial posit edss timedfoot walk tfw ascend trial negat outcom measur i would predict ascend trial longer durat may posit outcom particular tfw sensit chang edss unfortun ascend trial allow therapeut lag if hypothes correct treatment effect ocrelizumab greatest comparison placebo oratorio trial relat upper limb function assess use hole peg test we wait detail analys oratorio trial publish see case so learnt ascend trial that nonrelaps spms tractabl problem focus relev outcom ie neuron system suffici reserv capac demonstr treatment effect use respons outcom measur hpt abilhand chanc posit trial the abilhand valid patientrel outcom measur hand upper limb function if go continu use edss outcom measur either go studi earlier popul similar oratorio studi popul longer studi allow therapeut lag in opinion need ditch edss primari outcom measur progress ms trial for us old enough rememb seen evid argument relat interferon spms trial the european interferonbetab spms trial posit north american studi negat former younger less disabl popul wherea latter older disabl if go studi advanc ms need focus attent neuron system function reserv exampl upper limb bulbar function speech swallow for occur need bring regul ema fda board i think possibl urgent i suspect realist chanc modifi nonrelaps progress phase ms need use highlyeffect dmts i surpris ocrelizumab natalizumab produc posit trial result popul pleas note emphasi posit becaus i lob pharma trial advanc progress ms ppms spms combin high effect dmts ie alemtuzumab ocrelizumab daclizumab ofatumumab cladribin let see brave enough take challeng if pharma wont some caveat the cynic worri payer regul the cost effect calcul relat dmts base cost treatment versus save individu societi onc person ms lost mobil alreadi accru larg amount person societ cost these includ direct medic cost indirect cost exampl loss employ the sad thing person becom unemploy worth societi drop if case payer exampl nice may judg costeffect dmts advanc ms less favour word expens highcost drug natalizumab ocrelizumab may costeffect advanc ms compar earli ms preserv function save societi money this one reason pharma reluct take risk develop drug advanc progress ms a potenti way counter allow pharma payer agre differenti payment scale disabl person ms less compani abl charg drug this may sound crazi make lot sens would forc pharma move outcom base remuner system under system payer get better valu money pwms get treatment work this allow us move away fixedpr system valuebas price system we seem get use mani sector surg price system use airlin softwar industri uber if use uber know surg price i see world agent expens use earli ms patient becom disabl price drug less the question nhs pharmaceut sector readi valuedbas price i think alreadi explor oncolog whi nhs individu pay someth doesnt work on hand deni peopl progress ms drug x consid costeffect stage diseas you see i firedup aan mani idea whizz around head minut day attend confer provid think talk network downtim this aan except i would like conclud post huge thank biogen ball ascend studi spmser volunt take part studi without studi wouldnt insight final appreci thank wellmean generous pharma execut gave firstclass upgrad tri help get good night sleep when i sit ba loung wait board return flight vancouv senior pharma execut i know well came chat when heard i fli economi back london tri get busi class upgrad he call ba desk firstclass upgrad turn ask ba could upgrad instead they said would tri howev got board origin alloc seat i grate someon would tri give comfort first class upgrad tri help get good night sleep howev i would prefer lobbi compani spms trial base insight ascend studi coi multipl',\n",
       "  'NN'),\n",
       " ('hi kspell welcom grace im sorri wait unfortun answer arent clear come mainten without avaistin mani larg clinic trial conduct attempt identifi best treatment strategi patient nsclc the addit agent target vegf use histolog guid chemotherapi decis addit mainten therapi shown increment improv os particular nonsquam histolog target egfr wildtyp nsclc also result success improv os pemetrex bevacizumab transform treatment option patient nonsquam nsclc along erlotinib recast treatment paradigm includ welltoler mainten therapi extend surviv patient nsclc no data support combin mainten therapi superior singl agent whether optim singl agent exist clear the author favor choos platinum partner typic pemetrex paclitaxel base desir toxic profil ad bevacizumab unless contraind the induct phase follow mainten bevacizumab paclitaxelbas chemotherapi mainten pemetrex combin pemetrex bevacizumab mainten pemetrexedbas chemotherapi provid patient stabl respons diseas manag toxic four cycl platinum chemotherapi the ecog trial may help determin whether increment benefit bevacizumab possibl ad mainten pemetrex therapi httptheoncologistalphamedpressorgcontentful the question ask isnt checkpoint inhibitor consid it possibl autoimmun problem could caus problem contd',\n",
       "  'NN'),\n",
       " ('we decid second child ms i found i ms month birth daughter back i nisthagmus serious balanc problem i start treatment copaxon relaps month i switch gilenya my sight back normal balanc use doesnt bother normal life except yoga but sinc i extreem tire tire activ hour spread day i convers neurologist second child she worri i would end wheelchair i serious relaps region brain so realli worri sinc i feel like absent mum alreadi it would also duabl partner take care kid sinc i realli rest day so realli still brack heart make hard decis count bless accept fact kid isnt option us but i wasnt tire i guess would tri expand famili i would ask neurologist advic i know peopl kid get diagnos',\n",
       "  'WRB'),\n",
       " ('theyr keep eye scuse pun haemorrhag upper vision refer doctor perform wash out retina im guess vitrectomi cant help feel complet like ive read mani horror stori made vision wors it doesnt help either i dont fulli trust profession look eye everi time ive clinic laser differ consult ive peopl laser eye id prefer one meddl back know work one said coupl month back eye look like improv assur wouldnt get wors month well truli fill hope bodi differ idea',\n",
       "  'NN'),\n",
       " ('crohn diseas also call ileiti enter affect part gut mouth way anus in major case howev lower part small intestin ileum affect symptom unpleas they includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain common felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain the level pain vari individu depend inflamm gut most common pain felt lowerright side abdomen ulcer gut ulcer raw area gut may bleed if bleed patient might notic blood stool mouth ulcer these common symptom diarrhea this rang mild sever sometim may mucus blood pus the patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit there may time appetit low weight loss this result loss appetit anemia a loss blood lead anemia rectal bleed anal fissur the skin anus becom crack lead pain bleed other possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas while ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum the crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need highcalori liquid formula especi growth affect most patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol some peopl feel like eat in sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement the aim control inflamm correct nutrit problem reliev symptom there cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previous treatment recur symptom some peopl long period even year without symptom this known remiss howev usual recurr as period remiss vari much hard know effect treatment it imposs predict long period remiss go best food crohn diseas flareup eat right food help peopl manag symptom crohn diseas find read medic crohn diseas antiinflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor general treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol antidiarrh fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ they reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect some studi suggest use biolog reduc chanc person need abdomin surgeri within year percent befor introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid there differ type biolog drug individu react differ a doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri the major crohn diseas patient may need surgeri point when medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov some crohn diseas patient may requir one oper live in case colectomi need whole colon remov the surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma a pouch collect fece doctor say patient stoma carri lead normal activ life if surgeon remov diseas section intestin connect intestin stoma need the patient doctor need consid surgeri care it appropri everyon the patient bear mind oper diseas recur most peopl crohn diseas live normal activ live hold job rais famili function success caus the exact caus crohn diseas unclear thought stem abnorm reaction immun system the theori immun system attack food good bacteria benefici substanc unwant substanc dure attack white blood cell build line gut buildup trigger inflamm the inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close relat condit if ident twin crohn diseas twin percent chanc a bacterium virus may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi a doctor ask person sign symptom a physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth the follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut a long thin flexibl telescop endoscop goe esophagus stomach ct scan barium enema xray reveal chang insid bowel complic if symptom sever frequent likelihood complic higher the follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut there may also persist iron defici food absorpt problem slight higher risk develop bowel cancer relat coverag what stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year for reason doctor usual classifi crohn differ stage learn read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read what expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read crohn diseas surgeri what know while surgeri cannot cure crohn diseas help reduc person symptom prevent lifethreaten complic in articl learn differ type crohn diseas surgeri prepar expect recoveri read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd all refer avail refer tab refer this content requir javascript enabl baumgart m dogan b rishniw m weitzman g bosworth b yantiss r berg d cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni relat deplet clostridial crohn diseas involv ileum the ism journal retriev httpwwwnaturecomismejjournalvnabsismejahtml crohn diseas nd american societi colon rectal surgeon retriev httpswwwfascrsorgpatientsdiseaseconditioncrohnsdiseas crohn diseas caus april retriev httpwwwnhsukconditionscrohnsdiseasepagescausesaspx epidemiolog ibd march cdc retriev httpswwwcdcgovibdibdepidemiologyhtm leena halm paulina paavolasakki ulla turunen maarit lappalaccinen martti frkkil kimmo kontula june world journal gastroenterolog retriev httpswwwncbinlmnihgovpmcarticlespmc lichtenstein g r loftus e v isaac k l regueiro m d gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev httpgiorgguidelinemanagementofcrohnsdiseaseinadult what crohn diseas nd cleveland clinic retriev httpsmyclevelandclinicorghealtharticlescrohnsdiseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian what crohn diseas medic news today medilexicon intl dec web feb httpswwwmedicalnewstodaycomarticlesphp apa nordqvist c decemb what crohn diseas medic news today retriev httpswwwmedicalnewstodaycomarticlesphp pleas note if author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom a recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus this japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist can halt cellular age new drug combo show promis in first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer whi immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       "  'NN'),\n",
       " ('when i read option i thought use chemoradi place surgeri in word state option either nivolumab chemotherapi success surgeri chemorad that would pretti typic approach treatment stage iiia surgeri possibl otherwis chemoradi as far danger surgeri one situat often case arguabl resect stage iiia lung cancer demand particip experienc thorac surgeon special type surgeri oppos surgeon surgeri mani type im sure mskcc surgeon meet criteria it unusu begin chemo regimen adjust dosag andor switch cisplatin carboplatin side effect difficult as dr west said in term activ agent postop evid stronger cisplatin expert typic favor cisplatin patient toler there near mani studi carboplatin data set suggest carboplatin may shade less activ while wed want give effect treatment go valuabl therapi patient success get without prohibit side effect i would hesit recommend carboplatinbas chemo someon i thought cisplatinbas chemo like feasibl i mani patient done extrem well either switch cisplatin carboplatin due side effect start carboplatin begin one reason anoth httpcancergraceorgforumsindexphptopicmsgmsg pleas note comment dr sanborn regard pair platinum alimta like recommend alimta isnt good choic squamous jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'WRB'),\n",
       " ('blog beleiv gavin tell lazi mani keyword choos absenc site map proximus consid time pain possibl use inform treatment strategi at time tysabri best bet jcv ocrelizumab chang thing slight ocrelizumab get rid plasma cell idea hunt b cell ocrel first matur stage infnaci memori etc reach plasma stage if deal plasma cell kept bay tysabri ocrel let back i know i pain feel i start get b cell busi hope persist equal help other understand toni',\n",
       "  'NN'),\n",
       " ('the result keynot studi confirm os advantag pembrolizumab arm docetaxel patient higher pdl express tps pembrolizumab mgkg improv surviv month hazard ratio hr p pembrolizumab mgkg month hr p rpfs month longer pembrolizumab treatment arm compar docetaxel among patient pdl tps the author conclud surviv advantag patient tps dose pembrolizumab improv surviv month docetaxel median surviv month but result report separ pdl tps strata tps versus possibl strong os improv seen higher pdl tumor express drive os benefit toward statist signific total studi popul there rpfs differ treatment arm total studi popul perhap address concern abstract american societi clinic oncolog asco annual meet june present result analys subgroup patient lower pdl express tps for patient lower pdl express tps pembrolizumab mgkg fail meet statist signific os compar docetaxel hr ci the higher dose pembrolizumab mgkg appear improv os docetaxel month hr ci patient tps it appear howev author employ rigor determin statist signific threshold main analys both pembrolizumab arm lower median rpfs compar docetaxel cannot evalu side hypothesi test inher ignor effect opposit direct the second abstract pool data pembrolizumab arm contrast docetaxel quartil base pdl express demonstr superior surviv pembrolizumab docetaxel tps strata no surviv benefit observ tps strata weak associ versus month p found pembrolizumab docetaxel pdl tps sinc data pembrolizumab arm pool analys consid exploratori result interpret caution relat aggress local therapi improv surviv limitedmetastat nsclc these case highlight import watch neglig use statist form conclus one research research other close inspect aspect clinic trial necessari evalu drug efficaci includ mechan action patient popul tria l conduct statist method check see p valu met threshold statist signific refer goodman sn align statist scientif reason misunderstand misus statist signific imped scienc jun scienc doi scienceaaf herbst rs baa p kim dw et al pembrolizumab versus docetaxel previous treat pdlposit advanc nonsmallcel lung cancer keynot random control trial apr lancet doi epub ahead print garon eb herbst rs kim dw et al pembrolizumab vs docetaxel previous treat advanc nsclc pdl tumor proport score tps result keynot j clin oncol suppl abstr baa p garon eb herbst rs et al relationship level pdl express outcom keynot studi pembrolizumab vs docetaxel previous treat pdlposit nsclc j clin oncol suppl abstr',\n",
       "  'NN'),\n",
       " ('januari biotim enter agreement with orbit biomed deliveri opregen cell dri amd advertis biotim inc enter research option agreement orbit biomed limit two compani collabor use orbit proprietari inject technolog deliv opregen retin pigment epithelium transplant therapi phase iiia develop treatment dri amd orbit system design precis consist deliv therapeut subretin space via suprachoroid rout avoid need vitrectomi perfor retina more inform found httpsglobenewswirecomnewsreleaseenbiotimeentersintoexclusiveagreementwithorbitbiomedicalltdtoaccessinnovativedeviceforthesubretinaldeliveryofopregencellsforthetreatmentofdryamdhtml aeri announc accept ind applic ar aeri pharmaceut announc us food drug administr review investig new drug applic ind ar dexamethason intravitr implant effect allow aeri initi human studi treatment macular edema due retin vein occlus the ind submit decemb aeri expect initi phase clinic studi later first quarter ar bioerod implant administ intravitr inject design releas dexamethason sixmonth sustain period the potenti benefit ar compar steroid product includ sixmonth durat efficaci improv administr due smaller needl size possibl better safeti profil due lower peak drug level more inform found httpinvestorsaeriepharmacomnewsreleasesnewsreleasedetailsaeriepharmaceuticalsannouncesacceptanceitsinvestig result publish of phase trial neurotech nt use treat mactel neurotech pharmaceut collabor lowi medic research institut recent announc result phase studi nt publish ophthalmolog the nt renexus devic manufactur neurotech novel cellbas drug deliveri system cell encapsul semiperm hollow fiber membran releas ciliari neurotroph factor cntf shown reduc photoreceptor cell loss anim model retin degener the implant renexus devic result sustain deliveri cntf local retina the studi phase multicent random clinic trial test effect encapsul cellbas deliveri cntf retin degener patient macular telangiectasia type mactel the studi show nt treatment slow progress retin degener compar particip given sham treatment in addit nt provid function benefit read speed stabil patient receiv implant more inform found httpswwwprnewswirecomnewsreleasesneurotechpharmaceuticalsincandlowymedicalresearchinstituteannouncepublicationofntphaseresultshtml flavoprotein fluoresc may detect improv patient dme treat antivegf ocusci announc onlin public diabet macular edema studi the find suggest compani flavoprotein fluoresc fpf detect improv metabol function direct correl vision improv improv macular thick measur oct dme patient treat antivegf the studi follow eight patient clinic signific dme treatment antivegf inject research found chang fpf inject measur ocusci flagship devic ocumet beacon close correl chang bcva chang central macular thick bcva more inform found httpswwwbusinesswirecomnewshomeenocusciencesannouncespublicationshowingflavoproteinfluorescencedetect protect effect admramp system may make new therapeut target rvo investig util newli develop model central retin vein occlus crvo mice mimic mani clinic featur crvo human studi patholog effect retin occlus demonstr retinoprotect effect peptid adrenomedullin adm receptor activitymodifi protein ramp their report recent publish american journal patholog the crvo model generat combin intraperiton inject rose bengal photoactiv dye enhanc thrombus format laser photocoagul the promin chang note retin hemorrhag venous dilat tortuos measur retin thick reveal promin edema earli crvo induc follow gradual atrophi base find investig propos retinoprotect effect admramp system make novel therapeut target treatment crvo more inform found httpswwweurekalertorgpubreleasesepeophp gemini therapeut announc clariti diseas registri natur histori studi dri amd gemini therapeut announc initi clariti diseas registri natur histori studi design identifi character diseas progress subject noncentr geograph atrophi ncga secondari dri amd carrier highrisk genet variant clariti genet screen consent thousand subject enrol hundr base genet criteria use inform optim design futur intervent trial clariti investig dant pieramici md partner california retina consult said to date precis medicin limit select field oncolog lung metabol rare diseas clariti advanc field ophthalmolog evalu complex retin diseas use precis medicin approach more inform found httpswwwbusinesswirecomnewshomeengeminitherapeuticsannouncesinitiationclaritydiseaseregistri resourc this month calendar event imag month supplement magazin subscript newslett subscript about retin physician about public archiv articl feedback contact us social media facebook twitter linkedin retin physician therapeut surgic treatment posterior segment deliv indepth coverag latest advanc amd diabet retinopathi macular edema retin vein occlus well surgic intervent posterior segment care it reach retin specialist general ophthalmologist practic insight regard current futur treatment strategi medic surgic retina care the comprehens retin care journal retin physician put perspect scientif develop mean today practic discuss ramif new studi treatment patient manag strategi publish nine time per year',\n",
       "  'NN'),\n",
       " ('the time decis person issu crohn v uc diagnosi relev decisionmak some peopl good luck biolog remicad humira entyvio my husband tri three they didnt work thing prednison at point felt comfort decis move forward surgeri person import feel tri option in case addit drug option becam avail last minut xeljanz put remiss he fulli acknowledg day xeljanz stop work surgeri unless anoth great drug option time grate colon i dont think wrong answer spous diagnos uc develop antibodi remicad humira entyvio work infus onli thing seem work prednison earli march start xeljanz label it work no uc symptom abl eat almost everyth fresh fruit veget first time year struggl final taper prednison',\n",
       "  'NN'),\n",
       " ('object to character use safeti newer diseasemodifi therapi dmts children multipl sclerosi ms clinic isol syndrom cis treat year age method this cohort studi includ children ms cis follow outpati practic particip us network pediatr ms center dmt use includ durat dose side effect analyz newer dmts defin agent receiv food drug administr approv increas use adult ms result as juli pediatr patient ms n cis n enrol femal mean onset year mean followup year median visit per year of n ms n cis receiv dmt year age this consist least one newer dmt includ dimethyl fumar n natalizumab n rituximab n fingolimod n daclizumab n teriflunomid n among initi dmt prescrib newer agent dimethyl fumar natalizumab rituximab fingolimod teriflunomid over last year use newer agent increas particular year lesser extent year the shortterm side effect profil newer dmts differ report adult conclus newer dmts often use pediatr ms similar shortterm safeti toler side effect profil adult these find may help inform pediatr ms manag',\n",
       "  'NN'),\n",
       " ('chicagoth combin therapi gefitinib carboplatin pemetrex gcp may lead superior surviv outcom compar gefitinib monotherapi among patient advanc epiderm growth factor receptor egfr mutationposit nonsmallcel lung cancer nsclc accord data present american societi clinic oncolog annual meet monday june the standard care among patient advanc egfr mutat nsclc egfr tyrosin kinas inhibitor tki monotherapi improv progressionfre surviv pfs overal surviv os compar chemotherapi a previous studi shown gefitinib plus platinum doublet chemotherapi may improv overal surviv popul for openlabel phase nej studi research random assign previous untreat patient advanc stage stage iiiiv recurr nsclc harbor egfr activ mutat receiv oral gefitinib mg alon daili gefitinib mg carboplatin auc pemetrex mgm gcp everi week the baselin characterist studi group compar the primari outcom progressionfre surviv pfs progress next line therapi pfs overal surviv os relat articl keynot pembrolizumab improv overal surviv nonsmal cell lung cancer prophylact cranial irradi reduc incid brain metastas nsclc result show patient receiv gcp signific prolong pfs compar patient treat gefitinib alon vs month hazard ratio hr ci p the os also increas among patient treat gcp month versus month among patient treat gefitinib alon hazard ratio hr p the overal respons rate combin group monotherapi group respect further analysi show howev pfs differ signific studi arm median pfs among patient receiv gcp month versus month among patient receiv gefitinib monotherapi hr ci p grade wors advers effect observ greater frequenc gcp arm includ neutropenia anemia thrombocytopenia the author conclud gefitinib combin carboplatin pemetrex may effect treatment option firstlin treatment advanc egfrmut nsclc read cancer therapi advisor coverag american societi clinic oncolog asco meet visit confer page refer',\n",
       "  'VBP'),\n",
       " ('hello eyeprotect i second ozurdex implant th may i also see wormlik floater but vision improv day one i four eyelia doctor switch implant for ozurdex work great',\n",
       "  'NN'),\n",
       " ('thank respons jimc catdand doctor seem reluct biopsi i mention previous happen land far far away europ mayb way thing done might seem somewhat odddiffer we consult best surgeon countri special adren surgeri state would perform biopsi given evid histolog verifi primari nsclc ct scan lesion size growth recommend chemotherapi instead as immunotherapyi know ramucirumab pembrolizumab nivolumab avail i sure state insur fund would cover father case given year old exsmok advanc lung cancer thank respons support',\n",
       "  'NN'),\n",
       " ('my wife keytruda sinc mgkg everi week sinc may everi week i find also difficult know effect long term treatment she pneumon cough sometim strong could either caus lung cyberknif treatment immunotherapi what strang effect appear stope opdivo my feel effect antibodi taken year still bad known',\n",
       "  'VBN'),\n",
       " ('januari follow recent discuss us fda compani today announc voluntari withdraw us supplement biolog licens applic opdivo lowdos yervoy ipilimumab combin treatment firstlin advanc nonsmal cell lung cancer patient tumour mutat burden mutationsmegabas mutmb in octob compani announc submiss exploratori overal surviv os analysi tumour mutat burden tmb mutmb subgroup fda the fda determin time submiss new inform constitut major amend applcat extend review period three month move prescript drug user fee act date may after recent discuss fda compani believ evid relationship tmb pdl requir fulli evalu impact opdivo plus yervoy os firstlin nonsmal cell lung cancer patient this analysi requir avail final data checkmat part opdivo plus lowdos yervoy opdivo monotherapi versus chemotherapi patient whose tumour express pdl compani anticip avail firsthalf sinc data checkmat part avail within review cycl current applic compani decid withdraw read bms press releas',\n",
       "  'NNS'),\n",
       " ('progress ms treat long bac cree f paul univers california san francisco san francisco ca unit state neurocur clinic research center charit universittsmedizin berlin germani the vex therapeut challeng multipl sclerosi progress neurolog disabl occur independ relaps progress ms occur clinic onset primari progress follow histori relaps secondari progress progress ms classifi associ without diseas activ ie set ongo clinic relaps radiograph evid diseas activ determin mri until recent clinic trial immunomodulatori therapi known effect relaps ms yield disappoint result trial either primari progress secondari progress ms howev recent sever clinic trial target progress ms show benefit ocrelizumab bcell deplet anticd monoclon antibodi first medic prove slow disabl progress subgroup patient primari progress ms receiv regulatori approv treatment primari progress ms countri siponimod next generat select spsp sphingosin receptor modul shown larg registr trial slow accumul disabl patient secondari progress ms regulatori review md high dose biotin shown improv disabl patient either primari secondari progress ms multicent random control trial investig ongo multin studi md also avail countri name patient basi given success studi neurologist first time understand therapeut select progress form multipl sclerosi this case base cours review uptod understand progress form ms treat data recent success clinic trial provid insight therapeut select base patient characterist review inform case vignett present in addit diseas modifi therapi use symptomat treatment highlight last clinic import unansw question direct futur research outlin disclosur prof bruce cree md phd mas receiv person compens consult abbvi biogen emd serono novarti sanofi genzym prof friedemann paul md receiv person compens consult speak alexion biogen chugai medimmun merck serono novarti sanofi genzym shire',\n",
       "  'VBP'),\n",
       " ('speaker donald negroski md patient educ dinner discov ocrevus may right choic treat relaps ms preregistr requir contact organ regist',\n",
       "  'NN'),\n",
       " ('hey want give updat my sleep slight improv i think lot go realli low fiber diet although prednison seem take appetit never end i eat meal everi hour day seem like i feel like i put weight im eat especi sinc i eat least three full high protein low fiber meal day im also averag three sometim four stool hour period i still get one form stool usual even low fiber other loos wateri there occasion blood morn realli much im still thought i want tri entyvio get remiss i realli need get darn steroid talk gi want stay current plan next appoint week sinc ive shown improv i tell ya i could get rid pain orm stool occur i id scream joy diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free most dairi free sinc jan flare sinc june signific inflamm doc word',\n",
       "  'NN'),\n",
       " ('mlgilber i hope goe well understand feel littl nervous youll good hand dont worri much such shame ocrevus pass ppms suffer uk all best',\n",
       "  'JJS'),\n",
       " ('jarthur my wife yo nonsmok dxd stage iv nsclc left lung egfr tarceva continu year excel respons year chemo carboalimtaavastin local recurr good respons repeat chemo carboalimtaavastin local recurr good respons avastin mainten needl bx local recurrenceresult includ egfr tm pd all rx tarceva avastin dcd pend rx decis diseas still confin left chest what would option system rx indicatedtagrisso checkpoint inhibitoron two agent chemo we grate wife respond least temporarili rx thus far we never would expect longev date dx first made thank input',\n",
       "  'NN'),\n",
       " ('the diabet retinopathi clinic research network protocol s establish intravitr inject ranibizumab mg lucenti novarti new strategi manag prolif diabet retinopathi pdr howev applic studi result clinic practic challeng mani question pharmacotherapi panretin photocoagul prp need answer said francisco j rodriguez md woc guadalajara mexico ranibizumab allow us avoid complic prp includ peripher visual field loss decreas visual acuiti va develop worsen diabet macular oedema dme sever visual loss per cent patient howev treatment select individu patient influenc number paramet includ longterm efficaci predictor respons potenti side effect conveni patient famili physician import cost introduc payer anoth player note dr rodriguez scientif director fundacin oftalmolgica nacion chairman depart ophthalmolog escuela de medicina ciencia de la salud universidad del rosario bogota colombia more time need answer question chronic use antivascular endotheli growth factor antivegf therapi pdr determin best longterm strategi perhap combin laser pharmacotherapi ad emerg data protocol s undertaken emerg data dme clinic trial show antivegf treatment modul progress dr the studi randomis patient prompt prp complet one three sit within eight week ranibizumab mg four mandatori inject continu frequent everi four week the primari outcom analysi mean chang va two year show ranibizumab noninferior prp howev ranibizumab treatment offer advantag compar prp group eye assign antivegf inject group superior mean va two year better visual field decreas chanc vitrectomi less frequent develop dme we also know prp advantag compar antivegf therapi less expens carri risk endophthalm system vegf inhibit furthermor treatment typic complet one two visit often longlast dr rodriguez said look ahead dr rodriguez outlin sever issu need address better guidanc use antivegf therapi pdr we need know outcom achiev treat pdr mg dose ranibizumab antivegf agent said francisco j rodriguez',\n",
       "  'NN'),\n",
       " ('welcom lori realli realli tough stuff coincid stori came bloomberg news right i post ms patient chose death risk potent drug treatment httpwwwbusinessweekcomnew enthealth husband dx rrms dx dual jugular vein stenosi ccsvi httpccsviinmsblogspotcom top harryz famili elder post join tue may pm locat london on canada contact contact harryz icq re updat tysabrimay quot post harryz fri may hi cheer from first time drug appear ive alway said danger go caus lot problem line biogen market savior ms patient around world alway downplay nasti dark side drug they busi make money collater damag ms patient along way that life billion dollar revenu involv of cours i told i agenda held grudg biogen the name call nasti comment came dozen like i alway told potenti tysabri user learn could medic decid use pressur neuro start immedi you alway hear benefit vs risk real risk surfac isnt nice harri',\n",
       "  'NN'),\n",
       " ('most ms specialist advoc earli intervent although differ opinion exist within ms communiti hawkin vs amato pittock et al vs frohman et al the follow imag natur histori ms indic signific amount mri activ occur preclin phase earli relapsingremit ms gradual decreas inflammatori attack relaps time increas mri burden diseas occur along decreas brain volum this schemat support role dmts earli diseas cours explain patient famili member purpos diseasemodifi therapi ms manag rio et al set realist expect treatment unrealist expect common reason patient discontinu medic mohr et al instruct patient proper use medic particular inject techniqu rotat regimen minim skin reaction inject medic saunder et al webb monitor diseas activ mri see revis recommend cmsc task forc standard mri protocol clinic guidelin diagnosi followup multipl sclerosi monitor side effect provid manag strategi inadequ manag side effect anoth key reason peopl discontinu medic webb identifi suboptim respons cohen et al waubant treat suboptim respond increas lower dose higher dose ifn beta medic durelli et al panitch et al schwid panitch absenc neutral antibodi switch ifn beta medic glatiram acet vice versa freedman et al caon switch inject fingolimod marriott oconnor also consid firstlin option fda switch firstlin medic natalizumab mitoxantron rudick polman combin agent differ mechan action rudick polman consensus criteria consensus criteria suboptim respons cohen et al no relaps rate reduct relapseyear month continu dmt recurr new spinal cord brainstem lesion incomplet recoveri repeat relaps especi edss pdf score increas progress cognit motor impair disrupt adl regardless neurolog exam chang elimin influenc medic depress superimpos concurr ill polyregion diseas develop affect multipl neurolog system',\n",
       "  'NN'),\n",
       " ('object to assess whether presenc concomit diseas multipl sclerosi ms diagnosi associ choic treatment persist italian ms cohort method we includ newli diagnos patient follow ms center collect demograph clinic data we evalu baselin factor relat presenc comorbid associ comorbid clinic cours ms time first treatment switch result the studi cohort includ patient data comorbid avail patient a total patient least comorbid ms diagnosi age diagnosi odd ratio confid interv ci p baselin factor independ relat presenc comorbid comorbid signific associ choic first diseasemodifi treatment signific associ higher risk switch first treatment due intoler hazard ratio ci p associ comorbid risk switch intoler signific heterogen among treatment interferon glatiram acet natalizumab fingolimod interact test p conclus comorbid diagnosi taken account first treatment choic associ lower persist treatment',\n",
       "  'JJ'),\n",
       " ('yay peg so glad ocrevus help today i get th ivig infus it take hour repli with quot the follow user say thank agat howi jeani z jendi stillstannd',\n",
       "  'NN'),\n",
       " ('cc stelara work matter day if gi will jump hoop get probabl worth consid if one anti tnf stop work anoth pm ulcer coliti next surgeri schedul i problem skin loop i ad setup pm ulcer coliti next surgeri schedul im familiar hollist probabl they go first cut hole stoma go place direct skin it protect leak stay skin pm ulcer coliti humira remicad there cimzia simponi antitnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug pm ulcer coliti unexpect scope result jpouch buckey i think how appoint gi go i know issu complex mine i didnt see post anyth am ulcer coliti next surgeri schedul congratul id recommend get convex wafer new ostomi realli help liquid output as probabl know loop ileo time littl pm ulcer coliti after remicad infus id get test remicad antibodi i symptom i serum sick dont ignor mine got wors i start drop thing memori loss bone joint pain if pm ulcer coliti the superdonor phenomenon fecal microbiota transplant here segment cbc radio quirk quark show httpswwwcbccaradioquirksnotallpoopiscreatedequalandsuperpooperscouldbelifesav they test am ulcer coliti just saw gi hes recommend xeljanz im scare when start thread check box includ signatur i see med have thought ad entyvio either prednison entocort is blood test pm ulcer coliti just saw gi hes recommend xeljanz im scare have antitnf med like remicad you dont anyth list signatur are use rectal med steroid pm ulcer coliti recent takendown friend ive heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi gas diarrhea also caus sibo it easi test ive taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       "  'NN'),\n",
       " ('i dont find colonoscopi anxieti ridden freak inconveni af my ibd gi minut away i need someon pick sedat on top i need miss day work thursday recoveri day i need book week i go upper endoscopi pouchoscop ive put long everyon reason scope keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'JJ'),\n",
       " ('hi jimc i would like know often docetaxel use cyramza compar docetaxel alon circumst combo prefer can cyramza cross blood brain barrier is cyramza somewhat similar avastin use mainten i know docetaxel approv fda nd line agent i tri find recent research articl show advantag combo docetaxel cyramza tri find stanford oncologist prefer combo i research articl back support request i may abl convinc kaiser oncologist prescrib i hope i find answer thank kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('i talk dmard methotrex biolog humira it realli import visit iriti specialist fortun quit where locat',\n",
       "  'NN'),\n",
       " ('wow thank much that help well new test came back friend spot brain big enough take trial i guess good thing alway nice drug target cancer rest bodi she could potenti candid trial futur shall see for go put tagrisso also test trial found tumor spine explain vision problem shoulderneck pain she current two week radiat she diagnos juli amaz fight im wonder think tagrisso i facebook mayb i get account go check site and thank info bonni j addario foundat i heard check thank',\n",
       "  'VBD'),\n",
       " ('dh follow appoint today lymph node biopsi unfortun cancer return he port placement schedul begin folfiri avastin aug his dr also order mri femur spine brain rule met if anyth look suspici biopsi bone if clear pet scan show improv month send consult dr david bartlet upmc hillman center surgeri consult he might also undergo anoth lymph node biopsi look braf kras mutat she call oper super heroic oper said young strong otherwis healthi excel candid im grate left option husband look forward hell chemo life come especi diahrreah i still cant spell damn word hi brother age die lung cancer novemb anyhow lot digest today appoint i grate friendship site',\n",
       "  'JJ'),\n",
       " ('updat summari the us food drug administr approv expans use oral ms therapi gilenya fingolimod novarti ag includ treatment children adolesc year age older relaps ms this first therapi specif approv treat pediatr ms a larg phase clinic trial show benefit reduc relaps diseas activ mri the common side effect headach liver enzym elev diarrhea cough flu sinus back pain abdomin pain pain extrem a medic guid help inform patient famili use potenti risk for inform contact gilenya go program onlin phone gilenya',\n",
       "  'JJ'),\n",
       " ('wouldnt wonder rituxan good i hope ocrevus good have hope precious state',\n",
       "  'NN'),\n",
       " ('the lung pair coneshap breath organ chest the lung bring oxygen bodi breath they releas carbon dioxid wast product bodi cell breath each lung section call lobe the left lung two lobe the right lung slight larger three lobe two tube call bronchi lead trachea windpip right left lung the bronchi sometim also involv lung cancer tini air sac call alveoli small tube call bronchiol make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset a thin membran call pleura cover outsid lung line insid wall chest caviti this creat sac call pleural caviti the pleural caviti normal contain small amount fluid help lung move smooth chest breath there two main type lung cancer nonsmal cell lung cancer small cell lung cancer see follow pdq summari inform lung cancer small cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen there sever type nonsmal cell lung cancer each type nonsmal cell lung cancer differ kind cancer cell the cancer cell type grow spread differ way the type nonsmal cell lung cancer name kind cell found cancer cell look microscop squamous cell carcinoma cancer begin squamous cell thin flat cell look like fish scale this also call epidermoid carcinoma larg cell carcinoma cancer may begin sever type larg cell adenocarcinoma cancer begin cell line alveoli make substanc mucus other less common type nonsmal cell lung cancer pleomorph carcinoid tumor salivari gland carcinoma unclassifi carcinoma smoke major risk factor nonsmal cell lung cancer anyth increas chanc get diseas call risk factor have risk factor mean get cancer risk factor doesnt mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past this import risk factor lung cancer the earlier life person start smoke often person smoke year person smoke greater risk lung cancer be expos secondhand smoke be expos asbesto arsenic chromium beryllium nickel soot tar workplac be expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut have famili histori lung cancer be infect human immunodefici virus hiv take beta caroten supplement heavi smoker older age main risk factor cancer the chanc get cancer increas get older when smoke combin risk factor risk lung cancer increas sign nonsmal cell lung cancer includ cough doesnt go away short breath sometim lung cancer caus sign symptom it may found chest xray done anoth condit sign symptom may caus lung cancer condit check doctor follow chest discomfort pain a cough doesnt go away get wors time troubl breath wheez blood sputum mucus cough lung hoars loss appetit weight loss known reason feel tire troubl swallow swell face andor vein neck test examin lung use detect find diagnos stage nonsmal cell lung cancer test procedur detect diagnos stage nonsmal cell lung cancer often done time some follow test procedur may use physic exam histori an exam bodi check general sign health includ check sign diseas lump anyth els seem unusu a histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi these test help diagnos diseas plan check treatment monitor diseas time chest xray an xray organ bone insid chest an xray type energi beam go bodi onto film make pictur area insid bodi enlarg xray chest xray use take pictur organ bone chest xray pass patient onto film ct scan cat scan a procedur make seri detail pictur area insid bodi chest taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog a procedur pathologist view sampl sputum mucus cough lung microscop check cancer cell thoracentesi the remov fluid space line chest lung use needl a pathologist view fluid microscop look cancer cell if lung cancer suspect biopsi done one follow type biopsi usual use fineneedl aspir fna biopsi lung the remov tissu fluid lung use thin needl a ct scan ultrasound imag procedur use locat abnorm tissu fluid lung a small incis may made skin biopsi needl insert abnorm tissu fluid a sampl remov needl sent laboratori a pathologist view sampl microscop look cancer cell a chest xray done procedur make sure air leak lung chest enlarg fineneedl aspir biopsi lung the patient lie tabl slide comput tomographi ct machin take xray pictur insid bodi the xray pictur help doctor see abnorm tissu lung a biopsi needl insert chest wall area abnorm lung tissu a small piec tissu remov needl check microscop sign cancer an endoscop ultrasound eus type ultrasound may use guid fna biopsi lung lymph node area eus procedur endoscop insert bodi an endoscop thin tubelik instrument light len view a probe end endoscop use bounc highenergi sound wave ultrasound intern tissu organ make echo the echo form pictur bodi tissu call sonogram enlarg endoscop ultrasoundguid fineneedl aspir biopsi an endoscop ultrasound probe biopsi needl insert mouth esophagus the probe bounc sound wave bodi tissu make echo form sonogram comput pictur lymph node near esophagus the sonogram help doctor see place biopsi needl remov tissu lymph node this tissu check microscop sign cancer bronchoscopi a procedur look insid trachea larg airway lung abnorm area a bronchoscop insert nose mouth trachea lung a bronchoscop thin tubelik instrument light len view it may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi a bronchoscop insert mouth trachea major bronchi lung look abnorm area a bronchoscop thin tubelik instrument light len view it may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi a surgic procedur look organ insid chest check abnorm area an incis cut made two rib thoracoscop insert chest a thoracoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer in case procedur use remov part esophagus lung if certain tissu organ lymph node cant reach thoracotomi may done in procedur larger incis made rib chest open mediastinoscopi a surgic procedur look organ tissu lymph node lung abnorm area an incis cut made top breastbon mediastinoscop insert chest a mediastinoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer enlarg mediastinoscopi a mediastinoscop insert chest incis breastbon look abnorm area lung a mediastinoscop thin tubelik instrument light len view it may also cut tool tissu sampl may taken lymph node right side chest check microscop sign cancer in anterior mediastinotomi chamberlain procedur incis made besid breastbon remov tissu sampl lymph node left side chest anterior mediastinotomi a surgic procedur look organ tissu lung breastbon heart abnorm area an incis cut made next breastbon mediastinoscop insert chest a mediastinoscop thin tubelik instrument light len view it may also tool remov tissu lymph node sampl check microscop sign cancer this also call chamberlain procedur lymph node biopsi the remov part lymph node a pathologist view tissu microscop look cancer cell one follow laboratori test may done studi tissu sampl molecular test a laboratori test check certain gene protein molecul sampl tissu blood bodi fluid molecular test check certain gene chromosom chang occur nonsmal cell lung cancer immunohistochemistri a test use antibodi check certain antigen sampl tissu the antibodi usual link radioact substanc dye caus tissu light microscop this type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option the prognosi chanc recoveri treatment option depend follow the stage cancer size tumor whether lung spread place bodi the type lung cancer whether cancer mutat chang certain gene epiderm growth factor receptor egfr gene anaplast lymphoma kinas alk gene whether sign symptom cough troubl breath the patient general health for patient nonsmal cell lung cancer current treatment cure cancer if lung cancer found take part one mani clinic trial done improv treatment consid clinic trial take place part countri patient stage nonsmal cell lung cancer inform ongo clinic trial avail nci websit stage nonsmal cell lung cancer key point after lung cancer diagnos test done find cancer cell spread within lung part bodi there three way cancer spread bodi cancer may spread began part bodi the follow stage use nonsmal cell lung cancer occult hidden stage stage stage i stage ii stage iii stage iv after lung cancer diagnos test done find cancer cell spread within lung part bodi the process use find cancer spread within lung part bodi call stage the inform gather stage process determin stage diseas it import know stage order plan treatment some test use diagnos nonsmal cell lung cancer also use stage diseas see general inform section other test procedur may use stage process includ follow mri magnet reson imag a procedur use magnet radio wave comput make seri detail pictur area insid bodi brain this procedur also call nuclear magnet reson imag nmri ct scan cat scan a procedur make seri detail pictur area insid bodi brain abdomen lymph node taken differ angl the pictur made comput link xray machin a dye may inject vein swallow help organ tissu show clear this procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan a procedur find malign tumor cell bodi a small amount radioact glucos sugar inject vein the pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg pet positron emiss tomographi scan the patient lie tabl slide pet machin the head rest white strap help patient lie still a small amount radioact glucos sugar inject patient vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan a procedur check rapid divid cell cancer cell bone a small amount radioact materi inject vein travel bloodstream the radioact materi collect bone cancer detect scanner pulmonari function test pft a test see well lung work it measur much air lung hold quick air move lung it also measur much oxygen use much carbon dioxid given breath this also call lung function test bone marrow aspir biopsi the remov bone marrow blood small piec bone insert hollow needl hipbon breastbon a pathologist view bone marrow blood bone microscop look sign cancer there three way cancer spread bodi cancer spread tissu lymph system blood tissu the cancer spread began grow nearbi area lymph system the cancer spread began get lymph system the cancer travel lymph vessel part bodi blood the cancer spread began get blood the cancer travel blood vessel part bodi cancer may spread began part bodi when cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system the cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood the cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi the metastat tumor type cancer primari tumor for exampl nonsmal cell lung cancer spread brain cancer cell brain actual lung cancer cell the diseas metastat lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ this call metastat cancer this anim show cancer cell travel place bodi first form part bodi the follow stage use nonsmal cell lung cancer occult hidden stage in occult hidden stage cancer cannot seen imag bronchoscopi cancer cell found sputum bronchial wash sampl cell taken insid airway lead lung cancer may spread part bodi stage in stage abnorm cell found line airway these abnorm cell may becom cancer spread nearbi normal tissu stage may adenocarcinoma situ ai squamous cell carcinoma situ scis stage i in stage i cancer form stage i divid stage ia ib stage ia the tumor lung centimet smaller cancer spread lymph node stage ib the tumor larger centimet larger centimet cancer spread lymph node the tumor centimet smaller one follow found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node stage ii stage ii divid stage iia iib stage iia the tumor larger centimet larger centimet cancer spread lymph node one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon stage iib the tumor centimet smaller cancer spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node one follow found the tumor larger centimet larger centimet there one separ tumor lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart stage iii stage iii divid stage iiia iiib iiic stage iiia the tumor centimet smaller cancer spread lymph node side chest primari tumor the lymph node cancer around trachea trachea divid bronchi also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow found the tumor larger centimet larger centimet there one separ tumor lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart cancer may spread lymph node side chest primari tumor the lymph node cancer lung near bronchus also one follow found the tumor larger centimet there one separ tumor differ lobe lung primari tumor the tumor size cancer spread follow trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiib the tumor centimet smaller cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow may found cancer spread main bronchus spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon the tumor may size cancer spread lymph node side chest primari tumor the lymph node cancer around trachea trachea divid bronchi also one follow found there one separ tumor lobe differ lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiic the tumor may size cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow found there one separ tumor lobe differ lobe lung primari tumor cancer spread follow the membran line insid chest wall chest wall the nerv control diaphragm outer layer tissu sac around heart trachea carina esophagus breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iv stage iv divid stage iva ivb in stage iva tumor may size cancer may spread lymph node one follow found there one tumor lung primari tumor cancer found fluid around lung heart cancer spread one place organ near lung brain liver adren gland kidney bone sac around heart lymph node near lung in stage ivb cancer spread multipl place one organ near lung recurr nonsmal cell lung cancer recurr nonsmal cell lung cancer cancer recur come back treat the cancer may come back brain lung part bodi treatment option overview key point there differ type treatment patient nonsmal cell lung cancer ten type standard treatment use surgeri radiat therapi chemotherapi target therapi immunotherapi laser therapi photodynam therapi pdt cryosurgeri electrocauteri watch wait new type treatment test clinic trial chemoprevent radiosensit new combin treatment nonsmal cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment followup test may need there differ type treatment patient nonsmal cell lung cancer differ type treatment avail patient nonsmal cell lung cancer some treatment standard current use treatment test clinic trial a treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer when clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial some clinic trial open patient start treatment ten type standard treatment use surgeri four type surgeri use treat lung cancer wedg resect surgeri remov tumor normal tissu around when slight larger amount tissu taken call segment resect enlarg wedg resect lung part lung lobe contain cancer small amount healthi tissu around remov lobectomi surgeri remov whole lobe section lung enlarg lobectomi a lobe lung remov pneumonectomi surgeri remov one whole lung enlarg pneumonectomi the whole lung remov sleev resect surgeri remov part bronchus after doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use highenergi xray type radiat kill cancer cell keep grow there two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place direct near cancer stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment onc day sever day radiat machin aim larger usual dose radiat direct tumor by patient posit treatment less damag nearbi healthi tissu this procedur also call stereotact externalbeam radiat therapi stereotax radiat therapi stereotact radiosurgeri type extern radiat therapi use treat lung cancer spread brain a rigid head frame attach skull keep head still radiat treatment a machin aim singl larg dose radiat direct tumor brain this procedur involv surgeri it also call stereotax radiosurgeri radiosurgeri radiat surgeri for tumor airway radiat given direct tumor endoscop the way radiat therapi given depend type stage cancer treat it also depend cancer found extern intern radiat therapi use treat nonsmal cell lung cancer chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid when chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi when chemotherapi place direct cerebrospin fluid organ bodi caviti abdomen drug main affect cancer cell area region chemotherapi the way chemotherapi given depend type stage cancer treat see drug approv nonsmal cell lung cancer inform target therapi target therapi type treatment use drug substanc attack specif cancer cell target therapi usual caus less harm normal cell chemotherapi radiat therapi monoclon antibodi tyrosin kinas inhibitor two main type target therapi use treat advanc metastat recurr nonsmal cell lung cancer monoclon antibodi monoclon antibodi therapi cancer treatment use antibodi made laboratori singl type immun system cell these antibodi identifi substanc cancer cell normal substanc blood tissu may help cancer cell grow the antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus they may use alon carri drug toxin radioact materi direct cancer cell there differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form this may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell this stop cancer cell grow divid cetuximab necitumumab egfr inhibitor tyrosin kinas inhibitor tyrosin kinas inhibitor smallmolecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid some tyrosin kinas inhibitor also angiogenesi inhibitor effect there differ type tyrosin kinas inhibitor epiderm growth factor receptor egfr tyrosin kinas inhibitor egfr protein found surfac insid certain cell includ cancer cell epiderm growth factor attach egfr insid cell send signal tyrosin kinas area cell tell cell grow divid egfr tyrosin kinas inhibitor stop signal stop cancer cell grow divid erlotinib gefitinib afatinib osimertinib type egfr tyrosin kinas inhibitor some drug work better also mutat chang egfr gene kinas inhibitor affect cell certain gene chang certain chang alk ros gene caus much protein made block protein may stop cancer grow spread crizotinib use stop protein made alk ros gene ceritinib alectinib brigatinib use stop protein made alk gene dabrafenib use stop protein made braf gene trametinib use stop protein made mek gene see drug approv nonsmal cell lung cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer this type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac t cell help keep bodi immun respons check when pd attach anoth protein call pdl cancer cell stop t cell kill cancer cell pd inhibitor attach pdl allow t cell kill cancer cell nivolumab pembrolizumab atezolizumab durvalumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pdl tumor cell pd t cell help keep immun respons check the bind pdl pd keep t cell kill tumor cell bodi left panel block bind pdl pd immun checkpoint inhibitor antipdl antipd allow t cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer this anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv nonsmal cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell photodynam therapi pdt photodynam therapi pdt cancer treatment use drug certain type laser light kill cancer cell a drug activ expos light inject vein the drug collect cancer cell normal cell fiberopt tube use carri laser light cancer cell drug becom activ kill cell photodynam therapi caus littl damag healthi tissu it use main treat tumor skin line intern organ when tumor airway pdt given direct tumor endoscop cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu carcinoma situ this type treatment also call cryotherapi for tumor airway cryosurgeri done endoscop electrocauteri electrocauteri treatment use probe needl heat electr current destroy abnorm tissu for tumor airway electrocauteri done endoscop watch wait watch wait close monitor patient condit without give treatment sign symptom appear chang this may done certain rare case nonsmal cell lung cancer new type treatment test clinic trial this summari section describ treatment studi clinic trial it may mention everi new treatment studi inform clinic trial avail nci websit chemoprevent chemoprevent use drug vitamin substanc reduc risk cancer reduc risk cancer recur come back for lung cancer chemoprevent use lessen chanc new tumor form lung radiosensit radiosensit substanc make tumor cell easier kill radiat therapi the combin chemotherapi radiat therapi given radiosensit studi treatment nonsmal cell lung cancer new combin new combin treatment studi clinic trial treatment nonsmal cell lung cancer may caus side effect for inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial for patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment some clinic trial includ patient yet receiv treatment other trial test treatment patient whose cancer gotten better there also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found ncis clinic trial search webpag clinic trial support organ found clinicaltrialsgov websit followup test may need some test done diagnos cancer find stage cancer may repeat some test repeat order see well treatment work decis whether continu chang stop treatment may base result test some test continu done time time treatment end the result test show condit chang cancer recur come back these test sometim call followup test checkup treatment option stage for inform treatment list see treatment option overview section occult nonsmal cell lung cancer treatment occult nonsmal cell lung cancer depend stage diseas occult tumor often found earli stage tumor lung sometim cure surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage treatment stage may includ follow surgeri wedg resect segment resect photodynam therapi electrocauteri cryosurgeri laser surgeri tumor near bronchus use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage i nonsmal cell lung cancer treatment stage ia nonsmal cell lung cancer stage ib nonsmal cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi extern radiat therapi includ stereotact bodi radiat therapi patient cannot surgeri choos surgeri a clinic trial chemotherapi radiat therapi follow surgeri a clinic trial treatment given endoscop photodynam therapi pdt a clinic trial surgeri follow chemoprevent use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage ii nonsmal cell lung cancer treatment stage iia nonsmal cell lung cancer stage iib nonsmal cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi pneumonectomi chemotherapi follow surgeri surgeri follow chemotherapi extern radiat therapi patient cannot surgeri a clinic trial radiat therapi follow surgeri use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iiia nonsmal cell lung cancer treatment stage iiia nonsmal cell lung cancer remov surgeri may includ follow surgeri follow chemotherapi surgeri follow radiat therapi chemotherapi follow surgeri surgeri follow chemotherapi combin radiat therapi chemotherapi radiat therapi follow surgeri a clinic trial new combin treatment treatment stage iiia nonsmal cell lung cancer cannot remov surgeri may includ follow chemotherapi radiat therapi given period time one follow extern radiat therapi alon patient cannot treat combin therapi palliat treatment reliev symptom improv qualiti life intern radiat therapi laser surgeri palliat treatment reliev symptom improv qualiti life chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab a clinic trial new combin treatment for inform support care sign symptom includ cough short breath chest pain see pdq summari cardiopulmonari syndrom nonsmal cell lung cancer superior sulcus often call pancoast tumor begin upper part lung spread nearbi tissu chest wall larg blood vessel spine treatment pancoast tumor may includ follow radiat therapi alon surgeri chemotherapi radiat therapi follow surgeri a clinic trial new combin treatment some stage iiia nonsmal cell lung tumor grown chest wall may complet remov treatment chest wall tumor may includ follow surgeri surgeri radiat therapi radiat therapi alon chemotherapi combin radiat therapi andor surgeri a clinic trial new combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail stage iiib stage iiic nonsmal cell lung cancer treatment stage iiib nonsmal cell lung cancer stage iiic nonsmal cell lung cancer may includ follow chemotherapi follow extern radiat therapi chemotherapi radiat therapi given separ treatment period time chemotherapi radiat therapi given separ treatment period time dose radiat therapi increas time chemotherapi radiat therapi given separ treatment period time chemotherapi alon given treatment chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab extern radiat therapi alon patient cannot treat chemotherapi extern radiat therapi palliat therapi reliev symptom improv qualiti life laser therapi andor intern radiat therapi reliev symptom improv qualiti life clinic trial new extern radiat therapi schedul new type treatment a clinic trial chemotherapi radiat therapi combin radiosensit clinic trial target therapi combin chemotherapi radiat therapi for inform support care sign symptom cough short breath chest pain see follow pdq summari cardiopulmonari syndrom cancer pain use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail newli diagnos stage iv relaps recurr nonsmal cell lung cancer treatment newli diagnos stage iv relaps recurr nonsmal cell lung cancer may includ follow combin chemotherapi combin chemotherapi target therapi monoclon antibodi bevacizumab cetuximab necitumumab combin chemotherapi follow chemotherapi mainten therapi help keep cancer progress target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor osimertinib gefitinib erlotinib afatinib target therapi anaplast lymphoma kinas alk inhibitor alectinib crizotinib ceritinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor pembrolizumab without chemotherapi laser therapi andor intern radiat therapi tumor block airway extern radiat therapi palliat therapi reliev symptom improv qualiti life surgeri remov second primari tumor surgeri remov cancer spread brain follow radiat therapi whole brain stereotact radiosurgeri tumor spread brain cannot treat surgeri a clinic trial new drug combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail progress stage iv relaps recurr nonsmal cell lung cancer treatment progress stage iv relaps recurr nonsmal cell lung cancer may includ follow chemotherapi target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor erlotinib gefitinib afatinib osimertinib target therapi anaplast lymphoma kinas alk inhibitor crizotinib ceritinib alectinib brigatinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor nivolumab pembrolizumab atezolizumab a clinic trial new drug combin treatment use clinic trial search find ncisupport cancer clinic trial accept patient you search trial base type cancer age patient trial done general inform clinic trial also avail to learn more about nonsmal cell lung cancer for inform nation cancer institut nonsmal cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv nonsmal cell lung cancer target cancer therapi laser cancer treatment photodynam therapi cancer cryosurgeri cancer treatment tobacco includ help quit secondhand smoke cancer for general cancer inform resourc nation cancer institut see follow about cancer stage chemotherapi you support peopl with cancer radiat therapi you support peopl with cancer cope cancer question ask your doctor cancer for survivor caregiv about this pdq summari about pdq physician data queri pdq nation cancer institut ncis comprehens cancer inform databas the pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin most summari come two version the health profession version detail inform written technic languag the patient version written easytounderstand nontechn languag both version cancer inform accur date version also avail spanish pdq servic nci the nci part nation institut health nih nih feder govern center biomed research the pdq summari base independ review medic literatur they polici statement nci nih purpos this summari this pdq cancer inform summari current inform treatment nonsmal cell lung cancer it meant inform help patient famili caregiv it give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date these board made expert cancer treatment specialti relat cancer the summari review regular chang made new inform the date summari updat date recent chang the inform patient summari taken health profession version review regular updat need pdq adult treatment editori board clinic trial inform a clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori each trial answer certain scientif question order find new better way help cancer patient dure treatment clinic trial inform collect effect new treatment well work if clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial some clinic trial open patient start treatment clinic trial list pdq found onlin ncis websit for inform call cancer inform servic cancer permiss use this summari pdq regist trademark the content pdq document use freeli text it cannot identifi nci pdq cancer inform summari unless whole summari shown updat regular howev user would allow write sentenc ncis pdq cancer inform summari breast cancer prevent state risk follow way includ excerpt summari the best way cite pdq summari pdq adult treatment editori board pdq nonsmal cell lung cancer treatment bethesda md nation cancer institut updat mmddyyyy avail httpswwwcancergovtypeslungpatientnonsmallcelllungtreatmentpdq access mmddyyyy pmid imag summari use permiss author artist andor publish use pdq summari if want use imag pdq summari use whole summari must get permiss owner it cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim the inform summari use make decis insur reimburs more inform insur coverag avail cancergov manag cancer care page contact us more inform contact us receiv help cancergov websit found contact us help page question also submit cancergov websit email us',\n",
       "  'NN'),\n",
       " ('i take humira imuran i felt aw flu like symptom dizzi i could bare function my mom also crohn stelara clinic trial hopkin shes take remiss im hope i success thank repli',\n",
       "  'NN'),\n",
       " ('no evid progress nep new outcom measur coin oratorio clinic trial studi peopl primari progress ms ppms random assign receiv either ocrelizumab ocrevus placebo compar placebo group receiv ocrevus high likelihood no progress month period time the definit state signific chang month period differ neurolog test edss nine hole peg test time foot walk test each describ video it excit invent new metric explain amaz clinic find no evid of progress and amaz medic increas likelihood one patient experienc nep pleas leav question comment wehavem ms view news make impact affect multipl sclerosi',\n",
       "  'JJ'),\n",
       " ('i believ gilenya back around i look back post there mani ms treatment choos one side effect caution special dosag requir what inform deal skyhigh cost huge question pay drug keep busi full time figur one might work one doesnt seem work well go process keep tri various avail option at least that quit peopl seem i stop tri two type treatment tempt new one keep come along have consid tri treatment ms diagnos avonex copaxon member ms board sinc repli with quot the follow user say thank howi jeani z salpals stillstannd sunshin suzeq',\n",
       "  'NN'),\n",
       " ('patient receiv tremelimumab iv durvalumab iv minut everi week week absenc diseas progress unaccept toxic patient receiv durvalumab iv minut week last combin dose addit dose biolog durvalumab given iv other name imfinzi immunoglobulin g antihuman protein bh human monoclon medi heavi chain disulfid human monoclon medi kappachain dimer medi medi other laboratori biomark analysi correl studi biolog tremelimumab given iv other name antictla human monoclon antibodi cp cp cp cp ticilimumab experiment arm b tremelimumab durvalumab rt patient receiv tremelimumab durvalumab arm a begin week patient receiv high dose radiat therapi qd day fraction biolog durvalumab given iv other name imfinzi immunoglobulin g antihuman protein bh human monoclon medi heavi chain disulfid human monoclon medi kappachain dimer medi medi other laboratori biomark analysi correl studi radiat radiat therapi undergo radiat therapi other name cancer radiotherapi irradi irradi irradi radiat radiotherapeut radiotherapi rt therapi radiat biolog tremelimumab given iv other name antictla human monoclon antibodi cp cp cp cp ticilimumab experiment arm c tremelimumab durvalumab rt patient receiv tremelimumab durvalumab arm a begin week patient receiv low dose radiat therapi everi hour bid week biolog durvalumab given iv other name imfinzi immunoglobulin g antihuman protein bh human monoclon medi heavi chain disulfid human monoclon medi kappachain dimer medi medi other laboratori biomark analysi correl studi radiat radiat therapi undergo radiat therapi other name cancer radiotherapi irradi irradi irradi radiat radiotherapeut radiotherapi rt therapi radiat biolog tremelimumab given iv other name antictla human monoclon antibodi cp cp cp cp ticilimumab outcom measur go top page studi descript studi design arm intervent outcom measur elig criteria contact locat more inform primari outcom measur overal respons rate determin respons evalu criteria solid tumor recist time frame up year the proport patient respons complet respons partial respons accord recist compar pairwis comparison radiotherapi rtcontain therapi control use chi squar test the differ proport respond present confid interv for colorect cancer respons rate within twostag design calcul present confid interv estim use method atkinson brown allow twostag design secondari outcom measur progressionfre surviv pfs time frame from date random object diseas progress death whichev occur first assess year distribut summar use kaplanmei method median time therapi arm accompani confid interv base loglogendpoint methodolog for cohort pairwis comparison durvalumabtremelimumab alon durvalumabtremelimumab rt arm conduct use logrank test overal surviv os time frame from time random death caus assess year distribut summar use kaplanmei method median time therapi arm accompani confid interv base loglogendpoint methodolog for cohort pairwis comparison durvalumabtremelimumab alon durvalumabtremelimumab rt arm conduct use logrank test object respons per immunerel respons irorr criteria time frame up year will present exact binomi confid interv for cohort size cohort patient cohort confid interv wider respect for cohort pairwis comparison irorr rt control arm conduct use chisquar test incid advers event assess common terminolog criteria advers event version time frame up year safeti data summar treatment arm within cohort the proport subject grade higher advers event present exact binomi confid interv local control rate abscop respons rate time frame up year the proport patient local control within irradi field report within rt treatment arm present exact binomi confid interv similar present use abscop respons rate for cohort size cohort patient cohort confid interv wider respect prognost effect pdl express time frame up year clinic respons compar accord pdl express use fisher exact test prognost effect tcell infiltr time frame up year clinic respons compar accord infiltr use fisher exact test other outcom measur patient report symptomat advers eventsa time frame up year data evalu data qualiti character baselin symptom status patient studi chang time explor develop symptomat ae chang time explor patient score relev clinic inform includ limit clinician grade ae feasibl electron collect well complianc patient report captur elig criteria go top page studi descript studi design arm intervent outcom measur elig criteria contact locat more inform inform nation librari medicin choos particip studi import person decis talk doctor famili member friend decid join studi to learn studi doctor may contact studi research staff use contact provid for general inform learn about clinic studi age elig studi year older adult older adult sex elig studi all accept healthi volunt no criteria inclus criteria patient must histolog cytolog confirm nonsmal cell lung cancer cohort colorect cancer cohort patient must measur diseas defin least one lesion accur measur least one dimens longest diamet record nonnod lesion short axi nodal lesion mm cm convent techniqu mm cm spiral comput tomographi ct scan magnet reson imag mri calip clinic exam patient cohort must progress diseas follow prior therapi specif cohort nsclc patient must evid radiolog clinic diseas progress previous treatment system pd direct therapi andor deem deriv clinic benefit pd direct treatment includ patient demonstr initi respons subsequ progress prior treatment chemotherapi target agent requir interven therapi allow previous pd direct treatment requir interv prior pd treatment requir pd direct treatment includ treatment antibodi target pd receptor pembrolizumab nivolumab well pdl target antibodi medi durvalumab atezolizumab avelumab agent may administ part clinic trial cohort colorect cancer patient must progress one line chemotherapi at least day must elaps prior system therapi chemotherapi radiat eastern cooper oncolog group ecog perform status karnofski life expect greater month furthermor enrol patient greater measur lesion discourag patient must normal organ marrow function independ transfus least day prior screen independ growth factor support least day prior screen hemoglobin hgb gdl absolut neutrophil count mcl platelet mcl total bilirubin x normal institut limit appli patient confirm gilbert syndrom persist recurr hyperbilirubinemia predomin unconjug bilirubin absenc evid hemolysi hepat patholog allow consult physician aspart aminotransferas ast serum glutamicoxaloacet transaminas sgotalanin aminotransferas alt serum glutam pyruv transaminas sgpt x institut upper limit normal patient hepat metastas alt ast x ult measur creatinin clearanc cl mlmin or calcul creatinin clearanc cl mlmin determin cockcroftgault use actual bodi weight patient must least one lesion previous irradi within previous radiat field palliat radiat potenti indic could safe deliv radiat dose specifi protocol lesion must measur lesion still possibl determin respons rate outsid radiat treatment field lesion must within central nervous system cns brain spinal cord requir urgent emerg palliat radiat given time radiat specifi protocol furthermor lesion for cohort nsclc cohort lesion irradi must lung lymph node adren gland liver for cohort colorect cohort lesion irradi must liver evid postmenopaus status negat urinari serum pregnanc test femal premenopaus patient requir women consid postmenopaus amenorrh month without altern medic caus follow agespecif requir appli women year age would consid postmenopaus amenorrh month follow cessat exogen hormon treatment lutein hormon follicl stimul hormon level postmenopaus rang institut underw surgic steril bilater oophorectomi hysterectomi women year age would consid postmenopaus amenorrh month follow cessat exogen hormon treatment radiationinduc oophorectomi last mens year ago chemotherapyinduc menopaus year interv sinc last mens underw surgic steril bilater oophorectomi hysterectomi femal childbear potenti sexual activ non steril male partner must use least high effect method contracept time screen must agre continu use precaut day last dose durvalumab tremelimumab combin therapi day last dose durvalumab monotherapi nonsteril male partner femal patient must use male condom plus spermicid throughout period cessat birth control point discuss respons physician engag sexual activ total durat drug treatment drug washout period accept practic howev period abstin rhythm method withdraw method accept method birth control femal patient also refrain breastfeed throughout period nonsteril male sexual activ femal partner childbear potenti must use male condom plus spermicid screen day receipt final dose durvalumab tremelimumab combin therapi day receipt final dose durvalumab monotherapi engag sexual activ accept practic howev occasion abstin rhythm method withdraw method accept method contracept male patient refrain sperm donat throughout period femal partner childbear potenti male patient must also use high effect method contracept throughout period should woman becom pregnant suspect pregnant partner particip studi inform treat physician immedi abil patient legal author repres lar understand willing sign written inform consent document bodi weight kg must life expect least week cohort nsclc cohort abil undergo fresh tumor biopsi purpos screen clinic trial includ abl will give valid written consent abil provid avail archiv tumor sampl taken less month prior studi enrol obtain prior progress pdpdl inhibitor fresh tumor biopsi feasibl accept clinic risk tumor lesion use fresh biopsi lesion irradi possibl lesion use respons evalu criteria solid tumor recist target lesion unless lesion access addit option archiv tumor tissu also request prior pd direct therapi cohort colorect cohort abil undergo fresh tumor biopsi purpos screen clinic trial includ abl will give valid written consent abil provid avail archiv tumor sampl taken less month prior studi enrol fresh tumor biopsi feasibl accept clinic risk tumor lesion use fresh biopsi lesion irradi possibl lesion use recist target lesion unless lesion access microsatellit stabl mss tumor document either immunohistochemistri ihc test suggest loss mlh msh pms msh polymeras chain reaction pcr test suggest microsatellit instabl msi exclus criteria patient system chemotherapi biolog therapi radiotherapi within week week nitrosourea mitomycin c prior enter studi receipt prior radiotherapi condit reason would contribut radiat dose would exceed toler normal tissu discret treat physician patient recov advers event due prior anticanc therapi ie residu toxic grade patient receiv investig agent patient untreat brain metastas spinal cord compress leptomening carcinomatosi exclud clinic trial patient whose brain metastas treat may particip provid show radiograph stabil defin brain imag obtain treatment brain metastas imag scan obtain least four week apart show evid intracrani progress addit neurolog symptom develop either result brain metastas treatment must resolv stabl either without use steroid stabl steroid dose mgday prednison equival anticonvuls least day prior start treatment histori allerg reaction attribut compound similar chemic biolog composit tremelimumab medi previous toxic attribut medi pd pdl direct therapi led drug discontinu prior exposur immunemedi therapi includ durvalumab tremelimumab except antipd antipdl therapi includ durvalumab nsclc patient includ antictla agent prior treatment agent not allow either cohort exclud therapeut anticanc vaccin exclud therapeut anticanc vaccin exposur investig agent may permit discuss studi princip investig pi uncontrol intercurr ill includ limit ongo activ infect symptomat congest heart failur unstabl angina pectori cardiac arrhythmia psychiatr illnesssoci situat would limit complianc studi requir pregnant women exclud studi breastfeed discontinu mother treat medi durvalumab tremelimumab radiat femal patient pregnant breastfeed male femal patient reproduct potenti will employ effect birth control screen day last dose durvalumab monotherapi day last dose durvalumab tremelimumab combin therapi whichev later human immunodefici virus hivposit patient inelig appropri studi undertaken patient receiv combin antiretrovir therapi indic ani concurr chemotherapi immun therapi biolog hormon therapi cancer treatment current prior use immunosuppress medic within day first dose assign ip follow except criterion intranas inhal topic steroid local steroid inject eg intraarticular inject system corticosteroid physiolog dose exceed mgday prednison equival steroid premed hypersensit reaction eg ct scan premed major surgic procedur defin investig within day prior first dose ip note local surgeri isol lesion palliat intent accept histori allogen organ transplant activ prior document autoimmun inflammatori disord includ inflammatori bowel diseas diverticul except diverticulosi sarcoidosi syndrom serious gastrointestin gi chronic condit associ diarrhea system lupus erythematosus wegen syndrom granulomatosi polyangi myasthenia gravi grave diseas rheumatoid arthriti hypophys uveiti sarcoidosi syndrom etc within past year prior start treatment follow except criterion patient vitiligo alopecia patient hypothyroid eg follow hashimoto syndrom stabl hormon replac psoriasi requir system treatment ani chronic skin condit requir system therapi patient without activ diseas last year may includ consult studi physician patient celiac diseas control diet alon histori anoth primari malign except malign treat curat intent known activ diseas year first dose studi drug low potenti risk recurr adequ treat nonmelanoma skin cancer lentigo maligna without evid diseas adequ treat carcinoma situ without evid diseas eg cervic cancer situ mean qt interv correct heart rate qtc ms calcul electrocardiogram ecg use fridericia correct abnorm ecg repeat histori activ primari immunodefici known histori previous clinic diagnosi tuberculosi activ infect includ hepat b known posit hepat b virus hbv surfac antigen hbsag result hepat c patient past resolv hbv infect defin presenc hepat b core antibodi antihbc absenc hbsag elig patient posit hepat c hcv antibodi elig polymeras chain reaction negat hcv ribonucl acid rna negat serolog document past year suffici evid receipt live attenu vaccin within day prior first dose investig treatment note patient enrol receiv live vaccin studi day last dose investig treatment ani condit opinion investig would interfer evaluati contact locat go top page studi descript studi design arm intervent outcom measur elig criteria contact locat more inform inform nation librari medicin to learn studi doctor may contact studi research staff use contact inform provid sponsor pleas refer studi clinicaltrialsgov identifi nct number nct show studi locat sponsor collabor nation cancer institut nci',\n",
       "  'NN'),\n",
       " ('yesterday bad day first doctor visit went expect nowher what i mean much could done point symptom treat symptomat he doesnt realli think im experienc ms hug i dont even think realli understood ms hug hes doctor year first time ever i littl shock especi sinc first thing discuss soon i walk offic new drug ocrelizumab versus rituxan what also occur yesterday i offic i increas baclofen i hurt shoulder i also took upon decreas baclofen i wonder i caus muscl spasm return either way decid want bring back neurontin anoth symptom i i came back start either way decid want bring back neurontin anoth symptom i i came back start everi time i leav one neurologist doctor offic visit sort depress kick there someth go feel great walk still feel great realli know st point noth help feel better we tri treat symptom allevi discomfort pain noth take away complet so basic everi time i leav doctor noth ever differ i get depress i know id love say end day wasnt ive mention past blog i realli wasnt go today i accid time i got home yesterday came complet blue dont know even that complet threw edg yesterday i walk i couldnt even make stair then cours deal mess shower chang guess i ms all stuff exhaust so top everyth i exhaust tri short time els i go doim alon and thought hit im fuck alon my daughter go colleg next year my two dogsi love heart cant help my mom stepdad god know still work in middl mom call leav quick messag machin check someth all i know whatev say i curs bathroom like fault i call back absolut hyster thing i think head moment i enough i enough ms i enough diseas i enough i done could imagin get phone call kid she walk work couldnt even talk she pull ledg one minut somebodi wait it took minut come back everyth clean includ i abl go sit couch put tv my one dog came lick tear the puppi came first time ever laid lap instead crazi one i abl text mom tell ok the convers later even mayb i look get help part time im year old i marbl i multipl sclerosi i realli bad day yesterday normal i tri make blog posit i there shitti post sad post hope humor post one post real this realli daili life experi multipl sclerosi',\n",
       "  'NN'),\n",
       " ('where blog i alway thought driver relaps atrophi differ although relaps caus atrophyther treatment need differ i suspect ocrelizumab get rid plasma cell suspect major effect ocb',\n",
       "  'NN'),\n",
       " ('i debilit uc tri usual drug except biolog like humira decad littl relief i resist biolog sever reason all horrifi patient testimoni didnt help i final threw towel year ago i knew continu path resist go take road disabl jobless famili i wouldnt abl care proper support my doc put prednisob taper follow initi humira ive remiss ever sinc im nurs iron i work endoscopi i guess i want peopl know ok go optim i tri visual med heal agent truli save life i hope continu work readi give tri',\n",
       "  'NN'),\n",
       " ('today mark third month gilenya it rough ride sinc first dose march i fatigu i start gone wors howev im still give chanc see goe anoth coupl month i read numer feedback weve got patient gilenya feel better later so im go tri stick i hope get better time',\n",
       "  'NN'),\n",
       " ('hello bit background info got ms diagnos epilepsi due lesion tempor lobe am take gilenya oxcarbazepin i told april gilenya work well progress last year i extrem happi rd med i tri epilepsi control year award drive licenc back last octob annoy today i seizur morn was angri upset i feel like step forward one back cant help wonder seizur start i sensori issu leg coupl week ago epilept aura feel like im back crap bus guess im wonder anyon anyth similar expect i dont want medicationtest etc thought id abit time consid mri februari came back fine thank read x',\n",
       "  'NN'),\n",
       " ('how know attack i diagnos year ago major fall i immedi went tysabri but i dont ever recal attack i awar symptom everi day',\n",
       "  'NN'),\n",
       " ('i sure i allow take vitamin c tarceva i spoke oncologist didnt mind i also heard japan give iv vitamin c tarceva accord protocol',\n",
       "  'VBP'),\n",
       " ('hi mous pleas meet ive post quit either i start new job januari i dont get much free time i use work term time often pop see what happen now i work everi day so far good although i get tire save houseworkchor weekend finger cross i stay healthi at least i dont worri tax credit cut im gilenya trick ms far i thought id better show virtual face tracey x',\n",
       "  'NN'),\n",
       " ('i set cladribin uk group facebook i gilenya im treatment possibl start april easter',\n",
       "  'NN'),\n",
       " ('no doesnt help prednison feel like second diseas doesnt even make first one go away hug yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wks minor flare august flare sinc oct acut pancreat balsalazid hosp day start humira reaction entyvio taper pred mgmg',\n",
       "  'JJ'),\n",
       " ('you lucki sue good neurolog team ive never nurs i copaxon gilenya i good nurs gp offic blood i need great nurs infus centr tysabri ms nurs peopl i know say wouldnt without ms nurs dont know i i hear great thing place not everi place madden cheer',\n",
       "  'NN'),\n",
       " ('facebook group gilenya user sever report fewer smaller lesion mris time g i symptom clear within year copaxon clear follow year g i year the latter necessarili sign remyelin help g could',\n",
       "  'NN'),\n",
       " ('i see list havent tri dmts when i diagnos neurologist start predict drug sinc around i start rebif i tecfidera now day hit hard drug like lemtrada gilenya start i diagnos i new hard hit drug younger peopl i wasnt crazi rebif made feel like i get flu it help hole vision heal close i lesion touch optic nerv i took five year i skin reject time tecfidera offer ms patient i take year get sever week stomach issu after side effect relaps consid safe come long term problem your blood check month problem might come each drug quirk problem tri see one work best system i two aunt ms treatment i knew thing went exercis good nutrit medit seem help start research find think work if doesnt work alway quit chang anoth dmt potter',\n",
       "  'NN'),\n",
       " ('remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom havent found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas firstlin approach biolog therapi work block certain chemic caus inflamm intestin most biolog crohn diseas block protein call tumor necrosi factor tnf other biolog block immun cell call integrin other act protein call interleukin il interleukin il this biolog therapi stop inflamm gut antitnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week the three antitnf biolog humira remicad cimzia humira humira selfadminist treatment follow initi demonstr healthcar profession if doctor decid handl inject theyll give set pen dosagecontrol medic insid youll also given instruct mani inject take first day after initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flareup it may also help maintain remiss prevent symptom return remicad given direct bloodstream this allow work immedi reliev symptom it administ medic facil experienc healthcar profession close monitor side effect treatment remicad doesnt taken everi day after three starter dose patient often see benefit six dose per year the downsid remicad must given intraven medic facil twohour period cimzia cimzia administ small inject the inject either given doctor offic home if choos receiv treatment doctor offic option receiv treatment powder form the powder mix steril water inject the option use prefil syring the syring contain medic that alreadi mix measur dose these use home doctor offic if choos treatment youll get packag two syring instruct give treatment after first three dose given everi two week abl take cimzia everi four week the two antiintegrin biolog crohn tysabri entyvio tysabri this type biolog prevent inflammationcaus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week it take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl havent respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar serious side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml this result virus test advanc ani physician prescrib tysabri crohn warn patient risk they also explain enrol prescrib program call touch this program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas havent respond well intoler reason cant take tnf blocker immunomodul corticosteroid it work similar tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gutspecif doesnt appear risk pml entyvio given doctor care intraven infus it given minut first day therapi it repeat week two week six everi eight week thereaft if improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient uptod immun stelara the third class biolog il il agonist stelara drug class approv treat adult moder sever crohn havent respond well enough convent therapi the drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession the follow dose given via inject skin everi eight week either healthcar provid selfadminist patient train side effect although benefit often far outweigh risk biolog therapi present serious side effect the process biolog therapi reduc bodi abil fight infect this caus tuberculosi infect includ brain infect there also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen tcell lymphoma this type cancer often fatal becaus biolog therapi work differ other side effect may caus also vari ask doctor thorough explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm your doctor discuss option benefit risk help find effect treatment in case biosimilar generic version biolog drug may avail manag crohn also save money your doctor tell option',\n",
       "  'NN'),\n",
       " ('it would like cm mm sinc theyd bare see mm nodul they biopsi cm are major cancer center take care judi stage iiia adeno dx srs chemo carboalimta x ned local recurr surgeri remov lrl cm involv pleura chemo carboalimta x ned',\n",
       "  'VBD'),\n",
       " ('thank kind word help i found liver autoimmunu diseas i want get check ive heard come pair im take fingolimod also affect liver the gp never heard i see ive got explain ms team said i err side caution come possibl infect my partner block bile duct due gallston im certain agoni thank good grumbl constant sore i keep fight good fight answersadvic hope goe away mean time all best rebecca xx',\n",
       "  'JJ'),\n",
       " ('this wonder stori we four cat sooth soul whole ordeal knew worst day curl next i keep joke tri purr inflamm colon congratul remiss f diagnos feb mild activ uc sigmoid colon prednison mg cortifoam x daili previous tri rowasa balsalazid bad reaction mesalamin intoler start remicad diet modifi lowresidu dairi free daili multivitamin d supplement',\n",
       "  'JJ'),\n",
       " ('drug stelara may eas crohn diseas titl drug stelara may eas crohn diseasecategori health newscreat amlast editori review am sourc medicinenet digest general',\n",
       "  'JJ'),\n",
       " ('pleas do pleas do pleas do when i diagnos i read tysabri decid drug i want but time patient prove abc werent work i faith avonex shot week two month later i develop on two week major major flare my neuro spent entir day phone biogen prove case serious they put emerg tysabri it took month start feel normal damag done when i first diagnos i still function walk live full life if i could stop progress point i think i could carri normal but flare came damag done i get cane i numb feet memori problem fatigu cant imagin not mention wonder bladder bowel problem dont let damag start yes concern pml ms progress might well pml there still good news ocrelizumab might come soon like it power tysabri less risk you lucki seiz the opportun to save yourself from ms go tysabri switch ocrelizumab youv got made the expens someth worri there plenti assist program pleas go on tysabri pleas do pleas do pleas do',\n",
       "  'NN'),\n",
       " ('i feel like i wrote im get laser sinc may week i bleed hasnt stop drip blood laser still contain week ago i vitrectomi im still bleed well i start bleed day vitrectomi im scare everi day pray much knightmar end tight control wors eye hard know think i sure say i know feel',\n",
       "  'NN'),\n",
       " ('last may wife start combo tafinlarmekinist this combo show great promis melanoma trial patient braf ve mutat in melanoma mutat braf ve type soon smaller trial initi nsclc patient mutat abt lc patient this trial al show great promis earli last year trial longer admit new patient when reopen treatment naiv patient could consid my wife chemopaus time fortun got approv combo outsid trial two earlier scan show improv last week scan brought good news the groundless densiti resolv discret mass seen minim residu stabl sub pleural interstiti infiltr like reflect minor fibrot chang she continu treatment next scan month we grate gotten point fortun new better drug becam avail time benefit mani includ wife my wife yrs dx mar nsclc mbac ai mar lobectomi left ll lower ul scan may clean juli bilater ggos sep promin ggos dec worsen ggos w foci dens consolid feb scan growth met braf posit ve mar start carboalimta chemo follow alimta mainten initi shrinkag stabl till aptil june trial immunotherapi mpdla docetaxel was assign docetaxel late octob stop docetaxel cours side effect sever on chemo paus may start tafinlarmekinist combo initi sever side effect most high fever chill grade uveiti eye earli august reduc tafinlar dosag mg mg day kept mekinist mg day side effect manag scan earli aug late oct show improv latest scan wa',\n",
       "  'JJ'),\n",
       " ('updat after alectinib month result first pet scan begin alectinib previous identifi focal area hypermetabol activ involv pleura right middl lobe anterior signific decreas hypermetabol activ max suv compar prior exam max suv there is no significan measur mass remain previous identifi hypermetabol activ involv pleura right lung medial no longer visual on today exam stabl hypermetabol activ associ pleural thicken apex right lung signific chang compar prior examin i take',\n",
       "  'JJ'),\n",
       " ('rememb back januari februari i struggl pulmonari embol well im happi say i feel better that fatigu easili lack exercis total caus gain weight ugh i mad anymor itll come the excit news isim still aliv i surpass year file bankruptci day later day hospit stay more medic bill alreadi roll i total cant afford so dad friend hammer bar grill next atlanta airport hold benefit help pay i start rebuild credit cancer ruin financ now i dont credit card i dont cushion anyth go wrong i know last thing i worri money i plan live need credit score go back we havent set date yet sinc work around scan schedul i it like one last weekend april first weekend may i post soon i find i want say be thank health becaus blink eye could chang no warn i may stage lung cancer ive realiz get wors i bless god heal process go quick i pray don went still go thing nicol thought call us twinzi i wish instead took us but shes free give much peac this hard world part we may get knock lung cancer communiti tight we famili if caregiv lose spous know never lose famili we fight togeth patient caregiv we alway i love communiti well im get sleepi i thought i superwoman past day i crash but hous clean thank sweet word encourag throughout part life thank continu prayer us need you inspir get back god bless and sinc i dont realli pic post ill show made self wig non made self without this rare event show i would like thank tarceva make hair crazi refus growand save life far i think i look like two differ peopl almost forgot happi cancerversari stefani wardrep',\n",
       "  'NN'),\n",
       " ('strang back post new question site so like wife start gemzar i would love know latest treat particular nsclc type side effect encount i start read initi look like better side effect mani agent stope cell divis my wife like consid option also wonder anyon thought afatinib versus gemzar afatinib direct toward egfr famili mutat like wife her seem effect seem relat short last month pretti hefti side effect not familiar gemzar seem much better sideeffect profil still general effect tumor well dna base chemotherapi like carbo work well wife in particular sens rang time peopl gemzar degre caus problem wbc rbc would appreci anyth els think go oncologist discuss option thank wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met tumor growth liver met stabl all stabl addl growthoff trial gemzar tumor reduct stabl this topic modifi month week ago catdand forum moder this topic modifi month week ago catdand forum moder',\n",
       "  'NN'),\n",
       " ('agre it would worth ask team put one lowest efficaci dmts current think treat earli hard judg post neuro team follow i put copaxon serv well eleven year noth stronger avail had i would definit gone imo ms need stop track the good thing copaxon four lowefficaci crab copaxon rebif avonex betaseron least side effect no fluey reaction chill etc possibl skin reaction issu interest mode action never fulli understood the crab aim reduc relaps averag newer drug upward power found shut ms altogeth mani case howev i told relaps figur averag i lot better in eleven year i three four minor relaps avoid even minor flareup vital relaps may leav degre perman damag a drawback howev effect copaxon daili inject time leg i follow advic chang inject site nonetheless i notic disfigur dip thigh fat cell implod result daili inject lipoatrophi i believ quit common occurr when i develop new sensori symptom neuro offer move second three level drug i gilenya sinc that daili pill much easier inject far relaps it realli matter judg riskbenefit treatment offer we know untreat ms get wors noth imo definit riski although mani mser site categor disagre the crab drug least toxic system go second third level drug potent carri risk howev consider risk well known neuro patient regular monitor blood test mris etc problem spot dealt often switch drug it complic pictur hope youv read stumbler suggest youll abl ask neuro team right question decid what best x',\n",
       "  'NN'),\n",
       " ('ive done blood test long ago check much i need surpris said none and i test test start gilenya said everyth stabl need noth vitamin calcium for reason alway ignor shelv',\n",
       "  'NN'),\n",
       " ('indygirl gilenya seem welltoler diseas modifi therapi dmt the document list sideeffect seem scari manufactur legal oblig detail everi possibl sideeffect ever experienc dmt yes immunosuppress leav vulner common bug go around and yes power drug may serious sideeffect you regular monitor risk factor if breach accept risk threshold use dmt would review i hope make feel bit comfort choic dmt',\n",
       "  'JJ'),\n",
       " ('hi jimc the regimen irinotecan avastin actual recommend stanford oncologist she also want dad get radiat shrink main lung tumor big invad pericardium all ban kaiser oncologist prefer go standard care treatment taxol next line treatment i dont like said standard care that old school style now cancer patient treat individu base patient condit concurr med ethnic gene mutat irinotecan potent radiosensit agent i dont access medic research articl onlin unless i pay pocket get permiss read i found far httpsmeetinglibraryascoorgcont httpswwwresearchgatenetpubl httpswwwncbinlmnihgovpubm that i come ask help kkh diagnos stage nsclc egfr also posit tm year tarceva month rociletinib wbr follow month tarcrva pulsecarboplatinavastinalimta month tagrisso was diagnos leptomening metastasi nov now cm big tumor multipl nodul differ size most recent guardant test feb tp cf egfr exon delet egfr amp met hy met amp fgfr amp pikca amp ccne amp braf amp myc amp addit alter brca rc mtor ke nf vv met ek jak vf nd mapk ek nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       "  'NN'),\n",
       " ('dr gandhi said like pd inhibitor chemotherapi combin may provid similar benefit shown impow clinicaltrialsgov identifi nct evalu efficaci atezolizumab plus bevacizumab chemotherapi find clinic meaning pfs benefit patient includ egfr alk genom alter previous treat target therapi there lot figur combin work togeth said keynot realli pure clinic studi quick combin drug more research need term sequenc analyz drug determin actual happen serial biopsi said we need build base knowledg pembrolizumab chemotherapi in the clinic what keynot address whether combin pembrolizumab chemotherapi superior pembrolizumab alon still may good option patient greater pdl express there multipl option clinician patient but chemotherapi alon longer one said relat articl immunotherapi lung cancer are combin regimen path forward time report palliat care need lead more appropri endoflif care nsclc osimertinib improv qualityoflif global health status nonsmal cell lung cancer to date data sequenc pembrolizumab pemetrex platinumbas drug keynot keynot suggest earli introduct immunotherapi may import given dramat surviv differ studi despit crossov immunotherapi second line i would hesit extrapol regimen context combin that would evidencebas medicin said there slight higher risk kidney toxic pembrolizumab group pd pdl inhibitor affect kidney dr gandhi ad the rate serious acut kidney injuri still what futur hold while clear pembrolizumab chemotherapi high effect patient nsclc research still need determin combin superior pembrolizumab alon high pdl expressor what emerg present studi chemotherapi alon longer standard care nonsquam nsclc backbon therapi immunotherapi form dr gandhi conclud whether immunotherapi combin immunotherapi combin chemotherapi yet address our studi clear demonstr benefit patient could use patient clinician abil nuanc decis make refer gandhi l rodriguezabreu d gadgeel s et al pembrolizumab plus chemotherapi metastat nonsmal cell lung cancer n engl j med doi nejmoa hellmann md ciuleanu t pluzanski a et al nivolumab nivo ipilimumab ipi vs platinumdoublet chemotherapi ptdc firstlin l treatment tx advanc nonsmal cell lung cancer nsclc initi result checkmat present american associ cancer research annual meet april chicago il kowantz m socinski ma zou w et al impow efficaci atezolizumab atezo plus bevacizumab bev chemotherapi chemo l metastat nonsquam nsclc mnsclc across key subgroup present american associ cancer research annual meet april chicago il',\n",
       "  'NN'),\n",
       " ('i found site i must say point i talk experi on decemb i diagnos small cell lung cancer i fight everi step way find i pain my gall bladder remov still relief then i told schedul pet scan dont worri cancer spread fast just back ground inform all said done i chemo radiat treatment was told oncologist good result next scan saw scar tissu radiat given steroid scan growth origin spot addit spot show now im tri i opdivo im christian i trust god complet my thought havea qualiti life im abl ive told cure so i live one day time i dont know futur hold i know control go cruis week went punta cana niagra fall earlier year i intend see i i i im pray struggl form cancer',\n",
       "  'NN'),\n",
       " ('thank carm pdl isnt relev opdivo i believ think may keytruda is as stat dianem i understand your say good advic cancer includ nsclc isnt sclc nsclc mani new advanc stat longer reflect someon diagnos today no luck sclcnoth new long time though potenti sign progress recent so i know stat reflect individu case reflect overal realiti type cancer hope someth id rather avoid given prognosi id rather focus concret decis step take each time someon write lot encourag thing typic turn thet basic talk involv nsclcsclc anoth ball wax unfortun so fatal danger get excit general progress cancer treatment doesnt appli case overal im tri thank day take balanc view toward futurebas educ make plan make much room either hope worri despair',\n",
       "  'NN'),\n",
       " ('marmizuko i similar problem i start gilenya month ago month vision start get blurri day light bright place vision wors my neuro say might gilenya no sign macular edema im sure yet gilenya problem someon similar problem said could thin retin nerv fiber layer i wonder case proceed appreci adviceinput might thank',\n",
       "  'VBD'),\n",
       " ('i plan get pregnant right moment soon probabl i worri right i got yeast infect i usual get antibiot surpris wont go away i antibiot day still it realli annoy i dont want becom chronic anyth gilenya',\n",
       "  'JJ'),\n",
       " ('sara decid return school full time school work incred time consum crank ten blog worth essay paper last three year her last day monday graduat excit around we move san francisco ca silicon valley area two year ago work between sell home move cross countri get settl new job incred busi sara see neurologist ucsf ms research center one premier ms research facil world she realli incred experi team eager share detail sara also lot excit gilenya last year would like provid updat sinc earli adopte pass fda trial lot peopl follow experi sara interest experi tri find ms support group bay area hope better luck find new one soon i kill forum year half ago vanilla forum open sourc solut wasnt get much love ton gap spam prevent peopl tri use run link farm ride seo rank everi time i wordpress updat broke forum our hope would foster rich engag among communiti like mind ms suffer support network never got ground we may revisit site go the plugin theme site general lot love last three year tonight i notic site due broken plugin least week i notic sever similar problem time time last three year i go spend time next week lot cleanup work implement new theme revisit plugin i notic month ago sever implement ad cross site promot network stuff intent put site make site look like someth use modern visitor a lot peopl still use site were actual see visitor publish site regular ms becom well known understood diseas huge number treatment research develop wed like discuss',\n",
       "  'NN'),\n",
       " ('whi remov german noth disagre fr aza konnten konsistent effekt auf schubratenredukt und edss progress berwiegend durch metaanalysen gezeigt werden prospekt im rahmen von phaseiiistudien erhoben daten zu mrtomographischen endpunkten existieren nicht darber hinaus wird die bewertung der studiendaten durch den einschluss heterogen studienpopulationen sehr erschwert im gegensatz dazu konnt fr parenteral cladribin und cladribintabletten ein hoch signifikant schubratenredukt sowi ein redukt tgd anreichernd und neuer tlsionen mehreren phaseii und iiistudien gezeigt werden darber hinaus konnt ein effekt auf die edssprogress bei rrms mit cladribintabletten nachgewiesen werden which interpret there evid effect relaps reduct azathioprin howev main metaanalys paper luca massacesi et al publish discuss studi httpmultiplesclerosisresearchblogspotcomcheapaschipsazathioprineisbetterhtml without underpin mri data quit heterogen studi popul for cladribin specif highlight parenter oral formul high signific reduct relaps rate well reduct t gdenhanc t lesion signific effect edss shown over fact azathioprin induct treatment relat modest efficaci pwms quit often well toler use autoimmun condit exampl myasthenia gravi',\n",
       "  'NN'),\n",
       " ('a pilot studi warm cold compress reduc inject site erythema due peginterferon betaa multipl sclerosi get detail research studi vitamin a d a research studi compar level vitamin a peopl relaps remit secondari progress multipl sclerosi normal vitamin d level supplement vitamin d get normal level read get detail research studi generat stem cell ms research investig the new york stem cell foundat nyscf laboratori recruit peopl relaps remit secondari progress primari progress form ms undergo skin biopsi purpos generat stem cell line get detail clinic trial plegridi peginterferon real world effect safeti observ program the purpos observ studi find longterm safeti effect plegridi approxim fiveyear time period inform side effect exampl flulik symptom fls inject site reaction isr serio get detail ofatumumab versus teriflunomid to compar efficaci safeti ofatumumab administ subcutan sc everi week versus teriflunomid administ oral daili patient relaps multipl sclerosi get detail research studi investig seek tissu sampl previous obtain peopl ms similar diseas in order discov trigger ms nation ms societyfund investig univers utah seek collect exist brain biopsi tissu individu nationwid underw brain biopsi diagnos episod acut demyelin diseas get detail clinic trial gilenya fingolimod the purpos studi monitor safeti fingolimod diseasemodifi treatment patient relaps multipl sclerosi condit routin medic practic updat june the studi finish enrol particip med get detail clinic trial effect intermitt vs continu walk gait kinemat person ms previous studi shown person ms better gait endur less fatigu practic walk intermitt rather continu the purpos studi determin differ gait characterist intermitt con get detail clinic trial complementari altern medicin telerehabilit intervent the purpos studi compar effect two deliveri model evidencebas complementari altern medicin cam program combin neurorehabilit function exercis yoga pilat individu multipl sclerosi ms cam get detail clinic trial vitamin d supplement compar effect current recommend amount vitamin d supplement versus high dose vitamin d supplement reduc ms diseas activ ad standard therapi glatiram acet copaxon teva pharmaceut industri peop',\n",
       "  'NN'),\n",
       " ('hi terri thank ask we fine next week husband start third cycl chemo cislatin alimta so far bad tast mouth sore throat hasnt complain much his blood count normal rang have said oncologist suggest rat target therapi sinc tilerar chemo well he egfr posit henc we havent made decis yet i read lot day empow knowledg it help anxieti i read book like anti cancer etc whi h ake angri sad time there noth book didnt follow we cut sugar white floor etc year ago we alway plant base diet high medit cardiovascular exercis never smoke no alchoh our live far smooth other work relat stress trauma one we bless two beauti kid still struggl i wish i answer',\n",
       "  'NN'),\n",
       " ('repli post ahainlin my son start humira he abl first dose after start get anxious ask take i think could continu i hadnt he said needl wasnt bad burn medic went then switch citratefre humira burn near gone it oneclick pen syring easi use unfortun son develop antibodi humira switch differ biolog i regret didnt take methotrex humiraperhap would allow stay longer send best wish success new medic',\n",
       "  'JJ'),\n",
       " ('i coupl question turmer i search first seem recent thread that relev question year old i thought id broach question my wife neversmok diagnos stageiv nsclc adenocarcenoma lung septemb she infus carboplatin alimta get alimta mainten her main tumor smaller cm her regular oncologist ucsf mt zion gave referr integr oncologist across street hes much demand first open wasnt earlier month almost month got referr this oncologist expert kind support treatment regimen help cancer patient diet medit acupunctur have becom familiar wife case recommend varieti thing includ specif medicin mushroom turmer curcumin howev surpris learn unawar fresh turmer avail presum would take supplement consequ could recommend specif amount turmer add daili fresh veget juic carrot ginger black pepper cucumb celeri etc ive juic piec size pinki finger dont know might compar effect amount supplement search around onlin didnt result anyth use ani neversmok nsclc use turmer form approv oncologist anyon know anyth recommend amount might juic ani input would appreci wife neversmok dx w stageiv nsclc adenocarcenoma main cm mass upperright lobe met lymph node liver bone egfr rare submut round carboalimta maint alimta progr tarceva mg daili rad x ea hip stabl',\n",
       "  'NN'),\n",
       " ('i well copaxon year i relaps worth speak although effect earlier one led diagnosi never remit three year ago i start i thought minor sensori symptom the neuro immedi offer secondlin drug im gilenya far good i think realli must find nut bolt healthcar decis offici guidelin somewher certain wont person netherland want better choic treatment peopl buck system it may qualifi secondlin drug new symptom appear may neuro interpret guidelin creativ for exampl i diagnos i overheard consult say student it difficult say ladi attack whether symptom continu origin relaps im go presum new attack qualifi drug therapi xx',\n",
       "  'NN'),\n",
       " ('hi ant made decis medic take im current gilenya well need reevalu medic soon neuro i diagnos almost year ago day retreat follow om last year',\n",
       "  'VBP'),\n",
       " ('so prefac insur cover humira whatev dose necessari howev month use i began flare i antibiodi built i therapeut level system stop work infect either sever test flex sig my insur cove remicad simponi entyvio will cover cimzia i believ that doc recommend but i dont want use medic thing approv especi doctor never mention seem crohn im total oppos use infus drug like remicad sinc cover insur option anyway as far steroid go i hospit decemb due lack respond steroid even iv dose high steroid i still symptomat improv doctor said i becom steroid resist i achiev brief month remiss humira start show symptom march my doctor never prescrib multipl medic initi steroid wean drug choic i also never rectal med antibiot said wouldnt help wouldnt prescrib ill definit look afford option yall post well perhap financi assist make feasibl doesnt suck cant afford diseas sigh',\n",
       "  'JJ'),\n",
       " ('hello my year daughter offici diagnos week chron they wait result autoimmun blood test ensur caus her gi alreadi told us want go remicad base endoscopi colonoscopi one rare case remicad approv st line treatment i loss mean i wonder would insight kind question ask i need know my daughter symptom primarili extra intestin seem extrem consid healthi tall show defici howev endoscopi colonoscopi show lesion upper track rectum ani insight would great appreci thank',\n",
       "  'NN'),\n",
       " ('hi samdig welcom grace im sorri know mom cancer stage iv nsclc diseas want treat marathon oppos sprint slow steadi full forc ahead with metaphor mind mom take iressa one mildest anticanc agent avail part due compar low dose compar tarceva if well congrat if continu progress iressa tarceva gilotrif may next option it possibl well low dose tki long period time year when progress show longer benefit iressa move anoth treatment that next treatment may may tarceva gilotrif acquir tm mutat in case like would move rd gen drug tagrisso i hope well all best janin',\n",
       "  'NN'),\n",
       " ('neurologist today gave option ocrelizumab natalizumab anyon experi share thank',\n",
       "  'JJ'),\n",
       " ('unfortun laser photocoagul session massiv pain ophthalmologist explain due nerv eye deterior bad retin vasculatur i say without doubt session profound pain incid life now even though ac level never higher rang last decad i four laser session perhap result hyperglycem memori hyperglycemia i back decad mid invent home glucomet first made blood sugar control possibl there also publish theori peerreview journal retinopathi caus thing hyperglycemia genet continu autoimmun play role noth avastin without problem sinc peopl like one type diabet diabet blog stroke for month could speak articul fortun articul return i diagnos banner diabet progress sinc first time nephrologist becam will accept diabet dialysi laser photocoagul develop retinopathi but shouldnt someth better half centuri later sinc laser photocoagul slash burn rather cure amount littl new version amput treat cannot fix',\n",
       "  'JJ'),\n",
       " ('accord articl fighterm post ido tcell activ it clear activ tcell studi drug design benefit cancer resist t cell it seem like administ keytruda opdivo combin instead what need agent weaken cancer resist t cell this chemo tumordisrupt sure found synergi pembro tcell activ reactiv disclaim im field medicin biolog analysi may entir correct',\n",
       "  'NN'),\n",
       " ('hi im wonder anyon crohn whos stelara bruis issu problem blood draw ive stelara sinc end work great howev someth ive notic awhil whenev i get blood work done whenev i stelara inject i bruis area certain veri minor issu im curious anyon els experienc year old femal have crohn termin ileum sinc mid small bowel resect first had stop humira due neurolog side effect humira year current stelara sinc allergichypersensit pentasa entocort mp',\n",
       "  'NN'),\n",
       " ('hello i diagnos didnt relaps now least one per year i copaxon sinc diagnosi now neuro want take gilenya trifecedera anyon either scare pml',\n",
       "  'NN'),\n",
       " ('i enrol clinic trial use tecentriq infus surgeri the patholog report came back lymph node test posit negat cancer part tumor shrunk so work well',\n",
       "  'NN'),\n",
       " ('my ms specialist expect ocrelizumab approv fda long submit data correct he first thought would approv latter part year sinc genzym hasnt submit data yet wont rrms ocrelizumab receiv breakthrough status design ppms fda speed approv process approv ppms httpwwwnationalmssocietyorgabopydesign talk safeti drug thus far progress still progress believ pretti much thing whether spms wo relaps ppms good hear experienc posit result biotin thank suppli us link',\n",
       "  'VBP'),\n",
       " ('deep grey matter volum loss brain drive multipl sclerosi ms progress disabl particular evid peopl progress form diseas retrospect multicent studi suggest httponlinelibrarywileycomdoianaful howev recent studi found gilenya halt grey matter atrophi httpwwwsciencedirectcomsciencearticlepiisx howev gilenya less effect tysabri delay progress httpsonlinelibraryectrimscongresseuectrimsactrimsectrimsjwilliamlbrowntheeffectofdiseasemodifyingtreatmentsonconversiontohtmlfmediaspeak the risk assess hazard ratio convert spms among patient treat inject followup year gilenya followup year tysabri followup year lemtrada followup year compar match untreat patient the higher hazard ratio lesser risk hmmm',\n",
       "  'JJ'),\n",
       " ('the metaanalysi trial cladribin say cancer risk higher dmt my view dmts i would prefer drug i take forev i know peopl see thing differ the effect lemtrada cladribin good stop gilenya tecfidera i would advis anyon tri decid dmt follow second link i post all inform cladribin peopl ms know drug',\n",
       "  'NN'),\n",
       " ('updat the us food drug administr approv first generic form mg glatiram acet inject produc mylan this generic form mg copaxon teva pharmaceut industri ltd taken three time per week inject skin the agenc also approv mylan generic daili mg dose this second approv generic glatiram acet mg glatopa sandoz becam avail june these approv mean mylan provid evid generic medic equival brandnam copaxon there inform yet generic becom avail prescript might cost have addit generic option potenti increas afford access ms diseasemodifi therapi comment dr bruce bebo execut vice presid research nation ms societi earli ongo treatment fdaapprov ms diseas modifi therapi current best way know reduc futur diseas activ peopl relaps form ms ad select therapi done peopl ms collabor ms doctor take account varieti factor includ effect therapi current use weigh potenti risk benefit cost lifestyl factor more detail the fda approv generic medic shown equival mg glatiram acet taken three time week mg taken daili subcutan skin inject glatiram acet synthet protein mimic myelin basic protein compon myelin insul nerv fiber brain spinal cord this therapi seem block myelindamag tcell mechan complet understood this therapi long track record effect safeti as part generic medic approv process fda requir generic activ ingredi strength dosag mode administr brandnam medic manufactur accord feder qualiti control regul clinic trial general requir prove equival brandnam medic the nation ms societi provid inform generic form glatiram acet becom avail download prescrib inform mylan mg glatiram acet pdf download prescrib inform mylan mg glatiram acet pdf read diseasemodifi therapi treatment ms ms symptom frequent ask question approv generic glatiram acet when new generic therapi avail prescript there inform yet medic may avail unit state glatopa generic daili glatiram acet avail sinc what generic glatiram acet mylan cost there inform yet cost generic what mean therapi go generic copaxon still avail prescript for mani medic avail generic brandnam medic remain market from inform current avail expect copaxon continu avail prescript mg daili dose mg dose taken three time week what insur coverag generic copaxon i forc switch current medic coverag prescript differ among various insur at point dont know insur handl coverag copaxon versus generic glatiram acet do generic mg mg dose therapeut benefit copaxon the fda thorough review process guidelin place evalu equival propos generic drug brand name drug product if fda review approv generic medic mean medic maker provid suffici evid generic therapeut benefit brandnam product the us fda empow congress evalu generic drug candid abbrevi new drug applic the nation ms societi confid fdas process will patient support servic avail peopl prescrib new generic mylan at point specif inform support servic mylan announc intent provid type support mylan ms advoc tm patient support servic when addit inform becom avail provid updat copaxon regist trademark teva pharmaceut industri ltd glatopa trademark novarti ag mylan ms advoc trademark mylan faq about generic biosimilar medic the follow provid inform generic drug biosimilar may mean ms communiti what generic medic a generic medic product equival brandnam drug whose patent protect expir as part generic medic approv process fda requir generic activ ingredi strength dosag mode administr brandnam medic manufactur accord feder qualiti control regul generic maker requir show generic drug deliv amount activ ingredi person bloodstream amount time brandnam product refer bioequival what societi view generic therapi ms the nation ms societi advoc increas treatment option peopl form ms earli ongo treatment current bestknown way reduc futur diseas activ have approv generic potenti increas individu access ms therapi provid ms communiti treatment option doe nation ms societi recommend use new generic ms therapi the nation ms societi make individu treatment recommend approv therapi make inform avail constitu make inform decis treatment choic do generic medic therapeut benefit namebrand medic the fda thorough review process guidelin place evalu equival propos generic drug brand name drug product if fda review approv generic medic mean medic maker provid suffici evid generic therapeut benefit brandnam product the us fda empow congress evalu generic drug candid abbrevi new drug applic the nation ms societi confid fdas process will equival medic ms therapi it possibl eventu but medic may copi patent protect brandnam medic must expir then maker equival medic would need appli fda request approv medic the term generic technic appli product consid drug made chemic manufactur process some ms therapi classifi chemic drug patent expir would like elig manufactur generic these fdaapprov therapi classifi chemic drug aubagio copaxon gilenya tecfidera the ms therapi avonex betaseron extavia lemtrada ocrevus plegridi rebif tysabri zinbryta technic classifi biolog biolog product what differ biolog biolog general complex made human anim materi rather chemic process the technic term equival medic biolog biosimilar followon biolog how biosimilar product evalu fda the fda approv biosimilar product mechan action rout administr dosag form strength refer product addit biosimilar approv indic condit use previous approv refer product under law pass biolog product may demonstr biosimilar data show product high similar alreadyapprov biolog product clinic meaning differ term safeti puriti potenc refer product propos biosimilar expect produc clinic result what current progress toward develop equival medic ms therapi the fda approv three generic form glatiram acet agenc receiv abbrevi new drug applic generic form medic with except novantron copaxon diseasemodifi ms medic avail generic form where i get inform generic drug biosimilar the fdas websit inform generic drug biosimilar process approv',\n",
       "  'JJ'),\n",
       " ('hello how much coimbra protocol cost per month year is cheaper interferon gilenya tysabri',\n",
       "  'NN'),\n",
       " ('hi five welcom grace im sorri hear stepmom diagnosi your post rais question may affect futur treatment decis was treatment alimta effect stop alimta due progress cancer progress later has shown progress keytruda grow slowli rapid with stage iv diseas usual expect evid diseas disappear although small number patient achiev status instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept you want get maximum benefit treatment move anoth line therapi and immunotherapi keytruda patient dont show benefit immedi patient deriv longlast benefit treatment so base youv said i wouldnt assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress it would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question ive rais well tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('i much better interact mom doctor today regard clinic trial recent advanc sclc care advis even though still firstlin treatment wouldnt bad idea get understand secondlin fast diseas recur andor spread there lot new develop avail clinic trial even exist drug offlabel use pick rout go depend lot specif characterist tumor for exampl attract rout vs standard chemo isnt effect first line opdivoyervoy offlabel clinic trial particular effect cancer high tumor mutat burden tmb keytruda offlabel clinic trial particular effect high pdl express rovat clinic trial particular effect high dll express so question test specif characterist usual done sclc inde patholog report got didnt test rather random pick secondlin treatment id like opt one that like work so liter test order biopsi send away lab is advis proactiv would biopsi painfuldamag worth just sure go',\n",
       "  'JJ'),\n",
       " ('hi mazza glad hear osmertinib work well flauta trial i sure moder answer i want let know wife experi in cours last three year wife ct scan occasion shown sclerot lesion bone place didnt even know cancer the explan oncologist often bone site cancer resid small easili detect but chemotherapi success reduc remov cancer spot bone regrow place cancer resid result slight greater bone densiti result show sclerot ie solid spot basic oncologist said conjunct chemotherapi sclerot spot almost alway suggest place chemotherapi work bone natur regrow i hope continu great checkup best scohn wife lifelong nonsmok dx adeno nsclc stage iv poor diff bone met lymph node her exon mutat x carboalimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo not effectiveaddl growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl all stabl addl growthoff trial start gemzarlarg tumor reduct',\n",
       "  'NN'),\n",
       " ('greet my mom age diagnos adenocarcinoma stage iv nonsmal cell lung cancer april she abl walk talk abl basic thing she extens met brain bone lung adenoid later two month june spinal tap indic cancer cell spine fluid diagnos lepto mening metastas base egfr mutat given tarceva mg work beauti reduc met brain week stop work unabl breath proper lot inflamm lung due met reemerg she switch tagrisso mg take daili basi recogn us walk move i abl understand medic work diseas progress it stress see struggl respond recogn us even abl get bed can anyon help advis share progress diseas medic work i loos anyth i save near end life pleas help i bank someon help i apolog typo stress seek help please give suggest god bless angara',\n",
       "  'NN'),\n",
       " ('hi carolmcn welcom site glad sorri hear feel abandon onc you everi right feel know empow what next treatment plan everyon cancer journey uniqu jorola may abl share knowledg point get inform rout take possibl next step get concern address tell us need med chang tagrisso must tm mutat are test mutat',\n",
       "  'NN'),\n",
       " ('i aubagio wasnt work i schedul take first dose gilenya april th it scari i wont lie everyth ms scare i bad luck side effect aubagio my neuro said pill form option rrms aubagio gilenya tecfidera want tecfidera alot side effect lot paitent gilenya see year quarter checkup relaps seen tremend improv the paper work scari tylenol warn label could scare someon i guess right i ekg appoint opthomologist would give okay',\n",
       "  'JJ'),\n",
       " ('drs h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ director clinic research uc davi comprehens cancer center sandip patel medic oncologist associ professor medicin moor cancer center uc san diego health gather post meet discuss new inform asco regard lung cancer in roundtabl video doctor discuss checkmat combin nivolumab ipilimumab nivolumab chemotherapi grace thank follow sponsor support relat content asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc asco roundtabl lung cancer keynot cisplatin carboplatin alimta keytruda is practic chang approach asco roundtabl lung cancer potenti showdown two posit trial keynot impow video languag english join convers pleas feel free offer comment rais question discuss forum join the convers articl video categori cancer journey in remiss in treatment just diagnos survivorship cancer journey just diagnos in treatment in remiss survivorship cancer type lung cancer blood cancer head neck cancer diseas learn lung cancer blood cancer head neck cancer about howard jack west md founder presid medic director thorac oncolog program swedish cancer institut presid ceo global resourc advanc cancer educ grace seattl washington dr jack west medic oncologist medic director thorac oncolog program swedish cancer institut seattl washington he also serv presid medic educ websit onctalk llc global resourc advanc cancer educ grace read more search form search relat content lung cancer video librari mandarin chemotherapi immunotherapi combin advanc nonsquam nsclc video for mandarin speak communiti jenni j li md hematologyoncolog fellow mayo clinic rochest mn offer translat updat lung cancer video librari in video translat dr li discuss immunotherapi combin advanc nonsquam non small cell lung cancer qualifi social secur disabl benefit with cancer articl this articl provid disabl benefit help independ organ dedic help peopl age get social secur disabl benefit chanc cure advanc cancer what older patient believ articl at asco dr melissa loh present studi titl chanc cure advanc cancer what do older patient believ how are these belief relat their prefer this studi look patient belief regard cure cancer specif older patient advanc cancer patient certain could cure pose uniqu challeng physician show need clear communic patient physician regard outcom treatment qualiti life',\n",
       "  'NN'),\n",
       " ('good luck ucfireman i current fight insur get entyvio approv ive fail remicad primari nonrespond also want fail humira first nice xeljanz next drug choic there good facebook group that start xeljanz folk call xeljanz uc small group folk nice at rate i also tacrolimus add remicad coupl time good see someon els are suppositori im mgday tac level high dose per day oral tacrolimus thank good luck f diagnos feb leftsid uc steroidrefractori fail mesalamin intoler remicad partial respons short remiss fallwint flare sinc feb current tacrolimus supp x daili wait start entyvio zoloft most dairi free avoid carrageenan like plagu',\n",
       "  'NN'),\n",
       " ('bhaskar im sorri hear worsen symptom although fatigu could certain caus anticanc treatment includ tagrixtagrisso symptom typic treatment the presenc progress lmd someth appear scan particular well the primari method determin efficaci lmd treatment observ central nervous system symptom stabl improv drug work on hand cancer progress anoth part bodi could caus least symptom chest ct might help determin side effect drug monitor clinic examin patient exam report new symptom doctor if symptom appear relat treatment appropri followup measur initi jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('longboat when i first diagnos i drank lot i wouldnt say alcohol level everi day even i would drink on wife either breastfeed pregnant a lot thing chang life ms first child quit job depress etc i alway self medic alcohol past get tough time it got point wife liter pack bag threaten leav i didnt chang habit so i cut onli drank weekend even thing go fine i still crave drink everi day so mayb i alcohol level i didnt need i realli want now gilenya mess liver neuro ration two drink per week put addit pressur liver it hard good two drink tast good the booz didnt effect symptom it help forget i ms',\n",
       "  'NN'),\n",
       " ('after sever year drug i develop asthma chronic bronchiti end sever bout pneumonia this happen despit take vaccin pleas awar problem i told doctor realli listen i got sick agre part remicad',\n",
       "  'NN'),\n",
       " ('patient untreat nonsmal cell lung cancer nsclc mutat epiderm growth factor receptor egfr central nervous system cns metastas baselin report better cns progressionfre surviv pfs compar firstgener egfr tyrosin kinas inhibitor tkis gefitinib erlotinib cns pfs reach certain subset patient administ osimertinib month standard egfrtki therapi p these result preplan exploratori analysi phase flaura studi registr studi got osimertinib approv use firstlin therapi patient egfr mutat advanc nsclc report journal clinic oncolog the flaura studi random doubleblind studi patient untreat egfr nsclc compar osimertinib standard egfrtki therapi gefitinib erlotinib subset analysi patient from flaura with cns metastas the subset patient flaura includ current analys document cns metastas baselin seen brain scan assess neurologist blind manner relat articl pdpdl inhibitor may increas risk hyperprogress diseas nsclc s plus carboplatin may be effect nsclc patient with interstiti lung diseas gefitinib continu therapi may be effect nsclc postprogress of patient includ studi data provid patient measur andor nonmeasur cns metastas avail baselin brain scan cns fullanalysi set cfas sixtyon patient treat osimertinib standard egfrtki end point assess includ cns pfs cns object respons rate orr cns durat respons dor cns diseas control rate dcr cns progress median followup cns pfs month patient osimertinib month patient standard egfrtki while patient characterist balanc baselin median sum baselin cns tumor lesion size larger patient standard egfrtki vs mm osimertinib arm for end point cns pfs differ arm consid nomin statist signific cns progress seen approxim twice mani patient standard egfrtki vs osimertinib result new cns lesion patient osimertinib patient standard egfrtki cnn orr patient osimertinib patient standard egfrtki odd ratio or p in patient least measur lesion baselin cns evalu respons set cefr osimertinib patient standard egfrtki patient cns orr patient osimertinib patient standard egfrtki or p in cns evaluableforrespons set cefr popul median time respons week group howev median cns dor longer patient receiv egfrtki compar osimertinib vs month respect also popul cns dcr similar across group osimertinib egfrtki p the studi author note taken togeth data report flaura data indic subgroup patient without known treat cns metastas baselin osimertinib provid protect effect develop brain metastas',\n",
       "  'NNS'),\n",
       " ('it use treat type skin cancer melanoma it use treat lung cancer what i need tell doctor befor i take tafinlar if allergi dabrafenib part tafinlar dabrafenib if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if breastfeed do breastfe take tafinlar dabrafenib week last dose this medicin may interact drug health problem tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take tafinlar dabrafenib drug health problem do start stop chang dose drug without check doctor what thing i need know i take tafinlar tell health care provid take tafinlar dabrafenib this includ doctor nurs pharmacist dentist sometim dabrafenib taken trametinib if take dabrafenib trametinib sure know side effect happen drug when drug taken togeth chanc certain side effect may rais these side effect bad sometim dead this includ bleed bleed brain blood clot eye problem fever heart problem like heart failur high blood sugar cancer skin problem talk doctor chanc side effect drug this medicin may add chanc get type cancer talk doctor have skin check tell doctor skin chang like new wart skin sore reddish bump bleed heal chang color size mole have blood work check told doctor talk doctor if high blood sugar diabet talk doctor this medicin may rais blood sugar check blood sugar told doctor it common get rash tafinlar dabrafenib skin reaction may also happen sometim rash skin reaction bad may need treatment hospit call doctor right away acn skin red skin rash bother go away call doctor right away red irrit palm hand sole feet veri bad eye problem happen tafinlar dabrafenib sometim led loss eyesight call doctor right away blur eyesight loss eyesight chang eyesight call doctor right away see color dot halo bright light bother be care gpd defici anemia may happen if older use tafinlar dabrafenib care you could side effect this medicin may affect fertil fertil problem may lead abl get pregnant father child talk doctor this medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take tafinlar dabrafenib least week stop drug birth control pill hormonebas birth control may work well prevent pregnanc use kind birth control also like condom take tafinlar dabrafenib week stop tafinlar dabrafenib if get pregnant take tafinlar dabrafenib within week last dose call doctor right away how medicin tafinlar best taken use tafinlar dabrafenib order doctor read inform given follow instruct close take empti stomach take hour hour meal swallow whole do chew open crush talk doctor drink lot fluid way prevent fluid loss if lot fluid loss may side effect tafinlar dabrafenib to gain benefit miss dose keep take tafinlar dabrafenib told doctor health care provid even feel well what i i miss dose take miss dose soon think if less hour next dose skip miss dose go back normal time do take dose time extra dose see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign fluid electrolyt problem like mood chang confus muscl pain weak heartbeat feel normal bad dizzi pass fast heartbeat thirst seizur feel tire weak hungri unabl pass urin chang amount urin produc dri mouth dri eye bad upset stomach throw sign high blood sugar like confus feel sleepi thirst hungri pass urin often flush fast breath breath smell like fruit sign kidney problem like unabl pass urin chang much urin pass blood urin big weight gain weak side bodi troubl speak think chang balanc droop one side face blur eyesight fever chill dark urin yellow skin eye eye pain chest pain pressur veri bad headach this medicin may caus heart failur you need heart function check take tafinlar dabrafenib call doctor right away sign heart problem like cough short breath new wors swell ankl leg heartbeat feel normal weight gain pound hour dizzi pass what side effect tafinlar all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away hair loss chang skin hard thick headach muscl joint pain back pain constip cough nose throat irrit these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw tafinlar store room temperatur store dri place do store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin this medicin come extra patient fact sheet call medic guid read care read time tafinlar dabrafenib refil if question tafinlar dabrafenib pleas talk doctor pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'VBP'),\n",
       " ('fda approv lucenti treat form diabet retinopathi', 'JJ'),\n",
       " ('my niec made blond scalp doesnt show got shorter cute cut it stop come im bald like i wanna worri year old symptom sinc octob diagnos januari ibd ulcer coliti pancol current apriso humira uceri valtrex vari have tri almost everi healthfood thing world no help if could cure herb vitamin diet good day bad day lot sleep',\n",
       "  'NN'),\n",
       " ('sewingchickim goin stick tysabri see goesit suppos besti fingolimod year neuro said wasnt workingi dont know drug stop deteriort tri tysabri moid love tri hsct sometimeal want youstop ms get wors thank jimmi',\n",
       "  'NN'),\n",
       " ('hi father nsclc plureal effus start st cycl pembrolizumab due work schedul i would like check possibl delay nd cycl day will day delay make differ treatment or follow day cycl thank alot kind assist',\n",
       "  'NN'),\n",
       " ('genentech announc today ocrelizumab investig medicin longterm treatment relaps form ms also shown posit studi result phase iii oratorio studi primaryprogress multipl sclerosi ppms this first medic show posit effect disabl form diseas affect approxim percent ms popul to date diseasemodifi therapi dmts approv longterm treatment relaps form ms exhibit flareup remiss often seen ms howev treatment avail individu diagnos ppms whose ms steadili progress without remiss accord genentech phase iii oratorio studi met primari endpoint show treatment ocrelizumab signific reduc progress clinic disabl sustain least week compar placebo measur expand disabl status scale edss they also state overal incid advers event associ ocrelizumab similar placebo common advers event mildtomoder infusionrel reaction the incid serious advers event associ ocrelizumab includ serious infect also similar placebo oratorio random doubleblind global multicent trial studi effect safeti ocrelizumab peopl ppms everi six month two mg infus total mgs given two week apart member treatment group compar placebo group the primari endpoint studi time onset confirm disabl progress defin increas edss sustain least week on juli msaa post news item titl ocrelizumab show posit result phase iii trial announc ocrelizumab met primari major secondari endpoint phase iii opera i opera ii studi these studi evalu effect safeti ocrelizumab relaps form ms accord genentech compar rebif ocrelizumab show signific reduct annual relaps rate arr twoyear period progress clinic disabl measur expand disabl status scale edss number lesion brain area diseas activ measur mri ocrelizumab investig human monoclon antibodi design select target cdposit b cell genentech note specif type immun cell thought key contributor myelin axon damag result disabl peopl ms base preclin studi ocrelizumab bind cd cell surfac protein express certain b cell stem cell plasma cell therefor import function immun system may preserv genentech plan submit data three studi unit state food drug administr fda earli if approv medic could potenti use treat relaps form ms also primaryprogress ms would repres first treatment avail latter form diseas msaa chief medic offic dr jack burk state this excit news ocrelizumab first dmt posit disabl result in addit safeti data similar placebo control howev fda approv requir intens scrutini data effect combin safeti magic formula well see fda agre ocrelizumab meet requir approv relaps form ms ppms well for inform speak train client servic specialist pleas call msaa helplin extens question msaa client servic depart may also email written susan well courtney msaa senior writer creativ director review jack burk md msaa chief medic offic',\n",
       "  'NN'),\n",
       " ('hello snigdha my father diagnos lung cancer juli he took tarceva iressa tagrisso he took tagrisso last ten month unfortun pass away week ago hospit sinc decemb rd from end last year live well travel lot collater damag tagrisso realli good id like tell hospit admiss heart issu doctor say may caus tagrisso my father hasnt done heart exam start tagrisso i dont know exam could made live mayb would good talk cardiologist im send posit vibe i hope mom continu without pain i think mani year hapi father and lot time tell much love pleas contact whenev want best wish lms',\n",
       "  'NN'),\n",
       " ('at meet at limit recent pair promin immunologist took except i hint blockad interleukin perceiv fail ms modest efficaci i challeng i repli i say work counter much better beta interferon they said work drop oper reason oper reason i wonder did simpli realli mean wasnt good enough doe one know read blog care comment at time trial secrukinumab cosentyx stop earli said proofofconcept prove activ although primari endpoint met mean trial fail point it suggest novarti anoth antiil cjm better yet secrukinumab good enough use psoriasi skin autoimmun diseas havrdov e belova a goloborodko a tisser a wright a wallstroem e garren h maguir rp john dr activ secukinumab antiila antibodi brain lesion rrms result random proofofconcept studi j neurol howev endpoint indic interleukin effect main endpoint cumul uniqu activ lesion almost show differ chang p almost signific not number cumul new gadolinium lesion reduc p the annualis relaps rate drop drop week the immunologist said peopl amaz welly peopl well even get noth you simpli cant cherri pick like thatit eae experi so amazingi hear immunologist saybut put context beta interferon week there reduct mean cumul number new gadolinium lesion subcutan interferon betaa p efficaci safeti subcutan interferon relapsingremit multipl sclerosi outcom improv studi j neurol sci jan contrast ocrelizumab reduct mri lesion phase ii should get excit reduct an annualis relaps rate vers seen alemtuzumab cladribin ocrelizumab name three activ agent yes i know differ trial condit durat meanwhil seem plan quiet shelv next ms studi effect antiil we year line noth but happen anim th dogma generat what happen block il eae il knockout get eae sever drop sever bithard impress dont believ tri anoth studi antibodi i could go simpl answer isnt impress acut eae howev rememb antiil inert act b cell th may creat b cell aggreg eae howev import look data rhetor the bee knee best thing',\n",
       "  'VBG'),\n",
       " ('you definit make logic next step humira actual i think remicad first choic either one would good your last sentenc say at year age wont take antitnf long enough worri life long effect hope work my daughter diagnos feb yrs old time diagnosi crohn termin illium has use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mgs imuran',\n",
       "  'JJ'),\n",
       " ('if two cours alemtuzumab scan remain year see deterior hand function deterior due residu damag keep mind posit therapeut lag or do opt anoth therapi one elig stem cell neither cladribin ocrelizumab effect with littl definit guidelin treatment depend ms present mser go treatment consult favour time hope question get answer feel though peopl bounc treatment treatment',\n",
       "  'NN'),\n",
       " ('hello everyon i remicad year final develop antibodi i tri entyvio coupl year ago advers reaction i larg bowel resect end colostomi octob my crohn diseas symptom improv sinc surgeri howev eye jointmuscl pain inflamm poor i stop remicad antibodi my gi wonder howev said well tri humira cimzia stelara it one prefer it like crap shoot lol should i toss name cup draw one ani suggest would great appreci i develop crohn small intestin besid remicad i mg prednison daili thank much juli',\n",
       "  'NN'),\n",
       " ('relapsingremit ms thought primarili inflammatori diseas myelin cns the diseas process character period relaps follow complet incomplet recoveri simultan howev irrevers axon damag transect known occur trapp et al control inflamm earli diseas may also reduc damag axon coyl the medic current avail treat ms appear effect earli inflammatori phase ms becom less potent diseas transit neurodegen process sinc medic approv us food drug administr fda treatment relaps form ms jefferi one also approv primari progress ms the inform present design allow sidebyview medic option without suggest intermed comparison except specif support result headtohead clinic trial compar efficaci medic across trial mislead key differ popul outcom measur statist analys use studi fdaapprov diseasemodifi therapi dmts the fda approv dozen agent treatment relaps form ms one also approv primari progress ms anoth also approv secondari progress ms of deliv inject infus other oral inject option daclizumab zinbryta glatiram acet copaxon glatiram acet glatopa generic equival copaxon interferon ba avonex interferon ba rebif interferon bb betaseron interferon bb extavia pegyl interferon ba plegridi oral option dimethyl fumar tecfidera fingolimod gilenya teriflunomid aubagio infus option alemtuzumab lemtrada mitoxantron novantron natalizumab tysabri ocrelizumab ocrevus ms coalit evidencebas consensus paper dmts the multipl sclerosi coalit publish evidencebas consensus paper entitl the use diseasemodifi therapi multipl sclerosi principl current evid a consensus paper multipl sclerosi coalit this document develop endors eight coalit member organ subsequ endors america committe treatment research multipl sclerosi actrim the paper design summar current evid diseas modif ms highlight import earli ongo treatment provid support broad access fdaapprov ms diseasemodifi therapi peopl ms unit state a companion summari paper general audienc current develop fdaapprov dmts bird eye view indic dose rout administr pregnanc rate warn safeti manag strategi common side effect patient support program drug develop pipelin read compound current investig therapeut use ms',\n",
       "  'VBP'),\n",
       " ('in origin clinic trial diseasemodifi therapi approv treatment ms women requir use contracept trial discontinu trial becam pregnant as result littl inform effect medic pregnanc sinc ms primarili affect women childbear age becom pregnant unintent consid extrem import acquir inform medic affect pregnanc unborn children in august food drug administr issu guidelin requir manufactur medic develop pregnanc registri monitor women taken one drug within week becom pregnant pregnant although none medic approv use pregnanc woman may unintent becom pregnant treatment if woman unawar pregnant sever week may pass stop medic the purpos registri identifi outcom pregnanc includ miscarriag birth defect inform registri avonex registri complet final result report betaseron registri complet final result report rebif registri complet final result report tysabri registri complet final result report aubagio registri although aubagio approv use pregnanc registri establish monitor fetal outcom pregnant women expos aubagio physician encourag enrol pregnant women aubagio pregnanc registri women enrol call option gilenya registri although gilenya approv use pregnanc registri establish monitor fetal outcom pregnant women expos gilenya physician encourag enrol pregnant women gilenya pregnanc registri women enrol call visit gilenya pregnanc registri websit tecfidera registri although tecfidera approv use pregnanc registri establish monitor fetal outcom pregnant women expos tecfidera physician encourag enrol pregnant women tecfidera pregnanc registri women enrol call',\n",
       "  'NN'),\n",
       " ('my mother diagnos stage b lung cancer jan she finish chemo round juli they ct scan end treatment clear at six month check ct show nodular activ fluid lung after fluid remov liter test show cancer cell fluid pet scan show cancer lymph node lung they suggest manag chemo give carboplatintaxol session follow avastin has anyon experi drug lung cancer stage stage no cancer area left lung began last year ani comment would appreci',\n",
       "  'NN'),\n",
       " ('hi angi thank ask i the sacroplasti procedur went well i feel anyth haha in term stabil whole right flank area well i walk around hous eas ventur still painful i feet long although pain chang i think i patient give time heal i yesterday one fortnight opdivo treatment it make feel bit tire day stop thing go i think dad may need stimul keep go i dwell much cancer i learnt live i cannot chang i go clinic pilat given physiotherapist room keep leg arm muscl go mayb dad check area live if privat insur get refund session clinic pilat kept go i twice week i assum dad retir doe hobbi concentr the best thing cancer keep go let catch speak i wish well think clinic pilat first thing look take care margo',\n",
       "  'NN'),\n",
       " ('i diagnos inflammatori arthriti ra septemb year old first i plaquenil never seem help top i develop terribl hive rash went away i stop take next i tri humira that work great month symptom came back now im remicad almost year it work great i get infus everi week no symptom i love remicad it gave life back i slight concern though ive develop anoth rash wont seem go away month deal tri steroid etc etc cross finger remicad caus rash ill cri',\n",
       "  'NN'),\n",
       " ('i havent come across anyth regard ocrelizumab induc remyelin i suppos patient take earli enough diseas process drug would inhibit inflamm would allow bodi natur remyelin but i dont think drug remyelin properti',\n",
       "  'NN'),\n",
       " ('hello i interest nivolumab trial mom what msi status are non msihigh msihigh henri wrote hello my latest cea valu almost normal hope next month finger cross',\n",
       "  'NN'),\n",
       " ('i hag second dose ocrevus day christma it went fine with week i flare sure that normal after went away like week i realli cannot tell differ same symptom differ day i hope i feel amaz soon best luck',\n",
       "  'NN'),\n",
       " ('repli mser train view post by marinadca quick updat thing go well quick updat thing go well bike day week walk hour day week yoga class week i ocrevus infus glad',\n",
       "  'JJ'),\n",
       " ('thursday genentech announc new ceo assum role march alexand hardi current execut roch basel move san francisco assum genentech head post in companyrel news jnjs dismal outlook may indic what store year big pharma firm and bluebird bio outlin timelin expect compani next five year in big blow oncolog program bristolmy pull opdivoyervoy combo nsclc and advaxi also dealt blow fda put partial clinic hold cervic cancer studi elsewher basilea enter urotheli cancer studi roch vertex gene edit collabor merck kgaa come fruition',\n",
       "  'NN'),\n",
       " ('diabet retinopathi dr chronic progress potenti sightthreaten diseas retin microvasculatur associ prolong hyperglycaemia diabet mellitus diabet mellituslink condit hypertens diabet mellitus caus varieti eye problem common dr common caus sever sight impair among peopl work age england wale scotland other condit associ diabet eye includ cataract rubeosi iridi glaucoma ocular motor nerv palsi diabet retinopathi the exact mechan diabet lead dr fulli understood microvascular occlus caus retin ischaemia lead arterioven shunt neovascularis leakag result intraretin haemorrhag localis diffus oedema these process result characterist featur seen various stage dr microaneurysm physic weaken capillari wall predispos leakag hard exud precipit lipoproteinsoth protein leak retin blood vessel haemorrhag ruptur weaken capillari appear small dotslarg blot flame haemorrhag track along nervefibr bundl superfici retin layer haemorrhag aris larger superfici arteriol cotton wool spot buildup axon debri due poor axon metabol margin ischaem infarct neovascularis attempt residu healthi retina revascularis hypox retin tissu the classif dr base part retina affect degre patholog seen slitlamp examin eye it necessarili correl degre vision may almost normal late stage diseas littl done save broad speak dr fall two type diabet retinopathi background mild nonprolif dr least one microaneurysm moder nonprolif dr microaneurysm intraretin haemorrhag cotton wool spot venous bead intraretin microvascular abnorm irma sever sever nonprolif dr sometim refer preprolif diseas minimum number featur requir minimum number retin quadrant defin sever sever diseas nonhighrisk prolif dr new vessel disc nvd within one disc diamet new vessel elsewher nve highrisk prolif dr larg nvd nve defin compar optic disc surfac area presenc preretin haemorrhag in advanc diseas may also accompani retin detach diabet maculopathi focal diffus macular oedema area leakag may well circumscrib diffus ischaem maculopathi clinic appear may relat normal visual acuiti drop ischaemia seen fluorescein angiographi clinic signific macular oedema csmo may thicken retina hard exud found within specif distanc fovea found certain size defin csmo epidemiolog diabet common caus sever sight impair workingag peopl england wale scotland one studi found macular oedema present popul diabet in type diabet microaneurysm start appear five year case affect half case year near patient year prolif retinopathi defin format new vessel appear year affect year maculopathi follow similar pattern final affect case in type diabet chang may found diagnosi subclin hyperglycaemia may present prolong preced period over year signific cumul rate progress dr diabet macular oedema csmo risk factor progress retinopathi associ sever length time hyperglycaemia exist if diabet diagnos age incid dr year rise year there set glycaem threshold predict presenc otherwis dr hypertens cardiovascular risk factor influenc onset progress retinopathi there mark individu variat suscept retinopathi given vascular risk profil renal diseas evidenc proteinuria elev ureacreatinin level excel predictor presenc retinopathi pregnanc associ rapid progress dr particular there sever baselin retinopathi there poor glycaem control concept pregnanc postpartum period there rapid improv diabet control the diabet present long time the patient hypertens chronic pregnancyinduc minor ethnic communiti type diabet uk prone dr includ sightthreaten retinopathi maculopathi compar white european it thought intraocular surgeri may possibl increas risk progress dr see separ eye system diseas articl inform eye pregnanc present histori mani patient retain normal eyesight experi minim sometim unnotic reduct even presenc sightthreaten diseas diabet maculopathi prolif diseas a painless gradual reduct central vision may associ type dr similar painless gradual visual loss associ cataract format diabet otherwis haemorrhag result sudden onset dark painless floater may resolv sever day sever haemorrhag may obscur vitreous altogeth result painless visual loss an acut attack glaucoma precipit rubeosi iridi see eye condit less common associ diabet one situat patient present acut pain urgent referr essenti examin without slitlamp magnif fundus fundal photograph difficult make accur assess alway start check patient visual acuiti acut reduct good sign suggest urgenc referr caution prognost outcom discuss patient the best view obtain dilat pupil rememb patient wont abl drive six hour afterward befor home fundus check red reflex spot within suggest vitreous haemorrhag start disc systemat work way along main arteri branch effect end macula look direct light make bit quick comfort when look vessel note littl red dot dot haemorrhag small aneurysm irregular notch venous bead new vessel tend thinner disorganis preexist vessel as go along note welldemarc creamyyellow lesion often appear like cluster spot hard exud paler lesion less welldefin edg cotton wool spot it realli possibl assess csmo without slit lamp presenc haemorrhag macula import find diagnosi the gold standard diagnosi dilat retin photographi accompani ophthalmoscopi retin photograph inadequ qualiti eg cataract cloud view if dr present classifi further investig optic coher tomographi sort visual biopsi obtain similar fashion ultrasound scan use light wave fluorescein angiographi may requir refin diagnosi guid manag screen referr adult type type diabet arrang perform eye screen around time diagnosi adult type type diabet arrang repeat structur eye screen annual use mydriasi tropicamid photograph retina prior inform agreement follow discuss advantag disadvantag discuss includ precaut drive use qualityassur digit retin photographi programm use appropri train staff perform visual acuiti test routin part eye screen programm depend find follow structur eye screen routin review one year earlier review referr ophthalmologist arrang emerg review ophthalmologist sudden loss vision rubeosi iridi preretin vitreous haemorrhag retin detach arrang rapid review ophthalmologist new vessel format refer ophthalmologist accord nation screen committe criteria timelin refer hospit eye servic within four week result featur present refer maculopathi exud retin thicken within disc diamet centr fovea circin group exud within macula macula defin circl centr fovea diamet distanc tempor border optic disc fovea ani microaneurysm haemorrhag within disc diamet centr fovea associ deterior best visual acuiti wors refer preprolif retinopathi cotton wool spot present look care follow featur howev cotton wool spot defin preprolif retinopathi ani venous bead ani venous redupl ani intraretin microvascular abnorm multipl deep round blot haemorrhag ani larg sudden unexplain drop visual acuiti children young adult monitor dr begin year age type type diabet consid refer children young peopl type diabet younger year ophthalmologist retin examin blood glucos control suboptim investig fundus photographi examin suffici patient howev optic coher tomographi play increas import role assess presenc macular oedema record progress sever visit fluorescein angiographi may help csmo present guid laser treatment vision unexpect poor assess macular ischaemia manag primari prevent glycaem control optim glycaem control usual aim bring hbac level ideal around associ improv longterm outcom delay progress retinopathi howev case particular preprolif prolif retinopathi intens glycaem control eg hbac initi bring decompens worsen symptom sign also associ increas mortal blood pressur control good control blood pressur target mm hg lower reduc progress dr signific associ reduct diabetesrel death if possibl aim systol mm hg establish retinopathi andor nephropathi specif therapi block reninangiotensin system ras may addit benefit particular mild retinopathi discontinu pregnanc lipid control lipidlow therapi shown reduc risk progress diabet retinopathi particular macular oedema exud consid ad fenofibr statin nonprolif retinopathi type diabet a healthi balanc diet exercis discuss patient smoke cessat there recent trial look done individu glycaem blood pressur control good dr progress the diabet retinopathi candesartan trial direct look effect candesartan angiotensinii receptor antagonist patient found somewhat equivoc result in patient type diabet modest reduc incid retinopathi effect progress exist retinopathi in patient type diabet signific increas regress exist retinopathi progress reduc last find statist signific the fenofibr intervent event lower diabet field studi promis show fenofibr lipidlow fibrat reduc need laser treatment sightthreaten dr either macular oedema prolif retinopathi five year ophthalm intervent most patient dr need treatment if sever treatment modal avail laser treatment this mainstay treatment period year aim induc regress new blood vessel reduc central macular thicken it thought procedur work reduc releas vasoprolif mediat hypox retin vessel allow easier direct diffus oxygen choroid blood suppli laser treatment arrest progress dr unlik restor lost vision treatment target specif area focal treatment deliv entir peripheri retina panretin photocoagul prp burn may place retina session the choic depend natur dr macular oedema treat focal laser burn wherea retinopathi amen prp if retinopathi maculopathi macular oedema often treat first separ treatment prp laser treatment carri laser treatment clinic outpati basi at later date area laser treatment easili identifi welldemarc pale spot distinct darkbrown centr help patient cannot rememb previous treatment the decis whether carri laser treatment alway clearcut eg asymptomat patient csmo visual loss intravitr steroid a larg trial demonstr intravitr steroid initi effect treatment laser photocoagul two year posttreat eye treat laser actual better visual acuiti less maculopathi intravitr triamcinolon appear reduc csmo improv visual acuiti advanc case it may use primari adjunct therapi the effect maxim week may last six month the mechan action corticosteroid fulli understood this treatment modal associ complic see complic fluocinolon acetonid fluocinolon acetonid intravitr implant corticosteroid antiinflammatori antivascular endotheli growth factor properti fluocinolon acetonid intravitr implant recommend nation institut health care excel nice option treat chronic diabet macular oedema insuffici respons avail therapi implant use eye intraocular pseudophak len antivascular endotheli growth factor treatment in recent trial antivascular endotheli growth factor drug shown definit small benefit compar current therapeut option treatment diabet macular oedema pegaptanib bevacizumab ranibizumab investig promis result current price frequenc attend requir inject followup limit use treatment clinic practic ranibizumab current recommend nice treatment visual impair due diabet macular oedema surgeri a vitrectomi remov vitreous may requir follow intravitr bleed prolif dr not physic remov blood allow vision clear medium retin detach also repair intraop prp reduc stimulus neovascularis complic the main complic dr visual loss secondari macular oedema macular ischaemia vitreous haemorrhag traction retin detach howev treatment modal also associ risk complic focalgrid photocoagul impair central vision paracentr scotoma choroid neovascularis epiretin membran format worsen macular oedema minor complic panretin photocoagul prp constrict visual field nocturn diminut vision burn affect fovea centrali worsen macular oedema serous andor choroid detach ocular pain anterior chamber advers effect eg burn affect cornea len complic intravitr steroid triamcinolon cataract format rais intraocular pressur prognosi background retinopathi eventu progress sever form major individu if left untreat prolif dr lose sight within two year risk lose use vision year patient undergo treatment risk moder visual loss reduc subsequ three year those prp risk sever visual loss reduc compar untreat individu similar sever diseas other eye condit associ diabet cataract a classic diabet cataract rare the cataract manifest snowflak opac occur young person diabet it may resolv spontan matur more common agerel cataract precipit diabet patient form earlier would done otherwis eye condit less common associ diabet prematur presbyopia refract error due reduc pliabil len secondari alter metabol rubeosi iridi describ process sever ischaemia caus neovascularis extent vessel grow forward iri the vessel may seen larg individu entiti els give iri general red appear if block peripher trabecular meshwork aqueous drain way may precipit acut glaucoma need urgent treatment see separ primari openangl glaucoma articl occasion ocular motor nerv palsi occur presum due damag microvascular suppli cranial nerv patient presum intracrani mass proven otherwis via imag if truli palsi relat diabet microvasculopathi often resolv period month orthopt input may need other eye condit common found peopl diabet includ dri eye corneal abras anterior uveiti ocular ischaem syndrom papil orbit infect corneal abnorm may also found patient group asteroid hyalosi condit characteris littl white fleck seen vitreous it occur number reason usual asymptomat unless sever affect vision left alon eye condit rare associ diabet other problem occasion seen trace back diabet includ papillopathi various problem relat optic disc pupillari lightnear dissoci see separ examin eye pupillari abnorm articl rhinoorbit mucormycosi',\n",
       "  'NN'),\n",
       " ('most doctor dont like prednison fair good reasonlong term use good multipl cours year good so mani tri limit unless realli realli suffer i know frustrat i wound hospit doc would put back pred third time year just honest doctor qualiti life they may want tri ucerisbudesonid in experi better mild flare help knock back sever flare signific back normal way much stupid diseas bide time suffer walk line handl cant it dramat differ maladi ive ever experienc symptomat reliev greater extent normal come time your unlik get want obvious that dire onc i accept that way goe i need patient made bit easier deal imodium help bit function tho i found i alway paid next day gasx help bit cramp rectal med help interim dx left side flare sinc ct suggest advanc pancol rx lialda gx uceri sometim humira fail xeljanz toler current pred remicad',\n",
       "  'NN'),\n",
       " ('diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r negat m alk kras ros pd pdl met treatment st carboplatinpemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrexedavastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question is tagrisso good altern m negat never smoker if altern current treatment yale dr roggerio lilenbaum can suggest suitabl clinic trial ct mass ny can suggest doctor second opinion',\n",
       "  'NN'),\n",
       " ('hi maia knowunderstand differ drug keytruda look like pd inhibitor i wonder stop respond one anoth might work depend exact differenti drug',\n",
       "  'NN'),\n",
       " ('hi melissa the nurs compani suppli drug adveva kept call check told white cell low im reliabl cos i witter i may suscept infect so far ive noth shingl said common cold sore nada i must sound like mavenclad stalker cos i alway repli post it there hard info onlin new apolog im repetit im get blood done week ill let know good luck anna x',\n",
       "  'NN'),\n",
       " ('went neurologist today headach back guess put a quick furious pred taper who knew use pred headach mg today mg taper per day day total and i thought mg day lot i fli high now i know i wasnt quit mani headach prior month i pred anyway if headach continu like i might go prevent also check make sure sinus infect read back post one reason i make post remind i see headach spot sinc i start entyvio worri that would darn doubleedg sword wouldnt the thing cure also make ill i bare function anyway someth work i sure take headach matter sick miser make miser uc symptom time tell overal im happi free tenesmus poop day night but i confess i mini accid morn i pull pjs sit toilet but migrain med tend give diarrhea ive sht load last day eta nurs said pred mg i look packag theyr mg so mg yesterday duh thank heal well forum let tell deep dirti secret it great know understand arent gross tmi post edit flowersg am gmt',\n",
       "  'NN'),\n",
       " ('hi michell that quit list good stuff i understand oncologist astonish use natur medicin dont know work today updat i stage c adenocarcinoma lung cancer i went c far tumor in week i start radiat day week chemo time gram oil day gram vit c iv twice week after treatment put remiss i start someth call duvalumab year immunotherapi they genet test i tumor proport score tps high pdl express nsclc i hope scan clear enjoy season',\n",
       "  'NN'),\n",
       " ('tashia my mom diagnosi non small cell adenocarcinoma her origin diagnosi she first recurr diagnos she lobectomi follow chemo radiat immunotherapi avail initi diagnos for recurr test pdl she test posit cancer cell when went keytruda carboalimta fda approv month prior it work wonder come without side effect onc keytruda alon side effect mild noth cure uncl cancer mom lung cancer persist often pop back but slow cancer make disappear you ask treatment prolong life give qualiti life for mom i cant tell happen uncl but uncl receiv standard care advanc stage lung cancer in infus uncl anoth ct chest xray it may well look worsemi mom first scan look wors like lot peopl tumorsnodulesmass typic becom inflam look bigger scan month the begin treatment alway time question worri the question concern typic pleas feel free continu reach question concern take care steff',\n",
       "  'NN'),\n",
       " ('by pete farley unpreced effect relaps form diseas in find show effect new strategi treat multipl sclerosi ms research report posit result three larg intern multicent phase iii clinic trial investig drug ocrelizumab brand name ocrevus relaps multipl sclerosi rms primari progress multipl sclerosi ppms the trial result publish onlin dec the new england journal medicin nejm discuss accompani editori stephen hauser examin one ms patientsstephen hauser md serv chair scientif steer committe opera trial correspond author nejm paper report result trial photo barbara rie in multipl sclerosi immun system attack bodi make socal autoimmun diseas to date ms drug target immun system t cell ocrelizumab contrast deplet popul immun system b cell two companion paper nejm present data drug two ident design studi rms known opera i opera ii trial trial involv patient ppms call oratorio studi all three trial involv hundr patient dozen research sever countri sponsor f hoffmanla roch roch hold patent ocrelizumab the opera trial compar effect safeti ocrelizumab interferon betaa rebif current standardofcar medic rms magnet reson imag conduct trial show inflammatori lesion brain ocrelizumabtr group reduc percent compar receiv interferon reduc percent baselin level begin trial these imag result accompani percent reduct relaps symptom percent reduct disabl compar interferon unpreced result trial the reduct inflammatori brain lesion seen opera trial unpreced said uc san francisco stephen hauser md serv chair scientif steer committe opera trial correspond author nejm paper report result trial hauser professor chair ucsf depart neurolog colleagu long champion idea b cell play central role ms research mani decad instrument bring ocrelizumab clinic trial as exist treatment ppms oratorio trial compar ocrelizumab placebo clinic meaning reduct disabl progress marker worsen diseas seen result never observ ppms in three trial common advers event associ ocrelizumab infusionrel reaction infect most mild moder sever this work hope great benefit million peopl ms result longstand collabor global scientif communiti industri said hauser also director ucsf weill institut neurosci ms chronic diseas affect estim million peopl around world includ estim peopl unit state mani approv drug aim keep rms check approxim percent percent peopl ms diagnos ppms approv treatment there current cure either condit ms occur immun system abnorm attack myelin sheath fatti substanc insul support axon radiat nerv cell brain spinal cord optic nerv caus inflamm consequ damag interrupt normal flow communic nervous system this damag caus wide rang symptom includ muscl weak fatigu difficulti see may eventu lead perman disabl most peopl ms experi first symptom year age make diseas lead caus nontraumat disabl younger adult rms common form diseas character episod new worsen sign symptom relaps follow period full partial recoveri ppms debilit form diseas mark steadili worsen symptom typic without distinct relaps period remiss drug under review fda market applic ocrelizumab brand name ocrevus submit rms ppms genentech member roch group current review us food drug administr fda european medicin agenc ocrevus grant prioriti review design fda initi target action date dec extend march this extens result submiss addit data genentech regard commerci manufactur process ocrevus requir addit time fda review the extens relat drug efficaci safeti these new public indic b cell play central role ms hauser said in opera i opera ii rms studi ocrelizumab consist signific reduc diseas activ disabl progress compar standardofcar highdos interferon demonstr favor safeti profil the consist data effect seen clinic studi favor safeti profil may support treat ms earlier highefficaci diseasemodifi medicin httpswwwucsfedunewspositivemultiplesclerosisclinicaltrialresultssupportnewtreat',\n",
       "  'NN'),\n",
       " ('there good reason honest i want write post situat i found last friday afternoon time i stone cold panic think notion share someth incred horrifi the phone call came i make delight discoveri local boutiqu groceri store feast brilliant carri favorit ice cream brand call jeni splendid ice cream previous avail via mail order click link right nowdo ittrust thank later i sit car text fantast news niec phone start ring when i saw the great scott call pm friday i immedi got pit stomach well maribeth youv done im littl stump but base blood work appear test posit hepat b there convers end place convers i felt like person i i anoth diseas a high contagi communic diseas i freak std we wont even get ironi statement i see liver specialist determin inform new condit tgs schedul am monday morn holi crap fast would work determin i chanc get approv get new goo damag infect liver situat tgs alreadi spoken peopl genentech manufactur market ocrevus they werent keen prospect get approv take new drug it would danger i high likelihood develop liver complic mayb even liver cancer didnt like idea tgs tri calm tell wasnt give work togeth new liver doctor make case roll new medicin much inform unknown im optimist said im give i dont think either i dont know i explain went head minut discuss i reel frantic horrifi asham outrag mad rage like wildfir burn brain how could happen what kind joke univers play who cosmic entiti mightili thing like keep happen when enough enough alreadi love god panic would mild word desper would come closer i hope high i know buzz ms circl full hyperbol come ocrevus i get it complic might might danger anyon know blah blah blah i get i realli but option arent good otherwis tysabri one aggress dmt option didnt take dr scott extrem optimist get someth new good thing time tysabri run my jc posit status alway meant i short time tysabri id gone month origin agre i year risk would accept probabl great idea stay drug fifteen month mean im three month danger zone im excit and sinc im realli honest i blown away notion i diseas i probabl got unsaf sex year wild reckless abandon insan i took live life like i littl tini death wish or great big death wish it seem littl iron thing i prove lack worth undeserv shame exist might actual ruin life prevent treat proper ms mark giant letter b didnt stand beth actual stood dirti whore infect get close i know way insan i know mani way contract hepat b unsaf sex seem like like option inform i read mani web site chat room reddit thread dedic topic i spent weekend feel like i live altern dimens everyth look like regular life noth made sens i told peopl i dont even know i felt like kind dirti secret disclos least three peopl make feel even littl bit real so i disclos my therapist my best friend my closest famili member i didnt want anyon know realli time i want everyon know mayb everyon knew would make feel real dont drink water bottl peopl love god dont kiss jesus diseas joke it high contagi it horribl thing bodi most liver base nonstop scour interweb weekend wasnt whole lot good say current circumst i sudden found full empathi peopl infect dastard ill i want meet tell good peopl probabl didnt deserv deal i realiz probabl impract still i count minut am appoint new liver specialist all weekend felt like time would never come i page full question i want ask least i tell who danger do i call everyon ive ever sex i mean jesus pleas tell what make buddi did i spend rest life wrap plastic head toe like old ladi plastic bubbl protect everyon around infecti horribl dr goswami new liver doctor see actual due date second child she feet tall great child she ask million question i answer honest nos even look confus were go test said this test tell noth youv expos hbv virus there mani thing you may need medic rest life figur she hand four page blood work order order liver ultrasound pat head promis someon would probabl touch lord help hope babi born alreadi she quit ador i felt like i shit situat good hand my favorit part appoint dr goswami are current sexual activ multipl partner me um im i quit frank sexual inact zero partner jesus think time dr goswami when last time unprotect sex me umim sure maybeum god kind embarrass i cant realli rememb mayb year ago jason nurs room us entir time loud clear throat and cough while also say bullshit and turn bright red ok he didnt actual say bullshit choke he turn love shade crimson i wonder realli cut whole deal delic convers thing i think mine wasnt embarrass convers hed privi dr goswami exam room or mayb i left head straight lab less vial blood drawn vein they could taken i would ok i kind like idea take blood mayb replac better improv cleaner blood entir realist think i went back work head still whirl wonder kind hepat inform i would learn vial blood would i ever learn live how could i tell peopl lateish tuesday night blood result sudden got post health portal i sat front comput feel sick tri figur i nerv click id rather wait inevit phone call list danger drug hullabaloo would result confirm latest diagnosi im make light tell stori i suppos i havent dark place long time ive visit dark place one felt realli bad mayb age mayb much uncertainti life even littl felt like much handl i went work past coupl day act like normal person i didnt feel like normal person anymor not even normal person chronic ill like ms i felt decid bad i felt damag but tuesday night i click result i i held breath littl cursor arrow land top first line six differ hepat test nonreact nonreact nonreact nonreact nonreact nonreact i stare screen blank nonreact doe mean negat i think mean negat im afraid believ i better googl yes i think realli mean negat mayb i liver ultrasound schedul next morn mayb ultrasound would show diseas pathet liver prove test wrongi went bed feel muddl i want happi i afraid happi the next morn i ultrasound i drove work just like normal person just like i email doctor offic left messag voic mail nobodi call back then today i got word the great scott time voic mail maribeth seem wrong my first impress first test fals posit i investig howev deepli concern i need find happen i touch good news good good news the bad news probabl caus fret coupl day good i investig lab get back soon i know in email i receiv later afternoon explain particular test drug compani requir ocrevus sensit rate fals posit tgs team unawar experi investig discuss liver specialist enlighten he order particular test origin test requir ocrevus studi tgs want apolog make go with brand new drug learn drug requir togeth that said two good thing came your liver fine second set test verifi we move forward get switch ocrevus i know fact nurs a work prior author i walk back infus center inform approv move forward medic sother lesson learn lot lesson realli dont panic get inform dont assum your bad person deserv bad thing keep happen your probabl nobodi peopl lot deal from i learn hepat b mad lost weekend research i tell peopl suffer bad impact diseas incred burden judg harsh mani peopl around i empathet peopl suffer i empathet general peopl around deal heavi shit they may look fine may look littl tire may most look fine liter no idea go none zero nada dont judgey dont cruel tri understand oh i also learn never forget alway fals posit i never believ thing i thought i deserv new bad thing happen top bad thing alreadi happen know i didnt you probabl dont either nor ladi sit across bus be kind tri understand peopl deal lot even see wors see i promis be kind the end',\n",
       "  'VBP'),\n",
       " ('this entri post multipl sclerosi associ america tag cog fog ms forum ms onlin support ocrevus onlin communiti msaa bookmark permalink about msaa as nation nonprofit organ multipl sclerosi associ america lead resourc entir ms communiti improv live today vital servic support msaa provid free program servic tollfre helplin awardwin public includ magazin the motiv websit featur educ video research updat search program assist ms communiti learn differ treatment choic mobil phone app my ms manag resourc databas my ms resourc locat equip distribut rang grab bar wheelchair cool accessori heatsensit individu educ event activ mri fund insur advocaci for addit inform pleas visit httpwwwmymsaaorg call view post msaa',\n",
       "  'NN'),\n",
       " ('brainz i feel unfortun digress less effect dmts some suggest gain access lemtrada have consid cladribin if i uk near i would park bart sign cladribin if possibl get tysabri if possibl tri gilenya it probabl efficaci oral dmd i would use dmds i could get lemtrada cladribin sewingchick i review cladribin inform agre impress i would definit interest approv fda i live close bart hospit the safeti profil look good i seen anyth regard abil halt revers progress ms like lemtrada clinic trial also i would see whether recommend all form relaps ms includ relaps secondari progress if show languag like i would appreci if i requir anoth dmt lemtrada i would definit interest',\n",
       "  'NN'),\n",
       " ('this must difficult time famili he share week ago realli bad shape so sad read may peac yo femal diagnos wuc mid transvers uc crohn coliti remiss sinc confirm scope dec current med entyvio asacol hd tab xday capozid day hypertens omeprazol otc loratadin day multivitamin day',\n",
       "  'NN'),\n",
       " ('california offici alleg tuesday biopharma giant abbvi abbv made illeg kickback boost prescript ion blockbust drug humira accord complaint abbvi engag farreach scheme includ classic kickback cash meal drink gift trip patient referr sophist one free valuabl profession good servic physician induc reward humira prescript ion wwwinvestorscomnewstechnologyabbviekickbackhumirachargecalifornia moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa how long minut depend side bathroom door',\n",
       "  'VBP'),\n",
       " ('rituxan ocrevus great safeti recordsalmost side effect peopl take infus easili time evid repair limit repair real that talk game changer linda be kind woman feet hit floor morn devil saysoh crap shes repli with quot the follow user say thank agat howi jeani z pegakafarmgirl stillstannd sunshin suzeq',\n",
       "  'NN'),\n",
       " ('sorri pred truli aw remind temporari i hope humira longterm ticket clubremiss while pred tri limit salt intak reduc bloat water retent there prevent limit salt limit up calcium potassium intak pred wast two thing system if light weightbear exercis slow calcium wast ive pred number time year dure worst flare i lost pound weight due flare regain pound weight due insati pred appetit a week ceas pred i notic coupl pound disappear water retent howev major weight gain sustain due increas calor intak id eat big meal minut later id starv like i hadnt eaten day long tri eat fill low calor thing exampl airfil thing like bowl butterfre popcorn waterfil thing like bowl soup broth you fill stomach youll free bit the longer chronic ill easier get uc real rough bodi caus dramat weight loss pred caus dramat weight gain loos hair thing entir control we fret thing let go at one remicad infus i spoke nice ladi crohn year she say keep two set cloth one larger size one smaller size shes flare well got tire throw rebuy cloth differ size overandov feel well prioriti els worri cannot control noth make uc wors moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you might uc leav hous wear sock return none emerg tp post edit ipoop am gmt',\n",
       "  'NN'),\n",
       " ('you durvalumab twin crackup', 'NN'),\n",
       " ('oh yeah ive talk peopl whove done much i im entyvio thought zeljanz doctor read studi say low rate especi compar placebo good good remicad humira entyvio i guess',\n",
       "  'IN'),\n",
       " ('immunotherapi checkpoint inhibitor antiprogram cell death pd program deathligand pdl pembrolizumab nivolumab anticytotox tlymphocyt antigen ctla ipilimumab highdos interleukin il dual immunomodul dual checkpoint inhibit ctla inhibitor plus pd inhibitor signaltransduct inhibitor braf vraf murin sarcoma viral oncogen homolog b inhibitor patient test posit braf v mutat vemurafenib dabrafenib mek inhibitor trametinib cobimetinib kit inhibitor multikinas inhibitor sorafenib combin therapi signaltransduct inhibitor braf inhibitor plus mek inhibitor dabrafenib plus trametinib vemurafenib plus cobimetinib chemotherapi palliat local therapi two approachescheckpoint inhibit target mitogenactiv protein kinas mapk pathwaydemonstr improv progressionfre surviv pfs overal surviv os random trial antipd monotherapi pembrolizumab nivolumab demonstr improv efficaci outcom better safeti profil compar treatment use singleag antictla ipilimumab investig choic chemotherapi the combin antipd antictla immunotherapi nivolumab ipilimumab also prolong pfs os compar ipilimumab combin associ signific toxic becaus rapid develop new agent combin remain question patient physician encourag consid clinic trial initi treatment time progress clinic trial address follow issu optim dose combin immunotherapi decreas toxic preserv efficaci how select patient benefit combin immunotherapi versus monotherapi the role pdl express biomark efficaci the role mainten therapi the valu sequenc therapi immunotherapi target therapi intralesion therapi talimogen laherparepvec tvec tvec genet modifi herp simplex virus type hsv oncolyt therapi approv local intralesion inject unresect cutan subcutan nodal lesion patient melanoma recur initi surgeri tvec design replic within tumor caus lysi produc granulocytemacrophag colonystimul factor gmcsf releas antigen togeth viral deriv gmcsf may promot antitumor immun respons howev exact mechan action unknown the approv tvec us food drug administr fda base data demonstr shrinkag lesion howev improv os effect viscer metastas improv qualiti life shown evid tvec in multin random openlabel trial nct patient random assign intralesion tvec subcutan gmcsf least month inject lesion level evid iidiv elig patient stage iiib iiic iv melanoma unresect bidimension measur lesion the primari endpoint durabl respons rate drr complet respons cr partial respons pr last month assess independ review the studi stratifi site first recurr presenc liver metastas diseas stage previous nonadjuv system treatment the median patient age year rang year patient baselin eastern cooper oncolog group ecog perform status ps score stage iii diseas stage iv diseas ma mb mc previous therapi melanoma receiv patient the first dose administ plaqueform unit pfuml maximum ml lesion combin subsequ dose administ pfuml ml inject lesion combin inject volum base size lesion inject viscer lesion allow in patient treat tvec confid interv ci drr versus ci patient receiv gmcsf subgroup analysi suggest differ drrs tvec versus gmcsf may greater earlierstag diseas treatmentnav diseas patient stage iiib iiic drr tvec versus gmcsf versus respect patient stage iv ma diseas versus respect patient stage iv mb diseas versus respect patient stage iv mc diseas patient treat tvec gmcsf firstlin therapi drr versus howev patient receiv treatment secondlin therapi greater drr versus the median durat exposur tvec week month patient expos year the common advers event ae tvec group fatigu chill pyrexia nausea influenzalik ill inject site pain the rate discontinu result toxic tvec versus gmcsf group of ten death patient treat tvec eight death consid result pd salmonella infect one myocardi infarct none consid relat therapi base find investig precaut tvec live attenu hsv may caus lifethreaten dissemin herpet infect it contraind immunocompromis pregnant patient healthcar provid close contact avoid direct contact inject lesion biohazard precaut prepar administr handl provid label detail prescrib inform treatment cycl lesion size provid fda label immunotherapi checkpoint inhibitor antipd pdl the pd pathway key immunoinhibitori mediat tcell exhaust blockad pathway lead tcell activ expans enhanc effector function pd two ligand pdl pdl two antipd antibodi pembrolizumab nivolumab approv fda basi improv os random trial pembrolizumab evid pembrolizumab previous treat patient a total patient unresect metastat melanoma diseas progress within week last dose ipilimumab braf v mutat posit previous treatment braf inhibitor random assign one two dose pembrolizumab mgkg mgkgeveri week the trial exclud patient autoimmun diseas condit requir immunosuppress histori sever immunerel advers event ira treatment ipilimumab the median age year male ecog ps ecog ps eighteen percent patient tumor braf v mutat posit elev lactat dehydrogenas ldh mc diseas brain metastas undergon two therapi advanc diseas the primari outcom measur overal respons rate orr accord respons evalu criteria in solid tumor recist version criteria assess blind independ central review level evid iidiv the orr determin independ central review ci p mgkg arm consist one cr prs patient median followup month patient minimum month followup among patient object respons ongo respons rang month month respons rate mgkg arm similar consist respons patient respons seen patient without braf v mutat the approv dose mgkg administ intraven iv infus minut everi week pembrolizumab discontinu ae patient treat mgkg consid drugrel ae investig the common ae mgkg versus mgkg arm fatigu vs pruritus vs rash vs other common ae includ cough nausea decreas appetit constip arthralgia diarrhea the frequent serious ae occur total patient treat pembrolizumab includ renal failur dyspnea pneumonia cellul addit clinic signific ira includ pneumon coliti hypophys hyperthyroid hypothyroid nephriti hepat the fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat treat patient a multicent intern trial keynot nct random assign patient metastat melanoma ratio receiv pembrolizumab mgkg iv q week q week four cycl ipilimumab mgkg q week patient stratifi ecog ps vs line therapi firstlin vs secondlin pdl express posit vs negat the primari endpoint pfs os level evid iia approxim patient receiv previous system therapi advanc melanoma braf v mutat present patient approxim receiv previous braf inhibitor treatment the studi enrol patient braf v mutat high ldh level symptomat rapid progress diseas receiv anti braf therapi could provid rapid clinic benefit approxim patient pdlposit tissu sampl at time second interim analysi os result cross prespecifi efficaci boundari two pembrolizumab group superior os ipilimumab group prespecifi onesid alpha level the data monitor safeti board dmsb recommend studi result unblind pembrolizumab made avail patient diseas progress ipilimumab group the median durat followup time second interim analysi month patient death median os reach treatment group the year estim surviv patient receiv pembrolizumab everi week hazard ratio hr death compar ipilimumab group ci p patient receiv pembrolizumab everi week hr death compar ipilimumab ci p patient treat ipilimumab benefit seen across subgroup except patient pdlnegat tumor howev sinc subset small patient ci wide definit conclus could drawn studi grade ae consid relat studi drug pembrolizumab everi week pembrolizumab everi week ipilimumab rate studydrug discontinu result toxic pembrolizumab everi week pembrolizumab everi week ipilimumab the one death result cardiac arrest occur ipilimumab group patient type diabet mellitus caus metabol imbal associ ipilimumabinduc diarrhea nivolumab evid nivolumab previous treat patient acceler approv base plan noncompar interim analysi first patient receiv nivolumab least month followup multicent openlabel trial checkmat nct random assign patient nivolumab mgkg q week investig choic chemotherapi either dtic mgm iv q week combin carboplatin area curv plus paclitaxel mgm q week fda label level evid iiidiv patient requir unresect metastat melanoma progress treatment ipilimumab braf v mutationposit braf inhibitor the trial exclud patient autoimmun diseas condit requir immunosuppress histori sever ira treatment ipilimumab median age patient year patient male ecog ps patient braf v mutat present patient mc diseas elev ldh histori brain metastas receiv two system therapi previous metastat diseas orr os coprimari endpoint orr ci four crs prs assess recist criteria independ central review among patient respons ongo respons durat month respons seen patient without braf v mutat safeti analysi base patient nivolumab discontinu ae patient serious ae occur patient grade grade ae occur patient the common ae rash cough upper respiratori tract infect peripher edema other import ae includ ventricular arrhythmia iridocycl increas amylas lipas dizzi neuropathi the fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat patient a total patient unresect stage iii stage iv melanoma without braf mutat random assign doubleblind multicent trial receiv nivolumab mgkg q week dticmatch placebo q week dtic mgm q week nivolumabmatch placebo q week the primari endpoint os level evid ia the trial conduct center europ israel australia canada south america countri dtic standard firstlin treatment patient without braf mutat the dmsb note potenti differ os safeti review on june abbrevi report unplan interimdatabas lock review show signific differ os favor nivolumab the dmsb recommend studi unblind allow patient dtic receiv nivolumab the intend sampl size approxim patient total patient enter result doubleblind portion studi crossov amend show median os reach nivolumab group month ci dtic group the os rate year ci nivolumab group ci dacarbazin group the hr death ci p the common ae nivolumab group fatigu pruritus nausea diarrhea in nivolumab group patient discontinu studi treatment ae compar patient discontinu studi treatment dtic group ae potenti immunolog etiolog occur includ gastrointestin hepat pulmonari renal endocrin skin howev major resolv delay studi treatment glucocorticoid administr per manag guidelin nivolumab no death attribut drugrel ae either group chang dose regimen nivolumab metastat melanoma in popul pharmacokinet respons analysi doseexposurerespons analysi flat dose mg nivolumab everi week consid pharmacokinet equival dose regimen mgkg clinic safeti efficaci two dose appear similar across bodi weight tumor type melanoma nonsmal cell lung cancer renal cell carcinoma the dose regimen approv fda monotherapi chang mgkg mg iv everi week diseas progress intoler toxic the dose regimen mgkg iv nivolumab combin ipilimumab remain unchang therapi ipilimumab complet regimen chang mg dose everi week diseas progress intoler toxic anticytotox tlymphocyt antigen ctla ipilimumab ipilimumab human monoclon antibodi bind ctla therebi block abil downregul tcell activ prolifer effector function ipilimumab demonstr clinic benefit prolong os random trial approv fda two prospect random intern trial one previous untreat treat patient support use ipilimumab evid ipilimumab previous treat patient a total patient previous treat unresect stage iii stage iv diseas hlaaposit enter threearm multin random doubleblind doubleplacebo trial a total patient random assign receiv ipilimumab mgkg q week dose glycoprotein gp peptid vaccin one hundr thirtyseven patient receiv ipilimumab mgkg q week dose patient receiv gp vaccin patient stratifi baselin metastas previous receipt nonreceipt il therapi eightytwo patient metastas brain baselin level evid ia the median os month among patient receiv ipilimumab alon month among receiv ipilimumab gp vaccin compar month patient receiv vaccin alon hr ipilimumab alon vs gp alon p hr ipilimumab plus vaccin vs gp alon p an analysi year show among patient treat ipilimumab treat ipilimumab treat ipilimumab vaccin aliv compar patient receiv vaccin grade grade ira occur patient treat ipilimumab these ira often includ diarrhea coliti endocrinerel event eg inflamm pituitari these event requir cessat therapi institut antiinflammatori agent corticosteroid four case infliximab antitumor necrosi factoralpha antibodi there drugrel death seven death associ ira previous untreat patient a multicent intern trial random assign patient untreat metastat diseas adjuv treatment allow ratio receiv ipilimumab mgkg plus dtic mgm placebo plus dtic mgm week follow dtic alon everi week week patient stabl diseas object respons doselimit toxic effect receiv ipilimumab placebo everi week thereaft mainten therapi the primari endpoint surviv patient stratifi accord ecog ps metastat stage approxim patient ecog ps remaind patient ecog ps approxim patient stage mc diseas level evid ia the median os month ci ipilimumabdt group versus month ci placebodt group estim surviv rate ipilimumabdt group year year year hr death p placebodt group rate year year year the common studydrugrel ae classifi immun relat grade grade ira seen patient treat ipilimumab plus dtic versus patient treat placebo plus dtic common event hepat enterocol no drugrel death occur clinician patient awar immunemedi advers reaction may sever fatal earli identif treatment includ potenti administr system glucocorticoid immunosuppress accord immunemedi advers reaction manag guid provid manufactur necessari highdos il il approv fda basi durabl crs eight phase i ii studi phase iii trial compar highdos il retreat provid assess relat impact os conduct evid highdos il base pool analysi patient eight singl multiinstitut trial institut conduct highdos il demonstr cr rate with median followup time surviv patient least year median durat crs reach least month strategi improv therapi activ area investig dual immunomodul tcell coexpress sever receptor inhibit tcell function preclin data earli clinic data suggest coblockad two inhibitori receptor ctla pd may effect blockad either alon this led phase iii trial nct compar singl agent combin dual checkpoint inhibit ctla inhibitor plus pd inhibitor evid ipilimumab plus nivolumab previous untreat patient in intern random doubleblind trial checkmat previous untreat patient unresect stage iii iv melanoma random assign ratio arm nivolumab alon mgkg q week plus placebo arm nivolumab mgkg q week plus ipilimumab mgkg q week dose follow mg nivolumab q week arm ipilimumab alon mgkg q week dose plus placebo pfs os coprimari endpoint the studi power compar combin nivolumab plus ipilimumab ipilimumab monotherapi nivolumab monotherapi ipilimumab monotherapi studi power compar combin ipilimumab plus nivolumab nivolumab patient stratifi accord tumor pdl status assess central laboratori immunohistochem test posit vs negat indetermin braf mutat status v mutationposit vs wildtyp american joint committe cancer stage level evid iia characterist baselin includ patient ecog ps elev ldh braf mutat mc diseas a minor patient pdlposit tumor the prospect defin coprimari analysi pfs occur patient least month followup treatment nivolumab alon combin ipilimumab result signific longer pfs ipilimumab alon result consist across prespecifi stratif factor median pfs month ci nivolumab month ci nivolumab plus ipilimumab month ci ipilimumab the prospect specifi coprimari analysi os occur month with death rate os time point nivolumab group combin group ipilimumab group hr death combin vs ipilimumab ci p hr death nivolumab vs ipilimumab ci p in descript analysi minimum followup month follow data found os rate nivolumab group patient treat combin ipilimumab group the median os reach combin arm ci monthsnot reach median os singleag nivolumab ipilimumab group month ci reach month ci respect the hr death combin versus ipilimumab ci p nivolumab versus ipilimumab hr ci p ae highest combin arm need monitor care grade treatmentrel ae occur patient nivolumab group patient ipilimumab group patient combin group the frequent reason treatment discontinu diseas progress two monotherapi arm nivolumab ipilimumab the frequent reason discontinu combin group toxic four therapyrel death report attribut neutropenia nivolumab group colon perfor ipilimumab group liver necrosi autoimmun myocard combin ipilimumab nivolumab analys pdl express level associ os year indic level express alon poor predict biomark os signaltransduct inhibitor studi date indic braf mek mitogenactiv erkextracellular signalregul kinas activ kinas inhibitor singl agent combin signific impact natur histori melanoma although appear provid cure braf inhibitor vemurafenib vemurafenib oral avail small molecul select braf kinas inhibitor approv fda patient unresect metastat melanoma test posit braf ve mutat treatment vemurafenib discourag wildtyp braf melanoma data preclin model demonstr braf inhibitor enhanc rather downregul mapk pathway tumor cell wildtyp braf upstream ras mutat evid vemurafenib previous untreat patient the approv vemurafenib support intern multicent trial brim nct screen patient previous untreat stage iiic iv melanoma braf v mutat identifi patient via coba braf v mutat test patient random assign receiv either vemurafenib mg po bid dtic mgm iv q week coprimari endpoint rate os pfs at plan interim analysi dmsb determin os pfs endpoint met prespecifi criteria statist signific favor vemurafenib recommend patient dtic group allow cross receiv vemurafenib level evid iia iidiii a total patient evalu os although median surviv yet reach vemurafenib data immatur reliabl kaplanmei estim surviv curv os vemurafenib arm clear superior dtic arm the hr death vemurafenib group ci p the surviv benefit vemurafenib group observ prespecifi subgroup exampl age sex ecog ps tumor stage ldh geograph region the hr tumor progress vemurafenib arm ci p the estim median pfs month vemurafenib arm versus month dtic arm twenti patient non braf ve mutat braf vk braf vd four patient braf vk mutat respons vemurafenib ae requir dose modif interrupt patient receiv vemurafenib receiv dtic the common ae vemurafenib cutan event ie arthralgia fatigu cutan squamous cell carcinoma scc keratoacanthoma develop patient treat simpl excis the common ae dtic fatigu nausea vomit neutropenia refer pdq summari support palliat care inform cope cancer previous treat patient a total patient braf ve braf vk mutat enrol multicent phase ii trial vemurafenib administ mg po bid of enrol patient stage mc diseas elev ldh level all patient receiv one previous therapi advanc diseas median followup month level evid iiidiv an independ review committe irc report respons rate ci eight patient achiev cr median durat respons per irc assess month ci most respons evid first radiolog assess week howev patient respond receiv therapi month dabrafenib dabrafenib oral avail small molecul select braf inhibitor approv fda patient unresect metastat melanoma test posit braf ve mutat detect fdaapprov test dabrafenib braf inhibitor recommend treatment braf wildtyp melanoma vitro experi suggest may paradox stimul mapk signal result tumor promot evid dabrafenib an intern multicent trial break nct compar dabrafenib dtic a total patient unresect stage iii iv melanoma braf ve mutat random assign ratio dabrafenib mg po qd dtic mgm iv q week il allow previous treatment advanc diseas the primari endpoint pfs patient could cross time progress diseas confirm blind irc level evid iidiii with event hr pfs ci p the estim median pfs month dabrafenib versus month dtic os data limit median durat followup crossov the pr rate cr rate patient receiv dabrafenib versus pr rate cr rate receiv dtic the frequent ae patient treat dabrafenib cutan find ie hyperkeratosi papilloma palmarplantar erythrodysesthesia pyrexia fatigu headach arthralgia cutan scc keratoacanthoma occur patient basal cell carcinoma occur four patient mycosi fungoid occur one patient new melanoma occur two patient mek inhibitor trametinib trametinib oral avail smallmolecul select inhibitor mek mek braf activ mek mek protein turn activ mapk preclin data suggest mek inhibitor restrain growth induc cell death braf mutat human melanoma tumor braf activ mek mek protein turn activ mapk in trametinib approv fda patient unresect metastat melanoma braf ve vk mutat determin fdaapprov test evid trametinib a total patient screen braf mutat result elig patient braf ve braf vk one mutat one previous treatment biolog chemotherapi allow howev previous treatment braf mek inhibitor permit patient random assign ratio receiv trametinib mg qd iv chemotherapi either dtic mgm q week paclitaxel mgm q week crossov patient random assign chemotherapi allow therefor primari endpoint pfs the investigatorassess pfs month patient receiv trametinib versus month chemotherapi group hr pfs death ci p a radiolog review blindedtotreat arm result similar outcom median os reach ae lead dose interrupt occur patient trametinib group chemotherapi group ae lead dose reduct occur patient receiv trametinib receiv chemotherapi the common ae includ rash diarrhea nausea vomit fatigu peripher edema alopecia hypertens constip cardiomyopathi interstiti lung diseas central serous retinopathi retinalvein occlus uncommon serious ae associ trametinib onstudi cutan sccs observ refer pdq summari support palliat care inform cope cancer cobimetinib cobimetinib smallmolecul select mek inhibitor approv fda use combin braf inhibitor vemurafenib refer combin therapi signaltransduct inhibitor section summari inform kit inhibitor earli data suggest mucos acral melanoma activ mutat amplif ckit may sensit varieti ckit inhibitor phase ii phase iii trial avail patient unresect stage iii stage iv melanoma harbor ckit mutat multikinas inhibitor sorafenib the multikinas inhibitor sorafenib activ vascular endotheli growthfactor signal rafmekerk pathway this agent minim activ singl agent melanoma treatment two larg multicent placebocontrol random trial carboplatin paclitaxel without sorafenib show improv chemotherapi alon either firstlin treatment secondlin treatment combin therapi signaltransduct inhibitor secondari resist braf inhibitor monotherapi patient braf v mutat may associ reactiv mapk pathway therefor combin signaltransduct inhibitor block differ site pathway site multipl pathway activ area research braf inhibitor plus mek inhibitor dabrafenib plus trametinib evid dabrafenib plus trametinib previous untreat an intern doubleblind phase iii trial without crossov random assign previous untreat patient unresect stage iiic stage iv melanoma braf ve vk mutat receiv combin dabrafenib mg po bid plus trametinib mg po qd dabrafenib plus placebo the primari endpoint investigatorassess pfs the protocol includ prespecifi interim analysi os time analysi primari endpoint patient stratifi baselin ldh braf genotyp level evid idiii median pfs month combin versus month dabrafenib plus placebo the hr death progress ci p updat data time final analysi os reveal median pfs month combin versus month dabrafenib plus placebo the hr pfs death ci p unadjust multipl test a prespecifi final analysi os conduct event median os month dabrafenibplustrametinib group event versus month dabrafenibplusplacebo group event the hr ci p perman discontinu studi drug report patient combin patient treat dabrafenib the incid grade grade ae similar group incid combin incid dabrafenib pyrexia occur frequent combin treat immedi temporari cessat studi drug either group prophylact glucocorticoid may prevent recur episod hyperprolif cutan event includ cutan sccs consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor rare serious ae includ decreas eject fraction chorioretinopathi previous untreat an intern openlabel phase iii trial random assign previous untreat patient metastat melanoma braf v mutat receiv standard dose either combin dabrafenib plus trametinib vemurafenib firstlin therapi the primari endpoint os level evid iia an interim analysi os plan final event occur per protocol dmsb use adjust efficaci boundari actual event side p efficaci p futil the dmsb recommend stop efficaci interim analysi consid final analysi os a protocol amend issu allow crossov combin therapi arm a total patient combin arm vemurafenib group die hr ci p median os patient treat vemurafenib month median reach combin therapi arm vemurafenib plus cobimetinib evid vemurafenib plus cobimetinib previous untreat an intern phase iii trial random assign patient previous untreat unresect stage iiic stage iv melanoma braf v mutationposit melanoma receiv combin vemurafenib mg po qd cobimetinib mg po qd day follow day rest period vemurafenib plus placebo the primari endpoint investigatorassess pfs crossov time pfs allow patient stratifi stage geograph region two interim analys os prespecifi first specifi time analysi primari endpoint level evid idiii median pfs month combin versus month patient treat vemurafenib plus placebo the hr death progress ci p the first interim analysi os immatur event arm therefor median surviv reach either studi group rate withdraw therapi caus ae similar group rate found patient treat combin rate found patient treat vemurafenib six death attribut ae combin group three death attribut ae vemurafenibon group the incid grade grade ae similar group incid rate found patient treat combin rate found patient treat vemurafenib alon rare serious ae includ chorioretinopathi retin detach decreas eject fraction qt prolong hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor chemotherapi dtic approv basi orr phase iii trial indic orr rare crs observ an impact os demonstr random trial when use control arm recent registr trial ipilimumab vemurafenib previous untreat patient metastat melanoma dtic shown inferior os temozolomid oral alkyl agent hydrolyz activ moieti dtic appear similar dtic iv administr random phase iii trial primari endpoint os howev trial design superior sampl size inadequ prove equival the object respons rate dtic nitrosourea carmustin lomustin approxim respons usual shortliv rang month although longterm remiss occur limit number patient attain cr a random trial compar iv dtic temozolomid oral agent os month dtic versus month temozolomid hr ci while data suggest similar dtic temozolomid benefit surviv demonstr either dtic temozolomid therefor demonstr similar result approv temozolomid fda level evid iia an extend schedul escal dose temozolomid compar dtic multicent trial european organis research treatment cancer eortc eortc nct random assign patient no improv seen os pfs temozolomid group dose schedul result toxic standarddos singleag dtic level evid iia two random phase iii trial previous untreat patient metastat melanoma result fda approv vemurafenib ipilimumab includ dtic standard therapi arm both vemurafenib braf v mutant melanoma ipilimumab show superior os compar dtic two separ trial other agent modest singleag activ includ vinca alkaloid platinum compound taxan attempt develop combin regimen incorpor chemotherapi eg multiag chemotherapi combin chemotherapi tamoxifen combin chemotherapi immunotherapi demonstr improv os a publish data metaanalysi random trial surviv inform compar chemotherapi biochemotherapi ie chemotherapi plus interferon alon il report impact os level evidenceiia palliat local therapi melanoma metastat distant lymph nodebear area may palliat region lymphadenectomi isol metastas lung gastrointestin tract bone sometim brain may palliat resect occasion longterm surviv although melanoma relat radiationresist tumor palliat radiat therapi may allevi symptom retrospect studi shown symptom relief shrinkag tumor radiat therapi may occur patient follow multipl brain metastas bone metastas spinal cord compress the effect dosefraction schedul palliat melanoma metastat bone spinal cord unclear highdoseperfract schedul sometim use overcom tumor resist refer pdq summari cancer pain inform treatment option under clinic evalu unresect stage iii stage iv recurr melanoma immunotherapysingl agent combin immunomodul target therapysingleag combin therapi signaltransduct inhibitor includ pk phosphoinositid kinas akt protein kinas b inhibitor cdk cyclindepend kinas addit braf mek inhibitor antiangiogenesi agent preclin data suggest increas vascular endotheli growth factor product may implic resist braf inhibitor target therapi specif melanoma popul in smaller subset melanoma activ mutat may occur nras neuroblastoma ras viral vras oncogen homolog ckit melanoma aris chronic sundamag skin acral mucos melanoma cdk cyclindepend kinas wherea gnaq frequent mutat uveal melanoma drug develop target pathway activ mutat current clinic trial',\n",
       "  'JJ'),\n",
       " ('a novel crizotinibresist solventfront mutat respons cabozantinib therapi patient rosrearrang lung cancer httpwwwncbinlmnihgovpubm pleas updat blog this first time cabo shown work patient crizresist thank',\n",
       "  'NN'),\n",
       " ('happi new year for i focus sole journey obtain gilenya continu use i threw away needl felt great and what go meantim montel got ccsvi a new stem cell trial without chemotherapi almost underway new medic ahem bg wind way pipelin and also time much discov multipl sclerosi research recent reveal natur multipl sclerosi diseas need ever illumin these discoveri i find excit right fatti acid and relaps a link diet ms noth new i think weve heard swank diet great name opinion even wrote book onc upon time doctor notic ms patient never ate red meat dairi anyth delici signific less relaps us love chees filet mignon i last night he develop diet essenti involv red meat year limit serv unfortun absolut scientif proof back diet uc san diego skagg school of pharmaci and pharmaceut scienc specif mariann manchest leah p shriver discov someth fascin by studi quasievil immun cell central nervous system oxid fatti acid glucos fuel inflam tissu mous tissu inhibit specif enzym aid immun cell exploit fatti acid caus cell starv die in word glucos prevent immun cell like kill brain use fatti acid prevent relaps furthermor treatment involv target enzym mean model also work human littl risk compar medic avail us anoth bonus enzymeinhibitor use studi alreadi use human congest heart failur even loom challeng seem incred promis break through the bloodbrain barrier one challeng virtual everi ms treatment safe effect deliv therapi bloodbrain barrier cornel univers work issu discov adenosin occur natur bodi control passag larg molecul brain they believ exist drug lexiscan current use heart imag trigger receptor open barrier treatment deliveri or least work mice here hope work us remyelin with stem cell paul tesar case western reserv univers school of medicin actual found way mice myelin cell rapid use stem cell they use pluripot epiblast stem cell sound like neon past attempt fail team use signal protein growth factor thyroid hormon caus restor normal myelin day neurosteroid rage or not it seem like everi day bring hope even realist pessimist like the univers of alberta edmonton notabl alberta canada highest concentr ms world made discoveri add yet anoth piec whydowehavem puzzl those us multipl sclerosi remark less neruosteroid everyon els so appar thing call neurosteroid appar neurosteroid make brain cell work correct our brain cell obvious neither brain cell mice use studi research discov peopl ms signific lower level brain chemic specif allopregnanolon help build brain cell maintain function connect differ area activ brain trial via pill form alreadi underway neurolog diseas look especi promis ms mice studi treat allopregnanolon normal deriv cholesterol vitamin d result reduc inflamm repair nerv fiber reduct mslike sever increas mobil day',\n",
       "  'NN'),\n",
       " ('in phase b trial capmatinib plus gefitinib show accept safeti efficaci patient epiderm growth factor receptor egfr mutat mesenchymalepitheli transit factor metdysregul nonsmal cell lung cancer nsclc capmatinib inc met inhibitor shown preclin activ the trial result publish journal clinic oncolog patient enrol trial egfr mutat metdysregul nsclc progress prior egfrtyrosin kinas inhibitor tki treatment a total patient treat phase b portion trial patient treat phase phase b patient receiv gefitinib mg daili plus capmatinib capsul either mg per day twice per day phase patient treat recommend phase dose capmatinib mg twice per day plus gefitinib mg per day the primari endpoint phase overal respons rate orr in phase patient orr patient met amplifi tumor orr the diseas control rate median durat respons month ci month nausea peripher edema decreas appetit rash common advers event report phase b patient increas amylas lipas level common grade advers event relat articl world confer lung cancer key find treatmentrel hyperprogress concern continu mount palliat care survivorship the combin capmatinib gefitinib shown feasibl ration data studi suggest combin capmatinib egfrtki may promis treatment option patient egfr mutat metdysregul nsclc particular patient met amplifi tumor studi author conclud disclosur the studi fund novarti pharma ag refer',\n",
       "  'VBP'),\n",
       " ('the neuro suggest cholesterol level wife high due gilenya take apoatorvastatin pill month i wonder sinc side effect mention om book she keep strict om diet calori intak low is take pill realli necessari',\n",
       "  'NN'),\n",
       " ('hello i find truli suck all time did symptom come quick year i find prms happen like i alway ach pain like anyon els one day dizzi fall faint collaps weak pain one year now bodi alway like never i get break if anyth get wors i work physic labor doe anyon have bino the bino never goe away am i go lose abil walk soon again prms affect happen quick it seem like bodi fall piec fast doe progress fast i veri activ tri i feel i stop i die i keep push bodi i cant physic anymor i take gilenya day thank help',\n",
       "  'NN'),\n",
       " ('embed video asco roundtabl lung cancer keynot cisplatin carboplatin alimta ampamp keytruda is practic chang approach asco roundtabl lung cancer keynot cisplatin carboplatin alimta keytruda is practic chang approach drs h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ cancer journey in treatment cancer type lung cancer diseas learn general lung cancer non small cell lung cancer chemo medic immunotherapi chemotherapi embed video asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc drs h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ cancer journey in treatment cancer type lung cancer diseas learn general lung cancer non small cell lung cancer chemo medic immunotherapi chemotherapi embed video lung cancer video librari chemo immuno therapi combin advanc squamous nsclc lung cancer video librari chemo immuno therapi combin advanc squamous nsclc dr h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace offer updat lung cancer cancer journey in treatment cancer type lung cancer diseas learn general lung cancer non small cell lung cancer chemotherapi immunotherapi embed video case base panel discuss advanc non squamous nsclc high pdl no driver mutat what optim st line case base panel discuss advanc non squamous nsclc high pdl no driver mutat what optim st line drs zofia piotrowska h jack west taofeek owonikoko sit discuss seri casebas scenario in video doctor discuss optim st line treatment patient advanc non squamous non small cell lung cancer high pdl driver mutat cancer journey just diagnos in treatment cancer type lung cancer diseas learn general lung cancer non small cell lung cancer chemotherapi mainten therapi adjuv therapi target therapi immunotherapi embed video case base panel discuss advanc non squamous nsclc low pdl no driver mutat is there best system therapi option case base panel discuss advanc non squamous nsclc low pdl no driver mutat is there best system therapi option drs zofia piotrowska h jack west taofeek owonikoko sit discuss seri casebas scenario in video doctor discuss best system therapi option patient advanc nonsquam nsclc low pdl driver mutat cancer journey just diagnos in treatment cancer type lung cancer diseas learn general lung cancer non small cell lung cancer chemotherapi mainten therapi adjuv therapi target therapi immunotherapi',\n",
       "  'VB'),\n",
       " ('hello i recent diagnos rrms februari ill start first dose gilenya saturday im feel bit nervous make heart rate drop im medicin itll make real im go overal ive got good handl thing i good day bad has anyon use gilenya thought i know everyon diseas process differ well react differ i would like input thank advanc',\n",
       "  'NN'),\n",
       " ('well choic in case i diagnos ive never treatment but im think start gilenya although condit still fine not disabl anyhow but futur said i guess year i better accept take treatment see goe',\n",
       "  'NN'),\n",
       " ('hello everyon year ago i test posit jcv connect gilenya came i stop take med went dr jelinek overcom ms diet i lost lbs month felt great i great diet past sever month put back ugh start needless say i saw neurologist today happi i stop take med now i flare up tingl burn stab dizzi blurri thing feel come go i fortun linger effect so decid tri scare histor go dmts bad relaps hit hard within year two now i final gotten realli good job famili well i dont want take med i dont i also dont want get sucker punch bad relaps lose ground posit ive gain past month she suggest aubagio has anyon got experi pleas let know i new bloodwork new mri lesion brain spinal cord so know soon thank everyon wayn',\n",
       "  'NN'),\n",
       " ('wow ncot epic storyth case lost pill cam someth ive never one alway told tradit method better wonder neon colour someth trace like kinda microchip dog if time ever come ill sure poop plastic contain i pass have start entyvio yet opp yes ani notic chang',\n",
       "  'VBD'),\n",
       " ('hello smurf how could forget name like smurf you might right wont offer dmds the criteria usual relaps last year but often neurologist manag get categoris activ base new lesion get onto dmd anyway have problem wbcs past may take drug tabl it may depend type white blood cell deplet if lymphocyt dmds perhap eg tecfidera neutrophil eg gilenya could rule sinc side effect occur specif drug but other dont effect so may get onto decent treatment whatev happen know alway sue',\n",
       "  'NN'),\n",
       " ('it klaus schmierer i saw he recommend treatment end march i four week washout period stop gilenya so i first lot cladribin begin may two week ago id say im alreadi littl bit better i leg work bit better main but i probabl havent even full first dose yet i get lymphocyt count done four week first treatment depend theyll give inject week',\n",
       "  'JJ'),\n",
       " ('recombin human fusion protein vascular endotheli growth factor a vegfa placent growth factor plgf antagonist use eylea neovascular agerel macular degener treatment neovascular wet agerel macular degener clinic equival ranibizumab may provid advantag eg decreas treatment burden agent eg bevacizumab ranibizumab less frequent administr see dosag dosag administr macular edema follow retin vein occlus treatment macular edema follow retin vein occlus diabet macular edema treatment diabet macular edema diabet retinopathi patient diabet macular edema treatment diabet retinopathi patient diabet macular edema eylea dosag administr administr ophthalm administ intravitr inject affect eye must administ qualifi physician prior intravitr administr withdraw entir content aflibercept vial steril gaug filter needl provid manufactur ml syring provid manufactur use asept techniqu prior intravitr inject replac filter needl steril gaug inch needl provid manufactur to obtain appropri dose mg expel content syring plunger tip align line mark ml syring inject control asept condit includ surgic hand disinfect use steril glove steril drape steril eyelid speculum equival follow adequ anesthesia administr topic broadspectrum antiinfect agent monitor patient elev iop immedi follow intravitr inject monitor may includ evalu optic nerv head perfus tonometri a steril paracentesi needl avail requir use vial treatment singl eye discard unus portion if contralater eye requir treatment use new vial chang steril field syring glove drape eyelid speculum filter inject needl administ eye dosag adult neovascular agerel macular degener ophthalm intravitr inject mg affect eye everi week week mg everi week addit efficaci demonstr follow administr everi week compar everi week macular edema follow retin vein occlus ophthalm intravitr inject mg affect eye everi week diabet macular edema ophthalm intravitr inject mg affect eye everi week first inject follow mg everi week addit efficaci demonstr follow administr everi week compar everi week diabet retinopathi patient diabet macular edema ophthalm intravitr inject mg affect eye everi week first inject follow mg everi week addit efficaci demonstr follow administr everi week compar everi week special popul hepat impair no specif dosag recommend time renal impair no dosag adjust requir geriatr patient no dosag adjust requir caution eylea contraind ocular periocular infect activ intraocular inflamm known hypersensit eg sever intraocular inflamm aflibercept ingredi formul warningsprecaut sensit reaction hypersensit reaction report see contraind caution endophthalm retin detach intravitr inject includ aflibercept associ endophthalm retin detach alway use proper asept inject techniqu if sign symptom endophthalm retin detach eg red sensit light pain chang vision includ blur vision occur manag appropri increas iop acut increas iop observ within minut intravitr inject sustain increas iop also observ follow repeat intravitr inject vegf antagonist monitor iop perfus optic nerv head manag appropri thromboembol event potenti risk arteri thromboembol event follow intravitr inject vegf antagonist includ aflibercept immunogen incid immunoreact aflibercept similar week therapi no differ efficaci safeti patient without immunoreact specif popul pregnanc categori c no adequ wellcontrol studi pregnant women anim studi suggest possibl advers embryofet effect use potenti benefit justifi potenti risk fetus women childbear potenti use effect contracept prior initi therapi treatment month last intravitr inject administ lactat not known whether aflibercept distribut milk use recommend nurs women discontinu nurs drug pediatr use safeti efficaci establish geriatr use no substanti differ safeti efficaci relat younger adult renal impair no differ plasma concentr observ various degre renal impair see special popul pharmacokinet common advers effect conjunctiv hemorrhag eye pain cataract vitreous detach vitreous floater increas iop interact eylea no formal drug interact studi date eylea pharmacokinet absorpt bioavail follow intravitr inject mean peak plasma concentr attain day peak plasma concentr estim fold lower concentr requir halfmaxim bind system vegf free aflibercept undetect plasma week intravitr inject no accumul observ follow repeat intravitr inject ie everi week special popul follow intravitr inject everi week differ free plasma aflibercept concentr observ patient mild moder sever renal impair distribut extent not known whether aflibercept distribut milk elimin metabol expect undergo elimin targetmedi disposit via bind free endogen vegf via proteolysi halflif approxim day follow iv administr dose mgkg stabil storag ophthalm c do freez protect light store origin carton use action act solubl decoy receptor bind vegfa plgf inhibit biolog activ vegfa induc neovascular angiogenesi increas vascular permeabl appear play role pathogenesi progress neovascular wet agerel macular degener macular edema follow retin vein occlus diabet macular edema diabet retinopathi bind vegfa plgf prevent factor bind endogen vegf receptor ie vegfr vegfr reduc endotheli cell prolifer angiogenesi vascular permeabl bind affin aflibercept vegfa isoform higher endogen receptor aflibercept block vegf bind activ vegfr vegfr even low concentr advic patient possibl temporari visual disturb intravitr inject associ eye examin import avoid drive vehicl oper machineri visual function recov suffici risk endophthalm retin detach import immedi seek care ophthalmologist chang vision occur treat eye becom red sensit light pain import women inform clinician plan becom pregnant plan breastfe import inform clinician exist contempl concomit therapi includ prescript otc drug well concomit ill import inform patient import precautionari inform see caution',\n",
       "  'NN'),\n",
       " ('thank jim alway i much appreci input befor guardant test result came i offer carboalimtatagrisso trial opdivo second agent no explan offer pd l status seem matter i low level autoimmun diseas natur reluct go immunotherapi rout even though new evid suggest peopl low level autoimmun might still abl success tri option im skeptic dont want find potenti life threaten situat are tri figur combin opdivo agent increas current low respons rate patient popul i continu tagrisso therapi lung tumor reach certain size caus cough hoars cm rang right still first diagnos cm a hilar lymph node also increas densiti locat includ brain ned moment id love add stereotact radiat treatment regiment i know controversi stage also slim chanc take mother load might delay progress somewhat what opinion kempten',\n",
       "  'NN'),\n",
       " ('jarthur my wife yo nonsmok dxd stage iv nsclc left lung egfr tarceva continu year excel respons year chemo carboalimtaavastin local recurr good respons repeat chemo carboalimtaavastin local recurr good respons avastin mainten needl bx local recurrenceresult includ egfr tm pd all rx tarceva avastin dcd pend rx decis diseas still confin left chest what would option system rx indicatedtagrisso checkpoint inhibitoron two agent chemo we grate wife respond least temporarili rx thus far we never would expect longev date dx first made thank input',\n",
       "  'NN'),\n",
       " ('hi jacki i wonder kidney failur due platinum drug if still abl tri singl chemo like alimta alon peopl egfr mutat well howev like jim i hope well tagrisso long time all best janin',\n",
       "  'NN'),\n",
       " ('electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move the major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect it import replac miss electrolyt becom rebalanc how done depend sever imbal if minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi an mri scanner larg tube contain power magnet you lie insid tube scan mris help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimus astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes common caus scar surgeri less common scar due activ inflammatori bowel diseas adhes fibrous band form tissu caus pain blockag intestin post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit a bowel resect surgic procedur part larg small intestin remov post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit a hemicolectomi involv surgeri remov right left portion colon post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit hemicolectomi ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit partial subtot colectomi definit partial colectomi involv remov part colon may also refer subtot colectomi post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask ulcer coliti total colectomi definit when entir colon remov call total colectomi also known lane oper post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask inflammatori bowel diseas ulcer coliti colectomi definit a colectomi surgic procedur remov part colon your colon also call larg intestin long tubelik organ end digest tract colectomi may necessari treat prevent diseas condit affect colon there various type colectomi oper total colectomi involv remov entir colon partial colectomi involv remov part colon may also call subtot colectomi hemicolectomi involv remov right left portion colon proctocolectomi involv remov colon rectum sourc post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask surgeri ulcer coliti extens total coliti pancol definit extens coliti extend along colon extens coliti affect whole colon may call total coliti pancol extens total coliti caus frequent diarrhoea blood mucus sometim pus you may also sever abdomin cramp pain tenesmus weight loss in milder flareup main symptom may diarrhoea looser stool without blood veri rare inflamm sever digest gase may get trap colon make swell this known toxic megacolon caus high fever well pain tender abdomen it essenti get treatment quick condit may need surgeri post ibd superhero no comment email this blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti ibd ibd definit leftsid distal coliti definit in type ulcer coliti inflamm start rectum continu left side colon also known distal descend colon symptom includ diarrhoea blood mucus pain left hand side abdomen urgenc tenesmus',\n",
       "  'NN'),\n",
       " ('it appear differ monoclon antibodi develop i copi follow part neuro immunolog exact i look it turn rituximab patent expir us this mean time phase iii patent so profit invest to surpass inconveni genentech invent new drug anticd well human rituximab chimer call ocrelizumab start whole process then obvious got phase ii trial ocrelizumab ms result publish yet present ectrim meet showa expect almost equal efficaci profil rituximab but patient die ocrelizumab arm unexpect system inflammatori syndrom that could chanc still hope larger studi assur chanc sever rheumatoid arthriti trial ocrelizumab termin overal benefit risk profil ocrelizumab favor ra realli mean patient die unexpect high ocrelizumab dose arm trial so rituximab extraordinarili effect therapi use quit long time pretti safe never approv ms phase iii trial perform phase iii trial plan perform drug becom unprofit on hand equal effect therapi test phase ii trial date show pretti less safe profil point stop diseas potenti profit compani overcom safeti issu guess wich one approv year this terribl we dont mani choic give patient throw away best one wait sever year but terribl ms patient rituximab test small case seri myasthenia gravi neuromyel optica nmdar enceph lambert eaton myasthen syndrom cidp antimag neuropathi diseas ms may rituximab phase iii trial wont sure and case seri shown pretti good result need confirm order approv use routin if bad commerci decis halt rituximab develop commerci diseas ms includ shame stori neuroimmunolog so big pharma consortium neuroimmunolog depart perform expect phase iii trial bring rituximab back neuroimmunolog therapi if meantim ocrelizumab ofatumumab treatment develop result posit welcom singl effect drug left behind advertis linda be kind woman feet hit floor morn devil saysoh crap shes repli with quot the follow user say thank agat jeani z jendi stillstannd sunshin',\n",
       "  'JJ'),\n",
       " ('is oxycodon i somehow manag end realli high dose oxycodon coupl month first surgeri not sure anyon knew tbh long stori short i tri taper still went hell week first week worst my skin constant altern hot cold mad sensitiveprick i worst sens restlessnessagit ever i liter couldnt keep still didnt get wink sleep night after first week everyth becam bearabl apart skin sensit last month unfortun even year i still slight residu sensit occasion annoy still better height i doubt youll get skin issu i x dose oxi obvious bugger skin possibl surgeri someth well damag nerv end perhap but yeah i dont think fun week honesti just rememb pass perman dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('think patent end rituxan cheaper generic avail and rebrand market ocrevus tri keep cash cow come pleas note post may arbitrarili alter moder may reflect origin content per mike wein adminmod team doesnt provid forewarningwarningment alter member post it doesnt matter fix link remov link fix typo whatev repli with quot the follow user say thank howi jeani z jendi lazarus parsi stillstannd',\n",
       "  'NN'),\n",
       " ('last week panorama ran stori wonder hsct autolog haematopoiet stem cell transplant remark headlin bbc newssit use httpwwwbbccouknewshealth we also seen much nois made potenti ocrelizumab two thing though the first hsct aggress treatment the second ocrelizumab like go expens but cladribin seem data suggest effect current nice treatment it far cheaper ocrelizumab ever wont fight financi battl nhs trust get treatment and seem pretti safe cancer scare appear proven fals one we know ms degen we know smoulder lesion might caus damag far line we know cognit impair burden effect even benign ms cladribin appear believ i done read realli realli good altern so much i chose go recent frank result wonder my limp gone my brain fog clear my eyesight improv for first time long time i feel normal i one regret i didnt get offer treatment year ago we dont know bad ms get but patient awar get bad that degener might happen even feel abl function when late start treatment perhap never when earli start treatment perhap diagnosi cladribin seem drug work it seem drug cheap it seem drug safe least worth risk have chat neurologist i chose campath abov tysabri and i felt better i year',\n",
       "  'JJ'),\n",
       " ('among opdivoketrudatecentriq checkpoint inhibitor show effect nsclc patient opdivoketruda littl effect egfr nsclc subgroup patient howev tecentriq approv fda use egfr patient progress tki therapi for three checkpoint inhibitor use sclc patient opdivo yervoy submit',\n",
       "  'NN'),\n",
       " ('eugina i sorri hear mom diagnosi my mom lung cancer non small cell adenocarcinoma she st recurr she took alimtacarbokeytruda i assum also chemo combo mom prescrib my mom cancer cell pdl great candid keytruda her cancer respond well like mani other prescrib treatment i unfamiliar cancer center mom go cant suggest sin area i live wa you get second opinion anytim even mom get treatment my mom get nd opinion initi diagnosi recurr both treatment suggest standard care time feel reason nd opinion but everyon differ choos whether seek nd opinion as far support mom let eat want a well balanc diet alway best chemo affect tast good sit well let vent need let know strong take battl pleas rememb question may support may need take care steff',\n",
       "  'NN'),\n",
       " ('octob both report subject midwest cepac meet may the icer assess compar clinic effect valu new therapi secondari progress multipl sclerosi spms treatmentresist depress upcom report both report set review public meet midwest compar effect public advisori council midwest cepac may the spms review expect assess clinic effect valu siponimod novarti current undergo fda review approv decis expect march the treatmentresist depress review expect assess clinic effect valu esketamin janssen current undergo fda review approv decis expect may read icer announc',\n",
       "  'VBP'),\n",
       " ('i durvalumab month it work i develop plural efus thoracentisi procedur remov fluid the fluid test cancer came back posit that move stage luckili biomark test fluid i came back egfr then i switch tagrisso the tagrisso shut plueral effus i fluid remov sinc start tagrisso coupl month ago i told pharmacist pleural effus possibl side effect durvalumab if start experienc sever short breath go see pulmanologist check fluid build around lung if biomark test done i would ask in opinion target therapi determin biomark test right approach by design goe genet code engin cancer btw thoracentisi procedur big deal seem littl scarri hear if fluid build notic major improv breath remov check youtub video thoracentisi procedur dont underestim power prayer',\n",
       "  'NN'),\n",
       " ('the problem diseas especi chronic diseas dont struggl diseas also face treatment be diagnos multipl sclerosi ms hard we face uncertainti ms also manag side effect incred potent oftentim riski medic it wonder mani peopl diagnos forgo use diseasemodifi therapi altogeth i understand struggl howev possibl live full healthi life ms like take medicin fortun mani option year ago let take look sort good bad come whatev path choos copaxon in begin noth well sometim copaxon glatiram acet came onto market copaxon inject medic shown reduc relaps rate shown reduct clinic disabl time the side effect copaxon flu anxieti flush short breath swell inject site more serious symptom includ problem heart liver gastrointestin hematopoiet lymphat musculoskelet nervous respiratori urogenit system copaxon first market ms unfortun carri larg amount side effect less effect there generic form market call glatopa mg dose glatiram acet interferon the next drug come market interferon this group also come inject form the varianc medic usual matter choos differ size dosag fit lifestyl these drug avonex interferon betaa betaseron interferon betab extavia interferon betab plegridi peginterferon betaa rebif interferon betaa the side effect come along med matter choos the differ side effect stretch differ length time base upon dosag size interv set given medicin the side effect interferon hepat injuri anaphylaxi allerg reaction depress suicid congest heart failur inject site necrosi reaction leukopenia thrombot microangiopathi flulik symptom complex druginduc lupus erythematosus most peopl feel like flu get inject site reaction the sever side effect unlik nevertheless drug risk must taken consider interferon around mani year there mani choic peopl find interferon fit lifestyl also interferon effect copaxon reduc relaps rate clinic diseas progress see also multipl sclerosi care ms treatment center ms treatment medic ms symptom and treatment you might also like what say someon with ms zinbryta zinbryta daclizumab anoth inject administ month howev medic riski save peopl tri two medic without avail the potenti side effect zinbryta allerg reaction serious problem liver kidney heart swollen lymph gland fever rash swell face tongu throat troubl breath infect depress suicid inject medicin fair share side effect long time choos next page aubagio libbi experi ms medic aubagio then aubagio this medicin i dont person experi fair new market it effect modifi diseas cours ms side effect dont seem scari the possibl side effect aubagio headach nausea abnorm liver test hair loss diarrhea reduc white blood cell count numb tingl serious skin problem breath problem new worsen high blood pressur libbi ms medic experi when i diagnos four medic choos either interferon copaxon terrifi commit it took almost two year fail clinic trial i final commit rebif i tell straight i never thought i could get use give shot three time week eventu even i got use i one peopl never use auto injector part rebif good my side effect becam predict i would get flu symptom night inject i remain relapsefre five year i after five year pass i start think oral medic emerg a convers friend tri pill push curios decis transit rebif onto tecfidera tecfidera tecfidera newer medicin that effect interferon the main benefit fewer normal side effect peopl bonus worri needl fatigu bruis the side effect tecfidera allerg reaction progress multifoc leukoencephalopathi pml rare brain infect flush stomach problem my friend take tecfidera love side effect minim my person experi tecfidera fun i medic two year i extrem flush sever stomach pain twice day everi day i take also medicin new side effect might emerg time pass i found tecfidera seem great affect menstrual cycl hormon regul the first month i began medicin first time life period chang my flow becam heavi first cours month period dwindl noth sex drive went right along after two year forcefeed hope turn oompa loompa twice day pound extra bodi weight said eat menstrual cycl sex drive complet disappear i quit that decemb sinc bodi slowli crept back normal never tecfidera like i said peopl love i see also multipl sclerosi care ms treatment center ms treatment medic ms symptom and treatment you might also like cope with loss appetit gilenya final i bring gilenya favorit pill market it high effect prevent ms progress i medic januari april year unfortun bodi react well i forc stop take minut gilenya felt like i take noth serious i would take pill morn breakfast i would go day i often forgot i even ms i med great howev i one unlucki one major white blood cell deplet i point doctor took morn blood test forc stay insid hous away love germ virus week the potenti side effect gilenya slow heart rate low white blood cell count pml macular edema posterior revers encephalopathi syndrom pres breath problem liver problem higher blood pressur basal cell carcinoma more medicin horizon mani better safeti profil even effect user friend i know risk high there tough choic need made left liter pick poison i believ alway way i believ mani mani wonder opportun horizon there choic hope stay strong peopl',\n",
       "  'NN'),\n",
       " ('the success anticd monoclon antibodi put focus cd bcell could mechan action deplet cd tcell ocrelizumab deplet cd t cell multipl sclerosi patient httpswwwmdpicom ocrelizumab human monoclon anticd antibodi shown pronounc effect reduct diseas activ multipl sclerosi ms patient recent approv treatment patient relaps ms rms primari progress ms ppms cd main express b cell subset t cell cdcd t cell also express cd cd t cell known high activ cell popul the blood ms patient analyz multicolor flow cytometri two week treatment ocrelizumab regard phenotyp peripher blood mononuclear cell cdexpress cd t cell found blood sampl ms patient account cd lymphocyt constitut signific proport cd cell cdcd t cell cdcd b cell effect deplet two week singl administr mg ocrelizumab our result demonstr treatment ocrelizumab exclus target b cell also cd t cell account substanti amount cdexpress cell thus specul efficaci ocrelizumab might also mediat deplet cdexpress t cell view fulltext',\n",
       "  'JJ'),\n",
       " ('helpingmom i happi hear mom cancer stabl happi danc it uncommon peopl need take period treatment break immunotherapi my mom differ break past year keytruda effect day system and keytruda may still work mean immun system isnt still work overtim so take break session usual big deal it nice give bodi break happi new year',\n",
       "  'JJ'),\n",
       " ('my insur pay humira it cost month i bless sure i go see gi next wednesday here thought i yrs old i work life two employ i avascular necrosi alreadi got hip replac past decemb cd joint problem seem marriag made heaven disabl my job good ltd i go discuss doc right i point i energi much anyth focus think abil compromis so i guess question get right med right dose i ok i tri get high stress environ attempt save that question forum',\n",
       "  'NN'),\n",
       " ('older biolog humira remicad cheapest biolog insur tri get first reason in fact biosimilar closest thing generic biolog remicad ie inflectra also humira newer biolog like entyvioxeljanzstelara two three time cost remihumira there justifi reason might prefer xeljanz theyr safer simpl pill etc moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you never realli appreci youv got gone toilet paper good exampl nealzi regular member join apr post post pm gmt so week dosag remicad cost insur ml i hadnt yet gotten approv doubl dose move week gi i decid switch xeljanz actual work wherea remicad zippo the estim cost insur day suppli xeljanz mg pill bottl theyv told compar appl appl timefram week that k xeljanz vs remicad sure resist fact take month updat approv overal formulari someth get fda approv formulari whole preauthor appeal appeal process fortun pfizer interim servic hold free believ month suppli go approv given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post pm gmt we bcbs maryland also massachusett approv xeljanz the appeal handl quick although approv one pill day instead four our doctor offic realli top thing didnt take longer week recollect there downsid follow direct doc offic also call insur make sure went spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week curious crapper regular member join may post post pm gmt remicad cash price approxim per mg bottl so could extrapol whatev dosag get then factor cost infus if get hospit set cost usual lot clinic home infus servic the cash price list xeljanz month suppli mg day would ra patient get the cash price uc would doubl around k month these cash price though depend insur provid decid bill cover thing could make differ feelinglesscrappi new member join oct post post pm gmt i bcbs my doctor get approv bcbs didnt approv first dr explain current qualiti life approv nealzi regular member join apr post post am gmt veri help respons thank ill let know bcbs approv process differ side fda approv im week preauthor process bit longer readi taper mg pred monday st time sinc last year most hope continu sever pancol patient given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post am gmt blue cross blue shield maryland massachusett approv xeljanz us we appeal the whole process fast less two week i believ primarili i think doctor offic knew you feel free call doc offic also insur direct make sure realli submit correct specialti pharmaci spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post am gmt suzyq long spous prednison i see long took get wonder ive mg sinc april gis direct drop everi day so far good energi touch slow return eat still hook im current monday go day mg day assum xeljanz take uc ill get stuck whatev level i get stuck see spous experi im think either i need extend taper mayb suzyq spous pred high level year given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzyq regular member join sep post post pm gmt im realli glad hear xeljanz may work he steroid almost constant time diagnos even though full remiss octob xeljanz our lesson process gis understand prednison taper especi longterm he start feel quit ill oppos usual prednison lousi feel mg short breath memori issu usual also neuropathi seem get wors at point saw endocrinologist said taper correct may take longer shouldnt feel sick so went back slowli taper mg everi four week point went onto hydrocortison some depend toler feel lousi associ worri onc get mg may want go slower some peopl get low everi day see feel you alway go back level didnt feel lousi adjust thing go spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post pm gmt great advic one cut mg pred pill mani way dot powder thank i felt short breath occasion heart palpit like one week sluggish glad i ask year wow i cant imagin im pray uc symptom stay bay i taper cautious optimist thank share suzyq given clindamycin staph infect stye kick whole uc fun cdiff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred andrina veteran member join aug post post pm gmt stewiecat said i start notic improv coupl week xeljanz im doubledos x mg twice per day seem dose guidelin uc interest im take x mg i spoke pharmacist said dose uc i guess outcom im glad i fewer pill swallow uc sinc suzyq regular member join sep post post pm gmt nealzi there mg prednison tablet end need slowli taper spous diagnos uc remicad humira entyvio work onli thing work prednison march start xeljanz in remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week feelinglesscrappi new member join oct post post pm gmt i think prednison taper depend person length time prednison i year last mg done month i felt fine nealzi regular member join apr post post am gmt feelinglesscrappi that good know im drop mg start tomorrow path month day rough taper mg complet xeljanz hold mg',\n",
       "  'NN'),\n",
       " ('doe anyon know lemtrada effect alreadi lot lesion probabl ms long time i got diagnos rrms last year sudden onset symptom seem like i probabl ms quit year keep read lemtrada doesnt work dont earli i fifti realli would appreci guidanc there drug i could move one cladribin quit new even harder find much realli confus',\n",
       "  'NN'),\n",
       " ('the good news brain surgeri recoveri come along realli well ive even approv start drive jason take drive practic weekend howev life metastat lung cancer continu keep toe ive seem endless doctor appoint plan target radiat area surround remov cerebellum i also move new target medicin lorlatinib henc endless doctor appoint i penultim appoint entrectinib trial i current go washout period prepar expand access protocol trial lorlatinib as may recal crizotinib washout withdraw power med remark pain everi muscl bodi ach even muscl i didnt know i on monday i radiat plan appoint there radiat session everi day begin follow week the main side effect fatigu im even fatigu surgeri yet i due begin eap lorlatinib tuesday wednesday side effect come along one fatigu oh dont get wrong i immens grate treatment option i grate anoth target med switch and anoth trial one i grate i well enough withstand treatment i immens grate time famili but i admit lot deal i know everi day i treatment anoth day i get live i grate but day almost overwhelm i grate support communiti support i go lean next week thank much folk brought meal famili recoveri it comfort i cant help share particular ador theme meal receiv great work jenni tast great in news novemb lung cancer awar month the rosder rais money research treatment rare cancer i start fundrais back th birthday rais i reviv hope hit here link donat httpswwwsupportalcforgrostoritomalia also make sure get vote tuesday as natur citizen i take vote serious so serious fact i vote absente mail ballot hit road surgeri i didnt know kind shape i would novemb way i go miss vote post tori tomalia pm email this blogthi share twitter share facebook share pinterest label advocaci brain metastasi brain surgeri clinic trial communiti entrectinib lorlatinib ros stage iv stereotact radiosurgeri comment unknown said you continu amaz blog tori god bless may continu give strength fight horrid diseas pm anna brogan knight said send love energi pm anonym said glad hear surgeri smooth loratinib got approv past friday recheck doctor whether wash period i would minim best wish famili pm dearmaizi said your grace persever face challeng inspir thank share experi pm paul said this comment remov blog administr am monika davar said your courag stamina face battl inspir my lab work ros even frustrat time research stori journey fight realli keep us go work thank share best good recoveri am shaadi foral said veri use inform thank share you may read',\n",
       "  'NN'),\n",
       " ('ocrevus that matern grandmoth name old countri what coincid', 'IN'),\n",
       " ('the bad news multipl sclerosi drugmak coverag get narrow and even wors news the spread best worstcov med get wider the formulari show big drop overal ms coverag sank last year accord numbercrunch bernstein analyst formulari exclus also gone of track commerci plan use strategi lead exclus exposur commerci cover live analyst ronni gal wrote wednesday note client the gap have havenot expand tooand rule see chang prescript trend parallel coverag gal wrote the except note bottomfeed aubagioth oral therapi sanofiwhich seem quit well despit poor coverag mark teva blockbust copaxon lead pack term coverag follow biogen tecfidera avonex and there payer pressur come gal predict whenev addit product get market see round price correct figuresand addit product certain way roch one close watch prospect ocrelizumab come pipelin gal forecast last summer med would increas intermedi term formulari pressur expand scope payer avail choic read',\n",
       "  'JJ'),\n",
       " ('definit apolog shakespear im perplex stage crohn the norm becom i go day wo singl bm this total opposit i suffer year main so i start add gastric regul could bm day but regul caus lower right quadrant cramp sometim sever stab pain took remicad dose yesterday discuss issu doctor gave remi she ask whether i get cramp constip i said perfect fine cramp hit i bms she explain constip caus blood clot i got recent she recommend i continu regul i mention gi decid last time i saw i start slower taper budesonid reach mg pace i mg cortiment budesonid act colon steroid general almost year im steroiddepend when i get spasmod sooth pain i becom constip wherea i take regul i bm pain hit thing cant continu like i complain problem almost three month overshadow dental abscess hasnt clear till gerd perian fistula cd ib persist mouth ulcer fissur med remicad cortiment nexium imuran colifoam month b inj pred mg oct till jan previous mesalamin tablet supp failedazathioprin generic methotrex',\n",
       "  'NN'),\n",
       " ('i agre minim risk cancer mole biolog there newer gut specif biolog like entyvio stelara may affect mole im specul may want discuss gi dermatologist oncologist keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara sulfasalazin rotat antibiot',\n",
       "  'NN'),\n",
       " ('fact first comment keynot this phase iii trial compar pembrolizumab pembro placebo plus pemetrex carboplatin firstlin therapi metastat nsclc n random patient stratifi base pdl tumor proport score after median followup month median overal surviv reach pembro arm vs month control arm as compar patient control arm patient receiv pembro less like die overal high pdl score group less like die p the median time diseas progress month control arm patient pembrochemo p present keynot leena gandhi md phd director thorac medic oncolog laura isaac perlmutt cancer center nyu langon health the rational studi see io might add chemo rather see chemotherapi immunogen add expand benefit io monotherapi patient might high pdl express inde see alic t shaw md phd director center thorac cancer massachusett general hospit cancer center this landmark studi establish triplet new standard care advanc nonsquam lung cancer improv os addit pembro standard chemo across patient regardless pdl status realli strike checkmat nivolumab nivo plus ipilimumab ipi vs platinumdoublet chemotherapi firstlin treatment advanc nsclc note this studi amend includ coprimari endpoint base propos new biomark tumor mutat burden tmb high tmb defin greater mutat per megabas mutmb this interim report relat patient tmb status avail n random phase iii trial there patient identifi high tmb receiv nivoipi receiv standard chemo at minimum followup month ioio patient high tmb less like diseas progress compar chemo patient p patient tmbmutmb show differ benefit treatment arm the durat respons one year vs favor ioio treatment group p valu given present checkmat matthew hellmann md memori sloan ketter cancer center overal sens studi opportun introduc two new standard care patient nsclc first studi demonstr clinic valu nivo plus ipi treatment option patient tmb high durabl benefit spare st line chemo therebi preserv effect nd line option second studi valid tmb import independ biomark routin test treatment nave advanc nsclc patient texa talk comment investor event sponsor bloomberg intellig day prior aacr confer john heymach chair thorac cancer program md anderson cancer center specul outcom two trial regard keynot this alreadi wide use regimen keynot g result report realli surpris hazard ratio pfs so result look practic chang result look practic confirm result g power surviv for confirm pfs would solidifi regimen front line the hr report today regard use frontlin pdl high express communiti oncologist less experi nivoipi outsid melanoma yes manag there chemotherapi side effect there good chanc patient prefer io first delay chemo later but uneas ioio checkmat versus pembro easi give the question high pdl express qualifi ioio pembro monotherapi peopl go give that battl regard use tmb treatment manag decis cost major issu if use tmb approv interest see a lot differ assay produc tmb mani center smaller panel includ typic run plus gene mayb isnt enough right get good tmb data so mean center go chang use foundat medicin this signific potenti barrier adopt a view the street a quick qa patrick river vice presid research aquillo capit obr of result today strike find river the hr kn realli impress the strength phase ii data much smaller group patient enough get regimen approv firstlin nonsquam nsclc result substanti goto regimen broad number patient i surpris abl demonstr benefit egfr alk mutant patient well obr the result today dont realli suggest winner what would need see yet unseen would true differenti two pd drug river i dont believ nivolumab pembrolizumab appreci differ term actual drug properti they test differ clinic set differ patient select strategi like given rise differ result observ the way truli differenti would test headtohead know isnt go happen one question hasnt answer may critic move forward much benefit observ pd plus chemo look tmb stratif we ipi plus nivo vs chemo obr given scienc background river came bench tmb vs pdl stain opinion util river they independ variabl play import role may repres differ biolog principl pdl marker inflamm tmb surrog neoantigen burden i surpris show correl one anoth independ predict likelihood respons differ popul examin the key distinct pdl stain cheaper faster wellintegr routin patholog current util it sever year nextgen sequenc panel give tmb readout routin clinic practic obr do data swamp conceiv metoo is reason pursu nextgen anti pd river i dont believ reason pursu addit generat pd monoval antibodi what still need explor addit combin reveal new element biolog there mani environment factor tumor proper address pd ctla chemotherapi alon bispecif antibodi bind pdl one arm anoth target anoth arm may also yet reveal interest new approach overlap current pd use case a final word pepsi vs coke dr hellman the result two studi zero sum this huge step forward patient anyway look two posit phase iii studi differ complimentari messag use anti pd therapi firstlin set huge advanc although new question answer make best decis firstlin set great question grappl so im realli pleas data togeth by neil canavan soleburi trout',\n",
       "  'NN'),\n",
       " ('home ms inform public the motiv the motiv summerfal health well shingl overview vaccin safeti health well shingl overview vaccin safeti live attenu vaccin may issu individu ms compil susan well courtney review jack burk md shingl an overview shingl caus reactiv varicella zoster virus vzv virus caus varicella chickenpox this usual occur decad initi chickenpox infect the reactiv virus caus pain rash cluster fluidfil blister shingl contagi blister dri virusfil fluid transmit chickenpox someon previous expos virus come close contact open rash other symptom shingl includ fever headach chill upset stomach last week month even year postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain area rash occur this chronic debilit pain vari mild sever disrupt one sleep mood activ daili live phn reduc one qualiti life potenti lead social withdraw depress even suicid report scar anoth potenti longterm complic shingl rare case shingl infect lead pneumonia hear problem blind brain inflamm enceph death while peopl one episod shingl second third episod possibl for older individu ms risk shingl complic great without ms individu ms take immunosuppress medic associ risk becom even greater everyon risk shingl great increas get older particular age the risk develop phn caus continu chronic pain complic shingl increas age likelihood experienc longer last sever pain phn addit individu compromis suppress immun system also like experi complic shingl the shingl vaccin accord center diseas control prevent cdc vaccin shingl also known herp zoster zoster recommend use peopl year older reduc risk shingl this includ everyon age group contraind well peopl previous episod shingl andor chronic medic condit the specif chronic medic condit list cdc includ kidney failur diabet rheumatoid arthriti chronic pulmonari diseas the shingl vaccin approv food drug administr fda market brand name zostavax the shingl vaccin given one dose subcutan skin arm common side effect vaccin includ red sore swell itch shot site headach after receiv vaccin individu may around infant young children pregnant women peopl weaken immun system report made someon get chickenpox anoth person receiv shingl vaccin some peopl may develop chickenpoxlik rash near inject site if occur simpli precaut rash cover disappear the shingl vaccin contain thimeros preserv contain mercuri sometim use vaccin no serious advers event seen shingl vaccin test approxim peopl without ms age older the vaccin appear effect least six year may last longer while older individu may get vaccin age appear effect peopl year studi found shingl vaccin reduc risk shingl percent older adult reduc risk phn percent also reduc sever durat pain associ phn the safeti shingl vaccin difficult judg individu ms the current data support use reassur complet vaccin fulli investig ms the shingl vaccin thorough investig ill includ peopl whose immun system may compromis diseas drug use treat diseas the shingl vaccin live attenu vaccin issu individu ms mani vaccin use virus inactiv ie kill virus chanc infect anyon the shingl vaccin contain live virus attenu mean strength reduc point cant infect someon healthi uncompromis immun system as mani individu various health condit larg number individu ms take medic may modul suppress immun system a livevirus vaccin may conceiv abl infect someon whose immun system fulli function result either ill medic given treat ill in addit fdaapprov longterm diseasemodifi therapi ms larg dose extend use steroid frequent prescrib treat ms relaps also suppress immun system less common treatment consid evalu safeti shingl vaccin includ experiment treatment ms studi clinic trial ms patient offlabel treatment methotrex imuran azathioprin hematopoiet stem cell transplant hsct antivir medic guidelin shingl vaccin safeti accord extens report advisori committe immun practic harpaz r et al differ treatment need consid shingl vaccin may consid safe individu this report origin nation center immun respiratori diseas divis viral diseas part center diseas control prevent to follow general guidelin as remind individu strong advis consult physician safeti shingl vaccin doctor need look person situat casebycas basi individu get shingl vaccin wait includ anyon ever lifethreaten sever allerg reaction gelatin antibiot neomycin anoth compon shingl vaccin an individu weaken immun system hivaid diseas affect immun system someon take medic weaken immun system peopl immunosuppress therapi includ highdos corticosteroid mg per day prednison equival last two week wait least one month discontinu therapi anyon moder sever acut ill includ anyon temperatur degre fahrenheit higher usual wait recov get vaccin individu may receiv vaccin includ anyon minor acut ill cold may vaccin peopl receiv shortterm corticosteroid therapi less two week lowtomoder dose less mg per day prednison equival topic given via nasal skin inhal administr longterm alternateday treatment low moder dose shortact system corticosteroid consid suppress immun system enough caus concern vaccin safeti therapi lowdos methotrex equal less mgkgweek azathioprin equal less mgkgday consid suppress immun system enough caus concern vaccin safeti special group circumst peopl previous shingl may vaccin although need wait rash clear peopl normal immun system anticip immunosuppress pleas see next bullet point without prior shingl vaccin receiv vaccin soon possibl immun intact vaccin administ least day initi immunosuppress therapi although expert advis wait one month accord msaa chief medic offic jack burk md most ms drug consid immunosuppress consid immunomodul affect immun system differ nonetheless recommend patient consult doctor regard cdc recommend for exampl recommend gilenya fingolimod immun day start gilenya in regard individu receiv recombin human immun mediat immun modul especi antitumor necrosi factor agent adalimumab infliximab etanercept safeti efficaci shingl vaccin administ concurr unknown if possibl administ vaccin initi therapi patient immun status assess physician determin relev risk benefit otherwis vaccin defer least one month stop medic this categori would includ ms medic tysabri natalizumab well mani experiment therapi present clinic trial lemtrada alemtuzumab former campath daclizumab also known zenapax rituxan rituximab ocrelizumab ofatumumab also known arzerra individu take one drug advis talk doctor assess risk benefit shingl vaccin conjunct type diseasemodifi therapi peopl receiv blood product includ antibodycontain blood product may receiv shingl vaccin time list includ intraven immun globulin ivig plasma exchang would also fall categori specifi report patient receiv type treatment advis consult physician get shingl vaccin experi individu undergo hematopoiet stem cell transplant hsct limit consid casebycas basi patient immun status assess physician determin relev risk benefit shingl vaccin approv administ least two year month transplant antivir medic may interfer replic livevirus vaccin anyon take zovirax acyclovir famvir famciclovir valtrex valacyclovir regular discontinu medic least hour administr shingl vaccin possibl these medic use least day vaccin addit note shingl vaccin accord cdc shingl vaccin may given simultan vaccin includ flu vaccin each vaccin must administ use separ syring differ inject site if vaccin administ time shingl vaccin may still given time vaccin provid inactiv vaccin if receiv anoth live attenu vaccin addit shingl vaccin time patient need wait least four week shingl vaccin receiv differ live attenu vaccin the shingl vaccin recommend anyon receiv varicella chickenpox vaccin howev chickenpox vaccin becom avail unit state virtual peopl receiv vaccin chickenpox young receiv shingl vaccin for reason the cdc state healthcar provid need inquir one varicella vaccin histori sinc virtual person recommend age group least next decad receiv chickenpox vaccin addit cdc note anyon older without contraind get shingl vaccin regardless whether rememb chickenpox studi show percent american age chickenpox patient need ask histori chickenpox blood test antibodi insur coverag resourc the follow inform provid cdcs websit wwwcdcgov the shingl vaccin avail pharmaci doctor offic to find local facil offer vaccin pleas visit wwwzostavaxcom all medicar part d plan cover shingl vaccin costshar vaccin vari medicar part b cover shingl vaccin medicaid may may cover vaccin most privat health insur plan cover vaccin peopl age cover peopl age the merck vaccin patient assist program provid free vaccin elig adult usual individu without insur for inform pleas visit wwwmerckcommerckhelpsvaccin homehtml call vaccin inform statement avail spanish languag pleas see wwwimmunizeorgvi interest individu may also go cdcs websit inform shingl visit wwwcdcgovvaccin vpdvacshinglesdefaulthtm for inform vaccin ms pleas refer msaa onlin articl vaccin safeti ms news msaa for more inform in addit msaa websit individu may call msaa inform ms treatment question msaa client servic depart may email refer much inform articl obtain center diseas control cdc prevent harpaz r et al recommend advisori committe immun practic acip nation center immun respiratori diseas center diseas control prevent back',\n",
       "  'NN'),\n",
       " ('by ami tsang andrew pollack novarti bolster portfolio multipl sclerosi treatment friday agre buy experiment drug glaxosmithklin billion compani said novarti swiss pharmaceut giant acquir right year use drug ofatumumab treat cancer sell name arzerra this part broader swap asset complet march novarti took glaxo cancer drug glaxo took much novartiss vaccin busi the deal announc friday give novarti remain right ofatumumab develop treat relaps remit multipl sclerosi autoimmun condit have right one ownership would avoid complic could aris two compani sell drug differ use the deal also bolster portfolio drug novarti develop multipl sclerosi center around blockbust pill gilenya novarti pay million upfront glaxo anoth million latestag clinic trial start novarti would make payment million top depend whether develop target reach the compani also pay royalti percent glaxo futur net sale drug novarti pleas reinforc commit neurosci add excit new treatment strong ms portfolio david epstein divis head novarti pharmaceut said news releas in addit gilenya novarti sell multipl sclerosi drug call extavia recent began market generic version teva copaxon one wide use drug diseas it also drug develop gilenya could lose patent protect start so fill loss could anoth reason novarti want new drug but market multipl sclerosi drug crowd could limit sale new drug like ofatumumab could moreov ofatumumab readi enter latestag clinic trial put coupl year behind ocrelizumab similar drug develop roch both drug deplet b cell white blood cell part immun system b cell necessari fight infect go awri contribut autoimmun diseas like multipl sclerosi lymphoma both drug bind molecul surfac b cell known cd roch bigsel cancer drug rituxan rituxan approv multipl sclerosi approv treat rheumatoid arthriti anoth autoimmun diseas ofatumumab type protein call monoclon antibodi develop initi genmab danish biotechnolog compani receiv royalti sale david redfern chief strategi offic glaxo said news releas sale would allow compani focus core area includ hiv oncolog vaccin we pleas complet transact divest remain right ofatumumab crystal signific addit valu gsk sharehold mr redfern said the deal expect complet end year',\n",
       "  'IN'),\n",
       " ('aabreu i took inject form cladribin offlabel ms treatment the peopl bart london develop protocol i follow i got neuro prescrib drug found special pharmaci sacramento would sell i subq inject home it easi toler i abl miss work day minim blood monitor requir has stop ms i pretti sure slow lot year sinc i start my ms nonrelaps type easi tell i also take simvastatin potenti neuroprotect mgday biotin i realli wish i could taken back i much nerv damag the fact cladribin small molecul get brain lymph node slowli deplet b tcell make think drug best chanc slow progress ms the bart websit lot info cladribin httpmultiplesclerosisresearchblogspotcomcladribinemshtml it took fair amount effort get go most peopl comfort let selfinject iv cancer drug home send pm want info',\n",
       "  'JJ'),\n",
       " ('thank you wk i preach sever year i may borrow cynic so thank im big fan i wrote blog i diagnos admit i slack i conveni recipi treatment cure year i also know rituxanocrevus controversi yes i ocrevus damn i would bet donut dollar cure right now need figur hey make money wk im mad moment',\n",
       "  'NN'),\n",
       " ('these link news stori last week may interest peopl uk the link beneath item take origin stori pleas note ms trust write origin item endors content claim made to keep date latest news view research multipl sclerosi sign open door free newslett regular email alert cognit affect abil work peopl ms employ reduc hour like show sign cognit symptom accord uk studi sourc ms news today ms trust link think memori problem gender differ diagnosi a review trend diagnosi found proport women men diagnos grow women averag diagnos five year younger in primari progress ms slight men women diagnos averag age diagnosi around sourc ms news today ms trust link diagnosi rare gilenya side effect warn the fda us drug regul issu warn peopl stop gilenya fingolimod may experi wors symptom start treatment the effect describ rare recommend stop drug requir monitor sourc naton ms societi usa sourc medpag today ms trust link gilenya fingolimod fampyra turn scotland the scottish medicin consortium smc turn fampyra fampridin second time sourc ms news today ms trust link fampyra fampridin',\n",
       "  'NN'),\n",
       " ('okay look everyon list awesom list get complet hard agre everyth everyon said first ive come two sit repli drive nut today much like erash annoy symptom one bother present moment my specif everi singl morn drive nut i go stiff throughout entir bodi torso leg sometim i slide right chair without abl stop it realli stink over past sever infus ive ocrevus seem control sever month much much better this past infus earli januari though effect specif i ask what who know second ive athlet well coordin person entir life ms robb it drive nut tri take someth simpl straw get hand put straw hole cup i drink water my hand simpli respond mind tell quit often i truli hate enough im go go back work face theyr awesom i love everi one fanci',\n",
       "  'FW'),\n",
       " ('by jose e martnezrodrguez more particip attend nd congress european committe treatment research multipl sclerosi ectrim st annual confer rehabilit ms london septemb th toth the congress highlight last updat news ms field regard scientif clinic research present sever parallel session describ recent advanc neuroprotect neurodegener repair remyelin neuromyel optica neuroimmunolog symptomat therapi new techniqu neuroimag cis prognosi ms cognit comorbid diseas rehabilit sever present focus area innat immun system increas promin role myeloid cell antigenpres cell effector cell neuroinflamm recogn a benefici effect block mac fibrin receptor shown experiment murin model support involv innat immun system ms open potenti therapeut pathway futur new advanc present immunolog lymphocyt migrat cns particip neuroinflamm regard involv integrin alpha dicam alcam claudin further work assess sever aspect cortic patholog ms studi base intrathec inflamm new anim model cortic lesion the area gut food ms also extens cover studi support link gut microbiota immun regul research remyelin oligodendrocyt ongo describ potenti pathway favor myelin repair oligodendrocyt regener on clinic side ectrim provid addit evid diseasemodifi drug dmd start earli possibl confid diagnosi made order delay irrevers disabl differ argument support escal versus induct therapi sever studi present assess convent new risk model predict diseas evolut innov concept therapeut inertia brilliant introduc drgsaposnik failur escal therapi evid diseas activ dmdtreat patient compel ms physician assert upcom chang field ms treatment research environment factor continu evalu regard influenc herpesvirus smoke obes pregnanc vitamin d ms the search biomark ms assess risk stratif ongo highlight use serum neurofilamentlight chain level promis biomark assess diseas activ disabl result sever clinic trial neuroprotect amilorid lipoid acid fluoxetin also present variabl result a special mention goe negat result phase b clinic trial present drdcadavid evalu opicinumab antilingo relaps ms even though primari endpoint studi reach subanalysi result encourag investig keep go area remyelin studi bcell implic ms hot topic ectrim year import number present describ sever aspect bcell biolog ms the huge swedish experi offlabel use rituximab present drfpiehl retrospect compar anticd monoclon antibodi fingolimod natalizumab while await final public clinic trial perform ocrelizumab rrms ppms new data present ectrim describ safeti profil drug support posit clinic radiolog efficaci ms patient meanwhil studi anticd deplet therapi ofatumumab move forward phase iii drlkappo present much expect preliminari result phase iii studi siponimod secondari progress ms describ effect risk reduct threemonth confirm disabl progress subanalysi evalu result accord clinic activ edss time diseas evolut moreov evid present support clinic radiolog efficaci upcom new drug cladribin daclizumab special attent deserv first present ectrimsean clinic practic guidelin pharmacolog manag ms joint effort societi the guidelin await public introduc drsusana oteroromero use evidencebas recommend follow grade methodolog guidelin establish recommend consensus statement concern dmd manag ms patient some concern rais among audienc definit qualifi center ms treatment present general recommend base infrastructur avail assess treat patient capabl deal potenti side effect requir clarif aspect aim guidelin fulli implement routin clinic ms practic europ never ms field got mani differ drug avail clinic use better measur outcom predict prevent futur diseas although still far comprehens view better understand ms develop progress studi sponsor pharmaceut industri paramount battl ms howev want fulli defeat diseas futur nation intern collabor addit need answer question industri never go address drmhutchinson remain us clinic highlight present as result clinic trial ms shown us last year learn failur even abl proper manag success best ms communiti thank collabor effort huge amount differ profession specialti ectrim one event feel inflect point understand manag ms reach jose emartnezrodrguez md phd associ professor neurolog universitat autnoma de barcelona ms unit neurolog depart hospit del mar imim passeig martim barcelona email disclosur jose emartnezrodrguez receiv academ research grant merckserono biogen travel support andor compens lectur andor particip advisori board bayer roch merckserono',\n",
       "  'NN'),\n",
       " ('del gefitinib exhibit increas flexibl compar afatinib the increas flexibl observ gefitinib general aris noncoval natur interact kd contrast afatinib make coval bond cys kd restrict mobil due increas flexibl gefitinib water mediat halogen bond interact stabl result loos bound trap water molecul in contrast erlotinib lack halogen atom reduc interact result higher flexibl one loos bound water molecul resid time ns complex egfr wt egfr lr egfr',\n",
       "  'NN'),\n",
       " ('thankyou word true im day first lucenti inject keep think wont work drive crazi im scotland would mean lucenti made differ would tri eyelea ive read one im hope caught time i week total distort appear get inject sight deterior i went normal optician soon happen refer hospit i wait week get seen consult inject week later would day clinic full sinc inject ive notic chang eye fine',\n",
       "  'NN'),\n",
       " ('hi carolin it great hear anoth aussi were region vic coupl hour melbourn i wouldnt thought would take long im also impress ms neuro i pick mayb see new one come week get done mark urgent im definit follow info ocrevus reason someth follow tysabri ifwhen becom jcv i hope get asap wonder drug thank good wish actual bounc back brilliant time it steroid infus finish pretti much back i realli realli want keep way long possibl',\n",
       "  'NN'),\n",
       " ('no sarcasm intend i work st bartholomew hospit centr cancer research deal complic hsct week basi these rang graft vs host diseas pml leukoencephalopathi develop new autoimmun disord idiosyncrat se blind pulmonari emboli guillain barr syndrom hsct appeal clinician but clinician use also know manag complic lui high dose chemo follow autolog haematopoiet sct treatment pcnsl hsct provid good outcom atrophi better say natalizumab the sheffield group complet studi hsct versus tecfidera gilenya tysabri nov mayb theyll report next aan id interest see result',\n",
       "  'NN'),\n",
       " ('im glad vision respond fair well lucenti im similar place requir month inject eylea we tri increas interv everi five week didnt work happi holiday',\n",
       "  'JJ'),\n",
       " ('i diagnos earli may neurologist suggest either lemtrada tecfidera also mention ocrelizumab said would avail next year effect i think shock diagnosi start first full blown relaps i get i opt tecfidera i start day said i would like swap ocrelizumab next year i hope goe plan especi sinc discov site i read mani posit comment lemtrada i realis everyth within nhs take long timeit funni i told stress make ms wors yet stress i suffer worri time take get treatment',\n",
       "  'JJ'),\n",
       " ('pd my crp low flare soon i start reduc med prior surgeri start rise my sed rate entir time alway elev i alway pancol backwash ileus they alway thought i uc even colectomi bioposi my surgeon well known crohn surgeon crohn surgic procedur name said pretti confid i uc remov colon keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('mlgilber i would assum hes make suggest let continu i choosemi appoint discuss ive briefli talk phone far im definit consid switch neurologist alreadi obvious hes respect decis definit switch i dont get i would switch doesnt seem good argument did neuro bring major longterm side effect concern ocrevus ive never told',\n",
       "  'VBD'),\n",
       " ('have correl made time taken becom resist patient receiv st nd rd generat tkis for exampl patient becam resist tarceva month would expect similar time frame patient exhibit resist take afatinib tagrisso thank jacki',\n",
       "  'JJ'),\n",
       " ('ikhlaq the standard treatment brain metastas radiat high rate success tend provid symptom relief faster system therapi chemo target therapi although alectinib long track record success radiat option but make choic would import consid current level symptom brain met whether symptom get wors relat quick more significantburdensom symptom fast rate progress symptom would tend tilt balanc favor radiat if met less symptomat reason tri alectinib if followup scan doesnt show effect symptom start get wors radiat would still option if alimta stop due side effect diseas progress could tri point like brain met brought control alimta use treat diseas rest bodi jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'NN'),\n",
       " ('cora interest thing articl studi evid lucenti eye inject may effect laser this trial peopl it found',\n",
       "  'NN'),\n",
       " ('greater patient select may need first line nivolumab improv progressionfre surviv chemotherapi advanc lung cancer checkmat trial gave negat result broad group patient express pdl tumour cell the find present esmo congress copenhagen nivolumab repres standard care secondlin treatment advanc nonsmal cell lung cancer nsclc improv overal surviv compar docetaxel phase iii trial patient said lead author dr mark a socinski execut medic director florida hospit cancer institut us in first line set nivolumab show promis respons rate phase i trial advanc nsclc patient greater pdl express tumour cell continu the phase iii checkmat trial investig efficaci first line treatment nivolumab compar platinumbas doublet chemotherapi patient advanc nsclc pdl posit tumour defin present tumour cell patient egfr activ mutat alk transloc sensit target therapi exclud the primari endpoint progressionfre surviv assess independ radiolog review committe patient pdl tumour cell a total patient randomis nivolumab chemotherapi patient progress chemotherapi could crossov nivolumab second line treatment in patient greater pdl express progressionfre surviv month nivolumab month chemotherapi hazard ratio hr confid interv ci p overal surviv month nivolumab versus month chemotherapi hr ci among treat patient serious treatmentrel advers event nivolumab chemotherapi respect there new safeti signal nivolumab less toxic chemotherapi said socinski there number possibl reason disappoint progressionfre surviv result ad regard overal surviv high rate crossov immunotherapi chemotherapi arm overal surviv chemotherapi arm better histor standard could due fact greater proport women asian patient we conduct analys evalu result platinumbas chemotherapi standard first line treatment make patient live longer palliat symptom said socinski if go replac immunotherapi need confid identifi patient deriv greater benefit socinski conclud combin immunotherapi may increas proport patient benefit first line the phase iii checkmat trial investig treatment nivolumab plus ipilimumab first line set relat standard chemotherapi comment result professor johan vansteenkist professor medicin cathol univers leuven chief oncolog physician unit respiratori oncolog univers hospit ku leuven belgium said nivolumab improv progressionfre surviv chemotherapi studi in view reason trial includ broad rang patient low pdl express threshold greater standard first line treatment platinum doublet chemotherapi give progressionfre surviv six month beat may requir select receiv drug he continu more research need use pdl biomark select patient treatment nivolumab in addit phase i studi suggest combin immunotherapi improv respons rate outcom expens increas toxic compar singl agent immunotherapi nsclc so import investig strategi sourc esmo',\n",
       "  'VBD'),\n",
       " ('imuran pretti safe drug peopl ive mp sister med coupl year zero sideeffect you may get nausea week two first start that normal goe away vast major peopl as rarer serious sideeffect that blood test detect problem i would strong recommend go imuran take month start work slowact drug as scd diet work i would take amaz testimoni pinch salt not discourag ive seen lot peopl crohn uc forum hasnt help but wont know unless tri mean give go month see goe or consid tri ibdaid diet updat version scd slight less restrict wwwncbinlmnihgovpmcarticlespmc high drop rate one stuck diet everybodi saw improv symptom although nobodi appear go complet remiss diet dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('in canada rate ibd would highish mayb statist pancol uc sinc sept averag bmsday time respons remiss therapi salofalkasa enema oral g clinic trial drug fail therapi entyvio antimadcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       "  'NN'),\n",
       " ('i fail remicad cimzia humira entivyo sigh insur wont cover stelara experiment unsubstanti are sure experiment the fda approv stelara last year crohn if appeal decis probabl good chanc win appeal id get gis offic involv appeal also state insur regul keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri total hip replac thank prednison current condit chronic pouchiti not bad i thought would current med stelara',\n",
       "  'NN'),\n",
       " ('hi ub how tall lb doesnt sound overweight im feel slight overweight lb weight stay steadi sinc last surgeri ill never natur sylph i come short irish peasant stock look like short irish peasant stock but i cant bother diet i think occasion i lose live thought caloriecount drop thought i went obsess food calori i realli underweight year ago due crohn cours i think larg part scare go back eat disord way i would starv lose weight now i like feel eat enough feel full not stuf decent full enough keep go sever hour without feel hungri think food sorri horribl obvious question consid gym just lose weight walk lot doesnt give good bodi i found i becam skinnyfat much els to actual welldefin bodi flat stomach etc either need right gene hit gym spend lot time work dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start notsosicklygirl forum moder join dec post post pm gmt i thank hear your much better i dont know anyth stelara i know i feel well i eat lot you suffer long perhap your indulg bit your activ level diet sound good though fact your gain strang pound lot gain short time have thyroid check gone gp test the time i went normal weight type weight prednison moder uc current med step jpouch surgeri complet step complet step complet from sick uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       "  'JJ'),\n",
       " ('updat i first treatment ocrevus morn last hour my sideeffect metal tast mouth lump throat after alert nurs slow current treatment sideeffect clear around minut i feel went well look forward second cours two week everi six month disclaim everybodi differ react differ diseas modifi drug pleas seek advic neurologist ms specialist',\n",
       "  'JJ'),\n",
       " ('myopic cnv haemorrhag imag courtesi adrian koh md frcs the avail antivegf agent intravitr ranibizumab lucenti genentech revolutionis manag various form ocular neovascularis includ myopic cnv mcnv accord professor adrian koh md frcs the current gold standard treatment myopic cnv antivegf therapi achiev good visual result minim number treatment unlik agerel macular degener cnv prof koh said th euretina congress barcelona myopic cnv sightthreaten complic patholog myopia characteris neurosensori detach subretin haemorrhag fibrot membran format said prof koh in individu patholog myopia cnv develop approxim eye caucasian approxim asian said sever theori put forward explain caus mcnv said prof koh the mechan theori posit excess elong retina associ chang caus imbal angiogen antiangiogen factor therebi trigger condit the heredodegen theori argu refract error genet predetermin hemodynam theori propos perfus chang choroid circul myopic eye possibl caus standard test diagnos mcnv includ fundus biomicroscopi fluorescein angiographi optic coher tomographi oct fluorescein angiographi demonstr leakag cnv still current gold standard diagnosi said prof koh prior introduct antivegf agent verteporfin photodynam therapi vpdt approv treatment mcnv said prof koh pdt shown benefit placebo two year may delay visual acuiti deterior howev improv vision may induc chorioretin damag leakag cnv may persist said the introduct antivegf treatment chang paradigm mcnv manag in radianc trial ranibizumab demonstr letter gain median two inject said prof koh more patient treat ranibizumab gain letter month proport patient cnv leakag intraretin oedema decreas ranibizumab group a recent trial intravitr aflibercept eylea bayer pharma ag mcnv demonstr clinic import visual anatom benefit limit inject conclud prof koh adrian koh',\n",
       "  'NN'),\n",
       " ('msk sever clinic trial evalu immunotherapi various sarcoma type you learn httpswwwmskccorgcancercareclinicaltrialssearchkeysimmunoth if sarcoma carri type mutat call mmr defect may also treatabl immunotherapi drug pembrolizumab this therapi approv fda cancer carri mutat requir particip clinic trial thank comment',\n",
       "  'NN'),\n",
       " ('henri wrote i question patient opdivo told avoid sunlight exposur ani new updat keytruda opdivo i folfox butt i told avoid sun if i rememb correct make suscept sunburn are take opdivo alon conjunct chemo lee',\n",
       "  'NN'),\n",
       " ('phi not round cisplatinalimta with steroid mani bag fluid gave round i look like pillsburi doughboy right infus by second one face eye even swollen this gradual went away had nausea even learn peppermint candi work well better pain med had constip food issu food tast realli nasti peppermint lemon ice cream tast pretti good also donut so i wasnt healthi eater but i didnt lose weight thank steroid the thing i think infus long it took hour and youll read elsewher best bet keep record symptom first time plan deal theyll time infus by last one i tire drench night sweat i lost hair textur becam fine continu lose afterward so everyon differ experi if bring symptom forum youll get good suggest way deal hope goe well destroy littl evil cancer critter judi m',\n",
       "  'NN'),\n",
       " ('hi sch i sorri hear uncl diagnosi as note wife nsclc her mutat similar exon mutat egfr differ relat protein i agre janin found exon group help lot inform current develop treatment exon mutat they may suggest thing talk oncologist as mix result chemo definit in two case line treatment great lung noth liver tumor in case howev line treatment seem effect tumor although differ degre work better liver better lung my wife cancer hip seem good indic treatment work pain goe away quick pain come back usual treatment work overal for wife carboalimta work great alimta alon well opdivo she two clinic trial one work month one mix result the standard chemotherapi carbo gemzar abraxan type taxol one actual work best overal pleas let know question i answer i wish famili new year full peac health scohn',\n",
       "  'NN'),\n",
       " ('nikki i sorri hear mom diagnosi i daughter mom advanc stage lung cancer my mom non small cell adenocarcinoma current deal st recurr for bout mom receiv carboalimta keytruda her pdl she receiv cycl chemo keytruda went year keytruda she current treatment break due side effect you check first year mom treatment url my mom handl platinumbas chemo well first bout treatment the worst side effect sever acid reflux other great this time though mom didnt well she flu like symptom day nd infus so felt crappi day month combin treatment the import thing evid diseas near year i say hesit receiv result month ct scan tomorrow im alway scare i might jinx good news if question mom journey im happi share take care steff',\n",
       "  'JJ'),\n",
       " ('i could comfort bathroom instead one bathroom floor it access quantiti keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'JJ'),\n",
       " ('check httpmultiplesclerosisresearchblogspotcomcladribinehtml click cladribinem project top page',\n",
       "  'NN'),\n",
       " ('sharon this video releas two day ago excel inform current ms drug highlight ocrevus discuss current drug thought might find interest httpswwwyoutubecomwatchvjprsofdz',\n",
       "  'NN'),\n",
       " ('last may wife start combo tafinlarmekinist this combo show great promis melanoma trial patient braf ve mutat in melanoma mutat braf ve type soon smaller trial initi nsclc patient mutat abt lc patient this trial al show great promis earli last year trial longer admit new patient when reopen treatment naiv patient could consid my wife chemopaus time fortun got approv combo outsid trial two earlier scan show improv last week scan brought good news the groundless densiti resolv discret mass seen minim residu stabl sub pleural interstiti infiltr like reflect minor fibrot chang she continu treatment next scan month we grate gotten point fortun new better drug becam avail time benefit mani includ wife my wife yrs dx mar nsclc mbac ai mar lobectomi left ll lower ul scan may clean juli bilater ggos sep promin ggos dec worsen ggos w foci dens consolid feb scan growth met braf posit ve mar start carboalimta chemo follow alimta mainten initi shrinkag stabl till aptil june trial immunotherapi mpdla docetaxel was assign docetaxel late octob stop docetaxel cours side effect sever on chemo paus may start tafinlarmekinist combo initi sever side effect most high fever chill grade uveiti eye earli august reduc tafinlar dosag mg mg day kept mekinist mg day side effect manag scan earli aug late oct show improv latest scan wa',\n",
       "  'NN'),\n",
       " ('hi yo femal asian dx stage adneo del egfr tarceva almost year progress small progress almitacarbo cycl hold tissu biopsi tm lepid predomin adeno start tagrisso tomorrow repeat ct how long longest document durat progress free surviv tagrisso is lepid predomin histolog make differ respons tagrisso are good clinic trial patient develop resist tagrisso depend find someth grow biopsi see new mutat if one area grow sbrt help keep tagrisso go sorri mani question tri proactiv god bless help this topic modifi month week ago bfarz this topic modifi month week ago bfarz',\n",
       "  'NN'),\n",
       " ('i take humira imuran i felt aw flu like symptom dizzi i could bare function my mom also crohn stelara clinic trial hopkin shes take remiss im hope i success thank repli',\n",
       "  'NN'),\n",
       " ('mayb say repress immun system that work suppress bodi natur immun not but cours noth els work take question there show us cabl tv call the monster insid me it parasit i dont know mani episod discuss various parasit worm fungus bacteria larva everyday environ part harmless us normal immun system easili overwhelm someon compromis immun system while previous studi alreadi indic increas risk infect lymphoma evid publish journal american medic associ suggest remicad tripl risk skin cancer anoth black box issu describ cancer occur children young adult began take tnf blocker remicad humira cimzia along immunesuppress medicin mp the fda fix problem updat warn section drug label wwwhuffingtonpostcomrebeccakaplansocialsecurityadministrbhtml patient ibd depend medic antibiot antiinflammatori steroid immunosuppress control inflamm ulcer pain caus diseas while benefici medic caus sever side effect includ nausea vomit heartburn night sweat insomnia hyperact high blood pressur stunt growth children patient immunosuppress risk develop lymphoma tuberculosi kidney liver damag anaphylaxi seizur potenti serious fatal infect',\n",
       "  'NN'),\n",
       " ('dear jimc thank prompt thorough respons apolog i specif symptom thus far as far know sure progress diseas everyth happen fast past month my mother mention surgeri discharg hospit imag test perform after discharg followup dr chest pa show signific improv pleural effus hope control besid mani symptom mother start develop regular cough last day hospit seem worsen discharg cough almost gone we complet chang nutrit implement daili deep breath exercis could also combo tarceva work sure day tarceva could help cough quick she sleep around hour day occas activ short nap afternoon fatigu yet issu drastic chang life qualiti she experienc mild skin acn face sensit palat better bowel movement prior tarceva bowel movement would sporad usual resort sort laxat aid howev consist bowel movement could also due increas amount fluid water green tea drink natur vegetablesfruit consum no diarrhea like form surfac yet reach two week anniversari tarceva that partial reason crossroad administ adjuv wbrt moment hope well inform possibl we want regret influenti lifechang decis take know easier said hope done mani thank',\n",
       "  'NN'),\n",
       " ('in recent year excit develop treat lung cancer through genet test tumor sampl doctor identifi specif type lung tumor prescrib treatment design target immunotherapi also emerg treatment option certain type lung cancer these advanc made treatment effect often fewer side effect type lung cancer there two major type lung cancer nonsmal cell lung cancer nsclc small cell lung cancer sclc nsclc account percent lung cancer includ adenocarcinoma common form lung cancer unit state among men women squamous cell carcinoma larg cell carcinoma sclc tumor account remain percent lung cancer unit state they tend grow quick nsclc tumor tumor classifi stage stage base whether cancer local lung local advanc spread nearbi lymph node lung area metastat spread part bodi treatment option print email share tweet lungev lung cancer helplin cancer care partner lungev nation lead lung cancerfocus nonprofit organ provid lungev lung cancer helplin call lung view cancer care resourc help better cope lung cancer editor heather wakele md associ professor depart medicin divis oncolog stanford univers stanford cancer institut listen surgeri surgeri sometim combin chemotherapi common treatment option tumor confin lung advanc surgic techniqu allow doctor make much smaller incis remov tumor section lung affect cancer use videoassist thoracoscop surgeri vat surgeon insert tube call thoracoscop chest this devic light tini camera connect video monitor radiat therapi in case surgeri possibl mani local advanc cancer radiat therapi sometim use either alon combin chemotherapi these treatment may also use surgeri shrink tumor surgeri help prevent cancer come back recur extern beam radiat common use treat lung cancer standard extern beam radiat use machin direct beam multipl beam radiat tumor the use ct computer tomographi mri magnet reson imag pet positron emiss tomographi scan allow radiat oncologist accur target tumor shape radiat beam size dimens tumor help spare healthi tissu a newer form radiat call sbrt stereotact radiat stereotact ablat radiat therapi sabr sometim use treatment earlystag lung cancer instead surgeri sbrt deliv higher dose radiat shorter period time approach minim impact healthi tissu in patient high risk surgeri sbrt shown curat rate close expect rate surgeri ongo research tri determin patient could type focus radiat instead surgeri chemotherapi chemotherapi long effect treatment lung cancer continu one import element treatment mani patient chemotherapi extrem effect treat sclc also use treat nsclcs chemotherapi help patient earli stage cancer remov surgeri combin radiat local advanc cancer it also import part treatment patient advanc stage lung cancer chemotherapi drug approv fda treatment lung cancer includ cisplatin platinol carboplatin paraplatin these common medic use treat lung cancer most treatment approach includ either cisplatin carboplatin combin anoth chemotherapi drug pemetrex alimta pemetrex use combin chemotherapi cisplatin initi treatment advanc nonsquam nsclc pemetrex also approv use alon treat advanc nonsquam nsclc anoth chemotherapi given pemetrex use adenocarcinoma lung activ squamous cell lung cancer small cell lung cancer gemcitabin gemzar other these drug use treat nsclc either combin cisplatin carboplatin initi treatment singl drug chemotherapi given this drug work type nsclc paclitaxel taxol nabpaclitaxel abraxan docetaxel taxoter these drug form taxan chemotherapi given combin cisplatin carboplatin nsclc docetaxel frequent given alon later line therapi advanc stage lung cancer etoposid etopopho vepesid etoposid use combin cancer medic treatment sclc target treatment to destroy cancer cell target therapi focus specif cell mechan thought import growth surviv tumor these medic caus differ often less sever side effect chemotherapi research discov mutat gene call epiderm growth factor receptor egfr caus develop growth spread lung cancer approxim ten percent peopl lung cancer egfr mutat present tumor egfr inhibitor target therapi given pill form often use treat type lung cancer today four medic approv treatment option unit state lung cancer patient gene mutat erlotinib tarceva other the us food drug administr fda first approv use erlotinib lung cancer in erlotinib approv initi treatment patient nsclc spread part bodi certain type egfr mutat piec miss call delet egfr gene afatinib gilotrif in fda approv afatinib initi treatment metastat nsclc patient egfr gene mutat delet treat success erlotinib gefitinib iressa in juli fda approv gefitinib initi treatment patient nsclc whose tumor harbor specif type egfr gene mutat detect fdaapprov test osimertinib tagrisso in novemb fda approv osimertinib treatment patient nsclc whose tumor specif egfr gene mutat start regrow treatment erlotinib afatinib gefitinib if resist develop one drug tumor start grow newer egfrinhibitor drug call osimertinib tagrisso often work shrink cancer stop grow anoth gene mutat found lung cancer refer alk four target treatment fdaapprov option peopl whose cancer mutat crizotinib xalkori this treatment approv fda treat metastat nsclc tumor alk gene mutat crizotinib block mutat alk gene stop growth tumor in clinic trial found effect chemotherapi addit crizotinib approv treat peopl metastat nsclc tumor mutat ros gene ceritinib zykadia this medic approv peopl metastat alkposit lung cancer cannot toler crizotinib whose cancer continu grow treat crizotinib in approv newli diagnos patient alk posit lung cancer alectinib alcensa alectinib approv decemb patient lung cancer alreadi treat crizotinib as result larg clinic trial novemb alectinib approv given firstlin treatment choic prior treatment brigatinib alunbrig in april brigatinib approv patient alreadi treat crizotinib in june fda approv target therapi dabrafenib trametinib administ combin patient nsclc mutat braf ve gene detect fdaapprov test there gene mutat seen nsclc target therapi option may avail as gene mutat tend common adenocarcinoma type nsclc import patient adenocarcinoma discuss valu genet test oncologist becaus gene cancer cell evolv tumor may becom resist target therapi treatment medic meet challeng studi clinic trial cut off blood suppli tumor anoth approach destroy cancer cell chang blood suppli tumor need grow blood vessel grow sever way process depend presenc substanc call vascular endotheli growth factor vegf produc tumor normal cell this substanc stimul blood vessel penetr tumor suppli oxygen miner nutrient feed growth bevacizumab avastin monoclon antibodi work stop vegf stimul growth new blood vessel when combin chemotherapi bevacizumab shown like shrink tumor help patient certain type nsclcsuch adenocarcinomato live longer ramucirumab cyramza also use treat nsclc a monoclon antibodi target vegf receptor help stop format new blood vessel ramucirumab often given chemotherapi drug docetaxel later line therapi anoth treatment stop work immunotherapi our immun system constant work keep us healthi it recogn fight danger infect virus grow cancer cell in general term immunotherapi use immun system treatment cancer in march fda approv immunotherapi nivolumab opdivo treatment metastat squamous nsclc unsuccess treat chemotherapi nivolumab work interf molecular brake known pd prevent bodi immun system attack tumor two addit drug categori approv octob atezolizumab tecentriq pembrolizumab keytruda pembrolizumab drug categori approv firstlin initi treatment lung cancer in februari fda approv immunotherapi durvalumab imfinzi treatment patient stage iii nsclc whose tumor unabl surgic remov whose cancer progress treatment chemotherapi radiat treatment approach be studi the effect combin immunotherapi treatment nsclc studi mani clinic trial one promis approach pair nivolumab ipilimumab yervoy immunotherapi current approv fda treatment metastat melanoma anoth area ongo research combin immunotherapi chemotherapi firstlin treatment option in fda approv use pembrolizumab combin chemotherapi firstlin treatment metastat nsclc addit effect potenti side effect ad radiat therapi immunotherapi current studi introduct manag treatment side effect print email share tweet the import clinic trial clinic trial standard measur worth new treatment qualiti life patient receiv treatment for reason doctor research urg peopl cancer take part clinic trial your doctor guid make decis whether clinic trial right here thing know often peopl take part clinic trial gain access benefit new treatment befor particip clinic trial fulli inform risk benefit trial includ possibl side effect most clinic trial design test new treatment standard treatment find whether new treatment ad benefit you stop take part clinic trial time reason listen all cancer treatment caus side effect it import report side effect experi health care team help manag report right awaydont wait next appoint do improv qualiti life allow stick treatment plan it import rememb patient experi side effect patient may experi side effect list side effect chemotherapi the side effect chemotherapi depend type dose drug given length time use includ fatigu tire hair loss diarrhea constip increas risk infect white blood cell easi bruis bleed chang memori think peripher neuropathi numb tingl hand feet side effect radiat therapi treatment chang skin includ dryness swell peel red blister if reaction occur contact health care team appropri treatment prescrib it especi import contact health care team open skin pain area could indic infect infect treat oral antibiot topic antibiot cream side effect target therapi target therapi drug dont effect bodi chemotherapi drug still caus side effect some potenti side effect target therapi includ rash diarrhea liver problem elev liver enzym problem blood clot wound heal high blood pressur side effect immunotherapi immunotherapi travel bloodstream help prompt immun respons becaus trigger attack healthi cell well cancer cell certain side effect may experienc includ fatigu decreas appetit digest tract symptom the manag potenti side effect discuss later next section booklet manag digest tract symptom nausea vomit avoid food strong odor well over sweet greasi fri high season food nibbl dri cracker toast these bland food easi stomach have someth stomach take medic may help eas nausea mani effect medic nausea vomit develop recent year talk doctor whether may right diarrhea drink plenti water ask doctor use drink gatorad provid electrolyt well liquid electrolyt bodi salt must stay balanc cell work proper overthecount medicin loperamid imodium ad other prescript drug avail diarrhea use necessari if diarrhea bad enough need medicin discuss doctor nurs choos food contain solubl fiberfor exampl bean oat cereal orang flaxse highpectin food peach appl orang grapefruit banana apricot also help avoid diarrhea loss appetit to help maintain weight eat small meal throughout day that easi way take protein calori tri includ protein everi meal to keep feel full earli avoid liquid meal take small sip unless need liquid help swallow drink liquid meal focus liquid nutrit valu be physic activ sometim take short walk hour meal help feel hungri keep highcalori highprotein snack hand hardboil egg peanut butter chees ice cream granola bar liquid nutrit supplement pud nut can tuna trail mix if struggl maintain appetit talk health care team whether appetitebuild medic could right manag fatigu fatigu extrem tired help sleep one common side effect mani cancer treatment if take medic doctor may lower dose drug long make treatment less effect if experienc fatigu talk doctor whether take smaller dose right there number tip reduc fatigu take sever short nap break take short walk light exercis possibl tri easier shorter version activ enjoy ask famili friend help task find difficult tire save energi thing find import there also prescript medic may help modafinil your health care team provid guidanc whether medic right approach individu circumst manag pain there number option pain relief includ prescript overthecount medic it import talk member health care team take overth counter medic determin safe interfer treatment treatment option communic with your health care team print email share tweet listen as manag lung cancer import rememb consum health care the best way make decis health care educ diagnosi member health care team includ nurs social worker patient navig here tip improv communic health care team start health care journal have health care journal notebook allow keep health inform one place you may want write name contact inform member health care team well question doctor keep diari daili experi cancer treatment you separ journal notebook differ section help keep organ prepar list question befor next medic appoint write question concern becaus doctor may limit time ask import question first specif brief possibl bring someon appoint even journal prepar list question concern alway help support go appoint the person accompani serv second set ear he may also think question ask doctor rememb detail symptom treatment may forgotten write doctor answer take note help rememb doctor respons advic instruct if cannot write answer ask person accompani if mobil devic use take note write note help review inform later record visit doctor allow record convers doctor give chanc hear specif inform share famili member friend incorpor health care profession team your oncologist oncolog nurs essenti member health care team health care profession help manag diagnosi treatment make sure oncologist know medic condit pain experienc consult primari care physician specialist need rememb thing overcommun manag treatment side effect faq print email share tweet cancer care free support servic program oncolog social worker provid emot support peopl cancer love one these profession help cope challeng cancer diagnosi guid resourc cancer care offer free counsel profession oncolog social worker understand challeng face peopl cancer caregiv we work oneonon develop strategi cope treatment side effect oncolog social worker also help communic doctor member medic care team health care issu import support group provid care environ share concern other similar circumst support group member come togeth help one anoth provid insight suggest way cope at cancercar peopl cancer famili particip support group person onlin telephon financi help offer cancer care number organ assist cancerrel expens transport treatment child care home care to learn cancer care help pleas call us hope visit wwwcancercareorg wwwlungcancerorg listen frequent ask question q my breath affect surgeri chemotherapi what i a when surgeri reduc size lung cannot take much air some medic also chang lung function lead short breath ani time difficulti breath report doctor he prescrib pulmonari lung rehabilit therapi this therapi may includ exercis train energyconserv techniqu breath strategi nutrit counsel improv lung function q my lung cancer ret gene mutat are drug studi type tumor a ret protein send signal cell tell divid matur special perform specif function when mutat ret gene signal get stuck caus uncheck cell growth in discov mutat ret gene mutat link lung cancer three medic approv fda peopl type cancer ret mutat cabozantinib cometriq vandetanib caprelsa peopl thyroid cancer sunitinib sutent kidney cancer pancreat cancer gastrointestin stromal tumor gist talk doctor lung cancer clinic trial peopl ret gene mutat ask whether recommend prescrib medic label use prescript drug legal treat cancer drug approv fda q what happen treatment stop work a if happen discuss altern treatment option doctor their recommend base uniqu situat includ factor relat overal health note sever drug latephas clinic trial intend use initi lung cancer treatment becom less effect stop work q i stage a lung cancer surgic remov my doctor say i dont need chemo type treatment should i get second opinion a if cancer truli stage a treatment surgeri recommend howev import get ct scan everi six month first two year surgeri check recurr new cancer after first two year doctor recommend frequent get ct scan communic with your health care team print email share tweet resourc cancer care hope american cancer societi cancernet cancer support communiti lungcan lungcancerorg hope the lung cancer allianc nation cancer institut to find out about clinic trial emergingm',\n",
       "  'JJ'),\n",
       " ('if transit new med i would second previous recommend stelara stelara get good review new drug seem rival remicad effect hope get thing work soon',\n",
       "  'NN'),\n",
       " ('i ulcer coliti year went sever year undiagnos went steroid asacol pantroprzol hospit was asacol coupl year kept flare went humira year when stop work i went remicad when stop work i ileostomi total colectomi the surgeri half year ago i hard eat anyth far varieti i cant eat fruit ripe avocado fiber fresh veget etc realli eat chicken fish gluten free oatmeal mash potato drink kale cucumb juic pulp filter complet i eat time day ounc per meal i extens test chrohn h pylori stomach function pancrea issu etc negat i heat burn cant toler proton pump inhibitor i bloat gas throat feel like close i eat wonder anyon els symptom know might caus',\n",
       "  'NN'),\n",
       " ('repli post cbertucci has anyon communiti forum treat dr albert snow ulcer coliti put remiss claim cure i mild case uc year recent bad flare remicad prednison work next step surgeri ani inform would appreci',\n",
       "  'NN'),\n",
       " ('hi wschoop was treatment year diag time relaps lesion mri after gilenya first dmt well im last year had relaps stabl mris sinc feel good side effect report elev liver enzym coupl month good luck hope thing go well',\n",
       "  'NN'),\n",
       " ('chipofbag opdivo keytruda equival they go target t cell would unnecessari the opdivoyervoy combo make lot sens opdivo most act t cell tumor wherea yervoy most act t cell circul cytotox tlymphocyteassoci protein ctla blockad impact human immun system expand pool circul t cell may mechanist relat induct autoimmun inflammatori toxic httpclincancerresaacrjournalsorgcontentful what say reason pd inhibitor well toler wherea ctla inhibitor sever side effect also blockad differ target t cell shut immun escap rout cancer usual use',\n",
       "  'VB'),\n",
       " ('i would make appoint gi asap technic inflectra isnt ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra i idea honesti but better nd rd infus i would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'JJ'),\n",
       " ('alic t shaw director center thorac cancer paula okeeff endow chair thorac oncolog massachusett general hospit she also associ professor medicin harvard medic school she receiv ab biochemistri harvard md phd degre harvard medic school she resid intern medicin massachusett general hospit complet fellowship hematologyoncolog danafarbermassachusett general hospit she complet postdoctor work laboratori dr read alic shaw md phd grace faculti karen reckamp md ms grace faculti karen reckamp md ms associ professor depart medic oncolog therapeut research citi hope comprehens cancer center cohccc she receiv medic degre univers chicago master degre clinic investig ucla she complet resid train intern medicin barnesjewish hospit hematologyoncolog fellowship david geffen school medicin ucla read karen reckamp md ms grace faculti matt hiznay live forum moder patient advoc matt hiznay fiveyear survivor metastat alkposit nonsmal cell lung cancer he born youngstown ohio grew small town poland ohio matt graduat poland seminari high school john carrol univers bachelor scienc degre magna cum laud read matt hiznay live forum moder patient advoc janet freemandaili patient advoc live forum moder janet freemandaili writer scienc geek lung cancer patientactivist she receiv diagnosi advanc nonsmal cell lung cancer may becam metastat despit chemotherapi radiat after learn genom test precis medicin onlin patient communiti join clinic trial rosposit lung cancer evid diseas four year read janet freemandaili patient advoc live forum moder john cherol live forum moder patient advoc john cherol diagnos januari stage iv egfr lung cancer age he start gilotrif afatinib acquir resist month luckili blood test show develop tm mutat start tagrisso april year hes also treat nine brain met gamma knife cleveland clinic read john cherol live forum moder patient advoc heather wakele md grace faculti dr wakele assist professor medicin stanford univers divis oncolog colead lung cancer diseas manag group her focus clinic research lung cancer patient particular interest antiangiogenesi agent dr wakele princip investig ongo intern lung cancer intergroup trial e investig potenti role bevacizumab addit adjuv chemotherapi resect earlystag nonsmal cell lung cancer read heather wakele md grace faculti rachel sanborn md grace faculti after graduat oregon health scienc univers medic degre dr rachel sanborn complet resid intern medicin univers illinoi chicago then return portland fellowship hematolog medic oncolog oregon health scienc univers she boardcertifi medic oncolog intern medicin read rachel sanborn md grace faculti boon wilder goodgam md grace faculti boon wilder goodgam md grew uganda father taught nation medic school he move texa age complet high school he earn undergradu degre univers texa austin mechan engin complet medic school baylor colleg medicin houston read boon wilder goodgam md grace faculti melissa johnson md grace faculti dr melissa johnson assist professor northwestern univers feinberg school medicin chicago',\n",
       "  'IN'),\n",
       " ('re profg need solid scientif evid back point i agre want trial cladribin peopl advanc ms at moment evid dmts make differ pwppms ocrelizumab at moment ocrelizumab avail nhs',\n",
       "  'NN'),\n",
       " ('sorri repli chemo carboplatin taxol commoni use drug hope help all best mom chuck ps im caregiv done mani mani hundr hour research you might consid second opinion even call bms opdivo whether work even pdl express here link read ill leav the articl one year old interest comment pdl protein center clinic decis select patient like benefit treatment antipd antipdl drug none three fda approv mention express pdl prerequisit prescrib drug still consensus regard valu pdl express nsclc predict marker respons across board posit pdl predict respons alway guarante lack pdl exclud respons lead cliniciansagre would give antipd drug patient metastat lung cancer melanoma regardless pdl status right pdl good enough biomark exclud patient receiv antipd drug even pdlnegat patient deriv benefit pd blockad docetaxel standard chemotherapi drug i know lot digest one year old least imo worth consid my wife never pdl test opdivo work great platin type chemo drug gemzar all patient react quit differ god bless',\n",
       "  'NN'),\n",
       " ('i diagnos regular annoy symptom mani list i start tysabri infus june point i jcv negat see said jcv posit think may relat copaxon mayb talk doctor medic my neuro alreadi plan b i go jcv posit ocrevus it suppos similar tysabri i understand identifi success dmt ms i friend church wheel chair start tysabri within day wheel chair walk assist cane now like i said i tysabri sinc i jcv negat posit rule least great increas risk get pml doctor would even sign switch tysabri im pretti sure isnt doctor would sign give tysari jcv prosit as i sure know ms uniqu everyon success dmts uniqu everyon copaxon didnt work anoth friend church copaxon year work great i gave autoject sinc i purpos',\n",
       "  'NN'),\n",
       " ('entyvio slow work week moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa offic standdown the man held hostag hour pain within bathroom kept bowel sound like misunderstand',\n",
       "  'VBP'),\n",
       " ('mani patient rituxan switch ocrevus due insur issu there problem imo reason switch o rituxan develop antibodi drug rituxan year safeti profil',\n",
       "  'NN'),\n",
       " ('camidg r et al brigatinib vs crizotinib patient advanc alk inhibitorna advanc alk nsclc first report phase trial altal world confer lung cancer abstract pl',\n",
       "  'NN'),\n",
       " ('hi janiceb your stori sound like futur im cross road diagnos coupl month ago neuro sent blood test prepar gilenya im keen i realli dont want take drug symptom dont sound bad side effect im mobil apart back pain tingl littl brain fog i deal im fulli om sinc last month plant base last month i think im go wait see hope everyon well',\n",
       "  'NN'),\n",
       " ('biosimilar readi pounc abbvi humira europ biosimilar compani gear pounc abbvi inflamm blockbust humira adalimumab lose patent exclus across europ octob humira earn bn exus sale abbvi last year came europ expect see revenu rapid erod earli amgen copi amgevita samsung biogen imraldi gain full eu approv last year give lot time prepar market permit launch octob red letter day meanwhil sandoz novarti divis announc friday gain european approv biosimilar known hyrimoz the biosimilar expect undercut humira origin price healthcar system across europ get use drive hard bargain exploit competit firm get lowest price possibl in case seen origin compani match price biosimilar entrant order hold onto market share there mani biosimilar compani look get slice humira spend europ accord iqvia data worth annual uk alon hyrimoz approv use humira mani indic rheumatoid arthriti psoriasi crohn diseas kavya gopal head specialti sandoz uk said the approv hyrimoz potenti posit impact nhs term reduc medicin spend ultim increas patient access effect treatment the nhs current spend year humira avail hyrimoz competit environ provid opportun lower cost per patient allow patient treat support sustain healthcar system england budget holder nhs england expect four adalimumab biosimilar avail uk octob abbvi origin product humira three biosimilar amgen samsungbiogen sandoz as potenti save great nhs england commerci medicin unit cmu coordin nation procur process adalimumab loss patent exclus octob nhs england say ambit nhs achiev recurr annual save increas use best valu biolog medicin phrase mean doesnt preclud stick origin product provid best valu price it say alreadi achiev save use biosimilar medicin figur read nhs intern brief adalimumab biosimilar may hong kong could new biotech hub say beigen head bn floatat beigen part wave new chinabas biotech compani emerg rapid thank new rule hong kong stock market hkex introduc late april year new rule allow biotech compani without revenu launch initi public offer ipo allow compani alreadi list elsewher launch secondari list hong kong a total eight compani biotech research file sinc may beigen plan biggest yet alreadi list us biotech specialist exchang nasdaq beigen plan float hong kong august aim rais bn would recordbreak sum biotech compani product yet market speak south china morn post compani chief execut john oyler pictur said there lot global investor know biotechnolog know littl china in hong kong lot investor know china know littl biotechnolog we hope list hong kong help educ type investor he ad hong kong potenti attract mani biotechnolog firm list well investor trade the research analyst relat parti follow this creat ecosystem biotechnolog industri hong kong the beijingbas biotech toplin data pivot trial pd inhibitor chines patient relapsedrefractori classic hodgkin lymphoma hope file approv home market later year read biotech investor comment brad loncar blog eight biotech alreadi file hkex kymab report earli data lead antibodi uk biotech compani kymab releas phase data oxligand monoclon antibodi ky the cambridg ukbas compani tip one countri brightest biotech hope year ago hasnt quick move candid clinic trial now compani reassur toplin phase i data show antibodi favour safeti pharmacokinet pharmacodynam properti kymab say data support take ky patient phase ii studi patient atop dermat ox ox ligand oxl potenti treat number immun mediat inflammatori disord includ use oncolog a number big pharma compani x candid pipelin includ pfizer although roch abandon phase candid rg solid tumour last year rna drug specialist moderna also oxl candid mrna earli stage trial in next clinic studi ky test patient atop dermat condit especi high level oxl found the phase iia trial atop dermat expect begin late',\n",
       "  'IN'),\n",
       " ('i final got approv cimzia spell i remicad ten year stop work novemb last year got final dose remicad januari wouldnt listen complaint pain then june tri humira reaction put high dose steroid mainten dose mg gain much weight cant stop eat final rx sent specialti pharmaci it august th i frustrat i go look anoth doctor i dont trust anymor pleas say prayer i cant take crohn pain symptom anymor hate diseas mad hope',\n",
       "  'NN'),\n",
       " ('on april unit state food drug administr fda grant approv inject drug lucenti generic name ranibizumab treatment prolif diabet retinopathi pdr serious visionrel complic diabet previous fda approv lucenti treatment diabet macular edema dme buildup fluid macula center retina thus latest treatment advanc fda approv physician use lucenti manag diabet retinopathi peopl without diabet macular edema import background on research the journal american medic associ result import clinic trial reveal inject drug lucenti high effect treat prolif diabet retinopathi serious visionrel complic diabet the research titl panretin photocoagul ie laser treatment vs intravitr ranibizumab ie lucenti inject prolif diabet retinopathi a random clinic trial publish onlin opensourc articl novemb edit the journal american medic associ time coincid present studi author annual meet american academi ophthalmolog the author member write committe diabet retinopathi clinic research network the diabet retinopathi clinic research network drcrnet collabor research group support identif design implement multicent clinic research studi focus diabetesrel eye retin disord includ diabet retinopathi diabet macular edema the drcrnet form septemb current includ particip site physician throughout unit state it fund nation eye institut nei these find said dr paul siev director nation eye institut nei provid crucial evid safe effect altern laser therapi prolif diabet retinopathi the clinic trial fund nei describ lucenti first major advanc therapi prolif diabet retinopathi near year although longerterm followup need lucenti may provid reason treatment altern least two year person prolif diabet retinopathi about diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age what person diabet retinopathi see retinopathi general term describ damag retina the retina thin lightsensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls these electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif general term mean grow increas rapid rate produc new tissu cell when term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina nonprolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild nonprolif retinopathi at earli stage small area balloonlik swell occur retina tini blood vessel moder nonprolif retinopathi as diseas progress blood vessel nourish retina becom block sever nonprolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina the damag retina signal bodi produc new blood vessel prolif retinopathi at advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreous transpar gel fill interior eye becaus new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreous scar tissu develop tug retina caus damag even retin detach in addit fluid leak macula small sensit area center retina provid detail vision this fluid caus macular edema swell occur stage diabet retinopathi although like occur diseas progress lucenti an antiangiogen drug treat retin bleed angiogenesi term use describ growth new blood vessel play crucial role normal develop bodi organ tissu sometim howev excess abnorm blood vessel develop occur diseas cancer tumor growth retin diseas substanc stop growth excess blood vessel call antiangiogen antiagainst angiovessel genicdevelop antineovascular antiagainst neonew vascularblood vessel the focus current antiangiogen drug treatment retin diseas reduc level particular protein vascular endotheli growth factor vegf stimul abnorm blood vessel growth retina macula thus drug classifi antivegf treatment administ inject direct eye surfac numb at present antivegf drug lucenti avastin eylea requir month inject pro nata mean need prn regimen month control inject recurr persist blood vessel growth retin bleed more lucenti diabet retinopathi research excerpt lucenti prove effect prolif diabet retinopathi via scienc codex a clinic trial among patient found drug ranibizumab lucenti high effect treat prolif diabet retinopathi pdr complic diabet sever damag eyesight the result demonstr first major therapi advanc condit near year the trial compar lucenti inject type laser therapi call panretin photocoagul remain gold standard pdr sinc mid although laser therapi preserv central vision damag night side vision research sought therapi lack side effect patient receiv lucenti show littl bit better central vision much less loss side vision substanti less risk surgeri patient receiv laser treatment said lloyd paul aiello md phd director beetham eye institut joslin diabet center professor ophthalmolog harvard medic school these find chang avail treatment option patient pdr the drcrnet enrol particip eye pdr one eye clinic site across countri eye assign random treatment lucenti laser about half eye assign laser group requir one round laser treatment in group lucenti inject eye per month three consecut month need diseas resolv stabil becaus lucenti common inject treat diabet macular edema dme buildup fluid center retina studi permit use lucenti dme laser group necessari slight half percent eye laser group receiv lucenti inject treat dme about percent eye lucenti group receiv laser therapi most issu dme at two year vision lucenti group improv averag half line eye chart compar virtual chang laser group particip treat laser general lost substanti peripher vision given inject addit need vitrectomi surgeri lower lucenti group eye laser group eye overal drug benefit particular clear peopl pdr dme we know drug help treat condit time especi appeal treatment altern patient dr aiello note the studi also suggest lucenti may help prevent dme among peopl without condit start studi percent lucentistr eye develop compar percent laser group scientist follow result drcrnet continu track patient total five year more studi the journal american medic associ excerpt articl abstract full articl avail onlin import panretin photocoagul prp standard treatment reduc sever visual loss prolif diabet retinopathi howev prp damag retina result peripher vision loss worsen diabet macular edema dme object to evalu noninferior intravitr ranibizumab ie lucenti inject compar laser visual acuiti outcom patient prolif diabet retinopathi design set particip random clinic trial conduct us site among adult prolif diabet retinopathi enrol februari decemb mean age year femal white both eye enrol particip eye studi group total studi eye the final year visit complet januari intervent individu eye random assign receiv prp treatment complet visit n eye lucenti mg intravitr ie within eye inject baselin frequent everi week base structur retreat protocol n eye eye treatment group could receiv lucenti dme main outcom measur the primari outcom mean visual acuiti chang year letter noninferior margin intentiontotreat analysi secondari outcom includ visual acuiti area curv peripher visual field loss vitrectomi dme develop retin neovascular result mean visual acuiti letter improv year lucenti group vs prp group the mean treatment group differ visual acuiti area curv year mean peripher visual field sensit loss wors vitrectomi frequent dme develop frequent laser group vs lucenti group respect eye without activ regress neovascular year signific differ one eye lucenti group develop endophthalm ie inflamm eye usual caus infect no signific differ group rate major cardiovascular event identifi conclus relev among eye prolif diabet retinopathi treatment lucenti result visual acuiti noninferior wors laser treatment year although longerterm followup need lucenti may reason treatment altern least year patient prolif diabet retinopathi',\n",
       "  'NN'),\n",
       " ('adjuv treatment erlotinib may benefit patient earlystag nonsmal cell lung cancer nsclc epiderm growth factor receptor egfr mutat a new studi publish journal clinic oncolog found egfr mutant earlystag nsclc patient treat erlotinib experienc improv year diseasefre surviv dfs rate compar histor genotypematch control research found recurr rare patient receiv adjuv erlotinib in addit patient rechalleng erlotinib recurr found durabl benefit nathan a pennel md phd cleveland clinic taussig cancer institut ohio colleagu conduct openlabel phase trial includ patient resect stage ia iiia egfr mutant nsclc all patient treat small molecul egfr tyrosin kinas inhibitor tki erlotinib mg per day year standard adjuv chemotherapi without radiotherapi this agent demonstr superior patient metastat lung cancer harbor egfr mutat theoriz erlotinib could help improv outcom patient earlystag egfr mutant lung cancer the research found unexpect toxic grade advers event howev patient requir dose reduct mg per day dose reduct mg per day the intend year cours achiev patient relat articl fulvestr plus erlotinib may improv progressionfre surviv egfr wildtyp nsclc resist mechan identifi nsclc progress with firstlin osimertinib bevacizumab plus erlotinib may be new standard care nonsmal cell lung cancer the research found year dfs rate stage i stage ii stage iii median followup year the median dfs overal surviv os rate reach time public the studi show year dfs rate year os rate diseas recur patient recurr report erlotinib treatment the median time recurr month stop erlotinib refer pennel na neal jw chaft je et al select phase ii trial adjuv erlotinib patient resect epiderm growth factor receptormut nonsmal cell lung cancer publish onlin novemb j clin oncol doi jco',\n",
       "  'NN'),\n",
       " ('ocrelizumab versus interferon betaa relaps multipl sclerosi', 'IN'),\n",
       " ('if crizotinib effect mass stage iv nsclcros need stop side effect resum week how interrupt affect resist factoror have studi determin effect interrupt target therapi',\n",
       "  'JJ'),\n",
       " ('predictor respons vedolizumab ustekinumab ibd predictor respons vedolizumab ustekinumab ibd what factor patient characterist might help predict initi longterm respons vedolizumab ustekinumab inflammatori bowel diseasealimentari pharmacolog therapeut sourc medscap today headlin',\n",
       "  'NN'),\n",
       " ('hi kempten i think initi question would slight progress lung mass compar overal size has thought continu tagrisso bit confirm progress determin rate growth dr west often state often make sens stay welltoler treatment even face slow progress bad brake better brake of cours local doctor best abl judg question if origin percentag exon mutat unchang seem indic exon posit portion cancer progress sinc would expect percentag rise either way specul sinc unfortun dont understand resist progress well yet there discuss treat tarceva failur tagrisso that use tagrisso firstlin set even context isnt good evid yet efficaci dr ramalingam state two month ago tagrisso studi first line therapi set see shut t escap resist mechan proactiv improv outcom patient the approach shown promis earli result studi larg clinic trial this trial compar tagrisso direct tarceva iressa we still learn mechan resist observ patient treat tagrisso first line set it possibl subset patient use iressa tarceva receiv tagrisso might benefici earli time make firm statement issueth present avail data base laboratori experi confirm patient httpcancergraceorgtopictagrissofirstlineandthentarcevatherapypost continu jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa this repli modifi year month ago jimc forum moder this repli modifi year month ago jimc forum moder',\n",
       "  'NN'),\n",
       " ('multipl sclerosi ms chronic demyelin diseas affect central nervous system pharmacolog therapi ms includ symptomat drug treatment relaps corticosteroid intraven immunoglobulin diseas modifi drug dmds defin pharmacolog agent impact relaps rate disabl accumul radiolog outcom two differ therapeut approach wide use ms escal induct therapi escal therapi consist earli start first line dmds beta interferon glatiram acet teriflunomid dimethyl fumar dmds ineffect partial effect switch second line drug mitoxantron natalizumab fingolimod induct therapi consist earli use immunosuppress drug follow longterm mainten treatment general immunomodulatori agent while use natalizumab fingolimod first line drug indic aggress form ms indic mitoxantron induct treatment aris random studi demonstr induct therapi mitoxantron follow dmd mainten effect monotherapi beta interferon howev safeti profil induct drug indic accept therapeut strategi ms patient phase diseas the upcom challeng identifi patient high risk disabl develop clinic characterist radiolog find biomark furthermor futur studi establish individu safeti profil stratif need',\n",
       "  'VBD'),\n",
       " ('in general tumor resect best option followup chemoradi mani case the valu nivolumab context unproven im sure chemoradi would offer unless someth locat particular tumor make radiat infeas certain question ask reason obtain second opinion jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa',\n",
       "  'JJ'),\n",
       " ('this bizarr shouldnt chop chang biolog i bet cost issu humira cheaper i mean work remicad work still dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('i want tell experi suggest differ drug might think i diagnos probabl ms least five year i saw slowish steadi deterior next seven eight year in i start go downhil lot quicker also episod like relaps they werent bad relaps i got back bit function i lost time i offer rang interferon avail time understand time reduc relaps rate sinc i thought didnt slow progress i didnt start dmt by i use one stick lot problem bladder control late year i start tysabri hope slow progress i came end by walk poor slow i use two stick walker indoor wheelchair mobil scooter outsid i thought lemtrada drug offer hope end ms activ i chose cladribin lemtrada with cladribin three inject three day outpati stay overnight you may one two three inject month later then anoth set inject year later end cladribin lemtrada offer end ms treatment goe ever offer reduc diseas activ cladribin lead thyroid problem often seen lemtrada howev cladribin offer bart licens treatment ms australia russia i impress neurologist i seen bart dr schmierer might find hes kind doctor want see if want read cladribin find inform httpmultiplesclerosisresearchblogspotcomsupposetherewastherapyforallhtml',\n",
       "  'NN'),\n",
       " ('so youv fail coupl biolog alreadi one antitnf medic humira similar remicad i would tri find good surgeon consult it took month get book surgeri i chose wait best surgeon i could find i suffer time gi scope last week said pouch best hes ever seen my gi said coupl time i best color blood flow pouch time i zero inflamm thank stelara pouch keith dxd sever pancol june previous med asa predison mp remicad humira simponi cimzia cyclosporin step jpouch surgeri current condit chronic pouchiti not bad i thought would current med stelara total hip replac thank prednison wwwhealingwellcomcommunitydefaultaspxfm',\n",
       "  'NN'),\n",
       " ('i xalkori month a current ct scan show stage nsclc ros stabl an ekg show higher qtc sinc last ekg month ago sinc xalkori may affect would mere stop drug wait week two followup ekg recommend i concern',\n",
       "  'JJ'),\n",
       " ('hi leanne i came across post comment im kind go thing i gilenya two year pretti well relaps month ago so decid lemtrada way go i stop take gilenya right away i lymphocyt count i stop told washout period would still take week get back start infus i major relapserebound hasnt even full week sinc stop so measur lymphocyt count month ive recov steroid approv start lemtrada so i guess i want say stay top get blood work done awar symptom washout may take long say gluck manni',\n",
       "  'NN'),\n",
       " ('leader alcmi alcf recent attend world confer lung cancer toronto it banner year near attende around globe share latest updat advanc lung cancer research treatment there palpabl energi enthusiasm among particip highlight progress made field four confer present coincid public new england journal medicin among mani excit find present confer result pacif studi show durvalumab lead meaning improv overal surviv patient stage iii unresect nonsmal cell lung cancer nsclc progress follow chemoradiotherapi the altal studi show firstlin brigatinib improv progressionfre surviv treatmentnav alk nslcl patient advanc diseas result keynot studi found pembrolizumab plus chemotherapi signific prolong overal surviv progressionfre surviv among patient untreat metastat squamous nsclc the impow studi found addit pdl inhibitor atezolizumab carboplatin etoposid provid signific improv overal progressionfre surviv firstlin manag extens stage small cell lung cancer essclc this mark first major advanc sclc two decad the nelson screen studi found reduct mortal atrisk male pave way rollout lowdos ct screen europ dacomitinib receiv fda approv firstlin treatment patient metastat nsclc egfr exon delet exon lr substitut mutat',\n",
       "  'NN'),\n",
       " ('here link articl ocrelizumab work dmt ppms well rrms not avail yet come httpwwwmanagedcaremagcomnewsmultiplesclerosisdrugocrelizumabo',\n",
       "  'JJ'),\n",
       " ('im say dont uc soy if scope show uc obvious uc i would say howev diet doesnt seem work well still activ inflamm dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current status chronic flare do i kind current med mg mp entyvio start',\n",
       "  'NN'),\n",
       " ('the studi immun system recogn friend foe immunologist sir macfarlan burnet phrase distinguish self nonself driven import discoveri transform abil treat cancer over last centuri scientist clinician unravel complex interact innat adapt immun lead erad virus bacteria parasit cancer notabl cellular player includ t cell b cell natur killer nk cell neutrophil eosinophil basophil dendrit cell macrophag along host secret mediat antibodi complement cytokin chemokin fulfil particular immunolog function when immun system fail regul process autoimmun diseas consequ these diseas also occur share antigen recogn immun system normal cancer cell one exampl lamberteaton syndrom monoclon antibodi target tumor reactiv t cell eg nivolumab pembrolizumab also caus autoimmun diseas exampl includ graftvshost diseas gvhd allogen bone marrow transplant recipi cytokin releas syndrom crs associ adopt t cell therapi relat articl can understand gut microbiom improv clinic oncolog soft tissu sarcoma nivolumab with trabectedin is safe clinic activ spontan regress cancer explan predict through effort thousand investig start dr william coley centuri ago recent includ research drs macfarlan burnet lewi thoma steven rosenberg carl june jame allison lloyd old oncologist offer patient effect us food drug administr fdaapprov immunotherapi treatment design direct indirect attack cancer histor timelin fda approv repres immunotherapi relat drug select indic recombivax to prevent hepat b infect hepatocellular cancer caus viral infect interferon alfa b hairi cell leukemia subsequ approv renal cell cancer melanoma kaposi sarcoma bcg superfici bladder cancer filgrastim neutropenia chemotherapi interleukin renal cell cancer subsequ approv melanoma epoetin alfa anemia chemotherapi rituximab nonhodgkin lymphoma subsequ approv cancer type indic trastuzumab breast cancer subsequ approv gastric cancer esophag cancer alemtuzumab chronic lymphocyt leukemia bevacizumab colorect cancer subsequ approv mani cancer breast lung glioblastoma multiform uterin cervic cetuximab colorect cancer subsequ approv head neck cancer sipuleucel prostat cancer ipilimumab melanoma nivolumab melanoma subsequ approv mani cancer type includ nonsmal cell lung cancer hepatocellular cancer hodgkin lymphoma bladder cancer renal cancer colorect cancer pembrolizumab melanoma subsequ approv nonsmal cell lung cancer gastric cancer mani cancer microsatellit high express defici mismatch repair function gardasil to prevent human papilloma virus hpv infect cervic cancer cancer caus viral infect talimogen laherparepvec melanoma durvalumab nonsmal cell lung cancer bladder cancer tisagenlecleucel acut lymphoblast leukemia axicabtagen ciloleucel lymphoma',\n",
       "  'NN'),\n",
       " ('hello ann it nice meet of cours worri i understand complet one lc pal shock learn diagnosi follow broken arm minor car accid shes keytruda well today in read post best news onc will consult big dog denver there top lc expert denver knee deep cut edg research real box thinker you might want check the lung cancer live room bonni j addario foundat websit there denver lc doc featur guest it creativ doc will go beyond help advanc scienc sound like awesom doc team captain have faith doc god guid youv join countri largest prayer poss so togeth michell',\n",
       "  'NN'),\n",
       " ('san diego baselin expand disabl status scale score number relaps first year consist predictor disabl worsen relaps subsequ year longterm analysi three phase fingolimod trial those patient identifi higher risk wors longterm clinic outcom could benefit earli review multipl sclerosi ms treatment regimen help prevent worsen disabl pavl repov md phd said interview damian mcnamarafrontlin medic news dr pavl repov the idea time figur tell whether patient respond therapi earli dr repov said actrim forum held america committe treatment research multipl sclerosi to explor longterm clinic predictor disabl progress relaps risk dr repov colleagu analyz three phase trial assess fingolimod gilenya they evalu paramet baselin first year freedom freedom ii transform studi',\n",
       "  'NN'),\n",
       " ('just thought i ought give latest updat cladribin experi it negat i deterior great deal sinc i my walk much wors i longer walk two stick at best i use rollat worst wheelchair i dont day i dont need wheelchair befor cladribin i use stick hous rollat i need carri someth i need clonazepam tablet control leg twitch night mg i gradual increas one tablet i take year my bladder control less reliabl i fall frequent i week i return trigemin neuralgia i realli bad last year it quit mild compar last time seem confirm i see inflamatori activ rather nerv death it take someth like hour get dress morn slight less time get undress even in fact everyth take much longer that i dont come i dont enough time live life i want i tri get back gilenya hope slow deterior i see i feel tri cladribin probabl one biggest mistak i ever made',\n",
       "  'NN'),\n",
       " ('ok i forgot mention gi gave rx ciproflagyl i finish day worth the antibiot immedi made feel better also fistula definit heal i havent notic much week i hope day antibiot enough i took humira booster shot last weekend i realli felt better well first hour inject suck i feel better i drop prednison mg mg monday i feel good i start uceri foam day ago i think help it look complic clip dispos applic foam cannist realli easi way comfort use rowasa enema i enough energi thing my hous clean todo list check im make recip i found pinterest keep toddler wherea sick i couldnt stay awak i troubl sleep i need pace thoughim excit energi must rememb im still heal moder hard i mri bone densiti scan today i told fast made awar i would drink bunch icki slimi liquid time interv forget brand name clear slimi tast like squirt soda still better barium i drink twice i pee mri held minut left peed bit girl could get machin luckili i wear depend harm foul im becom fan dispos underweardont knock til tri ill take th humira inject tomorrow later usual toddler nd birthday i dont want feel like crap hope exhaust discomfort caus lessen i heal i dont want plan weekend around humira shot will updat result mri bone scan next week yr femal diagnos hospit uc current humira apriso prednison mg taper mgweek buproprion synthroid start humira feb previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri im glutenfre supp vsl calmag vit d krill oil post edit plucki pm gmt',\n",
       "  'NN'),\n",
       " ('your profi say base london you ask dad refer royal london contact team they would abl discuss whether cladribin good option they use offlabl probabl best bet',\n",
       "  'NN'),\n",
       " ('the us food drug administr fda recent accept supplement biolog licens applic sbla grant prioriti review atezolizumab tecentriq combin bevacizumab avastin paclitaxel carboplatin firstlin treatment metastat nonsquam nonsmal cell lung cancer nsclc the fda expect make decis approv septemb our phase iii result show atezolizumab combin bevacizumab paclitaxel carboplatin potenti provid signific surviv benefit initi treatment metastat nonsquam nonsmal cell lung cancer said sandra horn md chief medic offic head global product develop genentech this sbla base result phase iii impow studi met coprimari endpoint overal surviv progressionfre surviv initi treatment patient advanc nonsquam nsclc the safeti profil combin consist safeti profil individu medicin new safeti signal identifi atezolizumab current approv fda treat patient metastat nsclc diseas progress follow platinumcontain chemotherapi appropri fdaapprov target therapi tumor alk egfr gene abnorm more about impow studi impow multicent openlabel random control phase iii studi evalu efficaci safeti atezolizumab combin carboplatin paclitaxel without bevacizumab peopl stage iv nonsquam nsclc treat chemotherapi advanc diseas it enrol peopl alk egfr mutat exclud primari intentiontotreat analysi peopl random receiv atezolizumab plus carboplatin paclitaxel atezolizumab bevacizumab plus carboplatin paclitaxel bevacizumab plus carboplatin paclitaxel control arm the coprimari endpoint overal progressionfre surviv determin investig use respons evalu criteria solid tumor version recist version the primari analysi coprimari progressionfre surviv endpoint impow assess two popul random peopl without alk egfr genet mutat intentiontotreat wildtyp subgroup peopl specif biomark effector tcell teff gene signatur express the coprimari overal surviv endpoint assess random peopl without alk egfr genet mutat intentiontotreat wildtyp key secondari endpoint includ investigatorassess progressionfre overal surviv safeti intentiontotreat popul egfr alk mutat subgroup the content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       "  'NN'),\n",
       " ('repli post croninstc i ulcer coliti i diagnos year old i youngest sister child never even broken bone i never sick child famili histori ibd when i diagnos i disbelief i research found high rate activ involv research gi central iowa area also happen director iowa digest diseas center i pcp request take patient thank he end confirm diagnosi i seen ever sinc i rememb hard mom handl diagnosi convinc diseas come someth someth could pinpoint understand healthiest daughter fight lifetim diseas unfortun dieas came quick i believ stress factor dad go life threaten complic diabet i also stress job i collect client overdrawn account diet handl stress import factor manag ibd medic also import i realli sick first year diagnosi steriod mani medic fail i final approach gi discuss remicad serious medic chang life i went abl walk block i hunch pain exhaust pain continu abl live activ normal life after start remicad i abl leav unhealthi relationship later find healthi relationship healthi pregnanc husband i hope son abl find medic help diseas get wors unfortun i didnt option handl diseas oral medic thank option i sorri hear would impact plan rotc life continu up down i cant say i thank diseas charact becom stronger trial i face sinc diagnosi i becom understand compassion other understand diseas visabl good luck son support everyth lucki parent care much get input other i learn diseas treatment option connect other ibd communiti i read countless book tri understand diseas',\n",
       "  'NNS'),\n",
       " ('greet everyon this first post i introduc my name karen i diagnos moder ibd probabl ulcer coliti might crohn diseas dr uncertain septemb sinc decemb i remicad littl chang symptom i start mthotrex may slight improv symptom far i suffer emetophobia phobia vomit i like vomit it fear it paralyz affect lot aspect life it manag i start rmicad treatment learn it would lower immun system i would vulner infect food intox ad mthotrex didnt help so much i bare eat anymor i made mistak read internet indic follow compromis immun system i scare pretti much everi type food needless say i avoid restaur well am comfort reassur i one cook i live ensur toast sometim pasta while i seek help deal phobia i wonder rmicad rmicademthotrex much chang eat habbit besid food unabl eat due ibd avoid anyth els like mayonnais raw egg etc do keep go restaur have notic differ catch food intox often usualpeopl around if tip offer would help current issu i would love hear',\n",
       "  'VBP'),\n",
       " ('well know remicad work well id consid anoth similar biolog within class remicad cimzia humira tnfalphablock biolog develop antibodi one tnfalphablock doesnt mean develop antibodi cimziahumira molecular structur differ enough immun system must start groundup antibodi develop process you might never develop antibodi cimziahumira could increas odd stelara complet differ class biolog complet differ mechan action itd gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa there two certainti life pay tax prednison side effect',\n",
       "  'JJ'),\n",
       " ('chemotherapi treatment chemic kill cell divid grow rapid like cancer cell unfortun normal cell eg skin line digest tract hair follicl also rapid divid grow chemotherapi also affect cell may caus unwant side effect the kind chemotherapi doctor recommend depend individu situat the type lung cancer nonsmal cell small cell diagnos overal health goal treatment person prefer taken consider initi first line chemotherapi lung cancer often includ platinumbas drug cisplatin carboplatin anoth drug drug paclitaxel taxol docetaxel taxoter etoposid vp gemcitabin gemzar vinorelbin navelbin pemetrex alimta bevacizumab avastin may also use instead addit drug if first line chemotherapi decreas size cancer continu grow drug may use togeth separ chemotherapi initi round call second line type chemotherapi neoadjuv chemotherapi neoadjuv chemotherapi treatment chemotherapi use anoth treatment in lung cancer typic use tri shrink tumor surgeri possibl adjuv chemotherapi adjuv chemotherapi treatment chemotherapi use anoth treatment in lung cancer typic use goal kill stray cancer cell may remain surgeri chemotherapi recommend surgeri stage ia lung cancer when lung cancer stage ii remov surgeri chemotherapi typic recommend the use chemotherapi surgeri stage ib lung cancer remain controversi be sure talk doctor risk benefit adjuv chemotherapi make inform decis mainten chemotherapi mainten chemotherapi chemotherapi continu usual cycl continu mainten switch mainten new drug given longer period first treatment cycl complet one type chemotherapi pemetrex alimta approv mainten chemotherapi nonsmal cell lung cancer other may use doctor part clinic trial set one target drug erlotinib tarceva also approv use mainten nonsmal cell lung cancer certain circumst lung cancer specialist agre mainten chemotherapi use if lung cancer come back recur success treatment differ chemotherapi may use alon togeth',\n",
       "  'NN'),\n",
       " ('ncot brelax terrif idea look univers psycholog care ani univers psycholog phd program train clinic train graduat student becom psychologist see real patient the fee oper slide scale even top price fair inexpens anyon patient clinic dont student while clinician student student alway supervis one faculti member so actual get top notch care realli experienc peopl overse case they usual use cut edg treatment see wide varieti patient where uk locat i like help find clinic i firsthand knowledg yearold male diagnos crohn age happi humira year august fail remicad cimzia imuran mp mtx ileostomi april began entyvio juli med except nexium',\n",
       "  'NN'),\n",
       " ('repli post andygibson i remicad half year recent switch entivyo when i remicad i would sometim get someth similar bodi ach i sure awar remicad treat certain auto immun disord also caus one thing look pain continu consist basi rheumatoid arthriti while remicad i diagnos psoriasi told like i diagnos psoriat arthriti point happen yet i love remicad total game changer get psoriasi worth abl function without intens pain i uc also gi bone densiti scan prior go remicad i prednison longer ideal period that also someth may want discuss gi sever round steriod thank longest stint prednison month even long enough damag i still sometim wake feel like i intens workout day prior without normal physic activ day i chalk either season winter suck iowa bodi low nutrient need hope help',\n",
       "  'NN'),\n",
       " ('hello i slept last night sm woke pm my holiday begun stress work two week ago ad eyelin eye liquid one and make soducrem hope that written face that feaur thing ive done after felt huge pain eye ive dont corneal contact implant it scare load even felt implant contact bit but two week got pimpl eye eyel and anoth pimpl next ear i dont ever get pimpl accur sudden feel hate face regardless and feel period pain period time i feel exact like tum back and sleepi tire fatigu way much usual sinc oppen eye stair wors do think gilenya twice one day forgot',\n",
       "  'VBD'),\n",
       " ('the nation ms societi fast forward invest enabl tg therapeut inc laboratori test tgr umbralisib potenti oral treatment option progress ms renown ms research dr lawrenc steinman stanford univers lead research team effort this invest stem request propos releas fast forward project focus test exist therapi drug candid determin protect nervous system damag andor repair damag especi treatment progress ms tgr alreadi test peopl blood cancer readi test ms lab test suggest potenti benefit we hope proof concept studi support rational clinic develop tgr progress form ms treatment option said mark allegretta phd associ vice presid commerci research societi this invest exemplifi effort identifi clinicreadi candid expand pipelin therapi test use ms tgr use novel mechan inhibit product immun b cell known involv ms diseas activ anoth bcell therapi ocrevus ocrelizumab genentech member roch group recent approv primari progress relaps ms read more read fast forward read research progress ms ocrevus trademark genentech member roch group',\n",
       "  'JJ'),\n",
       " ('the american academi neurolog aan th annual meet took place philadelphia pennsylvania april thmay rd the aan associ neurologist neurosci profession dedic advanc care individu neurolog diseas everi year profession gather hear latest find research treatment neurolog condit includ multipl sclerosi ms to follow import highlight pleas note time write drug approv unit state food drug administr fda longterm treatment ms known diseasemodifi therapi dmts near drug continu show longterm safeti signific effect reduc msdiseas activ in addit dmts sever experiment treatment make way approv process fdaapprov medic ms result prospect evalu use avonex pen autoinjector selfadminist avonex interferon betaa intramuscular report user selfreport demonstr fear inject decreas percent percent month proport requir assist inject decreas percent percent betaseron interferon betaa first drug approv fda longterm treatment ms in benefit trial individu clinic isol syndrom cis random receiv earli treatment betaseron advanc clinic definit ms cdms quick began treatment later time studi particip began betaseron earli also experienc lower relaps rate treat later time patientreport outcom qualiti life qol remain high group treat patient a twoyear extens studi gala trial assess efficaci safeti copaxon glatiram acet newer mg dose inject subcutan threetim week this openlabel extens studi observ effect higherdos lessfrequ administr particip rrms dose administr origin approv mg inject subcutan daili the studi conclud earli treatment newer dose copaxon lower risk relaps well rate disabl progress relat start therapi later time safeti data similar copaxon wellestablish safeti profil advers event note general mild the major peopl relaps form ms use rebismart autoinjector selfadminist rebif interferon betaa rate conveni devic posit in separ studi research conduct posthoc analysi prism studi look data determin relaps rate patient rebif versus placebo cours one year the studi conclud treatment rebif associ rapid onset action zero three month despit titrat titrat refer start lower dose increas full dose time treat patient improv rate percent fewer relaps first year compar placebo two import factor contribut good outcom tysabri natalizumab treat individu diagnos progress multifoc leukoencephalopathi pmla rare sever complic treatment earli diagnosi treatment a case report patient success treat diagnos pml follow six year treatment tysabri in specif instanc patient went hospit follow disturb gait after pml diagnos underw prescrib therapi remov tysabri system plasma exchang accord studi the patient clinic stabl entir period initi gait disturb diminish week onli percent individu treat tysabri edss score progress edss score six year later addit affirm studi tysabri shown increas probabl confirm improv walk speed ciw a posthoc analysi found patient confirm improv walk speed better selfreport physic function the rate serious infect opportunist infect patient treat aubagio teriflunomid year differ treat placebo an opportunist infect one caus organ normal affect person healthi immun system may caus ill person compromis immun system anoth studi look two phase iii trial aubagio temso tower studi evalu drug effect clinic msdiseas activ studi particip a posthoc analysi studi perform determin proport patient remain free clinic msdiseas activ take aubagio the studi conclud approv diseasemodifi therapi reduc risk clinic diseas activ consist effect across wide rang patient relaps form ms onli percent patient relapsingremit ms rrms begin treatment gilenya fingolimod fti experienc cardiac rhythm abnorm these find consist previous studi up individu rrms enrol oneweek openlabel start studi in studi particip addit diagnost requir includ hour electrocardiogram ecg screen studi baselin ie start studi cardiologist evalu ecg record research also look effect gilenya reduc amount brainvolum loss individu ms treat gilenya phase iii extens trial the studi conclud annual percentag brainvolum chang pbvc patient individu show consist low rate brain atrophi versus placebo phase iii trial freedom freedom ii well versus avonex oneyear extens studi transform accord author support previous observ individu studi about half individu relapsingremit ms rrms take tecfidera dimethyl fumar report experienc gastrointestin symptom half report flush these rate similar found prior clinic trial sixteen percent discontinu treatment due sideeffect rate slight higher found previous studi effort reduc symptom ongo the use tecfidera frequent associ gastrointestin gi symptom includ abdomin discomfort diarrhea nausea vomit within group four individu took oral asthma medic montelukast mg daili continu treatment tecfidera gi symptom decreas within hour improv persist day symptom sever measur gastrointestin symptom rate scale gsrs decreas percent a fouryear followup conduct determin integr clinic efficaci result three studi use tecfidera treat rrms the studi includ phase iii defin confirm studi well fiveyear endors extens studi result analysi show low relaps rate low disabl progress continu fouryear followup these addit neuroradiolog efficaci found mri scan accept safeti profil ms treatment review fda efficaci better individu receiv plegridi pegyl interferon betaa everi two week receiv everi four week second year advanc phase ii studi peopl rrms the safeti profil consist year one advanc beta interferon versus placebo dose frequenc plegridi everi two week everi four week signific reduc risk week confirm disabl progress percent dosag signific reduc annual relaps rate percent percent respect given lower risk disabl year one author studi suggest plegridi may improv recoveri follow relaps fouryear followup data ongo carem extens studi found year zero four percent individu receiv lemtrada alemtuzumab former campath experienc thyroid advers event wellknown risk treatment drug none event result discontinu treatment lemtrada thyroidrel advers event treat convent treatment the incid event peak month decreas thereaft ongo patient educ quarter laboratori monitor allow time detect treatment threeyear followup data carem ii extens studi demonstr lemtrada durabl treatment effect eighti percent individu rrms receiv two year cours drug carem ii trial receiv third cours treatment seventi percent edss score stabl improv year three compar baselin measur upon entri trial impair visual function impact disabl individu diagnos rrms in carem ii studi individu take lemtrada improv visual outcom compar take rebif studi progress ms in random trial adult chronicprogress ms arm use neuroplast brain capac chang adapt improv use therapi call constraintinduc movement therapi ci this therapi forc use affect arm restrain unaffect arm sling these result suggest ci therapi may counteract progress loss function well central nervous system cns degener progress ms pixantron pix investig altern effect cardiotox drug novantron mitoxantron mix treatment aggress rrms secondaryprogress ms spms in phase iii studi patient aggress diseas pixantron effect novantron less cardiotox accord studi abstract pixantron structur similar novantron drug similar immunosuppress properti anim studi howev author state pixantron less toxic heart in phase ii doubleblind placebocontrol studi peopl spms srcrh well toler result signific improv sever secondari endpoint these endpoint includ ms function composit msfc time foot walk mean hole peg test hpt srcrh stabil neuropeptid also known aimspro larger longerterm studi warrant given promis result the allegro bravo trial studi effect laquinimod individu rrms pool data trial examin determin effect laquinimod confirm disabl progress cdp sever subgroup includ group least favor msfc score the result encourag suggest laquinimod may benefit peopl progress type ms laquinimod experiment oral medic work immunomodul a retrospect evalu clinic outcom individu spms demonstr percent stabil percent signific improv follow treatment rituxan rituximab no signific advers event report while rituxan like continu develop treatment ms data support continu develop nextgener anticd monoclon antibodi other experiment treatment ms vitamin d a total peopl ms rrms treat either mcg alfacalcidol vitamin d analog daili six month placebo patient alfacalcidoltr group reduc number relaps compar placebo group they also experienc signific improv fatigu base fatigu improv scale fis compar placebo group qualiti life scale posit affect well no serious advers event occur either arm studi stem cell transplant the safeti feasibl autolog patient mesenchym stem cell transplant studi stream phase ii trial individu high activ ms no advers event seen five patient infus date total patient recruit preliminari result support safeti feasibl mesenchym stem cell transplant popul no data avail indic whether ms affect ofatumumab result mirror week phase ii studi compar sever dose ofatumumab also known arzerra rrms report signific reduct new gadoliniumenhanc lesion seen treatment group compar placebo five serious advers event report highest dose treatment group no case pml observ ofatumumab also known arzerra anticd monoclon antibodi given via iv antilingo the design synergi phase ii trial studi safeti efficaci antilingo monoclon antibodi biib present a total subject activ rrms spms random intraven iv infus experiment medic placebo all subject also receiv onceweek inject avonex result expect aid decis develop drug cns neuroprotect repair antilingo agent investig potenti remyelin properti anim studi show block protein respons stop growth myelin daclizumab hyp result select select extens studi indic treatment daclizumab hyp high yield process may result reduct rate brain atrophi ms patient suggest drug may longterm neuroprotect effect daclizumab also known zenapax genet engin monoclon antibodi administ via iv studi individu rrms spms siponomid baf oral drug class drug gilenya safeti efficaci result bold extens studi individu rrms demonstr sustain efficaci these find consist core bold studi no new safeti concern identifi pregnanc take dmt despit requir reliabl contracept pregnanc report women either a take aubagio clinic trial b partner men take aubagio clinic trial upon learn pregnanc women instruct discontinu aubagio undergo procedur result rapid elimin drug pregnanc outcom consist nonm popul no structur function problem report infant expos aubagio context clinic trial women rrms plan becom pregnant advis discontinu treatment tysabri concept howev known high risk sever relaps follow discontinu tysabri relaps frequent requir highdos steroid treatment manag result prospect control studi women rrms discontinu treatment pregnanc report when compar healthi diseasematch control group rate major malform low birth weight prematur birth differ signific it import weigh risk benefit continu treatment tysabri risk benefit highdos steroid treatment pregnanc onli percent women ms respond reproductiveev questionnair said reason want becom pregnant concern rais child parent ms other reason record percent want children percent unsuccess tri becom pregnant percent spous percent consid pregnanc percent adopt a retrospect analysi populationbas databas british columbia found evid infant born father expos betaseron copaxon around time concept associ alter birth weight gestat age an italian studi found infant father ms take one dmts betaseron copaxon around time concept similar outcom infant father ms take drug ever around time concept no differ observ birth weight length frequenc preterm deliveri incid spontan abort no pregnanc deliveri complic infant malform report follow exposur drug cognit a studi peopl rrms found ms relaps caus signific declin test measur cognit function treatment tysabri shown superior placebo preserv cognit function first two year therapi an interim analysi data observ studi patient treat tysabri continu two year suggest treatment preserv possibl improv cognit function beyond two year continu therapi exampl other interest studi an estim percent case ms diagnos age pediatr ms in hispan one studi found pediatr onset occur percent peopl ms includ studi in observ studi peopl diagnos ms smoke cessat found signific reduc risk progress either edss spms in group peopl rrms individu highsodium intak time like develop new lesion averag eight t lesion mri low moderatesodium intak peopl medium highsodium intak fold greater chanc experienc worsen diseas lowsodium intak the find replic separ studi peopl ms previous studi estim preval rate tast dysfunct percent ms this studi peopl ms match control found almost percent peopl ms exhibit tast dysfunct all type tast affect includ sweet sour bitter salti pleas see msaa ms research updat addit detail fdaapprov diseasemodifi therapi experiment treatment ms research for inform speak train helplin consult pleas call msaa question msaa client servic depart may also email written margaret m mccormick rn bsn mscn review jack burk md msaa chief medic offic edit susan well courtney msaa senior writer creativ director editor note msaa endors recommend specif product therapi reader advis consult physician make chang medic diet exercis treatment regimen initi studi result therapeut agent investig consid preliminari sinc addit studi andor evalu may need prove safeti efficaci agent pleas note differ length text dedic topic way consid favorit toward one product the inform given articl sampl various highlight aan meet',\n",
       "  'NN'),\n",
       " ('hello i absent site i felt good took littl cancer vacat lead relat normal life thank stereotact control met show resist tagrisso therapi current month a new brain met discov cerebellum need zap soon light balanc issu this bring back old question sep guy answer time suggest chemo tagrisso resist i agre effect brain there kadmon trial tesevatinib show success brain have develop trial meantim sinc last year this question might ask sever time im sorri bug difficult research site length without activ reader along i diagnos decemb brain met along egfr pos exon adenocarcinoma lung this decemb i reach year surviv stage desper tri delay leptomening carcinomatosi thank much suggest kempten',\n",
       "  'VBD'),\n",
       " ('cladribin easier far', 'JJ'),\n",
       " ('a a type monoclon antibodi use cancer detect therapi monoclon antibodi laboratoryproduc substanc locat bind cancer cell aap alanin aminopeptidas an enzym use biomark detect damag kidney may use help diagnos certain kidney disord it found high level urin kidney problem also call alanin aminopeptidas abarelix abarelik a drug use reduc amount testosteron made patient advanc symptomat prostat cancer treatment option avail it belong famili drug call gonadotropinreleas hormon gnrh antagonist also call plenaxi abcd rate a stage system prostat cancer use abcd a b refer cancer confin prostat c refer cancer grown prostat spread lymph node place bodi d refer cancer spread lymph node place bodi also call jewett stage system whitmorejewett stage system abdomen abdohmen the area bodi contain pancrea stomach intestin liver gallbladd organ abdomin have abdomen part bodi chest hip contain pancrea stomach intestin liver gallbladd organ abdomin xray abdahmihnul exray an xray organ insid abdomen an xray type radiat pass bodi onto film make pictur area insid bodi xray may use help diagnos diseas abdominoperin resect surgeri remov anus rectum part sigmoid colon incis made abdomen the end intestin attach open surfac abdomen bodi wast collect dispos bag outsid bodi this open call colostomi lymph node contain cancer may also remov oper aberr crypt foci uhbayrunt kript fohsi acf cluster abnorm tubelik gland line colon rectum aberr crypt foci form colorect polyp one earliest chang seen colon may lead cancer also call acf abi a drug use treat breast cancer spread come back within month chemotherapi it also studi treatment newli diagnos breast cancer type cancer abi type mitot inhibitor also call nanoparticl paclitaxel proteinbound paclitaxel paclitaxel albuminstabil nanoparticl formul abraxan ablat ablayshun in medicin remov destruct bodi part tissu function ablat may perform surgeri hormon drug radiofrequ heat method abnorm not normal an abnorm lesion growth may cancer premalign like becom cancer benign abraxan uhbraxayn a drug use treat breast cancer spread come back within month chemotherapi it also studi treatment newli diagnos breast cancer type cancer abraxan type mitot inhibitor also call nanoparticl paclitaxel proteinbound paclitaxel paclitaxel albuminstabil nanoparticl formul abi abscess an enclos collect pus tissu organ confin space bodi an abscess sign infect usual swollen inflam absorpt ubsorpshun the process take nutrient digest system blood use bodi abt a substanc studi treatment lymphoma type cancer it block enzym keep cancer cell die it type bcl famili inhibitor abt a substanc studi treatment cancer it type angiogenesi inhibitor abt a substanc studi treatment cancer it belong famili drug call sulfonamid abt a substanc studi treatment type cancer it block enzym repair dna damag caus cancer treatment radiat drug abt type polyadpribos polymeras inhibitor abxegf a human monoclon antibodi use treat colorect cancer spread part bodi it use patient whose diseas gotten better treatment anticanc drug it also studi treatment type cancer monoclon antibodi made laboratori locat bind cancer cell abxegf bind epiderm growth factor receptor egfr may block tumor cell growth also call panitumumab vectibix acceler phase chronic myelogen leukemia aksehlehrayt fayz krahnik myehlahjehnus lookeemeeuh a phase chronic myelogen leukemia diseas progress in phase cell blood bone marrow blast cell immatur blood cell ace inhibitor angiotensinconvert enzym inhibitor a drug use lower blood pressur an ace inhibitor type antihypertens agent also call angiotensinconvert enzym inhibitor acetaminophen a drug reduc pain fever inflamm it belong famili drug call analges acetylcystein a drug usual use reduc thick mucus eas remov it also use revers toxic high dose acetaminophen also call nacetylcystein nacetyllcystein acf aberr crypt foci cluster abnorm tubelik gland line colon rectum acf form colorect polyp one earliest chang seen colon may lead cancer also call aberr crypt foci achlorhydria aklorhydreea a lack hydrochlor acid digest juic stomach hydrochlor acid help digest food acitretin a substanc use prevent cancer treatment psoriasi it belong famili drug call retinoid acn a substanc studi treatment type cancer acn weaken adenovirus carri p gene tumor cell caus die it type gene therapi also call recombin adenovirusp radp sch acn a disord skin oil gland hair gland becom inflam acoust ahkoostik have sound hear acoust neurofibromatosi akoostik noorohfybrohmuhtohsi a genet condit tumor form nerv inner ear caus loss hear balanc tumor may also occur brain nerv skull spinal cord may caus loss speech eye movement abil swallow also call neurofibromatosi type nf acquir immunodefici syndrom uhkwyerd ihmyoonohdihfihshunse sindrom aid a diseas caus human immunodefici virus hiv peopl acquir immunodefici syndrom increas risk develop certain cancer infect usual occur individu weak immun system also call aid acridin carboxamid daca a substanc studi treatment cancer it type topoisomeras inhibitor also call daca acromegali akrohmehguhle a condit pituitari gland make much growth hormon normal growth skeleton finish this caus bone hand feet head face grow larger normal acromegali caus pituitari gland tumor acrylonitril akrilownyetril a substanc use make plastic rubber textil be expos acrylonitril may increas risk develop certain cancer lung brain prostat cancer acth a hormon made pituitari gland acth act outer part adren gland control releas corticosteroid hormon more acth made time stress also call adrenocorticotrop hormon corticotropin actinex a drug put skin treat growth caus sun exposur a form nordihydroguaiaret acid taken mouth studi treatment prostat cancer nordihydroguaiaret acid antioxid may block certain enzym need tumor growth also call nordihydroguaiaret acid ndga masoprocol actin keratosi aktihnik kayruhtohsi a precancer condit thick scali patch skin also call solar keratosi senil keratosi action studi in cancer prevent clinic trial studi focus find whether action peopl take prevent cancer activas aktihvay a form tissu plasminogen activ made laboratori it help dissolv blood clot use treat heart attack stroke clot lung it also studi treatment cancer it type system thrombolyt agent also call recombin tissu plasminogen activ rtpa alteplas activ in biolog stimul cell rest state becom activ this caus biochem function chang activ cell activ daili live adl the task everyday life these activ includ eat dress get bed chair take bath shower use toilet instrument activ daili live activ relat independ live includ prepar meal manag money shop housework use telephon also call adl acto a drug use treat type diabet studi prevent head neck cancer it may abl stop leukoplakia precancer condit affect mouth develop cancer it belong famili drug call thiazolidinedion also call pioglitazon acupoint akyoopoynt a specif spot bodi acupunctur needl may insert control pain symptom also call acupunctur point acupressur akyooprehsh the applic pressur local massag specif site bodi control symptom pain nausea it type complementari altern medicin acupunctur akyoopunkch the techniqu insert thin needl skin specif point bodi control pain symptom it type complementari altern medicin acupunctur needl akyoopunkch needul a stainless steel needl slight thicker human hair acupunctur needl insert skin specif point bodi control pain symptom acupunctur point akyoopunkch poynt a specif spot bodi acupunctur needl may insert control pain symptom also call acupoint acupunctur point inject akyoopunkch poynt injekshun a procedur drug vitamin herbal extract fluid inject bodi acupunctur point use syring needl acustimul mild electr stimul acupunctur point control symptom nausea vomit acut uhkyoot symptom sign begin worsen quick chronic acut leukemia uhkyoot lookeemeeuh a rapid progress cancer start bloodform tissu bone marrow caus larg number white blood cell produc enter blood stream acut lymphoblast leukemia limfohblastik lookeemeeuh all a fastgrow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call all acut lymphocyt leukemia acut lymphocyt leukemia limfohsihtik lookeemeeuh all a fastgrow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call all acut lymphoblast leukemia acut myeloblast leukemia uhkyoot myehlohblastik lookeemeeuh a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myeloid leukemia acut myelogen leukemia acut nonlymphocyt leukemia anll acut myelogen leukemia uhkyoot myehlahjehnus lookeemeeuh a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myeloid leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll acut myeloid leukemia uhkyoot myehloyd lookeemeeuh a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myelogen leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll acut nonlymphocyt leukemia uhkyoot nonlimfohsihtik lookeemeeuh a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut myelogen leukemia acut myeloid leukemia acut myeloblast leukemia aml anll acut pain uhkyoot payn pain come quick sever last relat short time acut promyelocyt leukemia uhkyoot promyehlohsihtik lookeemeeuh apl an aggress fastgrow type acut myeloid leukemia mani immatur bloodform cell blood bone marrow it usual mark exchang part chromosom also call apl promyelocyt leukemia acyclovir a substanc use prevent treat cytomegalovirus herp simplex infect may occur bodi immunosuppress it belong famili drug call antivir ad a drug use treat bladder cancer respond bcg bacillus calmett guerin it anthracyclin type antitumor antibiot also call valrubicin adderal a combin drug use treatment attent deficit hyperact disord adhd narcolepsi sleep disord it type stimul also call dextroamphetamineamphetamin addict uncontrol crave seek use substanc drug alcohol adenocarcinoma adenohkarsihnohmuh cancer begin cell line certain intern organ glandlik secretori properti adenoid cystic carcinoma adehnoyd sistik karsihnohmuh a rare type cancer usual begin salivari gland adenoma adehnohmuh a noncancer tumor adenopathi adehnahpuhthe larg swollen lymph gland adenosin triphosph uhdehnuhseen tryfosfayt atp a substanc present live cell provid energi mani metabol process involv make rna adenosin triphosph made laboratori studi patient advanc solid tumor see decreas weight loss improv muscl strength also call atp adenosquam carcinoma adenohskwaymus karsihnohmuh a type cancer contain two type cell squamous cell thin flat cell line certain organ glandlik cell adenovirus adenohvyrus a group virus caus respiratori tract eye infect adenovirus use gene therapi alter carri specif tumorfight gene adipeg a substanc studi treatment melanoma liver cancer type cancer it break amino acid arginin may block growth cancer cell need arginin grow it type iminohydrolas also call pegyl arginin deiminas adjunct agent ajunkt ayjent in cancer therapi drug substanc use addit primari therapi adjunct therapi ajunkt thayruhpe anoth treatment use togeth primari treatment it purpos assist primari treatment also call adjunct therapi adjunct therapi ajunktiv thayruhpe anoth treatment use togeth primari treatment it purpos assist primari treatment also call adjunct therapi adjust disord uhjust disord a condit person respond stress event ill job loss divorc extrem emot action caus problem work home adjuv therapi ajoov thayruhpe treatment given primari treatment increas chanc cure adjuv therapi may includ chemotherapi radiat therapi hormon therapi biolog therapi adl activ daili live the task everyday life basic adl includ eat dress get bed chair take bath shower use toilet instrument activ daili live iadl activ relat independ live includ prepar meal manag money shop housework use telephon also call activ daili live administr admihnihstrayshun in medicin act give treatment drug patient it also refer way given dose often given adnex mass adneksul a lump tissu near uterus usual ovari fallopian tube adnex mass includ ovarian cyst ectop tubal pregnanc benign noncancer malign cancer tumor adren cancer uhdreenul kanser cancer form tissu adren gland two gland locat kidney the adren gland make hormon control heart rate blood pressur import bodi function adren cancer start outsid layer adren gland call adrenocort carcinoma adren cancer start center adren gland call malign pheochromocytoma adren cortex uhdreenul kortex the outer part adren gland small organ top kidney the adren cortex make androgen corticosteroid hormon adren gland uhdreenul a small gland make steroid hormon adrenalin noradrenalin these hormon help control heart rate blood pressur import bodi function there two adren gland one top kidney also call supraren gland adren medulla uhdreenul mehdooluh the inner part adren gland small organ top kidney the adren medulla make chemic epinephrin adrenalin norepinephrin noradrenalin involv send nerv signal adrenalectomi uhdreenulektohme surgeri remov one adren gland small organ top kidney adrenalin a hormon neurotransmitt also call epinephrin adrenocort uhdreenohkortihkol have made outer layer adren gland produc steroid hormon there adren gland top kidney adrenocort cancer uhdreenohkortihkol kanser a rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort carcinoma cancer adren cortex adrenocort carcinoma uhdreenohkortihkol karsihnohmuh a rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort cancer cancer adren cortex adrenocorticotrop hormon uhdreenohkortihkohtrohpik hormon acth a hormon made pituitari gland adrenocorticotrop hormon act outer part adren gland control releas corticosteroid hormon more adrenocorticotrop hormon made time stress also call corticotropin acth adriamycin pfs aydreeuhmysin a drug use treat mani type cancer studi treatment type cancer adriamycin pfs come bacterium streptomyc peucetius it damag dna molecul insid cell carri genet inform stop cell grow rapid grow tumor cell take adriamycin pfs may die it type anthracyclin antitumor antibiot also call doxorubicin hydrochlorid doxorubicin adriamycin rdf rubex adriamycin rdf aydreeuhmysin a drug use treat mani type cancer studi treatment type cancer adriamycin rdf come bacterium streptomyc peucetius it damag dna molecul insid cell carri genet inform stop cell grow rapid grow tumor cell take adriamycin rdf may die it type anthracyclin antitumor antibiot also call doxorubicin hydrochlorid doxorubicin adriamycin pfs rubex adult tcell leukemialymphoma atll an aggress fastgrow type tcell nonhodgkin lymphoma caus human tcell leukemia virus type htlv it mark bone skin lesion high calcium level enlarg lymph node spleen liver also call atll advanc direct a legal document state treatment care person wish receiv receiv becom unabl make medic decis exampl due unconsci coma some type advanc direct live will donotresuscit dnr order advanc cancer advanst kanser cancer spread place bodi usual cannot cure control treatment advanc malign mesothelioma muhlignunt mehzuhtheeleeohmuh malign mesothelioma stage ii iii iv advers effect an unwant side effect treatment advers event adver ehvent an unexpect medic problem happen treatment drug therapi advers event caus drug therapi may mild moder sever ae a substanc made shark cartilag studi abil prevent growth new blood vessel solid tumor it belong famili drug call angiogenesi inhibitor aee a substanc studi treatment cancer it belong famili drug call protein tyrosin kinas inhibitor angiogenesi inhibitor aeg a substanc studi treatment type cancer aeg may block protein call xiap chemotherapi abl kill tumor cell it type antisens oligonucleotid also call gem aerob in biochemistri reaction need oxygen happen happen oxygen present aerob metabol a chemic process oxygen use make energi carbohydr sugar also call aerob respir oxid metabol cell respir aerob respir a chemic process oxygen use make energi carbohydr sugar also call oxid metabol cell respir aerob metabol aerodigest tract the combin organ tissu respiratori tract upper part digest tract includ lip mouth tongu nose throat vocal cord part esophagus windpip aerosol in medicin turn liquid drug fine mist inhal aflatoxin afluhtoksin a harm substanc made certain type mold aspergillus flavus aspergillus parasiticus often found poor store grain nut consumpt food contamin aflatoxin risk factor primari liver cancer afp alphafetoprotein a protein normal produc fetus afp level usual undetect blood healthi adult men women pregnant an elev level afp suggest presenc either primari liver cancer germ cell tumor also call alphafetoprotein afp a substanc studi treatment cancer afp kill cancer cell stop divid it type aminoflavon ag a substanc studi treatment cancer it belong famili drug call angiogenesi inhibitor protein tyrosin kinas inhibitor ag a substanc studi treatment cancer it belong famili drug call glycinamid ribonucleotid formyl transferas inhibitor ag a substanc studi treatment cancer it matrix metalloproteinas inhibitor belong famili drug call angiogenesi inhibitor also call prinomastat ag a substanc studi treatment liver cancer it belong famili drug call thymidyl synthas inhibitor also call thymitaq nolatrex agent studi in cancer prevent clinic trial studi whether take certain medicin vitamin miner food supplement prevent cancer also call chemoprevent studi agglutinin a substanc make particl bacteria cell stick togeth form clump mass aggrav factor agruhvayt fakter someth make condit wors for exampl tobacco smoke aggrav factor asthma aggress a quick grow cancer aggress lymphoma a type lymphoma grow spread quick sever symptom it seen frequent patient hivposit aidsrel lymphoma also call intermediategrad lymphoma highgrad lymphoma agit ajihtayshun a condit person unabl relax still the person may tens irrit becom easili annoy small thing he may eager argument unwil work caregiv make situat better agnogen myeloid metaplasia agnohjenik myehloyd mehtuhplayzhuh a progress chronic diseas bone marrow replac fibrous tissu blood made organ liver spleen instead bone marrow this diseas mark enlarg spleen progress anemia also call chronic idiopath myelofibrosi primari myelofibrosi myelosclerosi myeloid metaplasia idiopath myelofibrosi agonist a drug trigger action cell anoth drug agranulocyt aygranyoolohsit a type white blood cell monocyt lymphocyt agranulocyt aid acquir immunodefici syndrom a diseas caus human immunodefici virus hiv peopl aid increas risk develop certain cancer infect usual occur individu weak immun system also call acquir immunodefici syndrom aidsrel cancer rehlaytid kanser certain cancer type like occur peopl infect human immunodefici virus hiv the common type kaposi sarcoma nonhodgkin lymphoma other aidsrel cancer includ hodgkin diseas cancer lung mouth cervix digest system ajcc stage system stayj sistem a system develop american joint committe cancer describ extent cancer patient bodi the descript includ tnm t describ size tumor invad nearbi tissu n describ lymph node involv m describ metastasi spread cancer one bodi part anoth alanin aminopeptidas aap an enzym use biomark detect damag kidney may use help diagnos certain kidney disord it found high level urin kidney problem also call aap alanin transferas an enzym found liver tissu a high level alanin transferas releas blood may sign liver damag cancer diseas also call serum glutam pyruv transaminas sgpt alanosin a substanc studi treatment cancer it belong famili drug call antimetabolit also call sdx albin albyenizem a group genet condit mark littl none pigment melanin skin hair andor eye peopl albin may vision problem white yellow hair reddish violet blue brown eye pale skin alcl an aggress fastgrow type nonhodgkin lymphoma usual tcell type the cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call anaplast larg cell lymphoma alcohol alkuhhol a chemic substanc found beer wine liquor alcohol also found medicin mouthwash essenti oil scent liquid taken plant household product alcohol depend a diseas person crave alcohol unabl limit drink need drink greater amount get effect withdraw symptom stop alcohol use alcohol depend affect physic mental health caus problem famili friend work also call alcohol alcohol alkuhhawlihzum a diseas person crave alcohol unabl limit drink need drink greater amount get effect withdraw symptom stop alcohol use alcohol affect physic mental health caus problem famili friend work also call alcohol depend aldara aldaruh a drug use treat earli basal cell skin cancer certain skin condit it studi treatment type cancer aldara belong famili drug call biolog respons modifi also call imiquimod aldehyd aldehhid a type chemic substanc made alcohol aldehyd found essenti oil scent liquid taken plant aldesleukin aldeslookin a drug use treat type cancer it interleukin cytokin normal made immun cell bodi made laboratori aldesleukin increas activ growth white blood cell call t cell b cell it type biolog respons modifi also call recombin human interleukin proleukin aldrich syndrom aldrich sindrom an inherit immun disord occur young boy it caus eczema type skin inflamm decreas number platelet blood cell help prevent bleed frequent bacteri infect peopl aldrich syndrom increas risk develop leukemia lymphoma also call wiskottaldrich syndrom alefacept uhlehfuhsept a drug use treat certain skin condit studi treatment cutan skinrel tcell cancer tcell nonhodgkin lymphoma alefacept made combin part antibodi protein block growth type t cell it type fusion protein immunosuppress also call amev alemtuzumab a type monoclon antibodi use treatment leukemia monoclon antibodi laboratoryproduc substanc locat bind cancer cell also call campathh alendron sodium uhlendrohnayt sohdeeum a drug use treat osteoporosi paget diseas also studi treatment hypercalcemia abnorm high level calcium blood bone pain caus cancer alendron sodium increas bone densiti slow bone destruct prevent loss calcium it type bisphosphon also call fosamax alimta uhlimtuh a drug use treat malign pleural mesothelioma advanc nonsmal cell lung cancer studi treatment type cancer it type enzym inhibitor also call pemetrex disodium ly alkalin alkalinihzayshun the process substanc becom alkali an alkali opposit acid alkaloid a member larg group chemic made plant nitrogen some alkaloid shown work cancer alkeran a drug use treat multipl myeloma ovarian epitheli cancer studi treatment type cancer it belong famili drug call alkyl agent also call melphalan alkyl agent a drug use treatment cancer it interfer cell dna inhibit cancer cell growth all acut lymphoblast leukemia a fastgrow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call acut lymphoblast leukemia acut lymphocyt leukemia alltran retino acid alltranz rehtihnohik asid atra a form vitamin a made bodi also made laboratori it use treat acut promyelocyt leukemia usual togeth drug treat acn it studi treatment prevent type cancer also call atra tretinoin retino acid vitamin a acid allergen alerjen a substanc caus allerg respons exampl includ pollen mold certain food allerg respons uhlerjik rehspont a hypersensit immun reaction substanc normal harmless would caus immun respons everyon an allerg respons may caus harm symptom itch inflamm tissu injuri allogen alohjehnayik taken differ individu speci also call allogen allogen bone marrow transplant alohjehnayik bone mayroh tranzplantayshun a procedur person receiv stem cell cell blood cell develop genet similar ident donor allogen stem cell transplant alohjehnayik stem sel tranzplantayshun a procedur person receiv bloodform stem cell cell blood cell develop genet similar ident donor this often sister brother could unrel donor allogen taken differ individu speci also call allogen allopath medicin alohpathik mehdihsin a system medic doctor healthcar profession nurs pharmacist therapist treat symptom diseas use drug radiat surgeri also call convent medicin western medicin mainstream medicin orthodox medicin biomedicin allopurinol a drug lower high level uric acid byproduct metabol blood caus cancer treatment allovectin a substanc studi gene therapi agent treatment cancer it increas abil immun system recogn cancer cell kill aloeemodin a substanc found certain plant includ alo vera it belong famili compound call anthraquinon shown antiinflammatori anticanc effect alopecia alohpeeshuh the lack loss hair area bodi hair usual found alopecia side effect cancer treatment alphafetoprotein alfuhfeetohprohteen afp a protein normal produc fetus afp level usual undetect blood healthi adult men women pregnant an elev level afp suggest presenc either primari liver cancer germ cell tumor also call afp alphalipo acid alfuhlihpohik asid a substanc studi abil protect normal cell side effect chemotherapi prevent peripher neuropathi numb tingl burn weak hand feet alphalipo acid made bodi found food organ meat spinach broccoli pea brussel sprout rice bran it also made laboratori alphalipo acid type antioxid chemoprotect agent alprazolam alprayzohlam a drug use treat anxieti disord panic attack it studi treatment nausea vomit caus cancer treatment it type benzodiazepin also call xanax alteplas altehplay a form tissu plasminogen activ made laboratori it help dissolv blood clot use treat heart attack stroke clot lung it also studi treatment cancer it type system thrombolyt agent also call recombin tissu plasminogen activ rtpa activas alter a chang result someth differ origin altern medicin allternuhtiv mehdihsin practic use instead standard treatment they general recogn medic communiti standard convent medic approach altern medicin includ dietari supplement megados vitamin herbal prepar special tea acupunctur massag therapi magnet therapi spiritu heal medit altretamin an anticanc drug belong famili drug call alkyl agent alum a type immun adjuv substanc use help boost immun respons vaccin also call aluminum sulfat aluminum sulfat a type immun adjuv substanc use help boost immun respons vaccin also call alum alvaccea vaccin a cancer vaccin contain canari pox virus alvac combin human carcinoembryon antigen cea gene alveoli alveeoh tini air sac end bronchiol lung alzheim dementia altshym dihmenshuh a brain disord usual start late middl age old age get wors time symptom includ loss memori confus problem think chang languag behavior person also call alzheim diseas alzheim diseas altshym dihzeez a brain disord usual start late middl age old age get wors time symptom includ loss memori confus problem think chang languag behavior person also call alzheim dementia amanita phalloid a type poison mushroom harm effect kidney liver it respons fatal case mushroom poison also call death cap ambien a drug use treat insomnia inabl sleep anxieti it type imidazopyridin sedat hypnot also call zolpidem amd a substanc studi abil move stem cell bone marrow circul blood collect use stem cell transplant stem cell transplant method replac bloodform stem cell destroy cancer treatment amd belong famili drug call stem cell mobil cxcr inhibitor amelanot melanoma a type skin cancer cell make melanin skin lesion often irregular may pink red light brown tan gray edg amethopterin uhmethopetayrin a drug use treat type cancer sever skin condit psoriasi rheumatoid arthriti amethopterin stop cell make dna it type antimetabolit also call methotrex rheumatrex amev amehveev a drug use treat certain skin condit studi treatment cutan skinrel tcell cancer tcell nonhodgkin lymphoma amev made combin part antibodi protein block growth type t cell it type fusion protein immunosuppress also call alefacept amg a type monoclon antibodi studi treatment multipl myeloma cancer form bone prevent treatment bone metastas cancer spread bone anoth organ monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell amg bind protein rankl help keep bone break also call denosumab amg a substanc studi treatment type cancer it belong famili drug call angiogenesi inhibitor protein kinas inhibitor amifostin a drug use chemoprotect drug control side effect chemotherapi radiat therapi amikacin an antibiot drug use treat infect it belong famili drug call aminoglycosid antibiot amino acid uhmeenoh asid one sever molecul join togeth form protein there common amino acid found protein amino acid sequenc uhmeenoh asid seekwent the arrang amino acid protein protein made differ kind amino acid structur function type protein determin kind amino acid use make arrang aminocamptothecin an anticanc drug belong famili drug call topoisomeras inhibitor aminoglutethimid ameenoglootethihmid an anticanc drug belong famili drug call nonsteroid aromatas inhibitor aminoglutethimid use decreas product sex hormon estrogen women testosteron men suppress growth tumor need sex hormon grow aminoglycosid antibiot a type antibiot work mani type bacteria includ streptomycin gentamicin neomycin aminoglycosid use treat bacteri infect aminolevulin acid uhmeenohlevyoolinik asid the activ ingredi drug use treat precancer skin condit call actin keratosi it also studi treatment skin cancer type cancer when absorb cell includ cancer cell expos blue light aminolevulin acid becom activ kill cell it type prodrug type prophotosensit agent aminopterin an anticanc drug belong famili drug call antimetabolit aml a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut myelogen leukemia acut myeloid leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll amonafid a substanc studi treatment cancer it belong famili drug call topoisomeras inhibitor intercal agent amoxicillin uhmokseesihlun a drug use treat bacteri infect amoxicillin form penicillin made laboratori it weaken bacteri cell wall caus bacteria break apart it type antibiot amoxicillinclavulan potassium uhmoksihsihlin klavyoolanayt puhtaseeum a drug use treat bacteri infect ad chemic clavulan potassium antibiot amoxicillin increas amount time antibiot stay activ bodi amoxicillinclavulan potassium type combin antibiot also call augmentin amphotericin b amfuhtayrihsin a drug use treatment infect caus fungi it type antifung amplimexon amplihmekson a substanc studi treatment type cancer includ pancreat lung breast prostat melanoma multipl myeloma it belong famili drug call cyanoaziridin deriv also call imexon ampulla a saclik enlarg canal duct ampulla vater an enlarg duct liver pancrea point enter small intestin ampulla vater cancer ampuhluh vahter kanser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampullari cancer ampullari cancer ampuhlayre kanser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampulla vater cancer amput ampyootayshun surgeri remov part limb appendag amrubicin amroobihsin a substanc studi treatment lung cancer it type anthracyclin analog amsacrin an anticanc drug belong famili drug call topoisomeras inhibitor amygdalin uhmigduhlin a substanc found pit mani fruit apricot papaya food it tri countri treatment cancer shown work clinic studi amygdalin approv use unit state also call laetril amylas amilaz an enzym help bodi digest starch amyloidosi amaloydoesi a group diseas protein deposit specif organ local amyloidosi throughout bodi system amyloidosi amyloidosi may either primari known caus secondari caus anoth diseas includ type cancer general primari amyloidosi affect nerv skin tongu joint heart liver secondari amyloidosi often affect spleen kidney liver adren gland anagrelid anagrelid a drug use decreas number platelet blood order prevent blood clot anakinra anakinra a substanc use treat rheumatoid arthriti studi treatment cancer anakinra block action interleukin il it type interleukin receptor antagonist also call kinaret anal aynul have anus posterior open larg bowel anal cancer aynul kanser cancer form tissu anus the anus open rectum last part larg intestin outsid bodi analgesia anuljeezeeuh pain relief analges a drug reduc pain analges includ aspirin acetaminophen ibuprofen analog in chemistri substanc similar ident anoth analysi a process anyth complex separ simpl less complex part anaphylact shock a sever sometim lifethreaten immun system reaction antigen person previous expos the reaction may includ itchi skin edema collaps blood vessel faint difficulti breath anaplast anahplastik a term use describ cancer cell divid rapid littl resembl normal cell anaplast larg cell lymphoma anuhplastik limfohmuh an aggress fastgrow type nonhodgkin lymphoma usual tcell type the cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call alcl anaplast thyroid cancer anuhplastik thyroyd kanser a rare aggress type thyroid cancer malign cancer cell look differ normal thyroid cell anastomosi anastamosi a procedur connect healthi section tubular structur bodi diseas portion surgic remov anastrozol an anticanc drug use decreas estrogen product suppress growth tumor need estrogen grow it belong famili drug call nonsteroid aromatas inhibitor anatom anuhtahmik have anatomi studi structur plant anim anatomi uhnatohme the studi structur plant anim ancestim ansesstim a drug studi abil increas number stem cell blood it belong famili drug call hematopoiet cell growth factor also call stem cell factor scf stemgen androblastoma androhblastohmuh a rare type ovarian tumor tumor cell secret male sex hormon this may caus viril appear male physic characterist femal also call arrhenoblastoma sertolileydig cell tumor ovari androgen androhjen a type hormon promot develop mainten male sex characterist androgen ablat androhjen ablayshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen suppress androgen depriv androgen depriv androhjen dehprihvayshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen suppress androgen ablat androgen suppress androhjen suhprehshun treatment suppress block product action male hormon this done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen depriv androgenindepend androhjen describ abil tumor cell grow absenc androgen hormon promot develop mainten male sex characterist mani earli prostat cancer requir androgen growth advanc prostat cancer often androgenindepend anecdot report an incomplet descript medic treatment histori one patient anecdot report may publish place peerreview scientif journal anemia aneemeea a condit number red blood cell normal anesthesia anestheezhuh drug substanc caus loss feel awar local anesthet caus loss feel part bodi general anesthet put person sleep anesthesiologist anestheezeeahlohjist a doctor special give drug agent prevent reliev pain surgeri procedur done hospit anesthet anesthehtik a substanc caus loss feel awar local anesthet caus loss feel part bodi general anesthet put person sleep anetholtrithion a substanc studi treatment cancer angelica root anjehlihkuh root the root group herb call angelica it use cultur treat certain medic problem includ gastrointestin problem loss appetit feel full gas angiogenesi anjeeohjenehsi blood vessel format tumor angiogenesi growth blood vessel surround tissu solid tumor this caus releas chemic tumor angiogenesi inhibitor a substanc may prevent format blood vessel in anticanc therapi angiogenesi inhibitor prevent growth blood vessel surround tissu solid tumor angiogram anjeeogram an xray blood vessel person receiv inject dye outlin vessel xray angiographi anjeeahgruhfe a procedur xray blood vessel the blood vessel seen inject dye show xray pictur angioimmunoblast tcell lymphoma an aggress fastgrow type tcell nonhodgkin lymphoma mark enlarg lymph node hypergammaglobulinemia increas antibodi blood other symptom may includ skin rash fever weight loss night sweat angiomyolipoma anjeeohmyohlihpohmuh a benign noncanc tumor fat muscl tissu usual found kidney angiomyolipoma rare caus symptom may bleed grow larg enough pain caus kidney failur they common patient tuber sclerosi genet disord benign tumor grow kidney brain eye heart lung skin caus seizur mental problem skin lesion angiosarcoma anjeeosarkoma a type cancer begin cell line blood vessel lymph vessel cancer begin blood vessel call hemangiosarcoma cancer begin lymph vessel call lymphangiosarcoma angiostatin a protein normal made bodi it also made laboratori studi treatment cancer angiostatin may prevent growth new blood vessel surround tissu solid tumor it belong famili drug call angiogenesi inhibitor angiotensinconvert enzym inhibitor ace inhibitor a drug use lower blood pressur an angiotensinconvert enzym inhibitor type antihypertens agent also call ace inhibitor angiozym a substanc studi treatment kidney cancer it may prevent growth blood vessel surround tissu tumor it belong famili drug call vegf receptor angiogenesi inhibitor also call rpi anhydrovinblastin an anticanc drug belong famili drug call mitot inhibitor anidulafungin a drug use treat infect caus fungi it belong famili drug call antifung anim model an anim diseas either like diseas human anim model use studi develop progress diseas test new treatment given human anim transplant human cancer tissu call xenograft model anim studi anihmul stuhde a laboratori experi use anim studi develop progress diseas anim studi also test safe effect new treatment test peopl animalassist therapi anihmuluhsist thayruhpe a type therapi use dog pet improv physic mental health patient certain acut chronic diseas it studi way reliev distress cancer patient undergo treatment pain also call petfacilit therapi anll a quick progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut nonlymphocyt leukemia acut myelogen leukemia acut myeloblast leukemia acut myeloid leukemia aml annamycin a substanc studi treatment cancer it belong famili drug call anthracyclin antibiot anorexia an abnorm loss appetit food anorexia caus cancer aid mental disord ie anorexia nervosa diseas anorexia nervosa an eat disord mark intens fear gain weight refus maintain healthi weight distort bodi imag peopl anorexia nervosa abnorm loss appetit food tri avoid eat eat littl possibl an autonom nervous system the part nervous system control muscl intern organ heart blood vessel lung stomach intestin gland salivari gland sweat gland one part an help bodi rest relax digest food anoth part help person fight take flight emerg also call autonom nervous system involuntari nervous system ansamycin an anticanc drug belong famili drug call antineoplast antibiot antagonist in medicin substanc stop action effect anoth substanc for exampl drug block stimul effect estrogen tumor cell call estrogen receptor antagonist anterior anteere in human anatomi front structur structur found toward front bodi anterior mediastinotomi anteere meedeeastihnahtohme a procedur tube insert chest view tissu organ area lung breastbon heart the tube insert incis next breastbon this procedur usual use get tissu sampl lymph node left side chest also call chamberlain procedur anterior mediastinum the area front part chest lung also call prevascular space anterior pelvic exenter anteere pelvik ekzenterayshun surgeri remov urethra lower part uret uterus cervix vagina bladder anterior urethr cancer anteere yooreethrul kanser a diseas malign cancer cell found part urethra tube urin leav bodi closest outsid bodi anthracenedion an anticanc drug belong famili drug call anticanc antibiot anthracyclin a type antibiot come fungus streptococcus peucetius anthracyclin use treatment cancer daunorubicin doxorubicin epirubicin anthracyclin anthraquinon a type anticanc drug anticd immunotoxin ihmyoonohtoksin a monoclon antibodi link toxic substanc it studi treatment type bcell cancer anticd immunotoxin made laboratori it bind cd protein surfac normal b cell bcell tumor kill cell anticd immunotoxin ihmyoonohtoksin a monoclon antibodi link toxic substanc it studi treatment type bcell cancer anticd immunotoxin made laboratori it bind cd protein surfac normal b cell bcell tumor kill cell anticd immunotoxin cat ihmyoonohtoksin a monoclon antibodi link toxic substanc it studi treatment type bcell cancer anticd immunotoxin cat made laboratori it bind cd protein surfac normal b cell bcell tumor kill cell also call cat anticea antibodi an antibodi carcinoembryon antigen cea protein present certain type cancer cell antiepcampseudomonasexotoxin fusion protein soodohmohnuseksohtoksin fyoozhun prohteen a substanc studi treatment certain type head neck cancer antiepcampseudomonasexotoxin fusion protein made link monoclon antibodi fragment toxic protein may kill cancer cell it bind epcam protein surfac epitheli cell type cancer cell also call vb proxinium antiidiotyp vaccin a vaccin made antibodi see antibodi antigen bind antiidiotyp vaccin stimul bodi produc antibodi tumor cell antiil chimer monoclon antibodi kymeerik mahnohklohnul antihbahde a chimer made human mous protein monoclon antibodi studi treatment advanc kidney cancer type cancer monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell antiil chimer monoclon antibodi work block inflamm tumor growth also call cnto cclb antiinflammatori have reduc inflamm antimesothelin monoclon antibodi morab anteemezohtheelin mahnohklohnul anteebahde a monoclon antibodi studi treatment type cancer monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell antimesothelin monoclon antibodi morab bind mesothelin protein made cancer cell stop cell divid also call morab antitgfbeta monoclon antibodi gc mahnohklohnul anteebahde a monoclon antibodi studi treatment kidney cancer melanoma pulmonari fibrosi monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell antitgfbeta monoclon antibodi gc bind protein transform growth factorbeta tgf may block growth cancer cell make also call gc antiandrogen anteeandrohjen a drug use block product interfer action male sex hormon antiandrogen therapi anteeandrohjen thayruhpe treatment drug use block product interfer action male sex hormon antiangiogenesi prevent growth new blood vessel antiangiogen have reduc growth new blood vessel antiapoptot someth prevent apoptosi apoptosi type cell death seri molecular step cell lead death antibacteri anteebakteereeul a substanc kill bacteria stop grow caus diseas antibiot antihbyahtik a drug use treat infect caus bacteria microorgan antibodi anteebahde a type protein made plasma cell type white blood cell respons antigen foreign substanc each antibodi bind one specif antigen the purpos bind help destroy antigen antibodi work sever way depend natur antigen some antibodi destroy antigen direct other make easier white blood cell destroy antigen antibodi therapi anteebahde thayruhpe treatment antibodi substanc direct kill specif tumor cell stimul immun system kill tumor cell anticachexia anteekakekseea describ drug effect work cachexia loss bodi weight muscl mass anticanc antibiot a type anticanc drug block cell growth interf dna genet materi cell also call antitumor antibiot antineoplast antibiot anticarcinogen anteekarsinojenik have prevent delay develop cancer anticoagul a drug help prevent blood clot form also call blood thinner anticonvuls anteekonvuls a drug substanc use prevent stop seizur convuls also call antiepilept antidepress a drug use treat depress antidiarrh anteedyuhreeul a substanc use treat diarrhea frequent wateri bowel movement antiemet anteeehmehtik a drug prevent reduc nausea vomit antiepilept anteeehpihleptik a drug substanc use prevent stop seizur convuls also call anticonvuls antiestrogen a substanc block activ estrogen famili hormon promot develop mainten femal sex characterist antifol a substanc block activ folic acid antifol use treat cancer also call folat antagonist antifung a drug treat infect caus fungi antigen a substanc caus immun system make specif immun respons antigenpres cell apc a cell show antigen surfac cell immun system this import part immun respons also call apc antigenpres cell vaccin a vaccin made antigen antigenpres cell apc also call apc vaccin antiglobulin test a laboratori test identifi antibodi bind surfac red blood cell platelet destroy this test use diagnos certain blood disord patient make antibodi red blood cell platelet it also use determin blood type also call coomb test antihistamin anteehistuhmeen a type drug block action histamin caus fever itch sneez runni nose wateri eye antihistamin use prevent fever patient receiv blood transfus treat allergi cough cold antihormon therapi anteehormon thayruhpe treatment drug surgeri radiat order block product action hormon antihormon therapi may use cancer treatment certain hormon abl stimul growth type tumor antimetabolit a drug similar natur chemic normal biochem reaction cell differ enough interfer normal divis function cell antimicrobi anteemykrohbeeul a substanc kill microorgan bacteria mold stop grow caus diseas antimicrotubul agent a type drug block cell growth stop mitosi cell divis antimicrotubul agent interfer microtubul cellular structur help move chromosom mitosi they use treat cancer antimitot agent a type drug block cell growth stop mitosi cell divis they use treat cancer also call mitot inhibitor antineoplast a substanc block format neoplasm growth may becom cancer antineoplast antibiot a type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antitumor antibiot antineoplaston a substanc isol normal human blood urin test type treatment tumor aid antioxid anteeoksihd a substanc protect cell damag caus free radic unstabl molecul made process oxid normal metabol free radic may play part cancer heart diseas stroke diseas age antioxid includ betacaroten lycopen vitamin a c e natur manufactur substanc antiparasit a drug use treat infect caus bacteria parasit it also use treatment cancer antiprogestin anteeprohjestin a substanc prevent cell make use progesteron hormon play role menstrual cycl pregnanc antiprogestin may stop cancer cell grow studi treatment breast cancer an antiprogestin type hormon antagonist antiretrovir therapi anteerehtrohvyrul thayruhpe treatment drug inhibit abil human immunodefici virus hiv type retrovirus multipli bodi antisens cfos synthet genet materi may slow stop growth cancer cell antithymocyt globulin anteethighmosit globyoolin a protein use reduc risk treat graftversushost diseas antituberculosi anteetooberkyoolowsi describ drug effect work tuberculosi contagi bacteri infect usual affect lung antitumor anteetoom have stop abnorm cell growth antitumor antibiot a type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antineoplast antibiot antivir a drug use treat infect caus virus anus aynus the open rectum outsid bodi anxieti angzyuhte feel fear dread uneasi may occur reaction stress a person anxieti may sweat feel restless tens rapid heart beat extrem anxieti happen often time may sign anxieti disord anxiolyt a drug use treatment anxieti muscl spasm aorta aortuh the largest arteri bodi it carri oxygenrich blood away heart vessel reach rest bodi aortocoronari bypass ayortohkoruhnayre bypass surgeri healthi blood vessel taken anoth part bodi use make new path blood around block arteri lead heart this restor flow oxygen nutrient heart also call coronari arteri bypass cab ap a drug use treat soft tissu bone sarcoma it also studi treatment solid tumor hematolog cancer ap may control growth blood vessel cancer it belong famili drug call rapamycin analog ap a substanc studi treatment head neck cancer it may kill cancer cell carri anticanc drug tumor it type platinum compound apc antigenpres cell a cell show antigen surfac cell immun system this import part immun respons also call antigenpres cell apc vaccin a vaccin made antigen antigenpres cell apc also call antigenpres cell vaccin apc a vaccin made immun system cell collect patient prostat cancer the cell treat laboratori growth factor attach protein found prostat cell cancer cell apc inject patient may stimul t lymphocyt kill tumor cell express prostat protein also call proveng sipuleucelt apheresi a procedur blood collect part blood platelet white blood cell taken rest blood return donor also call pheresi apl acut promyelocyt leukemia an aggress fastgrow type acut myeloid leukemia mani immatur bloodform cell blood bone marrow it usual mark exchang part chromosom also call acut promyelocyt leukemia promyelocyt leukemia aplast anemia a condit bone marrow unabl produc blood cell aplidin a substanc studi treatment cancer it obtain marin organ apocrin gland a type gland found skin breast eyelid ear apocrin gland breast secret fat droplet breast milk ear help form earwax apocrin gland skin eyelid sweat gland most apocrin gland skin armpit groin area around nippl breast apocrin gland skin scent gland secret usual odor anoth type gland eccrin gland simpl sweat gland produc sweat apolizumab a type monoclon antibodi studi treatment hematolog blood cancer monoclon antibodi laboratoryproduc substanc locat bind cancer cell apoptosi apoptohsi a type cell death seri molecular step cell lead death this bodi normal way get rid unneed abnorm cell the process apoptosi may block cancer cell also call program cell death appendectomi apendektohme surgeri remov appendix small fingershap pouch end first part larg intestin appendix a small fingerlik pouch stick cecum first part larg intestin near end small intestin appetit apehtit a desir satisfi physic mental need food sex adventur aprepit uhprehpihtunt a drug use prevent control nausea vomit caus chemotherapi it use togeth antivomit medicin it belong famili drug call antiemet agent also call emend aqueous have water arctigenin a substanc found certain plant includ burdock it shown antivir anticanc effect arctigenin belong group substanc call lignan arctiin a substanc found certain plant includ burdock it shown anticanc effect arctiin belong group substanc call lignan areola areeola the area darkcolor skin breast surround nippl arginin arjihneen one twenti common amino acid build block protein arginin studi nutrit supplement treatment prevent cancer condit also call larginin arginin butyr a substanc studi treatment cancer arixtra uhrikstruh a drug use prevent blood clot form insid blood vessel leg it studi prevent blood clot cancer patient includ women surgeri cancer reproduct tract it type anticoagul also call fondaparinux fondaparinux sodium aromasin uhrohmuhsin a drug use treat advanc breast cancer prevent recurr breast cancer postmenopaus women alreadi treat tamoxifen it also studi treatment type cancer aromasin caus decreas amount estrogen made bodi it belong famili drug call aromatas inhibitor also call exemestan aromatas inhibitor uhrohmuhtayz inhihbiht a drug prevent format estradiol femal hormon interf aromatas enzym aromatas inhibitor use type hormon therapi postmenopaus women hormonedepend breast cancer aromatherapist uhrohmuhthayruhpist a person practic type complementari medicin call aromatherapi this therapi use plant oil give strong pleasant smell promot relax sens wellb the plant oil usual inhal put skin use wet cloth bath massag aromatherapi uhrohmuhthayruhpe a type complementari altern medicin use plant oil give strong pleasant aroma smell promot relax sens wellb heal aromatherapi infus uhrohmuhthayruhpe infyoozhun the process heat without boil mixtur water essenti oil scent liquid taken plant releas pleasant aroma aromatherapi infus may also refer process heat herb liquid releas essenti oil inhal oxygen scent aromatherapi infus studi complementari therapi use addit standard treatment reliev pain shorten recoveri time patient undergo colonoscopi aromatherapi massag uhrohmuh thayruhpe muhsazh a type complementari altern medicin use rub knead skin plant oil give strong pleasant aroma smell promot relax sens wellb heal aromat aruhmatik have odor often pleasant spici arous uhrowzul the state alert readi respond wake sleep arranon ayrrahnon a drug use treat certain type tcell acut lymphoblast leukemia tall tcell lymphoblast lymphoma tlbl it belong famili drug call antimetabolit also call nelarabin u arrhenoblastoma uhreenohblastohmuh a rare type ovarian tumor tumor cell secret male sex hormon this may caus viril appear male physic characterist femal also call androblastoma sertolileydig cell tumor ovari arsenic a poison chemic use kill weed pest also use cancer therapi arsenic trioxid arsehnik tryoksid a drug use treat acut promyelocyt leukemia apl gotten better come back treatment anticanc drug it also studi treatment type cancer also call trisenox arteri embol arteere embolihzayshun the block arteri clot foreign materi this done treatment block flow blood tumor arteriogram arteereeogram an xray arteri person receiv inject dye outlin vessel xray arteriographi arteereeahgruhfe a procedur xray arteri the arteri seen inject dye outlin vessel xray arteri artuhre a blood vessel carri blood heart tissu organ bodi arthralgia arthraljuh joint pain arthriti a diseas caus inflamm pain joint artifici pacemak artihfihshul paysmayk an electron devic implant bodi monitor heart rate rhythm it give heart electr stimul beat normal it run batteri long thin wire connect heart also call pacemak cardiac pacemak asbesto asbestus a natur materi made tini fiber asbesto caus sever serious diseas includ cancer ascit uhsyteez abnorm buildup fluid abdomen may caus swell in latestag cancer tumor cell may found fluid abdomen ascit also occur patient liver diseas ascorb acid uhskorbik asid a key nutrient bodi need fight infect heal wound keep tissu healthi includ blood vessel cartilag ligament tendon bone muscl skin teeth gum it antioxid help prevent tissu damag caus free radic the bodi make store ascorb acid must taken everi day it found mani fruit veget especi green pepper citrus strawberri tomato broccoli leafi green potato cantaloup also call vitamin c asparaginas an enzym use treatment cancer it belong famili drug call antineoplast aspart transaminas an enzym found liver heart tissu a high level aspart transaminas releas blood may sign liver heart damag cancer diseas also call serum glutamicoxaloacet transaminas sgot aspergillosi an infecti fungal diseas occur often skin ear nasal sinus lung peopl suppress immun system aspergillus a famili fungi common found soil certain type may caus diseas especi peopl suppress immun system aspir aspirit fluid withdrawn lump often cyst nippl aspir asperayshun remov fluid tissu needl also accident breath food fluid lung aspirin a drug reduc pain fever inflamm blood clot aspirin belong famili drug call nonsteroid antiinflammatori agent it also studi cancer prevent assay assay a laboratori test find measur amount specif substanc assess uhsess in healthcar process use learn patient condit this may includ complet medic histori medic test physic exam test learn skill test find patient abl carri task daili live mental health evalu review social support communiti resourc avail patient assist devic uhsisstiv a tool help person disabl certain task exampl cane wheelchair scooter walker hear aid special bed assist technolog uhsistiv teknahlohje ani devic technolog help disabl person exampl special grip hold utensil comput screen monitor help person low vision read easili comput control talk telephon make sound louder lifter help person rise chair asthenia weak lack energi strength asthma azmuh a chronic diseas bronchial airway lung becom narrow swollen make difficult breath symptom includ wheez cough tight chest short breath rapid breath an attack may brought pet hair dust smoke pollen mold exercis cold air stress astrocyt astrohsit a starshap cell help nerv cell brain spinal cord work way an astrocyt type glial cell astrocytoma astrohsytohmuh a tumor begin brain spinal cord small starshap cell call astrocyt asymmetri lack absenc balanc proport part thing asymptomat have sign symptom diseas',\n",
       "  'NNS'),\n",
       " ('would like see ongo forum topic admor data becom avail educ decis csn made specif protocol stay keytruda ned the patient year old male diagnos stage iv adeo nsclc follow pleural effus cancer lung pleural caviti lymph node upper abdomen pdl express has keytruda three month remark pet scan show full remiss ned no side effect ftom keytruda ani new data potenti immun system learn find cancer use ani protocol establish recontinu treatment this topic modifi month ago hherpel this topic modifi month ago hherpel',\n",
       "  'VBP'),\n",
       " ('i know im good blogger right ive tri find time energi verv mayb it kind challeng post infus week i cannot lie hell it realli coupl damn day infus day brought yet anoth allerg reaction ocrevus they stop drip give benedryl twice turn infus day hour joy ride i lie it joy the benedryl made feel hop instead sleepi like usual i didnt sleep wink entir time i infus i also slept like crap night i got home there most new crop fellow infuse room time i die write bring next challeng my left hand sudden numb complet blue i cant feel left hand especi left pinki finger made type anyth phone real challeng write phone work pinch general led insight prolif work so ive avoid hell ive avoid ive main unconsci hope feel human next i open eye numb hand isnt help matter i promis better entertain write soon until im usual postinfus thing like tri panic get lot lot rest eat proper eff liquid diet enjoy gray day pajama whilst various confer call tomorrow better if tomorrow better day im tri cultiv posit outlook it thing keep post blog entri isnt mere eff word page upon page without end it suggest i might get reader i wasnt socolor use languag im tri resist urg not realli that would dumb if noth els im get realli good resist urg upsid detect wonder twin power activ shape ofposit form ofment patient anyway im hang my numb hand die write thumb type start irrit im gonna cut one bit short thank reach check it good know i couldnt disappear without trace nari soul notic you guy realli awesom way and everi way until i longer numb andor sleep hour day stay well friend ill back you wont rid easili namast',\n",
       "  'JJ'),\n",
       " ('first thank much help histolog we hear highunaccept risk pneumon go specif tagrissoazd immunotherapi i read articl said pdls lower risk pneumon pds due method action i see opdivopd tecentriqpdl advertis egfr patient progress chemo egfr target therapi that wife ani inform whether aforement higher risk go tagrisso immunotherapi true risk lower go pdltecentriq onli option us point appear chemo applic trialsegf asp hm recruit immunotherapi appear toxic sequenti treatment egfr inhibitor tagrisso immunotherapi stage iv nsclc adeno egfr mutat tarceva help carboavastinalimta month avastin mainten month afatanib month clovisco month tagrissoazd month progress',\n",
       "  'NN'),\n",
       " ('hi all i dont post often i read time i took final gilenya tablet last sunday begun scari wash period prelamtrada i week cours steroid go hope begin round those lemtrada regard listeria diet stay away take away my diet sheet say ensur food washedh correct cours cant ensur take away also luncheon meat includ ham i ask lemtrada specif page also thank x',\n",
       "  'NN'),\n",
       " ('in us ixifi pharmacolog class infliximab use for infliximabqbtx infliximabqbtx inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi it also use children treat crohn diseas infliximabqbtx inject monoclon antibodi work enhanc improv immun system infliximabqbtx avail doctor prescript befor use infliximabqbtx in decid use medicin risk take medicin must weigh good this decis doctor make for infliximabqbtx follow consid allergi tell doctor ever unusu allerg reaction infliximabqbtx medicin also tell health care profession type allergi food dye preserv anim for nonprescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatricspecif problem would limit use infliximabqbtx inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform date demonstr infliximabqbtx inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatricspecif problem would limit use infliximabqbtx inject elder howev elder patient like infect may requir caution patient receiv infliximabqbtx inject breast feed there adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur in case doctor may want chang dose precaut may necessari when receiv infliximabqbtx especi import healthcar profession know take medicin list the follow interact select basi potenti signific necessarili allinclus use infliximabqbtx follow medicin usual recommend may requir case if medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenovirus vaccin type live adenovirus vaccin type live alefacept anakinra bacillus calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza virus vaccin live ixekizumab measl virus vaccin live mump virus vaccin live natalizumab paclitaxel phenytoin poliovirus vaccin live quinidin rilonacept rituximab rotavirus vaccin live rubella virus vaccin live sarilumab sirolimus smallpox vaccin tacrolimus tocilizumab tofacitinib typhoid vaccin ustekinumab varicella virus vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact foodtobaccoalcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco other medic problem the presenc medic problem may affect use infliximabqbtx make sure tell doctor medic problem especi aspergillosi fungus infect histori blastomycosi fungus infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungus infect histori coccidioidomycosi fungus infect histori diabet guillainbarr syndrom nervous system disord histori hepat b activ histori histoplasmosi fungus infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungus infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet bloodus caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copdus caution may increas chanc new cancer congest heart failur moder severeshould given patient condit tuberculosi histori ofus caution patient may need addit tuberculosi treatment proper use infliximabqbtx a doctor train health profession give infliximabqbtx it given needl place one vein it must given slowli needl remain place least hour infliximabqbtx come medic guid read follow instruct care ask doctor question you may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut while use infliximabqbtx it import doctor check progress regular visit make sure infliximabqbtx work proper blood test may need check unwant effect infliximabqbtx may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat your bodi abil fight infect may reduc use infliximabqbtx it import call doctor first sign infect check doctor right away fever chill cough flulik symptom unusu tired weak you need skin test tuberculosi start receiv infliximabqbtx tell doctor anyon home ever posit reaction tuberculosi skin test a small number peopl includ children teenag use infliximabqbtx develop certain type cancer this common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light some teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen tcell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pus skin receiv infliximabqbtx may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer if chang growth skin abnorm vagin bleed pelvic pain check doctor right away it import heart check close receiv infliximabqbtx call doctor right away difficulti breath swell ankl feet sudden weight gain serious skin reaction occur receiv infliximabqbtx check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximabqbtx may increas chanc lupuslik syndrom liver diseas call autoimmun hepat check doctor right away dark browncolor urin fever chill general feel discomfort ill weak joint pain lightcolor stool nausea vomit rash cheek arm wors sun sever tired upper rightsid stomach pain yellow eye skin while treat infliximabqbtx immun vaccin without doctor approv live virus vaccin given infliximabqbtx your child vaccin must current receiv infliximabqbtx talk child doctor question women if babi receiv infliximabqbtx make sure babi doctor know receiv infliximabqbtx you need wait month give certain vaccin babi talk babi doctor question do take medicin unless discuss doctor this includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximabqbtx use medicin togeth infliximabqbtx may increas chanc serious unwant effect infliximabqbtx side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur more common black tarri stool bladder pain bloodi cloudi urin blur vision bodi ach pain chest pain chill cough cough produc mucus difficult burn pain urin difficulti breath dizzi dryness sore throat ear congest fever frequent urg urin headach hoars itch rash loss voic lower back side pain nasal congest nervous pain swell arm leg pain tender around eye cheekbon pain difficult urin pale skin pound ear slow fast heartbeat sneez sore ulcer white spot lip mouth stuffi runni nose swollen gland tender swollen gland neck tight chest troubl swallow troubl breath troubl breath exert unusu bleed bruis unusu tired weak voic chang rare bleed gum blood stool blue lip fingernail blur vision chang skin color tender foot leg chest discomfort confus cough sometim produc pink frothi sputum dark urin decreas urin dizzi faint lightheaded get sudden lie sit posit dri mouth fast noisi breath feel discomfort general feel ill general tired weak high fever hive increas heart rate increas sweat inflamm joint irregular heartbeat lightcolor stool muscl ach nausea pinpoint red spot skin puffi swell eyelid around eye face lip tongu rapid shallow breath sunken eye thirst upper right abdomin pain vomit weight loss wrinkl skin yellow eye skin incid known back pain sudden sever blister peel loosen skin bloodi nose burn tingl numb pain hand arm feet leg chang mental status claycolor stool diarrhea difficulti speak dilat neck vein doubl vision heavier menstrual period inabl move arm leg facial muscl inabl speak loss appetit muscl weak sudden progress red irrit eye red skin lesion often purpl center seizur sensat pin needl slow irregular breath slow speech stab pain temporari vision loss vomit blood weight gain some side effect may occur usual need medic attent these side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question more common belch diarrhea difficulti move feel warmth heartburn indigest muscl stiff red face neck arm occasion upper chest less common constip sever other side effect list may also occur patient if notic effect check healthcar profession call doctor medic advic side effect you may report side effect fda fda',\n",
       "  'NN'),\n",
       " ('chronic lymphocyt leukemia cll common leukemia adult focus headlin recent year enorm progress treatment within past six year seven novel drug approv health canada treat condit four monoclon antibodi rituxan rituximab campath alemtuzumab gazyva obinutuzumab arzerra ofatumumab three small molecul inhibitor imbruvica ibrutinib zydelig idelalisib venclexta venetoclax treanda bendamustin standard chemotherapi agent recent approv combin rituxan these new treatment would great news clinician patient except equal access across provinc in fact canada numer health system mean patient access often determin postal code still cll care continu chang outlook live what is cll cll origin bone marrow blood cell form the b lymphocyt matur type white blood cell start grow surviv beyond normal life span these leukemia cell may look somewhat normal microscop reproduc rapid surviv longer normal cell crowd blood cell main red cell involv oxygen deliveri platelet cell fragment help blood clot in sever case number neutrophil white blood cell part immun system may affect the cancer cell receiv growth surviv signal bone marrow lymph node caus circul blood system regular basi as result patient may symptom diagnosi except abnorm lymphocyt count each year peopl diagnos cll canada peopl die what are the symptom of cll at diagnosi peopl cll awar symptom say versha banerji md frcpc hematologist cll clinic univers manitoba cancercar manitoba veri often primari physician see elev white blood cell count routin blood test say sometim patient may fever chill notic weight loss most advanc stage diseas these symptom addit fatigu chang appetit sleep bleed bruis easili andor enlarg spleen liver lymph node call visit doctor how is cll diagnos and stage cll diagnos simpl blood test if person come high white cell count basic use flow cytometri type electron cell analysi look cll cell say banerji see patient everi year if result posit patient sent cll clinic treatment plan discuss there two stage system doctor use predict diseas progress rai stage system binet stage system banerji use rai system classifi cll five stage rang lowrisk vari degre highrisk associ presenc enlarg lymph node andor spleen elev lymphocyt count low platelet count andor low level hemoglobin protein whose job transport oxygen within bodi treatment decis determin right treatment plan cll complic ever banerji say initi standard treatment rang watch wait chemotherapi intermedi highrisk cll target therapi use chemotherapi cancer longer respond recur stem cell transplant still avail longer consid part routin care banerji consid three factor determin treatment age fit molecular marker age broken two categori year year fit score use cir ill rate scale predict patient abil toler certain treatment consid fit deem unfit this grade subject use heavili clinic trial cll identifi molecular marker genet mutat treatabl drug also import molecular marker help us determin patient live long period without treatment progress diseas say the abil identifi marker realli chang cll experi mani peopl one exampl test look mutat igvh gene we know peopl igvh mutat tend better outcom unmut igvh say but need test tell us manitoba exampl dont access unfortun everi patient cll access test canada fragment come test capabl say banerji it frustrat clinician patient may get treatment appropri target could as sever provinc unless compassion program offer manufactur patient privat insur option left pay pocket quit burdensom opt this prompt banerji take role advoc addit busi role clinician senior scientist togeth clinic team work provinci diagnost lab cancercar manitoba make treatmentguid test like one igvh avail manitoba the chang dialogu even without univers access test outlook patient cll improv great we mani option cll even year ago chang everyth banerji say earli discuss patient use desper now hope befor would tell patient chemotherapi transplant treatment would deal side effect went along now choic patient also play activ role health patient engag ever say we talk prognosi also want life goal futur the import of support despit good news cll cancer diagnosi still scari connect communiti familiar journey critic better understand diseas move forward treatment one communiti canadian cll patient advocaci group reach cllpagca other resourc includ leukemia lymphoma societi canada lymphoma canada lymphoma coalit cll challeng diagnosi say deborah baker past chair cll patient advocaci group board director one way patient caregiv feel control access communiti peopl share experi these peopl valuabl sourc educ advic support end connect great improv outcom this articl part bring cll communiti togeth program fund provid unrestrict educ grant pharmacycl abbvi compani janssen biotech inc',\n",
       "  'NN'),\n",
       " ('it aw diseas get least lot less fund oppos breast cancer etc due stigma origin attach smoker get i guess even time present symptom cancer perhap alreadi progress would like i guess i feel let oncologist slight alway name mum one special patient due fact fit healthi last summer right gene mutat perhap put much pedest patient azdtagrisso fine she say wonder made right decis put faith doctor medic staff i expect get letter oncologist still noth i sure tagrisso would work even though struggl get bed seat left hospit even realis would gone less two hour later i feel like i let ask dad die said doctor werent over clear look back i think nurs tri tell us i alway thought would ok even though knew diagnos termin take care jim',\n",
       "  'NN'),\n",
       " ('some med like fingolimod affect respons vaccin still respons bodi immun system the flu jab live vaccin safe take peopl dmt i alway flu vaccin flu could trigger relaps it may unlucki get doubl viral infect run first i obsess hand washinghand sanit i work educ student germ pool wish better',\n",
       "  'NN'),\n",
       " ('not sure week pred accomplish the minimum durat treatment month moder ulcer coliti john uc proctosigmoid rx remicad mgskgwks daili mgs mp g genericlialda rowasa you cannot spell suck without uc',\n",
       "  'JJ'),\n",
       " ('hi liz consid ms around long time much fund spent drug i chose none medic rout experi guinea pig ive trial mani natur remidi exercis eat balanc diet it far better health after offer fingolimod experi baclofen antidepress pot luck stuff life far better tri differ approach life seem work wonder along avoid stress head folk stuck routin all best terri',\n",
       "  'NN'),\n",
       " ('hello everyon i remicad year final develop antibodi i tri entyvio coupl year ago advers reaction i larg bowel resect end colostomi octob my crohn diseas symptom improv sinc surgeri howev eye jointmuscl pain inflamm poor i stop remicad antibodi my gi wonder howev said well tri humira cimzia stelara it one prefer it like crap shoot lol should i toss name cup draw one ani suggest would great appreci i develop crohn small intestin besid remicad i mg prednison daili thank much juli',\n",
       "  'NN'),\n",
       " ('my mom diagnos progress ms late i stage she wheelchair cant walk past year so im write post get advic she got first dose drug name ocrevusi anyon els take drug there one post feelingha help themi work ani inform would great appreci',\n",
       "  'NN'),\n",
       " ('cladribin label ukmayb start everyon clad fail tri one other what think it would save nhs alot cashhop lost legal fee as listen mexican doctorsmayb infus dont need hsctthe data',\n",
       "  'NN'),\n",
       " ('home ms inform public ms research updat ocrevus ocrelizumab ocrevus ocrelizumab in updat main articl introduct fdaapprov medic experiment medic new direct ms research close note approv diseasemodifi therapi ms pdf refer fdaapprov medic new data compani genentech roch pharma ag mg given via iv infus everi six month approv rms ppms next zinbryta ocrevus anticd monoclon antibodi while similar medic rituxan rituximab ocrevus potenti advantag human antibodi rituxan human monoclon antibodi antibodi nonhuman speci mice whose protein sequenc modifi increas similar antibodi produc natur human in march ocrevus fda approv use rms ppms the approv base larg result three import studi announc in relaps ms ocrelizumab met primari major secondari endpoint phase iii opera i opera ii studi the opera studi ident design the total combin enrol studi individu relaps form ms in opera studi individu receiv either mg ocrelizumab via intraven iv infus everi six month approv mcg dose rebif interferon betaa given via subcutan inject threetim week particip receiv ocrelizumab signific reduct studi annual relaps rate percent twoyear period versus interferon group addit ocrelizumab group new mri lesion reduc percent brain atrophi decreas percent risk progress sustain clinic disabl decreas percent a analysi opera trial data report februari found patient receiv ocrevus fare better receiv interferon betaa composit measur assess absenc relaps confirm disabl progress mri diseas activ the endpoint known evid progress activ diseas nepad the research found percent patient receiv ocrevus nepad week studi start versus percent peopl receiv interferon betaa the fdas approv ocrevus ppms base part result oratorio studi publish prior studi phase iii studi ppms success despit multipl attempt oratorio random doubleblind global multicent trial studi effect safeti ocrevus compar placebo peopl ppms everi six month two mg infus total mgs given two week apart member treatment group compar placebo group the studi primari endpoint time onset confirm disabl progress defin increas expand disabl status scale edss sustain least week the edss score function scale higher score refer disabl the oratorio studi met primari endpoint show ocrelizumab signific reduc progress clinic disabl sustain least week percent compar placebo walk speed measur time foot walk improv percent mri hyperintens t lesion actual reduc ocrevus brainvolum loss view mri reduc percent the incid advers event associ ocrevus similar placebo common advers event mildtomoder infusionrel reaction in post hoc set analys report februari investig found ocrevus reduc risk progress sever upper extrem disabl function impair frequent occur ppms when patient enter oratorio trial everi week thereaft throughout studi particip complet test involv place peg hole confirm progress measur chang time requir perform test compar placebo ocrevus reduc risk confirm signific progress percent greater increas test time hand percent week percent week ocrevus also reduc risk progress term patient selfidentifi best hand worst hand the period sinc fdas approv ocrevus also seen first report case progress multifoc leukoencephalopathi pml rare potenti fatal brain infect patient take medic assess role ocrevus may play develop pml advers event quit complic particular individu previous taken dmts known associ risk event for exampl first person take ocrevus report pml taken tysabri natalizumab three year prior begin ocrevus an increas risk pml previous link tysabri fda approv use relaps form ms also decemb postmarket surveil ocrevus record death among patient treat medic worldwid addit eight peopl die clinic trial involv rough particip the caus death vari case unknown cancer death report while physician regul medic manufactur other monitor postapprov efficaci safeti profil ocrevus difficult point discern signific data meanwhil januari european commiss approv ocrevus use treat rms ppms ongo research ocrevus includ openlabel studi peopl rrms assess impact medic individu suboptim respons dmts next zinbryta daclizumab',\n",
       "  'NN'),\n",
       " ('earli analysi studi human embryon stem cell hescderiv retin pigment epithelium rpe implant suggest procedur well toler patient dri amd indic structur retin improv accord eyal banin md phd hadassahhebrew univers medic center jerusalem israel dr banin group collabor dr benjamin reubinoff hadassah develop xenofre direct differenti protocol deriv rpe cell hesc invitro the proprietari product call opregen develop carri translat phase cellcur ltd subsidiari biotim inc test fdaapprov phase iiia clinic trial israel usa nct dr banin present inform first nine patient advanc dri amd geograph atrophi ga receiv subretin inject opregen cell suspens associ research vision ophthalmolog annual meet honolulu hawaii all patient dri amd geograph atrophi bestcorrect acuiti wors time enrol patient receiv k k cell deliv balanc salin suspens the cell deliv subretin inject follow convent gaug vitrectomi patient receiv system immunosuppress one week prior treatment one year the procedur appear well toler serious system treatmentrel advers effect note with two year followup bestcorrect acuiti remain stabl treat eye bestcorrect acuiti also remain stabl untreat eye improv note one treat eye could probabl attribut clear vitreous posterior capsul opac surgeri dr banin note imag studi the research perform retin function structur assess throughout studi in addit bestcorrect acuiti use colour fundus photographi optic coher tomographi oct fundus autofluoresc imag techniqu imag studi show creation subretin bleb surgeri follow absorpt subretin fluid within hour heal inject site within week imag also show sign subretin pigment treat area accompani hypo hyperfluoresc spot fundus autofluoresc imag develop first onetothre month postop particular interest appear irregular subretin hyperfluoresc oct imag treat area taken togeth imag result suggest potenti engraft transplant cell these find persist throughout followup two year firsttreat patient although slow loss cell could occur structur improv in patient sign alter reduc drusen treat area possibl restor rpe layer potenti structur improv seen photoreceptor layer ellipsoid zone cell inject surgeryrel advers event includ conjunctiv haemorrhag worsen cataract epiretin membran format seven nine patient develop new worsen epiretin membran four consid mild three advanc none case requir intervent some case may associ incomplet vitrectomi efflux rpe cell note no unexpect ocular advers event occur the phase iii studi ongo a new cohort involv patient less advanc diseas visual acuiti wors smaller area geograph atrophi opregen cell creat use proprietari process drive differenti human pluripot stem cell generat highpur rpe cell idelson et al cell stem cell the cell generat system xeno free deriv nihapprov hesc line produc gmp condit underw extens safeti test prior approv us fda current clinic trial prior test stem cellderiv rpe cell human research conduct anim studi upon inject rat rpe cell form monolay polaris began function both structur function improv observ mcgill et al transl vis sci technol the current studi also compar find observ pig eye human studi particip in vivo oct studi conduct follow transplant show similar find form irregular subretin hyperreflect area transplant in pig eye follow enucl subretin layer human hescrp transplant cell evid proven immunohistochem stain use humanspecif marker the research thus believ hyperreflect oct also seen human patient correl presenc transplant cell more dozen research group around world work approach stem cellbas rpe cell transplant dri amd one group recent report promis phase i result clinicalgrad retin implant made hescderiv rpe grown synthet substrat the implant well toler one patient show improv visual function ah kashani scienc translat medicin vol issu eaao',\n",
       "  'NN'),\n",
       " ('i diagnos ms year ago ms retreat twice i year old i beta feron year take drug month ago second jelinek retreat i well month ago i i describ mini relaps follow coupl stress day i cancel everyth stay home week im slowli get back normal i need get physic stronger i phone ms nurs set back advis investig start gilyenya i express concern return dmds well last month i book see neurologist mri book come tuesday i divid thought i realli would like remain drug free possibl also understand drug might help may avail futur i current edss scale i believ qualifi gilenya score edss scale although i sure i feel pressur go medic rout feel like failur i succumb drug i well om program i would appreci thought comment regard thank',\n",
       "  'NN'),\n",
       " ('hi everyon just updat dad lung tumor grew cm week gemzar so hes stop next week start combo opdivo yervoy he stop respond keytruda here hope combo work isnt harsh bodi his nurs comment today definit fighter take everi treatment throw pretti well here hope toler well get good result happi new year everyon',\n",
       "  'NN'),\n",
       " ('i j poucher whose diagnosi chang uc crohn i colon remov j pouch formedconnect i bump along wayfissur skintag excis help reduc fissur strictur inlet pouch surgeri open in everyth start fall apart i diagnos iron defici anemia start get iron infus my rectal area becam realli angryinflam i feel well overal they suspect crohn put remicad i love remicad develop antibodi year then i tri humira cimzia i luck i develop two fistula went seton path miser i sick time i got cleveland clinic left j pouch gave temp ileo sone relief i realli babi seton hate ha cleveland clinic remzi move ny told seen uc crohn diagnosi chang patient usual occur peopl pouch longer i guess mechanicalsurg errorscompl rather diseas often common caus earli pouch problem i dont think symptom point definit crohn either i never problem eat anyth abdomin pain promin symptom i feel like issu perian i realiz everyon differ seem like peopl varieti symptom shen told seen peopl terribl diseas minim symptom vice versa these diseas tricki mental drain if etc i hope get answer caus problem bc unknown frustrat good luck hang',\n",
       "  'NN'),\n",
       " ('the biolog price competit innov act bpci act sign law march part afford care act the bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product a total evid approach taken fda evalu biosimilar approv the result clinic trial import data preclin work also consid onc biosimilar approv use fda approv addit indic condit base concept call extrapol data if data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct for instanc clinic trial biosimilar filgrastimsndz studi effect safeti clinic trial whose particip treat breast cancer when approv grant fda filgrastimsndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth bloodform cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac bloodform stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastimsndz current twelv biosimilar approv fda treatment specif condit in fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas these drug list order approv infliximabdyyb inflectra origin product infliximab remicad etanerceptszz erelzi origin product etanercept enbrel adalimumabatto amjevita origin product adalimumab humira infliximababda renflexi origin product infliximab remicad adalimumabadbm cyltezo origin product adalimumab humira infliximabqbtx ixifi origin product infliximab remicad in septemb fda approv bevacizumabawwb mvasi treatment five type cancer nonsquam nonsmal cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumabawwb approv indic origin drug bevacizumab avastin could reach us market soon patent bevacizumab expir in decemb fda approv trastuzumabdkst ogivri treatment peopl herposit breast cancer herposit gastric cancer her growthpromot protein found surfac cancer cell the origin drug trastuzumab herceptin patent expir',\n",
       "  'NN'),\n",
       " ('it use treat skin cancer it use treat lung cancer what i need tell doctor befor i take trametinib if allergi trametinib part trametinib if allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign if breastfeed do breastfe take trametinib month last dose this medicin may interact drug health problem tell doctor pharmacist drug prescript otc natur product vitamin health problem you must check make sure safe take trametinib drug health problem do start stop chang dose drug without check doctor what thing i need know i take trametinib tell health care provid take trametinib this includ doctor nurs pharmacist dentist sometim dabrafenib taken trametinib if take dabrafenib trametinib sure know side effect happen drug when drug taken togeth chanc certain side effect may rais these side effect bad sometim dead this includ bleed bleed brain blood clot eye problem fever heart problem like heart failur high blood sugar cancer skin problem talk doctor chanc side effect drug high blood pressur happen trametinib have blood pressur check told doctor have blood work check told doctor talk doctor have eye pressur eyesight check told doctor blood clot happen trametinib tell doctor ever blood clot talk doctor call doctor right away sign blood clot like chest pain pressur cough blood short breath swell warmth numb chang color pain leg arm troubl speak swallow it common get rash trametinib skin reaction may also happen sometim rash skin reaction bad may need treatment hospit call doctor right away acn skin red skin rash bother go away call doctor right away red irrit palm hand sole feet veri bad eye problem happen trametinib sometim led loss eyesight call doctor right away blur eyesight loss eyesight chang eyesight call doctor right away see color dot halo bright light bother a bowel problem coliti hole bowel happen trametinib sometim dead call doctor right away diarrhea stomach pain cramp fever upset stomach if older use trametinib care you could side effect this medicin may caus fertil problem this may affect abl children talk doctor this medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take trametinib month last dose if get pregnant take trametinib within month last dose call doctor right away how medicin trametinib best taken use trametinib order doctor read inform given follow instruct close take trametinib time day take empti stomach take hour hour meal to gain benefit miss dose keep take trametinib told doctor health care provid even feel well what i i miss dose take miss dose soon think if less hour next dose skip miss dose go back normal time do take dose time extra dose see also dosag inform detail what side effect i need call doctor right away warningcaut even though may rare peopl may bad sometim dead side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign lung breath problem like short breath troubl breath cough fever sign fluid electrolyt problem like mood chang confus muscl pain weak heartbeat feel normal bad dizzi pass fast heartbeat thirst seizur feel tire weak hungri unabl pass urin chang amount urin produc dri mouth dri eye bad upset stomach throw sign high blood pressur like bad headach dizzi pass chang eyesight sign kidney problem like unabl pass urin chang much urin pass blood urin big weight gain fever chill feel tire weak this medicin may caus heart failur you need heart function check take trametinib call doctor right away sign heart problem like cough short breath new wors swell ankl leg heartbeat feel normal weight gain pound hour dizzi pass what side effect trametinib all drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away dri skin chang nail mouth irrit mouth sore upset stomach throw feel tire weak not hungri these side effect may occur if question side effect call doctor call doctor medic advic side effect you may report side effect fda fda you may also report side effect httpwwwfdagovmedwatch see also side effect detail if overdos suspect if think overdos call poison control center get medic care right away be readi tell show taken much happen how i store andor throw trametinib store refriger do freez keep tablet bottl come move pill holder store origin contain do take antimoistur cube packet protect light keep drug safe place keep drug reach children pet throw away unus expir drug do flush toilet pour drain unless told check pharmacist question best way throw drug there may drug takeback program area consum inform use if symptom health problem get better becom wors call doctor do share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin some drug may anoth patient inform leaflet check pharmacist if question trametinib pleas talk doctor nurs pharmacist health care provid if think overdos call poison control center get medic care right away be readi tell show taken much happen',\n",
       "  'JJ'),\n",
       " ('jasoncohen although would ad benefit express pdl ligand nesessari opdivo what pertin karnofski score activ level sound like would meet criteria you correct mani option scc mortal rate high aggress howev option mani immunotherapi often given label as long stay strong good qualiti life manag diseas success best luck ill alway around need addit inform carm',\n",
       "  'NN'),\n",
       " ('dear bmj that great news happi hear tarceva help bmet pleas keep updat aggress approach seem doctor seen take bmet what i research understand specialist prefer recommend lengthen systemat treatment long possibl patient symptomssid effect allow even light progress for mother specif would mean bmet respond tarceva primari lung tumor rest bodi good respons tarceva local treatment option bmet may explor combin tarceva oppos test tm switch systemat care tarceva work relat well everyth bmet i believ pleas correct im wrong much clinic studyevid switch erlotinib treatment osimertinib erlotinib still elicit good overal respons treat bmet not sure would effect overal durat pfs erlotinib may fulli exhaust it seem walk road limit option need valu everi option long abl howev i interest hear feedback receiv as allegra elomet cream i knowledg medic compar drug doxycylin from person experi standpoint mother start develop facial acn especi tzone inbetween eye nose around mouth roughen red rash cheek week take tarceva the acn bearabl noth high discomfort inflam blemish would pus nurs refer us dermatologist after take medic appli ointment skin condit improv within one week rash disappear acn lessen this repli modifi year month ago jc this repli modifi year month ago jc',\n",
       "  'NN'),\n",
       " ('hi khlaq i understand desir make good treatment decis here grace provid inform specif advic patient your brother medic team great deal inform situat provid could provid need make good therapi choic i add prematur state alectinib good leptomening the articl link janin provid state evid alectinib report activ alk nsclc patient leptomening diseas the footnot statement refer two report one discuss singl patient anoth dealt four patient as might imagin doctor tend write success stori dont necessarili hear patient respond inform like appear result larg clinic trial we dont yet full data effect alectinib leptomening diseas lung cancer in addit report state earli small data set show intracrani respons rate alectinib rang two thing note statement small data set may reflect experi observ larger group patient respons rate quot indic percent patient treat alectinib respond im way attempt talk tri alectinib purpos site provid relev inform help brother doctor make good choic leptomenig diseas difficult treat report cite articl encourag warrant studi dont enough data point jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carboalimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva at rest nov sinc httpcancergraceorgblogjimandlisa this repli modifi month week ago jimc forum moder this repli modifi month week ago jimc forum moder',\n",
       "  'NN'),\n",
       " ('i stage sinc i everi treatment chemosa radiat resect i done i use option i went opdivo day approv took year job i cancer free last year half i f work work they say work doesnt i stop take i need still work but realli never know road btw pharmaceut compani plan pay deduct expens this stuff cheap get doctor request',\n",
       "  'JJS'),\n",
       " ('congrat get hand latest poison ms this excit even reader blog as per usual keep us updat posit negat drug i read today ocrevus quick becom first line medic choic ms i alway thought would best tackl diseas aggress start',\n",
       "  'NN'),\n",
       " ('thank repli i male notsosick i think rule time month lol i havent spoken doctor yet last day happen i havent start new med chang diet so bit mysteri i think face look swollen could imagin i sure i see acn improv come week fact appear exact area pred taper strang ulcer coliti sinc juli off pred anoth year stint upadacitinib clinic trial colazid g entyvio vedolizumab sinc januari stop oct lost respons azathioprin mg stop due clinic trial',\n",
       "  'JJ'),\n",
       " ...]"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Parts of speech tagging for the testing set.\n",
    "parts_of_speech = nltk.pos_tag(df1['text'])\n",
    "parts_of_speech"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### WordCloud after preprocessing of the data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 2160x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Wordcloud after preprocessing of the data\n",
    "\n",
    "text_string = \" \".join(df['text'].str.lower())\n",
    "wordcloud = WordCloud(background_color='white').generate(text_string)\n",
    "plt.figure(figsize=(30,30))\n",
    "plt.clf()\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis('off')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 2160x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Wordcloud after preprocessing of the data\n",
    "\n",
    "text_string = \" \".join(df1['text'].str.lower())\n",
    "wordcloud = WordCloud(background_color='white').generate(text_string)\n",
    "plt.figure(figsize=(30,30))\n",
    "plt.clf()\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis('off')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Finding of the sentiment score."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>autoimmun diseas tend come cluster as gilenya ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>i complet understand youd want tri but result ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>interest target sp receptor rather like fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>veri interest grand merci now i wonder lemtrad...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>hi everybodi my latest mri result brain cervic...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment\n",
       "0  autoimmun diseas tend come cluster as gilenya ...     gilenya          2\n",
       "1  i complet understand youd want tri but result ...     gilenya          2\n",
       "2  interest target sp receptor rather like fingol...  fingolimod          2\n",
       "3  veri interest grand merci now i wonder lemtrad...     ocrevus          2\n",
       "4  hi everybodi my latest mri result brain cervic...     gilenya          1"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previous stabl natalizumab switch fingolimod</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>on fingolimod sinc decemb way i describ better...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>appar shingl i red spot left breast appear day...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>if docetaxel week x week week claim less harsh...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>cc stelara work matter day if gi will jump hoo...</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug\n",
       "0       previous stabl natalizumab switch fingolimod  fingolimod\n",
       "1  on fingolimod sinc decemb way i describ better...  fingolimod\n",
       "2  appar shingl i red spot left breast appear day...      humira\n",
       "3  if docetaxel week x week week claim less harsh...    tagrisso\n",
       "4  cc stelara work matter day if gi will jump hoo...     stelara"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Using TextBlob to Identify Polarity and Subjectivity."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Polarity is the level of sentiment in the text and Subjectivity is the level of opinion in the text."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "from textblob import TextBlob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Finding of the Polarity and Subjectivity for the training set.\n",
    "df['Polarity'] = df.apply(lambda x: TextBlob(x['text']).sentiment.polarity,axis=1)\n",
    "df['Subjectivity'] = df.apply(lambda x: TextBlob(x['text']).sentiment.subjectivity,axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Finding of the Polarity and Subjectivity for the training set.\n",
    "df1['Polarity'] = df1.apply(lambda x: TextBlob(x['text']).sentiment.polarity,axis=1)\n",
    "df1['Subjectivity'] = df1.apply(lambda x: TextBlob(x['text']).sentiment.subjectivity,axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "      <th>Polarity</th>\n",
       "      <th>Subjectivity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>autoimmun diseas tend come cluster as gilenya ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "      <td>0.366667</td>\n",
       "      <td>0.388889</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>i complet understand youd want tri but result ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "      <td>0.167708</td>\n",
       "      <td>0.287500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>interest target sp receptor rather like fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "      <td>0.014291</td>\n",
       "      <td>0.588332</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>veri interest grand merci now i wonder lemtrad...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>hi everybodi my latest mri result brain cervic...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "      <td>0.322727</td>\n",
       "      <td>0.475758</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>i cant give advic lemtrada i chose cladribin h...</td>\n",
       "      <td>cladribine</td>\n",
       "      <td>2</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>repli post jesszidek hi jess sorri read challe...</td>\n",
       "      <td>humira</td>\n",
       "      <td>0</td>\n",
       "      <td>0.150000</td>\n",
       "      <td>0.144444</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>well expect neurologist want start tysabri i k...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "      <td>0.058333</td>\n",
       "      <td>0.386111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>whi think fingolimod miser failur progress ms ...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>1</td>\n",
       "      <td>-0.166667</td>\n",
       "      <td>0.166667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>thank muchim learn lot grace i mention husband...</td>\n",
       "      <td>tagrisso</td>\n",
       "      <td>2</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment  \\\n",
       "0  autoimmun diseas tend come cluster as gilenya ...     gilenya          2   \n",
       "1  i complet understand youd want tri but result ...     gilenya          2   \n",
       "2  interest target sp receptor rather like fingol...  fingolimod          2   \n",
       "3  veri interest grand merci now i wonder lemtrad...     ocrevus          2   \n",
       "4  hi everybodi my latest mri result brain cervic...     gilenya          1   \n",
       "5  i cant give advic lemtrada i chose cladribin h...  cladribine          2   \n",
       "6  repli post jesszidek hi jess sorri read challe...      humira          0   \n",
       "7  well expect neurologist want start tysabri i k...     gilenya          2   \n",
       "8  whi think fingolimod miser failur progress ms ...  fingolimod          1   \n",
       "9  thank muchim learn lot grace i mention husband...    tagrisso          2   \n",
       "\n",
       "   Polarity  Subjectivity  \n",
       "0  0.366667      0.388889  \n",
       "1  0.167708      0.287500  \n",
       "2  0.014291      0.588332  \n",
       "3  0.500000      1.000000  \n",
       "4  0.322727      0.475758  \n",
       "5  0.000000      0.000000  \n",
       "6  0.150000      0.144444  \n",
       "7  0.058333      0.386111  \n",
       "8 -0.166667      0.166667  \n",
       "9  0.250000      0.333333  "
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>Polarity</th>\n",
       "      <th>Subjectivity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previous stabl natalizumab switch fingolimod</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>-0.166667</td>\n",
       "      <td>0.166667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>on fingolimod sinc decemb way i describ better...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.750000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>appar shingl i red spot left breast appear day...</td>\n",
       "      <td>humira</td>\n",
       "      <td>-0.025000</td>\n",
       "      <td>0.446296</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>if docetaxel week x week week claim less harsh...</td>\n",
       "      <td>tagrisso</td>\n",
       "      <td>-0.052381</td>\n",
       "      <td>0.345238</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>cc stelara work matter day if gi will jump hoo...</td>\n",
       "      <td>stelara</td>\n",
       "      <td>-0.059135</td>\n",
       "      <td>0.401948</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>janssen biotech inc receiv fda approv new biol...</td>\n",
       "      <td>stelara</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.454545</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>i i thought thing would better one year ms tal...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>0.067268</td>\n",
       "      <td>0.421164</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>dec basha fowler i diagnos rd week dec egfriv ...</td>\n",
       "      <td>tagrisso</td>\n",
       "      <td>0.185795</td>\n",
       "      <td>0.419318</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>hi i start gilenya week ago woeful anxieti tim...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>0.316667</td>\n",
       "      <td>0.700000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>my uncl still go treatment kind chemo keytruda...</td>\n",
       "      <td>keytruda</td>\n",
       "      <td>0.027778</td>\n",
       "      <td>0.340278</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  Polarity  \\\n",
       "0       previous stabl natalizumab switch fingolimod  fingolimod -0.166667   \n",
       "1  on fingolimod sinc decemb way i describ better...  fingolimod  0.000000   \n",
       "2  appar shingl i red spot left breast appear day...      humira -0.025000   \n",
       "3  if docetaxel week x week week claim less harsh...    tagrisso -0.052381   \n",
       "4  cc stelara work matter day if gi will jump hoo...     stelara -0.059135   \n",
       "5  janssen biotech inc receiv fda approv new biol...     stelara  0.136364   \n",
       "6  i i thought thing would better one year ms tal...     ocrevus  0.067268   \n",
       "7  dec basha fowler i diagnos rd week dec egfriv ...    tagrisso  0.185795   \n",
       "8  hi i start gilenya week ago woeful anxieti tim...     gilenya  0.316667   \n",
       "9  my uncl still go treatment kind chemo keytruda...    keytruda  0.027778   \n",
       "\n",
       "   Subjectivity  \n",
       "0      0.166667  \n",
       "1      0.750000  \n",
       "2      0.446296  \n",
       "3      0.345238  \n",
       "4      0.401948  \n",
       "5      0.454545  \n",
       "6      0.421164  \n",
       "7      0.419318  \n",
       "8      0.700000  \n",
       "9      0.340278  "
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAmAAAAJPCAYAAADbkWgzAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADl0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uIDIuMi4zLCBodHRwOi8vbWF0cGxvdGxpYi5vcmcvIxREBQAAIABJREFUeJzs3X+YZVV95/v3R1qQgMovrbRNx8axNaJ9RVMhZMwzKcHRFjOBPFeTNqhgSDqZwSTGzsTGZEajYYIZCVHHmNuKAR0UEWPoAYwhQN1cMwMYFEEghhY60tBClB/SGomN3/vHWY2ny+qu0/VjV52q9+t5znP2Xnvtvb5rV9Wu71l7n71TVUiSJKk7j5vvACRJkpYaEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmOZUkrcl+Z8zWP/PkvyX2YxJkgaVZDzJL+9h2Y8k2ZFkv1luc+DteowcXiZgGliSrUn+pR0Y7k3y50kOnss2q+rXquodrf2xJNvmsj1Ji1OSn0ryv5M8lOT+JH+X5Mdnss2q+mpVHVxVj84wtq1JXjKd7XqMHF4mYNpX/6GqDgZeCPw48Htz1dBsf6qUtDQleRJwGfBe4DBgBfD7wCPzGZeWNhMwTUtV3Q18Gnhekqcl2dw+VW5J8it7Wi/JJ5J8rX0K/dskz+1bdn6S9ye5Ism3gBe3sj9IclBr72ltBG5Ha/fbSQ7v28aPJfnnJI+fw+5LGi7PAqiqj1XVo1X1L1X111V108TLJJKsSlJJlvWt/2+SXN+OW5cmOWyyukmenOS8JNuT3N2OXfv1bftXktyW5OEktyZ5YZKPAD8C/K92XPud/u0mWZfk7/s7k+S3kmxu0x4jh5QJmKYlyUrgROALwMeAbcDTgFcC/y3JCXtY9dPAauCpwOeBCycs/0XgLOCJwGd3FVbVt4CXA/e0ofmDq+oeYBz4+b71XwNcVFXfnVEHJS0m/wg8muSCJC9Pcug+rv864JfoHeN2Au/ZQ70L2vJnAi8AXgr8MkCSVwFva9t6EvCzwDeq6rXAV2lnF6rqjyZsczPw7CSr+8p+EfhofyWPkcPHBEz76i+TPEgvOfp/gU3ATwFvrqrvVNWNwAeB1062clV9qKoerqpH6B2Mnp/kyX1VLq2qv6uq71XVdwaI5wJ6B5RdpyxfDXxkmn2TtAhV1TfpHacK+ADwz23UfmTATXykqr7Ukpz/Avz8xEsk2rZeDryxqr5VVfcB5wLrWpVfBv6oqj5XPVuq6p8GiP3bwKX0jm20ROxH6SVmg/AYuUCZgGlfnVxVh1TV06vqP9H7RHh/VT3cV+ef6F1jsZsk+yU5O8lXknwT2NoWHdFX7a59jOdS4OgkzwD+PfBQVV2/j9uQtMhV1W1VdVpVHQk8j96x608GXL3/uPRPwOPZ/bgF8PRWvj3Jg+2D6v9Db7QfYCXwlWmG/1FaAkZv9OsvW2I2CI+RC9SyqatIe3UPcFiSJ/YlYT8C3D1J3V8ETgJeQi/5ejLwAJC+OrWXtn5gWVV9J8nFwCn0PhX6yU7SXlXVPyQ5H/hVepdC/FDf4h+eZJWVfdM/AnwX+PqE8rvoXdR/RFXtnGQbdwH/Zk8hTRHyXwNHJDmGXiL2W4Nux2PkwuUImGakqu4C/jfwh0mekOT/Ak7nB6/tgt51XY8A36B3wPtv+9jcvcDhE05ZAnwYOI3eNRXTvueYpMUpyY8m2ZDkyDa/kl4icy1wI/Dv0rv31pOBMyfZxGuSHJ3kh4C3A5dMvEVEVW2nlyidk+RJSR6X5N8k+elW5YPAb7eL4JPkmUme3pbdCzxjT/G3hO4S4L/T+xbnlXuo6jFyiJiAaTa8GlhFbzTsU8Bbq2qyA8SH6Q3f3w3cSu/gN7Cq+gd6F/zf0Yb4n9bK/w74HvD5qto6zT5IWrweBn4CuK59w/pa4EvAhnas+jhwE3ADvdtVTPQR4Hzga8ATgN/YQzuvA/and3x7gF7StBygqj5B7wtGH23x/CW9ZArgD4Hfa8e1397Dtj9K7+zBJ/YwwuYxcsikaqqRT2nhS3I18NGq+uB8xyJpaWjXVd0OLKsF/s/UY+TC4zVgGnrp3c36hfSuL5OkrjwP2DoEyZfHyAXIU5AaakkuAP6G3le/H56qviTNhiRvoncbno3zHcveeIxcuDwFKUmS1DFHwCRJkjpmAiZJA2o3E/5Cksva/FFJrktye5KPJ9m/lR/Q5re05avmM25JC8+Cvgj/iCOOqFWrVs14O9/61rc46KCDZh7QkLS7VNu2zwu37RtuuOHrVfWUOQ6pC78J3EbvWX4A7wTOraqLkvwZvXvgvb+9P1BVz0yyrtX7hb1teF+Od/P5c58O451bxju35uxYV1UL9vVjP/ZjNRuuueaaWdnOsLS7VNu2zwu3beDvawEcU2byAo4ErgKOp3evqNC7G/qytvwngc+06c8AP9mml7V62dv29+V4N58/9+kw3rllvHNrro51noKUpMH8CfA79G5oCXA48GB9/6aY2/j+M1BX0J4f2JY/1OpLErDAT0FK0kKQ5GeA+6rqhiRju4onqVoDLOvf7npgPcDIyAjj4+MDxbNjx46B6y4Exju3jHduzVW8JmCSNLUXAT+b5ER6j6J5Er0RsUOSLGujXEfSexwX9EbDVgLbkiyj9+D5+ydutKo20buXFKOjozU2NjZQMOPj4wxadyEw3rllvHNrruL1FKQkTaGqzqyqI6tqFbAOuLqqTgGuAV7Zqp0KXNqmN7d52vKr2/UhkgSYgEnSTLwZeFOSLfSu8TqvlZ8HHN7K38QCv1u6pO55ClKS9kFVjQPjbfoO4NhJ6nwHeFWngUkaKo6ASZIkdcwETJIkqWMmYJIkSR3zGjDNqlUbL2fDmp2ctvFyALae/Yp5jkiS9s3Ndz/02DFsF49lmm2OgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DETMEmSpI7NKAFL8ltJbknypSQfS/KEJEcluS7J7Uk+nmT/VveANr+lLV81Gx2QpLnWjm3XJ/liO+b9fis/P8mdSW5sr2NaeZK8px3vbkrywvntgaSFZtoJWJIVwG8Ao1X1PGA/YB3wTuDcqloNPACc3lY5HXigqp4JnNvqSdIweAQ4vqqeDxwDrE1yXFv2n6vqmPa6sZW9HFjdXuuB93cesaQFbaanIJcBByZZBvwQsB04HrikLb8AOLlNn9TmactPSJIZti9Jc656drTZx7dX7WWVk4APt/WuBQ5Jsnyu45Q0PKadgFXV3cC7gK/SS7weAm4AHqyqna3aNmBFm14B3NXW3dnqHz7d9iWpS0n2S3IjcB9wZVVd1xad1U4znpvkgFb22PGu6T8WShKp2tuHuL2smBwKfBL4BeBB4BNt/q3tNCNJVgJXVNWaJLcAL6uqbW3ZV4Bjq+obE7a7nt6QPSMjIz920UUXTSu+fjt27ODggw+e8XaGpd35bPvmux9i5EC4919682tWPLmztpfi/h6WPr/4xS++oapG5zikTiQ5BPgU8OvAN4CvAfsDm4CvVNXbk1wO/GFVfbatcxXwO1V1w4RtTet4N58/9+kYtnjvu/+hx45hu3R5LNtXw7Z/F3O8+3KsWzaDmF4C3FlV/wyQ5C+Af0tvqH1ZG+U6Erin1d8GrAS2tVOWTwbun7jRqtpE70DG6OhojY2NzSDEnvHxcWZjO8PS7ny2fdrGy9mwZifn3Nz71dp6SncxLMX9vRT7PN+q6sEk48DaqnpXK34kyZ8Dv93mdx3vduk/FvZva1rHu2Hb98MW73svvPSxY9guXR7L9tWw7V/j7ZnJNWBfBY5L8kPtWq4TgFuBa4BXtjqnApe26c1tnrb86pru8JskdSjJU9rIF0kOpPcB9B92XdfVjoEnA19qq2wGXte+DXkc8FBVbZ+teG6++yFWbbz8sZek4TPtEbCqui7JJcDngZ3AF+h9krscuCjJH7Sy89oq5wEfSbKF3sjXupkELkkdWg5ckGQ/eh9cL66qy5JcneQpQIAbgV9r9a8ATgS2AN8GXj8PMUtawGZyCpKqeivw1gnFdwDHTlL3O8CrZtKeJM2HqroJeMEk5cfvoX4BZ8x1XJKGl3fClyRJ6pgJmCRJUsdMwCRJkjpmAiZJktSxGV2EL0nSMJnsth1bz37FjLcznW1oaXMETJIkqWMmYJIkSR0zAZMkSeqY14BJkjQFH/mk2eYImCRJUsdMwCRJkjrmKUhJ0pI28fTihjXzFIiWFEfAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJklTSPKEJNcn+WKSW5L8fis/Ksl1SW5P8vEk+7fyA9r8lrZ81XzGL2nhMQGTpKk9AhxfVc8HjgHWJjkOeCdwblWtBh4ATm/1TwceqKpnAue2epL0GBMwSZpC9exos49vrwKOBy5p5RcAJ7fpk9o8bfkJSdJRuJKGgAmYJA0gyX5JbgTuA64EvgI8WFU7W5VtwIo2vQK4C6Atfwg4vNuIJS1ky+Y7AEkaBlX1KHBMkkOATwHPmaxae59stKsmFiRZD6wHGBkZYXx8fKBYRg6EDWt2PjY/6HrzZceOHQsmxv79ticT9+8g5rN/C2n/DsJ4e0zAJGkfVNWDScaB44BDkixro1xHAve0atuAlcC2JMuAJwP3T7KtTcAmgNHR0RobGxsohvdeeCnn3Pz9w/fWUwZbb76Mj48zaN/m2mkbL5+yzoY1O3fbv4OYz5/BQtq/gzDeHk9BStIUkjyljXyR5EDgJcBtwDXAK1u1U4FL2/TmNk9bfnVV/cAImKSlyxEwSZracuCCJPvR++B6cVVdluRW4KIkfwB8ATiv1T8P+EiSLfRGvtbNR9CSFi4TMEmaQlXdBLxgkvI7gGMnKf8O8KoOQpM0pEzAJEmL1qoBrvmS5oPXgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljJmCSJEkdm1ECluSQJJck+YcktyX5ySSHJbkyye3t/dBWN0nek2RLkpuSvHB2uiBJkjRcZjoC9m7gr6rqR4HnA7cBG4Grqmo1cFWbB3g5sLq91gPvn2HbkiRJQ2nZdFdM8iTg3wGnAVTVvwL/muQkYKxVuwAYB94MnAR8uKoKuLaNni2vqu3Tjl6SpGbVxssXVNtbz37FPESiYTGTEbBnAP8M/HmSLyT5YJKDgJFdSVV7f2qrvwK4q2/9ba1MkiRpSZn2CFhb94XAr1fVdUnezfdPN04mk5TVD1RK1tM7RcnIyAjj4+MzCLFnx44ds7KdYWl3PtvesGYnIwf23oFOY1iK+3sp9lmSFoOZJGDbgG1VdV2bv4ReAnbvrlOLSZYD9/XVX9m3/pHAPRM3WlWbgE0Ao6OjNTY2NoMQe8bHx5mN7QxLu/PZ9mkbL2fDmp2cc3PvV2vrKd3FsBT391LssyQtBtM+BVlVXwPuSvLsVnQCcCuwGTi1lZ0KXNqmNwOva9+GPA54yOu/JEnSUjSTETCAXwcuTLI/cAfwenpJ3cVJTge+Cryq1b0COBHYAny71ZUkaUnwQn31m1ECVlU3AqOTLDphkroFnDGT9iRpPiRZCXwY+GHge8Cmqnp3krcBv0LvC0kAb6mqK9o6ZwKnA48Cv1FVn+k8cEkL1kxHwCRpKdgJbKiqzyd5InBDkivbsnOr6l39lZMcDawDngs8DfibJM+qqkc7jVrSguWjiCRpClW1vao+36YfpnfT6b3dRuck4KKqeqSq7qR36cWxcx+ppGHhCJg65TUQGnZJVgEvAK4DXgS8IcnrgL+nN0r2AL3k7Nq+1bzvoaTdmIBJ0oCSHAx8EnhjVX0zyfuBd9C7p+E7gHOAX2KO73vYf6896PZ+e9PR1T3j+vfJTEzcv9M1sc+TbXOY73U5XcbbYwKmOTWfjwaRZlOSx9NLvi6sqr8AqKp7+5Z/ALiszc7pfQ/fe+Glj91rD7q93950dHXPuNNm6XjTfy/DmZj4c5ksvtn42Q3bPfmMt8drwCRpCkkCnAfcVlV/3Fe+vK/azwFfatObgXVJDkhyFLAauL6reCUtfI6ASdLUXgS8Frg5yY2t7C3Aq5McQ+/04lbgVwGq6pYkF9O7OfVO4Ay/ASmpnwmYJE2hqj7L5Nd1XbGXdc4CzpqzoCQNNU9BSpIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI65m0oJElDySdtaJg5AiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBk6QpJFmZ5JoktyW5JclvtvLDklyZ5Pb2fmgrT5L3JNmS5KYkL5zfHkhaaEzAJGlqO4ENVfUc4DjgjCRHAxuBq6pqNXBVmwd4ObC6vdYD7+8+ZEkLmQmYJE2hqrZX1efb9MPAbcAK4CTgglbtAuDkNn0S8OHquRY4JMnyjsOWtICZgEnSPkiyCngBcB0wUlXboZekAU9t1VYAd/Wttq2VSRIAy+Y7AGmiVRsv/4GyrWe/Yh4ikXaX5GDgk8Abq+qbSfZYdZKymmR76+mdomRkZITx8fGB4hg5EDas2fnY/KDrzZcdO3bMSYz9+2A2Tdy/0zWxz5Ntczb2y1zt37livD0mYJI0gCSPp5d8XVhVf9GK702yvKq2t1OM97XybcDKvtWPBO6ZuM2q2gRsAhgdHa2xsbGBYnnvhZdyzs3fP3xvPWWw9ebL+Pg4g/ZtX5w2yYe12bBhzc7d9u90Tfy5TBbvbPzs5mr/zhXj7fEUpCRNIb2hrvOA26rqj/sWbQZObdOnApf2lb+ufRvyOOChXacqJQkcAdMCMNkpR2mBeRHwWuDmJDe2srcAZwMXJzkd+CrwqrbsCuBEYAvwbeD13YarhcBjm/bGBEySplBVn2Xy67oATpikfgFnzGlQkoaapyAlSZI6ZgImSZLUMRMwSZKkjpmASZIkdcwETJIkqWMzTsCS7JfkC0kua/NHJbkuye1JPp5k/1Z+QJvf0pavmmnbkiRJw2g2RsB+k96DaXd5J3BuVa0GHgBOb+WnAw9U1TOBc1s9SZKkJWdGCViSI4FXAB9s8wGOBy5pVS4ATm7TJ7V52vITspcHqUmSJC1WMx0B+xPgd4DvtfnDgQeratcTR7cBK9r0CuAugLb8oVZfkiRpSZn2nfCT/AxwX1XdkGRsV/EkVWuAZf3bXQ+sBxgZGRnqJ8XP5xPf56vtDWt2MnJg7302DdKXpbi/l2KfJWkxmMmjiF4E/GySE4EnAE+iNyJ2SJJlbZTrSOCeVn8bsBLYlmQZ8GTg/okbrapNwCaA0dHRmo0nkM/Xk9fn84nv89X2aRsvZ8OanZxz8+w+5WrrKWNT1lmK+3sp9lmSFoNpn4KsqjOr6siqWgWsA66uqlOAa4BXtmqnApe26c1tnrb86va8NEmSpCVlLu4D9mbgTUm20LvG67xWfh5weCt/E7BxDtqWJEla8GblPFFVjQPjbfoO4NhJ6nwHeNVstCdJkjTMZvdCHUmS5siqjZfPdwjSrPFRRJIkSR0zAZMkSeqYCZgkSVLHvAZMkqR5MvG6tq1nv2KeIlHXHAGTJEnqmAmYJE0hyYeS3JfkS31lb0tyd5Ib2+vEvmVnJtmS5MtJXjY/UUtayEzAJGlq5wNrJyk/t6qOaa8rAJIcTe/pIM9t6/xpkv06i1TSUPAaME2b9+TRUlFVf5tk1YDVTwIuqqpHgDvb0z+OBf7PHIUnaQg5AiZJ0/eGJDe1U5SHtrIVwF19dba1Mkl6jCNgkjQ97wfeAVR7Pwf4JSCT1K3JNpBkPbAeYGRkhPHx8YEaHjkQNqzZ+dj8oOvNlx07dsxKjP19nksT92+XprOfZmv/dsV4e0zAJGkaqureXdNJPgBc1ma3ASv7qh4J3LOHbWwCNgGMjo7W2NjYQG2/98JLOefm7x++t54y2HrzZXx8nEH7tjendXTZw4Y1O3fbv12azs9ytvZvV4y3x1OQkjQNSZb3zf4csOsbkpuBdUkOSHIUsBq4vuv4JC1sjoBJ0hSSfAwYA45Isg14KzCW5Bh6pxe3Ar8KUFW3JLkYuBXYCZxRVY/OR9ySFi4TMEmaQlW9epLi8/ZS/yzgrLmLSNKw8xSkJElSx0zAJEmSOmYCJkmS1DGvAZMkaYGY+ISRrWe/Yp4i0VxzBEySJKljJmCSJEkd8xSkJGnBmXgqTlpsHAGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DEvwtdQ8N44kqTFxBEwSZKkjpmASZIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI65n3AJEmdmuxB297bT0uNCZgGNtlBU1oKknwI+Bngvqp6Xis7DPg4sArYCvx8VT2QJMC7gROBbwOnVdXn5yPuYeLxRUuNpyAlaWrnA2snlG0Erqqq1cBVbR7g5cDq9loPvL+jGCUNERMwSZpCVf0tcP+E4pOAC9r0BcDJfeUfrp5rgUOSLO8mUknDwlOQGko+G1ILwEhVbQeoqu1JntrKVwB39dXb1sq2dxyfpAXMBEySZlcmKatJKybr6Z2mZGRkhPHx8YEaGDkQNqzZ+dj8oOvNlx07duwWY3/sC9HE/TufBvnZTty/C53x9piASdL03JtkeRv9Wg7c18q3ASv76h0J3DPZBqpqE7AJYHR0tMbGxgZq+L0XXso5N3//8L31lMHWmy/j4+P09+20BX7B/YY1O3fbv/NpkJ/txP270Blvj9eASdL0bAZObdOnApf2lb8uPccBD+06VSlJuyyMFF+SFrAkHwPGgCOSbAPeCpwNXJzkdOCrwKta9Svo3YJiC73bULy+84C1qE28BnbDmp0/MKrodbEL37QTsCQrgQ8DPwx8D9hUVe/23jiSFpuqevUeFp0wSd0CzpjbiCQNu5mcgtwJbKiq5wDHAWckORrvjSNJkrRX007Aqmr7rhGsqnoYuI3eV629N44kSdJezMpF+ElWAS8ArmPCvXGAqe6NI0mStKTM+CL8JAcDnwTeWFXf7F3qNXnVScp+4N44070vzt7M1z1H5vNeJ3PR9qD3xZmPe+iMj48vuv29kNud77YladjNKAFL8nh6ydeFVfUXrXhG98aZ7n1x9ma+7jkyn/c6mYu2B713z3zcQ2frKWOLbn8v5Hbnu21pqfAh5YvXtE9Btm81ngfcVlV/3LfIe+NIkiTtxUyGKV4EvBa4OcmNrewteG8cSVKfm+9+aMHf/V7q2rQTsKr6LJNf1wXeG0eSJGmPfBSRJElSx0zAJEmSOuazILUorNp4+Q88D81noUmSFipHwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpY34LUovWxGeo+a1ISdJCYQKmSfkAWEmS5o6nICVJkjpmAiZJktQxT0FK0gwk2Qo8DDwK7Kyq0SSHAR8HVgFbgZ+vqgfmK0ZJC48JmCTN3Iur6ut98xuBq6rq7CQb2/yb5yc0LUV+CWnh8xSkJM2+k4AL2vQFwMnzGIukBcgETJJmpoC/TnJDkvWtbKSqtgO096fOW3SSFiRPQUrSzLyoqu5J8lTgyiT/MOiKLWFbDzAyMsL4+PhA640cCBvW7HxsftD15svEeBe6xRjvQvod2bFjx4KKZypzFa8JmCTNQFXd097vS/Ip4Fjg3iTLq2p7kuXAfXtYdxOwCWB0dLTGxsYGavO9F17KOTd///C99ZTB1psvE+Nd6Das2bno4l1IvyPj4+MM+ru+EMxVvMPzGybN0GQ3l/XCVM1EkoOAx1XVw236pcDbgc3AqcDZ7f3S+YtS0kJkAiZJ0zcCfCoJ9I6nH62qv0ryOeDiJKcDXwVeNY8xdm7ih50Na+YpEGkBMwET4KOHpOmoqjuA509S/g3ghO4jkjQsTMAkSYD3jpK6ZAImSdIiN0hybQLeLRMwSZKkZmIiev7ag+akHW/EKkmS1DFHwCRJ0+YXeIaTP7f55wiYJElSxxwBW4L85CNJ0vxyBEySJKljjoBJffwatiSpCyZgkqSBeQmDNDs8BSlJktQxR8C0pPlpXtoz/z40FS/bmD5HwCRJkjrmCNgitGrj5WxYs5PT2icTP5HMrYn7G9znkobfZCOgHttmjwmYtBcegCRJc8EEbAnwOg5J0mzw/8nsMQEbMl7wKGk6HM3VQrYU/7eZgEmSpM7cfPdDu10zu1T5LUhJkqSOOQIm7aPpXAMxndM/njLSTHitjubDIL93G9Z0EMgQMAGbI94KQtJCZ5KmYTbs1411noAlWQu8G9gP+GBVnd11DIuJB9CFyZ+LPNZJ2ptOE7Ak+wHvA/49sA34XJLNVXVrF+0P2ykd/4lrIZn4+3j+2oPmKZKFr+tjnccKLTbD9v96OroeATsW2FJVdwAkuQg4CZjxQWkx/LA8iC4tc/XzHvZh+UVizo510lI11TFzkDxgIeUKXSdgK4C7+ua3AT/RcQz7bKp/aIP8IzW50myY+Hs08RFI09nGZEzaZmwoj3WSupOq6q6x5FXAy6rql9v8a4Fjq+rX++qsB9a32WcDX56Fpo8Avj4L2xmWdpdq2/Z54bb99Kp6ylwGs5AMcqxr5dM93s3nz306jHduGe/cmpNjXdcjYNuAlX3zRwL39Feoqk3AptlsNMnfV9XobG5zIbe7VNu2z0un7SEw5bEOpn+8G7Z9b7xzy3jn1lzF2/WNWD8HrE5yVJL9gXXA5o5jkKS55rFO0l51OgJWVTuTvAH4DL2vZn+oqm7pMgZJmmse6yRNpfP7gFXVFcAVHTc7q6c0h6Ddpdq2fV46bS94c3ysG7Z9b7xzy3jn1pzE2+lF+JIkSfJh3JIkSZ1bFAlYksOSXJnk9vZ+6CR1Xpzkxr7Xd5Kc3Jadn+TOvmXHzGbbrd6jfdvf3Fd+VJIf99yaAAAgAElEQVTr2vofbxfszma/j0nyf5LckuSmJL/Qt2yf+p1kbZIvJ9mSZOMkyw9ofdjS+rSqb9mZrfzLSV42aB/3oe03Jbm19fGqJE/vWzbpvp+ldk9L8s992//lvmWntp/N7UlOnYM+n9vX7j8meXCW+vyhJPcl+dIelifJe1pcNyV5Yd+yGfVZu5vJ39x8mMnf6XyYKt6+eq9MUknm9Zt7g8Sb5OfbPr4lyUe7jnFCLFP9PvxIkmuSfKH9Tpw4H3H2xTPtY9+0VNXQv4A/Aja26Y3AO6eofxhwP/BDbf584JVz2TawYw/lFwPr2vSfAf9xNtsGngWsbtNPA7YDh+xrv+ldSPwV4BnA/sAXgaMn1PlPwJ+16XXAx9v00a3+AcBRbTv77UM/B2n7xX0/z/+4q+297ftZavc04H/s4XfsjvZ+aJs+dDbbnlD/1+ld6D2jPrd1/x3wQuBLe1h+IvBpIMBxwHWz0Wdf0/r9m/RvbgHHu8e/04UYb6v3ROBvgWuB0YUcL7Aa+MKuvzvgqQs83k20/3n0/k9sna94WwzTOvZN97UoRsDoPeLjgjZ9AXDyFPVfCXy6qr49D20/JkmA44FLprP+IG1X1T9W1e1t+h7gPmA6N8R87NEqVfWvwK5Hq+wpnkuAE1ofTwIuqqpHqupOYEvb3qy1XVXX9P08r6V336WZGqTPe/Iy4Mqqur+qHgCuBNbOYduvBj62D9vfo6r6W3ofUPbkJODD1XMtcEiS5cy8z9rdTP7m5sN8/Z1O16B/Y++g92H3O10GN4lB4v0V4H3t74+quq/jGPsNEm8BT2rTT2aSe+V1aQbHvmlZLAnYSFVtB2jvT52i/jp+8J/VWW1I8dwkB8xB209I8vdJrk079QkcDjxYVTvb/DZ6jzCZ7bYBSHIsvU8iX+krHrTfkz1aZWKsj9VpfXqIXh8HWXdv9nX90+l9Stllsn0/m+3+320fXpJk1803O+tzO41zFHB1X/F0+zyT2GbaZ+1uJn9z82Gmf6ddmzLeJC8AVlbVZV0GtgeD7N9nAc9K8nftb38+PwANEu/bgNck2UbvG8O/zsI2q8e4zm9DMV1J/gb44UkW/e4+bmc5sIbe/Xl2ORP4Gr3kZBPwZuDts9z2j1TVPUmeAVyd5Gbgm5PU2+1rqbPc748Ap1bV91rxXvs9cRNTxbqXOoOsuzcDr5/kNcAo8NN9xT+w76vqK5OtP412/xfwsap6JMmv0RuNOH5fYp5B27usAy6pqkf7yqbb55nENtM+a3cz+ZubDzP9O+3aXuNN8jjgXHqXGSwEg+zfZfROQ47RG138/5I8r6oenLhiBwaJ99XA+VV1TpKfBD7S4v3eJOsuBLP69zY0CVhVvWRPy5Lcm2R5VW1vicbehl1/HvhUVX23b9vb2+QjSf4c+O3Zbrud/qOq7kgyDrwA+CS9Icxl7dPrZI9mmnHbSZ4EXA78Xhs2HajfEwzyaJVddbYlWUZvSPn+Adfdm4HWT/ISeonpT1fVI7vK97DvB0lGBnl01jf6Zj8AvLNv3bEJ644P0ObAbfdZB5wxIa7p9nkmsc20z9rdTP7m5sOM/k7nwVTxPhF4HjDezur+MLA5yc9W1d93FuX3Dfr7cG37/3Znki/TS8g+102IPxDLVPGeTrtMoar+T5In0Hvu4nyeOt2bmf4v291MLiBbKC/gv7P7xeh/tJe61wIvnlC2vL0H+BPg7Nlsm94FyQe06SOA22kXIwKfYPeL8P/TLLe9P3AV8MZJlg3cb3rJ+h30TnXtuqDyuRPqnMHuFwRf3Kafy+4X4d/Bvl2EP0jbuxKM1YPu+1lqd3nf9M/RO/hB70L0O1v7h7bpw2azz63es4GttHv6zbTPfdtYxZ4vRH0Fu1+Iev1s9NnXtH7/Jv2bW8DxTvp3ulDjnVB/nPm9CH+Q/bsWuKBNH0HvdNnhCzjeTwOntenn0Etm0nWsE2La52PftNuaz47O4g47nF6ScXt7P6yVjwIfnLBj7wYeN2H9q4GbgS8B/xM4eDbbBv5t2/4X2/vpfes/A7ie3oXpn6D945zFtl8DfBe4se91zHT6Te8bIP/YDqC/28reDvxsm35C68OW1qdn9K37u229LwMvn8bPeKq2/wa4t6+Pm6fa97PU7h8Ct7TtXwP8aN+6v9T2xRbg9bPd5zb/NiYkzrPQ54/R+7bsd+l94jsd+DXg19ryAO9rcd1M3z+lmfbZ1+z9zS3QeCf9O12o8U6oO848JmAD7t8Afwzc2v421y3weI8G/q4dq24EXjrP8U772Dedl3fClyRJ6thi+RakJEnS0DABkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYCpc0k+neTU+Y5DkqT5kqqa7xi0iCV5G/DMqnrNAojlfGBbVf3efMciSVraHAGTJEnqmAmYdpPkzUnuTvJwki8nOSHJ45JsTPKVJN9IcnGSw1r9VUkqyalJvprk60l+ty1bC7wF+IUkO5J8sZWPJ/nlNn1akr9Lcm6SB5PckeTftvK7ktzXf7oyyQFJ3tXaujfJnyU5sC0bS7ItyYa23vYkr2/L1gOnAL/TYvlfXe5XSZL6mYDpMUmeDbwB+PGqeiLwMmAr8BvAycBPA08DHgDeN2H1nwKeDZwA/Nckz6mqvwL+G/Dxqjq4qp6/h6Z/ArgJOBz4KHAR8OPAM4HXAP8jycGt7juBZwHHtOUrgP/at60fBp7cyk8H3pfk0KraBFwI/FGL5T/s4+6RJGnWmICp36PAAcDRSR5fVVur6ivArwK/W1XbquoR4G3AK5Ms61v396vqX6rqi8AXgT0lW5O5s6r+vKoeBT4OrATeXlWPVNVfA/8KPDNJgF8Bfquq7q+qh+kleOv6tvXdtu53q+oKYAe9xFCSpAVj2dRVtFRU1ZYkb6SXYD03yWeANwFPBz6V5Ht91R8FRvrmv9Y3/W3gYAZ3b9/0v7RYJpYdDDwF+CHghl4uBkCA/frqfqOqds4gFkmS5pwjYNpNVX20qn6KXtJV9E753QW8vKoO6Xs9oaruHmSTsxje1+klY8/ti+PJVTVoguVXfiVJC4IJmB6T5NlJjk9yAPAdesnOo8CfAWcleXqr95QkJw242XuBVUlm/LtWVd8DPgCcm+SpLZYVSV62D7E8Y6ZxSJI0UyZg6ncAcDa9kaavAU+l9y3GdwObgb9O8jBwLb0L5wfxifb+jSSfn4UY3wxsAa5N8k3gbxj8Gq/z6F3f9mCSv5yFWCRJmhZvxCpJktQxR8AkSZI6ZgImSZLUsYETsCT7JflCksva/FFJrktye5KPJ9m/lR/Q5re05av6tnFmK//yPlw4LUmStKjsywjYbwK39c2/Ezi3qlbTuzP66a38dOCBqnomcG6rR5Kj6d0w87nAWuBPk/Tfv0mSJGlJGCgBS3Ik8Argg20+wPHAJa3KBfQeVQNwUpunLT+h1T8JuKjd3fxOet9kO3Y2OiFJkjRMBr0T/p8AvwM8sc0fDjzYd8fxbfSevUd7vwugqnYmeajVX0Hv9gVMss6kjjjiiFq1atVAAX7rW9/ioIMOGqjuMFrM/bNvw2lf+nbDDTd8vaqeMschSdLQmDIBS/IzwH1VdUOSsV3Fk1StKZbtbZ3+9tYD6wFGRkZ417veNVWIAOzYsYODD168T5xZzP2zb8NpX/r24he/+J/mOBxJGiqDjIC9CPjZJCcCTwCeRG9E7JAky9oo2JHAPa3+NnoPU97WHtb8ZOD+vvJd+td5TFVtAjYBjI6O1tjY2EAdGR8fZ9C6w2gx98++DafF3DdJmmtTXgNWVWdW1ZFVtYreRfRXV9UpwDXAK1u1U4FL2/TmNk9bfnX17va6GVjXviV5FLAauH7WeiJJkjQkBr0GbDJvBi5K8gfAF+g95oX2/pEkW+iNfK0DqKpbklwM3ArsBM6oqkdn0L4kSdJQ2qcErKrGgfE2fQeTfIuxqr4DvGoP658FnLWvQUqSJC0m3glfkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktSxmdwHTNISsmrj5bvNn792cT7jUpK64AiYJElSx0zAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljUyZgSZ6Q5PokX0xyS5Lfb+XnJ7kzyY3tdUwrT5L3JNmS5KYkL+zb1qlJbm+vU+euW5IkSQvXsgHqPAIcX1U7kjwe+GyST7dl/7mqLplQ/+XA6vb6CeD9wE8kOQx4KzAKFHBDks1V9cBsdESSJGlYTDkCVj072uzj26v2sspJwIfbetcChyRZDrwMuLKq7m9J15XA2pmFL0mSNHwGugYsyX5JbgTuo5dEXdcWndVOM56b5IBWtgK4q2/1ba1sT+WSJElLyiCnIKmqR4FjkhwCfCrJ84Azga8B+wObgDcDbwcy2Sb2Ur6bJOuB9QAjIyOMj48PEiI7duwYuO4wWsz9s2/DYcOanbvNL6a+SVLXBkrAdqmqB5OMA2ur6l2t+JEkfw78dpvfBqzsW+1I4J5WPjahfHySNjbRS+gYHR2tsbGxiVUmNT4+zqB1h9Fi7p99Gw6nbbx8t/nz1x60aPomSV0b5FuQT2kjXyQ5EHgJ8A/tui6SBDgZ+FJbZTPwuvZtyOOAh6pqO/AZ4KVJDk1yKPDSViZJkrSkDDICthy4IMl+9BK2i6vqsiRXJ3kKvVOLNwK/1upfAZwIbAG+DbweoKruT/IO4HOt3tur6v7Z64okSdJwmDIBq6qbgBdMUn78HuoXcMYeln0I+NA+xihJkrSoeCd8SZKkjpmASZIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI6ZgImSZLUMRMwSZKkjpmASZIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI6ZgImSZLUMRMwSZKkjpmASZIkdcwETJIkqWMmYJIkSR2bMgFL8oQk1yf5YpJbkvx+Kz8qyXVJbk/y8ST7t/ID2vyWtnxV37bObOVfTvKyueqUJEnSQjbICNgjwPFV9XzgGGBtkuOAdwLnVtVq4AHg9Fb/dOCBqnomcG6rR5KjgXXAc4G1wJ8m2W82OyNJkjQMpkzAqmdHm318exVwPHBJK78AOLlNn9TmactPSJJWflFVPVJVdwJbgGNnpReSJElDZKBrwJLsl+RG4D7gSuArwINVtbNV2QasaNMrgLsA2vKHgMP7yydZR5IkaclYNkilqnoUOCbJIcCngOdMVq29Zw/L9lS+myTrgfUAIyMjjI+PDxIiO3bsGLjuMFrM/bNvw2HDmp27zS+mvklS1wZKwHapqgeTjAPHAYckWdZGuY4E7mnVtgErgW1JlgFPBu7vK9+lf53+NjYBmwBGR0drbGxsoNjGx8cZtO4wWsz9s2/D4bSNl+82f/7agxZN3ySpa4N8C/IpbeSLJAcCLwFuA64BXtmqnQpc2qY3t3na8qurqlr5uvYtyaOA1cD1s9URSZKkYTHICNhy4IL2jcXHARdX1WVJbgUuSvIHwBeA81r984CPJNlCb+RrHUBV3ZLkYuBWYCdwRju1KUmStKRMmYBV1U3ACyYpv4NJvsVYVd8BXrWHbZ0FnLXvYUqSJC0e3glfkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjo2ZQKWZGWSa5LcluSWJL/Zyt+W5O4kN7bXiX3rnJlkS5IvJ3lZX/naVrYlyca56ZIkSdLCtmyAOjuBDVX1+SRPBG5IcmVbdm5Vvau/cpKjgXXAc4GnAX+T5Flt8fuAfw9sAz6XZHNV3TobHZEkSRoWUyZgVbUd2N6mH05yG7BiL6ucBFxUVY8AdybZAhzblm2pqjsAklzU6pqASZKkJWWfrgFLsgp4AXBdK3pDkpuSfCjJoa1sBXBX32rbWtmeyiVJkpaUQU5BApDkYOCTwBur6ptJ3g+8A6j2fg7wS0AmWb2YPNmrSdpZD6wHGBkZYXx8fKD4duzYMXDdYbSY+2ffhsOGNTt3m19MfZOkrg2UgCV5PL3k68Kq+guAqrq3b/kHgMva7DZgZd/qRwL3tOk9lT+mqjYBmwBGR0drbGxskBAZHx9n0LrDaDH3z74Nh9M2Xr7b/PlrD1o0fZOkrg3yLcgA5wG3VdUf95Uv76v2c8CX2vRmYF2SA5IcBawGrgc+B6xOclSS/eldqL95drohSZI0PAYZAXsR8Frg5iQ3trK3AK9Ocgy904hbgV8FqKpbklxM7+L6ncAZVfUoQJI3AJ8B9gM+VFW3zGJfJEmShsIg34L8LJNf13XFXtY5CzhrkvIr9raeJEnSUuCd8CVJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1zARMkiSpYyZgkiRJHTMBkyRJ6pgJmCRJUsdMwCRJkjpmAiZJktQxEzBJkqSOmYBJkiR1bMoELMnKJNckuS3JLUl+s5UfluTKJLe390NbeZK8J8mWJDcleWHftk5t9W9PcurcdUuSJGnhGmQEbCewoaqeAxwHnJHkaGAjcFVVrQauavMALwdWt9d64P3QS9iAtwI/ARwLvHVX0iZJkrSUTJmAVdX2qvp8m34YuA1YAZwEXNCqXQCc3KZPAj5cPdcChyRZDrwMuLKq7q+qB4ArgbWz2htJkqQhsE/XgCVZBbwAuA4Yqart0EvSgKe2aiuAu/pW29bK9lQuSZK0pCwbtGKSg4FPAm+sqm8m2WPVScpqL+UT21lP79QlIyMjjI+PDxTfjh07Bq47jBZz/+zbcNiwZudu84upb5LUtYESsCSPp5d8XVhVf9GK702yvKq2t1OM97XybcDKvtWPBO5p5WMTyscntlVVm4BNAKOjozU2NjaxyqTGx8cZtO4wWsz9s2/D4bSNl+82f/7agxZN3ySpa4N8CzLAecBtVfXHfYs2A7u+yXgqcGlf+evatyGPAx5qpyg/A7w0yaHt4vuXtjJJkqQlZZARsBcBrwVuTnJjK3sLcDZwcZLTga8Cr2rLrgBOBLYA3wZeD1BV9yd5B/C5Vu/tVXX/rPRCkiRpiEyZgFXVZ5n8+i2AEyapX8AZe9jWh4AP7UuAkiRJi413wpckSeqYCZgkSVLHTMAkSZI6ZgImSZLUMRMwSZKkjpmASZIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI6ZgImSZLUMRMwSZKkjpmASZIkdcwETJIkqWMmYJIkSR0zAZMkSeqYCZgkSVLHTMAkSZI6ZgImSZLUMRMwSZKkjk2ZgCX5UJL7knypr+xtSe5OcmN7ndi37MwkW5J8OcnL+srXtrItSTbOflckSZKGwyAjYOcDaycpP7eqjmmvKwCSHA2sA57b1vnTJPsl2Q94H/By4Gjg1a2uJEnSkrNsqgpV9bdJVg24vZOAi6rqEeDOJFuAY9uyLVV1B0CSi1rdW/c5YkmSpCE3k2vA3pDkpnaK8tBWtgK4q6/Otla2p3JJkqQlZ8oRsD14P/AOoNr7OcAvAZmkbjF5oleTbTjJemA9wMjICOPj4wMFtGPHjoHrDqPF3D/7Nhw2rNm52/xi6pskdW1aCVhV3btrOskHgMva7DZgZV/VI4F72vSeyiduexOwCWB0dLTGxsYGiml8fJxB6w6jxdw/+zYcTtt4+W7z5689aNH0TZK6Nq1TkEmW983+HLDrG5KbgXVJDkhyFLAauB74HLA6yVFJ9qd3of7m6YctSZI0vKYcAUvyMWAMOCLJNuCtwFiSY+idRtwK/CpAVd2S5GJ6F9fvBM6oqkfbdt4AfAbYD/hQVd0y672RJEkaAoN8C/LVkxSft5f6ZwFnTVJ+BXDFPkUnSZK0CHknfEmSpI6ZgEmSJHXMBEySJKljJmCSJEkdMwGTJEnqmAmYJElSx0zAJEmSOmYCJkmS1DETMEmSpI6ZgEmSJHXMBEySJKljJmD/f3v3H2p3Xcdx/PlCLcIiNfE2dGnQ/sgwzcYy/OeKYNPACSkokVOMQRgV+M/ojwT7R/+oQAlj1dgMM8UyF61srS72j6KJ+QMTh4iuDVdOZsMoBu/+uN/VvXd3u+f++px9z54POJzv93M+53ven30cvvb9nvP9SJIkNWYAkyRJaswAJkmS1JgBTJIkqTEDmCRJUmMGMEmSpMYMYJIkSY0ZwCRJkhozgEmSJDU2ZwBLsjnJviQvTGk7I8mOJK90z6d37Ulyd5JdSZ5LcvGU96zv+r+SZP3yDEeSJOn4N8gZsC3A2hltG4GdVbUK2NntA1wJrOoeG4B7YTKwAbcDnwHWALcfDm2SJEknmjkDWFU9Duyf0bwO2NptbwWumdJ+X016AjgtyQrgc8COqtpfVW8DOzgy1EmSJJ0QFvodsLGq2gvQPZ/VtZ8NvDGl3+6u7WjtkiRJJ5yTl/h4maWtjtF+5AGSDUxevmRsbIyJiYmBPvjgwYMD9+2jUR6fY+uH2y44NG1/lMYmSa0tNIC9mWRFVe3tLjHu69p3Ayun9DsH2NO1j89on5jtwFW1CdgEsHr16hofH5+t2xEmJiYYtG8fjfL4HFs/3LTx19P2t6w9dWTGJkmtLfQS5Dbg8C8Z1wOPTmm/sfs15CXAge4S5WPAFUlO7758f0XXJkmSdMKZ8wxYkgeYPHt1ZpLdTP6a8U7goSS3AK8D13XdtwNXAbuAd4GbAapqf5JvA091/e6oqplf7JckSTohzBnAquqGo7x0+Sx9C7j1KMfZDGyeV3WSJEkjyDvhS5IkNWYAkyRJaswAJkmS1JgBTJIkqTEDmCRJUmNLfSd8ad6e/9uBaTf5fO3Ozw+xGkmSlp9nwCRJkhozgEmSJDVmAJMkSWrMACZJktSYAUySJKkxA5gkSVJjBjBJkqTGDGCSJEmNGcAkSZIaM4BJkiQ1ZgCTJElqbGTWgpy5niC4pqAkSTo+eQZMkiSpMQOYJElSY4sKYEleS/J8kmeTPN21nZFkR5JXuufTu/YkuTvJriTPJbl4KQYgSZLUN0txBuyyqrqoqlZ3+xuBnVW1CtjZ7QNcCazqHhuAe5fgsyVJknpnOS5BrgO2dttbgWumtN9Xk54ATkuyYhk+X5Ik6bi22ABWwO+S/DnJhq5trKr2AnTPZ3XtZwNvTHnv7q5NkiTphLLY21BcWlV7kpwF7Ejy12P0zSxtdUSnySC3AWBsbIyJiYmBChl7H9x2waFpbYO+tw8OHjw4UuOZaubcjdI4R2neZv79GqWxSVJriwpgVbWne96X5BFgDfBmkhVVtbe7xLiv674bWDnl7ecAe2Y55iZgE8Dq1atrfHx8oFruuf9RvvP89OG89sXB3tsHExMTDPpn0Tcz5855Oz7NvM/elrWnjszYJKm1BV+CTHJqkg8c3gauAF4AtgHru27rgUe77W3Ajd2vIS8BDhy+VClJknQiWcwZsDHgkSSHj/PTqvptkqeAh5LcArwOXNf13w5cBewC3gVuXsRnS5Ik9daCA1hVvQpcOEv7W8Dls7QXcOtCP0+SJGlUeCd8SZKkxgxgkiRJjRnAJEmSGjOASZIkNWYAkyRJaswAJkmS1JgBTJIkqTEDmCRJUmMGMEmSpMYMYJIkSY0ZwCRJkhozgEmSJDVmAJMkSWrMACZJktSYAUySJKkxA5gkSVJjBjBJkqTGDGCSJEmNGcAkSZIaM4BJkiQ1ZgCTJElqrHkAS7I2yctJdiXZ2PrzJUmShq1pAEtyEvB94ErgfOCGJOe3rEGSJGnYWp8BWwPsqqpXq+o/wM+AdY1rkCRJGqrWAexs4I0p+7u7NkmSpBPGyY0/L7O01bQOyQZgQ7d7MMnLAx77TOAf045117zrO54dMb4RMm1szls/XHbXvMZ27nLWIkl90zqA7QZWTtk/B9gztUNVbQI2zffASZ6uqtWLK+/4Ncrjc2z9NMpjk6Tl1voS5FPAqiQfTfIe4HpgW+MaJEmShqrpGbCqOpTkq8BjwEnA5qp6sWUNkiRJw9b6EiRVtR3YvgyHnvdly54Z5fE5tn4a5bFJ0rJKVc3dS5IkSUvGpYgkSZIa610Am2spoyTvTfJg9/qTSc5rX+XCDDC2m5L8Pcmz3ePLw6hzIZJsTrIvyQtHeT1J7u7G/lySi1vXuFADjG08yYEp8/at1jUuVJKVSf6Y5KUkLyb5+ix9ejt3kjQsvQpgAy5ldAvwdlV9DPge0Iu7Ss1jmaYHq+qi7vGjpkUuzhZg7TFevxJY1T02APc2qGmpbOHYYwP405R5u6NBTUvlEHBbVX0cuAS4dZb/Lvs8d5I0FL0KYAy2lNE6YGu3/TBweZLZbgB7vBnpZZqq6nFg/zG6rAPuq0lPAKclWdGmusUZYGy9VVV7q+qZbvufwEscuXpFb+dOkoalbwFskKWM/tenqg4BB4APNalucQZdpukL3WWeh5OsnOX1vhr1ZfBBt4gAAAGtSURBVKo+m+QvSX6T5BPDLmYhusv5nwKenPHSqM+dJC25vgWwOZcyGrDP8WiQun8FnFdVnwR+z//P9I2Cvs7bIJ4Bzq2qC4F7gF8OuZ55S/J+4OfAN6rqnZkvz/KWUZk7SVoWfQtgcy5lNLVPkpOBD9KPy0ODLNP0VlX9u9v9IfDpRrW1MMjc9lJVvVNVB7vt7cApSc4cclkDS3IKk+Hr/qr6xSxdRnbuJGm59C2ADbKU0TZgfbd9LfCH6sfNzuYc24zv1VzN5PdxRsU24MbuF3WXAAeqau+wi1oKST58+HuISdYw+ffureFWNZiu7h8DL1XVd4/SbWTnTpKWS/M74S/G0ZYySnIH8HRVbWPyfxY/SbKLyTNf1w+v4sENOLavJbmayV+m7QduGlrB85TkAWAcODPJbuB24BSAqvoBk6sjXAXsAt4Fbh5OpfM3wNiuBb6S5BDwL+D6nvyjAOBS4EvA80me7dq+CXwE+j93kjQs3glfkiSpsb5dgpQkSeo9A5gkSVJjBjBJkqTGDGCSJEmNGcAkSZIaM4BJkiQ1ZgCTJElqzAAmSZLU2H8BmDiMNqscZx0AAAAASUVORK5CYII=\n",
      "text/plain": [
       "<Figure size 720x720 with 4 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Histograms of Polarity and Subjectivty for the training set.\n",
    "\n",
    "df.hist(bins=50,figsize=(10,10))\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 360x360 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Histograms of Polarity and Subjectivty for the testing set.\n",
    "\n",
    "df1.hist(bins=50,figsize=(5,5))\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [],
   "source": [
    "def ratio(x):\n",
    "    if x>0:\n",
    "        return 'Positive'\n",
    "    elif x==0:\n",
    "        return 'Neutral'\n",
    "    else:\n",
    "        return 'Negative'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Sentiment'] = df['Polarity'].apply(ratio)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [],
   "source": [
    "df1['Sentiment'] = df1['Polarity'].apply(ratio)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>sentiment</th>\n",
       "      <th>Polarity</th>\n",
       "      <th>Subjectivity</th>\n",
       "      <th>Sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>autoimmun diseas tend come cluster as gilenya ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "      <td>0.366667</td>\n",
       "      <td>0.388889</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>i complet understand youd want tri but result ...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>2</td>\n",
       "      <td>0.167708</td>\n",
       "      <td>0.287500</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>interest target sp receptor rather like fingol...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>2</td>\n",
       "      <td>0.014291</td>\n",
       "      <td>0.588332</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>veri interest grand merci now i wonder lemtrad...</td>\n",
       "      <td>ocrevus</td>\n",
       "      <td>2</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>hi everybodi my latest mri result brain cervic...</td>\n",
       "      <td>gilenya</td>\n",
       "      <td>1</td>\n",
       "      <td>0.322727</td>\n",
       "      <td>0.475758</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  sentiment  \\\n",
       "0  autoimmun diseas tend come cluster as gilenya ...     gilenya          2   \n",
       "1  i complet understand youd want tri but result ...     gilenya          2   \n",
       "2  interest target sp receptor rather like fingol...  fingolimod          2   \n",
       "3  veri interest grand merci now i wonder lemtrad...     ocrevus          2   \n",
       "4  hi everybodi my latest mri result brain cervic...     gilenya          1   \n",
       "\n",
       "   Polarity  Subjectivity Sentiment  \n",
       "0  0.366667      0.388889  Positive  \n",
       "1  0.167708      0.287500  Positive  \n",
       "2  0.014291      0.588332  Positive  \n",
       "3  0.500000      1.000000  Positive  \n",
       "4  0.322727      0.475758  Positive  "
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "      <th>Polarity</th>\n",
       "      <th>Subjectivity</th>\n",
       "      <th>Sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>previous stabl natalizumab switch fingolimod</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>-0.166667</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>on fingolimod sinc decemb way i describ better...</td>\n",
       "      <td>fingolimod</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>Neutral</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>appar shingl i red spot left breast appear day...</td>\n",
       "      <td>humira</td>\n",
       "      <td>-0.025000</td>\n",
       "      <td>0.446296</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>if docetaxel week x week week claim less harsh...</td>\n",
       "      <td>tagrisso</td>\n",
       "      <td>-0.052381</td>\n",
       "      <td>0.345238</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>cc stelara work matter day if gi will jump hoo...</td>\n",
       "      <td>stelara</td>\n",
       "      <td>-0.059135</td>\n",
       "      <td>0.401948</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text        drug  Polarity  \\\n",
       "0       previous stabl natalizumab switch fingolimod  fingolimod -0.166667   \n",
       "1  on fingolimod sinc decemb way i describ better...  fingolimod  0.000000   \n",
       "2  appar shingl i red spot left breast appear day...      humira -0.025000   \n",
       "3  if docetaxel week x week week claim less harsh...    tagrisso -0.052381   \n",
       "4  cc stelara work matter day if gi will jump hoo...     stelara -0.059135   \n",
       "\n",
       "   Subjectivity Sentiment  \n",
       "0      0.166667  Negative  \n",
       "1      0.750000   Neutral  \n",
       "2      0.446296  Negative  \n",
       "3      0.345238  Negative  \n",
       "4      0.401948  Negative  "
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Countplot for the Sentiment in training set.\n",
    "sns.countplot(df['Sentiment'])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Countplot for the Sentiment in training set.\n",
    "sns.countplot(df1['Sentiment'])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "med_df = "
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
